/*
Navicat MySQL Data Transfer

Source Server         : localhost
Source Server Version : 50522
Source Host           : localhost:3310
Source Database       : bzpt_new

Target Server Type    : MYSQL
Target Server Version : 50522
File Encoding         : 65001

Date: 2016-05-26 20:52:20
*/

SET FOREIGN_KEY_CHECKS=0;

-- ----------------------------
-- Table structure for ade_admin_logs
-- ----------------------------
DROP TABLE IF EXISTS `ade_admin_logs`;
CREATE TABLE `ade_admin_logs` (
  `ID` varchar(36) NOT NULL,
  `CONTENT` varchar(100) NOT NULL,
  `IE_TYPE` varchar(36) NOT NULL,
  `IP` varchar(36) NOT NULL,
  `LOG_TYPE` varchar(60) NOT NULL,
  `MODULE_NAME` varchar(60) DEFAULT NULL,
  `OPERATE_TIME` datetime NOT NULL,
  `USER_ID` varchar(100) NOT NULL,
  PRIMARY KEY (`ID`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of ade_admin_logs
-- ----------------------------
INSERT INTO `ade_admin_logs` VALUES ('0880660E18884050A78E471B1A62097C', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-26 04:08:20', '张三');
INSERT INTO `ade_admin_logs` VALUES ('09A449D580F147F493842E77616BF9CD', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 17:25:46', '张三');
INSERT INTO `ade_admin_logs` VALUES ('0A1679723BED4700A1822D3B1BE947DD', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-20 14:32:14', '张三');
INSERT INTO `ade_admin_logs` VALUES ('0A57E69D67224A859ABFEDA6D28AF83D', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-19 15:05:00', '张三');
INSERT INTO `ade_admin_logs` VALUES ('0AA21E9A825F446CAFFD6212FB068FEC', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-24 21:59:44', '张三');
INSERT INTO `ade_admin_logs` VALUES ('10A5CBF6043A4C67BAB548B2DF66256A', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-20 14:16:05', '张三');
INSERT INTO `ade_admin_logs` VALUES ('15C86CC1CE5447418A239CCE26177E30', '用户【admin】使用IP【本地】登录系统', 'Chrome', '本地', '登录', '登录', '2016-05-19 09:21:55', '张三');
INSERT INTO `ade_admin_logs` VALUES ('1756259884D444E58DDD20F5F426A89F', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-20 13:47:04', '张三');
INSERT INTO `ade_admin_logs` VALUES ('18C16AB8B5CC4AA69FBF8BB0BE5C3480', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-24 23:59:36', '张三');
INSERT INTO `ade_admin_logs` VALUES ('1AD0B96CC6D74111AA24A34310CE1CFD', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-20 16:06:09', '张三');
INSERT INTO `ade_admin_logs` VALUES ('249095CFFC4C4CDD9578D64F494C0924', '用户【admin】使用IP【本地】登录系统', 'Chrome', '本地', '登录', '登录', '2016-05-26 09:03:54', '张三');
INSERT INTO `ade_admin_logs` VALUES ('24A5BEB150654F66B898C5BDA2F41075', '用户【admin】使用IP【本地】注销登录', 'Firefox', '本地', '注销', '注销', '2016-05-20 09:57:22', '张三');
INSERT INTO `ade_admin_logs` VALUES ('2AD8E9CCCD1C4ABD96EFDC5C291F3E6F', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 15:23:05', '张三');
INSERT INTO `ade_admin_logs` VALUES ('2B42445EDF6D4C1380622F19900B8131', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-20 09:53:01', '张三');
INSERT INTO `ade_admin_logs` VALUES ('2E357AF6901E4F7F99E7CDECF207655E', '前台用户管理:【删除】id为\"0223decde84a4a95b3b1c27960bb3c48\"的记录。', 'Firefox', '本地', '删除', '前台用户管理', '2016-05-18 16:48:00', '张三');
INSERT INTO `ade_admin_logs` VALUES ('2E6197FBC870441BA1ACFFC03A46141E', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-25 13:01:18', '张三');
INSERT INTO `ade_admin_logs` VALUES ('3210EFB9937C451FB10D7E388221F1D6', '用户【admin】使用IP【本地】注销登录', 'Firefox', '本地', '注销', '注销', '2016-05-18 13:01:05', '张三');
INSERT INTO `ade_admin_logs` VALUES ('324B4FA098ED433CB9511F1CE1293338', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-20 13:32:40', '张三');
INSERT INTO `ade_admin_logs` VALUES ('366CB87D5A1D400CB62945B2C0D58541', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 20:14:44', '张三');
INSERT INTO `ade_admin_logs` VALUES ('36A8D1EBCB4340F99190D57AC31E6149', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-26 04:55:12', '张三');
INSERT INTO `ade_admin_logs` VALUES ('3872D20AA1B9444FB9D838C63B46FECB', '前台用户管理:【删除】id为\"348899f712c84c65a31c1049577c75af\"的记录。', 'Firefox', '本地', '删除', '前台用户管理', '2016-05-18 20:17:50', '张三');
INSERT INTO `ade_admin_logs` VALUES ('3B2F3FEF37E446DA993FFA4EF88B40EC', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 17:09:19', '张三');
INSERT INTO `ade_admin_logs` VALUES ('3B5074F375344832980922C2291428EF', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-26 04:16:41', '张三');
INSERT INTO `ade_admin_logs` VALUES ('3E80800712E0444F93C027C5CF7F5152', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-20 15:50:04', '张三');
INSERT INTO `ade_admin_logs` VALUES ('3F8DCAE6DAFA466898D72D763A4BAD92', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-20 13:06:03', '张三');
INSERT INTO `ade_admin_logs` VALUES ('3FC166DAC55B4338AD2A888F77148608', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-26 04:31:01', '张三');
INSERT INTO `ade_admin_logs` VALUES ('438712B0FA3E45DCA9D4402D384F0C27', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-19 15:05:49', '张三');
INSERT INTO `ade_admin_logs` VALUES ('46C69878DC38404CBBB2A6E16788151D', '前台用户管理:【修改】id为\"0223decde84a4a95b3b1c27960bb3c48\"的记录。', 'Firefox', '本地', '修改', '前台用户管理', '2016-05-18 16:46:14', '张三');
INSERT INTO `ade_admin_logs` VALUES ('46CB0CD6FFCD4A6591FBC3418A956269', '前台用户管理:【删除】id为\"8bb552aa462948b8b853f053fcdcf8a3\"的记录。', 'Firefox', '本地', '删除', '前台用户管理', '2016-05-18 20:17:41', '张三');
INSERT INTO `ade_admin_logs` VALUES ('46CE014D46314F6D8A1169FBA17C5F06', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-19 15:03:18', '张三');
INSERT INTO `ade_admin_logs` VALUES ('49C0ADD04AAF4F028F5E1AECD881862B', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-20 13:35:02', '张三');
INSERT INTO `ade_admin_logs` VALUES ('4A1D2F663FBA41DBB8765E1C06CB7670', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-25 10:00:52', '张三');
INSERT INTO `ade_admin_logs` VALUES ('4A837F21B989415298BFBC7DA2FA8086', '用户【admin】使用IP【本地】登录系统', 'Chrome', '本地', '登录', '登录', '2016-05-19 17:13:54', '张三');
INSERT INTO `ade_admin_logs` VALUES ('4BB26B81C843467BAA8C7E479BC348AF', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-21 03:28:27', '张三');
INSERT INTO `ade_admin_logs` VALUES ('4D5ED218321B47EBB2302B2A9C49775F', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 14:53:14', '张三');
INSERT INTO `ade_admin_logs` VALUES ('522BC13EF7AD49ACA8B1D2AD3A4284A2', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 20:17:18', '张三');
INSERT INTO `ade_admin_logs` VALUES ('533CDC0A562A4FB7BDFD4E89D002AB0F', '用户【admin】使用IP【127.0.0.1】登录系统', 'Firefox', '127.0.0.1', '登录', '登录', '2016-05-18 11:49:59', '张三');
INSERT INTO `ade_admin_logs` VALUES ('56B63274AD974FCAB6A428379030410C', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-24 21:20:40', '张三');
INSERT INTO `ade_admin_logs` VALUES ('5B8300C8854D40D0B1CBE3DB23D579CF', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-21 03:25:39', '张三');
INSERT INTO `ade_admin_logs` VALUES ('5FBEB8C9034B4E01BB8A8A85B0CB8162', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-21 03:55:43', '张三');
INSERT INTO `ade_admin_logs` VALUES ('6052CD0CBAB44694BB0ABF6A31E273AE', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-26 03:51:39', '张三');
INSERT INTO `ade_admin_logs` VALUES ('7054B406E43241F4AFE889F0D787D48B', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-20 09:22:54', '张三');
INSERT INTO `ade_admin_logs` VALUES ('7308F2A1BBAA465F8161C17257BE33B5', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 11:40:02', '张三');
INSERT INTO `ade_admin_logs` VALUES ('73D19EC244B546A9AB22D6361E499BFA', '用户【admin】使用IP【本地】登录系统', 'Chrome', '本地', '登录', '登录', '2016-05-19 15:09:01', '张三');
INSERT INTO `ade_admin_logs` VALUES ('76415391BB084BFD8F7393ED5E9D211B', '前台用户管理:【删除】id为\"642175e5785b4035b3cb57633e4fc076\"的记录。', 'Firefox', '本地', '删除', '前台用户管理', '2016-05-18 20:17:46', '张三');
INSERT INTO `ade_admin_logs` VALUES ('78D26AEC0AB14952AB0527C642373AA0', '用户【admin】使用IP【本地】登录系统', 'MSIE 9.0', '本地', '登录', '登录', '2016-05-19 11:42:52', '张三');
INSERT INTO `ade_admin_logs` VALUES ('7A7BED0F766E44A6BC8FFFA7A942794E', '用户【admin】使用IP【本地】登录系统', 'Chrome', '本地', '登录', '登录', '2016-05-19 09:40:56', '张三');
INSERT INTO `ade_admin_logs` VALUES ('7E2A216099774EC08876B9D32D6DEFC1', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 13:00:59', '张三');
INSERT INTO `ade_admin_logs` VALUES ('80F6460974FF4D14B08253D78A0D512B', '用户【admin】使用IP【本地】登录系统', 'Chrome', '本地', '登录', '登录', '2016-05-19 09:28:08', '张三');
INSERT INTO `ade_admin_logs` VALUES ('84963B96B4864905BB11F15B1633064A', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-21 02:01:14', '张三');
INSERT INTO `ade_admin_logs` VALUES ('8511E6B122174FD8A9379AD573B5C4B2', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 20:40:05', '张三');
INSERT INTO `ade_admin_logs` VALUES ('8792041B17844D528C4A25A2C9E14731', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 14:12:11', '张三');
INSERT INTO `ade_admin_logs` VALUES ('8C75C30300F148B1A2AA283C9179EA2C', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-23 23:55:00', '张三');
INSERT INTO `ade_admin_logs` VALUES ('8CB94E9477C3476CBC6BFA85FE3DF9DE', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 13:01:15', '张三');
INSERT INTO `ade_admin_logs` VALUES ('8F9DA7E10D744F859DAA6579EB30D130', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 20:33:20', '张三');
INSERT INTO `ade_admin_logs` VALUES ('9053EBB2C6FA489AB5305346118A0B6A', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 19:49:02', '张三');
INSERT INTO `ade_admin_logs` VALUES ('90B72A87D62A49799BB76CBD46BF0DB7', '用户【admin】使用IP【本地】注销登录', 'Firefox', '本地', '注销', '注销', '2016-05-18 13:02:13', '张三');
INSERT INTO `ade_admin_logs` VALUES ('915A887DE4674CD0AAC4A976BAECD8B2', '前台用户管理:【删除】id为\"0e06dae9dd564d45a5d8166a37eea635\"的记录。', 'Firefox', '本地', '删除', '前台用户管理', '2016-05-18 17:04:20', '张三');
INSERT INTO `ade_admin_logs` VALUES ('91D045C86E6849F6AC58986170683CC1', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-25 10:47:34', '张三');
INSERT INTO `ade_admin_logs` VALUES ('92AC5ABD8C1040F39E0569C11AD331DA', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-23 22:02:28', '张三');
INSERT INTO `ade_admin_logs` VALUES ('94BB79BAB7E44191966CE3CD83DAC3AB', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-25 18:07:34', '张三');
INSERT INTO `ade_admin_logs` VALUES ('9747130F07B240DEA087540A3C3D570E', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-26 06:37:43', '张三');
INSERT INTO `ade_admin_logs` VALUES ('975F86010B3A476E80A708AFF553FA06', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-20 15:32:53', '张三');
INSERT INTO `ade_admin_logs` VALUES ('97DC303F686949D4921C1F4BA23D7233', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-20 15:07:43', '张三');
INSERT INTO `ade_admin_logs` VALUES ('97FE9C22F58A44DD8B241C632CC3C98E', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-20 18:09:02', '张三');
INSERT INTO `ade_admin_logs` VALUES ('989860892B4B4FAF90EFD716A24CDB3D', '用户【admin】使用IP【本地】登录系统', 'Chrome', '本地', '登录', '登录', '2016-05-26 08:52:34', '张三');
INSERT INTO `ade_admin_logs` VALUES ('98FCAAEEFB524CAD93D509F7FD3D5196', '用户【admin】使用IP【本地】登录系统', 'Chrome', '本地', '登录', '登录', '2016-05-26 09:47:21', '张三');
INSERT INTO `ade_admin_logs` VALUES ('9EC6A99D8D3247DAAEE1648FE1E4DE40', '用户【admin】使用IP【本地】登录系统', 'Chrome', '本地', '登录', '登录', '2016-05-26 08:10:47', '张三');
INSERT INTO `ade_admin_logs` VALUES ('A30A791DAAFB43569DAFD2F70081A381', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-25 09:45:59', '张三');
INSERT INTO `ade_admin_logs` VALUES ('A53F0DC431A74023AFD0D65B98841B2D', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-23 23:52:00', '张三');
INSERT INTO `ade_admin_logs` VALUES ('A6270776F62B4C27B5B82AD29245E884', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 13:02:30', '张三');
INSERT INTO `ade_admin_logs` VALUES ('ABEE000F061E4E16AB7D178B0F569FC5', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 17:25:00', '张三');
INSERT INTO `ade_admin_logs` VALUES ('AC17B259074D40C2B06C4ADF481B0B5A', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-24 21:13:19', '张三');
INSERT INTO `ade_admin_logs` VALUES ('AC79374E88E6408F8AD6F6C8E8247430', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 14:21:35', '张三');
INSERT INTO `ade_admin_logs` VALUES ('AD8FC412566C4827952AA59380BE7AF3', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-25 14:45:15', '张三');
INSERT INTO `ade_admin_logs` VALUES ('AE39B57A7CA94A3D8DCBAA0B7B83E867', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-20 16:04:21', '张三');
INSERT INTO `ade_admin_logs` VALUES ('B0E67DEF0DF644A3A53B618F39F47400', '前台用户管理:【删除】id为\"6b62ba5a93ef498285ad3114c7062c2d\"的记录。', 'Firefox', '本地', '删除', '前台用户管理', '2016-05-18 20:17:43', '张三');
INSERT INTO `ade_admin_logs` VALUES ('B1A331BC8C2E4292BB2784FDA9D76B0A', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-20 09:57:36', '张三');
INSERT INTO `ade_admin_logs` VALUES ('B2944FE1CE4B4691AEEB0F90E08070E9', '用户【admin】使用IP【127.0.0.1】登录系统', 'Firefox', '127.0.0.1', '登录', '登录', '2016-05-18 11:48:28', '张三');
INSERT INTO `ade_admin_logs` VALUES ('B47D6B2B495B4D44B0CA876464205EEE', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-20 09:51:16', '张三');
INSERT INTO `ade_admin_logs` VALUES ('B7D36C2234C0414980FE12DADA599EF3', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 16:36:29', '张三');
INSERT INTO `ade_admin_logs` VALUES ('B9BD978A1B5147CAB4E77576052053C2', '用户【admin】使用IP【本地】登录系统', 'Chrome', '本地', '登录', '登录', '2016-05-26 09:28:32', '张三');
INSERT INTO `ade_admin_logs` VALUES ('BC7B85F9BDFA4F558B396E0C11937DC9', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-20 16:52:05', '张三');
INSERT INTO `ade_admin_logs` VALUES ('BF07DC781FB94BC09A98D55C8283B5C2', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-26 07:00:24', '张三');
INSERT INTO `ade_admin_logs` VALUES ('C06DDD671A594DFA8EE3FCF521E7B21F', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 17:20:22', '张三');
INSERT INTO `ade_admin_logs` VALUES ('C2133717A8C144A9B897E4354E5E288A', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-25 10:23:09', '张三');
INSERT INTO `ade_admin_logs` VALUES ('C7F8D617B8B34319B8116A4CB216B3C9', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-23 20:15:01', '张三');
INSERT INTO `ade_admin_logs` VALUES ('C863A38396734A60BF35F8EF5117564D', '用户【admin】使用IP【本地】登录系统', 'Chrome', '本地', '登录', '登录', '2016-05-19 10:36:08', '张三');
INSERT INTO `ade_admin_logs` VALUES ('CA60523B8897444C98EE69FA543DB76E', '用户【admin】使用IP【127.0.0.1】登录系统', 'Firefox', '127.0.0.1', '登录', '登录', '2016-05-18 11:48:53', '张三');
INSERT INTO `ade_admin_logs` VALUES ('CC20B9BCE3CC4A669841C421BA00CA10', '用户【admin】使用IP【本地】登录系统', 'Chrome', '本地', '登录', '登录', '2016-05-26 08:19:59', '张三');
INSERT INTO `ade_admin_logs` VALUES ('CFD9717940AB49A383D5411B20FEF338', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-26 05:39:30', '张三');
INSERT INTO `ade_admin_logs` VALUES ('D20CA544EF5D4D54B9A6B938AACD202E', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 17:28:42', '张三');
INSERT INTO `ade_admin_logs` VALUES ('D38251D771494B92AD5980098B43587B', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-23 23:32:54', '张三');
INSERT INTO `ade_admin_logs` VALUES ('DAF18DAE6FC0463E8FA40A289BF5B378', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-26 06:36:08', '张三');
INSERT INTO `ade_admin_logs` VALUES ('DB0AA4CED3F249E6810CE31638CA8089', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-21 01:04:47', '张三');
INSERT INTO `ade_admin_logs` VALUES ('DCD07B6CF36D4ABAB70E69C704ABA310', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-21 02:07:33', '张三');
INSERT INTO `ade_admin_logs` VALUES ('DE04D0F8E98E40598A787DF5BB2FB905', '用户【admin】使用IP【本地】登录系统', 'MSIE 9.0', '本地', '登录', '登录', '2016-05-19 11:44:52', '张三');
INSERT INTO `ade_admin_logs` VALUES ('E01E9DDE8C624AA7A773A13097DC7621', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-21 04:22:02', '张三');
INSERT INTO `ade_admin_logs` VALUES ('E34B32893BD8480C91F1ED959E5FDE41', '用户【admin】使用IP【本地】登录系统', 'Chrome', '本地', '登录', '登录', '2016-05-19 17:34:15', '张三');
INSERT INTO `ade_admin_logs` VALUES ('E5F36AB48CDE4C2BB0574344B6A7F288', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 16:06:43', '张三');
INSERT INTO `ade_admin_logs` VALUES ('E6D897928603485190495B2375423F9B', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-25 10:36:53', '张三');
INSERT INTO `ade_admin_logs` VALUES ('E6D8F3F54EB4452BBD82A3C50A4A23B9', '前台用户管理:【删除】id为\"ea77d5df281f4a498b8a49167daf530a\"的记录。', 'Firefox', '本地', '删除', '前台用户管理', '2016-05-18 20:17:35', '张三');
INSERT INTO `ade_admin_logs` VALUES ('E743E93F1DFE4D9599C5FB19B35808BC', '用户【admin】使用IP【127.0.0.1】登录系统', 'Firefox', '127.0.0.1', '登录', '登录', '2016-05-18 11:50:17', '张三');
INSERT INTO `ade_admin_logs` VALUES ('E834448A007D4EE9A924465300865839', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-24 22:00:56', '张三');
INSERT INTO `ade_admin_logs` VALUES ('EBBE8B71B3B5466FBF2BB20E410AB855', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 20:12:02', '张三');
INSERT INTO `ade_admin_logs` VALUES ('F2990BC33185436E895BAD33B072828B', '用户【admin】使用IP【本地】登录系统', 'Chrome', '本地', '登录', '登录', '2016-05-19 15:09:32', '张三');
INSERT INTO `ade_admin_logs` VALUES ('F60EC2B17AAD41BEB5C89A6D17A6675B', '前台用户管理:【删除】id为\"fbc15611066c424ea071d27d14f8b447\"的记录。', 'Firefox', '本地', '删除', '前台用户管理', '2016-05-18 20:17:40', '张三');
INSERT INTO `ade_admin_logs` VALUES ('F808679C05514F40B72062C3128DD14E', '用户【admin】使用IP【本地】登录系统', 'Firefox', '本地', '登录', '登录', '2016-05-18 20:08:30', '张三');

-- ----------------------------
-- Table structure for ade_bug
-- ----------------------------
DROP TABLE IF EXISTS `ade_bug`;
CREATE TABLE `ade_bug` (
  `id` varchar(32) NOT NULL,
  `createdatetime` datetime DEFAULT NULL,
  `modifydatetime` datetime DEFAULT NULL,
  `name` varchar(100) DEFAULT NULL,
  `note` longtext,
  `bugtype_id` varchar(32) DEFAULT NULL,
  PRIMARY KEY (`id`),
  KEY `FK_5nrv3udsxi17efrlf8eoan1np` (`bugtype_id`) USING BTREE,
  CONSTRAINT `ade_bug_ibfk_1` FOREIGN KEY (`bugtype_id`) REFERENCES `ade_bugtype` (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of ade_bug
-- ----------------------------
INSERT INTO `ade_bug` VALUES ('7324A2908F7E49118B6CA14D49E30AD2', '2016-05-11 16:04:53', '2016-05-11 16:05:15', '111', 'adfadfafccccccafd', '1');

-- ----------------------------
-- Table structure for ade_bugtype
-- ----------------------------
DROP TABLE IF EXISTS `ade_bugtype`;
CREATE TABLE `ade_bugtype` (
  `id` varchar(32) NOT NULL,
  `name` varchar(100) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of ade_bugtype
-- ----------------------------
INSERT INTO `ade_bugtype` VALUES ('1', '后台管理');

-- ----------------------------
-- Table structure for ade_dictionary
-- ----------------------------
DROP TABLE IF EXISTS `ade_dictionary`;
CREATE TABLE `ade_dictionary` (
  `ID` varchar(32) NOT NULL,
  `ZD_CODE` varchar(60) NOT NULL,
  `ZD_DESC` varchar(255) DEFAULT NULL,
  `ZD_NAME` varchar(100) NOT NULL,
  `ZD_SORT` int(11) DEFAULT NULL,
  `ZD_USE` varchar(2) NOT NULL,
  `ZD_TYPE_ID` varchar(32) DEFAULT NULL,
  PRIMARY KEY (`ID`),
  KEY `FK_9l6p5uj5th2jlkyldo7by6tn2` (`ZD_TYPE_ID`) USING BTREE,
  CONSTRAINT `ade_dictionary_ibfk_1` FOREIGN KEY (`ZD_TYPE_ID`) REFERENCES `ade_dictionary_type` (`ID`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of ade_dictionary
-- ----------------------------
INSERT INTO `ade_dictionary` VALUES ('230A6DBA2F204B14AD4AC732889B88A7', 'input_textarea', '', '多行文本', '3', '1', '9D76DF55659D4B80BE896F29F69A321D');
INSERT INTO `ade_dictionary` VALUES ('4692925FCCE849F6B5B8B06F911EEE75', 'input_KindEdit', '', '大文本(KindEdit)', '4', '1', '9D76DF55659D4B80BE896F29F69A321D');
INSERT INTO `ade_dictionary` VALUES ('5F132255282A4FFA863280DBE4AC63FE', 'input_uploadify', '', '上传组件(uploadify)', '5', '1', '9D76DF55659D4B80BE896F29F69A321D');
INSERT INTO `ade_dictionary` VALUES ('80B3A4E762D94EB683F25CA73DAA163E', 'input_tree', '', '下拉树', '6', '1', '9D76DF55659D4B80BE896F29F69A321D');
INSERT INTO `ade_dictionary` VALUES ('ADDF8F10F5604108BCA7BAEC4E8D5757', 'input_select', '', '下拉框', '2', '1', '9D76DF55659D4B80BE896F29F69A321D');
INSERT INTO `ade_dictionary` VALUES ('E9A0AE4432234BF18BB7D508971A4388', 'input', '', '普通输入框', '1', '1', '9D76DF55659D4B80BE896F29F69A321D');

-- ----------------------------
-- Table structure for ade_dictionary_type
-- ----------------------------
DROP TABLE IF EXISTS `ade_dictionary_type`;
CREATE TABLE `ade_dictionary_type` (
  `ID` varchar(32) NOT NULL,
  `ZD_TYPE_CODE` varchar(32) NOT NULL,
  `ZD_TYPE_DESC` varchar(255) NOT NULL,
  `ZD_TYPE_NAME` varchar(100) NOT NULL,
  `ZD_TYPE_SORT` int(11) DEFAULT NULL,
  `ZD_TYPE_USE` varchar(2) NOT NULL,
  PRIMARY KEY (`ID`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of ade_dictionary_type
-- ----------------------------
INSERT INTO `ade_dictionary_type` VALUES ('9D76DF55659D4B80BE896F29F69A321D', 'dictionary_pageElement_type', '', '页面元素类型', '1', '1');

-- ----------------------------
-- Table structure for ade_group
-- ----------------------------
DROP TABLE IF EXISTS `ade_group`;
CREATE TABLE `ade_group` (
  `ID` varchar(32) NOT NULL,
  `CREATE_DATE` datetime DEFAULT NULL,
  `GROUP_DESC` varchar(255) NOT NULL,
  `GROUP_FULL_NAME` varchar(200) NOT NULL,
  `GROUP_SHORT_NAME` varchar(200) NOT NULL,
  `GROUP_SORT` varchar(255) DEFAULT NULL,
  `LAST_MODIFY_DATE` datetime DEFAULT NULL,
  `GROUP_PID` varchar(32) DEFAULT NULL,
  `CREATE_USER` varchar(32) DEFAULT NULL,
  `LAST_MODIFY_USER` varchar(32) DEFAULT NULL,
  PRIMARY KEY (`ID`),
  KEY `FK_17pra2yo53huwi5rmu3caaffl` (`GROUP_PID`) USING BTREE,
  KEY `FK_c7bfcx1bm8cy7y9062bn7r527` (`CREATE_USER`) USING BTREE,
  KEY `FK_std7kbn2hh1r2yworte564lev` (`LAST_MODIFY_USER`) USING BTREE,
  CONSTRAINT `ade_group_ibfk_1` FOREIGN KEY (`GROUP_PID`) REFERENCES `ade_group` (`ID`),
  CONSTRAINT `ade_group_ibfk_2` FOREIGN KEY (`CREATE_USER`) REFERENCES `ade_user` (`ID`),
  CONSTRAINT `ade_group_ibfk_3` FOREIGN KEY (`LAST_MODIFY_USER`) REFERENCES `ade_user` (`ID`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of ade_group
-- ----------------------------

-- ----------------------------
-- Table structure for ade_module
-- ----------------------------
DROP TABLE IF EXISTS `ade_module`;
CREATE TABLE `ade_module` (
  `ID` varchar(32) NOT NULL,
  `MODULE_DESC` varchar(255) DEFAULT NULL,
  `MODULE_ICON` varchar(100) DEFAULT NULL,
  `MODULE_NAME` varchar(100) NOT NULL,
  `MODULE_SORT` int(11) DEFAULT NULL,
  `MODULE_URL` varchar(200) DEFAULT NULL,
  `MODULE_PID` varchar(32) DEFAULT NULL,
  `MODULE_TYPE_ID` varchar(32) NOT NULL,
  PRIMARY KEY (`ID`),
  KEY `FK_potycga2poaka2davotg8a11m` (`MODULE_PID`) USING BTREE,
  KEY `FK_7vcirr62lwiv4av32h0iy1rxu` (`MODULE_TYPE_ID`) USING BTREE,
  CONSTRAINT `ade_module_ibfk_1` FOREIGN KEY (`MODULE_TYPE_ID`) REFERENCES `ade_module_type` (`ID`),
  CONSTRAINT `ade_module_ibfk_2` FOREIGN KEY (`MODULE_PID`) REFERENCES `ade_module` (`ID`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of ade_module
-- ----------------------------
INSERT INTO `ade_module` VALUES ('1DFFCBB4C0374626BEC9AD2F9D10D532', '', '', 'bug管理', '107', '/admin/bug/manager', 'xtgl', '0');
INSERT INTO `ade_module` VALUES ('263C3D124F754071B96BD959E4C120BC', '业务日志', '', '业务日志', '106', '/admin/userLogs/manage', 'xtgl', '0');
INSERT INTO `ade_module` VALUES ('2784ACB3175B43FE85A679B1BB275A6D', '', '', '字典管理', '100', '/admin/dictionary/manager', 'xtgl', '0');
INSERT INTO `ade_module` VALUES ('27B5CE52EBF5408A9DFEF905710834D2', '/admin/adminLogs', '', '系统日志', '105', '/admin/adminLogs/manage', 'xtgl', '0');
INSERT INTO `ade_module` VALUES ('3D17B0355C42440B8B71E6C4233AEDD6', '内容发布管理', 'building_add', '病种管理', '100', '', null, '0');
INSERT INTO `ade_module` VALUES ('404D882B37DD47418C493575FF2FFD18', '疾病管理', '', '疾病管理', '101', '/admin/disease/manager', '3D17B0355C42440B8B71E6C4233AEDD6', '0');
INSERT INTO `ade_module` VALUES ('417DF6F2C47E4D9AA33036B3515634D3', '', '', '页面管理', '109', '/admin/genPage/manager', 'xtgl', '0');
INSERT INTO `ade_module` VALUES ('45CCD876B40D4E5A8BCDBB095E135553', '', '', 'PageModel管理', '108', '/admin/genPageModel/manager', 'xtgl', '0');
INSERT INTO `ade_module` VALUES ('7C17F78FC0924899B29F8EE88468D1E1', '测试测试测试', '', '测试测试', '100', '111111', 'buggl', '1');
INSERT INTO `ade_module` VALUES ('9FAF885F07C8449A80CBA50A0DF85562', '前台用户管理', '', '前台用户管理', '104', '/admin/portalUser/manager', 'xtgl', '0');
INSERT INTO `ade_module` VALUES ('B043B3E837594283824407215B9142D4', '333333', 'folder_wrench', '3333', '100', '', 'zygl', '1');
INSERT INTO `ade_module` VALUES ('BAAE012B6AD84C87BD712B558BD96C83', '', 'asterisk_yellow', '字典管理', '100', '/admin/dictionary/manager', 'xtgl', '0');
INSERT INTO `ade_module` VALUES ('buggl', null, 'bug_bug', 'BUG管理', '4', '/admin/bug/manager', 'xtgl', '0');
INSERT INTO `ade_module` VALUES ('bugglAdd', null, 'bug_add', '添加BUG', '3', '/admin/bug/add', 'buggl', '1');
INSERT INTO `ade_module` VALUES ('bugglAddPage', null, 'bug_add', '添加BUG页面', '2', '/admin/bug/addPage', 'buggl', '1');
INSERT INTO `ade_module` VALUES ('bugglDateGrid', null, 'bug_link', 'BUG表格', '1', '/admin/bug/dataGrid', 'buggl', '1');
INSERT INTO `ade_module` VALUES ('bugglDelete', null, 'bug_delete', '删除BUG', '6', '/admin/bug/delete', 'buggl', '1');
INSERT INTO `ade_module` VALUES ('bugglEdit', null, 'bug_edit', '编辑BUG', '5', '/admin/bug/edit', 'buggl', '1');
INSERT INTO `ade_module` VALUES ('bugglEditPage', null, 'bug_edit', '编辑BUG页面', '4', '/admin/bug/editPage', 'buggl', '1');
INSERT INTO `ade_module` VALUES ('bugglView', null, 'bug_link', '查看BUG', '7', '/admin/bug/view', 'buggl', '1');
INSERT INTO `ade_module` VALUES ('FAC11905F8164D639068E0379A37B849', '', '', '权限管理', '101', '/admin/module/modulePermission', 'xtgl', '0');
INSERT INTO `ade_module` VALUES ('jsgl', null, 'tux', '角色管理', '2', '/admin/role/manager', 'xtgl', '0');
INSERT INTO `ade_module` VALUES ('jsglAdd', null, 'wrench', '添加角色', '3', '/admin/role/add', 'jsgl', '1');
INSERT INTO `ade_module` VALUES ('jsglAddPage', null, 'wrench', '添加角色页面', '2', '/admin/role/addPage', 'jsgl', '1');
INSERT INTO `ade_module` VALUES ('jsglDelete', null, 'wrench', '删除角色', '6', '/admin/role/delete', 'jsgl', '1');
INSERT INTO `ade_module` VALUES ('jsglEdit', null, 'wrench', '编辑角色', '5', '/admin/role/edit', 'jsgl', '1');
INSERT INTO `ade_module` VALUES ('jsglEditPage', null, 'wrench', '编辑角色页面', '4', '/admin/role/editPage', 'jsgl', '1');
INSERT INTO `ade_module` VALUES ('jsglGrant', null, 'wrench', '角色授权', '8', '/admin/role/grant', 'jsgl', '1');
INSERT INTO `ade_module` VALUES ('jsglGrantPage', null, 'wrench', '角色授权页面', '7', '/admin/role/grantPage', 'jsgl', '1');
INSERT INTO `ade_module` VALUES ('jsglTreeGrid', null, 'wrench', '角色表格', '1', '/admin/role/treeGrid', 'jsgl', '1');
INSERT INTO `ade_module` VALUES ('wjgl', null, 'server_database', '文件管理', '6', null, 'xtgl', '1');
INSERT INTO `ade_module` VALUES ('wjglUpload', null, 'server_database', '上传文件', '2', '/admin/file/upload', 'wjgl', '1');
INSERT INTO `ade_module` VALUES ('wjglView', null, 'server_database', '浏览服务器文件', '1', '/admin/file/fileManage', 'wjgl', '1');
INSERT INTO `ade_module` VALUES ('xtgl', null, 'plugin', '系统管理', '0', null, null, '0');
INSERT INTO `ade_module` VALUES ('yhgl', null, 'status_online', '用户管理', '3', '/admin/user/manager', 'xtgl', '0');
INSERT INTO `ade_module` VALUES ('yhglAdd', null, 'wrench', '添加用户', '3', '/admin/user/add', 'yhgl', '1');
INSERT INTO `ade_module` VALUES ('yhglAddPage', null, 'wrench', '添加用户页面', '2', '/admin/user/addPage', 'yhgl', '1');
INSERT INTO `ade_module` VALUES ('yhglBatchDelete', null, 'wrench', '批量删除用户', '7', '/admin/user/batchDelete', 'yhgl', '1');
INSERT INTO `ade_module` VALUES ('yhglDateGrid', null, 'wrench', '用户表格', '1', '/admin/user/dataGrid', 'yhgl', '1');
INSERT INTO `ade_module` VALUES ('yhglDelete', null, 'wrench', '删除用户', '6', '/admin/user/delete', 'yhgl', '1');
INSERT INTO `ade_module` VALUES ('yhglEdit', null, 'wrench', '编辑用户', '5', '/admin/user/edit', 'yhgl', '1');
INSERT INTO `ade_module` VALUES ('yhglEditPage', null, 'wrench', '编辑用户页面', '4', '/admin/user/editPage', 'yhgl', '1');
INSERT INTO `ade_module` VALUES ('yhglEditPwd', null, 'wrench', '用户修改密码', '11', '/admin/user/editPwd', 'yhgl', '1');
INSERT INTO `ade_module` VALUES ('yhglEditPwdPage', null, 'wrench', '用户修改密码页面', '10', '/admin/user/editPwdPage', 'yhgl', '1');
INSERT INTO `ade_module` VALUES ('yhglGrant', null, 'wrench', '用户授权', '9', '/admin/user/grant', 'yhgl', '1');
INSERT INTO `ade_module` VALUES ('yhglGrantPage', null, 'wrench', '用户授权页面', '8', '/admin/user/grantPage', 'yhgl', '1');
INSERT INTO `ade_module` VALUES ('zygl', '管理系统中所有的菜单或功能', 'database_gear', '模块管理', '1', '/admin/module/manager', 'xtgl', '0');
INSERT INTO `ade_module` VALUES ('zyglAdd', null, 'wrench', '添加模块', '4', '/admin/module/add', 'zygl', '1');
INSERT INTO `ade_module` VALUES ('zyglAddPage', null, 'wrench', '添加模块页面', '3', '/admin/module/addPage', 'zygl', '1');
INSERT INTO `ade_module` VALUES ('zyglDelete', null, 'wrench', '删除模块', '7', '/admin/module/delete', 'zygl', '1');
INSERT INTO `ade_module` VALUES ('zyglEdit', null, 'wrench', '编辑模块', '6', '/admin/module/edit', 'zygl', '1');
INSERT INTO `ade_module` VALUES ('zyglEditPage', null, 'wrench', '编辑模块页面', '5', '/admin/module/editPage', 'zygl', '1');
INSERT INTO `ade_module` VALUES ('zyglMenu', null, 'wrench', '功能菜单', '2', '/moduleController/tree', 'zygl', '1');
INSERT INTO `ade_module` VALUES ('zyglTreeGrid', '显示模块列表', 'wrench', '模块表格', '1', '/admin/module/treeGrid', 'zygl', '1');

-- ----------------------------
-- Table structure for ade_module_type
-- ----------------------------
DROP TABLE IF EXISTS `ade_module_type`;
CREATE TABLE `ade_module_type` (
  `ID` varchar(32) NOT NULL,
  `NAME` varchar(100) NOT NULL,
  PRIMARY KEY (`ID`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of ade_module_type
-- ----------------------------
INSERT INTO `ade_module_type` VALUES ('0', '系统菜单');
INSERT INTO `ade_module_type` VALUES ('1', '功能');

-- ----------------------------
-- Table structure for ade_role
-- ----------------------------
DROP TABLE IF EXISTS `ade_role`;
CREATE TABLE `ade_role` (
  `ID` varchar(32) NOT NULL,
  `ROLE_DESC` varchar(255) DEFAULT NULL,
  `ROLE_NAME` varchar(100) NOT NULL,
  `ROLE_SORT` int(11) DEFAULT NULL,
  `ROLE_PID` varchar(32) DEFAULT NULL,
  `ROLE_IS_BUILDIN` int(11) DEFAULT NULL,
  PRIMARY KEY (`ID`),
  KEY `FK_fe6sykvjkvvg2oc0mpe286in9` (`ROLE_PID`) USING BTREE,
  CONSTRAINT `ade_role_ibfk_1` FOREIGN KEY (`ROLE_PID`) REFERENCES `ade_role` (`ID`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of ade_role
-- ----------------------------
INSERT INTO `ade_role` VALUES ('0', '系统开发员角色，拥有系统中所有的模块访问权限', '系统开发员', '0', null, null);
INSERT INTO `ade_role` VALUES ('2458BE4F889B45AD9845897D38F6F23A', '维护系统中的所有内容管理信息', '信息管理员', '103', '0', null);
INSERT INTO `ade_role` VALUES ('2DC54FCBD7BF46DBA92B8B2DE0392B27', '能够操作系统中的所有的功能', '系统管理员', '100', '0', null);
INSERT INTO `ade_role` VALUES ('3340625951174C16A5938188D0FF0FC2', '数据征集管理员', '数据征集管理员', '102', '0', null);
INSERT INTO `ade_role` VALUES ('638CCDB7E8394465910F1423C2BA19FC', '反反复复', '呵呵', '100', null, null);
INSERT INTO `ade_role` VALUES ('66D9D2E49D1341DB8238BE8DE47240A2', '申报管理的日常维护者', '申报审核员', '101', '0', null);
INSERT INTO `ade_role` VALUES ('B99BC911F8E744F9B6B27A8604977713', '少时诵诗书', '日志管理', '100', null, null);
INSERT INTO `ade_role` VALUES ('BE08BECBE38645A58AE64614219FC774', '监管机构业务员', '监管机构业务员', '105', '0', null);

-- ----------------------------
-- Table structure for ade_role_module
-- ----------------------------
DROP TABLE IF EXISTS `ade_role_module`;
CREATE TABLE `ade_role_module` (
  `ROLE_ID` varchar(32) NOT NULL,
  `MODULE_ID` varchar(32) NOT NULL,
  PRIMARY KEY (`MODULE_ID`,`ROLE_ID`),
  KEY `FK_s8ixvsib2601l6a4m1xpapkcb` (`MODULE_ID`) USING BTREE,
  KEY `FK_sb6kki3iapqtjrw0krucaya3d` (`ROLE_ID`) USING BTREE,
  CONSTRAINT `ade_role_module_ibfk_1` FOREIGN KEY (`MODULE_ID`) REFERENCES `ade_module` (`ID`),
  CONSTRAINT `ade_role_module_ibfk_2` FOREIGN KEY (`ROLE_ID`) REFERENCES `ade_role` (`ID`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of ade_role_module
-- ----------------------------
INSERT INTO `ade_role_module` VALUES ('0', '1DFFCBB4C0374626BEC9AD2F9D10D532');
INSERT INTO `ade_role_module` VALUES ('0', '263C3D124F754071B96BD959E4C120BC');
INSERT INTO `ade_role_module` VALUES ('0', '2784ACB3175B43FE85A679B1BB275A6D');
INSERT INTO `ade_role_module` VALUES ('0', '27B5CE52EBF5408A9DFEF905710834D2');
INSERT INTO `ade_role_module` VALUES ('0', '3D17B0355C42440B8B71E6C4233AEDD6');
INSERT INTO `ade_role_module` VALUES ('0', '404D882B37DD47418C493575FF2FFD18');
INSERT INTO `ade_role_module` VALUES ('0', '417DF6F2C47E4D9AA33036B3515634D3');
INSERT INTO `ade_role_module` VALUES ('0', '45CCD876B40D4E5A8BCDBB095E135553');
INSERT INTO `ade_role_module` VALUES ('0', '9FAF885F07C8449A80CBA50A0DF85562');
INSERT INTO `ade_role_module` VALUES ('B99BC911F8E744F9B6B27A8604977713', 'buggl');
INSERT INTO `ade_role_module` VALUES ('0', 'jsgl');
INSERT INTO `ade_role_module` VALUES ('B99BC911F8E744F9B6B27A8604977713', 'jsgl');
INSERT INTO `ade_role_module` VALUES ('0', 'jsglAdd');
INSERT INTO `ade_role_module` VALUES ('0', 'jsglAddPage');
INSERT INTO `ade_role_module` VALUES ('0', 'jsglDelete');
INSERT INTO `ade_role_module` VALUES ('0', 'jsglEdit');
INSERT INTO `ade_role_module` VALUES ('0', 'jsglEditPage');
INSERT INTO `ade_role_module` VALUES ('0', 'jsglGrant');
INSERT INTO `ade_role_module` VALUES ('0', 'jsglGrantPage');
INSERT INTO `ade_role_module` VALUES ('0', 'jsglTreeGrid');
INSERT INTO `ade_role_module` VALUES ('0', 'wjgl');
INSERT INTO `ade_role_module` VALUES ('0', 'wjglUpload');
INSERT INTO `ade_role_module` VALUES ('0', 'wjglView');
INSERT INTO `ade_role_module` VALUES ('0', 'xtgl');
INSERT INTO `ade_role_module` VALUES ('0', 'yhgl');
INSERT INTO `ade_role_module` VALUES ('2DC54FCBD7BF46DBA92B8B2DE0392B27', 'yhgl');
INSERT INTO `ade_role_module` VALUES ('B99BC911F8E744F9B6B27A8604977713', 'yhgl');
INSERT INTO `ade_role_module` VALUES ('0', 'yhglAdd');
INSERT INTO `ade_role_module` VALUES ('0', 'yhglAddPage');
INSERT INTO `ade_role_module` VALUES ('0', 'yhglBatchDelete');
INSERT INTO `ade_role_module` VALUES ('0', 'yhglDateGrid');
INSERT INTO `ade_role_module` VALUES ('0', 'yhglDelete');
INSERT INTO `ade_role_module` VALUES ('0', 'yhglEdit');
INSERT INTO `ade_role_module` VALUES ('0', 'yhglEditPage');
INSERT INTO `ade_role_module` VALUES ('0', 'yhglEditPwd');
INSERT INTO `ade_role_module` VALUES ('0', 'yhglEditPwdPage');
INSERT INTO `ade_role_module` VALUES ('0', 'yhglGrant');
INSERT INTO `ade_role_module` VALUES ('0', 'yhglGrantPage');
INSERT INTO `ade_role_module` VALUES ('0', 'zygl');
INSERT INTO `ade_role_module` VALUES ('0', 'zyglAdd');
INSERT INTO `ade_role_module` VALUES ('0', 'zyglAddPage');
INSERT INTO `ade_role_module` VALUES ('0', 'zyglDelete');
INSERT INTO `ade_role_module` VALUES ('0', 'zyglEdit');
INSERT INTO `ade_role_module` VALUES ('0', 'zyglEditPage');
INSERT INTO `ade_role_module` VALUES ('0', 'zyglMenu');
INSERT INTO `ade_role_module` VALUES ('0', 'zyglTreeGrid');

-- ----------------------------
-- Table structure for ade_user
-- ----------------------------
DROP TABLE IF EXISTS `ade_user`;
CREATE TABLE `ade_user` (
  `ID` varchar(32) NOT NULL,
  `LOGIN_NAME` varchar(100) NOT NULL,
  `USER_NAME` varchar(50) DEFAULT NULL,
  `NAME_LETTER` varchar(10) DEFAULT NULL,
  `PASSWORD` varchar(100) NOT NULL,
  `SEX` varchar(2) DEFAULT NULL,
  `EMAIL` varchar(50) DEFAULT NULL,
  `TELE_PHONE` varchar(30) DEFAULT NULL,
  `USER_PHOTO` varchar(255) DEFAULT NULL,
  `MOBILE_PHONE` varchar(30) DEFAULT NULL,
  `USER_DESC` varchar(255) DEFAULT NULL,
  `USER_STATE` varchar(2) DEFAULT NULL,
  `CREATE_DATE` datetime DEFAULT NULL,
  `IP` text COMMENT '多个ip用;隔开',
  `AGENCY_FLAG` varchar(1) DEFAULT NULL,
  `UPDATE_DATE` datetime DEFAULT NULL,
  PRIMARY KEY (`ID`),
  UNIQUE KEY `UK_lub3dp8cwuw4mkn5e9nkw6c0i` (`LOGIN_NAME`) USING BTREE
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of ade_user
-- ----------------------------
INSERT INTO `ade_user` VALUES ('0', 'admin', '张三', 'Z', '21232f297a57a5a743894a0e4a801fc3', null, null, null, null, null, '', null, null, null, null, null);
INSERT INTO `ade_user` VALUES ('1F81D204CD1A4AB3B5E410CBE38EDCB3', 'edit1', 'edit1', 'E', 'e10adc3949ba59abbe56e057f20f883e', '女', 'xie@qq.com', '010-11011011', null, '13683151556', '', '1', '2016-05-11 16:00:47', '', null, '2016-05-11 18:12:33');
INSERT INTO `ade_user` VALUES ('348C768D5EB841B2AD51CBFDC5569799', '333333333333333333333333333', '', null, 'f2245ac72e6486b2d5c0a8b95bcab4b3', '男', '', '', null, '', '', '1', '2016-05-12 17:07:13', '', null, null);
INSERT INTO `ade_user` VALUES ('63F4339F9689474AB3AC97BADD392574', 'edit', '编辑者', 'B', 'e10adc3949ba59abbe56e057f20f883e', null, null, null, null, null, '', '1', '2016-05-10 15:10:40', null, null, null);
INSERT INTO `ade_user` VALUES ('831B54298A5548E7819997EE68089395', 'publish', '发布者', 'F', 'e10adc3949ba59abbe56e057f20f883e', null, '', '', null, '', '', '1', '2016-05-10 15:11:19', '', null, '2016-05-11 18:12:39');
INSERT INTO `ade_user` VALUES ('C44C32E76C8D43ECB9C24B98236C3FD7', 'audit', '审核者', 'S', 'e10adc3949ba59abbe56e057f20f883e', null, null, null, null, null, 'aaa', null, '2016-05-10 15:11:05', null, null, null);

-- ----------------------------
-- Table structure for ade_user_logs
-- ----------------------------
DROP TABLE IF EXISTS `ade_user_logs`;
CREATE TABLE `ade_user_logs` (
  `ID` varchar(36) NOT NULL,
  `CONTENT` varchar(255) NOT NULL,
  `IE_TYPE` varchar(36) NOT NULL,
  `IP` varchar(36) NOT NULL,
  `LOG_TYPE` varchar(60) NOT NULL,
  `OPERATE_TIME` datetime NOT NULL,
  `USER_ID` varchar(100) DEFAULT NULL,
  `VALUE1` varchar(100) DEFAULT NULL,
  `VALUE2` varchar(100) DEFAULT NULL,
  PRIMARY KEY (`ID`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of ade_user_logs
-- ----------------------------
INSERT INTO `ade_user_logs` VALUES ('000888F769B9453593672D0DD934F016', '标准管理:【修改】id为\"195\"的记录。', 'Chrome', '本地', '修改', '2016-05-12 10:18:59', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('00829F64E60445859A6754A8105CE64A', '标准管理:【审核】id为\"605\"的记录。', 'Chrome', '本地', '审核', '2016-05-10 15:33:54', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('00AC8C2BD6E04EE99654C65F963258AF', '疾病管理:【授权】id为\"56\"的记录。', 'MSIE 9.0', '本地', '授权', '2016-05-17 14:41:35', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('032DAFA6EDDF48E4B5F265E254B519E3', '疾病管理:【授权】id为\"e13b4e926d5141aa8473c314516bb044\"的记录。', 'Chrome', '本地', '授权', '2016-05-10 13:16:38', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('0336C134CBC8432495496D190A4E2F2E', '标准管理:【修改】id为\"14b59c3f76304480a108e46faf28b9f6\"的记录。', 'Chrome', '本地', '修改', '2016-05-10 18:27:54', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('037F83769A5B45DF8367DC8A382F00CA', '疾病管理:【修改】id为\"56\"的记录。', 'Chrome', '本地', '修改', '2016-05-17 17:54:23', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('03A950C3FA174D03A7CD9371FF3B579E', '疾病管理:【修改】id为\"57\"的记录。', 'Chrome', '本地', '修改', '2016-05-11 16:03:32', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('04CB5EDC0B404B73AEE689E11ACE4977', '标准管理:【修改】id为\"e745d12081ec4f58af7962a2ea6ba303\"的记录。', 'Chrome', '本地', '修改', '2016-05-10 18:16:45', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('0AD7AE2C0F7541AE879A603F926167CB', '标准管理:【审核】id为\"806156b61f1749558d416efb9b4819aa\"的记录。', 'Chrome', '本地', '审核', '2016-05-13 09:22:21', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('0CC42066BF3145FFAFAFF150DA74DF68', '标准管理:【提交审核】id为\"504c17409e934a358507741011c5a0e6\"的记录。', 'Chrome', '本地', '提交审核', '2016-05-13 09:52:56', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('116B6A68DA6F4DEAAA2CCABB3895544A', '标准管理:【修改】id为\"2338964a739f4e9d9f13b5f5cc1f26a2\"的记录。', 'Firefox', '本地', '修改', '2016-05-13 19:17:12', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('128F77395FFD4B178B752088D138318A', '标准管理:【审核】id为\"504c17409e934a358507741011c5a0e6\"的记录。', 'MSIE 10.0', '192.168.3.145', '审核', '2016-05-13 13:19:38', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('146A3905C7A640188C7BEB3793AE61B9', '标准管理:【增加】id为\"14b59c3f76304480a108e46faf28b9f6\"的记录。', 'Chrome', '本地', '增加', '2016-05-10 17:29:44', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('17C2FF263BFC43308333256E090F198B', '标准管理:【修改】id为\"504c17409e934a358507741011c5a0e6\"的记录。', 'Chrome', '本地', '修改', '2016-05-13 09:48:37', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('17F6A09945234136AE201BAA24D319CC', '标准管理:【修改】id为\"806156b61f1749558d416efb9b4819aa\"的记录。', 'MSIE 10.0', '192.168.3.145', '修改', '2016-05-13 13:59:31', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('1B579D826DF4465AA0E0C27FA2F36F1B', '标准管理:【增加】id为\"6073fb408b854b9b9fd4a1eb3a387487\"的记录。', 'Chrome', '本地', '增加', '2016-05-11 16:07:32', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('1BAECACCE0E448E784F23A9C30B983E5', '标准管理:【增加】id为\"8fc34696d353499caa5338477a047e7a\"的记录。', 'Chrome', '本地', '增加', '2016-05-10 18:51:52', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('1CDE3CC509404FD4BAFE27F2C36409E2', '标准管理:【修改】id为\"0e0f905d9f5244dda221521dec40a696\"的记录。', 'MSIE 9.0', '本地', '修改', '2016-05-19 11:43:09', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('1D4A142B9F6C4255A91C6D0720B90E86', '标准管理:【修改】id为\"34b2eca42c8740ad99341d639238d209\"的记录。', 'MSIE 10.0', '192.168.3.145', '修改', '2016-05-13 14:00:10', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('2454937D2AAA4090AEE6AD4ABE0782E7', '标准管理:【修改】id为\"504c17409e934a358507741011c5a0e6\"的记录。', 'Firefox', '本地', '修改', '2016-05-13 19:19:51', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('2483689A827545C9A7230149ECB27812', '标准管理:【修改】id为\"9b57a007ab8343d49db15caaa455ab2a\"的记录。', 'MSIE 9.0', '本地', '修改', '2016-05-13 16:28:27', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('26E25D1E73CC4A3EBA5E14C9A1F7B198', '标准管理:【修改】id为\"195\"的记录。', 'Chrome', '本地', '修改', '2016-05-12 10:20:08', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('26EF6F8CD6E740CABC44E803C9473F85', '标准管理:【修改】id为\"806156b61f1749558d416efb9b4819aa\"的记录。', 'MSIE 9.0', '本地', '修改', '2016-05-13 15:59:59', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('27BBE61236934BEAA2F1F5DF99551055', '标准管理:【发布】id为\"806156b61f1749558d416efb9b4819aa\"的记录。', 'Chrome', '本地', '发布', '2016-05-12 13:16:05', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('28949112459B401494047FE020787C22', '疾病管理:【增加】id为\"743cc405da304af58a4fc0a82e48f8f8\"的记录。', 'Chrome', '本地', '增加', '2016-05-10 13:40:03', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('30F65E6F2D984DF69B8675C3461CCA22', '标准管理:【修改】id为\"195\"的记录。', 'Chrome', '本地', '修改', '2016-05-12 10:34:45', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('315C9B400E4944CDB063D554C49C27E3', '标准管理:【发布】id为\"194\"的记录。', 'Chrome', '本地', '发布', '2016-05-11 16:28:29', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('31F922377AAB4218983C91933D5F5CE3', '标准管理:【审核】id为\"194\"的记录。', 'Chrome', '本地', '审核', '2016-05-11 16:28:25', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('3232392C8B4B409BA1885984F0A8F27E', '标准管理:【提交审核】id为\"504c17409e934a358507741011c5a0e6\"的记录。', 'Chrome', '本地', '提交审核', '2016-05-13 09:46:24', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('32BBA17AD76941BD947831010C0F0DAF', '疾病管理:【授权】id为\"56\"的记录。', 'Chrome', '本地', '授权', '2016-05-10 15:12:18', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('33CC5ADE79BC469B95475A010D1079EE', '标准管理:【发布】id为\"806156b61f1749558d416efb9b4819aa\"的记录。', 'Chrome', '本地', '发布', '2016-05-13 09:21:55', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('3597309583504A9AAEC890CEFA082318', '疾病管理:【增加】id为\"d645ea8e2fbb4beaa2f3aede222d74a6\"的记录。', 'Chrome', '本地', '增加', '2016-05-10 14:45:29', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('389B49302BF34C7E9F1595180F8B6A81', '标准管理:【增加】id为\"5fdcd0b62cf24d6894c253b05edb6bae\"的记录。', 'MSIE 9.0', '本地', '增加', '2016-05-13 16:28:43', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('3E15127F767745719BE526CABE7A7AD5', '标准管理:【修改】id为\"14b59c3f76304480a108e46faf28b9f6\"的记录。', 'Chrome', '本地', '修改', '2016-05-10 18:26:33', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('3F776594B4E54933BFC5EBFCE2431B85', '标准管理:【修改】id为\"8fc34696d353499caa5338477a047e7a\"的记录。', 'Chrome', '本地', '修改', '2016-05-10 18:52:54', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('40C691B482A9461E804F35950A8FE772', '疾病管理:【修改】id为\"3\"的记录。', 'MSIE 10.0', '192.168.3.145', '修改', '2016-05-11 17:27:19', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('4207C2F5D85A499DB79DB0FC22F56714', '标准管理:【增加】id为\"504c17409e934a358507741011c5a0e6\"的记录。', 'MSIE 9.0', '本地', '增加', '2016-05-12 20:21:43', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('47640D3270424AB8BAE92C6B42E490F9', '标准管理:【修改】id为\"607\"的记录。', 'Chrome', '本地', '修改', '2016-05-10 18:06:40', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('4C53F8A63544413187F24C4D1C72FCA3', '疾病管理:【增加】id为\"870a95fa921b42449ed7ae28607256e8\"的记录。', 'Chrome', '本地', '增加', '2016-05-10 13:24:41', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('4EEE6EDA40724D7C98E88F55AE84B850', '标准管理:【增加】id为\"ad22746ef39f4e3c90898a8f20d51001\"的记录。', 'Chrome', '本地', '增加', '2016-05-10 17:28:12', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('505F3B23C2234593BF9A5D4AFCB2CBBB', '标准管理:【增加】id为\"f44b3b54c20b425b86a8ff55975f1737\"的记录。', 'Chrome', '本地', '增加', '2016-05-11 16:07:08', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('51521619C8194FD28F83415306E092A6', '标准管理:【修改】id为\"195\"的记录。', 'Chrome', '本地', '修改', '2016-05-12 10:23:02', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('51AAB392E5054F94A1629E38D1129CD1', '标准管理:【修改】id为\"a3f6f81502e74ebb9b8b5403a419f4d2\"的记录。', 'Chrome', '本地', '修改', '2016-05-11 11:45:15', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('52FBAE9F752A4320ABC9448851ABF97A', '标准管理:【修改】id为\"9d5dff3294b948259a559b8f6f577f7f\"的记录。', 'Chrome', '本地', '修改', '2016-05-13 16:05:12', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('5ACB2D623B9D44ED8F28645D87DD2F77', '疾病管理:【修改】id为\"1\"的记录。', 'Chrome', '本地', '修改', '2016-05-10 15:29:14', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('5C8ABD1DE40A417AA892D6A4154E369E', '标准管理:【审核】id为\"806156b61f1749558d416efb9b4819aa\"的记录。', 'Chrome', '本地', '审核', '2016-05-13 09:22:59', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('5D56653F901B4A2CA0CAE533CD05FCAD', '标准管理:【修改】id为\"5fdcd0b62cf24d6894c253b05edb6bae\"的记录。', 'Firefox', '本地', '修改', '2016-05-13 19:14:50', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('5F483C82F4A145A28D6300E116BCF9C5', '标准管理:【增加】id为\"806156b61f1749558d416efb9b4819aa\"的记录。', 'Chrome', '本地', '增加', '2016-05-11 16:17:09', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('607BC990A38E476486375B5D0AA20EC8', '标准管理:【修改】id为\"0e0f905d9f5244dda221521dec40a696\"的记录。', 'MSIE 9.0', '本地', '修改', '2016-05-19 11:46:09', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('60D70E2830994643A1A1BF7B754D16AC', '标准管理:【修改】id为\"504c17409e934a358507741011c5a0e6\"的记录。', 'Chrome', '本地', '修改', '2016-05-17 16:38:48', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('62AE83B2B4BA47C1A1F8B008D32632FC', '标准管理:【审核】id为\"b17bd00f17304df5bf37f6ec0badf08a\"的记录。', 'Chrome', '本地', '审核', '2016-05-10 18:41:47', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('6561B20988BB45F1BC7C78659DBF3F30', '标准管理:【提交审核】id为\"532\"的记录。', 'Chrome', '本地', '提交审核', '2016-05-10 15:12:49', '编辑者', null, null);
INSERT INTO `ade_user_logs` VALUES ('69D0BACEABF945C0BEF39D1D7243BD7C', '疾病管理:【授权】id为\"1\"的记录。', 'Firefox', '本地', '授权', '2016-05-17 14:39:34', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('6C2DA70001DD4536844047A07D9ECAF8', '标准管理:【修改】id为\"504c17409e934a358507741011c5a0e6\"的记录。', 'Firefox', '本地', '修改', '2016-05-13 19:18:51', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('6C68A6AF7A1F460B9F8D7050CD657B37', '标准管理:【增加】id为\"98c5c256b698474fbebce8bcc3e7fd31\"的记录。', 'MSIE 10.0', '192.168.3.145', '增加', '2016-05-13 14:04:37', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('6C8AE6068A2743C68B717936A7BD6E56', '标准管理:【增加】id为\"9d5dff3294b948259a559b8f6f577f7f\"的记录。', 'Chrome', '本地', '增加', '2016-05-12 13:10:08', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('6D5F2436B9314D08B903E21169BBD93D', '疾病管理:【修改】id为\"2\"的记录。', 'Chrome', '本地', '修改', '2016-05-10 15:29:23', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('6E7065E00E744112BE586593510EECE4', '标准管理:【发布】id为\"b17bd00f17304df5bf37f6ec0badf08a\"的记录。', 'Chrome', '本地', '发布', '2016-05-10 18:41:52', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('6FD21251E8784838B276FF8A8C0E71D7', '标准管理:【修改】id为\"0e0f905d9f5244dda221521dec40a696\"的记录。', 'MSIE 9.0', '本地', '修改', '2016-05-19 11:45:02', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('70AB0C3DE0E746FCA4E30415E39BAF1D', '标准管理:【撤销发布】id为\"9d5dff3294b948259a559b8f6f577f7f\"的记录。', 'Chrome', '本地', '撤销发布', '2016-05-12 13:22:54', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('713A02D4FBBF4A2C8BE0F2AEB352EC57', '标准管理:【修改】id为\"0e0f905d9f5244dda221521dec40a696\"的记录。', 'Firefox', '本地', '修改', '2016-05-13 19:16:54', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('73454CC6602B4EE085BCDBFF43A182D8', '标准管理:【修改】id为\"0e0f905d9f5244dda221521dec40a696\"的记录。', 'MSIE 9.0', '本地', '修改', '2016-05-19 11:50:25', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('760C17656C0142F3BE6BED3649A13CD7', '标准管理:【修改】id为\"195\"的记录。', 'Chrome', '本地', '修改', '2016-05-12 09:20:52', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('7B1E883268BD45D485CBF5958975FEAB', '标准管理:【修改】id为\"34b2eca42c8740ad99341d639238d209\"的记录。', 'MSIE 10.0', '192.168.3.145', '修改', '2016-05-13 14:01:01', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('7ED7CED626EB47F1AD100C04A7B34EBF', '疾病管理:【增加】id为\"e13b4e926d5141aa8473c314516bb044\"的记录。', 'Chrome', '本地', '增加', '2016-05-10 13:16:16', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('844DB30259184EC98FD2A1F59F9E5A95', '标准管理:【发布】id为\"9d5dff3294b948259a559b8f6f577f7f\"的记录。', 'Chrome', '本地', '发布', '2016-05-12 13:21:42', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('88BBA209B6794144B0FB4125AA66599A', '标准管理:【修改】id为\"0e0f905d9f5244dda221521dec40a696\"的记录。', 'MSIE 9.0', '本地', '修改', '2016-05-19 11:45:10', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('8DE774DE612843FF9356D3638F61D2A1', '标准管理:【增加】id为\"9b57a007ab8343d49db15caaa455ab2a\"的记录。', 'MSIE 9.0', '本地', '增加', '2016-05-13 16:28:19', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('95A27D5D6D0F468781E9F712536D750A', '标准管理:【从回收站还原】id为\"194\"的记录。', 'Chrome', '本地', '从回收站还原', '2016-05-12 09:19:53', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('95C4E80843514066B3520A513C793303', '标准管理:【修改】id为\"14b59c3f76304480a108e46faf28b9f6\"的记录。', 'Chrome', '本地', '修改', '2016-05-10 18:28:27', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('9ACCF2666FC843D3BEFF3196B7756FD1', '标准管理:【撤销发布】id为\"806156b61f1749558d416efb9b4819aa\"的记录。', 'Chrome', '本地', '撤销发布', '2016-05-13 09:23:23', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('9C73B483770345A39E7974D6BF38C8E7', '标准管理:【审核】id为\"607\"的记录。', 'Chrome', '本地', '审核', '2016-05-11 10:43:00', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('9DB5946DDB194A9F85C74F50E474790B', '标准管理:【修改】id为\"e745d12081ec4f58af7962a2ea6ba303\"的记录。', 'Chrome', '本地', '修改', '2016-05-10 18:17:58', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('9F1434E9A992441D98A3822A578008C6', '标准管理:【审核】id为\"806156b61f1749558d416efb9b4819aa\"的记录。', 'Chrome', '本地', '审核', '2016-05-12 12:53:02', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('9F40B44606E94E03B634438AC4440477', '标准管理:【增加】id为\"2338964a739f4e9d9f13b5f5cc1f26a2\"的记录。', 'Firefox', '本地', '增加', '2016-05-13 19:14:17', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('A0B5A70226CD474983DB3554DCDF53A2', '标准管理:【提交审核】id为\"605\"的记录。', 'Chrome', '本地', '提交审核', '2016-05-10 15:33:56', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('A15917D6C69640C6B06F681F4169F5C8', '标准管理:【删除到回收站】id为\"194\"的记录。', 'Chrome', '本地', '删除到回收站', '2016-05-12 09:19:47', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('A28CE4D038784C5AB2FFC52D07D0C14B', '标准管理:【修改】id为\"14b59c3f76304480a108e46faf28b9f6\"的记录。', 'Chrome', '本地', '修改', '2016-05-10 18:15:51', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('A564115B421B48C082D62A411E5608EF', '标准管理:【提交审核】id为\"605\"的记录。', 'Chrome', '本地', '提交审核', '2016-05-10 15:33:46', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('A685B45510E54BB4A060A6143ECCED01', '标准管理:【增加】id为\"b17bd00f17304df5bf37f6ec0badf08a\"的记录。', 'Chrome', '本地', '增加', '2016-05-10 17:29:55', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('A8EB812794294407A0DF77CCC807C809', '疾病管理:【修改】id为\"870a95fa921b42449ed7ae28607256e8\"的记录。', 'MSIE 10.0', '192.168.3.145', '修改', '2016-05-11 17:28:46', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('A926E3DF1AE74E399D685FBA07903A50', '标准管理:【提交审核】id为\"9d5dff3294b948259a559b8f6f577f7f\"的记录。', 'Chrome', '本地', '提交审核', '2016-05-12 13:10:11', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('A95D1CEB7DB24D9EBA01E01945A86DC5', '标准管理:【提交审核】id为\"194\"的记录。', 'Chrome', '本地', '提交审核', '2016-05-11 16:28:21', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('AA346DAF75EA488FBE8E50199761975B', '标准管理:【增加】id为\"502dcfc4e01c4b2c81b391b772eb6b1a\"的记录。', 'Chrome', '本地', '增加', '2016-05-10 18:52:30', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('AD8A580F63D947BEA22AD360A0D25EFE', '标准管理:【修改】id为\"195\"的记录。', 'Chrome', '本地', '修改', '2016-05-12 10:15:57', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('B070611BED1C42B284A18311ADED2AFD', '标准管理:【增加】id为\"b1e2d7ffbb4f48698a19d5e269194636\"的记录。', 'Chrome', '本地', '增加', '2016-05-11 16:14:11', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('B0811AE8902549B790551539382D751C', '标准管理:【发布】id为\"806156b61f1749558d416efb9b4819aa\"的记录。', 'Chrome', '本地', '发布', '2016-05-13 09:23:05', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('B5394FCA707C48E08ADEDB9E2CC32435', '标准管理:【提交审核】id为\"a3f6f81502e74ebb9b8b5403a419f4d2\"的记录。', 'Chrome', '本地', '提交审核', '2016-05-10 15:12:46', '编辑者', null, null);
INSERT INTO `ade_user_logs` VALUES ('B756EC423E28465CA956DE9A48C8A2A2', '标准管理:【修改】id为\"f44b3b54c20b425b86a8ff55975f1737\"的记录。', 'Chrome', '本地', '修改', '2016-05-11 16:14:28', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('B9826E8F65FB42CCA57EBF7C3D6F4751', '标准管理:【审核】id为\"9d5dff3294b948259a559b8f6f577f7f\"的记录。', 'Chrome', '本地', '审核', '2016-05-12 13:21:24', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('BA2CB169D1AD457EBFC285235598B22E', '疾病管理:【增加】id为\"0ad8f18c39e14b1d892ee0bc6a7e3f24\"的记录。', 'Chrome', '本地', '增加', '2016-05-11 16:03:58', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('BADEE2F15B764F6589931DC5AF22E745', '标准管理:【修改】id为\"806156b61f1749558d416efb9b4819aa\"的记录。', 'Chrome', '本地', '修改', '2016-05-13 09:56:20', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('BD4611B1B992455FB6F3AEDF1816F88B', '标准管理:【修改】id为\"195\"的记录。', 'Chrome', '本地', '修改', '2016-05-12 10:31:30', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('C4093DCBE1E24D508493D9B56243E8B3', '标准管理:【发布】id为\"194\"的记录。', 'Chrome', '本地', '发布', '2016-05-11 16:28:40', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('C488F4FCA30C44DA8F456795CC2BFA13', '标准管理:【审核】id为\"a3f6f81502e74ebb9b8b5403a419f4d2\"的记录。', 'Chrome', '本地', '审核', '2016-05-10 15:13:10', '审核者', null, null);
INSERT INTO `ade_user_logs` VALUES ('C552E1D893684D17A056A274817B3949', '标准管理:【发布】id为\"806156b61f1749558d416efb9b4819aa\"的记录。', 'Chrome', '本地', '发布', '2016-05-13 09:22:32', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('C6357B0737D84C50BCA46E97D7AACB17', '标准管理:【增加】id为\"e745d12081ec4f58af7962a2ea6ba303\"的记录。', 'Chrome', '本地', '增加', '2016-05-10 17:28:31', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('C6BDBEA1E6614CE1ACC7CE66EE62B4E1', '标准管理:【提交审核】id为\"806156b61f1749558d416efb9b4819aa\"的记录。', 'Chrome', '本地', '提交审核', '2016-05-12 11:11:34', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('CAAC564B7CC747FEBCE11BF50EC36B3A', '疾病管理:【修改】id为\"870a95fa921b42449ed7ae28607256e8\"的记录。', 'MSIE 10.0', '192.168.3.145', '修改', '2016-05-11 17:29:06', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('D0EEF00F916F41F4B11125EC35A7F572', '标准管理:【提交审核】id为\"607\"的记录。', 'Chrome', '本地', '提交审核', '2016-05-11 10:42:54', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('D12D40D7840E42B0A79BFB3EE9ECB1B1', '疾病管理:【增加】id为\"93c7f31d31364f1e87d32a5233629036\"的记录。', 'MSIE 9.0', '本地', '增加', '2016-05-13 15:45:47', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('D1E254E2BFA740F39E9550E5476863A0', '标准管理:【审核】id为\"34b2eca42c8740ad99341d639238d209\"的记录。', 'MSIE 10.0', '192.168.3.145', '审核', '2016-05-13 13:19:01', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('DB04029B99144A74821B07150D4B946B', '标准管理:【增加】id为\"08072c965e694f5080605351a1e3ddfd\"的记录。', 'MSIE 10.0', '192.168.3.145', '增加', '2016-05-11 17:43:20', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('DF9402B954B74D669B162A0EAAE50E4F', '标准管理:【修改】id为\"504c17409e934a358507741011c5a0e6\"的记录。', 'MSIE 10.0', '192.168.3.145', '修改', '2016-05-13 13:17:25', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('E1C45BAA9FB748DEBD89902F04A9A0B2', '标准管理:【撤销发布】id为\"806156b61f1749558d416efb9b4819aa\"的记录。', 'Chrome', '本地', '撤销发布', '2016-05-12 13:16:19', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('E5FB4D3809834097A3F15F215D810C28', '标准管理:【修改】id为\"806156b61f1749558d416efb9b4819aa\"的记录。', 'Chrome', '本地', '修改', '2016-05-12 16:07:18', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('E6AE8C4B23624FD2ACFE3E507B146D01', '标准管理:【撤销发布】id为\"194\"的记录。', 'Chrome', '本地', '撤销发布', '2016-05-11 16:28:33', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('EE2710CF5033481DA647AB4A576A26DE', '标准管理:【增加】id为\"34b2eca42c8740ad99341d639238d209\"的记录。', 'Chrome', '本地', '增加', '2016-05-12 16:10:47', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('EE2A57CE1744431EB6C1DA7FAE0169DF', '标准管理:【修改】id为\"2338964a739f4e9d9f13b5f5cc1f26a2\"的记录。', 'Firefox', '本地', '修改', '2016-05-13 19:15:11', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('EEB91D7CB780401A8A8B63E114B952DF', '标准管理:【修改】id为\"504c17409e934a358507741011c5a0e6\"的记录。', 'Firefox', '本地', '修改', '2016-05-13 19:19:19', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('EFE9AB57C95045EE9B4B779C737B4048', '标准管理:【增加】id为\"0e0f905d9f5244dda221521dec40a696\"的记录。', 'Firefox', '本地', '增加', '2016-05-13 19:16:45', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('F17A6B73FD0044E28AED4464D2E62634', '标准管理:【修改】id为\"195\"的记录。', 'Chrome', '本地', '修改', '2016-05-12 10:21:05', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('F283943C6681492EA7C6C5F185915568', '标准管理:【修改】id为\"34b2eca42c8740ad99341d639238d209\"的记录。', 'MSIE 10.0', '192.168.3.145', '修改', '2016-05-13 14:01:48', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('FA016FA4173B4BE49C3BEFBB90DC209F', '标准管理:【修改】id为\"194\"的记录。', 'MSIE 10.0', '192.168.3.145', '修改', '2016-05-11 17:43:45', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('FAEF050D606342C6AFC8EAEE8009D56A', '标准管理:【增加】id为\"584a1c2a835a40ccad58ff670e1ee41c\"的记录。', 'Chrome', '本地', '增加', '2016-05-13 09:58:03', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('FB817124DE834D84903BCC6811DEFCCC', '标准管理:【修改】id为\"0e0f905d9f5244dda221521dec40a696\"的记录。', 'MSIE 9.0', '本地', '修改', '2016-05-19 11:51:31', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('FCDFD9D798B341ECB89F50E7E40DB899', '标准管理:【修改】id为\"504c17409e934a358507741011c5a0e6\"的记录。', 'Firefox', '本地', '修改', '2016-05-13 19:19:05', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('FE58A08CCE004187A0EBEAA220D5001E', '标准管理:【修改】id为\"195\"的记录。', 'Chrome', '本地', '修改', '2016-05-12 10:14:30', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('FEC158232B714876AE34F87E3E0375DA', '标准管理:【增加】id为\"abfd7bb30dc040e28e8a860cf6ce965e\"的记录。', 'Chrome', '本地', '增加', '2016-05-10 19:29:36', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('FEE8FBD4C4CD40A89919864AADA73262', '疾病管理:【授权】id为\"56\"的记录。', 'MSIE 9.0', '本地', '授权', '2016-05-17 14:41:14', '张三', null, null);
INSERT INTO `ade_user_logs` VALUES ('FF974034EB9A44C88EA2E0B09BEAFD1F', '标准管理:【提交审核】id为\"34b2eca42c8740ad99341d639238d209\"的记录。', 'MSIE 9.0', '本地', '提交审核', '2016-05-12 16:56:53', '张三', null, null);

-- ----------------------------
-- Table structure for ade_user_role
-- ----------------------------
DROP TABLE IF EXISTS `ade_user_role`;
CREATE TABLE `ade_user_role` (
  `USER_ID` varchar(32) NOT NULL,
  `ROLE_ID` varchar(32) NOT NULL,
  PRIMARY KEY (`ROLE_ID`,`USER_ID`),
  KEY `FK_8vmilpq0v3wkfbw2jiwl5h2jy` (`ROLE_ID`) USING BTREE,
  KEY `FK_fb1o8fuyirvvk9t5g7e4v0o5f` (`USER_ID`) USING BTREE,
  CONSTRAINT `ade_user_role_ibfk_1` FOREIGN KEY (`ROLE_ID`) REFERENCES `ade_role` (`ID`),
  CONSTRAINT `ade_user_role_ibfk_2` FOREIGN KEY (`USER_ID`) REFERENCES `ade_user` (`ID`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of ade_user_role
-- ----------------------------
INSERT INTO `ade_user_role` VALUES ('0', '0');

-- ----------------------------
-- Table structure for biz_attach_standard
-- ----------------------------
DROP TABLE IF EXISTS `biz_attach_standard`;
CREATE TABLE `biz_attach_standard` (
  `id` varchar(32) NOT NULL COMMENT '主键UUID',
  `standard_id` varchar(32) DEFAULT NULL COMMENT '标准id',
  `name` varchar(500) DEFAULT NULL COMMENT '附件名称',
  `url` varchar(500) DEFAULT NULL COMMENT '附件url(时间分隔路径)，固定盘符下',
  `size` varchar(50) DEFAULT NULL COMMENT '附件大小',
  `order_num` int(11) DEFAULT '0' COMMENT '排序号',
  `create_user` varchar(32) DEFAULT NULL COMMENT '上传人',
  `create_time` datetime DEFAULT NULL COMMENT '上传时间',
  PRIMARY KEY (`id`),
  KEY `standard_id` (`standard_id`) USING BTREE,
  CONSTRAINT `biz_attach_standard_ibfk_1` FOREIGN KEY (`standard_id`) REFERENCES `biz_standard` (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of biz_attach_standard
-- ----------------------------
INSERT INTO `biz_attach_standard` VALUES ('24545298651023176', '08072c965e694f5080605351a1e3ddfd', '北京市海淀区中关村东路清华科技园搜狐网络大厦北京市海淀区中关村东路的清华科技园搜狐网络大厦中关村东路.pdf', 'images/standard/2016/4/12/北京市海淀区中关村东路清华科技园搜狐网络大厦北京市海淀区中关村东路的清华科技园搜狐网络大厦中关村东路.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023177', '14b59c3f76304480a108e46faf28b9f6', 'aaaa.pdf', 'images/standard/2016/4/12/aaaa.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023178', '502dcfc4e01c4b2c81b391b772eb6b1a', 'addd.pdf', 'images/standard/2016/4/12/addd.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023179', '6073fb408b854b9b9fd4a1eb3a387487', 'bbb.pdf', 'images/standard/2016/4/12/bbb.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023181', '8fc34696d353499caa5338477a047e7a', '序号1.pdf', 'images/standard/2016/4/12/序号1.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023182', 'a3f6f81502e74ebb9b8b5403a419f4d2', 'bb.pdf', 'images/standard/2016/4/12/bb.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023183', 'abd594b94bf7494681d61494728af7ab', 'aaaaa.pdf', 'images/standard/2016/4/12/aaaaa.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023184', 'abfd7bb30dc040e28e8a860cf6ce965e', 'adf.pdf', 'images/standard/2016/4/12/adf.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023185', 'ad22746ef39f4e3c90898a8f20d51001', 'adfad.pdf', 'images/standard/2016/4/12/adfad.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023186', 'b17bd00f17304df5bf37f6ec0badf08a', 'aaaaa.pdf', 'images/standard/2016/4/12/aaaaa.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023187', 'b1e2d7ffbb4f48698a19d5e269194636', 'dd.pdf', 'images/standard/2016/4/12/dd.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023188', 'e745d12081ec4f58af7962a2ea6ba303', 'aaa.pdf', 'images/standard/2016/4/12/aaa.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023189', 'f44b3b54c20b425b86a8ff55975f1737', 'aa.pdf', 'images/standard/2016/4/12/aa.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023190', '1', 'D02_001.pdf', 'images/standard/2016/4/12/D02_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023191', '10', 'D02_010.pdf', 'images/standard/2016/4/12/D02_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023192', '100', 'R01_001.pdf', 'images/standard/2016/4/12/R01_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023193', '101', 'R01_002.pdf', 'images/standard/2016/4/12/R01_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023194', '102', 'R01_003.pdf', 'images/standard/2016/4/12/R01_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023195', '103', 'R01_004.pdf', 'images/standard/2016/4/12/R01_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023196', '104', 'Q01_001.pdf', 'images/standard/2016/4/12/Q01_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023197', '105', 'Q01_002.pdf', 'images/standard/2016/4/12/Q01_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023198', '106', 'Q01_003.pdf', 'images/standard/2016/4/12/Q01_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023199', '107', 'Q01_004.pdf', 'images/standard/2016/4/12/Q01_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023200', '108', 'Q01_005.pdf', 'images/standard/2016/4/12/Q01_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023201', '109', 'Q01_006.pdf', 'images/standard/2016/4/12/Q01_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023202', '11', 'D02_011.pdf', 'images/standard/2016/4/12/D02_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023203', '110', 'Q01_007.pdf', 'images/standard/2016/4/12/Q01_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023204', '111', 'M02_001.pdf', 'images/standard/2016/4/12/M02_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023205', '112', 'M02_002.pdf', 'images/standard/2016/4/12/M02_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023206', '113', 'M02_003.pdf', 'images/standard/2016/4/12/M02_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023207', '114', 'M02_004.pdf', 'images/standard/2016/4/12/M02_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023208', '115', 'M02_005.pdf', 'images/standard/2016/4/12/M02_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023209', '116', 'M02_006.pdf', 'images/standard/2016/4/12/M02_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023210', '117', 'M02_007.pdf', 'images/standard/2016/4/12/M02_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023211', '118', 'M02_008.pdf', 'images/standard/2016/4/12/M02_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023212', '119', 'M02_009.pdf', 'images/standard/2016/4/12/M02_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023213', '12', 'D02_012.pdf', 'images/standard/2016/4/12/D02_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023214', '120', 'M02_010.pdf', 'images/standard/2016/4/12/M02_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023215', '121', 'M02_011.pdf', 'images/standard/2016/4/12/M02_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023216', '122', 'M02_012.pdf', 'images/standard/2016/4/12/M02_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023217', '123', 'M02_013.pdf', 'images/standard/2016/4/12/M02_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023218', '124', 'M02_014.pdf', 'images/standard/2016/4/12/M02_014.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023219', '125', 'M02_015.pdf', 'images/standard/2016/4/12/M02_015.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023220', '126', 'M02_016.pdf', 'images/standard/2016/4/12/M02_016.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023221', '127', 'M02_017.pdf', 'images/standard/2016/4/12/M02_017.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023222', '128', 'M02_018.pdf', 'images/standard/2016/4/12/M02_018.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023223', '129', 'M02_019.pdf', 'images/standard/2016/4/12/M02_019.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023224', '13', 'G02_001.pdf', 'images/standard/2016/4/12/G02_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023225', '130', 'M02_020.pdf', 'images/standard/2016/4/12/M02_020.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023226', '131', 'M02_021.pdf', 'images/standard/2016/4/12/M02_021.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023227', '132', 'M02_022.pdf', 'images/standard/2016/4/12/M02_022.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023228', '133', 'M02_023.pdf', 'images/standard/2016/4/12/M02_023.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023229', '134', 'M02_024.pdf', 'images/standard/2016/4/12/M02_024.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023230', '135', 'M02_025.pdf', 'images/standard/2016/4/12/M02_025.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023231', '136', 'M07_001.pdf', 'images/standard/2016/4/12/M07_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023232', '137', 'M07_002.pdf', 'images/standard/2016/4/12/M07_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023233', '138', 'M07_003.pdf', 'images/standard/2016/4/12/M07_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023234', '139', 'M07_004.pdf', 'images/standard/2016/4/12/M07_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023235', '14', 'G02_002.pdf', 'images/standard/2016/4/12/G02_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023236', '140', 'M07_005.pdf', 'images/standard/2016/4/12/M07_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023237', '141', 'M07_006.pdf', 'images/standard/2016/4/12/M07_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023238', '142', 'M07_007.pdf', 'images/standard/2016/4/12/M07_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023239', '143', 'M07_008.pdf', 'images/standard/2016/4/12/M07_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023240', '144', 'X01_001.pdf', 'images/standard/2016/4/12/X01_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023241', '145', 'X01_002.pdf', 'images/standard/2016/4/12/X01_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023242', '146', 'X01_003.pdf', 'images/standard/2016/4/12/X01_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023243', '147', 'X01_004.pdf', 'images/standard/2016/4/12/X01_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023244', '148', 'X01_005.pdf', 'images/standard/2016/4/12/X01_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023245', '149', 'X01_006.pdf', 'images/standard/2016/4/12/X01_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023246', '15', 'G02_003.pdf', 'images/standard/2016/4/12/G02_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023247', '150', 'X01_007.pdf', 'images/standard/2016/4/12/X01_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023248', '151', 'X01_008.pdf', 'images/standard/2016/4/12/X01_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023249', '152', 'X01_009.pdf', 'images/standard/2016/4/12/X01_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023250', '153', 'X01_010.pdf', 'images/standard/2016/4/12/X01_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023251', '154', 'X01_011.pdf', 'images/standard/2016/4/12/X01_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023252', '155', 'X01_012.pdf', 'images/standard/2016/4/12/X01_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023253', '156', 'X01_013.pdf', 'images/standard/2016/4/12/X01_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023254', '157', 'X01_014.pdf', 'images/standard/2016/4/12/X01_014.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023255', '158', 'X01_015.pdf', 'images/standard/2016/4/12/X01_015.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023256', '159', 'X01_016.pdf', 'images/standard/2016/4/12/X01_016.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023257', '16', 'G02_004.pdf', 'images/standard/2016/4/12/G02_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023258', '160', 'X01_017.pdf', 'images/standard/2016/4/12/X01_017.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023259', '161', 'X01_018.pdf', 'images/standard/2016/4/12/X01_018.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023260', '162', 'X01_019.pdf', 'images/standard/2016/4/12/X01_019.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023261', '163', 'X01_020.pdf', 'images/standard/2016/4/12/X01_020.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023262', '164', 'X01_021.pdf', 'images/standard/2016/4/12/X01_021.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023263', '165', 'X01_022.pdf', 'images/standard/2016/4/12/X01_022.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023264', '166', 'X01_023.pdf', 'images/standard/2016/4/12/X01_023.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023265', '167', 'X01_024.pdf', 'images/standard/2016/4/12/X01_024.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023266', '168', 'X01_025.pdf', 'images/standard/2016/4/12/X01_025.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023267', '169', 'X01_026.pdf', 'images/standard/2016/4/12/X01_026.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023268', '17', 'G02_005_E.pdf', 'images/standard/2016/4/12/G02_005_E.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023269', '170', 'X01_027.pdf', 'images/standard/2016/4/12/X01_027.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023270', '171', 'X01_028.pdf', 'images/standard/2016/4/12/X01_028.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023271', '172', 'X01_029.pdf', 'images/standard/2016/4/12/X01_029.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023272', '173', 'X01_030.pdf', 'images/standard/2016/4/12/X01_030.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023273', '174', 'X01_031.pdf', 'images/standard/2016/4/12/X01_031.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023274', '175', 'X01_032.pdf', 'images/standard/2016/4/12/X01_032.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023275', '176', 'X01_033.pdf', 'images/standard/2016/4/12/X01_033.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023276', '177', 'X01_034.pdf', 'images/standard/2016/4/12/X01_034.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023277', '178', 'X01_035.pdf', 'images/standard/2016/4/12/X01_035.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023278', '179', 'X01_036.pdf', 'images/standard/2016/4/12/X01_036.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023279', '18', 'G02_005_C.pdf', 'images/standard/2016/4/12/G02_005_C.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023280', '180', 'X01_037.pdf', 'images/standard/2016/4/12/X01_037.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023281', '181', 'X01_038.pdf', 'images/standard/2016/4/12/X01_038.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023282', '182', 'X01_039.pdf', 'images/standard/2016/4/12/X01_039.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023283', '183', 'X01_040.pdf', 'images/standard/2016/4/12/X01_040.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023284', '184', 'X01_041.pdf', 'images/standard/2016/4/12/X01_041.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023285', '185', 'X01_042.pdf', 'images/standard/2016/4/12/X01_042.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023286', '186', 'X01_043.pdf', 'images/standard/2016/4/12/X01_043.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023287', '187', 'X01_044.pdf', 'images/standard/2016/4/12/X01_044.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023288', '188', 'X01_045.pdf', 'images/standard/2016/4/12/X01_045.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023289', '189', 'X01_046.pdf', 'images/standard/2016/4/12/X01_046.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023290', '19', 'G02_007.pdf', 'images/standard/2016/4/12/G02_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023291', '190', 'X01_047.pdf', 'images/standard/2016/4/12/X01_047.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023292', '191', 'X01_048.pdf', 'images/standard/2016/4/12/X01_048.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023293', '192', 'X01_049.pdf', 'images/standard/2016/4/12/X01_049.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023294', '193', 'X01_050.pdf', 'images/standard/2016/4/12/X01_050.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023295', '194', 'T01_001.pdf', 'images/standard/2016/4/12/T01_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023296', '195', 'T01_002.pdf', 'images/standard/2016/4/12/T01_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023297', '196', 'T01_003.pdf', 'images/standard/2016/4/12/T01_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023298', '197', 'T01_004.pdf', 'images/standard/2016/4/12/T01_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023299', '198', 'T01_005.pdf', 'images/standard/2016/4/12/T01_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023300', '199', 'T01_006.pdf', 'images/standard/2016/4/12/T01_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023301', '2', 'D02_002.pdf', 'images/standard/2016/4/12/D02_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023302', '20', 'G02_008.pdf', 'images/standard/2016/4/12/G02_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023303', '200', 'T01_007.pdf', 'images/standard/2016/4/12/T01_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023304', '201', 'T01_008.pdf', 'images/standard/2016/4/12/T01_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023305', '202', 'T01_009.pdf', 'images/standard/2016/4/12/T01_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023306', '203', 'T01_010.pdf', 'images/standard/2016/4/12/T01_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023307', '204', 'T01_011.pdf', 'images/standard/2016/4/12/T01_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023308', '205', 'T01_012.pdf', 'images/standard/2016/4/12/T01_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023309', '206', 'T01_013.pdf', 'images/standard/2016/4/12/T01_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023310', '207', 'T01_014.pdf', 'images/standard/2016/4/12/T01_014.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023311', '208', 'T01_015.pdf', 'images/standard/2016/4/12/T01_015.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023312', '209', 'T01_016.pdf', 'images/standard/2016/4/12/T01_016.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023313', '21', 'G02_009.pdf', 'images/standard/2016/4/12/G02_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023314', '210', 'T01_017.pdf', 'images/standard/2016/4/12/T01_017.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023315', '211', 'B01_001.pdf', 'images/standard/2016/4/12/B01_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023316', '212', 'B01_002.pdf', 'images/standard/2016/4/12/B01_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023317', '213', 'B01_003.pdf', 'images/standard/2016/4/12/B01_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023318', '214', 'B01_004.pdf', 'images/standard/2016/4/12/B01_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023319', '215', 'B01_005.pdf', 'images/standard/2016/4/12/B01_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023320', '216', 'B01_006.pdf', 'images/standard/2016/4/12/B01_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023321', '217', 'B01_007.pdf', 'images/standard/2016/4/12/B01_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023322', '218', 'B01_008.pdf', 'images/standard/2016/4/12/B01_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023323', '219', 'B01_009.pdf', 'images/standard/2016/4/12/B01_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023324', '22', 'G02_010.pdf', 'images/standard/2016/4/12/G02_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023325', '220', 'B01_010.pdf', 'images/standard/2016/4/12/B01_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023326', '221', 'B01_011.pdf', 'images/standard/2016/4/12/B01_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023327', '222', 'B01_012.pdf', 'images/standard/2016/4/12/B01_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023328', '223', 'D03_001.pdf', 'images/standard/2016/4/12/D03_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023329', '224', 'D03_002.pdf', 'images/standard/2016/4/12/D03_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023330', '225', 'D03_003.pdf', 'images/standard/2016/4/12/D03_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023331', '226', 'D03_004.pdf', 'images/standard/2016/4/12/D03_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023332', '227', 'D03_005.pdf', 'images/standard/2016/4/12/D03_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023333', '228', 'D03_006.pdf', 'images/standard/2016/4/12/D03_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023334', '229', 'D03_007.pdf', 'images/standard/2016/4/12/D03_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023335', '23', 'G02_011.pdf', 'images/standard/2016/4/12/G02_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023336', '230', 'D03_008.pdf', 'images/standard/2016/4/12/D03_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023337', '231', 'D03_009.pdf', 'images/standard/2016/4/12/D03_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023338', '232', 'D03_010.pdf', 'images/standard/2016/4/12/D03_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023339', '233', 'G08-001.pdf', 'images/standard/2016/4/12/G08-001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023340', '234', 'G08-002.pdf', 'images/standard/2016/4/12/G08-002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023341', '235', 'G08-003.pdf', 'images/standard/2016/4/12/G08-003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023342', '236', 'G08_004.pdf', 'images/standard/2016/4/12/G08_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023343', '237', 'G08_005.pdf', 'images/standard/2016/4/12/G08_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023344', '238', 'G08_006.pdf', 'images/standard/2016/4/12/G08_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023345', '239', 'G08_007.pdf', 'images/standard/2016/4/12/G08_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023346', '24', 'G02_012.pdf', 'images/standard/2016/4/12/G02_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023347', '240', 'G08_008.pdf', 'images/standard/2016/4/12/G08_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023348', '241', 'G08_009.pdf', 'images/standard/2016/4/12/G08_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023349', '242', 'G08_010.pdf', 'images/standard/2016/4/12/G08_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023350', '243', 'G08_011.pdf', 'images/standard/2016/4/12/G08_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023351', '244', 'G08_012.pdf', 'images/standard/2016/4/12/G08_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023352', '245', 'G08_013.pdf', 'images/standard/2016/4/12/G08_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023353', '246', 'G08_014.pdf', 'images/standard/2016/4/12/G08_014.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023354', '247', 'G08_015.pdf', 'images/standard/2016/4/12/G08_015.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023355', '248', 'G08_016.pdf', 'images/standard/2016/4/12/G08_016.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023356', '249', 'G08_017.pdf', 'images/standard/2016/4/12/G08_017.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023357', '25', 'G02_013.pdf', 'images/standard/2016/4/12/G02_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023358', '250', 'G08_018.pdf', 'images/standard/2016/4/12/G08_018.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023359', '251', 'G08_019.pdf', 'images/standard/2016/4/12/G08_019.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023360', '252', 'G08_020.pdf', 'images/standard/2016/4/12/G08_020.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023361', '253', 'G08_021.pdf', 'images/standard/2016/4/12/G08_021.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023362', '254', 'G08_022.pdf', 'images/standard/2016/4/12/G08_022.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023363', '255', 'G08_023.pdf', 'images/standard/2016/4/12/G08_023.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023364', '256', 'G08_024.pdf', 'images/standard/2016/4/12/G08_024.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023365', '257', 'G08_025.pdf', 'images/standard/2016/4/12/G08_025.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023366', '258', 'G08_026.pdf', 'images/standard/2016/4/12/G08_026.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023367', '259', 'G08_027.pdf', 'images/standard/2016/4/12/G08_027.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023368', '26', 'G02_014.pdf', 'images/standard/2016/4/12/G02_014.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023369', '260', 'G08_028.pdf', 'images/standard/2016/4/12/G08_028.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023370', '261', 'G08_029.pdf', 'images/standard/2016/4/12/G08_029.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023371', '262', 'G08_030.pdf', 'images/standard/2016/4/12/G08_030.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023372', '263', 'G08_031.pdf', 'images/standard/2016/4/12/G08_031.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023373', '264', 'G08_032.pdf', 'images/standard/2016/4/12/G08_032.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023374', '265', 'G08_033.pdf', 'images/standard/2016/4/12/G08_033.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023375', '266', 'G08_034.pdf', 'images/standard/2016/4/12/G08_034.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023376', '267', 'G08_035.pdf', 'images/standard/2016/4/12/G08_035.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023377', '268', 'G08_036.pdf', 'images/standard/2016/4/12/G08_036.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023378', '269', 'G08_037.pdf', 'images/standard/2016/4/12/G08_037.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023379', '27', 'G02_015.pdf', 'images/standard/2016/4/12/G02_015.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023380', '270', 'G08_038.pdf', 'images/standard/2016/4/12/G08_038.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023381', '271', 'G08_039.pdf', 'images/standard/2016/4/12/G08_039.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023382', '272', 'G08_040.pdf', 'images/standard/2016/4/12/G08_040.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023383', '273', 'G08_041.pdf', 'images/standard/2016/4/12/G08_041.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023384', '274', 'B02_001.pdf', 'images/standard/2016/4/12/B02_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023385', '275', 'B02_002.pdf', 'images/standard/2016/4/12/B02_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023386', '276', 'B02_003.pdf', 'images/standard/2016/4/12/B02_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023387', '277', 'B02_004.pdf', 'images/standard/2016/4/12/B02_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023388', '278', 'B02_005.pdf', 'images/standard/2016/4/12/B02_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023389', '279', 'B02_006.pdf', 'images/standard/2016/4/12/B02_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023390', '28', 'G02_016.pdf', 'images/standard/2016/4/12/G02_016.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023391', '280', 'B02_007.pdf', 'images/standard/2016/4/12/B02_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023392', '281', 'B02_008.pdf', 'images/standard/2016/4/12/B02_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023393', '282', 'B02_009.pdf', 'images/standard/2016/4/12/B02_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023394', '283', 'B02_010.pdf', 'images/standard/2016/4/12/B02_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023395', '284', 'B02_011.pdf', 'images/standard/2016/4/12/B02_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023396', '285', 'B02_012.pdf', 'images/standard/2016/4/12/B02_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023397', '286', 'B02_013.pdf', 'images/standard/2016/4/12/B02_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023398', '287', 'B02_014.pdf', 'images/standard/2016/4/12/B02_014.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023399', '288', 'B02_015.pdf', 'images/standard/2016/4/12/B02_015.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023400', '289', 'B02_016.pdf', 'images/standard/2016/4/12/B02_016.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023401', '29', 'T02_001.pdf', 'images/standard/2016/4/12/T02_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023402', '290', 'B02_017.pdf', 'images/standard/2016/4/12/B02_017.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023403', '291', 'D04-001.pdf', 'images/standard/2016/4/12/D04-001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023404', '292', 'D04-002.pdf', 'images/standard/2016/4/12/D04-002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023405', '293', 'D04-003.pdf', 'images/standard/2016/4/12/D04-003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023406', '294', 'D04-004.pdf', 'images/standard/2016/4/12/D04-004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023407', '296', 'G01_002.pdf', 'images/standard/2016/4/12/G01_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023408', '297', 'G01_003.pdf', 'images/standard/2016/4/12/G01_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023409', '298', 'G01_004.pdf', 'images/standard/2016/4/12/G01_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023410', '299', 'G01_006.pdf', 'images/standard/2016/4/12/G01_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023411', '3', 'D02_003.pdf', 'images/standard/2016/4/12/D02_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023412', '30', 'T02_002.pdf', 'images/standard/2016/4/12/T02_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023413', '300', 'G01_007.pdf', 'images/standard/2016/4/12/G01_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023414', '301', 'G01_008.pdf', 'images/standard/2016/4/12/G01_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023415', '302', 'G01_009.pdf', 'images/standard/2016/4/12/G01_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023416', '303', 'G01_010.pdf', 'images/standard/2016/4/12/G01_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023417', '304', 'G01_011.pdf', 'images/standard/2016/4/12/G01_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023418', '305', 'G01_012.pdf', 'images/standard/2016/4/12/G01_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023419', '306', 'G01_013.pdf', 'images/standard/2016/4/12/G01_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023420', '307', 'G01_014.pdf', 'images/standard/2016/4/12/G01_014.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023421', '308', 'G01_015.pdf', 'images/standard/2016/4/12/G01_015.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023422', '309', 'G01_016.pdf', 'images/standard/2016/4/12/G01_016.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023423', '31', 'T02_003.pdf', 'images/standard/2016/4/12/T02_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023424', '310', 'G01_017.pdf', 'images/standard/2016/4/12/G01_017.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023425', '311', 'G01_018.pdf', 'images/standard/2016/4/12/G01_018.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023426', '312', 'G01_019.pdf', 'images/standard/2016/4/12/G01_019.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023427', '313', 'G01_021.pdf', 'images/standard/2016/4/12/G01_021.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023428', '314', 'G01_022.pdf', 'images/standard/2016/4/12/G01_022.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023429', '315', 'G01_023.pdf', 'images/standard/2016/4/12/G01_023.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023430', '316', 'G01_024.pdf', 'images/standard/2016/4/12/G01_024.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023431', '317', 'G01_025.pdf', 'images/standard/2016/4/12/G01_025.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023432', '318', 'G01_026.pdf', 'images/standard/2016/4/12/G01_026.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023433', '319', 'G01_027.pdf', 'images/standard/2016/4/12/G01_027.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023434', '32', 'T02_004.pdf', 'images/standard/2016/4/12/T02_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023435', '320', 'G01_028.pdf', 'images/standard/2016/4/12/G01_028.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023436', '321', 'G01_029.pdf', 'images/standard/2016/4/12/G01_029.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023437', '322', 'G01_030.pdf', 'images/standard/2016/4/12/G01_030.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023438', '323', 'G01_031.pdf', 'images/standard/2016/4/12/G01_031.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023439', '324', 'G01_032.pdf', 'images/standard/2016/4/12/G01_032.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023440', '325', 'G01_033.pdf', 'images/standard/2016/4/12/G01_033.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023441', '326', 'G01_034.pdf', 'images/standard/2016/4/12/G01_034.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023442', '327', 'G01_035.pdf', 'images/standard/2016/4/12/G01_035.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023443', '328', 'G01_036.pdf', 'images/standard/2016/4/12/G01_036.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023444', '329', 'G01_038.pdf', 'images/standard/2016/4/12/G01_038.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023445', '33', 'T02_005.pdf', 'images/standard/2016/4/12/T02_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023446', '330', 'G01_039.pdf', 'images/standard/2016/4/12/G01_039.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023447', '331', 'G01_040.pdf', 'images/standard/2016/4/12/G01_040.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023448', '332', 'G01_041.pdf', 'images/standard/2016/4/12/G01_041.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023449', '333', 'G01_042.pdf', 'images/standard/2016/4/12/G01_042.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023450', '334', 'G01_043.pdf', 'images/standard/2016/4/12/G01_043.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023451', '335', 'G01_044.pdf', 'images/standard/2016/4/12/G01_044.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023452', '336', 'G01_045.pdf', 'images/standard/2016/4/12/G01_045.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023453', '337', 'G01_046.pdf', 'images/standard/2016/4/12/G01_046.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023454', '338', 'G01_047.pdf', 'images/standard/2016/4/12/G01_047.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023455', '339', 'G01_048.pdf', 'images/standard/2016/4/12/G01_048.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023456', '34', 'T02_006.pdf', 'images/standard/2016/4/12/T02_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023457', '340', 'G01_049.pdf', 'images/standard/2016/4/12/G01_049.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023458', '341', 'G01_050.pdf', 'images/standard/2016/4/12/G01_050.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023459', '342', 'G01_053.pdf', 'images/standard/2016/4/12/G01_053.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023460', '343', 'G01_054.pdf', 'images/standard/2016/4/12/G01_054.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023461', '344', 'G01_055.pdf', 'images/standard/2016/4/12/G01_055.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023462', '345', 'G01_056.pdf', 'images/standard/2016/4/12/G01_056.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023463', '346', 'G01_057.pdf', 'images/standard/2016/4/12/G01_057.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023464', '347', 'Y04_001.pdf', 'images/standard/2016/4/12/Y04_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023465', '348', 'Y04_002.pdf', 'images/standard/2016/4/12/Y04_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023466', '349', 'Y04_003.pdf', 'images/standard/2016/4/12/Y04_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023467', '35', 'T02_007.pdf', 'images/standard/2016/4/12/T02_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023468', '350', 'Y04_004.pdf', 'images/standard/2016/4/12/Y04_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023469', '351', 'Y04_006.pdf', 'images/standard/2016/4/12/Y04_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023470', '352', 'Y04_007.pdf', 'images/standard/2016/4/12/Y04_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023471', '353', 'Y04_008.pdf', 'images/standard/2016/4/12/Y04_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023472', '354', 'Y04_009.pdf', 'images/standard/2016/4/12/Y04_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023473', '355', 'Y04_010.pdf', 'images/standard/2016/4/12/Y04_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023474', '356', 'Y04_011.pdf', 'images/standard/2016/4/12/Y04_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023475', '357', 'Y04_012.pdf', 'images/standard/2016/4/12/Y04_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023476', '358', 'Y04_013.pdf', 'images/standard/2016/4/12/Y04_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023477', '359', 'Y04_014.pdf', 'images/standard/2016/4/12/Y04_014.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023478', '36', 'T02_008.pdf', 'images/standard/2016/4/12/T02_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023479', '360', 'Y04_015.pdf', 'images/standard/2016/4/12/Y04_015.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023480', '361', 'Y04_016.pdf', 'images/standard/2016/4/12/Y04_016.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023481', '362', 'Y04_017.pdf', 'images/standard/2016/4/12/Y04_017.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023482', '363', 'Y04_018.pdf', 'images/standard/2016/4/12/Y04_018.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023483', '364', 'Y04_001.pdf', 'images/standard/2016/4/12/Y04_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023484', '365', 'Y04_002.pdf', 'images/standard/2016/4/12/Y04_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023485', '366', 'Y04_003.pdf', 'images/standard/2016/4/12/Y04_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023486', '367', 'Y04_004.pdf', 'images/standard/2016/4/12/Y04_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023487', '368', 'Y04_006.pdf', 'images/standard/2016/4/12/Y04_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023488', '369', 'Y04_007.pdf', 'images/standard/2016/4/12/Y04_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023489', '37', 'M03_001.pdf', 'images/standard/2016/4/12/M03_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023490', '370', 'Y04_008.pdf', 'images/standard/2016/4/12/Y04_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023491', '371', 'Y04_009.pdf', 'images/standard/2016/4/12/Y04_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023492', '372', 'Y04_010.pdf', 'images/standard/2016/4/12/Y04_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023493', '373', 'Y04_011.pdf', 'images/standard/2016/4/12/Y04_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023494', '374', 'Y04_012.pdf', 'images/standard/2016/4/12/Y04_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023495', '375', 'Y04_013.pdf', 'images/standard/2016/4/12/Y04_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023496', '376', 'Y04_014.pdf', 'images/standard/2016/4/12/Y04_014.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023497', '377', 'Y04_015.pdf', 'images/standard/2016/4/12/Y04_015.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023498', '378', 'Y04_016.pdf', 'images/standard/2016/4/12/Y04_016.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023499', '379', 'Y04_017.pdf', 'images/standard/2016/4/12/Y04_017.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023500', '38', 'M03_002.pdf', 'images/standard/2016/4/12/M03_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023501', '380', 'Y04_018.pdf', 'images/standard/2016/4/12/Y04_018.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023502', '381', 'G06_001.pdf', 'images/standard/2016/4/12/G06_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023503', '382', 'G06_002.pdf', 'images/standard/2016/4/12/G06_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023504', '383', 'G06_003.pdf', 'images/standard/2016/4/12/G06_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023505', '384', 'G06_004.pdf', 'images/standard/2016/4/12/G06_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023506', '385', 'G06_006.pdf', 'images/standard/2016/4/12/G06_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023507', '386', 'G06_007.pdf', 'images/standard/2016/4/12/G06_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023508', '387', 'G06_008.pdf', 'images/standard/2016/4/12/G06_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023509', '388', 'G06_009.pdf', 'images/standard/2016/4/12/G06_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023510', '389', 'G06_010.pdf', 'images/standard/2016/4/12/G06_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023511', '39', 'M03_003.pdf', 'images/standard/2016/4/12/M03_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023512', '390', 'Y01_001.pdf', 'images/standard/2016/4/12/Y01_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023513', '391', 'Y01_002.pdf', 'images/standard/2016/4/12/Y01_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023514', '392', 'Y01_003.pdf', 'images/standard/2016/4/12/Y01_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023515', '393', 'Y01_004.pdf', 'images/standard/2016/4/12/Y01_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023516', '394', 'Y02_001.pdf', 'images/standard/2016/4/12/Y02_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023517', '395', 'Y02_002.pdf', 'images/standard/2016/4/12/Y02_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023518', '396', 'Y02_003.pdf', 'images/standard/2016/4/12/Y02_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023519', '397', 'Y02_004.pdf', 'images/standard/2016/4/12/Y02_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023520', '398', 'Y02_005.pdf', 'images/standard/2016/4/12/Y02_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023521', '399', 'Y02_006.pdf', 'images/standard/2016/4/12/Y02_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023522', '4', 'D02_004.pdf', 'images/standard/2016/4/12/D02_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023523', '40', 'M03_004.pdf', 'images/standard/2016/4/12/M03_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023524', '400', 'Y02_007.pdf', 'images/standard/2016/4/12/Y02_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023525', '401', 'Y02_008.pdf', 'images/standard/2016/4/12/Y02_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023526', '402', 'Y02_009.pdf', 'images/standard/2016/4/12/Y02_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023527', '403', 'Y02_010.pdf', 'images/standard/2016/4/12/Y02_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023528', '404', 'Y02_011.pdf', 'images/standard/2016/4/12/Y02_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023529', '405', 'Y02_012.pdf', 'images/standard/2016/4/12/Y02_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023530', '406', 'Y02_013.pdf', 'images/standard/2016/4/12/Y02_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023531', '407', 'Y02_014.pdf', 'images/standard/2016/4/12/Y02_014.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023532', '408', 'Y02_015.pdf', 'images/standard/2016/4/12/Y02_015.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023533', '409', 'Y02_016.pdf', 'images/standard/2016/4/12/Y02_016.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023534', '41', 'M03_005.pdf', 'images/standard/2016/4/12/M03_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023535', '410', 'Y02_017.pdf', 'images/standard/2016/4/12/Y02_017.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023536', '411', 'Y02_018.pdf', 'images/standard/2016/4/12/Y02_018.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023537', '412', 'Y02_019.pdf', 'images/standard/2016/4/12/Y02_019.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023538', '413', 'Y02_020.pdf', 'images/standard/2016/4/12/Y02_020.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023539', '414', 'Y02_021.pdf', 'images/standard/2016/4/12/Y02_021.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023540', '415', 'Y02_022.pdf', 'images/standard/2016/4/12/Y02_022.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023541', '416', 'Y02_023.pdf', 'images/standard/2016/4/12/Y02_023.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023542', '417', 'Y02_024.pdf', 'images/standard/2016/4/12/Y02_024.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023543', '418', 'Y02_025.pdf', 'images/standard/2016/4/12/Y02_025.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023544', '419', 'Y02_026.pdf', 'images/standard/2016/4/12/Y02_026.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023545', '42', 'M03_006.pdf', 'images/standard/2016/4/12/M03_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023546', '420', 'Y02_027.pdf', 'images/standard/2016/4/12/Y02_027.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023547', '421', 'Y02_028.pdf', 'images/standard/2016/4/12/Y02_028.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023548', '422', 'Y02_029.pdf', 'images/standard/2016/4/12/Y02_029.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023549', '423', 'Y02_030.pdf', 'images/standard/2016/4/12/Y02_030.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023550', '424', 'Y02_031.pdf', 'images/standard/2016/4/12/Y02_031.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023551', '425', 'Y02_032.pdf', 'images/standard/2016/4/12/Y02_032.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023552', '426', 'M04_001.pdf', 'images/standard/2016/4/12/M04_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023553', '427', 'M04_002.pdf', 'images/standard/2016/4/12/M04_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023554', '428', 'M04_003.pdf', 'images/standard/2016/4/12/M04_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023555', '429', 'M04_004.pdf', 'images/standard/2016/4/12/M04_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023556', '43', 'M03_007.pdf', 'images/standard/2016/4/12/M03_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023557', '430', 'M04_005.pdf', 'images/standard/2016/4/12/M04_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023558', '431', 'C01_001.pdf', 'images/standard/2016/4/12/C01_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023559', '432', 'C01_002.pdf', 'images/standard/2016/4/12/C01_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023560', '433', 'C01_003.pdf', 'images/standard/2016/4/12/C01_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023561', '434', 'C01_004.pdf', 'images/standard/2016/4/12/C01_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023562', '435', 'C01_005.pdf', 'images/standard/2016/4/12/C01_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023563', '436', 'C01_006.pdf', 'images/standard/2016/4/12/C01_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023564', '437', 'C01_007.pdf', 'images/standard/2016/4/12/C01_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023565', '438', 'C01_008.pdf', 'images/standard/2016/4/12/C01_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023566', '439', 'Z03_001.pdf', 'images/standard/2016/4/12/Z03_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023567', '44', 'M03_008.pdf', 'images/standard/2016/4/12/M03_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023568', '440', 'Z03_002.pdf', 'images/standard/2016/4/12/Z03_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023569', '441', 'Z03_003.pdf', 'images/standard/2016/4/12/Z03_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023570', '442', 'Z03_004.pdf', 'images/standard/2016/4/12/Z03_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023571', '443', 'Z03_005.pdf', 'images/standard/2016/4/12/Z03_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023572', '444', 'Z03_006.pdf', 'images/standard/2016/4/12/Z03_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023573', '445', 'Z03_007.pdf', 'images/standard/2016/4/12/Z03_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023574', '446', 'Z03_008.pdf', 'images/standard/2016/4/12/Z03_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023575', '447', 'Z03_009.pdf', 'images/standard/2016/4/12/Z03_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023576', '448', 'Z03_010.pdf', 'images/standard/2016/4/12/Z03_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023577', '449', 'Z03_011.pdf', 'images/standard/2016/4/12/Z03_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023578', '45', 'M03_009.pdf', 'images/standard/2016/4/12/M03_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023579', '450', 'Z03_012.pdf', 'images/standard/2016/4/12/Z03_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023580', '451', 'Z03_013.pdf', 'images/standard/2016/4/12/Z03_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023581', '452', 'S02_001.pdf', 'images/standard/2016/4/12/S02_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023582', '453', 'S02_002.pdf', 'images/standard/2016/4/12/S02_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023583', '454', 'S02_003.pdf', 'images/standard/2016/4/12/S02_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023584', '455', 'S02_004.pdf', 'images/standard/2016/4/12/S02_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023585', '456', 'S02_005.pdf', 'images/standard/2016/4/12/S02_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023586', '457', 'S02_006.pdf', 'images/standard/2016/4/12/S02_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023587', '458', 'S02_007.pdf', 'images/standard/2016/4/12/S02_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023588', '459', 'S02_008.pdf', 'images/standard/2016/4/12/S02_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023589', '46', 'M06_001.pdf', 'images/standard/2016/4/12/M06_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023590', '460', 'S02_009.pdf', 'images/standard/2016/4/12/S02_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023591', '461', 'S02_010.pdf', 'images/standard/2016/4/12/S02_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023592', '462', 'S02_011.pdf', 'images/standard/2016/4/12/S02_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023593', '464', 'M05_001.pdf', 'images/standard/2016/4/12/M05_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023594', '465', 'M05_002.pdf', 'images/standard/2016/4/12/M05_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023595', '466', 'M05_003.pdf', 'images/standard/2016/4/12/M05_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023596', '467', 'M05_004.pdf', 'images/standard/2016/4/12/M05_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023597', '468', 'M05_005.pdf', 'images/standard/2016/4/12/M05_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023598', '469', 'M05_006.pdf', 'images/standard/2016/4/12/M05_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023599', '47', 'M06_002.pdf', 'images/standard/2016/4/12/M06_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023600', '470', 'X03_001.pdf', 'images/standard/2016/4/12/X03_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023601', '471', 'X03_002.pdf', 'images/standard/2016/4/12/X03_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023602', '472', 'Y05_001.pdf', 'images/standard/2016/4/12/Y05_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023603', '473', 'Y05_002.pdf', 'images/standard/2016/4/12/Y05_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023604', '474', 'Y05_003.pdf', 'images/standard/2016/4/12/Y05_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023605', '475', 'Y05_004.pdf', 'images/standard/2016/4/12/Y05_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023606', '476', 'Y05_005.pdf', 'images/standard/2016/4/12/Y05_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023607', '477', 'Y05_006.pdf', 'images/standard/2016/4/12/Y05_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023608', '478', 'Y05_007.pdf', 'images/standard/2016/4/12/Y05_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023609', '479', 'Y05_008.pdf', 'images/standard/2016/4/12/Y05_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023610', '48', 'M06_003.pdf', 'images/standard/2016/4/12/M06_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023611', '480', 'Y05_009.pdf', 'images/standard/2016/4/12/Y05_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023612', '481', 'Y05_010.pdf', 'images/standard/2016/4/12/Y05_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023613', '482', 'Y05_011.pdf', 'images/standard/2016/4/12/Y05_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023614', '483', 'Y05_012.pdf', 'images/standard/2016/4/12/Y05_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023615', '484', 'Y05_013.pdf', 'images/standard/2016/4/12/Y05_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023616', '485', 'Y05_014.pdf', 'images/standard/2016/4/12/Y05_014.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023617', '486', 'Y05_015.pdf', 'images/standard/2016/4/12/Y05_015.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023618', '487', 'Y05_016.pdf', 'images/standard/2016/4/12/Y05_016.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023619', '488', 'Y05_017.pdf', 'images/standard/2016/4/12/Y05_017.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023620', '489', 'Y05_018.pdf', 'images/standard/2016/4/12/Y05_018.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023621', '49', 'M06_004.pdf', 'images/standard/2016/4/12/M06_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023622', '490', 'Y05_019.pdf', 'images/standard/2016/4/12/Y05_019.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023623', '491', 'Y05_020.pdf', 'images/standard/2016/4/12/Y05_020.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023624', '492', 'Y05_022.pdf', 'images/standard/2016/4/12/Y05_022.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023625', '493', 'Y05_023.pdf', 'images/standard/2016/4/12/Y05_023.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023626', '494', 'Y05_024.pdf', 'images/standard/2016/4/12/Y05_024.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023627', '495', 'X02_001.pdf', 'images/standard/2016/4/12/X02_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023628', '496', 'X02_002.pdf', 'images/standard/2016/4/12/X02_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023629', '497', 'X02_003.pdf', 'images/standard/2016/4/12/X02_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023630', '498', 'X02_004.pdf', 'images/standard/2016/4/12/X02_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023631', '499', 'X02_005.pdf', 'images/standard/2016/4/12/X02_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023632', '5', 'D02_005.pdf', 'images/standard/2016/4/12/D02_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023633', '50', 'M06_005.pdf', 'images/standard/2016/4/12/M06_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023634', '500', 'X02_006.pdf', 'images/standard/2016/4/12/X02_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023635', '501', 'X02_007.pdf', 'images/standard/2016/4/12/X02_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023636', '502', 'X02_008.pdf', 'images/standard/2016/4/12/X02_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023637', '503', 'X02_009.pdf', 'images/standard/2016/4/12/X02_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023638', '504', 'X02_010.pdf', 'images/standard/2016/4/12/X02_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023639', '505', 'X02_011.pdf', 'images/standard/2016/4/12/X02_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023640', '506', 'X02_019.pdf', 'images/standard/2016/4/12/X02_019.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023641', '507', 'Y03_002.pdf', 'images/standard/2016/4/12/Y03_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023642', '508', 'Y03_004.pdf', 'images/standard/2016/4/12/Y03_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023643', '509', 'Y03_005.pdf', 'images/standard/2016/4/12/Y03_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023644', '51', 'M06_006.pdf', 'images/standard/2016/4/12/M06_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023645', '510', 'Y03_011.pdf', 'images/standard/2016/4/12/Y03_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023646', '511', 'Y03_012.pdf', 'images/standard/2016/4/12/Y03_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023647', '512', 'Y03_013.pdf', 'images/standard/2016/4/12/Y03_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023648', '513', 'Y03_013.pdf', 'images/standard/2016/4/12/Y03_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023649', '514', 'Y03_013.pdf', 'images/standard/2016/4/12/Y03_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023650', '515', 'Y03_013.pdf', 'images/standard/2016/4/12/Y03_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023651', '516', 'Y03_013.pdf', 'images/standard/2016/4/12/Y03_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023652', '517', 'Y03_013.pdf', 'images/standard/2016/4/12/Y03_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023653', '518', 'Y03_014.pdf', 'images/standard/2016/4/12/Y03_014.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023654', '519', 'Y03_015.pdf', 'images/standard/2016/4/12/Y03_015.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023655', '52', 'M06_007.pdf', 'images/standard/2016/4/12/M06_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023656', '520', 'Y03_017.pdf', 'images/standard/2016/4/12/Y03_017.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023657', '521', 'Y03_018.pdf', 'images/standard/2016/4/12/Y03_018.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023658', '522', 'Y03_020.pdf', 'images/standard/2016/4/12/Y03_020.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023659', '523', 'Y03_022.pdf', 'images/standard/2016/4/12/Y03_022.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023660', '524', 'Y03_024.pdf', 'images/standard/2016/4/12/Y03_024.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023661', '525', 'Y03_025.pdf', 'images/standard/2016/4/12/Y03_025.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023662', '526', 'Y03_026.pdf', 'images/standard/2016/4/12/Y03_026.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023663', '527', 'Z02_007.pdf', 'images/standard/2016/4/12/Z02_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023664', '528', 'Z02_008.pdf', 'images/standard/2016/4/12/Z02_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023665', '529', 'Z02_012.pdf', 'images/standard/2016/4/12/Z02_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023666', '53', 'M06_008.pdf', 'images/standard/2016/4/12/M06_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023667', '530', 'Z02_027.pdf', 'images/standard/2016/4/12/Z02_027.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023668', '531', 'Z02_028.pdf', 'images/standard/2016/4/12/Z02_028.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023669', '532', 'Z02_030.pdf', 'images/standard/2016/4/12/Z02_030.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023670', '533', 'Z02_031.pdf', 'images/standard/2016/4/12/Z02_031.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023671', '534', 'Z02_032.pdf', 'images/standard/2016/4/12/Z02_032.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023672', '535', 'Z02_037.pdf', 'images/standard/2016/4/12/Z02_037.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023673', '536', 'Z02_038.pdf', 'images/standard/2016/4/12/Z02_038.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023674', '537', 'Z02_046.pdf', 'images/standard/2016/4/12/Z02_046.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023675', '538', 'Z02_061.pdf', 'images/standard/2016/4/12/Z02_061.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023676', '539', 'Z02_052.pdf', 'images/standard/2016/4/12/Z02_052.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023677', '54', 'M06_009.pdf', 'images/standard/2016/4/12/M06_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023678', '540', 'Z02_017.pdf', 'images/standard/2016/4/12/Z02_017.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023679', '541', 'Z02_029.pdf', 'images/standard/2016/4/12/Z02_029.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023680', '542', 'Z02_004.pdf', 'images/standard/2016/4/12/Z02_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023681', '543', 'Z02_003.pdf', 'images/standard/2016/4/12/Z02_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023682', '544', 'P01_001.pdf', 'images/standard/2016/4/12/P01_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023683', '545', 'P01_002.pdf', 'images/standard/2016/4/12/P01_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023684', '546', 'P01_003.pdf', 'images/standard/2016/4/12/P01_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023685', '547', 'P01_004.pdf', 'images/standard/2016/4/12/P01_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023686', '548', 'P01_005.pdf', 'images/standard/2016/4/12/P01_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023687', '549', 'P01_006.pdf', 'images/standard/2016/4/12/P01_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023688', '55', 'M06_010.pdf', 'images/standard/2016/4/12/M06_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023689', '550', 'P01_007.pdf', 'images/standard/2016/4/12/P01_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023690', '551', 'P01_008.pdf', 'images/standard/2016/4/12/P01_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023691', '552', 'P01_009.pdf', 'images/standard/2016/4/12/P01_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023692', '553', 'P01_010.pdf', 'images/standard/2016/4/12/P01_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023693', '554', 'P01_011.pdf', 'images/standard/2016/4/12/P01_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023694', '555', 'P01_012.pdf', 'images/standard/2016/4/12/P01_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023695', '556', 'P01_013.pdf', 'images/standard/2016/4/12/P01_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023696', '557', 'P01_014.pdf', 'images/standard/2016/4/12/P01_014.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023697', '558', 'P01_015.pdf', 'images/standard/2016/4/12/P01_015.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023698', '559', 'P01_016.pdf', 'images/standard/2016/4/12/P01_016.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023699', '56', 'M06_011.pdf', 'images/standard/2016/4/12/M06_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023700', '560', 'P01_017.pdf', 'images/standard/2016/4/12/P01_017.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023701', '561', 'P01_018.pdf', 'images/standard/2016/4/12/P01_018.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023702', '562', 'P01_019.pdf', 'images/standard/2016/4/12/P01_019.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023703', '563', 'P01_020.pdf', 'images/standard/2016/4/12/P01_020.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023704', '564', 'P01_021.pdf', 'images/standard/2016/4/12/P01_021.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023705', '565', 'P01_022.pdf', 'images/standard/2016/4/12/P01_022.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023706', '566', 'P01_023.pdf', 'images/standard/2016/4/12/P01_023.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023707', '567', 'P01_024.pdf', 'images/standard/2016/4/12/P01_024.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023708', '568', 'P01_025.pdf', 'images/standard/2016/4/12/P01_025.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023709', '569', 'P01_026.pdf', 'images/standard/2016/4/12/P01_026.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023710', '57', 'M06_012.pdf', 'images/standard/2016/4/12/M06_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023711', '570', 'P01_027.pdf', 'images/standard/2016/4/12/P01_027.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023712', '571', 'P01_028.pdf', 'images/standard/2016/4/12/P01_028.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023713', '572', 'M09_001.pdf', 'images/standard/2016/4/12/M09_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023714', '573', 'M09_002.pdf', 'images/standard/2016/4/12/M09_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023715', '574', 'M09_003.pdf', 'images/standard/2016/4/12/M09_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023716', '575', 'M09_004.pdf', 'images/standard/2016/4/12/M09_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023717', '576', 'M09_005.pdf', 'images/standard/2016/4/12/M09_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023718', '577', 'M09_006.pdf', 'images/standard/2016/4/12/M09_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023719', '578', 'M09_007.pdf', 'images/standard/2016/4/12/M09_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023720', '579', 'M09_008.pdf', 'images/standard/2016/4/12/M09_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023721', '58', 'M06_013.pdf', 'images/standard/2016/4/12/M06_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023722', '580', 'M09_009.pdf', 'images/standard/2016/4/12/M09_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023723', '581', 'M09_010.pdf', 'images/standard/2016/4/12/M09_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023724', '582', 'M09_011.pdf', 'images/standard/2016/4/12/M09_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023725', '583', 'M08_001.pdf', 'images/standard/2016/4/12/M08_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023726', '584', 'M08_002.pdf', 'images/standard/2016/4/12/M08_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023727', '585', 'M08_003.pdf', 'images/standard/2016/4/12/M08_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023728', '586', 'M08_004.pdf', 'images/standard/2016/4/12/M08_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023729', '587', 'M08_005.pdf', 'images/standard/2016/4/12/M08_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023730', '588', 'M08_006.pdf', 'images/standard/2016/4/12/M08_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023731', '589', 'M08_007.pdf', 'images/standard/2016/4/12/M08_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023732', '59', 'S01_001.pdf', 'images/standard/2016/4/12/S01_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023733', '590', 'Z02_018.pdf', 'images/standard/2016/4/12/Z02_018.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023734', '591', 'Z02_019.pdf', 'images/standard/2016/4/12/Z02_019.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023735', '592', 'Z02_013.pdf', 'images/standard/2016/4/12/Z02_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023736', '593', 'Z02_039.pdf', 'images/standard/2016/4/12/Z02_039.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023737', '594', 'Z02_064.pdf', 'images/standard/2016/4/12/Z02_064.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023738', '595', 'Z02_040.pdf', 'images/standard/2016/4/12/Z02_040.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023739', '596', 'Z02_041.pdf', 'images/standard/2016/4/12/Z02_041.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023740', '597', 'Z02_042.pdf', 'images/standard/2016/4/12/Z02_042.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023741', '598', 'Z02_069.pdf', 'images/standard/2016/4/12/Z02_069.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023742', '599', 'Z02_064.pdf', 'images/standard/2016/4/12/Z02_064.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023743', '6', 'D02_006.pdf', 'images/standard/2016/4/12/D02_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023744', '60', 'S01_002.pdf', 'images/standard/2016/4/12/S01_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023745', '600', 'Z02_063.pdf', 'images/standard/2016/4/12/Z02_063.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023746', '601', 'Z02_060.pdf', 'images/standard/2016/4/12/Z02_060.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023747', '602', 'Z02_053.pdf', 'images/standard/2016/4/12/Z02_053.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023748', '603', 'Z02_002.pdf', 'images/standard/2016/4/12/Z02_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023749', '604', 'Z02_003.pdf', 'images/standard/2016/4/12/Z02_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023750', '605', 'Z02_003.pdf', 'images/standard/2016/4/12/Z02_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023751', '606', 'Z02_024.pdf', 'images/standard/2016/4/12/Z02_024.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023752', '607', 'Z02_025.pdf', 'images/standard/2016/4/12/Z02_025.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023753', '608', 'Z02_021.pdf', 'images/standard/2016/4/12/Z02_021.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023754', '609', 'Z02_022.pdf', 'images/standard/2016/4/12/Z02_022.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023755', '61', 'S01_003.pdf', 'images/standard/2016/4/12/S01_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023756', '62', 'S01_004.pdf', 'images/standard/2016/4/12/S01_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023757', '63', 'S01_005.pdf', 'images/standard/2016/4/12/S01_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023758', '64', 'S01_006.pdf', 'images/standard/2016/4/12/S01_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023759', '65', 'S01_007.pdf', 'images/standard/2016/4/12/S01_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023760', '66', 'S01_008.pdf', 'images/standard/2016/4/12/S01_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023761', '67', 'S01_009.pdf', 'images/standard/2016/4/12/S01_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023762', '68', 'S01_010.pdf', 'images/standard/2016/4/12/S01_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023763', '69', 'S01_011.pdf', 'images/standard/2016/4/12/S01_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023764', '7', 'D02_007.pdf', 'images/standard/2016/4/12/D02_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023765', '70', 'S01_012.pdf', 'images/standard/2016/4/12/S01_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023766', '71', 'S01_013.pdf', 'images/standard/2016/4/12/S01_013.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023767', '72', 'S01_014.pdf', 'images/standard/2016/4/12/S01_014.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023768', '73', 'F04_001.pdf', 'images/standard/2016/4/12/F04_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023769', '74', 'F04_002.pdf', 'images/standard/2016/4/12/F04_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023770', '75', 'F04_003.pdf', 'images/standard/2016/4/12/F04_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023771', '76', 'F04_004.pdf', 'images/standard/2016/4/12/F04_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023772', '77', 'F04_005.pdf', 'images/standard/2016/4/12/F04_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023773', '78', 'F04_006.pdf', 'images/standard/2016/4/12/F04_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023774', '79', 'F04_007.pdf', 'images/standard/2016/4/12/F04_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023775', '8', 'D02_008.pdf', 'images/standard/2016/4/12/D02_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023776', '80', 'F04_008.pdf', 'images/standard/2016/4/12/F04_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023777', '81', 'F04_009.pdf', 'images/standard/2016/4/12/F04_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023778', '82', 'F04_010.pdf', 'images/standard/2016/4/12/F04_010.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023779', '83', 'F04_011.pdf', 'images/standard/2016/4/12/F04_011.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023780', '84', 'F04_012.pdf', 'images/standard/2016/4/12/F04_012.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023781', '85', 'G03_001.pdf', 'images/standard/2016/4/12/G03_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023782', '86', 'G03_002.pdf', 'images/standard/2016/4/12/G03_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023783', '87', 'G03_003.pdf', 'images/standard/2016/4/12/G03_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023784', '88', 'G03_004.pdf', 'images/standard/2016/4/12/G03_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023785', '89', 'G03_005.pdf', 'images/standard/2016/4/12/G03_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023786', '9', 'D02_009.pdf', 'images/standard/2016/4/12/D02_009.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023787', '90', 'G03_006.pdf', 'images/standard/2016/4/12/G03_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023788', '91', 'G03_007.pdf', 'images/standard/2016/4/12/G03_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023789', '92', 'J04_001.pdf', 'images/standard/2016/4/12/J04_001.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023790', '93', 'J04_002.pdf', 'images/standard/2016/4/12/J04_002.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023791', '94', 'J04_003.pdf', 'images/standard/2016/4/12/J04_003.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023792', '95', 'J04_004.pdf', 'images/standard/2016/4/12/J04_004.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023793', '96', 'J04_005.pdf', 'images/standard/2016/4/12/J04_005.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023794', '97', 'J04_006.pdf', 'images/standard/2016/4/12/J04_006.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023795', '98', 'J04_007.pdf', 'images/standard/2016/4/12/J04_007.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('24545298651023796', '99', 'J04_008.pdf', 'images/standard/2016/4/12/J04_008.pdf', null, '0', null, null);
INSERT INTO `biz_attach_standard` VALUES ('2c53a1f7ef06404b8d68fe553112f2bf', '806156b61f1749558d416efb9b4819aa', '中医医案知识服务与共享平台_Bug.xls', 'images/standard/2016/5/13/1463119169656.xls', '206336', '1', null, '2016-05-13 13:59:31');
INSERT INTO `biz_attach_standard` VALUES ('48b3cb5643e54928b1ef9fa03ba5968e', '504c17409e934a358507741011c5a0e6', 'DiagnosticsTap.dll', 'images/standard/2016/5/12/1463055695597.dll', '174592', '1', 'admin', '2016-05-12 20:21:43');
INSERT INTO `biz_attach_standard` VALUES ('67c3186fe40a486f8ddc7a35d92da265', '195', '', 'images/standard/2016/5/12\\1463020288891.jpg', '207525', '1', null, '2016-05-12 10:31:30');
INSERT INTO `biz_attach_standard` VALUES ('c34f03a53556418dab14a79bf8ebc21f', '34b2eca42c8740ad99341d639238d209', '1.sh', 'images/standard/2016/5/13/1463119307109.sh', '40', '1', null, '2016-05-13 14:01:48');
INSERT INTO `biz_attach_standard` VALUES ('dff1a1b4db424a2aba494366815ac5ab', '9d5dff3294b948259a559b8f6f577f7f', 'QBUtils.dll', 'images/standard/2016/5/13/1463126710027.dll', '2803904', '1', null, '2016-05-13 16:05:12');
INSERT INTO `biz_attach_standard` VALUES ('e7ce6a1781fb4270a50b2120d7bfafab', '34b2eca42c8740ad99341d639238d209', '数据权限按钮.docx', 'images/standard/2016/5/13/1463119200218.docx', '19952', '1', null, '2016-05-13 14:00:10');
INSERT INTO `biz_attach_standard` VALUES ('ea6ed1662b9448daaa8b6291296ec916', '195', 'be28af43472ffac10648573f1779efbe.jpg', 'images/standard/2016/5/12/1463020484722.jpg', '207525', '1', null, '2016-05-12 10:34:45');

-- ----------------------------
-- Table structure for biz_disease
-- ----------------------------
DROP TABLE IF EXISTS `biz_disease`;
CREATE TABLE `biz_disease` (
  `id` varchar(32) NOT NULL COMMENT '主键UUID',
  `first_letter` varchar(2) DEFAULT NULL COMMENT '首字符,分组字段',
  `code` varchar(50) DEFAULT NULL COMMENT '疾病代码',
  `name` varchar(200) DEFAULT NULL COMMENT '广安门医院命名的病名',
  `tcm_disease_name` varchar(500) DEFAULT NULL COMMENT '中医病名',
  `mm_disease_name` varchar(1500) DEFAULT NULL COMMENT '西医病名',
  `en_name` varchar(1500) DEFAULT NULL COMMENT '英文名称',
  `remark` text COMMENT '备注',
  `create_user` varchar(32) DEFAULT NULL COMMENT '创建者',
  `create_time` datetime DEFAULT NULL COMMENT '创建时间',
  `update_user` varchar(32) DEFAULT NULL COMMENT '修改人',
  `update_time` datetime DEFAULT NULL COMMENT '修改时间',
  `order_num` int(11) DEFAULT NULL COMMENT '排序号:共菜单显示用',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of biz_disease
-- ----------------------------
INSERT INTO `biz_disease` VALUES ('0ad8f18c39e14b1d892ee0bc6a7e3f24', 'B', 'bb', 'cccc', 'ccc', '', '', '', 'admin', '2016-05-11 16:03:58', null, '2016-05-11 16:03:58', '5');
INSERT INTO `biz_disease` VALUES ('1', 'T', 'T01', '糖尿病', '消渴；消瘅', '糖尿病；', 'Diabetes Mellitus；Type 1 diabetes mellitus；Type 2 diabetes mellitus；Diabetes mellitus in pregnancy', 'aaa', null, null, 'admin', '2016-05-10 15:29:14', '1');
INSERT INTO `biz_disease` VALUES ('10', 'D', 'D02', '代谢综合征', '代谢综合征', '代谢综合征；代谢综合征X；抗胰岛素性综合征X；', 'Metabolic Syndrome；Insulin Resistance Syndrome；Metabolic Syndrome X；Syndrome X；Dysmetabolic Syndrome X', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('11', 'G', 'G03', '更年期综合征', '更年期综合征；绝经前后诸症', '绝经综合征；围绝经期综合征', 'Climacteric Syndrome；Menopausal And Female Climacteric States；Symptoms Of The Menopause；Postmenopausal Symptoms', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('12', 'D', 'D03', '单纯性肥胖症', '肥胖', '单纯性肥胖症；肥胖症；肥胖；超重', 'Obesity；Overweight；Simple Obesity；Obesity, Abdominal；', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('13', 'L', 'L02', '老年期痴呆', '呆病', '老年期痴呆；老年痴呆；痴呆；阿尔兹海默病；血管性痴呆', 'Senile Dementia；Dementia；Alzheimer Disease（AD）；Vascular Dementia（VD）', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('14', 'F', 'F03', '肺癌', '肺癌', '肺癌；肺肿瘤；肺部肿瘤；非小细胞肺癌；小细胞肺癌', 'Lung Neoplasms；Lung Cancer；Pulmonary Cancer；Pulmonary Neoplasms；Cancer Of Lung；Non-Small-Cell Lung Cancer；Non-Small-Cell Lung Carcinoma；Small Cell Lung Cancer；Malignant Neoplasm Of Bronchus And Lung', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('15', 'J', 'J03', '甲状腺功能亢进', '瘿病', '甲状腺功能亢进；甲亢', 'Hyperthyroidism；Graves Disease；Thyrotoxicosis', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('16', 'G', 'G07', '高尿酸血症', '高尿酸血症', '高尿酸血症', 'Hyperuricemia；Hyperuricacidemia；', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('17', 'F', 'F04', '肺源性心脏病', '喘病；肺胀', '肺源性心脏病；肺心病', 'Pulmonary Heart Disease；Cor Pulmonale ', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('18', 'J', 'J04', '急性气管-支气管炎', '咳嗽', '急性气管-支气管炎', 'Tracheobronchitis；Tracheo Bronchitis ', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('19', 'D', 'D04', '胆囊炎', '胆囊炎', '胆囊炎；慢性胆囊炎；急性胆道系统感染', 'acute cholangitis and cholecystitis；Cholecystitis(K81)', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('2', 'J', 'J01', '上呼吸道感染', '伤风；感冒；上感 ', '普通感冒；流行性感冒；病毒性咽炎和喉炎；疱疹性咽峡炎；咽结膜热；细菌性咽-扁桃体炎；鼻炎；鼻窦炎；百日咳；鼻咽炎；', 'upper respiratory tract infection；Acute upper respiratory infections；Acute nasopharyngitis [common cold]；Acute sinusitis；Acute pharyngitis；Acute tonsillitis；Acute laryngitis and tracheitis；Acute obstructive laryngitis [croup] and epiglottitis；Acute upper respiratory infections of multiple and unspecified sites；Acute laryngopharyngitis', 'aa', null, null, 'admin', '2016-05-10 15:29:23', '-1');
INSERT INTO `biz_disease` VALUES ('20', 'B', 'B02', '不孕症', '（女性）不孕', '不育（女性）；不孕（育）症', 'infertile female，infertility；Endometriosis and infertility（子宫内膜异位导致的不孕症)；infertility in women with polycystic ovary syndrome（多囊卵巢综合征导致的不孕症）等等；Female infertility（N97）', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('21', 'B', 'B01', '变应性鼻炎', '变应性鼻炎', '变应性鼻炎', 'Allergic rhinitis；Vasomotor and allergic rhinitis(J30)', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('22', 'G', 'G06', '功能性消化不良', '功能性消化不良，消化不良', '功能性消化不良；消化不良', 'Functional Gastrointestinal Disorders；Indigestion；Functional dyspepsia(K30)', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('23', 'G', 'G08', '病毒性肝炎', '病毒性肝炎；甲型；乙型，慢性乙型肝炎', '病毒性肝炎；肝炎，病毒性，人；甲型肝炎；甲肝；甲型肝炎；乙型肝炎，慢性乙型肝炎；乙肝；慢乙肝；乙型肝炎；丙型肝炎；丙肝；丁型肝炎；戊型肝炎', 'viral hepatitis；Viral hepatitis(B15-B19)；Other acute viral hepatitis(B17.8,B17.9)；viral hepatitis A；Acute hepatitis A（B15）；viral hepatitis B；Acute hepatitis B(B16)；Acute delta-(super)infection of hepatitis B carrier(B17.0)；Chronic viral hepatitis(B18,B18.0,B18.1)；viral hepatitis C；Acute hepatitis C(B17.1)；Chronic viral hepatitis C(B18.2)；viral hepatitis D；Unspecified viral hepatitis；viral hepatitis E；Acute hepatitis E(B17.2)', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('24', 'F', 'F01', '非酒精性脂肪肝', '非酒精性脂肪肝', '非酒精性脂肪肝；非酒精性脂肪性肝炎；非酒精性脂肪性肝病', 'Non-alcoholic Fatty Liver Disease；nonalcoholic steatohepatitis (K75.8)；Fatty (change of) liver(K76.0)', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('25', 'M', 'M01', '慢性胃炎', '慢性胃炎', '慢性胃炎；慢性浅表性胃炎；慢性萎缩性胃炎', 'Chronic gastritis；Chronic superficial gastritis(K29.3)；Chronic atrophic gastritis(K29.4)；Chronic gastritis, unspecified(29.5)', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('26', 'B', 'B03', '急性扁桃体炎', '急性扁桃体炎，乳蛾', '急性（化脓性）扁桃体炎；扁桃体周围脓肿；小儿咽扁桃体肿大', 'Tonsillitis，Peritonsillar Abscess；Acute tonsillitis(J03)', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('27', 'C', 'C01', '痤疮', '粉刺；肺风粉刺', '寻常性痤疮；职业性痤疮；化妆品痤疮；痤疮', 'Acne vulgaris；Acne conglobata；Acne varioliformis；Acne necrotica miliaris；Acne tropica；Infantile acne；Acné excoriée；Acné excoriée des jeunes filles；Other acne；Acne, unspecified', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('28', 'Z', 'Z03', '痔疮', '痔；痔疮；内痔；外痔；混合痔；内外痔', '痔；痔疮；内痔；外痔；混合痔', 'Hemorrhoids；Haemorrhoids and perianal venous thrombosis', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('29', 'M', 'M05', '心力衰竭', null, '心力衰竭；心脏衰竭；心衰；右心衰；左室衰竭；充血性心力衰竭；心脏代偿失调；舒张性心力衰竭；收缩性心力衰竭', 'Heart Failure；Heart failure,unspecified；Left ventricular failure；Left heart failure；Congestive heart failure；Congestive heart disease；Right ventricular failure；Cardiac Failure；Heart Decompensation', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('3', 'G', 'G04', '冠状动脉粥样硬化性心脏病', '胸痹；心痛；真心痛', '冠心病；冠状动脉疾病；心绞痛', 'coronary atherosclerotic heart disease；Atherosclerotic heart disease；Angina Pectoris；', '', null, null, 'admin', '2016-05-11 17:27:19', '1');
INSERT INTO `biz_disease` VALUES ('30', 'X', 'X03', '骨关节炎', '骨痹', '骨关节炎；骨关节病；退行性关节炎；变形性骨关节病；骨性关节炎；膝关节骨关节炎；膝骨关节炎；髋骨关节炎；手骨关节炎；周围关节的骨关节炎；肩关节骨关节炎', 'Osteoarthritis；Knee osteoarthritis；Hip osteoarthritis；Osteoarthritis in peripheral joints；osteoarthritis of the hand；', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('31', 'S', 'S02', '肾病综合征', null, '肾病综合征；激素敏感、复发、依赖型肾病综合征；激素耐药型肾病综合征；小儿原发性肾病综合征', 'Nephrotic Syndrome', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('32', 'G', 'G02', '高脂血症', null, '血脂异常;\n高脂血症;\n高胆固醇血症;\n高甘油三酯血症;\n混合型高脂血症;\n低高密度脂蛋白血症;\n高TG血症;\n', 'Hyperlipidemia;\nHyperlipidemias；\nHyperlipemia; \n  ', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('33', 'T', 'T02', '痛风', '痛风', '急性痛风；关节炎, 痛风性;', 'gout；Acute gout;Arthritis, Gouty；Hyperuricemia（Gouty）  ', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('34', 'M', 'M03', '慢性肾功能衰竭', null, '慢性肾衰；肾功能衰竭, 慢性；肾脏功能衰竭, 慢性;Frasier综合征；', 'Kidney Failure, Chronic；CRF；Renal Failure, Chronic；Frasier syndrome；', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('35', 'M', 'M06', '泌尿系结石', null, '尿路结石症；尿石症；肾石病；肾结石；\n输尿管结石症；输尿管结石；\n膀胱结石症；膀胱结石；膀胱石；', 'Urolithiasis；Nephrolithiasis；Kidney Calculi；Kidney stones;Ureterolithiasis； Ureteral Calculi ；Urinary Bladder Calculi；Bladder Stones; Urinary Bladder Stones; Vesical Calculi; Bladder Calculi；', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('36', 'S', 'S01', '肾小球肾炎', null, '肾小球肾炎;\n抗肾小球基膜疾病; \n肾小球肾炎, IGA;\n肾小球肾炎, 膜增生性;\n肾小球肾炎, 膜性;\n肾小球硬化症, 局灶节段性;\n狼疮肾炎;', 'glomerulonephritis；\nAnti-Glomerular Basement Membrane Disease ；\nGlomerulonephritis, IGA；\nGlomerulonephritis, Membranoproliferative；\nGlomerulonephritis, Membranous；\nGlomerulosclerosis, Focal Segmental；\nLupus Nephritis；  ', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('37', 'X', 'X01', '心律失常', '心悸', '心律失常；心性心律失常：窦性心律失常；心房颤动；心房扑动；心动过缓；Brugada综合征；早搏心脏复合征；心震荡；心脏传导阻滞；QT延长综合征；并行收缩；预激综合征；心动过速；心室颤动；心室扑动；病窦综合征；心脏窦性停搏；心房早搏复合征；室性早搏复合征；阿-斯综合征；房室传导阻滞；束支传导阻滞；病窦综合征；窦房结功能障碍；窦房阻滞；Andersen综合征；Jervell-Lange Nielsen综合征；Romano-Ward综合征；Lown-Ganong-Levine综合征；Mahaim型预激综合征；W', 'Cardiac Arrhythmias；Sinus Arrhythmia；Auricular Fibrillation；Auricular Flutter；Bradyarrhythmia；Brugada Syndrome；Premature Cardiac Complexes；Premature Beats；Extrasystole；Ectopic Heartbeats；Cardiac Concussion；Heart Block；Long QT Syndrome；Parasystole；Pre-Exci', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('38', 'M', 'M02', '慢性阻塞性肺疾病', '肺胀；喘病', '慢性阻塞性肺气肿；慢性支气管炎；慢性阻塞肺疾病；慢性气道阻塞性疾病；慢性气道阻塞', 'Chronic Obstructive Pulmonary Disease；COPD；COAD；Chronic Obstructive Airway Disease；Chronic Obstructive Lung Disease；Chronic Airflow Obstruction；Chronic Bronchitis；Simple Chronic Bronchitis；Mucopurulent Chronic Bronchitis；Mixed Simple and Mucopurulent Chro', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('39', 'Q', 'Q01', '前列腺增生症', '淋证；癃闭', '前列腺增生症；前列腺增生；前列腺肥大；前列腺腺瘤；良性前列腺增生', 'Prostatic Hyperplasia；Benign Prostatic Hyperplasia', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('4', 'G', 'G05', '骨质疏松症', '骨痹；骨痿', '骨质疏松症；原发性骨质疏松症；骨质疏松性骨折；继发性骨质疏松症；糖皮质激素性骨质疏松症；年龄相关骨质疏松；骨质丢失, 年龄相关；老年性骨质疏松', 'osteoporosis；Age-Related Osteoporosis；Bone Loss, Age-Related；Senile Osteoporosis', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('40', 'R', 'R01', '乳腺增生病', '乳癖', '乳腺增生病；乳腺增生症；乳腺纤维囊性病；乳腺囊性增生症；乳房纤维囊性乳腺病', 'Fibrocystic Disease of Breast；Fibrocystic Breast Disease；Fibroadenosis of breast；Breast Hyperplasia', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('41', 'M', 'M07', '盆腔炎', null, '盆腔炎性疾病；子宫附件炎；子宫内膜炎；子宫内膜炎症；卵巢炎；子宫旁组织炎；盆腔蜂窝织炎；输卵管炎；急性盆腔炎；慢性盆腔炎；急性子宫内膜炎；慢性子宫内膜炎；急性输卵管炎；慢性输卵管炎；盆腔炎症性疾病', 'Pelvic Inflammatory Disease；Adnexitis；Endometritis；Endomyometritis；Oophoritis；Parametritis；Pelvic Cellulitis；Salpingitis', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('42', 'G', 'G01', '高血压病', '眩晕；头痛\n', ' 高血压；高血压, 恶性；高血压, 妊娠性；高血压, 肾性；高血压性视网膜病变；隐性高血压；白大衣高血压；恶性高血压；妊娠高血压；肾性高血压; \n', 'Hypertension ；Blood Pressure, HighHypertensive diseases；Essential (primary) hypertension ；Hypertensive heart disease ；Hypertensive renal disease；Hypertensive heart and renal disease；Secondary hypertension  ', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('43', 'Z', 'Z02', '中风病', '中风；卒中', '脑中风；血管意外, 脑；脑血管中风；脑卒中；脑血管意外；卒中；脑梗死；静脉梗塞, 脑；脑干梗死；大脑梗死；中风, 腔隙性；腔隙性脑梗死', 'Stroke；Acute Stroke； Cerebral Stroke；Vascular Accident, Brain；Cerebrovascular Apoplexy； CVA (Cerebrovascular Accident)；CVAs (Cerebrovascular Accident); Apoplexy；Cerebrovascular Accident；Cerebral infarction；Cerebral infarction due to thrombosis of precereb', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('44', 'Z', 'Z02', '颅内栓塞和血栓形成 ', null, '颅内栓塞和血栓形成；脑动脉栓塞和血栓形成；脑栓塞和血栓形成；颅内栓塞；栓塞, 颅内；栓塞, 脑；脑栓塞；脑动脉栓塞；颅内血栓形成；血栓形成, 颅内；脑血栓形成；脑血栓症；血栓形成, 脑', 'Intracranial Embolism and Thrombosis；Cerebral Embolism and Thrombosis；Brain Embolism and Thrombosis；Embolism, Intracrania； Brain Embolism； Embolism, Brain；Cerebral Embolism；Intracranial Thrombosis；Thrombosis, Intracranial；Cerebral Thrombosis；Brain Thrombo', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('45', 'Z', 'Z02', '脑缺血', null, '短暂性脑缺血发作；脑缺血', 'Transient Ischaemic Attack (TIA)；', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('46', 'Y', 'Y03', '抑郁症', '郁病；郁证；', '神经症, 抑郁性；郁症, 内因性；抑郁综合征；抑郁症, 神经官能性；忧郁症；单相抑郁症；抑郁症, 单相；抑郁症, 产后；抑郁症, 更年期；抑郁症, 难治性；心境恶劣障碍；季节性情感障碍', 'Neurosis, Depressive；Depression, Endogenous；Depressive Syndrome；Depression, Neurotic；Melancholia；Unipolar Depression；Depression, Unipolar；Post-schizophrenic depression；Neonatal cerebral depression；Bipolar affective disorder, current episode mild or modera', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('47', 'X', 'X02', '消化性溃疡', '胃痛；腹痛\n', '十二指肠溃疡；消化性溃疡穿孔；吻合口溃疡；胃十二指肠溃疡；\n', 'Gastroduodenal Ulcer；Marginal Ulcer；Gastric ulcer；Duodenal ulcer； Gastric ulcer : acute with haemorrhage； Gastric ulcer : acute with perforation； Gastric ulcer: acute with both haemorrhage and perforation ；Gastric ulcer : acute without haemorrhage or perf', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('48', 'Y', 'Y04', '银屑病', '白疕  \n', '脓疱病, 掌跖；掌跖脓疱病；掌蹠脓疱病；掌跖脓疱性银屑病；牛皮癣；', 'Psoriasis；Pustulosis of Palms and Soles；Pustulosis Palmaris et Plantaris； Palmoplantaris Pustulosis；Pustular Psoriasis of Palms and Soles；Psoriasis vulgaris；Generalized pustular psoriasis；Acrodermatitis continua ；Pustulosis palmaris et plantaris；Guttate p', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('49', 'Y', 'Y05', '胰腺炎', '腹痛；', '脾心痛；结胸； 胰腺炎, 急性坏死性；胰腺炎, 酒精性；胰腺炎, 慢性；胰腺炎, 移植；', 'Pancreatitis；Cytomegaloviral pancreatitis；\nMumps pancreatitis；Acute pancreatitis；Idiopathic acute pancreatitis；Biliary acute pancreatitis；Alcohol-induced acute pancreatitis；Drug-induced acute pancreatitis；Other acute pancreatitis；Acute pancreatitis, unspe', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('5', 'D', 'D01', '动脉粥样硬化', '脉痹，中风，胸痹，坏疽', '动脉粥样硬化', 'atheroma；atherosclerosis；arteriolosclerosis；arteriosclerosis；arteriosclerotic vascular disease', '', null, null, 'admin', '2016-05-09 10:42:47', '0');
INSERT INTO `biz_disease` VALUES ('50', 'Y', 'Y01', '腰椎间盘突出症', '腰椎间盘突出症', '腰椎间盘移位', 'Intervertebral Disc Displacement Lumbar； Lumbar Intervertebral Disc Displacement ；Lumbar Disc Herniation with Radiculopathy', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('51', 'Y', 'Y02', '月经不调', '月经先期；月经后期；月经先后无定期；月经过多；月经过少；经期延长；痛经；闭经；崩漏', '月经失调；月经逆行；月经失常；月经过少；月经频发；闭经；痛经；月经过多；月经稀发；功能失调性子宫出血', 'Menstruation Disturbances；Menstruation Disorders; Menstruation, Retrograde; Polymenorrhea； Hypomenorrhea；Amenorrhea；Dysmenorrhea；Menorrhagia；Hypermenorrhea；Oligomenorrhea；Premenstrual Syndrome；', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('52', 'M', 'M04', '慢性前列腺炎', '癃闭；淋证', '慢性前列腺炎', 'Chronic prostatitis；', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('53', 'P', 'P01', '偏头痛', '', '', '', '', 'admin', '2016-05-05 15:32:52', null, '2016-05-05 15:32:52', null);
INSERT INTO `biz_disease` VALUES ('54', 'M', 'M09', '泌尿系感染', '', '', '', '', 'admin', '2016-05-05 15:33:22', null, '2016-05-05 15:33:22', null);
INSERT INTO `biz_disease` VALUES ('55', 'K', 'M08', '溃疡性结肠炎', '', '', '', '', 'admin', '2016-05-05 15:36:02', null, '2016-05-05 15:36:02', null);
INSERT INTO `biz_disease` VALUES ('56', 'N', 'Z02', '脑出血脑出血脑出脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血脑出血', '', '', '', '', 'admin', '2016-05-05 16:10:12', 'admin', '2016-05-17 17:54:23', '1');
INSERT INTO `biz_disease` VALUES ('57', 'N', 'Z02', '脑栓塞', '', '', '', '', 'admin', '2016-05-05 16:13:48', 'admin', '2016-05-11 16:03:31', '-3');
INSERT INTO `biz_disease` VALUES ('6', 'J', 'J02', '颈椎病', '颈椎病', '颈椎病', 'Cervical spondylosis；Spondylosis  ', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('7', 'C', 'C01', '哮喘', '喘病；哮病', '支气管哮喘；哮喘；哮喘, 支气管；', 'Asthma；Asthma, Bronchial；Bronchial Asthma', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('743cc405da304af58a4fc0a82e48f8f8', 'A', 'aa', 'a', 'aa', 'aa', 'aa', 'aa', 'admin', '2016-05-10 13:40:03', null, '2016-05-10 13:40:03', '3');
INSERT INTO `biz_disease` VALUES ('8', 'L', 'L01', '类风湿性关节炎', '历节风，痹，顽痹', '类风湿性关节炎', 'Arthritis, Rheumatoid；Rheumatoid Arthritis', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('870a95fa921b42449ed7ae28607256e8', '1', 'aa', '11', '1', '11', '1', '中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥4中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥', 'admin', '2016-05-10 13:24:41', 'admin', '2016-05-11 17:29:06', '2');
INSERT INTO `biz_disease` VALUES ('9', 'F', 'F02', '肺炎', '风温，咳嗽，肺热病，肺炎喘嗽', '社区获得型肺炎；医院获得性肺炎；肺孢子菌肺炎；特发性间质性肺炎；外源过敏性肺泡炎（急性/慢性）；慢性嗜酸性粒细胞性肺炎；放射性肺炎；支气管肺炎；支原体肺炎；肺炎链球菌性疾病；支原体肺炎；病毒性肺炎；肺部炎症；肺炎症', 'Pneumonia；Pneumonitis；Lung Inflammation；Pulmonary Inflammation', null, null, null, null, null, null);
INSERT INTO `biz_disease` VALUES ('93c7f31d31364f1e87d32a5233629036', 'B', 'aa', 'aabb', 'a', 'aaa', 'aaa', 'aa', 'admin', '2016-05-13 15:45:47', null, '2016-05-13 15:45:47', '6');
INSERT INTO `biz_disease` VALUES ('d645ea8e2fbb4beaa2f3aede222d74a6', 'BB', '1', '1', '1', '', '1', '1', 'admin', '2016-05-10 14:45:29', null, '2016-05-10 14:45:29', '4');
INSERT INTO `biz_disease` VALUES ('e13b4e926d5141aa8473c314516bb044', 'A', 'aa', 'aa', 'aa', 'aa', 'a', 'a', 'admin', '2016-05-10 13:16:13', null, '2016-05-10 13:16:13', '1');

-- ----------------------------
-- Table structure for biz_disease_privilege
-- ----------------------------
DROP TABLE IF EXISTS `biz_disease_privilege`;
CREATE TABLE `biz_disease_privilege` (
  `user_id` varchar(32) NOT NULL COMMENT '用户ID',
  `disease_id` varchar(32) NOT NULL COMMENT '疾病ID',
  `privilege_code_id` varchar(32) NOT NULL COMMENT '疾病的权限的ID',
  PRIMARY KEY (`user_id`,`privilege_code_id`,`disease_id`),
  KEY `disease_id` (`disease_id`) USING BTREE,
  KEY `privilege_code_id` (`privilege_code_id`) USING BTREE,
  CONSTRAINT `biz_disease_privilege_ibfk_1` FOREIGN KEY (`user_id`) REFERENCES `ade_user` (`ID`),
  CONSTRAINT `biz_disease_privilege_ibfk_2` FOREIGN KEY (`disease_id`) REFERENCES `biz_disease` (`id`),
  CONSTRAINT `biz_disease_privilege_ibfk_3` FOREIGN KEY (`privilege_code_id`) REFERENCES `biz_privilege_info` (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of biz_disease_privilege
-- ----------------------------
INSERT INTO `biz_disease_privilege` VALUES ('0', '1', '1');
INSERT INTO `biz_disease_privilege` VALUES ('1F81D204CD1A4AB3B5E410CBE38EDCB3', '1', '2');
INSERT INTO `biz_disease_privilege` VALUES ('348C768D5EB841B2AD51CBFDC5569799', '1', '3');
INSERT INTO `biz_disease_privilege` VALUES ('63F4339F9689474AB3AC97BADD392574', '56', '1');
INSERT INTO `biz_disease_privilege` VALUES ('831B54298A5548E7819997EE68089395', '56', '3');
INSERT INTO `biz_disease_privilege` VALUES ('C44C32E76C8D43ECB9C24B98236C3FD7', '56', '2');
INSERT INTO `biz_disease_privilege` VALUES ('0', '57', '1');
INSERT INTO `biz_disease_privilege` VALUES ('0', '57', '2');
INSERT INTO `biz_disease_privilege` VALUES ('0', '57', '3');
INSERT INTO `biz_disease_privilege` VALUES ('0', 'e13b4e926d5141aa8473c314516bb044', '1');

-- ----------------------------
-- Table structure for biz_portal_user
-- ----------------------------
DROP TABLE IF EXISTS `biz_portal_user`;
CREATE TABLE `biz_portal_user` (
  `id` varchar(32) NOT NULL COMMENT '主键UUID',
  `loginName` varchar(40) CHARACTER SET utf8 COLLATE utf8_bin DEFAULT NULL COMMENT '登录名',
  `password` varchar(40) DEFAULT NULL COMMENT '密码',
  `userName` varchar(40) DEFAULT NULL COMMENT '用户名',
  `unit` varchar(200) DEFAULT NULL COMMENT '所属单位',
  `remark` text COMMENT '备注',
  `is_del` varchar(2) DEFAULT NULL COMMENT '是否删除：1删除，非1正常',
  `create_user` varchar(32) DEFAULT NULL COMMENT '创建人',
  `create_time` datetime DEFAULT NULL COMMENT '创建时间',
  `update_user` varchar(32) DEFAULT NULL COMMENT '修改人',
  `update_time` datetime DEFAULT NULL COMMENT '修改时间',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of biz_portal_user
-- ----------------------------
INSERT INTO `biz_portal_user` VALUES ('026f34e3036d47b7941387731f506c8b', '1', 'c4ca4238a0b923820dcc509a6f75849b', 'ad', 'adsfaf', 'asdfasdf', '0', null, '2016-05-09 13:24:18', null, '2016-05-09 13:24:18');
INSERT INTO `biz_portal_user` VALUES ('3b1ca3e4f1034bd1abb8d49dec98b18b', '2', 'c4ca4238a0b923820dcc509a6f75849b', 'aa', 'aa', 'aa', '0', null, '2016-05-06 17:53:40', null, '2016-05-06 17:53:40');
INSERT INTO `biz_portal_user` VALUES ('3fe03a97a6bf4a0896bb56a61653afb9', '3', 'c4ca4238a0b923820dcc509a6f75849b', 'edit', '11', '22222', '0', null, '2016-05-06 17:47:54', null, '2016-05-06 17:47:54');
INSERT INTO `biz_portal_user` VALUES ('4e00d073dc034ebd9d32cd0dc29d5cc2', '4', 'c4ca4238a0b923820dcc509a6f75849b', 'xxx', '111', '11111', '0', null, '2016-05-09 11:02:50', null, '2016-05-09 11:02:50');
INSERT INTO `biz_portal_user` VALUES ('5625f5a7afec4f388d7e3ae05330a880', '5', 'c4ca4238a0b923820dcc509a6f75849b', 'ccc', 'ccc', 'ccccc', '0', null, '2016-05-09 11:03:18', null, '2016-05-09 11:03:18');
INSERT INTO `biz_portal_user` VALUES ('5be988c65a06407d882edb425784ad49', '6', 'c4ca4238a0b923820dcc509a6f75849b', 'edit', '11', '22222', '0', null, '2016-05-06 17:48:01', null, '2016-05-06 17:48:01');
INSERT INTO `biz_portal_user` VALUES ('6419cd0a896e492a9ad32872ec19f9e6', '7', 'c4ca4238a0b923820dcc509a6f75849b', 'ggg', 'ggg', 'gggg', '0', null, '2016-05-09 15:01:29', null, '2016-05-09 15:01:29');
INSERT INTO `biz_portal_user` VALUES ('7a7468c9b98e4d10a034c4412e06f15f', '8', 'c4ca4238a0b923820dcc509a6f75849b', 'adfad', 'adsa', 'adfads', '0', null, '2016-05-09 15:11:31', null, '2016-05-09 15:11:31');
INSERT INTO `biz_portal_user` VALUES ('87dd1025bc9a4d0b93bc399c6ef3581a', '9', 'c4ca4238a0b923820dcc509a6f75849b', 'e', 'e', 'e', '0', null, '2016-05-09 11:14:57', null, '2016-05-09 11:14:57');
INSERT INTO `biz_portal_user` VALUES ('d1c71dad56be452caecae5c4f09505ec', 'yangjY', 'c4ca4238a0b923820dcc509a6f75849b', 'aa', 'aaaa', 'aaaadfadsfasd', '0', null, '2016-05-09 11:15:47', null, '2016-05-09 15:11:55');
INSERT INTO `biz_portal_user` VALUES ('fcc32a0210174330a69dc99be102f597', '11', 'c4ca4238a0b923820dcc509a6f75849b', 'sd', 'ddd', 'ddddd', '0', null, '2016-05-09 11:14:04', null, '2016-05-09 11:14:04');

-- ----------------------------
-- Table structure for biz_privilege_info
-- ----------------------------
DROP TABLE IF EXISTS `biz_privilege_info`;
CREATE TABLE `biz_privilege_info` (
  `id` varchar(32) NOT NULL COMMENT '主键UUID',
  `code` varchar(50) DEFAULT NULL COMMENT '权限代码',
  `name` varchar(50) DEFAULT NULL COMMENT '权限中文名称',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of biz_privilege_info
-- ----------------------------
INSERT INTO `biz_privilege_info` VALUES ('1', null, null);
INSERT INTO `biz_privilege_info` VALUES ('2', null, null);
INSERT INTO `biz_privilege_info` VALUES ('3', null, null);

-- ----------------------------
-- Table structure for biz_standard
-- ----------------------------
DROP TABLE IF EXISTS `biz_standard`;
CREATE TABLE `biz_standard` (
  `id` varchar(32) NOT NULL COMMENT '主键UUID',
  `disease_id` varchar(32) DEFAULT NULL COMMENT '疾病ID',
  `order_num` varchar(50) DEFAULT NULL COMMENT '序号(T01代表疾病名称，_001代表标准顺序号，如：F04_001)',
  `type` varchar(2) DEFAULT NULL COMMENT '标准类型：0中医标准,1西医标准',
  `cn_title` varchar(500) DEFAULT NULL COMMENT '中文题名',
  `en_title` varchar(500) DEFAULT NULL COMMENT '英文题名',
  `publish_org` varchar(500) DEFAULT NULL COMMENT '发布机构',
  `publish_date` int(11) DEFAULT NULL COMMENT '发布日期',
  `source` varchar(5000) DEFAULT NULL COMMENT '来源',
  `language` varchar(50) DEFAULT NULL COMMENT '全文语种',
  `type_stag` text COMMENT '分型分期',
  `mm_disease_name` varchar(500) DEFAULT NULL COMMENT '西医病名',
  `tcm_disease_name` varchar(500) DEFAULT NULL COMMENT '中医病名',
  `tcm_disease_dialectical` text COMMENT '中医辨证',
  `mm_standard` text COMMENT '西医诊断标准',
  `tcm_standard` text COMMENT '中医诊断标准',
  `effect_target` text COMMENT '疗效指标',
  `effect_standard` text COMMENT '疗效判定标准',
  `remark` text COMMENT '备注',
  `status` varchar(2) DEFAULT NULL COMMENT '发布状态（1:新建，2:待审核,3:审核通过,4:审核未通过,5:发布通过,6:发布未通过,7:发布撤销）',
  `is_del` varchar(2) DEFAULT NULL COMMENT '是否删除：0:正常,1:回收站',
  `create_user` varchar(100) DEFAULT NULL COMMENT '创建人',
  `create_time` datetime DEFAULT NULL COMMENT '创建时间',
  `update_user` varchar(100) DEFAULT NULL COMMENT '最后更新人',
  `update_time` datetime DEFAULT NULL COMMENT '修改时间',
  PRIMARY KEY (`id`),
  KEY `disease_id` (`disease_id`) USING BTREE,
  CONSTRAINT `biz_standard_ibfk_1` FOREIGN KEY (`disease_id`) REFERENCES `biz_disease` (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of biz_standard
-- ----------------------------
INSERT INTO `biz_standard` VALUES ('08072c965e694f5080605351a1e3ddfd', '1', '北京市海淀区中关村东路清华科技园搜狐网络大厦北京市海淀区中关村东路的清华科技园搜狐网络大厦中关村东路', '0', '中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥', '', '中国未来发展能否避开中等收入陷阱，能否重启未来发展新动力，都系于分配改革。财政部财科所所长刘尚希建议，应抓住契机进一步深化收入分配相关改革，包括抓紧推进综合与分类相结合的个人所得税改革有关工作更好发挥', '2008', '', '中文', '', '', '', '', '', '', '', '', '', '1', '0', 'admin', '2016-05-11 17:43:20', 'admin', '2016-05-11 17:43:20');
INSERT INTO `biz_standard` VALUES ('0e0f905d9f5244dda221521dec40a696', '4', '111111111111', '0', '111111', 'ab', '11111111111111111', null, 'a', '中文', '<img alt=\"\" src=\"/bzpt/images/2016/5/13/872e4775a4144849aa93ac687b979e4c.jpg\" />', '', '', '<img alt=\"\" src=\"/bzpt/images/2016/5/13/921b7660f6d14bf184887762ec9e0950.jpg\" />aabbbb', '<img alt=\"\" src=\"/bzpt/images/2016/5/13/e3988ae6a0994b74b6bdfbf244a0b746.jpg\" />', '<img alt=\"\" src=\"/bzpt/images/2016/5/13/95fa1990967a4f29bacf548d02dfd42a.png\" />', '<img alt=\"\" src=\"/bzpt/images/2016/5/13/5a8c7c46bbbd4b24bb10d0cf705ffd96.jpg\" />', '<img alt=\"\" src=\"/bzpt/images/2016/5/13/c25886a548b64bc59e1b6c34f062064b.jpg\" />', '<img alt=\"\" src=\"/bzpt/images/2016/5/13/f31f77046f9c4f8c9663f30a8b063818.png\" />11111', '1', '0', 'admin', '2016-05-13 19:16:45', 'admin', '2016-05-19 11:51:31');
INSERT INTO `biz_standard` VALUES ('1', '10', 'D02_001', '1', '中华医学会糖尿病学分会关于代谢综合征的建议', '无', '中华医学会糖尿病学分会代谢综合征研究协作组', '2004', '中华医学会糖尿病学分会关于代谢综合征的建议[J].中华糖尿病杂志,2004,12(3):156-161.', '中文', null, '代谢综合征', null, null, '中华医学会糖尿病学分会（CDS）建议MS诊断标准见下表：D02_001_图表1', null, null, ' ', '应用较多', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('10', '10', 'D02_010', '1', '美国心脏协会与国家心脏、肺和血液研究所关于代谢综合征诊断、管理的科学共识', 'Diagnosis and Management of the Metabolic Syndrome An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement', '美国心脏协会；美国国家心脏、肺和血液研究所（American Heart Association; National Heart, Lung, and Blood Institute）', '2005', 'Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung,and Blood Institute Scientific Statement. Circulation. 2005 Oct 25;112(17):2735-52.', '英文', null, 'Metabolic Syndrome', null, null, 'D02_010_图表1', null, '1.Lifestyle risk factors：body weight、Reduced intake of saturated fat, trans fat, cholesterol<br />&nbsp;&nbsp;2.Metabolic risk factors：LDL-C、HDL-C、BP、IFG、hemoglobin A1C、Reduce thrombotic and fibrinolytic', 'D02_010_图表2', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('100', '40', 'R01_001', '0', '中医外科病证诊断疗效标准', 'Criteria of diagnosis and therapeutic effect of surgical diseases and syndromes in traditional Chinese medicine', '国家中医药管理局', '1994', '国家中医药管理局.ZY／T001.2-94，中医病证诊断疗效标准·中医外科病证诊断疗效标准[S].南京：南京大学出版社，1994.\nZY/T 001.2-94, 中医外科病证诊断疗效标准[S].', '中文', null, null, '乳癖', '肝郁痰凝；冲任失调', '1多数在乳房外上象限有一扁平肿块，扣之有豆粒大小韧硬结节，可有触痛。肿块边界欠清，与周围组织不粘连。<br />&nbsp;&nbsp;2乳房可有胀痛，每随喜怒而消长，常在月经前加重，月经后缓解。<br />&nbsp;&nbsp;3本病多见于20～40岁妇女。<br />&nbsp;&nbsp;4钼钯X线乳房摄片、冷光源强光照射、液晶热图像等检查有助诊断。必要时作组织病理学检查。<br />&nbsp;&nbsp;', '1肝郁痰凝：多见于青壮年妇女。乳房肿块随喜怒消长，伴有胸闷胁胀，善郁易怒，失眠多梦，心烦口苦。舌苔薄黄，脉弦滑。<br />&nbsp;&nbsp;2冲任失调：多见于中年妇女。乳房肿块月经前加重，经后缓减。伴有腰酸乏力，神疲倦怠，月经先后失调，量少色淡，或经闭。舌淡，苔白，脉沉细。<br />&nbsp;&nbsp;', '乳房肿块；乳房疼痛', '1治愈：乳房肿块及疼痛消失。<br />&nbsp;&nbsp;2好转：乳房肿块缩小，疼痛减轻或消失。<br />&nbsp;&nbsp;3未愈：乳房肿块及疼痛无变化。<br />&nbsp;&nbsp;', '为中医标准。本标准规定了中医外科38个病证的病证名、诊断依据、证候分类、疗效评定。本标准适用于中医临床医疗质量评定，中医科研、教学亦可参照使用。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('101', '40', 'R01_002', '1', '中华医学会临床诊疗指南', '无', ' 中华医学会', '2009', '中华医学会.临床诊疗指南外科学分册[M].北京：人民卫生出版社，2006.', '中文', null, '乳腺囊性增生症', null, null, '1临床表现<br />&nbsp;&nbsp;1.1乳房胀痛：特点是疼痛与月经周期有关，往往在月经前（一般月经来潮前7天左右）疼痛加重，月经来潮后减轻或消失，但病程较长者以上规律可以消失。<br />&nbsp;&nbsp;1.2乳房肿块：一侧或二侧乳腺有弥漫性增厚，呈颗粒状、结节状或片状，增厚区与周围乳腺组织分界不明显，质地韧，有弹性，可活动，以外上象限为多，可伴有触痛。少数病人可有乳头溢液，为无色或黄色。腋窝无肿大淋巴结。<br />&nbsp;&nbsp;2辅助检查<br />&nbsp;&nbsp;2.1钼钯X线检查：增生的乳腺组织呈棉絮状或毛玻璃状密度增强影，如有囊性增生可见增强影中有圆形透亮阴影。<br />&nbsp;&nbsp;2.2红外透照检查：利用乳腺组织对红外光的吸收程度不同，其透射图像可显示乳腺内部结构，乳腺囊性增生症透光一般无明显异常，增生明显处透光度可减弱，血管图像正常。<br />&nbsp;&nbsp;2.3B超检查对诊断有一定帮助。<br />&nbsp;&nbsp;2.4细针穿刺细胞学检查、切除或切取活检是可靠的诊断手段。<br />&nbsp;&nbsp;', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('102', '40', 'R01_003', '0', '中医外科病证诊断疗效标准（试行）', '无', '国家中医药管理局', '1986', '中医外科病证诊断疗效标准（试行）.国家中医药管理局.', '中文', null, '乳腺增生病', null, '肝郁痰凝证；冲任失调证', '1本病多见于30～40岁之间妇女。<br />&nbsp;&nbsp;2一侧或两侧乳房发生多个大小不同的圆形，韧硬的结节。结节常分散于整个乳房，也可局限在乳房的一部。<br />&nbsp;&nbsp;3肿块边界不清，与皮肤不相连，推之可动，肿块每随喜怒而消长，始终不会溃破。<br />&nbsp;&nbsp;4乳房部有明显胀痛，常在月经前加重，月经后减轻。<br />&nbsp;&nbsp;', '1肝郁痰凝证：伴有胸闷胁胀，易愁善怒，失眠梦多，心烦口苦。舌苔薄黄，脉象弦滑等症。<br />&nbsp;&nbsp;2冲任失调证：伴有腰酸乏力，神疲倦怠，月经先后无定期，经水量少，色淡，或经闭。舌淡苔白，脉象沉细等症。<br />&nbsp;&nbsp;', '乳房肿块；乳房疼痛', '1痊愈：乳房疼痛及肿块消失。<br />&nbsp;&nbsp;2好转：乳房疼痛减轻，肿块缩小。<br />&nbsp;&nbsp;3无效：乳房疼痛不减，肿块未见缩小。<br />&nbsp;&nbsp;', '为试行标准，具备完整的诊断及疗效判定标准，具有指导意义。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('103', '40', 'R01_004', '0', '乳腺增生病诊断及疗效评定标准', '无', ' 中华全国中医学会外科学会', '1987', '韩梅.乳腺增生病诊断及疗效评定标准(修订稿)[J]. 中国医药学报,1988,3（3）:66.', '中文', null, '乳腺增生病', null, null, '1临床上有乳腺肿块、且多数伴有乳房疼痛等症状，连续3个月不能自行缓解。<br />&nbsp;&nbsp;2排除生理性乳房疼痛，如经前乳房胀痛，青春期乳痛及仅有乳痛而无肿块的乳痛症。<br />&nbsp;&nbsp;3利用铂钯X线、干板、B超、热象图等现代检测手段做为辅助诊断，并排除乳腺癌、乳腺纤维腺瘤等其它乳腺疾病。<br />&nbsp;&nbsp; ', null, '乳房肿块；乳房疼痛', '1临床治愈：肿块消失、乳痛消失，停药后3个月不复发。<br />&nbsp;&nbsp;2显效：肿块最大直径缩小1/2口上，乳痛消失。<br />&nbsp;&nbsp;3有效：3.1肿块最大直径缩小不足1/2，乳痛减轻；3.2肿块缩小1/2以上，乳痛不减轻。<br />&nbsp;&nbsp;4无效：1.1肿块不缩小，或反而增大变硬者；4.2单纯乳痛缓解，而肿块不缩小。<br />&nbsp;&nbsp; ', '为中医标准。中华全国中医学会外科学会乳腺病组修订的专病标准，更具专指性。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('104', '39', 'Q01_001', '0', '中医外科病证诊断疗效标准', 'Criteria of diagnosis and therapeutic effect of surgical diseases and syndromes in traditional Chinese medicine', '国家中医药管理局', '1994', '国家中医药管理局.ZY／T001.2-94，中医病证诊断疗效标准·中医外科病证诊断疗效标准[S].南京：南京大学出版社，1994.', '中文', null, null, '精癃', '肺热失宣；湿热下注；中气下陷；肾阴亏虚；肾阳虚损；气滞血瘀', '1.开始尿频，尤其夜尿次数增多，渐有排尿困难，余溺不尽，严重时可有尿闭或小便失禁。<br />&nbsp;&nbsp;2.本病多见于老年男性。<br />&nbsp;&nbsp;3.直肠指诊：精室肥大，表面光滑而无结节，边缘清楚，中等硬度而富弹性，中央沟变浅或消失。<br />&nbsp;&nbsp;4.B超检查：前列腺大小测定较正常增大，膀胱残留尿大于60毫升。<br />&nbsp;&nbsp;', '1.肺热失宣：小便不畅或点滴不通。兼见咽干，口燥，胸闷，呼吸不利，咳嗽咯痰。舌质红，苔薄黄，脉滑数。<br />&nbsp;&nbsp;2.湿热下注：尿少黄赤，尿频涩痛，点滴不畅，甚至尿闭，小腹胀满。口渴不欲饮，发热或大便秘结。舌质红，苔黄腻，脉数。<br />&nbsp;&nbsp;3.中气下陷：小腹坠胀，小便欲解不爽，尿失禁或夜间遗尿。精神倦怠，少气懒言。舌质淡，苔薄白，脉濡细。<br />&nbsp;&nbsp;4.肾阴亏虚：小便频数不爽，淋漓不尽。伴有头晕目眩，腰酸膝软，失眠多梦，咽干。舌红，苔黄，脉细数。<br />&nbsp;&nbsp;5.肾阳虚损：排尿无力，失禁或遗尿，点滴不尽。面色㿠白，神倦畏寒，腰膝酸软无力，手足不温。舌质淡，苔白，脉沉细。<br />&nbsp;&nbsp;6.气滞血瘀：小便努责方出或点滴全无，会阴、小腹胀痛，偶有血尿或血精。舌质紫暗或有瘀斑，苔白或黄，脉沉弦或细涩。<br />&nbsp;&nbsp;', '排尿；前列腺检查', '1.治愈：排尿通畅，前列腺检查明显缩小，无残余尿。<br />&nbsp;&nbsp;2.好转：排尿症状好转，残余尿减少。<br />&nbsp;&nbsp;3.未愈：症状和各项检查均无改善。<br />&nbsp;&nbsp;', '为中医标准，规定了中医外科38个病证的病证名、诊断依据、证候分类、疗效评定。本标准适用于中医临床医疗质量评定，中医科研、教学亦可参照使用。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('105', '39', 'Q01_002', '0', '中华中医药学会标准-癃闭', '无', '中华中医药学会', '2008', 'ZYYXH/T 37-2008, 癃闭[S].', '中文', null, null, '癃闭', '膀胱湿热证；肺热壅盛证；肝郁气滞证；浊瘀阻塞证；脾气不升证；肾阳衰惫证', '1.诊断要点<br />&nbsp;&nbsp;1.1小便不利，点滴不畅，或小便闭塞不通，尿道无涩痛，小腹胀满。<br />&nbsp;&nbsp;1.2凡小腹胀满、小便欲解不出，触叩小腹部膀胱区明显胀满者为尿潴留如小便量少或不通，<br />&nbsp;&nbsp;无排尿感觉和小腹胀满，叩触小腹膀胱区也无明显充盈征象，此属肾功能衰竭所致的无尿或少尿。<br />&nbsp;&nbsp;1.3多见于老年男性，或产后妇女及手术后患者。<br />&nbsp;&nbsp;1.4结合病史中发病经过和症状，结合体检如肛门指诊、B超、CT、膀胱镜、肾功能检查等可确定由何种疾病引起的癃闭。<br />&nbsp;&nbsp;2.鉴别诊断<br />&nbsp;&nbsp;2.1淋证：淋证以小便频数短涩、滴沥刺痛、欲出未尽为特征。淋证尿频且疼痛，一日排出小便<br />&nbsp;&nbsp;总量多正常；癃闭则无排尿刺痛，一日小便总量少于正常，甚至无尿排出。<br />&nbsp;&nbsp;2.2关格：关格是指小便不通与呕吐并见的病证；癃闭单纯指小便闭塞不通，没有呕吐及大便不通。<br />&nbsp;&nbsp;2.3转胞：转胞为脐下急痛、小便不通证，或有呕吐，为妇科病范畴，因妊娠胎气下压膀胱。癃闭以排尿困难、小便量少为特点，无脐下急痛等表现。<br />&nbsp;&nbsp;', '1.膀胱湿热证：小便点滴不通，或量少而短赤灼热，小腹胀满，口苦口黏，口干不欲饮，或大便不畅，舌质红苔根黄腻，脉数。<br />&nbsp;&nbsp;2.肺热壅盛证：小便不畅或者点滴不通，咽干，烦渴欲饮，呼吸急促或有咳嗽，舌质红，苔薄黄，脉数。<br />&nbsp;&nbsp;3.肝郁气滞证：小便突然不通或者通而不畅，胁腹胀满，情志抑郁或者心烦易怒，舌红，苔薄白或薄黄，脉弦。<br />&nbsp;&nbsp;4.浊瘀阻塞证：小便点滴而下或尿细如线，甚至阻塞不通，小腹胀满疼痛，舌质紫暗或有瘀斑，脉涩。<br />&nbsp;&nbsp;5.脾气不升证：时欲小便而不得出，或量少而不爽利，小腹坠胀，气短，语声低微，精神疲乏，不思纳食，舌淡苔薄，脉弱。<br />&nbsp;&nbsp;6.肾阳衰惫证：小便不通或者点滴不爽，排出无力，面色㿠白，神气怯弱，畏寒肢冷，腰膝冷而酸软，舌淡苔白，脉沉细而尺弱。<br />&nbsp;&nbsp;', null, null, '为中医标准，明确诊断要点及鉴别诊断，明确辨证分型并有相应详细的中医药治疗方法，欠缺疗效标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('106', '39', 'Q01_003', '0', '中华中医药学会标准-淋证', '无', '中华中医药学会', '2009', 'ZYYXH/T 38-2008, 淋证[S].', '中文', null, null, '淋证', '热淋；石淋；气淋；血淋；膏淋；劳淋', '1.诊断要点<br />&nbsp;&nbsp;1.1小便频急淋沥涩痛、小腹拘急、腹部酸痛为各种淋证的主症，是诊断的主要依据。<br />&nbsp;&nbsp;1.2病久或者反复发作后，常伴有低热、小腹坠胀、腹部酸痛、疲劳乏力等症。<br />&nbsp;&nbsp;1.3多见于已婚女性，多因感受外邪、情绪变化、疲劳过度而诱发。<br />&nbsp;&nbsp;1.4理化检查，如尿常规、尿细菌培养、X线腹部摄片、肾盂静脉造影、B超、膀胱镜等以明确诊断。<br />&nbsp;&nbsp;2.鉴别诊断<br />&nbsp;&nbsp;2.1癃闭：以排尿困难、小便量少，甚至点滴全无为特征。其小便量少、排尿困难与淋证相<br />&nbsp;&nbsp;似。淋证尿频而痛，尿量正常庭闭则无尿痛，尿量低于正常，严重时无尿排出。<br />&nbsp;&nbsp;2.2尿血：尿血与血淋都有小便出血，尿色红赤，但一般以小便痛者为血淋，不痛者为尿血。<br />&nbsp;&nbsp;2.3尿浊：尿浊虽然小便浑浊，白如浴浆，与膏淋相似，但排尿时无疼痛滞涩感。<br />&nbsp;&nbsp;', '1.热淋：小便频数，灼热刺痛，小便黄赤，腹痛拒按，寒热起伏，口苦，呕恶，便秘，舌苔黄腻，脉濡数或者滑数。<br />&nbsp;&nbsp;2.石淋：尿中时夹沙石，小便艰涩，尿时疼痛或突然中断，中腹绞痛难忍，尿中带血，舌质红，苔薄黄，脉弦或带数。<br />&nbsp;&nbsp;3.气淋：实证可见小便涩滞，淋沥不畅，少腹满痛，舌苔薄白，脉沉弦；虚证可见小腹坠胀，尿有余沥，面色㿠白，舌质淡，脉虚细无力。<br />&nbsp;&nbsp;4.血淋：实证可见小便涩痛带血，尿时夹有血块，疼痛满急加剧，心烦，舌尖红，苔黄，脉数；虚证可见尿色淡红，尿痛涩滞不显，腰膝酸软，神疲乏力，舌淡红，脉细数。<br />&nbsp;&nbsp;5.膏淋：实证可见小便浑浊如米泔水，尿道热涩疼痛，舌红苔黄腻，脉濡数；虚证可见淋出为脂，涩痛反见减轻，形瘦，眩晕，腰膝酸软乏力，舌淡苔腻，脉细弱无力。<br />&nbsp;&nbsp;6.劳淋：小便不甚赤涩，但淋沥不已，时作时出，遇劳即发，腰膝酸软，神疲乏力，舌质淡，脉弱。<br />&nbsp;&nbsp;', null, null, '为中医标准，明确诊断要点及鉴别诊断，明确辨证分型并有相应详细的中医药治疗方法，欠缺疗效标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('107', '39', 'Q01_004', '1', '中国泌尿外科疾病诊断治疗指南', '无', '中华医学会泌尿外科学会', '2011', '中华医学会泌尿外科学会-中国泌尿外科疾病诊断治疗指南', '中文', null, '良性前列腺增生', null, null, '以下尿路症状为主诉就诊的50岁以上男性患者，首先应该考虑BPH的可能。为明确诊断，需作以下临床评估。<br />&nbsp;&nbsp;1初始评估<br />&nbsp;&nbsp;1.1 病史询问 (medical history)（推荐）<br />&nbsp;&nbsp;1.1.1下尿路症状的特点、持续时间及其伴随症状<br />&nbsp;&nbsp;1.1.2手术史、外伤史，尤其是盆腔手术或外伤史<br />&nbsp;&nbsp;1.1.3既往史和性传播疾病、糖尿病、神经系统疾病<br />&nbsp;&nbsp;1.1.4药物史，可了解患者目前或近期是否服用了影响膀胱出口功能的药物<br />&nbsp;&nbsp;1.1.5患者的一般状况<br />&nbsp;&nbsp;1.1.6国际前列腺症状评分(I-PSS,表1)<br />&nbsp;&nbsp;I-PSS评分标准是目前国际公认的判断BPH患者症状严重程度的最佳手段。<br />&nbsp;&nbsp;I-PSS评分是BPH患者下尿路症状严重程度的主观反映，它与最大尿流率、残余尿量以及前列腺体积无明显相关性。<br />&nbsp;&nbsp;I-PSS评分患者分类如下：（总分0-35分）<br />&nbsp;&nbsp;轻度症状      0-7分<br />&nbsp;&nbsp;中度症状     8-19分<br />&nbsp;&nbsp;重度症状    20-35分<br />&nbsp;&nbsp;1.1.7生活质量评分（QOL）：QOL评分（0-6分）是了解患者对其目前下尿路症状水平伴随其一生的主观感受，其主要关心的是BPH患者受下尿路症状困扰的程度及是否能够忍受。因此，又叫困扰评分。<br />&nbsp;&nbsp;以上两种评分尽管不能完全概括下尿路症状对BPH患者生活质量的影响，但是它们提供了医生与患者之间交流的平台，能够使医生很好地了解患者的疾病状态。<br />&nbsp;&nbsp;Q01_004表1.2体格检查（physical examination）（推荐）<br />&nbsp;&nbsp;1.2.1外生殖器检查：除外尿道外口狭窄或畸形所致的排尿障碍。<br />&nbsp;&nbsp;1.2.2直肠指诊（digital rectal examination）：下尿路症状患者行直肠指诊非常重要，需在膀胱排空后进行。直肠指诊可以了解前列腺的大小、形态、质地、有无结节及压痛、中央沟是否变浅或消失以及肛门括约肌张力情况。直肠指诊对前列腺体积的判断不够精确，目前经腹超声或经直肠超声检查可以更精确描述前列腺的形态和体积。<br />&nbsp;&nbsp;直肠指诊还可以了解是否存在前列腺癌。国外学者临床研究证实，直肠指诊怀疑有异常的患者最后确诊为前列腺癌的有26%～34%。而且其阳性率随着年龄的增加呈上升趋势。<br />&nbsp;&nbsp;1.2.3局部神经系统检查（包括运动和感觉）<br />&nbsp;&nbsp;1.3尿常规 (urinalysis)（推荐）  尿常规可以确定下尿路症状患者是否有血尿、蛋白尿、脓尿及尿糖等。<br />&nbsp;&nbsp;1.4血清PSA（推荐）  前列腺癌、BPH、前列腺炎都可能使血清PSA升高。因此，血清PSA不是前列腺癌特有的。另外，泌尿系感染、前列腺穿刺、急性尿潴留、留置导尿、直肠指诊及前列腺按摩也可以影响血清PSA值。<br />&nbsp;&nbsp;血清PSA与年龄和种族有密切关系。一般40岁以后血清PSA会升高，不同种族的人群PSA水平也不相同。血清PSA值和前列腺体积相关，但血清PSA与BPH的相关性为0.30ng/ml，与前列腺癌为3.5ng/ml。血清PSA升高可以作为前列腺癌穿刺活检的指征。一般临床将PSA≥4ng/ml作为分界点。血清PSA作为一项危险因素可以预测BPH的临床进展，从而指导治疗方法的选择。<br />&nbsp;&nbsp;1.5超声检查 (ultrasonography)（推荐）  超声检查可以了解前列腺形态、大小、有无异常回声、突入膀胱的程度，以及残余尿量(postvoid residual volume)。经直肠超声（transrectal ultrasonography，TRUS）还可以精确测定前列腺体积（计算公式为0.52×前后径×左右径×上下径）。另外，经腹部超声检查可以了解泌尿系统（肾、输尿管）有无积水、扩张，结石或占位性病变。<br />&nbsp;&nbsp;1.6尿流率检查 (uroflowmetry)（推荐）  尿流率有两项主要指标（参数）：最大尿流率（Qmax）和平均尿流率（average flow rate，Qave），其中最大尿流率更为重要。但是最大尿流率减低不能区分梗阻和逼尿肌收缩力减低，必要时行尿动力学等检查。最大尿流率存在个体差异和容量依赖性。因此，尿量在150～200ml时进行检查较为准确，必要时可重复检查。<br />&nbsp;&nbsp;2根据初始评估结果需要的进一步检查<br />&nbsp;&nbsp;2.1排尿日记 (voiding charts)（可选择）  如以夜尿为主的下尿路症状患者排尿日记很有价值，记录24小时排尿日记有助于鉴别夜间多尿和饮水过量。<br />&nbsp;&nbsp;2.2血肌酐 (creatinine)（可选择）  由于BPH导致的膀胱出口梗阻可以引起肾功能损害、血肌酐升高。MTOPS的研究数据认为如果排空正常的情况下可以不必检测血肌酐，因为由于BPH所致的肾功能损害在达到血肌酐升高已经有许多其他的变化，如肾积水、输尿管扩张返流等，而这些可以通过超声检查及静脉肾盂造影检查得到明确的结果。仅在已经发生上述病变，怀疑肾功能不全时建议选择此检查。<br />&nbsp;&nbsp;2.3静脉尿路造影（intravenous urography）检查（可选择）  如果下尿路症状患者同时伴有反复泌尿系感染、镜下或肉眼血尿、怀疑肾积水或者输尿管扩张返流、泌尿系结石应行静脉尿路造影检查。应该注意，当患者造影剂过敏或者肾功能不全时禁止行静脉尿路造影检查。<br />&nbsp;&nbsp;2.4尿道造影 (urethrogram)（可选择）  怀疑尿道狭窄时建议此项检查。<br />&nbsp;&nbsp;2.5尿动力学检查（urodynamics）（可选择） 尿动力学检查是区分膀胱出口梗阻和膀胱逼尿肌无力的有效方法，有以下情况如多次尿流率检查尿量在150ml以下；残余尿量>300ml；盆腔外科手术后；BPH侵袭性治疗效果欠佳者，可以选择尿动力学检查。结合其他相关检查，除外神经系统病变或糖尿病所致神经源性膀胱的可能。<br />&nbsp;&nbsp;2.6尿道膀胱镜（urethrocystoscopy）检查（可选择）  怀疑BPH患者合并尿道狭窄、膀胱内占位性病变时建议行此项检查。<br />&nbsp;&nbsp;通过尿道膀胱镜检查可了解以下情况：2.6.1前列腺增大所致的尿道或膀胱颈梗阻特点；2.6.2膀胱颈后唇抬高所致的梗阻；2.6.3膀胱小梁及憩室的形成；2.6.4膀胱结石；2.6.5残余尿量测定；2.6.6膀胱肿瘤；2.6.7尿道狭窄的部位和程度。<br />&nbsp;&nbsp;3不推荐检查项目<br />&nbsp;&nbsp;计算机断层扫描（computed tomography，CT）和磁共振成像（magnetic resonance imaging，MRI)由于检查费用高，一般情况下不建议该项检查。<br />&nbsp;&nbsp;4BPH患者初始评估小结<br />&nbsp;&nbsp;4.1推荐检查项目  4.1.1病史及I-PSS、QOL评分；4.1.2体格检查（直肠指诊）；4.1.3尿常规；4.1.4血清PSA；4.1.5超声检查（包括残余尿量测定）；4.1.6尿流率。<br />&nbsp;&nbsp;4.2可选择性检查项目  4.2.1排尿日记；4.2.2尿动力学检查；4.2.3静脉尿路造影；4.2.4尿道造影；4.2.5尿道膀胱镜检查。<br />&nbsp;&nbsp;4.3不推荐检查项目  4.3.1计算机断层扫描；4.3.2磁共振成像。<br />&nbsp;&nbsp;', null, null, null, '为西医标准，是修订版。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('108', '39', 'Q01_005', '1', '中国泌尿外科疾病诊断治疗指南', '无', '中华医学会泌尿外科学会', '2014', '中华医学会泌尿外科学会-中国泌尿外科疾病诊断治疗指南', '中文', null, '良性前列腺增生', null, null, '一、初始评储<br />&nbsp;&nbsp;    1．病史询问( lViedical history)（推荐）<br />&nbsp;&nbsp;    (1)下尿路症状的特点、持续时间及其伴随症状<br />&nbsp;&nbsp;    (2)手术史、外伤史，尤其是盆腔手术或外伤史<br />&nbsp;&nbsp;    (3)既往史：包括性传播疾病、糖尿病、神经系统疾病、可能与夜尿症有关的心脏疾病病史。<br />&nbsp;&nbsp;    (4)药物史，可了解患者目前或近期是否服用了影响膀胱出口功能或导致LUTS的药物<br />&nbsp;&nbsp;    (5)患者的一般状况<br />&nbsp;&nbsp;    (6)国际前列腺症状评分Q01_005表1<br />&nbsp;&nbsp;    IPSS是目前国际公认的判断BPH患者症状严重程度的最佳手段。<br />&nbsp;&nbsp;    IPSS是BPH患者下尿路症状严重程度的主观反映，它与最大尿流率、残余尿量以及前列腺体积无明显相关性。<br />&nbsp;&nbsp;    IPSS患者分类如下：（总分0-35分）<br />&nbsp;&nbsp;    轻度症状0-7分<br />&nbsp;&nbsp;    中度症状8-19分<br />&nbsp;&nbsp;    重度症状20-35分<br />&nbsp;&nbsp;    (7)生活质量(QOL)评分：QOL评分(0~6分)是了解患者对其目前LUTS水平的主观感受，其主要关心的是BPI患者受LUTS困扰的程度及是否能够忍受。因此，又称之为困扰评分。Q01_005表2<br />&nbsp;&nbsp;    以上两种评分尽管不能完全概括下尿路症状对BPH患者生活质量的影响，但是它们提供了医生与患者之间交流的平台，能够使医生很好地了解患者的疾病状态。<br />&nbsp;&nbsp;    2．休格检查(Physicalexarnination)（推荐）<br />&nbsp;&nbsp;    (1)外生殖器检查：除外尿道外口狭窄或其他可能影响排尿的疾病（如：包茎，阴茎肿瘤等）。<br />&nbsp;&nbsp;    (2)直肠指诊(Digital rectal  examination，DRE):DRE是BPH患者重要检查项目之一，需在膀胱排空后进行。DRE可以了解前列腺的大小、形态、质地、有无结节及压痛、中央沟是否变浅或消失以及肛门括约肌张力情况。DRE对前列腺体积的判断不够精确，目前经腹超声或经直肠超声检查可以更精确描述前列腺的形态和体积。<br />&nbsp;&nbsp;    DRE还是前列腺癌筛查的一个重要手段。国外学者临床研究证实，DRE异常的患者最后确诊为前列腺癌的比例为26t70-340-/015]，而且其阳性率随着年龄的增加呈上升趋势。<br />&nbsp;&nbsp;(3)局部神经系统检查（包括运动和感觉）肛周和会阴外周神经系统的检查以提示是否存在神经源性疾病导致的神经源性膀胱功能障碍。<br />&nbsp;&nbsp;    3．尿常规( Urinalysis)（推荐）尿常规可以确定下尿路症状患者是否有血尿、蛋白尿、脓尿及尿糖等。<br />&nbsp;&nbsp;    4。血清前列腺特异抗原( PSA)（推荐）血清PSA不是前列腺癌特有的，前列腺癌、BPH、前列腺炎都可能使血清PSA升高。另外，泌尿系感染、前列腺穿刺、急性尿潴留、留置导尿、直肠指诊及前列腺按摩等也可以影响疯清PSA值。<br />&nbsp;&nbsp;    血清PSA与年龄和种族有密切关系。一般40岁以后血清PSA会升高，不同种族的人群PSA水平也不相同。血清PSA值和前列腺体积相关，但血清PSA与BPH的相关性为0.30ng/nl/ml，与前列腺癌为3.5ng/ml/ml。血清PSA升高可以作为前列腺癌穿刺活检的指征。一般临床将PSA≥4ng/ml作为分界点。血清PSA作为一项危险因素可以预测BPH的临床进展，从而指导治疗方法的选择。<br />&nbsp;&nbsp;    5．前列腺超声检查(Prostate ultrasonography)（推荐）超声检查可以了解前列腺形态、大小、有无异常回声、突人膀胱的程度，以及残余尿量(Postvoid residual volume)，经直肠超声(Transrectalultrasonography，TRUS)还可以精确测定前列腺体积（计算公式为0.52×前后径×左右径×上下径）。经腹部超声检查可以了解膀胱壁的改变以及有无结石、憩室或占位性病变。<br />&nbsp;&nbsp;    6．尿流率检查（U roflowmetry）（推荐）尿流率检查有两项主要指标（参数）：最大尿流率(Qmax)和平均尿流率(Average flow rate，Qave)，其中最大尿流率更为重要。但是最大尿流率下降不能区分梗阻和逼尿肌收缩力减低，必要时行尿动力学等检查。最大尿流率存在个体差异和容量依赖性。因此，尿量在150-200ml时进行检查较为准确，重复检查会增加可靠性。<br />&nbsp;&nbsp;二、根据初始评估结果需要的进一步检查<br />&nbsp;&nbsp;    1．排尿日记( Voiding diary)（可选择）  以夜尿或尿频为主的下尿路症状患者应记录排尿日记，24小时排尿日记不但可发现饮水过量导致的排尿次数增加，而且也有助于鉴别尿崩症、夜间多尿症和膀胱容量减少。<br />&nbsp;&nbsp;    2．血肌酐（Creatinine）（可选择）BPH导致的膀胱出口梗阻可以引起肾功能损害、血肌酐升高。MTOPS的研究数据认力如果膀胱排空正常的情况下可以不必检测血肌酐，因为由于BPH所致的肾功能损害在达到血肌酐升高已经有许多其他的变化，如肾积水、输尿管扩张反流等，而这些可以通过超声检查及静脉尿路造影检查得到明确的结果。仅在已经发生上述病变，怀疑肾功能不全时建议选择此检查。<br />&nbsp;&nbsp;    3．静脉尿路造影( Intravenous urography)检查（可选择）如果下尿路症状患者同时伴有反复泌尿系感染、镜下或肉眼血尿、怀疑肾积水或者输尿管扩张反流、泌尿系结石应行静脉尿路造影检查。应该注意，当患者造影剂过敏或者肾功能不全时禁止行静脉尿路造影检查。<br />&nbsp;&nbsp;    4.尿道造影( Urethrogram)（可选择）怀疑尿道狭窄时建议此项检查。<br />&nbsp;&nbsp;    5.尿动力学检查（Urodynamics）（可选择）对引起膀胱出口梗阻的原因有疑问或需要对膀胱功能进行评估时建议行此项检查。BPH患者拟行手术及微创治疗前如出现以下情况，建议行尿动力学检查：<br />&nbsp;&nbsp;    ①尿量≤150ml;②50岁以下或80岁以上；③残余尿>300ml；④怀疑有神经系统病变或糖尿病所致神经源性膀胱；⑤双侧肾积水；⑥既往有盆腔或尿道的手术史。<br />&nbsp;&nbsp;    6．尿道膀胱镜( Ure{hrocystoscopy)裣查（可选择）怀疑BPH患者合并尿道狭窄、膀胱内占位性病变时建议行此项检查。<br />&nbsp;&nbsp;    通过尿道膀胱镜检查可了解以下情况：①前列腺增大所致的尿道或膀胱颈梗阻特点；②膀胱颈后唇抬高所致的梗阻；③膀胱小梁及憩室的形成；④膀胱结石；⑤残余尿量测定；⑥膀胱肿瘤；⑦尿道狭窄的部位和程度。<br />&nbsp;&nbsp;    7．上尿路超声检查( Upper urinary tractultrasonography)检查（可选择）：可了解肾、输尿管有无扩张、积水、结石或占位病变。尿常规分析异常、大量残余尿、肾功能不全或有泌尿系统疾病史的患者推荐该检查。<br />&nbsp;&nbsp;三、不推荐检查项目<br />&nbsp;&nbsp;  计算机断层扫描( Computed tomography，CT)和磁共振成像( Magnetic resonance imaging，MRI)由于检查费用高，一般情况下不建议该项检查。<br />&nbsp;&nbsp;四、BPH诊断流程图Q01_005表3', null, null, null, '为西医标准，是修订版。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('109', '39', 'Q01_006', '1', '美国泌尿协会指南:良性前列腺增生的管理', 'AMERICAN UROLOGICAL ASSOCIATION GUIDELINE: MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)', '美国泌尿外科学会（AUA,American Urological Association）', '2010', 'http://www.auanet.org/education/guidelines/benign-prostatic-hyperplasia.cfm', '英文', null, '良性前列腺增生', null, null, 'The Panel decided that the diagnostic section of the 2003 Guideline required updating. After review of the recommendations for diagnosis published by the 2005 International Consultation of Urologic Diseases12 and reiterated in 2009 in an article by Abrams et al (2009), the Panel unanimously agreed that the contents were valid and reflected \"best practices\". 13 The diagnostic guidelines by Abrams et al (2009) are revisited in Appendix A7. 13 Two treatment algorithms, one on the basic management of LUTS in men and one on the detailed management for persistent bothersome LUTS —were adapted for this Guideline and are included in Appendix A1 as Figures 1.1 and 1.2, respectively. ', null, null, ' ', '为国外指南，主要为诊断及推荐。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('11', '10', 'D02_011', '1', '美国内分泌协会胰岛素抵抗综合征立场声明', 'American College of Endocrinology Position Statement on the Insulin Resistance Syndrome', '美国内分泌协会（American College of Endocrinology）', '2002', 'https://www.aace.com/files/american-college-of-endocrinology-position-statement-on-the-insulin-resistance-syndrome.pdf', '英文', null, 'Insulin Resistance Syndrome', null, null, 'D02_011_图表1', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('110', '39', 'Q01_007', '1', '韩国良性前列腺增生的临床实践指南', 'Korean clinical practice guideline for benign prostatic hyperplasia', '韩国泌尿外科协会（KUA,Korean Urological Association）', '2016', 'Investig Clin Urol .2016;57:30-44', '英文', null, '良性前列腺增生', null, null, '1.Diagnostic evaluation of BPH\nKQ 1. Is the International Prostate Symptom Score (IPSS) questionnaire more helpful than a simple medical history for diagnosis during initial assessment in BPH patients?\n1-1. The IPSS is recommended f or an objective assessment of  symptoms at initial contact, for follow-up of  symptom evolution for those on watchful waiting, and for evaluation of  response to treatment. (level of  evidence, B; level of  recommendation, strong)\nThe International Prostate Symptom Score (IPSS) was adopted as a basic questionnaire standard at the International Council of  BPH organized by the World Health Organization  in 1993, and various studies on epidemiology and therapeutic ef f icacy have been done using the IPSS. The IPSS is used to assess the severity of  storage symptoms and voiding symptoms with one additional quality of  life question. The IPSS can also be performed multiple times to compare the progression of  symptoms and their severity over months and years. However, because the \nIPSS and other diagnostic tests are not entirely consistent, symptom scores alone will not absolutely determine the patient’s problem.\nKQ 2. Is a voiding diary more helpful than a simple medical history to diagnose BPH patients?\n2-1. A voiding diary is helpful for clarifying the information obtained from history taking and for accurate diagnosis. (level of  evidence, B; level of  recommendation, strong)\nA f requency volume chart (time and volume of  voids including any episodes of  incontinence) or a bladder diary (a 24-hour record of  liquid intake and urine output) is recommended for men with daytime or nocturnal frequency. A voiding diary provides objective clinical information about the patient. Patients must be instructed to continue their normal activities during the course of  the assessment, so as to obtain an accurate representation of  their normal lower urinary tract  function. Nocturnal polyuria (>33%) of the 24-hour urine excretion overnight) can be diagnosed only by a bladder diary. Voiding diaries are simple noninvasive, and cost-ef fective and are frequently part of the initial evaluation of  patients complaining of  LUTS particularly those who have storage symptoms such as increased urinary frequency and incontinence.\nKQ 3. Do urof lowmetry and measurement of postvoid residual volume (PVR) have advantages \nin the establishment of  treatment strategy in BPH patients?\n3-1. Urof lowmetry can be conducted selectively in patients with LUTS. (level of  evidence, C; level of recommendation, strong)\n3-2. Measurement of  PVR can be conducted selectively in patients with LUTS. (level of  evidence, C; level of recommendation, strong)\n3-3. Urof lowmetry and measurement of  PVR can be conducted in patients with LUTS and in those who need the specif ic evaluation of  urologists. (level of evidence, B; level of  recommendation, strong)\nUroflowmetry is one of  the broadly used evaluation tools that can provide essential information about voiding function, and it is noninvasive and swif t. If  maximal f low rate is low in urof lowmetry, pathologic f indings including bladder outlet obstruction (BOO) or decreased detrusor muscle contraction are suspected. However, the big pitfall of  urof lowmetry and measurement of  PVR is that it lacks reproducibility.\nFor evaluation of  PVR, two representative methods including sonography and catheterization can be introduced.Sonography has been validated for use as a substitute for direct catheterization for evaluation of  PVR and could be useful  in patients with  large PVR.\nKQ 4. Does transrectal ultrasonography have a better role than digital rectal examination (DRE) for the measurement of  prostatic anatomy in BPH patients?\n4-1. For precise evaluation of  prostatic anatomy, besides DRE, transrectal ultrasonography is warranted. (level of  evidence, B; level of  recommendation, strong)\nThe DRE is one of  the essential tests in the initial evaluation of  BPH patients. In cases of  palpable nodules by DRE, prostate biopsy is warranted. In the treatment of BPH, the precise measurement of  prostate size is a quite important issue, because prostate size itself  can af fect the whole course of  BPH treatment. Using prostate ultrasonography, physicians can estimate the degree of intravesical prostate protrusion (IPP), which is categorized as mild (less than 5 mm), moderate (f rom 5 mm to less than 10 mm), and severe (more than 10 mm). This degree of  IPP is known to be related to the degree of  BOO. The accuracy of  prostate ultrasonography in the measurement of  prostate size has been validated for its superiority over DRE. In a large population cohort study of  men who underwent radical prostatectomy for prostate cancer, the accuracy of DRE compared with a real prostate specimen was inferior to that of  prostate ultrasonography, and the discrepancy was larger in cases of  small prostate. In cases of  a large prostate size of  more than 40 mL, measurement of  prostate size using DRE could underestimate the real prostate size.\nKQ 5. Should prostate-specif ic antigen (PSA) be measured in BPH patients?\n5-1. PSA should be measured in patients aged 40 years or older with LUTS. (level of  evidence, A; level of recommendation, strong)\nThe PSA test should only be performed if  life expectancy is greater than 10 years and if  a diagnosis of  prostate cancer would modify the management approach. Among patients without prostate cancer, serum PSA may also be a useful surrogate marker of  prostate size and may also\npredict risk of  BPH progression .\nIn Korea, a large-scale multicenter study showed that the prostate volume and serum PSA level had an age-dependent log-linear relationship, and PSA had good predictive value for various prostate volume thresholds (30, 40, and 50 mL). Many studies have reported that baseline PSA levels are positively related to overall BPH progression and the incidence rate of  invasive therapy (e.g., surgery) . Laguna et al.reported that the change in quality of  life was negatively related to pretreatment PSA levels. When multiple logistic regression equations were used to obtain the odds ratio (OR) of  moderate plus severe symptomatic (>7) versus mild IPSS (≤7, reference category), the OR (and 95% conf idence  interval [CI]) of  moderate plus severe IPSS (>7) increased as PSA  levels  increased (PSA≤2: 1.0, PSA>2–4: 1.62 [1.2–2.2], PSA>4–10: 2.64 [1.5–4.7], PSA>10: 4.28 [1.8–10.3]) .\n', null, null, ' ', '为国外指南，主要为诊断及推荐。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('111', '38', 'M02_001', '1', '中华医学会临床诊疗指南', '无', ' 中华医学会', '2009', '中华医学会.临床诊疗指南呼吸病学分册[M].北京：人民卫生出版社，2009.', '中文', '1单纯型 符合慢性支气管炎诊断标准，具有反复咳嗽、咳痰两项症状。<br />&nbsp;&nbsp;2喘息型 符合慢性支气管炎诊断标准，除咳嗽、咳痰外尚有喘息症状，并经常伴有或多次出现哮鸣音。<br />&nbsp;&nbsp;', '慢性支气管炎', null, null, '1.诊断要点<br />&nbsp;&nbsp; 1.1临床有慢性或反复咳嗽、咳痰或伴有喘息，每年发病至少3个月，并连续2年或以上者。<br />&nbsp;&nbsp;1.2如每年发病持续不足3个月，而有明确的客观检查依据（如X线、肺功能等）亦可诊断。<br />&nbsp;&nbsp;1.3排除其他心、肺疾患（如肺结核、肺尘埃沉着病、支气管哮喘、支气管扩张、肺癌、心脏病、心功能不全、慢性鼻炎等）引起的咳嗽、咳痰或伴有喘息等。<br />&nbsp;&nbsp;2.鉴别诊断<br />&nbsp;&nbsp;2.1支气管扩张 有咳嗽、反复大量咳脓痰，或较多的反复咯血症状；两肺下部可闻及湿啰音；胸部X线检查下野支气管纹理增粗、紊乱、卷发状阴影；支气管碘油造影示柱状或囊状支气管扩张。<br />&nbsp;&nbsp;2.2肺癌 多发生在40岁以上男性，长期吸烟者，刺激性咳嗽，咳少量黏痰，常有痰中带血或慢性咳嗽有性质改变者，反复阻塞性肺炎，经抗生素治疗未能完全消散者，痰脱落细胞及纤维支气管镜等检查，可明确诊断。<br />&nbsp;&nbsp;2.3支气管哮喘 起病年龄轻，常有家族或个人过敏性病史；以发作性哮喘为特征；发作时两肺满布哮鸣音，缓解后可毫无症状；以咳嗽为主要症状的支气管哮喘病例，在1个月时期中可无喘息或哮鸣音。<br />&nbsp;&nbsp;2.4肺间质纤维化 慢性临床经过的肺间质纤维化开始阶段只是咳嗽、咳痰、偶感气短，胸部下后侧可闻及爆裂音，杵状指，血气分析示动脉血氧分压下降。<br />&nbsp;&nbsp;2.5肺结核 常伴有低热、无力、盗汗、咯血、消瘦等症状，痰结核菌图片及胸部X线检查，可明确诊断。<br />&nbsp;&nbsp;2.6心脏病 因肺瘀血而引起的咳嗽，常为干咳，痰量不多；病史中有心悸、气短、下肢水肿、心脏杂音等征象；体格检查、X线胸片、心电图和超声心动图检查可协助诊断。<br />&nbsp;&nbsp;', null, null, ' ', '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('112', '38', 'M02_002', '1', '慢性支气管炎临床诊断及疗效判断标准', '无', '全国慢性支气管炎临床专业会议', '1979', '内科疾病诊断标准 (一)呼吸系统疾病[J].黑龙江医药科学,1985,（2）:142-167', '中文', '1分型<br />&nbsp;&nbsp;1.1单纯型慢性支气管炎：诊断符合慢性支气管炎诊断标准。具有咳嗽、咳痰二项症状。<br />&nbsp;&nbsp;1.2喘息型慢性支气管炎：诊断符合慢性支气管炎诊断标准。具有喘息症状，并经常或多次出现哮鸣音。<br />&nbsp;&nbsp;2分期<br />&nbsp;&nbsp;2.1急性发作期：一周内出现脓性或粘液脓性痰，痰量明显增多或伴有其他炎症表现；或一周内咳、痰、喘症状任何一项加剧至重度，或重度病人明显加重者。<br />&nbsp;&nbsp;2.2慢性迁延期：指病人有不同程度的咳、痰、喘症状，迁延不愈，或急性发作期症状一个月后仍未恢复到发作前水平。<br />&nbsp;&nbsp;2.3临床缓解期：指病人经过治疗或自然缓解症状不足轻度维持二个月或以上。<br />&nbsp;&nbsp;', '慢性支气管炎', null, null, ' 1临床上以咳嗽、咳痰为主耍症状或伴有喘息，每年发病持续三个月，并连续两年或以上。<br />&nbsp;&nbsp;2排除具有咳嗽、咳痰、喘息症状的其他疾病(如肺结核、尘肺、肺脓肿、心脏病、心功能不全、支气管扩张、支气管哮喘、慢性鼻咽疾患等)。<br />&nbsp;&nbsp;', null, '咳；痰；喘；哮鸣音', '1单项症状疗效判断<br />&nbsp;&nbsp;1.1临床控制(临控)：症状及肺部哮鸣音不足轻度者，或咳、痰、喘症状好转九成以上。<br />&nbsp;&nbsp;1.2显效：咳、痰、喘症状好转六成以上，或症状及肺部哮鸣音明显好转(+++→+)。<br />&nbsp;&nbsp;1.3好转：咳、痰、喘症状好转三成以上，或症状及肺部哮鸣音有好转(+++→++、或++→+)。<br />&nbsp;&nbsp;1.4无效：症状及肺部哮鸣音无改变，或好转不足三成者，以及症状及肺部哮鸣音加重者。<br />&nbsp;&nbsp;2急性发作期疗效判断<br />&nbsp;&nbsp;2.1临控：咳、痰.喘及肺部哮鸣音恢复到急性发作前水平。可参考其他客观检查指标。<br />&nbsp;&nbsp;2.2减轻：咳、痰、喘及肺部哮鸣音有好转，但未恢复到急性发作前水平。可参考其他客观检查指标。<br />&nbsp;&nbsp;2.3无效：咳、痰、喘及肺部哮鸣音一个月内仍未恢复到发作前水平。可参考其他客观检查指标。<br />&nbsp;&nbsp;3慢性迁延期疗效判断：至少要经过一个冬春的观察。<br />&nbsp;&nbsp;3.1单纯型：以咳嗽、咯痰两项为病情疗效判定标准。<br />&nbsp;&nbsp;①临控：咳嗽、咯痰均有好转，病情不足轻度。<br />&nbsp;&nbsp;②显效：咳嗽、咯痰均达显效标准。或其中一项达临控标准，另一项为显效或好转。<br />&nbsp;&nbsp;③好转：咳嗽、咯痰，一项达好转以上，另一项为无效。<br />&nbsp;&nbsp;④无效：咳嗽、咯痰均无改变，或未达到好转标准，以及咳嗽、咯痰均较前加重者。<br />&nbsp;&nbsp;3.2喘息型：以咳、痰、喘、哮鸣音四项为疗效判定标准。<br />&nbsp;&nbsp;①临控：咳、痰、喘、哮鸣音四项中三项达临控，另一项达显效。<br />&nbsp;&nbsp;②显效：咳、痰、喘、哮鸣音四项中三项达显效，另一项达好转；或两项临控，两项显效或好转或一项临控，两项显效，一项好转。<br />&nbsp;&nbsp;③好转：凡不具备显效及无效标准，均属好转范围。<br />&nbsp;&nbsp;④无效：咳、痰、喘、哮鸣音四项均无效或仅一项好转，以及四项中有一项或以上加重，其余各项亦无好转者。<br />&nbsp;&nbsp;4远期疗效判断<br />&nbsp;&nbsp;4.1临床治愈：停用对症药治疗二年后，临床症状及肺部哮鸣音均不足轻度者。<br />&nbsp;&nbsp;4.2显效：病情达显效水平持续二年或以上。<br />&nbsp;&nbsp;4.3好转：病情达好转水平持续二年或以上。<br />&nbsp;&nbsp;4.4无效：病情稳定在原级或经过两个冬春治疗病情反见加重者。<br />&nbsp;&nbsp; ', '此标准制定较早，为行业专业会议共识，标准内容较为全面。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('113', '38', 'M02_003', '0', '中华中医药学会标准-慢性阻塞性肺疾病', '无', '中华中医药学会', '2008', 'ZYYXH/T 70-2008, 慢性阻塞性肺疾病[S].', '中文', null, '慢性阻塞性肺疾病', null, '外寒内饮证；风热犯肺证；痰热郁肺证；气虚血瘀痰阻证；肺肾气虚证', '1.临床表现<br />&nbsp;&nbsp;1.1症状<br />&nbsp;&nbsp;慢性咳嗽：常为首发症状。初期咳嗽呈间歇性，早晨较重，以后早晚或整日均有咳嗽，但夜间咳嗽并不显著。<br />&nbsp;&nbsp;咳痰：咳嗽后通常咳少量黏液性痰，部分患者在清晨较多；合并感染时痰量增多，常有脓性痰。<br />&nbsp;&nbsp;气短或呼吸困难：是COPD的标志性症状，是使患者焦虑不安的主要原因，早期仅于劳力时出现，以后逐渐加重，以致日常活动甚至休息时也感气短。<br />&nbsp;&nbsp;喘息和胸闷：部分患者特别是重度患者有喘息；胸部紧闷感通常于劳力后发生。<br />&nbsp;&nbsp;其他症状：晚期患者常有体重下降、食欲减退、精神抑郁和（或）焦虑等，合并感染时可咳血痰或咯血。<br />&nbsp;&nbsp;1.2体征：早期体征可不明显。随疾病进展，常有以下体征：<br />&nbsp;&nbsp;胸廓形态异常，包括胸部过度膨胀、前后径增大、剑突下胸骨下角增宽及腹部膨隆等；常见呼吸变浅，频率增快，辅助呼吸肌参加呼吸运动，重症可见胸腹矛盾运动；患者不时采用缩唇呼吸以增加呼出气量；呼吸困难加重时常采取前倾坐位；低氧血症者可出现豁膜及皮肤发给，伴右心衰者可见下肢水肿、肝脏增大。<br />&nbsp;&nbsp;由于肺过度充气使心浊音界缩小，肺肝界降低，肺叩诊可呈过清音。<br />&nbsp;&nbsp;两肺呼吸音可减低，呼气延长，可闻及干、湿性啰音；心音遥远，剑突部心音较清晰响亮。<br />&nbsp;&nbsp;2.理化检查<br />&nbsp;&nbsp;2.1肺功能检查：第一秒用力呼气量与用力肺活量之比（FEV1：FVC）是COPD的一项敏感指标；FEV1占预计值的百分比是中、重度气流受限的良好指标，应作为COPD肺功能检查的基本项目。吸人支气管舒张剂后FEV1＜80%预计值且FEV1：FVC＜70%者，可确定为不能完全可逆的气流受限。<br />&nbsp;&nbsp;2.2胸部X线检查：早期胸片无明显变化，以后出现肺纹理增多、紊乱等改变；主要X线征为肺过度充气。并发肺动脉高压和肺源性心脏病时，除右心增大的X线征外，还可有肺动脉圆锥膨隆，肺门血管影扩大及右下肺动脉增宽等。<br />&nbsp;&nbsp;2.3胸部CT检查：高分辨率CT（HRCT）可辨别小叶中央型或全小叶型肺气肿及确定肺大泡的大小和数量。<br />&nbsp;&nbsp;2.4血气检查：血气异常首先表现为轻、中度低氧血症。随疾病进展，低氧血症逐渐加重，并出现高碳酸血症。<br />&nbsp;&nbsp;2.5其他：低氧血症时，红细胞及血红蛋白可增高。并发感染时，痰涂片可见大量中性粒细胞，痰培养可检出各种病原菌，如肺炎链球菌、流感嗜血杆菌和肺炎克雷白杆菌等。<br />&nbsp;&nbsp;3.诊断要点<br />&nbsp;&nbsp;COPD的诊断应根据病史、危险因素接触史（尤其吸烟史）、症状、体征及实验室检查等资料，综合分析确定。存在不完全可逆性气流受限是诊断COPD的必备条件。凡有逐渐加重的气急史，肺功能测试示残气量（RV）：肺总量（TLC）值增加，FEV1：FVC值减低，最大通气量（MBC）降低，气体分布不匀；经支气管扩张剂治疗，肺功能无明显改善，诊断即可成立。<br />&nbsp;&nbsp;', '1.外寒内饮证：咳逆喘满不得卧，气短气急，咯痰白稀，呈泡沫状，胸部膨满，口干不欲饮，面色青暗，周身酸楚，恶寒，舌体胖大，舌质暗淡，舌苔白滑，脉浮紧。<br />&nbsp;&nbsp;2.风热犯肺证：咳嗽气促，喘逆胸闷，咯痰不爽，痰黏稠或稠黄，常伴恶风身热、头痛口渴、鼻流黄涕等表证，舌苔薄黄，脉浮数或浮滑。<br />&nbsp;&nbsp;3.痰热郁肺证：咳逆喘息气粗，胸满，咯痰黄或白，黏稠难咯，身热烦躁，溲黄便干，口渴欲饮，舌质暗红，苔黄或黄腻，脉滑数。<br />&nbsp;&nbsp;4.气虚血瘀痰阻证：胸憋气短，动则尤甚，咳嗽痰多，色白或呈泡沫，身倦乏力，面色晦暗，唇甲紫绀，舌质暗或暗紫，苔腻或浊腻，脉弦滑。<br />&nbsp;&nbsp;', null, ' ', '为中医标准。有详细诊断及中医辨证分型，并附单方验方、针刺、灸法、穴位贴敷、穴位按摩等其他治法。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('114', '38', 'M02_004', '1', '慢性阻塞性肺疾病诊断标准', 'Diagnosis criteria for chronic obstructive pulmonary disease', '中华人民共和国卫生部', '2010', 'WS 318-2010, 慢性阻塞性肺疾病诊断标准[S].', '中文', null, '慢性阻塞性肺疾病', null, null, '1.危险因素<br />&nbsp;&nbsp;1.1吸烟史：长期大量吸烟史；<br />&nbsp;&nbsp;1.2职业史、环境有害物质接触史；<br />&nbsp;&nbsp;1.3室内外空气污染，如生物燃料燃烧史；<br />&nbsp;&nbsp;1.4家族史：COPD有家族聚集倾向。<br />&nbsp;&nbsp;2.临床表现<br />&nbsp;&nbsp;2.1症状<br />&nbsp;&nbsp;2.1.1慢性咳嗽：常为首发症状。初起咳嗽呈间歇性，晨起为著，后期早晚或整日均有咳嗽，但夜间咳嗽并不明显；<br />&nbsp;&nbsp;2.1.2咳痰：通常咳白色黏液或泡沫样痰，偶带血丝，一般清晨较多；合并感染时痰量增多，常有脓性痰。少数病例咳嗽不伴咳痰；<br />&nbsp;&nbsp;2.1.3气短或呼吸困难：最主要的临床症状，早期于劳力时出现，后渐加重，日常活动甚至休息时也感气短；<br />&nbsp;&nbsp;2.1.4喘息和胸闷：部分患者，特别是重度患者常有喘息；胸部紧闷感通常于劳力后发生；<br />&nbsp;&nbsp;2.1.5全身性症状：体重下降、食欲减退、肌肉萎缩和活动障碍、精神抑郁和（或）焦虑等。<br />&nbsp;&nbsp;2.2体征<br />&nbsp;&nbsp;早期体征不明显，疾病进展可出现以下体征：<br />&nbsp;&nbsp;2.2.1视诊、触诊：缩唇呼吸；皮肤及黏膜紫绀；呼吸变浅快；桶状胸，肋间隙增宽；并发右心功能不全时可出现颈静脉充盈，肝-颈回流征阳性，肝脏肿大，双下肢水肿；<br />&nbsp;&nbsp;2.2.2叩诊：心浊音界缩小，肺肝界降低，叩诊呈过清音；<br />&nbsp;&nbsp;2.2.3听诊：两肺呼吸音可减低，呼气相延长，可闻干啰音和（或）湿啰音；心音遥远，剑突部心音较清晰响亮。<br />&nbsp;&nbsp;3.辅助检查和实验室检查<br />&nbsp;&nbsp;3.1肺功能检查<br />&nbsp;&nbsp;FWV1与FVC之比（FWV1/FVC%）＜70%。FEV1占预计值的百分比可正常或下降。此外，还可出现以下改变：肺总量、功能残气量和残气容量增高，肺活量减低；残气容量/肺总量增高；一氧化碳弥散量（DLco）降低等。<br />&nbsp;&nbsp;3.2胸部X线检查<br />&nbsp;&nbsp;3.2.1早期胸片：无明显变化。<br />&nbsp;&nbsp;3.2.2后期胸片：肺纹理增多、紊乱或稀疏等非特征性改变。<br />&nbsp;&nbsp;3.2.3动脉血气检查<br />&nbsp;&nbsp;初期正常，疾病进展可出现呼吸衰竭。<br />&nbsp;&nbsp;3.2.4其他实验室检查<br />&nbsp;&nbsp;血红蛋白、红细胞及红细胞压积可增高。<br />&nbsp;&nbsp;痰涂片及痰培养查病原菌。<br />&nbsp;&nbsp;4.诊断原则<br />&nbsp;&nbsp;4.1根据危险因素、临床表现及辅助检查和实验室检查综合分析确定。<br />&nbsp;&nbsp;4.2肺功能检查应用支气管舒张剂后FWV1/FVC%＜70%可确定气流受限，是诊断的必备条件。<br />&nbsp;&nbsp;4.3基于气流受限的程度，COPD严重度分为4级见M02_004表。<br />&nbsp;&nbsp;5.鉴别诊断<br />&nbsp;&nbsp;5.1支气管哮喘；<br />&nbsp;&nbsp;5.2充血性心力衰竭；<br />&nbsp;&nbsp;5.3支气管扩张；<br />&nbsp;&nbsp;5.4肺结核；<br />&nbsp;&nbsp;5.5闭塞性细支气管炎；<br />&nbsp;&nbsp;5.6弥漫性泛细支气管炎；<br />&nbsp;&nbsp;5.7间质性肺疾病。<br />&nbsp;&nbsp;6.并发症<br />&nbsp;&nbsp;6.1自发性气胸；<br />&nbsp;&nbsp;6.2慢性肺原性心脏病；<br />&nbsp;&nbsp;6.3呼吸衰竭。<br />&nbsp;&nbsp;', null, null, ' ', '为西医标准。来源权威，为国家发布的权威诊断标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('115', '38', 'M02_005', '0', '中华中医药学会标准-喘病', '无', '中华中医药学会', '2008', 'ZYYXH/T 6-2008, 喘病[S].', '中文', null, null, '喘病', '1.实喘；1.1风寒闭肺证；1.2痰热壅肺证；1.3痰浊阻肺证；1.4肝气犯肺证；1.5水凌心肺证；2.虚喘；2.1肺虚证；2.2肾虚证；2.3肺肾气虚证', '1.诊断要点<br />&nbsp;&nbsp;1.1以喘促不宁，呼吸困难，甚至张口抬肩，鼻翼煽动，不能平卧，或口唇青紫为主要临床表现。<br />&nbsp;&nbsp;1.2多有慢性咳嗽、胸痹等心、肺疾病史。<br />&nbsp;&nbsp;1.3发病多有外感六淫、情志刺激等诱因。<br />&nbsp;&nbsp;2.鉴别诊断<br />&nbsp;&nbsp;2.1哮病：哮与喘都表现为呼吸困难，但哮指声响言，呼吸困难而兼喉中哮鸣；喘指气息言，为呼吸气促困难而无喉中哮鸣，可见于多种急、慢性疾病中。一般来说，哮必兼喘，喘未必兼哮。<br />&nbsp;&nbsp;2.2肺痿：肺痿系肺气受损，津液耗伤，肺叶痿弱不用，以咳嗽、气短、咳吐浊唾涎沫为特征，晚期可表现为喘促、呼吸困难。喘病日久也可致肺叶痿弱不用而成肺痿。<br />&nbsp;&nbsp;', '1.实喘<br />&nbsp;&nbsp;1.1风寒闭肺证：喘息，呼吸气促，胸部胀闷，伴见咳嗽，痰多稀薄色白，头痛，鼻塞，喷嚏，流清涕，无汗，恶寒，或伴发热，口不渴，舌苔薄白而滑，脉浮紧。<br />&nbsp;&nbsp;1.2痰热壅肺证：喘咳气涌，胸闷烦热，痰多黏稠色黄，或痰中带血，面红咽干，渴喜冷饮，尿赤便秘，舌质红，苔黄或黄腻，脉滑数。<br />&nbsp;&nbsp;1.3痰浊阻肺证：喘息胸闷，咳嗽痰多，黏腻色白，咯吐不利，或脘闷，呕恶，纳呆，口黏不渴，舌质淡，苔厚腻色白，脉滑。<br />&nbsp;&nbsp;1.4肝气犯肺证：每遇情志刺激而诱发，突然呼吸短促，胸闷发憋，咽中如窒，但喉中痰声不著，平素多忧思抑郁，或失眠，心悸，或不思饮食，大便不爽，或心烦易怒，面红目赤，舌质淡或红，苔薄白或薄黄，脉象弦或弦而数。<br />&nbsp;&nbsp;1.5水凌心肺证：喘咳气逆，倚息难以平卧，伴咯痰稀白，心悸，面目肢体浮肿，小便量少，怯寒肢冷，或面色晦暗，唇甲青紫，舌淡胖或胖暗或有瘀斑、瘀点，舌下青筋显露，苔白滑，脉沉细或带涩。<br />&nbsp;&nbsp;2.虚喘<br />&nbsp;&nbsp;2.1肺虚证：喘促短气，气怯声低，咳声低弱，咯痰稀薄，自汗畏风，或呛咳少痰质黏，烦热口干，咽喉不利，舌质淡红或舌红苔剥，脉细数。<br />&nbsp;&nbsp;2.2肾虚证：喘促日久，动则喘甚，呼多吸少，气不得续，面青唇紫，汗出肢冷，舌苔淡白，脉微细或沉弱。<br />&nbsp;&nbsp;2.3肺肾气虚证：平素气息短促，动则为甚，腰酸腿软，脑转耳鸣，不耐劳累，下肢欠温，小便清长，舌质淡，脉沉细。<br />&nbsp;&nbsp;', null, ' ', '为中医标准。有详细诊断及中医辨证分型，并附单方验方、针刺、穴位贴敷、调摄与预防等其他治法。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('116', '38', 'M02_006', '0', '中华中医药学会标准-肺胀', '无', '中华中医药学会', '2008', 'ZYYXH/T 7-2008, 肺胀[S].', '中文', null, null, '肺胀', '外寒内饮证；痰浊阻肺证；痰热郁肺证；肺肾气虚证；阳虚水泛证', '1.诊断要点<br />&nbsp;&nbsp;1.1典型临床表现为胸部膨满，胸中憋闷如塞，咳逆上气，痰多喘息，动则加剧；日久可见心慌动悸，面唇紫绀，肢体浮肿；严重者可出现喘脱，神昏，谵语，出血等。<br />&nbsp;&nbsp;1.2有慢性肺系疾患病史，反复发作，经久难愈；发病年龄多为老年，中青年少见。<br />&nbsp;&nbsp;1.3常因外感诱发，其他如饮食、劳倦、情绪等亦可诱发加重。<br />&nbsp;&nbsp;1.4胸部X线、心电图、超声心动图、肺功能等检查有助于诊断和鉴别诊断。<br />&nbsp;&nbsp;2.鉴别诊断<br />&nbsp;&nbsp;2.1哮病：哮病是一种发作性的痰鸣气喘疾患，常突然发病，经治疗或可自行缓解，以夜间发作多见。肺胀为多种慢性肺部疾病长期反复发作、迁延不愈发展而来，以喘促、咳嗽、咯痰、胸部膨满、憋闷如塞等为临床特征，二者有明显区别。哮病长期反复发作，可发展为肺胀。<br />&nbsp;&nbsp;2.2喘病：喘病以喘促、呼吸困难为临床表现，可见于哮病、肺胀、胸痹等多种急、慢性疾病过程中。肺胀为多种慢性肺部疾病长期反复发作、迁延不愈而成，临床除喘促、呼吸困难外，尚具有咳嗽、咯痰、胸部膨满、憋闷如塞等特征，喘促仅是肺胀的一个症状。<br />&nbsp;&nbsp;', '1.外寒内饮证：咳逆喘满不得卧，气短息促，咯痰稀白量多，呈泡沫状，胸部膨满，面色青暗，周身酸楚，头痛，恶寒，无汗，舌体胖大，舌质暗淡，苔白滑，脉浮紧。<br />&nbsp;&nbsp;2.痰浊阻肺证：胸膺满闷，短气喘息，咳嗽痰多，色白黏腻或呈泡沫，畏风易汗，脘腹痞胀，纳少，泛恶，便溏，倦怠乏力，舌质偏淡或淡胖，苔薄腻或浊腻，脉细滑。<br />&nbsp;&nbsp;3.痰热郁肺证：咳嗽喘急，胸满气粗，咯痰黄或白，黏稠难咯，身热，烦躁，微恶寒，有汗不多，口渴欲饮，尿黄，便干，舌质红或边尖红，舌苔黄或黄腻，脉滑数或浮滑数。<br />&nbsp;&nbsp;4.肺肾气虚证：呼吸浅短难续，甚则张口抬肩，倚息不能平卧，咳嗽，痰白如沫，咯吐不利，胸闷心慌，形寒汗出，或腰膝酸软，小便清长，或尿后余沥，或咳则小便自遗，舌淡或暗紫，苔白润，脉沉细虚数无力，或有结代。<br />&nbsp;&nbsp;5.阳虚水泛证：喘咳不能平卧，咯痰清稀，心悸，胸满气憋，面浮，下肢肿，甚则一身悉肿，腹部胀满有水，尿少，脘痞，纳差，怕冷，面唇青紫，舌胖质暗，苔白滑，脉沉细滑或结代。<br />&nbsp;&nbsp;', null, ' ', '为中医标准。有详细诊断及中医辨证分型，并附单方验方、针刺、灸法、调摄与预防等其他治法。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('117', '38', 'M02_007', '0', '慢性阻塞性肺疾病中医诊疗指南（2011版）', '无', '中华中医药学会内科分会肺系病专业委员会', '2011', '慢性阻塞性肺疾病中医诊疗指南（2011版）[J].中华中医药学会内科分会肺系病专业委员会.中医杂志，2012,53（1）：80-84.', '中文', null, '慢性阻塞性肺疾病', null, '1急性加重期；1.1风寒袭肺；1.2外寒内饮；1.3痰热壅肺；1.4痰湿阻肺；1.5痰蒙神窍；2稳定期；2.1肺气虚；2.2肺脾气虚；2.3肺肾气虚；2.4肺肾气阴两虚', '1.诊断依据<br />&nbsp;&nbsp;    根据临床表现、危险因素接触史、体征及实验室检查资料综合分析确定。COPD的主要症状[慢性咳嗽、咳痰和（或）呼吸困难]、危险因素接触史、存在不完全可逆性气流受限是诊断COPD的必备条件。肺功能指标是诊断COPD的金标准。用支气管舒张剂后第一秒用力呼气容积(FEV1)／肺活量(FVC)<70%可确定为不完全可逆性气流受限。COPD早期轻度气流受限时可有或无临床症状。胸部X线检查有助于确定肺过度充气的程度。排除支气管哮喘、支气管扩张症、充血性心力衰竭、肺结核等其他肺部疾病。<br />&nbsp;&nbsp;2疾病分期<br />&nbsp;&nbsp;2.1急性加重期  急性加重是指患者出现超越日常状况的持续恶化，并需改蛮基础用药。通常在疾病过程中，短期内患者咳嗽、咳痰、气短和（或）喘息加重，痰量增多，呈脓性或黏液脓性，可伴发热等炎症明显加重的表现。当患者出现运动耐力下降、发热和（或）胸部影像异常时可能为COPD加重的征兆。2006年慢性阻塞性肺疾病全球创议(GOLD)首次将急性加重期定义为在COPD病程中出现呼吸困难、咳嗽、咳痰急性加重，病情变化大于每日自然病程变化程度，并且需要改变日常治疗方案。<br />&nbsp;&nbsp;2.2稳定期  指患者咳嗽、咳痰、气短等症状稳定或症状轻微。<br />&nbsp;&nbsp;1.3严重程度分级<br />&nbsp;&nbsp;    基于研究目的不同，COPD严重程度可根据肺功能、功能性呼吸困难程度、生活质量、是否存在合并症（呼吸衰竭、心力衰竭）等进行评估，其中反映气流受限程度的FEV1，下降有重要参考意义。根据肺功能的变化等将COPD严重性分为4级。<br />&nbsp;&nbsp;    I级(轻度COPD)：轻度气流受限(FEV1/FVC×100%<70%，但FEV1占预计值百分比≥80%)，通常可伴有或不伴有咳嗽、咳痰。<br />&nbsp;&nbsp;    Ⅱ级(中度COPD)：气流受限进一步恶化(50%≤FFV1占预计值百分比<80%)，并有症状进展和气短，运动后气短更为明显。此时，由于呼吸困难或疾病的加量，患者常去医院就诊。<br />&nbsp;&nbsp;    Ⅲ级(重度C()PD)：气流受限进一步恶化(30%≤FEV1占预计值百分比<50%)，气短加剧，并且反复出现急性加重，影响患者的生存质量。<br />&nbsp;&nbsp;    Ⅳ级(极重度COPD)：严重的气流受限（FEV1、占预计值百分比<30%预计值）或者合并有慢性呼吸衰竭。此时，患者的生存质量明显下降，如果出现急性加重则可能有生命危险。<br />&nbsp;&nbsp;此外，BODE指数（包含体重指数、气流阻塞程度、呼吸困难、运动能力等）和COPD急性加重次数也可作为COPD严重程度监测指标。<br />&nbsp;&nbsp;', '1急性加重期<br />&nbsp;&nbsp;1.1风寒袭肺<br />&nbsp;&nbsp;主症：咳嗽，喘息，恶寒，痰白、清稀，舌苔薄白，脉紧。次症：发热，无汗，鼻塞、流清涕，肢体酸痛，脉浮。诊断：①咳嗽或喘息，咳痰白、清稀；②发热、恶寒、无汗，或肢体酸痛；③鼻塞、流清涕；④舌苔白，或脉浮，或浮紧。具备①、②2项，加③、④中的1项。<br />&nbsp;&nbsp;1.2外寒内饮<br />&nbsp;&nbsp;主症：咳嗽，喘息气急，痰多，痰白稀薄、泡沫，胸闷，不能平卧，恶寒，舌苔白、滑，脉弦、紧。次症：痰易咯出，喉中痰鸣，无汗，肢体酸痛，鼻塞、流清涕，脉浮。诊断：①咳嗽或喘息；②恶寒、无汗，或鼻塞、流清涕，或肢体酸痛；③痰白稀薄或兼泡沫、痰易咯出；④喉中痰鸣；⑤胸闷甚至气逆不能平卧；⑥舌苔白滑，或脉弦紧或浮弦紧。具备①、②2项，加③、④、⑤、⑥中的2项。<br />&nbsp;&nbsp;1.3痰热壅肺<br />&nbsp;&nbsp;主症：咳嗽，喘息，胸闷，痰多，痰黄、白黏干，咯痰不爽，舌质红，舌苔黄、腻，脉滑、数。次症：胸痛，发热，口渴喜冷饮，大便干结，舌苔厚。诊断：①咳嗽或喘息气急；②痰多色黄或白黏，咯痰不爽；③发热或口渴喜冷饮；④大便干结；⑤舌质红、舌苔黄或黄腻，脉数或滑数。具备①、②2项，加③、④、⑤中的2项。<br />&nbsp;&nbsp;1.4痰湿阻肺<br />&nbsp;&nbsp;主症：咳嗽，喘息，痰多，痰白黏，口黏腻，舌苔白、腻，脉滑。次症：气短，痰多泡沫，痰易咳出，胸闷，胃脘痞满，纳呆，食少，舌质淡，脉弦。诊断：①咳嗽或喘息、气短；②痰多、白黏或呈泡沫状；③胃脘痞满；④口黏腻，纳呆或食步；⑤舌苔白腻，脉滑或弦滑。具备①、②2项，加③、④、⑤中的2项。<br />&nbsp;&nbsp;1.5痰蒙神窍<br />&nbsp;&nbsp;主症：喘息气促，神志恍惚、嗜睡、昏迷、谵妄，舌苔白、腻、黄。次症：喉中痰鸣，肢体瘛疯甚则抽搐，舌质暗红、绛、紫，脉滑、数。诊断：①神志异常（烦躁、恍惚、嗜睡、谵妄、昏迷）；②肢体瘛癜甚则抽搐；③喘息气促；④喉中痰鸣；⑤舌质淡或红、舌苔白腻或黄腻，或脉滑或数。具备①、②中1项加③、④、⑤中的2项。<br />&nbsp;&nbsp;2稳定期<br />&nbsp;&nbsp;2.1肺气虚<br />&nbsp;&nbsp;主症：咳嗽，乏力，易感冒。次症：喘息，气短，动则加重，神疲，自汗，恶风，舌质淡，舌苔白，脉细、沉、弱。诊断：①咳嗽或喘息、气短，动则加重；②神疲、乏为，或自汗；③恶风，易感冒；④舌质淡、苔白，脉沉细或细弱。具备①、②、③、④中的3项。<br />&nbsp;&nbsp;2.2肺脾气虚<br />&nbsp;&nbsp;主症：咳嗽，喘息，气短，动则加重，纳呆，乏力，易感冒，舌体胖大、齿痕，舌质淡，舌苔白。次症：神疲，食少，脘腹胀满，便溏，自汗，恶风，脉沉、细、缓、弱。诊断：①咳嗽或喘息、气短，动则加重；②神疲、乏力或自汗，动则加重；③恶风，易感冒；④纳呆或食少；⑤胃脘胀满或腹胀或便溏；⑥舌体胖大或有齿痕，舌苔薄白或白腻，脉沉细或沉缓或细弱。具备①、②、③中的2项，加④、⑤、⑥中的2项。<br />&nbsp;&nbsp;2.3肺肾气虚<br />&nbsp;&nbsp;主症：喘息，气短，动则加重，神疲，乏力，腰膝酸软，易感冒，舌质淡，舌苔白，脉细。次症：恶风，自汗，面目浮肿，胸闷，耳鸣，夜尿多，咳而遗溺，舌体胖大、有齿痕，脉沉、弱。诊断①喘息，气短，动则加重，②乏力，或自汗，动则加重；③易感冒，恶风；④腰膝酸软；⑤耳鸣，头昏或面目虚浮；⑥小便频数、夜尿多，或咳而遗溺；⑦舌质淡、舌苔白，脲沉细或细弱。具备①、②、③中的2项，加④、⑤、⑥、⑦中的2项。<br />&nbsp;&nbsp;2.4肺肾气阴两虚<br />&nbsp;&nbsp;主症：咳嗽，喘息，气短，动则加重，乏力，自汗，盗汗．腰膝酸软，易感冒，舌质红，脉细、数。次症：口干，咽干，干咳，痰少，咯痰不爽，手足心热，耳鸣，头昏，头晕，舌质淡，舌苔少、花剥，脉弱、沉、缓、弦。诊断：①喘息、气短，动则加重，②自汗或乏力，动则加重；③易感冒；④腰膝酸软；⑤耳鸣，头昏或头晕；⑥干咳或少痰、咯痰不爽；⑦盗汗；⑧手足心热；⑨舌质淡或红，舌苔薄少或花剥，脉沉细或细弱或细数。具备①、②、③中2项加④、⑤中的1项加⑥、⑦、⑧、⑨中的2项。<br />&nbsp;&nbsp;兼证——血瘀证：主症：口唇青紫，舌质暗红、紫暗、瘀斑，脉涩、沉。次症：胸闷痛，面色紫暗。诊断：①面色紫暗；②唇甲青紫；③舌质紫喑或有瘀斑或瘀点；④舌下静脉迂曲、粗乱。具备①、②、③、④中的1项。<br />&nbsp;&nbsp;', null, null, '参照2008年版《慢性阻塞性肺疾病中医诊疗指南》、依据指南研究与评价的评审、指南标准化会议确定的评价指南标准和苏格兰指南制定组织所归纳的指南制定步骤，以循证医学思想为指导，注重中医特色，对既往和现有的相关证据进行了充分收集和评价，并采用共识法最终形成证据的推荐意见编写而成。该指南供中医内科、中西医结合内科医生临床使用。适合于COPD的中医辨证治疗，对于合并支气管哮喘、支气管扩张、闭塞性细支气管炎、弥漫性泛细支气管炎的COPD患者的诊治可参考使用。\n', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('118', '38', 'M02_008', '1', '慢性阻塞性肺疾病诊疗规范（2011年版）', '无', ' 卫生部医政司', '2011', '卫生部医政司.慢性阻塞性肺疾病诊疗规范（2011年版）[J].中国医学前沿杂志，2012,4（1）：69-76.', '中文', '1.COPD严重程度分级 根据FEV1/FVC、FEV1%预计值和临床表现，可对COPD的严重程度作出临床严重度分级。M02_008表<br />&nbsp;&nbsp;2.COPD病程分期<br />&nbsp;&nbsp;2.1稳定期：患者咳嗽、咳痰、气短等症状稳定或症状较轻。<br />&nbsp;&nbsp;2.2急性加重期：在疾病过程中，病情出现超越日常状况的持续恶化，并需改变COPD的日常基础用药。通常指患者短期内咳嗽、咳痰、气短和（或）喘息加重，痰量增多，呈脓性或黏脓性，可伴发热等炎症明显加重的表现。<br />&nbsp;&nbsp;', '慢性阻塞性肺疾病', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1症状<br />&nbsp;&nbsp;1.1.1慢性咳嗽 常为首发症状。初为间断性咳嗽，早晨较重，以后早晚或整日均可有咳嗽，夜间咳嗽常不显著。少数患者无咳嗽症状，但肺功能显示明显气流受限。<br />&nbsp;&nbsp;1.1.2咳痰 咳少量黏液性痰，清晨较多。合并感染时痰量增多，可有脓性痰。少数患者咳嗽不伴咳痰。<br />&nbsp;&nbsp;1.1.3气短或呼吸困难 是COPD的典型表现。早期仅于活动后出现，后逐渐加重，严重时日常活动甚至休息时也感气短。<br />&nbsp;&nbsp;1.1.4喘息 部分患者，特别是重度患者可出现喘息症状。<br />&nbsp;&nbsp;1.1.5全身性症状 体重下降、食欲减退、外周肌肉萎缩和功能障碍、精神抑郁和（或）焦虑等。<br />&nbsp;&nbsp;1.2体征 COPD早期体征不明显。随着疾病进展可出现以下体征：<br />&nbsp;&nbsp;1.2.1一般情况 黏膜及皮肤发绀，严重时呈前倾坐位，球结膜水肿，颈静脉充盈或怒张。<br />&nbsp;&nbsp;1.2.2呼吸系统 呼吸浅快，辅助呼吸肌参与呼吸运动，严重时可呈胸腹矛盾呼吸；桶状胸，胸廓前后径增大，肋间隙增宽，剑突下胸骨下角增宽；双侧语颤减弱；肺叩诊可呈过清音，肺肝界下移；两肺呼吸音减低，呼气相延长，有时可闻干性啰音和（或）湿性啰音。<br />&nbsp;&nbsp;1.2.3心脏 可见剑突下心尖搏动；心脏浊音界缩小；心音遥远，剑突部心音较清晰响亮，出现肺动脉高压和肺心病时P2＞A2，三尖瓣区可闻收缩期杂音。<br />&nbsp;&nbsp;1.2.4腹部 肝界下移，右心功能不全时肝颈反流征阳性，出现腹水移动性浊音阳性。<br />&nbsp;&nbsp;1.2.5其他 长期低氧病例可见杵状指/趾，高碳酸血症或右心衰竭病例可出现双下肢可凹性水肿。<br />&nbsp;&nbsp;1.3 肺功能检查：肺功能检查尤其是通气功能检查对COPD诊断及病情严重程度分级评估具有重要意义。<br />&nbsp;&nbsp;1.3.1第一秒用力呼气容积占用力肺活量百分比（FEV1/FVC%）是评价气流受限的一项敏感指标。第一秒用力呼气容积占预计值百分比（FEV1%预计值）常用于COPD病情严重程度的分级评估，其变异性小，易于操作。吸入支气管舒张剂后FEV1/FVC＜70%，提示为不能完全可逆的气流受限。<br />&nbsp;&nbsp;1.3.2肺总量（TLC）、功能残气量（FRC）、残气量（RV）增高和肺活量（VC）减低，提示肺过度充气。由于TLC增加不及RV增加程度明显，故RV/TLC增高。<br />&nbsp;&nbsp;1.3.3一氧化碳弥散量（DLco）及DLco与肺泡通气量（VA）比值（DLco/VA）下降，表明肺弥散功能受损，提示肺泡间隔的破坏及肺毛细血管床的丧失。<br />&nbsp;&nbsp;1.3.4支气管舒张试验 以吸入短效支气管舒张剂后FEV1改善率≥12%且FEV1绝对值增加超过200 ml，作为支气管舒张试验阳性的判断标准。其临床意义在于：①有助于COPD与支气管哮喘的鉴别，或提示二者可能同时存在；②不能可靠预测患者对支气管舒张剂或糖皮质激素治疗的反应及疾病的进展；③受药物治疗等因素影响，敏感性和可重复性较差。<br />&nbsp;&nbsp;1.4胸部X线影像学检查<br />&nbsp;&nbsp;1.4.1X线胸片检查 发病早期X线胸片可无异常，以后出现肺纹理增多、紊乱等非特异性改变；发生肺气肿时可见相关表现：肺容积增大，胸廓前后径增长，肋骨走向变平，肺野透亮度增高，横膈位置低平，心脏悬垂狭长，外周肺野纹理纤细稀少等；并发肺动脉高压和肺源性心脏病时，除右心增大的X线征象外，还可有肺动脉圆锥膨隆，肺门血管影扩大，右下肺动脉增宽和出现残根征等。胸部X线检查对确定是否存在肺部并发症及与其他疾病（如气胸、肺大疱、肺炎、肺结核、肺间质纤维化等）鉴别有重要意义。<br />&nbsp;&nbsp;1.4.2胸部CT检查 高分辨CT（HRCT）对辨别小叶中心型或全小叶型肺气肿及确定肺大疱的大小和数量，有很高的敏感性和特异性，有助于COPD的表型分析，对判断肺大疱切除或外科减容手术的指征有重要价值，对COPD与其他疾病的鉴别诊断有较大帮助。<br />&nbsp;&nbsp;1.5血气分析检查 可据以诊断低氧血症、高碳酸血症、酸碱平衡失调、呼吸衰竭及其类型。<br />&nbsp;&nbsp;1.6其他实验室检查 血红蛋白、红细胞计数和血细胞比容可增高。合并细菌感染时白细胞可升高，中性粒细胞百分比增加。痰涂片及痰培养可帮助诊断细菌、真菌、病毒及其他非典型病原微生物感染；血液病原微生物核酸及抗体检查、血培养可有阳性发现；病原培养阳性行药物敏感试验有助于合理选择抗感染药物。可行其他有助于病理生理判断和并发症诊断的相关检查。<br />&nbsp;&nbsp;2.诊断<br />&nbsp;&nbsp;根据吸烟等发病危险因素、临床症状、体征及肺功能检查等综合分析确定。不完全可逆的气流受限是COPD诊断的必备条件。吸入支气管舒张药后FEV1/FVC＜70%可确定为不完全可逆性气流受限。少数患者并无咳嗽、咳痰、明显气促等症状，仅在肺功能检查时发现FEV1/FVC＜70%，在除外其他疾病后，亦可诊断为COPD。<br />&nbsp;&nbsp;3.鉴别诊断<br />&nbsp;&nbsp;一些已知病因或具有特征病理表现的气流受限疾病，如支气管哮喘、支气管扩张症、肺结核纤维化病变、肺囊性纤维化、弥漫性泛细支气管炎以及闭塞性细支气管炎等，有其特定发病规律、临床特点和诊疗方法，不属于COPD范畴，临床上须加区别。<br />&nbsp;&nbsp;支气管哮喘的气流受限多呈可逆性，但部分患者由于气道炎症持续存在导致气道重塑，可发展为固定性气流受限，表现为兼有哮喘和COPD两种疾病的临床和病理特点，目前认为其可能为COPD的临床表型之一。<br />&nbsp;&nbsp;', null, null, ' ', '为西医标准。明确定义、危险因素、发病机制、病理、病理生理、临床表现、诊断、严重程度分级及病程分期、鉴别诊断、并发症以及详细治疗方法。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('119', '38', 'M02_009', '1', '慢性阻塞性肺疾病诊治指南', '无', '中华医学会呼吸病学分会慢性阻塞性肺疾病学组', '2002', '中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南[J].中华内科杂志，2002，,4（9）：640-646.', '中文', 'COPD严重度分级是基于气流受限的程度。气流受限是诊断COPD的主要指标，也反映了病理改变的严重度。由于FEV1下降与气流受限有很好的相关性，故FEV1的变化是严重度分级的主要依据。此外，还应考虑临床症状及合并症的程度。<br />&nbsp;&nbsp;    临床严重度分为四级见M02_009表。<br />&nbsp;&nbsp;    由于COPD是一个渐进性疾病，早期防范尤为重要。严重程度分级中将具有危险因素及慢性咳嗽、咳痰症状而肺功能尚属正常者定为0级，即高危患者。这是基于不少COPD患者在慢性咳嗽、咳痰症状数年后，方出现气流受限的自然病程而设置的。对这部分患者应定期进行肺功能监测，以及早发现气流受限。<br />&nbsp;&nbsp;    II级（中度）有较宽的FEVi范围，大部分患者属此级，是COPD致残的关键时期和长期监测、治疗的重点。区分为lI A和IIB级是出于治疗的目的，因FEVI<50%预计值者(IIB级)急性加重显著增多，而反复急性加重可加速病情进展且严重影响生活质量．需加强监测及治疗。<br />&nbsp;&nbsp;    COPD病程可分为急性加重期与稳定期。COPD急性加重期是指在疾病过程中，患者短期内咳嗽、咳痰、气短和（或）喘息加重，痰量增多，呈脓性或黏液脓性，可伴发热等炎症明显加重的表现。稳定期则指患者咳嗽、咳痰、气短等症状稳定或症状轻微。<br />&nbsp;&nbsp;', '慢性阻塞性肺疾病', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1症状：1.1.1慢性咳嗽：通常为首发症状。初起咳嗽呈间歇性，早晨较重，以后早晚或整日均有咳嗽，但夜间咳嗽并不显著。少数病例咳嗽不伴咳痰，也有少数病例虽育明显气流受限但无咳嗽症状。1.1.2咳痰：咳嗽后通常咳少量黏液性痰，部分患者在清晨较多；合并感染时痰量增多，常有脓性痰。1.1.3气短或呼吸困难：这是COPD的标志性症状，是使患者焦虑不安的主要原因，早期仅丁^劳力时出现后逐渐加重，以致日常活动甚至休息时也感气短。1.1.4喘息和胸闷：不是COPD的特异性症状。部分患者特别是重度患者有喘息；胸部紧闷感通常予劳力后发生，与呼吸费力、肋间肌等容性收缩有关。1.1.5其他症状：晚期患者常有体重下降、食欲减退、精神抑郁和（或）焦虑等，合并感染时可咯血痰或咯血。<br />&nbsp;&nbsp;1.2病史：COPD患病过程应有以下特征：1.2.1吸烟史：多有长期较大量吸烟史。1.2.2职业性或环境有害物质接触史：如较长期粉尘、烟雾、有害颗粒或有害气体接触史。1.2.3家族史：COPD有家族聚集倾向。1.2.4发病年龄及好发季节：多于中年以后发病，症状好发于秋冬寒冷季节，常有反复呼吸道感染及急性加重史。随病情进展．急性加重愈渐频繁。1.2.5慢性肺原性心脏病史：COPD后期出现低氧血症和（或）高碳酸血症，可并发慢性肺原性心脏病和右心衰竭。<br />&nbsp;&nbsp;1.3体征：COPD早期体征可不明显。随疾病进展常有以下体征：1.3.1视诊及触诊：胸廊形态异常，包括胸部过度膨胀、前后径增大、剑突下胸骨下角（腹上角）增宽及腹部膨凸等；常见呼吸变浅，频率增快，辅助呼吸肌如斜角肌及胸锁乳突肌参加呼吸运动，重症可见胸腹矛盾运动；患者不时采用缩唇呼吸以增加呼出气量；呼吸困难加重时常采取前倾坐位；低氧血症者可出现黏膜及皮肤发绀，伴右心衰者可见下肢水肿，触诊时肝脏增大。1.3.2叩诊：由于肺过度充气使心浊音界缩小，肺肝界降低肺叩诊可呈过度清音。1.3.3听诊：两肺呼吸音可减低，呼气延长平静呼吸时可闻干性哕音，两肺底或其他肺野可闻湿哕音；心音遥远剑突部心音较清晰响亮。<br />&nbsp;&nbsp;2.实验室检查及特殊检查<br />&nbsp;&nbsp;2.1肺功能检查：肺功能检查是判断气流受限增高且重复性好的客观指标，对COPD的诊断、严重度评价、疾病进展、预后及治疗反应等均有重要意义。气流受限是以FEV1和FEV1与FVC之比(FEV1／FVC)降低来确定的。FEV1／FVC是COPD的一项敏感指标可检出轻度气流受限。FEVi占预计值的百分比是中、重度气流受限的良好指标，它变异性小，易于操作，应作为COPD肺功能检查的基本项目。吸入支气管舒张剂后FEV1< 80%预计值且FEV1／FVC < 70%者，可确定为不能完全可逆的气流受限。呼气峰流速(PEF)及最大呼气流量一容积曲线(M EFV)也可作为气流受限的参考指标但COPD时PEF与FEV1的相关性不够强PⅡ1有可能低估气流阻塞的程度。气流受限可导致肺过度充气，使肺总量(TLC)、功能残气量(FRC)和残气容积(RV)增高，肺活量(VC)减低。TLC增加不及RV增加的程度大，故RV/TLC增高。肺泡隔破坏及肺毛细血管床丧失可使弥散功能受损，一氧化碳弥散量(DLCO)降低DLCO与肺泡通气量(VA)之比(DLCO/VA)比单纯DL 00更敏感。作为辅助检查，支气管舒张诚验有一定价值，因为：(l)有利于鉴别COPD与支气管哮喘；(2)可获知患者能达到的最佳肺功能状态；(3)与预后有更好的相关性；(4)可预测患者对支气管舒张剂和吸入皮质激素的治疗反应。<br />&nbsp;&nbsp;2.2胸部X线检查：X线检查对确定肺部并发症及与其他疾病（如肺间质纤维化、肺结核等）鉴别有重要意义。COPD早期X线胸片可无明显变化，以后出现肺纹理增多、紊乱等非特征性改变；主要X线征为肺过度充气：肺容积增大，胸腔前后径增长，肋骨走向变平，肺野透亮度增高，横膈位置低平，心脏悬垂狭长，肺门血管纹理呈残根状，肺野外周血管纹理纤细稀少等，有时可见肺大疱形成。并发肺动脉高压和肺原性心脏病时．除右心增大的X线征外，还可有肺动脉圆锥膨隆、肺门血管影扩大及右下肺动脉增宽等。<br />&nbsp;&nbsp;2.3胸部CT检查：CT检查一般不作为常规检查但当诊断有疑问时，高分辨率CT( HRCT)有助于鉴别诊断。另外，HRCT对辨别小叶中央型或全小叶型肺气肿及确定肺大疱的大小和数量，有很高的敏感性和特异性，对预计肺大庖切除或外科减容手术等的效果有一定价值。<br />&nbsp;&nbsp;2.4血气分析：血气分析对晚期患者十分重要。FEV1<40%预计值者及具有呼吸衰竭或右心衰竭临床征象者，均应做血气贫析。血气异常首先表现为轻、中度低氧血症。随疾病进展，低氧血症逐渐加重，并出现高碳酸血症。呼吸衰竭的血气诊断标准为海平面吸空气时动脉血氧分压(Pa02)<60 mm Hg(1 mm Hg=0.133 kPa)，伴或不伴动脉血二氧化碳分压( PaCO2)增高(≥50 mm Hg)。<br />&nbsp;&nbsp;2.5其他化验检查：低氧血症，即Pa02<55 mm Hg时，血红蛋白及红细胞可增高，红细胞压积＞55%可诊断为红细胞增多症。并发感染时，痰涂片可见大量中性粒细胞痰培养可检出各种病原菌，常见者为肺炎链球菌、流感嗜血杆菌、卡他摩拉菌、肺炎克雷白杆菌等。<br />&nbsp;&nbsp;3.诊断与鉴别诊断<br />&nbsp;&nbsp;    COPD的诊断应根据病史、危险因素接触史、体征及实验室检查等资料综合分析确定。存在不完全可逆性气流受限是诊断COPD的必备条件。肺功能检查是诊断COPD的金标准。用支气管舒张剂后，FEV1<80%预计值及FEV1/ FVC<70%可确定为不完全可逆性气流受限。COPD早期轻度气流受限时可有或无临床症状。胸部X线检查有助于确定肺过度充气的程度及与其他肺部疾病鉴别。<br />&nbsp;&nbsp;    COPD应与支气管哮喘、支气管舒张症、充血性心力衰竭、肺结核等鉴别。与支气管哮喘的鉴别有时存在一定困难。COPD多予中年后起病，哮喘则多在儿童或青少年期起病；COPD症状缓慢进展逐渐加重，哮喘则症状起伏大；COPD多有长期吸烟史和（或）有害气体、颗粒接触史，哮喘则常伴过敏体质、过敏性鼻炎和（或）湿疹等，部分患者有哮喘家族史；COPD时气流受限基本为不可逆性，哮喘时则多为可逆性。然而，部分病程长的哮喘患者已发生气道重构，气流受限不能完全逆转；而少数COPD患者伴有气道高反应性，气流受限部分可逆。此时应根据临床及实验室所见全面分析，必要时作支气管激发试验、支气管舒张试验和（或）PEF昼夜变异率来进行鉴别。在少部分患者中，两种疾病可重叠存在。<br />&nbsp;&nbsp;', null, null, ' ', '为西医标注。是在在1997年《COPD诊治规范》（草案）基础上参照GOLD有关内容制定的。初步制定了慢性阻塞性肺疾病的定义、发病机制、病理、病理生理、危险因素、临床表现、实验室检查及特殊检查、诊断与鉴别诊断、严重程度分级、稳定期治疗、加重期治疗等。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('12', '10', 'D02_012', '1', '欧洲胰岛素抵抗研究组关于世界卫生组织临时报的评论', 'Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR)', '欧洲胰岛素抵抗研究组（European Group for the Study of Insulin Resistance）', '1999', 'Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442– 443.', '英文', null, 'Insulin Resistance Syndrome', null, null, 'The definition we propose is for nondiabetic individuals only because there is no simple way to measure insulin resistance in diabetes individuals. We suggest the syndrome is defined by the presence of insulin resistance or fasting hyperinsulinaemia(the highest 2.5%) and two of hyperglycaemia (fasting plasma glucose≥6.1 mmol/l, but nondiabetic); hypertension (systolic/diastolic blood pressures≥140/90mm Hg or treated for hypertension); dyslipidaemia (triglycerides>2.0 mmol/l or HDL-cholesterol<1.0 mmol/l or treated for dyslipidaemia); Central obesity (waist circumference≥94 cm in men and≥80cm in women). All of these criteria must be measured before it is possible to evaluate the presence of the syndrome. Hyperglycaemia should be defined at fasting (fasting plasma glucose≥6.1 mmol/l or impaired fasting glucose) in nondiabetic individuals. Only the fasting criteria are suggested to provide simpler criteria.', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('120', '38', 'M02_010', '1', '慢性阻塞性肺疾病诊治指南（2007年修订版）', '无', '中华医学会呼吸病学分会慢性阻塞性肺疾病学组', '2007', '中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南（2007年修订版）[J].中华结核和呼吸杂志，2007,30（1）：8-17.', '中文', '1.严重程度分级<br />&nbsp;&nbsp;COPD严重程度评估需根据患者的症状、肺功能异常、是否存在合并症（呼吸衰竭、心力衰竭）等确定，其中反映气流受限程度的FEV1下降有重要参考意义。根据肺功能有COPD严重性分为4级。M02_010表2<br />&nbsp;&nbsp;Ⅰ级（轻度COPD）：其特征为轻度气流受限，FEV1/FVC＜70%但FEV1≥80%预计值，通常伴有或不伴有咳嗽、咳痰。此时患者本人可能还没有认识到自己的肺功能是异常的。<br />&nbsp;&nbsp;Ⅱ级（中度COPD）：其特征为气流受限进一步恶化，50%≤FEV1＜81%预计值，并有症状进展和气短，运动后气短更为明显。此时，由于呼吸困难或疾病加重。患者常去医院就诊。<br />&nbsp;&nbsp;Ⅲ（重度COPD）：其特征为气流受限进一步恶化经，FEV1＜30%≤50%预计值，气短加剧，并且反复出现急性加剧，影响患者的生活质量。<br />&nbsp;&nbsp;Ⅳ（极重度COPD）：其特征为严重的气流受限，FEV1＜30%预计值或合并慢性呼吸衰竭。此时，患者的生活质量明显下降，如果出现急性加重则可能有生命危险。<br />&nbsp;&nbsp;虽然FEV1%预计值对反映COPD严重程度、健康状况及病死率有用，但FEV1并不能完全反映COPD复杂的严重情况，除FEV1以外，已证明体重指数（BMI）和呼吸困难分级在预测COPD生存率等方面有意义。<br />&nbsp;&nbsp;BMI等于体重（kg)/身高（m)的平方，BMI＜21kg/m2的患者死亡率增加。<br />&nbsp;&nbsp;功能性呼吸困难分级：可用呼吸困难量表来评价：0级：除非剧烈活动，无明显呼吸困难；1级：当快走或上缓坡时有气短；2级：由于呼吸困难比同龄人步行的慢，或者以自己的速度在平地上行走要停下来呼吸；3级：在平地上步行100m或数分钟后需要停下来呼吸；4级：明显的呼吸困难而不能离开房屋或者当穿脱衣服时气短。<br />&nbsp;&nbsp;如果将FEV1作为反映气流阻塞（obstruction)的指标，呼吸困难（dyspnea)分级作为症状的指标，BMI作为反映营养状况的指标，再加上6min步行距离作为运动耐力（exercise)的指标，将这四方面综合起来建立一个多因素分级系统（BODE）被认为可比FEV1更好地反映COPD的预后。<br />&nbsp;&nbsp;生活质量评估：广泛应用于评价COPD患者的病情严重程度、药物治疗的疗效、非药物治疗的疗效（如肺康复治疗、手术）和急性发作的影响等。生活质量评估还可用于预测死亡风险，而与年龄、PEF及体重指数无关。常用的生活质量评估方法有圣乔治呼吸问卷（SGRQ）和治疗结果研究（SF－36）等。<br />&nbsp;&nbsp;此外，COPD病程急性加重次数也可作为COPD严重程度的一项监测指标。<br />&nbsp;&nbsp;COPD病程可分为急性加重期和稳定期。COPD急性加重期是指者出现超越日常善的持续恶化，并需要改变基础COPD的常规用药者，通常在疾病过程中，者短期咳嗽、咳痰、气短和（或）喘息加重，痰量增多，呈脓性或黏脓性，可伴发热等炎症明显加重的表现。稳定期则指者咳嗽、咳痰、气短等症状稳定或症状轻微。<br />&nbsp;&nbsp;', '慢性阻塞性肺疾病', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1症状：1.1.1慢性咳嗽:通常为首发症状.初起咳嗽呈间歇性,早晨较重,以后早晚或整日均有咳嗽,但夜间咳嗽并不显著.少数病例咳嗽不伴咳痰。也有部分病例虽有明显气流受限，但无咳嗽症状。1.1.2咳痰：咳嗽后通常咳少量黏液性痰，部分患者在清晨较多；合并感染时痰量增多，常伴有脓性痰。1.1.3气短或呼吸困难：这是COPD的标志性症状，是使患者焦虑不安的主要原因，早期仅在劳力时出现，后逐渐加重，以致日常活动甚至休息时也感气短。1.1.4喘息和胸闷：不是COPD的特异性症状。部分患者特别是重度患者有喘息；胸部紧闷感通常发生于劳力后，与呼吸费力、肋间肌等容性收缩有关。1.1.5全身性症状：在疾病的临床过程中，特别在较重患者，可能会发生全身性症状，如体重下降、食欲减退、外周肌肉萎缩和功能障碍、精神抑郁和（或）焦虑等。合并感染时可咯血痰或咯血。<br />&nbsp;&nbsp;1.2病史特征：COPD患病过程应有以下特征：1.2.1吸烟史：多有长期大量吸烟史。1.2.2职业性或环境有害物质接触史：如较长期粉尖、烟雾、有害颗粒或有害气体接触史。1.2.3家庭史：COPD有家族聚集倾向。1.2.4发病年龄及好发季节：多于中年以后发病，症状好发于秋冬寒冷季节，常有反复呼吸道感染及急性加重史。随病情进展，急性加重愈渐频繁。1.2.5慢性肺原性心脏病史：COPD后期出现低氧血症和（或）高碳酸血症，可并发慢性肺原性心脏病和右心衰竭。<br />&nbsp;&nbsp;1.3体征：COPD早期体征可不明显。随疾病进展，常有以下体征：1.3.1视诊和触诊：胸廓形态异常，包括胸部过度膨胀、前后径增大、剑突下胸骨下角（腹上角）增宽及腹部膨凸等；常见呼吸变浅，频率增快，辅助呼吸肌如斜角肌及胸锁乳突肌参加呼吸运动，重症患者可见胸腹矛盾运动；患者不时采用缩唇呼吸以增加呼出气量；呼吸困难加重时常采取前倾坐位；低氧血症者可出现黏膜及皮肤紫绀，伴右心衰竭者可见下肢水肿，肝脏增大。1.3.2叩诊：由于肺过度充气使心浊音界缩小，肺肝界降低，肺叩诊可呈过度清音。1.3.3听诊：两肺呼吸音可减低，呼气相延长，平静呼吸时可闻干性音，两肺底或其他肺野可闻湿性啰音；心音遥远，剑突部心音较清晰响亮。<br />&nbsp;&nbsp;2.实验室检查及其他检测指标<br />&nbsp;&nbsp;2.1肺功能检查：肺功能检查是判断气流受限的客观指标，其重复性好，对COPD的诊断、严重程度评价、疾病程度评价、疾病进展、预后及治疗反应等均有重要意义。气流受限是以FEV1和FEV1/FVC降低来确定的。FEV1/FVC是COPD的一项敏感指标，可检出轻度气流受限。FEV1占预计值的百分比是中、重度气流受限的良好指标，它变异性小，易于操作。应作为COPD肺功能检查的基本项目。吸入支气管舒张剂后FEV1/FVC＜70%，可确定为不完全可逆的气流受限。呼气峰流速（PEF）最大呼气流量-容积曲线（MEFV）也可作为气流受限的参考指标，但COPD时PEF与FEV1的相关性不免够强，PEF有时可能低估气流阻塞的程度。气流受限可导致肺过度充气，使肺总量（TLC）、功能残气量（FRC）和残气容积（RV）增高，肺活量（VC）降低。TLC增加不及RV增加的程度大，故RV/TLC增高。肺泡隔破坏及肺毛细血管床丧失，可使弥散功能受损，一氧化碳弥散量（DLCO）降低，DLCO与肺泡通气量（VA）之比（DLCO/VA）比单纯DLCO更敏感。深吸气量（IC）是潮气量与补吸气量之和。IC/TLC是反映肺过度膨胀的指标，它在反映COPD呼吸困难程度甚至反映COPD生存率上具有意义。作为辅助检查，不论是用支气管舒张剂还是口服糖皮质激素进行支气管舒张试验，都不能预测疾病的进展。用药后FEV1改善较少，也不能预测患者对治疗的反应。患者在不同时间进行支气管舒张试验，其结果也可能不同。但在某些患者（如儿童时期有不典型哮喘史、夜间咳嗽、喘息表现），则有一定意义。<br />&nbsp;&nbsp;2.2胸部X线检查：X线检查对确定肺部并发症及与其他疾病（如肺间质纤维化、肺结核等）鉴别有重要意义。COPD早期X线胸片可无明显变化，以后出现肺纹理增多、紊乱等非特异怀特征；主要X线征是肺过度充气；肺容积增大，胸腔前后径增长，肋骨走向变平，肺野透亮度增高，横膈位置低平，心脏悬垂狭长，肺门血管纹理呈残根状，肺野外周血管纹理纤细稀少等。并发肺动脉高压、肺源性心脏病时，除右心增大的X线征外，还可能有肺动脉圆锥膨隆，肺门血管影扩大及右下肺动脉增宽等。<br />&nbsp;&nbsp;2.3胸部CT检查：CT检查一般不作为常规检查。但是，在鉴别诊断时CT检查有益，高分辨CT（HRCT）对辨别小叶中心型或全小叶型肺气肿及确定肺大疱的大小和数量，有很高的敏感性和特异性，对预计肺大疱切除或外科减容手术的效果有一定价值。<br />&nbsp;&nbsp;2.4血气检查：FEV1＜40%预计值时或具有呼吸衰竭或右心衰竭的COPD患者均应做血气检查。血气异常首先表现为轻、中度低氧血症。随疾病进展，低氧血症逐渐加重，并出现高碳酸血症。呼吸衰竭的血气诊断标准为静息状态下海平面吸空气时动脉血氧分压（PaO2)＜60mmHg（1mmHg=0.133Kpa)伴或不伴有动脉血二氧化碳分压（PaCO2)＞50mmHg。<br />&nbsp;&nbsp;2.5其他实验室检查：低氧血症，即PaO2＜55mmHg时，血红蛋白及红细胞可增高，红细胞压积＞55%时可诊断为红细胞增多症。并发感染时痰涂片可见大量中性粒细胞，痰培养可检查多种病原菌，常见者肺炎链球菌、流感嗜血杆菌、卡他莫拉菌、肺炎克雷伯杆菌等。<br />&nbsp;&nbsp;3.诊断和鉴别诊断<br />&nbsp;&nbsp;3.1全面采集病史进行评估：诊断COPD时，首先应全面采集病史，包括症状、既往史和系统回顾、接触史。症状包括慢性咳嗽、咳痰、气短。既往史和系统回顾应注意：出生时低体重、童年时有无哮喘、变态反应性疾病，感染及其他呼吸道疾病史如结核病史；COPD和呼吸系统疾病家族史；COPD急性加重和住院治疗病史；有相同危险因素（吸烟）的其他疾病，如心脏、外周血管和神经系统疾病；不能解释的体重下降；其他非特异性症状，喘息、胸闷、胸痛和晨起头痛，要注意吸烟史（以包/年计算）及职业、环境有害物质接触史等。<br />&nbsp;&nbsp;3.2诊断；COPD的诊断应根据临床表现、危险因素接触史、体征及实验室检查等资料综合分析确定。考虑COPD的主要症状是慢性咳嗽、咳痰和（或）呼吸困难及危险因素接触史；存在不完全可逆性气流受限是诊断COPD的必备条件。肺功能测定指标是诊断COPD的金标准。用支气管舒张剂后FEV1/FVC＜70%可确定为不完全可逆性气流受限。凡具有吸烟史及（或）环境职业污染接触史及（或）咳嗽、咳痰或呼吸困难史者均应进行肺功能检查。COPD早期轻度气流受限时可有或无临床症状。胸部X线检查有助于确定肺过度充气的程度及与其他肺部疾病鉴别。<br />&nbsp;&nbsp;3.3鉴别诊断：COPD应与支气管哮喘、支气管扩张症、充血性心力衰竭、肺结核等鉴别（表一）。与支气管哮喘的鉴别有时存在一定困难。COPD多于中年后起病，哮喘则多在儿童或青少年起病；COPD症状缓慢进展，逐渐加重，哮喘则症状起伏大；COPD多有长期吸烟史和（或）有害气体、颗粒接触史，哮喘则常伴过敏体质、过敏性鼻炎和（或）湿疹等，部分哮喘患者有哮喘家族史气流受限基本为不可逆性，哮喘时则多为可逆性。然而，部分病程长的哮喘口才已发生气道重塑，气流受限不能完全逆转；而少数COPD患者伴有气道高反应性，气流受限部分可逆。此时应根据临床和实验室所见全面分析，必要时支气管舒张试验敘（或）PEF昼夜变异率来进行鉴别。在少部分患者中这两种疾病可以重叠存在。M02_010表1<br />&nbsp;&nbsp;', null, null, ' ', '为西医标准。是修订版，标准规重点完善了严重程度分级与分期。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('121', '38', 'M02_011', '1', '中华医学会临床诊疗指南', '无', ' 中华医学会', '2009', '中华医学会.临床诊疗指南呼吸病学分册[M].北京：人民卫生出版社，2009.', '中文', '1.根据肺功能分级，结合临床表现，估计COPD患者的临床严重程度：<br />&nbsp;&nbsp;Ⅰ级(轻度COPD)，除有Ⅰ级肺功能异常外，通常可伴有或不伴有咳嗽、咳痰。此时，患者可能还没认识到自己的肺功能是异常的。<br />&nbsp;&nbsp;Ⅱ级（中度COPD），有Ⅱ级肺功能异常。症状进展，有气短症状，主要是运动后气短加重。患者常因此就诊。<br />&nbsp;&nbsp;Ⅲ级(重度COPD)，具有Ⅲ级肺功能异常。气短症状加剧，并反复出现急性加重，影响生活质量。<br />&nbsp;&nbsp;Ⅳ级（极重度COPD），肺功能严重受损（Ⅳ级），患者生活质量明显下降，如果发生急性加重，可危及生命。<br />&nbsp;&nbsp;此外，患者体重指数（BMI），6分钟步行距离(6MD)以及生活质量评估（如圣乔治呼吸问卷）亦可作为估计COPD病情严重程度的指征。<br />&nbsp;&nbsp;2.COPD病程分期：急性加重期（慢性阻塞性肺疾病急性加重）指患者出现超越日常状况的持续恶化，并需改变基础COPD常规用药者；通常在疾病过程中，短期内咳嗽、咳痰、气短和（或）喘息加重、痰量增多，呈脓性或黏液脓性，可伴发热等症状。稳定期则指患者咳嗽、咳痰、气短等症状稳定或症状轻微。', '慢性阻塞性肺疾病', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1症状<br />&nbsp;&nbsp;缓慢起病、病程长。主要症状：<br />&nbsp;&nbsp;1.1.1慢性咳嗽  通常为首发症状。常晨间咳嗽明显，睡眠时有阵咳或排痰。<br />&nbsp;&nbsp;1.1.2咳痰  一般为白色黏液或浆液性泡沫性痰，偶可带血丝，清晨排痰较多。<br />&nbsp;&nbsp;1.1.3气短或呼吸困难  是COPD标志性症状，早期在劳力时出现，后逐渐加重，以致在日常活动甚至休息时也感到气短。<br />&nbsp;&nbsp;1.1.4喘息和胸闷  部分病人特别是重度患者可出现。<br />&nbsp;&nbsp;1.1.5其他  晚期病人有体重下降，肌肉萎缩、无力，食欲减退等。<br />&nbsp;&nbsp;1.2体征<br />&nbsp;&nbsp;早期体征不明显。随疾病进展出现以下体征。<br />&nbsp;&nbsp;1.2.1视诊及触诊  胸廓前后径增大，剑突下胸骨下角增宽—桶状胸。有些患者呼吸变浅，频率增快，缩唇呼吸等；<br />&nbsp;&nbsp;1.2.2叩诊  心界缩小，肝浊音界下降，肺部过清音。<br />&nbsp;&nbsp;1.2.3听诊  两肺呼吸音减弱，呼气延长，有些患者可闻干性啰音和（或）湿性啰音。<br />&nbsp;&nbsp;    此外，患者常有吸烟史，有的有粉尘、烟雾或有害气体接触史。<br />&nbsp;&nbsp;2.实验室检查及特殊检查<br />&nbsp;&nbsp;2.1肺功能检查：是判断气流受限的主要客观指标，对COPD诊断，严重程度评价，疾病<br />&nbsp;&nbsp;进展有重要意义，有条件者应当进行。<br />&nbsp;&nbsp;2.1.1一秒钟用力呼气容积占用力肺活量百分比(FEV1/FVC)是评价气流受限的一项敏感指标。<br />&nbsp;&nbsp;    一秒钟用力呼气容积占预计值百分比（FEV1%预计值），是评估COPD严重程度的良好指标，其变异性较小，易于操作。<br />&nbsp;&nbsp;吸入支气管扩张剂后FEVl/FVC<70%者，可确定为不能完全可逆的气流受限。<br />&nbsp;&nbsp;2.1.2肺总量(TLC)、功能残气量(FRC)和残气量(RV)增高，肺活量(VC)降低，表明肺过度充气，有参考价值。<br />&nbsp;&nbsp;    由于TLC增加不及RV增高程度大，故RV/TLC增高。<br />&nbsp;&nbsp;2.1.3深吸气量(IC)降低，IC/TLC下降，是反映肺过度膨胀的指标，与呼吸困难程度甚至COPD生存率有关。<br />&nbsp;&nbsp;2.1.4一氧化碳弥散量(DLCO)及DLCO与肺泡通气量(VA)比值(DL-CO/VA)下降，该项指标供诊断参考。<br />&nbsp;&nbsp;2.2胸部X线检查：COPD早期胸片可无变化，以后可出现肺纹理增粗，紊乱等非特异性改变，也可出现肺气肿改变。<br />&nbsp;&nbsp;X线胸片改变对COPD诊断意义不很大，主要作为确定肺部并发症及与其他肺疾病鉴别之用。<br />&nbsp;&nbsp;2.3胸部CT检查：CT检查不应作为COPD的常规检查。高分辨率CT，对有疑问病例的鉴别诊断有一定意义。<br />&nbsp;&nbsp;2.4血气检查：确定发生低氧血症、高碳酸血症及酸碱平衡紊乱，因此仅适用于COPD合并呼吸衰竭者。<br />&nbsp;&nbsp;2.5其他：COPD合并细菌感染时，血白细胞增高，中性粒细胞核左移；痰细菌培养可能检出病原菌；常见病原菌为肺炎链球菌、流感嗜血杆菌、卡他莫拉菌、肺炎克雷白杆菌等。<br />&nbsp;&nbsp;3.诊断与严重程度分级<br />&nbsp;&nbsp;主要根据临床疰状、体征、吸烟等高危因素史以及肺功能检查等综合分析确定。不完全可逆的气流受限是COPD诊断的必备条件。即吸人支气管舒张剂后FEV1/FVC< 70%可确定为不完全可逆性气流受限。凡具有吸烟史和（或）环境职业污染接触史、有咳嗽、咳痰或呼吸困难症状者均应行肺功能检查。<br />&nbsp;&nbsp;有少数患者并无咳嗽、咳痰症状，仅在肺功能检查时FEV1/FVC<70%及／或FEV1<80%预计值，对这些病人在除外其他疾病后，亦可考虑诊断为COPD。<br />&nbsp;&nbsp;根据吸人支气管舒张剂后FEV1/FVC及FEV1%预计值结果，可作COPD肺功能分级。M02_011表<br />&nbsp;&nbsp;根据肺功能分级，结合临床表现，估计COPD患者的临床严重程度：<br />&nbsp;&nbsp;Ⅰ级(轻度COPD)，除有Ⅰ级肺功能异常外，通常可伴有或不伴有咳嗽、咳痰。此时，患者可能还没认识到自己的肺功能是异常的。<br />&nbsp;&nbsp;Ⅱ级（中度COPD），有Ⅱ级肺功能异常。症状进展，有气短症状，主要是运动后气短加重。患者常因此就诊。<br />&nbsp;&nbsp;Ⅲ级(重度COPD)，具有Ⅲ级肺功能异常。气短症状加剧，并反复出现急性加重，影响生活质量。<br />&nbsp;&nbsp;Ⅳ级（极重度COPD），肺功能严重受损（Ⅳ级），患者生活质量明显下降，如果发生急性加重，可危及生命。<br />&nbsp;&nbsp;此外，患者体重指数（BMI），6分钟步行距离(6MD)以及生活质量评估（如圣乔治呼吸问卷）亦可作为估计COPD病情严重程度的指征。<br />&nbsp;&nbsp;COPD病程分期：急性加重期（慢性阻塞性肺疾病急性加重）指患者出现超越日常状况的持续恶化，并需改变基础COPD常规用药者；通常在疾病过程中，短期内咳嗽、咳痰、气短和（或）喘息加重、痰量增多，呈脓性或黏液脓性，可伴发热等症状。稳定期则指患者咳嗽、咳痰、气短等症状稳定或症状轻微。<br />&nbsp;&nbsp;4.鉴别诊断<br />&nbsp;&nbsp;4.1支气管哮喘：多在儿童或青少年期起病，以发作性哮喘为特征，发作时两肺布满哮鸣音，缓解后症状消失，常有家庭或个人过敏史。哮喘的气流受限多为可逆性，其支气管舒张试验阳性。<br />&nbsp;&nbsp;4.2支气管扩张：有反复发作咳嗽、咳痰以及咯血症状。合并感染时有多量脓性痰。有肺部湿性啰音、杵状指。部分胸部X片显示肺纹理粗乱或呈卷发状，高分辨CT可见支气管扩张改变。<br />&nbsp;&nbsp;4.3肺结核：可有低热、乏力、盗汗等结核中毒症状，痰检可发现结核分枝杆菌、胸部X线片检查可发现结核病灶。<br />&nbsp;&nbsp;4.4肺癌：有慢性咳嗽、咳痰，近期痰中可带血，并反复发生，胸部X线片及CT可发现占位病变或阻塞性肺不张或肺炎。痰细胞学检查、可屈支气管镜检查以至肺部病变活检，可有助于明确诊断。<br />&nbsp;&nbsp;4.5其他：如较少见的闭塞性细支气管炎，弥漫性泛细支气管炎亦需注意鉴别。<br />&nbsp;&nbsp;', null, null, ' ', '为西医标准。有详细诊断流程，且有详细的治疗。内容包括概述、临床表现、实验室检查及特殊检查、诊断、鉴别诊断、并发症及治疗。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('122', '38', 'M02_012', '1', '慢性阻塞性肺疾病诊治指南（2013年修订版）', '无', '中华医学会呼吸病学分会慢性阻塞性肺疾病学组', '2013', '中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南（2013年修订版）[J].中国医学前沿杂志，2014,6（2）：67-80.', '中文', null, '慢性阻塞性肺疾病', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1症状慢阻肺的特征性症状是慢性和进行性加重的呼吸困难，咳嗽和咳痰。慢性咳嗽和咳痰常先于气流受限多年而存在，然而有些患者也可以无慢性咳嗽和咳痰的症状。常见症状：①呼吸困难：这是慢阻肺最重要的症状，也是患者体能丧失和焦虑不安的主要原因。患者常描述为气短、气喘和呼吸费力等。早期仅在劳力时出现，之后逐渐加重，以致日常活动甚至休息时也感到气短；②慢性咳嗽：通常为首发症状，初起咳嗽呈间歇性，早晨较重，以后早晚或整日均有咳嗽，但夜间咳嗽并不显著，少数病例咳嗷不伴有咳痰，也有少数病例虽有明显气流受限但无咳嗽症状；③咳痰：咳嗽后通常咳少量黏液性痰，部分患者在清晨较多，合并感染时痰量增多，常有脓性痰；④喘息和胸闷：这不是慢阻肺的特异性症状，部分患者特别是重症患者有明显的喘息，听诊有广泛的吸气相或呼气相哮鸣音，胸部紧闷感常于劳力后发生，与呼吸费力和肋间肌收缩有关。临床上如果听诊未闻及哮鸣音，并不能排除慢阻肺的诊断，也不能由于存在上述症状而确定哮喘的诊断；⑤其他症状：在慢阻肺的临床过程中，<br />&nbsp;&nbsp;特别是程度较重的患者可能会发生全身性症状，如体重下降、食欲减退、外周肌肉萎缩和功能障碍、精神抑郁和（或）焦虑等，长时间的剧烈咳嗽可导致咳嗽性晕厥，合并感染时可咯血痰。<br />&nbsp;&nbsp;1.2病史①危险因素：吸烟中、职业性或环境有害物质接触史；②既往史：包括哮喘史、过敏史、儿童时期呼吸道感染及其他呼吸系统疾病；③家族史：慢阻肺有家族聚集倾向；④发病年龄和好发季节：多于中年以后发病，症状好发于秋冬寒冷季节，常有反复呼吸道感染及急性加重史，随着病情进展，急性加重愈渐频繁；⑤并发症：心脏病、骨质疏松、骨骼肌肉疾病和肺癌等；⑥慢阻肺对患者生命质量的影响：多为活动能力受限、劳动力丧失、抑郁和熊虑等；⑦慢性肺源性心脏病史：慢阻肺后期出现低氧血症和（或）高碳酸血症，可合并慢性肺源性心脏病和右心衰竭。<br />&nbsp;&nbsp;1.3体征慢阻肺的早期体征可不明显，随着疾病讲展，常出现以下体征：①视诊及触诊：胸廓形态异常，如胸部过度膨胀、前后径增大、剑突下胸骨下角（腹上角）增宽和腹部膨凸等，常见呼吸变浅、频率增快、辅助呼吸肌（如斜角肌和胸锁乳突肌）参加呼吸运动，重症患者可见胸腹矛盾运动，患者不时用缩唇呼吸以增加呼出气量，呼吸困难加重时常采取前倾坐位，低氧血症患者可出现黏膜和皮肤发绀，伴有右心衰竭的患者可下肢水肿和肝脏增大；②叩诊：肺过度充气可使心浊音界缩小，肺肝界降低，肺叩诊可呈过度清音；③听诊：双肺呼吸音可减低，呼气延长，平静呼吸时可闻及干性哕音，双肺底或其他肺野可闻及湿哕音，心音遥远，剑突部心音较清晰响亮。<br />&nbsp;&nbsp;2.实验室检查及其他监测指标<br />&nbsp;&nbsp;2.1肺功能检查  肺功能检查是判断气流受限的重复性较好的客观指标，对慢阻肺的诊断、严重程度评价、疾病进展、预后及治疗反应等均有重要意义。气流受限是以FEV1和FEV1/FVC降低来确定的。FEV1/FVC是慢阻肺的一项敏感指标，可检出轻度气流受限。FEV1占预计值%是评价中、重度气流受限的良好指标，因其变异性小，易于操作，应作为慢阻肺的肺功能检查基本项目。患者吸入支气管舒张剂后的FEV1/FVC<70%，可以确定为持续存在气流受限。目前已经认识到，正常情况下随着年龄的增长，肺容积和气流可能受到影响，应用FEV1/FVC<70%这个固定比值可能导致某些健康老年人被诊所为轻度慢阻肺，也会对<45岁的成年人造成慢阻肺的诊断不足。因此，目前很难科学地确定用哪项标准诊断慢阻肺更合适。应用固定比值造成个别患者产生慢阻肺的误诊和诊断过度，其风险有限。因为肺功能仅仅是确立慢阻肺临床诊断的一项参数，其他参数包括症状和危险因素。<br />&nbsp;&nbsp;    气流受限可导致肺过度充气，使肺总量、功能残气量和残气容积增高，肺活量减低。肺总量增加不及残气容积增加的程度大，故残气容积与肺总量之比增高。肺泡隔破坏及肺毛细血管床丧失可使弥散功能受损，DLCO降低，DLCO与肺泡通气量之比较单纯DLCO更敏感。深吸气量是潮气量与补吸气量之和，深吸气量与肺总量之比是反映肺过度膨胀的指标，在反映慢阻肺呼吸困难程度甚至预测慢阻肺生存率方面具有意义。<br />&nbsp;&nbsp;    支气管舒张试验作为辅助检查，不论是用支气管舒张剂还是口服糖皮质激素（简称激素）进行支气管舒张试验，患者在不同的时间进行支气管舒张试验，其结果可能并不相同。因此，支气管舒张试验不能预测疾病的进展，也不能可靠预测患者对治疗的反应。目前气流受限的可逆程度没有作为慢阻肺的诊断条件，也未用于哮喘和慢阻肺的鉴别诊断。<br />&nbsp;&nbsp;2.2胸部X线检查  X线检查对确定肺部并发症及与其他疾病（如肺间质纤雏化、肺结核等）鉴别具有重要意义。慢阻肺早期X线胸片可无明显变化，以后出现肺纹理增多和紊乱等非特征性改变；主要X线征象为肺过度充气：肺容积增大，胸腔前后径增长，肋骨走向变平，肺野透亮度增高，横膈位置低平，心脏悬垂狭长，肺门血管纹理呈残根状，肺野外周血管纹理纤细稀少等，有时可见肺大疱形成。并发肺动脉高压和肺源性心脏病时，除右心增大的X线特征外，还可有肺动脉圆锥膨隆，肺门血管影扩大及右下肺动脉增宽等。<br />&nbsp;&nbsp;2.3胸部CT检查  CT检查一般不作为常规检查。但是在鉴别诊断时，CT检查有益，高分辨率CT对辨别小叶中心型或全小叶型肺气肿及确定肺大疱的大小和数量，有很高的敏感性和特异性，对预计肺大疱切除或外科减容手术等的效果有一定价值。<br />&nbsp;&nbsp;2.4脉搏氧饱和度(SPO2)监测和血气分析 慢阻肺稳定期患者如果FEV1占预计值%<40%，或临床症状提示有呼吸衰竭或右侧心力衰竭时应监测SPO2。如果SPO2<92%，应该进行血气分析检查。呼吸衰竭的血气分析诊断标准为海平面呼吸空气时Pa02<60 mmHg(1 mmHg=0.133 kPa)，伴或不伴有PaCO2>50mmHg。<br />&nbsp;&nbsp;2.5其他实验室检查  低氧血症(Pa02<55mmHg)对血红蛋白和红细胞可以增高，血细胞比容>0.55可诊断为红细胞增多症，有此患者表现为贫血。患者合并感染时，痰涂片中可见大量中性白细胞，痰培养可检出各种病原菌。<br />&nbsp;&nbsp;3.诊断与鉴别诊断<br />&nbsp;&nbsp;3.1全面采集病史进行评估  诊断慢阻肺时，首先应全面采集病史，包括症状、接触史、既往史和系统回顾。症状包括慢性咳嗽、咳痰和气短。既往史和系统回顾应注意：童年时期有无哮喘、变态反应性疾病、感染及其他呼吸道疾病（如肺结核），慢阻肺和呼吸系统疾病家族史，慢阻肺急性加重和住院治疗病史，有相同危险因素（吸烟）的其他疾病（如心脏、外周血管和神经系统疾病），不能解释的体重下降，其他非特异性症状（喘息、胸闷、胸痛和晨起头痛，还要注意吸烟史（以包年计算）及职业、环境有害物质接触史等。<br />&nbsp;&nbsp;3.2诊断  慢阻肺的诊断应根据临床表现、危险因素接触史、体征及实验室检查等资料，综合分析确定。任何有呼吸困难、慢性咳嗽或咳痰，且有暴露于危险因素病史的患者，临床上需要考虑慢阻肺的诊断。诊断慢阻肺需要进行肺功能检查，吸入支气管舒张剂后FEVi/FVC<70%即明确存在持续的气流受限，除外其他疾病后可确诊为慢阻肺。因此，持续存在的气流受限是诊断慢阻肺的必备条件。肺功能检查是诊断慢阻肺的金标准。凡具有吸烟史和（或）环境职业污染及生物燃料接触史，临床上有呼吸困难或咳嗽、咳痰病史者，均应进行肺功能检查。慢阻肺患者早期轻度气流受限时可有或无临床症状。胸部X线检查有助于确定肺过度充气的程度及与其他肺部疾病鉴别。<br />&nbsp;&nbsp;3.3鉴别诊断  慢阻肺应与哮喘、支气管扩张症、充血性心力衰竭、肺结核和弥漫性泛细支气管炎等相鉴别，尤其要注恚与哮喘进行鉴别。慢阻肺多于中年后起病，而哮喘则多在儿童或青少年期起病；慢阻肺症状缓慢进展，逐渐加重，而哮喘则症状起伏较大；慢阻肺多有长期吸烟史和（或）有害气体和颗粒接触史，而哮喘常伴有过敏体质、过敏性鼻炎和（或）湿疹等，部分患者有哮喘家族史。然而，应用目前的影像学和生理测定技术对某些慢性哮喘与慢阻肺患者进行明确的鉴别诊断是不可能的，这两种疾病可同时在少数患者中重叠存在，应个体化应用抗炎药物和其他各种治疗方法。其余可能潜在的疾病，通常容易与慢阻肺相鉴别。M02_011表<br />&nbsp;&nbsp;', null, null, ' ', '为西医标准。是修订版，该标准重点完善了诊断过程中症状、体征、实验室检查等，并对与其他病的鉴别诊断做了说明。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('123', '38', 'M02_013', '1', '稳定期慢性阻塞性肺疾病的诊断和管理:美国医师学会的临床实践指南', 'Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians', '美国医师学会（ACP,American College of Physicians）', '2007', 'http://guide.medlive.cn/guideline/549', '英文', null, '稳定期慢性阻塞性肺疾病', null, null, '1.CLINICAL EXAMINATION FOR PREDICTION OF AIRFLOW OBSTRUCTION<br />&nbsp;&nbsp;The National Health and Nutrition Examination Survey III and a systematic review of 19 studies examining the accuracy of clinical examination to predict AO were used to estimate the prevalence of COPD and AO and clinical diagnostic accuracy. Cigarette smoking is the most common cause of COPD. A 70–pack-year history of smoking was the best predictor of AO, with a positive likelihood ratio of 8.0 but a sensitivity of only 40%. Theliterature showed that ﬁndings from physical examination also had high speciﬁcity (90%) but poor sensitivity. In addition, sputum production or wheezing was also associated with an increased likelihood of AO. Evidence to assess the utility of combining items that were included in a clinical examination to predict AO showed that combinations of ﬁndings were more helpful for diagnosing the presence of A. The best combination to exclude COPD included never having smoked, no reported wheezing, and no wheezing on examination. A patient with any combination of 2 ﬁndings (0–pack-year history ofsmoking, history of COPD, or decreased breath sounds)can be considered likely to have AO (deﬁned as FEV1 lessthan 60% predicted or FEV1–FVC ratio less than 0.60)(positive likelihood ratio, 34) .<br />&nbsp;&nbsp;2.INCREMENTAL VALUE OF SPIROMETRY<br />&nbsp;&nbsp;Spirometry may be useful to identify patients who may beneﬁt from initiating therapy (Table 2). The evidence supports inhaled treatment in patients who have symptoms and FEV1 less than 60% predicted. The literature also showed that respiratory symptom status is not a reliable indicator of the presence of AO. However, as spirometric values worsened, individuals reported more respiratory symptoms, such as cough, sputum, wheezing, or dyspnea.But 33% of individuals with normal spirometric values reported respiratory symptoms. In addition, 21% of individuals who had severe to very severe AO by spirometry reported no symptoms. Nearly 80% of persons reporting any respiratory symptom had normal airﬂow, and only 3%to 4% had severe to very severe AO (8).Evidence is insufﬁcient to support widespread use of spirometry for testing adults with no respiratory symptoms, including those with current and past exposure to COPD risk factors. Spirometry may be beneﬁcial in symptomatic adults who have an FEV1 greater than 60% predicted for determining when to initiate therapy. The evidence does not support periodic spirometry after initiation of therapy to monitor ongoing disease status or to modify therapy. Furthermore, no high-quality evidence supports the use of obtaining and providing spirometry results to improve smoking cessation, identify and treat asymptomatic individuals to prevent future respiratory symptoms, or reduce spirometric decline in lung function. M02_013表', null, null, null, '该指导原则的目的是展示效果\n慢性阻塞性肺病的诊断和管理的证据。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('124', '38', 'M02_014', '1', '卫生保健指南:慢性阻塞性肺病(COPD)的诊断和管理', 'Health Care Guideline:Diagnosis and Management of Chronic Obstructive Pulmonary Disease (COPD)', '临床系统改进协会（ICSI,Institute for Clinical Systems Improvement）', '2009', 'www.icsi.org', '英文', null, '慢性阻塞性肺疾病', null, null, '1.  Establish Diagnosis of COPD<br />&nbsp;&nbsp;Key Points:<br />&nbsp;&nbsp;•  The diagnosis of COPD should be suspected based on the patient\'s medical history and <br />&nbsp;&nbsp;physical examination.<br />&nbsp;&nbsp;•  Spirometry is necessary for COPD diagnosis.<br />&nbsp;&nbsp;The European Respiratory Society (ERS) defnes COPD as follows:<br />&nbsp;&nbsp;•  A disorder characterized by reduced maximum expiratory fows and slow, forced emptying of the <br />&nbsp;&nbsp;lungs; features do not change markedly over several months<br />&nbsp;&nbsp;•  Airfow limitation due to varying combinations of airway disease and emphysema<br />&nbsp;&nbsp;•  Patients exhibit minimal reversibility of airfow limitation with bronchodilators<br />&nbsp;&nbsp;(European Respiratory Society, 1995 [R])<br />&nbsp;&nbsp;Recommended Etiological Evaluations for the Diagnosis of COPD from Other Guidelines<br />&nbsp;&nbsp;•  Spirometry recommended by ATS, BTS, ERS and GOLD<br />&nbsp;&nbsp;•  Pre- and post-bronchodilator recommended by ATS, BTS, ERS and GOLD<br />&nbsp;&nbsp;•  Screening for Alpha 1-antitrypsin concentration recommended by ERS, GOLD and ATS in patients <br />&nbsp;&nbsp;who develop COPD at a young age.<br />&nbsp;&nbsp;•  Resting oxygen saturation measurement suggested by ERS in moderate or severe disease, and BTS in severe disease<br />&nbsp;&nbsp;•  Arterial blood gas (ABG) measurement recommended by ERS in moderate or severe disease or if oxygen saturation is less than 92%, by ATS in moderate or severe disease, and by BTS and GOLD in severe disease Symptoms of and Risk Factors for COPD<br />&nbsp;&nbsp;COPD may be indicated by the presence of one of the following symptoms:<br />&nbsp;&nbsp;•  Chronic cough (duration greater than three months) with or without sputum production<br />&nbsp;&nbsp;•  Dyspnea with or without wheezing<br />&nbsp;&nbsp;COPD should also be considered if the patient has one or more of the following risk factors:<br />&nbsp;&nbsp;•  History of tobacco use or prolonged exposure to secondhand or environmental smoke<br />&nbsp;&nbsp;•  Asthma.<br />&nbsp;&nbsp;•  Occupations with exposure to dust and chemicals (e.g., frefghters, welders) <br />&nbsp;&nbsp;•  Alpha 1-antitrypsin defciency<br />&nbsp;&nbsp;•  Chronic respiratory infections<br />&nbsp;&nbsp;The diagnosis of COPD should be suspected based on the patient\'s medical history and physical examination, but requires spirometry to determine the degree of airfow limitation.  Spirometry is necessary for the diagnosis of COPD (U.S. Preventive Services Task Force, 2008 [R]).<br />&nbsp;&nbsp;Signs/symptoms for which COPD may be suspected:<br />&nbsp;&nbsp;•  Wheezing, prolonged expiratory phase of respiration, rhonchi and cough<br />&nbsp;&nbsp;•  Dyspnea (exertional or at rest)<br />&nbsp;&nbsp;•  Chronic sputum production<br />&nbsp;&nbsp;•  Hyperinfation of the chest with increased anterior-posterior (A-P) diameter<br />&nbsp;&nbsp;•  Use of accessory muscles of respiration<br />&nbsp;&nbsp;•  Pursed-lip breathing<br />&nbsp;&nbsp;•  Signs of cor pulmonale:<br />&nbsp;&nbsp;-   Increased pulmonic component of the second heart sound<br />&nbsp;&nbsp;-   Neck vein distention<br />&nbsp;&nbsp;-  Lower extremity edema<br />&nbsp;&nbsp;-  Hepatomegaly<br />&nbsp;&nbsp;NOTE:  fnger clubbing is not characteristic of COPD and should alert the clinician to another condition such as  idiopathic pulmonary fbrosis  (IPF), cystic fbrosis,  lung cancer or asbestosis.<br />&nbsp;&nbsp;Spirometry<br />&nbsp;&nbsp;Spirometry is an established and important method of measuring lung function for the diagnosis and management of patients with COPD.  It is recommended for symptomatic patients at risk of COPD, particularly smokers greater than 45 years of age, and for regular follow-up of patients with documented COPD (Wilt, 2005 [M]).  Large population screening is not recommended.<br />&nbsp;&nbsp;Airfow obstruction is measured by spirometry and shows a reduced forced expiratory volume in one second (FEV1) and FEV1/FVC (forced vital capacity) ratio.  Measuring pre- and post-bronchodilator spirometry is important to identify those patients with partial reversibility of airfow obstruction.  Partial reversibility is defned as improvement in airfow by 12% of baseline and 200 mL after administration of a bronchodilator.  <br />&nbsp;&nbsp;Pre- and Post-bronchodilator FEV1<br />&nbsp;&nbsp;It is important to distinguish COPD from asthma, because treatment and prognosis differ.  Measurement of pre- and post-bronchodilator FEV1 can assist with  this differentation.    In asthma,  the spirometric abnormality tends to return to normal with bronchodilators, although this distinction between COPD and asthma is not strictly rigid.  Factors commonly used to distinguish COPD from asthma include age of onset, smoking history, triggering factors and occupational history. <br />&nbsp;&nbsp;If the results of available spirometry are unclear, formal spirometry in a pulmonary function test lab should be considered.  Full pulmonary function tests with lung volumes and diffusion capacity (DLCO) are not recommended nor necessary to establish diagnosis or severity of COPD.<br />&nbsp;&nbsp;Spirometry, interpretation strategies, selection of reference values and quality control should be performed in compliance with the American Thoracic Society Statement on Standardization of Spirometry  (American Thoracic Society, 1995b [R]).<br />&nbsp;&nbsp;•  The  spirometer must meet  or  exceed  requirements  proposed  by  the American Thoracic Society.<br />&nbsp;&nbsp;•  Automated maneuver acceptability and reproducibility messages must be displayed and reported. Spirometers should produce a paper record.<br />&nbsp;&nbsp;•  The use of a nose clip for all spirometric maneuvers is strongly recommended.<br />&nbsp;&nbsp;•  Subjects may be studied in either the sitting or standing position.<br />&nbsp;&nbsp;•  Universal precautions should be applied in all instances in which there is potential for blood and body fuid exposure.  Appropriate use of gloves and hand washing are highly recommended.<br />&nbsp;&nbsp;•  Patients suspected of having M. tuberculosis or other airborne organisms should be tested in areas complying with the U.S. Public Health Service recommendations for air exchange and ventilation.<br />&nbsp;&nbsp;•  Daily calibration prior to testing using a calibrated known volume syringe with a volume of at  least  three  liters performed  to manufacturer\'s  recommendations  is  recommended.   A  log documenting instrument calibrations should be maintained. <br />&nbsp;&nbsp;•  Discussion of spirometry results with current smokers should be accompanied by strong advice to quit smoking and referral to smoking cessation resources.<br />&nbsp;&nbsp;(American Association for Respiratory Care Clinical Practice Guideline, 1996 [R]; American Thoracic Society, 1995a [R]; Ferguson, 2000 [R])<br />&nbsp;&nbsp;Although peak fow meters  should not be used  to diagnose or monitor COPD, monitoring of peak expiratory fow at home and at work can be used in certain situations to determine reversibility of and variability in airway obstruction.  <br />&nbsp;&nbsp;Reversibility Testing (measurement of pre- and post-bronchiodilator)<br />&nbsp;&nbsp;•  Global Initiative for Chronic Obstructive Lung Disease (GOLD):<br />&nbsp;&nbsp;-  Generally performed only once at time of diagnosis, this test is useful to help rule out asthma, to establish a patient\'s best attainable lung function, to gauge a patient\'s prognosis, and to guide treatment decisions.<br />&nbsp;&nbsp;-  Even patients who do not show a signifcant FEV1 response to a short-acting bronchodilator test can beneft symptomatically from long-term bronchodilator treatment.<br />&nbsp;&nbsp;•  British Thoracic Society, COPD Guidelines Group of the Standards of Care Committee:<br />&nbsp;&nbsp;-  A positive bronchodilator response (FEV1 greater than 200 mL and 15% over baseline value) suggests asthma.<br />&nbsp;&nbsp;-  More  than 20% variability  in absolute measurement of serial peak expiratory fow may suggest asthma.<br />&nbsp;&nbsp;•  European Respiratory Society (ERS):<br />&nbsp;&nbsp;-  Atopy and marked improvement of spirometry with administration of bronchodilators or glucocor-ticosteroids favor the diagnosis of asthma.<br />&nbsp;&nbsp;-  Testing of bronchoconstrictor  response  is of doubtful clinical value  in patients with established airfow limitation.<br />&nbsp;&nbsp;•  American Thoracic Society (ATS):<br />&nbsp;&nbsp;-  Signifcant reversibility is indicated by an increase of over 12% and 200 mL after inhaling a short-acting bronchodilator.<br />&nbsp;&nbsp;•  Alpha 1-antitrypsin<br />&nbsp;&nbsp;Alpha 1-antitrypsin defciency (A1AD or Alpha-1) is a genetic disorder caused by defective production of alpha 1-antitrypsin (A1AT), leading to decreased A1AT activity in the blood and lungs, and deposition of excessive abnormal A1AT protein in liver cells (Stoller, 2005 [R]).  There are several forms and degrees of defciency. Severe A1AD causes emphysema and/or COPD in adult life in nearly all people with the condition.  Cigarette smoke is especially harmful to individuals with A1AD.  In addition to increasing the  infammatory reaction  in  the airways, cigarette smoke directly  inactivates alpha 1-antitrypsin by oxidizing essential methionine residues to sulfoxide forms, decreasing the enzyme activity by a factor of 2000.  A1AD screening is appropriate in patients of Caucasian descent who develop COPD at a young age (less than 45 years) or who have a strong family history of the disease (Global Initiative for Chronic Obstructive Lung Disease, 2008 [R]).<br />&nbsp;&nbsp;Differential diagnosis <br />&nbsp;&nbsp;The chest radiograph in COPD is often normal but may show signs of hyperinfation, a fattened diaphragm, or bullae.<br />&nbsp;&nbsp;In  addition  to  asthma, possible differential diagnoses  for COPD  include bronchiectasis,  cystic fbrosis, obliterative bronchiolitis, congestive heart failure and upper airway lesions. <br />&nbsp;&nbsp;For more information on diagnosis and treatment of asthma, please refer to the ICSI Diagnosis and Treatment of Asthma guideline.<br />&nbsp;&nbsp;2.  Ask/Advise About Tobacco Use/Exposure at Every Visit<br />&nbsp;&nbsp;Key Points:<br />&nbsp;&nbsp;•  Tobacco cessation and oxygen therapy for those with resting hypoxemia are the only interventions proven to prolong survival of patients with COPD.<br />&nbsp;&nbsp;Ten to ffteen percent of long-term smokers develop COPD with accelerated rates of decline in FEV1. Advice and support from physicians and other health professionals are potentially powerful infuences on tobacco cessation.  According to the U.S. Surgeon General, tobacco use is one of the most important public health issues of our time.  The National Cancer Institute, which is the primary federal agency for tobacco control, states that the keys to patient awareness and education about tobacco cessation in a clinical setting are: <br />&nbsp;&nbsp;ASK    about tobacco use at every visit<br />&nbsp;&nbsp;ADVISE   all users to stop <br />&nbsp;&nbsp;ASSESS    users\' willingness to make a quit attempt<br />&nbsp;&nbsp;ASSIST    users\' efforts to quit<br />&nbsp;&nbsp;ARRANGE  follow-up<br />&nbsp;&nbsp;3.  Support Tobacco Cessation in Patients Who Use Tobacco<br />&nbsp;&nbsp;Reinforcement of tobacco cessation and follow-up for patients with COPD are extremely important.  Pharmacotherapy, social support and skills training/problem solving are the key treatments for tobacco cessation.  Nicotine patches, nasal sprays, inhalers and oral medication are all available to help patients achieve cessation (Dale, 2001 [A]; Fiore MC, 2008 [R]).M02_014表<br />&nbsp;&nbsp;4.  Acute Exacerbation?<br />&nbsp;&nbsp;Signs and symptoms of an acute exacerbation of COPD may include any of the following:<br />&nbsp;&nbsp;•  Increased dyspnea<br />&nbsp;&nbsp;•  Increased heart rate<br />&nbsp;&nbsp;•  Increased cough<br />&nbsp;&nbsp;•  Increased sputum production<br />&nbsp;&nbsp;•  Change in sputum color or character<br />&nbsp;&nbsp;•  Use of accessory muscles of respiration<br />&nbsp;&nbsp;•  Peripheral edema<br />&nbsp;&nbsp;•  Development or increase in wheezing<br />&nbsp;&nbsp;•  Change in mental status<br />&nbsp;&nbsp;•  Fatigue<br />&nbsp;&nbsp;•  Fever<br />&nbsp;&nbsp;•  Increased respiratory rate<br />&nbsp;&nbsp;•  Decrease in FEV1<br />&nbsp;&nbsp; or peak expiratory fow<br />&nbsp;&nbsp;•  Hypoxemia<br />&nbsp;&nbsp;•  Chest tightness<br />&nbsp;&nbsp;Change in mental status or a combination of two or more of the following new symptoms indicates a severe acute exacerbation:<br />&nbsp;&nbsp;•  Dyspnea at rest<br />&nbsp;&nbsp;•  Cyanosis<br />&nbsp;&nbsp;•  Respiratory rate of greater than 25 breaths per minute<br />&nbsp;&nbsp;•  Heart rate of greater than 110 beats per minute<br />&nbsp;&nbsp;•  Use of accessory muscles of respiration<br />&nbsp;&nbsp;5.  Evaluation<br />&nbsp;&nbsp;When a patient with known COPD presents with a moderate  to severe exacerbation,  the  following key elements of the history, physical examination and laboratory/radiology evaluation should be considered:<br />&nbsp;&nbsp;History<br />&nbsp;&nbsp;•  Baseline respiratory status<br />&nbsp;&nbsp;•  Present treatment regimen and recent medication use<br />&nbsp;&nbsp;•  Signs of airway infection, e.g., fever and/or change in volume and/or color of sputum<br />&nbsp;&nbsp;•  Duration of worsening symptoms<br />&nbsp;&nbsp;•  Limitation of activities<br />&nbsp;&nbsp;•  History of previous exacerbations<br />&nbsp;&nbsp;•  Increased cough<br />&nbsp;&nbsp;•  Decrease in exercise tolerance<br />&nbsp;&nbsp;•  Chest tightness<br />&nbsp;&nbsp;•  Change in alertness<br />&nbsp;&nbsp;•  Other non-specifc symptoms including malaise, diffculty sleeping and fatigue<br />&nbsp;&nbsp;•  Symptoms associated with comorbid acute and chronic conditions<br />&nbsp;&nbsp;•  Although rarely used, non-selective beta-blockers may contribute to bronchospasms<br />&nbsp;&nbsp;Physical Examination<br />&nbsp;&nbsp;•  Measurement of heart rate and blood pressure<br />&nbsp;&nbsp;•  Measurement of respiratory rate<br />&nbsp;&nbsp;•  Measurement of oxygen saturations using pulse oximetry<br />&nbsp;&nbsp;•  Measurement of temperature<br />&nbsp;&nbsp;•  Respiratory distress<br />&nbsp;&nbsp;•  Accessory respiratory muscle use<br />&nbsp;&nbsp;•  Increased pulmonary fndings (e.g., wheezing, decreased air entry, prolonged expiratory phase)<br />&nbsp;&nbsp;•  Peripheral edema<br />&nbsp;&nbsp;•  Somnolence and/or hyperactivity<br />&nbsp;&nbsp;•  Acute comorbid conditions<br />&nbsp;&nbsp;Laboratory/Radiology<br />&nbsp;&nbsp;•  Chest radiograph (in patients with suspected pneumonia)<br />&nbsp;&nbsp;•  Arterial blood gas (if oxygen saturation less than 88%, positive history of hypercapnia, questionable accuracy of oximetry, somnolence or other evidence of  impending respiratory failure [e.g., respiratory rate greater than 40 breaths per minute])<br />&nbsp;&nbsp;•  Theophylline level (if theophylline is being utilized)<br />&nbsp;&nbsp;•  White blood count (in patients with suspected severe respiratory infection)<br />&nbsp;&nbsp;•  A sputum culture with susceptibilities, if available, should be performed when an infectious exacerbation does not respond to initial antibiotic treatment (Global Initiative for Chronic Obstructive Lung Disease, 2008 [R]).  It is important that the sputum specimen is of good quality.<br />&nbsp;&nbsp;•  Brain natriuretic peptide (BNP), a simple blood lab test, can be of some use in evaluating a patient presenting with dyspnea, although its interpretation needs to be carefully applied along with clinical and other lab data such as chest radiograph and echocardiogram. Its sensitivity and specifcity in this setting increase at levels above 400 but do not differentiate between acute left ventricular (LV) failure, cor pulmonale or pulmonary embolism (McCullough, 2002 [B]).  It is of particular value if the level is very low.  The probability of left ventricular failure as a cause of dyspnea is less than 10% if the brain natriuretic peptide is less than 100 (Maisel, 2002 [B]).<br />&nbsp;&nbsp;In patients with an acute COPD exacerbation, spirometry is of little value.  For that reason, oximetry and/or arterial blood gases should be monitored.<br />&nbsp;&nbsp;There is little evidence regarding the contribution of additional laboratory testing or the usefulness of electrocardiography or echocardiography in an acute exacerbation of COPD.  They may be a useful consideration if the diagnosis is unclear, in order to evaluate other comorbid conditions.<br />&nbsp;&nbsp;', null, null, null, '为第七版。该指南旨在帮助临床医生通过提供一个分析框架评估和治疗的患者,不是为了取代临床医生的判断或建立一个协议对所有患者特定的条件。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('125', '38', 'M02_015', '1', '卫生保健指南:慢性阻塞性肺病(COPD)的诊断和管理', 'Health Care Guideline:Diagnosis and Management of Chronic Obstructive Pulmonary Disease (COPD)', '临床系统改进协会（ICSI,Institute for Clinical Systems Improvement）', '2011', 'www.icsi.org', '英文', null, '慢性阻塞性肺疾病', null, null, '1.Establish Diagnosis of COPD<br />&nbsp;&nbsp;Key Points:<br />&nbsp;&nbsp;•The diagnosis of COPD should be suspected based on the patient\'s medical history and physical examination.<br />&nbsp;&nbsp;•Spirometry is necessary for COPD diagnosis and to establish severity of disease.<br />&nbsp;&nbsp;The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defnes COPD as follows:<br />&nbsp;&nbsp;•A preventable and  treatable disease characterized by chronic airfow  limitation  that  is not  fully reversible.  Airfow limitation is usually progressive and associated with an abnormal infammatory response of the lungs.<br />&nbsp;&nbsp;•Chronic obstructive bronchitis  is defned as partially reversible airfow  limitation as well as  the presence of chronic productive cough for three months in each of two successive years in a patient in whom other causes of chronic cough have been excluded.<br />&nbsp;&nbsp;•Emphysema is defned as an abnormal permanent enlargement of the air spaces distal to the terminal bronchioles, accompanied by destruction of their walls and without obvious fbrosis.<br />&nbsp;&nbsp;(Global Initiative for Chronic Obstructive Lung Disease, 2009 [R])<br />&nbsp;&nbsp;Recommended Etiological Evaluations for the Diagnosis of COPD from Other Guidelines<br />&nbsp;&nbsp;•Spirometry and pre- and post-bronchodilator recommended by ATS, BTS, ERS and GOLD<br />&nbsp;&nbsp;•Screening for Alpha 1-antitrypsin concentration recommended by ERS, GOLD and ATS in patients who develop COPD at a young age<br />&nbsp;&nbsp;•Resting oxygen saturation measurement suggested by ERS in moderate or severe disease, and BTS in severe disease<br />&nbsp;&nbsp;•Arterial blood gas (ABG) measurement recommended by ERS in moderate or severe disease or if oxygen saturation is less than 92%, by ATS in moderate or severe disease, and by BTS and GOLD in severe disease<br />&nbsp;&nbsp;Symptoms of and Risk Factors for COPD<br />&nbsp;&nbsp;COPD may be indicated by the presence of one of the following symptoms:<br />&nbsp;&nbsp;•Chronic cough (duration greater than three months) with or without sputum production<br />&nbsp;&nbsp;•Dyspnea with or without wheezing<br />&nbsp;&nbsp;COPD should also be considered if the patient has one or more of the following risk factors:<br />&nbsp;&nbsp;•  History of tobacco use or prolonged exposure to secondhand or environmental smoke<br />&nbsp;&nbsp;•  Asthma<br />&nbsp;&nbsp;•  Occupations with exposure to dust and chemicals (e.g., frefghters, welders) <br />&nbsp;&nbsp;•  Alpha 1-antitrypsin defciency<br />&nbsp;&nbsp;•  Chronic respiratory infections<br />&nbsp;&nbsp;Signs/symptoms for which COPD may be suspected:<br />&nbsp;&nbsp;•  Wheezing, prolonged expiratory phase of respiration, rhonchi and cough<br />&nbsp;&nbsp;•  Dyspnea (exertional or at rest)<br />&nbsp;&nbsp;•  Chronic sputum production<br />&nbsp;&nbsp;•  Hyperinfation of the chest with increased anterior-posterior (A-P) diameter<br />&nbsp;&nbsp;•  Use of accessory muscles of respiration<br />&nbsp;&nbsp;•  Pursed-lip breathing<br />&nbsp;&nbsp;•  Signs of cor pulmonale:<br />&nbsp;&nbsp;-   Increased pulmonic component of the second heart sound<br />&nbsp;&nbsp;-   Neck vein distention<br />&nbsp;&nbsp;-  Lower extremity edema<br />&nbsp;&nbsp;-  Hepatomegaly<br />&nbsp;&nbsp;NOTE:  fnger clubbing is not characteristic of COPD and should alert the clinician to another condition such as idiopathic pulmonary fbrosis (IPF), cystic fbrosis, lung cancer or asbestosis.<br />&nbsp;&nbsp;The diagnosis of COPD should be suspected based on the patient\'s medical history and physical examination, but requires spirometry to determine the degree of airfow limitation.  Spirometry is necessary for the diagnosis of COPD (U.S. Preventive Services Task Force, 2008 [R]).<br />&nbsp;&nbsp;Spirometry<br />&nbsp;&nbsp;Spirometry is an established and important method of measuring lung function for the diagnosis and management of patients with COPD.  It is recommended for symptomatic patients at risk of COPD, particularly smokers greater than 45 years of age, and for regular follow-up of patients with documented COPD (Wilt, 2005 [M]).  According to the GOLD criteria, COPD is defned as an FEV1/FVC ratio less than 70% after treatment (Global Initiative for Chronic Obstructive Lung Disease, 2009 [R]). Large population screening is not recommended.<br />&nbsp;&nbsp;Airfow obstruction  is measured by  spirometry and  shows a  reduced FEV1/FVC  (forced vital capacity) ratio.  The American Thoracic Society does not include a low FEV1 in the defnition of airfow obstruction <br />&nbsp;&nbsp;– people can have a normal FEV1 (i.e., FEV1 > 80%)  and a FEV1/FVC ratio below the 95th percentile – are still being defned as having airfow obstruction).  Measuring pre- and post-bronchodilator spirometry is important to identify those patients with partial reversibility of airfow obstruction.  Reversibility is defned as improvement in airfow by 12% of baseline and 200 mL of either FEV1 or FVC after administration of a bronchodilator.  This does not exclude the diagnosis of COPD unless the ratio of FEV1/FVC improves to greater than 70%.<br />&nbsp;&nbsp;The signs, symptoms and airfow limitation in COPD vary with the severity of the disease.  The stages of severity of COPD may be categorized according to Table I.M02_015表1<br />&nbsp;&nbsp;The best correlation with morbidity and mortality is a decrease in FEV1. With FEV1 greater than 1.0 L, there is a slight increase in mortality at 10 years. With FEV1 less than 0.75 L, the approximate mortality rate at one year is 30%, and at 10 years is 95%.  Because of the relationship of prognosis and FEV1, the severity of COPD is staged on the basis of this spirometry measurement.  Patients are categorized as mild, moderate, severe or very severe.   The COPD work group selected  the COPD severity categories recommended by Global Initiative for Chronic Obstructive Lung Disease because they are straightforward and correlate with clinical experience.  However, it is clear that there are widespread differences relative to disease severity classifcation among published guidelines (Global Initiative for Chronic Obstructive Lung Disease, 2009 [R]; Hodgkin, 1990 [R]).<br />&nbsp;&nbsp;Pre- and Post-bronchodilator FEV1<br />&nbsp;&nbsp;It is important to distinguish COPD from asthma, because treatment and prognosis differ.  Measurement of pre- and post-bronchodilator FEV1 can assist with this differentiation.  In asthma, the spirometric abnormality tends to return to normal with bronchodilators, although this distinction between COPD and asthma is not strictly rigid.  If the FEV1/FVC ratio improves to > 70% after bronchial dilation, a diagnosis of COPD can be ruled out.   Factors commonly used  to distinguish COPD from asthma  include age of onset, smoking history, triggering factors and occupational history. <br />&nbsp;&nbsp;If the results of available spirometry are unclear, formal spirometry in a pulmonary function test lab should be considered.   Full pulmonary function tests with lung volumes and diffusion capacity (DLCO) can be helpful but are not necessary to establish diagnosis or severity of COPD.<br />&nbsp;&nbsp;Spirometry, interpretation strategies, selection of reference values and quality control should be performed in compliance with the American Thoracic Society Statement on Standardization of Spirometry (American Thoracic Society, 2005 [R]).<br />&nbsp;&nbsp;•  The spirometer must meet or exceed requirements proposed by the American Thoracic Society. <br />&nbsp;&nbsp;•  Automated maneuver acceptability and reproducibility messages must be displayed and reported.<br />&nbsp;&nbsp;•  The use of a nose clip for all spirometric maneuvers is strongly recommended.<br />&nbsp;&nbsp;•  Subjects should be studied in the sitting position for safety reasons.<br />&nbsp;&nbsp;•  Universal precautions should be applied in all instances in which there is potential for blood and body fuid exposure.  Appropriate use of gloves and hand washing are highly recommended.<br />&nbsp;&nbsp;•  Patients suspected of having M. tuberculosis or other airborne organisms should be tested in areas complying with the U.S. Public Health Service recommendations for air exchange and ventilation.<br />&nbsp;&nbsp;•  Daily calibration prior to testing using a calibrated known volume syringe with a volume of at least three liters performed to manufacturer\'s recommendations is recommended.  A log documenting instrument calibrations should be maintained.<br />&nbsp;&nbsp;•  Establish or participate in a training program for all those who perform spirometry testing and a quality control program that monitors technician performance.<br />&nbsp;&nbsp;•  Discussion of spirometry results with current smokers should be accompanied by strong advice to quit smoking and referral to smoking cessation resources.<br />&nbsp;&nbsp;(Ferguson, 2000 [R]; American Association for Respiratory Care Clinical Practice Guideline, 1996 [R]; American Thoracic Society, 1995 [R])<br />&nbsp;&nbsp;Although peak fow meters should not be used to diagnose or monitor COPD, monitoring of peak expiratory fow at home and at work can be used in certain situations to determine reversibility of and variability in airway obstruction.  <br />&nbsp;&nbsp;Reversibility Testing (measurement of pre- and post-bronchodilator)<br />&nbsp;&nbsp;•  Generally performed only once at time of diagnosis, this test is useful to help rule out asthma, to establish a patient\'s best attainable lung function, to gauge a patient\'s prognosis, and to guide treatment decisions.<br />&nbsp;&nbsp;•  Even patients who do not show a signifcant FEV1 response to a short-acting bronchodilator test can beneft symptomatically from long-term bronchodilator treatment.<br />&nbsp;&nbsp;•  A positive bronchodilator response (FEV1 greater than 200 mL and 15% over baseline value) suggests asthma.<br />&nbsp;&nbsp;•  More than 20% variability in absolute measurement of serial peak expiratory fow may suggest asthma.<br />&nbsp;&nbsp;•  Atopy and marked improvement of spirometry with administration of bronchodilators or glucocorticosteroids favor the diagnosis of asthma.<br />&nbsp;&nbsp;•  Testing of bronchoconstrictor response is of doubtful clinical value in patients with established airfow limitation.<br />&nbsp;&nbsp;•  Signifcant reversibility is indicated by an increase of over 12% and 200 mL after inhaling a short-acting bronchodilator.<br />&nbsp;&nbsp;Alpha 1-Antitrypsin<br />&nbsp;&nbsp;Alpha 1-antitrypsin defciency (A1AD or Alpha-1) is a genetic disorder caused by defective production of alpha 1-antitrypsin (A1AT), leading to decreased A1AT activity in the blood and lungs, and deposition of excessive abnormal A1AT protein in liver cells (Stoller, 2005 [R]).  There are several forms and degrees of defciency. Severe A1AD causes emphysema and/or COPD  in adult  life  in nearly all people with  the condition.  Cigarette smoke is especially harmful to individuals with A1AD.  In addition to increasing the infammatory reaction in the airways, cigarette smoke directly inactivates alpha 1-antitrypsin by oxidizing essential methionine residues to sulfoxide forms, decreasing the enzyme activity by a factor of 2000.  A1AD screening is appropriate in patients of Caucasian descent who develop COPD at a young age (less than 45 years) or who have a strong family history of the disease (Global Initiative for Chronic Obstructive Lung Disease, 2009 [R]).<br />&nbsp;&nbsp;Differential Diagnosis <br />&nbsp;&nbsp;The chest radiograph in COPD is often normal but may show signs of hyperinfation, a fattened diaphragm, or bullae.<br />&nbsp;&nbsp;In  addition  to  asthma, possible differential diagnoses  for COPD  include bronchiectasis,  cystic fbrosis, obliterative bronchiolitis, congestive heart failure and upper airway lesions. \nFor more information on diagnosis and treatment of asthma, please refer to the ICSI Diagnosis and Treatment of Asthma guideline.<br />&nbsp;&nbsp;2.Ask/Advise about Tobacco Use/Exposure at Every Visit and Offer Cessation Support as Needed<br />&nbsp;&nbsp;Key Points:<br />&nbsp;&nbsp;•  Tobacco cessation and oxygen therapy for those with resting hypoxemia are the only interventions proven to prolong survival of patients with COPD.<br />&nbsp;&nbsp;Ten to ffteen percent of long-term smokers develop COPD with accelerated rates of decline in FEV1.  Advice and support from physicians and other health professionals are potentially powerful infuences on tobacco cessation.  According to the U.S. Surgeon General, tobacco use is one of the most important public health issues of our time.  The National Cancer Institute, which is the primary federal agency for tobacco control, states that the keys to patient awareness and education about tobacco cessation in a clinical setting are: <br />&nbsp;&nbsp;ASK    about tobacco use at every visit<br />&nbsp;&nbsp;ADVISE   all users to stop <br />&nbsp;&nbsp;ASSESS    users\' willingness to make a quit attempt<br />&nbsp;&nbsp;ASSIST    users\' efforts to quit<br />&nbsp;&nbsp;ARRANGE  follow-up<br />&nbsp;&nbsp;Reinforcement of tobacco cessation and follow-up for patients with COPD are extremely important.  Pharmacotherapy, social support and skills training/problem solving are the key treatments for tobacco cessation.  Nicotine patches, nasal sprays, inhalers and oral medication are all available to help patients achieve cessation (Fiore, 2008 [R]; Dale, 2001 [A]).  See the Resources Table for more information.<br />&nbsp;&nbsp;3.Pharmacologic Management<br />&nbsp;&nbsp;Key Points:<br />&nbsp;&nbsp;•  Drug therapy is determined by severity of symptoms.<br />&nbsp;&nbsp;Each  level of severity  in Table II represents an  intervention  that  should be considered only  if  the previous course of action fails to improve symptoms of COPD.<br />&nbsp;&nbsp;A table of estimated comparative daily dosages for inhaled corticosteroids is attached in Appendix A, \"Estimated Comparative Daily Dosage for Inhaled Corticosteroids.\"<br />&nbsp;&nbsp;A table of hydrofuoro-alkane (HFAs) is attached in Appendix B, \"Hydrofuoro-alkane (HFA) Directory.\"<br />&nbsp;&nbsp;', null, null, null, '为第八版。该指南旨在帮助临床医生通过提供一个分析框架评估和治疗的患者,不是为了取代临床医生的判断或建立一个协议对所有患者特定的条件。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('126', '38', 'M02_016', '1', '慢性阻塞性疾病全球倡议-慢性阻塞性肺疾病的诊断、处理和预防', 'GLOBAL STRATEGY FOR THE DIAGNOSIS,MANAGEMENT,AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE.', '慢性阻塞性肺疾病全球倡议（GOLD,The Global Initiative for Chronic Obstructive Lung Disease）', '2011', 'http://guide.medlive.cn/guideline/2181', '英文', null, '慢性阻塞性肺疾病', null, null, 'KEY POINTS:<br />&nbsp;&nbsp;• A clinical diagnosis of COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease.<br />&nbsp;&nbsp;• Spirometry is required to make the diagnosis in this clinical context; the presence of a post-bronchodilator FEV1/FVC < 0.70 confrms the presence of persistent airfow limitation and thus of COPD. <br />&nbsp;&nbsp;• The goals of COPD assessment are to determine the severity of the disease, including the severity of airfow limitation, the impact on the patient’s health status, and the risk of future events (such as exacerbations, hospital admissions, or death), in order to guide therapy.  <br />&nbsp;&nbsp;• Comorbidities occur frequently in COPD patients, including cardiovascular disease, skeletal muscle dysfunction, metabolic syndrome, osteoporosis, depression, and lung cancer. Given that they can occur in patients with mild, moderate and severe airfow limitation and infuence mortality and hospitalizations independently, comorbidities should be actively looked for, and treated appropriately if present.<br />&nbsp;&nbsp;DIAGNOSIS<br />&nbsp;&nbsp;A clinical diagnosis of COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease (Table 2.1).  Spirometry is required to make the diagnosis in this clinical context; the presence of a postbronchodilator FEV1/FVC < 0.70 confrms the presence of persistent airfow limitation and thus of COPD.<br />&nbsp;&nbsp;The spirometric criterion for airfow limitation remains a post-bronchodilator fxed ratio of FEV1/FVC < 0.70. This criterion is simple, independent of reference values, and has been used in numerous clinical trials forming the evidence base from which most of our treatment recommendations are drawn. Diagnostic simplicity and consistency are key for the busy non-specialist clinician.<br />&nbsp;&nbsp;While post-bronchodilator spirometry is required for the diagnosis and assessment of severity of COPD, the degree of reversibility of airfow limitation (e.g., measuring FEV1 before and after bronchodilator or corticosteroids) is no longer recommended. The degree of reversibility has never been shown to add to the diagnosis, differential diagnosis with asthma, or to predicting the response to long-term treatment with bronchodilators or corticosteroids.M02_016表1<br />&nbsp;&nbsp;The role of screening spirometry in the general population is controversial.  Both FEV1 and FVC predict all-cause mortality independent of tobacco smoking, and abnormal lung function identifes a subgroup of smokers at increased risk for lung cancer.  This has been the basis of an argument that screening spirometry should be employed as a global health assessment tool .  However, there are no data to indicate that screening spirometry is effective in directing management decisions or in improving COPD outcomes in patients who are identifed before the \ndevelopment of signifcant symptoms. Thus, GOLD advocates active case fnding but not screening spirometry.<br />&nbsp;&nbsp;The use of the fxed FEV1/FVC ratio to defne airfow limitation will result in more frequent diagnosis of COPD in the elderly, and less frequent diagnosis in adults younger than 45 years106<br />&nbsp;&nbsp;, especially of mild disease, compared to using a cutoff based on the lower limit of normal (LLN) <br />&nbsp;&nbsp;values for FEV1/FVC. These LLN values are based on the normal distribution and classify the bottom 5% of the healthy population as abnormal.  From a scientifc perspective it is diffcult to determine which of these criteria is correct to diagnose COPD, and no studies exist comparing clinical diagnosis based on the two approaches. However, LLN values are highly dependent on the choice of valid reference equations using post-bronchodilator FEV1, and neither longitudinal studies validating the use of the LLN nor studies using reference equations in populations where smoking is not the major cause of COPD are available.  The risk of misdiagnosis and over-treatment of individual patients using the fxed ratio as a diagnostic criterion is limited, as spirometry is only one parameter for establishing the clinical diagnosis of COPD, the others being symptoms and risk factors.<br />&nbsp;&nbsp;Symptoms<br />&nbsp;&nbsp;The characteristic symptoms of COPD are chronic and progressive dyspnea, cough, and sputum production. Chronic cough and sputum production may precede the development of airfow limitation by many years. Individuals, particularly those exposed to COPD risk factors, who present with these symptoms should be examined to search for an underlying cause(s) and appropriate interventions taken.  Conversely, signifcant airfow limitation may develop without chronic cough and sputum production.  Although COPD is defned on the basis of airfow limitation, in practice the decision to seek medical help (and so permit the diagnosis to be made) is usually determined by the impact of a symptom on a patient’s daily life. A person may seek medical attention either because of chronic symptoms or because of a frst exacerbation.<br />&nbsp;&nbsp;Dyspnea.  Dyspnea, a cardinal symptom of COPD, is a major cause of disability and anxiety associated with the disease. Typical COPD patients describe their dyspnea as a sense of increased effort to breathe, heaviness, air hunger, or gasping. However, the terms used to describe dyspnea vary both by individual and by culture.<br />&nbsp;&nbsp;Cough. Chronic cough, often the frst symptom of COPD to develop, is frequently discounted by the patient as an expected consequence of smoking and/or environmental exposures.  Initially, the cough may be intermittent, but later is present every day, often throughout the day. The chronic cough in COPD may be unproductive. In some cases, signifcant airfow limitation may develop without the presence of a cough. Table 2.2 lists some of the other causes of chronic cough.<br />&nbsp;&nbsp;Sputum production.  COPD patients commonly raise small quantities of tenacious sputum after coughing bouts.Regular production of sputum for 3 or more months in 2 consecutive years (in the absence of any other conditions that may explain it) is the epidemiological defnition of chronic bronchitis, but this is a somewhat arbitrary defnition that does not refect the range of sputum production in COPD patients.  Sputum production is often diffcult to evaluate because patients may swallow sputum rather than expectorate it, a habit subject to signifcant cultural and gender variation.  Patients producing large volumes of sputum may have underlying bronchiectasis. M02_016表2<br />&nbsp;&nbsp;The presence of purulent sputum refects an increase in infammatory mediators, and its development may identify the onset of a bacterial exacerbation.<br />&nbsp;&nbsp;Wheezing and Chest Tightness. Wheezing and chest tightness are nonspecifc symptoms that may vary between days, and over the course of a single day. Audible wheeze may arise at a laryngeal level and need not be accompanied by auscultatory abnormalities. Alternatively, widespread inspiratory or expiratory wheezes can be present on listening to the chest.  Chest tightness often follows exertion, is poorly localized, is muscular in character, and may arise from isometric contraction of the intercostal muscles.  An absence of wheezing or chest tightness does not exclude a diagnosis of COPD, nor does the presence of these sypmtoms confrm a diagnosis of asthma.<br />&nbsp;&nbsp;Additional Features in Severe Disease.Fatigue, weight loss and anorexia are common problems in patients with severe and very severe COPD. They are prognostically important and can also be a sign of other diseases (e.g., tuberculosis, lung cancer), and therefore should always be investigated. Cough syncope occurs due to rapid increases in intrathoracic pressure during prolonged attacks of coughing. Coughing spells may also cause rib fractures,which are sometimes asymptomatic. Ankle swelling may be the only symptomatic pointer to the development of cor pulmonale.  Symptoms of depression and/or anxiety merit specifc enquiry in the clinical history because they are common in COPD and are associated with increased risk of exacerbations and poorer health status.<br />&nbsp;&nbsp;Medical History<br />&nbsp;&nbsp;A detailed medical history of a new patient known or thought to have COPD should assess:<br />&nbsp;&nbsp;•  Patient’s exposure to risk factors, such as smoking and occupational or environmental exposures<br />&nbsp;&nbsp;•  Past medical history, including asthma, allergy, sinusitis, or nasal polyps; respiratory infections in childhood; other respiratory diseases<br />&nbsp;&nbsp;•  Family history of COPD or other chronic respiratory disease<br />&nbsp;&nbsp;•  Pattern of symptom development: COPD typically develops in adult life and most patients are conscious of increased breathlessness, more frequent or prolonged “winter colds,” and some social restriction for a number of years before seeking medical help<br />&nbsp;&nbsp;•  History of exacerbations or previous hospitalizations for respiratory disorder: Patients may be aware of periodic worsening of symptoms even if these episodes have not been identifed as exacerbations of COPD<br />&nbsp;&nbsp;•  Presence of comorbidities, such as heart disease, osteoporosis, musculoskeletal disorders, and malignancies that may also contribute to restriction of activity<br />&nbsp;&nbsp;•  Impact of disease on patient’s life, including limitation of activity, missed work and economic impact, effect on family routines, feelings of depression or anxiety, well being and sexual activity<br />&nbsp;&nbsp;•  Social and family support available to the patient<br />&nbsp;&nbsp;•  Possibilities for reducing risk factors, especially smoking<br />&nbsp;&nbsp;Physical Examination<br />&nbsp;&nbsp;Although an important part of patient care, a physical examination is rarely diagnostic in COPD. Physical signs of airfow limitation are usually not present until signifcant impairment of lung function has occurred,, and their detection has a relatively low sensitivity and specifcity.  A number of physical signs may be present in COPD, but their absence does not exclude the diagnosis.<br />&nbsp;&nbsp;Spirometry<br />&nbsp;&nbsp;Spirometry is the most reproducible and objective measurement of airfow limitation available.  Peak expiratory fow measurement alone cannot be reliably used as the only diagnostic test, despite its good sensitivity, because of its weak specifcity. Good quality spirometric measurement is possible in any health care setting and all health care workers who care for COPD patients should have access to spirometry.  Table 2.3 summarizes some of the factors needed to achieve accurate test results.<br />&nbsp;&nbsp;Spirometry should measure the volume of air forcibly exhaled from the point of maximal inspiration (forced vital capacity, FVC) and the volume of air exhaled during the frst second of this maneuver (forced expiratory volume in one second, FEV1), and the ratio of these two measurements (FEV1/FVC) should be calculated. The ratio between FEV1 and slow vital capacity (VC), FEV1/VC, is sometimes measured instead of the FEV1/FVC ratio. This will often lead to lower values of the ratio, especially in pronounced airfow limitation; however, the cut-off point of 0.7 should still be applied.  Spirometry measurements are evaluated by comparison with reference values based on age, height, sex, and race.M02_016表3<br />&nbsp;&nbsp;Figure 2.1A shows a normal spirometry tracing; Figure 2.1B a spirometry tracing typical of a patient with obstructive disease.  Patients with COPD typically show a decrease in both FEV1 and FVC.', null, null, null, 'COPD表型更利于治疗选择，纳入急性加重和合并症，治疗策略亦需依据新指标。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('127', '38', 'M02_017', '1', '慢性阻塞性疾病全球倡议-慢性阻塞性肺疾病的诊断、处理和预防', 'GLOBAL STRATEGY FOR THE DIAGNOSIS,MANAGEMENT,AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE.', '慢性阻塞性肺疾病全球倡议（GOLD,The Global Initiative for Chronic Obstructive Lung Disease）', '2010', 'http://guide.medlive.cn/guideline/1366', '英文', 'Assessment of COPD severity is based on the patient’s level of symptoms, the severity of the spirometric abnormality (Figure 1-2), and the presence of complications such as respiratory failure, right heart failure, weight loss, and arterial hypoxemia.\nAlthough the presence of airfow limitation is key to the assessment of COPD severity, it may be valuable from a public health perspective to identify individuals at risk for the disease before signifcant airfow limitation develops (Figure 1-3). A majority of people with early COPD identifed in large studies complained of at least one respiratory symptom, such as cough, sputum production, wheezing, or breathlessness. These symptoms may be present at a time of relatively minor or even no spirometric abnormality. While not all individuals with such symptoms will go on to develop COPD, presence of these symptoms should help defne a high-risk population that should be targeted for preventive intervention. Much depends on the success of convincing such people, as well as health care workers, that even minor respiratory symptoms are not normal and may be markers of future ill health.\nWhen evaluating symptomatic patients presenting to a physician, the severity of the patient’s symptoms and the degree to which they affect his or her daily life, not just the severity of airfow obstruction, are the major determinants of health status . The severity of a patient’s breathlessness is important and can be usefully gauged by the MRC scale (Figure 5.1-2). Other forms of symptom severity scoring have yet to be validated in different populations and commonly rely on individual clinical judgment, although a clinical COPD questionnaire has been validated in family practice.\nObjectively measured exercise impairment, assessed by a reduction in self-paced walking distance or during incremental exercise testing in a laboratory, is a powerful indicator of health status impairment and predictor of prognosis. The ratio of inspiratory capacity to total lung capacity determined plethysmographically has also been found to be prognostically useful. Similarly, weight loss and reduction in the arterial oxygen tension identify patients at increased risk for mortality.\nA relatively simple approach to identifying disease severity using a combination of most of the above variables has been proposed. The BODE method gives a composite score (Body mass index, Obstruction, Dyspnea and Exercise) that is a better predictor of subsequent survival than any component singly, and its properties as a measurement tool are under investigation.\nFor patients diagnosed with Stage II: Moderate COPD and beyond, the following additional investigations may be considered:\nBronchodilator reversibility testing. Despite earlier hopes, neither bronchodilator nor oral glucocorticosteroid reversibility testing predicts disease progression, whether judged by decline in FEV1, deterioration of health status, or frequency of exacerbations in patients with a clinical diagnosis of COPD and abnormal spirometry. Small changes in FEV1 (e.g., < 400 ml) after administration of a bronchodilator do not reliably predict the patient’s respons to treatment (e.g., change in exercise capacity). Minor variations in initial airway caliber can lead to different classifcation of reversibility status depending on the day of testing, and the lower the pre-bronchodilator FEV1,the greater the chance of a patient being classifed as reversible even when the 200 ml volume criterion is included.\nIn some cases (e.g., a patient with an atypical history such as asthma in childhood and regular night waking with cough or wheeze) a clinician may wish to perform a bronchodilator and/or glucocorticosteroid reversibility test and a possible protocol is suggested in Figure 5.1-6.M02_017表6\nChest X-ray. An abnormal chest X-ray is seldom diagnostic in COPD unless obvious bullous disease is present, but it is valuable in excluding alternative diagnoses and establishing the presence of signifcant comorbidities such as cardiac failure. Radiological changes associated with COPD include signs of hyperinfation (fattened diaphragm on the lateral chest flm, and an increase in the volume of the retrosternal air space), hyperlucency of the lungs, and rapid tapering of the vascular markings. Computed tomography (CT) of the chest is not routinely recommended. However, when there is doubt about the diagnosis of COPD, high resolution CT (HRCT) scanning might help in the differential diagnosis. In addition, if a surgical procedure such as lung volume reduction is contemplated, a chest CT scan is necessary since the distribution of emphysema is one of the most important determinants of surgical suitability.\nArterial blood gas measurement. In advanced COPD, measurement of arterial blood gases while the patient is breathing air is important. This test should be performed in stable patients with FEV1 < 50% predicted or with clinical signs suggestive of respiratory failure or right heart failure. Several considerations are important to ensure accurate test results. The inspired oxygen concentration (FiO2normally 21% at sea level) should be noted, a particularly important point if patient is using an O2-driven nebulizer. Changes in arterial blood gas tensions take time to occur, \nespecially in severe disease. Thus, 20-30 minutes should pass before rechecking the gas tensions when the FiO2 has been changed, e.g., during an assessment for domiciliary oxygen therapy. Adequate pressure must be applied at the arterial puncture site for at least one minute, as failure to do so can lead to painful bruising.\nAlpha-1 antitrypsin defciency screening. In patients of Caucasian descent who develop COPD at a young age (< 45 years) or who have a strong family history of the disease, it may be valuable to identify coexisting alpha-1 antitrypsin defciency. This could lead to family screening or appropriate counseling. A serum concentration of alpha-1 antitrypsin below 15-20% of the normal value is highly suggestive of homozygous alpha-1 antitrypsin defciency.\nDifferential Diagnosis \nIn some patients with chronic asthma, a clear distinction from COPD is not possible using current imaging and physiological testing techniques, and it is assumed that asthma and COPD coexist in these patients. In these cases, current management is similar to that of asthma. Other potential diagnoses are usually easier to distinguish from COPD (Figure 5.1-7). M02_017表7', '慢性阻塞性肺疾病', null, null, 'KEY POINTS: \n•  A clinical diagnosis of COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease. The diagnosis should be confrmed by spirometry. \n•  For the diagnosis and assessment of COPD, spirometry is the gold standard as it is the most reproducible, standardized, and objective way of measuring airfow limitation. The presence of a postbronchodilator FEV1/FVC < 0.70 confrms the presence of airfow limitation that is not fully reversible. \n•  Health care workers involved in the diagnosis and management of COPD patients should have access to spirometry. \n•  Assessment of COPD severity is based on the patient’s level of symptoms, the severity of the spirometric abnormality, and the presence of complications. \n•  Measurement of arterial blood gas tensions should be considered in all patients with FEV1 < 50% predicted or clinical signs suggestive of respiratory failure or right heart failure. \n•  COPD is usually a progressive disease and lung function can be expected to worsen over time, even with the best available care. Symptoms and objective measures of airfow limitation should be monitored to determine when to modify therapy and to identify any complications that may develop. \n•  Comorbidities are common in COPD and should be actively identifed. Comorbidities often complicate the management of COPD, and vice versa.\nINITIAL DIAGNOSIS\nA clinical diagnosis of COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease . The diagnosis should be confrmed by spirometry. The presence of a postbronchodilator FEV1/FVC < 0.70 confrms the presence of airfow limitation that is not fully reversible.M02_017表1\nAssessment of Symptoms \nAlthough exceptions occur, the general patterns of symptom development in COPD is well established. The main symptoms of patients in Stage I: Mild COPD are chronic cough and sputum production. These symptoms can be present for many years before the development of airfow limitation and are often ignored or discounted by patients and attributed to aging or lack of conditioning. As airfow limitation worsens in Stage II: Moderate COPD, patients often experience dyspnea, which may interfere with their daily activities1. Typically, this is the stage at which they seek medical attention and may be diagnosed with COPD. However, some patients do not experience cough, sputum production, or dyspnea in Stage I: Mild COPD or Stage II: Moderate COPD, and do not come to medical attention until their airfow limitation becomes more severe or their lung function is worsened acutely by a respiratory tract infection. As airfow limitation worsens and the patient enters Stage III: Severe COPD, the symptoms of cough and sputum production typically continue, dyspnea worsens, and additional symptoms heralding complications (such as respiratory failure, right heart failure, weight loss, and arterial hypoxemia) may develop. It is important to note that, since COPD may be diagnosed at any stage, any of the symptoms described below may be present in a patient presenting for the frst time.\nDyspnea. Dyspnea, the hallmark symptom of COPD, is the reason most patients seek medical attention and is a major cause of disability and anxiety associated with the disease. Typical COPD patients describe their dyspnea as a sense of increased effort to breathe, heaviness, air hunger, or gasping2. However, the terms used to describe dyspnea vary both by individual and by culture3. It is often possible to distinguish the breathlessness of COPD from that due to other causes by analysis of the terms used, although there is considerable overlap with descriptors of bronchial asthma. A simple way to quantify the impact of breathlessness on a patient’s health status is the British Medical Research Council (MRC) questionnaire. This questionnaire relates well to other measures of health status and predicts future mortality risk.M02_017表2\nBreathlessness in COPD is characteristically persistent and progressive. Even on good days COPD patients experience dyspnea at lower levels of exercise than unaffected people of the same age. Initially, breathlessness is only noted on unusual effort (e.g., walking or running up a fight of stairs) and may be avoided entirely by appropriate behavioral change (e.g., using an elevator). As lung function deteriorates, breathlessness becomes more intrusive, and patients may notice that they are unable to walk at the same speed as other people of the same age or carry out activities that require use of the accessory respiratory muscles (e.g., carrying grocery bags). Eventually, breathlessness is present during everyday activities (e.g., dressing, washing) or at rest, leaving the patient confned to the home.\nCough. Chronic cough, often the frst symptom of COPD to develop, is often discounted by the patient as an expected consequence of smoking and/or environmental exposures. Initially, the cough may be intermittent, but later is present every day, often throughout the day. The chronic cough in COPD may be unproductive. In some cases, signifcant airfow limitation may develop without the presence of a cough. lists some of the other causes of chronic cough in individuals with a normal chest X-ray. M02_017表3\nSputum production. COPD patients commonly raise small quantities of tenacious sputum after coughing bouts. Regular production of sputum for 3 or more months in 2 consecutive years (in the absence of any other conditions that may explain it) is the epidemiological defnition of chronic bronchitis, but this is a somewhat arbitrary defnition that does not refect the range of sputum production in COPD patients. Sputum production is often diffcult to evaluate because patients may swallow sputum rather than expectorate it, a habit subject to signifcant cultural and gender variation. Patients producing large volumes of sputum may have underlying bronchiectasis. The presence of purulent sputum refects an increase in infammatory mediators10\n, and its development may identify the onset of an exacerbation.\nWheezing and chest tightness. Wheezing and chest tightness are nonspecifc symptoms that may vary between days, and over the course of a single day. These symptoms may be present in Stage I: Mild COPD, but are more characteristic of asthma or Stage III: Severe COPD and Stage IV: Very Severe COPD. Audible wheeze may arise at a laryngeal level and need not be accompanied by auscultatory abnormalities. Alternatively, widespread inspiratory or expiratory wheezes can be present on listening to the chest. Chest tightness often follows xertion, is poorly localized, is muscular in character, and may arise from isometric contraction of the intercostal muscles. An absence of wheezing or chest tightness does not exclude a diagnosis of COPD, nor does their presence confrm a diagnosis of asthma. Additional features in severe disease. Weight loss and anorexia are common problems in advanced COPD. They are prognostically important and can also be a sign of other diseases (e.g., tuberculosis, bronchial tumors), and therefore should always be investigated. Cough syncope occurs due to rapid increases in intrathoracic pressure during attacks of coughing. Coughing spells may also cause rib fractures, which are sometimes asymptomatic. Ankle swelling may be the only symptomatic pointer to the development of cor pulmonale.  Psychiatric morbidity, especially anxiety and depression are increased in COPD and high levels of anxiety are associated with poorer outcomes. Anxiety and depression merit specifc enquiry in the clinical history. \nMedical History \nA detailed medical history of a new patient known or thought to have COPD should assess: \n•  Patient’s exposure to risk factors, such as smoking and occupational or environmental exposures.\n•  Past medical history, including asthma, allergy, sinusitis, or nasal polyps; respiratory infections in childhood; other respiratory diseases \n•  Family history of COPD or other chronic respiratory disease \n•  Pattern of symptom development: COPD typically develops in adult life and most patients are conscious of increased breathlessness, more frequent winter colds, and some social restriction for a number of years before seeking medical help. \n•  History of exacerbations or previous hospitalizations for respiratory disorder: Patients may be aware of periodic worsening of symptoms even if these episodes have not been identifed as exacerbations of COPD. \n•  Presence of comorbidities, such as heart disease, malignancies, osteoporosis, and musculoskeletal disorders, which may also contribute to restriction of activity.\n•  Appropriateness of current medical treatments: For example, betablockers commonly prescribed for heart disease are usually contraindicated in COPD. \n•  Impact of disease on patient?s life, including limitation of activity, missed work and economic impact, effect on family routines, feelings of depression or anxiety \n•  Social and family support available to the patient \n•  Possibilities for reducing risk factors, especially smoking cessation.\nPhysical Examination \nThough an important part of patient care, a physical examination is rarely diagnostic in COPD. Physical signs of airfow limitation are usually not present until signifcant impairment of lung function has occurred, and their detection has a relatively low sensitivity and specifcity. A number of physical signs may be present in COPD, but their absence does not exclude the diagnosis.\nInspection.   \n•  Central cyanosis, or bluish discoloration of the mucosal membranes, may be present but is diffcult to detect in artifcial light and in many racial groups. \n•  Common chest wall abnormalities, which refect the pulmonary hyperinfation seen in COPD, include relatively horizontal ribs, “barrel-shaped” chest, and protruding abdomen. \n•  Flattening of the hemidiaphragms may be associated with paradoxical indrawing of the lower rib cage on inspiration, and widening of the xiphosternal angle. \n•  Resting respiratory rate is often increased to more than 20 breaths per minute and breathing can be relatively shallow. \n•  Patients commonly show pursedlip breathing, which may serve to slow expiratory fow and permit more effcient lung emptying. \n•  COPD patients often have resting muscle activation while lying supine. Use of the scalene and sternocleidomastoid muscles is a further indicator of respiratory distress. \n•   Ankle or lower leg edema can be a sign of right heart failure.Palpation and percussion. \n•  These are often unhelpful in COPD. \n•  Detection of the heart apex beat may be diffcult due to pulmonary hyperinfation. \n•  Hyperinfation also leads to downward displacement of the liver and an increase in the ability to palpate this organ without it being enlarged.\nAuscultation. \n•  Patients with COPD often have reduced breath sounds,but this fnding is not suffciently characteristic to make the diagnosis. \n•  The presence of wheezing during quiet breathing is a useful pointer to airfow limitation. However, wheezing heard only after forced expiration has not been validated as a diagnostic test for COPD. \n•  Inspiratory crackles occur in some COPD patients but are of little help diagnostically. \n•  Heart sounds are best heard over the xiphoid area.\nMeasurement of Airfow Limitation (Spirometry)\nSpirometry should be undertaken in all patients who may have COPD. It is needed to make a confdent diagnosis of COPD and to exclude other diagnoses that may present with similar symptoms. Although spirometry does not fully capture the impact of COPD on a patient’s health, it remains the gold standard for diagnosing the disease and monitoring its progression. It is the best standardized, most reproducible, and most objective measurement of airfow limitation available. Good quality spirometric measurement is possible and all health care workers who care for COPD patients should have access to spirometry. summarizes some of the factors needed to achieve accurate test results. Spirometry should measure the volume of air forcibly exhaled from the point of maximal inspiration (forced vital capacity, FVC) and the volume of air exhaled during \nthe frst second of this maneuver (forced expiratory volume in one second, FEV1), and the ratio of these two measurements (FEV1/FVC) should be calculated. Spirometry measurements are evaluated by comparison with reference values based on age, height, sex, and race (use appropriate reference values, e.g., see reference ). M02_017表4\nFigure 5.1-5 shows a normal spirogram and a spirogram typical of patients with mild to moderate COPD. Patients with COPD typically show a decrease in both FEV1 and FVC. The degree of spirometric abnormality generally refects the severity of COPD (Figure 1-2). The presence of airfow limitation is defned by a postbronchodilator FEV1/FVC < 0.70. This approach to is a pragmatic one in view of the fact that universally applicable reference values for FEV1 and FVC are not available. Spirometry should be performed after the administration of an adequate  dose of a short-acting inhaled bronchodilator (e.g., 400 µg salbutamol) in order to minimize variability Where possible, values should be compared to age-related normal values to avoid over-diagnosis of COPD in the elderly. Using the fxed ratio (FEV1/FVC) is particularly problematic in older adults since the ratio declines with age leading to the potential for labeling healthy older adults as having COPD. Post- bronchodilator reference values in this population are urgently needed to avoid potential overdiagnosis. M02_017表5\nPeak expiratory fow is sometimes used as a measure of airfow limitation, but in COPD may underestimate the degree of airways obstruction. Data from the US National Health and Nutrition Examination Survey suggest that peak expiratory fow has good sensitivity, identifying over 90% of COPD cases that can be diagnosed with spirometry, but because its specifcity is weaker it cannot be relied on as the only diagnostic test.\nThe role of screening spirometry in the general populat or in a population at risk for COPD is controversial. Bot FEV1 and FVC predict all-cause mortality independent tobacco smoking, and abnormal lung function identifes a subgroup of smokers at increased risk for lung cancer. This has been the basis of an argument that screening spirometry should be employed as a global health assessment tool. However, there are no data to indicate that screening spirometry is effective in directin management decisions or in improving COPD outcome in patients who are identifed before the development of signifcant symptoms.\nAssessment of COPD Severity \nAssessment of COPD severity is based on the patient’s level of symptoms, the severity of the spirometric abnormality (Figure 1-2), and the presence of complications such as respiratory failure, right heart failure, weight loss, and arterial hypoxemia.\nAlthough the presence of airfow limitation is key to the assessment of COPD severity, it may be valuable from a public health perspective to identify individuals at risk for the disease before signifcant airfow limitation develops (Figure 1-3). A majority of people with early COPD identifed in large studies complained of at least one respiratory symptom, such as cough, sputum production, wheezing, or breathlessness. These symptoms may be present at a time of relatively minor or even no spirometric abnormality. While not all individuals with such symptoms will go on to develop COPD, presence of these symptoms should help defne a high-risk population that should be targeted for preventive intervention. Much depends on the success of convincing such people, as well as health care workers, that even minor respiratory symptoms are not normal and may be markers of future ill health.\nWhen evaluating symptomatic patients presenting to a physician, the severity of the patient’s symptoms and the degree to which they affect his or her daily life, not just the severity of airfow obstruction, are the major determinants of health status . The severity of a patient’s breathlessness is important and can be usefully gauged by the MRC scale (Figure 5.1-2). Other forms of symptom severity scoring have yet to be validated in different populations and commonly rely on individual clinical judgment, although a clinical COPD questionnaire has been validated in family practice.\nObjectively measured exercise impairment, assessed by a reduction in self-paced walking distance or during incremental exercise testing in a laboratory, is a powerful indicator of health status impairment and predictor of prognosis. The ratio of inspiratory capacity to total lung capacity determined plethysmographically has also been found to be prognostically useful. Similarly, weight loss and reduction in the arterial oxygen tension identify patients at increased risk for mortality.\nA relatively simple approach to identifying disease severity using a combination of most of the above variables has been proposed. The BODE method gives a composite score (Body mass index, Obstruction, Dyspnea and Exercise) that is a better predictor of subsequent survival than any component singly, and its properties as a measurement tool are under investigation.\nFor patients diagnosed with Stage II: Moderate COPD and beyond, the following additional investigations may be considered:\nBronchodilator reversibility testing. Despite earlier hopes, neither bronchodilator nor oral glucocorticosteroid reversibility testing predicts disease progression, whether judged by decline in FEV1, deterioration of health status, or frequency of exacerbations in patients with a clinical diagnosis of COPD and abnormal spirometry. Small changes in FEV1 (e.g., < 400 ml) after administration of a bronchodilator do not reliably predict the patient’s respons to treatment (e.g., change in exercise capacity). Minor variations in initial airway caliber can lead to different classifcation of reversibility status depending on the day of testing, and the lower the pre-bronchodilator FEV1,the greater the chance of a patient being classifed as reversible even when the 200 ml volume criterion is included.\nIn some cases (e.g., a patient with an atypical history such as asthma in childhood and regular night waking with cough or wheeze) a clinician may wish to perform a bronchodilator and/or glucocorticosteroid reversibility test and a possible protocol is suggested in Figure 5.1-6.M02_017表6\nChest X-ray. An abnormal chest X-ray is seldom diagnostic in COPD unless obvious bullous disease is present, but it is valuable in excluding alternative diagnoses and establishing the presence of signifcant comorbidities such as cardiac failure. Radiological changes associated with COPD include signs of hyperinfation (fattened diaphragm on the lateral chest flm, and an increase in the volume of the retrosternal air space), hyperlucency of the lungs, and rapid tapering of the vascular markings. Computed tomography (CT) of the chest is not routinely recommended. However, when there is doubt about the diagnosis of COPD, high resolution CT (HRCT) scanning might help in the differential diagnosis. In addition, if a surgical procedure such as lung volume reduction is contemplated, a chest CT scan is necessary since the distribution of emphysema is one of the most important determinants of surgical suitability.\nArterial blood gas measurement. In advanced COPD, measurement of arterial blood gases while the patient is breathing air is important. This test should be performed in stable patients with FEV1 < 50% predicted or with clinical signs suggestive of respiratory failure or right heart failure. Several considerations are important to ensure accurate test results. The inspired oxygen concentration (FiO2normally 21% at sea level) should be noted, a particularly important point if patient is using an O2-driven nebulizer. Changes in arterial blood gas tensions take time to occur, \nespecially in severe disease. Thus, 20-30 minutes should pass before rechecking the gas tensions when the FiO2 has been changed, e.g., during an assessment for domiciliary oxygen therapy. Adequate pressure must be applied at the arterial puncture site for at least one minute, as failure to do so can lead to painful bruising.\nAlpha-1 antitrypsin defciency screening. In patients of Caucasian descent who develop COPD at a young age (< 45 years) or who have a strong family history of the disease, it may be valuable to identify coexisting alpha-1 antitrypsin defciency. This could lead to family screening or appropriate counseling. A serum concentration of alpha-1 antitrypsin below 15-20% of the normal value is highly suggestive of homozygous alpha-1 antitrypsin defciency.\nDifferential Diagnosis \nIn some patients with chronic asthma, a clear distinction from COPD is not possible using current imaging and physiological testing techniques, and it is assumed that asthma and COPD coexist in these patients. In these cases, current management is similar to that of asthma. Other potential diagnoses are usually easier to distinguish from COPD (Figure 5.1-7). M02_017表7\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('128', '38', 'M02_018', '1', '慢性阻塞性疾病全球倡议-慢性阻塞性肺疾病的诊断、处理和预防', 'GLOBAL STRATEGY FOR THE DIAGNOSIS,MANAGEMENT,AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE.', '慢性阻塞性肺疾病全球倡议（GOLD,The Global Initiative for Chronic Obstructive Lung Disease）', '2013', 'http://guide.medlive.cn/guideline/4189', '英文', null, '慢性阻塞性肺疾病', null, null, 'KEY POINTS:\n• A clinical diagnosis of COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and a history of exposure to risk factors for the disease.\n• Spirometry is required to make the diagnosis in this clinical context; the presence of a post-bronchodilator FEV1/FVC < 0.70 confrms the presence of persistent airfow limitation and thus of COPD. \n• The goals of COPD assessment are to determine the severity of the disease, including the severity of airfow limitation, the impact on the patient’s health status, and the risk of future events (such as exacerbations, hospital admissions, or death), in order to guide therapy.  \n• Comorbidities occur frequently in COPD patients, including cardiovascular disease, skeletal muscle dysfunction, metabolic syndrome, osteoporosis, depression, and lung cancer. Given that they can occur in patients with mild, moderate and severe airfow limitation and infuence mortality and hospitalizations independently, comorbidities should be actively looked for, and treated appropriately if present.\nDIAGNOSIS\nA clinical diagnosis of COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and a history of exposure to risk factors for the disease (Table 2.1).  Spirometry is required to make the diagnosis in this clinical context; the presence of a postbronchodilator FEV1/FVC < 0.70 confrms the presence of persistent airfow limitation and thus of COPD.  \nThe spirometric criterion for airfow limitation remains a post-bronchodilator fxed ratio of FEV1\n/FVC < 0.70. This criterion is simple, independent of reference values, and has been used in numerous clinical trials forming the evidence base from which most of our treatment recommendations are drawn. Diagnostic simplicity and consistency are key for the busy non-specialist clinician.\nWhile post-bronchodilator spirometry is required for the diagnosis and assessment of severity of COPD, the degree of reversibility of airfow limitation (e.g., measuring FEV1before and after bronchodilator or corticosteroids) is nolonger recommended. The degree of reversibility has never been shown to add to the diagnosis, differential diagnosis with asthma, or to predicting the response to long-term treatment with bronchodilators or corticosteroids. M02_018表1\nThe role of screening spirometry in the general population is controversial.  Both FEV1  and FVC predict all-cause mortality independent of tobacco smoking, and abnormal lung function identifes a subgroup of smokers at increased risk for lung cancer.  This has been the basis of an argument that screening spirometry should be employed as a global health assessment tool. However, there are no data to indicate that screening spirometry is effective in directing management decisions or in improving COPD outcomes in patients who are identifed before the development of signifcant symptoms. Thus, GOLD advocates active case fnding but not screening spirometry.\nThe use of the fxed FEV1/FVC ratio to defne airfow limitation will result in more frequent diagnosis of COPD in the elderly, and less frequent diagnosis in adults younger than 45 years, especially of mild disease, compared to using a cutoff based on the lower limit of normal (LLN) values for FEV1/FVC.  These LLN values are based on the normal distribution and classify the bottom 5% of the healthy population as abnormal.  From a scientifc perspective it is diffcult to determine which of these criteria is correct to diagnose COPD, and no studies exist comparing clinical diagnosis based on the two approaches. \nHowever, LLN values are highly dependent on the choice of valid reference equations using post-bronchodilator FEV1, and neither longitudinal studies validating the use of the LLN nor studies using reference equations in populations where smoking is not the major cause of COPD are available.  The risk of misdiagnosis and over-treatment of individual patients using the fxed ratio as a diagnostic criterion is limited, as spirometry is only one parameter for establishing the clinical diagnosis of COPD, the others being symptoms and risk factors.\nSymptoms\nThe characteristic symptoms of COPD are chronic and progressive dyspnea, cough, and sputum production that can be variable from day-to-day. Chronic cough and sputum production may precede the development of airfow limitation by many years.  Individuals, particularly those exposed to COPD risk factors, who present with these symptoms should be examined to search for an underlying cause(s) and appropriate interventions taken.  Conversely, signifcant airfow limitation may develop without chronic cough and sputum production.  Although COPD is defned on the basis of airfow limitation, in practice the decision to seek medical help (and so permit the diagnosis to be made) is usually determined by the impact of a symptom on a patient’s daily life. A person may seek medical attention either because of chronic symptoms or because of a frst exacerbation.\nDyspnea.  Dyspnea, a cardinal symptom of COPD, is a major cause of disability and anxiety associated with the disease. Typical COPD patients describe their dyspnea as a sense of increased effort to breathe, heaviness, air hunger, or gasping. However, the terms used to describe dyspnea vary both by individual and by culture.\nCough. Chronic cough, often the frst symptom of COPD to develop, is frequently discounted by the patient as an expected consequence of smoking and/or environmental exposures.  Initially, the cough may be intermittent, but later is present every day, often throughout the day.  The chronic cough in COPD may be unproductive.  In some cases, signifcant airfow limitation may develop without the presence of a cough. Table 2.2 lists some of the other causes of chronic cough.\nSputum production.  COPD patients commonly raise small quantities of tenacious sputum after coughing bouts. Regular production of sputum for 3 or more months in 2 consecutive years (in the absence of any other conditions that may explain it) is the epidemiological defnition of chronic bronchitis, but this is a somewhat arbitrary defnition that does not refect the range of sputum production in COPD patients.  Sputum production is often diffcult to evaluate because patients may swallow sputum rather than expectorate it, a habit subject to signifcant cultural and gender variation.  Patients producing large volumes of sputum may have underlying bronchiectasis.  The presence of purulent sputum refects an increase in infammatory mediators\n, and its development may identify the onset of a bacterial exacerbation.M02_018表2\nWheezing and Chest Tightness.  Wheezing and chest tightness are nonspecifc symptoms that may vary between days, and over the course of a single day.  Audible wheeze may arise at a laryngeal level and need not be accompanied by auscultatory abnormalities.  Alternatively, widespread inspiratory or expiratory wheezes can be present on listening to the chest.  Chest tightness often follows exertion, is poorly localized, is muscular in character, and may arise from isometric contraction of the intercostal muscles.  An absence of wheezing or chest tightness does not exclude a diagnosis of COPD, nor does the presence of these sypmtoms confrm a diagnosis of asthma.\nAdditional Features in Severe Disease.  Fatigue, weight loss and anorexia are common problems in patients with severe and very severe COPD. They are prognostically important and can also be a sign of other diseases (e.g., tuberculosis, lung cancer), and therefore should always be investigated.  Cough syncope occurs due to rapid increases in intrathoracic pressure during prolonged attacks of coughing.  Coughing spells may also cause rib fractures, which are sometimes asymptomatic.  Ankle swelling may be the only symptomatic pointer to the development of cor pulmonale.  Symptoms of depression and/or anxiety merit specifc enquiry in the clinical history because they are common in COPD and are associated with increased risk of exacerbations and poorer health status.\nMedical History\nA detailed medical history of a new patient known or thought to have COPD should assess:\n•  Patient’s exposure to risk factors, such as smoking and occupational or environmental exposures\n•  Past medical history, including asthma, allergy, sinusitis, or nasal polyps; respiratory infections in childhood; other respiratory diseases\n•  Family history of COPD or other chronic respiratory disease\n•  Pattern of symptom development: COPD typically develops in adult life and most patients are conscious of increased breathlessness, more frequent or prolonged “winter colds,” and some social restriction for a number of years before seeking medical help\n•  History of exacerbations or previous hospitalizations for respiratory disorder: Patients may be aware of periodic worsening of symptoms even if these episodes have not been identifed as exacerbations of COPD\n•  Presence of comorbidities, such as heart disease, osteoporosis, musculoskeletal disorders, and malignancies that may also contribute to restriction of activity\n•  Impact of disease on patient’s life, including limitation of activity, missed work and economic impact, effect on family routines, feelings of depression or anxiety, well being and sexual activity\n•  Social and family support available to the patient\n•  Possibilities for reducing risk factors, especially smoking cessation\nPhysical Examination\nAlthough an important part of patient care, a physical examination is rarely diagnostic in COPD. Physical signs of airfow limitation are usually not present until signifcant impairment of lung function has occurred, and their detection has a relatively low sensitivity and specifcity.  A number of physical signs may be present in COPD, but their absence does not exclude the diagnosis. \nSpirometry\nSpirometry is the most reproducible and objective measurement of airfow limitation available.  Peak expiratory fow measurement alone cannot be reliably used as the only diagnostic test, despite its good sensitivity, because of its weak specifcity. Good quality spirometric measurement is possible in any health care setting and all health care workers who care for COPD patients should have access to spirometry.  Table 2.3 summarizes some of the factors needed to achieve accurate test results.\nSpirometry should measure the volume of air forcibly exhaled from the point of maximal inspiration (forced vital capacity, FVC) and the volume of air exhaled during the frst second of this maneuver (forced expiratory volume in one second, FEV1), and the ratio of these two measurements (FEV1/FVC) should be calculated.  The ratio between FEV1 and slow vital capacity (VC), FEV1/VC, is sometimes measured instead of the FEV1/FVC ratio. This will often lead to lower values of the ratio, especially in pronounced airfow limitation; however, the cut-off point of 0.7 should still be applied.  Spirometry measurements are evaluated by comparison with reference values based on age, height, sex, and race. M02_018表3', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('129', '38', 'M02_019', '1', '慢性阻塞性疾病全球倡议-慢性阻塞性肺疾病的诊断、处理和预防', 'GLOBAL STRATEGY FOR THE DIAGNOSIS,MANAGEMENT,AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE.', '慢性阻塞性肺疾病全球倡议（GOLD,The Global Initiative for Chronic Obstructive Lung Disease）', '2014', 'http://guide.medlive.cn/guideline/5395', '英文', null, '慢性阻塞性肺疾病', null, null, 'KEY POINTS:\n• A clinical diagnosis of COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and a history of exposure to risk factors for the disease.\n• Spirometry is required to make the diagnosis in this clinical context; the presence of a post-bronchodilator FEV1/FVC < 0.70 confrms the presence of persistent airfow limitation and thus of COPD. \n• The goals of COPD assessment are to determine the severity of the disease, including the severity of airfow limitation, the impact on the patient’s health status, and the risk of future events (such as exacerbations, hospital admissions, or death), in order to guide therapy.  \n• Comorbidities occur frequently in COPD patients, including cardiovascular disease, skeletal muscle dysfunction, metabolic syndrome, osteoporosis, depression, and lung cancer. Given that they can occur in patients with mild, moderate and severe airfow limitation and infuence mortality and hospitalizations independently, comorbidities should be actively looked for, and treated appropriately if present.\nDIAGNOSIS\nA clinical diagnosis of COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and a history of exposure to risk factors for the disease (Table 2.1).  Spirometry is required to make the diagnosis in this clinical context; the presence of a post-bronchodilator FEV1/FVC < 0.70 confrms the presence of persistent airfow limitation and thus of COPD.  \nThe spirometric criterion for airfow limitation remains a post-bronchodilator fxed ratio of FEV1\n/FVC < 0.70. This criterion is simple, independent of reference values, and has been used in numerous clinical trials forming the evidence base from which most of our treatment recommendations are drawn. Diagnostic simplicity and consistency are key for the busy non-specialist clinician.\nWhile post-bronchodilator spirometry is required for the diagnosis and assessment of severity of COPD, the degreof reversibility of airfow limitation (e.g., measuring FEV1 before and after bronchodilator or corticosteroids) is no longer recommended. The degree of reversibility has never been shown to add to the diagnosis, differential diagnosis with asthma, or to predicting the response to long-term treatment with bronchodilators or corticosteroids.M02_019表1\nThe role of screening spirometry in the general population is controversial.  Both FEV1 and FVC predict all-cause mortality independent of tobacco smoking, and abnormal lung function identifes a subgroup of smokers at increased risk for lung cancer.  This has been the basis of an argument that screening spirometry should be employed as a global health assessment tool.  However, there are no data to indicate that screening spirometry is effective in directing management decisions or in improving COPD outcomes in patients who are identifed before the development of signifcant symptoms.  Thus, GOLD advocates active case fnding but not screening spirometry.\nThe use of the fxed FEV1/FVC ratio to defne airfow limitation will result in more frequent diagnosis of COPD in the elderly, and less frequent diagnosis in adults younger than 45 years, especially of mild disease, compared to using a cutoff based on the lower limit of normal (LLN) \nvalues for FEV1/FVC.  These LLN values are based on the normal distribution and classify the bottom 5% of the healthy population as abnormal.  From a scientifc perspective it is diffcult to determine which of these criteria is correct to diagnose COPD, and no studies exist comparing clinical diagnosis based on the two approaches.However, LLN values are highly dependent on the choice ovalid reference equations using post-bronchodilator FEV1, and neither longitudinal studies validating the use of the LLN nor studies using reference equations in populations where smoking is not the major cause of COPD are available.  The risk of misdiagnosis and over-treatment of individual patients using the fxed ratio as a diagnostic criterion is limited, as spirometry is only one parameter for establishing the clinical diagnosis of COPD, the others being symptoms and risk factors.\nSymptoms\nThe characteristic symptoms of COPD are chronic and progressive dyspnea, cough, and sputum production that can be variable from day-to-day.  Chronic cough and sputum production may precede the development of airfow limitation by many years.  Individuals, particularly those exposed to COPD risk factors, who present with these symptoms should be examined to search for an underlying cause(s) and appropriate interventions taken.  Conversely, signifcant airfow limitation may develop without chronic cough and sputum production.  Although COPD is defned on the basis of airfow limitation, in practice the decision to seek medical help (and so permit the diagnosis to be made) is usually determined by the impact of a symptom on a patient’s daily life. A person may seek medical attention either because of chronic symptoms or because of a frst exacerbation.\nDyspnea.  Dyspnea, a cardinal symptom of COPD, is a major cause of disability and anxiety associated with the disease. Typical COPD patients describe their dyspnea as a sense of increased effort to breathe, heaviness, air hunger, or gasping.  However, the terms used to describe dyspnea vary both by individual and by culture.\nCough. Chronic cough, often the frst symptom of COPD to develop, is frequently discounted by the patient as an expected consequence of smoking and/or environmental exposures.  Initially, the cough may be intermittent, but later is present every day, often throughout the day.  The chronic cough in COPD may be unproductive. In some cases, signifcant airfow limitation may develop without the presence of a cough. Table 2.2 lists some of the other causes of chronic cough.\nSputum production.  COPD patients commonly raise small quantities of tenacious sputum after coughing bouts Regular production of sputum for 3 or more months in 2 consecutive years (in the absence of any other conditions that may explain it) is the epidemiological defnition of chronic bronchitis, but this is a somewhat arbitrary defnition that does not refect the range of sputum \nproduction in COPD patients.  Sputum production is often diffcult to evaluate because patients may swallow sputum rather than expectorate it, a habit subject to signifcant cultural and gender variation.  Patients producing large volumes of sputum may have underlying bronchiectasis. The presence of purulent sputum refects an increase in infammatory mediators, and its development may identify the onset of a bacterial exacerbation.M02_019表2\nWheezing and Chest Tightness.  Wheezing and chest tightness are nonspecifc symptoms that may vary between days, and over the course of a single day.  Audible wheeze may arise at a laryngeal level and need not be accompanied by auscultatory abnormalities.  Alternatively, widespread inspiratory or expiratory wheezes can be present on listening to the chest.  Chest tightness often follows exertion, is poorly localized, is muscular in character, and may arise from isometric contraction of the intercostal muscles.  An absence of wheezing or chest tightness does not exclude a diagnosis of COPD, nor does the presence of these sypmtoms confrm a diagnosis of asthma.\nAdditional Features in Severe Disease.  Fatigue, weight loss and anorexia are common problems in patients with severe and very severe COPD. They are prognostically important and can also be a sign of other diseases (e.g., tuberculosis, lung cancer), and therefore should always be investigated.  Cough syncope occurs due to rapid increases in intrathoracic pressure during prolonged attacks of coughing.  Coughing spells may also cause rib fractures,which are sometimes asymptomatic.  Ankle swelling may be the only symptomatic pointer to the development of cor pulmonale.  Symptoms of depression and/or anxiety merit specifc enquiry in the clinical history because they are common in COPD and are associated with increased risk of exacerbations and poorer health status.\nMedical History\nA detailed medical history of a new patient known or thought to have COPD should assess:\n•  Patient’s exposure to risk factors, such as smoking and occupational or environmental exposures\n•  Past medical history, including asthma, allergy, sinusitis, or nasal polyps; respiratory infections in childhood; other respiratory diseases\n•  Family history of COPD or other chronic respiratory disease\n•  Pattern of symptom development: COPD typically develops in adult life and most patients are conscious of increased breathlessness, more frequent or prolonged “winter colds,” and some social restriction for a number of years before seeking medical help\n•  History of exacerbations or previous hospitalizations for respiratory disorder: Patients may be aware of periodic worsening of symptoms even if these episodes have not been identifed as exacerbations of COPD\n•  Presence of comorbidities, such as heart disease, osteoporosis, musculoskeletal disorders, and malignancies that may also contribute to restriction of activity\n•  Impact of disease on patient’s life, including limitation of activity, missed work and economic impact, effect on family routines, feelings of depression or anxiety, well being and sexual activity\n•  Social and family support available to the patient\n•  Possibilities for reducing risk factors, especially smoking cessation\nPhysical Examination\nAlthough an important part of patient care, a physical examination is rarely diagnostic in COPD. Physical signs of airfow limitation are usually not present until signifcantimpairment of lung function has occurred, and their detection has a relatively low sensitivity and specifcity.  A number of physical signs may be present in COPD, but their absence does not exclude the diagnosis.  \nSpirometry\nSpirometry is the most reproducible and objective measurement of airfow limitation available.  Peak expiratory fow measurement alone cannot be reliably used as the only diagnostic test, despite its good sensitivity, because of its weak specifcity. Good quality spirometric measurement is possible in any health care setting and all health care workers who care for COPD patients should have access to spirometry.  Table 2.3 summarizes some of the factors needed to achieve accurate test results.\nSpirometry should measure the volume of air forcibly exhaled from the point of maximal inspiration (forced vital capacity, FVC) and the volume of air exhaled during the frst second of this maneuver (forced expiratory volume in one second, FEV1), and the ratio of these two measurements (FEV1/FVC) should be calculated.  The ratio between FEV1 and slow vital capacity (VC), FEV1/VC, is sometimes measured instead of the FEV1/FVC ratio. This will often lead to lower values of the ratio, especially in pronounced airfow limitation; however, the cut-off point of 0.7 should still be applied.  Spirometry measurements are evaluated by comparison with reference values based on age, height, sex, and race.M02_019表3', null, null, null, '2014年更新版指南的主要变化是在原第6章COPD与并发症中增加了关于支气管扩张的内容。并新增了第7章，哮喘和慢性阻塞性肺疾病重叠综合征（ACOS）。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('13', '32', 'G02_001', '0', 'ZYYXH/T60-2008高脂血症', ' 无', '中华中医药学会', '2008', 'ZYYXH/T60-2008高脂血症[S]', '中文', '根据病因不同，分为原发性与继发性两类。', '高脂血症；\n高胆固醇血症；\n高甘油三酯血症；\n混合型高脂血症；\n低高密度脂蛋白血症；', '属“痰饮”的范畴', '湿热蕴结证<br />&nbsp;&nbsp;\n湿热蕴结证<br />&nbsp;&nbsp;\n湿热蕴结证<br />&nbsp;&nbsp;\n湿热蕴结证<br />&nbsp;&nbsp;\n肝肾阴虚证<br />&nbsp;&nbsp;\n肝肾阴虚证<br />&nbsp;&nbsp;', '1.2 理化检查<br />&nbsp;&nbsp;\n1.2.1 血清TC：在5.20mmol/L(200mg/dl)以下为合适范围，5.23~5.69mmol/L(201~219mg/dl)为边缘升高,5.72 mmol/L(220mg/dl)以上为升高。<br />&nbsp;&nbsp;\n1.2.2 血清LDL-C：在3.12mmol/L(120mg/dl)以下合适范围，3.15~3.61mmol/L(121~139mg/dl)为边缘升高，3.64mmol/L(140mg/dl)以上为升高。<br />&nbsp;&nbsp;\n1.2.3 血清HDL-C：在1.04mmol/L(40mg/dl)以上为合适范围，0.91mmol/L(35mg/dl)以下为减低。<br />&nbsp;&nbsp;\n1.2.4 血清TG：在1.70mmol/L(150mg/dl)以下为合适范围，1.70mmol/L(150mg/dl)以上为升高。<br />&nbsp;&nbsp;\n1.3诊断要点<br />&nbsp;&nbsp;\n1.3.1 高胆固醇血症：血清TC水平增高。<br />&nbsp;&nbsp;\n1.3.2 高甘油三酯血症：血清TG水平增高。<br />&nbsp;&nbsp;\n1.3.3 混合型高脂血症：血清TC和TG水平增高。<br />&nbsp;&nbsp;\n1.3.4 低高密度脂蛋白血症：血清HDL-C水平降低。<br />&nbsp;&nbsp;\n', null, '总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、脂蛋白胆固醇（LDL-C）、甘油三酯(TG)。', ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('130', '38', 'M02_020', '1', '慢性阻塞性疾病全球倡议-慢性阻塞性肺疾病的诊断、处理和预防', 'GLOBAL STRATEGY FOR THE DIAGNOSIS,MANAGEMENT,AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE.', '慢性阻塞性肺疾病全球倡议（GOLD,The Global Initiative for Chronic Obstructive Lung Disease）', '2016', 'http://guide.medlive.cn/guideline/10239', '英文', null, '慢性阻塞性肺疾病', null, null, 'KEY POINTS:\n• A clinical diagnosis of COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and a history of exposure to risk factors for the disease.\n• Spirometry is required to make the diagnosis in this clinical context; the presence of a post-bronchodilator FEV1/FVC < 0.70 confrms the presence of persistent airfow limitation and thus of COPD. \n• The goals of COPD assessment are to determine the severity of the disease, including the severity of airfow limitation, the impact on the patient’s health status, and the risk of future events (such as exacerbations, hospital admissions, or death), in order to guide therapy.  \n• Comorbidities occur frequently in COPD patients, including cardiovascular disease, skeletal muscle dysfunction, metabolic syndrome, osteoporosis, depression, and lung cancer. Given that they can occur in patients with mild, moderate and severe airfow limitation and infuence mortality and hospitalizations independently, comorbidities should be actively looked for, and treated appropriately if present.\n• Non-surgical bronchoscopic lung volume reduction techniques should not be used outside clinical trials until more data are available.\nDIAGNOSIS\nA clinical diagnosis of COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and a history of exposure to risk factors for the disease (Table 2.1).  Spirometry is required to make the diagnosis in this clinical context; the presence of a posbronchodilator FEV1/FVC < 0.70 confrms the presence of persistent airfow limitation and thus of COPD.  The spirometric criterion for airfow limitation remains a post-bronchodilator fxed ratio of FEV1/FVC < 0.70. This criterion is simple, independent of reference values, and has been used in numerous clinical trials forming the evidence base from which most of our treatment recommendations are drawn. Diagnostic simplicity and consistency are key for the busy non-specialist clinician.While post-bronchodilator spirometry is required for the diagnosis and assessment of severity of COPD, the degree of reversibility of airfow limitation (e.g., measuring FEV1 before and after bronchodilator or corticosteroids) is no longer recommended. The degree of reversibility has never been shown to add to the diagnosis, differential diagnosis with asthma, or to predicting the response to long-term treatment with bronchodilators or corticosteroids The role of screening spirometry in the general population is controversial.  Both FEV1 and FVC predict all-cause mortality independent of tobacco smoking, and abnormal lung function identifes a subgroup of smokers at increased risk for lung cancer.  This has been the basis of an argument that screening spirometry should be employed as a global health assessment tool.  However, there are no data to indicate that screening spirometry is effective in directing management decisions or in improving COPD outcomes in patients who are identifed before the development of signifcant symptoms. Thus, GOLD advocates active case fnding but not screening spirometry.M02_020表1\nThe use of the fxed FEV1/FVC ratio to defne airfow limitation will result in more frequent diagnosis of COPD in the elderly, and less frequent diagnosis in adults younger than 45 years, especially of mild disease, compared to using a cutoff based on the lower limit of normal (LLN) \nvalues for FEV1/FVC.  These LLN values are based on the normal distribution and classify the bottom 5% of the healthy population as abnormal.  From a scientifc perspective it is diffcult to determine which of these criteria is correct to diagnose COPD, and no studies exist comparing clinical diagnosis based on the two approaches. However, LLN values are highly dependent on the choice of valid reference equations using post-bronchodilator FEV1, and neither longitudinal studies validating the use of the LLN nor studies using reference equations in populations where smoking is not the major cause of COPD are available.  The risk of misdiagnosis and over-treatment of individual patients using the fxed ratio as a diagnostic criterion is limited, as spirometry is only one parameter for establishing the clinical diagnosis of COPD, the others being symptoms and risk factors.\nSymptoms\nThe characteristic symptoms of COPD are chronic and progressive dyspnea, cough, and sputum production that can be variable from day-to-day. Chronic cough and sputum production may precede the development of airfow limitation by many years.  Individuals, particularly those exposed to COPD risk factors, who present with these symptoms should be examined to search for an underlying cause(s) and appropriate interventions taken. Conversely, signifcant airfow limitation may develop without chronic cough and sputum production.  Although COPD is defned on the basis of airfow limitation, in practice the decision to seek medical help (and so permit the diagnosis to be made) is usually determined by the impact of a symptom on a patient’s daily life. A person may seek medical attention either because of chronic symptoms or because of a frst exacerbation.\nDyspnea.  Dyspnea, a cardinal symptom of COPD, is a major cause of disability and anxiety associated with the disease. Typical COPD patients describe their dyspnea as a sense of increased effort to breathe, heaviness, air hunger, or gasping.  However, the terms used to describe dyspnea vary both by individual and by culture. \nCough. Chronic cough, often the frst symptom of COPD to develop, is frequently discounted by the patient as an expected consequence of smoking and/or environmental exposures.  Initially, the cough may be intermittent, but later is present every day, often throughout the day.  The chronic cough in COPD may be unproductive. In some cases, signifcant airfow limitation may develop without the presence of a cough. Table 2.2 lists some of the other causes of chronic cough.\nSputum production.  COPD patients commonly raise small quantities of tenacious sputum after coughing bouts. Regular production of sputum for 3 or more months in 2 consecutive years (in the absence of any other conditions that may explain it) is the epidemiological defnition of chronic bronchitis, but this is a somewhat arbitrary defnition that does not refect the range of sputum production in COPD patients.  Sputum production is often diffcult to evaluate because patients may swallow sputum rather than expectorate it, a habit subject to signifcant cultural and gender variation.  Patients producing large volumes of sputum may have underlying bronchiectasis. The presence of purulent sputum refects an increase.M02_020表2\nin infammatory mediators, and its development may identify the onset of a bacterial exacerbation.\nWheezing and Chest Tightness.  Wheezing and chest tightness are nonspecifc symptoms that may vary between days, and over the course of a single day.  Audible wheeze may arise at a laryngeal level and need not be accompanied by auscultatory abnormalities.  Alternatively, widespread inspiratory or expiratory wheezes can be present on listening to the chest.  Chest tightness often follows exertion, is poorly localized, is muscular in character, and may arise from isometric contraction of the intercostal muscles.  An absence of wheezing or chest tightness does not exclude a diagnosis of COPD, nor does the presence of these sypmtoms confrm a diagnosis of asthma.\nAdditional Features in Severe Disease. Fatigue, weight loss and anorexia are common problems in patients with severe and very severe COPD. They are prognostically important and can also be a sign of other diseases (e.g.,tuberculosis, lung cancer), and therefore should always be investigated.  Cough syncope occurs due to rapid increases in intrathoracic pressure during prolonged attack of coughing.  Coughing spells may also cause rib fractures which are sometimes asymptomatic.  Ankle swelling may be the only symptomatic pointer to the development of cor pulmonale.  Symptoms of depression and/or anxiety merit specifc enquiry in the clinical history because they are common in COPD and are associated with increased risk of exacerbations and poorer health status.\nMedical History\nA detailed medical history of a new patient known or thought to have COPD should assess:\n•  Patient’s exposure to risk factors, such as smoking and occupational or environmental exposures\n•  Past medical history, including asthma, allergy, sinusitis, or nasal polyps; respiratory infections in childhood; other respiratory diseases\n•  Family history of COPD or other chronic respiratory disease\n•  Pattern of symptom development: COPD typically develops in adult life and most patients are conscious of increased breathlessness, more frequent or prolonged “winter colds,” and some social restriction for a number of years before seeking medical help\n•  History of exacerbations or previous hospitalizations for respiratory disorder: Patients may be aware of periodic worsening of symptoms even if these episodes have not been identifed as exacerbations of COPD\n•  Presence of comorbidities, such as heart disease, osteoporosis, musculoskeletal disorders, and malignancies that may also contribute to restriction of activity\n•  Impact of disease on patient’s life, including limitation of activity, missed work and economic impact, effect on family routines, feelings of depression or anxiety, well being and sexual activity\n•  Social and family support available to the patient\n•  Possibilities for reducing risk factors, especially smoking cessation\nPhysical Examination\nAlthough an important part of patient care, a physical examination is rarely diagnostic in COPD. Physical signs of airfow limitation are usually not present until signifcant impairment of lung function has occurred, and their detection has a relatively low sensitivity and specifcity.  A number of physical signs may be present in COPD, but their absence does not exclude the diagnosis. \nSpirometry\nSpirometry is the most reproducible and objective measurement of airfow limitation available.  Peak expiratory fow measurement alone cannot be reliably used as the only diagnostic test, despite its good sensitivity, because of its weak specifcity. Good quality spirometric measurement is possible in any health care setting and all health care workers who care for COPD patients should have access to spirometry.  Table 2.3 summarizes some of the factors needed to achieve accurate test results.\nSpirometry should measure the volume of air forcibly exhaled from the point of maximal inspiration (forced vital capacity, FVC) and the volume of air exhaled during the frst second of this maneuver (forced expiratory volume in one second, FEV1), and the ratio of these two measurements (FEV1/FVC) should be calculated.  The ratio between FEV1 and slow vital capacity (VC), FEV1/VC, is sometimes measured instead of the FEV1/FVC ratio. This will often lead to lower values of the ratio, especially in pronounced airfow limitation; however, the cut-off point of 0.7 should still be applied.  Spirometry measurements are evaluated by comparison with reference values based on age, height, sex, and race. M02_020表3', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('131', '38', 'M02_021', '1', '慢阻肺的诊断和治疗指南(慢性阻塞性肺病)', 'Guidelines for the Diagnosis and Treatment of COPD (Chronic Obstructive Pulmonary Disease)', '日本呼吸学会（JRS,the Japanese Respiratory Society）', '2010', 'http://guide.medlive.cn/guideline/2258', '英文', '● Stage  classification  of COPD  uses FEV1 value which expresses the degree of airflow limitation. The classification reflects the severity of the disease. The FEV1 /FVC ratio is not used because it does not appropriately reflect  the degree of severity  in cases of moderate or more  severe COPD. The  stage  classification  uses the post-bronchodilator FEV1.\n● The  stages  of COPD  are  stage  0  :  the  group  at  risk,stage I : mild COPD （FEV1 ≧ 80% of predicted value） ,stage  II  : moderate COPD（50% ≦ FEV1 <  80%  predicted） , stage III : severe COPD （30% ≦ FEV1 < 50%predicted） ,  stage  IV  :  very  severe COPD  :（FEV1 <30% predicted or FEV1 < 50% predicted accompanied with chronic respiratory  failure or right heart  failure）. M02_021表5\n● The  special  features  of  these  staging  system  are  the addition of stage 0 : group at risk, stage I : mild COPD,and  also  addition  of  the  chronic  respiratory  failure  or\nright heart failure to the classification of stage IV : very severe COPD.\n', '慢性阻塞性肺疾病', null, null, '● In  the  presence  of  clinical  symptoms  such  as  cough,sputum,  or  dyspnea  on  exertion,  or middle  aged  or older people who have risk factors such as a history of smoking, COPD must always be suspected （Table 2） .\n● Spirometry is essential for diagnosis of COPD. Airflow limitation  is  judged  to be present when  the FEV1（Forced Expiratory Volume  in  one  second）/ FVC（Forced Vital Capacity）ratio  is  less  than  70%  afteradministration of bronchodilators（Table 3, 4） .\n● For  a  definitive  diagnosis,  it  is  necessary  to  exclude various other diseases by means of diagnostic imaging and detailed pulmonary  function examinations. One of the most  problematic  differential  diagnoses  is bronchial asthma（Table 5） \n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('132', '38', 'M02_022', '1', '成人慢性阻塞性肺疾病的初级和二级保健', 'Chronic obstructive pulmonary disease. Management of chronic obstructive pulmonary disease in adults in primary and secondary care.', '美国国家指导中心（U.S.Department of Health & Human services）', '2010', 'https://www.nice.org.uk/guidance/cg101', '英文', null, '慢性阻塞性肺疾病', null, null, '1.Identification of signs and symptoms and risk factors for chronic obstructive pulmonary disease (COPD)\n2.Spirometry (Note: reversibility testing not routinely recommended)\n3.Further investigations, as needed, including chest radiograph, full blood count, body mass index, alpha-1 antitrypsin measurement, serial domiciliary peak flow measurement, transfer factor for carbon monoxide (TLCO), computed tomography (CT) scan of the thorax, electrocardiogram, echocardiogram, pulse oximetry, sputumculture\n4.Identification of early disease to facilitate interventions to slow disease progression\n5.Assessment of severity of airflow obstruction\n6.Referral for specialist advice\n', null, null, null, '这条指导原则更新前一版本:国家合作中心慢性病。慢性阻塞性肺疾病。国家临床指导方针管理成人慢性阻塞性肺疾病的初级和二级保健。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('133', '38', 'M02_023', '1', 'COPDX计划:澳大利亚和新西兰的慢性阻塞性肺疾病管理指南', 'The COPDX Plan:Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease', '澳大利亚肺脏基金会（THE AUSTRALIAN LUNG FOUNDATION）；澳大利亚和新西兰胸科协会（The Thoracic Society of Australia and New Zealand）', '2003', 'http://www.ncbi.nlm.nih.gov/pubmed/12633498', '英文', 'Spirometry is the most reproducible, standardised and objective way of measuring airflow limitation, and FEV1 is the variable most closely associated with prognosis. The grades of severity according to FEV1 and the likely symptoms and complications are shown in Box 6. However, it should be noted that patients with an FEV1 > 80% predicted, although within the normal range, may have airflow limitation (FEV /FVC ratio < 70%).M02_023表3', '慢性阻塞性肺疾病', null, null, 'History\nConsider COPD in all smokers and ex-smokers over the age of 35 years [evidence level B]\nThe main symptoms of COPD are breathlessness, cough and sputum production.Patients often attribute breath-lessness to ageing or lack of fitness. A persistent cough,typically worse in the mornings with mucoid sputum, is common in smokers. Other symptoms such as chest tight-ness, wheezing and airway irritability are common. Acute exacerbations, usually infective, occur from time to time and may lead to a sharp deterioration in coping ability. Fatigue, poor appetite and weight loss are more common in advanced disease.The functional limitation from breathlessness due to COPD can be quantified easily in clinical practice.M02_023表1\nPhysical examination\nThe sensitivity of physical examination for detecting mild to moderate COPD is poor. Wheezing is not an indicator of severity of disease and is often absent in stable, severe COPD. In more advanced disease, physical features commonly found are hyperinflation of the chest, reduced chest expansion, hyperresonance to percussion, soft breath sounds and a prolonged expiratory phase. Right heart failure may complicate severe disease.\nDuring an acute exacerbation, tachypnoea, tachycardia,use of accessory muscles, tracheal tug and cyanosis are common.\nThe presence and severity of airflow limitation are impossible to determine by clinical signs. Objective measurements such as spirometry are strongly recommended. Peak expiratory flow (PEF) is not a sensitive measure of airway function in COPD patients, as it is effort dependent and has a wide range of normal values.\nSpirometry\nThe diagnosis of COPD rests on the demonstration of airflow limitation which is not fully reversible[evidence level B]\nSpirometry is the gold standard for diagnosing, assessing and monitoring COPD (see Box 5). Most spirometers provide predicted (“normal”) values obtained from healthy population studies, and derived from formulas based on height, age, sex and ethnicity.\nAirflow limitation is non-reversible when, after administration of bronchodilator medication, the ratio of FEV1 to forced vital capacity (FVC) is <70% and the FEV1 is <80% of the predicted value. The ratio of FEV1 to vital capacity(VC) is a sensitive indicator for mild COPD.M02_023表2\nIndications for spirometry include:\n■ breathlessness that seems inappropriate;\n■ chronic (daily for two months) or intermittent, unusual\ncough;\n■ frequent or unusual sputum production;\n■ relapsing acute infective bronchitis; and\n■ risk factors such as exposure to tobacco smoke, occupational dusts and chemicals, and a strong family history of COPD.\nFlow volume tests\nElectronic spirometers allow for the simultaneous measurement of flow and volume during maximal expiration.Reduced expiratory flows at mid and low lung volumes are the earliest indicators of airflow limitation in COPD and may be abnormal even when FEV1 is within the normal range (>80%).', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('134', '38', 'M02_024', '1', '稳定期慢性阻塞性肺疾病的诊断和管理:临床实践指南更新来自美国内科医师学会，美国胸科医师学会,美国胸科学会,欧洲呼吸协会', 'Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians,\nAmerican Thoracic Society, and European Respiratory Society', '美国内科医师学会（The American College of Physicians）；美国胸科医师学会（American College of Chest Physicians）；美国胸科学会（American Thoracic Society）；欧洲呼吸学会（European Respiratory Society）', '2011', 'mir Qaseem, MD, PhD, etc.Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians,American Thoracic Society, and European R畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭턀ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼', '英文', null, '慢性阻塞性肺疾病', null, null, '1.对于有症状的气流阻塞的诊断需要进行肺功能检查，但如果没有症状则不需要进行肺功能检查（等级：强推荐，证据质量中度）\n2.对于有症状FEV1在60％～80％的稳定期COPD，可使用支气管舒张剂（等级：弱推荐，证据质量低）\n3.对于有症状FEV1小于60％的稳定期COPD推荐使用支气管舒张剂（分级：强推荐，证据质量中等）\n4.推荐对有症状且FEV1小于60％的患者选择LAMA或LABA单药治疗（级别：强推荐，证据质量中度），药物的选择应基于患者的喜好、价格及不良反应的考虑\n5.对于有症状FEV1小于60％的稳定期COPD可以给予联合治疗（LAMA、LABA、ICS）（级别：弱推荐，证据质量中等）\n6.对于有症状FEV1小于50％的COPD患者须进行呼吸康复治疗（分级：强推荐，证据质量中度）；对于有症状或活动受限，FEV1大于50％者，可考虑呼吸康复治疗（分级：弱推荐，证据质量中度）\n7.静息时存在严重低氧血症（PaO2≤55 mm Hg 或SpO2≤88%）的患者须给予持续氧疗（级别：强推荐，证据质量中度）\nRecommendation 1: ACP, ACCP, ATS, and ERS recommend that spirometry should be obtained to diagnose airflow obstruction in patients with respiratory symptoms (Grade: strong recommendation moderate-quality evidence). Spirometry should not be used to screen for airflow obstruction in individuals without respiratory symptom(Grade: strong recommendation, moderate-quality evidence).\nRecommendation 2: For stable COPD patients with respiratory symptoms and FEV1 between 60% and 80% predicted, ACP, ACCP, ATS and ERS suggest that treatment with inhaled bronchodilators may be used (Grade: weak recommendation, low-quality evidence).\nRecommendation 3: For stable COPD patients with respiratory symptoms and FEV1  60% predicted, ACP, ACCP, ATS, and ERS recommend treatment with inhaled bronchodilators (Grade: strong recommendation, moderate-quality evidence)\nRecommendation 4: ACP, ACCP, ATS, and ERS recommend that clinicians prescribe monotherapy using either long-acting inhaled anticholinergics or long-acting inhaled  -agonists for symptomatic patients with COPD and FEV1  60% predicted. (Grade: strong recommendation, moderate-quality evidence). Clinicians should base the choice of specific monotherapy on patient preference, cost, and adverse effect profile.\nRecommendation 5: ACP, ACCP, ATS, and ERS suggest that clinicians may administer combination inhaled therapies (long-acting inhaled anticholinergics, long-acting inhaled  -agonists, or inhaled corticosteroids)for symptomatic patients with stable COPD and FEV1 60% predicted(Grade: weak recommendation, moderate-quality evidence).\nRecommendation 6: ACP, ACCP, ATS, and ERS recommend that clinicians should prescribe pulmonary rehabilitation for symptomatic patients with an FEV1  50% predicted (Grade: strong recommendation,moderate-quality evidence). Clinicians may consider pulmonary rehabilitation for symptomatic or exercise-limited patients with an FEV1  50%predicted. (Grade: weak recommendation, moderate-quality evidence).\nRecommendation 7: ACP, ACCP, ATS, and ERS recommend that clinicians should prescribe continuous oxygen therapy in patients with COPD who have severe resting hypoxemia (PaO2  55 mm Hg or SpO2 88%) (Grade: strong recommendation, moderate-quality evidence)', null, null, null, '确定了指南中对何时进行肺量计检测的推荐，增加了何时对稳定期COPD考虑药物治疗及关于呼吸康复治疗的推荐意见，澄清了在不同种类药物间如何进行选择 。本指南使用ACP指南评级系统对证据及推荐进行分级，前者基于证据推荐分级的评估、制定与评价（grading of  recommendations,assessment ,development ,   and  evalu-   at ion，GRADE）工作组的评级体系。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('135', '38', 'M02_025', '1', '慢性阻塞性肺疾病（慢阻肺）', 'Chronic obstructive pulmonary disease (COPD).', '美国内科医师学会（The American College of Physicians）；美国胸科医师学会（American College of Chest Physicians）；美国胸科学会（American Thoracic Society）；欧洲呼吸学会（European Respiratory Society）', '2011', 'http://www.guideline.gov/content.aspx?id=38897&search=chronic+bronchitis', '英文', null, '慢性阻塞性肺疾病', null, null, 'Diagnosis\nChronic obstructive pulmonary disease (COPD) is under-diagnosed. A definitive diagnosis is made with spirometry.\na.Signs and Symptoms Indicating the Need for Spirometry Testing\nUse clinical judgment to select patients for spirometry testing. Consider spirometry testing for new COPD patients at high risk:*\n  Smokers or ex-smokers 40 years of age or older\n  Persistent cough or sputum production\n  Frequent respiratory infections\n  Unexplained shortness of breath\nChest X-ray is usually done to exclude co-morbidities. A chest X-ray may suggest COPD, but the definitive diagnosis of COPD requires spirometry.\n*Some patients with COPD may not have used tobacco. Other risk factors include: occupational exposures, alpha-1 antitrypsin deficiency, early childhood lung infections,\nand exposure to air pollutants, particularly where wood is burned indoors.\nb.Diagnosis by Spirometry\nNote: In office spirometry requires approval by the College of Physicians and Surgeons Diagnostic Accreditation Program.\nA post bronchodilator forced expiratory volume in the first second to forced vital capacity ratio (FEV1/FVC) of less than 0.7 defines airflow obstruction that is not fully\nreversible and establishes a diagnosis of COPD.\nNote: COPD and asthma commonly coexist.\n  Compared to the baseline FEV1, asthmatic patients will have a 12% or greater improvement in FEV1 15 minutes after the use of an inhaled short-acting beta2 agonist.\nIn adults, the FEV1 also increases by more than 200 ml.\n  Long term improvements in spirometry may indicate asthma.\n  In some situations, a corticosteroid trial may be appropriate to differentiate COPD from asthma.\nc.COPD Classification by Symptoms and Spirometry.M02_024表\nAdapted from the Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update.\n*Symptoms may not correlate directly with clinical signs. As a result, patients may belong in more than 1 COPD stage (namely, clinical versus spirometric stages).\nIf clinical uncertainty of the diagnosis remains, specialist consultation is recommended.', null, null, null, '当前版本的指南。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('136', '41', 'M07_001', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南妇产科学分册[M].北京：人民卫生出版社，2009.', '中文', null, '急性子宫内膜炎', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1发热  体温一般小超过38.5℃。有时起病急，恶寒甚至寒战，发热高达40℃，全身乏力、出汗。<br />&nbsp;&nbsp;1.2下腹部疼痛、下坠，腰酸。<br />&nbsp;&nbsp;1.3阴道排液增多，水样混浊或脓性有臭味。宫颈口堵塞者可无阴道排液增多。<br />&nbsp;&nbsp;1.4严重者出现败血症症状，有时并发感染性休克。<br />&nbsp;&nbsp;1.5妇科检查  下腹部压痛，子宫略增大、质软、压痛，宫颈口见大量脓性或血性混浊臭味分泌物流出。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1病史  多见于产后、有宫腔或宫颈手术史、有不洁性交史者。<br />&nbsp;&nbsp;2.2症状  发热、下腹疼痛、脓性或血性白带。<br />&nbsp;&nbsp;2.3体征体温升高，子宫压痛，子宫颈口可见大量脓性或血性分泌物流出，严重者出现败血症。对宫腔积脓者，以探针进入宫腔后见大量脓液流出可确诊。<br />&nbsp;&nbsp;2.4血白细胞计数及中性粒细胞数增高，血沉增快和／或C反应蛋白增高。<br />&nbsp;&nbsp;2.5宫腔分泌物培养及药敏试验  无菌操作下吸取宫腔分泌物行病原体培养，以寻找致病原因。<br />&nbsp;&nbsp;2.6影像学检查  可见子宫增大、内膜肿胀、增厚、中等回声；宫腔积脓者可见到液性囤声。<br />&nbsp;&nbsp;', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('137', '41', 'M07_002', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南妇产科学分册[M].北京：人民卫生出版社，2009.', '中文', null, '慢性子宫内膜炎', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1可无任何症状。<br />&nbsp;&nbsp;1.2可有少量或多量血浆性、脓性或脓血性分泌物，伴或不伴下腹坠胀；一些患者可出现子宫不规则出血或闭经。<br />&nbsp;&nbsp;1.3子宫正常或增大，有触痛。宫旁结缔组织可有明昆增厚，或可扪及附件的炎性包块。寓腔积脓者可见恶臭分泌物排出。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1病史及临床表现  卵巢功能衰退的妇女、胎盘长期残留、输卵管炎、阴道宫颈炎症和子宫黏膜下肌瘤、息肉等患者，出现下腹坠痛、子宫不规则出血或分泌物增多、子宫压痛。<br />&nbsp;&nbsp;2.2影像学检查  有胎盘残留、输卵管炎、子宫肌瘤、息肉及宫腔积脓者，可见到相应的影像学变化。<br />&nbsp;&nbsp;2.3诊断性刮宫病理检查  内膜组织中有大量浆细胞及淋巴细胞，可明确诊断。<br />&nbsp;&nbsp;', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('138', '41', 'M07_003', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南妇产科学分册[M].北京：人民卫生出版社，2009.', '中文', null, '急性输卵管炎', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1发热，体温可达39～40℃，脉搏加快，可伴寒战。<br />&nbsp;&nbsp;1.2下腹部两侧疼痛。<br />&nbsp;&nbsp;1.3白带脓性或血性。<br />&nbsp;&nbsp;1.4月经失调，经量多，经期持续时间长，甚至有不规则少量阴道流血。<br />&nbsp;&nbsp;1.5可有腹胀、腹泻、便秘、尿频、尿急。<br />&nbsp;&nbsp;1.6下腹两侧压痛，也可有肌紧张、压痛、反跳痛。<br />&nbsp;&nbsp;1.7妇科检查  子宫颈触痛，有血性分泌物流出；双侧输卵管部位明显压痛，或可扪及增厚、包块。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1病史  多发生于月经期前后，分娩及流产后。<br />&nbsp;&nbsp;2.2临床表现  发热，脓性或脓血性白带，下腹部疼痛、压痛，附件区增厚或扪及包块。<br />&nbsp;&nbsp;2.3血白细胞升高，中性粒细胞数增加，血沉增快。<br />&nbsp;&nbsp;2.4B超检查发现输卵管肿大或形成包块，边界欠清。<br />&nbsp;&nbsp;2.5后穹隆穿刺可抽出渗液或脓液，并送细菌培养及药敏。<br />&nbsp;&nbsp;2.6本病需与输卵管妊娠、卵巢肿瘤蒂扭转、急性阑尾炎、急性肾盂肾炎、急性结肠憩室炎等相鉴别。<br />&nbsp;&nbsp;', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('139', '41', 'M07_004', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南妇产科学分册[M].北京：人民卫生出版社，2009.', '中文', null, '慢性输卵管炎', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1下腹疼痛  疼痛程度不一，多为主诉下腹部不适、腰背及骶部酸痛、发胀、下坠感，于月经前后、性交及劳累后更甚。也可有膀胱或直肠充盈痛或排空时痛，或膀胱直肠刺激症状。慢性输卵管炎急性发作时可使症状加重，并可伴发热。<br />&nbsp;&nbsp;1.2月经紊乱  表现为月经过多、月经过频，共至不规则阴道流血、淋漓不净。<br />&nbsp;&nbsp;1.3痛经  多在月经前2～7天即有腹痛，经期加重，经后消失。<br />&nbsp;&nbsp;1.4不孕  多为继发性不孕。<br />&nbsp;&nbsp;1.5白带增多，性交疼痛等。<br />&nbsp;&nbsp;1.6其他  可有胃肠道障碍、乏力、精神抑郁、精神神经症状等。<br />&nbsp;&nbsp;1.7妇科检查  下腹部可有压痛；子宫后位或后倾，活动度稍差或固定；双侧附件增厚或扪及包块，输卵管呈条索状或形成积水或炎性包块，不易推动，可有触痛。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1曾有急性输卵管炎或急性盆腔炎的病史。<br />&nbsp;&nbsp;2.2临床表现  下腹疼痛，月经紊乱，继发不孕，白带增多，性交疼痛；盆腔检查子宫后倾、活动度差，附件区增厚或扪及包块。<br />&nbsp;&nbsp;2.3B超检查可见子宫及附件边界欠清，可伴或不伴积液。输卵管积水可呈烧瓶状图像，内为液性回声区。有时可见盆腔粘连形成的炎性包块回声。<br />&nbsp;&nbsp;2.4子宫输卵管碘油造影  常见子宫正常，输卵管通而不畅或不通。<br />&nbsp;&nbsp;2.5本病需与陈旧性宫外孕、子宫内膜异位症、卵巢囊肿等鉴别。<br />&nbsp;&nbsp;', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('14', '32', 'G02_002', '1', '中国儿童青少年血脂防治专家共识', ' Expert：control of hyperfipid in children and adolescents in China', '中国医师协会儿童健康专业委员会；\n中华心血管病学会动脉粥样硬化学组；', '2008', '中国医师协会儿童健康专业委员会和中华心血管病学会动脉粥样硬化学组.中国儿童青少年血脂防治专家共识[J].中国热带医学,2008,8(1)：124-127.', '中文', '基于是否继发于全身性系统性疾病，高脂血症可分为原发性、继发性两种。', '小儿高脂血症', null, null, 'G02_002_01_2岁以上小儿高脂血症诊断标准.docx', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('140', '41', 'M07_005', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南妇产科学分册[M].北京：人民卫生出版社，2009.', '中文', null, '急性盆腔炎', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1腹痛  一般为下腹痛，弥漫性腹膜炎为全腹痛。<br />&nbsp;&nbsp;1.2发热  严重者出现高热，伴畏寒、寒战、头痛、食欲不振。<br />&nbsp;&nbsp;1.3阴道分泌物增多  脓性成脓血性白带，月经期患者出现经量增多、经期延长。<br />&nbsp;&nbsp;1.4消化系统症状  恶心、呕吐、腹胀、腹泻等。<br />&nbsp;&nbsp;1.5膀胱直肠刺激症状  排尿困难、尿急、尿频和里急后重、排便困难。<br />&nbsp;&nbsp;1.6全身检查  急性病容，体温高，心率快，腹胀，下腹部肌紧张、压痛、反跳痛，肠呜音减弱或消失。<br />&nbsp;&nbsp;1.7妇科检查  阴道可有充血，宫颈举痛，宫颈口可有脓性分泌物流出；子宫稍大，有压痛，一侧或两侧附件增厚，压痛明显，扪及包块；宫骶韧带增粗、触痛；若有脓肿形成且位置较低时，可扪及穹隆有肿块且有波动感。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1病史  常有产后、流产后和盆腔手术感染史，或有经期卫生不良、放置宫内节育器、慢性盆腔炎及不良性生活史等。<br />&nbsp;&nbsp;2.2临床表现  发热，下腹痛，白带增多，膀胱和直肠刺激症状，腹膜刺激征阳性，宫颈举痛，宫颈口可有脓性分泌物流出；子宫稍大，有压痛，附件增厚，压痛明显，可扪及包块。<br />&nbsp;&nbsp;2.3辅助检查<br />&nbsp;&nbsp;2.3.1白细胞及中性粒细胞升高，血沉增快，C反应蛋白增高；<br />&nbsp;&nbsp;2.3.2血液培养，宫颈管分泌物和后穹隆穿刺液涂片，免疫荧光检测，病原体培养及药物敏感试验等，若涂片找到淋球菌则可确诊；<br />&nbsp;&nbsp;2.3.3后穹隆穿刺抽出脓液有助于盆腔炎的诊断；<br />&nbsp;&nbsp;2.3.4B超可发现输卵管卵巢脓肿、盆腔积脓；<br />&nbsp;&nbsp;2.3.5腹腔镜可见输卵管表面充血、管壁水肿、伞部或浆膜面有脓性渗出物，取分泌物做病原体培养和药敏最准确。<br />&nbsp;&nbsp;2.4诊断标准  需同时具备三项必备条件，即下腹压痛、附件压痛和宫颈举痛或摇摆痛。下列附加条件可增加诊断的特异性，包括：体温>38℃，血WBC>10×109/L，宫颈分泌物涂片或培养见淋球菌或沙眼衣原体阳性，后穹隆穿刺抽出脓液，双合诊或B超发现盆腔脓肿或炎性包块。<br />&nbsp;&nbsp;2.5鉴别诊断  需与急性阑尾炎、输卵管妊娠流产或破裂、卵巢囊肿蒂扭转或破裂相鉴别。<br />&nbsp;&nbsp;', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('141', '41', 'M07_006', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南妇产科学分册[M].北京：人民卫生出版社，2009.', '中文', null, '慢性盆腔炎', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1慢性盆腔疼痛  下腹坠胀痛、腰骶部痛、性交痛等，常在劳累、性交后及月经前后加重。<br />&nbsp;&nbsp;1.2不孕及异位妊娠输卵管粘连堵塞所致。<br />&nbsp;&nbsp;1.3月经失调  表现为周期不规则，经量增多，经期延长或伴痛经。<br />&nbsp;&nbsp;1.4白带增多。<br />&nbsp;&nbsp;1.5全身症状  多不明显，可有低热、乏力、精神不振、全身不适、失眠等。<br />&nbsp;&nbsp;1.6急性发作  当身体抵抗力降低时，易急性或亚急性发作。<br />&nbsp;&nbsp;1.7妇科检查  子宫内膜炎患者子宫可增大、压痛；输卵管炎患者可在一侧或双侧附件区触及条索状物，有压痛；附件周围炎以粘连为主，附件炎可形成输卵管卵巢炎性肿块，亦可形成输卵管积水或输卵管卵巢囊肿，可在附件区触及囊性肿物，大者可超过脐上。盆腔结缔组织炎者可有圭韧带、宫骶韧带组织增厚、压痛，子官一侧或两侧片状增厚、粘连、压痛，子宫常呈后位，活动受限，甚至粘连固定形成冰冻骨盆。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1病史  曾有急性盆腔炎史、盆腔炎反复发作史、不孕史等。<br />&nbsp;&nbsp;2.2临床表现慢性下腹及腰骶部坠痛，不孕、月经异常及乏力或神经衰弱表现。妇科检查子宫可增大，呈后倾后曲，压痛、活动受限，附件区触及条索状物、囊性肿物或片状增厚，主韧带、宫骶韧带增粗、压痛。<br />&nbsp;&nbsp;2.3B超  于附件区可见不规则、实性、囊性或囊实性包块。<br />&nbsp;&nbsp;2.4腹腔镜  可见内生殖器周围粘连，组织增厚，包块形成。<br />&nbsp;&nbsp;2.5鉴别诊断  需与子宫内膜异位症、卵巢囊肿、卵巢癌、盆腔结核、盆腔静脉淤血症、陈旧性宫外孕等相鉴别。<br />&nbsp;&nbsp;', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('142', '41', 'M07_007', '1', '盆腔炎症性疾病诊治规范（修订版）', '无', '中华医学会妇产科学分会感染性疾病协作组', '2014', '中华医学会妇产科学分会感染性疾病协作组.盆腔炎症性疾病诊治规范（修订版）[J].中华妇产科杂志，2014,49（6）：401-403.', '中文', null, '盆腔炎症性疾病', null, null, 'PID的临床表现各异，因此其诊断通常依据临床症状、体征和实验室检查综合决定。<br />&nbsp;&nbsp;    1.PID诊断的最低标准：在性活跃女性及其他存在STI风险者，如排除其他病因且满足以下条件之一者，应诊断PID并给予PID经验性治疗：1.1子宫压痛；1.2附件压痛；1.3子宫颈举痛。下腹疼痛同时伴有下生殖道感染征象时，诊断PID酌可能性增加。<br />&nbsp;&nbsp;    2.PID诊断的附加标准：2.1口腔温度≥38.3℃；2.2子宫颈或阴道脓性分泌物；2.3阴道分泌物显微镜检查有白细胞增多；2.4红细胞沉降率升高；2.5C反应蛋白水平升高；2.6实验室检查证实有子宫颈淋病奈瑟菌或沙眼衣原体感染。大多数PID患者有子宫颈脓性分泌物或阴道分泌物镜检有白细胞增多。如果子宫颈分泌物外观正常，并且阴道分泌物镜检无白细胞，则诊断PID的可能性不大，需要考虑其他可能引起下腹痛的病因。如果有条件，应积极寻找致病微生物，尤其是与STI相关的病原微生物。<br />&nbsp;&nbsp;    3.PID诊断的特异性标准：3.1子宫内膜活检显示有子宫内膜炎的组织病理学证据；3.2经阴道超声检查或MRI检查显示输卵管管壁增厚、管腔积液，可伴有盆腔游离液体或输卵管卵巢包块；3.3腹腔镜检查见输卵管表面明显充血、输卵管水肿、输卵管伞端或浆膜层有脓性渗出物等。<br />&nbsp;&nbsp;', null, null, null, '为西医诊治规范。明确盆腔炎症性疾病的最低标准、附加标准及特异性标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('143', '41', 'M07_008', '1', '英国国家2011年盆腔炎性疾病的管理方针', 'UK national guideline for the management of pelvic inflammatory disease 2011.', '英国性卫生和艾滋病毒协会（BASHH，British Association for Sexual Health and HIV）', '2011', 'http://www.guideline.gov/content.aspx?id=36068&search=pelvic+inflammatory+disease', '英文', null, '盆腔炎症性疾病', null, null, '诊断：<br />&nbsp;&nbsp;盆腔炎(PID)可能有症状或无症状。即使现在，临床症状和体征缺乏敏感性和特异性(与腹腔镜诊断比较，乐观的预测临床诊断的价值是65%到90%)。<br />&nbsp;&nbsp;检测淋病和衣原体下生殖道建议以来积极支持PID的诊断结果。没有感染然而不排除PID。<br />&nbsp;&nbsp;升高红细胞沉降率(ESR)、C反应蛋白支持诊断，但非特异性。<br />&nbsp;&nbsp;没有子宫或阴道脓细胞具有良好的阴性预测值(95%)诊断为PID，但他们的存在非特异性(积极预测价值仅为17%)。<br />&nbsp;&nbsp;年轻女性下腹部疼痛的鉴别诊断包括：<br />&nbsp;&nbsp;异位妊娠，妊娠应排除在所有女性疑似PID。<br />&nbsp;&nbsp;急性阑尾炎，多数阑尾炎患者出现恶心和呕吐，但只有50%的PID。颈椎运动疼痛会发生在约四分之一与阑尾炎的女性。<br />&nbsp;&nbsp;子宫内膜异位的症状，月经周期之间的关系可能有助于建立一个诊断。<br />&nbsp;&nbsp;卵巢囊肿的并发症(如蒂扭转或破裂)常突然发病。<br />&nbsp;&nbsp;尿路感染，常存在排尿困难和/或尿频。<br />&nbsp;&nbsp;功能性疼痛，可能与长期存在的有关症状。<br />&nbsp;&nbsp;Diagnosis<br />&nbsp;&nbsp;Pelvic inflammatory disease (PID) may be symptomatic or asymptomatic. Even when present， clinical symptoms and signs lack sensitivity and specificity (the positive predictive value of a clinical diagnosis is 65% to 90% compared with laparoscopic diagnosis).<br />&nbsp;&nbsp;Testing for gonorrhoea and chlamydia in the lower genital tract is recommended since a positive result supports the diagnosis of PID. The absence of infection at this site does not exclude PID however.<br />&nbsp;&nbsp;An elevated erythrocyte sedimentation rate (ESR) or C reactive protein also supports the diagnosis but is non-specific.<br />&nbsp;&nbsp;The absence of endocervical or vaginal pus cells has a good negative predictive value (95%) for a diagnosis of PID but their presence is non-specific (poor positive predictive value – 17%).<br />&nbsp;&nbsp;The differential diagnosis of lower abdominal pain in a young woman includes:<br />&nbsp;&nbsp;Ectopic pregnancy - pregnancy should be excluded in all women suspected of having PID.<br />&nbsp;&nbsp;Acute appendicitis - nausea and vomiting occur in most patients with appendicitis but only 50% of those with PID. Cervical movement pain will occur in about a quarter of women with appendicitis.<br />&nbsp;&nbsp;Endometriosis - the relationship between symptoms and the menstrual cycle may be helpful in establishing a diagnosis.<br />&nbsp;&nbsp;Complications of an ovarian cyst (e.g.， torsion or rupture) often of sudden onset.<br />&nbsp;&nbsp;Urinary tract infection – often associated with dysuria and/or urinary frequency<br />&nbsp;&nbsp;Functional pain - may be associated with longstanding symptoms.<br />&nbsp;&nbsp;', null, null, null, '为西医标准，为修订版。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('144', '37', 'X01_001', '0', '中华中医药学会标准-心悸', '无', '中华中医药学会', '2008', 'ZYYXH/T 19-2008, 心悸[S].', '中文', null, null, '心悸', '心虚胆怯证；心脾两虚证；阴虚火旺证；心阳不振证；水饮凌心证；痰火扰心证；心血瘀阻证', null, '1.诊断<br />&nbsp;&nbsp;1.1诊断要点<br />&nbsp;&nbsp;心悸为主要症状，病人自觉心中跳动，惊慌不安，不能自主；脉象可见结脉、代脉、促脉、疾脉、数脉、涩脉、缓脉、迟脉等。<br />&nbsp;&nbsp;1.2鉴别诊断<br />&nbsp;&nbsp;1.2.1惊悸与怔忡：心悸可分为惊悸与怔忡。惊悸发病多与情绪因素有关，可由骤遇惊恐、忧思恼怒、悲哀过极或过度紧张而诱发，多为阵发性；病来虽速，病情较轻，实证居多，可自行缓解，不发时如常人。怔忡多由久病体虚、心脏受损所致，无精神刺激等因素也可发生，常持续心悸、心中惕惕、不能自控、活动后加重，多属虚证，或虚中夹宴；病来虽渐，病情较重，不发时亦可兼见脏腑虚损症状。惊悸日久不愈亦可形成怔忡。<br />&nbsp;&nbsp;1.2.2奔豚：奔豚发作时，觉心胸躁动不安。其鉴别要点在于心悸为心中剧烈跳动，发自于心；奔豚乃上下冲逆，发自少腹。<br />&nbsp;&nbsp;1.2.3卑谍：阜谍之胸中不适由于痞塞，其病因在于心血不足；而心悸则缘于心跳，有时坐卧不安，并不避人。卑悌是一种以神志异常为主的病证，一般无促、结、代、疾、迟等脉象出现。<br />&nbsp;&nbsp;1.2.4心下悸、心下痞：心下指胃脘，心下悸指胃脘惕惕然跳动；心下痞指胃脘满闷不适，按之柔软不痛。鉴别要点在于心下悸与心下痞病位皆在胃，而心悸病位在心。<br />&nbsp;&nbsp;2辨证论治<br />&nbsp;&nbsp;2.1心虚胆怯证：心悸不宁，善惊易恐，坐卧不安，少寐多梦而易惊醒，食少纳呆，恶闻声响，苔薄白，脉细数或虚数。<br />&nbsp;&nbsp;2.2心脾两虚证：心悸不宁，动则尤甚，神疲倦怠，面色不华，头晕，舌质淡，苔薄白，脉细弱或结代。<br />&nbsp;&nbsp;2.3阴虚火旺证：心悸易惊，心烦失眠，五心烦热，口干，盗汗；思虑劳心则症状加重，伴有耳鸣，腰酸，头晕目眩；舌红少津，苔少或无，脉细数。<br />&nbsp;&nbsp;2.4心阳不振证：怔忡胸闷，面色㿠白，体倦懒言，形寒肢冷，舌淡苔白，脉虚无力。<br />&nbsp;&nbsp;2.5水饮凌心证：心悸，胸闷痞满，渴不欲饮，小便短少，下肢浮肿，形寒肢冷；伴有头晕，恶心呕吐，流涎；舌淡胖，苔滑．脉弦滑或沉细，或结、代。<br />&nbsp;&nbsp;2.6痰火扰心证：心悸胸闷，恶心纳呆，口黏痰多，头身困重，苔白腻或滑腻，脉滑。<br />&nbsp;&nbsp;2.7心血瘀阻证：心悸不宁，胸痛时作，面唇色暗，舌质紫暗或有瘀斑，舌下脉络迂曲，脉涩或结代。<br />&nbsp;&nbsp;', null, null, '为中医标准。有详细诊断及中医辨证分型，并附单方验方、针刺、穴位注射、推拿、调摄与预防等。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('145', '37', 'X01_002', '0', '中华中医药学会标准-室性早搏', '无', '中华中医药学会', '2008', 'ZYYXH/T 65-2008, 室性早搏[S].', '中文', null, '室性早搏', null, '气阴两虚证；心阳不振证；心脉瘀阻证；肝气郁结证；痰湿阻滞证', '1.临床表现<br />&nbsp;&nbsp;1.1症状：最常见的症状是心悸不适，部分患者还可以出现头晕、乏力、胸闷，甚至晕厥；较轻的室性期前收缩常无症状。<br />&nbsp;&nbsp;1.2体征：心脏听诊有心搏提前，其后有较长的间歇；室早的第二心音减弱或消失，仅能听到第一心音；桡动脉搏动减弱或消失。<br />&nbsp;&nbsp;2.理化检查<br />&nbsp;&nbsp;2.1心电图特征：提前出现的宽大畸形的QRS波群，时限>0.12秒，其前无P波，其后有完全性代偿间期，T波方向与QRS波群主渡方向相反。<br />&nbsp;&nbsp;2.2窒性早搏的类型：室性早搏可孤立或规律出现，每个窦性P渡后跟随一个室性早搏，称为二联律；每2个窦性P波后出现一个室性早搏，称为三联律；连续发生2个室性早搏，称成对室早；连续3个或以上室性早搏称室速；位于2个正常窦性心律之间的室性早搏称为间位性室早。若室性早搏的形态与窦性QRS渡的偶联间期均固定，称为单形性室早；同一患者出现2种或2种以上形态的室性早搏，且与窦性QRS波的偶联间期存在差异，称为多源性室早。<br />&nbsp;&nbsp;3.诊断要点<br />&nbsp;&nbsp;3.1可见于正常人及各种心脏病患者；药物中毒，电解质紊乱，应急状态，精神因素，过量烟、酒、咖啡易诱发。<br />&nbsp;&nbsp;3.2患者有心悸不适，部分患者可无自觉症状。<br />&nbsp;&nbsp;3.3听诊有心搏提前，其后有较长的间歇；桡动脉搏动减弱或消失。<br />&nbsp;&nbsp;3.4心电图可见提前出现的宽大畸形的QRS波群，时限>0.12秒，其前无P波，其后有完全性代偿间期，T波方向与QRS波群主渡方向相反。<br />&nbsp;&nbsp;3.5Lown分级：多用于急性心肌梗死患者室性早搏危险程度的分级。<br />&nbsp;&nbsp;  0级 无室性期前收缩。<br />&nbsp;&nbsp;  1级 偶发，单一形态室性期前收缩<30次／分。<br />&nbsp;&nbsp;  2级 频发，单一形态室性期前收缩≥30次／分。<br />&nbsp;&nbsp;  3级 频发，多形室性期前收缩。<br />&nbsp;&nbsp;  4A级 连续的成对室性期前收缩。<br />&nbsp;&nbsp;  4B级 连续的≥3次的室性期前收缩。<br />&nbsp;&nbsp;  5级 R-on-T现象。<br />&nbsp;&nbsp;', '1.气阴两虚证：以心悸怔忡、五心烦热、气短乏力主症，兼见头晕口干、失眠多梦等症，舌红，少苔，脉细数兼结代。<br />&nbsp;&nbsp;2.心阳不振证：以心悸怔忡、形寒肢冷为主症，兼见胸闷气短、面色㿠白、畏寒喜温，或伴心痛等症，舌淡，苔白，脉沉迟或结代。<br />&nbsp;&nbsp;3.心脉瘀阻证：以心悸怔忡、心前区刺痛、入夜尤甚为主症，兼见面色紫暗、唇甲青紫等症，舌质紫暗或有瘀斑，脉涩或结代。<br />&nbsp;&nbsp;4.肝气郁结证：以心悸怔忡、胸闷胁胀、情绪变化可诱发或加重为主症，兼见暖气叹息、心烦失眠、大便不畅等症，舌质暗红，苔薄黄，脉弦或结代。<br />&nbsp;&nbsp;5.痰湿阻滞证：以心悸怔忡、胸脘胀满为主症，兼见口黏纳呆、大便黏而不爽等症，舌质暗红，苔白厚腻或黄腻，脉滑。<br />&nbsp;&nbsp;', null, null, '为中医标准。有详细诊断及中医辨证分型，并附针刺、推拿等其它治法。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('146', '37', 'X01_003', '0', '中医内科病证诊断疗效标准', 'Criteria of diagnosis and therapeutic effect of internal diseases and syndromes in traditional Chinese medicine', '国家中医药管理局', '1994', 'ZY/T 001.1-94, 中医内科病证诊断疗效标准[S].', '中文', null, null, '心悸', '心虚胆怯；心脾两虚；阴虚火旺；心血瘀阻；水气凌心', '1.自觉心搏异常，或快速或缓慢，或跳动过重，或忽跳忽止。呈阵发性或持续不解，神情紧张，心慌不安。<br />&nbsp;&nbsp;2.伴有胸闷不适，心烦寐差，颤抖乏力，头晕等症。中老年患者，可伴有心胸疼痛，甚则喘促，汗出肢玲，或见晕厥。<br />&nbsp;&nbsp;3.可见数、促、结、代、缓、迟等脉象。<br />&nbsp;&nbsp;4.常有情志刺激，惊恐，紧张，劳倦，饮酒等诱发因素。<br />&nbsp;&nbsp;5.血常规、血沉、抗“O”、T3、T4及心电图，X线胸部摄片、测血压等检查，有助明确诊断。<br />&nbsp;&nbsp;', '1.心虚胆怯：心悸因惊恐而发，悸动不安，气短自汗，神倦乏力，少寐多梦。舌淡，苔薄白，脉细弦。<br />&nbsp;&nbsp;2.心脾两虚：心悸不安，失眠健忘，面色㿠白，头晕乏力，气短易汗，纳少胸闷。舌淡红，苔薄白，脉弱。<br />&nbsp;&nbsp;3.阴虚火旺：心悸不宁，思虑劳心尤甚，心中烦热，少寐多梦，头晕目眩，耳鸣，口干，面颊烘热。舌质红，苔薄黄，脉细弦数。<br />&nbsp;&nbsp;4.心血瘀阻：心悸怔忡，胸闷心痛阵发，或面唇紫暗。舌质紫气或有瘀斑，脉细涩或结代。<br />&nbsp;&nbsp;5.水气凌心：心悸怔忡不已，胸闷气喘，咳吐大量泡沫痰涎，面浮足肿，不能平卧，目眩，尿少，苔白腻或白滑，脉弦滑数疾。<br />&nbsp;&nbsp;6.心阳虚弱：心悸动则为甚，胸闷气短，畏寒肢冷，头晕，面色苍白。舌被胖，苔白，脉沉细迟或结代。<br />&nbsp;&nbsp;', '1.治愈：症状及心律失常消失，心电图等实验室检查恢复正常。<br />&nbsp;&nbsp;2.好转：症状减轻或发作间歇时间延长，实验室检查有改善。<br />&nbsp;&nbsp;3未愈：症状及心律失常无变化。<br />&nbsp;&nbsp;', null, '为中医标准，规定了中医内科57个病证的病证名、诊断依据、证候分类、疗效评定。本标准适用于中医临床医疗质量评定，中医科研、教学亦可参照使用。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('147', '37', 'X01_004', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', null, '窦性心动过速', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1临床特点：患者常主诉心悸，心率在100～180次／分，有时也可达到200次／分。自律性增加者为心率逐渐增快。窦房结折返性心动过速临床症状轻微或缺失，易情绪激动。体力负荷增加等为诱因，可有自主神经失调的表现。发作呈突发突止特点，多由异位搏动引发，而不是生理因素导致。心悸时可伴有恐惧及多尿。开始发作较少，之后逐渐增加。不适当窦性心动过速患者表现为持久的心悸，静息状态下心率达到或超过I00次／分，症状严重者近似晕厥，发作和终止均有移行过程。<br />&nbsp;&nbsp;1.2心电图特点：频率在100～180次／分，P波形态、激动顺序与窦性P波相同或相似。窦房结折返性心动过速发作之初可有心律不齐，终止时可见PP间期逐渐延长（窦房折返环中的文氏现象），终止后间歇等于或略长于窦性周期。刺激迷走神经可使频率减慢，停止后又恢复原来水平。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1具有上述临床表现及心电图特点。<br />&nbsp;&nbsp;2.2诊断不适当窦性心动过速需确定症状与静息状态下或极易诱发的窦性心动过速有关，排除房性心动过速以及其他自律性增高的窦性心动过速。Holter监测白天心率在100次／分以上，夜间心率可正常。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('148', '37', 'X01_005', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', null, '窦性心动过缓', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1临床特点  窦性心动过缓心率不低于50次／分时，患者通常无症状。心率过低可因心搏出量减少而导致血压降低，有头晕、乏力眼花甚至晕厥症状，严重者可诱发心绞痛或心力衰竭。<br />&nbsp;&nbsp;1.2心电图表现窦性心律，P波形态与正常窦性P波一致，心率小于60次／分，常伴有窦性心律不齐，严重者可有逸搏。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1伴或不伴心动过缓症状。<br />&nbsp;&nbsp;2.2心电图或Holter平均心率小于60次／分。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('149', '37', 'X01_006', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', null, '窦性停搏', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1临床特点  长时间窦性停搏无逸搏发生时，患者会出现头晕、黑曚、抽搐或短暂意识障碍，严重者可发生Adams-Stokes综合征乃至死亡。<br />&nbsp;&nbsp;1.2心电图特点  心电图表现为较正常的PP间期显著长的间期内无P波产生，或P波与QRS波均无，长的PP间期与基本窦性PP间期无倍数关系。长间歇后可出现交界性或室性逸搏。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1窦性停搏的相关症状。<br />&nbsp;&nbsp;2.2心电图长时间无P波产生。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('14b59c3f76304480a108e46faf28b9f6', '57', 'aaaa', '0', 'aaaa11122', 'aa', 'aaaa', null, '', '中文', '', '', '', '', '', '', '', '', '', '1', '0', 'admin', '2016-05-10 17:29:44', 'admin', '2016-05-10 18:28:27');
INSERT INTO `biz_standard` VALUES ('15', '32', 'G02_003', '1', '儿童青少年血脂异常防治专家共识', ' 无', ' 《中华儿科杂志》编辑委员会；\n中华医学会儿科学分会儿童保健学组；\n中华医学会儿科学分会心血管学组；\n中华医学会心血管病学分会动脉粥样硬化学组；', '2009', '儿童青少年血脂异常防治专家共识[J].中华儿科杂志.2009,47(6):426-428.', '中文', '1．临床分类法：①高胆固醇血症：是指空腹血浆胆固醇水平高于正常；②高TG血症：系指空腹血浆TG水平增高；③混合性高脂血症：是指除空腹血浆胆固醇升高外，TG水平亦高于正常值；④低HDL-C血症：空腹血浆HDL-C水平降低。<br />&nbsp;&nbsp;\n2．病因分类法：基于是否继发于全身性系统性疾病分为原发性、继发性两种。<br />&nbsp;&nbsp;\n', '高脂血症;血脂异常', null, null, 'G02_003_01_2岁以上小儿高脂血症诊断标准.docx', null, 'LDL-C', ' 药物治疗目标：LDL-C<3.37mmol/L(130mg/dl)，理想状态：LDL-C<2.85mmol/L(110mg/dl)', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('150', '37', 'X01_007', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', null, '窦房传导阻滞', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1临床特点  同窦性停搏。<br />&nbsp;&nbsp;1.2心电图特点  窦房阻滞按其程度可分为一度、二度和三度。由于体表心电图不能显示窦房结电活动，因而诊断一度窦房阻滞，三度窦房阻滞与窦性停搏鉴别困难，只有二度窦房阻滞可以从心电图上表现出来。二度窦房阻滞分为莫氏Ⅰ型（文氏）阻滞和莫氏Ⅱ型阻滞。文氏阻滞表现为PP间期逐渐缩短，直至脱落出现一次长PP间期，此长PP间期短于基本PP间期的两倍，应与窦性心律不齐鉴别。莫氏Ⅱ型阻滞表现为P波之间出现长间歇，是基本PP间期的倍数，由此可区别于窦性停搏。窦房阻滞后可出现交界性或室性逸搏心律。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1临床症状。<br />&nbsp;&nbsp;2.2二度窦房阻滞主要由心电图诊断。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('151', '37', 'X01_008', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', null, '病窦综合征', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1临床特点  本病发病年龄不限、病程不一，患者表现为与心动过缓、心动过速有关的症状。①心动过缓所致症状：以脑、心、肾等脏器供血不足尤其是脑血供不足症状为主。轻者乏力、反复发作的头昏、眼花、失眠、胸痛、心悸、胸闷、记忆力差、反应迟钝或易激动等，易被误诊为神经症，老年人还易被误诊为脑血管意外或衰老综合征。严重者可引起短暂黑曚、近乎晕厥、晕厥、抽搐或Adams-Stokes综合征发作。心排出量过低严重影响肾脏等脏器灌注，还可致尿少、消化不良。②心动过速所致症状：部分患者合并短阵室上性快速心律失常发作，即慢快综合征。快速心律失常发作时，心率可突然加速达100次／分以上，持续时间长短不一，患者可有心悸、心绞痛等症状，心动过速突然中止后可有心脏暂停伴或不伴晕厥发作。③原有心脏病症状加重，引起心力衰竭，可因冠状动脉供血不足表现为心悸、胸闷、气促、心绞痛甚至心肌梗死。<br />&nbsp;&nbsp;1.2心电图特点  心电图可表现为非药物引起的严重而持久的窦性心动过缓、窦性停搏或窦房阻滞、交界性或室性逸搏心律、房室传导阻滞、慢快综合征（缓慢性心律失常与快速心律失常交替出现，后者多为心房扑动或心房颤动以及房性心动过速），快速心律失常自动停止后，窦性心律常于长达2秒以上的间歇后出现。双结病变患者心电图表现为房室交界区逸搏延迟出现（逸搏周期>1.5秒）、房室交界区逸搏心律过缓（交界区心率<40次／分）、房室传导阻滞，偶见合并束支传导阻滞。Holter检查可有与症状相关的显著心动过缓。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1临床症状即心电图典型表现可确定诊断。<br />&nbsp;&nbsp;2.2Holter记录到与晕厥等症状相关的显著心动过缓，可提供有力证据。<br />&nbsp;&nbsp;2.3固有心率测定低于正常值。<br />&nbsp;&nbsp;2.4阿托品试验或运动试验不能使心率明显增加，存在窦房结变时功钝能不良。<br />&nbsp;&nbsp;2.5食管调搏或心内电生理检查测定窦房结恢复时间或窦房传导时间异常，但敏感性和特异性较差，临床意义不大。<br />&nbsp;&nbsp;2.6除外生理性如老年、睡眠或运动员心动过缓，排除药物和甲状腺功能减退、黄疸等其他病理状态。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('152', '37', 'X01_009', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', null, '房性期前收缩', null, null, '房性期前收缩依靠心电图诊断，心电图表现为与窦性P波不同的房性期前收缩的P波提前发生。发生很早的房性期前收缩可重叠于前面的T波之上，且不能下传心室，易误认为窦性停搏或窦房传导阻滞。房性期前收缩常伴不完全性代偿间期，少数房性期前收缩发生为能扰乱窦房结的节律伴完全性代偿间期。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('153', '37', 'X01_010', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', null, '局灶性房性心动过速', null, null, '1.临床表现：症状表现为心悸、眩晕、胸痛、呼吸困难、疲乏及晕厥。儿童可出现进食困难、呕吐及呼吸急促。局灶性房速多呈短阵性、阵发持续性，少数呈无休止牲。呈短阵性发作或持续时间短的房速，患者很少有症状。局灶性房速患者的临床一般为良性过程，但如无休止性发作可以导致心律失常性心肌病。<br />&nbsp;&nbsp;2.诊断<br />&nbsp;&nbsp;2.1心电图诊断  局灶性房速时，心电图常表现为长RP’心动过速，如出现房速伴房室传导阻滞，则可以排除阵发性室上速。<br />&nbsp;&nbsp;2.2心电图P’形态与房速的起源部位根据局灶性房速时体表12导联心电图的P’波形态，可以初步判定其起源部位。P’波在Ⅰ和aVL导联呈负相，或Vl导联呈正相，提示左房起源。此外，下壁导联P’波呈负相，提示激动呈由足向头部方向的传导；下壁导联P’波呈正相，提示激动呈由头部向足方向的传导。起源于高位终末嵴或右上肺静脉房速的P’波形态可以与窦性心律的P波形态相似。然而前者的P波在Vl导联多呈正相。<br />&nbsp;&nbsp;2.3心内电生理诊断  心内电生理检查表现为心房激动是从一个局灶点呈放射状传导，心内膜的激动不占据整个心房激动周长，为局灶性房速的显著特点。常规的心内电生理检查方法可以通过以下特征作出诊断：①在房速时，能标测到较体表心电图P’波明显提前和比其他心房部位更早的局部最早心房激动点；②心房激动顺序符合从该局部最早心房激动点呈单一的放射状和规律性传导；③在该局部行心房SISl刺激的激动JI顷序与房速时完全相同；④在局灶点行单点消融可以终止心动过速发作；⑤排除大折返机制的房速。三维标测系统可直观展现房速的激动顺序，可见激动从最早起源点向周隔传播。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('154', '37', 'X01_011', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', null, '三尖瓣峡部依赖的心房扑动', null, null, '1.临床表现：房扑患者常有心悸、呼吸困难、乏力或胸痛等症状，房扑1:1下传会引起极快心室率，可导致心力衰竭、心肌缺血、晕厥和心动过速性心肌病。此外，房扑时心房机械收缩功能减低，增加了心房血栓形成引起血栓栓塞的风险。<br />&nbsp;&nbsp;2.诊断<br />&nbsp;&nbsp;2.1体表心电图  逆钟向房扑下壁导联F波向下，而V1导联F波向上，V6导联F波向下。顺钟向房扑下壁导联F波向上。<br />&nbsp;&nbsp;2.2心内电生理检查  多极电极的激动标测显示逆钟向房扑表现为右心房游离壁从头到足的方向激动，而顺钟向房扑表现为由足到头的方向激动。拖带标测有助于明确房扑的折返路径，通常以小于房扑周长10～30毫秒的周长起搏，如果心电图F波的形态没有变化，起搏后间期( postpacing interval，PPI)与房扑的周长相差≤20毫秒，刺激间期与激动间期相等即可诊断力折返性心动过速。CARTO和EnSite是临床常用的三维电解剖标测系统，两者皆可以进行激动顺序标测，可以直观的显示出房扑的折返路径、验证峡部的双向阻滞。CARTO进行房扑的激动顺序标测要求心动过速持续，周长稳定，折返性心动过速具有特征性的早晚相接现象存在。在冠状窦口和低位右心房起搏时行激动顺序标测，可明确判断峡部的激动顺序，验证峡部的双向阻滞。EnSite(Array)系统理论上可以在一次心跳标测出房扑的激动顺序，对不持续的房扑的标测具有优势。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('155', '37', 'X01_012', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', '房颤分为初发房颤和反复发作的房颤。初发房颤定义为首次出现的房颤，不论其有无症状和能否自动复律。房颤发作≥2次则称为反复发作的房颤，包括阵发性房颤、持续性房颤和永久性房颤。阵发性房颤(paroxysmal AF)指能自行转复，持续时间<7天的房颤，一般<48小时。持续性房颤(persistentAF)为持续时间>7天的房颤，一般不能自行转复，需要进行药物或电复律。既可以由阵发性房颤发展而来也可以是房颤的首次表现。永久性房颤(permanent AF)是指复律失败或非复律适应证或复律24小时内又复发的房颤。', '心房颤动', null, null, '1.临床表现：临床表现无特异性的诊断价值，房颤的症状取决于发作时的心室率、心功能、伴随的疾病、房颤持续时间以及患者感知症状的敏感性等多种因素。大多数患者有心悸、呼吸困难、胸痫、疲乏、头晕和黑嚎等症状，由于心房利钠肽的分泌增多还可引起多尿。部分房颤患者无任何症状，而在偶然的机会或者当出现房颤的严重并发症如卒中、栓塞或心力衰竭时才被发现。同一患者即可存在症状性房颤发作也可发生无症状性房颤。<br />&nbsp;&nbsp;2.诊断：记录到房颤发作时的心电图是诊断房颤的“金标准”。如果房颤发作不甚频繁，可使用动态心电图；如果发作不频繁，事件记录仪对获得房颤发作的心电学资料有所帮助。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('156', '37', 'X01_013', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', null, '房室交界区性期前收缩', null, null, '1.临床表现：患者可无症状，或觉心悸、漏跳感等。当期前收缩发作频繁时可有胸闷、头晕、乏力等症状。<br />&nbsp;&nbsp;2.诊断要点：房室交界区性期前收缩依据心电图而诊断。心电图特征：交界区提前出现的激动向上逆传心房产生逆行P波，向下激动心室产生提前的QRS波；逆传P波出现在QRS波之前（PR间期<0.12秒）、之后（PR间期<0.20秒）或埋藏在QRS波之中；QRS波多形态正常，一般多出现完全性代偿间歇，若存在室内差异传导，则出现宽大畸形的QRS波，不易与室性期前收缩鉴别。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('157', '37', 'X01_014', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', null, '房室交界区性逸搏与逸搏心律', null, null, '1.临床表现<br />&nbsp;&nbsp;患者可有胸闷、头昏、乏力，与心动过缓有关。若心房收缩正逢三尖瓣处于关闭状态，查体时可见颈静脉搏动时的大a波。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;心电图特征：在长于正常窦性PP间期的间歇之后出现一个正常的QRS波，P波缺如，或可见逆行性P波位于QRS波之前或之后；有时也可以见到未下传到心事的窦性P波，即QRS波前有窦性P波，PR间期<0.12秒；房室交界区性逸搏的频率多为40～60次／分，QRS波形态多正常；有时也可见独立和缓慢的窦性P波，此时心房率慢于心室率，称为房室分离。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('158', '37', 'X01_015', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', null, '非阵发性房室交界区性心动过速', null, null, '1.临床表现<br />&nbsp;&nbsp;患者可表现为阵发性心悸、胸闷、头晕以及原有心脏病症状加重，但一般没有明显的血流动力学改变。洋地黄中毒者还会有洋地黄中毒的其他表现。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;心电图特征：非阵发性房室交界区性心动过速的发作渐始渐止，心率逐渐变化，心动过速频率多为70～130次／分；QRS波多呈室上性，其前或后可伴逆行P波。多呈规则节律，但洋地黄中毒常合并房室交界区文氏型传导阻滞而表现不规则的心室节律；多数情况下，心房活动由窦房结或心房异位节律点支配，表现为房室分离。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('159', '37', 'X01_016', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', null, '房室结折返性心动过速', null, null, '1.临床表现<br />&nbsp;&nbsp;AVNRT的症状与有无器质性心脏病、心动过速时的心室率以及发作持续时间有关。心动过速呈突发突止的特点，轻者可有心悸、胸闷、紧张和焦虑；重者可出现心绞痛、心衰、晕厥甚至休克。如果发作时心室率过快，或心动过速终止时未能及时恢复窦性心律可发生晕厥。查体时可见心率增快、第一心音强度固定和心室律绝对规则。不伴有器质性心脏病的患者通常预后良好。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1心电图特征  起始突然，常由房性期前收缩诱发；QRS波呈室上性；心率130～250次／分，成人多为150～200次／分，儿童可能更快，偶有低于130次／分的情况；慢一快型者P波常埋于QRS波内不易辨认，也可在QRS起始形成假性q波，或在QRS终末形成假性s波或r’波；快一慢型者可见逆行P波，R-P\'>P’-R；少数患者由于心动过速频率过快可能出现QRS电交替现象。<br />&nbsp;&nbsp;2.2心电生理检查时慢-快型表现  心动过速可由心房程序电刺激反复诱发和终止；心动过速的发作时多伴有A-H间期的突然延长；心房程序刺激时有房室传导的“跳跃现象”，表明存在房室结双径路；由于折返环路位于房室结内，因此心房和心室本身并不参与折返环路的形成，因此心动过速时心房和心室可表现为2:1房室传导阻滞；心室刺激显示逆行激动顺序正常，逆传的最早心房电活动位于房室结和希氏束区域。而快-慢型AVNRT在心内电生理检查时表现为房室结逆传跳跃现象，RP间期大于PR间期，这时需要与房性心动过速以及慢旁路参与的房室折返性心动过速相鉴别。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('16', '32', 'G02_004', '1', '2014年中国胆固醇教育计划血脂异常防治专家建议', '无', '2014年中国胆固醇教育计划血脂异常防治建议专家组;\n中华心血管病杂志编辑委员会;\n血脂与动脉粥样硬化循证工作组;\n中华医学会心血管病学分会流行病学组;', '2014', '2014年中国胆固醇教育计划血脂异常防治建议专家组,中华心血管病杂志编辑委员会,血脂与动脉粥样硬化循证工作组,中华医学会心血管病学分会流行病学组.2014 年中国胆固醇教育计划血脂异常防治专家建议[J].中华心血管病杂志，2014,42（8）:633-636.', '中文', null, '血脂异常；高胆固醇血症；高甘油三酯血症；低高密度脂蛋白血症；混合型高脂血症；', null, null, null, null, '总胆固醇(TC)；高密度脂蛋白胆固醇(HDL-C)；高密度脂蛋白胆固醇(LDL-C)；极低密度脂蛋白胆固醇(VLDL-C)；甘油三酯(TG)。', 'G02_004_01_ASCVD一级预防与二级预防降胆固醇治疗的目标值', '我国整体人群的ASCVD风险水平和平均胆固醇水平低于欧美国家居民，且我国患者对于大剂量他汀类药物治疗的耐受性较差，因此中等强度他汀类药物治疗适合于我国多数血脂异常患者的一级预防和二级预防。2013年ACC／AHA降胆固醇治疗新指南中所提倡的多数患者应用大剂量、高强度他汀类药物治疗的策略不适用于我国ASCVD的防治。<br />&nbsp;&nbsp;', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('160', '37', 'X01_017', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', null, '预激综合征', null, null, '1.临床表现<br />&nbsp;&nbsp;房室旁路本身不会引起症状。心动过速主要类型是房室折返性心动过速（约占80%），也可为房颤或心房扑动（房扑）。心动过速可以发生在任何年龄，在某些患者，随着年龄增加发作会减少。房室折返性心动过速有突发突止的特点。心动过速的症状可因基础心脏疾病、心律失常类型、心窒率以及发作持续时间等而轻重不一，发生房颤时可因极快的心室率和明显不规则的节律导致室颤，甚至发生猝死。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1心电图表现<br />&nbsp;&nbsp;2.1.1窦性心律的心电图表现：PR间期短于0.12秒；QRS波起始部粗顿（预激波），QRS宽大畸形，部分导联QRS波宽度大于0.12秒；ST-T呈继发性改变，方向通常与预激波或向量方向相反；旁路位置不同引起的心电图QRS波形态也不同，根据胸前导联，尤其是Vl导联可将WPW综合征分为A、B两型，A型胸前导联的QRS波均为正向，提示为左侧旁路，B型Vl导联的QRS波负向而V5～6 QRS波正向，提示为右侧旁路。部分患者的心电图预激波间歇出现，为间歇性预激现象，是由于传导特性的变化造成。部分房室旁路不具有前向传导（心房到心室的传导）的特性，但具有逆向传导（心室到心房的传导）功能，窦性心律时心电图无预激现象，但由于具有逆向传导功能，故可通过室房传导引起阵发性室上性心动过速，这种旁路称为隐匿性旁路。<br />&nbsp;&nbsp;2.1.2心动过速的心电图表现：绝大多数房室折返性心动过速表现为顺向型，此时QRS波形态正常，频率150～250次／分，有时在QRS波后可见逆行P波a逆向型房室折返性心动过速QRS波宽大畸形，类似心室完全预激时的形态，需要与室性心动过速鉴别。在极少数患者，由于存在多条房室旁路，心电图形态可能变化较多，不同旁路与房室结之间、不同旁路之间形成的折返环路会使心电图的表现更为复杂。房颤时冲动除经过房室结激动心室外，还可经旁路下传心室，出现不规则的QRS波节律和正常QRS波与宽大畸形QRS波并存或交替的现象。若旁路不应期很短，心室率可以极快，甚至演变为心室颤动致猝死。<br />&nbsp;&nbsp;2.2心电生理检查  通过心电生理检查可以明确心动过速的确切机制，同时可以明确旁路的类型、位置和数目，测定旁路的不应期以间接推测房颤和房扑时的心室率。目前心电生理检查主要适用于同时要求行导管射频消融治疗的患者。WPW综合征的心电生理特征有：心房程序刺激可反复诱发和终止心动过速；心动过速的诱发主要表现为心房期前刺激在旁路传导受阻，QRS突然正常化，随后出现心动过速；心室刺激显示偏心性传导，最早逆传心房电活动在房室旁路所在房室环处；心房和心室本身都是折返环路的组成部分，心动过速时心房和心室冲动均呈1:1关系。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('161', '37', 'X01_018', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', null, '室性期前收缩和非持续性室性心动过速', null, null, '1.临床表现<br />&nbsp;&nbsp;通常VPB不引起症状，多因偶尔心电图检查发现或触摸脉搏有“偷停”（代偿间歇）来就诊o VPB和NSVT最常见的症状是心悸，也可出现头部沉重感及头晕，频繁发作的VPB偶有影响血流动力学，持续较长时间的NSVT偶可导致晕厥。患者常会由心悸而焦虑，从而又使期前收缩增加。肥厚梗阻型心肌病期前收缩后由于代偿间歇后更有力收缩加重梗阻，即Brockenbrough征。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1心电图、动态心电图或住院心电监护是诊断VPB和NSVT的主要方法。VPB心电特点是提前出现的宽大畸形的QRS波群，时限至少120毫秒，T波与QRS主波方向相反，其后多有完全代偿间歇，也可有不完全代偿间歇，如不影响原来的室率为插人性VPB，多见于心率较为缓慢时。右心室流出道VPB最为常见，特征性的心电图形态是左束支阻滞样图形，额面电轴向下，当Vl及V2导联R:S大于30%或R：QRS大于50%，提示VPB起源友心室流出道。VPB形态一致称为单源VPB，不一致为多源。室性期前收缩与前一个窦性综合波有同定的联律间期，通常提示为折返机制。如联律间期不等，提示并行心律，是独立发放、自主节律的起搏点。室性期前收缩落在T波顶点或起始点附近称为“R-ON-T\"现象，与室颤相关。正常心律和VPB持续性交替出现，为室早二联律，可引起血流动力学障碍，三、四联律则影响较小。两个VPB连续出现为成对VPBo连续3个及以上室性心律，持续不超过30秒为NSVT，通常频率在100～200次／分。<br />&nbsp;&nbsp;2.2器质性心脏病患者进行运动试验诱发复杂VPB或非持续性VT有预后意义，对于患有严重冠状动脉疾病者尤其如此。对于儿茶酚胺敏感性VT和长QT综合征患者运动试验可以诱发VPB、NSVT甚至室颤。<br />&nbsp;&nbsp;2.3对于有复杂VPB或NSVT的器质性心脏病患者行心率变异性、晚电位、T波电交替等检查，对预测心脏性死亡或猝死有一定意义。近年发现VPB后的心率振荡是预测预后更好的指标。<br />&nbsp;&nbsp;2.4．心内电生理检查和程序电刺激对于无器质性心脏病的VPB和NSVT无意义，但对于有器质性心脏病患者发生恶性心律失常和猝死有一定预测意义。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('162', '37', 'X01_019', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', null, '室性心动过速', null, null, '1.临床表现<br />&nbsp;&nbsp;VT的临床表现取决于有无基础心脏疾病及其严重程度、发作的频率及持续时间、对心脏收缩功能的影响，故症状多种多样。通常表现为心悸伴有心排出量减少和低血压的症状，包括头晕、眩晕、意识改变（如焦虑）、视觉障碍、出汗、先兆晕厥和晕厥，或者血流动力学衰竭、休克甚至猝死。少数较慢频率的VT患者，尤其无器质心脏疾病者无明显症状，于体检或常规心电图检查时发现。无休止性VT长期发作导致原先正常的心脏扩大、心力衰竭，称为心动过速介导性心肌病。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1体表心电图和动态心电图  体表心电图和动态心电图是VT诊断的主要依据，多数VT频率在IOO～250次／分之间，持续性VT多数在180次／分，小于100次／分者通常称为加速性室性自主节律。单形性VT的RR间期相对规则，多形性VT则可以极不规则。多数VT的QRS波群时限大于120毫秒，起源于高位室间隔或束支的VT也可小于120毫秒。仔细阅读记录图有时可见室性夺获和室性融合波。常用采用Brugada标准鉴别宽QRS心动过速的方法为：所有胸前导联均无RS形，诊断VT（否则进行下一步，以下同）；心前区导联QRS有RS型，且RS大于100毫秒，诊断VT；存在房室分离，诊断VT；胸前导联Vl和V6形态符合VT诊断标准，即Vl呈RS型，RS大于70毫秒，U起始为正向波，R/S大于1即诊断VT。<br />&nbsp;&nbsp;    标准的12导联心电图(ECG)不仅可以识别与室性心律失常和心脏性猝死(SCD)相关的各种先天性疾病（如：长QT综合征，短QT综合征，Brugada综合征和致心律失常性右心室心肌病），还可以识别不同ECG参数，以鉴别是否有电解质的异常，或潜在的结构改变（如：束支传导阻滞、房室传导阻滞、心室肥厚，提示缺血性心脏病或心肌病的病理性Q波）。持续动态心电监测能够检测心律失常，QT间期的变化，T波电交替，或ST段的变化，以评价风险，判断疗效。如果传统方法不能明确诊断，而临床上高度怀疑晕厥或症状与心律失常相关时，可置人埋藏式事件记录仪。<br />&nbsp;&nbsp;2.2运动试验  有室性心律失常的成年患者，运动试验可以帮助除外冠心病，对于临床上怀疑运动诱发室性心律失常者，如儿茶酚胺敏感性VT、长QT综合征等，运动实验可诱发VT，明确诊断。运动试验也可以用于已知运动诱发VT的患者对药物或消融治疗的疗效判断。<br />&nbsp;&nbsp;2.3心血管影像和功能检查  对有室性心律失常者结合临床情况，选择性进行超声心动图、运动或药物负荷核素心肌显像、药物负荷心脏超声、磁共振成像(MRI)和心脏CT等技术，以及冠状动脉造影等检查，除外VT的器质性心脏疾病基础。<br />&nbsp;&nbsp;2.4无创心电技术  对于曾经有VT或者VT高危患者，尤其伴有严重器质性心脏病者，进行心率变异、晚电位、T波电交替、心率振荡等检查，对于预测心脏性死亡或猝死也有一定意义。<br />&nbsp;&nbsp;2.5心内电生理检查(EP)  EP检查通过记汞心内电图和电刺激以及结合术中用药评价室性心律失常和对心源性猝死危险分层。EP检查可以诱发VT指导导管消融、评价药物作用、评价VT复发和心源性猝死的风险、意识丧失临床上高度怀疑室性心律失常者、协助判断ICD的指征。<br />&nbsp;&nbsp;2.6基因筛查  离子通道病包括一组遗传相关的疾病，如长QT综合征、Brugada综合征、儿茶酚胺敏感性VT、短QT综合征等，目前已确定与离子通道病相关的多个基因和位点，如怀疑VT是由离子通道疾病导致者可以进行基因筛查协助诊断。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('163', '37', 'X01_020', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', null, '心室扑动；心室颤动', null, null, '1.临床表现<br />&nbsp;&nbsp;许多心脏性和非心脏性原因均可导致心室颤动和心源性猝死，但大部分患者均有器质性心脏病，尤其是慢性冠心病。故发生心源性猝死前患者多有相应的基础心脏疾病表现，如冠心病、肥厚型和扩张型心肌病、敢心律失常性右心室心肌病、充血性心衰等的临床表现。有些患者有晕厥、心悸等室性心律失常发生的病史。通常没有前驱症状，即使出现症状也是非特异性的，包括胸部不适、心悸、气短及虚弱。一旦发生可造成晕厥、意识丧失、抽搐、呼吸停止，抢救不及时最终死亡。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1既往基础疾病和诱冈的诊断  心源性猝死绝大部分发生于器质性心脏病患者，如冠心病、肥厚型和扩张型心肌病、致心律失常性右心室心肌病、充血性心衰等，通过相应的检查了解患者的基础疾病及严重程度有助于预测猝死的发生。与遗传相关的疾病如离子通道病、肥厚型心肌病可能提供阳性家族史。有些诱因也有助于诊断，如胸前受到撞击而猝死要怀疑心脏震击综合征。<br />&nbsp;&nbsp;2.2体表心电图和动态心电图  心室扑动的心电图特点为规则的、连续的波形，通常振幅较大，图形很像连续的正弦波，不能区分QRS波群、ST段和T波。频率常大于200次／分，与VT的鉴别主要根据波形而不是频率，如果不能识别单个的QRS波群就诊断为心室扑动。心室颤动是指心脏混乱的、非同步的、碎裂电活动。心电图表现为各个波的振幅和形态均不规则。不能识别P波、QRS波群和T波，频率常在150～500次／分之间。长时间的心电监测，尤其是埋藏式闭环事件记录仪可明确不明原因的晕厥是否由严重室性心律失常所致。但临床只能在偶然的情况下才能记录到。更重要的是识别室颤高危患者。<br />&nbsp;&nbsp;2.3其他  基因检查有助于与遗传相关的如离子通道病的诊断。心脏的运动或药物负荷试验、无创和有创电生理检查对于明确诊断和预测猝死均有意义（具体见“VT的诊断要点”）。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('164', '37', 'X01_021', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', null, '房室传导阻滞', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1一度房室阻滞患者通常无症状。听诊时心尖部第一心音减弱。<br />&nbsp;&nbsp;1.2二度房室传导阻滞患者可有心搏暂停感觉，心跳可变慢、不规律或两者都有，可能会引起心悸、乏力、心功能不全、头晕或晕厥等症状。听诊时可有第一心音减弱及心搏脱漏。<br />&nbsp;&nbsp;1.3三度（完全性）房室传导阻滞时，心房至心室间冲动的传导被完全阻断，心脏另一部分组织充当起搏点以建立心室节律，较正常起搏点的心率慢，而且经常不规律、不可靠。因此，三度房室传导阻滞常导致疲倦、乏力、心绞痛、头晕或晕厥等症状，这取决于是否建立了心室自主节律及心室率和心肌的基本情况。自主节律点较高如恰位于希氏束下方，心室率较快达40～60次／分，患者可能无症状。双束支病变者心室自主节律点低，心室率慢在40次／分以下，可出现心功能不全和脑缺血综合征（Adams-Stokes Syndrome，阿一斯综合征），患者可出现短暂性意识丧失甚至抽搐，严重者可猝死。如果心室自主节律未及时建立则出现心室俘搏。心室率缓慢常引起收缩压升高和脉压增宽。三度房室阻滞的第一心音强度经常变化，不规则地出现响亮的第一心音。第二心音可有反常分裂。每搏量增大产生肺动脉瓣区收缩期喷射性杂音和第三心音。当心房与心室同时收缩时，颈静脉出现巨大a波。<br />&nbsp;&nbsp;2.心电图表现<br />&nbsp;&nbsp;2.1一度房室阻滞  心房至心室间冲动的传导被轻度延迟。表现为：①每个P波后，均有QRS波群；②PR间期>0. 20秒。X01_021图1<br />&nbsp;&nbsp;2.2二度房室阻滞  部分心房激动不能传至心室，一些P波后没有QRS波群，房室传导比例可能是2：1；3：2；3：1；4:3等。通常将二度房室阻滞分为I型和U型，二度l型房室阻滞又称文氏现象，或称莫氏Ⅰ型；二度Ⅱ型房室阻滞义称莫氏Ⅱ型。<br />&nbsp;&nbsp;2.2.1二度Ⅰ型房室阻滞一文氏现象：是最常见的房室阻滞类型，心房冲动的传导逐渐受阻。表现为：①PR间期进行性延长，直至P波受阻不能下传至心室；②RR间期进行性缩短，直至P波不能下传心室；③包含受阻P波的RR间期<2 PP间期。X01_021图2<br />&nbsp;&nbsp;2.2.2二度Ⅱ型房室阻滞一莫氏Ⅱ型：心房冲动的传导突然受阻。表现为：①PR间期恒定不变，可正常或延长；②QRS波群有间期性脱漏，阻滞程度可经常变化。X01_021图3<br />&nbsp;&nbsp;一度和二度I型房室阻滞，阻滞部位多在房室结，其QRS波群形态与时限均正常；二度Ⅱ型房室阻滞，其阻滞部位多在希氏束以下，此时QRS波群呈束支阻滞图形。<br />&nbsp;&nbsp;2.3三度房室阻滞  心房冲动全部不能下传至心室表现为：①房室分离；②心房节律可为窦性或起源于异位，心房率快于心室率；③心室节律由交界区或心室自主起搏点维持，心室率一般<45次／分；④RR间期>2PP间期。另外，心房率一般不宜超过135次／分，因心房率>135次／分时，不能除外生理不应期引起的干扰性分离。房颤时心室率<45次／分且室律匀齐也应考虑三度房室阻滞。X01_021图4<br />&nbsp;&nbsp;QRS渡群的形态主要取决于阻滞的部位，如阻滞位于希氏束分支以上，QRS波群不增宽。如阻滞位于双束支，QRS波群增宽或畸形。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('165', '37', 'X01_022', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].北京：人民卫生出版社，2009.', '中文', null, '室内传导阻滞', null, null, '1.临床表现<br />&nbsp;&nbsp;    单支、双支阻滞通常无临床表现。完全性三分支阻滞的临床表现与完全性房室阻滞相同。<br />&nbsp;&nbsp;    单支、双支阻滞间可听到第一、二心音分裂。完全性三分支阻滞心率常极为缓慢。<br />&nbsp;&nbsp;    临床上除心音分裂外无其他特殊表现。诊断主要依靠心电图。<br />&nbsp;&nbsp;2.心电图表现<br />&nbsp;&nbsp;2.1完全性右束支阻滞  ①QRS时限≥0.12秒；②Vl、V2导联呈rsR’，r波狭小，R’波粗钝；③V5、V6导联呈qRs或Rs，S波宽；④l导联有明显增宽的S波、aVR导联有宽R波；⑤T波与QRS主波方向相反。不完全性右柬支阻滞图形与上述相似，但QRS时限<0.12秒。X01_022图1<br />&nbsp;&nbsp;2.2完全性左束支阻滞  ①QRS时限≥0.12秒；②V5、V6导联R波宽大，顶部粗钝或有切迹（M形R波），其前方无q波；③Vl、V2导联多呈宽阔QS或rS波形，S波宽大；④I导联R波宽大或有切迹；⑤T波与QRS主波方向相反。不完全性左束支阻滞图形与上述相似，但QRS时限<0.12秒。X01_022图2<br />&nbsp;&nbsp;2.3左前分支阻滞  ①额面平均QRS电轴左偏达-45°～-90°;②I、aVL导联呈qR波形，RaVL>RⅠ；③Ⅱ、Ⅲ、aVF导联呈rS波形，SⅢ >SⅡ；④QRS时限正常或稍延长，<0.12秒，aVL的室壁激动时间可延长，大于0.045秒，V1～3的r波低小呈rS，V5、V6可出现较深的S波。X01_022图3<br />&nbsp;&nbsp;2.4左后分支阻滞①额面平均QRS电轴右偏达+90°～+120°;②I、aVL导联呈rS波形；Ⅱ、Ⅲ、aVF导联呈qR波形，且RⅢ >RⅡ；③QRS时限<0.12秒；并除外常见引起电轴右偏的病变如右心室肥厚、肺气肿、侧壁心肌梗死等。X01_022图4<br />&nbsp;&nbsp;2.5双束支传导阻滞  双束支传导阻滞是指左、右束支主干部位传导发生障碍引起的室内传导阻滞。每一侧束支传导阻滞有一、二及三度之分。若两侧阻滞程度不一致，必然造成许多形式的组合，出现间歇性、规则或不规则的左、右束支传导阻滞，可同时伴有房室传导阻滞。如果两侧束支同时出现三度传导阻滞，则表现为完全性房室阻滞口<br />&nbsp;&nbsp;2.6双分支与三分支传导阻滞前者指室内传导系统三分支中的任何两分支同时发生阻滞。不同阻滞部位导致不同心电图表现。<br />&nbsp;&nbsp;2.6.1右束支合并左前分支传导阻滞：临床上多见，心电图特点：肢体导联QRS波群与左前分支传导阻滞相似，但由于终末附加向量，故Ⅲ、aVF导联出现终末r波，胸前导联与右束支传导阻滞的波形相同。X01_022图5<br />&nbsp;&nbsp;2.6.2右束支合并左后分支传导阻滞：临床上很少见，心电图特点：肢体导联QRS波群与左后分支传导阻滞相似；胸前导联与右束支传导阻滞相似。X01_022图6<br />&nbsp;&nbsp;2.6.3左前分支合并左后分支传导阻滞：这种传导阻滞心电图很难诊断，只有在两支阻滞程度不同时诊断方能确立。<br />&nbsp;&nbsp;三分支传导阻滞指右束支、左前分支、左后分支均有阻滞证据，也可以为双分支阻滞合并一度房室传导阻滞。阻滞可呈永久性，也可呈间歇性；三分支的组织程度、传导比例、传导同步性可以相同，也可以不同，因此，心电图表现复杂多样。如果三分支同时发生完全阻滞，表现为三度房室阻滞。X01_022图7<br />&nbsp;&nbsp;2.7不定型室内传导阻滞与浦肯野纤维传导阻滞  不定型室内传导阻滞指激动在心室内的传导发生了阻滞，但确切部位难以确定。心电图可见QRS间期≥0.12秒，波形既不符合完全性右束支传导阻滞，也不符合完全性左束支传导阻滞的特征。多见于广泛心肌病患者，病变多累及双侧束支，预后较单支传导阻滞为差。<br />&nbsp;&nbsp;    浦肯野纤维在心室内膜深层广泛交织形成浦肯野纤维网，使激动得以在心室内迅速传布，其阻滞的心电图可见QRS波群钝挫、切迹，多表现左束支传导阻滞的特点，可伴有T波及QT间期延长。', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('166', '37', 'X01_023', '1', '室上性快速心律失常治疗指南', '无', '中华医学会心血管病学分会；中国生物医学工程学会心脏起搏与电生理分会；中国心脏起搏与心电生理杂志编辑委员会；中华心血管病杂志编辑委员会', '2004', '蔡迺绳 ,曹克将 ,郭林妮 ,等.室上性快速心律失常治疗指南[J]. 中国心脏起搏与心电生理杂志,2005,19（1）:4-16.', '中文', null, '室上性快速心律', null, null, '1.无心电图记录朐心动过速的诊断<br />&nbsp;&nbsp;1.1病史和体检  阵发性心律失常患者在就诊时经常无症状，阵发性心悸是重要的诊断线索。室上速见于各个年龄段，如果心律失常反复出现，且突发突止，则应定义为阵发性。相反，窦速是非阵发性、逐渐加速和逐渐终止。有规律的、突发突止的阵发性心悸（常指阵发性室上速）通常是由AVRT或AVNRT引起；刺激迷走神经可以终止的心动过速，则提示该折返有房室结参与。由于心房收缩适逢房室瓣关闭，导致心房压力增高，心房肽分泌增多，引起多尿，后者支持持续性室上性心律失常。<br />&nbsp;&nbsp;    在室上速中，少数患者发生晕厥，常出现在快速室上速的起始后或心动过速突然终止时，出现较长的心脏停搏间歇。晕厥也可因房颤通过旁道下传引起，或者提示伴有心脏结构的异常，如主动脉瓣狭窄、肥厚型心肌病或有脑血管疾病。症状取决于心室率、潜在的心脏疾病、室上速的持续时间、患者的自我感觉。持续数周、数月的室上速并伴有快速心室率者可以引起心动过速介导的心肌病。<br />&nbsp;&nbsp;1.2诊断记录静息状态下12导联心电图，可提供异常节律、预激、QT间期延长、窦速、ST段异常或潜在性心脏病的证据。有阵发性规律性心悸病史的患者，静息心电图上出现预激，提示为AVRT。预激患者幽现无规律的阵发性心悸，强烈提示房颤，该类患者易发生猝死，需进行电生理评估。此外，在诊断时，至少应记录到1次心动过速发作时的12导联心电图。12导联心电图自动分析系统不可靠，常作出错误的心律失常诊断。不明原因的宽QRS波心动过速应由心内科专科进行治疗。对那些窄QRS波心动过速，如药物不能控制或不能耐受以及药物治疗顺从性差者，也应请心内科医师进行治疗。<br />&nbsp;&nbsp;由于预激患者如果出现房颤则有潜在致命性危险，因此对这一类患者需要进一步评估。对于已经确诊的持续性室上速，为了排除可能存在的器质性心脏病，除常规体格检查和记录12导联心电图外，还应进行心脏超声检查。<br />&nbsp;&nbsp;    对于频发（如每周几次）短暂心动过速的患者应行24h Holter检查。对于发作次数少的患者，国外多采用事件记录器或可携带循环记录器，它比24h Holter检查更有用。对于发作少（如每月少于2次），但发作时伴有严重血流动力学不稳定的患者，可选择埋置型循环记录器，这对记录事件有利。运动试验很少用丁诊断，除非心律失常明显与运动有关。<br />&nbsp;&nbsp;    如果临床病史不充分或采用其他措施未能证实的心律失常患者，可选择经食管心房起搏进行诊断或诱发阵发性快速心律失常。对于有明显阵发性规律性心悸的痛例，可采用有创电生理检查和导管消融进行治疗。X01_023图1<br />&nbsp;&nbsp;2.有心电图记录的心动过速的诊断<br />&nbsp;&nbsp;诊断及鉴别诊断描记完整的（窦律下和心动过速时12导联）心电图对心动过速诊断最重要。对下血流动力学不稳定、需紧急电转复者，可通过除颤电极板尽可能记录下心动过速心电图。<br />&nbsp;&nbsp;A．窄QRS波心动过速：心动过速时体表心电图QRS波时限<120ms为窄QRS波心动过速。窄QRS波心动过速一般为室上速，可以有多种机制。诊断应记录12导联心电图，必要时经食管导联描记P波，分析P波与R波关系；观察腺苷和颈动脉窦按摩反应，有助于窄QRS波心动过速的鉴别诊断。①RR间期规则，且心电图无明显P波，则AVNRT可能性最大。AVNRT时，P波可部分隐藏在QRS波内，使QRS波变形，在V．导联上呈“伪r波”，下壁导联(Ⅱ、Ⅲ、aVF)呈“伪s波”。②若P波重叠在ST段，与QRS波分开达70 ms．支持AVRT。③若RP长予PR，可能的机制是非典型AVNRT、PJRT或房速。<br />&nbsp;&nbsp;B．宽QRS波心动过速：心动过速时体表心电图QRS波时限≥120ms为宽QRS波心动过速。诊断宽QRS波心动过速首先考虑室性心动过速（简称室速）诊断，但也不能除外某些特殊类型的室上速（图3）。a．室速：多种心电图特征有助于室速的鉴别诊断。①房室分离：宽QRS波心动过速伴房室分离且室率快于房率，支持室速诊断，但房室分离现象只见于30%的室速患者。按摩颈动脉窦可引发房室分离现象，室速的维持无需心房（P波）参与。有时宽QRS波心动过速时心电图上P波识别困难，可设法找出房室分离的其他证据，如不规则的大炮波、第一心音强弱不等、收缩压波动等；也可使用食管电极导联记录P波，帮助鉴别诊断。②融合波：心室融合波是室速的一个重要诊断依据。③QRS波时限：QRS波时限在右束支阻滞(RBBB)图形时超过0.14s，左束支阻滞(LBBB)时超过0.16s，支持室速诊断。但室上速经旁道前传、室上速合并束支阻滞或室上速使用Ia、Ic类抗心律失常药物时，QRS波时限也可在0.14 s以上。④心动过速时QRS波图形特征：V1和V6导联的形态对鉴别室上速和室速有帮助，支持室速诊断的心电图特征为：胸前导联上RS波时限>100ms(R波起始到S波低点)；胸前导联上QRS波均为负向，呈QS型（著为正向一致性，有可能是经左后旁道前传的AVRT）。QR型提示心肌瘢痕，见于大约40%的AMI后室速患者（AMI和器质性心脏病史对室速的诊断很重要）。注意：尽管室速有上述心电图特征，但仍有不少误诊的机会。QRS波时限及形态标准的特异性在服用抗心律失常药和高血钾症及严重心衰患者中会受影响。b．室上速合并束支阻滞或差异传导：束支阻滞可以是在窦律下就已存在，或在心动过速时才出现的，是由于心室率过快，在束支系统产生的差异传导。大多数差异传导不仅仅只与频率过快有关，也可由于开始的长短周期现象引发。发生旁道同侧束支差异传导，可使心动过速频率相应减慢。c．室上速合并旁道前传：多种室上速可合并旁道前传，如房速、房扑、房颤等。由旁道参与的AVRT可经旁道前传．而经正常房室传导系统或另一条旁道逆传。表现为LBBB的宽QRS波心动过速也可由少数特殊房室旁道（如房束旁道、结束旁道和结室旁道）引起。X01_023图2<br />&nbsp;&nbsp;', null, null, null, '参考美国心脏病学院、 美国心脏学会及欧洲心脏病学会发表的室上性心律失常治疗指南，并将国外发表的循证医学资料与我国成功的经验加以综合。本指南叙述了各类型室上性快速心律失常的主要机制、诊断要点、临床特征、急性发作时的处理、 预防复发的药物及非药物治疗、 可能的并发症及预后等。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('167', '37', 'X01_024', '1', '室上性快速心律失常治疗指南', '无', '中华医学会心血管病学分会；中国生物医学工程学会心脏起搏与电生理分会；中国心脏起搏与心电生理杂志编辑委员会；中华心血管病杂志编辑委员会', '2004', '蔡迺绳 ,曹克将 ,郭林妮 ,等.室上性快速心律失常治疗指南[J]. 中国心脏起搏与心电生理杂志,2005,19（1）:4-17.', '中文', null, '生理性窦性快速心律失常', null, null, '正常窦性心律时，标准12导联中I、Ⅱ、aVF导联P波直立，aVR导联P波倒置；P波额面电轴介于0～+90°，而在水平面上指向正前方伴轻度左偏；因此，V1、V2导联P波可以倒置，但V3～V6导联P波必须直立。窦速时P波形态正常，但因振幅增加而变得高尖。生理性窦速呈非阵发性，不同于折返所致的寞速。', null, null, null, '参考美国心脏病学院、 美国心脏学会及欧洲心脏病学会发表的室上性心律失常治疗指南，并将国外发表的循证医学资料与我国成功的经验加以综合。本指南叙述了各类型室上性快速心律失常的主要机制、诊断要点、临床特征、急性发作时的处理、 预防复发的药物及非药物治疗、 可能的并发症及预后等。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('168', '37', 'X01_025', '1', '室上性快速心律失常治疗指南', '无', '中华医学会心血管病学分会；中国生物医学工程学会心脏起搏与电生理分会；中国心脏起搏与心电生理杂志编辑委员会；中华心血管病杂志编辑委员会', '2004', '蔡迺绳 ,曹克将 ,郭林妮 ,等.室上性快速心律失常治疗指南[J]. 中国心脏起搏与心电生理杂志,2005,19（1）:4-18.', '中文', null, '不适当的窦性快速心律失常', null, null, '1.临床表现不适当的窦速在医务人员较多见，而且近90%为女性，年龄38±12岁，可能与医务人员容易觉察自己的心率有关。心悸是主要症状，但胸痛、气短、头昏、眩晕以及接近晕厥等也有报道。不适的程度变化极大，患者可完全没有症状而仅在常规体检时发现；症状严重者需用药物，辅以心理治疗。临床体检和常规检查可以排除心动过速的继发性原因。<br />&nbsp;&nbsp;2.诊断①Holter监测白天心率>100次／分，而夜间心率正常；②心动过速和相关症状呈非阵发性；③P波形态与心内激动顺序和赛性心律时一致；④除外继发性原因（如甲亢、嗜铬细胞瘤、心衰、贫血、心肌炎等）。', null, null, null, '参考美国心脏病学院、 美国心脏学会及欧洲心脏病学会发表的室上性心律失常治疗指南，并将国外发表的循证医学资料与我国成功的经验加以综合。本指南叙述了各类型室上性快速心律失常的主要机制、诊断要点、临床特征、急性发作时的处理、 预防复发的药物及非药物治疗、 可能的并发症及预后等。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('169', '37', 'X01_026', '1', '室上性快速心律失常治疗指南', '无', '中华医学会心血管病学分会；中国生物医学工程学会心脏起搏与电生理分会；中国心脏起搏与心电生理杂志编辑委员会；中华心血管病杂志编辑委员会', '2004', '蔡迺绳 ,曹克将 ,郭林妮 ,等.室上性快速心律失常治疗指南[J]. 中国心脏起搏与心电生理杂志,2005,19（1）:4-19.', '中文', null, '窦房结折返性心动过速', null, null, '1.临床表现  在因室上速而行电生理检查的患者中，窦房结折返性心动过速的检出率为1.8%～16.9%；而在局灶性房速的患者中，窦房折返可高达27%。伴有器质性心脏病患者的窦房结折返性心动过速发病率较高。患者有心悸、头晕和接近晕厥。晕厥相当少见，因为心动过速的频率很少超过180次／分。阵发性发作是诊断的重要线索。<br />&nbsp;&nbsp;2.诊断  ①心动过速和相关症状呈阵发性；②P波形态和窦性P波相同；③心内心房激动顺序和窦性心律时相同；④房性早搏刺激可诱发和（或）终止心动过速；⑤刺激迷走神经成腺苷可终止发作；⑥心律失常的诱发与房内或房室结传导时间无关。', null, null, null, '参考美国心脏病学院、 美国心脏学会及欧洲心脏病学会发表的室上性心律失常治疗指南，并将国外发表的循证医学资料与我国成功的经验加以综合。本指南叙述了各类型室上性快速心律失常的主要机制、诊断要点、临床特征、急性发作时的处理、 预防复发的药物及非药物治疗、 可能的并发症及预后等。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('17', '32', 'G02_005_E', '1', '国际动脉粥样硬化学会立场报告：全球血脂异常诊治建议', 'An International Atherosclerosis Society Position Paper:Global Recommendations for the Management of Dyslipidemia', 'INTERNATIONAL ATHEROSCLEROSIS SOCIETY', '2013', 'http://www.athero.org/download/IASPPGuidelines_FullReport_20131011.pdf', '英文', null, 'Dyslipidemia', null, null, ' ', null, 'LDL Cholesterol;Non-HDL Cholesterol', '根据一项研究,在未经治疗的高危病人,最优目标为apo B<90mg/dl相当于一个LDL-C<100 mg/dl,非-HDL-C<130 mg/dl;接受他汀类药物治疗的最优目标：apoB<90 mg/dl,非HDL-C<100 mg/dl或LDL-C< 70mg/dl。<br />&nbsp;&nbsp; According to one study, in untreated, high risk patients, an apo B level of < 90 mg/dl is roughly equivalent to an LDL-C level < 100 mg/dl and a non-HDL-C level < 130 mg/dl; but during statin therapy, to consistently reach an apoB target of < 90 mg/dl it is necessary to reduce non-HDL-C to < 100 mg/dl or to reduce LDL-C to < 70 mg/dl.', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('170', '37', 'X01_027', '1', '室上性快速心律失常治疗指南', '无', '中华医学会心血管病学分会；中国生物医学工程学会心脏起搏与电生理分会；中国心脏起搏与心电生理杂志编辑委员会；中华心血管病杂志编辑委员会', '2004', '蔡迺绳 ,曹克将 ,郭林妮 ,等.室上性快速心律失常治疗指南[J]. 中国心脏起搏与心电生理杂志,2005,19（1）:4-20.', '中文', null, '阵发性室上速', null, null, 'AVNRT是临床上较常见的阵发性室上速，多发生于没有器质性心脏病的患者，女性多于男性，频率常常为140～250次／分。阵发性心悸、头晕和四肢乏力是常见的临床表现。<br />&nbsp;&nbsp;AVNRT的折返环位于房室交界区，由房室结自身和结周心房肌构成的功能相互独立的快径和慢径组成。前者位于Koch\'s三角的顶部而邻近His束，后者位于Koch\' s三角的底部，沿三尖瓣环隔侧缘分布，向后下延伸至房室结及邻近冠状静脉窦。典型的AVNRT以慢径前向传导、快径逆向传导，故称为慢-快型AVNRT;由于快径逆向传导至心房的时间较短（40ms），心电图上P波多位于QRS波中或紧随QRS波之后，而在V1导联上显示“伪r波”。约5%～10%的AVNRT其折返运行方向与上述类型相反，以快径前向传导，慢径逆向传导，亦称为快-慢型AVNRT或少见型AVNRT；慢径逆向传导时间较长，心电图上P波位于下一个QRS波之前，表现为长RP心动过速。少见情况下，AVNRT的折返环由两条传导速度较慢的径路组成，亦即慢一慢型AVNRT；心电图上P波位于QRS波之后，其RP间期>70 ms。', null, null, null, '参考美国心脏病学院、 美国心脏学会及欧洲心脏病学会发表的室上性心律失常治疗指南，并将国外发表的循证医学资料与我国成功的经验加以综合。本指南叙述了各类型室上性快速心律失常的主要机制、诊断要点、临床特征、急性发作时的处理、 预防复发的药物及非药物治疗、 可能的并发症及预后等。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('171', '37', 'X01_028', '1', '小儿过早搏动（期前收缩）的诊断治疗建议', '无', '中国生物医学工程学会心脏起搏与电生理分会儿科学组', '2001', '中国生物医学工程学会心脏起搏和电生理分会儿科学组.小儿过早搏动（期前收缩）的诊断治疗建议[J].中国实用儿科杂志，2001,16（5）：309-310.', '中文', null, '心房早搏复合征', null, null, '心电图1.期前出现的P被，形态与窦性不同；2.多数房早之P-R间期长于窦性P-R间期，QRS波形态正常；3.房早可未下传到心室，特征为异位P波过早发生，可重叠于T波上，其后无QRS波；4.房性早搏后多为不完全代偿间期。', null, null, null, '为儿科过早搏动的诊断治疗建议。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('172', '37', 'X01_029', '1', '小儿过早搏动（期前收缩）的诊断治疗建议', '无', '中国生物医学工程学会心脏起搏与电生理分会儿科学组', '2001', '中国生物医学工程学会心脏起搏和电生理分会儿科学组.小儿过早搏动（期前收缩）的诊断治疗建议[J].中国实用儿科杂志，2001,16（5）：309-311.', '中文', null, '交界性早搏', null, null, '心电图1.期前出现的P波可表现为：a.逆行P波出现在QRS波群之前，Ⅱ、Ⅲ、aVF导联P波倒置，aVR导联P波直立．P-R间期<0.10s；b.逆行P波出现在QRS波之后，其R-P间期<0.20s；c.QRS波群前后均无P波。2.交界性早搏后多伴有完全代偿间期。', null, null, null, '为儿科过早搏动的诊断治疗建议。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('173', '37', 'X01_030', '1', '小儿过早搏动（期前收缩）的诊断治疗建议', '无', '中国生物医学工程学会心脏起搏与电生理分会儿科学组', '2001', '中国生物医学工程学会心脏起搏和电生理分会儿科学组.小儿过早搏动（期前收缩）的诊断治疗建议[J].中国实用儿科杂志，2001,16（5）：309-312.', '中文', null, '室性早搏', null, null, '1.心电图表现  1.1期前出现的QRS渡群，期前无相关P波；1.2期前出现的QRS波群形态宽大错综，QRS波间期多>0.10s，QRS波主波方向与T波相反；1.3室早后多伴有完全代偿间期；1.4室早有时可为插入性、二联律、三联律，成对连发的室早或并行心律。<br />&nbsp;&nbsp;2.复杂性（ccmploc）室性旱搏指频发的室早(≥6/min)，多形性室早，成对室早，连续3个或以上的室早（室性心动过速）及R-on-T型室早。', null, null, null, '为儿科过早搏动的诊断治疗建议。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('174', '37', 'X01_031', '1', '心房颤动的命名和分类国际共识', 'International consensus on nomenclature and classiﬁcation of atrial ﬁbrillation', '欧洲心脏病学会（ESC,European Society of Cardiology）；心律协会（HRS,Heart Rhythm Society）', '2003', 'S. Le ´vy, A. J. Camm, S. Saksena,etc.International consensus on nomenclature and classiﬁcation of atrial ﬁbrillation.Europace ，2003，5, 119–122.', '英文', 'As stressed before, AF has a heterogeneous clinical presentation. It may occur in the presence or absence of detectable heart disease and in the presence or absence of related symptoms. An attack of AF may beself-terminating or require medical interventio畻坴畿\0\0\0\0醼畻聱盯	\0\0\0痭쫐ਘༀƙ\0ਘĀ\0	\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔⶠ௲ਘĀ\0௱彿㎽奋㎽巫㎽砌௲馜௲彿㎽馐௲塚㎽馜௲ꍈ㏂\0\0ⶠ௲學㎽漸㏂圔㎽ⶠ௲圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0㠰੟䐺盭暼痭㠰੟ༀƙ \0㠰੟ð\0\0㺣盭㠰੟\0ﱔ㠴੟\0팃目㠴੟࣐㠴੟큁目㠴੟ⷔ௲﫬\0Item\0\0騠௲\0\0\0\0\0\0Count\0\0ﱬﬄ㡤੟琴௩\0\0㠴੟\0\0\0\0௩寶目琸௩矵䥷㎽砌௲\0\0騠௲�㏂馐௲\0\0\0௩\0\0\0謁ﱔ\0\0㎾Ḍ\0ﱜ\0\0x�㏂馐௲\0\0隲W騠௲\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx	\0霪W露W\0\0ﱴxt\0Љ\0\0\0梘ƚ鲬࣐菮畻\0\0\0\0玈௩Eo\0\0珜௩\0\0훀੪훀੪珠௩Ⳕ௲寶目珠௩Ⳕ௲i\0\0ﱄ﷜ﱴﲔ먙㎼Ⳕ௲珠௩i\0\0ﱄ﷜ﱴ먰㎼﷜Ⳕ௲�㏂ⱄ௲\0\0릎㎼Ⳕ௲i\0╪췬目╾췬目Љ\0镴࣐\0￿￿目Љ\0镨࣐梘ƚ竗梘ƚ目W\0竗\0\0\0賓器目\0\0\0\0ⷔ௲\0目瑉浥目\0\0\0\0ⷔ௲\0目潃湵t\0\0\0\0ɜ\0\0ဠ\0\0侠̓ﯬ侠̓̙\0\0\0\0\0\0\0̙῰̓\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0῰̓\0\0\0\0̙ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚЉ\0\0\0⟒췬⟚췬目Љ\0鲸࣐\0￿￿目Љ\0鲬࣐梘ƚ觴梘ƚ目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨⳔ௲目潅f摲敳t盡燎捥盦通묞￾￿吊盡璀߾#ｘƥ돜ै璀綻眶E\0߾#\0\0ྻ搁.\0\0\0\0䛌E\0덐ɫ‾Q岛@\0䛌E\0덐ɫ‾Q岛@\0⎐ۓ﮵S豀ɳ\0덐ɫ\0﯏S臀ɳ\0豀ɳ\0䛌E\0템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂奈瞒⫠\0\0\0瞒⪌쀕瞒若〠\0䪔㏂\0T\0\0⪌쀕\0\0ꀀ翽翽凜瞒郎瘝䪔㏂\0邰ƙ\0\0ࠀᴒ眊\0\0䪔㏂瘝\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ﫜Ⳕ௲ﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀勤﬘眿捻ฒ騠௲﫨ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿﫜￿￿\0\0﫦\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ\0\0\0\0\0奰畿⫡췬臭焚畻邰ƙࠀ﫜￿￿㏂￿￿\0\0\0\0愈煔畻:\0﫜￿￿㏂￿￿奰畿\0\0\0\0﬘㎾ࠄ\0\0﫜￿￿㏂㎾x\0\0�㏂馐௲\0\0頲Wאּ\0\0\0\0ࠄ\0顇WValu\0\0﫜שּׁ騠௲ﱜ\0\0\0\0\0\0﫜\0﫨\0ﰰ餀Wﱜﲈ	\0ﳸ\0\0揜ৼ\0\r\0\0\0\0\0꣜भ\0\0ﮀ⮒췬ﮀ뜩@﷩\0\0\0\0ﮠ䗧@ﭸ蕶@提ৼﱰ﯌\0뮩@ﮰ믆@믎@ﱰ﷩\0釚@ﱰﱰ﷩\0ༀƙﱴༀƙ﯐戤痝\0Ɨ\0\0א੫ﯴ௱௱忉㎽飔௲奁㎽௱	\0飠௲馜௲彿㎽ﱤ䦕盭馜௲	\0馜௲忉㎽ﱔ䥷盭馜௲\0\0	\0ﱬ騠௲ﱴ馘Bﱜﳸxﲈﲈ駰Bﱴ癘৯๠হ\0௲\0\0ﱔ︜ﱜx︜x︄ﳸxﲔx︜ﲠx︜︸x︜\0\0癘৯뿄x\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0\0\0ⷔ௲䗆@	\0ⷔ௲騠௲\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0ʎCⷔ௲︜Cⷔ௲\0\0\0\0\0௲\0\0\0\0௲﷜￿\0\0\0\0\0\0￿\0\0\0\0\0Аহ\0\0	\0ﺄ\0\0ﺈ弐ɪ\0\0\0՜੫\0\0\0\0돜भﺐ嵿{ﹸ\0\0\0\0\0ﺄ﹄庱{ﺐﺘ彨{ﺐ\0\0\0\0ﺰ୩ྫྷ৅ﹼ邏S\0\0ㄐ঵\0\0쥈ɯ\0\0\0弐ɪ\0\0䁌ɬ\0\0ﻨⰛEﺤⰺEﻨﺰⱹEﻨﺼⳗEﻨﻰ⳶Eﻨ\0\0\0\0ᦀम\0\0\0\0秨৯ﺀ୩ﻰĒ８䳫Tｄ䴙T８\0\0\0\0츐ɳ\0\0\0\0\0Ā츐ɳｬ㻨T਌\0\0\0\0\0\0蹭Áɜ\0Ȫ\0ꋴĵ䈆Tｐ䈐Tｬｸ䉉Tｬ\0\0\0\0ꋴĵ츐ɳﾈ잜Ĳꀀ翽ￄ枴@ﾈ\0\0ﾔ眿ꀀ翽ￔ㭓瞖ꀀ翽ᮒ眊\0\0\0\0ꀀ翽\0\0\0\0\0\0ﾠ\0\0￿￿瞑\0\0￬㬦瞖얼Ĳꀀ翽\0\0\0\0\0\0\0\0얼Ĳꀀ翽\0\0譕召�䖋倌䶋謈ᢑ＀菒ӄ䶋༈醷ش\0숻Ѵ쀳⏫䖋倌䶋脈ⳁ儀喋謈ᒂ＀菐ࣄ�쀛삃嬁쉝쳌쳌쳌쳌쳌쳌삋鱠è\0堀%￰￿⑴倨탿삅ᕵ憝è\0堀%￰诿Ҁ＀㏠觀⑄鴠쉡쳌쳌쳌邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐譕臬⣬였웿옒웂온贀�觿��诿櫒栀Ȑ\0趍﷠￿橑謁ౕ譒ࡅ袋М\0퇿삅մ跩\0ༀ閷﷠￿䖋༈袷࠾\0턻ɴ盫喋脈㛂刀薋﷤￿譐ࡍ醋Д\0틿쒃蔈痀譓ࡅ褀��跿ﱍ橑贄��勿䖋謈⒈儀ｪ喋謈₂＀跐ﱍ橑贅譒ࡅ袋Ш\0橑诿ࡕ芋Р\0탿쉝쳌쳌쳌쳌쳌즋譐⑄茌￸⍵ｘ倒䒋ࠤ鱠è\0嬀￿卐￾鷿塡⣂堀ዿ⣂찀쳌쳌쳌쳌쳌邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐`劁眿邐邐邐邐邐邐犡瞕⍤瞓慌瞔靷睁盠屖瞔C:\\Program Files\\360\\360safe\\safemon\\safemon.dll\0邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐`\\KnownDlls\\user32.dll\0\\邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐*邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐', '心房颤动', null, null, null, null, null, null, '为心房纤颤的命名及分类国际共识。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('175', '37', 'X01_032', '1', '心房颤动管理临床指南( CG180)', 'NICE guidelines [CG180] Atrial fibrillation: the management of atrial fibrillation', '英国国家卫生与临床优化研究所（NICE,National Institute for Health and Clinical Excellence）', '2014', 'guidance.nice.org.uk/cg180', '英文', null, '心房颤动', null, null, '1.Perform manual pulse palpation to assess for the presence of an irregular pulse that may indicate underlying atrial fibrillation in people presenting with any of the following:<br />&nbsp;&nbsp;breathlessness/dyspnoea<br />&nbsp;&nbsp;palpitations<br />&nbsp;&nbsp;syncope/dizziness<br />&nbsp;&nbsp;chest discomfort<br />&nbsp;&nbsp;stroke/transient ischaemic attack. [2006]<br />&nbsp;&nbsp;2. Perform an electrocardiogram (ECG) in all people, whether symptomatic or not, in whom atrial fibrillation is suspected because an irregular pulse has been detected. [2006]<br />&nbsp;&nbsp;3. In people with suspected paroxysmal atrial fibrillation undetected by standard ECG recording:<br />&nbsp;&nbsp;use a 24-hour ambulatory ECG monitor in those with suspected asymptomatic episodes or symptomatic episodes less than 24 hours apart<br />&nbsp;&nbsp;use an event recorder ECG in those with symptomatic episodes more than 24 hours apart. [2006]<br />&nbsp;&nbsp;4. Perform transthoracic echocardiography (TTE) in people with atrial fibrillation:<br />&nbsp;&nbsp;for whom a baseline echocardiogram is important for long-term management<br />&nbsp;&nbsp;for whom a rhythm-control strategy that includes cardioversion (electrical or pharmacological) is being considered<br />&nbsp;&nbsp;in whom there is a high risk or a suspicion of underlying structural/functional heart disease (such as heart failure or heart murmur) that influences their subsequent management (for example, choice of antiarrhythmic drug)<br />&nbsp;&nbsp;in whom refinement of clinical risk stratification for antithrombotic therapy is needed (see section 1.4 Assessment of stroke and bleeding risks and section 1.5 Interventions to prevent stroke). [2006, amended 2014]<br />&nbsp;&nbsp;5. Do not routinely perform TTE solely for the purpose of further stroke risk stratification in people with atrial fibrillation for whom the need to initiate anticoagulation therapy has already been agreed on appropriate clinical criteria (see section 1.4 Assessment of stroke and bleeding risks and section 1.5 Interventions to prevent stroke). [2006, amended 2014]<br />&nbsp;&nbsp;6. Perform transoesophageal echocardiography (TOE) in people with atrialfibrillation:<br />&nbsp;&nbsp;when TTE demonstrates an abnormality (such as valvular heart disease) that warrants further specific assessment<br />&nbsp;&nbsp;in whom TTE is technically difficult and/or of questionable quality and where there is a need to exclude cardiac abnormalities<br />&nbsp;&nbsp;for whom TOE-guided cardioversion is being considered. [2006]', null, null, null, '《BMJ》杂志发表了NICE房颤管理指南2014版本，是对2006年指南的更新。NICE基于现有的最佳证据对指南进行了更新，提出了推荐意见，特别是对一些不确定和争议问题。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('176', '37', 'X01_033', '1', '2015美国心脏协会/美国心脏病学会/美国心律学会指南：成人室上性心动过速患者的管理（执行摘要）', '2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary', '美国心脏协会（AHA,American Heart Association）；美国心脏病学会（ACC,American College of Cardiology）；心律协会（HRS,Heart Rhythm Society）', '2015', 'Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭털੣ༀƙ\0੣°\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼', '英文', null, '室上性心动过速', null, null, 'Clinical Presentation and Differential Diagnosis on the Basis of Symptoms The diagnosis of SVT is often made in the emergency department, but it is common to elicit symptoms suggestive of SVT before initial electrocardiographic documentation. SVT symptom onset often begins in adulthood; in one study in adults, the mean age of symptom onset was 32 ± 18 years of age for AVNRT, versus 23 ± 14 years of age for AVRT. In contrast, in a study conducted in pediatric populations, the mean ages of symptom onset of AVRT and AVNRT were 8 and 11 years, respectively. In comparison with AVRT, patients with AVNRT are more likely to be female, with an age of onset >30 years. SVT has an impact on quality of life, which varies according to the frequency of episodes, the duration of SVT, and whether symptoms occur not only with exercise but also at rest. In 1 retrospective study in which the records of patients <21 years of age with WPW pattern on the ECG were reviewed, 64% of patients had symptoms at resentation, and an additional 20% developed symptoms during follow-up. Modes of presentation included documented SVT in 38%, palpitations in 22%, chest pain in 5%, syncope in 4%, AF in 0.4%, and sudden cardiac death (SCD) in 0.2% . A confounding factor in diagnosing SVT is the need to differentiate symptoms of SVT from symptoms of panic and anxiety disorders or any condition of heightened awareness of sinus chycardia (such as postural orthostatic tachycardia syndrome). When AVNRT and AVRT are compared, symptoms appear to differ substantially. Patients with AVNRT more frequently describe symptoms of “shirt flapping” or “neck pounding” that may be related to pulsatile reversed flow when the atria contract against a closed tricuspid valve (cannon a-waves).<br />&nbsp;&nbsp;True syncope is infrequent with SVT, but complaints of light-headedness are common. In patients with WPW syndrome, syncope should be taken seriously but is not necessarily associated with increased risk of SCD . The rate of AVRT is faster when AVRT is induced during exercise (26), yet the rate alone does not explain symptoms of near-syncope. Elderly patients with AVNRT are more prone to syncope or near-syncope than are younger patients, but the tachycardia rate is generally slower in the elderly.<br />&nbsp;&nbsp;In a study on the relationship of SVT with driving, 57% of patients with SVT experienced an episode while driving, and 24% of these considered it to be an obstacle to driving . This sentiment was most common in patients who had experienced syncope or near-syncope. Among patients who experienced SVT while driving, 77% felt fatigue, 50% had symptoms of near-syncope, and 14% experienced syncope. Women had more symptoms in each category.', null, null, null, '新版指南参考了近\n些年来众多临床试验、基础研究、新药开发以及诊\n疗手段等多个方面的进展，对各种类型室上性心动\n过速（SVT）的诊断，尤其是治疗方案的选择给出了最\n新的推荐意见，具有很强的临床指导价值。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('177', '37', 'X01_034', '1', '2015欧洲心脏病学会室性心律失常治疗与心脏性猝死预防指南', '2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death', '欧洲心脏病学会（ESC,European Society of Cardiology）', '2015', 'http://guide.medlive.cn/guideline/9324', '英文', null, '长QT综合征', null, null, 'X01_034图1', null, null, null, '是对2006年美国心脏病学会（ACC）/美国心脏协会（AHA）/ESC《室性心律失常处理与心脏性猝死预防指南》的再版更新。风险评估策略和治疗在出现并发症、寿命限制和影响生活质量及其他条件下应考虑做出适当调整。涉及高危人群以及不同的器械治疗以预防心血管事件的相关推荐。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('178', '37', 'X01_035', '1', '2015欧洲心脏病学会室性心律失常治疗与心脏性猝死预防指南', '2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death', '欧洲心脏病学会（ESC,European Society of Cardiology）', '2015', 'http://guide.medlive.cn/guideline/9324', '英文', null, '短QT综合征', null, null, 'X01_035图1', null, null, null, '是对2006年美国心脏病学会（ACC）/美国心脏协会（AHA）/ESC《室性心律失常处理与心脏性猝死预防指南》的再版更新。风险评估策略和治疗在出现并发症、寿命限制和影响生活质量及其他条件下应考虑做出适当调整。涉及高危人群以及不同的器械治疗以预防心血管事件的相关推荐。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('179', '37', 'X01_036', '1', '2015欧洲心脏病学会室性心律失常治疗与心脏性猝死预防指南', '2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death', '欧洲心脏病学会（ESC,European Society of Cardiology）', '2015', 'http://guide.medlive.cn/guideline/9324', '英文', null, 'Brugada综合征', null, null, 'X01_036图1', null, null, null, '是对2006年美国心脏病学会（ACC）/美国心脏协会（AHA）/ESC《室性心律失常处理与心脏性猝死预防指南》的再版更新。风险评估策略和治疗在出现并发症、寿命限制和影响生活质量及其他条件下应考虑做出适当调整。涉及高危人群以及不同的器械治疗以预防心血管事件的相关推荐。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('18', '32', 'G02_005_C', '1', '国际动脉粥样硬化学会立场报告：全球血脂异常诊治建议（中文翻译）', 'An International Atherosclerosis Society Position Paper:Global Recommendations for the Management of Dyslipidemia（Chinese translation）', '国际动脉粥样硬化学会', '2013', 'http://www.athero.org/download/IASPPChinese_20131014.pdf', '中文', null, '高胆固醇血症;血脂异常', null, null, ' ', null, 'LDL-C;非HDL-C', '一级预防<br />&nbsp;&nbsp;导致动脉粥样硬化性胆固醇的优化水平：LDL-C<100 mg/dL(2.6 mmol/L)，非HDL-C<130 mg/dL (3.4 mmol/L)。上述数值更适于高风险人群，低风险人群应能够耐受较高的LDL-C或非HDL-C水平而不会面临太大风险。<br />&nbsp;&nbsp;二级预防<br />&nbsp;&nbsp;确诊ASCVD患者LDL-C的优化水平为<70 mg/dL(1.8 mmol/L)(或非HDL-C<100 mg/dL[2.6 mmol/L])。', '••本立场报告中的主要创新如下：<br />&nbsp;&nbsp;\n••以多类型研究证据为基础的国际共识性指南。<br />&nbsp;&nbsp;\n••提出非高密度脂蛋白胆固醇(非HDL-C)为致动脉粥样硬化性胆固醇的主要形式。<br />&nbsp;&nbsp;\n••提出致动脉粥样硬化性胆固醇为低密度脂蛋白胆固醇(LDL-C)或非HDL-C。<br />&nbsp;&nbsp;\n••提出一级和二级预防中致动脉粥样硬化性胆固醇(包括LDL-C和非HDL-C)的优化水平。<br />&nbsp;&nbsp;\n••指出长期风险分级优于短期风险分级。<br />&nbsp;&nbsp;\n••根据不同国家或地区人群的基线风险调整风险评估。<br />&nbsp;&nbsp;\n••生活方式干预为首要措施，其次为药物治疗。<br />&nbsp;&nbsp;\n ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('180', '37', 'X01_037', '1', '2015欧洲心脏病学会室性心律失常治疗与心脏性猝死预防指南', '2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death', '欧洲心脏病学会（ESC,European Society of Cardiology）', '2015', 'http://guide.medlive.cn/guideline/9324', '英文', null, '儿茶酚胺敏感性室性心动过速', null, null, 'X01_037图1', null, null, null, '是对2006年美国心脏病学会（ACC）/美国心脏协会（AHA）/ESC《室性心律失常处理与心脏性猝死预防指南》的再版更新。风险评估策略和治疗在出现并发症、寿命限制和影响生活质量及其他条件下应考虑做出适当调整。涉及高危人群以及不同的器械治疗以预防心血管事件的相关推荐。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('181', '37', 'X01_038', '1', '2013法国老年学及老年病学学会/法国心血管学会老年房颤患者管理专家共识', 'Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial ﬁbrillation in elderly people', '法国老年学及老年病学学会（FSGG,French Society of Gerontology and Geriatrics）；法国心血管学会（FSC,French Society of Cardiology）', '2013', 'Arch Cardiovasc Dis. 2013 May;106(5):303-23.', '英文', null, '心房颤动', null, null, '1.Clinical presentations<br />&nbsp;&nbsp;In the elderly, AF is often asymptomatic and an incidental ﬁnding. Palpitations are less frequent in elderly patients compared with younger adults. When present,AF symptoms are diverse: dyspnoea, palpitations,thoracic pain, faintnesses, falls, syncope, asthenia, anxiety,etc. <br />&nbsp;&nbsp;AF can also be discovered when a complication, such as an embolic accident or heart failure, occurs.<br />&nbsp;&nbsp;AF in the elderly is often of acute onset during the course of stress secondary to an infectious episode (particularly bronchopneumonia), a surgical procedure and cardiac or respiratory decompensation. The occurrence of AF in the elderly indicates a high probability of an underlying cardiovascular disease and a higher risk of AF recurrence compared with that in younger people.<br />&nbsp;&nbsp;2. Clinical assessment<br />&nbsp;&nbsp;The aim of the clinical assessment is to deﬁne the type of AF (paroxysmal, persistent or permanent), to specify the illness history and to evaluate symptoms, trigger factors,cardiovascular diseases, complications, co-morbidities and current therapeutics.<br />&nbsp;&nbsp;2.1History of atrial ﬁbrillation<br />&nbsp;&nbsp;The  history  of  AF  in  elderly  patients  is  often  difﬁcult  to  reconstitute;  questioning  the  patient’s  family circle  and/or  general  practitioner  may  be  necessary.  A trigger  factor  must  be  systematically  sought:  infectious episode,  cardiac  or  respiratory  decompensation,  myocardial ischaemia, electrolyte  disorders  (hypokalaemia), hyperthyroidism,  iatrogenic  factors,  diuretics,  theophylline,salbutamol, etc.<br />&nbsp;&nbsp;2.2Ventricular  rate<br />&nbsp;&nbsp;Searching  for  pulse  irregularity  should  be  done  systematically.  Pulse  palpation  has  a  high  sensitivity  but  low  speciﬁcity for  AF  [54,58].  The  diagnosis  of  AF  must  be  conﬁrmed  by an  ECG.  A  very  rapid  ventricular  rate  suggests  an  associated extracardiac  factor,  especially  in  case  of  well-tolerated  permanent  AF.  Bradyarrhythmia  may  be  due  to  an  iatrogenic effect  (antiarrhythmic  drugs,  digitalis,  calcium  channel antagonists,  inhibitors  of  cholinesterase,  beta-blockers)  or an  associated  conduction  disorder. <br />&nbsp;&nbsp;2.3Comprehensive  assessment  of  the  elderly  subject with atrial  ﬁbrillation<br />&nbsp;&nbsp;It  is  necessary  to  look  for  co-morbidities  and  complications of AF,  evaluate  the  thromboembolic  and  haemorrhagic  risks and  carry  out  a  CGA.<br />&nbsp;&nbsp;3.Diagnostic  tests<br />&nbsp;&nbsp;3.1Twelve-lead  ECG<br />&nbsp;&nbsp;A  12-lead  ECG  is  indispensable  to  conﬁrm  the  diagnosis (Table  2).  When  paroxysmal  AF  is  suspected,  repeated  ECG monitoring  or  long-term  recordings  should  be  considered. When  AF  is  associated  with  a  slow  ventricular  rate,  an  atrioventricular  block  should  be  suspected.<br />&nbsp;&nbsp;3.2Chest X-ray<br />&nbsp;&nbsp;A  chest  X-ray  allows  heart  size  measurement  and  analysis  of the  pulmonary  parenchyma  (interstitial  oedema,  pneumonia,  pulmonary  sequelae);  it  helps  detection  of  interstitial pneumonia  due  to  long-term  amiodarone  therapy. Ambulatory  long-term  ECG  recordings Ambulatory  long-term  ECG  recordings  can  be  useful  to  conﬁrm  paroxysmal  AF  or  in  case  of  symptoms  that  can  be related  to  a  slow  ventricular  rate  (syncope,  faintness)  or a  very  rapid  ventricular  rate  despite  treatment.<br />&nbsp;&nbsp;3.3Ambulatory  long-term  ECG  recordings<br />&nbsp;&nbsp;Ambulatory  long-term  ECG  recordings  can  be  useful  to  conﬁrm  paroxysmal  AF  or  in  case  of  symptoms  that  can  be related  to  a  slow  ventricular  rate  (syncope,  faintness)  or a  very  rapid  ventricular  rate  despite  treatment.<br />&nbsp;&nbsp;3.4Transthoracic  echocardiography<br />&nbsp;&nbsp;Transthoracic  echocardiography  is  recommended  in  all  AF patients;  it  is  used  to  detect  ventricular,  valvular  and  atrial disease.  The  presence  or  absence  of  an  underlying  cardiomyopathy  is  important  for  the  choice  of  antiarrhythmic  and antithrombotic  drugs.<br />&nbsp;&nbsp;3.5Transoesophageal  echocardiography<br />&nbsp;&nbsp;Transoesophageal  echocardiography  is  the  only  examination that enables the analysis of intra-atrial thrombosis; it is, however,  rarely  carried  out  in  the  elderly.  The  two  main  indications  are:  reversion  to  sinus  rhythm  without  prior  effective anticoagulation  (for  at  least  3  weeks);  and  a  search  for  the underlying cause  in  case  of  recurrent  stroke  or  transient ischaemic  attack  of  unknown  aetiology.<br />&nbsp;&nbsp;3.6Blood  tests<br />&nbsp;&nbsp;A systematic  work-up  must  be  carried  out:  complete  blood count,  international  normalized  ratio  (INR)  for  patients  on a  vitamin  K  antagonist,  partial  thromboplastin  time,  serum electrolytes,  creatinine  (with  its  clearance  calculated  by the  Cockcroft  formula),  glycaemia  and  thyroid-stimulating hormone.  According  to  the  clinical  picture,  the  following tests  can  be  added:  troponin  assay,  C-reactive  protein,  liver function  tests,  serum  albumin  and  urine  test  strip  ±  urine culture.  This  work-up  is  necessary  for  the  detection  of  trigger factors  and  for  therapeutic  management.<br />&nbsp;&nbsp;', null, null, null, '2013年3月，法国老年学及老年病学学会(FSGG)联合法国心血管学会(FSC)共同发布的老年房颤患者管理的专家共识。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('182', '37', 'X01_039', '1', '欧洲心律学会/心律协会/亚太心律学会室性心律失常专家共识', 'EHRA/HRS/APHRS expert consensus on ventricular arrhythmias', '欧洲心律学会（EHRA,European Heart Rhythm Association）；心律协会（HRS,Heart Rhythm Society）；亚太心律学会（APHRS,Asia Pacific Heart Rhythm Society）', '2014', 'Europace (2014) 16, 1257–1283.', '英文', null, '持续性单形性室性心动过速', null, null, 'X01_039表', null, null, null, '该共识阐述了各种室性心律失常进行诊断性检查的指征、危险分层的现状和已被证明有效的治疗策略，推荐转诊病人至专业的心律失常诊疗中心，同时也建议读者在需要时参考其他心律失常诊疗的相关文献，如埋藏式复律除颤器（ICD）植入、导管消融、遗传性心律失常综合征、先天性心脏病、胺碘酮的使用、如何处理ICD放电患者、晕厥和临终患者的诊疗。该共识采用I 、II a 、II b、III 推荐等级和相应表达术语。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('183', '37', 'X01_040', '1', '2005新西兰指南组织：房颤和房扑的患者管理', '2005 NZGG The Management of Atrial Fibrillation and Flutter', '新西兰指南组织（NZGG,New Zealand Guidelines Group）', '2005', 'http://guide.medlive.cn/guideline/1214', '英文', null, '心房颤动；心房扑动', null, null, 'X01_040图1\n1.CLINICAL HISTORY AND PHYSICAL EXAMINATION\nClinical history and physical examination are very important to:\n•  deﬁne the nature of any symptoms \n•  categorise the type of AF–ﬁrst episode, paroxysmal, persistent, permanent \n•  establish the likely duration, frequency, precipitating factors and modes of termination of AF\n•  assess blood pressure and assess for the presence of underlying heart disease, alcohol consumption or other important comorbidities\n•  provide  information  regarding  the appropriateness of antiarrhythmic agents, and any response to previous therapy, if applicable.\nAssessment of heart-rate control is necessary for those in whom a rate-control strategy has been chosen.\n2.OTHER INVESTIGATIONS\nAn ECG conﬁ rming AF, whether from a single-lead rhythm strip, 12-lead ECG or other monitor (Holter monitor, event recorder) is critical for the documentation and diagnosis of AF (see Figure 4.1). In sinus rhythm, it may give information on P-wave morphology, and evidence of left ventricular hypertrophy (LVH), pre-excitation, previous myocardial infarction, bundle branch block or sinus node dysfunction, all of which are potentially  important. Assessment of heart rate, QRS duration and QT interval are also important, both prior to starting antiarrhythmic drug therapy and for monitoring its effect.\nAssessment of heart-rate control may sometimes require formal testing with either exercise testing or 24-hour Holter monitoring. Exercise testing may also be used to assess for the presence of underlying  ischaemic heart disease  (important when considering  the use of ﬂ ecainide or propafenone) or to reproduce exercise-induced AF. Simply taking the person with AF/AFL for a walk and assessing heart rate immediately afterwards, is often a viable alternative to exercise testing or 24-hour Holter monitoring.\nA chest x-ray may be required if clinical assessment suggests pulmonary disease. \nBlood tests should include thyroid function testing with TSH when AF presents for the ﬁrst time. Renal and sometimes liver function may be important prior to any decision regarding antiarrhythmic therapy and anticoagulation.\nAn electrophysiological study is rarely required, except when an accessory pathway  is apparent or suspected, or where ablation is being considered, (either atrioventricular (AV) node ablation, ﬂutter ablation or pulmonary vein isolation procedure).X01_040图2\n3. TRANSTHORACIC ECHOCARDIOGRAPHY\nTTE has a central role in the assessment of people with AF/AFL, the main reason being that AF  is often a marker of underlying structural heart disease, which requires further evaluation. There are other important practical reasons. Information on left ventricular (LV) function, and possible valve disease or LV hypertrophy (LVH), may impact on assessment of  thromboembolic  risk.  Intracardiac  thrombus or  spontaneous echo contrast may be present. Left atrial size  is also  important, especially when considering a  rhythm-control strategy. Assessment of LV function is important to assess the risk of proarrhythmia when antiarrhythmic  therapy  is being considered. The  timing of TTE will vary depending on individual circumstances. TTE may be less crucial in people for whom a strategy of rate control and anticoagulation has already been decided and when information on underlying structural heart disease is not needed or wanted.', null, null, null, '基于来自流行病学研究和其他研究的证据，建议通过系统的共识过程，指导开发团队的经验。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('184', '37', 'X01_041', '1', '美国心脏协会/美国心脏病学会/欧洲心脏病学会2006房颤患者管理指南', 'ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text', '美国心脏协会（AHA,American Heart Association）；美国心脏病学会（ACC,American College of Cardiology）；欧洲心脏病学会（ESC,European Society of Cardiology）', '2006', 'Europace (2006) 8, 651–745', '英文', null, '心房颤动', null, null, '1.Basic evaluation of the patient with atrial ﬁbrillation<br />&nbsp;&nbsp;1.1 Clinical history and physical examination<br />&nbsp;&nbsp;The diagnosis of AF is based on history and clinical examination and conﬁrmed by ECG recording, sometimes in the form of bedside telemetry or ambulatory Holter recordings. The initial evaluation of a patient with suspected or proved AF involves characterizing the pattern of the arrhythmia as paroxysmal or persistent, determining its cause, and deﬁning associated cardiac and extracardiac factors pertinent to the etiology, tolerability, and history of prior management (Table 6). A thorough history will result in a wellplanned, focused workup that serves as an effective guideto therapy. The workup of a patient with AF can usually take place and therapy initiated in a single outpatient encounter. Delay occurs when the rhythm has not been speciﬁcally documented and additional monitoring is necessary.<br />&nbsp;&nbsp;Typically, AF occurs in patients with underlying heart disease, such as hypertensive heart disease. (See Section 6, Causes, Associated Conditions, Clinical anifestations, and Quality of Life.) Atherosclerotic or valvular heart diseases are also common substrates, whereas pulmonary pathology, preexcitation syndromes, and thyroid disease are less frequent causes.Because of reports of genetic transmission of AF, the family history is important as well. Although various environmental triggers can initiate episodes of AF, this aspect may not emerge from the history given spontaneously by the patient and often requires speciﬁc inquiry. Commonly mentioned triggers include alcohol, sleep deprivation, and emotional stress, but vagally mediated AF may occur during sleep or after a large meal and is more likely to arise during a period of rest succeeded by a period of stress. Stimulants such as caffeine or exercise may also precipitate AF.<br />&nbsp;&nbsp;The physical examination may suggest AF on the basis of irregular pulse, irregular jugular venous pulsations, and variation in the intensity of the ﬁrst heart sound or absence of a fourth sound heard previously during sinus rhythm. Examination may also disclose associated valvular heart disease, myocardial abnormalities, or HF. The ﬁndings are similar in patients with atrial ﬂutter, except that the rhythm may be regular and rapid venous oscillations may occasionally be visible in the jugular pulse. X01_041表1<br />&nbsp;&nbsp;1.2. Investigations<br />&nbsp;&nbsp;The diagnosis of AF requires ECG documentation by at least a single-lead recording during the arrhythmia, which may be facilitated by review of emergency department records, Holter monitoring, or transtelephonic or telemetric recordings. A portable ECG recording tool may help establish the diagnosis in cases of paroxysmal AF and provide a permanent ECG record of the arrhythmia. In patients with implanted pacemakers or deﬁbrillators, the diagnostic and memory functions may allow accurate and automatic detection of AF. A chest radiograph may detect enlargement of thecardiac chambers and HF but is valuable mostly to detect intrinsic pulmonary pathology and evaluate the pulmonary vasculature. It is less important than echocardiography for routine evaluation of patients with AF. As part of the initial evaluation, all patients with AF should have 2-dimensional, Doppler echocardiography to assess LA and LV dimensions and LV wall thickness and function and to exclude occult valvular or pericardial disease and HCM. LV systolic and diastolic performance helps guide decisions regarding antiarrhythmic and antithrombotic therapy. Thrombus should be sought in the LA but is seldom detected without TEE.<br />&nbsp;&nbsp;Blood tests are routine but can be abbreviated. It is important that thyroid, renal, and hepatic function, serum electrolytes, and the hemogram be measured at least once in the course of evaluating a patient with AF.<br />&nbsp;&nbsp;2. Additional investigation of selected patients with atrial ﬁbrillation<br />&nbsp;&nbsp;Abnormalities in P-wave duration detected by signal averaged ECG during sinus rhythm that reﬂect slow intra-atrial conduction are associated with an increased risk of developing AF. The sensitivity and negative predictive value of signal-averaged P-wave ECG are high, but speciﬁcity and positive predictive value are low, limiting the usefulness of this technique.Measurement of HRV has failed to provide useful information for risk stratiﬁcation.<br />&nbsp;&nbsp;Both B-type natriuretic peptide (assessed by measuring BNP or N-terminal pro-BNP), which is produced mainly in the ventricles, and atrial naturetic peptide (ANP), which is produced primarily in the atria, are associated with AF. Plasma levels of both peptides are elevated in patients with paroxysmal and persistent AF and decrease rapidly after restoration of sinus rhythm. Thus, the presence of AF should be considered when interpreting plasma levels of these peptides. In the absence of HF, there is an inverse correlation between LA volume and ANP/BNP levels; spontaneous conversion to sinus rhythm is associated with higher ANP levels during AF and with smaller LA volumes.In long-standing persistent AF, lower plasma ANP levels may be related to degeneration of atrial myocytes. High levels of BNP may be predictive of thromboembolism and recurrent AF,but further studies are needed to evaluate the utility of BNP as a prognostic marker.<br />&nbsp;&nbsp;2.1. Electrocardiogram monitoring and exercise testing<br />&nbsp;&nbsp;Prolonged or frequent monitoring may be necessary to reveal episodes of asymptomatic AF, which may be a cause of cryptogenic stroke. Ambulatory ECG (e.g., Holter) monitoring is also useful to judge the adequacy of rate control. This technology may provide valuable information to guide drug dosage for rate control or rhythm management.<br />&nbsp;&nbsp;Exercise testing should be performed if myocardial ischemia is suspected and prior to initiating type IC antiarrhythmic drug therapy. Another reason for exercise testing is to study the adequacy of rate control across a full spectrum of activity, not only at rest, in patients with persistent or permanent AF.<br />&nbsp;&nbsp;2.2. Transesophageal echocardiography<br />&nbsp;&nbsp;TEE is not part of the standard initial investigation of patients with AF. By placing a high-frequency ultrasound transducer close to the heart, however, TEE provides high quality images of cardiac structure and function.It is the most sensitive and speciﬁc technique to detect sources and potential mechanisms for cardiogenic embolism. The technology has been used to stratify stroke risk in patients with AF and to guide cardioversion. (See Section 8.1.4, Preventing Thromboembolism.) Several TEE features have been associated with thromboembolism in patients with nonvalvular AF, including LA/LAA thrombus, LA/LAA SEC, reduced LAA ﬂow velocity, and aortic atheromatous abnormalities. Although these features are associated with cardiogenic embolism, prospective investigations are needed to compare these TEE ﬁndings with clinical and transthoracic echocardiographic predictors of thromboembolism. Detection of LA/LAA thrombus in the setting of stroke or systemic embolism is convincing evidence of a cardiogenic mechanism.<br />&nbsp;&nbsp;TEE of patients with AF before cardioversion has shown LA or LAA thrombus in 5% to 15%, but thromboembolism after conversion to sinus rhythm has been reported even when TEE did not show thrombus.These events typically occur relatively soon after cardioversion in patients who were not treated with anticoagulation, reinforcing the need to maintain continuous therapeutic anticoagulation in patients with AF undergoing cardioversion even when no thrombus is identiﬁed. For patients with AF of greater than 48-h duration, a TEE-guided strategy or the traditional strategy of anticoagulation for 4 wk before and 4 wk after elective cardioversion resulted in similar rates of thromboembolism (less than 1% during the 8 wk). Contrast-enhanced magnetic resonance imaging is an emerging technique for detection of intracardiac thrombi that appears more sensitive than precordial echocardiography and comparable to TEE.<br />&nbsp;&nbsp;2.3. Electrophysiological study<br />&nbsp;&nbsp;An EP study can be helpful when AF is a consequence of reentrant tachycardia such as atrial ﬂutter, intra-atrial reentry, or AV reentry involving an accessory pathway. Detection of a delta wave on the surface ECG in a patient with a history of AF or syncope is a ﬁrm indication for EP study and ablation of the bypass tract. Some patients with documented atrial ﬂutter also have AF, and ablation of ﬂutter can eliminate AF, although this is not common and successful ablation of ﬂutter does not eliminate the possibility of developing AF in the future. AF associated with rapid ventricular rates and wide-complex QRS morphology may sometimes be mislabeled as ventricular tachycardia, and an EP study will differentiate the 2 arrhythmias. In short, EP testing is indicated when ablative therapy of arrhythmias that trigger AF or ablation of AF is planned. In patients with AF who are candidates for ablation, an EP study is critical to deﬁne the targeted site or sites of ablation in the LA and/or right-sided structures. Evolving strategies in the ablation of AF are discussed in Section 8.0.', null, null, null, '2006年美国心脏病学会（ACC）/美国心脏协会（AHA）/欧洲心脏病学会（ESC）房颤指南强调了房颤的分型不具有排他性。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('185', '37', 'X01_042', '1', '2010欧洲心脏病学会房颤管理指南', '2010 Guidelines for the management of atrial fibrillation', '欧洲心脏病学会（ESC,European Society of Cardiology）', '2010', 'http://eurheartj.oxfordjournals.org/content/31/19/2369.long', '英文', null, '心房颤动', null, null, 'X01_042图', null, null, null, '该指南是欧洲心脏病学会单独发布的指南，之前他们均与ＡＨＡ／ＡＣＣ 联合发布指南，今后世界上只有一个指南的格局将发生改变。新版指南与２００６ 年ＡＨＡ／ＡＣＣ／ＥＳＣ 联合公布的房颤指南（以下简称２００６ 版指南）相比，流行病学、抗凝、心室率控制等方面发生了很大变化。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('186', '37', 'X01_043', '1', '2011美国心脏病学会基金会/美国心脏协会/心律协会心房颤动治疗指南(更新2006版指南）', '2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines', '美国心脏协会（AHA,American Heart Association）；心律协会（HRS,Heart Rhythm Society）；美国心脏病学会基金会（ACCF,American College of Cardiology Foundation）', '2011', 'http://guide.medlive.cn/guideline/814', '英文', null, '心房颤动', null, null, '1. Basic Evaluation of the Patient With Atrial Fibrillation<br />&nbsp;&nbsp;1.1. Clinical History and Physical Examination<br />&nbsp;&nbsp;The diagnosis of AF is based on history and clinical examination and conﬁrmed by ECG recording, sometimes in the form of bedside telemetry or ambulatory Holter recordings. The initial evaluation of a patient with suspected or proved AF involves characterizing the pattern of the arrhythmia as paroxysmal or persistent, determining its cause, and deﬁning associated cardiac and extracardiac factors pertinent to the etiology, tolerability, and history of prior management (Table6). A thorough history will result in a well-planned, focused workup that serves as an effective guide to therapy. The workup of a patient with AF can usually take place and therapy initiated in a single outpatient encounter. Delay occurs when the rhythm has not been speciﬁcally documented and additional monitoring is necessary.X01_043表1<br />&nbsp;&nbsp;Typically, AF occurs in patients with underlying heart disease, such as hypertensive heart disease . (See Section 6, Causes, Associated Conditions, Clinical Manifestations, and Quality of Life.) Atherosclerotic or valvular heart diseases are also common substrates, whereas pulmonary pathology, preexcitation syndromes, and thyroid disease are less frequent causes. Because of reports of genetic transmission of AF, the family history is important as well . Although various environmental triggers can initiate episodes of AF, this aspect may not emerge from the history given spontaneously by the patient and often requires speciﬁc inquiry. Commonly mentioned triggers include alcohol, sleep deprivation, and emotional stress, but vagally mediated AF may occur during sleep or after a large meal and is more likely to arise during a period of rest succeeded by a period of stress. Stimulants such as caffeine or exercise may also precipitate AF.<br />&nbsp;&nbsp;The physical examination may suggest AF on the basis of irregular pulse, irregular jugular venous pulsations, and variation in the intensity of the ﬁrst heart sound or absence of a fourth sound heard previously during sinus rhythm. Examination may also disclose associated valvular heart disease, myocardial abnormalities, or HF. The ﬁndings are similar in patients with atrial ﬂutter, except that the rhythm may be regular and rapid venous oscillations may occasionally be visible in the jugular pulse.<br />&nbsp;&nbsp;1.2. Investigations<br />&nbsp;&nbsp;The diagnosis of AF requires ECG documentation by at least a single-lead recording during the arrhythmia, which may be facilitated by review of emergency department records, Holter monitoring, or transtelephonic or telemetric recordings. A portable ECG recording tool may help establish the diagnosis in cases of paroxysmal AF and provide a permanent ECG record of the arrhythmia. In patients with implanted pacemakers or deﬁbrillators, the diagnostic and memory functions may allow accurate and automatic detection of AF . A chest radiograph may detect enlargement of the cardiac chambers and HF but is valuable mostly to detect intrinsic pulmonary pathology and evaluate the pulmonary vasculature. It is less important than echocardiography for routine evaluation of patients with AF. As part of the initial evaluation, all patients with AF should have 2-dimensional, Doppler echocardiography to assess LA and LV dimensions and LV wall thickness and function and to exclude occult valvular or pericardial disease and HCM. LV systolic and diastolic performance helps guide decisions regarding antiarrhythmic and antithrombotic therapy. Thrombus should be sought in the LA but is seldom detected without TEE.<br />&nbsp;&nbsp;Blood tests are routine but can be abbreviated. It is important that thyroid, renal, and hepatic function, serum electrolytes, and the hemogram be measured at least once in the course of evaluating a patient with AF.<br />&nbsp;&nbsp;2. Additional Investigation of Selected Patients With Atrial Fibrillation<br />&nbsp;&nbsp;Abnormalities in P-wave duration detected by signal-averaged ECG during sinus rhythm that reﬂect slow intra-atrial conduction are associated with an increased risk of developing AF. The sensitivity and negative predictive value of signal-averaged P-wave ECG are high, but speciﬁcity and positive predictive value are low, limiting the usefulness of this technique. Measurement of HRV has failed to provide useful information for risk stratiﬁcation.<br />&nbsp;&nbsp;Both B-type natriuretic peptide (assessed by measuring BNP or N-terminal pro-BNP), which is produced mainly in the ventricles, and atrial naturetic peptide (ANP), which is produced primarily in the atria, are associated with AF. Plasma levels of both peptides are elevated in patients with paroxysmal and persistent AF and decrease rapidly after restoration of sinus rhythm. Thus, the presence of AF should be considered when interpreting plasma levels of these peptides. In the absence of HF, there is an inverse correlation between LA volume and ANP/BNP levels; spontaneous conversion to sinus rhythm is associated with higher ANP levels during AF and with smaller LA volumes . In long-standing persistent AF, lower plasma ANP levels may be related to degeneration of atrial myocytes . High levels of BNP may be predictive of thromboembolism  and recurrent AF, but further studies are needed to evaluate the utility of BNP as a prognostic marker.<br />&nbsp;&nbsp;2.1. Electrocardiogram Monitoring and Exercise Testing<br />&nbsp;&nbsp;Prolonged or frequent monitoring may be necessary to reveal episodes of asymptomatic AF, which may be a cause of cryptogenic stroke. Ambulatory ECG (e.g., Holter) monitoring is also useful to judge the adequacy of rate control. This technology may provide valuable information to guide drug dosage for rate control or rhythm management.<br />&nbsp;&nbsp;Exercise testing should be performed if myocardial ischemia is suspected and prior to initiating type IC antiarrhythmic drug therapy. Another reason for exercise testing is to study the adequacy of rate control across a full spectrum of activity, not only at rest, in patients with persistent or permanent AF.<br />&nbsp;&nbsp;2.2. Transesophageal Echocardiography<br />&nbsp;&nbsp;TEE is not part of the standard initial investigation of patients with AF. By placing a high-frequency ultrasound transducer close to the heart, however, TEE provides high-quality images of cardiac structure  and function . It is the most sensitive and speciﬁc technique to detect sources and potential mechanisms for cardiogenic embolism . The technology has been used to stratify stroke risk in patients with AF and to guide cardioversion. (See Section 8.1.4, Preventing Thromboembolism.) Several TEE features have been associated with thromboembolism in patients with nonvalvular AF, including LA/LAA thrombus, LA/LAA SEC, reduced LAA ﬂow velocity, and aortic atheromatous abnormalities (252). Although these features are associated with cardiogenic embolism, prospective investigations are needed to compare these TEE ﬁndings with clinical and transthoracic echocardiographic predictors of thromboembolism. Detection of LA/LAA thrombus in the setting of stroke or systemic embolism is convincing evidence of a cardiogenic mechanism.<br />&nbsp;&nbsp;TEE of patients with AF before cardioversion has shownLA or LAA thrombus in 5% to 15% , but thromboembolism after conversion to sinus rhythm has been reported even when TEE did not show thrombus . These events typically occur relatively soon after cardioversion in patients who were not treated with anticoagulation, reinforcing the need to maintain continuous therapeutic anticoagultion in patients with AF undergoing cardioversion even when no thrombus is identiﬁed. For patients with AF of greater than 48-h duration, a TEE-guided strategy or the traditional strategy of anticoagulation for 4 wk before and 4 wk after elective cardioversion resulted in similar rates of thromboembolism (less than 1% during the 8 wk). Contrast enhanced magnetic resonance imaging is an emerging technique for detection of intracardiac thrombi that appears more sensitive than precordial echocardiography and comparable to TEE.<br />&nbsp;&nbsp;2.3. Electrophysiological Study<br />&nbsp;&nbsp;An EP study can be helpful when AF is a consequence of reentrant tachycardia such as atrial ﬂutter, intra-atrial reentry, or AV reentry involving an accessory pathway. Detection of a delta wave on the surface ECG in a patient with a history of AF or syncope is a ﬁrm indication for EP study and ablation of the bypass tract. Some patients with documented atrial ﬂutter also have AF, and ablation of ﬂutter can eliminate AF, although this is not common and successful ablation of ﬂutter does not eliminate the possibility of developing AF in the future. AF associated with rapid ventricular rates and wide-complex QRS morphology may sometimes be mislabeled as ventricular tachycardia, and an EP study will differentiate the 2 arrhythmias. In short, EP testing is indicated when ablative therapy of arrhythmias that trigger AF or ablation of AF is planned.<br />&nbsp;&nbsp;In patients with AF who are candidates for ablation, an EP study is critical to deﬁne the targeted site or sites of ablation in the LA and/or right-sided structures. Evolving strategies in the ablation of AF are discussed in Section 8.0.', null, null, null, '指南在治疗指征方面更为细化，并根据循证医学临床试验的结果，提出各种治疗方案的证据水平，更新一些传统认识。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('187', '37', 'X01_044', '1', '2013美国心律协会/欧洲心律学会/亚太心律学会遗传性心律失常综合征诊治专家共识', 'HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes: Document endorsed', '欧洲心律学会（EHRA,European Heart Rhythm Association）；心律协会（HRS,Heart Rhythm Society）；亚太心律学会（APHRS,Asia Pacific Heart Rhythm Society）', '2013', 'http://paper.medlive.cn/literature/1039481', '英文', null, '长QT综合征', null, null, 'LQTS传统诊断标准为排除心率校正QT间期（QTc）延长的继发性因素后，无论男女，QTc> 500 ms 作为LQTS的诊断标准。共识在此基础上，综合大规模临床观察资料提出：LQTS危险评分≥3.5和（或）有明确的致病基因突变，或多次12导联心电图QTc≥500 ms以及无致病基因突变、不明原因晕厥、QTc 反复在480～499 ms者可诊断为LQTS。<br />&nbsp;&nbsp;激发试验（如仰卧一立位试验）、运动试验恢复期或肾上腺素输注期间测定QTc，对诊断静息状态QTc 正常患者的诊断可能有帮助。<br />&nbsp;&nbsp;The diagnosis of LQTS is mainly based on measurement of the QT interval corrected for heart rate (QTc) using Bazett\'s formula. When using a prolonged QTc to diagnose LQTS, one must exclude secondary causes of QTc prolongation that can occur with drugs, acquired cardiac conditions, electrolyte imbalance, and unbalanced diets. A scoring system has been established, which takes into account the age of the patient, medical and family history, symptoms, and QTc and provides a probability of the diagnosis of LQTS.<br />&nbsp;&nbsp;Approximately 20%–25% of patients with LQTS conﬁrmed by the presence of an LQTS gene mutation may have a normal range QTc.The use of provocative tests for QT measurement during change from a supine to standing position, in the recovery phase of exercise testing, or during infusion of epinephrine has been proposed to unmask LQTS patients with normal QTc at resting ECG. These tests may be considered in uncertain cases. However, the clinical use of this test requires more extensive validation.', null, null, null, '首个遗传性心律失常综合征患者诊断和治疗专家共识的颁布，为该综合征的诊断、危险分层和治疗提供依据。该共识的撰写工作涵盖了北美地区、欧洲地区和亚太地区的专家，充分显示其临床应用的可信度。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('188', '37', 'X01_045', '1', '2013美国心律协会/欧洲心律学会/亚太心律学会遗传性心律失常综合征诊治专家共识', 'HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes: Document endorsed', '欧洲心律学会（EHRA,European Heart Rhythm Association）；心律协会（HRS,Heart Rhythm Society）；亚太心律学会（APHRS,Asia Pacific Heart Rhythm Society）', '2013', 'http://paper.medlive.cn/literature/1039481', '英文', null, 'Brugada综合征', null, null, '1型BrS 的既往诊断标准是：自发性或静脉给Ⅰ类抗心律失常药物诱发心电图第4肋间V1 和V2联 ST段1 型抬高≥0.2 mV。共识对诊断标准更新处是建议可将V1和V2导联记录位置高至第 2或3 肋间，有利于提高诊断的敏感性。<br />&nbsp;&nbsp;静脉给Ⅰ类抗心律失常药物激发试验引起第2、3或 4肋间V1、V2导联中≥1 个导联ST段呈2或3 型抬高≥0.2mV，可诊断为2或 3型BrS。BrS 心电图特征由原来 3型改2型，原来的2和3 型合并为 2型。<br />&nbsp;&nbsp;无症状而心电图有Brugada特征的患者，如有以下情况，应考虑BrS的诊断：（1）运动负荷试验达极限时ST段抬高不明显，运动后恢复期又出现ST段抬高。（2）Ⅰ度房室传导阻滞（AVB）和电轴左偏。（3）心房颤动（AF）。（4）晚电位阳性。（5） QRS碎裂波群。(6) ST-T电交替，自发的QRS 波群，呈左束支传导阻滞图形的室性期前收缩（VPB）。（7）电生理检查（EPS）记录心室有效不应期（ERP）<200 ms且HV 间期>60 ms。（8）缺乏结构性心脏病包括心肌缺血。<br />&nbsp;&nbsp;Diagnostic criteria from the Report of the Second Consensus Conference in 2005 have been used for the diagnosis of BrS.Since some clinical studies on the sensitivity and the speciﬁcity of the ECG diagnosis of BrS have been reported, new diagnostic criteria of BrS are proposed here. BrS is deﬁnitively diagnosed when a type I ST-segment elevation is observed either spontaneously or after intravenous administration of a sodium channel blocking agent (ajmaline, ﬂecainide, pilsicainide, or procainamide) in at least one right precordial lead (V1 and V2), which are placed in a standard or a superior position (up to the 2nd intercostal space). <br />&nbsp;&nbsp;The differential diagnosis includes a number of diseases and conditions that can lead to Brugada-like ECG abnormality, including atypical right bundle branch block (RBBB), left ventricular hypertrophy, early repolarization, acute pericarditis, acute myocardial ischemia or infarction, acute stroke, pulmonary embolism, Prinzmetal angina, dissecting aortic aneurysm, various central and autonomic nervous system abnormalities, Duchenne muscular dystrophy, thiamine deﬁciency, hyperkalemia, hypercalcemia, arrhythmogenic right ventricular cardiomyopathy (ARVC), pectus excavatum, hypothermia, and mechanical compression of the right ventricular outﬂow tract (RVOT) as occurs in mediastinal tumor or hemopericardium.<br />&nbsp;&nbsp;Many subjects displaying a type I ECG, spontaneous or drug-induced, are asymptomatic. In asymptomatic patients, the following ﬁndings are considered supportive for the diagnosis of BrS:<br />&nbsp;&nbsp;1. Attenuation of ST-segment elevation at peak of exercise stress test followed by its appearance during recovery phase.It should be noted, however, that in selected BrS patients, usually SCN5A mutation-positive patients, it has been observed that ST-segment elevation might become more evident during exercise.<br />&nbsp;&nbsp;2. Presence of ﬁrst-degree atrioventricular (AV) block and left-axis deviation of the QRS.<br />&nbsp;&nbsp;3. Presence of atrial ﬁbrillation.<br />&nbsp;&nbsp;4. Signal-averaged ECG; late potentials.<br />&nbsp;&nbsp;5. Fragmented QRS.<br />&nbsp;&nbsp;6. ST-T alternans, spontaneous left bundle branch block(LBBB) ventricular premature beats (VPB) during prolonged ECG recording.<br />&nbsp;&nbsp;7. Ventricular effective refractory period (ERP) o200 ms recorded during electrophysiological study (EPS) and HV interval 460 ms.<br />&nbsp;&nbsp;8. Absence of structural heart disease including myocardial ischemia.', null, null, null, '首个遗传性心律失常综合征患者诊断和治疗专家共识的颁布，为该综合征的诊断、危险分层和治疗提供依据。该共识的撰写工作涵盖了北美地区、欧洲地区和亚太地区的专家，充分显示其临床应用的可信度。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('189', '37', 'X01_046', '1', '2013美国心律协会/欧洲心律学会/亚太心律学会遗传性心律失常综合征诊治专家共识', 'HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes: Document endorsed', '欧洲心律学会（EHRA,European Heart Rhythm Association）；心律协会（HRS,Heart Rhythm Society）；亚太心律学会（APHRS,Asia Pacific Heart Rhythm Society）', '2013', 'http://paper.medlive.cn/literature/1039481', '英文', null, '儿茶酚胺敏感性室性心动过速', null, null, '以下情况可诊断为 CPVT：（1）<40 岁，心脏结构和心电图正常，运动或儿茶酚胺诱发双向VT或多形性VPB或VT。（2）有 CPVT致病基因突变的患者。（3）CPVT先证者亲属，运动可诱发 VPB或双向／多形性 VT。（4）>40岁，心脏结构、冠状动脉和心电图均正常，运动或儿茶酚胺可诱发双向VT或多形性VPB或VT。<br />&nbsp;&nbsp;CPVT patients present a normal resting ECG, occasionally with a lower than normal heart rate. When patients start exercising ventricular ectopy develops, increasing in complexity as the heart rate increases. Indeed, initially monomorphic VPBs appear and they may be followed by polymorphic VPBs and bidirectional or polymorphic VT. Holter monitoring, exercise stress test or implantable loop recorders are therefore pivotal investigations for establishing the diagnosis of CPVT. Adrenergically mediated atrial arrhythmias (premature atrial beats, atrial tachycardias and atrial ﬁbrillation) are also common manifestations of the disease.<br />&nbsp;&nbsp;Programmed electrical stimulation has no diagnostic or prognostic value in CPVT as either bidirectional or polymorphic VT is not inducible. Drug challenge with epinephrine or isoproterenol may elicit arrhythmias and is useful in patients who are unable to exercise (for example, after resuscitation or because of young age). Exercise-induced atrial arrhythmias, including atrial ﬁbrillation, are part of the clinical phenotype of CPVT.', null, null, null, '首个遗传性心律失常综合征患者诊断和治疗专家共识的颁布，为该综合征的诊断、危险分层和治疗提供依据。该共识的撰写工作涵盖了北美地区、欧洲地区和亚太地区的专家，充分显示其临床应用的可信度。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('19', '32', 'G02_007', '1', '绝经后女性血脂异常管理的中国专家共识', '无', '中国医师协会心血管内科医师分会;\n中华医学会心血管病学分会;', '2014', null, '中文', 'G02_007_01_表1血脂异常危险分层方案', '血脂异常', null, null, null, null, 'TC；LDL-C；非HDL-C；', 'G02_007_02_绝经后女性血脂治疗目标值', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('190', '37', 'X01_047', '1', '2013美国心律协会/欧洲心律学会/亚太心律学会遗传性心律失常综合征诊治专家共识', 'HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes: Document endorsed', '欧洲心律学会（EHRA,European Heart Rhythm Association）；心律协会（HRS,Heart Rhythm Society）；亚太心律学会（APHRS,Asia Pacific Heart Rhythm Society）', '2013', 'http://paper.medlive.cn/literature/1039481', '英文', null, '短QT综合征', null, null, 'SQTS的诊断尚存争议，焦点在于QTc的界值，目前共识认同≤330ms 为诊断标准。使用Bazett 公式时应注意避免心动过速和心动过缓对QTc 计算的影响；QTc<360 ms 合并以下一项或多项时，也可诊断SQTS：（1）存在基因突变。（2）有SQTS 家族史。（3）有猝死年龄≤40岁的家族史。（4）无器质性心脏病而发生 VT/VF的幸存者。<br />&nbsp;&nbsp;The diagnosis of SQTS is still a matter of debate. A major point of discussion in the deﬁnition of diagnostic criteria is represented by the cutoff value at the lower end of the QTc that should be used to diagnose the disease. QTc should be calculated avoiding tachycardia and bradycardia to prevent the use Bazett’s formula at rates in which its correction is not linear and may lead to underestimation or overestimation of QTc values.<br />&nbsp;&nbsp;The proposed diagnostic scoring scheme that has been put forward by Gollob etal, has not been accepted unanimously. In analogy to the Schwartz score for the LQTS the score uses a number of clinical criteria with a gradual score for the QTc interval and a signiﬁcant role for clinical and genetic criteria.<br />&nbsp;&nbsp;This group has reached a consensus that a cutoff value≤330 ms should be used for the diagnosis. Gollob etal in their “diagnostic score” also used 330 ms as the cutoff with the heaviest weight. This QTc value is well below the standard deviations (±350 ms in males and ±365 ms in females).In the Finnish cohort reported by Anttonen et al only 0.4% of individuals had a QTc＜340 ms and 0.1% of the population had a QTc＜320 ms.', null, null, null, '首个遗传性心律失常综合征患者诊断和治疗专家共识的颁布，为该综合征的诊断、危险分层和治疗提供依据。该共识的撰写工作涵盖了北美地区、欧洲地区和亚太地区的专家，充分显示其临床应用的可信度。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('191', '37', 'X01_048', '1', '2013美国心律协会/欧洲心律学会/亚太心律学会遗传性心律失常综合征诊治专家共识', 'HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes: Document endorsed', '欧洲心律学会（EHRA,European Heart Rhythm Association）；心律协会（HRS,Heart Rhythm Society）；亚太心律学会（APHRS,Asia Pacific Heart Rhythm Society）', '2013', 'http://paper.medlive.cn/literature/1039481', '英文', null, '早期复极', null, null, '1.原因不明的VF／多形性 VT复苏患者，心电图有≥2个连续下壁和（或）侧壁导联记录到J 点抬高≥1 mm。<br />&nbsp;&nbsp;2.死于SCD，尸检阴性，生前心电图记录≥2 个连续下壁和（或）侧壁导联 J点抬高≥1 mm。<br />&nbsp;&nbsp;X01_048图1<br />&nbsp;&nbsp;', null, null, null, '首个遗传性心律失常综合征患者诊断和治疗专家共识的颁布，为该综合征的诊断、危险分层和治疗提供依据。该共识的撰写工作涵盖了北美地区、欧洲地区和亚太地区的专家，充分显示其临床应用的可信度。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('192', '37', 'X01_049', '1', '2013美国心律协会/欧洲心律学会/亚太心律学会遗传性心律失常综合征诊治专家共识', 'HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes: Document endorsed', '欧洲心律学会（EHRA,European Heart Rhythm Association）；心律协会（HRS,Heart Rhythm Society）；亚太心律学会（APHRS,Asia Pacific Heart Rhythm Society）', '2013', 'http://paper.medlive.cn/literature/1039481', '英文', null, '进行性心脏传导疾病', null, null, '心脏结构正常，无骨骼肌肉疾病，年龄<50 岁，发生原因不明的心脏进行性传导障碍，尤其在有PCCD 家族史，可诊断 PCCD。心电图主要为表现 P波时程延长，PR间期延长和QRS波增宽及电轴偏移。无器质性心脏病及心脏以外异常者为孤立型PCCD，伴有先天性心脏病，心肌病或心脏以外异常者，为非孤立型PCCD。<br />&nbsp;&nbsp;The diagnosis of PCCD in an index patient is based on clinical data including history, family history, and 12-lead ECG. The potential presence of congenital heart disease and/or cardiomyopathy must be investigated by 2-D echocar-diography or other imaging modalities, such as cardiac MRI.Early-onset PCCD in the absence of structural heart disease should prompt consideration of PCCD genetic testing, particularly if there is a positive family history of conduction abnormalities, pacemaker implants, or sudden death.<br />&nbsp;&nbsp;(Targeted) genetic testing may be considered as part of the diagnostic evaluation for patients with either isolated PCCD or PCCD with concomitant structural heart disease, especially when there is documentation of a positive family history of PCCD.<br />&nbsp;&nbsp;', null, null, null, '首个遗传性心律失常综合征患者诊断和治疗专家共识的颁布，为该综合征的诊断、危险分层和治疗提供依据。该共识的撰写工作涵盖了北美地区、欧洲地区和亚太地区的专家，充分显示其临床应用的可信度。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('193', '37', 'X01_050', '1', '2013美国心律协会/欧洲心律学会/亚太心律学会遗传性心律失常综合征诊治专家共识', 'HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes: Document endorsed', '欧洲心律学会（EHRA,European Heart Rhythm Association）；心律协会（HRS,Heart Rhythm Society）；亚太心律学会（APHRS,Asia Pacific Heart Rhythm Society）', '2013', 'http://paper.medlive.cn/literature/1039481', '英文', null, '特发性室颤', null, null, '排除已知心脏、呼吸、代谢和毒理学病因，有VF心电图记录的心脏骤停幸存者。<br />&nbsp;&nbsp;IVF is deﬁned as a resuscitated cardiac arrest victim, preferably with documentation of VF, in whom known cardiac, respiratory, metabolic and toxicological etiologies have been excluded through clinical evaluation.', null, null, null, '首个遗传性心律失常综合征患者诊断和治疗专家共识的颁布，为该综合征的诊断、危险分层和治疗提供依据。该共识的撰写工作涵盖了北美地区、欧洲地区和亚太地区的专家，充分显示其临床应用的可信度。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('194', '1', 'T01_001', '1', '中国2型糖尿病防治指南-2013', '无', '中华医学会糖尿病学分会', '2013', '中国2型糖尿病防治指南(2013年版)[J]. 中国糖尿病杂志,2014,08:2-42.', '中文', '', '2型糖尿病', '', '', '糖尿病的临床诊断应依据静脉血浆血糖而不是毛细血管血的血糖检测结果。若无特殊提示，文中所提到的血糖均为静脉血浆葡萄糖水平值。<br />\r\n&nbsp;&nbsp;血糖的正常值和糖代谢异常的诊断切点主要依据血糖值与糖尿病特有的慢性并发症（糖尿病视网膜病变）和糖尿病发生风险的关系来确定。目前常用的诊断标准和分类有WHO（1999年)标准和ADA（2003年）标准。本指南采用WHO（1999年)糖尿病诊断、糖代谢状态分类标准（表2、3）和糖尿病的分型体系（表4），FPG或75g OGTT后的2h血糖值可单独用于流行病学调查或人群筛查。但我国资料显示仅查FPG糖尿病的漏诊率较高。理想的调查是同时检查FPG及OGTT后2h血糖值，OGTT其他时间点血糖不作为诊断标准。建议已达到糖调节受损的人群，应行OGTT检查，以降低糖尿病的漏诊率。<br />\r\n&nbsp;&nbsp;T01_001_01.jpg<br />\r\n&nbsp;&nbsp;T01_001_02.jpg<br />\r\n&nbsp;&nbsp;T01_001_03.jpg<br />\r\n&nbsp;&nbsp;', '', '血糖（mmol/L）（空腹/非空腹）；HbA1c（%）；血压（mm Hg）；TC（mmol/L）；TG（mmol/L）；HDL-C（mmol/L）（男/女）；LDL-C（mmol/L）（未合并冠心病/合并冠心病）；BMI（kg/m2）；尿白蛋白/肌酐比值（男/女），或：尿白蛋白排泄率[μg/min（mg/24 h）]；主动有氧活动（分/周）', '2型糖尿病理想的综合控制目标视患者的年龄、合并症、并发症等不同而异（表7）。治疗未能达标不应视为治疗失败，控制指标的任何改善对患者都将有益，将会降低相关危险因素引发并发症的风险，如HbA1c水平的降低与糖尿病患者微血管并发症及神经病变的减少密切相关（图1，HbA1c从10%降至9%对减低并发症发生风险的影响要大于其从7%降至6%）。<br />\r\n&nbsp;&nbsp;制定2型糖尿病患者综合调控目标的首要原则是个体化，应根据患者的年龄、病程、预期寿命、并发症或合并症病情严重程度等进行综合考虑。<br />\r\n&nbsp;&nbsp;HbA1c是反映长期血糖控制水平的主要指标之一。对大多数非妊娠成年2型糖尿病患者而言，合理的HbA1c控制目标为＜7%。更严格的HbA1c控制目标（如＜6．5%，甚或尽可能接近正常）适合于病程较短、预期寿命较长、无并发症、未合并心血管疾病的2型糖尿病患者，其前提是无低血糖或其他不良反应。相对宽松的HbA1c目标（如＜8．0%）可能更适合于有严重低血糖史、预期寿命较短、有显著的微血管或大血管并发症，或有严重合并症、糖尿病病程很长和尽管进行了糖尿病自我管理教育、适当的血糖监测、接受有效剂量的多种降糖药物包括胰岛素治疗仍很难达到常规治疗目标的患者。儿童、孕妇、住院尤其是病情危重患者等特殊人群的控制标准参见相关章节。应该避免因过度放宽控制标准而出现急性高血糖症状或与其相关的并发症。在治疗调整中，可将HbA1c≥7%作为2型糖尿病启动临床治疗或需要调整治疗方案的重要判断标准。血糖控制应根据ＳMＢＧ的结果及HbA1c水平综合判断。表8列举了HbA1c浓度与平均血糖水平的关系。<br />\r\n&nbsp;&nbsp;糖尿病合并高血压的情况临床常见。较年轻和病程较短的患者，可能不需要过多治疗就可以实现将血压降至130/80mmHg以下。老年患者血压目标值可适当放宽至150/90mmHg。<br />\r\n&nbsp;&nbsp; T01_001_04.jpg<br />\r\n&nbsp;&nbsp;', '关于用HbAlc诊断糖尿病的问题<br />\r\n&nbsp;&nbsp;部分国家将HbAle作为筛查糖尿病高危人群和诊断糖尿病的一种方法。HhAle较OGTT试验简便易行，结果稳定，变异性小，且不受进食时间及短期生活方式改变的影响，患者依从性好。2010年ADA指南将HbAle≥6.5%作为糖尿病诊断标准之一。2011年WHO也建议在条件具备的国家和地区采用这一切点诊断糖尿病。但鉴于HbAle检测在我国尚不普遍，检测方法的标准化程度不够，测定HbAle的仪器和质量控制尚不能符合目前糖尿病诊断标准的要求。本指南仍不推荐在我国采用HbAle诊断糖尿病。但对于采用标准化检测方法，并有严格质量控制，正常参考值在4.0%-6.0%的医院，HbAlc≥6.5%可作为诊断糖尿病的参考。', '5', '0', 'admin', null, 'admin', '2016-05-11 17:43:45');
INSERT INTO `biz_standard` VALUES ('195', '1', 'T01_002', '1', 'ADA糖尿病医学诊疗标准-2005', 'Standards of Medical Care in Diabetesd-2005', '美国糖尿病学会（American Diabetes Association）', '2005', 'http://care.diabetesjournals.org/content/28/suppl_1/s4.full.pdf', '英文', '', '糠尿病', '', 'a', '非妊娠成年人糖尿病诊断指标如表2，有3种方法可用于诊断糖尿病，但无论哪种方法都必须次日重复确认，除非病人已有明确的高血糖症状, 虽然口服75g 葡萄糖耐量试验(OGTT)对诊断糖尿病比FPG 更敏感和正规，但其重复性差而且实际很少用，而FPG因其应用方便，病人易接受和费用低，建议可选用FPG作为糖尿病诊断试验，必须指出绝大多数由OGTT而不是由FPG试验结果诊断的人，其A1C&lt;7%，所以目前不主张用A1C诊断糖尿病。<br />\r\n&nbsp;&nbsp;IFG=FPG100～125mg/dl<br />\r\n&nbsp;&nbsp;IGT=2hPG140～199mg/dl<br />\r\n&nbsp;&nbsp;最近已将IFG与IGT正式命名为“糖尿病前期(Prediabetes)”，两者都是糖尿病与心血管病(CVD)的危险因素。<br />\r\n&nbsp;&nbsp;表2　糖尿病诊断指标<br />\r\n&nbsp;&nbsp;1.有糖尿病症状和随意血糖≥200mg/dl。“随意”是指一天内任何时间，无论进食与否。糖尿病典型症状包括多尿、多饮和不可解释的体重减轻<br />\r\n&nbsp;&nbsp;或<br />\r\n&nbsp;&nbsp;2.FPG≥126mg/dl。“空腹”指至少8h未进食(未摄入热量)<br />\r\n&nbsp;&nbsp;或<br />\r\n&nbsp;&nbsp;3.OGTT试验2hPG≥200mg/dl。试验需按WHO要求用75g无水葡萄糖溶于水<br />\r\n&nbsp;&nbsp;建议<br />\r\n&nbsp;&nbsp;1.可选用FPG作为儿童和非妊娠成人的糖尿病诊断试验<br />\r\n&nbsp;&nbsp;2.目前不推荐用糖化血红蛋白(A1C)诊断糖尿病<br />\r\n&nbsp;&nbsp;最近已将IFG与IGT正式命名为“糖尿病前期(Prediabetes)”，两者都是糖尿病与心血管病(CVD)的危险因素。<br />\r\n&nbsp;&nbsp;妊娠糖尿病的筛查及诊断<br />\r\n&nbsp;&nbsp;应该在怀孕后第一次检查时进行GDM危险评估。具有GDM高危临床表现(如显著肥胖，有GDM病史、尿糖或糖尿病家族史)者应尽可能早的检测血糖水平。如果空腹血糖(FPG)≥7mmol/L或任意血糖≥11.1mmol/L且有明确的高血糖症状，即满足糖尿病的诊断标准，否则需要再测一次血糖以确诊。对于初次筛查时未诊为GDM的高危妇女及中等危险的妇女应在妊娠24～28周时进行以下推荐检查之一。<br />\r\n&nbsp;&nbsp;一步检查:行100g口服葡萄糖耐量试验(OGTT)。<br />\r\n&nbsp;&nbsp;二步检查:口服50g葡萄糖(葡萄糖耐量试验，GCT)后1h进行初次筛查，测血浆或血清葡萄糖水平，对于GCT中血糖超过阈值的妇女进行再诊断性的100gOGTT。如果GCT中把葡萄糖阈值定为≥7.77mmol/L，则可确诊近80%的GDM妇女，而将切点定为≥7.22mmol/L时，则可确诊者增加到90%。<br />\r\n&nbsp;&nbsp;100gOGTT诊断标准:空腹≥5.27mmol/L，1h血糖≥10mmol/L，2h血糖≥8.60mmol/L，3h血糖≥7.77mmol/L。以上不同时点血浆葡萄糖水平有两项或多项满足标准即可诊断GDM。另外，应该在清晨隔夜空腹8～14h时进行检测。也可做75g糖负荷试验，但其在鉴别高危婴儿及母亲的有效性方面不如100gOGTT。<br />\r\n&nbsp;&nbsp;对于满足以下所有条件的低危妇女无需检测血糖:(1)年龄&lt;25岁。(2)怀孕前体重正常。(3)属于GDM发病率低的种族。(4)一级亲属没有糖尿病患者。(5)没有糖耐量异常史。(6)没有难产史。<br />\r\n&nbsp;&nbsp;建议<br />\r\n&nbsp;&nbsp;1.孕期内宜作OGTT筛查糖尿病<br />\r\n&nbsp;&nbsp;2.GDM 妇女产后6周重复OGTT以筛查糖尿病，并在以后定期随诊, 筛查是否发生糖尿病或糖尿病前期<br />\r\n&nbsp;&nbsp;Criteria for the diagnosis of diabetes innonpregnant adults are shown in Table 2.Three ways to diagnose diabetes are available,and each must be confirmed on asubsequent day unless unequivocalsymptoms of hyperglycemia are present.Although the 75-g oral glucose tolerancetest (OGTT) is more sensitive and modestlymore specific than fasting plasmaglucose (FPG) to diagnose diabetes, it ispoorly reproducible and rarely performedin practice. Because of ease of use, acceptabilityto patients, and lower cost, theFPG is the preferred diagnostic test. Itshould be noted that the vast majority ofpeople who meet diagnostic criteria fordiabetes by OGTT, but not by FPG, willhave an A1C value＜7.0%. The use of theA1C for the diagnosis of diabetes is notrecommended at this time.<br />\r\n&nbsp;&nbsp;Hyperglycemia not sufficient to meetthe diagnostic criteria for diabetes is categorizedas either IFG or impaired glucosetolerance (IGT), depending on whether itis identified through a FPG or an OGTT:<br />\r\n&nbsp;&nbsp;IFG = FPG 100 mg/dl (5.6mmol/l) to125 mg/dl (6.9mmol/l)<br />\r\n&nbsp;&nbsp;IGT = 2-h plasma glucose 140 mg/dl(7.8mmol/l) to 199 mg/dl (11.0mmol/l)<br />\r\n&nbsp;&nbsp;Recently, IFG and IGT have been officiallytermed “pre-diabetes.” Both categories,IFG and IGT, are risk factors forfuture diabetes and cardiovascular disease(CVD).<br />\r\n&nbsp;&nbsp;Table 2 Criteria for the diagnosis of diabetes<br />\r\n&nbsp;&nbsp;1. Symptoms of diabetes and a casual plasma glucose ≥ 200 mg/dl (11.1mmol/l). Casual is defined as any time of day without regard to time since last meal. The classic symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss.<br />\r\n&nbsp;&nbsp;OR<br />\r\n&nbsp;&nbsp;2. FPG ≥ 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h. <br />\r\n&nbsp;&nbsp;OR <br />\r\n&nbsp;&nbsp;3. 2-h plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT. The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water. <br />\r\n&nbsp;&nbsp;In the absence of unequivocal hyperglycemia, these criteria should be confirmed by repeat testing on a different day. The OGTT is not recommended for routine clinical use, but may be required in the evaluation of patients with IFG (see text) or when diabetes is still suspected despite a normal FPG as with the postpartum evaluation of women with GDM.<br />\r\n&nbsp;&nbsp;Recommendations<br />\r\n&nbsp;&nbsp;1.The FPG is the preferred test to diagnosediabetes in children and nonpregnantadults. <br />\r\n&nbsp;&nbsp;2.The use of the A1C for the diagnosis ofdiabetes is not recommended at thistime. <br />\r\n&nbsp;&nbsp;Detection and diagnosis of gestational diabetes mellitus (GDM)<br />\r\n&nbsp;&nbsp;Risk assessment for GDM should be undertaken at the first prenatal visit. Women with clinical characteristics consistent with a high risk for GDM (those with marked obesity, personal history of GDM, glycosuria, or a strong family history of diabetes) should undergo glucose testing as soon as possible. An FPG ≥ 126 mg/dl or a casual plasma glucose ≥ 200 mg/dl meets the threshold for the diagnosis of diabetes and needs to be confirmed on a subsequent day unless unequivocal symptoms of hyperglycemia are present. High-risk women not found to haveGDM at the initial screening and average-risk women should be tested between 24 and 28 weeks of gestation. Testing should follow one of two approaches: <br />\r\n&nbsp;&nbsp;One-step approach: perform a diagnostic 100-g OGTT<br />\r\n&nbsp;&nbsp;Two-step approach: perform an initial screening by measuring the plasma or serum glucose concentration 1 h after a 50-g oral glucose load (glucose challenge test [GCT]) and perform a diagnostic 100-g OGTT on that subset of women exceeding the glucose threshold value on the GCT. When the two-step approach is used, a glucose threshold value ≥ 140 mg/dl identifies 80% of women with GDM, and the yield is further increased to 90% by using a cutoff of ≥ 130 mg/dl. <br />\r\n&nbsp;&nbsp;Diagnostic criteria for the 100-g OGTT are as follows: ≥ 95 mg/dl fasting, ≥ 180 mg/dl at 1 h, ≥ 155 mg/dl at 2 h, and ≥ 140 mg/dl at 3 h. Two or more of the plasma glucose values must be met or exceeded for a positive diagnosis. The test should be done in the morning after an overnight fast of 8–14 h. The diagnosis can be made using a 75-g glucose load, but that test is not as well validated for detection of at-risk infants or mothers as the 100-g OGTT. <br />\r\n&nbsp;&nbsp;Low-risk status requires no glucose testing, but this category is limited to those women meeting all of the following characteristics: <br />\r\n&nbsp;&nbsp;Age＜ 25 years.<br />\r\n&nbsp;&nbsp;Weight normal before pregnancy. <br />\r\n&nbsp;&nbsp;Member of an ethnic group with a low prevalence of GDM. <br />\r\n&nbsp;&nbsp;No known diabetes in first-degree relatives.<br />\r\n&nbsp;&nbsp;No history of abnormal glucose tolerance. <br />\r\n&nbsp;&nbsp;No history of poor obstetric outcome. <br />\r\n&nbsp;&nbsp;Recommendations<br />\r\n&nbsp;&nbsp;1.Screen for diabetes in pregnancy using risk factor analysis and, if appropriate, use of an OGTT.<br />\r\n&nbsp;&nbsp;2.Women with gestational diabetes should be screened for diabetes 6 weeks postpartum and should be followed up with subsequent screening for the development of diabetes or prediabetes.<br />\r\n&nbsp;&nbsp;', '', '', 'Recommended glycemic goals for nonpregnant individuals are shown in Table 6.<br />\r\n&nbsp;&nbsp;T01_002_01.jpg<br />\r\n&nbsp;&nbsp;', '', '1', '0', 'admin', null, 'admin', '2016-05-12 10:34:45');
INSERT INTO `biz_standard` VALUES ('196', '1', 'T01_003', '1', 'ADA糖尿病医学诊疗标准-2006', 'Standards of Medical Care in Diabetesd-2006', '美国糖尿病学会（American Diabetes Association）', '2006', 'http://care.diabetesjournals.org/content/29/suppl_1/s4.full.pdf', '英文', 'ADA1997年发布了新的诊断与分型标准，2003年进行了修改，提出空腹血糖受损(IFG)诊断标准。糖尿病分为4种临床类型:<br />&nbsp;&nbsp;1.型糖尿病(由β细胞功能破坏所致,常导致胰岛素分泌的绝对缺乏)。<br />&nbsp;&nbsp;2.型糖尿病(在胰岛素抵抗的基础上发生进行性胰岛素分泌缺陷)。<br />&nbsp;&nbsp;3.其他特殊类型糖尿病(由其他原因引起,如遗传性β细胞功能缺陷、胰岛素作用的基因缺陷、胰腺外分泌疾病(例如囊包性纤维症)、药物或化学因素诱导等（例如艾滋病和器官移植后的治疗）)。<br />&nbsp;&nbsp;4.妊娠糖尿病(GDM)(在妊娠期间诊断的糖尿病)。<br />&nbsp;&nbsp;In 1997, the ADA issued new diagnostic and classification criteria; in 2003, modifications were made regarding the diagnosis of impaired fasting glucose (IFG). The classification of diabetes includes four clinical classes:<br />&nbsp;&nbsp;Type 1 diabetes (results from β-cell destruction, usually leading to absolute insulin deficiency).<br />&nbsp;&nbsp;Type 2 diabetes (results from a progressive insulin secretory defect on the background of insulin resistance).<br />&nbsp;&nbsp;Other specific types of diabetes (due to other causes, e.g., genetic defects in β-cell function, genetic defects in insulin action, diseases of the exocrine pancreas (such as cystic fibrosis), and drug or chemical induced (such as in the treatment of AIDS or after organ transplantation).<br />&nbsp;&nbsp;Gestational diabetes mellitus (GDM) (diagnosed during pregnancy). <br />&nbsp;&nbsp;', '糠尿病', null, null, '建议<br />&nbsp;&nbsp;1.可选用FPG 作为儿童和非妊娠成人的糖尿病诊断试验<br />&nbsp;&nbsp;2.目前不推荐用糖化血红蛋白(A1C)诊断糖尿病<br />&nbsp;&nbsp;非妊娠成年人糖尿病诊断指标如表2，有3种方法可用于诊断糖尿病，但无论哪种方法都必须次日重复确认，除非病人已有明确的高血糖症状, 虽然口服75g 葡萄糖耐量试验(OGTT)对诊断糖尿病比FPG 更敏感和正规，但其重复性差而且实际很少用，而FPG因其应用方便，病人易接受和费用低，建议可选用FPG作为糖尿病诊断试验，必须指出绝大多数由OGTT而不是由FPG试验结果诊断的人，其A1C<7%，所以目前不主张用A1C诊断糖尿病。<br />&nbsp;&nbsp;IFG=FPG100～125mg/dl<br />&nbsp;&nbsp;IGT=2hPG140～199mg/dl<br />&nbsp;&nbsp;最近已将IFG与IGT正式命名为“糖尿病前期(Prediabetes)”，两者都是糖尿病与心血管病(CVD)的危险因素。<br />&nbsp;&nbsp;对没有明确的高血糖表现者，这些指标都必须在改日重复，OGTT不推荐作临床常规检查，但在评价IFG或FPG正常而仍疑为糖尿病者以及对GDM产后评价需要作OGTT。<br />&nbsp;&nbsp;表2　糖尿病诊断指标<br />&nbsp;&nbsp;1.有糖尿病症状和随意血糖≥200mg/dl。“随意”是指一天内任何时间，无论进食与否。糖尿病典型症状包括多尿、多饮和不可解释的体重减轻<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;2.FPG≥126mg/dl。“空腹”指至少8h未进食(未摄入热量)<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;3.OGTT试验2hPG≥200mg/dl。试验需按WHO要求用75g无水葡萄糖溶于水<br />&nbsp;&nbsp;妊娠糖尿病(GDM)的鉴别与诊断<br />&nbsp;&nbsp;建议<br />&nbsp;&nbsp;1.孕期内宜作OGTT筛查糖尿病<br />&nbsp;&nbsp;2.GDM 妇女产后6-12周重复OGTT以筛查糖尿病，并在以后定期随诊, 筛查是否发生糖尿病或糖尿病前期<br />&nbsp;&nbsp;应该在怀孕后第一次检查时进行GDM危险评估。具有GDM高危临床表现(如显著肥胖，有GDM病史、尿糖或糖尿病家族史)者应尽可能早的检测血糖水平。如果空腹血糖(FPG)≥7mmol/L或任意血糖≥11.1mmol/L且有明确的高血糖症状，即满足糖尿病的诊断标准，否则需要再测一次血糖以确诊。对于初次筛查时未诊为GDM的高危妇女及中等危险的妇女应在妊娠24～28周时进行以下推荐检查之一。<br />&nbsp;&nbsp;一步检查:行100g口服葡萄糖耐量试验(OGTT)。<br />&nbsp;&nbsp;二步检查:口服50g葡萄糖(葡萄糖耐量试验，GCT)后1h进行初次筛查，测血浆或血清葡萄糖水平，对于GCT中血糖超过阈值的妇女进行再诊断性的100gOGTT。如果GCT中把葡萄糖阈值定为≥7.77mmol/L，则可确诊近80%的GDM妇女，而将切点定为≥7.22mmol/L时，则可确诊者增加到90%。<br />&nbsp;&nbsp;100gOGTT诊断标准:空腹≥5.27mmol/L，1h血糖≥10mmol/L，2h血糖≥8.60mmol/L，3h血糖≥7.77mmol/L。以上不同时点血浆葡萄糖水平有两项或多项满足标准即可诊断GDM。另外，应该在清晨隔夜空腹8～14h时进行检测。也可做75g糖负荷试验，但其在鉴别高危婴儿及母亲的有效性方面不如100gOGTT。<br />&nbsp;&nbsp;对于满足以下所有条件的低危妇女无需检测血糖:(1)年龄<25岁。(2)怀孕前体重正常。(3)属于GDM发病率低的种族。(4)一级亲属没有糖尿病患者。(5)没有糖耐量异常史。(6)没有难产史。<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp;1. The FPG is the preferred test to diagnose diabetes in children and nonpregnant adults. <br />&nbsp;&nbsp;2. The use of the A1C for the diagnosis of diabetes is not recommended at this time. <br />&nbsp;&nbsp;Criteria for the diagnosis of diabetes in nonpregnant adults are shown in Table 2. Three ways to diagnose diabetes are available, and each must be confirmed on a subsequent day unless unequivocal symptoms of hyperglycemia are present. Although the 75-g oral glucose tolerance test (OGTT) is more sensitive and modestly more specific than fasting plasma glucose (FPG) to diagnose diabetes, it is poorly reproducible and rarely performed in practice. Because of ease of use, acceptability to patients, and lower cost, the FPG is the preferred diagnostic test. It should be noted that the vast majority of people who meet diagnostic criteria for diabetes by OGTT, but not by FPG, will have an A1C value＜7.0%. The use of the A1C for the diagnosis of diabetes is not recommended at this time.<br />&nbsp;&nbsp;Hyperglycemia not sufficient to meet the diagnostic criteria for diabetes is categorized as either IFG or impaired glucose tolerance (IGT), depending on whether it is identified through a FPG or an OGTT:<br />&nbsp;&nbsp;IFG = FPG 100 mg/dl (5.6mmol/l) to 125 mg/dl (6.9mmol/l)<br />&nbsp;&nbsp;IGT = 2-h plasma glucose 140 mg/dl (7.8mmol/l) to 199 mg/dl (11.0mmol/l) <br />&nbsp;&nbsp;Recently, IFG and IGT have been officially termed “pre-diabetes.” Both categories, IFG and IGT, are risk factors for future diabetes and cardiovascular disease (CVD).<br />&nbsp;&nbsp;In the absence of unequivocal hyperglycemia, these criteria should be confirmed by repeat testing on a different day. The OGTT is not recommended for routine clinical use, but may be required in the evaluation of patients with IFG (see text) or when diabetes is still suspected despite a normal FPG as with the postpartum evaluation of women with GDM.<br />&nbsp;&nbsp;Table 2 Criteria for the diagnosis of diabetes<br />&nbsp;&nbsp;1. Symptoms of diabetes and a casual plasma glucose ≥ 200 mg/dl (11.1mmol/l). Casual is defined as any time of day without regard to time since last meal. The classic symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss.<br />&nbsp;&nbsp;OR<br />&nbsp;&nbsp;2. FPG ≥ 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h. <br />&nbsp;&nbsp;OR <br />&nbsp;&nbsp;3. 2-h plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT. The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water. <br />&nbsp;&nbsp;Detection and diagnosis of gestational diabetes mellitus (GDM)<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp;1. Screen for diabetes in pregnancy using risk factor analysis and, if appropriate, use of an OGTT.<br />&nbsp;&nbsp;2. Women with gestational diabetes should be screened for diabetes 6-12 weeks postpartum and should be followed up with subsequent screening for the development of diabetes or prediabetes.<br />&nbsp;&nbsp;Risk assessment for GDM should be undertaken at the first prenatal visit. Women with clinical characteristics consistent with a high risk for GDM (those with marked obesity, personal history of GDM, glycosuria, or a strong family history of diabetes) should undergo glucose testing as soon as possible. An FPG ≥ 126 mg/dl or a casual plasma glucose ≥ 200 mg/dl meets the threshold for the diagnosis of diabetes and needs to be confirmed on a subsequent day unless unequivocal symptoms of hyperglycemia are present. High-risk women not found to have GDM at the initial screening and average-risk women should be tested between 24 and 28 weeks of gestation. Testing should follow one of two approaches: <br />&nbsp;&nbsp;One-step approach: perform a diagnostic 100-g OGTT<br />&nbsp;&nbsp;Two-step approach: perform an initial screening by measuring the plasma or serum glucose concentration 1 h after a 50-g oral glucose load (glucose challenge test [GCT]) and perform a diagnostic 100-g OGTT on that subset of women exceeding the glucose threshold value on the GCT. When the two-step approach is used, a glucose threshold value ≥ 140 mg/dl identifies 80% of women with GDM, and the yield is further increased to 90% by using a cutoff of ≥ 130 mg/dl. <br />&nbsp;&nbsp;Diagnostic criteria for the 100-g OGTT are as follows: ≥ 95 mg/dl fasting, ≥ 180 mg/dl at 1 h, ≥ 155 mg/dl at 2 h, and ≥ 140 mg/dl at 3 h. Two or more of the plasma glucose values must be met or exceeded for a positive diagnosis. The test should be done in the morning after an overnight fast of 8–14 h. The diagnosis can be made using a 75-g glucose load, but that test is not as well validated for detection of at-risk infants or mothers as the 100-g OGTT. <br />&nbsp;&nbsp;Low-risk status requires no glucose testing, but this category is limited to those women meeting all of the following characteristics: <br />&nbsp;&nbsp;Age＜ 25 years.<br />&nbsp;&nbsp;Weight normal before pregnancy. <br />&nbsp;&nbsp;Member of an ethnic group with a low prevalence of GDM. <br />&nbsp;&nbsp;No known diabetes in first-degree relatives.<br />&nbsp;&nbsp;No history of abnormal glucose tolerance. <br />&nbsp;&nbsp;No history of poor obstetric outcome. <br />&nbsp;&nbsp;', null, 'A1C；Preprandial capillary plasma glucose；Peak postprandial capillary plasma glucose+', 'Recommended glycemic goals for nonpregnant individuals are shown in Table 6.<br />&nbsp;&nbsp;T01_003_01.jpg<br />&nbsp;&nbsp;', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('197', '1', 'T01_004', '1', 'ADA糖尿病医学诊疗标准-2007', 'Standards of Medical Care in Diabetesd-2007', '美国糖尿病学会（American Diabetes Association）', '2007', 'http://care.diabetesjournals.org/content/30/suppl_1/S4.full.pdf', '英文', 'ADA1997年发布了新的诊断与分型标准，2003年进行了修改，提出空腹血糖受损(IFG)诊断标准。糖尿病包括4类临床型:<br />&nbsp;&nbsp;1型糖尿病(T1DM):由于β细胞受到破坏导致胰岛素绝对缺乏<br />&nbsp;&nbsp;2型糖尿病(T2DM):由于在胰岛素抵抗背景下进行性的胰岛素分泌缺陷<br />&nbsp;&nbsp;其他特殊型糖尿病:即由其他原因如β细胞功能的遗传缺陷，胰岛素作用的遗传缺陷，胰腺外分泌疾病(如囊性纤维病)以及药物或化学原因引起的(如治疗AIDS病或器官移植后)糖尿病<br />&nbsp;&nbsp;妊娠糖尿病(GDM):妊娠期间诊断的糖尿病<br />&nbsp;&nbsp;有些病人不能明确归为1型或2型，其临床表现和疾病进展同时具有两型的特征，如个别表现为T2DM可能有酮症酸中毒，同样有的T1DM病人尽管有自身免疫疾病表现，但其发病晚进展缓慢，这种诊断困难可见于儿童、青少年和成年人，确切诊断将会随着时间推移而明确。<br />&nbsp;&nbsp;In 1997, the ADA issued new diagnostic and classification criteria; in 2003, modifications were made regarding the diagnosis of impaired fasting glucose (IFG). The classification of diabetes includes four clinical classes:<br />&nbsp;&nbsp;Type 1 diabetes (results from β-cell destruction, usually leading to absolute insulin deficiency).<br />&nbsp;&nbsp;Type 2 diabetes (results from a progressive insulin secretory defect on the background of insulin resistance).<br />&nbsp;&nbsp;Other specific types of diabetes (due to other causes, e.g., genetic defects in β-cell function, genetic defects in insulin action, diseases of the exocrine pancreas(such as cystic fibrosis), and drug or chemical induced (such as in the treatment of AIDS or after organ transplantation).<br />&nbsp;&nbsp;Gestational diabetes mellitus (GDM) (diagnosed during pregnancy).<br />&nbsp;&nbsp;Some patients cannot be clearly classified as type 1 or type 2 diabetes. Clinical presentation and disease progression vary considerably in both types of diabetes. Occasionally, patients who otherwise have type 2 diabetes may present with ketoacidosis. Similarly, patients with type 1 may have a late onset and slow (but relentless) progression of disease despite having features of autoimmune disease. Such difficulties in diagnosis may occur in children, adolescents, and adults. The true diagnosis may become more obvious over time.<br />&nbsp;&nbsp;', '糠尿病', null, null, '建议<br />&nbsp;&nbsp;1.可选用FPG 作为儿童和非妊娠成人的糖尿病诊断试验<br />&nbsp;&nbsp;2.目前不推荐用糖化血红蛋白(A1C)诊断糖尿病<br />&nbsp;&nbsp;非妊娠成年人糖尿病诊断指标如表2，有3种方法可用于诊断糖尿病，但无论哪种方法都必须次日重复确认，除非病人已有明确的高血糖症状, 虽然口服75g 葡萄糖耐量试验(OGTT)对诊断糖尿病比FPG 更敏感和正规，但其重复性差而且实际很少用，而FPG因其应用方便，病人易接受和费用低，建议可选用FPG作为糖尿病诊断试验，必须指出绝大多数由OGTT而不是由FPG试验结果诊断的人，其A1C<7%，所以目前不主张用A1C诊断糖尿病。<br />&nbsp;&nbsp;IFG=FPG100～125mg/dl<br />&nbsp;&nbsp;IGT=2hPG140～199mg/dl<br />&nbsp;&nbsp;最近已将IFG与IGT正式命名为“糖尿病前期(Prediabetes)”，两者都是糖尿病与心血管病(CVD)的危险因素。<br />&nbsp;&nbsp;对没有明确的高血糖表现者，这些指标都必须在改日重复，OGTT不推荐作临床常规检查，但在评价IFG或FPG正常而仍疑为糖尿病者以及对GDM产后评价需要作OGTT。<br />&nbsp;&nbsp;表2　糖尿病诊断指标<br />&nbsp;&nbsp;1.有糖尿病症状和随意血糖≥200mg/dl。“随意”是指一天内任何时间，无论进食与否。糖尿病典型症状包括多尿、多饮和不可解释的体重减轻<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;2.FPG≥126mg/dl。“空腹”指至少8h未进食(未摄入热量)<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;3.OGTT试验2hPG≥200mg/dl。试验需按WHO要求用75g无水葡萄糖溶于水<br />&nbsp;&nbsp;妊娠糖尿病(GDM)的鉴别与诊断<br />&nbsp;&nbsp;建议<br />&nbsp;&nbsp;1.孕期内宜作OGTT筛查糖尿病<br />&nbsp;&nbsp;2.GDM 妇女产后6-12周重复OGTT以筛查糖尿病，并在以后定期随诊, 筛查是否发生糖尿病或糖尿病前期<br />&nbsp;&nbsp;应该在怀孕后第一次检查时进行GDM危险评估。具有GDM高危临床表现(如显著肥胖，有GDM病史、尿糖或糖尿病家族史)者应尽可能早的检测血糖水平。如果空腹血糖(FPG)≥7mmol/L或任意血糖≥11.1mmol/L且有明确的高血糖症状，即满足糖尿病的诊断标准，否则需要再测一次血糖以确诊。对于初次筛查时未诊为GDM的高危妇女及中等危险的妇女应在妊娠24～28周时进行以下推荐检查之一。<br />&nbsp;&nbsp;一步检查:行100g口服葡萄糖耐量试验(OGTT)。<br />&nbsp;&nbsp;二步检查:口服50g葡萄糖(葡萄糖耐量试验，GCT)后1h进行初次筛查，测血浆或血清葡萄糖水平，对于GCT中血糖超过阈值的妇女进行再诊断性的100gOGTT。如果GCT中把葡萄糖阈值定为≥7.77mmol/L，则可确诊近80%的GDM妇女，而将切点定为≥7.22mmol/L时，则可确诊者增加到90%。<br />&nbsp;&nbsp;100gOGTT诊断标准:空腹≥5.27mmol/L，1h血糖≥10mmol/L，2h血糖≥8.60mmol/L，3h血糖≥7.77mmol/L。以上不同时点血浆葡萄糖水平有两项或多项满足标准即可诊断GDM。另外，应该在清晨隔夜空腹8～14h时进行检测。也可做75g糖负荷试验，但其在鉴别高危婴儿及母亲的有效性方面不如100gOGTT。<br />&nbsp;&nbsp;对于满足以下所有条件的低危妇女无需检测血糖:(1)年龄<25岁。(2)怀孕前体重正常。(3)属于GDM发病率低的种族。(4)一级亲属没有糖尿病患者。(5)没有糖耐量异常史。(6)没有难产史。<br />&nbsp;&nbsp;因为GDM妇女发生糖尿病的危险增加，必须产后6 ～12周和以后定期进行糖尿病筛查。<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp;1. The FPG is the preferred test to diagnose diabetes in children and nonpregnant adults. <br />&nbsp;&nbsp;2. The use of the A1C for the diagnosis of diabetes is not recommended at this time. <br />&nbsp;&nbsp;Criteria for the diagnosis of diabetes in nonpregnant adults are shown in Table 2. Three ways to diagnose diabetes are available, and each must be confirmed on a subsequent day unless unequivocal symptoms of hyperglycemia are present. Although the 75-g oral glucose tolerance test (OGTT) is more sensitive and modestly more specific than fasting plasma glucose (FPG) to diagnose diabetes, it is poorly reproducible and rarely performed in practice. Because of ease of use, acceptability to patients, and lower cost, the FPG is the preferred diagnostic test. It should be noted that the vast majority of people who meet diagnostic criteria for diabetes by OGTT, but not by FPG, will have an A1C value＜7.0%. The use of the A1C for the diagnosis of diabetes is not recommended at this time.<br />&nbsp;&nbsp;Hyperglycemia not sufficient to meet the diagnostic criteria for diabetes is categorized as either IFG or impaired glucose tolerance (IGT), depending on whether it is identified through a FPG or an OGTT:<br />&nbsp;&nbsp;IFG = FPG 100 mg/dl (5.6mmol/l) to 125 mg/dl (6.9mmol/l)<br />&nbsp;&nbsp;IGT = 2-h plasma glucose 140 mg/dl (7.8mmol/l) to 199 mg/dl (11.0mmol/l) <br />&nbsp;&nbsp;Recently, IFG and IGT have been officially termed “pre-diabetes.” Both categories, IFG and IGT, are risk factors for future diabetes and cardiovascular disease (CVD).<br />&nbsp;&nbsp;In the absence of unequivocal hyperglycemia, these criteria should be confirmed by repeat testing on a different day. The OGTT is not recommended for routine clinical use, but may be required in the evaluation of patients with IFG (see text) or when diabetes is still suspected despite a normal FPG as with the postpartum evaluation of women with GDM.<br />&nbsp;&nbsp;Table 2 Criteria for the diagnosis of diabetes<br />&nbsp;&nbsp;1. Symptoms of diabetes and a casual plasma glucose ≥ 200 mg/dl (11.1mmol/l). Casual is defined as any time of day without regard to time since last meal. The classic symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss.<br />&nbsp;&nbsp;OR<br />&nbsp;&nbsp;2. FPG ≥ 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h. <br />&nbsp;&nbsp;OR <br />&nbsp;&nbsp;3. 2-h plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT. The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water. <br />&nbsp;&nbsp;Detection and diagnosis of gestational diabetes mellitus (GDM)<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp;1. Screen for diabetes in pregnancy using risk factor analysis and, if appropriate, use of an OGTT.<br />&nbsp;&nbsp;2. Women with gestational diabetes should be screened for diabetes 6-12 weeks postpartum and should be followed up with subsequent screening for the development of diabetes or prediabetes.<br />&nbsp;&nbsp;Risk assessment for GDM should be undertaken at the first prenatal visit. Women with clinical characteristics consistent with a high risk for GDM (those with marked obesity, personal history of GDM, glycosuria, or a strong family history of diabetes) should undergo glucose testing as soon as possible. An FPG ≥ 126 mg/dl or a casual plasma glucose ≥ 200 mg/dl meets the threshold for the diagnosis of diabetes and needs to be confirmed on a subsequent day unless unequivocal symptoms of hyperglycemia are present. High-risk women not found to have GDM at the initial screening and average-risk women should be tested between 24 and 28 weeks of gestation. Testing should follow one of two approaches: <br />&nbsp;&nbsp;One-step approach: perform a diagnostic 100-g OGTT<br />&nbsp;&nbsp;Two-step approach: perform an initial screening by measuring the plasma or serum glucose concentration 1 h after a 50-g oral glucose load (glucose challenge test [GCT]) and perform a diagnostic 100-g OGTT on that subset of women exceeding the glucose threshold value on the GCT. When the two-step approach is used, a glucose threshold value ≥ 140 mg/dl identifies～80% of women with GDM, and the yield is further increased to 90% by using a cutoff of≥ 130 mg/dl. <br />&nbsp;&nbsp;Diagnostic criteria for the 100-g OGTT are as follows: ≥ 95 mg/dl fasting, ≥ 180 mg/dl at 1 h, ≥ 155 mg/dl at 2 h, and ≥ 140 mg/dl at 3 h. Two or more of the plasma glucose values must be met or exceeded for a positive diagnosis. The test should be done in the morning after an overnight fast of 8–14 h. The diagnosis can be made using a 75-g glucose load, but that test is not as well validated for detection of at-risk infants or mothers as the 100-g OGTT. <br />&nbsp;&nbsp;Low-risk status requires no glucose testing, but this category is limited to those women meeting all of the following characteristics: <br />&nbsp;&nbsp;Age＜ 25 years.<br />&nbsp;&nbsp;Weight normal before pregnancy. <br />&nbsp;&nbsp;Member of an ethnic group with a low prevalence of GDM. <br />&nbsp;&nbsp;No known diabetes in first-degree relatives.<br />&nbsp;&nbsp;No history of abnormal glucose tolerance. <br />&nbsp;&nbsp;No history of poor obstetric outcome. <br />&nbsp;&nbsp;Because women with a history of GDMhave an increased subsequent risk for diabetes,they should be screened for diabetes6–12 weeks postpartum and shouldbe followed up with subsequent screeningfor the development of diabetes orpre-diabetes.<br />&nbsp;&nbsp;', null, 'A1C；Preprandial capillary plasma glucose；Peak postprandial capillary plasma glucose+', 'Recommended glycemic goals for nonpregnant individuals are shown in Table 6.<br />&nbsp;&nbsp; T01_004_01.jpg<br />&nbsp;&nbsp;非妊娠成年糖尿病患者血糖推荐标准总结如表6。<br />&nbsp;&nbsp;T01_004_02.jpg<br />&nbsp;&nbsp;', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('198', '1', 'T01_005', '1', 'ADA糖尿病医学诊疗标准-2008', 'Standards of Medical Care in Diabetesd-2008', '美国糖尿病学会（American Diabetes Association）', '2008', 'http://care.diabetesjournals.org/content/31/Supplement_1/S12.full.pdf', '英文', 'ADA1997年发布了新的诊断与分型标准，2003年进行了修改，提出空腹血糖受损(IFG)诊断标准。糖尿病包括4类临床型:<br />&nbsp;&nbsp;1型糖尿病(T1DM):由于β细胞受到破坏导致胰岛素绝对缺乏<br />&nbsp;&nbsp;2型糖尿病(T2DM):由于在胰岛素抵抗背景下进行性的胰岛素分泌缺陷<br />&nbsp;&nbsp;其他特殊型糖尿病:即由其他原因如β细胞功能的遗传缺陷，胰岛素作用的遗传缺陷，胰腺外分泌疾病(如囊性纤维病)以及药物或化学原因引起的(如治疗AIDS病或器官移植后)糖尿病<br />&nbsp;&nbsp;妊娠糖尿病(GDM):妊娠期间诊断的糖尿病<br />&nbsp;&nbsp;有些病人不能明确归为1型或2型，其临床表现和疾病进展同时具有两型的特征，如个别表现为T2DM可能有酮症酸中毒，同样有的T1DM病人尽管有自身免疫疾病表现，但其发病晚进展缓慢，这种诊断困难可见于儿童、青少年和成年人，确切诊断将会随着时间推移而明确。<br />&nbsp;&nbsp;In 1997, the ADA issued new diagnostic and classification criteria; in 2003, modifications were made regarding the diagnosis of impaired fasting glucose (IFG). The classification of diabetes includes four clinical classes:<br />&nbsp;&nbsp;Type 1 diabetes (results from β-cell destruction, usually leading to absolute insulin deficiency).<br />&nbsp;&nbsp;Type 2 diabetes (results from a progressive insulin secretory defect on the background of insulin resistance).<br />&nbsp;&nbsp;Other specific types of diabetes (due to other causes, e.g., genetic defects in β-cell function, genetic defects in insulin action, diseases of the exocrine pancreas(such as cystic fibrosis), and drug or chemical induced (such as in the treatment of AIDS or after organ transplantation).<br />&nbsp;&nbsp;Gestational diabetes mellitus (GDM) (diagnosed during pregnancy).<br />&nbsp;&nbsp;Some patients cannot be clearly classified as type 1 or type 2 diabetes. Clinical presentation and disease progression vary considerably in both types of diabetes. Occasionally, patients who otherwise have type 2 diabetes may present with ketoacidosis. Similarly, patients with type 1 may have a late onset and slow (but relentless) progression of disease despite having features of autoimmune disease. Such difficulties in diagnosis may occur in children, adolescents, and adults. The true diagnosis may become more obvious over time.<br />&nbsp;&nbsp;', '糠尿病', null, null, '建议<br />&nbsp;&nbsp;1. 空腹血糖(FPG)检测是目前青少年及非妊娠成人首要诊断检测方法；<br />&nbsp;&nbsp;2. 目前不建议采用糖化血红蛋白(HbA1c)指标来诊断糖尿病(E)。<br />&nbsp;&nbsp;表2列出了当前非妊娠成人糖尿病的诊断标准。此表共推荐了3种诊断糖尿病的方法，除非出现明确的高血糖症状，两次诊断试验(于不同的两天进行)结果都达到诊断标准，才可明确诊断为糖尿病。75g口服葡萄糖耐量试验(OGTT)诊断糖尿病的敏感性和特异性优于空腹血浆葡萄糖(FPG)检测，但操作起来比较麻烦。由于FPG检测操作简单、患者易于接受及成本较低，已经成为诊断糖尿病的首选检测方法。虽然FPG检测敏感性不如OGTT，不过，大部分FPG检测不满足而OGTT满足糖尿病诊断标准的患者，A1C水平在7．0%以下。<br />&nbsp;&nbsp;虽然OGTT不被推荐常规应用于临床，但是，OGTT检测可用于对那些高度怀疑糖尿病的FPG正常者或IFG患者进行进一步评价(见I.C)。<br />&nbsp;&nbsp;由于缺乏全球性的标准化检测方法以及诊断标准的不明确，A1C不被推荐用于诊断糖尿病。<br />&nbsp;&nbsp;表2糖尿病诊断标准<br />&nbsp;&nbsp;1. FPG≥126mg/dl(7.0mmol/L)。空腹是指至少8小时无热量摄入。<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;2. 出现高血糖症状，且随机血糖≥200mg/dl(11.1mmol/L)。随机是指一天当中的任何时间，高血糖的典型症状是指多尿、多饮及不明原因的体重减轻。<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;3. OGTT2小时血糖≥200mg/dl(11.1mmol/L)。该检测应当按照世界卫生组织的标准，需饮用75g无水葡萄精的水溶液。<br />&nbsp;&nbsp;如果无高血糖症状，两次诊断试验(于不同的两天进行)结果都达到诊断标准才可明确诊断为糖尿病。<br />&nbsp;&nbsp;妊娠糖尿病的筛查及诊断<br />&nbsp;&nbsp;建议<br />&nbsp;&nbsp;1.孕期内宜作OGTT筛查糖尿病。<br />&nbsp;&nbsp;2.GDM妇女产后6～12周重复OGTT以筛查糖尿病，并在以后定期随诊，筛查是否发生糖尿病或糖尿病前期。<br />&nbsp;&nbsp;表5 GDM筛查及诊断标准<br />&nbsp;&nbsp;首次产前检查即进行GDM风险评估<br />&nbsp;&nbsp;有GDM极高风险的妇女，妊娠后应当尽快筛查糖尿病。超高风险的标准如下： <br />&nbsp;&nbsp;1.重度肥胖<br />&nbsp;&nbsp;2.有GDM病史或高龄分娩史<br />&nbsp;&nbsp;3.尿糖阳性<br />&nbsp;&nbsp;4.患有PCOS <br />&nbsp;&nbsp;5.明显的2型糖尿病家族史<br />&nbsp;&nbsp;妊娠期间的筛查/诊断应当采用标准的检测手段(表2)<br />&nbsp;&nbsp;所有非GDM低风险的妇女，包括上述在妊娠早期没有发现GDM者，都应当在妊娠24～28周筛查GDM。不需要筛查GDM的低风险状态，要包含所有以下特征： <br />&nbsp;&nbsp;1.年龄<25岁<br />&nbsp;&nbsp;2.妊娠前体重正常<br />&nbsp;&nbsp;3.属于糖尿病患病率低的族群<br />&nbsp;&nbsp;4.一级亲属无糖尿病患者<br />&nbsp;&nbsp;5.无糖耐量异常史<br />&nbsp;&nbsp;6.无产科异常病史<br />&nbsp;&nbsp;妊娠24～28周筛查GDM，可按照下述两种方法进行： <br />&nbsp;&nbsp;1．两步法：<br />&nbsp;&nbsp;A．先做50g葡萄糖负荷后1h血糖筛查试验。80%GDM血糖≥140mg/dl(7.8mmol/L)，90%GDM血糖≥l30mg/dl(7.2mmol/L)。<br />&nbsp;&nbsp;B．第一步检测血糖值超标者，选另外一天做l00g0GTT。<br />&nbsp;&nbsp;2．一步法(门诊首选确定GDM高危者的方法)： <br />&nbsp;&nbsp;所有妊娠24～28周的妇女都进行100g0GTT。<br />&nbsp;&nbsp;100g0GTT应当在早上进行(检测前夜间至少要空腹8小时)，确诊GDM，必须满足以下条件： <br />&nbsp;&nbsp;空腹≥95mg/dl(5.3mmol/L)<br />&nbsp;&nbsp;lh≥180mg/dl (10mmol/L)<br />&nbsp;&nbsp;2h≥155mg/dl (8.6mmol/L)<br />&nbsp;&nbsp;3h≥140mg/dl (7.8mmol/L)<br />&nbsp;&nbsp;GDM是指妊娠期间首发或首次发现任意程度的葡萄糖耐量减低。虽然大部分患者在分娩后血糖恢复正常，但是，不管妊娠后高血糖是否恢复正常，以及葡萄糖耐量减低发生在妊娠之前或妊娠期间，该定义都适用。大约7%(根据研究人群和检测手段的不同，比率分布在1%～14%之间)的妊娠妇女会患上GDM，结果造成每年新增超过200000名GDM患者。<br />&nbsp;&nbsp;由于GDM可危机母婴健康，因此必须进行筛查和诊断。筛查及诊断标准(表5)是基于2004年ADA关于GDM的声明制定的。<br />&nbsp;&nbsp;高血压与妊娠预后不良研究(The Hyperglycemia and Adverse Pregnancy Outcomes study) 是一项大规模(纳入25000名妊娠妇女)跨国流行病学研究。该研究证明，妊娠24～28周随着母体血糖升高，可导致母体、胎儿及新生儿不良预后风险持续升高，甚至先前被认为对妊娠无影响的血糖范围也被证明是有害的。目前，GDM大部分并发症尚无统一的风险标准。因此，应当认真地重新考虑GDM的诊断标准。目前，一个代表产科病、糖尿病组织的多学科国际团队正试图达成以下两个方面的共识：(1)GDM诊断检测手段的国际标准；(2)合理的诊断切点。<br />&nbsp;&nbsp;有GDM病史的妇女此后患糖尿病的风险很高，因此，应当在产后6～12周采用非妊娠OGTT标准进行糖尿病筛查，并且应当随访筛查糖尿病或糖尿病前期(见II)。<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp;1. The fasting plasma glucose (FPG) test is the preferred test to diagnose diabetes in children and nonpregnant adults.<br />&nbsp;&nbsp;2. Use of the A1C for the diagnosis of diabetes is not recommended at this time. <br />&nbsp;&nbsp;Criteria for the diagnosis of diabetes in nonpregnant adults are shown in Table 2 Three ways to diagnose diabetes are available, and each must be confirmed on a subsequent day unless unequivocal symptoms of hyperglycemia are present. Although the 75-g oral glucose tolerance test (OGTT) is more sensitive and modestly more specific than the FPG to diagnose diabetes, it is poorly reproducible and difficult to perform in practice. Because of ease of use, acceptability to patients, and lower cost, the FPG is the preferred diagnostic test. Although the FPG is less sensitive than the OGTT, the vast majority of people who do not meet diagnostic criteria for diabetes by the FPG but would by the OGTT will have an A1C value well below 7.0%. <br />&nbsp;&nbsp;Although the OGTT is not recommended for routine clinical use, it may be useful for further evaluation of patients in whom diabetes is still strongly suspected but who have normal FPG or impaired fasting glucose (IFG).<br />&nbsp;&nbsp;Due to lack of evidence on prognostic significance and diagnostic thresholds, the use of the A1C for the diagnosis of diabetes is not recommended at this time. <br />&nbsp;&nbsp;Table 2 Criteria for the diagnosis of diabetes<br />&nbsp;&nbsp;1. FPG≥ 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at<br />&nbsp;&nbsp;least 8 h.<br />&nbsp;&nbsp;OR<br />&nbsp;&nbsp;2. Symptoms of hyperglycemia and a casual plasma glucose≥ 200 mg/dl (11.1mmol/l). Casual is defined as any time of day without regard to time since last<br />&nbsp;&nbsp;meal. The classic symptoms of hyperglycemia include polyuria, polydipsia, and<br />&nbsp;&nbsp;unexplained weight loss.<br />&nbsp;&nbsp;OR<br />&nbsp;&nbsp;3. 2-h plasma glucose≥ 200 mg/dl (11.1 mmol/l) during an OGTT. The test<br />&nbsp;&nbsp;should be performed as described by the World Health Organization, using a<br />&nbsp;&nbsp;glucose load containing the equivalent of 75 g anhydrous glucose dissolved in<br />&nbsp;&nbsp;water.<br />&nbsp;&nbsp;In the absence of unequivocal hyperglycemia, these criteria should be confirmed by repeat testing on adifferent day.<br />&nbsp;&nbsp;Detection and diagnosis of gestational diabetes mellitus (GDM)<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp;1. Screen for GDM using risk factor analysis and, if appropriate, use of an OGTT. <br />&nbsp;&nbsp;2. Women with GDM should be screened for diabetes 6–12 weeks postpartum and should be followed up with subsequent screening for the development of diabetes or pre-diabetes.<br />&nbsp;&nbsp;Gestational diabetes mellitus is defined as any degree of glucose intolerance with onset or first recognition during pregnancy. Although most cases resolve with delivery, the definition applies whether or not the condition persists after pregnancy and does not exclude the possibility that unrecognized glucose intolerance may have antedated or begun concomitantly with the pregnancy. Approximately 7% of all pregnancies (ranging from 1 to 14% depending on the population studied and the diagnostic tests used) are complicated by GDM, resulting in more than 200,000 cases annually. <br />&nbsp;&nbsp;Because of the risks of GDM to the mother and neonate, screening and diagnosis are warranted. The screening and diagnostic strategies, based on the 2004 ADA position statement on gestational diabetes mellitus, are outlined in Table 5. <br />&nbsp;&nbsp;Results of the Hyperglycemia and Adverse Pregnancy Outcomes study were reported at ADA’s 67th Annual Scientific Sessions in June 2007. This large-scale (25,000 pregnant women), multinational, epidemiologic study demonstrated that risk of adverse maternal, fetal, and neonatal outcomes continuously increased as a function of maternal glycemia at 24–28 weeks, even within ranges previously considered normal for pregnancy. For most complications, there was no threshold for risk. These results may call for careful reconsideration of the diagnostic criteria for GDM. <br />&nbsp;&nbsp;Because women with a history of GDM have a greatly increased subsequent risk for diabetes (24), they should be screened for diabetes 6–12 weeks postpartum, using standard criteria, and should be followed up with subsequent screening for the development of diabetes or pre-diabetes, as outlined in Section II. <br />&nbsp;&nbsp;Table 5—Screening for and diagnosis of GDM<br />&nbsp;&nbsp;Carry out GDM risk assessment at the first prenatal visit.<br />&nbsp;&nbsp;Women at very high risk for GDM should be screened for diabetes as soon as possible after the confirmation of pregnancy. Criteria for very high risk are:<br />&nbsp;&nbsp;1. Severe obesity<br />&nbsp;&nbsp;2. Prior history of GDM or delivery of large-for-gestational-age infant<br />&nbsp;&nbsp;3. Presence of glycosuria<br />&nbsp;&nbsp;4. Diagnosis of PCOS<br />&nbsp;&nbsp;5. Strong family history of type 2 diabetes <br />&nbsp;&nbsp;Screening/diagnosis at this stage of pregnancy should use standard diagnostic testing (Table 2) All women of higher than low risk of GDM, including those above not found to have diabetes early in pregnancy, should undergo GDM testing at 24–28 weeks of gestation. Low risk status, which does not require GDM screening, is defined as women with all of the following characteristics:<br />&nbsp;&nbsp;1. Age25 years<br />&nbsp;&nbsp;2. Weight normal before pregnancy<br />&nbsp;&nbsp;3. Member of an ethnic group with a low prevalence of diabetes<br />&nbsp;&nbsp;4. No known diabetes in first-degree relatives<br />&nbsp;&nbsp;5. No history of abnormal glucose tolerance<br />&nbsp;&nbsp;6. No history of poor obstetrical outcome <br />&nbsp;&nbsp;Two approaches may be followed for GDM screening at 24–28 weeks: <br />&nbsp;&nbsp;1. Two-step approach:<br />&nbsp;&nbsp; A. Perform initial screening by measuring plasma or serum glucose 1 h after a 50-g oral glucose load. A glucose threshold after 50-g load of≥ 140 mg/dl identifies～ 80% of women with GDM, while the sensitivity is further increased to～ 90% by a threshold of≥ 130 mg/dl. <br />&nbsp;&nbsp;B. Perform a diagnostic 100-g OGTT on a separate day in women who exceed the chosen threshold on 50-g screening.<br />&nbsp;&nbsp;2. One-step approach (may be preferred in clinics with high prevalence of GDM): Perform a diagnostic 100-g OGTT in all women to be tested at 24–28 weeks. <br />&nbsp;&nbsp;The 100-g OGTT should be performed in the morning after an overnight fast of at least 8 h. <br />&nbsp;&nbsp;A diagnosis of GDM requires at least two of the following plasma glucose values:<br />&nbsp;&nbsp;Fasting:≥ 95 mg/dl (5.3 mmol/l) <br />&nbsp;&nbsp;1 h:≥ 180 mg/dl (10.0 mmol/l) <br />&nbsp;&nbsp;2 h:≥ 155 mg/dl (8.6 mmol/l) <br />&nbsp;&nbsp;3 h:≥ 140 mg/dl (7.8 mmol/l) <br />&nbsp;&nbsp;', null, 'A1C；Preprandial capillary plasma glucose；Peak postprandial capillary plasma glucose+', 'Recommended glycemic goals for nonpregnant individuals are shown in Table 8.<br />&nbsp;&nbsp;T01_005_01.jpg<br />&nbsp;&nbsp;', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('199', '1', 'T01_006', '1', 'ADA糖尿病医学诊疗标准-2009', 'Standards of Medical Care in Diabetesd-2009', '美国糖尿病学会（American Diabetes Association）', '2009', 'http://care.diabetesjournals.org/content/32/Supplement_1/S13.full.pdf', '英文', '1997年，ADA公布了新的糖尿病诊断和分类标准；2003年，对空腹血糖受损的诊断标准进行了修订。糖尿病在临床上分为以下4类： <br />&nbsp;&nbsp;l型糖尿病(因β细胞被破坏所致，常导致胰岛素绝对缺乏) <br />&nbsp;&nbsp;2型糖尿病(在胰岛素抵抗基础上出现进行性胰岛素分泌不足) <br />&nbsp;&nbsp;其他特殊类型的糖尿病，发病原因有多种，例如：β细胞基因缺陷，胰岛素作用基因缺陷，胰腺外分泌腺疾病(例如：囊肿性纤维化)，药物或化学原因诱发(例如：AIDS或器官移植后的治疗) <br />&nbsp;&nbsp;妊娠糖尿病(GDM)(妊娠期间诊断为糖尿病) <br />&nbsp;&nbsp;一些患者不能明确归为l型或2型糖尿病。有时候，2型糖尿病可能发生酮症酸中毒，而l型糖尿病患者虽然有自身免疫性疾病的特征，却延迟发病，且进展缓慢(但呈持续性)。这可能给儿童、青少年和成人糖尿病的诊断带来困难。不过，随着疾病的进展，诊断会越来越明确。<br />&nbsp;&nbsp;In 1997, the ADA issued new diagnostic and classification criteria; in 2003, modifications were made regarding the diagnosis of impaired fasting glucose (IFG). The classification of diabetes includes four clinical classes:<br />&nbsp;&nbsp;Type 1 diabetes (results from β-cell destruction, usually leading to absolute insulin deficiency).<br />&nbsp;&nbsp;Type 2 diabetes (results from a progressive insulin secretory defect on the background of insulin resistance).<br />&nbsp;&nbsp;Other specific types of diabetes (due to other causes, e.g., genetic defects in β-cell function, genetic defects in insulin action, diseases of the exocrine pancreas(such as cystic fibrosis), and drug or chemical induced (such as in the treatment of AIDS or after organ transplantation).<br />&nbsp;&nbsp;Gestational diabetes mellitus (GDM) (diagnosed during pregnancy).<br />&nbsp;&nbsp;Some patients cannot be clearly classified as type 1 or type 2 diabetes. Clinical presentation and disease progression vary considerably in both types of diabetes. Occasionally, patients who otherwise have type 2 diabetes may present with ketoacidosis. Similarly, patients with type 1 may have a late onset and slow (but relentless) progression of disease despite having features of autoimmune disease. Such difficulties in diagnosis may occur in children, adolescents, and adults. The true diagnosis may become more obvious over time.<br />&nbsp;&nbsp;', '糠尿病', null, null, '表2列出了当前非妊娠成人糖尿病的诊断标准。此表共推荐了3种诊断糖尿病的方法，除非出现明确的高血糖症状，两次诊断试验(于不同的两天进行)结果都达到诊断标准，才可明确诊断为糖尿病。75g口服葡萄糖耐量试验(OGTT)诊断糖尿病的敏感性和特异性优于空腹血浆葡萄糖(FPG)检测，但操作起来比较麻烦。由于FPG检测操作简单、患者易于接受及成本较低，已经成为诊断糖尿病的首选检测方法。虽然FPG检测敏感性不如OGTT，不过，大部分FPG检测不满足而OGTT满足糖尿病诊断标准的患者，A1C水平在7．0%以下。<br />&nbsp;&nbsp;虽然OGTT不被推荐常规应用于临床，但是，OGTT检测可用于对那些高度怀疑糖尿病的FPG正常者或IFG患者进行进一步评价(见I.C)。<br />&nbsp;&nbsp;以前，由于缺乏全球性的标准化检测方法以及诊断标准的不明确，A1C不被推荐用于诊断糖尿病。但是，随着A1C检测方法全球标准化趋势的增强，以及支持A1C用于预测糖尿病的观察性研究证据的逐渐增多，2008年，美国糖尿病协会(ADA)、欧洲糖尿病研究协会(EASD)与国际糖尿病联盟(IDF)成立了一个联合委员会，该委员会将有可能推荐A1C作为诊断糖尿病的首选检测指标，本指南发布时，关于诊断糖尿病的A1C切点问题，正在讨论当中，最新进展将发布在((Diabetes Care))及diabetes．org。<br />&nbsp;&nbsp;表2糖尿病诊断标准<br />&nbsp;&nbsp;1. FPG≥126mg/dl(7.0mmol/L)。空腹是指至少8小时无热量摄入。<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;2. 出现高血糖症状，且随机血糖≥200mg/dl(11.1mmol/L)。随机是指一天当中的任何时间，高血糖的典型症状是指多尿、多饮及不明原因的体重减轻。<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;3. OGTT2小时血糖≥200mg/dl(11.1mmol/L)。该检测应当按照世界卫生组织的标准，需饮用75g无水葡萄精的水溶液。<br />&nbsp;&nbsp;如果无高血糖症状，两次诊断试验(于不同的两天进行)结果都达到诊断标准才可明确诊断为糖尿病。<br />&nbsp;&nbsp;妊娠糖尿病的筛查及诊断<br />&nbsp;&nbsp;建议<br />&nbsp;&nbsp;1.孕期内宜作OGTT筛查糖尿病。<br />&nbsp;&nbsp;2.GDM妇女产后6～12周重复OGTT以筛查糖尿病，并在以后定期随诊，筛查是否发生糖尿病或糖尿病前期。<br />&nbsp;&nbsp;表5 GDM筛查及诊断标准<br />&nbsp;&nbsp;首次产前检查即进行GDM风险评估<br />&nbsp;&nbsp;有GDM极高风险的妇女，妊娠后应当尽快筛查糖尿病。超高风险的标准如下： <br />&nbsp;&nbsp;1.重度肥胖<br />&nbsp;&nbsp;2.有GDM病史或高龄分娩史<br />&nbsp;&nbsp;3.尿糖阳性<br />&nbsp;&nbsp;4.患有PCOS <br />&nbsp;&nbsp;5.明显的2型糖尿病家族史<br />&nbsp;&nbsp;妊娠期间的筛查/诊断应当采用标准的检测手段(表2)<br />&nbsp;&nbsp;所有非GDM低风险的妇女，包括上述在妊娠早期没有发现GDM者，都应当在妊娠24～28周筛查GDM。不需要筛查GDM的低风险状态，要包含所有以下特征： <br />&nbsp;&nbsp;1.年龄<25岁<br />&nbsp;&nbsp;2.妊娠前体重正常<br />&nbsp;&nbsp;3.属于糖尿病患病率低的族群<br />&nbsp;&nbsp;4.一级亲属无糖尿病患者<br />&nbsp;&nbsp;5.无糖耐量异常史<br />&nbsp;&nbsp;6.无产科异常病史<br />&nbsp;&nbsp;妊娠24～28周筛查GDM，可按照下述两种方法进行： <br />&nbsp;&nbsp;1．两步法：<br />&nbsp;&nbsp;A．先做50g葡萄糖负荷后1h血糖筛查试验。80%GDM血糖≥140mg/dl(7.8mmol/L)，90%GDM血糖≥l30mg/dl(7.2mmol/L)。<br />&nbsp;&nbsp;B．第一步检测血糖值超标者，选另外一天做l00g0GTT。<br />&nbsp;&nbsp;2．一步法(门诊首选确定GDM高危者的方法)： <br />&nbsp;&nbsp;所有妊娠24～28周的妇女都进行100g0GTT。<br />&nbsp;&nbsp;100g0GTT应当在早上进行(检测前夜间至少要空腹8小时)，确诊GDM，必须满足以下条件： <br />&nbsp;&nbsp;空腹≥95mg/dl(5.3mmol/L)<br />&nbsp;&nbsp;lh≥180mg/dl (10mmol/L)<br />&nbsp;&nbsp;2h≥155mg/dl (8.6mmol/L)<br />&nbsp;&nbsp;3h≥140mg/dl (7.8mmol/L)<br />&nbsp;&nbsp;GDM是指妊娠期间首发或首次发现任意程度的葡萄糖耐量减低。虽然大部分患者在分娩后血糖恢复正常，但是，不管妊娠后高血糖是否恢复正常，以及葡萄糖耐量减低发生在妊娠之前或妊娠期间，该定义都适用。大约7%(根据研究人群和检测手段的不同，比率分布在1%～14%之间)的妊娠妇女会患上GDM，结果造成每年新增超过200000名GDM患者。<br />&nbsp;&nbsp;由于GDM可危机母婴健康，因此必须进行筛查和诊断。筛查及诊断标准(表5)是基于2004年ADA关于GDM的声明制定的。<br />&nbsp;&nbsp;高血压与妊娠预后不良研究(The Hyperglycemia and Adverse Pregnancy Outcomes study) 是一项大规模(纳入25000名妊娠妇女)跨国流行病学研究。该研究证明，妊娠24～28周随着母体血糖升高，可导致母体、胎儿及新生儿不良预后风险持续升高，甚至先前被认为对妊娠无影响的血糖范围也被证明是有害的。目前，GDM大部分并发症尚无统一的风险标准。因此，应当认真地重新考虑GDM的诊断标准。目前，一个代表产科病、糖尿病组织的多学科国际团队正试图达成以下两个方面的共识：(1)GDM诊断检测手段的国际标准；(2)合理的诊断切点。<br />&nbsp;&nbsp;有GDM病史的妇女此后患糖尿病的风险很高，因此，应当在产后6～12周采用非妊娠OGTT标准进行糖尿病筛查，并且应当随访筛查糖尿病或糖尿病前期(见II)。<br />&nbsp;&nbsp;Current criteria for the diagnosis of diabetes in nonpregnant adults are shown in Table 2. Three ways to diagnose diabetes are recommended at the time of this statement, and each must be confirmed on a subsequent day unless unequivocal symptoms of hyperglycemia are present. Although the 75-g oral glucose tolerance test (OGTT) is more sensitive and modestly more specific than the fasting plasma glucose (FPG) to diagnose diabetes, it is poorly reproducible and difficult to perform in practice. Because of ease of use, acceptability to patients, and lower cost, the FPG has been the preferred diagnostic test. Though FPG is less sensitive than the OGTT, the vast majority of people who do not meet diagnostic criteria for diabetes by FPG but would by OGTT will have an A1C value well under 7.0%. <br />&nbsp;&nbsp;Though the OGTT is not recommended for routine clinical use, it may be useful for further evaluation of patients in whom diabetes is still strongly suspected but who have normal FPG or IFG. <br />&nbsp;&nbsp;The use of the A1C for the diagnosis of diabetes has previously not been recommended due to lack of global standardization and uncertainty about diagnostic thresholds. However, with a world-wide move toward a standardized assay and with increasing observational evidence about the prognostic significance of A1C, an Expert Committee on the Diagnosis of Diabetes was convened in 2008. This joint committee of ADA, the European Association for the Study of Diabetes, and the International Diabetes Federation will likely recommend that the A1C become the preferred diagnostic test for diabetes. Diagnostic cut-points are being discussed at the time of publication of this statement. Updated recommendations will be published in Diabetes Care and will be available at diabetes.org.<br />&nbsp;&nbsp;Table 2 Criteria for the diagnosis of diabetes<br />&nbsp;&nbsp;1. FPG ≥ 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at<br />&nbsp;&nbsp;least 8 h.<br />&nbsp;&nbsp;OR<br />&nbsp;&nbsp;2. Symptoms of hyperglycemia and a casual plasma glucose ≥ 200 mg/dl (11.1<br />&nbsp;&nbsp;mmol/l). Casual is defined as any time of day without regard to time since last<br />&nbsp;&nbsp;meal. The classic symptoms of hyperglycemia include polyuria, polydipsia, and<br />&nbsp;&nbsp;unexplained weight loss.<br />&nbsp;&nbsp;OR<br />&nbsp;&nbsp;3. 2-h plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT. The test<br />&nbsp;&nbsp;should be performed as described by the World Health Organization, using a<br />&nbsp;&nbsp;glucose load containing the equivalent of 75 g anhydrous glucose dissolved in<br />&nbsp;&nbsp;water.<br />&nbsp;&nbsp;In the absence of unequivocal hyperglycemia, these criteria should be confirmed by repeat testing on a different day.<br />&nbsp;&nbsp;Detection and diagnosis of gestational diabetes mellitus (GDM)<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp;1. Screen for GDM using risk factor analysis and, if appropriate, use of an OGTT. <br />&nbsp;&nbsp;2. Women with GDM should be screened for diabetes 6–12 weeks postpartum and should be followed up with subsequent screening for the development of diabetes or pre-diabetes.<br />&nbsp;&nbsp;Gestational diabetes mellitus is defined as any degree of glucose intolerance with onset or first recognition during pregnancy. Although most cases resolve with delivery, the definition applies whether or not the condition persists after pregnancy and does not exclude the possibility that unrecognized glucose intolerance may have antedated or begun concomitantly with the pregnancy. Approximately 7% of all pregnancies (ranging from 1 to 14% depending on the population studied and the diagnostic tests used) are complicated by GDM, resulting in more than 200,000 cases annually. <br />&nbsp;&nbsp;Because of the risks of GDM to the mother and neonate, screening and diagnosis are warranted. The screening and diagnostic strategies, based on the 2004 ADA position statement on gestational diabetes mellitus, are outlined in Table 5. <br />&nbsp;&nbsp;Results of the Hyperglycemia and Adverse Pregnancy Outcomes study were reported at ADA’s 67th Annual Scientific Sessions in June 2007. This large-scale (25,000 pregnant women), multinational, epidemiologic study demonstrated that risk of adverse maternal, fetal, and neonatal outcomes continuously increased as a function of maternal glycemia at 24–28 weeks, even within ranges previously considered normal for pregnancy. For most complications, there was no threshold for risk. These results may call for careful reconsideration of the diagnostic criteria for GDM. <br />&nbsp;&nbsp;Because women with a history of GDM have a greatly increased subsequent risk for diabetes (24), they should be screened for diabetes 6–12 weeks postpartum, using standard criteria, and should be followed up with subsequent screening for the development of diabetes or pre-diabetes, as outlined in Section II. <br />&nbsp;&nbsp;Table 5Screening for and diagnosis of GDM<br />&nbsp;&nbsp;Carry out GDM risk assessment at the first prenatal visit.<br />&nbsp;&nbsp;Women at very high risk for GDM should be screened for diabetes as soon as possible after the confirmation of pregnancy. Criteria for very high risk are:<br />&nbsp;&nbsp;1. Severe obesity<br />&nbsp;&nbsp;2. Prior history of GDM or delivery of large-for-gestational-age infant<br />&nbsp;&nbsp;3. Presence of glycosuria<br />&nbsp;&nbsp;4. Diagnosis of PCOS<br />&nbsp;&nbsp;5. Strong family history of type 2 diabetes <br />&nbsp;&nbsp;Screening/diagnosis at this stage of pregnancy should use standard diagnostic testing (Table 2).<br />&nbsp;&nbsp;All women of higher than low risk of GDM, including those above not found to have diabetes early in pregnancy, should undergo GDM testing at 24–28 weeks of gestation. Low risk status, which does not require GDM screening, is defined as women with all of the following characteristics:<br />&nbsp;&nbsp;1. Age25 years<br />&nbsp;&nbsp;2. Weight normal before pregnancy<br />&nbsp;&nbsp;3. Member of an ethnic group with a low prevalence of diabetes<br />&nbsp;&nbsp;4. No known diabetes in first-degree relatives<br />&nbsp;&nbsp;5. No history of abnormal glucose tolerance<br />&nbsp;&nbsp;6. No history of poor obstetrical outcome <br />&nbsp;&nbsp;Two approaches may be followed for GDM screening at 24–28 weeks: <br />&nbsp;&nbsp;1. Two-step approach: <br />&nbsp;&nbsp;A. Perform initial screening by measuring plasma or serum glucose 1 h after a 50-g oral glucose load. A glucose threshold after 50-g load of ≥ 140 mg/dl identifies ～ 80% of women with GDM, while the sensitivity is further increased to ～ 90% by a threshold of ≥ 130 mg/dl. <br />&nbsp;&nbsp;B. Perform a diagnostic 100-g OGTT on a separate day in women who exceed the chosen threshold on 50-g screening.<br />&nbsp;&nbsp;2. One-step approach (may be preferred in clinics with high prevalence of GDM): Perform a diagnostic 100-g OGTT in all women to be tested at 24–28 weeks. <br />&nbsp;&nbsp;The 100-g OGTT should be performed in the morning after an overnight fast of at least 8 h. <br />&nbsp;&nbsp;A diagnosis of GDM requires at least two of the following plasma glucose values:<br />&nbsp;&nbsp;Fasting: ≥ 95 mg/dl (5.3 mmol/l) <br />&nbsp;&nbsp;1 h: ≥ 180 mg/dl (10.0 mmol/l) <br />&nbsp;&nbsp;2 h: ≥ 155 mg/dl (8.6 mmol/l) <br />&nbsp;&nbsp;3 h: ≥ 140 mg/dl (7.8 mmol/l) <br />&nbsp;&nbsp;', null, 'A1C；Preprandial capillary plasma glucose；Peak postprandial capillary plasma glucose+', 'Recommended glycemic goals for nonpregnant individuals are shown in Table 9.<br />&nbsp;&nbsp;T01_006_01.jpg<br />&nbsp;&nbsp;T01_006_02.jpg<br />&nbsp;&nbsp;', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('2', '10', 'D02_002', '0', '糖尿病中医防治指南', 'Guidelines for TCM diabetes Prevention and Treatment', '中华中医药学会', '2007', 'ZYYXH/T3.1～3.15-2007,糖尿病中医防治指南[S].', '中文', null, null, '代谢综合征', '1.气滞湿阻证<br />&nbsp;&nbsp;2.痰瘀互结证<br />&nbsp;&nbsp;3.气阴两虚证<br />&nbsp;&nbsp;4.脾肾气虚证', '1.临床表现<br />&nbsp;&nbsp;1.1症状<br />&nbsp;&nbsp;MS部分患者可无临床症状，或见体胖腹满、食多、气短、容易疲劳，或胸胁闷胀、头晕目眩、头痛、烦躁易怒、口渴喜饮等。<br />&nbsp;&nbsp;1.2体征<br />&nbsp;&nbsp;MS多见中心性肥胖、体重超重、血压偏高等。<br />&nbsp;&nbsp;2.理化检查<br />&nbsp;&nbsp;2.1血脂异常<br />&nbsp;&nbsp;2.2血糖代谢异常<br />&nbsp;&nbsp;2.3体脂分布异常<br />&nbsp;&nbsp;3.诊断标准<br />&nbsp;&nbsp;3.1国际糖尿病联盟2005年诊断标准：一个个体在具有必备指标的基础上至少还具有其他指标中的任何两项可被诊断为MS。目前多以此标准为准。<br />&nbsp;&nbsp;3.1.1必备指标<br />&nbsp;&nbsp;中心性肥胖（不同种族腰围有各自的参考值，推荐中国人腹围切点：男性≥85cm；女性≥80cm）。<br />&nbsp;&nbsp;3.1.2其他指标<br />&nbsp;&nbsp;甘油三酯（TG）水平升：>1.7mmol/L（150mg/dl），或已接受针对性治疗。<br />&nbsp;&nbsp;高密度脂蛋白-胆固醇（HDL-C）水平降低：男性<0.9mmol/L（40mg/dl），女性<1.1mmol/L（50mg/dl），或已接受针对性治疗。<br />&nbsp;&nbsp;血压升高：收缩压≥130mmHg或舒张压≥85mmHg，或已接受降压治疗或此前已被诊断为高血压。<br />&nbsp;&nbsp;空腹血糖（FPG）升高：FPG≥5.6mmol/L（100mg/dl），或此前已被诊断为2型糖尿病。<br />&nbsp;&nbsp;如果≥5.6mmol/L（100mg/dl），强烈推荐进行口服葡萄糖耐量试验（OGTT），但是OGTT在诊断MS时并非必要。<br />&nbsp;&nbsp;3.2中华医学会糖尿病学分会（CDS）2004年诊断标准：具有以下4项中的3项或全部者即可确诊。<br />&nbsp;&nbsp;3.2.1超重或体重指数（BMI）≥25kg/m2。<br />&nbsp;&nbsp;3.2.2空腹血糖（FPG）≥6.1mmol/L（110mg/dl）和（或）75g葡萄糖负荷后2小时血糖（2hPG）≥7.8mmol/L（140mg/dI）和（或）确诊为DM并治疗者。<br />&nbsp;&nbsp;3.2.3血压（BP）≥140/90mmHg和（或）已确诊为高血压并治疗者。<br />&nbsp;&nbsp;3.2.4甘油三酯（TG）≥1.7mmo1/L（150mg/dl）和（或）高密度脂蛋白（HDL-C）中男<0.9mmo1/L（35mg/dl）、女<1.0mmol/L（38.9mg/dl）。<br />&nbsp;&nbsp;4.鉴别诊断<br />&nbsp;&nbsp;皮质醇增多症患者的肥胖呈向心性分布，同时伴有满月脸、高血压、多血质外貌、痤疮等。单纯性肥胖与皮质醇增多症的实质区别是确定有无皮质醇分泌过多。实验室检查：24小时尿游离皮质醇测定、皮质醇昼夜节律测定、过夜1mg地塞米松抑制试验。', 'MS与脾、肝、肾三脏关系密切，以痰浊、瘀滞为其病机核心。脾失健运，肝失疏泄，脾肾不足；水湿内生，痰浊停滞，瘀血内阻而为本病。病久郁积化热，耗气伤阴，本虚标实。<br />&nbsp;&nbsp;1.气滞湿阻证<br />&nbsp;&nbsp;症状：患者可没有明显不适，仅有体胖腹满、食多、不耐疲劳等症状，舌苔厚腻，脉象弦或略滑。<br />&nbsp;&nbsp;2.痰瘀互结证<br />&nbsp;&nbsp;症状：胸院腹胀，头身困重，或四肢倦怠，胸胁刺痛，舌质暗、有瘀斑，脉弦或沉涩。<br />&nbsp;&nbsp;3.气阴两虚证<br />&nbsp;&nbsp;症状：疲倦乏力，气短自汗，口干多饮，大便干结，舌质淡红，少苔，脉沉细无力或细数。<br />&nbsp;&nbsp;4.脾肾气虚证<br />&nbsp;&nbsp;症状：气短乏力，小便清长，腰膝酸痛，夜尿频多，大便塘泄，或下肢水肿，尿浊如脂，阳痰，头昏耳鸣，舌淡胖，苔薄白或嫩，脉沉细或细弱无力。', null, ' ', '疾病诊断标准采用的是国际糖尿病联盟2005年诊断标准和中华医学会糖尿病学分会2004年诊断标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('20', '32', 'G02_008', '1', '中国成人血脂异常防治指南', '无', '中国成人血脂异常防治指南制订联合委员会', '2007', '中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J]. 中华心血管病杂志,2007,35（05）:390-419.;\n', '中文', '一、继发性或原发性高脂血症<br />&nbsp;&nbsp;\n二、高脂蛋白血症的表型分型法<br />&nbsp;&nbsp;\nG02_008_01_表2血脂异常的临床分型<br />&nbsp;&nbsp;\n三、高脂血症的基因分型法<br />&nbsp;&nbsp;\nG02_008_02_表3家族性高脂血症<br />&nbsp;&nbsp;\n', '继发性高脂血症；原发性高脂血症；高胆固醇血症；高甘油三酯血症；混合型高脂血症；低高密度脂蛋白血症；家族性高胆固醇血症；家族性apo B缺陷症；家族性混合型高脂血症；家族性异常β脂蛋白血症；多基因家族性高胆固醇血症；家族性脂蛋白(a)血症；家族性高甘油三酯血症；', null, null, '我国人群的血脂合适水平<br />&nbsp;&nbsp;\nG02_008_03_血脂水平分层.docx<br />&nbsp;&nbsp;\n心血管病综合危险的评价<br />&nbsp;&nbsp;\nG02_008_04_血脂异常危险分层方案.docx<br />&nbsp;&nbsp;', null, 'TC;LDL', 'G02_008_05_血脂异常患者开始调脂治疗的TC和LDL<br />&nbsp;&nbsp;\n    血清TG的理想水平是(1.7Ommol/L(l5Omg/dl), HDL-C≥l.04mmol/L(40mgdl)。对于特殊的血脂异常类型，如轻、中度TG升高[2.26～5.63mmog/L(200～5OOmg/dl)]，LDL-C达标仍为主要目标，非HDL-C达标为次要目标，即非HDL-C＝TC - HDL-C，其目标值为LDL-C目标值+0.78mmol/L(30mg/dI)；而重度高甘油三酯血症[≥5.65mmol/L(5OOmg/dl)]，为防止急性胰腺炎的发生，首先应积极降低TG。<br />&nbsp;&nbsp;', '本指南由中华医学会心血管病学分会、糖尿病学分会、内分泌学分会、检验分会和卫生部心血管病防治中心血脂异常防治委员会共同起草。指南将作为多学科专家根据目前循证医学的证据而达成的共识来指导我国血脂异常的防治工作。<br />&nbsp;&nbsp;\n《中国成人血脂异常防治指南》(以下简称《指南》)在吸收国内外循证医学证据和经验的基础上, 结合我国人群的特点来制定的, 尤其是在血脂异常分层切点的确定上, 参照我国的流行病学资料, 更符合国人的情况。在危险分层上本《指南》将高血压单列, 等同于任何其他3 项危险因素的集合, 对极高危人群的确定更明确, 目标值也符合临床实际, 更加强调了血脂异常的非药物治疗, 以及药物治疗中他汀类药物的地位, 并且要关注调脂治疗中的监测。<br />&nbsp;&nbsp;\n血脂分层切点的确定<br />&nbsp;&nbsp;《指南》中血脂分层切点与1997 年的《建议》比较有所不同, 见表1 。血脂分层进一步细化, 与美国A TP Ⅲ一致, 见表2 。与《建议》比较, 《指南》中增加了血脂边缘性升高及升高;HDL-C 的合时范围升高及减低也作了修订, 与美国ATPⅢ标准是一致的。但ATPⅢ 以HDL-C ≥60mg/dL 为合适范围, 而《指南》以>60mg/dL 定为升高, 主要因为我国队列研究发现, HDL-C <40mg/dL 与≥60mg/dL 比较, 缺血性心血管病危险增加50 %, 差异具有统计学意义。血脂分层切点中, 最重要改变应为胆固醇及LDL-C , 《建议》中胆固醇≥220mg/dL 为升高, 而《指南》中明确将上移切点为≥240mg/dL ;边缘升高由201 ～ 219mg/dL , 更改为201 ～239mg/dL ;《指南》中LDL-C 升高相应升高为≥160mg/dL , 边缘升高为130 ～ 159mg/dL , 与美国ATPⅢ完全一致。但《指南》中LDL-C , 无ATPⅢ中的极高(>190mg/dL)一层, 合适范围LDL-C 美国A TP Ⅲ为<100mg/dL , 我国《指南》中为<130mg/dL 。《指南》中胆固醇及LDL-C 分层的切点确定, 不仅更便于与美国标准接轨, 更主要的是我国自己流行病学的队列研究亦显示胆固醇或LDL-C 升高是冠心病和缺血性脑卒中的独立危险因素之一。队列研究显示胆固醇从<140mg/dL 开始, 随着胆固醇的升高, 缺血性心血管病发病危险升高其关系为连续性并无明显拐点。诊断为高胆固醇血症的切点只能人为确定, 胆固醇增加到200mg ～239mg/dL 时, 缺血性心血管病发病危险较胆固醇<140mg/dL 增加50 %左右;而增到胆固醇240mg/dL 以上, 则缺血性心血管病危险为<140mg/dL 者的2 倍以上, 具有统计学意义。因此, 本次《指南》将胆固醇切点从1997 年《建议》中的≥220mg/dL 上调到≥240mg/dL 为升高, 及201 ～ 239mg/dL 为边缘性升高。<br />&nbsp;&nbsp;', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('200', '1', 'T01_007', '1', 'ADA糖尿病医学诊疗标准-2010', 'Standards of Medical Care in Diabetesd-2010', '美国糖尿病学会（American Diabetes Association）', '2010', 'http://care.diabetesjournals.org/content/33/Supplement_1/S11.full.pdf', '英文', '糖尿病在临床上分为以下4类： <br />&nbsp;&nbsp;l型糖尿病(因β细胞被破坏所致，常导致胰岛素绝对缺乏) <br />&nbsp;&nbsp;2型糖尿病(在胰岛素抵抗基础上出现进行性胰岛素分泌不足) <br />&nbsp;&nbsp;其他特殊类型的糖尿病，发病原因有多种，例如：β细胞基因缺陷，胰岛素作用基因缺陷，胰腺外分泌腺疾病(例如：囊肿性纤维化)，药物或化学原因诱发(例如：AIDS或器官移植后的治疗) <br />&nbsp;&nbsp;妊娠糖尿病(GDM)(妊娠期间诊断为糖尿病) <br />&nbsp;&nbsp;一些患者不能明确归为l型或2型糖尿病。有时候，2型糖尿病可能发生酮症酸中毒，而l型糖尿病患者虽然有自身免疫性疾病的特征，却延迟发病，且进展缓慢(但呈持续性)。这可能给儿童、青少年和成人糖尿病的诊断带来困难。不过，随着疾病的进展，诊断会越来越明确。<br />&nbsp;&nbsp;The classification of diabetes includes four clinical classes:<br />&nbsp;&nbsp;Type 1 diabetes (results from β-cell destruction, usually leading to absolute insulin deficiency).<br />&nbsp;&nbsp;Type 2 diabetes (results from a progressive insulin secretory defect on the background of insulin resistance).<br />&nbsp;&nbsp;Other specific types of diabetes (due to other causes, e.g., genetic defects in β-cell function, genetic defects in insulin action, diseases of the exocrine pancreas(such as cystic fibrosis), and drug or chemical induced (such as in the treatment of AIDS or after organ transplantation).<br />&nbsp;&nbsp;Gestational diabetes mellitus (GDM) (diagnosed during pregnancy).<br />&nbsp;&nbsp;Some patients cannot be clearly classified as type 1 or type 2 diabetes. Clinical presentation and disease progression vary considerably in both types of diabetes. Occasionally, patients who otherwise have type 2 diabetes may present with ketoacidosis. Similarly, patients with type 1 may have a late onset and slow (but relentless) progression of disease despite having features of autoimmune disease. Such difficulties in diagnosis may occur in children, adolescents, and adults. The true diagnosis may become more obvious over time.<br />&nbsp;&nbsp;', '糠尿病', null, null, '目前的糖尿病诊断标准在表2 中已列出。<br />&nbsp;&nbsp;表2 糖尿病诊断标准<br />&nbsp;&nbsp;1.糖化血红蛋白A1C≥6.5%。试验应用经过NGSP认证，且由DCCT试验标化的方法在实验室内测定。<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;2.FPG≥126mg/dl（7.0mmol/L）。空腹指禁食至少8小时。<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;3.OGTT试验2小时血糖≥200mg/dl（11.1mmol/L）。试验应按照世界卫生组织（WHO）的标准进行，用75 g无水葡萄糖溶于水中作为糖负荷。<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;4. 患者有高血糖症状或高血糖危象，随机血糖≥200mg/dl（11.1mmol/L）。<br />&nbsp;&nbsp;*如果没有明确的高血糖，标准1-3应通过重复检测来确定诊断。<br />&nbsp;&nbsp;建议：<br />&nbsp;&nbsp;多年来，糖尿病诊断都是以血浆葡萄糖（PG）水平为标准，包括FPG值或口服75克葡萄糖耐量试验（OGTT）2小时血糖值。1997年，糖尿病诊断与分类专家委员会第一次会议修订了诊断标准，即以观测的视网膜病变出现与血糖水平之间的关联为关键因素，确定FPG与2-hPG水平的临界值。委员会检验了三项横断面流行病学研究结果，内容包括应用眼底摄像或眼底镜直接评估视网膜病变、测定FPG、2-hPG以及HbA1c（A1C）。这些研究证明血糖水平在阈值以下，视网膜病变发病减少，而在阈值以上则视网膜病变增加，它们之间成明显的线性关系。与视网膜病变增加相对应的FPG、2-hPG以及HbA1c（A1C）值，在每一个研究群体中用相应的测定方法得出的结果是相同的。对研究结果的分析有助于提出一项新的FPG界值即≥126mg/dl(7.0mmol/L)，也确定了存在很长时间的2-hPG诊断值，即≥200mg/dl(11.1mmol/L)。<br />&nbsp;&nbsp;ADA以往没有推荐将糖化血红蛋白A1C作为糖尿病诊断依据，从某种程度上讲原因在于实验结果缺乏标准化。然而，现在A1C已高度标准化了，可以将其结果应用在不同时间和不同人群中。一份近期报告提到，一个国际专家委员会在对目前已有的和新出现的流行病学证据进行全面回顾后，建议将A1C试验用于糖尿病诊断，界值为≥6.5%，而ADA也确定了这项决议。诊断实验将应用一种经过国家糖化血红蛋白标准化计划（NGSP）授权的方法进行测定，同时经由糖尿病控制与并发症研究结果（DCCT）进行追踪和标化。而目前将A1C实验检测用于诊断还不够准确。<br />&nbsp;&nbsp;流行病学数据显示的糖化血红蛋白A1C和视网膜病变之间的联系，与FPG和2-hPG阈值与视网膜病变之间的联系是一致的。而A1C比FPG有更多的优点，包括更方便，因为无需空腹；证据显示有更好的分析前稳定性；应激和疾病时期的逐日变化也较小。这些优势必须与其更高的价格相平衡，因为在发展中国家部分地区A1C测定实用性受限，在一些个体中也存在A1C与平均血糖之间的关联不完整。此外，对于一些特定的贫血与血红蛋白疾病患者，A1C也会引起误导。因为对于红细胞更新速率正常的血红蛋白疾病患者，如镰刀样细胞，未受异常血红蛋白干扰的A1C化验是可以应用的（A1C化验的更新以及异常血红蛋白对其影响与否参见网址www.ngsp.org/prog/index3.html）。而在某些红细胞更新速率异常的情况下，如妊娠、溶血性贫血和铁缺乏症，糖尿病诊断就必须应用血糖标准了。<br />&nbsp;&nbsp;用于糖尿病诊断的血糖标准（FPG和2-hPG）仍然有效。伴严重高血糖的患者，如近期存在明显高血糖症状或高血糖危象的患者，仍可依据餐后随机（或偶然）血糖值≥200mg/dl(11.1mmol/L)来诊断。在这种情况下，医生也可将A1C作为早期评估糖尿病严重程度的一种方法，其对应值也应在诊断界值以上。但是，诸如某些1型糖尿病儿童，A1C的升高可能无法与病情的快速进展同步。<br />&nbsp;&nbsp;正如FPG和2-hPG之间并非百分之百吻合一样，A1C与血糖基础试验也没有完全一致。美国健康与营养普查（NHANES）结果分析指出，假设对所有未诊断者以糖化血红蛋白A1C≥6.5%进行筛查，其结果将比以FPG≥126mg/dl(7.0mmol/L)进行筛查减少三分之一的病例（E.Gregg，私人联系）。但是，事实上很大一部分糖尿病人群仍然不知道他们的病情。因此尽管目前已指定的A1C切点的诊断敏感性比较低，但随着试验技术的实用性增强，这一缺点也可以弥补，且A1C检测的广泛普及也可使明确诊断的病例增加。<br />&nbsp;&nbsp;与大多数诊断试验相同，一项糖尿病诊断试验结果为排除试验误差应是可重复的，除非患者已经有了明确的临床表现，如已经出现了高血糖临床表现或高血糖危象。由于血糖升高的患者不是糖尿病的可能性也是存在的，最好的情况是同样的试验可以重复以确认诊断结果。例如，如果A1C是7.0%，而重复检测的结果是6.8%，则可以诊断为糖尿病。但是，也有同一患者存在两种不同试验（如FPG和A1C）结果的情况。此时，如果这两种不同的试验结果都在诊断界值以上，则可以确定糖尿病。<br />&nbsp;&nbsp;另一方面，如果同一个体两种不同试验结果不一致，则结果在阈值以上的诊断试验就应再次测定，以确定的结果为依据进行诊断。换言之，如果一位患者达到了A1C诊断标准（两次测定结果都≥6.5%），但FPG没有达到诊断标准（＜126mg/dl或7.0mmol/L），或者二者结果相反，都应考虑患者已有糖尿病。诚然，大多数情况下，“非糖尿病患者”的试验结果可能很接近糖尿病诊断界值。<br />&nbsp;&nbsp;由于所有试验都存在分析前及分析时的可变性，可能出现的情况是：结果在阈值以上的一项试验，经过第二次测定后其结果在诊断界值以下。这种情况在糖化血红蛋白A1C的测定中不太会出现，偶尔存在于FPG检测，而可能性最大的是2-hPG测定。除了实验室误差，这类患者往往其测定结果接近诊断阈值。医生可对其进行随访，在3到6个月后重新做诊断试验。<br />&nbsp;&nbsp;妊娠糖尿病的筛查及诊断<br />&nbsp;&nbsp;建议<br />&nbsp;&nbsp;1.对妊娠糖尿病（GDM）进行筛查可以使用应用风险因素分析的方法，如果条件允许，还可以使用OGTT试验。<br />&nbsp;&nbsp;2.对患有GDM的妇女应该在产后6～12周进行糖尿病的筛查并且以后应该随访进行糖尿病以及糖尿病前期的筛查。<br />&nbsp;&nbsp;多年来，GDM被定义为妊娠期发生或首次发现的任何程度的血糖不耐受。虽然多数病例产后恢复正常，但此定义包括了产后持续血糖不耐受的情况，以及在孕前就发生的未识别的和与妊娠同时开始的血糖不耐受的可能情况。这个定义是为了使GDM 的筛查和分类一致而被采用的，但多年来其局限性也是明显的。随着肥胖和糖尿病发生率增加，育龄期女性2型糖尿病也增多，而妊娠女性患有未被识别的2 型糖尿病的情况也增加。2008-2009年，包括ADA 在内、由多个妇产科和糖尿病组织的代表组成的国际糖尿病与妊娠研究协会（IDAPSG）经过商议后达成一致共识，推荐首次产前检查用诊断标准（表2）发现糖尿病的高危女性应诊断为显性糖尿病而不是妊娠糖尿病。<br />&nbsp;&nbsp;所有妊娠妇女中约7%（根据人群研究和诊断试验应用情况范围为1%～ 14%）存在GDM，每年有超过20 万的病例数。<br />&nbsp;&nbsp;由于GDM 对母体与新生儿都有危险，筛查与诊断是必然要实施的。当前筛查和诊断方法以2004 年ADA 提出的GDM 标准为依据，在表6 中列出。<br />&nbsp;&nbsp;高血糖与不良妊娠结局研究（HAPO）是一项大型（约25,000 妊娠妇女参加）多国流行病学研究，证明了妊娠24-28 周母体血糖增高将会导致母亲、胎儿及新生儿不良结局风险持续增加，即使之前被认为正常妊娠的人也一样。大多数并发症没有风险阈值。这种情况需要对GDM 的诊断十分谨慎。IADPSG 建议所有未知糖尿病情况的女性都要在妊娠24-28 周时接受75g OGTT 筛查。IADPSG 提出了空腹、1-h PG和2-h PG血糖的诊断切点，与HAPO研究中平均血糖水平的女性相比，其不良结局的比数比（odds ratio）至少为1.75。<br />&nbsp;&nbsp;在此次糖尿病诊疗指南的更新中，ADA 计划与美国妇产科组织一道考虑采用IADPSG 诊断标准，讨论改变细节。虽然这项改变会大大增加GDM 的患病率，但越来越多的证据显示即使治疗轻度GDM 也可降低母婴发病率。<br />&nbsp;&nbsp;由于有GDM 病史的女性分娩后发生糖尿病的风险很高，这类人群应在产后6-12 周时应用非孕期OGTT 标准做糖尿病筛查，并随后进行糖尿病或糖尿病前期的筛查随访，如“Ⅱ . 无症状患者糖尿病检测”所述。<br />&nbsp;&nbsp;表6 GDM筛查及诊断标准<br />&nbsp;&nbsp;首次产前检查即进行糖尿病风险评估。<br />&nbsp;&nbsp;极高危女性应在确定妊娠后尽快做糖尿病筛查。极高危标准如下：<br />&nbsp;&nbsp;• 严重肥胖<br />&nbsp;&nbsp;• 既往GDM病史或分娩过大于胎龄（LGA）儿<br />&nbsp;&nbsp;• 存在糖尿<br />&nbsp;&nbsp;• 诊断多囊卵巢综合征<br />&nbsp;&nbsp;• 2型糖尿病强家族史<br />&nbsp;&nbsp;在该妊娠时期进行的筛查/诊断应以标准诊断检查为准（表2）。<br />&nbsp;&nbsp;所有非GDM低危女性，包括上述在妊娠早期未发现糖尿病者，应在孕24-28周进行GDM筛查。<br />&nbsp;&nbsp;不需要进行GDM筛查的低危女性被定义为具有以下所有特征者：<br />&nbsp;&nbsp;• 年龄小于25岁<br />&nbsp;&nbsp;• 孕前体重正常<br />&nbsp;&nbsp;• 属于糖尿病低发病率的种族<br />&nbsp;&nbsp;• 一级亲属无糖尿病<br />&nbsp;&nbsp;• 无糖耐量异常病史<br />&nbsp;&nbsp;• 无不良生产史<br />&nbsp;&nbsp;妊娠24-28周的GDM筛查有两种方法：<br />&nbsp;&nbsp;1.两步法：<br />&nbsp;&nbsp;A.先用50g葡萄糖负荷后1小时的血浆或血清葡萄糖水平进行初筛，≥140mg/dl可识别大约80%的GDM女性，如果以≥130mg/dl为界值则敏感性可进一步增加至90%。<br />&nbsp;&nbsp;B.50g葡萄糖负荷筛查结果超过上述阈值的女性择日进行诊断性100g OGTT检查。<br />&nbsp;&nbsp;2.一步法（GDM高发的医疗机构首选）：所有女性在妊娠24-28周时行100gOGTT诊断性检查。<br />&nbsp;&nbsp;100g OGTT应在夜间禁食至少8小时后的早上进行。<br />&nbsp;&nbsp;为诊断GDM，血浆葡萄糖至少达到以下标准中的两条：<br />&nbsp;&nbsp;• 空腹≥95mg/dl<br />&nbsp;&nbsp;• 1-h≥180mg/dl<br />&nbsp;&nbsp;• 2-h≥155mg/dl<br />&nbsp;&nbsp;• 3-h≥140mg/dl<br />&nbsp;&nbsp;The current diagnostic criteria for diabetes are summarized in Table 2.<br />&nbsp;&nbsp;Table 2Criteria for the diagnosis of diabetes<br />&nbsp;&nbsp;1.A1C ≥ 6.5%. The test should be performed in a laboratory using a methodthat is NGSP certified and standardized to the DCCT assay.<br />&nbsp;&nbsp;OR<br />&nbsp;&nbsp;2. FPG ≥ 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at<br />&nbsp;&nbsp;least 8 h.<br />&nbsp;&nbsp;OR<br />&nbsp;&nbsp;3. Two-hour plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT.<br />&nbsp;&nbsp;The test should be performed as described by the World HealthOrganization, using a glucose load containing the equivalent of 75 ganhydrous glucose dissolved in water.<br />&nbsp;&nbsp;OR<br />&nbsp;&nbsp;4. In a patient with classic symptoms of hyperglycemia or hyperglycemiccrisis, a random plasma glucose ≥ 200 mg/dl (11.1 mmol/l).<br />&nbsp;&nbsp;In the absence of unequivocal hyperglycemia, criteria 1-3 should be confirmed by repeat testing.<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp;略<br />&nbsp;&nbsp;Detection and diagnosis of gestational diabetes mellitus (GDM)<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp;略<br />&nbsp;&nbsp;Current screeningand diagnostic strategies, based on the2004 ADA position statement on GDM(25), are outlined in Table 6.<br />&nbsp;&nbsp;Table 6 Screening for and diagnosis of GDM<br />&nbsp;&nbsp;Carry out GDM risk assessment at the first prenatal visit.<br />&nbsp;&nbsp;Women at very high risk for GDM should be screened for diabetes as soon as possible after the confirmation of pregnancy. Criteria for very high risk are:<br />&nbsp;&nbsp;1. Severe obesity<br />&nbsp;&nbsp;2. Prior history of GDM or delivery of large-for-gestational-age infant<br />&nbsp;&nbsp;3. Presence of glycosuria<br />&nbsp;&nbsp;4. Diagnosis of PCOS<br />&nbsp;&nbsp;5. Strong family history of type 2 diabetes <br />&nbsp;&nbsp;Screening/diagnosis at this stage of pregnancy should use standard diagnostic testing (Table 2).<br />&nbsp;&nbsp;All women of higher than low risk of GDM, including those above not found to have diabetes early in pregnancy, should undergo GDM testing at 24–28 weeks of gestation. Low risk status, which does not require GDM screening, is defined as women with all of the following characteristics:<br />&nbsp;&nbsp;1. Age25 years<br />&nbsp;&nbsp;2. Weight normal before pregnancy<br />&nbsp;&nbsp;3. Member of an ethnic group with a low prevalence of diabetes<br />&nbsp;&nbsp;4. No known diabetes in first-degree relatives<br />&nbsp;&nbsp;5. No history of abnormal glucose tolerance<br />&nbsp;&nbsp;6. No history of poor obstetrical outcome <br />&nbsp;&nbsp;Two approaches may be followed for GDM screening at 24–28 weeks: <br />&nbsp;&nbsp;1. Two-step approach: <br />&nbsp;&nbsp;A. Perform initial screening by measuring plasma or serum glucose 1 h after a 50-g oral glucose load. A glucose threshold after 50-g load of ≥ 140 mg/dl identifies ～ 80% of women with GDM, while the sensitivity is further increased to ～ 90% by a threshold of ≥ 130 mg/dl. <br />&nbsp;&nbsp;B. Perform a diagnostic 100-g OGTT on a separate day in women who exceed the chosen threshold on 50-g screening.<br />&nbsp;&nbsp;2. One-step approach (may be preferred in clinics with high prevalence of GDM): Perform a diagnostic 100-g OGTT in all women to be tested at 24–28 weeks. <br />&nbsp;&nbsp;The 100-g OGTT should be performed in the morning after an overnight fast of at least 8 h. <br />&nbsp;&nbsp;A diagnosis of GDM requires at least two of the following plasma glucose values:<br />&nbsp;&nbsp;Fasting: ≥ 95 mg/dl (5.3 mmol/l) <br />&nbsp;&nbsp;1 h: ≥ 180 mg/dl (10.0 mmol/l) <br />&nbsp;&nbsp;2 h: ≥ 155 mg/dl (8.6 mmol/l) <br />&nbsp;&nbsp;3 h: ≥ 140 mg/dl (7.8 mmol/l) <br />&nbsp;&nbsp;', null, 'A1C；Preprandial capillary plasma glucose；Peak postprandial capillary plasma glucose+', 'Recommended glycemic goals for nonpregnant individuals are shown in Table 11.<br />&nbsp;&nbsp;T01_007_01.jpg<br />&nbsp;&nbsp;', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('201', '1', 'T01_008', '1', 'ADA糖尿病医学诊疗标准-2011', 'Standards of Medical Care in Diabetesd-2011', '美国糖尿病学会（American Diabetes Association）', '2011', 'http://care.diabetesjournals.org/content/34/Supplement_1/S11.full.pdf', '英文', '糖尿病包括4种临床类型：<br />&nbsp;&nbsp;1型糖尿病——由β细胞破坏引起，通常导致胰岛素绝对缺乏<br />&nbsp;&nbsp;2型糖尿病——由胰岛素抵抗情况下胰岛素进行性分泌不足引起<br />&nbsp;&nbsp;其他特殊类型糖尿病——由β细胞功能遗传缺陷、胰岛素作用遗传缺陷、胰腺外分泌疾病(例如囊性纤维化)和药物或化学试剂诱发(人体免疫缺损病毒HIV/艾滋病AIDS或器官移植后的治疗)等其他原因引起<br />&nbsp;&nbsp;妊娠糖尿病(GDM)——妊娠期间诊断的糖尿病，非明确显性糖尿病<br />&nbsp;&nbsp;有些患者不能明确归为1型或2型糖尿病。虽然两种类型糖尿病的临床表现和疾病进程有很大的不同，但有时2型糖尿病患者也会出现酮症酸中毒，同样，1型糖尿病患者尽管有自身免疫性疾病的特征，却发病迟且进展慢(但呈持续性)，这可能给儿童、青少年和成人的糖尿病诊断带来困难。不过，随着疾病的进展，诊断会越来越明确。<br />&nbsp;&nbsp;The classification of diabetes includes fourclinical classes:<br />&nbsp;&nbsp;Type 1 diabetes (results fromβ-cell destruction, usually leading to absolute insulin deficiency)<br />&nbsp;&nbsp;Type 2 diabetes (results from a progressive insulin secretory defect on the background of insulin resistance) <br />&nbsp;&nbsp;Other specific types of diabetes due to other causes, e.g., genetic defects invβ-cell function, genetic defects in insulin action, diseases of the exocrine pancreas (such as cystic fibrosis), and drug- or chemicalinduced (such as in the treatment of HIV/ AIDS or after organ transplantation)<br />&nbsp;&nbsp;Gestational diabetes mellitus (GDM) (diabetes diagnosed during pregnancy that is not clearly overt diabetes)<br />&nbsp;&nbsp;Some patients cannot be clearly classified as having type 1 or type 2 diabetes. Clinical presentation and disease progression vary considerably in both types of diabetes. Occasionally, patients who otherwise have type 2 diabetes may present with ketoacidosis. Similarly, patients with type 1may have a late onset and slow (but relentless) progression of disease despite having features of autoimmune disease. Such difficulties in diagnosis may occur in children, adolescents, and adults. The true diagnosis may become more obvious over time.<br />&nbsp;&nbsp;', '糠尿病', null, null, '目前的糖尿病诊断标准在表2 中已列出。<br />&nbsp;&nbsp;表2 糖尿病诊断标准<br />&nbsp;&nbsp;1.糖化血红蛋白A1C≥6.5%。试验应用经过NGSP认证，且由DCCT试验标化的方法在实验室内测定。<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;2.FPG≥126mg/dl（7.0mmol/L）。空腹指禁食至少8小时。<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;3.OGTT试验2小时血糖≥200mg/dl（11.1mmol/L）。试验应按照世界卫生组织（WHO）的标准进行，用75 g无水葡萄糖溶于水中作为糖负荷。<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;4. 患者有高血糖症状或高血糖危象，随机血糖≥200mg/dl（11.1mmol/L）。<br />&nbsp;&nbsp;*如果没有明确的高血糖，标准1-3应通过重复检测来确定诊断。<br />&nbsp;&nbsp;妊娠期糖尿病的筛查和诊断<br />&nbsp;&nbsp;建议<br />&nbsp;&nbsp;1.在有危险因素的个体中，产前首次就诊时用标准的诊断方法筛查未诊断的2型糖尿病。<br />&nbsp;&nbsp;2.未知是否具有糖尿病的孕妇，在妊娠24~28周用75g 2h OGTT筛查妊娠糖尿病，诊断切点见“2012年糖尿病诊疗标准”表6。<br />&nbsp;&nbsp;3.妊娠糖尿病的妇女在产后6~12周用除A1C以外的方法筛查永久性糖尿病。<br />&nbsp;&nbsp;4.有妊娠糖尿病病史的妇女应至少每3年筛查是否发展为糖尿病或糖尿病前期。<br />&nbsp;&nbsp;表6 GDM筛查及诊断标准<br />&nbsp;&nbsp;对于既往为被诊断为显性糖尿病的妇女，应在妊娠24-28周进行75g OGTT，并检测空腹以及负荷后1小时、2小时的血糖浓度。<br />&nbsp;&nbsp;OGTT应在早晨进行，并在检查前夜至少空腹8小时。<br />&nbsp;&nbsp;当血浆葡萄糖浓度高于下列任意数值是，妊娠糖尿病的诊断成立：<br />&nbsp;&nbsp;1.空腹≥5.1 mmol/l<br />&nbsp;&nbsp;2.1 h: ≥10.0 mmol/l<br />&nbsp;&nbsp;3.2 h: ≥8.5 mmol/l<br />&nbsp;&nbsp;The current diagnostic criteria for diabetes are summarized in Table 2.<br />&nbsp;&nbsp;Table 2—Criteria for the diagnosis of diabetes<br />&nbsp;&nbsp;A1C ≥ 6.5%. The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay.<br />&nbsp;&nbsp;or<br />&nbsp;&nbsp;FPG ≥ 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h.<br />&nbsp;&nbsp;or<br />&nbsp;&nbsp;2-h plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT. The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.<br />&nbsp;&nbsp;or<br />&nbsp;&nbsp;In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥ 200 mg/dl (11.1 mmol/l)<br />&nbsp;&nbsp;In the absence of unequivocal hyperglycemia, result should be confirmed by repeat testing.<br />&nbsp;&nbsp;Detection and diagnosis of gestational diabetes mellitus (GDM)<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp;1. Screen for undiagnosed type 2 diabetesat the first prenatal visit in those withrisk factors, using standard diagnosticcriteria. <br />&nbsp;&nbsp;2. In pregnant women not known to havediabetes, screen for GDM at 24 –28weeks of gestation, using a 75-g 2-hOGTT and the diagnostic cut points inTable 6. <br />&nbsp;&nbsp;3. Screen women with GDM for persistentdiabetes 6–12 weeks postpartum. <br />&nbsp;&nbsp;4. Women with a history of GDM shouldhave lifelong screening for the developmentof diabetes or prediabetes at leastevery 3 years. <br />&nbsp;&nbsp;Table 6Screening for and diagnosis ofGDM<br />&nbsp;&nbsp;Perform a 75-g OGTT, with plasma glucosemeasurement fasting and at 1 and 2 h,at 24–28 weeks of gestation in womennot previously diagnosed with overtdiabetes.<br />&nbsp;&nbsp;The OGTT should be performed in themorning after an overnight fast of atleast 8 h.<br />&nbsp;&nbsp;The diagnosis of GDM is made when any ofthe following plasma glucose values areexceeded:<br />&nbsp;&nbsp;1. Fasting: ≥ 92 mg/dl (5.1 mmol/l) <br />&nbsp;&nbsp;2. 1 h: ≥ 180 mg/dl (10.0 mmol/l) <br />&nbsp;&nbsp;3. 2 h: ≥ 153 mg/dl (8.5 mmol/l) <br />&nbsp;&nbsp;', null, 'A1C；Preprandial capillary plasma glucose；Peak postprandial capillary plasma glucose+', 'Recommended glycemic goals for nonpregnant individuals are shown in Table 10.<br />&nbsp;&nbsp;T01_008_01.jpg<br />&nbsp;&nbsp;', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('202', '1', 'T01_009', '1', 'ADA糖尿病医学诊疗标准-2012', 'Standards of Medical Care in Diabetesd-2012', '美国糖尿病学会（American Diabetes Association）', '2012', 'http://care.diabetesjournals.org/content/35/Supplement_1/S11.full.pdf', '英文', '糖尿病包括4种临床类型：<br />&nbsp;&nbsp;1型糖尿病——由β细胞破坏引起，通常导致胰岛素绝对缺乏<br />&nbsp;&nbsp;2型糖尿病——由胰岛素抵抗情况下胰岛素进行性分泌不足引起<br />&nbsp;&nbsp;其他特殊类型糖尿病——由β细胞功能遗传缺陷、胰岛素作用遗传缺陷、胰腺外分泌疾病(例如囊性纤维化)和药物或化学试剂诱发(人体免疫缺损病毒HIV/艾滋病AIDS或器官移植后的治疗)等其他原因引起<br />&nbsp;&nbsp;妊娠糖尿病(GDM)——妊娠期间诊断的糖尿病，非明确显性糖尿病<br />&nbsp;&nbsp;有些患者不能明确归为1型或2型糖尿病。虽然两种类型糖尿病的临床表现和疾病进程有很大的不同，但有时2型糖尿病患者也会出现酮症酸中毒，同样，1型糖尿病患者尽管有自身免疫性疾病的特征，却发病迟且进展慢(但呈持续性)，这可能给儿童、青少年和成人的糖尿病诊断带来困难。不过，随着疾病的进展，诊断会越来越明确。<br />&nbsp;&nbsp;The classification of diabetes includes fourclinical classes:<br />&nbsp;&nbsp;Type 1 diabetes (results fromβ-cell destruction, usually leading to absolute insulin deficiency)<br />&nbsp;&nbsp;Type 2 diabetes (results from a progressive insulin secretory defect on the background of insulin resistance) <br />&nbsp;&nbsp;Other specific types of diabetes due to other causes, e.g., genetic defects invβ-cell function, genetic defects in insulin action, diseases of the exocrine pancreas (such as cystic fibrosis), and drug- or chemicalinduced (such as in the treatment of HIV/ AIDS or after organ transplantation)<br />&nbsp;&nbsp;Gestational diabetes mellitus (GDM) (diabetes diagnosed during pregnancy that is not clearly overt diabetes)<br />&nbsp;&nbsp;Some patients cannot be clearly classified as having type 1 or type 2 diabetes. Clinical presentation and disease progression vary considerably in both types of diabetes. Occasionally, patients who otherwise have type 2 diabetes may present with ketoacidosis. Similarly, patients with type 1may have a late onset and slow (but relentless) progression of disease despite having features of autoimmune disease. Such difficulties in diagnosis may occur in children, adolescents, and adults. The true diagnosis may become more obvious over time.<br />&nbsp;&nbsp;', '糠尿病', null, null, '目前的糖尿病诊断标准在表2 中已列出。<br />&nbsp;&nbsp;表2 糖尿病诊断标准<br />&nbsp;&nbsp;1.A1C≥6.5%。化验应在使用经NGSP认证、合乎DCCT化验方法的实验室完成。<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;2.FPG≥7.0mmol/l(126mg/dl)。空腹的定义是至少8小时不摄入热量。<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;3.OGTT2hPG≥11.1mmol/l(200mg/dl)。试验应按照世界卫生组织(WHO)的标准进行，所用葡萄糖负荷为包含相当于75g无水葡萄糖的水溶液。<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;4.有高血糖典型症状或高血糖危症的患者，随机血糖≥11.1 mmol/l(200mg/dl)。<br />&nbsp;&nbsp;缺乏明确的高血糖，结果应经复查证实。<br />&nbsp;&nbsp;建议<br />&nbsp;&nbsp;几十年来，是根据血浆血糖标准诊断糖尿病，检查空腹血糖(FPG)或75g口服葡萄糖耐量试验(OGTT)中的2小时后血糖(2hPG)。<br />&nbsp;&nbsp;2009年，一个包括本协会、国际糖尿病联合会、欧洲糖尿病研究协会(EASD)代表的国际专家委员会，建议用糖化血红蛋白(A1C)化验来诊断糖尿病，其临界值为≥6.5%。2010年，本协会采用了这个标准。诊断化验应采用经国家A1C标准化计划(NGSP)认证、合乎或可追溯至糖尿病控制和并发症试验(DCCT)证明的化验方法。现在，因检查水平未经认证，用于诊断目的的即时A1C化验的准确度不足。<br />&nbsp;&nbsp;流行病学资料显示，A1C和视网膜病变的关系，与相应的FPG和2hPG临界值相似。A1C比FPG、OGTT的优势在于：因不需空腹，更方便；证据显示的分析前稳定性更大；在应激和患病期间的日间扰动更小。这些优势必定由更大的成本平衡，在发展中世界的某些地区，A1C化验使用受限，而且，某些人A1C和平均血糖不完全相关。此外，A1C可随患者的人种/种族而不同。有人假定种族间糖化率不同(例如非洲裔美国人的糖化率较高)，但存争议。最近的流行病学研究发现，与FPG匹配时，非洲裔美国人(±糖尿病)的A1C确实高于白人，但果糖胺和糖化白蛋白也更高，1,5-脱水葡萄糖醇较低，表明其血糖负担(尤其是餐后)可能更高。推荐使用的A1C诊断糖尿病的流行病学研究均出自成人。诊断儿童2型糖尿病的切点是否相同尚未确定[10]。对于血红蛋白异常但红血球细胞周转正常的患者，例如镰刀型贫血，A1C化验不受异常血红蛋白干扰，应使用(www.ngsp.org/interf.asp提供了更新的一览表)。对于红细胞周转异常的疾病，例如怀孕、最近失血或输血及某些贫血症，糖尿病诊断必须使用专门血糖标准。<br />&nbsp;&nbsp;诊断糖尿病的葡萄糖标准(FPG和2hPG)仍然有效，见表2。正如FPG和2hPG之间的一致性<100%，A1C与任何基于葡萄糖的化验也不存在完美一致。国家卫生和营养检查调查分析(NHANES)，承担未确诊的普遍筛查，其资料表明，A1C≥6.5%截点比FPG≥7.0mmol/l(126mg/dl)截点少鉴别了1/3的未确诊糖尿病病例[11]。然而，实践中，很大一部分糖尿病患者仍然不知道自己的病情，因此，化验的更大实用性会抵消A1C在指定截点的较低敏感性，而且，更方便的化验(A1C)会应用得更广泛，切实增加了作出诊断的数量。<br />&nbsp;&nbsp;除非有临床根据(例如有高血糖危症或高血糖典型症状，并且随机血糖≥11.1mmol/l或200mg/dl的患者)得出明确诊断，如同大多数的诊断化验，糖尿病的诊断化验结果应反复排除实验室误差，最好是重复进行相同的化验来确认，因为这种情况下一致的可能性更大。例如，如果A1C是7.0%，而复查结果是6.8%，糖尿病诊断被确认。然而，如果两个不同的化验(例如A1C和FPG)都在诊断临界值之上，糖尿病的诊断也可确认。<br />&nbsp;&nbsp;另一方面，如果同一个人两个不同化验的结果不一致，结果在诊断截点之上的化验应复查，诊断应基于确认化验作出。也就是说，如果一人符合A1C糖尿病标准(2次结果≥6.5%)，但FPG不是(<7.0mmol/l或126mg/dl)，此人应该被认定患有糖尿病，反之亦然。<br />&nbsp;&nbsp;因为所有化验都有分析前和分析的变异性，当结果在诊断临界值之上而进行复查时，第2个值低于诊断截点也是可能的。这一点，A1C至少是可能的，FPG有几分更大的可能，2hPG的可能最大。除非实验室错误，这类患者的化验结果很可能接近诊断临界值边缘，医疗专业人士可能会选择密切随访，并在3～6个月复查。<br />&nbsp;&nbsp;妊娠期糖尿病的筛查和诊断<br />&nbsp;&nbsp;建议<br />&nbsp;&nbsp;1.有风险因素的，在第1次产前检查时，使用标准的诊断标准筛查未确诊的2型糖尿病。<br />&nbsp;&nbsp;2.孕妇不知患有糖尿病，在妊娠24~28周，使用OGTT2hPG和表6中的诊断截点，筛查GDM。3.GDM女性，在产后6~12周，采取除A1C以外的检查筛查持续性糖尿病。<br />&nbsp;&nbsp;4.有GDM史的女性，至少每3年，终身筛查糖尿病或糖尿病前期的进展。<br />&nbsp;&nbsp;5.有GDM史的女性发现糖尿病前期，应接受生活方式干预或二甲双胍以预防糖尿病。<br />&nbsp;&nbsp;多年来，GDM的定义为妊娠期间首发或第1次发现任意程度的葡萄糖耐量异常，不论妊娠后疾病是否持续，不排除妊娠前或妊娠开始时存在未确认的葡萄糖耐量异常的可能性。这个定义促成了GDM发现和分类的统一，但多年来已经认识到其局限性。肥胖和糖尿病的持续流行，导致育龄妇女更多的2型糖尿病，未确诊2型糖尿病的孕妇数量增加[31]。正因为如此，在第1次产前检查时应使用标准的诊断标准(见表2)，对有2型糖尿病风险因素(见表4)的女性进行糖尿病筛查。在检查中发现患有糖尿病的女性，应接受一个公开的、停止妊娠的、糖尿病的诊断结果。<br />&nbsp;&nbsp;GDM给母亲和新生儿带来风险。高血糖与不良妊娠结果(HAPO)项目是一个大型(约25000名孕妇)的跨国流行病学研究，结果表明，在24~28周，产妇、胎儿和新生儿的不良结果风险随以产妇血糖为变量的函数不断增加，范围甚至涉及以前认为正常的妊娠。大多数并发症没有风险临界值。这些结果引发对GDM诊断标准的认真复议。经2008~2009年的审议，糖尿病和妊娠研究组国际协会(IADPSG)——一个来自多个产科和糖尿病组织(包括本协会)的代表组成的国际共识小组，制定了修订的GDM诊断建议。该小组建议，所有不知患有糖尿病的女性在妊娠24~28周进行75gOGTT。此外，该小组提出了空腹、1小时和2小时血糖测量的诊断截点，通报的不良结果可能比率，与HAPO研究中的平均血糖比较，至少为1.75。目前的筛查和诊断措施基于IADPSG“妊娠高血糖诊断和分类的建议”，列于表6。<br />&nbsp;&nbsp;这些新标准将大大提高GDM发病率，主要原因是只要一个而不是两个值异常，就足以作出诊断。本协会确认，经此标准确诊的GDM发病率可预期地显著增加，敏锐地关注以前诊断为正常的妊娠“被医疗化”。肥胖和糖尿病比率在全球范围令人不安的增长，在此背景下，这些诊断标准的变化正在作出，意在优化女性及其婴儿的妊娠结果。<br />&nbsp;&nbsp;现在，仅依据一个血糖值高于特定血糖截点，女性将被确诊为GDM(旧标准规定至少有两个异常值)，但有关其治疗干预的随机临床试验资料确实很少。然而，有新出现的观察和回顾证据表明，用新标准(即使旧标准未确诊)与以前标准确诊的女性，升高的妊娠不良结果率相似。干预试验推断了她们妊娠和后代的预期好处，这些试验聚焦的女性，与旧GDM诊断标准确定的相比，高血糖比较轻微，发现少量好处。她们的随访和血糖监测频率目前尚不清楚，但可能会没有旧标准确诊的女性那么密集。重要的是要注意，两项轻度GDM研究中的80~90%女性(其血糖值与本文建议的临界值重叠)仅经生活方式治疗。<br />&nbsp;&nbsp;美国妇产科学院在2011年继续建议使用以前的标准诊断GDM。其他几个国家采用了新标准，WHO关于此问题的报告有待这些标准的出版。<br />&nbsp;&nbsp;由于某些GDM可能已经存在未被诊断的2型糖尿病，有GDM史的女性应在产后6~12周使用非妊娠OGTT标准筛查糖尿病。因其产前的高血糖治疗，不推荐产后检查使用A1C诊断持久性糖尿病。有GDM史女性的随后糖尿病风险大大增加，应继续糖尿病进展或糖尿病前期的随后筛查，如第2章中所述。<br />&nbsp;&nbsp;有GDM史女性发生糖尿病前期，应进行生活方式干预或二甲双胍治疗，讨论见第4章。<br />&nbsp;&nbsp;表6 GDM筛查及诊断<br />&nbsp;&nbsp;以前未确诊明显糖尿病的女性，在妊娠24~28周，进行75gOGTT，测量空腹、1小时和2小时血糖。<br />&nbsp;&nbsp;OGTT应在至少8小时夜间禁食后的次日早晨进行。<br />&nbsp;&nbsp;出现下列任1种血糖情况时，GDM确诊：<br />&nbsp;&nbsp;1.空腹≥5.1mmol/l(92mg/dl)<br />&nbsp;&nbsp;2.1小时≥10.0mmol/l(180mg/dl)<br />&nbsp;&nbsp;3.2小时≥8.5mmol/l(153mg/dl)<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp;略<br />&nbsp;&nbsp;The current diagnostic criteria for diabetes are summarized in Table 2.<br />&nbsp;&nbsp;Table 2—Criteria for the diagnosis of diabetes<br />&nbsp;&nbsp;A1C ≥ 6.5%. The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay.<br />&nbsp;&nbsp;or<br />&nbsp;&nbsp;FPG ≥ 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h.<br />&nbsp;&nbsp;or<br />&nbsp;&nbsp;2-h plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT. The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.<br />&nbsp;&nbsp;or<br />&nbsp;&nbsp;In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥ 200 mg/dl (11.1 mmol/l)<br />&nbsp;&nbsp;In the absence of unequivocal hyperglycemia, result should be confirmed by repeat testing.<br />&nbsp;&nbsp;Detection and diagnosis of gestational diabetes mellitus (GDM)<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp;1. Screen for undiagnosed type 2 diabetesat the first prenatal visit in thosewith riskfactors, using standard diagnostic criteria.<br />&nbsp;&nbsp;2. In pregnant women not previouslyknown to have diabetes, screen for GDMat 24–28 weeks’ gestation, using a 75-g2-h OGTT and the diagnostic cut pointsin Table 6. <br />&nbsp;&nbsp;3. Screen women with GDM for persistentdiabetes at 6–12 weeks’ postpartum,using a test other than A1C.<br />&nbsp;&nbsp;4. Women with a history of GDM shouldhave lifelong screening for the developmentof diabetes or prediabetes atleast every 3 years. <br />&nbsp;&nbsp;5. Women with a history of GDM foundto have prediabetes should receive lifestyleinterventions or metformin to preventdiabetes. <br />&nbsp;&nbsp;Table 6Screening for and diagnosis ofGDM<br />&nbsp;&nbsp;Perform a 75-g OGTT, with plasma glucosemeasurement fasting and at 1 and 2 h,at 24–28 weeks of gestation in womennot previously diagnosed with overtdiabetes.<br />&nbsp;&nbsp;The OGTT should be performed in themorning after an overnight fast of atleast 8 h.<br />&nbsp;&nbsp;The diagnosis of GDM is made when any ofthe following plasma glucose values areexceeded:<br />&nbsp;&nbsp;1. Fasting: ≥ 92 mg/dl (5.1 mmol/l) <br />&nbsp;&nbsp;2. 1 h: ≥ 180 mg/dl (10.0 mmol/l) <br />&nbsp;&nbsp;3. 2 h: ≥ 153 mg/dl (8.5 mmol/l) <br />&nbsp;&nbsp;', null, 'A1C；Preprandial capillary plasma glucose；Peak postprandial capillary plasma glucose+', 'Recommended glycemic goals for nonpregnant individuals are shown in Table 9.<br />&nbsp;&nbsp;T01_009_01.jpg<br />&nbsp;&nbsp;', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('203', '1', 'T01_010', '1', 'ADA糖尿病医学诊疗标准-2013', 'Standards of Medical Care in Diabetesd-2013', '美国糖尿病学会（American Diabetes Association）', '2013', 'http://care.diabetesjournals.org/content/36/Supplement_1/S11.full.pdf', '英文', '糖尿病包括4种临床类型：<br />&nbsp;&nbsp;1型糖尿病——由β细胞破坏引起，通常导致胰岛素绝对缺乏<br />&nbsp;&nbsp;2型糖尿病——由胰岛素抵抗情况下胰岛素进行性分泌不足引起<br />&nbsp;&nbsp;其他特殊类型糖尿病——由β细胞功能遗传缺陷、胰岛素作用遗传缺陷、胰腺外分泌疾病(例如囊性纤维化)和药物或化学试剂诱发(人体免疫缺损病毒HIV/艾滋病AIDS或器官移植后的治疗)等其他原因引起<br />&nbsp;&nbsp;妊娠糖尿病(GDM)——妊娠期间诊断的糖尿病，非明确显性糖尿病<br />&nbsp;&nbsp;有些患者不能明确归为1型或2型糖尿病。虽然两种类型糖尿病的临床表现和疾病进程有很大的不同，但有时2型糖尿病患者也会出现酮症酸中毒，同样，1型糖尿病患者尽管有自身免疫性疾病的特征，却发病迟且进展慢(但呈持续性)，这可能给儿童、青少年和成人的糖尿病诊断带来困难。不过，随着疾病的进展，诊断会越来越明确。<br />&nbsp;&nbsp;The classification of diabetes includes fourclinical classes:<br />&nbsp;&nbsp;Type 1 diabetes (results fromβ-cell destruction, usually leading to absolute insulin deficiency)<br />&nbsp;&nbsp;Type 2 diabetes (results from a progressive insulin secretory defect on the background of insulin resistance) <br />&nbsp;&nbsp;Other specific types of diabetes due to other causes, e.g., genetic defects invβ-cell function, genetic defects in insulin action, diseases of the exocrine pancreas (such as cystic fibrosis), and drug- or chemicalinduced (such as in the treatment of HIV/ AIDS or after organ transplantation)<br />&nbsp;&nbsp;Gestational diabetes mellitus (GDM) (diabetes diagnosed during pregnancy that is not clearly overt diabetes)<br />&nbsp;&nbsp;Some patients cannot be clearly classified as having type 1 or type 2 diabetes. Clinical presentation and disease progression vary considerably in both types of diabetes. Occasionally, patients who otherwise have type 2 diabetes may present with ketoacidosis. Similarly, patients with type 1may have a late onset and slow (but relentless) progression of disease despite having features of autoimmune disease. Such difficulties in diagnosis may occur in children, adolescents, and adults. The true diagnosis may become more obvious over time.<br />&nbsp;&nbsp;', '糠尿病', null, null, '目前的糖尿病诊断标准在表2 中已列出。<br />&nbsp;&nbsp;表2 糖尿病诊断标准<br />&nbsp;&nbsp;1.A1C≥6.5%。化验应在使用经NGSP认证、合乎DCCT化验方法的实验室完成。<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;2.FPG≥7.0mmol/l(126mg/dl)。空腹的定义是至少8小时不摄入热量。<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;3.OGTT2hPG≥11.1mmol/l(200mg/dl)。试验应按照世界卫生组织(WHO)的标准进行，所用葡萄糖负荷为包含相当于75g无水葡萄糖的水溶液。<br />&nbsp;&nbsp;或<br />&nbsp;&nbsp;4.有高血糖典型症状或高血糖危症的患者，随机血糖≥11.1 mmol/l(200mg/dl)。<br />&nbsp;&nbsp;缺乏明确的高血糖，结果应经复查证实。<br />&nbsp;&nbsp;建议<br />&nbsp;&nbsp;略<br />&nbsp;&nbsp;妊娠期糖尿病的筛查和诊断<br />&nbsp;&nbsp;建议<br />&nbsp;&nbsp;1.有风险因素的，在第1次产前检查时，使用标准的诊断标准筛查未确诊的2型糖尿病。<br />&nbsp;&nbsp;2.孕妇不知患有糖尿病，在妊娠24~28周，使用OGTT2hPG和表6中的诊断截点，筛查GDM。3.GDM女性，在产后6~12周，采取除A1C以外的检查筛查持续性糖尿病。<br />&nbsp;&nbsp;4.有GDM史的女性，至少每3年，终身筛查糖尿病或糖尿病前期的进展。<br />&nbsp;&nbsp;5.有GDM史的女性发现糖尿病前期，应接受生活方式干预或二甲双胍以预防糖尿病。<br />&nbsp;&nbsp;表6 GDM筛查及诊断<br />&nbsp;&nbsp;以前未确诊明显糖尿病的女性，在妊娠24~28周，进行75gOGTT，测量空腹、1小时和2小时血糖。<br />&nbsp;&nbsp;OGTT应在至少8小时夜间禁食后的次日早晨进行。<br />&nbsp;&nbsp;出现下列任1种血糖情况时，GDM确诊：<br />&nbsp;&nbsp;1.空腹≥5.1mmol/l(92mg/dl)<br />&nbsp;&nbsp;2.1小时≥10.0mmol/l(180mg/dl)<br />&nbsp;&nbsp;3.2小时≥8.5mmol/l(153mg/dl)<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp;略<br />&nbsp;&nbsp;The current diagnostic criteria for diabetes are summarized in Table 2.<br />&nbsp;&nbsp;Table 2—Criteria for the diagnosis of diabetes<br />&nbsp;&nbsp;A1C ≥ 6.5%. The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay.<br />&nbsp;&nbsp;or<br />&nbsp;&nbsp;FPG ≥ 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h.<br />&nbsp;&nbsp;or<br />&nbsp;&nbsp;2-h plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT. The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.<br />&nbsp;&nbsp;or<br />&nbsp;&nbsp;In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥ 200 mg/dl (11.1 mmol/l)<br />&nbsp;&nbsp;In the absence of unequivocal hyperglycemia, result should be confirmed by repeat testing.<br />&nbsp;&nbsp;Detection and diagnosis of gestational diabetes mellitus (GDM)<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp;1. Screen for undiagnosed type 2 diabetesat the first prenatal visit in thosewith riskfactors, using standard diagnostic criteria.<br />&nbsp;&nbsp;2. In pregnant women not previouslyknown to have diabetes, screen for GDMat 24–28 weeks’ gestation, using a 75-g2-h OGTT and the diagnostic cut pointsin Table 6. <br />&nbsp;&nbsp;3. Screen women with GDM for persistentdiabetes at 6–12 weeks’ postpartum,using a test other than A1C.<br />&nbsp;&nbsp;4. Women with a history of GDM shouldhave lifelong screening for the developmentof diabetes or prediabetes atleast every 3 years. <br />&nbsp;&nbsp;5. Women with a history of GDM foundto have prediabetes should receive lifestyleinterventions or metformin to preventdiabetes. <br />&nbsp;&nbsp;Table 6 Screening for and diagnosis of GDM<br />&nbsp;&nbsp;Perform a 75-g OGTT, with plasma glucosemeasurement fasting and at 1 and 2 h,at 24–28 weeks of gestation in womennot previously diagnosed with overtdiabetes.<br />&nbsp;&nbsp;The OGTT should be performed in themorning after an overnight fast of atleast 8 h.<br />&nbsp;&nbsp;The diagnosis of GDM is made when any ofthe following plasma glucose values areexceeded:<br />&nbsp;&nbsp;1. Fasting: ≥ 92 mg/dl (5.1 mmol/l) <br />&nbsp;&nbsp;2. 1 h: ≥ 180 mg/dl (10.0 mmol/l) <br />&nbsp;&nbsp;3. 2 h: ≥ 153 mg/dl (8.5 mmol/l) <br />&nbsp;&nbsp;', null, 'A1C；Preprandial capillary plasma glucose；Peak postprandial capillary plasma glucose+', 'Recommended glycemic goals for nonpregnant individuals are shown in Table 9.<br />&nbsp;&nbsp;T01_010_01.jpg<br />&nbsp;&nbsp;', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('204', '1', 'T01_011', '1', 'ADA糖尿病医学诊疗标准-2014', 'Standards of Medical Care in Diabetesd-2014', '美国糖尿病学会（American Diabetes Association）', '2014', 'http://care.diabetesjournals.org/content/37/Supplement_1/S14.full.pdf', '英文', '糖尿病包括4种临床类型：<br />&nbsp;&nbsp;1型糖尿病——由β细胞破坏引起，通常导致胰岛素绝对缺乏<br />&nbsp;&nbsp;2型糖尿病——由胰岛素抵抗情况下胰岛素进行性分泌不足引起<br />&nbsp;&nbsp;其他特殊类型糖尿病——由β细胞功能遗传缺陷、胰岛素作用遗传缺陷、胰腺外分泌疾病(例如囊性纤维化)和药物或化学试剂诱发(人体免疫缺损病毒HIV/艾滋病AIDS或器官移植后的治疗)等其他原因引起<br />&nbsp;&nbsp;妊娠糖尿病(GDM)——妊娠期间诊断的糖尿病，非明确显性糖尿病<br />&nbsp;&nbsp;The classification of diabetes includes fourclinical classes:<br />&nbsp;&nbsp;Type 1 diabetes (results from β-cell destruction, usually leading to absolute insulin deficiency)<br />&nbsp;&nbsp;Type 2 diabetes (results from a progressive insulin secretory defect on the background of insulin resistance) <br />&nbsp;&nbsp;Other specific types of diabetes due to other causes, e.g., genetic defects invβ-cell function, genetic defects in insulin action, diseases of the exocrine pancreas (such as cystic fibrosis), and drug- or chemicalinduced (such as in the treatment of HIV/ AIDS or after organ transplantation)<br />&nbsp;&nbsp;Gestational diabetes mellitus (GDM) (diabetes diagnosed during pregnancy that is not clearly overt diabetes)<br />&nbsp;&nbsp;', '糠尿病', null, null, 'The current diagnostic criteria for diabetes are summarized in Table 2.<br />&nbsp;&nbsp;Table 2—Criteria for the diagnosis of diabetes<br />&nbsp;&nbsp;A1C ≥ 6.5%. The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay.<br />&nbsp;&nbsp;or<br />&nbsp;&nbsp;FPG ≥ 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h.<br />&nbsp;&nbsp;or<br />&nbsp;&nbsp;2-h plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT. The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.<br />&nbsp;&nbsp;or<br />&nbsp;&nbsp;In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥ 200 mg/dl (11.1 mmol/l)<br />&nbsp;&nbsp;Detection and diagnosis of gestational diabetes mellitus (GDM)<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp;1. Screen for undiagnosed type 2 diabetes at the first prenatal visit in those with risk factors, using standard diagnostic criteria. <br />&nbsp;&nbsp;2. Screen for GDM at 24–28 weeks of gestation in pregnant women not previously known to have diabetes.<br />&nbsp;&nbsp;3. Screen women with GDM for persistent diabetes at 6–12 weeks postpartum, using the OGTT and nonpregnancy diagnostic criteria. <br />&nbsp;&nbsp;4. Women with a history of GDMshould have lifelong screening for the development of diabetes or prediabetes at least every 3 years. <br />&nbsp;&nbsp;5. Women with a history of GDM found to have prediabetes should receive lifestyle interventions or metformin to prevent diabetes. <br />&nbsp;&nbsp;6. Further research is needed to establish a uniform approach to diagnosing GDM.<br />&nbsp;&nbsp;T01_011_01.jpg<br />&nbsp;&nbsp;', null, 'A1C；Preprandial capillary plasma glucose；Peak postprandial capillary plasma glucose+', 'Recommended glycemic goals for nonpregnant individuals are shown in Table 9.<br />&nbsp;&nbsp;T01_011_02.jpg<br />&nbsp;&nbsp;', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('205', '1', 'T01_012', '1', 'ADA糖尿病医学诊疗标准-2015', 'Standards of Medical Care in Diabetesd-2015', '美国糖尿病学会（American Diabetes Association）', '2015', 'http://care.diabetesjournals.org/content/38/Supplement_1/S8.full.pdf', '英文', 'Diabetes can be classified into the following general categories:<br />&nbsp;&nbsp;1. Type 1 diabetes (due to b-cell destruction, usually leading to absolute insulin deficiency)<br />&nbsp;&nbsp;2. Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance) <br />&nbsp;&nbsp;3. Gestational diabetes mellitus (GDM) (diabetes diagnosed in the second or third trimester of pregnancy that is not clearly overt diabetes)<br />&nbsp;&nbsp;4. Specific types of diabetes due to other causes, e.g., monogenic diabetes syndromes (such as neonatal diabetes and maturity-onset diabetes of the young [MODY]), diseases of the exocrine pancreas (such as cystic fibrosis), and drug- or chemical-induced diabetes (such as in the treatment of HIV/AIDS or after organ transplantation) <br />&nbsp;&nbsp;', '糠尿病', null, null, 'The current diagnostic criteria for diabetes are summarized in Table 2.<br />&nbsp;&nbsp;Table 2—Criteria for the diagnosis of diabetes<br />&nbsp;&nbsp;T01_012_01.jpg<br />&nbsp;&nbsp;Detection and diagnosis of gestational diabetes mellitus (GDM)<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp;1. Test for undiagnosed type 2 diabetes at the first prenatal visit in those with risk factors, using standard diagnostic criteria. <br />&nbsp;&nbsp;2. Test for GDM at 24–28 weeks of gestation in pregnant women not previously known to have diabetes. <br />&nbsp;&nbsp;3. Screen women with GDM for persistent diabetes at 6–12 weeks postpartum, using the OGTT and clinically appropriate nonpregnancy diagnostic criteria. <br />&nbsp;&nbsp;4. Women with a history of GDM should have lifelong screening for the development of diabetes or prediabetes at least every 3 years. <br />&nbsp;&nbsp;5. Women with a history of GDM found to have prediabetes should receive lifestyle interventions or metformin to prevent diabetes. <br />&nbsp;&nbsp;Table 6 Screening for and diagnosis of GDM<br />&nbsp;&nbsp;T01_012_02.jpg<br />&nbsp;&nbsp;NDDG, National Diabetes Data Group. *The American College of Obstetricians and Gynecologists (ACOG) recommends a lower threshold of 135 mg/dL (7.5 mmol/L) in high-risk ethnic minorities with higher prevalence of GDM; some experts also recommend 130 mg/dL (7.2 mmol/L).<br />&nbsp;&nbsp;', null, 'A1C；Preprandial capillary plasma glucose；Peak postprandial capillary plasma glucose+', 'Recommended glycemic goals for nonpregnant individuals are shown in Table 6.2.<br />&nbsp;&nbsp;T01_012_03.jpg<br />&nbsp;&nbsp;', '一、2015年标准的主要推荐内容2015年标准推荐：<br />&nbsp;&nbsp;(1)有高危冈素的孕妇在首次产前检查时，根据非妊娠期的糖尿病诊断标准，全面筛查2型糖尿病。<br />&nbsp;&nbsp;(2)未被诊断为糖尿病的孕妇，应在妊娠24～28周采用一步法或两步法筛查GDM。<br />&nbsp;&nbsp;(3)GDM孕妇产后6～12周时，应进行门服葡萄糖耐量试验(oralglucosetolerancetest，OGTT)，并根据非妊娠期的标准筛查糖尿病。<br />&nbsp;&nbsp;(4)有GDM病史的妇女，至少每3年筛查1次是否已经发展为糖尿病或糖尿病前期状态。<br />&nbsp;&nbsp;(5)有GDM病史的妇女，如果已经发展为糖尿病前期状态，需要进行生活方式干预或二甲双胍等药物十预，预防发生糖尿病。<br />&nbsp;&nbsp;二、GDM的不同诊断标准南<br />&nbsp;&nbsp;多个国家参与的高血糖与妊娠不良结局(the hyperglycemia and adverse pregnancy outcome，HAPO)研究表明，即使妊娠24周前的血糖水平正常，但如果妊娠24～28周时InL糖水平升高，母儿不良结局的发生风险相应增加，且大多数合并症的发生并没有风险阈值。ADA建}义采用一步法或两步法诊断GDM。<br />&nbsp;&nbsp;1．一步法：2011年以来，ADA推荐国际糖尿病与妊娠研究组(International Association of Diabetesand Pregnancy Study Group，IADPSG)的GDM诊断标准．即未被诊断为糖尿病的孕妇，于妊娠24～28周行75gOGTT，空腹、服糖后l和2h血糖界值分别为5.1、lO.0和8.5mmol/L。任意一项达到或超过上述界值诊断为GDM。以此标准诊断的GDM孕妇，发生不良妊娠结局的风险至少为HAPO研究中处于平均血糖水平孕妇的1．75倍。根据此诊断标准，GDM孕妇数量增加，社会医疗费用也会相应增加，并有正常孕妇过度医疗的风险。但考虑到肥胖和糖尿病的患病率逐年增加，此诊断标准有利于改善GDM孕妇及其子代的预后，对控制远期糖尿病的发生也有重大意义，所以ADA仍推荐这一诊断标准。<br />&nbsp;&nbsp;目前研究发现，对轻度高血糖(0GTT空腹血糖≤5．3mmol/L)的孕妇进行十预，可降低大于胎龄儿及子痫的发生风险。2项有关轻度GDM(血糖水平为IADPSG诊断标准的界值)的随机对照实验研究显示，80%～90%的孕妇仅通过十预生活方式即可控制GDM。但对轻度高血糖孕妇进行干预，是否能降低远期2型糖尿病的发病风险，以及子代发生肥胖、糖尿病及其他代谢紊乱的风险，目前尚缺乏证据阐明其作用机制。ADA认为，还需要设计更好的临床试验，来确定最合适的GDM一步法筛查及治疗界值。<br />&nbsp;&nbsp;2．两步法：2013年，美国国立卫生研究院(National Institutes of Health，NIH)组织了15个来自不同领域的专家组成员进行讨论，建议仍采用两步法诊断GDM。NIH指出，目前尚缺乏大量临床干预研究支持一步法优于两步法；GDM患者的大量增多会加重医疗负担且会造成过度医疗干预；对两步法诊断的GDM妇进行治疗，可以有效降低巨大儿、大于胎龄儿及肩难产的发生率，但并不增加小于胎龄儿的发生率。美国妇产科医师学会(American College of Obstetriciansand Gynecologists，ACOG)在2013年的指南巾也支持采用两步法诊断GDM。<br />&nbsp;&nbsp;', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('206', '1', 'T01_013', '1', 'ADA糖尿病医学诊疗标准-2016', 'Standards of Medical Care in Diabetesd-2016', '美国糖尿病学会（American Diabetes Association）', '2016', 'http://care.diabetesjournals.org/content/39/Supplement_1/S13.full.pdf', '英文', 'Diabetes can be classified into the following general categories:<br />&nbsp;&nbsp;1. Type 1 diabetes (due to b-cell destruction, usually leading to absolute insulin deficiency)<br />&nbsp;&nbsp;2. Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance) <br />&nbsp;&nbsp;3. Gestational diabetes mellitus (GDM) (diabetes diagnosed in the second or third trimester of pregnancy that is not clearly overt diabetes)<br />&nbsp;&nbsp;4. Specific types of diabetes due to other causes, e.g., monogenic diabetes syndromes (such as neonatal diabetes and maturity-onset diabetes of the young [MODY]), diseases of the exocrine pancreas (such as cystic fibrosis), and drug- or chemical-induced diabetes (such as in the treatment of HIV/AIDS or after organ transplantation)<br />&nbsp;&nbsp;', '糠尿病', null, null, 'The current diagnostic criteria for diabetes are summarized in Table 2.<br />&nbsp;&nbsp;Table 2—Criteria for the diagnosis of diabetes<br />&nbsp;&nbsp;T01_013_01.jpg<br />&nbsp;&nbsp;Detection and diagnosis of gestational diabetes mellitus (GDM)<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp;1. Test for undiagnosed type 2 diabetes at the first prenatal visit in those with risk factors, using standard diagnostic criteria. <br />&nbsp;&nbsp;2. Test for GDM at 24–28 weeks of gestation in pregnant women not previously known to have diabetes. <br />&nbsp;&nbsp;3. Screen women with GDM for persistent diabetes at 6–12 weeks postpartum, using the OGTT and clinically appropriate nonpregnancy diagnostic criteria. <br />&nbsp;&nbsp;4. Women with a history of GDM should have lifelong screening for the development of diabetes or prediabetes at least every 3 years. <br />&nbsp;&nbsp;5. Women with a history of GDM found to have prediabetes should receive lifestyle interventions or metformin to prevent diabetes. <br />&nbsp;&nbsp;Table 6 Screening for and diagnosis of GDM<br />&nbsp;&nbsp;T01_013_02.jpg<br />&nbsp;&nbsp;NDDG, National Diabetes Data Group. *The American College of Obstetricians and Gynecologists (ACOG) recommends a lower threshold of 135 mg/dL (7.5 mmol/L) in high-risk ethnic minorities with higher prevalence of GDM; some experts also recommend 130 mg/dL (7.2 mmol/L).<br />&nbsp;&nbsp;', null, 'A1C；Preprandial capillary plasma glucose；Peak postprandial capillary plasma glucose+', 'Recommended glycemic goals for nonpregnant individuals are shown in Table 5.2.<br />&nbsp;&nbsp;T01_013_03.jpg<br />&nbsp;&nbsp;', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('207', '1', 'T01_014', '1', '妊娠期糖尿病诊断-WS 331-2011', ' ', '中华人民共和国卫生部', '2011', 'http://wsbzw.jdzx.net.cn/wsbzw/upload/news/1327336770738.pdf', '中文', 'GDM分为以下2级:<br />&nbsp;&nbsp;1. Al级:GDM只需单纯用饮食治疗即可把血搪控制在正常范围；<br />&nbsp;&nbsp;2. A2级:需加用胰岛素治疗才能把血搪控制在正常范围的GDM。<br />&nbsp;&nbsp;', '妊娠糖尿病；gestational diabetes mellitus；GDM', null, null, 'GDM诊断一步法：不必行50g GCT，而妊娠24周～28周直接行75g 0GTT。一步法适用于有GDM高危因素的孕妇或有条件的医疗机构进行。<br />&nbsp;&nbsp;GDM诊断两步法：第一步：进行FPG,FPG≥5.1mmol/Ll_则诊断GDM；如FPG≥4.4 mmol/L但<5.1mmol/L者进行第二步：75g OGTT，如果OGTT结果异常者则诊断为GDM。或者第一步：进行50g GCT，结果异常者，进行第二步：如果50 g GCT血糖≥11.1mmol/l，即测FPG，FPG异常则诊断GDM；如FPG结果正常，尽早行75G OGTT。<br />&nbsp;&nbsp;75g9 0GTT的正常值：空腹、服葡萄糖后1h、2h血糖值分别小于5.1mmol/L、10.0 mmol/L、8.5 mmol/L。任意一点血糖值异常者应诊断为GDM。<br />&nbsp;&nbsp;', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('208', '1', 'T01_015', '1', '糖尿病的筛查和诊断-WS 397-2012', ' ', '中华人民共和国卫生部', '2012', 'http://wsbzw.jdzx.net.cn/wsbzw/upload/news/1358320813523.pdf', '中文', '1.1型糖尿病：由于胰岛β细胞破坏或功能缺失导致胰岛素分泌绝对缺乏所引起的糖尿病，不包括已阐明特殊病因导致胰岛β细胞破坏所引起的糖尿病。1型糖尿病可进一步分为自身免疫性（1A型）和特发性(1B型)两个亚型。<br />&nbsp;&nbsp;2.2型糖尿病：由于胰岛素抵抗为主伴胰岛素分泌相对不足，或胰岛素分泌缺陷为主伴胰岛素抵抗所致是最常见的糖尿病类型。<br />&nbsp;&nbsp;3.其他特殊类型糖尿病：一些病因比较明确或有其他显著临床特征的糖尿病，包括继发于特殊情况的糖尿病和与特殊疾病或综合征相关的糖尿病。其中包括：<br />&nbsp;&nbsp;a)胰岛β细胞功能遗传性缺陷；<br />&nbsp;&nbsp;b)胰岛素作用遗传性缺陷；<br />&nbsp;&nbsp;c)胰腺外分泌疾病；<br />&nbsp;&nbsp;d)内分泌疾病；<br />&nbsp;&nbsp;e)药物和化学品所致；<br />&nbsp;&nbsp;f)感染所致；<br />&nbsp;&nbsp;g)不常见的免疫介导性糖尿病；<br />&nbsp;&nbsp;h)其他与糖尿病相关的遗传综合征。<br />&nbsp;&nbsp;4.妊娠期糖尿病：妊娠期首次发生的不同程度的糖代谢异常，不包括妊娠前已经存在的糖尿病。<br />&nbsp;&nbsp;', '糖尿病；diabetes mellitus', null, null, ' 1.诊断糖尿病的血糖切点：<br />&nbsp;&nbsp;a)空腹血糖≥7.0mmol/L(126 mg/dL)；<br />&nbsp;&nbsp;b)OGTT 2 h血糖≥11.1 mmol/L(200 mg/dL)；<br />&nbsp;&nbsp;c)随机血糖≥ll.1mmol/L (200mg/dL)。<br />&nbsp;&nbsp;2.有典型的糖尿病症状（多饮、多尿、多食、体．霞减轻等）．并符合1a）、b）或c<br />&nbsp;&nbsp;）中任何一条者即可诊断为糖尿病。无明确的糖尿病症状者，只有符合1a）或b）才可作为诊断条件，并且需在另一天进行复查核实。<br />&nbsp;&nbsp;3.应激状态（感染、创伤、手术等）F出现的高血糖可能是暂时性的，不应\\即做出糖尿病诊断，应在应激状态消失后再次复查血糖，以迸一步明确诊断。<br />&nbsp;&nbsp;4.静脉血浆葡萄糖应作为测定和报告血糖水平的标准方法，不推荐使用毛细血管血样检测的血糖值作为糖尿病的诊断指标。暂不推荐将HbAlc检测作为糖尿病的诊断方法。<br />&nbsp;&nbsp;', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('209', '1', 'T01_016', '1', '中华医学会临床诊疗指南-内分泌及代谢性疾病分册-糖尿病-2005', ' ', '中华医学会', '2005', '中华医学会.临床诊疗指南(内分泌及代谢性疾病分册)[M].人民卫生出版社,2005.', '中文', '1型；2 型；特殊类型；妊娠糖尿病', '糖尿病', null, null, ' 1.糖尿病的典型三多一少症状加上随时血糖*≥11.1mmol/L（200mg/dl）,或<br />&nbsp;&nbsp;2.空腹**血糖注7.0mmol/L (l40mg/dl)，或<br />&nbsp;&nbsp;3.口服75g 葡萄糖耐盘试验(OGTT2小时血糖值≥11.1mmol/L。<br />&nbsp;&nbsp;以上各条诊断标准均应另日重复核实。<br />&nbsp;&nbsp;注：*,随时血牺指一日之中任何时间来血，不考虑与前餐的时间关系；**，空腥指禁<br />&nbsp;&nbsp;食8小时以上；OGTT 2hPPG 7.8-11.1mmol/L为糖耐量减低，小子7.8mmol/L为正常。<br />&nbsp;&nbsp;疗效指标：FPG（mmol/L）；PPG（mmol/L）；AIC（%）；lhPPG（mmol/L）；2hPPG（mmol/L）<br />&nbsp;&nbsp;疗效判定标准：<br />&nbsp;&nbsp;一般要求空腹及餐后血糖控制达标，按ADA(2002)或IDF西太区目标，FPG<6.1mmol/L，PPG<7.8mmol/L，AIC<7%或<6.5%。妊娠糖尿病FPG≤5.8mmol/L，lhPPG≤8.6mmol/L，2hPPG≤7.2mmol/L。特殊情况如老、幼、已有较重晚期并发症或反复发作低血糖者，血糖控制标准可适当放宽(FPG<7.8mmoI/L，PPG<12mmol/L)。<br />&nbsp;&nbsp;', null, 'FPG；PPG；AIC', '一般要求空腹及餐后血糖控制达标.按ADA(2002) 或IDF 西太区目标，FPG<6.1mmol/L，PPG<7. 8mmol/L，AIC<7%或<6.5%。妊娠糖尿病FPG≤5.8mmol/L，lhPPG≤8.6mmol/L，2hPPG≤7.2mmol/L.特殊情况如老、幼、已有较重晚期并发症或反复发作低血糖者，血糖控制标准可适当放宽(FPG<7.8mmol/L，PPG<12mmol/L)。<br />&nbsp;&nbsp;', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('21', '32', 'G02_009', '1', '甘油三酯增高的血脂异常防治中国专家共识', '无 ', '中华医学会心血管病学分会循证医学评论专家组;中国老年学学会心脑血管病专业委员会', '2011', '胡大一,郭艺芳.甘油三酯增高的血脂异常防治中国专家共识[J].中国医学前沿杂志(电子版),2011,3(05):115-120.;\n中华医学会心血管病学分会循证医学评论专家组,中国老年学学会心脑血管病专业委员会.甘油三酯增高的血脂异常防治中国专家共识[J].实用糖尿病杂志.2012,8(1):14-18.', '中文', null, '甘油三酯增高的血脂异常;高TG血症', null, null, '依据2007年《中国成人血脂异常防治指南》的划分标准，空腹（禁食12小时）TG在1.70 mmol/L以下为合适水平；1.70～2.25 mmol/L为边缘升高；≥2.26 mmol/L为升高。非空腹血浆TG＜2.26 mmol/L与空腹血浆TG＜1.70 mmol/L相对应。', null, 'TC；LDL-C；非HDL-C；', 'TG轻中度升高（2.26～5.64 mmol/L）时LDL-C达标仍为主要目标，非HDL-C达标（LDL-C的目标值+0.78 mmol/L）为次要目标。TG严重升高时（≥5.65 mmol/L）应立即启动降低TG的药物治疗，以预防急性胰腺炎。', '该指南由4 部分组成：①高甘油三酯血症的流行病学现状；②甘油三酯增高与动脉粥样硬化性心血管疾病的关系；③甘油三酯的临床测定；④高甘油三酯血症的治疗。<br />&nbsp;&nbsp;当前虽然提出了甘油三酯的参考范围，但并没有提出降低甘油三酯时应达到的目标值，这是因为尚缺乏大规模临床试验的证据支持降低甘油三酯确能减少冠心病事件危险性。所以，在目前临床实践中应采取的策略是， 对严重高甘油三酯血症者，需积极治疗以预防急性胰腺炎发生；对于轻、中度高甘油三酯血症者， 若伴冠心病或属心血管高危者，可考虑在使用他汀类药物的基础上联合应用降低甘油三酯的药物。<br />&nbsp;&nbsp;', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('210', '1', 'T01_017', '1', '中国1型糖尿病防治指南-2013', ' ', '中华医学会糖尿病学分会', '2013', '中国1型糖尿病诊治指南制定委员会.中国1型糖尿病诊治指南[M].人民卫生出版社,2013.', '中文', null, '1型糖尿病；T1MD', null, null, ' 1. T1DM的定义<br />&nbsp;&nbsp;特指因胰岛β细胞破坏而导致胰岛素绝对缺乏，具有酮症倾向的糖尿病，患者需要终身依赖胰岛素维持生命。<br />&nbsp;&nbsp;2. T1DM的诊断依据T1DM主要依据临床表现而诊断，由于β细胞破坏所致的依赖胰岛素治疗是诊断T1DM的“金标准”。因此T1DM实际上是一种回顾性诊断，在患者起病初期进行分型诊断有时非常困难。<br />&nbsp;&nbsp;单用临床症状和血糖水平不能准确区分1型还是2型糖尿病；即使是被视为T1DM典型特征的酮症酸中毒，也可以发生在2型糖尿病患者。T1DM目前尚无确切的诊断标准，主要根据临床特征来诊断。支持T1DM诊断的临床特征包括：（1）起病年龄：大多数患者20岁以前起病，但也可以在任何年龄发病；20岁以前发病的患者中约80%是T1DM；（2）起病方式：起病较急，多数患者的口干、多饮和多尿、体重下降等“三多一少”症状较为典型，有部分患者直接表现为脱水、循环衰竭或昏迷等酮症酸中毒的症状；（3）治疗方式：依赖胰岛素治疗。一般在临床上年轻起病、发病较急、“三多一少”症状明显，且伴有酮症或酮症酸中毒者，应警惕T1DM可能，先给予胰岛素治疗，定期观察患者对胰岛素治疗的依赖程度，同时注意与其他类型的糖尿病相鉴别，最终根据治疗后的临床表现特别是对胰岛素治疗的依赖程度确定分型。表2.3列出了T1DM、2型糖尿病及单基因突变糖尿病的鉴别要点。应在年龄<6月龄的患儿、有家族史或伴有如神经性耳聋、视神经萎缩等特殊症状的患者中进行基因检测，以排除单基因突变所致的糖尿病。$$$T01_017_01.jpg<br />&nbsp;&nbsp;<br />&nbsp;&nbsp;起病初期患者的胰岛功能对糖尿病的分型诊断也有参考意义。临床上常用的评价胰岛功能的方法为测定空腹及餐后（或其他刺激后）的C肽水平。这尤其适用于使用外源性胰岛素的糖尿病患者。目前尚无界定T1DM患者的C肽截点，但国内外学者倾向于认为多数经典T1DM患者发病1年后，其血清C肽水平多低于检测下限值。若起病初期，患者的空腹C肽<200 pmol/L，应疑诊为T1DM，然后随访观察C肽的变化，进行最终分型。<br />&nbsp;&nbsp;3. T1DM的病因分型诊断<br />&nbsp;&nbsp;临床诊断的T1DM患者，应进一步进行胰岛自身抗体的检测以明确病因。胰岛自身抗体是胰岛β细胞遭受免疫破坏的标志物，是诊断自身免疫性T1DM的关键指标，包括胰岛细胞抗体（islet cell antibody, ICA）、谷氨酸脱羧酶抗体（glutamic acid decarboxylase antibody, GAD-Ab）、蛋白酪氨酸磷酸酶自身抗体（insulinoma-associated 2 molecule antibody, IA-2A）、胰岛素自身抗体（insulin autoantibody, IAA）、锌转运蛋白8抗体（Zinc transporter 8 antibody, ZnT8-Ab）等，其中以GAD-Ab的敏感性最高。推荐使用国际标准化的放射配体法进行检测，以确保较高的敏感性和特异性。<br />&nbsp;&nbsp;高加索人中，约80-90%的T1DM患者可检测到上述胰岛自身抗体，以GAD-Ab和IA-2A多见。在中国人群中，胰岛自身抗体阳性的比例较低；约有50-70%的患者体内可检测到胰岛自身抗体，在病因上属于自身免疫性T1DM。但有少数患者起病初期胰岛自身抗体阴性，但随着病程进展，可出现抗体阳转，这同样应归属于自身免疫性糖尿病。约有30-50%的患者体内一直检测不到胰岛自身抗体或其他的免疫学证据，可考虑为特发性T1DM的可能。<br />&nbsp;&nbsp;4. 特殊类型的T1DM<br />&nbsp;&nbsp;如前所述，经典的T1DM通常急性起病，常在起病1-6月内发生酮症或酮症酸中毒，但仍需注意少数特殊类型的患者。<br />&nbsp;&nbsp;暴发性1型糖尿病(fulminant type 1 diabetes)是日本学者Imagawa等2000年提出的T1DM的新亚型。该型糖尿病呈急骤起病，如未及时诊断和治疗，常导致患者在短期内死亡，多见于东亚人群。目前国际上多采用日本学者Imagawa提出的诊断标准：(1)高血糖症状1周内出现酮症或酮症酸中毒；(2)血清空腹C肽<100 pmoL/L和餐后2h C肽<170 pmol/L；(3)初诊首次血糖>16 mmol/L和HbAlc<8.5％。以上三条需同时具备方能诊断。暴发性T1DM起病急骤凶险，常有感染、药疹或妊娠等诱因，酮症酸中毒程度较重，胰岛在短期内被彻底破坏，很难恢复。目前具体病因不明，少数患者体内可检测到胰岛自身抗体。<br />&nbsp;&nbsp;总体来说，T1DM临床表现形式多样，存在数种亚型。疾病的起病方式（急性酮症起病）、治疗方式（对胰岛素的治疗有依赖性）、胰岛功能衰竭（C肽水平低下）以及胰岛自身抗体的状态均可为诊断T1DM提供有力线索。推荐所有疑诊患者均按T1DM给予胰岛素治疗，同时检测胰岛自身抗体和C肽水平，并进行随访；根据患者对胰岛素的依赖与否或C肽水平明确T1DM的诊断；对年龄<6月龄的患儿、有家族史或伴有如神经性耳聋、视神经萎缩等特殊症状的患者进行基因检测，以排除单基因突变所致的糖尿病。具体可参考图2.2。值得注意的是，上述诊断流程不适用于诊断LADA和暴发等特殊类型的T1DM。这部分患者有较为明确的诊断标准，具体请参见《关于成人隐匿性自身免疫糖尿病（LADA）诊疗的共识》。<br />&nbsp;&nbsp;T01_017_02.jpg<br />&nbsp;&nbsp;<br />&nbsp;&nbsp;', null, 'HbA1c；血糖（空腹或餐前、餐后、睡前、凌晨）', '降低高血糖和防止低血糖是T1DM血糖控制的两大目标，因此目前公认的血糖控制标准为：在最少发生低血糖风险的情况下应使患者的血糖尽可能接近正常水平。对于个体患者而言，血糖控制目标的制定应考虑到以下方面：患者的年龄、患者本人或其家庭管理和认识糖尿病的能力、血糖监测频率及就诊的方便性与积极性。建议我国T1DM血糖控制目标是：在尽量避免低血糖基础上，儿童和青春期HbA1c<7.5%；成人HbA1c<7.0%；老年人HbA1c<7.5%；不同年龄阶段的T1DM患者的血糖控制目标不同（表3.1）。<br />&nbsp;&nbsp;T01_017_03.jpg<br />&nbsp;&nbsp;', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('211', '21', 'B01_001', '0', '变应性鼻炎的诊治原则和推荐方案', null, '中华耳鼻喉头颈外科杂志编辑委员会 中华医学会耳鼻咽喉科分会', '2004', '中华耳鼻喉头颈外科杂志，2004，,4(3),166_167.', '中文', '1.间歇性<br />&nbsp;&nbsp;2.持续性<br />&nbsp;&nbsp;1.轻度<br />&nbsp;&nbsp;2.中-重度<br />&nbsp;&nbsp;1.季节性鼻炎<br />&nbsp;&nbsp;2.常年性变应性鼻炎', '变应性鼻炎', null, null, '1.间歇性：症状发生的天数<4d/周或病程<4周<br />&nbsp;&nbsp;2.持续性：症状发生的天数>4d/周或病程>4周<br />&nbsp;&nbsp;1.轻度：睡眠正常、日常生活、体育和娱乐正常、工作和学习正常<br />&nbsp;&nbsp;2.中-重度：不能正常睡眠、日常生活、体育锻炼、娱乐受影响、不能正常工作或学习、有令人烦恼的症状（参见B01-001-图表1）<br />&nbsp;&nbsp;1.季节性鼻炎：每年发病季节基本一致，且与致敏花粉传粉期相符合（临床研究报告应至少2年在同一季节发病），变应原皮肤试验阳性，主要以室外变应原为主<br />&nbsp;&nbsp;2.常年性鼻炎：在1年内半数以上的日子里有上述症状，变应原皮肤试验阳性，主要以室内变应原（螨、室内尘土等）为主', null, '症状和体征计分评定疗效：(治疗前总分-治疗后总分)/治疗前总分*100%', '显效：>=66%<br />&nbsp;&nbsp;有效：65%-26%<br />&nbsp;&nbsp;无效：<=25%', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('212', '21', 'B01_002', '0', '变应性鼻炎诊断和治疗指南', null, '中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组 中华医学会耳鼻咽喉头颈外科学分会鼻科学组\n', '2015', 'http://d.dxy.cn/preview/9100133', '中文', '1.季节性AR<br />&nbsp;&nbsp;2.常年性AR<br />&nbsp;&nbsp;1.间歇性AR<br />&nbsp;&nbsp;2.持续性AR1.<br />&nbsp;&nbsp;轻度2.<br />&nbsp;&nbsp;中－重度', '变应性鼻炎', '未提及', '未提及', '症状：打喷嚏、流清水样涕、鼻痒和鼻塞等症状出现2个或以上，每天症状持续或累计在1小时以上，可伴有眼痒、流泪和眼红等眼部症状<br />&nbsp;&nbsp;体征：常见鼻黏膜苍白、水肿，鼻腔水样分泌物；变应原检测：至少一种变应原SPT或血清特异性IgE阳性<br />&nbsp;&nbsp;1.季节性AR：症状发作呈季节性<br />&nbsp;&nbsp;2.常年性AR：症状发作呈常年性<br />&nbsp;&nbsp;1.间歇性AR：症状发作<4天／周，且<连续4周<br />&nbsp;&nbsp;2.持续性AR：症状发作≥4天／周，且≥连续4周1.<br />&nbsp;&nbsp;轻度：症状轻微，对生活质量（包括睡眠、日常生活、工作和学习）未产生明显影响3.<br />&nbsp;&nbsp;中－重度：症状较重或严重，对生活质量产生明显影响。\n', '未提及', '未提及', '未提及', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('213', '21', 'B01_003', '1', '临床指南：变应性鼻炎', 'Clinical Practice Guideline: Allergic Rhinitis', '美国耳鼻咽喉头颈外科学会（American Academy of Otolaryngology-Head and Neck Surgery）', '2014', 'http://guide.medlive.cn/guideline/preview/1/7771?token=6fcf05d66c45829de6c5389687455770', '英文', '1.季节性AR(seasonal)<br />&nbsp;&nbsp;2.持续/常年性的A(perennial/year-round)R<br />&nbsp;&nbsp;3.偶发性AR(episodic)<br />&nbsp;&nbsp;1.间歇性AR(intermittent)<br />&nbsp;&nbsp;2.持续性AR(persistent)<br />&nbsp;&nbsp;1.轻度(mild)<br />&nbsp;&nbsp;2.重度(more severe)', '变应性鼻炎', '未提及', '未提及', '1.病史和症状体征：有以下一种或多种症状，鼻塞、流鼻涕、鼻痒、打喷嚏（PATIENT HISTORY AND PHYSICAL EXAMINATION: Clinicians should make the clinical diagnosis of AR when patients present with a history and physical examination consistent with an allergic cause and 1 or more of the following symptoms: nasal congestion, runny nose, itchy nose, or sneezing.）参见B01-003-图表2<br />&nbsp;&nbsp;2.过敏检查：特异性IgE抗体的检测（ALLERGY TESTING: Clinicians should perform and interpret, or refer to a clinician who can perform and interpret, specific IgE (skin or blood) allergy testing for patients）<br />&nbsp;&nbsp;3.影像检查：观察鼻窦成像（IMAGING: Clinicians should not routinely perform sinonasal imaging in patients presenting with symptoms consistent with a diagnosis of AR.）<br />&nbsp;&nbsp;.1.季节性AR:由花粉等引起(seasonal：pollens)<br />&nbsp;&nbsp;2.持续/常年性的A：由尘螨等引起(perennial/year-round：dust mites)R<br />&nbsp;&nbsp;3.偶发性AR：患者暴露于不正常的环境中引起(episodic：environmental from exposures not normally encountered in the patient’s environment,eg, visiting a home with pets)<br />&nbsp;&nbsp;1.间歇性AR：<4d/周或<4周/年(intermittent：(<4 days per week or <4 weeks per year)<br />&nbsp;&nbsp;2.持续性AR：>4d/周或>4周/年(persistent：>4 days per week and >4 weeks per year)<br />&nbsp;&nbsp;1.轻度:症状存在时不影响生活质量(mild：when symptoms are present but are not interfering with quality of life)<br />&nbsp;&nbsp;3.重度：症状严重到影响生活质量(more severe：when symptoms are bad enough to interfere with quality of life)参见B01-003-图表1', '未提及', '症状  ', '改善鼻塞等症状、提高生活质量、改善睡眠（Improved symptom control,efficacy in controlling nasal congestion and other symptoms improved quality of life, better sleep）', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('214', '21', 'B01_004', '1', '变应性鼻炎诊断标准及疗效评定标准(1997年修订,海口)', '无', '中华医学会耳鼻咽喉科学分会、中华耳鼻咽喉科杂志编辑委员会', '1997', '中华医学会耳鼻咽喉科学分会,中华耳鼻咽喉科杂志编辑委员会.变应性鼻炎诊断标准及疗效评定标准(1997年修订,海口).中华耳鼻咽喉科杂志.1998.6(33):134-135', '中文', '1.常年性变应性鼻炎2.花粉症', '变应性鼻炎', '未报告', '未报告', '1.常年性变应性鼻炎6-8分，可疑变异性鼻炎3-5分，非变异性鼻炎0-2分；2.花粉症：季节性发病、发作期有典型的临床症状和体征、3.发作期鼻分泌物(和/或结膜刮片)嗜酸粒细胞阳性, 或鼻粘膜刮片肥大细胞(嗜碱粒细胞)阳性、4.花粉变应原皮肤试验呈阳性反应, 至少一种为(++)或(++)以上, 或变应原鼻激发试验阳性、眼结膜试验阳性。', '未报告', '体征、症状', '（治疗前总分-治疗后总分）/治疗前总分*100。>=51%显效，50%-21%有效，<=20%无效。\n体征分级:下鼻甲与鼻底、鼻中隔紧靠, 见不到中鼻甲, 或中鼻甲粘膜息肉样变、息肉形成, 记录为3分;下鼻甲与鼻中隔(或鼻底)紧靠, 下鼻甲与鼻底(或鼻中隔)之间尚有小缝隙, 记录为2分;下鼻甲轻度肿胀, 鼻中隔、中鼻甲尚可见,记录为1分。\n症状分级记分标准：\n1 分喷嚏(一次连续个数)：3～9、流涕(每日擤鼻次数)：≤4、鼻堵鼻痒：偶有间断\n2 分喷嚏(一次连续个数)：10～14、流涕(每日擤鼻次数)：5～9 、鼻堵鼻痒：介于两者之间蚁行感, 但可忍受\n3 分喷嚏(一次连续个数)：≥15、流涕(每日擤鼻次数)：≥10、鼻堵鼻痒：几乎全天用口呼吸蚁行感, 难忍', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('215', '21', 'B01_005', '1', '变应性鼻炎诊断和治疗指南', '无', '中华耳鼻咽喉头颈外科杂志编委会鼻科组、中华医学会耳鼻咽喉头颈外科学分会鼻科学组', '2009', '中华耳鼻咽喉头颈外科杂志编委会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科学组.变应性鼻炎诊断和治疗指南(2009年，武夷山).中华耳鼻咽喉头颈外科杂志.2009.12(44):977-978', '中文', '根据症状持续时间分为间歇性变应性鼻炎和持续性变应性鼻炎；根据患者症状的严重程度，以及是否影响患者生活质量(包括睡眠、日常生活、工作和学习)，将变应性鼻炎分为轻度和中-重度', '变应性鼻炎', '未报告', '未报告', '1．临床症状：喷嚏、清水样涕、鼻塞、鼻痒等症状出现2项以上(含2项)，每天症状持续或累计在1h以上。可伴有眼痒、结膜充血等眼部症状。2．体征：常见鼻黏膜苍白、水肿，鼻腔水样分泌物。酌情行鼻内镜和鼻窦CT等检查。3．皮肤点刺试验(skin prick teat，SPT)：使用标准化变应原试剂，在前臂掌侧皮肤点刺，20min后观察结果。每次试验均应进行阳性和阴性对照，阳性对照采用组胺。阴性对照采用变应原溶媒。按相应的标准化变应原试剂说明书判定结果。皮肤点刺试验应在停用抗组胺药物至少7d后进行。4．血清特异性IgE检测：可作为变应性鼻炎诊断的实验室指标之一。确诊变应性鼻炎需临床表现与皮肤点刺试验或血清特异性IgE检测结果相符。', '未报告', '视觉模拟量表(visual analogue scale，VAS)', '采用视觉模拟量表(visual analogue scale，VAS)对治疗前后的总体症状和鼻部分类症状分别进行临床疗效评定。', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('216', '21', 'B01_006', '1', '变应性鼻炎特异性免疫治疗专家共识', '无', '中华耳鼻咽喉头颈外科杂志编委会鼻科组、中华医学会耳鼻咽喉头颈外科学分会鼻科学组', '2011', '中华耳鼻咽喉头颈外科杂志编委会鼻科组、中华医学会耳鼻咽喉头颈外科学分会鼻科学组.变应性鼻炎特异性免疫治疗专家共识.中华耳鼻咽喉头颈外科杂志.2011,46(12)', '中文', '根据症状持续时间分为间歇性变应性鼻炎和持续性变应性鼻炎两类;依据症状的严重程度和对生活质量的影响分为轻度和中一重度', '变应性鼻炎', '未报告', '未报告', '未报告', '未报告', '药物联合评分、VAS评分', '计算治疗开始前与治疗结束后症状和药物联合评分或VAS评分，进行统计学处理与比较', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('217', '21', 'B01_007', '1', '儿童变应性鼻炎诊断和治疗指南(2010年，重庆)', '无', '中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组\n中华医学会耳鼻咽喉头颈外科学分会鼻科学组、小儿学组\n中华儿科杂志编辑委员会', '2011', '中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组，中华医学会耳鼻咽喉头颈外科学分会鼻科学组、小儿学组，中华儿科杂志编辑委员会.儿童变应性鼻炎诊断和治疗指南(2010年，重庆).中华耳鼻咽喉头颈外科杂志.2011,46(1):7-8', '中文', '未报告', '变应性鼻炎', '未报告', '未报告', '一、症状:清水样涕、鼻痒、鼻塞、喷嚏等症状出现2项以上(含2项)，每天症状持续或累计约1 h以上。可伴有眼痒、结膜充血等眼部症状。症状严重的患儿可有所谓的“变应性敬礼”(allergic salute)动作，即为减轻鼻痒和使鼻腔通畅而用手掌或手指向上揉鼻。二、体征:常见鼻黏膜苍白、水肿，鼻腔水样分泌物。症状严重的患儿可出现：①变应性黑眼圈(allergic shiner)：由于下眼睑肿胀而出现的下睑暗影；②变应性皱褶(allergic crease)：由于经常向上揉搓鼻尖而在鼻部皮肤表面出现横行皱纹。三、皮肤点刺试验(skin prick test，SPT):在停用抗组胺药物至少7 d后进行。使用标准化变应原试剂，在前臂掌侧皮肤点刺，20 rain后观察结果。每次试验均应进行阳性和阴性对照，阳性对照采用组胺，阴性对照采用变应原溶媒。按相应的标准化变应原试剂说明书判定结果。四、血清特异性IgE检测适用于任何年龄，是诊断儿童变应性鼻炎重要的实验室指标之一。具有上述临床表现(症状、体征)，并同时具备皮肤点刺试验或血清特异性IgE检测2项中任何一项的阳性结果，方能确诊儿童变应性鼻炎。', '未报告', '视觉模拟量表', '根据儿童合作和理解的程度，尽可能采用视觉模拟量表(visual analogue scale，VAS) 对治疗前后的总体症状和鼻部分类症状分别进行临床疗效评定。', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('218', '21', 'B01_008', '0', '中医耳鼻咽喉科常见病诊疗指南', '无', '中华中医药学会耳鼻喉科分会', '2010', '世界中联耳鼻喉口腔科专业委员会第五届学术年会、中华中医药学会耳鼻喉科分会第十九届学术交流会暨贵州省中西医结合学会耳鼻咽喉分会第二次学术交流会论文汇编.中医耳鼻咽喉科常见病诊疗指南-鼻鼽（变应性鼻炎等）初稿', '中文', '未报告', '变应性鼻炎', '鼻鼽', '肺气虚寒、脾气虚弱、肾阳不足、肺经伏热', '1 病史：可有过敏史及家族史。.2 临床症状：具有突发性和反复发作的特点。以鼻痒、阵发性喷嚏、大量水样鼻涕、鼻塞为主要表现，或伴有眼痒、咽痒、腭痒等症状。3 局部检查：发作期鼻黏膜多为苍白、灰白或浅蓝色，亦可充血色红，鼻甲肿大，鼻腔有较多水样分泌物。间歇期上述体征多不明显。4 其他检查：免疫学检查如皮肤变应原测试、血清IgE 检测等有助于本病的诊断。\n', '1 肺气虚寒证\n发作性鼻痒，喷嚏连作，清涕量多，鼻塞，嗅觉减退；鼻黏膜色淡、肿胀；语声低，易患感冒，经常咳嗽、咳痰；舌淡红，苔薄白，脉细弱。\n2 脾气虚弱证\n发作性鼻痒，喷嚏连作，清涕量多，鼻塞，嗅觉减退；鼻黏膜色淡、肿胀；食少，便溏，倦怠乏力；舌淡红或胖，边有齿痕，苔薄白，脉细弱。\n3 肾阳不足证\n发作性鼻痒，喷嚏连作，清涕量多，鼻塞，嗅觉减退；鼻黏膜苍白、肿胀；畏寒，肢冷，腰膝酸软；舌淡，苔白，脉沉细。\n4 肺经伏热证\n发作性鼻痒，喷嚏连作，清涕量多或为黏稠涕，鼻塞、嗅觉减退；鼻黏膜偏红、肿胀；口干；畻坴畿\0\0\0\0醼畻', '未报告', '未报告', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('219', '21', 'B01_009', '0', '中医耳鼻咽喉科常见病诊疗指南', '无', '中华中医药学会', '2012', '世界中联耳鼻喉口腔专业委员会换届大会及第三次学术年会暨中华中医药学会耳鼻喉科分会第十七次学术交流会暨广东省中医及中西医结合学会耳鼻喉科学术交流会论文汇编。中医耳鼻咽喉科常见病诊疗指南-鼻鼽（变应性鼻炎等）定稿', '中文', '未报告', '变应性鼻炎', '鼻鼽', '肺气虚寒、脾气虚弱、肾阳不足、肺经伏热', '1 病史：可有过敏史及家族史。.2 临床症状：具有突发性和反复发作的特点。以鼻痒、阵发性喷嚏、大量水样鼻涕、鼻塞为主要表现，或伴有眼痒、咽痒、腭痒等症状。3 局部检查：发作期鼻黏膜多为苍白、灰白或浅蓝色，亦可充血色红，鼻甲肿大，鼻腔有较多水样分泌物。间歇期上述体征多不明显。4 其他检查：免疫学检查如皮肤变应原测试、血清IgE 检测等有助于本病的诊断。', '1 肺气虚寒证\n发作性鼻痒，喷嚏连作，清涕量多，鼻塞，嗅觉减退；鼻黏膜色淡、肿胀；语声低，易患感冒，经常咳嗽、咳痰；舌淡红，苔薄白，脉细弱。\n2 脾气虚弱证\n发作性鼻痒，喷嚏连作，清涕量多，鼻塞，嗅觉减退；鼻黏膜色淡、肿胀；食少，便溏，倦怠乏力；舌淡红或胖，边有齿痕，苔薄白，脉细弱。\n3 肾阳不足证\n发作性鼻痒，喷嚏连作，清涕量多，鼻塞，嗅觉减退；鼻黏膜苍白、肿胀；畏寒，肢冷，腰膝酸软；舌淡，苔白，脉沉细。\n4 肺经伏热证\n发作性鼻痒，喷嚏连作，清涕量多或为黏稠涕，鼻塞、嗅觉减退；鼻黏膜偏红、肿胀；口干；畻坴畿\0\0\0\0醼畻', '未报告', '未报告', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('22', '32', 'G02_010', '1', 'ESC/EAS血脂异常管理指南', 'ESC/EAS Guidelines for the management of dyslipidaemias', '欧洲心脏病学会（ESC）；欧洲动脉粥样硬化学会（EAS）', '2011', 'http://www.escardio.org/Guidelines-%26-Education/Clinical-Practice-Guidelines/Dyslipidaemias-Management-of.', '英文', null, '高甘油三酯血症', null, null, '心血管疾病高危\nThe burden of HTG as a CVD risk factor is highlighted by the fact that about one-third of adult individuals have TG .1.7 mmol/L (more than  150 mg/dL).', null, 'LDL-C；非高密度脂蛋白胆固醇（non-HDL-C）；载脂蛋白B（ApoB）', 'G02_010_01_LDL-C的治疗建议目标', '2011年ESC/EAS指南将控制LDL-C水平作为血脂管理的首要靶目标（Ⅰ/A），取消高密度脂蛋白胆固醇（HDL-C）作为干预靶点，但同时也提出非高密度脂蛋白胆固醇（non-HDL-C）及载脂蛋白B（ApoB）亦为应考虑的调脂目标，尤其对合并混合型血脂异常、糖尿病或慢性肾脏疾病的患者更应如此（Ⅱa/C），应将non-HDL-C列为次要目标，non-HDL-C目标值应比LDL-C高0.8 mmol/L（30 mg/dl）。<br />&nbsp;&nbsp;\n对于高危及极高危患者，指南推荐立即启动药物治疗；LDL-C＞2.6 mmol/L（100 mg/dl）中危患者和LDL-C＞4.9 mmol/L（190 mg/dl）低危患者除进行生活方式干预外，亦应考虑药物治疗。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('220', '21', 'B01_010', '1', '过敏性鼻炎及其对哮喘的影响（2008）', 'Allergic Rhinitis and its Impact on Asthma (ARIA) 2008', '世界卫生组织过敏性鼻炎及其对哮喘的影响工作组（ARIA）', '2008', 'Allergic Rhinitis and its Impact on Asthma (ARIA) World Health Organization (WHO) workshop.Allergic Rhinitis and its Impact on Asthma (ARIA) 2008.Allergy 2008:63 (Suppl.86): 8-160', '英文', '轻度、重度、重度', '变应性鼻炎', '未报告', '未报告', '•过敏性鼻炎的诊断是基于典型的过敏史和诊断测试。\n•过敏性鼻炎的典型症状包括鼻溢、打喷嚏、鼻塞和瘙痒。\n•眼部症状很常见,特别是患者对室外过敏原过敏。\n•诊断测试是基于演示中有浓度过敏原特异性IgE皮肤(皮肤测试)或血液(特定的IgE)。\n', '未报告', '未报告', '未报告', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('221', '21', 'B01_011', '1', '过敏性鼻炎及其对哮喘的影响的指南（2010版本）', 'Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines:2010 Revision', null, '2010', 'Allergic Rhinitis and its Impact on Asthma (ARIA) World Health Organization (WHO) workshop.Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines:2010 Revision.ALLERGY CLINIMMUNOL.2010:126:466-476', '英文', '未报告', '变应性鼻炎', '未报告', '未报告', '未报告', '未报告', '未报告', 'GRADE推荐等级', '全文均以临床问题问答形式呈现，回答了预防、治疗具体方法是否推荐，没有报告诊断、疗效评价相关信息，但是一篇循证的指南，与上一篇相同为WHO牵头全球专家共同制定，感觉在地位较高', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('222', '21', 'B01_012', '1', '变应性鼻炎', 'Allergic rhinitis', '密西根大学健康系统', '2013', 'University of Michigan Health System. Allergic rhinitis. Ann Arbor (MI): University of Michigan Health System (UMHS); 2013 Oct. 17 p.', '英文', '未报告', '变应性鼻炎', '未报告', '未报告', '诊断通常是由过敏史和检测(发痒,喷嚏,鼻塞)。\n症状日记和试验药物可能有助于确定诊断。\n诊断一般不需要过敏测试,但可能有利于检测患者对多个潜在的过敏原的敏感性', '未报告', '发病率、频率和过敏症状的严重程度的过敏症状、药物副作用、治疗的成本效益', '系统综述', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('223', '12', 'D03_001', '0', '中医内科常见病诊疗指南西医疾病部分', 'Guidelines for Diagnosis and Treatment of Common Internal Diseases in Chinese Medicine Diseases of Modern Medicine', '中华中医药学会', '2008', 'ZYYXH/T50～135—2008,中医内科常见病诊疗指南西医疾病部分[S].', '中文', null, '肥胖', null, '1.脾虚湿阻证<br />&nbsp;&nbsp;2.胃热湿阻证<br />&nbsp;&nbsp;3.肝郁气滞证<br />&nbsp;&nbsp;4.脾肾两虚证<br />&nbsp;&nbsp;5.气滞血瘀证<br />&nbsp;&nbsp;6.阴虚内热证', '1.WHO1998年推荐的诊断要点<br />&nbsp;&nbsp;1998年WHO制定了肥胖诊断的推荐标准（表1），将BMI> 25kg/m2和BMI> 0kg/m2分别定为超重和肥胖。D03_001_图表1<br />&nbsp;&nbsp;2.亚太地区推荐的肥胖诊断要点<br />&nbsp;&nbsp;1998年WHO的肥胖标准是基于欧洲人群的标准，并非适用于亚太地区。因此，世界卫生组织西太平洋地区官员、国际肥胖研究协会及国际肥胖工作组认为有必要对这一地区人群的肥胖制定不同的标准，2000年提出亚太地区肥胖标准（表2）。D03_001_图表2<br />&nbsp;&nbsp;3.中国人肥胖的判定标准<br />&nbsp;&nbsp;国际生命科学学会中国办事处中国肥胖问题工作组联合数据汇总分析协作组，2001年提出中国成人体重指数分类的推荐意见（表3）。D03_001_图表3', '1.WHO1998年推荐的诊断要点<br />&nbsp;&nbsp;1998年WHO制定了肥胖诊断的推荐标准（表1），将BMI> 25kg/m2和BMI> 0kg/m2分别定为超重和肥胖。D03_001_图表1<br />&nbsp;&nbsp;2.亚太地区推荐的肥胖诊断要点<br />&nbsp;&nbsp;1998年WHO的肥胖标准是基于欧洲人群的标准，并非适用于亚太地区。因此，世界卫生组织西太平洋地区官员、国际肥胖研究协会及国际肥胖工作组认为有必要对这一地区人群的肥胖制定不同的标准，2000年提出亚太地区肥胖标准（表2）。D03_001_图表2<br />&nbsp;&nbsp;3.中国人肥胖的判定标准<br />&nbsp;&nbsp;国际生命科学学会中国办事处中国肥胖问题工作组联合数据汇总分析协作组，2001年提出中国成人体重指数分类的推荐意见（表3）。D03_001_图表3', null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('224', '12', 'D03_002', '1', '临床诊疗指南 内分泌及代谢性疾病分册', '无', '中华医学会', '2005', '中华医学会编著.临床诊疗指南 内分泌及代谢性疾病分册[M].北京：人民卫生出版社.2005.', '中文', null, '肥胖症', null, null, '1.测量身体的肥胖程度和体内脂肪分布。<br />&nbsp;&nbsp;1.1体重指数（body mass index，BMI）：测量身体的肥胖程度。<br />&nbsp;&nbsp;BMI（kg/m2）=体重(kg)/[身长(m )]2<br />&nbsp;&nbsp;1.2理想体重(ideal body weight，IBW)：测量身体的肥胖程度。<br />&nbsp;&nbsp;IBW(kg)=身高(cm)-105<br />&nbsp;&nbsp;或=[身高(cm)-100]0.9(男性〉或/0.85(女性)<br />&nbsp;&nbsp;1.3腰围或腰/臀比(waist/hip ratio，W/H)：反映体内脂肪分布。病人取直立体位，腰围在腰部肋下缘与髂骨上缘间中点水平测量，臀围于耻骨联合水平测量臀部最大周径。<br />&nbsp;&nbsp;1.4CT或MRI，估计或计算皮下脂肪厚度或内脏脂肪量，是评估体内脂肪分布最准确的方法，但不作为常规检查项目。<br />&nbsp;&nbsp;1.5其他：身体密度测量法、生物电阻抗测量法、双能X线（DEXA）吸收法测定体脂总量等。<br />&nbsp;&nbsp;2.诊断标准 我国成人超童和肥胖界限建议（中国肥胖问题工作组2002）：<br />&nbsp;&nbsp;我国成人BMI18.5~23.9为正常范围，<18.5为体重过低，≥24为超重，≥28为肥胖，男性腰围≥85cm、女性腰围≥80 腹部脂肪积聚。<br />&nbsp;&nbsp;3.鉴别诊断<br />&nbsp;&nbsp;3.1鉴别水潴留性肥胖症。<br />&nbsp;&nbsp;3.2鉴别继发性肥胖症、下丘脑性肥胖、皮质醇增多症和多囊卵巢综合征等。<br />&nbsp;&nbsp;4.肥胖并发症及伴随病的诊断 如糖尿病或糖耐量异常、血脂异常、高血压、冠心病、痛风、胆石症、呼吸睡眠暂停等，应予以诊断以便给于相应的治疗。', '1.测量身体的肥胖程度和体内脂肪分布。<br />&nbsp;&nbsp;1.1体重指数（body mass index，BMI）：测量身体的肥胖程度。<br />&nbsp;&nbsp;BMI（kg/m2）=体重(kg)/[身长(m )]2<br />&nbsp;&nbsp;1.2理想体重(ideal body weight，IBW)：测量身体的肥胖程度。<br />&nbsp;&nbsp;IBW(kg)=身高(cm)-105<br />&nbsp;&nbsp;或=[身高(cm)-100]0.9(男性〉或/0.85(女性)<br />&nbsp;&nbsp;1.3腰围或腰/臀比(waist/hip ratio，W/H)：反映体内脂肪分布。病人取直立体位，腰围在腰部肋下缘与髂骨上缘间中点水平测量，臀围于耻骨联合水平测量臀部最大周径。<br />&nbsp;&nbsp;1.4CT或MRI，估计或计算皮下脂肪厚度或内脏脂肪量，是评估体内脂肪分布最准确的方法，但不作为常规检查项目。<br />&nbsp;&nbsp;1.5其他：身体密度测量法、生物电阻抗测量法、双能X线（DEXA）吸收法测定体脂总量等。<br />&nbsp;&nbsp;2.诊断标准 我国成人超童和肥胖界限建议（中国肥胖问题工作组2002）：<br />&nbsp;&nbsp;我国成人BMI18.5~23.9为正常范围，<18.5为体重过低，≥24为超重，≥28为肥胖，男性腰围≥85cm、女性腰围≥80 腹部脂肪积聚。<br />&nbsp;&nbsp;3.鉴别诊断<br />&nbsp;&nbsp;3.1鉴别水潴留性肥胖症。<br />&nbsp;&nbsp;3.2鉴别继发性肥胖症、下丘脑性肥胖、皮质醇增多症和多囊卵巢综合征等。<br />&nbsp;&nbsp;4.肥胖并发症及伴随病的诊断 如糖尿病或糖耐量异常、血脂异常、高血压、冠心病、痛风、胆石症、呼吸睡眠暂停等，应予以诊断以便给于相应的治疗。', null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('225', '12', 'D03_003', '1', '中国成人超重和肥胖症预防控制指南', '无', '中华人民共和国卫生部疾病控制司', '2003', '中华人民共和国卫生部疾病控制司. 中国成人超重和肥胖症预防控制指南[M]. 人民卫生出版社, 2006.', '中文', null, '肥胖症', null, null, '以BMI 值“24”为中国成人超重的界限，BMI“28”为肥胖的界限；男性腰围≥85cm，女性腰围≥80cm 为腹部脂肪蓄积的界限。', '以BMI 值“24”为中国成人超重的界限，BMI“28”为肥胖的界限；男性腰围≥85cm，女性腰围≥80cm 为腹部脂肪蓄积的界限。', null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('226', '12', 'D03_004', '1', '中国肥胖问题工作组数据汇总分析协作组建议的我国成人超重和肥胖界限', '无', '中国肥胖问题工作组数据汇总分析协作组', '2002', '我国成人体重指数和腰围对相关疾病危险因素异常的预测价值:适宜体重指数和腰围切点的研究[J]. 中华流行病学杂志,2002,23(1):10-15.', '中文', null, '肥胖', null, null, 'D03_004_图表1', 'D03_004_图表1', null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('227', '12', 'D03_005', '1', '成人体重判定', 'Criteria of weight for adults', '中华人民共和国国家卫生和计划生育委员会', '2013', 'WS/T 428—2013,成人体重判定[S].', '中文', '1.中心型肥胖<br />&nbsp;&nbsp;1.1中心型肥胖前期<br />&nbsp;&nbsp;1.2中心型肥胖', '肥胖', null, null, '以BMI为依据对成人体重分类，见表1。D03_005_图表1<br />&nbsp;&nbsp;中心型肥胖可以腰围直接判定，见表2。D03_005_图表2', '以BMI为依据对成人体重分类，见表1。D03_005_图表1<br />&nbsp;&nbsp;中心型肥胖可以腰围直接判定，见表2。D03_005_图表2', null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('228', '12', 'D03_006', '1', '单纯性肥胖病的诊断及疗效评定标准', '无', '全国第五届肥胖病研究学术会议', '1998', '单纯性肥胖病的诊断及疗效评定标准[J]. 中国中西医结合杂志,1998,18（5）:317-319.', '中文', '1.超重<br />&nbsp;&nbsp;2.轻度肥胖<br />&nbsp;&nbsp;3.中度肥胖<br />&nbsp;&nbsp;4.重度肥胖', '单纯性肥胖病', null, '1.脾虚湿阻型<br />&nbsp;&nbsp;2.胃热湿阻型<br />&nbsp;&nbsp;3.肝瘀气滞型<br />&nbsp;&nbsp;4.脾肾两虚型（肾脾阳虚）<br />&nbsp;&nbsp;5.阴虚内热型', ' 1.单纯性肥胖病的诊断<br />&nbsp;&nbsp;1.1单纯性肥胖病 主要指因机体内热量的摄入大于消耗，造成脂肪在体内积聚过多，导致体重超常的病症。<br />&nbsp;&nbsp;1.2成人体重标准 〔身高(cm)-100〕×0.9 =标准体重（kg）。<br />&nbsp;&nbsp;1.3儿童体重标准 婴儿（1～6个月）：出生时体重（g）+月龄×600=标准体重（g）；幼儿（7～12个月）：出生时体重（g）+月龄×500=标准体重（g）；1岁以上：年龄×2+8=标准体重（kg）；若儿童身高超过标准参照成人计算。<br />&nbsp;&nbsp;1.4实测体重超过标准体重的测定方法。<br />&nbsp;&nbsp;1.4.1标准体重测定 可作为肥胖病诊断指标之一。实测体重超过标准体重，但<20%者属超重；实测体重超过标准体重20%～<30%，属于轻度肥胖；实测体重超过标准体重30%～<50%，属于中度肥胖；超标准体重50%以上者，属于重度肥胖。<br />&nbsp;&nbsp;1.4.2体重指数测定 体重指数（BMI）=体重（kg）/〔身高(m)〕2可作为肥胖病诊断指标之一。超过25～26为超重，>26～<30属于轻度肥胖，>30～<40属于中度肥胖，>40属重度肥胖；体重指数<25者属Ⅰ级，26～30者属Ⅱ级，30～40者属Ⅲ级，>40者属Ⅳ级。一般认为体重指数和体密度有很好的相关性，是间接法中估计体内脂肪含量最好办法，临床应用最多，其值的大小和肥胖病患者的预后及死亡率高低呈正相关。<br />&nbsp;&nbsp;1.4.3脂肪百分率（F%）测定 判断肥胖与否单凭测体重是不够确切，主要看脂肪在全身的比例（见表2标准），可按下列公式计算：F%=（0.570/D-4.142)×100。其中体密度（D）依照表1测算，然后代入公式内。D03_006_图表1<br />&nbsp;&nbsp;1.4.4肥胖度测定D03_006_图表2<br />&nbsp;&nbsp;1.5肥胖病局部脂肪贮积的测定<br />&nbsp;&nbsp;1.5.1皮下脂肪厚度 B超测定法：测定位点4个：A点为右三角肌下缘臂外侧正中点，B点为右肩胛下角，C点为右脐旁3cm，D点为右髂前上棘。测定三头肌和肩胛下角部位的正常值高限：男性为51mm，女性为70mm，此方法影响因素较多，压力不同，皮下脂肪组织分布不同，皮下脂肪和深部脂肪含量的比例的个体差异较大。皮卡钳法：测定位点同上。<br />&nbsp;&nbsp;1.5.2心包膜脂肪厚度 B超测量法：测定点位6个。A点为动脉根部水平；B点为二尖瓣口水平;C点为心尖四腔切面（测量右心室心尖部）；D点为右心室心尖右侧1.5cm处；E点为左心室心尖部；F点为左心室心尖部左侧1.5cm处。<br />&nbsp;&nbsp;1.5.3脂肪肝测定 B超法。<br />&nbsp;&nbsp;1.5.4腰髋比值测定（腰臀比值） 腰部周径测量部位是第十二肋下缘水平，髋部周径指的是臀部最大周径，一般以髂前上嵴相连为准，或从实际测得的最大周径为准，若腰髋周径比大于0.72时，可认为是肥胖，但只有当比值大于1.0（男）及0.9（女）时，肥胖带来的并发症才明显增加。<br />&nbsp;&nbsp;1.6血脂测定 采用六项血脂标准：血清总胆固醇（TC），甘油三酯（TG），高密度脂蛋白胆固醇（HDL-C），低密度脂蛋白胆固醇（LDL-C），LDL-C/HDL-C，HDL-C/TC。<br />&nbsp;&nbsp;1.7脂肪细胞大小及数目测定 脂肪细胞大小及数目可直接反映体内脂肪蓄积的状态，但测定方法复杂，难于在临床上应用，只能作为一种脂肪代谢的研究方法。测定方法是被测定者前一天晚餐后禁食，次晨空腹时，用针抽取三头肌、腹部脐旁及臂部外上限的脂肪，经处理计算出3个部位的脂肪细胞的平均大小，同时以同位素法测定出体内脂肪的总含量，然后以总体脂含量除以上述3个部位所计算出的脂肪细胞平均大小，即总体脂÷脂肪细胞平均大小=脂肪细胞数。<br />&nbsp;&nbsp;2.诊断为单纯性肥胖病须具备以下条件<br />&nbsp;&nbsp;2.1病史、体检和实验室检查可除外症状性肥胖（继发性肥胖）。<br />&nbsp;&nbsp;2.2实测体重超过标准体重的20%以上，脂肪百分率超过30%，体重指数超过26以上者，3项均符合者可诊断为肥胖病，或3项中有2项符合者亦可诊断。<br />&nbsp;&nbsp;2.3为估计肥胖病预后，应同时测腰髋周径比值。<br />&nbsp;&nbsp;为除外症状性（继发性）肥胖病可考虑做以下检查：（1）X线检查蝶鞍是否扩大，骨质有无明显破坏。（2）检查血清皮质醇。（3）T3、T4、TSH以除外间脑性、垂体性、肾上腺皮质功能、甲状腺功能和植物神经紊乱等。由于肥胖病引起的一系列内分泌功能障碍而引起的上述的检查不正常者不包括在内。', ' 1.单纯性肥胖病的诊断<br />&nbsp;&nbsp;1.1单纯性肥胖病 主要指因机体内热量的摄入大于消耗，造成脂肪在体内积聚过多，导致体重超常的病症。<br />&nbsp;&nbsp;1.2成人体重标准 〔身高(cm)-100〕×0.9 =标准体重（kg）。<br />&nbsp;&nbsp;1.3儿童体重标准 婴儿（1～6个月）：出生时体重（g）+月龄×600=标准体重（g）；幼儿（7～12个月）：出生时体重（g）+月龄×500=标准体重（g）；1岁以上：年龄×2+8=标准体重（kg）；若儿童身高超过标准参照成人计算。<br />&nbsp;&nbsp;1.4实测体重超过标准体重的测定方法。<br />&nbsp;&nbsp;1.4.1标准体重测定 可作为肥胖病诊断指标之一。实测体重超过标准体重，但<20%者属超重；实测体重超过标准体重20%～<30%，属于轻度肥胖；实测体重超过标准体重30%～<50%，属于中度肥胖；超标准体重50%以上者，属于重度肥胖。<br />&nbsp;&nbsp;1.4.2体重指数测定 体重指数（BMI）=体重（kg）/〔身高(m)〕2可作为肥胖病诊断指标之一。超过25～26为超重，>26～<30属于轻度肥胖，>30～<40属于中度肥胖，>40属重度肥胖；体重指数<25者属Ⅰ级，26～30者属Ⅱ级，30～40者属Ⅲ级，>40者属Ⅳ级。一般认为体重指数和体密度有很好的相关性，是间接法中估计体内脂肪含量最好办法，临床应用最多，其值的大小和肥胖病患者的预后及死亡率高低呈正相关。<br />&nbsp;&nbsp;1.4.3脂肪百分率（F%）测定 判断肥胖与否单凭测体重是不够确切，主要看脂肪在全身的比例（见表2标准），可按下列公式计算：F%=（0.570/D-4.142)×100。其中体密度（D）依照表1测算，然后代入公式内。D03_006_图表1<br />&nbsp;&nbsp;1.4.4肥胖度测定D03_006_图表2<br />&nbsp;&nbsp;1.5肥胖病局部脂肪贮积的测定<br />&nbsp;&nbsp;1.5.1皮下脂肪厚度 B超测定法：测定位点4个：A点为右三角肌下缘臂外侧正中点，B点为右肩胛下角，C点为右脐旁3cm，D点为右髂前上棘。测定三头肌和肩胛下角部位的正常值高限：男性为51mm，女性为70mm，此方法影响因素较多，压力不同，皮下脂肪组织分布不同，皮下脂肪和深部脂肪含量的比例的个体差异较大。皮卡钳法：测定位点同上。<br />&nbsp;&nbsp;1.5.2心包膜脂肪厚度 B超测量法：测定点位6个。A点为动脉根部水平；B点为二尖瓣口水平;C点为心尖四腔切面（测量右心室心尖部）；D点为右心室心尖右侧1.5cm处；E点为左心室心尖部；F点为左心室心尖部左侧1.5cm处。<br />&nbsp;&nbsp;1.5.3脂肪肝测定 B超法。<br />&nbsp;&nbsp;1.5.4腰髋比值测定（腰臀比值） 腰部周径测量部位是第十二肋下缘水平，髋部周径指的是臀部最大周径，一般以髂前上嵴相连为准，或从实际测得的最大周径为准，若腰髋周径比大于0.72时，可认为是肥胖，但只有当比值大于1.0（男）及0.9（女）时，肥胖带来的并发症才明显增加。<br />&nbsp;&nbsp;1.6血脂测定 采用六项血脂标准：血清总胆固醇（TC），甘油三酯（TG），高密度脂蛋白胆固醇（HDL-C），低密度脂蛋白胆固醇（LDL-C），LDL-C/HDL-C，HDL-C/TC。<br />&nbsp;&nbsp;1.7脂肪细胞大小及数目测定 脂肪细胞大小及数目可直接反映体内脂肪蓄积的状态，但测定方法复杂，难于在临床上应用，只能作为一种脂肪代谢的研究方法。测定方法是被测定者前一天晚餐后禁食，次晨空腹时，用针抽取三头肌、腹部脐旁及臂部外上限的脂肪，经处理计算出3个部位的脂肪细胞的平均大小，同时以同位素法测定出体内脂肪的总含量，然后以总体脂含量除以上述3个部位所计算出的脂肪细胞平均大小，即总体脂÷脂肪细胞平均大小=脂肪细胞数。<br />&nbsp;&nbsp;2.诊断为单纯性肥胖病须具备以下条件<br />&nbsp;&nbsp;2.1病史、体检和实验室检查可除外症状性肥胖（继发性肥胖）。<br />&nbsp;&nbsp;2.2实测体重超过标准体重的20%以上，脂肪百分率超过30%，体重指数超过26以上者，3项均符合者可诊断为肥胖病，或3项中有2项符合者亦可诊断。<br />&nbsp;&nbsp;2.3为估计肥胖病预后，应同时测腰髋周径比值。<br />&nbsp;&nbsp;为除外症状性（继发性）肥胖病可考虑做以下检查：（1）X线检查蝶鞍是否扩大，骨质有无明显破坏。（2）检查血清皮质醇。（3）T3、T4、TSH以除外间脑性、垂体性、肾上腺皮质功能、甲状腺功能和植物神经紊乱等。由于肥胖病引起的一系列内分泌功能障碍而引起的上述的检查不正常者不包括在内。', '1.临床症状<br />&nbsp;&nbsp;2.体重下降<br />&nbsp;&nbsp;3.F%<br />&nbsp;&nbsp;4.体重指数', 'D03_006_图表3', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('229', '12', 'D03_007', '1', '2013 美国心脏协会/美国心脏病学会/美国肥胖学会 成人超重与肥胖管理指南', '2013 AHA/ACC/TOS Guideline for the Management\nof Overweight and Obesity in Adults', '美国心脏协会；美国心脏病学会；美国肥胖学会（American Heart Association；the American College of Cardiology；The Obesity Society）', '2013', '2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014 Jun 24;129(25 Suppl 2畻坴畿\0\0\0\0醼', '英文', '1.overweight<br />&nbsp;&nbsp;2.class I obese<br />&nbsp;&nbsp;3.class II obese<br />&nbsp;&nbsp;4.class III obese (extreme obesity)', 'Overweight and Obesity', null, null, 'D03_007_图表1<br />&nbsp;&nbsp;BMI 25-29.9 (overweight), BMI 30-34.9 (class I obese), BMI 35-39.9 (class II obese), or BMI ≥40 (class III obese [extreme obesity]) <br />&nbsp;&nbsp;These BMI cutpoints define overweight and class I to III obese individuals and identify adults who may be at increased risk for CVD and other obesity-related conditions. Within these categories, additional personal risk assessment is needed because degree of risk can vary.', 'D03_007_图表1<br />&nbsp;&nbsp;BMI 25-29.9 (overweight), BMI 30-34.9 (class I obese), BMI 35-39.9 (class II obese), or BMI ≥40 (class III obese [extreme obesity]) <br />&nbsp;&nbsp;These BMI cutpoints define overweight and class I to III obese individuals and identify adults who may be at increased risk for CVD and other obesity-related conditions. Within these categories, additional personal risk assessment is needed because degree of risk can vary.', null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('23', '32', 'G02_011', '1', '血脂异常管理:合作方式:联合委员会包括-心血管护理;动脉硬化、血栓形成,血管生物学;基本心血管科学;心血管疾病在年轻的时候;临床心脏病学;流行病学和预防;营养,体育活动,和新陈代谢,和中风,预防心血管护士协会', 'Managing Abnormal Blood Lipids: A Collaborative Approach: Cosponsored by the Councils on Cardiovascular Nursing; Arteriosclerosis, Thrombosis, and Vascular Biology; Basic Cardiovascular Sciences; Cardiovascular Disease in the Young; Clinical Cardiology; E畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭䛰ડ໰%\0ડĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖矢\0\0\0𢡄㖞๹ડĀ\0è๹彿矣奋矣巫矣犚๹鴲๹彿矣鴦๹塚矣鴲๹ꍈ矨\0\0㖞๹學矣漸矨圔矣㖞๹圞矣\0\0圭矣𢡄霪W໰% \0໰%', ' 美国心脏学会（American Heat Association）；心血管护理委员会（Councils on Cardiovascular Nursing）', '2005', 'http://circ.ahajournals.org/content/112/20/3184.full.pdf+html?sid=0c04d710-188b-441e-ae63-bc984d11261d.[2016-02-29]', '英文', null, '高脂血症', null, null, 'G02_011_01_2-19岁人群胆固醇水平.docx<br />&nbsp;&nbsp;\nG02_011_02_血脂异常的识别<br />&nbsp;&nbsp;\n药物治疗的5种临床表现：(1)低密度脂蛋白升高;(2)non-HDL-C升高患者的高水平的TGs(200 - 200 mg/dL)尽管实现低密度目标;(3)高密度脂蛋白胆固醇降低;(4)糖尿病血脂异常;(5)非常高的TGs和/或乳糜微粒血症综合征。<br />&nbsp;&nbsp;\nThe 5 most common clinical situations in which drug therapy is needed are (1) elevated LDL-C; (2) elevated non-HDL-C in patients with high levels of TGs (200 to 500 mg/dL) despite attainment of LDL-C goals; (3) low HDL-C; (4) diabetic dyslipidemia; and (5) very high TGs and/or chylomicronemia syndrome. \n', null, '胆固醇；甘油三酯；（cholesterol\nand triglyceride ）', null, 'G02_011_03_ATP III的特点.docx', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('230', '12', 'D03_008', '1', '美国临床内分泌协会与美国内分泌学会2014 年关于肥胖作为慢性疾病新诊断框架立的场声明', 'American Association of Clinical Endocrinologists And American College of Endocrinology Position Statement on the 2014 Advanced Framework for A New Diagnosis of Obesity as A Chronic Disease', '美国临床内分泌协会；美国内分泌学会（American Association of Clinical Endocrinologists；the American College of Endocrinology）', '2014', 'http://journals.aace.com/doi/10.4158/EP14280.PS?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed', '英文', null, 'Obesity', null, null, 'The new obesity diagnostic algorithm incorporates two components: 1) an assessment of body mass, including validated ethnicity-adjusted anthropometrics to identify individuals with increased adipose tissue placing them at risk and 2) the presence and severity of obesity-related complications. Thus, the complete diagnosis does not simply depend upon BMI level but also the impact of that weight gain on health. Individuals with BMI ≥25 kg/m2 (or in certain populations a BMI of 23-25 kg/m2) then require evaluation for the presence and severity of specific obesityrelated complications to complete the diagnostic process. Each complication is evaluated for severity and impact on the patient’s health as Stage 0 (no complication is present), Stage 1 (complication is mild-moderate), or Stage 2 (complication is severe) using complication-specific criteria. D03_008_图表1，D03_008_图表2<br />&nbsp;&nbsp;The new diagnosis aligns itself with a 4-step approach for the evaluation of patients with obesity, and entrains professionals by providing them with a structured paradigm for patient management consistent with high-quality care. The 4 recommended steps are: 1) screening with BMI with adjustments for ethnic differences, 2) clinical evaluation for the presence of obesity-related complications using a checklist, 3) staging for the severity of complications using complication-specific criteria, and 4) selection of prevention and/or intervention strategies targeting specific complications as guided by the AACE/ACE obesity management algorithm. D03_008_图表3', 'The new obesity diagnostic algorithm incorporates two components: 1) an assessment of body mass, including validated ethnicity-adjusted anthropometrics to identify individuals with increased adipose tissue placing them at risk and 2) the presence and severity of obesity-related complications. Thus, the complete diagnosis does not simply depend upon BMI level but also the impact of that weight gain on health. Individuals with BMI ≥25 kg/m2 (or in certain populations a BMI of 23-25 kg/m2) then require evaluation for the presence and severity of specific obesityrelated complications to complete the diagnostic process. Each complication is evaluated for severity and impact on the patient’s health as Stage 0 (no complication is present), Stage 1 (complication is mild-moderate), or Stage 2 (complication is severe) using complication-specific criteria. D03_008_图表1，D03_008_图表2<br />&nbsp;&nbsp;The new diagnosis aligns itself with a 4-step approach for the evaluation of patients with obesity, and entrains professionals by providing them with a structured paradigm for patient management consistent with high-quality care. The 4 recommended steps are: 1) screening with BMI with adjustments for ethnic differences, 2) clinical evaluation for the presence of obesity-related complications using a checklist, 3) staging for the severity of complications using complication-specific criteria, and 4) selection of prevention and/or intervention strategies targeting specific complications as guided by the AACE/ACE obesity management algorithm. D03_008_图表3', null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('231', '12', 'D03_009', '1', 'EASO 立场声明：成人肥胖的多学科管理', 'An EASO Position Statement on Multidisciplinary Obesity Management in Adults', '欧洲肥胖症研究协会（European Association for the Study of Obesity）', '2014', 'http://easo.org/wp-content/uploads/2014/03/Multidisciplinary-Obesity-Management-in-Adults.pdf', '英文', null, 'Obesity', null, null, ' ', ' ', 'weight loss; prevention and treatment of co-morbidities; risk reduction and health improvement', 'The management and treatment of obesity have wider objectives than weight loss alone and include risk reduction and health improvement. These may be achieved by modest weight loss, improved nutritional content of the diet and even modest increases in phys畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭㭰ਕༀƙ\0ਕ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔ⛠ఄਕ\0ః彿㎽奋㎽巫㎽繼ఄ髐ఄ彿㎽髄ఄ塚㎽髐ఄꍈ㏂\0\0⛠ఄ學㎽漸㏂圔㎽⛠ఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0ƥ䐺盭暼痭ƥༀƙ \0ƥ\0\0㺣盭ƥ\0ﱔƥ\0팃目ƥ࣎ƥ큁目ƥ✔ఄ﫬\0Item\0\0魔ఄ\0\0\0\0\0\0Count\0\0ﱬﬄƥ㳜੪\0\0ƥ\0\0\0\0੪寶目㳠੪矵䥷㎽繼ఄ\0\0魔ఄ�㏂髄ఄ\0\0\0੪\0\0\0謁ﱔ\0\0㎾ࠒ\0ﱜ\0\0x�㏂髄ఄ\0\0隲W魔ఄ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\0霪W露W\0\0ﱴxt\0Љ\0\0\0꒰௥鲬࣎菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0⑰ਫ਼⑰ਫ਼㲈੪☔ఄ寶目㲈੪☔ఄi\0\0ﱄ﷜ﱴﲔ먙㎼☔ఄ㲈੪i\0\0ﱄ﷜ﱴ먰㎼﷜☔ఄ�㏂▄ఄ\0\0릎㎼☔ఄi\0╪췬目╾췬目Љ\0镴࣎\0￿￿目Љ\0镨࣎꒰௥竗꒰௥目W\0竗\0\0\0賓器目\0\0\0\0✔ఄ\0目瑉浥目\0\0\0\0✔ఄ\0目潃湵tḁ\0\0\0✴௢翽捥盦Ȓ묞￾￿옎盡伛盡\0\0ٰդТ\rđ\0܎̀܎O菔Ƭ伦盡㋪췭菀Ƭđ\0\0\0\0\0\0\0\0\0\0捥盦謺묞￾￿伦盡侍盡菀Ƭ☶췬目Љ\0⟆췬目Љ\0⟒췬⟚췬目Љ\0鲸࣎\0￿￿目Љ\0鲬࣎꒰௥觴꒰௥目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨ☔ఄ目潅f摲敳t盡燎捥盦通묞￾￿吊盡璀܎O੫ै璀綻眶E\0܎O\0\0ඞḁ.\0\0\0\0䛌E\0덐ɫ‾Q岛@\0䛌E\0덐ɫ‾Q岛@\0⎐ۓ﮵S豀', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('232', '12', 'D03_010', '1', '美国内分泌学会肥胖药物管理临床实践指南', 'Pharmacological Management of Obesity: An\nEndocrine Society Clinical Practice Guideline', '美国内分泌学会', '2015', 'http://press.endocrine.org/doi/pdf/10.1210/jc.2014-3415', null, null, null, null, null, null, null, null, ' ', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('233', '23', 'G08-001', '1', '慢性乙型肝炎防治指南（2015年版）', '无', '中华医学会肝病学分会，中华医学会感染病学会分会', '2015', '中华实验和临床感染病杂志(电子版),2015,05:570_589.', '中文', '1.慢性HBV携带者<br />&nbsp;&nbsp;2.HBeAg阳性慢性乙型肝炎<br />&nbsp;&nbsp;3.HBeAg阴性慢性乙型肝炎<br />&nbsp;&nbsp;4.非活动性HBsAg携带者<br />&nbsp;&nbsp;5.隐匿性CHB<br />&nbsp;&nbsp;6.乙型肝炎肝硬化', '慢性乙型肝炎', '未提及', '未提及', '1.慢性HBV携带者：多为年龄较轻的处于免疫耐受期的HBsAg、HBeAg和HBV DNA阳性者，1年内连续随访3次，每次至少间隔3个月，均显示血清ALT和AST在正常范围，HBV DNA通常处于高水平，肝组织学检查无病变或病变轻微。<br />&nbsp;&nbsp;2.HBeAg阳性慢性乙型肝炎：血清HBsAg阳性，HBeAg阳性，HBV DNA阳性，ALT持续或反复异常或肝组织学检查有肝炎病变。<br />&nbsp;&nbsp;3.HBeAg阴性慢性乙型肝炎：血清HBsAg阳性，HBeAg持续阴性，HBV DNA阳性，ALT持续或反复异常，或肝组织学有肝炎病变。<br />&nbsp;&nbsp;4.非活动性HBsAg携带者：血清HBsAg阳性、HBeAg阴性、抗-HBe阳性或阴性，HBV DNA低于检测下限，1年内连续随访3次以上，每次至少间隔3个月，ALT和AST均在正常范围。肝组织学检查显示：组织学活动指数（HAI）评分＜ 4或根据其他的半定量计分系统判定病变轻微。<br />&nbsp;&nbsp;5.隐匿性CHB：血清HBsAg阴性，但血清和（或）肝组织中HBV DNA阳性，并有慢性乙型肝炎的临床表现。除HBV DNA阳性外，患者可有血清抗-HBs、抗-HBe和（或）抗-HBc阳性，但约20%隐匿性CHB患者的血清学标志物均为阴性。诊断主要通过HBV DNA检测，尤其对抗-HBc持续阳性者。<br />&nbsp;&nbsp;6.乙型肝炎肝硬化：建立HBV相关肝硬化临床诊断的必备条件包括：①组织学或临床提示存在肝硬化的证据；②病因学明确的HBV感染证据。通过病史或相应的检查予以明确或排除其他常见引起肝硬化的病因，如HCV感染、酒精和药物等。', '未提及', '1.HBeAg<br />&nbsp;&nbsp;2.HBsAg血清学转换<br />&nbsp;&nbsp;3.ALT<br />&nbsp;&nbsp;4.病毒学应答', '1.理想的终点：HBeAg阳性与HBeAg阴性患者，停药后获得持久的HBsAg 消失，可伴或不伴HBsAg血清学转换。<br />&nbsp;&nbsp;2.满意的终点：HBeAg阳性患者，停药后获得持续的病毒学应答，ALT复常，并伴有HBeAg血清学转换；HBeAg阴性患者，停药后获得持续的病毒学应答和ALT复常。<br />&nbsp;&nbsp;3.基本的终点：如无法获得停药后持续应答，抗病毒治疗期间长期维持病毒学应答（HBVDNA低于检测下限）。', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('2338964a739f4e9d9f13b5f5cc1f26a2', '4', 'adfa', '0', 'adf', '', 'adfa', null, '', '中文', 'aaa<img src=\"/bzpt/images/2016/5/13/60d0854f8af7403a98001dfcf5a802f6.jpg\" alt=\"\" />', '', '', '<img src=\"/bzpt/images/2016/5/13/8389a8da1996487d9565d56c2bab434c.jpg\" alt=\"\" />', '', '', '', '', '<img src=\"/bzpt/images/2016/5/13/73cf567856dd441bbb66291fb3efe073.png\" alt=\"\" />', '1', '0', 'admin', '2016-05-13 19:14:17', 'admin', '2016-05-13 19:17:12');
INSERT INTO `biz_standard` VALUES ('234', '23', 'G08-002', '1', '丙型肝炎防治指南（2015 年更新版）', '无', '中华医学会肝病学分会、中华医学会感染病学分会', '2015', '中华实验和临床感染病杂志(电子版),2015,05:590_607.', '中文', '1.急性丙型肝炎<br />&nbsp;&nbsp;2.慢性丙型肝炎', '丙型肝炎', '未提及', '未提及', '1.急性丙型肝炎的诊断<br />&nbsp;&nbsp;1.1 流行病学史：有明确的就诊前6个月以内的流行病学史，如输血史、应用血液制品史或明确的HCV暴露史。<br />&nbsp;&nbsp;1.2 临床表现：可有全身乏力、食欲减退、恶心和右季肋部疼痛等，少数伴低热，轻度肝肿大，部分患者可出现脾肿大，少数患者可出现黄疽。部分患者无明显症状，表现为隐匿性感染。<br />&nbsp;&nbsp;1.3  实验室检查：ALT多呈轻度和中度升高，也可在正常范围之内， 有明确的6 个月以内抗-HCV和/ 或HCV RNA检测阳性结果的检测史。HCV RNA常在ALT恢复正常前低于检测下限，但也有ALT恢复正常而HCV RNA持续阳性者。<br />&nbsp;&nbsp;有上述（1.1 + 1.2 + 1.3）或（1.2 + 1.3）者可诊断。<br />&nbsp;&nbsp;2.慢性丙型肝炎的诊断<br />&nbsp;&nbsp;2.1 诊断依据：HCV感染超过6个月，或有6月以前的流行病学史，或发病日期不明。抗-HCV及HCVRNA阳性，肝脏组织病理学检查符合慢性肝炎。或根据症状、体征、实验室及影像学检查结果综合分析，亦可诊断。<br />&nbsp;&nbsp;1.2 病变程度判定：肝活检病理诊断可以判定肝脏炎症分级和纤维化分期。HCV单独感染极少引起重型肝炎，HCV重叠HIV、HBV等病毒感染、过量饮酒或应用肝毒性药物时，可发展为重型肝炎。<br />&nbsp;&nbsp;1.3 慢性丙型肝炎肝外表现：肝外临床表现或综合征可能是机体异常免疫反应所致，包括类风湿性关节炎、眼口干燥综合征、扁平苔藓、肾小球肾炎、混合型冷球蛋白血症、B细胞淋巴瘤和迟发性皮肤卟啉症等。', '未提及', '清除HCV', '抗病毒治疗的目标是清除HCV，获得治愈，清除或减轻HCV相关肝损害，阻止进展为肝硬化、失代偿期肝硬化、肝功能衰竭或肝癌，改善患者的长期生存率，提高患者的生活质量。', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('235', '23', 'G08-003', '1', '病毒性肝炎防治方案', '无', '中华医学会传染病与寄生虫病学分会、肝病学分会', '2000', '中华传染病杂志,2001,01:55_61.', '中文', '1.急性肝炎<br />&nbsp;&nbsp;1.1急性无黄疸型<br />&nbsp;&nbsp;1.2急性黄疸型<br />&nbsp;&nbsp;2.慢性肝炎<br />&nbsp;&nbsp;2.1轻度<br />&nbsp;&nbsp;2.2中度<br />&nbsp;&nbsp;2.3重度<br />&nbsp;&nbsp;3.重型肝炎<br />&nbsp;&nbsp;3.1急性重型肝炎<br />&nbsp;&nbsp;3.2亚急性重型肝炎<br />&nbsp;&nbsp; 3.3慢性重型肝炎<br />&nbsp;&nbsp;4.淤胆型肝炎<br />&nbsp;&nbsp;5.肝炎肝硬化', '病毒性肝炎', '未提及', '未提及', '1.急性肝炎<br />&nbsp;&nbsp;1.1急性无黄疸型肝炎:应根据流行病学史、临床症状、体征、化验及病原学检测结果综合判断, 并排除其他疾病。① 流行病学史:如密切接触史和注射史等。密切接触史是指与确诊病毒性肝炎患者(特别是急性期)同吃、同住、同生活或经常接触肝炎病毒污染物(如血液、粪便)或有性接触而未采取防护措施者。注射史是指在半年内曾接受输血、血液制品及用未经严格消毒的器具注射药物、免疫接种和针刺治疗等。②症状:指近期内出现的、持续几天以上但无其他原因可解释的症状, 如乏力、食欲减退、恶心等。③体征:指肝肿大并有压痛、肝区叩击痛, 部分患者可有轻度脾肿大。④化验:主要指血清ALT 升高。⑤病原学检测阳性。凡化验阳性, 且流行病学史、症状和体征三项中有两项阳性或化验及体征(或化验及症状)均明显阳性, 并排除其他疾病者可诊断为急性无黄疸型肝炎。凡单项血清ALT 升高, 或仅有症状、体征, 或有流行病学史及②、③、④3 项中有1 项阳性者, 均为疑似病例。对疑似病例应进行动态观察或结合其他检查(包括肝组织病理学检查)做出诊断。疑似病例如病原学诊断阳性, 且除外其他疾病者可确诊。<br />&nbsp;&nbsp; 1.2急性黄疸型肝炎:凡符合急性肝炎诊断条件, 血清胆红素>17.1 μmol/ L, 或尿胆红素阳性, 并排除其他原因引起的黄疸, 可诊断为急性黄疸型肝炎。<br />&nbsp;&nbsp;2.慢性肝炎: 急性肝炎病程超过半年, 或原有乙型、丙型、丁型肝炎或HBsAg 携带史, 本次又因同一病原再次出现肝炎症状、体征及肝功能异常者可以诊断为慢性肝炎。发病日期不明或虽无肝炎病史, 但肝组织病理学检查符合慢性肝炎, 或根据症状、体征、化验及B 超检查综合分析, 亦可作出相应诊断。为反映肝功能损害程度, 慢性肝炎临床上可分为: <br />&nbsp;&nbsp; 2.1轻度:临床症状、体征轻微或缺如, 肝功能指标仅1或2 项轻度异常; <br />&nbsp;&nbsp;2.2中度:症状、体征、实验室检查居于轻度和重度之间; <br />&nbsp;&nbsp;2.3重度:有明显或持续的肝炎症状, 如乏力、纳差、腹胀、尿黄、便溏等, 伴有肝病面容、肝掌、蜘蛛痣、脾大并排除其他原因, 且无门脉高压症者。实验室检查血清ALT 和/或天门冬氨酸转氨酶(AST)反复或持续升高,白蛋白降低或A/G 比值异常、丙种球蛋白明显升高。除前述条件外, 凡白蛋白≤32 g/ L , 胆红素大于5 倍正常值上限, 凝血酶原活动度为60% ～ 40%, 胆碱酯酶<2 500 U/ L, 4 项检测中有1 项达上述程度者即可诊断为重度慢性肝炎，B 超检查结果可供慢性肝炎诊断的参考:(1)轻度:B超检查肝脾无明显异常改变;(2)中度:B 超检查可见肝内回声增粗, 肝脏和/ 或脾脏轻度肿大, 肝内管道(主要指肝静脉)走行多清晰, 门静脉和脾静脉内径无增宽;(3) 重度:B超检查可见肝内回声明显增粗, 分布不均匀;肝表面欠光滑, 边缘变钝;肝内管道走行欠清晰或轻度狭窄、扭曲;门静脉和脾静脉内径增宽;脾脏肿大;胆囊有时可见\" 双层征\" 。<br />&nbsp;&nbsp;3.重型肝炎<br />&nbsp;&nbsp;3.1急性重型肝炎:以急性黄疸型肝炎起病, ≤2 周出现极度乏力, 消化道症状明显, 迅速出现Ⅱ 度以上(按Ⅳ度划分)肝性脑病, 凝血酶原活动度低于40%并排除其他原因者, 肝浊音界进行性缩小, 黄疸急剧加深;或黄疸很浅, 甚至尚未出现黄疸, 但有上述表现者均应考虑本病。<br />&nbsp;&nbsp;3.2亚急性重型肝炎:以急性黄疸型肝炎起病, 15 d 至24 周出现极度乏力, 消化道症状明显, 同时凝血酶原时间明显延长, 凝血酶原活动度低于40 %并排除其他原因者,黄疸迅速加深, 每天上升≥17.1 μmol/ L 或血清总胆红素大于正常值10 倍, 首先出现Ⅱ 度以上肝性脑病者, 称脑病型(包括脑水肿、脑疝等);首先出现腹水及其相关症候(包括胸水等)者, 称为腹水型。<br />&nbsp;&nbsp;3.3慢性重型肝炎:其发病基础有:①慢性肝炎或肝硬化病史;② 慢性乙型肝炎病毒携带史;③无肝病史及无HBsAg 携带史, 但有慢性肝病体征(如肝掌、蜘蛛痣等)、影像学改变(如脾脏增厚等)及生化检测改变者(如丙种球蛋白升高, 白/ 球蛋白比值下降或倒置);④肝组织病理学, 检查支持慢性肝炎。慢性乙型或丙型肝炎, 或慢性HBsAg 携带者重叠甲型、戊型或其他肝炎病毒感染时要具体分析, 应除外由甲型、戊型和其他型肝炎病毒引起的急性或亚急性重型肝炎。慢性重型肝炎起病时的临床表现同亚急性重型肝炎, 随着病情发展而加重, 达到重型肝炎诊断标准(凝血酶原活动度低于40%, 血清总胆红素大于正常10 倍)。为便于判定疗效及估计预后, 亚急性重型和慢性重型肝炎可根据其临床表现分为早、中、晚3 期:(1)早期:符合重型肝炎的基本条件, 如严重乏力及消化道症状, 黄疸迅速加深, 血清胆红素大于正常10 倍, 凝血酶原活动度≤40 %～ >30 %, 或经病理学证实。但未发生明显的脑病, 亦未出现腹水;(2)中期:有Ⅱ 度肝性脑病或明显腹水、出血倾向(出血点或瘀斑), 凝血酶原活动度≤30 %～ >20%;(3)晚期:有难治性并发症如肝肾综合征、消化道大出血、严重出血倾向(注射部位瘀斑等)、严重感染、难以纠正的电解质紊乱或Ⅱ 度以上肝性脑病、脑水肿, 凝血酶原活动度≤20 %。<br />&nbsp;&nbsp;4.淤胆型肝炎起病类似急性黄疸型肝炎, 但自觉症状常较轻, 皮肤瘙痒, 大便灰白, 常有明显肝脏肿大, 肝功能检查血清胆红素明显升高, 以直接胆红素为主, 凝血酶原活动度>60 %或应用维生素K 肌注后1 周可升至60%以上, 血清胆汁酸、γ谷氨酰转肽酶、碱性磷酸酶、胆固醇水平可明显升高, 黄疸持续3 周以上, 并除外其它原因引起的肝内外梗阻性黄疸者, 可诊断为急性淤胆型肝炎。在慢性肝炎基础上发生上述临床表现者, 可诊断为慢性淤胆型肝炎。<br />&nbsp;&nbsp;5.肝炎肝硬化<br />&nbsp;&nbsp;5.1肝炎肝纤维化:主要根据肝组织病理学检查结果诊断, B 超检查结果可供参考。B 超检查表现为肝实质回声增强、增粗, 肝脏表面不光滑, 边缘变钝, 肝脏、脾脏可增大, 但肝表面尚无颗粒状, 肝实质尚无结节样改变。肝纤维化的血清学指标如透明质酸(HA)、Ⅲ 型前胶原(PC -Ⅲ)、Ⅳ型胶原(Ⅳ -C)、层连蛋白(LN)四项指标与肝纤维化分期有一定相关性, 但不能代表纤维沉积于肝组织的量。<br />&nbsp;&nbsp;5.2肝炎肝硬化:是慢性肝炎的发展结果, 肝组织病理学表现为弥漫性肝纤维化及结节形成。二者必须同时具备, 才能诊断。①代偿性肝硬化:指早期肝硬化, 一般属Child-Pugh A 级。虽可有轻度乏力、食欲减少或腹胀症状,但无明显肝功能衰竭表现。血清白蛋白降低, 但仍≥35 g/L, 胆红素≤35 μmol/ L, 凝血酶原活动度多大于60 %。血清ALT 及AST 轻度升高, AST 可高于ALT ,γ-谷氨酰转肽酶可轻度升高。可有门脉高压症, 如轻度食管静脉曲张, 但无腹水、肝性脑病或上消化道出血。②失代偿性肝硬化:指中晚期肝硬化, 一般属Child -Pug h B、C 级。有明显肝功能异常及失代偿征象, 如血清白蛋白<35g/ L, A/G <1 .0,明显黄疸, 胆红素>35μmol/ L, ALT 和AST 升高, 凝血酶原活动度<60 %。患者可出现腹水、肝性脑病及门脉高压症引起的食管、胃底静脉明显曲张或破裂出血。根据肝脏炎症活动情况, 可将肝硬化区分为:①活动性肝硬化:慢性肝炎的临床表现依然存在, 特别是ALT 升高;黄疸, 白蛋白水平下降, 肝质地变硬, 脾进行性增大, 并伴有门脉高压症。②静止性肝硬化:ALT 正常, 无明显黄疸, 肝质地硬, 脾大, 伴有门脉高压症, 血清白蛋白水平低。肝硬化的影像学诊断　B 超见肝脏缩小, 肝表面明显凹凸不平, 锯齿状或波浪状, 肝边缘变钝, 肝实质回声不均、增强, 呈结节状, 门脉和脾门静脉内径增宽, 肝静脉变细, 扭曲, 粗细不均, 腹腔内可见液性暗区。', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('236', '23', 'G08_004', '1', '慢性丙型肝炎抗病毒治疗专家共识', '无', '慢性丙型肝炎抗病毒治疗专家委员会', '2009', '中华实验和临床感染病杂志(电子版),2009,03:343_352.', '中文', '未提及', '慢性丙型肝炎', '未提及', '未提及', '未提及', '未提及', '1.病毒学应答<br />&nbsp;&nbsp;2生化学应答<br />&nbsp;&nbsp;3.肝组织学应答等指标。', '1.病毒学应答；2.生化学应答；3.肝组织学应答等指标。其中病毒学应答指标中的持续病毒学应答(sustained virological response, SVR)是当前评判疗效的最主要指标。常见病毒学应答相关定义见G08_004_图表1.', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('237', '23', 'G08_005', '1', '戊型病毒性肝炎诊疗规范', '无', '中国医师协会感染科医师分会', '2009', '第二届传染病诊治高峰论坛暨2009年浙江省感染病、肝病学术年会论文汇编.2009.4', '中文', '1.急性黄疽型肝炎<br />&nbsp;&nbsp;2.急性无黄疽型肝炎<br />&nbsp;&nbsp;3.淤胆型肝炎<br />&nbsp;&nbsp;4.肝衰竭<br />&nbsp;&nbsp;4.1急性肝衰竭$$$44.2亚急性肝衰竭<br />&nbsp;&nbsp;5.几种特殊类型的戊型肝炎<br />&nbsp;&nbsp;5.1妊娠合并戊型肝炎<br />&nbsp;&nbsp;5.2老年戊型肝炎<br />&nbsp;&nbsp;5.3重叠感染的戊型肝炎<br />&nbsp;&nbsp;5.4慢性肝病合并戊型肝炎<br />&nbsp;&nbsp;5.5亚临床型感染', '戊型病毒性肝炎', '未提及', '未提及', '1 戊型肝炎的诊断<br />&nbsp;&nbsp;戊型肝炎潜伏期2~9 周, 平均约4 0天。应根据流行病学史、临床症状和体征、实验室检查结果, 并结合患者具体情况及动态变化进行综合分析, 做出诊断。<br />&nbsp;&nbsp;1.1 流行病学史: 若患者有接触戊型肝炎病人、食用烹煮不当的猪内脏、饮用或频繁接触未经适当处理的沟河水、密切接触生猪、在外不洁饮食、近期输血或频繁透析治疗等明确的危险因素暴露史, 则有助于戊型肝炎的诊断。但由于我国为戊型肝炎高流行区, H EV 感染在全国各地均较常见, 即使没有上述这些危险因素,也不能排除戊型肝炎。<br />&nbsp;&nbsp;1.2 临床症状和体征: 近期内出现的、持续几天以上但无其他原因可解释的症状, 如乏力、纳差( 食欲不振)、厌油、恶心、呕吐、上腹不适、肝区疼痛、腹胀、腹泻等。部分患者可有肝脏轻度肿大、触痛和叩击痛, 尿色逐渐加深。体检可见肝脏肿大并有压痛、肝区叩击痛、巩膜黄染等。一般比甲型肝炎病程更长、病情更重。<br />&nbsp;&nbsp;1.3 实验室检查<br />&nbsp;&nbsp;1.3.1 肝功能指标短期内突然出现血清丙氨酸转氨酶( A LT ) 和天门冬氨酸转氨酶( A S T ) 升高。A TL 的升高较慢性肝炎更为明显, 通常不低于2.5倍的正常值上限。与甲型肝炎相比, 戊型肝炎患者的血清胆红素往往更高, 凝血时间往往更长。<br />&nbsp;&nbsp;1.3.2 病原学指标HE v 急性感染的诊断指标包括: O1抗-HEv IgM 抗体阳性; O 2抗-HEv IgG抗体阳转或含量有4倍及以上升高; O3血清和/或粪便HEV RNA 阳性。一般情况下这三项指标的任何一项阳性都可作为HEV 急性感染的临床诊断依据, 如同时有两项指标阳性则可确诊。<br />&nbsp;&nbsp;1.3.2.1抗-HEv IgM 抗体阳性。戊型肝炎临床症状出现时绝大部分己可检出I gM 抗体, 并且在3个月内快速消退, 但少数患者在6个月后仍可检出较低水平的IgM 抗体。因此, 当抗-H EV IgM抗体水平较低时( 检测值低于试剂盒临界值的2倍), 还应结合抗-HEv IgG 抗体水平及其动态变化、HEv NRA 检测结果、患者自身所处的免疫功能状态等进行综合判断。<br />&nbsp;&nbsp;1.3.2.2抗-HEv Ig G 抗体阳转或含量有4 倍及以上升高。这一指标需定量检测双份血清, 不利于早期诊断。由于H Ev 感染的潜伏期相对较长, 在患者就诊时gI G 抗体常已阳转并达到较高水平, 限制了这一指标的诊断敏感性。<br />&nbsp;&nbsp;1.3.2.3血清和/或粪便HEV RNA 阳性。HEV RNA的检出是HEV 现症感染的直接证据。但考虑到目前HEV RNA 的检测主要采用逆转录聚合酶链反应( RT-PCR ) 的方法, 易因操作不当或环境条件不佳而造成假阳性。因此在H E v NR A 阳性时, 还需结合血清抗-HEv IgM、抗-HEv I gG抗体水平或动态变化等进行综合判断。在戊型肝炎临床症状开始的1一2周内, 约70 % -80 % 患者的粪便、血清中可检出HEV RNA , 随后阳性率显著下降。由于HEV 感染的潜伏期相对较长, 约20 % 一30 % 的患者在发病时体内H EV 已基本被清除, 因此HEV RNA 阴性并不能排除HEV 急性感染。<br />&nbsp;&nbsp;在一般临床实践和临床研究中, 抗-HEV IgG抗体的检测结果因试剂和方法的不同会有较大差异, 而且单份血清的IgG检测阳性难以区分急性感染和既往感染, 因此除非能比较双份血清的动态变化, 一般不宜作为HEV急性感染的诊断依据。国内外依赖于构象性抗原研制的抗-H EV lgM 抗体检测试剂已较成熟,抗-HEV IgM抗体己成为临床上最主要的HEV急性感染诊断指标, IgM抗体阳性且IgG 抗体阳性一般即可诊断; 若l gM 抗体阴性而患者处于发病早期则需进行动态观察; 在个别情况下I gM抗体阳性但l gG 抗体阴性, 也需进行动态观察。<br />&nbsp;&nbsp;2 戊型肝炎的临床分型<br />&nbsp;&nbsp;感染H E V 后, 可表现为临床型和亚临床型。临床型可表现为急性黄疽型肝炎、急性无黄疽型肝炎、淤胆型肝炎和肝衰竭, 基本上均表现为急性自限性, 一般不会发展成慢性肝炎。最近国外有报道发现肝脏移植病人感染HEV 后部分可转为慢性, 长期免疫抑制治疗的病人感染H E V 后也可以呈现病程迁延或反复发作的倾向, 并可能在较长时间携带病毒。<br />&nbsp;&nbsp;戊型肝炎的临床经过与甲型肝炎相似, 但肝衰竭的发生率较高, 病死率为1%-4%, 但孕妇感染后的病死率可高达20 %。<br />&nbsp;&nbsp;2.1 急性黄疸型肝炎：符合戊型肝炎的临床表现、生化改变及病原学检测, 且患者在病程中出现尿黄和/或皮肤巩膜黄染, 血清总胆红素水平超过正常值上限的2 倍。<br />&nbsp;&nbsp;2.2 急性无黄疸型肝炎：符合戊型肝炎的临床表现、生化改变及病原学检测, 但患者在病程中未出现黄疸, 血清总胆红素水平未超过正常值上限的2倍。<br />&nbsp;&nbsp;2.3 淤胆型肝炎：表现为较长期(3 周以上) 肝内阻塞性黄疽如皮肤瘙痒、粪便颜色变浅、肝脏肿大和梗阻性黄疽( 化验结果以直接胆红素升高为主, 血清碱性磷酸酶、5’核昔酸酶和Y 谷氨酞转肤酶增高, 三酞甘油和胆固醇增高)。肝脏影像学检查肝内外胆管无扩张。<br />&nbsp;&nbsp;2.4 肝衰竭<br />&nbsp;&nbsp;2.4.1 急性肝衰竭:起病14 天内出现极度乏力, 消化道症状明显, 黄疽急剧加深(每日上升幅度大于17.1 u mol/ L), 肝浊音界进行性缩小, 迅速出现n 度以上(按W 度划分)肝性脑病, 凝血酶原活动度低于40 %并排除其他原因者。<br />&nbsp;&nbsp;2.4.2 亚急性肝衰竭: 起病巧天心6周以上出现极度乏力, 消化道症状明显, 血清总胆红素高于正常值上限的10倍以上, 凝血酶原活动度低于40 %, 中晚期患者常出现腹水和/或肝性脑病。<br />&nbsp;&nbsp;2.5 几种特殊类型的戊型肝炎: <br />&nbsp;&nbsp;2.5.1 妊娘合并戊型肝炎: 孕妇感染H E V 后, 病情较为严重, 尤其是妊娠中晚期孕妇感染H EV, 病死率可高达20 %。孕妇感染H E V 后易发展成肝衰竭, 也易致早产、死胎、产后大出血, 加重病情。<br />&nbsp;&nbsp;2.5.2 老年戊型肝炎: 临床症状重, 持续时间长, 淤胆型肝炎及肝衰竭的发生率较青壮年明显增高, 且黄疸深, 皮肤瘙痒多见, 容易出现合并症和并发症, 治疗效果差。<br />&nbsp;&nbsp;2.5.3 重叠感染的戊型肝炎：在我国, 多见于慢性乙型肝炎患者重叠感染H E V, 也可见慢性丙型肝炎患者重叠感染HEV。重叠感染后, 可使原来肝脏病变加重, 肝衰竭的发生率及病死率均明显增高。<br />&nbsp;&nbsp;2.5.4 慢性肝病合并戊型肝炎酒精性肝硬化、药物性肝炎及其他原因不明慢性肝病合并戊型肝炎, 可使原来肝脏病变加重, 肝衰竭的发生率及病死率均较未合并戊型肝炎的慢性肝病高。2.5.5 亚临床型感染：与其它嗜肝病毒一样,HEV 感染后可能不发病而仅仅引发一个特异性免疫过程。', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('238', '23', 'G08_006', '1', '中国肝病诊疗管理规范白皮书( 节选)', 'Chinese standards for diagnosis and treatment of liver disease －White paper excerpt', '中国医院协会', '2014', '临床肝胆病杂志,2014,03:197_209', '中文', '1.急性乙肝<br />&nbsp;&nbsp;2.慢性乙型病毒性肝炎<br />&nbsp;&nbsp;2.1 HBeAg 阳性慢性乙肝<br />&nbsp;&nbsp;2.2 HBeAg 阴性慢性乙肝', '乙型病毒性肝炎', '未提及', '未提及', '1.急性乙肝诊断标准: ①近期出现的、无其他原因可解释的乏力、消化道症状，可有尿黄、眼黄和皮肤黄染; ②肝生化检查异常，主要是血清ALT和AST 升高，可有血清胆红素升高;③HBsAg 阳性;④有明确的证据表明6 个月内曾检测血清HBsAg 阴性;⑤抗HBc IgM阳性1∶ 1000 以上( 标准检测试剂) ; ⑥肝组织学检查符合急性病毒性肝炎改变; ⑦恢复期血清HBsAg 阴转，抗HBs 阳转。同时符合②、③项或②、③项可诊断为“疑似病例”确诊病例为“疑似病例”+④或⑤或⑥或⑦项。<br />&nbsp;&nbsp;2.慢性乙型病毒性肝炎：既往有乙肝病史或HBsAg 阳性超过6 个月，现HBsAg 和/或HBV DNA 仍为阳性者，可诊断为慢性HBV 感染。根据HBV 感染者的血清学、病毒学、生物化学试验及其他临床和辅助检查结果，可将慢性HBV 感染分为: <br />&nbsp;&nbsp;2.1 HBeAg 阳性慢性乙肝: 血清HBsAg、HBeAg 阳性、抗－HBe 阴性，HBV DNA 阳性，ALT 持续或反复升高，或肝组织学检查有肝炎病变。<br />&nbsp;&nbsp;2.2 HBeAg 阴性慢性乙肝: 血清HBsAg 阳性，HBeAg 持续阴性，抗－ HBe 阳性或阴性，HBV DNA 阳性，ALT 持续或反复异常，或肝组织学检查有肝炎病变。', '未提及', '慢性乙肝：1.慢性乙肝治疗的首要目标是持久地抑制病毒复制。2短期目标：HBeAg 血清学转换和/或HBV DNA 抑制、ALT 复常的初始应答，预防肝功能失代偿的发生，并确保持久应答，以降低治疗中/后肝脏炎症和纤维化的发生。3. 最终目标是预防肝功能失代偿，减少或预防疾病进展至肝硬化和/或肝细胞癌( HCC) ，以延长存活时间。', '慢性乙肝的治疗目标：HBV 复制是肝脏损害和疾病进展的关键，在慢性乙肝的治疗中，持续的病毒抑制是最重要的。因此，慢性乙肝治疗的首要目标是持久地抑制病毒复制，以降低病毒的传染性及致病性，从而减少肝组织的损伤。在临床上，治疗的短期目标是达到HBeAg 血清学转换和/或HBV DNA 抑制、ALT 复常的初始应答，预防肝功能失代偿的发生，并确保持久应答，以降低治疗中/后肝脏炎症和纤维化的发生。治疗的最终目标是预防肝功能失代偿，减少或预防疾病进展至肝硬化和/或肝细胞癌( HCC) ，以延长存活时间。', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('239', '23', 'G08_007', '1', '中国丙型病毒性肝炎医院感染防控指南', '无', '中华预防医学会医院感染控制分会', '2012', '中国医学前沿杂志(电子版),2012,11:57_62.', '中文', '1.急性丙型病毒性肝炎<br />&nbsp;&nbsp;2.慢性丙型病毒性肝炎', '丙型病毒性肝炎', '未提及', '未提及', '1.急性丙型病毒性肝炎的诊断 ①流行病学史：有输血史、应用血液制品史或明确的HCV暴露史；②临床表现：全身乏力、食欲减退、恶心和右季肋部疼痛等，少数伴低热，轻度肝肿大，部分可出现脾肿大，少数可出现黄疸。部分患者无明显症状，表现为隐匿性感染；③实验室检查：ALT多呈轻度和中度升高，抗HCV和HCVRNA阳性。患者HCV RNA常在ALT恢复正常前低于检测下限，但也有患者ALT恢复正常而HCVRNA持续阳性者。上述①+②+③或②+③者可诊断。<br />&nbsp;&nbsp;2.慢性丙型病毒性肝炎的诊断 HCV感染超过6个月，或发病日期不明、无肝炎史，但肝脏组织病理学检查符合慢性肝炎，抗-HCV和HCV RNA阳性。', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('24', '32', 'G02_012', '1', '加拿大心血管病学立场声明-血脂异常的诊断、治疗及心血管疾病预防建议', 'Canadian Cardiovascular Society position statement–Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease', '加拿大心血管病学(Canadian Cardiovascular Society)', '2006', 'http://www.ccs.ca/images/Guidelines/Guidelines_POS_Library/Lipids_PS_2006.pdf;$$$$McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular Society.Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatme畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭萰ੱ໰%\0ੱà\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖矢\0\0\0𢡄㖞๹ੱà\0è๹彿矣奋矣巫矣祂๹齦๹彿矣齚๹', '英文', null, '高脂血症', null, null, 'G02_012_01_风险分类与治疗建议.docx', null, 'LDL-C；TC/HDL-C', '心血管疾病高风险患者治疗目标：<br />&nbsp;&nbsp;主要目标：LDL-C <2.0 mmol/L<br />&nbsp;&nbsp;\n二级目标: TC/HDL-C <4.0<br />&nbsp;&nbsp;\n', '•高风险患者治疗目标  LDL-C<2.0 2.0 mmol/L;<br />&nbsp;&nbsp;\n•大多数低风险的患者降脂治疗目标点：LDL-C 5.0 mmol/L或总胆固醇(TC)与高密度脂蛋白胆固醇 (HDL-C)的比率6.0; <br />&nbsp;&nbsp;\n• LDL-C treatment target of lower than 2.0 mmol/L for igh-risk patients; <br />&nbsp;&nbsp;\n• Intervention point for initiation of lipid-lowering therapy in most low-risk individuals changed to an LDL-C of 5.0 mmol/L or a total cholesterol (TC) to high-density lipoprotein cholesterol (HDL-C) ratio of 6.0; and<br />&nbsp;&nbsp;\n', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('240', '23', 'G08_008', '1', '丙型病毒性肝炎筛查及管理', '无', '中华人民共和国国家卫生和计划生育委员会', '2014', '传染病信息,2015,01:1_2,22.', '中文', '1.急性丙型肝炎病毒感染<br />&nbsp;&nbsp;2.慢性丙型肝炎病毒感染', '丙型病毒性肝炎', '未提及', '未提及', '1.急性丙型肝炎病毒感染：既往无HCV 感染，6个月内存在高危因素暴露史，可无症状；也可呈急性发病，可有乏力、消化道症状、黄疽等临床表现，可出现肝功能异常，结合抗-HCV 阳性（早期可呈阴性），应高度怀疑急性丙型肝炎病毒感染，确诊有赖于HCV RNA 检测。<br />&nbsp;&nbsp;2.慢性丙型肝炎病毒感染：6 个月前有HCV 感染或高危因素暴露史，可无症状；也可呈隐匿发病，可有乏力、食欲减退、慢性肝病体征等临床表现，可出现肝功能异常，结合抗-HCV 阳性，应高度怀疑慢性丙型肝炎病毒感染，确诊有赖于HCV RNA 检测。', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('241', '23', 'G08_009', '1', '乙型肝炎病毒母婴传播预防临床指南(第1版)', '无', '中华医学会妇产科学分会产科学组', '2013', '中华妇产科杂志,2013,02:151_154.', '中文', '未提及', '乙型肝炎病毒感染', '未提及', '未提及', '慢性HBV感染是指HBsAg阳性持续6个月以上。如果肝功能正常，称为慢性HBV携带；如果肝功能异常，且排除其他原因，则诊断为慢性乙型肝炎，慢性HBV携带者每6—12个月需复查肝功能和其他必要检查。<br />&nbsp;&nbsp; HBV母婴传播，即HBsAg阳性孕产妇将HBV传给子代，主要发生在分娩过程中和分娩后，而垂直传播(分娩前的宫内感染)感染率<3％，多见于HBeAg阳性孕妇。检测乙型肝炎血清学标志物，即HBsAg、乙型肝炎表面抗体(抗．HBs)、HBeAg、乙型肝炎e抗体(抗-HBe)以及乙型肝炎核心抗体(抗-HBc)，可判断有无感染或有无免疫力，其临床诊断的意义见G08_009_图表1。<br />&nbsp;&nbsp; HBsAg阳性，表明病毒在复制，有传染性；HBeAg阳性是病毒复制活跃、病毒载量高的标志，传染性强。抗-HBs是中和抗体，血清抗-HBs水平≥10 mIU／ml即具有保护力。<br />&nbsp;&nbsp;荧光实时定量PCR技术检测HBV DNA水平，可反映病毒载量的高低。然而，30％左右的孕妇HBsAg阳性而HBeAg阴性者(俗称小三阳)，甚至少数HBeAg阳性者(俗称大三阳)，HBV DNA低于检测下限，即所谓“HBV DNA阴性”,但血液中仍有HBV，具有传染性。因此，孕妇HBsAg阳性时，无论其HBV DNA水平高低，甚至是“阴性”，其新生儿如不采取免疫预防，均有感染的可能性。', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('242', '23', 'G08_010', '1', '慢性乙型肝炎抗病毒治疗专家共识', '无', '慢性乙型肝炎抗病毒治疗专家委员会', '2010', '中华实验和临床感染病杂志(电子版),2010,01:82_91.', '中文', 'HBV感染自然史可分为4个阶段:1.免疫耐受期;2.免疫清除期;3非活动期及恢复期。', '慢性乙型肝炎', '未提及', '未提及', '1.免疫耐受期(immunetolerantphase):血清HBsAg和HBeAg阳性、HBV复制活跃、血清ALT正常、肝组织学无或轻微炎症、无肝纤维化或进展缓慢。围产期和婴幼儿时期感染者的免疫耐受期会持续多年, 病情无明显进展, 自发的HBsAg清除率低。<br />&nbsp;&nbsp;2.免疫清除期(immuneclearancephase):HBeAg阳性、HBVDNA水平降低、ALT水平反复波动、肝组织学有炎症坏死、纤维化进展程度较快。大部分HBV感染者都会由免疫耐受期进展为免疫清除期, 这一时期自发的HBsAg清除率增加。<br />&nbsp;&nbsp;3.非活动期(inactivephase):HBeAg消失、出现抗-HBe、HBVDNA水平很低或检测不到、ALT正常、肝脏炎症减轻。此期患者发展为肝硬化和肝癌的风险较低。<br />&nbsp;&nbsp;4.恢复期(recoveryphase): 活动期HBV感染者中, HBsAg清除者临床预后一般较HBsAg持续阳性者好, 肝脏炎症和纤维化不断改善, 称为恢复期。HBV感染是HCC的重要相关因素。HBV感染者在不发生肝硬化的情况下,发展为HCC的几率也较低。肝硬化患者发生HCC的高危因素有男性、年龄、嗜酒、黄曲霉素、合并HCV感染、HBVDNA持续高水平、ALT高水平、HBeAg阳性和HBV基因C型。', '未提及', '未提及', '1. 治疗目标:<br />&nbsp;&nbsp; CHB抗病毒治疗的总体目标:最大限度地长期抑制或消除HBV, 减轻肝细胞炎症、坏死及肝纤维化, 延缓和阻止疾病进展, 减少和防止肝脏失代偿、肝硬化、HCC及其并发症的发生, 从而改善生活质量并延长生存时间。<br />&nbsp;&nbsp; 2. 治疗终点:<br />&nbsp;&nbsp; CHB患者的抗病毒治疗必须将HBVDNA降至尽可能低的水平。抑制病毒复制一方面可使生物化学指标恢复、组织学改善、预防并发症的发生;另一方面还能降低核苷(酸)类似物(NUCs)的耐药风险, 增加HBeAg阳性CHB患者的HBeAg血清学转换率以畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭�ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᢂఄਘĀ\0ః彿㎽奋㎽巫㎽瀞ఄ贮ఄ彿㎽财ఄ塚㎽贮ఄꍈ㏂\0\0ᢂఄ學㎽漸㏂圔㎽ᢂఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0쒠ਘ䐺盭暼痭쒠ਘༀƙ \0쒠ਘ`\0\0㺣盭쒠ਘ\0ﱔ쒤ਘ\0팃目쒤ਘ࣎쒤ਘ큁目쒤ਘᢶఄ﫬\0Item\0\0趲ఄ\0\0\0\0\0\0Count\0\0ﱬﬄ쓔ਘᏜ௷\0\0쒤ਘ\0\0\0\0௷寶目Ꮰ௷矵䥷㎽瀞ఄ\0\0趲ఄ�㏂财ఄ\0\0\0௷\0\0\0謁ﱔ\0\0㎾Ҝ\0ﱜ\0\0x�㏂财ఄ\0\0隲W趲ఄ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('243', '23', 'G08_011', '1', '丙型病毒性肝炎诊断标准', 'Diagnostic criteria for viral hepatitis C', '中华人民共和国卫生部', '2008', 'WS 298-2008, 甲型病毒性肝炎诊断标准[S].', '中文', '1.急性丙型病毒性肝炎<br />&nbsp;&nbsp; 2.慢性丙型病毒性肝炎<br />&nbsp;&nbsp; 3.慢性丙型病毒性肝炎肝硬化 ', '丙型病毒性肝炎', '未提及', '未提及', '1 诊断依据<br />&nbsp;&nbsp;1. 1 流行病学史<br />&nbsp;&nbsp; 1.1.1 曾接受过血液、血液制品或其他人体组织、细胞成分治疗，或器官移植。<br />&nbsp;&nbsp; 1.1.2 有血液透析史、不洁注射史，或其他消毒不严格的有创检查、治疗史，有静脉注射毒品史。<br />&nbsp;&nbsp; 1.1.3 职业供血者，特别是接受过成分血单采回输者。<br />&nbsp;&nbsp; 1.1.4 与HCV感染者有性接触史，或HCV感染者（母亲）所生的婴儿。<br />&nbsp;&nbsp; 1.2 临床表现 <br />&nbsp;&nbsp;1.2.1 急性丙型病毒性肝炎 <br />&nbsp;&nbsp;1.2.1.1 病程在6个月以内，全身乏力、食欲减退、恶心和右季肋部疼痛或不适等。<br />&nbsp;&nbsp; 1.2.1.2 可有轻度肝肿大、部分患者可出现脾肿大；少数患者可伴低热或出现黄疽。<br />&nbsp;&nbsp; 1.2.1.3 部分患者可有关节疼痛等肝外表现。<br />&nbsp;&nbsp;1.2.1.4 部分患者可无明显症状和体征。<br />&nbsp;&nbsp; 1.2.2 慢性丙型病毒性肝炎<br />&nbsp;&nbsp; 1.2.2.1 病程超过6个月，全身乏力、食欲减退、恶心和右季肋部疼痛或不适等。<br />&nbsp;&nbsp; 1.2.2.2 部分患者可有肝病面容、肝掌、蜘蛛痣及轻度肝、脾肿大。<br />&nbsp;&nbsp; 1.2.2.3 部分患者可无明显症状和体征。<br />&nbsp;&nbsp; 1.2.3 丙型病毒性肝炎肝硬化<br />&nbsp;&nbsp; 1.2.3.1 可有全身乏力、食欲减退、恶心和右季肋部疼痛或不适等。<br />&nbsp;&nbsp; 1.2.3.2 可有肝病面容、肝掌、蜘蛛痣及腹壁或食管、胃底静脉曲张及脾脏肿大和脾功能亢进。<br />&nbsp;&nbsp; 1.2.3.3 失代偿期患者可有腹水、肝性脑病及消化道出血史。<br />&nbsp;&nbsp; 1.3.1 急性丙型病毒性肝炎有血清ALT. AST升高，部分病例可有血清胆红素升高。部分慢性丙型 病毒性肝炎和丙型病毒性肝炎肝硬化患者亦可有ALT、AST升高。<br />&nbsp;&nbsp; 1.3.2 血清抗一HCV阳性（抗-HCV的检测方法见附录A) <br />&nbsp;&nbsp; 1. 3. 3 血清HCV RNA阳性（HCV RNA的检测方法见附录B及附录C)。<br />&nbsp;&nbsp;1. 4 组织病理学检查<br />&nbsp;&nbsp;1.4.1 急性丙型病毒性肝炎<br />&nbsp;&nbsp; 可有小叶内及汇管区炎症等多种病变，其组织学特征包括<br />&nbsp;&nbsp;： a)单核细胞增多症样病变，即单个核细胞浸润于肝窦中，形成串珠状；<br />&nbsp;&nbsp;b)肝细胞大泡性脂肪变性；<br />&nbsp;&nbsp;c)胆管损伤伴汇管区大量淋巴细胞浸润，甚至有淋巴滤泡形成；<br />&nbsp;&nbsp;d)常见界面性炎症。<br />&nbsp;&nbsp;1.4.2 慢性丙型病毒性肝炎<br />&nbsp;&nbsp;肝组织中常可观察到不同程度的界面炎、汇管区淋巴浸润甚至淋巴滤泡形成、胆管损伤及不同程度的纤维化，小叶内肝细胞脂肪变性、库普弗细胞或淋巴细胞聚集。<br />&nbsp;&nbsp;1.4.3 慢性丙型病毒性肝炎肝硬化<br />&nbsp;&nbsp;在慢性丙型 病毒性肝炎病历改变的基础上出现肝纤维化及小叶结构的改变，即假小叶形成。<br />&nbsp;&nbsp;1. 5 影像学检查<br />&nbsp;&nbsp;1.5.1 急性丙型病毒性肝炎<br />&nbsp;&nbsp;B超、CT或MRI显示肝脾轻度肿大。<br />&nbsp;&nbsp;1.5.2 慢性丙型病毒性肝炎<br />&nbsp;&nbsp;BB超、CT或MRI显示肝实质不均匀，课件肝脏或脾脏轻度增大。<br />&nbsp;&nbsp; 1.5.3 丙型病毒性肝炎肝硬化<br />&nbsp;&nbsp;B超、CT或MRI可显示肝脏边缘不光滑甚至锯齿状、肝实质不均匀甚至呈结节状，门静脉增宽，脾脏增大。<br />&nbsp;&nbsp;2 诊断原则 <br />&nbsp;&nbsp;依据流行病学资料、症状、体征和肝功能试验结果进行初步诊断，确诊丙型病毒性肝炎须依据HCV RNA检测。区分急性、慢性丙型病毒性肝炎及丙型病毒性肝炎肝硬化须根据明确的暴露时间、影像学及组织病理学检查结果。<br />&nbsp;&nbsp;3 诊断<br />&nbsp;&nbsp; 3. 1 疑似丙肝病例 <br />&nbsp;&nbsp;符合下列任何一项可诊断<br />&nbsp;&nbsp;3. 1. 1 符合1. 1和1. 2。<br />&nbsp;&nbsp;3. 1.2 符合1. 1和1.3.1。<br />&nbsp;&nbsp;3. 2 临床诊断丙肝病例 <br />&nbsp;&nbsp;3.2. 1 符合1.3.2和1.10 。<br />&nbsp;&nbsp;3.2.2 符合1.3.2和1.2。<br />&nbsp;&nbsp; 3.2.3 符合1.3.2和1.3.10。<br />&nbsp;&nbsp; 3. 3 确诊丙肝病例 <br />&nbsp;&nbsp;疑似病例或临床诊断病例和1.3.3， <br />&nbsp;&nbsp;3.3.1 急性丙肝诊符合下列任何一项可诊断：<br />&nbsp;&nbsp; 3.3.1.1 符合1.3.3和1.2.1. <br />&nbsp;&nbsp;3.3.1.2 符合1.3.3和1.4.1. <br />&nbsp;&nbsp;3.3.2 慢性丙肝诊断 <br />&nbsp;&nbsp;符合下列任何一项可诊断： <br />&nbsp;&nbsp;3.3.2. 1 符合1.3.3和1.2.2. <br />&nbsp;&nbsp; 3.3.2.2 符合1.3.3和1.4.2. <br />&nbsp;&nbsp;3.3.2.3 符合1.3.3和1.5.2. <br />&nbsp;&nbsp;3.3.3 丙肝肝硬化 <br />&nbsp;&nbsp;符合下列任何一项可诊断：<br />&nbsp;&nbsp;3.3.3.1符合1.3.3和1.2.3。<br />&nbsp;&nbsp;  3.3.3.2符合1.3.3和1.4.3. <br />&nbsp;&nbsp; 3.3.3.3符合1.3.3和1.5.3. <br />&nbsp;&nbsp;4 鉴别诊断<br />&nbsp;&nbsp;4.1  其他病毒性肝炎<br />&nbsp;&nbsp;其他病毒性肝炎临床表现和肝功能检查结果可以和丙型病毒性肝炎相似，鉴别诊断主要依靠相应的血清学和（或）病毒学检查阳性，而抗- HCV阴性、特别是HCV RNA阴性。<br />&nbsp;&nbsp;4.2丙型肝炎病毒感染后已被清除<br />&nbsp;&nbsp;HCV感染后自行恢复或经治疗后病毒已清除者，抗-HCV可以长时间阳性，但反复检测HCV RNA均应为阴性。<br />&nbsp;&nbsp;4.3  自身免疫性疾病伴抗-HCV阳性<br />&nbsp;&nbsp; 一些自身免疫性疾病患者也可出现抗-HCV阳性，但通常有多种自身抗体阳性，而HCV RNA始终阴性，可以与丙型病毒性肝炎鉴别。<br />&nbsp;&nbsp;4.4  母婴抗-HCV被动传输<br />&nbsp;&nbsp;母体的IgG型抗-HCV可以通过胎盘进入到胎儿体内，因此6个月以内的婴儿抗HCV阳性并不一定代表HCV感染。应以婴儿HCV RNA阳性（出生2个月以后）作为其HCV感染的依据<br />&nbsp;&nbsp;附  录  A<br />&nbsp;&nbsp;(规范性附录) <br />&nbsp;&nbsp;丙型病毒性肝炎病毒抗体(抗-HCV)的检测目前常用的抗—HCV检测试剂盒为第三代，含有NS4抗原(c100-3)、核心抗原(c22)、NS3抗原(c33)和NS5抗原，其灵敏度和特异度均更高。常用方法为酶联免疫吸附试验(ELISA)法或其他酶免疫分析法(EIA)。应采用国家食品药品监督管理局批准的诊断试剂盒。<br />&nbsp;&nbsp;A．1  基本原理<br />&nbsp;&nbsp;本方法采用基因工程重组或人工合成的丙型病毒性肝炎病毒抗原肽片段包被聚苯乙烯珠或板，以辣根过氧化物酶、碱性磷酸酶或化学发光物标记的羊或鼠抗人IgG抗体为示踪物，EIA方法检测人血清中的IgG型丙肝病毒抗体。<br />&nbsp;&nbsp;A. 2  试剂由试剂盒提供。<br />&nbsp;&nbsp;A．3  步骤<br />&nbsp;&nbsp;具体操作步骤和结果判定应严格依据各试剂盒的说明书进行，尤其是应按照说明书的要求设置阴性和阳性对照，并按说明书提供的方法判断结果。最好有质控血清。<br />&nbsp;&nbsp;附  录  B<br />&nbsp;&nbsp; (规范性附录) <br />&nbsp;&nbsp;丙型病毒性肝炎病毒核糖核酸(HCVRNA)的检测方法<br />&nbsp;&nbsp;B．1  丙型病毒性肝炎病毒核糖核酸(HCVRNA)定性检测：逆转录—多聚酶链反应(RT-PCR) <br />&nbsp;&nbsp; B．1．1  原理<br />&nbsp;&nbsp;纯化的HCVRNA在逆转录酶催化下合成cDNA；再以此DNA为模板，加上引物和dNTP，在耐热DNA聚合酶(Taq酶)催化下合成与原DNA链完全互补的DNA链，从而实现DNA倍增。定性分析的最低检测限较低(即灵敏度相对较高)，主要用于确定丙型病毒性肝炎的诊断。<br />&nbsp;&nbsp;B．1．2  试剂<br />&nbsp;&nbsp;B．1．2．1  引物：引物通常由HCV基因保守区5’非编码区(5\'NCR)的15～26个碱基组成，注意引物中核苷酸不要自身产生互补。<br />&nbsp;&nbsp; B．1．2．2  dNTP：包括dATP、dGTP、dCTP、dTTP，使用pH为8．3。<br />&nbsp;&nbsp;B．1．2．3  逆转录酶和耐热的DNA聚合酶(Taq酶)。<br />&nbsp;&nbsp;  B．1．2．4  阴性和阳性对照品<br />&nbsp;&nbsp; B．1．3  操作步骤<br />&nbsp;&nbsp;各厂家生产的PCR药盒均有详细的使用方法介绍，应严格按说明书的操作程序进行，不可随意。<br />&nbsp;&nbsp; B．2  丙型病毒性肝炎病毒核糖核酸(1tCVRNA)定量检测：实时荧光定量多聚酶链反应(FQ—PCR)实时荧光定量PCR技术，是指在PCR反应体系中加入荧光基团，利用荧光信号积累实时监测整个PCR进程，最后通过标准曲线对未知模板进行定量分析的方法。定量分析的最低检测限一般高于定性分析(即灵敏度相对较低)，主要用于决定是否开始治疗及考察治疗效果。<br />&nbsp;&nbsp; B．2．1  原理(以TagUan法为例) <br />&nbsp;&nbsp;  PCR扩增时，在加入一对引物的同时加人一个特异性的荧光探针，该探针为一寡核苷酸，两端分别标记一个报告荧光基团和一个淬灭荧光基团。探针完整时，报告基团发射的荧光信号被淬灭基团吸收；<br />&nbsp;&nbsp;PCR扩增时，Taq酶的5，—3，外切酶活性将探针酶切降解，使报告荧光基团和淬灭荧光基团分离，从而荧光监测系统可接收到荧光信号，即每扩增一条DNA链，就有一个荧光分子形成，实现了荧光信号的累积与PCR产物形成完全同步。，扩增长度一般为50bp一100bp。两端的引物必须与cDNA链相同或互补，探针靠近一端引物。反应时(一般为42~C，30min)RNA先在反转录酶作用下逆转录为cDNA，然后在Taq聚合酶的作用下进行指数扩增。其操作过程包括95~C变性，使双链DNA分离，然后60~C迅速退火和延伸。<br />&nbsp;&nbsp; B．2．2  荧光实时定量PCR仪<br />&nbsp;&nbsp; B．2．3  试剂<br />&nbsp;&nbsp;B．2．3．1  引物和探针：引物和探针通常由HCV基因保守区5’非编码区(5\'NCR)的15～25个碱基组成，注意引物中核苷酸不要自身产生互补和引物二聚体。<br />&nbsp;&nbsp;B．2．3．2  dNTPs包括dATP、dGTP、dCTP、dTTP，pH8．3。<br />&nbsp;&nbsp; B．2．3．3  反转录酶和耐热DNA聚合酶。<br />&nbsp;&nbsp;B．2．3．4  阳性参比晶(一般为10‘拷贝／mL～10’拷贝／mL)。<br />&nbsp;&nbsp; B．2．4  操作步骤<br />&nbsp;&nbsp;各厂家生产的荧光定量PCR药盒均有详细的使用方法介绍，应严格按说明书的操作程序进行，不可随意改动。<br />&nbsp;&nbsp;附    录    C<br />&nbsp;&nbsp;（资料性附录）<br />&nbsp;&nbsp;抗-HCV和HCV RNA检测的临床意义及HCV  RNA  PCR 测定注意事项<br />&nbsp;&nbsp;C.1抗-HCV和 HCV RNA检测的临床意义<br />&nbsp;&nbsp;C.1.1抗-HCV阳性，但反复检测HCV 和RNA均为阴性：可能既往HCV感染已自行恢复，或经治疗病毒已清除；一些自身免疫性疾病患者偶可出现抗-HCV阳性，但HCV RNA始终为阴性。<br />&nbsp;&nbsp;C.1.2HCV RNA阳性，但抗-HCV阴性：可能为HCV感染早期，抗-HCV尚未产生；处于严重免疫抑制状态或免疫受损（如HIV感染），或接受血液透析的患者，亦可在HCV RNA阳性的情况下呈抗-HCV阴性。<br />&nbsp;&nbsp;C.1.3母体的IgG型抗-HCV可以通过胎盘进入到胎儿体内，因此6个月以内的婴儿抗-HCV阳性并不一代表HCV感染。应以HCV RNA阳性作为HCV感染的依据。<br />&nbsp;&nbsp;C.2  HCV RNA  PCR测定注意事项<br />&nbsp;&nbsp;C.2.1严格按照行业行政主管部门颁发的有关基因扩增实验室管理规范进行工作。<br />&nbsp;&nbsp;C.2.2实验室应严格分为PCR前准备区，样本处理区和检测区。<br />&nbsp;&nbsp;C.2.3各区物品应当专用，以防交叉污染。<br />&nbsp;&nbsp;C.2.4使用的器皿和加样器均应专用，离心管、吸头等均应高压灭茵。<br />&nbsp;&nbsp;C.2.5定期对实验台及各种实验室用品进行消毒。<br />&nbsp;&nbsp;C.2.6由于HCV为RNA病毒，在血清采集、分离、保存及RNA提取过程中应特别注意防止RNA酶对RNA的降解作用。<br />&nbsp;&nbsp;C.2.7特别要注意应在无茵条件下采血，并在4h内将血清冻存在-30℃以下。<br />&nbsp;&nbsp;C.2.8必须正确设置阴性和阳性对照。<br />&nbsp;&nbsp;', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('244', '23', 'G08_012', '1', '甲型病毒性肝炎诊断标准', 'Diagnostic criteria for viral hepatitis A', '中华人民共和国卫生部', '2008', 'WS 299-2008, 乙型病毒性肝炎诊断标准[S].', '中文', '1.甲型肝炎<br />&nbsp;&nbsp; 2.急性甲型肝炎（无黄疸型）<br />&nbsp;&nbsp;3.急性甲型肝炎（黄疸型）', '甲型病毒性肝炎', '未提及', '未提及', '1.诊断依据<br />&nbsp;&nbsp;1.1  流行病学史（参见附录C的C.2）<br />&nbsp;&nbsp;发病前2周～7周内有不洁饮食史或不清饮水史；或与甲型肝炎急性患者有密切接触史；或当地出现甲型肝炎暴发或流行；或有甲型肝炎流行区旅行史。<br />&nbsp;&nbsp;1.2  临床表现（详见附录C的C.3）<br />&nbsp;&nbsp;1.2.1  发热、乏力和纳差、恶心、呕吐或者腹胀、便秘等消化道症状。肝脏肿大，伴有触痛或叩痛。<br />&nbsp;&nbsp;1.2.2  有巩膜、皮肤黄染并排除其他疾病所致黄疸者。<br />&nbsp;&nbsp;1.3  实验室检查（见附录A、附录B）<br />&nbsp;&nbsp;1.3.1  血清丙氨酸氨基转移酶(ALT)明显升高。<br />&nbsp;&nbsp;1.3.2  血清总胆红素( TBIL)大于正常上限数值一倍以上和（或）尿胆红素阳性。<br />&nbsp;&nbsp;1.3.3  血清学检测：抗-HAV IgM阳性或抗-HAV IgG双份血清呈4倍升高。<br />&nbsp;&nbsp;2 诊断原则<br />&nbsp;&nbsp;根据流行病学、临床症状、体征、实验室检查等进行综合分析和诊断。因为甲型肝炎的临床表现与其他急性病毒性肝炎极其相似，确诊依赖于特异性的血清学检查。<br />&nbsp;&nbsp;3 诊断标准<br />&nbsp;&nbsp;甲型肝炎分为急性无黄疽型和急性黄疸型。<br />&nbsp;&nbsp;3.1  临床诊断病例<br />&nbsp;&nbsp;3.1.1  甲型肝炎<br />&nbsp;&nbsp;符合下列一条即可诊断：<br />&nbsp;&nbsp;3.1.1.1  1.1和1.2和1.3.1；<br />&nbsp;&nbsp;3.1.1.2  1.1和1.2和1.3.1和1.3.2；<br />&nbsp;&nbsp;3.1.1.3  1.2和1.3.1；<br />&nbsp;&nbsp;3.1.1.4  1.2和1.3.1和1.3.2。<br />&nbsp;&nbsp;3.1.2  急性甲型肝炎（无黄疸型）<br />&nbsp;&nbsp;符合下列一条即可诊断：<br />&nbsp;&nbsp;3.1.2.1  1.1和1.2.1；<br />&nbsp;&nbsp;3.1.2.2  1.1和1.3.1；<br />&nbsp;&nbsp;3.1.2.3  1.2.1和1.3.1。<br />&nbsp;&nbsp;3.1.3  急性甲型肝炎（黄疸型）<br />&nbsp;&nbsp;符合下列一条即可诊断：<br />&nbsp;&nbsp;3.1.3.1  1.1和1.2.1和1.2.2和1.3.2；<br />&nbsp;&nbsp;3.1.3.2  1.1和1.2 .2和1.3.1和1.3.2；<br />&nbsp;&nbsp;3.1.3.3  1.2.1和1.2.2和1.3.1和1.3.2。<br />&nbsp;&nbsp;3.2  确诊病例<br />&nbsp;&nbsp;3.2.1  甲型肝炎<br />&nbsp;&nbsp;临床诊断病例和4.3.3。<br />&nbsp;&nbsp;3.2.2  急性甲型肝炎（无黄疸型）<br />&nbsp;&nbsp;临床诊断病例和4.3.3。<br />&nbsp;&nbsp;3.2.3  急性甲型肝炎（黄疸型）<br />&nbsp;&nbsp;临床诊断病例和4.3.3。<br />&nbsp;&nbsp;4 鉴别诊断<br />&nbsp;&nbsp;发病早期与上呼吸道感染、肠道感染和关节炎等区别，同时需与其他型别的病毒性肝炎、药物性肝炎、中毒性肝炎、传染性单核细胞增多症、钩端螺旋体病，巨细胞病毒性肝炎和阻塞性黄疸区别。', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('245', '23', 'G08_013', '1', '乙型病毒性肝炎诊断标准', 'Diagnostic criteria for viral hepatitis B', '中华人民共和国卫生部', '2008', 'WS 213-2008, 丙型病毒性肝炎诊断标准[S].', '中文', '1.急性乙肝<br />&nbsp;&nbsp;2.慢性乙肝<br />&nbsp;&nbsp;3.乙肝肝硬化<br />&nbsp;&nbsp;4.乙肝病毒相关的原发性肝细胞癌', '乙型病毒性肝炎', '未提及', '未提及', '1 诊断原则<br />&nbsp;&nbsp;乙肝的诊断依据流行病学资料、临床表现、实验室检查、病理学及影像学检查等进行初步诊断，确诊须依据血清HBV标志和HBV DNA检测结果。<br />&nbsp;&nbsp;2 诊断分类<br />&nbsp;&nbsp;根据临床特点和实验室检查等将乙肝分为不同临床类型，包括急性乙肝、慢性乙肝、乙肝肝硬化、乙肝病毒相关的原发性肝细胞癌等。<br />&nbsp;&nbsp;3 诊断<br />&nbsp;&nbsp;3.1 急性乙肝<br />&nbsp;&nbsp;3.1.1 近期出现无其他原因可解释的乏力和消化道症状，可有尿黄、眼黄和皮肤黄疸。3.1.2 肝脏生化检查异常，主要是血清ALT和AST升高，可有血清胆红素升高。<br />&nbsp;&nbsp;3.1.3 HBsAg阳性。<br />&nbsp;&nbsp;3.1.4 有明确的证据表明6个月内曾检测血清HbsAg阴性。<br />&nbsp;&nbsp;3.1.5 抗HBCIgM阳性1:1000以上。<br />&nbsp;&nbsp;3.1.6 胆组织学符合急性病毒性肝炎改变。<br />&nbsp;&nbsp;3.1.7 恢复期血清HbsAg阴转，抗HBs阳转。<br />&nbsp;&nbsp;3.1.8 疑似急性乙肝病例<br />&nbsp;&nbsp;符合下列任何一项可诊断：<br />&nbsp;&nbsp;3.1.8.1 同时符合3.1.1和3.1.3<br />&nbsp;&nbsp;3.1.8.2 同时符合3.1.2和3.1.3<br />&nbsp;&nbsp;3.1.9 确诊急性乙肝病例<br />&nbsp;&nbsp;符合下列任何一项可诊断：<br />&nbsp;&nbsp;3.1.9.1 疑似病例同时符合3.1.4<br />&nbsp;&nbsp;3.1.9.2 疑似病例同时符合3.1.5<br />&nbsp;&nbsp;3.1.9.3 疑似病例同时符合3.1.6<br />&nbsp;&nbsp;3.1.9.4 疑似病例同时符合3.1.7<br />&nbsp;&nbsp;3.2 慢性乙肝<br />&nbsp;&nbsp;3.2.1 急性HBV感染超过6个月仍HbsAg阳性或发现HbsAg阳性超过6个月（参见附录A）<br />&nbsp;&nbsp;3.2.2 HbsAg阳性持续时间不详，抗HbcIgM阴性。<br />&nbsp;&nbsp;3.2.3 慢性肝病患者的体征如肝病面容，肝掌、蜘蛛痣和肝、脾肿大等（参见附录B）<br />&nbsp;&nbsp;3.2.4 血甭ALT反复或持续升高，可有血浆白蛋白降低和（或）球蛋白升高，或胆红素升高等（参见附录B）<br />&nbsp;&nbsp;3.2.5 肝脏病理学有慢性病毒性肝炎的特点（参见附录B）<br />&nbsp;&nbsp;3.2.6 血清HbsAg阳性或可检出HBV DNA，并排除其他导致ALT升高的原因（见附录C）3.2.7 疑似慢性乙肝病例<br />&nbsp;&nbsp;符合下列任何一项可诊断：<br />&nbsp;&nbsp;3.2.7.1 符合3.2.1和3.2.33.2.7.2 符合3.2.2和3.2.3<br />&nbsp;&nbsp;3.2.7.3 符合3.2.2和3.2.4<br />&nbsp;&nbsp;3.2.8 确诊慢性乙肝病例<br />&nbsp;&nbsp;符合下列任何一项可诊断：<br />&nbsp;&nbsp;3.2.8.1 同时符合3.2.1、3.2.4和3.2.6<br />&nbsp;&nbsp;3.2.8.2 同时符合3.2.1、3.2.5和3.2.6<br />&nbsp;&nbsp;3.2.8.3 同时符合3.2.1、3.2.4和3.2.6<br />&nbsp;&nbsp;3.2.8.4 同时符合3.2.2、3.2.5和3.2.6<br />&nbsp;&nbsp;3.3 乙肝肝硬化<br />&nbsp;&nbsp;3.3.1 血清HbsAg阳性，或有明确的慢性乙肝病史<br />&nbsp;&nbsp;3.3.2 血清白蛋白降低或血清ALT或AST升高，或血清胆红素升高，伴有脾功能亢进（血小板和或白细胞减少），或明确食管、胃底静脉曲张，或肝性脑病或腹水（参见附录B）。<br />&nbsp;&nbsp;3.3.3 腹部B型超声、CT或MRT等影像学检查有肝硬化的典型表现（参见附录B）。<br />&nbsp;&nbsp;3.3.4 肝组织学表现为弥漫性纤维化及假小叶形成。<br />&nbsp;&nbsp;3.3.5 符合下列任何一项可诊断：<br />&nbsp;&nbsp;3.3.5.1 符合3.3.1和3.3.2<br />&nbsp;&nbsp;3.3.5.2 符合3.3.1和3.3.3<br />&nbsp;&nbsp;3.3.5.3 符合3.3.1和3.3.4<br />&nbsp;&nbsp;3.4 乙肝病毒相关的原发性肝细胞癌<br />&nbsp;&nbsp;3.4.1 血清HbsAg阳性，或有慢性乙肝病史（见附录A）<br />&nbsp;&nbsp;3.4.2 一种影像学技术（B超、CT、MRI或血管造影）发现＞2cm的动脉性多血管性结节病灶，同时AFP≥400Ug/l，并能排除妊娠、生死系胚胎源性肿瘤及转移性肝癌（见附录B）<br />&nbsp;&nbsp;3.4.3 两种影像学技术（B超、CT、MRI或血管造影）均发现＞2cm的动脉性多血管性结节病灶。<br />&nbsp;&nbsp;3.4.4 肝脏占位性病变的组织学检查证实为肝细胞癌。<br />&nbsp;&nbsp;3.4.5 符合下列任何一项可诊断：<br />&nbsp;&nbsp;3.4.5.1 符合3.4.1和3.4.2<br />&nbsp;&nbsp;3.4.5.2 符合3.4.1和3.4.3<br />&nbsp;&nbsp;3.4.5.3 符合3.4.1和3.4.4<br />&nbsp;&nbsp;4 鉴别诊断<br />&nbsp;&nbsp;4.1 慢性HBV携带者<br />&nbsp;&nbsp;4.1.1 血清HbsAg阳性史6个月以上。<br />&nbsp;&nbsp;4.1.2 1年内连续随访3次或以上，血清ALT和AST均在正常范围，且无慢性肝炎的体征如肝掌、蜘蛛痣、脾大等。<br />&nbsp;&nbsp;4.1.3 HbsAg阳性，血清HBV DNA可检出。<br />&nbsp;&nbsp;4.1.4肝组织学检查无明显炎症、坏死和纤维化。<br />&nbsp;&nbsp;4.1.5 疑似病例：符合4.1.1、4.1.2和4.1.3<br />&nbsp;&nbsp;4.1.6 确诊病例：疑似病例同时符合4.1.4<br />&nbsp;&nbsp;4.2 非活动性HbsAg携带者<br />&nbsp;&nbsp;4.2.1 血清HbsAg阳性6个月以上。<br />&nbsp;&nbsp;4.2.2 一年内连续随访3次以上，血清ALT和AST均在正常范围。<br />&nbsp;&nbsp;4.2.3 血清HbsAg阴性，抗-Hbe阳性或阴性，血清HBV DNA检测不到。<br />&nbsp;&nbsp;4.2. 4 肝脏组织学检查无明显炎症和炎症轻微。<br />&nbsp;&nbsp;4.2.5 疑似病例：符合4.2.1、4.2.2和4.2.3<br />&nbsp;&nbsp;4.2.6 确诊病例：疑似病例同时符合4.2.4<br />&nbsp;&nbsp;4.3 其他肝炎病毒引起的病毒性肝炎，非嗜肝病毒引起的肝炎、药物性肝炎、酒精性肝炎，自身免疫性肝炎，以及其他病因所致肝炎。<br />&nbsp;&nbsp;4.4 乙肝和上述其他肝炎也可合并发生。', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('246', '23', 'G08_014', '1', '丁型病毒性肝炎诊断标准', 'Diagnostic criteria for viral hepatitis D', '中华人民共和国卫生部', '2008', 'WS 300-2008, 丁型病毒性肝炎诊断标准[S].', '中文', '未提及', '丁型病毒性肝炎', '未提及', '未提及', '1. 诊断依据<br />&nbsp;&nbsp;1.1流行病学史<br />&nbsp;&nbsp;1.1.1　既往无HBV感染史，6个月内接受过血及血制品，或有其他医源性感染HBV及HDV的可能性、生活中同其他HBV感染者有密切接触（尤其是性接触）等，符合该病史者提示急性HBV与HDV同时感染的可能性。<br />&nbsp;&nbsp;1.1.2　既往有慢性HBV感染史，6个月内接受过血及血制品、或有其他医源性感染HDV的可能性，生活中同其他HDV感染者有密切接触（尤其是性接触）等，符合该病史者提示慢性HBV感染的基础上重迭急性HDV感染的可能性。<br />&nbsp;&nbsp;1.1.3既往HBV感染史不详，近期偶然发现HBV感染（无急性起病的临床表现），此类患者多为慢性HBV感染。如同时检出HDV感染，则亦多为慢性HDV感染，即慢性HBV感染重迭慢性HDV感染，但不能区分是HBV与HDV的同时感染转为慢性，抑或是慢性HBV感染的基础上重迭HDV感染。<br />&nbsp;&nbsp;1.2临床表现<br />&nbsp;&nbsp;1.2.1乏力、食欲不振、恶心、呕吐、腹胀、肝区不适或隐痛、尿黄、眼黄等。急性患者可有肝脏肿大，触痛或叩痛；慢性患者可能脾大、肝掌、蜘蛛痣等。<br />&nbsp;&nbsp;1.2.2HBV与HDV同时感染<br />&nbsp;&nbsp;成年急性HBV与HDV感染大多表现为自限性肝炎经过。急性丁型肝炎的症状体征与急性乙型肝炎的症状体征重迭出现，不能区分。如急性乙型肝炎患者有血清ALT和胆红素的双相升高，应怀疑为HBV与HDV的同时感染。<br />&nbsp;&nbsp;1.2.3HBV与HDV重迭感染<br />&nbsp;&nbsp;慢性HBV感染者突然出现病情活动或加重，或迅速发展为重型肝炎，应考虑重迭感染HDV的可能性。<br />&nbsp;&nbsp;1.3　实验室检测<br />&nbsp;&nbsp;1.3.1　肝功能检测<br />&nbsp;&nbsp;血清ALT升高<br />&nbsp;&nbsp;1.3.2　HDV标志物检测<br />&nbsp;&nbsp;使用国家标准诊断试剂盒，按说明书操作<br />&nbsp;&nbsp;1.3.2.1血清HDAg阳性<br />&nbsp;&nbsp;1.3.2. 2血清HDVRNA阳性<br />&nbsp;&nbsp;1.3.2.3血清抗HDV阳性<br />&nbsp;&nbsp;1.3.2.4血清抗HDVIgM阳性<br />&nbsp;&nbsp;1.3.2.5肝组织HDAg阳性<br />&nbsp;&nbsp;1.3.2.6肝组织HDVRNA阳性<br />&nbsp;&nbsp;1.3.3　HBV感染标志物检测<br />&nbsp;&nbsp;1.3.3.1乙型肝炎表面抗原（HBsAg）阳性<br />&nbsp;&nbsp;2. 诊断原则<br />&nbsp;&nbsp;丁型病毒性肝炎的诊断须依据流行病学资料、临床表现和实验室检查，包括病毒学检查、肝功能检查等进行综合诊断，确诊须依据患者血清和或肝组织中HBV和HDV标志物的检测。3. 诊断<br />&nbsp;&nbsp;3.1　疑似诊断丁型病毒性肝炎病例<br />&nbsp;&nbsp;符合下列任何一项即可诊断：<br />&nbsp;&nbsp;3.1.1　1.1和1.2和1.3.1和1.3.3.1<br />&nbsp;&nbsp;3.1.2　1.2和1.3.1和1.3.3.1<br />&nbsp;&nbsp;3.1.3　1.2和1.3.3.1<br />&nbsp;&nbsp;3.2　确诊丁型病毒性肝炎病例<br />&nbsp;&nbsp;3.2.1　3.1和3.3.2中任一项<br />&nbsp;&nbsp;3.2.2　急性丁型肝炎与急性乙型肝炎同时感染<br />&nbsp;&nbsp;符合下列任何一项即可诊断：<br />&nbsp;&nbsp;3.2.2.1　1.1.1和1.2.1和1.2.2和1.3.1和1.3.3.1和1.3.2中任一项。<br />&nbsp;&nbsp;3.2.2.2 1.1.1和1.3.1和1.3.3.1和1.3.2中任一项。<br />&nbsp;&nbsp;3.2.2.3 1.1.1和1.3.3.1和1.3.2中任任一项。<br />&nbsp;&nbsp;3.2.2.4 1.2.2和1.3.2中任一项。<br />&nbsp;&nbsp;3.2.3 急性丁型肝炎与慢性乙型肝炎重迭感染。<br />&nbsp;&nbsp;符合下列任何一项即可诊断。<br />&nbsp;&nbsp;3.2.3.1 4.1.2和1.2.1和1.2.3和1.3.1和1.3.3.1和1.3.2中任一项。<br />&nbsp;&nbsp;3.2.3.2 4.1.2和1.3.1和1.3.3.1和1.3.2中任一项。<br />&nbsp;&nbsp;3.2.3.3 4.1.2和1.3.3.1和1.3.2中任一项。<br />&nbsp;&nbsp;3.2.3.4 4.2.3和1.3.2中任一项。<br />&nbsp;&nbsp;4. 鉴别诊断<br />&nbsp;&nbsp;因为HDV的感染表现为与HBV的同时感染或重迭感染，因此二者的临床表现亦重迭发生，不易区分。<br />&nbsp;&nbsp;HDV同其他病毒性肝炎和其他肝脏损伤性疾病的鉴别只能依赖HDV和HBV病毒指标的检测。符合HDV诊断标准，则诊断为丁型肝炎。', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('247', '23', 'G08_015', '1', '戍型病毒性肝炎诊断标准', 'Diagnostic criteria for viral hepatitis E', '中华人民共和国卫生部', '2008', 'WS 301-2008, 戊型病毒性肝炎诊断标准[S].', '中文', '1.急性戊型病毒性肝炎，无黄疸型<br />&nbsp;&nbsp;2.急性戊型病毒性肝炎，黄疸型<br />&nbsp;&nbsp;3.戊型病毒性肝炎，急性肝衰竭<br />&nbsp;&nbsp;4.戊型病毒性肝炎，亚急性肝衰竭', '戍型病毒性肝炎', '未提及', '未提及', '1.诊断依据<br />&nbsp;&nbsp;1.1流行病学史<br />&nbsp;&nbsp;发病前l5d-75d内有不洁饮食（水）史、或有接触戊型病毒性肝炎患者史，或到戊型病毒性肝炎高发区或流行区出差、旅游史。<br />&nbsp;&nbsp;1.2临床表现<br />&nbsp;&nbsp;1.2.1无其他原因可解释的持续乏力、食欲减退或其他消化道症状和（或）肝肿大伴有触痛或叩击痛。<br />&nbsp;&nbsp;1.2.2尿黄、皮肤巩膜黄疸，并排除其他疾病所致的黄疸。<br />&nbsp;&nbsp;1.2.3肝衰竭患者表现为乏力、消化道症状、黄疸等临床表现进行性加重，并可出现腹水和（或）神经精神症状（表现为烦躁不安，定向力障碍，甚至神志不清、嗜睡、昏迷）。<br />&nbsp;&nbsp;1.3实验室检测<br />&nbsp;&nbsp;1.3.1  血清学检测抗HEV IgG和（或）抗-HEV IgM阳性。检测方法见附录A。<br />&nbsp;&nbsp;1.3.2血清丙氨酸氨基转移酶(ALT)明显升高。<br />&nbsp;&nbsp;1.3.3血清总胆红素(TBIL)＞17. lumol/L(l0mg/L)和（或）尿胆红素阳性。<br />&nbsp;&nbsp;1.3.4凝血酶原活动度肝衰竭患者的凝血酶原活动度进行性降低至40%以下。<br />&nbsp;&nbsp;1.3.5血清学排除急性甲、乙、丙型肝炎。<br />&nbsp;&nbsp;2.诊断原则<br />&nbsp;&nbsp;依据流行病学史、症状、体征及实验室检查进行综合诊断。因为戊型病毒性肝炎的临床表现与其他急性肝炎极其相似，确诊依赖于特异性的血清学检查。<br />&nbsp;&nbsp;3.诊断<br />&nbsp;&nbsp;3.1 I临床诊断<br />&nbsp;&nbsp;3.1.1急性戊型病毒性肝炎，无黄疸型：1.1和1.2.1和1.3.2和1.3.5。<br />&nbsp;&nbsp;3.1.2急性戊型病毒性肝炎，黄疸型：3.1.1和1.2.2和1.3.3。<br />&nbsp;&nbsp;3.1.3戊型病毒性肝炎，急性肝衰竭：符合3.1.2和起病l4d内出现1.2.3和1.3.4。<br />&nbsp;&nbsp;3.1.4戊型病毒性肝炎，亚急性肝衰竭：符合3.1.2和起病后l4d以上至6个月出现1.2.3和1.2.4。<br />&nbsp;&nbsp;3.2确定诊断<br />&nbsp;&nbsp;3.2.1急性戊型病毒性肝炎，无黄疸型：符合3.1.1和1.3.1。<br />&nbsp;&nbsp;3.2.2急性戊型病毒性肝炎，黄疸型：符合3.1.2和1.3.1。<br />&nbsp;&nbsp;3.2.3戊型病毒性肝炎，急性肝衰竭：符合3.1.3和1.3.1。<br />&nbsp;&nbsp;3.2.4戊型病毒性肝炎，亚急性肝衰竭：符合3.1.4和1.3.1。<br />&nbsp;&nbsp;4. 鉴别诊断<br />&nbsp;&nbsp;4.1  其他急性病毒性肝炎<br />&nbsp;&nbsp;4.2  巨细胞病毒(CMV)性肝炎<br />&nbsp;&nbsp;临床表现与病毒性肝炎有相似之处，但CMV IgM抗体阳性，而抗-HEV阴性。<br />&nbsp;&nbsp;4.3 EB病毒性肝炎<br />&nbsp;&nbsp;血清中均可检出EB病毒IgM抗体，而抗-HEV阴性。<br />&nbsp;&nbsp;4.4传染性单核细胞增多症<br />&nbsp;&nbsp;其特征为发热、咽痛、肝脾淋巴结肿大，外周血淋巴细胞碌著增多；血清中可检出EB病毒IgM抗体，而抗HEV阴性。<br />&nbsp;&nbsp;4.5中毒性肝炎<br />&nbsp;&nbsp;往往急性起病，有明确的化学、感染等中毒因素的存在。<br />&nbsp;&nbsp;4.6药物性肝炎<br />&nbsp;&nbsp;药物性肝炎往往在服用药物后发生，停药聍疾病缓解，抗HEV阴性。<br />&nbsp;&nbsp;4.7酒精性肝病<br />&nbsp;&nbsp;在长期大量饮洒后发生。抗-HEV阴性。<br />&nbsp;&nbsp;4.8妊娠急性脂肪肝<br />&nbsp;&nbsp;常常发生于围产期，B超检查有助于鉴别诊断，抗HEV阴性。<br />&nbsp;&nbsp;4.9肝外胆道梗阻、胆石症<br />&nbsp;&nbsp;B超检查有助于鉴别诊断，抗-HEV阴性。<br />&nbsp;&nbsp;4.10钩端螺旋体病<br />&nbsp;&nbsp;以寒颤、发热、乏力伴有淋巴结肿大、腓肠肌痛为特点，显凝试验阳性，抗HEV阳性。', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('248', '23', 'G08_016', '0', '病毒性肝炎中医辩证标准(试行)', '无', '中国中医药学会内科肝病专业委员会', '1992', '中医杂志, 1992(05): 39_40.', '中文', '未提及', '病毒性肝炎', '未提及', '1急性病毒性肝炎<br />&nbsp;&nbsp;1.1急性黄疸型肝炎<br />&nbsp;&nbsp;1.1.1阳黄证<br />&nbsp;&nbsp;1.1.2阴黄证<br />&nbsp;&nbsp;1.2急性无黄疸型肝炎<br />&nbsp;&nbsp;1.2.1湿阻脾胃证<br />&nbsp;&nbsp;1.2.2肝郁气滞证<br />&nbsp;&nbsp;2慢性迁延性肝炎及慢性活动性肝炎<br />&nbsp;&nbsp;2.1湿热中阻证<br />&nbsp;&nbsp;2.2肝郁脾虚证<br />&nbsp;&nbsp;2.3肝肾阴虚证<br />&nbsp;&nbsp;2.4瘀血阻络证<br />&nbsp;&nbsp;2.5脾肾阳虚证<br />&nbsp;&nbsp;3淤胆型肝炎', '未提及', '1急性病毒性肝炎<br />&nbsp;&nbsp;1.1急性黄疸型肝炎<br />&nbsp;&nbsp;1.1.1阳黄证：临床表现为尿黄。身目俱黄，色泽鲜明，恶心，厌油，纳呆。口干苦，头身困重，胸脘痞满，乏力，大便干，小便黄赤，苔黄腻，脉弦滑数。<br />&nbsp;&nbsp;主证：①尿黄，身目俱黄，色泽鲜明；②恶心．厌油，纳呆；③苔黄腻。<br />&nbsp;&nbsp;次证：①口干苦；②大便干；③头身困重；④胸脘痞满。<br />&nbsp;&nbsp;辩证要求：(1)具备主证①及②、③两项中的1项者，即属本证；(2)具备主证①及次证①或②者，属于热重于湿证：(3)具备主证①及次证③或④者，属于湿重于热证；(4)具备主证①及次证畻坴畿\0\0\0\0醼畻聱盯\r\0\0\0痭�ਘༀƙ\0ਘĀ\0\r\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᢂఄਘĀ\0ః彿㎽奋㎽巫㎽毦ఄ讶ఄ彿㎽讪ఄ塚㎽讶ఄꍈ㏂\0\0ᢂఄ學㎽漸㏂圔㎽ᢂఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0쒠ਘ䐺盭暼痭쒠ਘༀƙ \0쒠ਘ`\0\0㺣盭쒠ਘ\0ﱔ쒤ਘ\0팃目쒤ਘ࣎쒤ਘ큁目쒤ਘᢶఄ﫬\0Item\0\0谺ఄ\0\0\0\0\0\0Count\0\0ﱬﬄ쓔ਘᏜ௷\0\0쒤ਘ\0\0\0\0௷寶目Ꮰ௷矵䥷㎽毦ఄ\0\0谺ఄ�㏂讪ఄ\0\0\0௷\0\0\0謁ﱔ\0\0㎾ᑐ\0ﱜ\0\0x�㏂讪ఄ\0\0隲W谺ఄ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\r\0霪W露W\0\0ﱴxt\0Љ\0\0\0렘௥鲬࣎菮畻\0\0\0\0ጰ௷Eo\0\0ᎄ௷\0\0⑰ਫ਼⑰ਫ਼ᎈ௷ាఄ寶目ᎈ௷ាఄi\0\0ﱄ﷜ﱴﲔ먙㎼ាఄᎈ௷i\0\0ﱄ﷜ﱴ먰㎼﷜ាఄ�㏂ᜦఄ\0\0릎㎼ាఄi\0╪췬目╾췬目Љ\0镴࣎\0￿￿目Љ\0镨࣎렘௥竗렘௥目W\0竗\0\0\0賓器目\0\0\0\0ᢶఄ\0目瑉浥目\0\0\0\0ᢶఄ\0目潃湵t\0\0\0\0ǵ\0\0ဠ\0\0侠̓ﯬ侠̓̙\0\0\0\0\0\0\0̙῰̓\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0῰̓\0\0\0\0̙ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚЉ\0\0\0⟒췬⟚췬目Љ\0鲸࣎\0￿￿目Љ\0鲬࣎렘௥觴렘௥目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨាఄ目潅f摲敳t盡燎捥盦通묞￾￿吊盡璀ৄ+௧ै璀綻眶4\0ৄ+\0\0ඞḁ.\0\0\0\0䛌E\0덐ɫ‾Q岛@\0⎐ۓ﮵S豀ɳ\0덐ɫ\0﯏S臀ɳ\0豀ɳ\0䛌E\0뛀ɫ‾Q岛@\0䛌E\0템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂奈瞒⫠\0\0\0瞒⪌쀕瞒若〠\0䪔㏂\0T\0\0⪌쀕\0\0ꀀ翽翽凜瞒郎瘝䪔㏂\0邰ƙ\0\0ࠀᴒ眊\0\0䪔㏂瘝\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ﫜ាఄﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀勤﬘眿捻ฒ谺ఄ﫨ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿﫜￿￿\0\0﫦\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ\0\0\0\0\0奰畿⫡췬臭焚畻邰ƙࠀ﫜￿￿㏂￿￿\0\0\0\0愈煔畻:\0﫜￿￿㏂￿￿奰畿\0\0\0\0﬘㎾ࠄ\0\0﫜￿￿㏂㎾x\0\0�㏂讪ఄ\0\0頲Wאּ\0\0\0\0ࠄ\0顇WValu\0\0﫜שּׁ谺ఄﱜ\0\0\0\0\0\0﫜\0﫨\0ﰰ餀Wﱜﲈ	\0ﳸ\0\0辌ौř\0Ț\0\0\0\0\0渜ɪ\0\0ﮀ⮒췬ﮀ뜩@﷩\0\0\0³\0ﮠ䗧@ﭸ蕶@辀ौﱰ﯌´\0뮩@ﮰ믆@믎@ﱰ﷩\0釚@ﱰﱰ﷩\0ༀƙﱴༀƙ﯐戤痝\0Ɨ\0\0௫ﯴఃః忉㎽諮ఄ奁㎽ః	\0諺ఄ讶ఄ彿㎽ﱤ䦕盭讶ఄ	\0讶ఄ忉㎽ﱔ䥷盭讶ఄ\0\0	\0ﱬ谺ఄﱴ馘Bﱜﳸxﲈﲈ駰Bﱴ宀ঽᓐ৺\0ఄ\0\0ﱔ︜ﱜx︜x︄ﳸxﲔx︜ﲠx︜︸x︜\0\0宀ঽ뿄x\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0\0\0ᢶఄ䗆@	\0ᢶఄ谺ఄ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0ʎCᢶఄ︜Cᢶఄ\0\0\0\0\0ఄ\0\0\0\0ఄ﷜￿\0\0\0\0\0\0￿\0\0\0\0\0Ð৺\0\0\r\0ﺄ\0\0ﺈ焐ɪ\0\0\0젤ఌ\0\0\0\0眜ɪﺐ嵿{ﹸ\0\0\0\0\0ﺄ﹄庱{ﺐﺘ彨{ﺐ\0\0\0\0ﺰ୩ڬ৅ﹼ邏S\0\0ㄐ঵\0\0춀ɯ\0\0\0焐ɪ\0\0৺\0\0ﻨⰛEﺤⰺEﻨﺰⱹEﻨﺼⳗEﻨﻰ⳶Eﻨ\0\0\0\0穠म\0\0\0\0宰ঽﺀ୩ﻰĒ８䳫Tｄ䴙T８\0\0\0\0츐ɳ\0\0\0\0\0Ā츐ɳｬ㻨T਌\0\0\0\0\0\0燹āǵ\0Ǉ\0ꋴĵ䈆Tｐ䈐Tｬｸ䉉Tｬ\0\0\0\0ꋴĵ츐ɳﾈ잜Ĳꀀ翽ￄ枴@ﾈ\0\0ﾔ眿ꀀ翽ￔ㭓瞖ꀀ翽ᮒ眊\0\0\0\0ꀀ翽\0\0\0\0\0\0ﾠ\0\0￿￿瞑\0\0￬㬦瞖얼Ĳꀀ翽\0\0\0\0\0\0\0\0얼Ĳꀀ翽\0\0譕召�䖋倌䶋謈ᢑ＀菒ӄ䶋༈醷ش\0숻Ѵ쀳⏫䖋倌䶋脈ⳁ儀喋謈ᒂ＀菐ࣄ�쀛삃嬁쉝쳌쳌쳌쳌쳌쳌삋鱠è\0堀%￰￿⑴倨탿삅ᕵ憝è\0堀%￰诿Ҁ＀㏠觀⑄鴠쉡쳌쳌쳌邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐譕臬⣬였웿옒웂온贀�觿��诿櫒栀Ȑ\0趍﷠￿橑謁ౕ譒ࡅ袋М\0퇿삅մ跩\0ༀ閷﷠￿䖋༈袷࠾\0턻ɴ盫喋脈㛂刀薋﷤￿譐ࡍ醋Д\0틿쒃蔈痀譓ࡅ褀��跿ﱍ橑贄��勿䖋謈⒈儀ｪ喋謈₂＀跐ﱍ橑贅譒ࡅ袋Ш\0橑诿ࡕ芋Р\0탿쉝쳌쳌쳌쳌쳌즋譐⑄茌￸⍵ｘ倒䒋ࠤ鱠è\0嬀￿卐￾鷿塡⣂堀ዿ⣂찀쳌쳌쳌쳌쳌邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐`劁眿邐邐邐邐邐邐犡瞕⍤瞓慌瞔靷睁盠屖瞔C:\\Program Files\\360\\360safe\\saf', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('249', '23', 'G08_017', '0', '病毒性肝炎中医疗效判定标准( 试行)', '无', '中国中医药学会内科肝病专业委员会', '1992', '中医杂志, 1992(06): 53.', '中文', '1.急性肝炎<br />&nbsp;&nbsp;2.慢性迁延性肝炎<br />&nbsp;&nbsp;3.慢性活动性肝炎', '病毒性肝炎', '未提及', '未提及', '未提及', '未提及', '未提及', '1 急性肝炎<br />&nbsp;&nbsp;1.1基本治愈:( 1) 该证候中的主次证消失,( 2) 肝脏恢复正常或明显回缩, 肝区无明显压痛或叩痛;( 3) 肝功能检查恢复正常,(4) 妇对乙型肝炎病人要求H B s A g 阴转; (5 ) 以上各项随访半年无复发者。<br />&nbsp;&nbsp;1.2治愈: 除要求随访1 年无异常改变外, 其余各项与基本治愈标准相同。<br />&nbsp;&nbsp;2 慢性迁延性肝炎<br />&nbsp;&nbsp;2.1临床基本治愈:( 1) 该证候的主次证消失,( 2) 肝脏恢复正常或明显回缩, 肝区无明显压痛或叩痛,( 3) 肝功能检查恢复正常,(4) 畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭쒠ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᢂఄਘĀ\0ః彿㎽奋㎽巫㎽瀞ఄ贮ఄ彿㎽财ఄ塚㎽贮ఄꍈ㏂\0\0ᢂఄ學㎽漸㏂圔㎽ᢂఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0취ਘ䐺盭暼痭취ਘༀƙ \0취ਘĀ\0\0㺣盭취ਘ\0ﱔ췬ਘ\0팃目췬ਘ࣎췬ਘ큁目췬ਘᢶఄ﫬\0Item\0\0趲ఄ\0\0\0\0\0\0Count\0\0ﱬﬄ츜ਘᏜ௷\0\0췬ਘ\0\0\0\0௷寶目Ꮰ௷矵䥷㎽瀞ఄ\0\0趲ఄ�㏂财ఄ\0\0\0௷\0\0\0謁ﱔ\0\0㎾ࡤ\0ﱜ\0\0x�㏂财ఄ\0\0隲W趲ఄ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\0霪W露W\0\0ﱴxt\0Љ\0\0\0렘௥鲬࣎菮畻\0\0\0\0ጰ௷Eo\0\0ᎄ௷\0\0⑰ਫ਼⑰ਫ਼ᎈ௷ាఄ寶目ᎈ௷ាఄi\0\0ﱄ﷜ﱴﲔ먙㎼ាఄᎈ௷i\0\0ﱄ﷜ﱴ먰㎼﷜ាఄ�㏂ᜦఄ\0\0릎㎼ាఄi\0╪췬目╾췬目Љ\0镴࣎\0￿￿目Љ\0镨࣎렘௥竗렘௥目W\0竗\0\0\0賓器目\0\0\0\0ᢶఄ\0目瑉浥目\0\0\0\0ᢶఄ\0目潃湵t\0\0\0\0ǵ\0\0ဠ\0\0侠̓ﯬ侠̓̙\0\0\0\0\0\0\0̙῰̓\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0῰̓\0\0\0\0̙ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚЉ\0\0\0⟒췬⟚췬目Љ\0鲸࣎\0￿￿目Љ\0鲬࣎렘௥觴렘௥目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨាఄ目潅f摲敳t盡燎捥盦通묞￾￿吊盡璀ৄ+௧ै璀綻眶4\0ৄ+\0\0ඞḁ.\0\0\0\0䛌E\0덐ɫ‾Q岛@\0⎐ۓ﮵S豀ɳ\0덐ɫ\0﯏S臀ɳ\0豀ɳ\0䛌E\0뛀ɫ‾Q岛@\0䛌E\0템瞕풒瞕(\0', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('25', '32', 'G02_013', '1', 'VA/DoD 血脂异常治疗临床实践指南', 'VA/DoD CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF DYSLIPIDEMIA', '国防部退伍军人事务部（Department of Veterans Affairs Department of Defense）', '2006', 'http://www.healthquality.va.gov/guidelines/CD/lipids/lip05_950_final2.pdf', '英文', null, '高脂血症', null, null, '脂质水平最好是空腹状态下获得的。然而,如果测试在非空腹状态下,只有TC和HDL的值将是可用的。在低风险的人(0 - 1风险因素),如果高密度脂蛋白胆固醇水平> 40 mg / dL,TC是< 200 mg/dL，则不需要进一步的测试。有多个(2 +)风险因素的人,低密度脂蛋白水平需要作为指导临床管理。<br />&nbsp;&nbsp;\n建议：\n1.应该获得患者空腹血脂与其他冠状动脉疾病的危险因素。(A)<br />&nbsp;&nbsp;\n2.临床决策要基于相距1到8周 (禁食)的血脂水平，LDL-L或TC的差异< 30 mg / dL。[I] <br />&nbsp;&nbsp;\n3. 8周内急性住院、手术、外伤或感染的血脂水平不考虑,除非采集12 - 24小时内的数据,以确保准确性。[I] <br />&nbsp;&nbsp;\n4.孕妇产后三四个月内不测量血脂水平[I] <br />&nbsp;&nbsp;\nLipid levels are preferably obtained in a fasting state. However, if the testing opportunity is nonfasting, only the values for TC and HDL will be usable. In otherwise low-risk persons (0–1 risk factor), further testing is not required if the HDL-C level is > 40 mg/dL and TC is <200 mg/dL. For persons with multiple (2+) risk factors, LDL-C levels are needed as a guide to clinical management.<br />&nbsp;&nbsp;\nRECOMMENDATIONS<br />&nbsp;&nbsp;\n1. A complete fasting lipid profile should be obtained in an individual with other risk factors for coronary disease. [A] <br />&nbsp;&nbsp;\n2. Clinical decisions should be based upon lipid profiles done 1 to 8 weeks apart (fasting) with an LDL-C or TC difference of <30 mg/dL. [I] <br />&nbsp;&nbsp;\n3. Lipid profiles should not be obtained within 8 weeks of acute hospitalization, surgery, trauma, or infection unless they are obtained within 12-24 hours of the event to ensure accuracy. [I] <br />&nbsp;&nbsp;\n4. Lipid profiles should not be measured in pregnant women until three to four months post partum. [I] <br />&nbsp;&nbsp;\nG02_013_01_血脂分类.docx', null, 'LDL-C', 'G02_013_02_治疗目标', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('250', '23', 'G08_018', '1', '慢性乙型肝炎防治指南(2010年版)', 'The guideline of prevention and treatment for chronic hepatitis B(2010 version)', '中华医学会肝病学分会中华医学会感染病学分会', '2010', '中国预防医学杂志, 2011(01): 1_15.', '中文', '1慢性乙型肝炎<br />&nbsp;&nbsp;2乙型肝炎肝硬化<br />&nbsp;&nbsp;2.1代偿期肝硬化<br />&nbsp;&nbsp;2.2失代偿期肝硬化<br />&nbsp;&nbsp;3携带者<br />&nbsp;&nbsp;3.1慢性HBV携带者<br />&nbsp;&nbsp;3.2非活动性HBsAg携带者<br />&nbsp;&nbsp;4隐匿性慢性乙型肝炎', '慢性乙型肝炎', '未提及', '未提及', '既往有乙型肝炎病史或HBsAg阳性超过6个月，现HBsAg和(或)HBV DNA仍为阳性者，可诊断为慢性HBV感染。根据HBV感染者的血清学、病毒学、生物化学试验及其他临床和辅助检查结果，可将慢性HBV感染分为：<br />&nbsp;&nbsp;1慢性乙型肝炎<br />&nbsp;&nbsp; 1.1 HBeAg阳性慢性乙型肝炎：血清HBsAg、HBeAg阳性、抗一HBe阴性，HBV DNA阳性，ALT持续或反复升高，或肝组织学检查有肝炎病变。<br />&nbsp;&nbsp;1.2 HBeAg阴性慢性乙型肝炎：血清HBsAg阳性，HBeAg持续阴性，抗一HBe阳性或阴性，HBVDNA阳性，ALT持续或反复异常，或肝组织学检查有肝炎病变。根据生物化学试验及其他临床和辅助检查结果，上述两型慢性乙型肝炎也可进一步分为轻度、中度和重度。<br />&nbsp;&nbsp;2乙型肝炎肝硬化<br />&nbsp;&nbsp;乙型肝炎肝硬化是慢性乙型肝炎发展的结果，其病理学定义为弥漫性肝纤维化伴有假小叶形成。<br />&nbsp;&nbsp;2.1代偿期肝硬化：一般属Child—Push A级。影像学、生物化学或血液学检查有肝细胞合成功能障碍或门静脉高压症(如脾功能亢进及食管胃底静脉曲张)证据，或组织学符合肝硬化诊断，但无食管胃底静脉曲张破裂出血、腹水或肝性脑病等严重并发症。<br />&nbsp;&nbsp;2.2失代偿期肝硬化：一般属Child—Pugh B、C级。患者已发生食管胃底静脉曲张破裂出血、肝性脑病、腹水等严重并发症。亦可将代偿期和失代偿期肝硬化再分为活动期或静止期。<br />&nbsp;&nbsp;3携带者<br />&nbsp;&nbsp;3.1慢性HBV携带者：多为处于免疫耐受期的HBsAg、HBeAg和HBV DNA阳性者，1年内连续随访3次以上均显示血清ALT和AST在正常范围，肝组织学检查无明显异常。<br />&nbsp;&nbsp;3.2非活动性HBsAg携带者：血清HBsAg阳性、HBeAg阴性、抗一HBe阳性或阴性，HBV DNA低于最低检测限，1年内连续随访3次以上，ALT均在正常范围。肝组织学检查显示Knodell肝炎活动指数(HAl)<4或根据其他的半定量计分系统判定病变轻微。<br />&nbsp;&nbsp;4隐匿性慢性乙型肝炎<br />&nbsp;&nbsp;血清HBsAg阴性，但血清和(或)肝组织中HBVDNA阳性，并有慢性乙型肝炎的临床表现。除HBV DNA阳性外，患者可有血清抗一HBs、抗一HBe和(或)抗一HBc阳性，但约20％隐匿性慢性乙型肝炎患者的血清学标志均为阴性。诊断需排除其他病毒及非病毒因素引起的肝损伤。', '未提及', '未提及', '慢性乙型肝炎治疗的总体目标是：最大限度地长期抑制HBV，减轻肝细胞炎症坏死及肝纤维化，延缓和减少肝脏失代偿、肝硬化、HCC及其并发症的发生，从而改善生活质量和延长存活时间。慢性乙型肝炎治疗主要包括抗病毒、免疫调节、抗炎和抗氧化、抗纤维化和对症治疗，其中抗病毒治疗是关键，只要有适应证，且条件允许，就应进行规范的抗病毒治疗', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('251', '23', 'G08_019', '0', '慢性乙型肝炎中医诊疗专家共识(2012年1月)', 'Guidelines for traditional Chinese medical diagnosis of chromc hepatitis B', '中华中医药学会内科肝胆病学组，世界中医药联合学会肝病专业委员会，中国中西医结合学会肝病分组', '2012', '临床肝胆病杂志, 2012(03): 164_168.', '中文', '未提及', '慢性乙型肝炎', '未提及', '1湿热蕴结证<br />&nbsp;&nbsp;2肝郁气滞证<br />&nbsp;&nbsp;3肝郁脾虚证<br />&nbsp;&nbsp;4肝肾阴虚证<br />&nbsp;&nbsp;5脾肾阳虚证<br />&nbsp;&nbsp;6瘀血阻络证', '未提及', '1湿热蕴结证<br />&nbsp;&nbsp;主症：①身目黄染，黄色鲜明；②小便黄赤；③口干苦或口臭；④舌苔黄腻。次症：①脘闷，或纳呆，或腹胀；②恶心或呕吐；③大便秘结或粘滞不畅；④胸胁胀；⑤脉弦滑或滑数。凡具备主症中2项加次症2项，可定为本证。<br />&nbsp;&nbsp;2肝郁气滞证<br />&nbsp;&nbsp;主症：①两胁胀痛；②善太息，嗳气稍舒；③情志抑郁。次症：①胸闷；②腹胀；③嗳气；④乳房胀痛或结块；⑤舌质淡红，苔薄白或薄黄，脉弦。凡具备主症中2项加次症2项，可定为本证。<br />&nbsp;&nbsp;3肝郁脾虚证<br />&nbsp;&nbsp;主症：①胁肋胀痛；②情绪抑郁；③纳差或食后胃脘胀满；④倦怠乏力。畻坴畿\0\0\0\0醼畻聱盯\r\0\0\0痭�ਘༀƙ\0ਘĀ\0\r\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᢂఄਘĀ\0ః彿㎽奋㎽巫㎽毦ఄ讶ఄ彿㎽讪ఄ塚㎽讶ఄꍈ㏂\0\0ᢂఄ學㎽漸㏂圔㎽ᢂఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0쒠ਘ䐺盭暼痭쒠ਘༀƙ \0쒠ਘ`\0\0㺣盭쒠ਘ\0ﱔ쒤ਘ\0팃目쒤ਘ࣎쒤ਘ큁目쒤ਘᢶఄ﫬\0Item\0\0谺ఄ\0\0\0\0\0\0Count\0\0ﱬﬄ쓔ਘᏜ௷\0\0쒤ਘ\0\0\0\0௷寶目Ꮰ௷矵䥷㎽毦ఄ\0\0谺ఄ�㏂讪ఄ\0\0\0௷\0\0\0謁ﱔ\0\0㎾Ղ\0ﱜ\0\0x�㏂讪ఄ\0\0隲W谺ఄ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\r\0霪W露W\0\0ﱴxt\0Љ\0\0\0렘௥鲬࣎菮畻\0\0\0\0ጰ௷Eo\0\0ᎄ௷\0\0⑰ਫ਼⑰ਫ਼ᎈ௷ាఄ寶目ᎈ௷ាఄi\0\0ﱄ﷜ﱴ', '1 生化学应答血清ALT、AST、TBil<br />&nbsp;&nbsp;2 病毒学应答血清HBV DNA<br />&nbsp;&nbsp;3 血清学应答血清HBeAg<br />&nbsp;&nbsp;4 组织学应答肝脏组织学炎症坏死或纤维化程度<br />&nbsp;&nbsp;5 中医证候疗效', '1 生化学应答血清ALT、AST、TBil恢复正常。<br />&nbsp;&nbsp;2 病毒学应答血清HBV DNA检测不到(PCR法)或低于检测下限，或较基线下降一>2log10<br />&nbsp;&nbsp;3 血清学应答血清HBeAg转阴或HBeAg血清学转换或HBsAg转阴或HBsAg血清学转换。<br />&nbsp;&nbsp;4 组织学应答肝脏组织学炎症坏死或纤维化程度改善达到某一规定值。<br />&nbsp;&nbsp;5 中医证候疗效<br />&nbsp;&nbsp;显效：临床症状、体征明显改善，中医证候积分减少≥70％。<br />&nbsp;&nbsp;有效：临床症状、体征均有好转，中医证候积分减少≥30％。<br />&nbsp;&nbsp;无效：临床症状、体征畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭�ਘༀƙ\0ਘĀ\0\0㺣盭\0\0', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('252', '23', 'G08_020', '1', '亚太地区慢性乙型肝炎治疗共识(2012最新版)', 'Asian—pacific∞nsensas statement OH the management of chronic hepatitis B：a 20 1 2 update', '亚太肝病学会慢性乙型肝炎治疗共识工作组', '2012', '临床肝胆病杂志, 2012(08): 641_661.', '中文', '未提及', '慢性乙型肝炎', '未提及', '未提及', '未提及', '未提及', '未提及', '慢性HBV感染的治疗目标: 现已明确活动性HBV复制是肝损伤和疾病进展的主要驱动因素，因此持续抑制病毒至关重要闱。。慢性乙型肝炎抗病毒治疗的主要目的是持久抑制HBV复制，从而减低病毒的感染性和致病性，减轻肝脏坏死性炎症。临床治疗的短期目标是获得仞始应答，即HBeAg血清学转换和(或)HBV DNA抑制、ALT正常和防肝功能失代偿；在治疗期间和治疗后确保“维持／持续应答”以减轻肝脏坏死性炎症和纤维化。治疗的最终和长期目标是防止肝功能失代偿，减轻或阻止进展为肝硬化和(或)HCC，延长生存期”。', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('253', '23', 'G08_021', '1', '慢性乙型肝炎指南', 'Chronic Hepatitis B (CHB) Recommendations', '澳大利亚胃肠病学会(GESA,Gastroenterological Seciety of Australia)', '2009', 'http://guide.medlive.cn/guideline/205', '英文', '1. 新获得的感染(newly acquired infections)<br />&nbsp;&nbsp;2. 慢性感染(chronic infection)', '慢性乙型肝炎', '未提及', '未提及', '乙肝表面抗原(HBsAg)或血清中HBV DNA的检测证实了乙型肝炎病毒感染。除了病人接触史,血清学可以帮助确定是否新感染或慢性感染。<br />&nbsp;&nbsp;1. 新获得感染的诊断需要符合下列其中之一：<br />&nbsp;&nbsp;1.1 病人的HBsAg指标在过去24个月内是阴性的。<br />&nbsp;&nbsp;1.2 HBsAg和HBcIgM缺乏先前感染慢性乙型肝炎的证据。<br />&nbsp;&nbsp;1.3 HBV DNA和HBcIgM缺乏先前感染慢性乙型肝炎的证据。<br />&nbsp;&nbsp;2. 慢性感染的诊断要求：<br />&nbsp;&nbsp;2.1 病人血清HBsAg 或者 HBV DNA (PCR )检测两次至少相距6个月。<br />&nbsp;&nbsp;2.2 没有急性乙型肝炎的临床或实验室证据。(HBV infection is confirmed by the detection of hepatitis B surface antigen (HBsAg) or HBV DNA in serum. In addition to patient exposure history, serology can assist in determining whether infections are newly acquired or chronic.<br />&nbsp;&nbsp;1. Diagnosis of newly acquired infections requires one of the following:<br />&nbsp;&nbsp;1.1 HBsAg in a patient shown to be negative within the last 24 months<br />&nbsp;&nbsp;1.2 HBsAg and high levels of specific IgM to hepatitis B core antigen (HBcIgM) in the absence of prior evidence of HBV infection. <br />&nbsp;&nbsp;1.3 HBV DNA and high levels of specific IgM to hepatitis B core antigen (HBcIgM) in the absence of prior evidence of HBV infection . <br />&nbsp;&nbsp;2. Diagnosis of chronic infection requires: <br />&nbsp;&nbsp;2.1 Detection of HBsAg or HBV DNA (PCR ) in the serum of a patient on two occasions at least six months apart. <br />&nbsp;&nbsp;2.2 No clinical or laboratory evidence of acute hepatitis B. <br />&nbsp;&nbsp;)', '未提及', '未提及', '1.治疗目标：主要目标是通过预防或延缓肝硬化和肝细胞癌的发展改善病人生存。<br />&nbsp;&nbsp;2.治疗目的：关键治疗目的是：<br />&nbsp;&nbsp;2.1 HBV DNA抑制(< 2000 IU/mL；PCR检测< 60 IU/mL) <br />&nbsp;&nbsp;2.2 HbsAg消失和血清转变<br />&nbsp;&nbsp;2.3 HBeAg消失和血清转变<br />&nbsp;&nbsp;2.4 生化和组织学改善<br />&nbsp;&nbsp;根除乙型肝炎病毒感染目前没有可行的治疗，为了防止进一步的肝损伤，治疗的主要目的是保持HBV DNA抑制(< 2000 IU/mL)。长期病毒抑制与减少坏死性炎症、肝纤维化和肝硬化有关畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭취ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᢂఄਘĀ\0ః彿㎽奋㎽巫㎽瀞ఄ贮ఄ彿㎽财ఄ塚㎽贮ఄꍈ㏂\0\0ᢂఄ學㎽漸㏂圔㎽ᢂఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0취ਘ䐺盭暼痭취ਘༀƙ \0취ਘ`\0\0㺣盭취ਘ\0ﱔ췬ਘ\0팃目췬ਘ࣎췬ਘ큁目췬ਘᢶఄ﫬\0Item\0\0趲ఄ\0\0\0\0\0\0Count\0\0ﱬﬄ츜ਘᏜ௷\0\0췬ਘ\0\0\0\0௷寶目Ꮰ௷矵䥷㎽瀞ఄ\0\0趲ఄ�㏂财ఄ\0\0\0௷\0\0\0謁ﱔ\0\0㎾ീ\0ﱜ\0\0x�㏂财ఄ\0\0隲W趲ఄ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\0霪W露W\0\0ﱴxt\0Љ\0\0\0렘௥鲬࣎菮畻\0\0\0\0ጰ௷Eo\0\0ᎄ௷\0\0⑰ਫ਼⑰ਫ਼ᎈ௷ាఄ寶目ᎈ௷ាఄi\0\0ﱄ﷜ﱴﲔ먙㎼ាఄᎈ௷i\0\0ﱄ﷜ﱴ먰㎼﷜ាఄ�㏂ᜦఄ\0\0릎㎼ាఄi\0╪췬目╾췬目Љ\0镴࣎\0￿￿目Љ\0镨࣎렘௥竗렘௥目W\0竗\0\0\0賓器目\0\0\0\0ᢶఄ\0目瑉浥目\0\0\0\0ᢶఄ\0目潃湵t\0\0\0\0ǵ\0\0ဠ\0\0侠̓ﯬ侠̓̙\0\0\0\0\0\0\0̙῰̓\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0῰̓\0\0\0\0̙ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚЉ\0\0\0⟒췬⟚췬目Љ\0鲸࣎\0￿￿目Љ\0鲬࣎렘௥觴렘௥目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨាఄ目潅f摲敳t盡燎捥盦通묞￾￿吊盡璀ৄ+௧ै璀綻眶4\0ৄ+\0\0ඞḁ.\0\0\0\0䛌E\0덐ɫ‾Q岛@\0⎐ۓ﮵S豀ɳ\0덐ɫ\0﯏S臀ɳ\0豀ɳ\0䛌E\0뛀ɫ‾Q岛@\0䛌E\0템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂奈瞒⫠\0\0\0瞒⪌쀕瞒若〠\0䪔㏂\0T\0\0⪌쀕\0\0ꀀ翽翽凜瞒郎瘝䪔㏂\0邰ƙ\0\0ࠀᴒ眊\0\0䪔㏂瘝\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ﫜ាఄﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀勤﬘眿捻ฒ趲ఄ﫨ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿﫜￿￿\0\0﫦\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ\0\0\0\0\0奰畿⫡췬臭焚畻邰ƙࠀ﫜￿￿㏂￿￿\0\0\0\0愈煔畻:\0﫜￿￿㏂￿￿奰畿\0\0\0\0﬘㎾ࠄ\0\0﫜￿￿㏂㎾x\0\0�㏂财ఄ\0\0頲Wאּ\0\0\0\0ࠄ\0顇WValu\0\0﫜שּׁ趲ఄﱜ\0\0\0\0\0\0﫜\0﫨\0ﰰ餀Wﱜﲈ	\0ﳸ\0\0ह	\0\n\0\0\0\0\0尴ঽ\0\0ﮀ⮒췬ﮀ뜩@﷩\0\0\0\0ﮠ䗧@ﭸ蕶@हﱰ﯌\0뮩@ﮰ믆@믎@ﱰ﷩\0釚@ﱰﱰ﷩\0ༀƙﱴༀƙ﯐戤痝\0Ɨ\0\0蜈ਝﯴఃః忉㎽豦ఄ奁㎽ః	\0豲ఄ贮ఄ彿㎽ﱤ䦕盭贮ఄ	\0贮ఄ忉㎽ﱔ䥷盭贮ఄ\0\0	\0ﱬ趲ఄﱴ馘Bﱜﳸxﲈﲈ駰Bﱴ尐ঽᗀ৺\0ఄ\0\0ﱔ︜ﱜx︜x︄ﳸxﲔx︜ﲠx︜︸x︜\0\0尐ঽ뿄x\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0\0\0ᢶఄ䗆@	\0ᢶఄ趲ఄ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('254', '23', 'G08_022', '1', '特殊的感染—乙型肝炎病毒感染的处理和治疗', 'Management and Treatment of Specific Infections Hepatitis B Virus Infection', '加拿大公共卫生署(PHAC,Public Health Agency of Canada)', '2006', 'http://guide.medlive.cn/guideline/37', '英文', '1.急性乙型肝炎感染（Acute hepatitis B infection）<br />&nbsp;&nbsp;2.慢性乙型肝炎（Chronic hepatitis B）', '乙型肝炎', '未提及', '未提及', '尽管HBV 是亲肝的并且肝脏是感染的唯一的器官，病毒血症也可能会导致免疫复合物形成的相关临床表现。<br />&nbsp;&nbsp;1. 所有正在评估性传播感染的患者应该询问他们的疫苗接种史，风险史，黄疸病史和先前的肝炎检测结果。<br />&nbsp;&nbsp;2. 临床上急性乙型肝炎感染通常是不明显的， 50 - 70%的成人病例无症状。有症状的病例可能是非特异性症状（疲劳、恶心、呕吐、厌食、皮疹、关节痛），少数的病例表现为黄疸，这些可以与其他病毒或重度导致的肝炎项区别。<br />&nbsp;&nbsp;3. 慢性乙型肝炎可以检测到HBsAg的持久性，可能是也可能不是与肝转氨酶的高度有关，它通常无症状，直到出现肝硬化、门脉高压或肝细胞癌的临床体征。<br />&nbsp;&nbsp;3.1 肝血清学可以检测一些潜在迹象<br />&nbsp;&nbsp;3.2 诊断急性感染症状的人<br />&nbsp;&nbsp;3.3 检测慢性无症状感染的人<br />&nbsp;&nbsp;3.4 作为一个预先免疫识别哪些无免疫力的人可能受益于乙肝疫苗接种。<br />&nbsp;&nbsp;4. 乙肝血清学标志物参见G08_022_图表1。<br />&nbsp;&nbsp;5. 选择血清学检查急性或慢性病例取决于临床情况和应该补充的肝功能、肝转氨酶检测。对于那些anti-HBs和anti-HBc抗体发展前可能在窗口期的HBsAg阳性患者，anti-HBc IgM阳性证实早期感染。<br />&nbsp;&nbsp;6. 在接种疫苗之前是否需要需要预选高危人群，以及血清学的检测筛查的最佳选择是有争议的，对于高危人群和后续进展时无法保证的，明智的做法是在血液筛查血清学之后给首次剂量的疫苗。<br />&nbsp;&nbsp;7. 评估一个高风险的人的身份不应该推迟免疫。(Although HBV is hepatotropic and the liver is the sole site of infection, viremia may lead to clinical manifestations related to immune complex formation. <br />&nbsp;&nbsp;1. All patients being assessed for STIs should be asked about their vaccination history, risk history, previous icteric illness and previous hepatitis testing. <br />&nbsp;&nbsp;2. Acute hepatitis B infection is often not clinically apparent, with 50–70% of adult cases being asymptomatic. Symptomatic cases may be non-specific (fatigue, nausea, vomiting, anorexia, rash, arthralgia). A smaller proportion of cases are icteric; these can be clinically indistinguishable from other viral or toxic causes of hepatitis. <br />&nbsp;&nbsp;3.Chronic hepatitis B can be detected by persistence of HBsAg, may or may not be associated with elevations in hepatic transaminases and is generally asymptomatic until clinical signs of cirrhosis, portal hypertension or hepatocellular carcinoma supervene. <br />&nbsp;&nbsp;3.1 Hepatitis serologic testing can be done for a number of potential indications: <br />&nbsp;&nbsp;3.2 To diagnose acute infection in symptomatic persons. <br />&nbsp;&nbsp;3.3To detect chronic infection in asymptomatic persons. <br />&nbsp;&nbsp;3.4 As a preimmunization screen to identify non-immune persons who may benefit from hepatitis B vaccination. <br />&nbsp;&nbsp;4. See G08_022_ Table 1 for serologic markers for hepatitis B. <br />&nbsp;&nbsp;The choice of serologic testing for suspected acute or chronic cases is determined by the clinical situation and should be supplemented by the addition of liver function testing and hepatic transaminases. For those who are HBsAg positive, who may be in the window period before development of anti-HBs and anti-HBc antibodies, a positive anti-HBc IgM confirms that this is due to early infection. <br />&nbsp;&nbsp;5 There is controversy surrounding the need to prescreen high-risk individuals before vaccination, as well as the optimal choice of serologic tests for screening. For those at high risk and for whom follow-up cannot be ensured, it is prudent to give the first dose of vaccine on the initial visit after drawing blood for screeningserology. <br />&nbsp;&nbsp;6 Evaluating the status of a high-risk person should not delay immunization)', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('255', '23', 'G08_023', '1', '乙型肝炎病毒感染', 'Hepatitis B Virus Infections', '加拿大公共卫生署(PHAC,Public Health Agency of Canada)', '2008', 'http://guide.medlive.cn/guideline/2653', '英文', '1.急性乙型肝炎感染（Acute hepatitis B infection）<br />&nbsp;&nbsp;2.慢性乙型肝炎（Chronic hepatitis B）', '乙型肝炎', '未提及', '未提及', '尽管HBV 是亲肝的并且肝脏是感染的唯一的器官，病毒血症也可能会导致免疫复合物形成的相关临床表现。<br />&nbsp;&nbsp;1. 所有正在评估性传播感染的患者应该询问他们的疫苗接种史，风险史，黄疸病史和先前的肝炎检测结果。<br />&nbsp;&nbsp;2. 临床上急性乙型肝炎感染通常是不明显的， 50 - 70%的成人病例无症状。有症状的病例可能是非特异性症状（疲劳、恶心、呕吐、厌食、皮疹、关节痛），少数的病例表现为黄疸，这些可以与其他病毒或重度导致的肝炎项区别。<br />&nbsp;&nbsp;3. 慢性乙型肝炎可以检测到HBsAg的持久性，可能是也可能不是与肝转氨酶的高度有关，它通常无症状，直到出现肝硬化、门脉高压或肝细胞癌的临床体征。<br />&nbsp;&nbsp;3.1 肝血清学可以检测一些潜在迹象<br />&nbsp;&nbsp;3.2 诊断急性感染症状的人<br />&nbsp;&nbsp;3.3 检测慢性无症状感染的人<br />&nbsp;&nbsp;3.4 作为一个预先免疫识别哪些无免疫力的人可能受益于乙肝疫苗接种。<br />&nbsp;&nbsp;4. 乙肝血清学标志物参见G08_023_图表1。<br />&nbsp;&nbsp;5. 选择血清学检查急性或慢性病例取决于临床情况和应该补充的肝功能、肝转氨酶检测。对于那些anti-HBs和anti-HBc抗体发展前可能在窗口期的HBsAg阳性患者，anti-HBc IgM阳性证实早期感染。<br />&nbsp;&nbsp;6. 在接种疫苗之前是否需要需要预选高危人群，以及血清学的检测筛查的最佳选择是有争议的，对于高危人群和后续进展时无法保证的，明智的做法是在血液筛查血清学之后给首次剂量的疫苗。<br />&nbsp;&nbsp;7. 评估一个高风险的人的身份不应该推迟免疫。(Although HBV is hepatotropic and the liver is the sole site of infection, viremia may lead to clinical manifestations related to immune complex formation. <br />&nbsp;&nbsp;1. All patients being assessed for STIs should be asked about their vaccination history, risk history, previous icteric illness and previous hepatitis testing. <br />&nbsp;&nbsp;2. Acute hepatitis B infection is often not clinically apparent, with 50–70% of adult cases being asymptomatic. Symptomatic cases may be non-specific (fatigue, nausea, vomiting, anorexia, rash, arthralgia). A smaller proportion of cases are icteric; these can be clinically indistinguishable from other viral or toxic causes of hepatitis. <br />&nbsp;&nbsp;3.Chronic hepatitis B can be detected by persistence of HBsAg, may or may not be associated with elevations in hepatic transaminases and is generally asymptomatic until clinical signs of cirrhosis, portal hypertension or hepatocellular carcinoma supervene. <br />&nbsp;&nbsp;3.1 Hepatitis serologic testing can be done for a number of potential indications: <br />&nbsp;&nbsp;3.2 To diagnose acute infection in symptomatic persons. <br />&nbsp;&nbsp;3.3To detect chronic infection in asymptomatic persons. <br />&nbsp;&nbsp;3.4 As a preimmunization screen to identify non-immune persons who may benefit from hepatitis B vaccination. <br />&nbsp;&nbsp;4. See G08_023_ Table 1 for serologic markers for hepatitis B. <br />&nbsp;&nbsp;The choice of serologic testing for suspected acute or chronic cases is determined by the clinical situation and should be supplemented by the addition of liver function testing and hepatic transaminases. For those who are HBsAg positive, who may be in the window period before development of anti-HBs and anti-HBc antibodies, a positive anti-HBc IgM confirms that this is due to early infection. <br />&nbsp;&nbsp;5 There is controversy surrounding the need to prescreen high-risk individuals before vaccination, as well as the optimal choice of serologic tests for screening. For those at high risk and for whom follow-up cannot be ensured, it is prudent to give the first dose of vaccine on the initial visit after drawing blood for screeningserology. <br />&nbsp;&nbsp;6 Evaluating the status of a high-risk person should not delay immunization)', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('256', '23', 'G08_024', '1', '丙型肝炎指南：美国肝病研究学会-美国感染病学会对成人HCV感染的检测、管理和治疗建议', 'HEPATITIS C GUIDANCE: AASLD-IDSA RECOMMENDATIONS FOR TESTING, MANAGING, AND TREATING ADULTS INFECTED WITH HEPATITIS C VIRUS', '美国肝病研究学会(AASLD,American Association for the Study of Liver Diseases); 美国感染病学会(IDSA,Infectious Diseases Society of America)', '2015', 'http://guide.medlive.cn/guidelinesub/2847', '英文', '未提及', '丙型肝炎', '未提及', '未提及', '以下建议可作为ＨＣＶ急性感染的诊断与治疗流程：<br />&nbsp;&nbsp;1.存在暴露因素临床症状和转氨酶升高而怀疑急性ＨＣＶ感染者，推荐检测抗－ＨＣＶ抗体和ＨＣＶＲＮＡ以明确诊断。（Ｉ－Ｃ）<br />&nbsp;&nbsp;2.实验室指标的监测：急性ＨＣＶ感染者在６～１２个月内，建议每４～８周检测１次肝功能及ＨＣＶＲＮＡ，直至ＡＬＴ正常和ＨＣＶＲＮＡ检测不到，表明病毒已自发清除。（Ｉ－Ｂ）<br />&nbsp;&nbsp;3.如果在ＨＣＶ急性感染期决定抗病毒治疗，建议治疗前监测ＨＣＶＲＮＡ至少１２～１６周，以了解治疗前病毒是否自发清除。（Ⅱａ－Ｃ）<br />&nbsp;&nbsp;4.如果医生和患者均同意推迟治疗，至少观察６个月病毒是否自发清除。（Ⅱａ－Ｃ）<br />&nbsp;&nbsp;5.建议急性ＨＣＶ感染者多进行必要的咨询来避免肝损伤，包括损肝药物（如对乙酰氨基酚类）和饮酒，并避免传染给他人。（Ⅰ －Ｃ）<br />&nbsp;&nbsp;6.对于急性ＨＣＶ感染且仍静脉注射毒品者，建议由１位成瘾医学专家作指导。（Ⅰ －Ｂ）(The following are recommended in the diagnosis and initial management of acute hepatitis C <br />&nbsp;&nbsp;1.HCV antibody and HCV RNA testing are recommended when acute HCV infection is suspected due to exposure, clinical presentation, or elevated aminotransferase levels. (I-C) <br />&nbsp;&nbsp;2.Regular laboratory monitoring (every 4 weeks to 8 weeks for 6 months to 12 months) is recommended in the setting of acute HCV infection until the alanine aminotransferase (ALT) level normalizes and HCV RNA becomes repeatedly undetectable, suggesting spontaneous resolution. (I-B) <br />&nbsp;&nbsp;3.If a decision has been made to initiate treatment during the acute infectionperiod, monitoring HCV RNA for at least 12 weeks to 16 weeks is recommended to detect spontaneous clearance before starting treatment. (IIa-C) <br />&nbsp;&nbsp;4.If the practitioner and patient have decided that a delay in treatment initiation is acceptable, monitoring for spontaneous clearance is recommended for a minimum of 6 months. (IIa-C) <br />&nbsp;&nbsp;5.Counseling is recommended for patients with acute HCV infection to avoid hepatotoxic insults, including hepatotoxic drugs (e.g., acetaminophen) and alcohol consumption, and to reduce the risk of HCV transmission to others. (I C) <br />&nbsp;&nbsp;6.Referral to an addiction medicine specialist is recommended for patients with acute HCV infection related to injection drug use. (I-B))', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('257', '23', 'G08_025', '1', '急性病毒性肝炎检测-美国，2006', 'Surveillance for Acute Viral Hepatitis —United States, 2006', '美国疾病控制与预防中心(CDC,Centers for Disease Control and Prevention)', '2006', 'http://guide.medlive.cn/guideline/42', '英文', '1.急性甲型肝炎（Acute hepatitis A）<br />&nbsp;&nbsp;2.急性乙型肝炎（Acute hepatitis B）<br />&nbsp;&nbsp;3.急性丙型肝炎（Acute hepatitis C）', '急性病毒性肝', '未提及', '未提及', '1.急性病毒性肝炎病例的定义<br />&nbsp;&nbsp;2006年，病例需要满足以下CSTE认可的病例定义中规定的急性肝炎的临床定义和特异性实验室诊断标准。<br />&nbsp;&nbsp;2.临床病例定义<br />&nbsp;&nbsp;急性肝炎被定义为具有①离散发病的症状（如，恶心、厌食、发热、不适或腹痛）②黄疸或血清转氨酶水平升高的急性疾病。<br />&nbsp;&nbsp;3.肝炎的实验室诊断标准<br />&nbsp;&nbsp;由于所有类型的急性病毒性肝炎的临床特点是相同的，实验室检测才能确定具体的何种病毒引起的疾病。每种类型的急性病毒性肝炎的实验室诊断标准如下：<br />&nbsp;&nbsp;3.1急性甲型肝炎：<br />&nbsp;&nbsp;甲肝病毒免疫球蛋白M(IgM)抗体(anti-HAV)阳性。<br />&nbsp;&nbsp;3.2急性乙型肝炎<br />&nbsp;&nbsp;①乙型肝炎核心抗原(anti-HBc)I gM抗体阳性或乙型肝炎表面抗原(HBsAg)阳性和<br />&nbsp;&nbsp;②IgM anti-HAV阴性(如果执行) <br />&nbsp;&nbsp;3.3急性丙型肝炎<br />&nbsp;&nbsp;①血清丙氨酸转氨酶水平高于正常上限的7倍，和<br />&nbsp;&nbsp;②IgM anti-HAV阴性，和<br />&nbsp;&nbsp;③IgM anti-HBc阴性，或者如果不执行，HBsAg阴性，和<br />&nbsp;&nbsp;④以下其中之一：<br />&nbsp;&nbsp;另一个更加特异的检验证实丙型肝炎病毒抗体(anti-HCV)检测阳性（如，重组免疫印迹法检测anti-HCV，或者核酸检测HCV RNA）<br />&nbsp;&nbsp;或者，一个特异检测证实一个显著的预测值Anti-HCV更加真实的阳性（如：>3.8 或酶免疫测定）。（1.Case Definitions for Acute Viral Hepatitis<br />&nbsp;&nbsp;In 2006, cases were required to meet the clinical definition for acute hepatitis and virus-specific laboratory criteria for diagnosis specified in the following CSTE-approved case definitions. <br />&nbsp;&nbsp;2.Clinical Case Definition<br />&nbsp;&nbsp;Acute hepatitis was defined as acute illness with 1) discrete onset of symptoms (e.g., nausea, anorexia, fever, malaise, or abdominal pain) and 2) jaundice or elevated serum aminotransferase levels. <br />&nbsp;&nbsp;3.Laboratory Criteria for Diagnosis of Hepatitis<br />&nbsp;&nbsp;Because the clinical characteristics are the same for all types of acute viral hepatitis, laboratory testing is needed to identify the specific viral cause of illness. The laboratory criteria for confirming each type of acute viral hepatitis are as follows: <br />&nbsp;&nbsp;3.1Acute hepatitis A<br />&nbsp;&nbsp;Immunoglobulin M (IgM) antibody to hepatitis A virus (anti-HAV) positive<br />&nbsp;&nbsp;3.2Acute hepatitis B<br />&nbsp;&nbsp;①IgM antibody to hepatitis B core antigen (anti-HBc) positive or hepatitis B surface antigen (HBsAg) positive and<br />&nbsp;&nbsp;②IgM anti-HAV negative (if performed) <br />&nbsp;&nbsp;3.3Acute hepatitis C<br />&nbsp;&nbsp;①Serum alanine aminotransferase levels higher than seven times the upper limit of normal, and②IgM anti-HAV negative, and<br />&nbsp;&nbsp;③IgM anti-HBc negative, or if not performed, HBsAg negative, and<br />&nbsp;&nbsp;④One of the following<br />&nbsp;&nbsp;Antibody to hepatitis C virus (anti-HCV) screening-test-positive, verified by an additional more specific assay (e.g., RIBA for anti-HCV or nucleic acid testing for HCV RNA)，OR<br />&nbsp;&nbsp;Anti-HCV screening-test positive with a signal to cut-off ratio predictive of a true positive as determined for the particular assay (e.g., >3.8 or the enzyme immunoassays). <br />&nbsp;&nbsp;）', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('258', '23', 'G08_026', '1', '儿童时期慢性乙型肝炎的诊治指南: 欧洲儿科胃肠病学、肝病学和营养协会临床实践指南', 'Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines Consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition', '欧洲儿科胃肠病学、肝病学和营养协会(ESPGHAN,European Society for Paediatric Gastroenterology, Hepatology, and Nutrition)', '2013', 'http://guide.medlive.cn/guideline/5522', '英文', '未提及', '慢性乙型肝炎', '未提及', '未提及', '未提及', '未提及', '1.生化学应答(Biochemical response) <br />&nbsp;&nbsp;2.HBeAg 的血清学应答(Serological response for HBeAg) <br />&nbsp;&nbsp;3.病毒学应答(Virological response ) <br />&nbsp;&nbsp;4.完全应答(Complete response) <br />&nbsp;&nbsp;5.治疗结束后持续病毒学应答(Sustained off-treatment virological response) <br />&nbsp;&nbsp;6.维持病毒学应答(Maintained virological respons畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭쒠ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᢂఄਘĀ\0ః彿㎽奋㎽巫㎽渂ఄ豲ఄ彿㎽豦ఄ塚㎽豲ఄꍈ㏂\0\0ᢂఄ學㎽漸㏂圔㎽ᢂఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0취ਘ䐺盭暼痭취ਘༀƙ \0취ਘĀ\0\0㺣盭취ਘ\0ﱔ췬ਘ\0팃目췬ਘ', '治疗终点及应答的定义<br />&nbsp;&nbsp;儿童和成人抗HBV 治疗的目标都是通过减少肝病进展、肝硬化及HCC 的风险来改善长期生存率和生活质量。<br />&nbsp;&nbsp;对所有患者来说，理想的治疗终点是持续HBsAg 清除，因为这样可中止疾病进展，减少HCC 的风险，尽管这种理想的情况只发生在极少数接受治疗的患者（A1）。如果没有获得HBsAg 血清学清除，对于HBeAg 阳性患者，停止治疗后持续病毒抑制（用敏感的实时PCR 试剂测不出HBV DNA）和与此相关的持久的HBeAg 血清学转换，也是一个好的终点，与预后的改善包括降低HCC畻坴畿\0\0\0\0醼畻聱盯\0\0\0畿Ɉե́\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ᢂఄ\0\0\0\0\0\0垱㎽\0\0\0贮ఄ彿㎽财ఄ塚㎽贮ఄꍈ㏂\0\0ᢂఄ學㎽漸㏂圔㎽ᢂఄ圞㎽\0\0圭㎽쁞ఈༀƙ \0ༀƙ戤痝\0Ɨ\0\0취ਘ䐺盭暼痭취ਘༀƙ \0취ਘĀ\0\0㺣盭취ਘ\0췬ਘ\0팃目췬ਘ࣎췬ਘ큁目췬ਘᢶఄ\0Item\0\0趲ఄ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0츜ਘᏜ௷\0\0췬ਘ\0\0\0\0寶目Ꮰ௷壑䥷㎽瀞ఄ\0\0趲ఄ�㏂财ఄ\0\0\0௷\0\0\0\0\0㎾◬\0\0\0x�㏂财ఄ\0\0隲W趲ఄ\0\0�Ĳ\0\0\0\0\0霈W霫Wﲈx\0쁞ఈ㚰௣Ā\0ÿ\0	\0㙼௣㐼௣຺ೂ댔ఈ쁞ఈ\n\0 \0쀀ఈꀀ఍ᠹೂ\0\0\0\0\0醼畻擃㈆\0\0ÿ\0庮㈆ﶪ௵ÿ\0\0\0ꃆ఍썍೅ༀƙÿ\0ༀƙ戤痝\0Ɨ\0\0☠੎䐺盭暼痭☠੎ༀƙÿ\0☠੎ \0\0\0㺣盭☠੎ \0\0 \0㐒췬目Љ\0镴࣎\0￿￿目Љ\0镨࣎렘௥竗렘௥目W\0竗\0\0\0目\0\0\0\0ᢶఄ\0目瑉浥က௶Ɉ௶룀ఈ܄௶룀ఈɈ௶рೂԎೂ떔ఈ\0\0\0T01糖尿病$\0펀ࡕ볨ೂꖒ఍칻ೂ\0\0\0\0\0\0ꗿ\0ߠ఍\0ೂ఍㉾ೂ\0\0ߠ\0ߠ\0©\0眜㐘⼜೅(\0(\0댔ఈ(\0㖴ೂ\0(\0\0\0\0㞴௣捥盦Ȓ묞￾￿옎盡伛盡\0\0ގդ\0\0\0\0\0\0\0\0\0\0ꃪ఍⊢췭歐Ʃﶈ௵\0\0\0﫧￿Ɛ捥盦\0\0\0\0\0\0\0\0\0\0ꃪ఍⁕封依盡ﶈ௵Ɛ\0\0\0﫧￿奸瞔ༀƙ︄ༀƙ戤痝\0Ɨ\0\0௫䐺盭暼痭௫ༀƙ︄௫ᧀ\0\0㺣盭௫΀\0\0︄΀\0䡰盭௫ﱈ\0ﱴ顠B顥B駵B︄ﱜ鵫B\0\0駯B擅@\0\0\0\0က擤@\0\0\0\0\0\0燙瞔ﱈﱈ爔瞔ﱈ熫瞔ﱈ駰B\0ﱈﮁ瞑喘瞔ﮮ瞑\0\0\0\0\0\0鵑屧 \0\0\0\0〲㌱\0\0\0邰ƙ\0\0ࠀ﬍鶢屧염屧\0\0\0\0\0邰ƙ\0\0ࠀាఄﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀﬘眿ฒ趲ఄﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿￿￿\0\0\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ\0\0\0\0\0奰畿㦅췬焚畻邰ƙࠀ￿￿㏂￿￿\0\0\0\0煔畻:\0￿￿㏂￿￿奰畿\0\0\0\0㎾ࠄ\0\0￿￿㏂㎾x\0\0�㏂财ఄ\0\0頲W\0\0\0\0ࠄ\0顇WValu\0\0趲ఄ\0\0\0\0\0\0\0\0餀W	\0ﳘ\0\0\0\0鋠ఈɈե妀畿鋠ఈ鋘ఈ쬱畻\0Ɨ癢畻㩪췬끜㐗⫠଩翠\0翠\0\0鋠ఈెȂ�畼ꚮ뢅￾￿癢畻㮒೅\0\0䅳೅Ɍե\0\0鋠ఈᤸ௣鋰ఈ\0\0䉁೅鋰ఈꩠఈ다ఈ㢰௣ꩠఈ䂐೅鋰ఈ\0\0\0\0\0\0ᜲఄ贮ఄ彿㎽䦕盭贮ఄ	\0贮ఄ忉㎽䥷盭贮ఄﲈ	\0趲ఄ馘Bﳘxﲈ駰B\0\0x\0ఄ\0\0︜x︜x︄ﳘx\0\0魠盁ह\0\0\0\0\0\0燙瞔ﲈ燭瞔ﲈ熫瞔ﲈx\0\0ﲈ履瞑ﲈxఌက\0Ɨ⏰௰瞑￾￿愓瞕帠瞕☊\0☠\0ᅂ௱ᅀ௱妀畿Ȱե́\0‘\0௰௰妀畿r\0\0ကë瀷瞔쀀\0\0\0魠盁\0\0\0က?\0\0\0\0\0\0\0\0\0\0\0\0ቲ\0䀠\0￿\0䠞@ܺﺜহ#\0\0\0\0\0\0\0\0\0ꀀ䀂\0\0\0\0\0\0\0\0耀㿿䃦�쫌䀽ﾸ돳⑄졎쀼뀀挷䀨鿗䀴Nb\\䀽\0\0\0\0;\0#\0#\0ఌက\0\0Ƃ\0ᘈ魠盁\0Ȃ!#\0ቲ䀠\0ܺ䠞@\0ﺜহ#\0ᾠ\0￿\0\0\0\0\0\0\0\0\0\0\0\0ꀀ䀂\0\0\0\0\0\0\0\0\0\0\0\0\0\0耀㿿\0\0\0䃦�쫌䀽\0\0\0ﾸ돳⑄졎쀼\0\0\0뀀挷䀨鿗䀴\0\0\0Nb\\䀽\0\0\0\0\0\0\0\0\0\0\0 activity has not been used as a criterion to evaluate r\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0怀\0\0ఀ評樮葇帵ꇘ￿￿\0\0\0ﴴ￿ˤ\0ﴴ￿ˌ\0\0\0\0◬\0젤ఌ䘨盭젤ఌ◬\0䪂ఄ☀\0\0\0嗯㎽ༀƙ嘿㎽◬\0财ఄ瀞ఄﬔx\0\0\0瀞ఄః�ਘ治疗终点及应答的定义<br />&nbsp;&nbsp;儿童和成人抗HBV 治疗的目标都是通过减少肝病进展、肝硬化及HCC 的风险来改善长期生存率和生活质量。<br />&nbsp;&nbsp;对所有患者来说，理想的治疗终点是持续HBsAg 清除，因为这样可中止疾病进展，减少HCC 的风险，尽管这种理想的情况只发生在极少数接受治疗的患者（A1）。如果没有获得HBsAg 血清学清除，对于HBeAg 阳性患者，停止治疗后持续病毒抑制（用敏感的实时PCR 试剂测不出HBV DNA）和与此相关的持久的HBeAg 血清学转换，也是一个好的终点，与预后的改善包括降低HCC畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭쒠ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᢂఄਘĀ\0ః彿㎽奋㎽巫㎽瀞ఄ贮ఄ彿㎽财ఄ塚㎽贮ఄꍈ㏂\0\0ᢂఄ學㎽漸㏂圔㎽ᢂఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0쒠ਘ䐺盭暼痭쒠ਘༀƙ \0쒠ਘĀ\0\0㺣盭쒠ਘ\0ﱔ쒤ਘ\0팃目쒤ਘ࣎쒤ਘ큁目쒤ਘᢶఄ﫬\0Item\0\0趲ఄ\0\0\0\0\0\0Count\0\0ﱬﬄ쓔ਘᏜ௷\0\0쒤ਘ\0\0\0\0௷寶目Ꮰ௷矵䥷㎽瀞ఄ\0\0趲ఄ�㏂财ఄ\0\0\0௷\0\0\0謁ﱔ\0\0㎾◬\0ﱜ\0\0x�㏂财ఄ\0\0隲W趲ఄ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0擤@ﬔﱈ擤@ﬔ\0\0ﱜx\0霪W露W\0\0ﱴxt\0Љ\0\0\0렘௥鲬࣎菮畻\0\0\0\0ጰ௷Eo\0\0ᎄ௷\0\0⑰ਫ਼⑰ਫ਼ᎈ௷ាఄ寶目ᎈ௷ាఄi\0\0ﱄ﷜ﱴﲔ먙㎼ាఄᎈ௷i\0\0ﱄ﷜ﱴ먰㎼﷜ាఄ�㏂ᜦఄ\0\0릎㎼ាఄi\0╪췬目╾췬目Љ\0镴࣎\0￿￿目Љ\0镨࣎렘௥竗렘௥目W\0竗\0\0\0賓器目\0\0\0\0ᢶఄ\0目瑉浥目\0\0\0\0ᢶఄ\0目潃湵t\0\0\0\0ǵ\0\0ဠ\0\0侠̓ﯬ侠̓̙\0\0\0\0\0\0\0̙῰̓\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0῰̓\0\0\0\0̙ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚЉ\0\0\0⟒췬⟚췬目Љ\0鲸࣎\0￿￿目Љ\0鲬࣎렘௥觴렘௥目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨាఄ目潅f摲敳t盡燎捥盦通묞￾￿吊盡璀ৄ+௧ै璀綻眶4\0ৄ+\0\0ඞḁ.\0\0\0\0䛌E\0덐ɫ‾Q岛@\0⎐ۓ﮵S豀ɳ\0덐ɫ\0﯏S臀ɳ\0豀ɳ\0䛌E\0뛀ɫ‾Q岛@\0䛌E\0템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂奈瞒⫠\0\0\0瞒⪌쀕瞒若〠\0䪔㏂\0T\0\0⪌쀕\0\0ꀀ翽翽凜瞒郎瘝䪔㏂\0邰ƙ\0\0ࠀᴒ眊\0\0䪔㏂瘝\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ﫜ាఄﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀勤﬘眿捻ฒ趲ఄ﫨ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿﫜￿￿\0\0﫦\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ\0\0\0\0\0奰畿⫡췬臭焚畻邰ƙࠀ﫜￿￿㏂￿￿\0\0\0\0愈煔畻:\0﫜￿￿㏂￿￿奰畿\0\0\0\0﬘㎾ࠄ\0\0﫜￿￿㏂㎾x\0\0�㏂财ఄ\0\0頲Wאּ\0\0\0\0ࠄ\0顇WValu\0\0﫜שּׁ趲ఄﱜ\0\0\0\0\0\0﫜\0﫨\0ﰰ餀Wﱜﲈ	\0ﳸ\0\0⚼ु̌\0Բ\0\0\0\0\0⌜ɲ\0\0ﮀ⮒췬ﮀ뜩@﷩\0\0\0ǟ\0ﮠ䗧@ﭸ蕶@⚰ुﱰ﯌Ǡ\0뮩@ﮰ믆@믎@ﱰ﷩\0釚@ﱰﱰ﷩\0ༀƙﱴༀƙ﯐戤痝\0Ɨ\0\0젠ఌﯴఃః忉㎽豦ఄ奁㎽ః	\0豲ఄ贮ఄ彿㎽ﱤ䦕盭贮ఄ	\0贮ఄ忉㎽ﱔ䥷盭贮ఄ\0\0	\0ﱬ趲ఄﱴ馘Bﱜﳸxﲈﲈ擤@ﱴ嬸ঽᗀ৺\0ఄ\0\0ﱔ︜ﱜx︜x︄ﳸxﲔ抴@︜ﲠx︜︸x︜\0\0嬸ঽ뿄x\0\0\0\0\0\0\0\0	瞕ᢶఄ\0盁	ᢶఄ趲ఄ\0\0	\0\0\0ᢶఄ䗆@	\0ᢶఄ趲ఄ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0ʎCᢶఄ︜Cᢶఄ\0\0\0\0\0ఄ\0\0\0\0ఄ﷜￿\0\0\0\0\0\0￿\0\0\0\0\0เ৺\0\0\0ﺄ\0\0ﺈ焐ɪ\0ఄ\0\0ﱔ︜\0\0䑬֮ﺐ嵿{ﹸ\0\0\0\0\0ﺄ﹄庱{ﺐﺘ彨{ﺐ\0\0\0\0ﺰ୩ڬ৅ﹼ邏S\0\0ㄐ঵\0\0춀ɯ\0\0\0焐ɪ\0\0﫼হ\0\0ﻨⰛEﺤⰺEﻨﺰⱹEﻨﺼⳗEﻨﻰ⳶Eﻨ\0\0\0\0穠म\0\0\0\0宰ঽﺀ୩ﻰĒ８䳫Tｄ䴙T８\0\0\0\0츐ɳ\0\0\0\0\0Ā츐ɳｬ㻨T਌\0\0\0\0\0\0燹āǵ\0Ǉ\0ꋴĵ䈆Tｐ䈐Tｬｸ䉉Tｬ\0\0\0\0ꋴĵ츐ɳﾈ잜Ĳꀀ翽ￄ枴@ﾈ\0\0ﾔ眿ꀀ翽ￔ㭓瞖ꀀ翽ᮒ眊\0\0\0\0ꀀ翽\0\0\0\0\0\0ﾠ\0\0￿￿瞑\0\0￬㬦瞖얼Ĳꀀ翽\0\0\0\0\0\0\0\0얼Ĳꀀ翽\0\0譕召�䖋倌䶋謈ᢑ＀菒ӄ䶋༈醷ش\0숻Ѵ쀳⏫䖋倌䶋脈ⳁ儀喋謈ᒂ＀菐ࣄ�쀛삃嬁쉝쳌쳌쳌쳌쳌쳌삋鱠è\0堀%￰￿⑴倨탿삅ᕵ憝è\0堀%￰诿Ҁ＀㏠觀⑄鴠쉡쳌쳌쳌邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐譕臬⣬였웿옒웂온贀�觿��诿櫒栀Ȑ\0趍﷠￿橑謁ౕ譒ࡅ袋М\0퇿삅մ跩\0ༀ閷﷠￿䖋༈袷࠾\0턻ɴ盫喋脈㛂刀薋﷤￿譐ࡍ醋Д\0틿쒃蔈痀譓ࡅ褀��跿ﱍ橑贄��勿䖋謈⒈儀ｪ喋謈₂＀跐ﱍ橑贅譒ࡅ袋Ш\0橑诿ࡕ芋Р\0탿쉝쳌쳌쳌쳌쳌즋譐⑄茌￸⍵ｘ倒䒋ࠤ鱠è\0嬀￿卐￾鷿塡⣂堀ዿ⣂찀쳌쳌쳌쳌쳌邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐`劁眿邐邐邐邐邐邐犡瞕⍤瞓慌瞔靷睁盠屖瞔C:\\Program Files\\360\\360safe\\safemon\\safemon.dll\0邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('259', '23', 'G08_027', '1', '欧洲肝脏研究学会临床实践指南：慢性乙型肝炎病毒感染的管理', 'EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection', '欧洲肝脏研究学会(EASL,European Association for the Study of the Liver)', '2012', 'http://guide.medlive.cn/guideline/2870', '英文', '未提及', '慢性乙型肝炎', '未提及', '未提及', '未提及', '未提及', '未提及', '1.治疗目标<br />&nbsp;&nbsp;治疗目标是提高CHB患者的生活质量和延长生存期，防止疾病进展为肝硬化、失代偿期肝硬化、终末期肝病、肝癌和死亡。<br />&nbsp;&nbsp;如果可以持续地抑制乙肝病毒复制，这个目标可以实现。然后,减少相应的慢乙肝肝硬化组织学活动的风险和降低肝癌的风险，尤其是在非肝硬化病人。然而,慢性乙型肝炎病毒感染不能完全根除取决于在被感染的肝细胞的细胞核中共价闭合环状DNA的持久性(cccDNA)，这或许可以解释乙肝病毒复活。此外，乙肝病毒基因组整合到宿主基因组，这可能会导致肿瘤的形成和肝细胞癌的发展。<br />&nbsp;&nbsp;2.治疗终畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭취ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᢂఄਘĀ\0ః彿㎽奋㎽巫㎽瀞ఄ贮ఄ彿㎽财ఄ塚㎽贮ఄꍈ㏂\0\0ᢂఄ學㎽漸㏂圔㎽ᢂఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0취ਘ䐺盭暼痭취ਘༀƙ \0취ਘĀ\0\0㺣盭취ਘ\0ﱔ췬ਘ\0팃目췬ਘ࣎췬ਘ큁目췬ਘᢶఄ﫬\0Item\0\0趲ఄ\0\0\0\0\0\0Count\0\0ﱬﬄ츜ਘᏜ௷\0\0췬ਘ\0\0\0\0௷寶目Ꮰ௷矵䥷㎽瀞ఄ\0\0趲ఄ�㏂财ఄ\0\0\0௷\0\0\0謁ﱔ\0\0㎾ᓾ\0ﱜ\0\0x�㏂财ఄ\0\0隲W趲ఄ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\0霪W露W\0\0ﱴxt\0Љ\0\0\0렘௥鲬࣎菮畻\0\0\0\0ጰ௷Eo\0\0ᎄ௷\0\0⑰ਫ਼⑰ਫ਼ᎈ௷ាఄ寶目ᎈ௷ាఄi\0\0ﱄ﷜ﱴﲔ먙㎼ាఄᎈ௷i\0\0ﱄ﷜ﱴ먰㎼﷜ាఄ�㏂ᜦఄ\0\0릎㎼ាఄi\0╪췬目╾췬目Љ\0镴࣎\0￿￿目Љ\0镨࣎렘௥竗렘௥目W\0竗\0\0\0賓器目\0\0\0\0ᢶఄ\0目瑉浥目\0\0\0\0ᢶఄ\0目潃湵t\0\0\0\0ǵ\0\0ဠ\0\0侠̓ﯬ侠̓̙\0\0\0\0\0\0\0̙῰̓\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0῰̓\0\0\0\0̙ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚЉ\0\0\0⟒췬⟚췬目Љ\0鲸࣎\0￿￿目Љ\0鲬࣎렘௥觴렘௥目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨាఄ目潅f摲敳t盡燎捥盦通묞￾￿吊盡璀ৄ+௧ै璀綻眶4\0ৄ+\0\0ඞḁ.\0\0\0\0䛌E\0덐ɫ‾Q岛@\0⎐ۓ﮵S豀ɳ\0덐ɫ\0﯏S臀ɳ\0豀ɳ\0䛌E\0뛀ɫ‾Q岛@\0䛌E\0템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂奈瞒⫠\0\0\0瞒⪌쀕瞒若〠\0䪔㏂\0T\0\0⪌쀕\0\0ꀀ翽翽凜瞒郎瘝䪔㏂\0邰ƙ\0\0ࠀᴒ眊\0\0䪔㏂瘝\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ﫜ាఄﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀勤﬘眿捻ฒ趲ఄ﫨ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿﫜￿￿\0\0﫦\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ\0\0\0\0\0奰畿⫡췬臭焚畻邰ƙࠀ﫜￿￿㏂￿￿\0\0\0\0愈煔畻:\0﫜￿￿㏂￿￿奰畿\0\0\0\0﬘㎾ࠄ\0\0﫜￿￿㏂㎾x\0\0�㏂财ఄ\0\0頲Wאּ\0\0\0\0ࠄ\0顇WValu\0\0﫜שּׁ趲ఄﱜ\0\0\0\0\0\0﫜\0﫨\0ﰰ餀Wﱜﲈ	\0ﳸ\0\0ह	\0\n\0\0\0\0\0嬬ঽ\0\0ﮀ⮒췬ﮀ뜩@﷩\0\0\0\0ﮠ䗧@ﭸ蕶@हﱰ﯌\0뮩@ﮰ믆@믎@ﱰ﷩\0釚@ﱰﱰ﷩\0ༀƙﱴༀƙ﯐戤痝\0Ɨ\0\0穠ਝﯴఃః忉㎽豦ఄ奁㎽ః	\0豲ఄ贮ఄ彿㎽ﱤ䦕盭贮ఄ	\0贮ఄ忉㎽ﱔ䥷盭贮ఄ\0\0	\0ﱬ趲ఄﱴ馘Bﱜﳸxﲈﲈ駰Bﱴ寠ঽᗀ৺\0ఄ\0\0ﱔ︜ﱜx︜x︄ﳸxﲔx︜ﲠx︜︸x︜\0\0寠ঽ뿄x\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0\0\0ᢶఄ䗆@	\0ᢶఄ趲ఄ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0ʎCᢶఄ︜Cᢶఄ\0\0\0\0\0ఄ\0\0\0\0ఄ﷜￿\0\0\0\0\0\0￿\0\0\0\0\0เ৺\0\0\0ﺄ\0\0ﺈ焐ɪ\0\0\0蜌ਝ\0\0\0\0ꐜभﺐ嵿{ﹸ\0\0\0\0\0ﺄ﹄庱{ﺐﺘ彨{ﺐ\0\0\0\0ﺰ୩ڬ৅ﹼ邏S\0\0ㄐ঵\0\0춀ɯ\0\0\0焐ɪ\0\0৺\0\0ﻨⰛEﺤⰺEﻨﺰⱹEﻨﺼⳗEﻨﻰ⳶Eﻨ\0\0\0\0穠म\0\0\0\0宰ঽﺀ୩ﻰĒ８䳫Tｄ䴙T８\0\0\0\0츐ɳ\0\0\0\0\0Ā츐ɳｬ㻨T਌\0\0\0\0\0\0燹āǵ\0Ǉ\0ꋴĵ䈆Tｐ䈐Tｬｸ䉉Tｬ\0\0\0\0ꋴĵ츐ɳﾈ잜Ĳꀀ翽ￄ枴@ﾈ\0\0ﾔ眿ꀀ翽ￔ㭓瞖ꀀ翽ᮒ眊\0\0\0\0ꀀ翽\0\0\0\0\0\0ﾠ\0\0￿￿瞑\0\0￬㬦瞖얼Ĳꀀ翽\0\0\0\0\0\0\0\0얼Ĳꀀ翽\0\0譕召�䖋倌䶋謈ᢑ＀菒ӄ䶋༈醷ش\0숻Ѵ쀳⏫䖋倌䶋脈ⳁ儀喋謈ᒂ＀菐ࣄ�쀛삃嬁쉝쳌쳌쳌쳌쳌쳌삋鱠è\0堀%￰￿⑴倨탿삅ᕵ憝è\0堀%￰诿Ҁ＀㏠觀⑄鴠쉡쳌쳌쳌邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐譕臬⣬였웿옒웂온贀�觿��诿櫒栀Ȑ\0趍﷠￿橑謁ౕ譒ࡅ袋М\0퇿삅մ跩\0ༀ閷﷠￿䖋༈袷࠾\0턻ɴ盫喋脈㛂刀薋﷤￿譐ࡍ醋Д\0틿쒃蔈痀譓ࡅ褀��跿ﱍ橑贄��勿䖋謈⒈儀ｪ喋謈₂＀跐ﱍ橑贅譒ࡅ袋Ш\0橑诿ࡕ芋Р\0탿쉝쳌쳌쳌쳌쳌즋譐⑄茌￸⍵ｘ倒䒋ࠤ鱠è\0嬀￿卐￾鷿塡⣂堀ዿ⣂찀쳌쳌쳌쳌쳌邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐`劁眿邐邐邐邐邐邐犡瞕⍤瞓慌瞔靷睁盠屖瞔C:\\Program Files\\360\\360safe\\safemon\\safemon.dll\0邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('26', '32', 'G02_014', '1', '2009CCS 指南推荐：成人血脂异常的诊断_治疗及心血管疾病预防', '2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of\ndyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations', '加拿大心血管协会(Canadian Cardiovascular Society)', '2009', 'http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2782500/', '英文', null, '高脂血症', null, null, 'G02_014_01_血脂水平目标.docx', null, ' LDL-C;TC/HDL', 'G02_014_02_治疗目标.docx', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('260', '23', 'G08_028', '1', '欧洲肝脏研究学会丙型肝炎的治疗建议2015', 'EASL Recommendations on Treatment of Hepatitis C 2015', '欧洲肝脏研究学会(EASL,European Association for the Study of the Liver)', '2015', 'http://guide.medlive.cn/guideline/8297', '英文', '1.急性丙型肝炎（acute hepatitis C）<br />&nbsp;&nbsp;2.慢性乙型肝炎（chronic hepatitis C）', '丙型肝炎', '未提及', '未提及', '急性和慢性丙型肝炎的诊断<br />&nbsp;&nbsp;1.判定是否存在ＨＣＶ感染，首先检测抗ＨＣＶ抗体（Ａ１）。<br />&nbsp;&nbsp;2.疑似急性丙型肝炎或者免疫功能低下患者，则同时还需检测ＨＣＶＲＮＡ（Ａ１）。<br />&nbsp;&nbsp;3.如果抗ＨＣＶ抗体检测阳性，则需采用灵敏的分子诊断法检测ＨＣＶＲＮＡ（Ａ１）。<br />&nbsp;&nbsp;4.抗ＨＣＶ阳性、ＨＣＶＲＮＡ阴性的患者，应在３个月后再次检测ＨＣＶＲＮＡ以确认病毒获得清除（Ａ１）。<br />&nbsp;&nbsp;(Diagnosis of acute and chronic hepatitis C<br />&nbsp;&nbsp;1. Anti-HCV antibodies are the first-line diagnostic test for HCV infection (A1) <br />&nbsp;&nbsp;2.In the case of suspected acute hepatitis C or in immunocompromised patients, HCV RNA testing should be part of the initial evaluation (A1) <br />&nbsp;&nbsp;3.If anti-HCV antibodies are detected, HCV RNA should be determined by a sensitive molecular method (A1) <br />&nbsp;&nbsp;4.Anti-HCV-positive, HCV RNA negative individuals should be retested for HCV RNA three months later to confirm true convalescence (A1))', '未提及', '未提及', '1.HCV感染的治疗目标是清除病毒，从而阻止进展为肝硬化、失代偿期肝硬化、肝细胞癌（HCC）、严重的肝外表现和死亡（A1）。<br />&nbsp;&nbsp;2.治疗终点是治疗结束后12和24周用灵敏的试剂检测不到HCV RNA（<15 IU/ml），即持续病毒学应答(sustained virological response,SVR)12和SVR 24（A1）。<br />&nbsp;&nbsp;3.对于进展期纤维化和肝硬化患者，清除HCV能减少失代偿的发生率，虽然不能阻止，但是能减少HCC的发生风险。因此这些患者还需要继续进行HCC的监测（A1）。$$畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭취ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᢂఄਘĀ\0ః彿㎽奋㎽巫㎽瀞ఄ贮ఄ彿㎽财ఄ塚㎽贮ఄꍈ㏂\0\0ᢂఄ學㎽漸㏂圔㎽ᢂఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0쒠ਘ䐺盭暼痭쒠ਘༀƙ \0쒠ਘ`\0\0㺣盭쒠ਘ\0ﱔ쒤ਘ\0팃目쒤ਘ࣎쒤ਘ큁目쒤ਘᢶఄ﫬\0Item\0\0趲ఄ\0\0\0\0\0\0Count\0\0ﱬﬄ쓔ਘᏜ௷\0\0쒤ਘ\0\0\0\0௷寶目Ꮰ௷矵䥷㎽瀞ఄ\0\0趲ఄ�㏂财ఄ\0\0\0௷\0\0\0謁ﱔ\0\0㎾࡚\0ﱜ\0\0x�㏂财ఄ\0\0隲W趲ఄ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\0霪W露W\0\0ﱴxt\0Љ\0\0\0렘௥鲬࣎菮畻\0\0\0\0ጰ௷Eo\0\0ᎄ௷\0\0⑰ਫ਼⑰ਫ਼ᎈ௷ាఄ寶目ᎈ௷ាఄi\0\0ﱄ﷜ﱴﲔ먙㎼ាఄᎈ௷i\0\0ﱄ﷜ﱴ먰㎼﷜ាఄ�㏂ᜦఄ\0\0릎㎼ាఄi\0╪췬目╾췬目Љ\0镴࣎\0￿￿目Љ\0镨࣎렘௥竗렘௥目W\0竗\0\0\0賓器目\0\0\0\0ᢶఄ\0目瑉浥目\0\0\0\0ᢶఄ\0目潃湵t\0\0\0\0ǵ\0\0ဠ\0\0侠̓ﯬ侠̓̙\0\0\0\0\0\0\0̙῰̓\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0῰̓\0\0\0\0̙ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚЉ\0\0\0⟒췬⟚췬目Љ\0鲸࣎\0￿￿目Љ\0鲬࣎렘௥觴렘௥目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨាఄ目潅f摲敳t盡燎捥盦通묞￾￿吊盡璀ৄ+௧ै璀綻眶4\0ৄ+\0\0ඞḁ.\0\0\0\0䛌E\0덐ɫ‾Q岛@\0⎐ۓ﮵S豀ɳ\0덐ɫ\0﯏S臀ɳ\0豀ɳ\0䛌E\0뛀ɫ‾Q岛@\0䛌E\0템瞕풒', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('261', '23', 'G08_029', '1', '日本肝脏病学会指南：乙型肝炎病毒感染的管理', 'JSH Guidelines for the Management of Hepatitis B Virus Infection', '日本肝脏学会(JSH,The Japan Society of Hepatology)', '2014', 'http://guide.medlive.cn/guideline/7066', '英文', '未提及', '乙型肝炎', '未提及', '未提及', '乙型重型肝炎：乙型重型肝炎病原学诊断：HBsAg，anti-HBs抗体，anti-IgM-HBc抗体，anti-HBc抗体和HBV DNA水平。测定HBV基因型、前核心区的存在和核心启动子突变的存在也是可取的。<br />&nbsp;&nbsp;( Fulminant hepatitis B: HBsAg, anti-HBs antibody, anti-IgM-HBc antibody, anti-HBc antibody, and HBV DNA levels shouldbe determined in patients with fulminant hepatitis B to make the etiological diagnosis. Determination of HBV genotype and the presence of precore and core promoter mutations is also desirable.)', '未提及', '未提及', '1.持续的乙型肝炎病毒感染患者的抗病毒治疗的目标是防止肝衰竭、抑制肝癌、抑制活动性肝炎和肝纤维化的进展, 从而提高患者的预期寿命和总体生命质量。<br />&nbsp;&nbsp;2.实现这种治疗的目标，HBsAg被认为是最有效的替代指标，抗病毒治疗的长期目标是消除表面HBsAg。3.抗病毒治疗前消除表面HBsAg的三个短期目标是ALT的持续正常化，HBeAg阴性和阳性anti-HBe抗体，和抑制乙肝病毒DNA复制。<br />&nbsp;&nbsp;4.治疗时期的目标是HBV DNA转阴，这适用于慢性肝炎和肝硬化。<br />&nbsp;&nbsp;5.因为预计完成治疗后消除HBeAg畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭쒠ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᢂఄਘĀ\0ః彿㎽奋㎽巫㎽瀞ఄ贮ఄ彿㎽财ఄ塚㎽贮ఄꍈ㏂\0\0ᢂఄ學㎽漸㏂圔㎽ᢂఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0�ਘ䐺盭暼痭�ਘༀƙ \0�ਘĀ\0\0㺣盭�ਘ\0ﱔ�ਘ\0팃目�ਘ࣎�ਘ큁目�ਘᢶఄ﫬\0Item\0\0趲ఄ\0\0\0\0\0\0Count\0\0ﱬﬄ�ਘᏜ௷\0\0�ਘ\0\0\0\0௷寶目Ꮰ௷矵䥷㎽瀞ఄ\0\0趲ఄ�㏂财ఄ\0\0\0௷\0\0\0謁ﱔ\0\0㎾జ\0ﱜ\0\0x�㏂财ఄ\0\0隲W趲ఄ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\0霪W露W\0\0ﱴxt\0Љ\0\0\0렘௥鲬࣎菮畻\0\0\0\0ጰ௷Eo\0\0ᎄ௷\0\0⑰ਫ਼⑰ਫ਼ᎈ௷ាఄ寶目ᎈ௷ាఄi\0\0ﱄ﷜ﱴﲔ먙㎼ាఄᎈ௷i\0\0ﱄ﷜ﱴ먰㎼﷜ាఄ�㏂ᜦఄ\0\0릎㎼ាఄi\0╪췬目╾췬目Љ\0镴࣎\0￿￿目Љ\0镨࣎렘௥竗렘௥目W\0竗\0\0\0賓器目\0\0\0\0ᢶఄ\0目瑉浥目\0\0\0\0ᢶఄ\0目潃湵t\0\0\0\0ǵ\0\0ဠ\0\0侠̓ﯬ侠̓̙\0\0\0\0\0\0\0̙῰̓\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0῰̓\0\0\0\0̙ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚЉ\0\0\0⟒췬⟚췬目Љ\0鲸࣎\0￿￿目Љ\0鲬࣎렘௥觴렘௥目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨាఄ目潅f摲敳t盡燎捥盦通묞￾￿吊盡璀ৄ+௧ै璀綻眶4\0ৄ+\0\0ඞḁ.\0\0\0\0䛌E\0덐ɫ‾Q岛@\0⎐ۓ﮵S豀ɳ\0덐ɫ\0﯏S臀ɳ\0豀ɳ\0䛌E\0뛀ɫ‾Q岛@\0䛌E\0템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂奈瞒⫠\0\0\0瞒⪌쀕瞒若〠\0䪔㏂\0T\0\0⪌쀕\0\0ꀀ翽翽凜瞒郎瘝䪔㏂\0邰ƙ\0\0ࠀᴒ眊\0\0䪔㏂瘝\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ﫜ាఄﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀勤﬘眿捻ฒ趲ఄ﫨ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿﫜￿￿\0\0﫦\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ\0\0\0\0\0奰畿⫡췬臭焚畻邰ƙࠀ﫜￿￿㏂￿￿\0\0\0\0愈煔畻:\0﫜￿￿㏂￿￿奰畿\0\0\0\0﬘㎾ࠄ\0\0﫜￿￿㏂㎾x\0\0�㏂财ఄ\0\0頲Wאּ\0\0\0\0ࠄ\0顇WValu\0\0﫜שּׁ趲ఄﱜ\0\0\0\0\0\0﫜\0﫨\0ﰰ餀Wﱜﲈ	\0ﳸ\0\0ह	\0\n\0\0\0\0\0岔ঽ\0\0ﮀ⮒췬ﮀ뜩@﷩\0\0\0\0ﮠ䗧@ﭸ蕶@हﱰ﯌\0뮩@ﮰ믆@믎@ﱰ﷩\0釚@ﱰﱰ﷩\0ༀƙﱴༀƙ﯐戤痝\0Ɨ\0\0穠ਝﯴఃః忉㎽豦ఄ奁㎽ః	\0豲ఄ贮ఄ彿㎽ﱤ䦕盭贮ఄ	\0贮ఄ忉㎽ﱔ䥷盭贮ఄ\0\0	\0ﱬ趲ఄﱴ馘B', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('262', '23', 'G08_030', '1', '日本肝脏病学会指南：丙型肝炎病毒感染的管理（基因1型和基因2型）', 'JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2', '日本肝脏学会(JSH,The Japan Society of Hepatology)', '2016', 'http://guide.medlive.cn/guideline/10471', '英文', '未提及', '丙型肝炎', '未提及', '未提及', '未提及', '未提及', '未提及', '1.丙型肝炎治疗的目标是改善因持续HCV感染所致慢性肝病的长期预后———尤其是预防肝癌的形成以及肝病相关的死亡。为达到此目标，应进行抗病毒治疗以清除HCV。<br />&nbsp;&nbsp;2.即便干扰素（IFN）治疗后获得HCV RNA清除，也不能完全预防肝癌的形成。<br />&nbsp;&nbsp;3.目前尚不清楚使用无IFN的直接抗病毒药物治疗清除HCV 预防肝癌是否与使用IFN有同等效果。<br />&nbsp;&nbsp;4.即便HCV清除后，仍需对肝癌的形成进行随访以改善长期预后。中老年及晚期肝纤维化患者是肝癌的高危人群，尤需密切监测。<br />&nbsp;&nbsp;(1. The goal o畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭�ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᢂఄਘĀ\0ః彿㎽奋㎽巫㎽瀞ఄ贮ఄ彿㎽财ఄ塚㎽贮ఄꍈ㏂\0\0ᢂఄ學㎽漸㏂圔㎽ᢂఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0�ਘ䐺盭暼痭�ਘༀƙ \0�ਘĀ\0\0㺣盭�ਘ\0ﱔ�ਘ\0팃目�ਘ࣎�ਘ큁目�ਘᢶఄ﫬\0Item\0\0趲ఄ\0\0\0\0\0\0Count\0\0ﱬﬄ�ਘᏜ௷\0\0�ਘ\0\0\0\0௷寶目Ꮰ௷矵䥷㎽瀞ఄ\0\0趲ఄ�㏂财ఄ\0\0\0௷\0\0\0謁ﱔ\0\0㎾ा\0ﱜ\0\0x�㏂财ఄ\0\0隲W趲ఄ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\0霪W露W\0\0ﱴxt\0Љ\0\0\0렘௥鲬࣎菮畻\0\0\0\0ጰ௷Eo\0\0ᎄ௷\0\0⑰ਫ਼⑰ਫ਼ᎈ௷ាఄ寶目ᎈ௷ាఄi\0\0ﱄ﷜ﱴﲔ먙㎼ាఄᎈ௷i\0\0ﱄ﷜ﱴ먰㎼﷜ាఄ�㏂ᜦఄ\0\0릎㎼ាఄi\0╪췬目╾췬目Љ\0镴࣎\0￿￿目Љ\0镨࣎렘௥竗렘௥目W\0竗\0\0\0賓器目\0\0\0\0ᢶఄ\0目瑉浥目\0\0\0\0ᢶఄ\0目潃湵t\0\0\0\0ǵ\0\0ဠ\0\0侠̓ﯬ侠̓̙\0\0\0\0\0\0\0̙῰̓\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0῰̓\0\0\0\0̙ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚЉ\0\0\0⟒췬⟚췬目Љ\0鲸࣎\0￿￿目Љ\0鲬࣎렘௥觴렘௥目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨាఄ目潅f摲敳t盡燎捥盦通묞￾￿吊盡璀ৄ+௧ै璀綻眶4\0ৄ+\0\0ඞḁ.\0\0\0\0䛌E\0덐ɫ‾Q岛@\0⎐ۓ﮵S豀ɳ\0덐ɫ\0﯏S臀ɳ\0豀ɳ\0䛌E\0뛀ɫ‾Q岛@\0䛌E\0템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂奈瞒⫠\0\0\0瞒⪌쀕瞒若〠\0䪔㏂\0T\0\0⪌쀕\0\0ꀀ翽翽凜瞒郎瘝䪔㏂\0邰ƙ\0\0ࠀᴒ眊\0\0䪔㏂瘝\0邰ƙ\0\0ࠀ\0\0\0邰ƙ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('263', '23', 'G08_031', '1', '丙肝病毒感染者的筛查，护理和治疗指南', 'GUIDELINES FOR THE SCREENING,CARE AND TREATMENT OF PERSONS WITH HEPATITIS C INFECTION', '世界卫生组织(WHO,The World Health Organization)', '2014', 'http://guide.medlive.cn/guideline/5658', '英文', '未提及', '丙肝病毒感染者', '未提及', '未提及', '未提及', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('264', '23', 'G08_032', '1', '慢性乙型肝炎感染患者的预防，护理和治疗指南', 'Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection', '世界卫生组织(WHO,The World Health Organization)', '2015', 'http://guide.medlive.cn/guideline/8018', '英文', '未提及', '慢性乙型肝炎', '未提及', '未提及', '未提及', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('265', '23', 'G08_033', '1', '美国慢性乙型病毒感染的治疗规范：2015年更新', 'A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update', 'keeffe等８名肝病学家组成的美国专家小组', '2015', 'http://guide.medlive.cn/guideline/9861', '英文', '未提及', '慢性乙型病毒感染', '未提及', '未提及', '未提及', '未提及', '未提及', '慢性乙型肝炎的治疗目标是持久清除或显著抑制HBV DNA复制，从而阻止肝病进展为肝硬化、肝衰竭或肝细胞癌。因此，抗病毒治疗的首要直接目标是降低HBV DNA水平，使之持久保持在尽可能的最低水平，进而会达成肝组织学改善和ＡＬＴ复常的目标。反过来,这将促进其他的治疗，包括组织学改善和ALT正常化。HBeAg阳性的初治患者还有另外一个治疗目标，即HBeAg清除和HBeAg／抗－HBe血清学转换，尽管长期口服抗病毒治疗的有效性尚不清楚。HBeAg清除虽然极为理想，但仅有极少数接受抗病毒治疗的患者能达到此目标。$$畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭취ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᢂఄਘĀ\0ః彿㎽奋㎽巫㎽瀞ఄ贮ఄ彿㎽财ఄ塚㎽贮ఄꍈ㏂\0\0ᢂఄ學㎽漸㏂圔㎽ᢂఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0�ਘ䐺盭暼痭�ਘༀƙ \0�ਘĀ\0\0㺣盭�ਘ\0ﱔ�ਘ\0팃目�ਘ࣎�ਘ큁目�ਘᢶఄ﫬\0Item\0\0趲ఄ\0\0\0\0\0\0Count\0\0ﱬﬄ�ਘᏜ௷\0\0�ਘ\0\0\0\0௷寶目Ꮰ௷矵䥷㎽瀞ఄ\0\0趲ఄ�㏂财ఄ\0\0\0௷\0\0\0謁ﱔ\0\0㎾ࣄ\0ﱜ\0\0x�㏂财ఄ\0\0隲W趲ఄ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\0霪W露W\0\0ﱴxt\0Љ\0\0\0렘௥鲬࣎菮畻\0\0\0\0ጰ௷Eo\0\0ᎄ௷\0\0⑰ਫ਼⑰ਫ਼ᎈ௷ាఄ寶目ᎈ௷ាఄi\0\0ﱄ﷜ﱴﲔ먙㎼ាఄᎈ௷i\0\0ﱄ﷜ﱴ먰㎼﷜ាఄ�㏂ᜦఄ\0\0릎㎼ាఄi\0╪췬目╾췬目Љ\0镴࣎\0￿￿目Љ\0镨࣎렘௥竗렘௥目W\0竗\0\0\0賓器目\0\0\0\0ᢶఄ\0目瑉浥目\0\0\0\0ᢶఄ\0目潃湵t\0\0\0\0ǵ\0\0ဠ\0\0侠̓ﯬ侠̓̙\0\0\0\0\0\0\0̙῰̓\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0῰̓\0\0\0\0̙ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚЉ\0\0\0⟒췬⟚췬目Љ\0鲸࣎\0￿￿目Љ\0鲬࣎렘௥觴렘௥目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨាఄ目潅f摲敳t盡燎捥盦通묞￾￿吊盡璀ৄ+௧ै璀綻眶4\0ৄ+\0\0ඞḁ.\0\0\0\0䛌E\0덐ɫ‾Q岛@\0⎐ۓ﮵S豀ɳ\0덐ɫ\0﯏S臀ɳ\0豀ɳ\0䛌E\0뛀ɫ‾Q岛@\0䛌E\0템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂奈瞒⫠\0\0\0瞒⪌쀕瞒若', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('266', '23', 'G08_034', '1', '亚太共识声明：慢性乙型肝炎的治疗：2012年更新', 'Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update', '亚太肝脏研究学会(APASL,Asian-Pacific Association for the Study of the Liver)', '2012', 'http://guide.medlive.cn/guideline/3465', '英文', '未提及', '慢性乙型肝炎', '未提及', '未提及', '未提及', '未提及', '未提及', '慢性HBV感染的治疗目标：现已明确活动性HBV复制是肝损伤和疾病进展的主要驱动因素，因此持续抑制病毒至关重要闱。。慢性乙型肝炎抗病毒治疗的主要目的是持久抑制HBV复制，从而减低病毒的感染性和致病性，减轻肝脏坏死性炎症。临床治疗的短期目标是获得仞始应答，即HBeAg血清学转换和(或)HBV DNA抑制、ALT正常和防止肝功能失代偿；在治疗期间和治疗后确保“维持／持续应答”以减轻肝脏坏死性炎症和纤维化。治疗的最终和长期目标是防止肝功能失代偿，减轻或阻止进展为肝硬化和(或)肝细胞癌，延长生存期。<br />&nbsp;&nbsp;(Goa畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭�ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᢂఄਘĀ\0ః彿㎽奋㎽巫㎽瀞ఄ贮ఄ彿㎽财ఄ塚㎽贮ఄꍈ㏂\0\0ᢂఄ學㎽漸㏂圔㎽ᢂఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0�ਘ䐺盭暼痭�ਘༀƙ \0�ਘĀ\0\0㺣盭�ਘ\0ﱔ�ਘ\0팃目�ਘ࣎�ਘ큁目�ਘᢶఄ﫬\0Item\0\0趲ఄ\0\0\0\0\0\0Count\0\0ﱬﬄ�ਘᏜ௷\0\0�ਘ\0\0\0\0௷寶目Ꮰ௷矵䥷㎽瀞ఄ\0\0趲ఄ�㏂财ఄ\0\0\0௷\0\0\0謁ﱔ\0\0㎾ࣶ\0ﱜ\0\0x�㏂财ఄ\0\0隲W趲ఄ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\0霪W露W\0\0ﱴxt\0Љ\0\0\0렘௥鲬࣎菮畻\0\0\0\0ጰ௷Eo\0\0ᎄ௷\0\0⑰ਫ਼⑰ਫ਼ᎈ௷ាఄ寶目ᎈ௷ាఄi\0\0ﱄ﷜ﱴﲔ먙㎼ាఄᎈ௷i\0\0ﱄ﷜ﱴ먰㎼﷜ាఄ�㏂ᜦఄ\0\0릎㎼ាఄi\0╪췬目╾췬目Љ\0镴࣎\0￿￿目Љ\0镨࣎렘௥竗렘௥目W\0竗\0\0\0賓器目\0\0\0\0ᢶఄ\0目瑉浥目\0\0\0\0ᢶఄ\0目潃湵t\0\0\0\0ǵ\0\0ဠ\0\0侠̓ﯬ侠̓̙\0\0\0\0\0\0\0̙῰̓\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0῰̓\0\0\0\0̙ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚЉ\0\0\0⟒췬⟚췬目Љ\0鲸࣎\0￿￿目Љ\0鲬࣎렘௥觴렘௥目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨាఄ目潅f摲敳t盡燎捥盦通묞￾￿吊盡璀ৄ+௧ै璀綻眶4\0ৄ+\0\0ඞḁ.\0\0\0\0䛌E\0덐ɫ‾Q岛@\0⎐ۓ﮵S豀ɳ\0덐ɫ\0﯏S臀ɳ\0豀ɳ\0䛌E\0뛀ɫ‾Q岛@\0䛌E\0템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂奈瞒⫠\0\0\0瞒⪌쀕瞒若〠\0䪔㏂\0T\0\0⪌쀕\0\0ꀀ翽翽凜瞒郎', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('267', '23', 'G08_035', '1', '阿德福韦酯和干扰素α-2a治疗慢性乙型肝炎', 'Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B', '英国国家卫生与临床优化研究所 (NICE,National Institute for Health and Clinical Excellence)', '2006', 'http://guide.medlive.cn/guideline/20', '英文', '未提及', '慢性乙型肝炎', '未提及', '未提及', '慢性乙型肝炎的诊断是基于血液中特征明显的血清学标记。乙型肝炎病毒DNA(HBV DNA)表现为急性和慢性乙型肝炎。在急性和慢性感染时，乙型肝炎表面抗原(HBsAg)是一种血液中的病毒蛋白检测。慢性乙型肝炎是在急性感染后6个月或更长时间持续的HBsAg 。乙肝“e”抗原(HBeAg)是病毒复制的一个指标，尽管一些变异形式的病毒HBeAg不表达。活跃的感染依据HBeAg是否分泌可以被描述为HBeAg阳性或者HBeAg阴性。<br />&nbsp;&nbsp; (The diagnosis of chronic hepatitis B is based on the presence of well-characterised serological markers in the blood. Hepatitis B viral DNA (HBV DNA) is present in both acute and chronic hepatitis B. Hepatitis B surface antigen (HBsAg) is a viral protein detectable in the blood in both acute and chronic infection. Chronic hepatitis B is defined as persistence of HBsAg for 6 months or more after acute infection. Hepatitis B ‘e’ antigen (HBeAg) is an indicator of viral replication, although some variant forms of the virus do not express HBeAg (see section 2.5.5 below). Active infection can be described as HBeAg-positive or HBeAg-negative according to whether HBeAg is secreted.)', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('268', '23', 'G08_036', '1', '英国国家指南：甲型、乙型和丙型肝炎病毒的管理', 'United Kingdom National Guideline on the Management of the viral hepatitides A, B and C', '英国性健康与艾滋病协会(BASHH,British Association for Sexual Health and HIV)', '2015', 'http://guide.medlive.cn/guideline/10275', '英文', '1.甲型肝炎（Hepatitis A）<br />&nbsp;&nbsp;2.乙型肝炎（Hepatitis B）<br />&nbsp;&nbsp;2.1急性感染（Acute infection）<br />&nbsp;&nbsp;2.2慢性感染（Chronic infection）<br />&nbsp;&nbsp;3.丙型肝炎（Hepatitis C）<br />&nbsp;&nbsp;3.1急性感染（Acute infection）<br />&nbsp;&nbsp;3.2慢性感染（Chronic infection）', '甲型、乙型和丙型肝炎', '未提及', '未提及', '1.甲型肝炎<br />&nbsp;&nbsp;1.1血清学<br />&nbsp;&nbsp;血清甲肝病毒-特异免疫球蛋白(HAV-IgM)阳性确诊，它通常保持阳性45-60天，可能阳性6个月或更长时间。HAV-IgG并不区分现在或过去的感染，它可能终生保持阳性。对所有未确诊何种类型急性肝炎的患者也需检测乙肝病毒，丙肝病毒和戊肝病毒。戊肝病毒在英国与甲肝病毒一样常见，大多数病例是由于吃加工过的猪肉产品出现。<br />&nbsp;&nbsp;1.2其他检测<br />&nbsp;&nbsp;通常，血清/血浆转氨酶(AST / ALT)是在500 - 10000 IU / l，胆红素上升到500 mmoles/l，碱性磷酸酶水平<2倍正常水平，但如果有胆汁淤积会更高。PT延长超过5秒是严重感染的迹象。ALF通常与PT有关，延长50秒或更多。<br />&nbsp;&nbsp;2.乙型肝炎<br />&nbsp;&nbsp;2.1 G08_036_ 图表 1. <br />&nbsp;&nbsp;2.2.1急性感染：见甲型肝炎。<br />&nbsp;&nbsp;2.2.2慢性感染：在大多数情况下，血清转氨酶水平只会轻微异常，大多数肝脏酶正常。<br />&nbsp;&nbsp;3.丙型肝炎<br />&nbsp;&nbsp;3.1血清学<br />&nbsp;&nbsp;3.1.1急性感染<br />&nbsp;&nbsp;近期接触丙肝病毒后，病人HCV-RNA阳性但anti-HCV阴性或者血清转化从anti-HCV阴性到阳性。在急性感染后几个月抗体测试可能不会阳性，但是两周后HCV-RNA测试通常是阳性的(1A).。<br />&nbsp;&nbsp;3.1.2慢性感染<br />&nbsp;&nbsp;①筛选抗体或抗体/抗原酶免疫测定等试验(EIA)或者其他免疫测定最初表现和RNA检测证实了积极感染。②在HIVþ患者低CD4细胞计数(<200 cells/mm3)，EIA可能是阴性的，需要HCV-RNA检测诊断。<br />&nbsp;&nbsp;③如果在第一次检测HCV-RNA阳性后6个月仍阳性确诊慢性感染。<br />&nbsp;&nbsp;④所有的病人都应该做病毒RNA测试以确认病毒血症和丙肝病毒基因型(1A)。<br />&nbsp;&nbsp;3.2其他检查<br />&nbsp;&nbsp;①急性感染——同甲型肝炎<br />&nbsp;&nbsp;②慢性感染——同乙型肝炎<br />&nbsp;&nbsp;(1. Hepatitis A<br />&nbsp;&nbsp;1.1 Serology<br />&nbsp;&nbsp;Confirmed by a positive serum Hepatitis A virus – specific IgM (HAV-IgM) which usually remains positive for 45–60 days, although can be positive for six months or more. HAV-IgG does not distinguish between current or past infection and may remain positive for life. For all patients with an undiagnosed type of acute hepatitis also test for HBV, HCV and hepatitis E (HEV). HEV in the UK is as common as HAV and most cases arise from eating processed pork products. <br />&nbsp;&nbsp;1.2 Other tests. <br />&nbsp;&nbsp;Typically, the serum/plasma aminotransferases (AST/ALT) is in the range 500–10,000 IU/l, the bilirubin up to 500 mmoles/l, alkaline phosphatase levels <2* the upper limit of normal, but higher if there is cholestasis. PT prolongation by more than 5 s is a sign of severe infection. ALF is typically associated with PT prolongation by 50 s or more. <br />&nbsp;&nbsp;2. Hepatitis B<br />&nbsp;&nbsp;2.1 Table: G08_036_ Table 1. <br />&nbsp;&nbsp;2.2 Biochemistry<br />&nbsp;&nbsp;2.2.1Acute infection: see hepatitis A. <br />&nbsp;&nbsp;2.2.2Chronic infection: in most cases the only abnormality will be mildly elevated serum aminotransferase levels; in many the liver enzymes will be normal. <br />&nbsp;&nbsp;3. Hepatitis C<br />&nbsp;&nbsp;3.1 Serology<br />&nbsp;&nbsp;3.1.1Acute infection<br />&nbsp;&nbsp;This is defined as recent exposure to HCV following which the patient is HCV-RNA positive but anti-HCV negative or seroconverts from anti-HCV negative to positive. An antibody test may not become positive for several months after acute infection but a test for HCV-RNA will usually be positive after two weeks. <br />&nbsp;&nbsp;3.1.2Chronic Infection<br />&nbsp;&nbsp;①A screening antibody or antibody/antigen test such as an Enzyme immunoassay (EIA) or other immunoassay is initially performed and RNA detection confirms active infection (1A). <br />&nbsp;&nbsp;②In HIVþ patients with a low CD4 count (<200 cells/mm3) the EIA may be negative and HCV-RNA detection may be needed for diagnosis. <br />&nbsp;&nbsp;③Chronic infection is confirmed if an HCV-RNA assay is positive six months after the first positive test.④All patients should have a viral RNA test to confirm viraemia and the HCV genotype should also be identified(1A). <br />&nbsp;&nbsp;3.2 Other tests<br />&nbsp;&nbsp;①Acute infection - as for hepatitis A <br />&nbsp;&nbsp;②Chronic infection - as for hepatitis B )', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('269', '23', 'G08_037', '1', '注射毒品者艾滋病、病毒性肝炎和其他感染检测指南', 'Guidelines for testing HIV, viral hepatitis and other infections in injecting drug users', '欧洲药品与药品成瘾监测中心（Europen Monitoring Centre for Drugs and Drug Addiction）', '2010', 'http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19735', '英文', '1.甲型肝炎(Hepatitis A) <br />&nbsp;&nbsp;2.乙型肝炎(Hepatitis B)<br />&nbsp;&nbsp;3.丙型肝炎(Hepatitis C)<br />&nbsp;&nbsp;4.丁型肝炎(Hepatitis D)', '病毒性肝炎', '未提及', '未提及', '1.甲型肝炎<br />&nbsp;&nbsp;甲型肝炎血清学检测应该包括：甲型肝炎免疫球蛋白抗体(anti-HAV IgG); 甲型肝炎IgM抗体(anti-HAV IgM)—仅急性感染<br />&nbsp;&nbsp;2.乙型肝炎<br />&nbsp;&nbsp;感染的诊断和分期取决于血清学资料。乙型肝炎检测应该包括以下检测以下检测：乙型肝炎表面抗原(HBsAg)；<br />&nbsp;&nbsp;乙型肝炎表面抗体(anti-HBs)；型肝炎核心抗体(anti-HBc total)；乙型肝炎核心IgM抗体(anti-HBc IgM) <br />&nbsp;&nbsp;3.丙型肝炎<br />&nbsp;&nbsp;标准的筛选试验是丙型肝炎抗体(anti-HCV)ELISA测试，阳性结果的测试应该确认通过核酸扩增(pcr试验)测试，或者如果这是负重组免疫印迹分析RIBA。单独的阳性抗体测试是先前暴露于丙型肝炎病毒的证据。，但没有迹象表明了该病毒是否仍然存在。窗口期是四到六个月。<br />&nbsp;&nbsp;4.丁型肝炎<br />&nbsp;&nbsp;应考虑个人的HBsAg阳性或最近的乙型肝炎病毒感染的证据或者最近的乙型肝炎病毒感染，重复感染的诊断或合并感染后的丁型肝炎病毒是根据病毒血清学测试（总anti-HDV抗体）。(1.Hepatitis A<br />&nbsp;&nbsp;Hepatitis A serology should include testing for: hepatitis A IgG antibody (anti-HAV IgG); hepatitis A IgM antibody (anti-HAV IgM) — only in acute infections.2.Hepatitis B<br />&nbsp;&nbsp;The diagnosis and stage of infection can be determined from the serology profile. The followingtests should be included in the panel of hepatitis B tests: hepatitis B surface antigen (HBsAg); hepatitis B surface antibody (anti-HBs); hepatitis B core antibody (anti-HBc total); hepatitis B core IgM antibody (anti-HBc IgM). <br />&nbsp;&nbsp;3.Hepatitis C<br />&nbsp;&nbsp;The standard screening test is the hepatitis C antibody (anti-HCV) ELISA test. A positive testshould be confirmed by using a nucleic acid amplification test (PCR-test), or if this is negative witha recombinant immunoblot assay, RIBA. A positive antibody test alone is evidence of previous exposure to the hepatitis C virus, but gives no indication of whether the virus is still present. The window period is four to six months. <br />&nbsp;&nbsp;4.Hepatitis D<br />&nbsp;&nbsp;Hepatitis D should be considered in individuals who are HBsAg positive or who have evidence of recent HBV infection. A diagnosis of superinfection or co-infection with the hepatitis D virus is made following serologic tests for the virus (total anti-HDV antibodies).)', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('27', '32', 'G02_015', '1', '卫生保健指南：成人血脂管理', 'Health Care Guideline:Lipid Management in Adults', '临床系统改进协会(Institute For Clinical Systems Improvement)', '2009', null, '英文', null, '高脂血症', null, null, 'G02_015_01_风险与治疗目标.docx', null, ' LDL', 'G02_15_01_风险与治疗目标.docx', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('270', '23', 'G08_038', '1', '国家临床实践指南：丙型肝炎管理', 'Management of hepatitis C. A national clinical guideline', '苏格兰校际指南网络——国家政府机构(Scottish Intercollegiate Guidelines Network - National Government Agency)', '2006', 'http://www.guideline.gov/content.aspx?id=47029&search=management+of+hepatitis+c.+a+national+clinical+guideline', '英文', '未提及', '丙型肝炎', '未提及', '未提及', '丙型肝炎病毒诊断检测<br />&nbsp;&nbsp;B级证据：可能的情况下应该执行诊断性检测血清或血浆中丙肝病毒。<br />&nbsp;&nbsp;D级证据：如果考虑进行抗病毒治疗应该检测丙肝病毒基因。<br />&nbsp;&nbsp;D级证据：单独的急性经皮接触血液感染，或强烈怀疑已经感染，接触慢性丙型肝炎病毒、医疗保健专业人员应该在第6、12、24周检测丙肝病毒核糖核酸(RNA)，第12、24周检测anti-HCV。<br />&nbsp;&nbsp;（HCV Diagnostic Testing<br />&nbsp;&nbsp;B - Diagnostic testing for HCV should be performed on serum or plasma where possible. <br />&nbsp;&nbsp;D - HCV genotyping should be undertaken if antiviral therapy is being considered. <br />&nbsp;&nbsp;D - Following an isolated acute percutaneous exposure to blood infected, or strongly suspected of being infected, with HCV, healthcare professionals should be offered HCV ribonucleic acid (RNA) testing at six, 12 and 24 weeks and anti-HC V testing at 12 and 24 weeks.）', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('271', '23', 'G08_039', '1', '丙型肝炎管理临床指南', 'Clinical guidelines on the management of hepatitis C', '英国胃肠病学会（British Society of Gastroenterology）', '2001', 'http://www.library.nhs.uk/guidance/details.aspx?t=Clinical+guidelines+on+the+management+of+hepatitis+C&stfo=True&sc=gui.rms.guidelinesfinder,gui.rms.niceguidance,gui.rms.cks&p=1&sf=srt.publicationdate&sr=gui.rms&sfld=&tab=gui.rms&did=30243&pc=1&id=0', '英文', '未提及', '丙型肝炎', '未提及', '未提及', '1.疑似感染丙肝病毒的患者应做一个最新的（目前第三代）ELISA检测 anti-HCV。（C级证据）$$$42. 尽管是阴性的或者血清学测试不确定，所有抗体检测呈阳性的患者和有丙肝病毒感染风险的患者应该进行PCR血清检测。阳性的结果证实了当前有病毒血症而阴性结果表明非病毒感染期。（B级证据）<br />&nbsp;&nbsp;3. 患者ELISA阳性但是PCR阴性应该做重组免疫印迹试验以确认抗体的状态。（B级证据）<br />&nbsp;&nbsp;4. 疑似感染丙肝病毒的免疫缺陷患者建议做定性PCR检测。（B级证据）<br />&nbsp;&nbsp;5. 例行肝检测的结果与肝活组织检查的坏死性炎症和纤维化评分关系不大。（B级证据）<br />&nbsp;&nbsp;6. 对于评估肝脏炎症状态,潜在的肝纤维化、肝硬化的存在与否，肝活检是有价值的。为了阐明这些问题并评估是否适合治疗, 无论肝功能测试是否异常，建议病毒感染期患者进行肝活检。由一个适当的有经验的病理学家进行标准组织学评分，鼓励使用统一的组织学报告。肝脏活组织检查的风险和利益必须与患者充分讨论。<br />&nbsp;&nbsp;7. 建议根据血清中HCV RNA浓度的测量和HCV基因型的检测确定治疗的持续时间。（A级证据）<br />&nbsp;&nbsp;(1.Patients with suspected HCV infection should be tested for anti-HCV by an up-to-date (currently third generation) ELISA test (C). <br />&nbsp;&nbsp;2. All patients with positive antibody tests and those patients thought to be at risk of HCV infection despite negative or indeterminate serological tests should undergo PCR testing of the serum. A positive result confirms current viraemia whereas a negative test suggests non-viraemic infection, transient absence of viraemia or recovered infection, a level of viraemia below the detection limit of the assay or may reflect a non-specific ELISA result (B). <br />&nbsp;&nbsp;3. Patients with positive ELISA but negative PCR should therefore be tested with recombinant immunoblot assay to confirm antibody status (B). <br />&nbsp;&nbsp;4. A qualitative PCR test is recommended in immunodeficient patients with suspected HCV infection(B). <br />&nbsp;&nbsp;5. The results of routine liver tests correlate poorly with both necro-inflammatory and fibrosis scores found on liver biopsy (B). <br />&nbsp;&nbsp;6. Liver biopsy is valuable for assessing status of liver inflammation, potential progression of fibrosis and the presence or absence of cirrhosis. To clarify these, and to assess suitability for treatment, liver biopsy is recommended for patients found to be viraemic, whether or not liver function tests are abnormal. Standard histological scoring systems by a suitably experienced pathologist, should be used to encourage uniformity of histological reports. The risks and benefits of liver biopsies must be fully discussed with the patient (B). <br />&nbsp;&nbsp;7. The measurement of HCV RNA concentrations in serum and the determination of HCV genotype are recommended and should be used to determine the duration of treatment (see later) (A). <br />&nbsp;&nbsp;)', '未提及', '未提及', '未提及', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('272', '23', 'G08_040', '1', '儿童、青年和成人慢性乙型肝炎诊断和管理指南', 'Diagnosis and management of chronic hepatitis B in children, young people and adults', '英国国家卫生与临床优化研究所 (NICE,National Institute for Health and Clinical Excellence)', '2013', 'http://guide.medlive.cn/guideline/4642', '英文', '未提及', '慢性乙型肝炎', '未提及', '未提及', '未提及', '未提及', '未提及', '慢性乙型肝炎（乙肝）的治疗目标是预防肝硬化、肝癌和肝衰竭。ＡＬＴ正常化，炎症计分下降、肝活检示肝纤维化改善或未加重，抑制血清ＨＢＶ　ＤＮＡ 至检测不到水平，ＨＢｅＡｇ消失和抗－ＨＢｅ血清学转换，ＨＢｓＡｇ消失和抗－ＨＢｓ血清学转换等是监测疾病进展和治疗应答的替代指标。<br />&nbsp;&nbsp;(The goal of treatment for chronic hepatitis B is to prevent cirrhosis, HCC and liver failure. In clinical practice s畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭�ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᢂఄਘĀ\0ః彿㎽奋㎽巫㎽瀞ఄ贮ఄ彿㎽财ఄ塚㎽贮ఄꍈ㏂\0\0ᢂఄ學㎽漸㏂圔㎽ᢂఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0�ਘ䐺盭暼痭�ਘༀƙ \0�ਘĀ\0\0㺣盭�ਘ\0ﱔ�ਘ\0팃目�ਘ࣎�ਘ큁目�ਘᢶఄ﫬\0Item\0\0趲ఄ\0\0\0\0\0\0Count\0\0ﱬﬄ�ਘᏜ௷\0\0�ਘ\0\0\0\0௷寶目Ꮰ௷矵䥷㎽瀞ఄ\0\0趲ఄ�㏂财ఄ\0\0\0௷\0\0\0謁ﱔ\0\0㎾ՠ\0ﱜ\0\0x�㏂财ఄ\0\0隲W趲ఄ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\0霪W露W\0\0ﱴxt\0Љ\0\0\0렘௥鲬࣎菮畻\0\0\0\0ጰ௷Eo\0\0ᎄ௷\0\0⑰ਫ਼⑰ਫ਼ᎈ௷ាఄ寶目ᎈ௷ាఄi\0\0ﱄ﷜ﱴﲔ먙㎼ាఄᎈ௷i\0\0ﱄ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('273', '23', 'G08_041', '1', '韩国肝脏病研究学会临床实践指南：丙肝的管理', 'KASL clinical practice guidelines: management of hepatitis C', '韩国肝脏病研究学会(KASL,Korean Association for the Study of the Liver)', '2016', 'http://guide.medlive.cn/guideline/10778', '英文', '未提及', '丙肝', '未提及', '未提及', '1. 随着丙肝病毒感染发病率越来越高，丙肝病毒筛查应该考虑那些超过40岁人群的风险。（C1级证据）<br />&nbsp;&nbsp;2. 疑似有急性或慢性丙肝病毒感染的病人应该检查Anti-HCV 。（A1级证据）<br />&nbsp;&nbsp;3. anti-HCV测试阳性的患者应该测试HCV RNA以确诊。（A1级证据）<br />&nbsp;&nbsp;4. 即使anti-HCV是阴性的，疑似急性丙肝病毒感染、原因不明存在免疫抑制肝脏疾病的患者，应当检测丙肝病毒RNA。（B1级证据）<br />&nbsp;&nbsp;5. 进行抗病毒治疗之前应该分析丙肝病毒核糖核酸定量和基因分型 /基因亚型(1 a / b) 。（A1级证据）<br />&nbsp;&nbsp;6.接触被感染的血液或体液后立即检测anti-HCV和血清ALT水平。如果anti-HCV是阴性的,暴露后4-6周分析丙肝病毒RNA以进行早期诊断。（B2级证据）<br />&nbsp;&nbsp;7. 抗病毒治疗之前，肝脏疾病严重程度的评估是至关重要的。（A1级证据）<br />&nbsp;&nbsp;8. 根据肝活检和/或非侵入性的测试评估肝纤维化做出处理决定和预测预后。（B1级证据）<br />&nbsp;&nbsp;(1. Screening for HCV infection could be considered in populations at risk as well as those over 40 years old with increasing increasing prevalence of HCV infection (C1). <br />&nbsp;&nbsp;2. Anti-HCV should be tested in patients suspected of having acute or chronic HCV infection (A1). <br />&nbsp;&nbsp;3. HCV RNA should be tested in patients with a positive anti-HCV test to confirm the diagnosis (A1). <br />&nbsp;&nbsp;4. Even if anti-HCV is negative, HCV RNA testing is required when acute HCV infection is suspected or in the presence of unexplained liver disease in immunosuppressed patients (B1). <br />&nbsp;&nbsp;5. HCV RNA quantitative assay and genotyping/subgenotyping (1a/1b) should be performed prior to antiviral treatment (A1). <br />&nbsp;&nbsp;6. Immediately following exposure to infected blood or body fluids, anti-HCV and serum ALT level testing should be performed. If anti-HCV is negative, an HCV RNA assay should be conducted 4-6 weeks after exposure for early diagnosis. If all baseline tests are negative, follow-up testing for anti- HCV and serum ALT level should be performed 4-6 months after the exposure (B2). <br />&nbsp;&nbsp;7. Assessment of liver disease severity is essential prior to antiviral treatment (A1). <br />&nbsp;&nbsp;8. Liver biopsy and/or noninvasive tests for assessment of hepatic fibrosis can be performed to make treatment decision and predict prognosis (B1).)', '未提及', '未提及', '1. 丙型肝炎治疗的目标是消除丙肝病毒和防止肝硬化并发症、肝细胞癌、肝外表现的丙肝病毒感染和死亡。（A1级证据）<br />&nbsp;&nbsp;2. 丙型肝炎治疗的短期目标是实现持续病毒学应答，是指在治疗结束后，使用一种敏感的化验方法检测难以发现的血清HCV RNA。（A1级证据）<br />&nbsp;&nbsp;(1. The goals of hepatitis C treatment are to eradicate HCV and to prevent complications of liver cirrhosis, hepatocellula畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭�ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᢂఄਘĀ\0ః彿㎽奋㎽巫㎽瀞ఄ贮ఄ彿㎽财ఄ塚㎽贮ఄꍈ㏂\0\0ᢂఄ學㎽漸㏂圔㎽ᢂఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0�ਘ䐺盭暼痭�ਘༀƙ \0�ਘĀ\0\0㺣盭�ਘ\0ﱔ�ਘ\0팃目�ਘ࣎�ਘ큁目�ਘᢶఄ﫬\0Item\0\0趲ఄ\0\0\0\0\0\0Count\0\0ﱬﬄ�ਘᏜ௷\0\0�ਘ\0\0\0\0௷寶目Ꮰ௷矵䥷㎽瀞ఄ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('274', '20', 'B02_001', '1', '委员会意见：女性不孕诊断评估', 'Diagnostic evaluation of the infertile female: a committee opinion', '美国生殖医学会（American Society for Reproductive Medicine)', '2015', 'http://www.fertstert.org/article/S0015-0282(15)00224-1/pdf', '英文', '未提及', '不孕症', '未提及', '未提及', '1.病史<br />&nbsp;&nbsp;不孕持续时间及先前的诊疗结果；月经史（初潮年龄、月经周期、性状、经前不适、痛经程度）、怀孕史（孕次、产次及相关并发症）、使用过的避孕方法；性交频率和性功能障碍；手术史、住院治疗史、有无严重疾病、盆腔炎性疾病、或是否接触过性传染性疾病；甲状腺疾病、乳溢、多毛症、盆腔、腹痛或性交通；巴氏涂片检验异常和后续的治疗；目前用药情况和过敏情况；家族性的出生缺陷、发育迟缓、早期绝经或生殖问题；是否处于有危害的环境下；烟草、酒精和其他非法药物的使用。<br />&nbsp;&nbsp;2.体格检查<br />&nbsp;&nbsp;体重、身体质量指数、血压及脉搏；甲状腺是否肿大、疼痛或有结节；乳房和分泌物的检查；雄激素过多的征兆；阴道或宫颈分泌物排泄是否异常；盆腔或腹部疼痛、器官肿大或有肿块；子宫大小、形状、位置和能动性；器官附件是否有肿块，是否疼痛；子宫直肠窝是否有肿块、疼痛、结节。<br />&nbsp;&nbsp;3.实验室检查<br />&nbsp;&nbsp;女性排卵功能、生殖系统通畅性的检查和男性精液检查（子宫输卵管造造影、子宫内膜活检等）；（1.History<br />&nbsp;&nbsp;Duration of infertility and results of any previous evaluation and treatment;Menstrual history (age at menarche,cycle length and characteristics,presence of molimina, and onset/severity of dysmenorrhea)Pregnancy history (gravidity, parity, pregnancy outcome, and associated complications);Previous methods of contraception;Coital frequency and sexual dysfunction; Past surgery (procedures, indications, and outcomes), previou hospitalizations, serious illnesses or injuries, pelvic inflammatory disease,or exposure to sexually transmitted infections; Thyroid disease, galactorrhea, hirsutism, pelvic or abdominal pain,\nand dyspareunia; Previous abnormal pap smears and any subsequent treatment; Current medications and allergies; Family history of birth defects, developmental delay, early menopause,or reproductive problems; Occupation and exposure to known environmental hazards; Use of tobacco, alcohol, and recreational or illicit drugs）<br />&nbsp;&nbsp;2.Physical examination<br />&nbsp;&nbsp;Weight, body mass index (BMI), blood pressure, and pulse; Thyroid enlargement and presence of any nodules or tenderness; Breast characteristics and evaluation for secretions  Signs of androgen excess; Vaginal or cervical abnormality, secretions, or discharge; Pelvic or abdominal tenderness, organ enlargement, or\nmasses; Uterine size, shape, position, and mobility; Adnexal masses or tenderness; Cul-de-sac masses, tenderness, or nodularity<br />&nbsp;&nbsp;3.Routine laparoscopy<br />&nbsp;&nbsp;Diagnostic evaluation for infertility should include assessment of ovulatory function, structure, and patency of the female reproductive tract, and semen analysis.)', '未提及', '未提及', '未提及', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('275', '20', 'B02_002', '1', '委员会意见：女性不孕诊断评估', 'Diagnostic evaluation of the infertile female: a committee opinion', '美国生殖医学会（American Society for Reproductive Medicine)', '2012', 'http://www.fertstert.org/article/S0015-0282(12)00586-9/pdf', '英文', '未提及', '不孕症', '未提及', '未提及', '1.病史<br />&nbsp;&nbsp;不孕持续时间及先前的诊疗结果；月经史（初潮年龄、月经周期、性状、经前不适、痛经程度）、怀孕史（孕次、产次及相关并发症）、使用过的避孕方法；性交频率和性功能障碍；手术史、住院治疗史、有无严重疾病、盆腔炎性疾病、或是否接触过性传染性疾病；甲状腺疾病、乳溢、多毛症、盆腔、腹痛或性交通；巴氏涂片检验异常和后续的治疗；目前用药情况和过敏情况；家族性的出生缺陷、发育迟缓、早期绝经或生殖问题；是否处于有危害的环境下；烟草、酒精和其他非法药物的使用。<br />&nbsp;&nbsp;3.体格检查<br />&nbsp;&nbsp;体重、身体质量指数、血压及脉；甲状腺是否肿大、疼痛或有结节；乳房和分泌物的检查；雄激素过多的征兆；阴道或宫颈分泌物排泄是否异常；盆腔或腹部疼痛、器官肿大或有肿块；子宫大小、形状、位置和能动性；器官附件是否有肿块，是否疼痛；子宫直肠窝是否有肿块、疼痛、结节。<br />&nbsp;&nbsp;3.实验室检查<br />&nbsp;&nbsp;女性排卵功能、生殖系统通畅性的检查和男性精液检查（子宫输卵管造造影、子宫内膜活检等）；（1.History<br />&nbsp;&nbsp;Duration of infertility and results of any previous evaluation and treatment;Menstrual history (age at menarche,cycle length and characteristics,presence of molimina, and onset/severity of dysmenorrhea)Pregnancy history (gravidity, parity, pregnancy outcome, and associated complications);Previous methods of contraception;Coital frequency and sexual dysfunction; Past surgery (procedures, indications, and outcomes), previou hospitalizations, serious illnesses or injuries, pelvic inflammatory disease,or exposure to sexually transmitted infections; Thyroid disease, galactorrhea, hirsutism, pelvic or abdominal pain,\nand dyspareunia; Previous abnormal pap smears and any subsequent treatment; Current medications and allergies; Family history of birth defects, developmental delay, early menopause,or reproductive problems; Occupation and exposure to known environmental hazards; Use of tobacco, alcohol, and recreational or illicit drugs）<br />&nbsp;&nbsp;2.Physical examination<br />&nbsp;&nbsp;Weight, body mass index (BMI), blood pressure, and pulse; Thyroid enlargement and presence of any nodules or tenderness; Breast characteristics and evaluation for secretions  Signs of androgen excess; Vaginal or cervical abnormality, secretions, or discharge; Pelvic or abdominal tenderness, organ enlargement, or\nmasses; Uterine size, shape, position, and mobility; Adnexal masses or tenderness; Cul-de-sac masses, tenderness, or nodularity<br />&nbsp;&nbsp;3.Routine laparoscopy<br />&nbsp;&nbsp;Diagnostic evaluation for infertility should include assessment of ovulatory function, structure, and patency of the female reproductive tract, and semen analysis.)Ħ', '未提及', '未提及', '未提及', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('276', '20', 'B02_003', '1', '委员会意见:输卵管手术在辅助生殖技术时代的角色', 'Committee opinion: role of tubal surgery in the era of assisted reproductive technology', '美国生殖医学会（American Society for Reproductive Medicine)', '2012', 'Fertil Steril, 2012, 97(3): 539-545.', '英文', '未提及', '输卵管性不孕症', '未提及', '未提及', '1.病史<br />&nbsp;&nbsp;异位妊娠史、骨盆炎症性疾病、子宫内膜异位症或是否接受过盆腔手术<br />&nbsp;&nbsp;2.实验室检查<br />&nbsp;&nbsp;子宫输卵管造影术、腹腔镜检查、子宫输卵管声学造影、经阴道注水腹腔镜检查<br />&nbsp;&nbsp;（1.History<br />&nbsp;&nbsp;A history of ectopic pregnancy, pelvic inflammatory disease (PID), endometriosis,or prior pelvic surgery raises the index of suspicion for tubal factor infertility.<br />&nbsp;&nbsp;2.Laboratory tests<br />&nbsp;&nbsp;hysterosalpingography(HSG)、Sonohysterosalpingography and transvaginal hydrolaparoscopy）', '未提及', '预后情况（prognosis）', '1.预后良好<br />&nbsp;&nbsp;输卵管附件粘连在允许范围以内、轻度扩张（<3cm）、管壁薄而柔韧、输卵管内膜有丰富的粘膜褶皱<br />&nbsp;&nbsp;2.预后不良<br />&nbsp;&nbsp;输卵管周粘连严重、输卵管扩张明显、纤维壁厚、粘膜稀疏或无（1.good prognosis<br />&nbsp;&nbsp;no more than limited filmy adnexal adhesions, mildly dilated tubes (<3 cm) with thin and pliable walls, and a lush endosalpinx with preservation of the mucosal folds<br />&nbsp;&nbsp;2.poor prognosis<br />&nbsp;&nbsp;extensive dense peritubal adhesions, massively dilated tubes with thick fibrotic walls, and/or sparse or absent luminal mucosa)', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('277', '20', 'B02_004', '1', '委员会意见:子宫内膜异位症与不孕症', 'Endometriosis and infertility: a committee opinion', '美国生殖医学会（American Society for Reproductive Medicine)', '2012', 'Fertil Steril, 2012, 98(3): 591-598.', '英文', '1.子宫内膜异位I期(I endometriosis)<br />&nbsp;&nbsp;2.子宫内膜异位II期(II endometriosis)<br />&nbsp;&nbsp;3.子宫内膜异位III期(III endometriosis)<br />&nbsp;&nbsp;4.子宫内膜异位IV期(IV endometriosis)', '子宫内膜异位性不孕症', '未提及', '未提及', '1.腹腔镜检查(Laparoscopy);2.组织学鉴定(Histologic evaluation);3.病史和体格检查（history and physical examination: cyclic or chronic pelvic pain, dysmenorrhea, dyspareunia, a fixed retroverted uterus, an adnexal mass, and uterosacral ligament nodularity, thickening, or tenderness);4.超声波检查(ultrasound)', '未提及', '1.受孕率(pregnancy rate)<br />&nbsp;&nbsp;2.疼痛缓解情况（pain relieving）', '受孕率提高（improvement in pregnancy rate）', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('278', '20', 'B02_005', '1', '优化自然生育力', 'Optimizing natural fertility', '美国生殖医学会（American Society for Reproductive Medicine) 生殖内分泌与不孕症协会(Society for Reproductive Endocrinology and Infertility)', '2008', 'Fertil Steril, 2008, 90(5 Suppl): 1-6.', '英文', '未提及', '不孕症', '未提及', '未提及', '1.用药史（medical history）<br />&nbsp;&nbsp;2.身体检查（physical findings）', '未提及', '未提及', '未提及', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('279', '20', 'B02_006', '1', '教育公告：孕酮补充在黄体期、怀孕初期及不孕不育治疗中的作用 ', 'Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin', '美国生殖医学会（American Society for Reproductive Medicine) 生殖内分泌与不孕症协会(Society for Reproductive Endocrinology and Infertility)', '2008', 'Fertil Steril, 2008, 90(5 Suppl): 150-153.', '英文', '未提及', '不孕症', '未提及', '未提及', '未提及', '未提及', '未提及', '未提及', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('28', '32', 'G02_016', '1', '卫生保健指南：成人血脂管理', 'Health Care Guideline:Lipid Management in Adults', '临床系统改进协会(Institute For Clinical Systems Improvement)', '2013', 'https://www.icsi.org/_asset/qz5ydq/LipidMgmt-Interactive1111.pdf', '英文', null, '高脂血症', null, null, null, null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('280', '20', 'B02_007', '1', '吸烟与不孕症', 'Smoking and infertility', '美国生殖医学会（American Society for Reproductive Medicine) 生殖内分泌与不孕症协会(Society for Reproductive Endocrinology and Infertility)', '2008', 'Fertil Steril, 2008, 90(5 Suppl): 254-259.', '英文', '未提及', '不孕症', '未提及', '未提及', '未提及', '未提及', '未提及', '未提及', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('281', '20', 'B02_008', '1', '委员会意见：年龄与生育率下降的关系', 'Age-related fertility decline: a committee opinion', '美国生殖医学会（American Society for Reproductive Medicine)、美国妇产科医师学会(American Society for Reproductive Medicine)', '2008', 'Fertil Steril, 2008, 90(5 Suppl): 154-155.', '英文', '未提及', '不孕症', '未提及', '未提及', '未提及', '未提及', '未提及', '未提及', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('282', '20', 'B02_009', '1', '原因不明性不孕症的治疗及疗效', 'Effectiveness and treatment for unexplained infertility', '美国生殖医学会（American Society for Reproductive Medicine) 生殖内分泌与不孕症协会(Society for Reproductive Endocrinology and Infertility)', '2006', 'Fertil Steril, 2006, 86(4 Suppl): 111-114.', '英文', '未提及', '不孕症', '未提及', '未提及', '基本的不孕症检查不能查明原因即为原因不明性不孕症 basic infertility evaluation(evaluation of ovulation, adequate sperm production and patency of the fallopian tubes) fails to reveal an obvious abnormality', '未提及', '能否怀孕（whether can be pregnant）', '未提及', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('283', '20', 'B02_010', '1', '女性不孕症与年龄的关系', 'Aging and infertility in women', '美国生殖医学会（American Society for Reproductive Medicine) 生殖内分泌与不孕症协会(Society for Reproductive Endocrinology and Infertility)', '2006', 'Fertil Steril, 2006, 86(4 Suppl): 248-252.', '英文', '未提及', '不孕症', '未提及', '未提及', '1.无保护性交一年尚未怀孕( inability to conceive after one year of unprotected intercourse, normal older women may take longer than one year to conceive)<br />&nbsp;&nbsp;2.卵巢储备功能检查，包括克罗米芬兴奋试验、促卵泡激素、雌二醇水平(ovarian reserve test，Clinical tests to estimate ovarian reserve include FSH and estradiol levels in the early follicular phase (e.g., day 3) or a clomiphene citrate challenge test.)<br />&nbsp;&nbsp;3.孕前检查（preconception medical evaluation）', '未提及', '未提及', '未提及', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('284', '20', 'B02_011', '1', '原发性不孕症和继发性不孕症的腹腔镜诊断', 'Diagnostic Laparoscopy in Primary and Secondary Infertility', '美国胃肠内镜外科医师学会(Society of American Gastrointestinaland Endoscopic Surgeons)', '2007', 'http://www.sages.org/publications/guidelines/guidelines-for-diagnostic-laparoscopy/', '英文', '未提及', '不孕症', '未提及', '未提及', '输卵管造影术和腹腔镜检查（salpingography and laparoscopy: to find lesions,endometriosis and adhesions.)', '未提及', 'Whether can be pregnant or not', '治疗后一年内怀孕(become pregnant within 1 year)', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('285', '20', 'B02_012', '1', '手术减肥在不孕症中的角色', 'The Role of Bariatric Surgery in the Management of Female Fertility', '英国皇家妇产科医师学院(Royal College of Obstetricians and Gynaecologists)', '2010', 'Scientific Impact Paper，2010.17: 1-7.', '英文', '未提及', '不孕症', '未提及', '未提及', '未提及', '未提及', '未提及', '1.多囊卵巢综合征的改善<br />&nbsp;&nbsp;2.能否怀孕（bariatric surgery improves the markers of polycystic ovary syndrome；Case series suggest improvement in the ability to conceive after bariatric surgery）', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('286', '20', 'B02_013', '1', '二甲双胍疗法在多囊卵巢综合征不孕患者中的应用', 'Metformin Therapy for the Management of Infertility in Women with Polycystic Ovary Syndrome', '英国皇家妇产科医师学院(Royal College of Obstetricians and Gynaecologists)', '2008', 'Scientific Impact Paper NO. 13. 2008: 1-5.', '英文', '未提及', '多囊卵巢综合征', '未提及', '未提及', '高雄激素血症（多毛，痤疮，脱发）月经失调伴有无排卵性不孕（hyperandrogenism (hirsutism, acne,alopecia) and menstrual irregularity with associated anovulatory infertility）', '未提及', '未提及', '血清雄激素水平降低、月经周期恢复正常、恢复排卵功能（lowering serum androgen levels and restoring menstrual cyclicity and was effective in achieving ovulation）', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('287', '20', 'B02_014', '1', '生育类疾病的评估及治疗', 'Fertility problems: assessment and treatment', '英国卫生和临床规范研究所（National Institute for Health and Clinical Excellence)', '2013', 'https://www.nice.org.uk/guidance/cg156', '英文', '1.不孕症<br />&nbsp;&nbsp;2.原因不明性不孕症（1.infertility；2.Unexplained infertility）', '不孕症', '未提及', '未提及', '1.不孕症<br />&nbsp;&nbsp;$育龄期女性无保护性交1年后尚未怀孕者(A woman of reproductive age who has not conceived after 1year of unprotected vaginal sexual intercourse)<br />&nbsp;&nbsp;2.原因不明性不孕症<br />&nbsp;&nbsp;无保护性交1年后尚未怀孕者(women with unexplained infertility who have not conceived after 2 years (this can include up to 1 year before their fertility investigations) of regular unprotected sexual intercourse)', '未提及', '未提及', '未提及', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('288', '20', 'B02_015', '1', '晚期育龄与生育', 'Advanced Reproductive Age and Fertility', '加拿大妇产科学会(The Society of Obstetricians and Gynaecologists of Canada)', '2011', 'Journal of Obstetrics and Gynaecology Canada, 2011, 33(11): 1165-1175.', '英文', '未提及', '不孕症', '未提及', '未提及', '卵巢衰老，包括促卵泡激素增多、月经周期变长、月经失调、卵母细胞增多（OVARIAN AGING，the rise in FSH，cycles lengthen and become more irregular，the rate of oocyte aneuploidy increases）', '未提及', '1.怀孕能力<br />&nbsp;&nbsp;2.卵母细胞（1.pregnancy2.oocytes）', '增强生育能力，缩短怀孕时间，增加成熟卵母细胞数量，平衡每月卵母细胞质量的降低（increasing monthly fecundity and decreasing the time to conception.increase the number of mature oocytes each month to balance decreasing oocyte quality）', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('289', '20', 'B02_016', '0', '子宫内膜异位症、妊娠高血压综合征及女性不孕症的中西医结合诊疗标准(试行草案)', '无', '中国中西医结合研究会妇产科专业委员', '1986', '中国中西医结合研究会妇产科专业委员会第二次学术会议.子宫内膜异位症、妊娠高血压综合征及女性不孕症的中西医结合诊疗标准(试行草案).中西医结合杂志.1987,7(5):319-320', '中文', '未报告', '女性不孕症', '未报告', '1.排卵功能障碍：肾虚痰实（多囊卵巢综合症）、肾阴阳两虚（无排卵型月经不调）、肝肾阴虚（高泌乳血症）、肾虚血瘀（无排卵滤泡黄素化综合征）、阴虚火旺（无反应卵巢综合征）、肾虚（黄体不健）2.子宫内膜异位症：血瘀3.输卵管炎（生殖道结核不列入）：气滞血瘀4.子宫肌腺病：胞宫血瘀5.宫腔黏连：气滞血瘀6.免疫性不育：可无证候', '1.排卵功能障碍2.子宫内膜异位症3.输卵管炎（生殖道结核不列入）4.子宫肌腺病5.宫腔黏连6.免疫性不育', '1.排卵功能障碍：肾虚痰实（多囊卵巢综合症）、肾阴阳两虚（无排卵型月经不调）、肝肾阴虚（高泌乳血症）、肾虚血瘀（无排卵滤泡黄素化综合征）、阴虚火旺（无反应卵巢综合征）、肾虚（黄体不健）2.子宫内膜异位症：血瘀3.输卵管炎（生殖道结核不列入）：气滞血瘀4.子宫肌腺病：胞宫血瘀5.宫腔黏连：气滞血瘀6.免疫性不育：可无证候', '妊娠', '治疗后2年以内妊娠者为痊愈', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('29', '33', 'T02_001', '1', '原发性痛风诊断和治疗指南', '无', '中华医学会风湿病学分会(CRA,Chinese Rheumatology Association)', '2012', '中华医学会风湿病学分会.原发性痛风诊断和治疗指南[J]. 柳州医学,2012,25(03):184-188.', '中文', '急性发作期；<br />&nbsp;&nbsp;间歇发作期；<br />&nbsp;&nbsp;慢性痛风石病变期；<br />&nbsp;&nbsp;肾脏病变(慢性尿酸盐肾病;尿酸性尿路结石；急性尿酸性肾病)<br />&nbsp;&nbsp;', '痛风', null, null, '2临床表现<br />&nbsp;&nbsp;\n95%的痛风发生于男性, 起病一般在40岁以后, 且患病率随年龄而增加, 但近年来有年轻化趋势女性患者大多出现在绝经期以后。痛风的自然病程可分为急性发作期、间歇发作期、慢性痛风石病变期。<br />&nbsp;&nbsp;\n2.1症状和体征<br />&nbsp;&nbsp;\n2.1.1急性发作期<br />&nbsp;&nbsp;\n发作前可无先兆, 典型发作者常于深夜被关节痛惊醒,疼痛进行性加剧,在12h左右达到高峰, 呈撕裂样、刀割样或咬噬样,难以忍受。受累关节红肿灼热、皮肤紧绷、触痛明显、功能受限。多于数天或2周内自行缓解,恢复正常。首次发作多侵犯单关节, 50%以上发生在第一跖趾关节,在以后的病程中, 患者累及该部位。足背、足跟、踝、膝等关节也可受累。<br />&nbsp;&nbsp;\n部分患者可有发热、寒战、头痛、心悸、恶心等全身症状, 可伴有白细胞升高、红细胞沉降率（ESR）增快。<br />&nbsp;&nbsp;\n2.1.2 间歇发作期<br />&nbsp;&nbsp;\n急性关节炎缓解后一般无明显后遗症状, 有时仅有患部皮肤色素沉着、脱屑、刺痒等。多数患者在初次发作后1~2年内复发, 随着病情的进展, 发作次数逐渐增多,症状持续时间延长,无症状间歇期缩短,甚至症状不能完全缓解,且受累关节逐渐增多。从下肢向上肢、从远端小关节向大关节发展, 出现指、腕、肘等关节受累,少数患者可影响到肩、髋、骶髂、胸锁或脊柱关节,也可累及关节周围滑囊、肌腱、腔鞘等部位,症状和体征渐趋不典型。<br />&nbsp;&nbsp;\n2.1.3 慢性痛风石病变期<br />&nbsp;&nbsp;\n皮下痛风石和慢性痛风石性关节炎是长期显著的高尿酸血症未获满意控制, 体内尿酸池明显扩大, 大量MSU晶体沉积于皮下、关节滑膜、软骨、骨质及关节周围软组织的结果。皮下痛风石发生的典型部位是耳廓,也常见于反复发作的关节周围, 以及鹰嘴、跟腱、髌骨滑囊等处。外观为皮下隆起的大小不一的黄白色赘生物,皮肤表面菲薄,破溃后排出白色粉状或糊状物, 经久不愈。皮下痛风石常与慢性痛风石性关节炎并存。关节内大量沉积的痛风石可造成关节骨质破坏、关节周围组织纤维化、继发退行性改变等。临床表现为持续关节肿痛、压痛、畸形、功能障碍。慢性期症状相对缓和,但也可有急性发作。<br />&nbsp;&nbsp;\n2.1.4肾脏病变<br />&nbsp;&nbsp;\n2.1.4.1慢性尿酸盐肾病：微小的尿酸盐晶体沉积于肾间质, 特别是肾髓质部乳头处, 导致慢性肾小管一间质性肾炎, 引起肾小管萎缩变形、间质纤维化, 严重者可引起肾小球缺血性硬化。临床表现为尿浓缩功能下降, 出现夜尿增多、低比重尿、小分子蛋白尿、白细胞尿、轻度血尿及管型等。晚期可致肾小球滤过功能下降, 出现肾功能不全及高血压、水肿、贫血等。<br />&nbsp;&nbsp;\n2.1.4.2尿酸性尿路结石：尿中尿酸浓度增加呈过饱和状态, 在泌尿系统沉积并形成结石。在痛风患者中的发生率在以上,且可能出现于痛风关节炎发生之前。结石较小者呈砂砾状随尿排出,可无明显症状较大者可阻塞尿路, 引起肾绞痛、血尿、排尿困难、泌尿系感染、肾孟扩张、积水等。<br />&nbsp;&nbsp;\n2.1.4.3急性尿酸性肾病：血及尿中尿酸水平急骤升高,大量尿酸结晶沉积于肾小管、集合管等处, 造成急性尿路梗阻。临床表现为少尿、无尿, 急性肾功能衰蝎尿中可见大量尿酸晶体。这种情况在原发性痛风中少见,多由恶性肿瘤及其放射治疗、化学治疗（即肿瘤溶解综合征）等继发原因引。<br />&nbsp;&nbsp;\n2.2辅助检查<br />&nbsp;&nbsp;\n2.2.1血尿酸的测定：以尿酸酶法应用最广。流行病学研究显示成年男性血尿酸值约为35~70mg/L（1mg=5.945μmol/L）。女性约为25~60mg/L,绝经期后接近男性。在人体的生理条件下, 血中至少98%的尿酸以钠盐的形式存在。MSU的溶解度约为70mg/L,另有4%~5%的MSU与血浆蛋白可逆性结合。因此不分性别、年龄, 血清中MSU的最大饱和量约为70 mg/L,超过此值即为高尿酸血症。由于血尿酸受多种因素影响而波动,应反复测定。<br />&nbsp;&nbsp;\n2.2.2尿尿酸的测定多采用尿酸酶法检测。低嘌呤饮食后, 24h尿尿酸排泄量为>600mg为尿酸生成过多型（约占10%）提示尿酸排泄减少型（约占90%）, 但不能除外同时存在两方面缺陷的情况。在正常饮食情况下, 24h尿尿酸排泄量以800mg进行区分。这项检查对有痛风家族史、年龄较轻、血尿酸水平明显升高、伴有肾结石的患者更为必要。通过检测,可初步判定高尿酸血症的生化分型,有助于降尿酸药物选择及判断尿路结石的性质。<br />&nbsp;&nbsp;\n2.2.3尿酸盐检查：偏振光显微镜下表现为2~20μm强的负性双折光的针状或杆状的MSU晶体。急性发作期关节滑液中可见白细胞内、外的这种晶体在痛风石的抽吸物中,也可发现同样晶体在发作间歇期, 曾受累关节的滑液中也有较高的阳性发现率。普通显微镜也可用来观察,但效果较差。<br />&nbsp;&nbsp;\n2.2.4影像学检查：急性发作期仅见受累关节周围非对称性软组织肿胀反复发作的间歇期可出现一些不典型的放射学改变慢性痛风石病变期可见MSU晶体沉积造成关节软骨下骨质破坏, 出现偏心性圆形或卵圆形囊性变,甚至呈虫噬样、穿凿样缺损,边界较清, 相邻的骨皮质可膨起或骨刺样翘起。重者可使关节面破坏,造成关节半脱位或脱位,甚至病理性骨折也可破坏软骨, 出现关节间隙狭窄以及继发退行性改变、局部骨质疏松等。<br />&nbsp;&nbsp;\n2.2.5超声检查：受累关节的超声检杳可发现关节积液、滑膜增生、关节软骨及骨质破坏、关节内或周围软组织的痛风石、钙质沉积等。超声下出现肾髓质特别是锥体乳头部散在强回声光点,则提示尿酸盐肾病,也可发现X线下不显影的尿酸性尿路结石。超声波检查还可诊断痛风患者经常伴发的脂肪肝。<br />&nbsp;&nbsp;\n3 诊断要点<br />&nbsp;&nbsp;\n原发性痛风的诊断在排除继发性因素后, 还应包括病程分期、生化分型、是否并发肾脏病变、是否伴发其他相关疾病等内容。痛风各期的诊断常有赖于急性发作史, 因此急性痛风性关节炎的诊断最为重要。<br />&nbsp;&nbsp;\n3.1 诊断特点<br />&nbsp;&nbsp;\n3.1.1特征性关节炎：多见于中老年男性,部分患者发作前存在明确的诱因,包括进食高嘌呤食物、酗酒、饥饿、疲劳、受凉、外伤、手术等。自限性的急骤进展的关节炎,特别是累及第一跖趾关节时,高度提示痛风。反复发作多年后, 关节炎呈慢性化,并可出现皮下痛风石。<br />&nbsp;&nbsp;\n3.1.2高尿酸血症：血尿酸升高是痛风发生的最重要的生化基础和最直接的危险因素。随着血尿酸水平的增高,痛风的患病率也逐渐升高, 然而大多数高尿酸血症并不发展为痛风少部分急性期患者,血尿酸水平也可在正常范围,因此,高尿酸血症不能等同于痛风。仅依据血尿酸水平既不能确定诊断、也不能排除诊断。只有特征性关节炎伴高尿酸血症时, 才有助于痛风的临床诊断。<br />&nbsp;&nbsp;\n3.1.3查找MSU晶体：关节滑液或痛风石抽吸物中发现并经鉴定为特异性晶体, 是确诊痛风的金标准。对一些不典型的炎性关节炎, 在关节滑液中查找MSU晶体更为必要。同时应进行革兰染色涂片和病原菌培养, 以除外感染性关节炎。<br />&nbsp;&nbsp;\n3.1.4影像学检查：急性期或早期痛风仅有非对称性软组织肿胀, X线检查对诊断帮助不大, 对慢性痛风石性痛风可见特征性改变,有助于诊断。同时影像学检查可用于痛风的鉴别诊断。<br />&nbsp;&nbsp;\n3.1.5肾脏病变：大约1/3的痛风患者可出现肾脏病变,主要表现为慢性尿酸盐肾病、尿酸性尿路结石等。除尿常规、肾功能检查外, 超声波检查有助于发现肾脏受损情况。<br />&nbsp;&nbsp;\n3.2诊断与鉴别诊断<br />&nbsp;&nbsp;\n急性痛风性关节炎是痛风的主要临床表现, 常为首发症状。反复发作的急性关节炎、无症状的间歇期、高尿酸血症,对秋水仙碱治疗有特效的典型病例, 临床诊断并不困难, 然而也有不典型起病者。在关节滑液或痛风石中检测到晶体可以确诊。目前多采用年美国风湿病学会1977年的分类标准（见表1）进行诊断, 同时应与蜂窝织炎、丹毒、感染化脓性关节炎、创伤性关节炎、反应性关节炎、假性痛风等相鉴别。<br />&nbsp;&nbsp;\nT02_001_01_表11977年ACR急性痛风性关节炎分类标准.docx.<br />&nbsp;&nbsp;\n3.2.2间歇期痛风：此期为反复急性发作之间的缓解状态,通常无明显关节症状, 因此间歇期的诊断有赖于既往急性痛风性关节炎反复发作的病史及高尿酸血症。部分病史较长、发作较频繁的受累关节可出现轻微的影像学改变。此期<br />&nbsp;&nbsp;在曾受累关节滑液中发现MSU晶体, 可确诊。<br />&nbsp;&nbsp;\n3.2.3慢性期痛风：皮下痛风石多于首次发作年以上出现,是慢性期标志。反复急性发作多年,受累关节肿痛等症状持续不能缓解,结合骨关节的X线检查及在痛风石抽吸物中发现晶体, 可以确诊。此期应与类风湿关节炎、强直性脊柱炎、银屑病关节炎、骨关节炎、骨肿瘤等相鉴别。<br />&nbsp;&nbsp;\n3.2.4肾脏病变：慢性尿酸盐肾病可有夜尿增多, 出现尿比重和渗透压降低、轻度红白细胞尿及管型、轻度蛋白尿等,甚至肾功能不全。此时应与肾脏疾病引起的继发性痛风相鉴别。尿酸性尿路结石则以肾绞痛和血尿为主要临床表现,X线片大多不显影,而B超检查则可发现。对于肿瘤广泛播散或接受放射治疗、化学治疗的患者突发急性肾功能衰蝎,应考虑急性尿酸性肾病,其特点是血及尿中尿酸急骤显著升高。<br />&nbsp;&nbsp;\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('290', '20', 'B02_017', '0', '子宫内膜异位症、妊娠高血压综合征及女性不孕症的中西医结合诊疗标准', '无', '中国中西医结合研究会妇产科专业委员', '1990', '中国中西医结合研究会妇产科专业委员会第三届学术会议.子宫内膜异位症、妊娠高血压综合征及女性不孕症的中西医结合诊疗标准.中西医结合杂志.1991,11(6):378-379', '中文', '未报告', '女性不孕症', '未报告', '1.排卵功能障碍：肾虚痰实（多囊卵巢综合症）、肾阴阳两虚（无排卵型月经不调）、肝肾阴虚（高泌乳血症）、肾虚血瘀（无排卵滤泡黄素化综合征）、阴虚火旺（无反应卵巢综合征）、肾虚（黄体不健）2.子宫内膜异位症：血瘀3.输卵管炎（生殖道结核不列入）：气滞血瘀4.子宫肌腺病：胞宫血瘀5.宫腔黏连：气滞血瘀6.免疫性不育：可无证候', '1.排卵功能障碍2.子宫内膜异位症3.输卵管炎（生殖道结核不列入）4.子宫肌腺病5.宫腔黏连6.免疫性不育', null, '妊娠', '治疗后2年以内妊娠者为痊愈', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('291', '19', 'D04-001', '1', '东京指南', 'Results of the Tokyo Consensus Meeting Tokyo Guidelines', null, '2006', 'Toshihiko Mayumi, Tadahiro Takada, Yoshifumi Kawarada, et al.Results of the Tokyo Consensus Meeting Tokyo Guidelines.J Hepatobiliary Pancreat Surg (2007) 14:114–121 DOI 10.1007/s00534-006-1163-8', '英文', '见word截图', '胆囊炎', '未提及', '未提及', '见word截图', '未提及', '未提及', '未提及', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('292', '19', 'D04-002', '1', '急性胆道系统感染的诊断和治疗指南', '无', '中华医学会外科学分会胆道外科学组', '2011', '中华医学会外科学分会胆道外科学组.急性胆道系统感染的诊断和治疗指南[J]中华消化外科杂志,2011,10(1):9-13．', '中文', '轻度:胆囊炎症较轻，未达到中、重度评估标准\n中度:1．白细胞>18×109／L2．右上腹可触及包块3．发病持续时间>72 h4．局部炎症严重：坏疽性胆囊炎。胆囊周围脓肿，胆源性腹膜炎，肝脓肿\n重度:I．低血压，需要使用多巴胺>5ug/kg·min)维持，或需要使用多巴酚丁胺2．意识障碍3．氧合指数<300mmHg(1 mm Hg=O．133 kPa)4．凝血酶原时间国际标准化比值>15 5．少尿(尿量<17 ml／h)，血肌酐>20 mg／L6．血小板<10×109／L', '胆囊炎', '未提及', '未提及', '1.症状和体征:右上腹疼痛(可向右肩背部放射)，Mushy征阳性、右上腹包块／压痛／肌紧张／反跳痛;2.全身反应:发热，c反应蛋白升高(≥30 mr／L)，白细胞升高;3.影像学检查:超声、CT、MBI检查发现胆囊增大，胆囊壁增厚，胆囊颈部结石嵌顿、胆囊周围积液等表现', '未提及', '未提及', '未提及', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('293', '19', 'D04-003', '1', '中国慢性胆囊炎、胆囊结石内科诊疗共识意见', '无', '中华消化杂志编辑委员会', '2014', '中华消化杂志编辑委员会.中国慢性胆囊炎、胆囊结石内科诊疗共识意见(2014年,上海)[J].临床肝胆病杂志,2015,01:7-11', '中文', '未提及', '慢性胆囊炎', '未提及', '未提及', '( 1) 反复发作性的右上腹痛，可向右肩胛下区放射。腹痛发生可与高脂、高蛋白饮食有关。( 2) 可伴消化不良症状，体格检查可有或无右上腹压痛。( 3) 超声等影像学检查发现胆囊结石，和( 或) CCK － HIDA 评估为胆囊低喷射指数( ＜ 35%) 。( 4) 须与急性胆囊炎、功能性消化不良、消化性溃疡、肝脓肿、急性心肌梗死等可能出现右上腹痛的疾病相鉴别', '未提及', '未提及', '未提及', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('294', '19', 'D04-004', '0', '胆囊炎中医诊疗共识意见', '无', '中华中医药学会脾胃病分会', '2011', '中华中医药学会脾胃病分会.胆囊炎中医诊疗共识意见(2011年,海南)[J].中国中西医结合杂志,2012,11(32):1461-1465.', '中文', '未提及', '胆囊炎', '未提及', '1.急性胆囊炎证型：胆腑郁热证、热毒炽盛证 2.慢性胆囊炎证型：肝胆气滞证、肝胆湿热证、胆热脾寒证、气滞血瘀证、肝郁脾虚证、肝阴不足证', '未提及', '3. 1 急性胆囊炎证型\n3. 1. 1 胆腑郁热证主症: ( 1) 持续右胁部剧烈灼痛或绞痛; ( 2) 胁痛阵发性加剧，甚则痛引肩背。次症: ( 1) 口苦口黏; ( 2) 恶心呕吐; ( 3) 发热恶寒; ( 4) 身目明显黄染; ( 5) 小便短赤，大便秘结; ( 6) 舌质红，苔黄或厚腻; ( 7) 脉滑数。主症2 项加次症2 项即可诊断。\n3. 1. 2 热毒炽盛证主症: ( 1) 持续高热; ( 2) 右胁疼痛剧烈; ( 3) 胁痛拒按。次症: ( 1) 身目发黄，黄色鲜明; ( 2) 大便秘结，小便短赤; ( 3) 烦躁不安; ( 4) 舌质红绛，舌苔黄燥; ( 5) 脉弦数。主症2 项加次症2 项即可诊断。\n3. 2 慢性胆囊炎证型\n3. 2. 1 肝胆气滞证主症: ( 1) 右胁胀痛或隐痛; ( 2) 疼痛因情志变化而加重或减轻。次症: ( 1) 厌油腻; ( 2) 恶心呕吐; ( 3) 脘腹满闷; ( 4) 嗳气频作; ( 5)舌质淡红，舌苔薄白或腻; ( 6) 脉弦。主症2 项加次症2 项即可诊断。\n3. 2. 2 肝胆湿热证主症: ( 1) 胁肋疼痛，或胀痛或钝痛; ( 2) 口苦咽干。次症: ( 1) 身目发黄; ( 2) 身重困倦; ( 3) 脘腹胀满; ( 4) 小便短黄; ( 5) 大便不爽或秘结;( 6) 舌质红，苔黄或厚腻; ( 7) 脉弦滑数。主症2 项加次症2 项即可诊断。\n3. 2. 3 胆热脾寒证主症: ( 1) 胁肋疼痛，或胀痛或紧痛; ( 2) 恶寒发热。次症: ( 1) 口干口苦、恶心欲呕; ( 2) 腹部胀满、大便溏泄; ( 3) 肢体疼痛，遇寒加重;( 4) 舌质淡红，苔薄白腻; ( 5) 脉弦滑。主症2 项加次症2 项即可诊断。\n3. 2. 4 气滞血瘀证主症: ( 1) 右胁疼痛，胀痛或刺痛; ( 2) 口苦咽干。次症: ( 1) 胸闷，善太息; ( 2) 右胁疼痛夜间加重; ( 3) 大便不爽或秘结; ( 4) 舌质紫暗，苔厚腻; ( 5) 脉弦或弦涩。主症2 项加次症2 项即可诊断。\n3. 2. 5 肝郁脾虚证主症: ( 1) 右胁胀痛，情志不舒; ( 2) 腹胀便溏。次症: ( 1) 倦怠乏力; ( 2) 腹痛欲泻; ( 3) 善太息; ( 4) 纳食减少; ( 5) 舌质淡胖，苔白;( 6) 脉弦或弦细。主症2 项加次症2 项即可诊断。\n3. 2. 6 肝阴不足证主症: ( 1) 右胁部隐痛不适; ( 2) 两目干涩。次症: ( 1) 头晕目眩; ( 2) 心烦易怒;(3) 肢体困倦; ( 4) 纳食减少; ( 5) 失眠多梦; ( 6) 舌质红，苔少; ( 7) 脉弦细。主症2 项加次症2 项即可诊断。', '综合疗效、超声疗效、症候疗效', '1 急性胆囊炎的综合疗效评定标准临床痊愈: 服药3 ～ 5 天，症状、体征完全消失、体温、血象恢复正常，超声检查胆囊影像正常。显效: 服药3 ～ 5 天，症状、体征消失，体温、血象基本恢复正常，超声检查胆囊或胆管壁的壁厚、毛糙、透声3 项中2 项或2 项以上改善。有效: 服药3 ～ 5 天，症状、体征基本消失，体温、血象基本正常，超声检查胆囊或胆管壁的壁厚、毛糙、透声3 项中1 项或1 项以上改善。无效: 服药3 ～ 5 天，症状、体征及体温、血象无变化，超声胆囊影像无改善\n\n2.胆囊超声疗效评定标准临床痊愈: 超声检查胆囊或胆管壁的壁厚、毛糙、透声3 项恢复正常。显效: 超声检查胆囊或胆管壁的壁厚、毛糙、透声3 项中2 项或2 项以上改善。有效: 超声检查胆囊或胆管壁的壁厚、毛糙、透声3 项中1 项或1 项以上改善。无效: 超声检查均无改善。\n\n3.证候疗效评定标准所有症状都分为无、轻、中、重4 级，在主症分别记0、2、4、6，在次症则分别记0、1、2、3 分。对于舌脉则分为正常和非正常2 级，在主症分别记0、2 分，在次症分别记0、1 分。证候疗效判定标准的计算方法，参照《中药新药临床研究指导原则( 试行) 》［28］的疗效评定标准，采用尼莫地平法计算。疗效指数( %) = ［( 治疗前积分－治疗后积分) /治疗前积分］× 100%。临床痊愈: 症状、体征消失或基本消失，证候积分减少≥95%。显效: 症状、体征明显改善，证候积分减少70% ～ 95%。有效: 症状、体征均有好转，证候积分减少30% ～70%。无效: 症状、体征均无明显好转，甚或加重，证候积分减少＜30%', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('296', '42', 'G01_002', '1', '中国高血压防治指南', null, '中国高血压防治指南修订委员会', '1999', 'http://wenku.baidu.com/view/d5f512619b6648d7c1c7462f.html', '中文', null, '高血压；Hypertension ；Blood Pressure, High', null, null, '收缩压＜120mmHg，舒张压＜80mmHg为正常血压', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('297', '42', 'G01_003', '1', '美国高血压检测治疗全国联合委员会1980年报告', null, '美国高血压检测治疗全国联合委员会', '1980', '刘章永. 高血压的治疗:美国高血压检测治疗全国联合委员会1980年报告[J]. 心血管病译文,1981,04:54-58.', '中文', '1.轻度高血压<br />&nbsp;&nbsp;2.中度高血压<br />&nbsp;&nbsp;3.重度高血压', null, null, null, '轻度高血压（舒张压90-140mmhg）；中度高血压（105-114mmhg）；重度高血压（≥115mmhg）', null, null, '获得并维持舒张压90mmhg一下，另一个合理的目的是获得一个既安全又能耐受的最低舒张压。', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('298', '42', 'G01_004', '1', '高血压防治指南', null, '中国高血压防治指南修订委员会', '2005', '中国高血压防治指南修订委员会. 2004年中国高血压防治指南(实用本)[J]. 高血压杂志, 2004(12):1060-1064.', '中文', '1.1级高血压（轻度）<br />&nbsp;&nbsp;2.亚 组 临 界 高 血 压<br />&nbsp;&nbsp;3.2级 高 血 压（中度）：收缩压<br />&nbsp;&nbsp;4.3级高血压（重度）<br />&nbsp;&nbsp;5.单纯收缩期高血压', '高血压；Hypertension ；Blood Pressure, High', null, null, '收缩压＜120mmHg，舒张压＜80mmHg为正常血压；１级高血压（轻度）：收缩压（140～159）mmHg，舒 张 压（90～99）mmHg。亚 组 临 界 高 血 压：收缩压（140～149）mmHg，舒 张 压 （90～94）mmHg。2级 高 血 压（中度）：收缩压（160～179）mmHg，舒 张 压（100～109）mmHg。3级高血压（重度）：收缩压≥180mmHg，舒张压≥110mmHg。单纯收缩期高血压：收缩压 ≥140 mmHg，舒张压 ＜90 mmHg。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('299', '42', 'G01_006', '1', '中国高血压防治指南2010', null, '高血压联盟（中国）和国家心血管病中心', '2010', '中国高血压防治指南修订委员会. 中国高血压防治指南2010[J]. 中华心血管病杂志, 2011, 39(7):579-616.', '中文', '1级高血压.<br />&nbsp;&nbsp;2.级高血压<br />&nbsp;&nbsp;3.级高血压', '高血压；Hypertension ；Blood Pressure, High', null, null, '在未使用降压药物的情况下，收缩压≥140mmHg和（或）舒张压≥90mmHg；根据血压升高 水 平，又 进 一 步 将 高 血 压 分 为 1 级、2 级 和 3级。一般需要非同日测量3次来判断血压升高及其分级，尤其是轻、中度血压升高者。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('3', '10', 'D02_003', '1', '中国2型糖尿病防治指南（2007年版）', '无', '中华医学会糖尿病学分会', '2007', '2007年版中国2型糖尿病防治指南[J].中华内分泌代谢杂志,2008,24(2):插1-插22', '中文', null, '代谢综合征', null, null, ' ', null, '1.体重降低；<br />&nbsp;&nbsp;2.血压；<br />&nbsp;&nbsp;3.LDL-C、TG、HDL-C；<br />&nbsp;&nbsp;4.空腹血糖、负荷后2h血糖、HbA1c<6.5％。', '针对各种危险因素如糖尿病或糖调节受损、高血压、血脂紊乱以及肥胖等的药物治疗，治疗目标如下：<br />&nbsp;&nbsp;1.体重降低5％以上；<br />&nbsp;&nbsp;2.血压<130/80mmHg；<br />&nbsp;&nbsp;3.LDL-C<2.6mmol/L（100mg/dl）、TG<1.7mmol/L（150mg/dl）、HDL-C>1.04mmol/L（40mg/dl）（男）或>1.3mmol/L（50mg/dl）（女）；<br />&nbsp;&nbsp;4.空腹血糖<6.1mmol/L（110mg/dl）、负荷后2h血糖<7.8mmol/L（140mg/dl）及HbA1c<6.5％。', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('30', '33', 'T02_002', '1', '临床诊疗指南-痛风', '无', '中华医学会', '2005', '中华医学会.临床诊疗指南内分泌及代谢性疾病分册[M].北京：人民卫生出版社，2009.', '中文', '(一)无症状期<br />&nbsp;&nbsp;$\n(二)急性关节炎期<br />&nbsp;&nbsp;\n(三)间歇期<br />&nbsp;&nbsp;\n(四)慢性关节炎与肾病变期<br />&nbsp;&nbsp;\n1.慢性关节炎<br />&nbsp;&nbsp;\n2.肾脏病变，表现为三种形式：<br />&nbsp;&nbsp;\n(1)痛风性肾病<br />&nbsp;&nbsp;\n(2)尿酸性肾结石<br />&nbsp;&nbsp;\n(3)急性肾衰竭<br />&nbsp;&nbsp;', '痛风', null, null, '1.临床表现<br />&nbsp;&nbsp;好发于40岁以上的中老年男性（约占95%），患者常有家族遗传史。临床表现可分为四个阶段：<br />&nbsp;&nbsp;(一)无症状期<br />&nbsp;&nbsp;仅有血尿酸波动性或持续性增高。从血尿酸增高至症状出现可长达数年至数十年，甚至终身无临床症状，称为无症状性高尿酸血症。高尿酸血症同时伴痛风性关节炎，才可诊断为痛风。<br />&nbsp;&nbsp;(二)急性关节炎期<br />&nbsp;&nbsp;是原发性痛风最常见的首发症状，初发时往往仅罩及小关节，后发展为多关节受罩，以足拇趾的趾关节为好发部位，其次为足底、踝、足跟、膝、腕、指和肘，第一次发作通常在夜间，数小时内局部关节即出现红、肿、热、痛，并伴有发热、白细胞增多与血沉增快等全身症状。疼痛往往十分剧烈，轻度按压便可有剧烈疼痛，患者常在夜间痛醒而难以忍受。受寒、劳累、副酒、食物过敏、进食含呤食物、感染、创伤和手术等，为常见的诱发因素。<br />&nbsp;&nbsp;(三)间歇期<br />&nbsp;&nbsp;少数患者终身可只发作一次便不再复发.也有偶尔5-10年后复发，一般在6个月至2年内会第二次发作。通常病程愈长、发作愈多，病情也愈重，并出现X线改变。<br />&nbsp;&nbsp;(四)慢性关节炎与肾病变期<br />&nbsp;&nbsp;1.慢性关节炎多见于未经治疗或治疗不规则、反复发作者。其病理基础是痛风石在骨关节周围组织中形成井引起关节的慢性损伤，称为痛风性慢性关节炎。此期关节炎发作较频，间歇期缩短，疼痛日益加剧，甚至发作后不能完全缓解。痛风石的形成是由于尿酸盐沉积在软骨、滑膜、肌胞和软组织的结果，为本期常见的特征性表现。痛风石常见于耳廓、阳趾、指间、掌指、肘等关节附近。<br />&nbsp;&nbsp;亦可见于尺骨鹰嘴滑车和跟腔内。痛风本身虽然不痛，但若痛风石形成过多并毁损关节可致于足畸形、功能障碍。痛风石表面的皮肤可变得十分薄弱，一旦渍破可排出白色粉末状尿酸盐结晶，此时病变一般已至晚期。<br />&nbsp;&nbsp;2.肾脏病变病程较长的痛风患者约1/3 有肾脏损害，表现为三种形式：<br />&nbsp;&nbsp;(1)痛风性肾病：为过多的尿酸盐沉积在肾间质内所致。早期可仅有间歇性蛋白尿和显微镜下血尿，随着病程进展逐渐转为持续性蛋白尿，肾浓缩功能受损，出现夜尿增多、等渗尿等。晚期发展为慢性肾功能不金。部分患者以痛风性肾病为最先的临床表现，而关节炎症状不明显，易与肾小球肾炎和原发性高血压合并肾病混淆。<br />&nbsp;&nbsp;(2)尿酸性肾结石：部分患者可以尿酸性肾结石为首发表现。若为细小泥沙样结石.因可随尿液排出故可无症状，而较大结石则常引起肾绞痛、血尿及尿路感染等症状。<br />&nbsp;&nbsp;(3)急性肾衰竭：由于大量尿酸盐结晶堵塞在肾小管、肾孟及输尿管内，引起尿路梗塞. 患者突然出现少尿甚至元尿，如不及时处理.可迅速发展为急性肾衰竭。<br />&nbsp;&nbsp;\n2.实验室检查<br />&nbsp;&nbsp;\n2.1血尿酸测定<br />&nbsp;&nbsp;\n用尿酸酶法所测得的血清尿酸正常范围为150~380μmol/L(2.4~6.4mg/dL)(男性)和100~300mol/L[1.6~3.2mg/dl(女性)]。男性高尿酸血症者一般血尿酸值大于420μmol/L，女性大于300μmol/L。<br />&nbsp;&nbsp;\n2.2 尿尿酸测定<br />&nbsp;&nbsp;\n痛风患者在限制嘌呤饮食后尿尿酸仍超过3.57mmol/L(600mg/d)，提示尿酸生成增多。<br />&nbsp;&nbsp;\n2.3滑囊液检查<br />&nbsp;&nbsp;\n急性痛风性关节炎时，关节滑囊穿刺液内可发现自细胞内有双折光性针形尿酸盐结晶，常伴多形核白细胞增多。<br />&nbsp;&nbsp;\n2.4痛凤结节内容物检查<br />&nbsp;&nbsp;\n痛风结节破溃物或穿刺液内可发现尿酸结晶。<br />&nbsp;&nbsp;\n2.5特殊位查<br />&nbsp;&nbsp;\nX线检查可发现受累关节的骨软骨缘邻近关节的骨质可有圆形或不整齐、穿凿样透亮缺损，系尿酸盐侵蚀骨质所致，为痛风的X线特征。<br />&nbsp;&nbsp;\n3.诊断要点<br />&nbsp;&nbsp;\n以下为诊断依据，尤以前三点最为重要：<br />&nbsp;&nbsp;\n3.1血尿酸增高；<br />&nbsp;&nbsp;\n3.2关节腔穿刺取滑囊液，证实存在尿酸盐结晶；<br />&nbsp;&nbsp;\n3.3痛风石活检或穿刺内容物，证实为尿酸盐结晶；<br />&nbsp;&nbsp;\n3.4受累关节X 线检查，呈痛风的X线特征；<br />&nbsp;&nbsp;\n急性关节炎期确诊有困难时，可试用秋水仙碱作诊断性治疗，如为痛风，服秋水仙碱后症状迅速缓解，具诊断意义。<br />&nbsp;&nbsp;\n\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('300', '42', 'G01_007', '1', '《1984美国成人高血压管理指南（JNC3）》', 'The third report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.', '美国高血压全国联合会', '1984', null, '英文', '1.正常偏高血压<br />&nbsp;&nbsp;2.\n轻度高血压<br />&nbsp;&nbsp;3.\n中度高血压<br />&nbsp;&nbsp;4.\n重度高血压<br />&nbsp;&nbsp;5.\n单纯收缩期高血压<br />&nbsp;&nbsp;6.\n临界收缩期高血压', '高血压；Hypertension ；Blood Pressure, High', null, null, ' SP  DP\n正常血压 SP<140，DP <85\n正常偏高血压 DP 85～89\n轻度高血压 DP 90～104\n中度高血压  DP105～114\n重度高血压  DP≥115\n单纯收缩期高血压 SP≥160 DP<90\n临界收缩期高血压 SP141～139 DP<90\n', null, null, null, '1.正常血压定为<140 /85,与原来140 /90仍属正常,显然不同,同时首次提出正常偏高血压的概念,认为DP85～ 89非属完全正常。2.重视了单纯性收缩期血压的增高,但在高血压分度中, SP水平并未起作用。3.未提出1978年WHO高血压分期标准。4.轻度高血压标准放宽, DP由原95～改为90～', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('301', '42', 'G01_008', '1', '《1993美国成人高血压管理指南（JNC5）》', 'The fifth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.', '美国高血压全国联合会', '1993', 'http://archinte.jamanetwork.com/article.aspx?articleid=616929\nArch Intern Med. 1993 Jan 25;153(2):154-83.', '英文', '4', '高血压；Hypertension ；Blood Pressure, High', null, null, '  \n正常血压 SP<130DP <85\n正常高值血压SP 130～139 DP85～89\nⅠ期(轻度)SP 140～159 DP90～99\nⅡ期(中度)SP 160～179 DP100～109\nⅢ期(重度)SP 180～209 DP110～119\nⅣ期(极重度) SP≥210 DP≥120\n', null, null, null, '1.进一步地重视SP的作用,表现为:①正常SP变得严格,为<130;而130～ 139列为正常高限,应定期随访,开始非药物性治疗;②开始重视SP在高血压分度中作用,只要DP或DP一项达到高一级水平,即属高一度,改变了以往多年来分度仅以DP水平为准的状况。2.初步地重视了高血压患者其他危险因素作用。3.高血压以分期代替原分度。4.取消了临界性高血压,将其归属于轻度高血压范畴。5.将高血压严重度从三级改为四级。轻度是对重度相对而言,在预后方面并非轻度均是良性,各期均能引起并发症,不过血压越高发生TOD愈多。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('302', '42', 'G01_009', '1', '《1997美国成人高血压管理指南（JNC6）》', 'The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.', '美国高血压全国联合会', '1997', 'http://www.nhlbi.nih.gov/files/docs/guidelines/jnc6_archive.pdf\nArch Intern Med. 1997 Nov 24;157(21):2413-46.', '英文', '1.Ⅰ期<br />&nbsp;&nbsp;2.Ⅱ期<br />&nbsp;&nbsp;3.Ⅲ期', '高血压；Hypertension ；Blood Pressure, High', null, null, '  \nLaboratory Tests and Other Diagnostic Procedures<br />&nbsp;&nbsp;Routine laboratory tests reoommended beforeinitiating  therapy  are teststo det ermine the pres-enoe of target organ damage and other risk fac-tors  These routinetestsindude urinalyss, oom-plete blood畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭턀ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽⩐ఆ䥠ఆ彿㎽䥔ఆ塚㎽䥠ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂圔㎽ﺼఅ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0턀ਘ䐺盭暼痭턀ਘༀƙ \0턀ਘĀ\0\0㺣盭턀ਘ\0ﱔ턄ਘ\0팃目턄ਘ࣒턄ਘ큁目턄ਘﻰఅ﫬\0Item\0\0䧤ఆ\0\0\0\0\0\0Count\0\0ﱬﬄ턴ਘ㳜੪\0\0턄ਘ\0\0\0\0੪寶目㳠੪矵䥷㎽⩐ఆ\0\0䧤ఆ�㏂䥔ఆ\0\0\0੪\0\0\0謁ﱔ\0\0㎾৖\0ﱜ\0\0x�㏂䥔ఆ\0\0隲W䧤ఆ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\n\0霪W露W\0\0ﱴxt\0Љ\0\0\0௱鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0쓠ఌ쓠ఌ㲈੪ﷰఅ寶目㲈੪ﷰఅi\0\0ﱄ﷜ﱴﲔ먙㎼ﷰఅ㲈੪i\0\0ﱄ﷜ﱴ먰㎼﷜ﷰఅ�㏂ﵠఅ\0\0릎㎼ﷰఅi\0╪췬目╾췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒௱竗௱目W\0竗\0\0\0賓器目\0\0\0\0ﻰఅ\0目瑉浥目\0\0\0\0ﻰఅ\0目潃湵t￿\0\0\0兔੏翽捥盦Ȓ묞￾￿옎盡伛盡\0\0٣դल9đ\0Т̀Т#璴Ʃ伦盡㋪췭璠Ʃđ\0\0\0\0\0\0\0\0\0\0捥盦謺묞￾￿伦盡侍盡璠Ʃ☶췬目Љ\0⟆췬目Љ\0⟒췬⟚췬目Љ\0鲸࣒\0￿￿目Љ\0鲬࣒௱觴௱目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨﷰఅ目潅f摲敳t盡燎捥盦通묞￾￿吊盡璀Т#괠ਝ葌৻璀綻眶g\0Т#\0\0≻뤁.\0ሱ\0\0\0䛌E\0덐ɫ‾Q岛@\0䛌E\0덐ɫ‾Q岛@\0⎐ۓ﮵S豀ɳ\0덐ɫ\0﯏S臀ɳ\0豀ɳ\0䛌E\0템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂奈瞒⫠\0\0\0瞒⪌쀕瞒若〠\0䪔㏂\0T\0\0⪌쀕\0\0ꀀ翽翽凜瞒郎瘝䪔㏂\0邰ƙ\0\0ࠀᴒ眊\0\0䪔㏂瘝\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ﫜ﷰఅﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀勤﬘眿捻ฒ䧤ఆ﫨ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿﫜￿￿\0\0﫦\0\0￿', null, null, null, '1.增添了理想血压,临床流行病学调查,BP120 /80以下并发症机率最低,冠心病易患率很低。并发肾病患者,血压应降至理想血压水平,延缓肾病变发展。2.扩大了WHO关于TOD内容(5项),但不作为EH的分期用,而作为其危险分度用。3.鉴于JNC-Ⅴ之间Ⅳ期高血压临床少见,与Ⅲ期合并。4.增添了自测血压和24小时ABPM正常标准。5.重视了高血压的危险分层在治疗中的作用,将TOD、RF,与血压水平有机结合起来制定了三个危险层。按不同层次决定不同治疗方法,做到对心血管病进行整体性和综合性控制。对血压正常高限人畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭턀ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('303', '42', 'G01_010', '1', '美国高血压联合会第七次报告', 'JNC-7', '美国高血压全国联合会', '2003', 'http://hyper.ahajournals.org/content/42/6/1206.full', '英文', '1.正常血压<br />&nbsp;&nbsp;2.高血压前期<br />&nbsp;&nbsp;3.1级高血压<br />&nbsp;&nbsp;4.2级高血压', '高血压；Hypertension ；Blood Pressure, High', null, null, '美国JNC7将血压分为4档，即：正常血压、高血压前期（prehypertensive）、1级高血压、2级高血压；收 缩 压（120～129）mmHg或 舒 张 压（80～89）mmHg称为高血压前期；收 缩 压（140～159）mmHg或 舒 张压（90～99）mmHg称为1期高血压；收缩压≥160 mmHg或 舒 张 压 ≥100 mmHg称 为“2期 高血压', null, null, '合并症的高血压患者（目标血压<140/90mmHg）与糖尿病和慢性肾病等心血管高危人群（目标血压＜130/80 mmHg）；JNC7 指南中建议将老年高血压患者控制在＜140/90 mmHg ', '50岁以上的成年人，收缩压＞140，是比舒张压更为重要的心血管疾病危险因素。①去掉了理想血压；②将正常血压及高值血压合并为高血压前期血压；③将原3级高血压去掉，将2级血压和3级血压合并为2级血压；④无收缩期高血压岁临界高血压部分。新的分类体现了高血压个体的治疗提前了，强调对收缩压的控制，尤其是５０岁以上年龄的患者。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('304', '42', 'G01_011', '1', '2006AACE 高血压的诊断和治疗临床实践指南', '2006AACE American Association of Clinical Endocrinologist medical guidelines for clinical practice for the diagnosis and treatment of hypertension', '\n美国临床内分泌医师学会(AACE,American Association of Clinical Endocrinologists)', '2006', 'Endocr Pract. 2006 Mar-Apr;12(2):193-222.', '英文', null, '高血压；Hypertension ；Blood Pressure, High', null, null, '采用JNC/1999WHO', null, null, 'Optimal BPlevels for those patients with advancing renal insufficiency or substantial proteinuria (or both) have previously been proposed as 120/75 mmHg or below', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('305', '42', 'G01_012', '1', '《2014美国成人高血压管理指南（JNC8）》', 'JNC Late', '美国国家高血压防治委员会', '2014', 'James P A, Oparil S, Carter B L, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults[J]. Jama Journal of the American Medical Association, 2014, 30(2):611.', '英文', null, '高血压；Hypertension ；Blood Pressure, High', null, null, null, null, null, '60岁以上老年高血压患者的高血压治疗目标值应为 150/90mmHg；30-59岁高血压患者舒张压应低于90mmHg。但是这一年龄段高血压患者收缩压的推荐治疗目标值目前没有充足的证据支持，30岁以下高血压患者舒张压的治疗目标值也没有证据支持。因此专家组推荐，这类人群的高血压治疗目标应低于140/90mmHg。此外，对于60岁以下罹患高血压合并糖尿病，或高血压合并非糖尿病性慢性肾脏疾病(CKD)患者，指南推荐的治疗目标值和60岁以下普通高血压人群一致。', '（1）对于≥60岁的老年患者，当血压≥150/90mmHg时可考虑启动药物治疗，并将血压降至此值以下。\n年龄＜60岁者和（或）糖尿病和慢性肾病患者，血压≥140/90mmHgg即考虑启动降压药物治疗，并将血压控制在此值以下。\n（2）噻嗪类利尿剂、CCB、ACEI 和 ARB 四大类药物作为初始治疗药物（一线治疗药物，黑人仅利尿剂与 CCB），可单独或联合使用；β 受体阻滞剂退出一线，降至四线，与螺内酯同等地位。  （3）新指南强调了达标和维持目标（长期达标）[The main objective of h畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽㤤ఆ亴ఆ彿㎽亨ఆ塚㎽亴ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂圔㎽ﺼఅ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0턀ਘ䐺盭暼痭턀ਘༀƙ \0턀ਘĀ\0\0㺣盭턀ਘ\0ﱔ턄ਘ\0팃目턄ਘ࣒턄ਘ큁目턄ਘﻰఅ﫬\0Item\0\0伸ఆ\0\0\0\0\0\0Count\0\0ﱬﬄ턴ਘ㳜੪\0\0턄ਘ\0\0\0\0੪寶目㳠੪矵䥷㎽㤤ఆ\0\0伸ఆ�㏂亨ఆ\0\0\0੪\0\0\0謁ﱔ\0\0㎾Ѩ\0ﱜ\0\0x�㏂亨ఆ\0\0隲W伸ఆ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('306', '42', 'G01_013', '1', '《美国社区高血压管理临床实践指南》', 'Clinical Practice Guidelines for the Management of Hypertension in the Community A Statement by the American Society of Hypertension and the International Society of Hypertension', '美国高血压学会（ASH）和国际高血压学会（ISH）', '2013', 'J Hypertens. 2014 Jan;32(1):3-15.', '英文', '1.高血压前期<br />&nbsp;&nbsp;2.高血压第一阶段<br />&nbsp;&nbsp;3.高血压第二阶段', '高血压；Hypertension ；Blood Pressure, High', null, null, '高血压前期：收缩压120-139 mmHg，或舒张压80-89 mmHg；不应接受降压药物，但应该鼓励改变生活方式，延缓进展为高血压的进程；高血压第一阶段：收缩压140-159 mmHg，或舒张压90-99 mmHg；\n高血压第二阶段：收缩压≥160 mmHg，或舒张压≥100 mmHg；', null, '（1）治疗目标是：管理血压并处理其他确定的心血管危险因素，包括脂质异常、糖耐量受损或糖尿病、肥胖和吸烟等。2）目标值：＜140/90mmHg。3）对于上述目标值是否存在例外？多数对于心血管和肾脏结局的证据均基于55-80岁的中老年患者。进来有试验显示≥80岁的老年人血压＜150 mmHg对心血管疾病和卒中有更好的保护作用，因此推荐该组人群目标值为＜150/90 mmHg。几乎没有年龄＜50岁患者目标值的临床试验；该年龄段舒张压可能更重要，所以优先考虑舒张压目标值——＜90 mmHg；此外，低于140/90畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0', null, 'ASH指南与JNC8指南的异同。共同点——均放宽了特殊人群血压控制目标，均降低了β阻滞剂的地位；不同点——JNC8认为4类一线药物可任选，而ASH建议年轻选ACEI/ARB，老年人选CCB与利尿剂，这与英国指南相似。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('307', '42', 'G01_014', '1', '2014高血压诊断与治疗指南', 'Health Care Guideline:Hypertension Diagnosis and Treatment', 'ICSI(institute for clinical systems improvement)', '2014', 'ICSI官网', '英文', '1.高血压前期<br />&nbsp;&nbsp;2.高血压第一阶段<br />&nbsp;&nbsp;3.高血压第二阶段', '高血压；Hypertension ；Blood Pressure, High', null, null, 'Hypertension Stages Systolic(BPmmHg)  Diastolic(BPmmHg)\nPrehypertension 120-139 or 80-89\nStage1 hypertension 140-159 or 90-99\nStage2 hypertension >160 or >100 \n\n', null, 'Possible measures of accomplishing this aim:a. Percentage of adult patients with a blood pressure documented at every clinic visit.b. Percentage of adult patients who have a blood pressure reading less than 140/90 mmHg at theirclinic visit. (MN Community 畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽㈨ఆ䱐ఆ彿㎽䱄ఆ塚㎽䱐ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂圔㎽ﺼఅ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0ਘ䐺盭暼痭ਘༀƙ \0ਘĀ\0\0㺣盭ਘ\0ﱔਘ\0팃目ਘ࣒ਘ큁目ਘﻰఅ﫬\0Item\0\0䳔ఆ\0\0\0\0\0\0Count\0\0ﱬﬄਘ㳜੪\0\0ਘ\0\0\0\0੪寶目㳠੪矵䥷㎽㈨ఆ\0\0䳔ఆ�㏂䱄ఆ\0\0\0੪\0\0\0謁ﱔ\0\0㎾٦\0ﱜ\0\0x�㏂䱄ఆ\0\0隲W䳔ఆ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\0霪W露W\0\0ﱴxt\0Љ\0\0\0௱鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0쓠ఌ쓠ఌ㲈੪ﷰఅ寶目㲈੪ﷰఅi\0\0ﱄ﷜ﱴﲔ먙㎼ﷰఅ㲈੪i\0\0ﱄ﷜ﱴ먰㎼﷜ﷰఅ�㏂ﵠఅ\0\0릎㎼ﷰఅi\0╪췬目╾췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒௱竗௱目W\0竗\0\0\0賓器目\0\0\0\0ﻰఅ\0目瑉浥目\0\0\0\0ﻰఅ\0目潃湵t￿\0\0\0兔੏翽捥盦Ȓ묞￾￿옎', null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('308', '42', 'G01_015', '1', '2008ICSI 高血压诊断和治疗指南', '2008ICSI Health Care Guideline: Hypertension Diagnosis and Treatment', 'ICSI(institute for clinical systems improvement)\n临床系统改进协会(ICSI,Institute for Clinical Systems Improvement)', '2008', 'ICSI官网', '英文', '1.高血压前期<br />&nbsp;&nbsp;2.高血压第一阶段<br />&nbsp;&nbsp;3.高血压第二阶段', '高血压；Hypertension ；Blood Pressure, High', null, null, '\nNormal < 120mmHg  and < 80mmHg \nPrehypertension 120-139mmHg  or 80-89mmHg \nStage 1 hypertension 140-159mmHg  or 90-99mmHg \nStage 2 hypertension > 160mmHg  or > 100mmHg <br />&nbsp;&nbsp;A. Primary Reports of New Data Collection:\nClass A: Randomized, controlled trial\nC畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭쳠ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽⩐ఆ䥠ఆ彿㎽䥔ఆ塚㎽䥠ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂圔㎽ﺼఅ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0쳠ਘ䐺盭暼痭쳠ਘༀƙ \0쳠ਘĀ\0\0㺣盭쳠ਘ\0ﱔ쳤ਘ\0팃目쳤ਘ࣒쳤ਘ큁目쳤ਘﻰఅ﫬\0Item\0\0䧤ఆ\0\0\0\0\0\0Count\0\0ﱬﬄ촔ਘ㳜੪\0\0쳤ਘ\0\0\0\0੪寶目㳠੪矵䥷㎽⩐ఆ\0\0䧤ఆ�㏂䥔ఆ\0\0\0੪\0\0\0謁ﱔ\0\0㎾ט\0ﱜ\0\0x�㏂䥔ఆ\0\0隲W䧤ఆ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\n\0霪W露W\0\0ﱴxt\0Љ\0\0\0௱鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0쓠ఌ쓠ఌ㲈੪ﷰఅ寶目㲈੪ﷰఅi\0\0ﱄ﷜ﱴﲔ먙㎼ﷰఅ㲈੪i\0\0ﱄ﷜ﱴ먰㎼﷜ﷰఅ�㏂ﵠఅ\0\0릎㎼ﷰఅi\0╪췬目╾췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒௱竗', null, 'Goal office blood pressures should be less than 140/90 mm Hg for adults with uncomplicated hypertension (in the absence of comorbidities). [Conclusion Grade II: See Conclusion Grading Worksheet A – Annota-tion #7 (Goal Blood Pressure for Patients with Car畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭쳠ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽㈨ఆ䱐ఆ彿㎽䱄ఆ塚㎽䱐ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂圔㎽ﺼఅ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0쳠ਘ䐺盭暼痭쳠ਘༀƙ \0쳠ਘĀ\0\0㺣盭쳠ਘ\0ﱔ쳤ਘ\0팃目쳤ਘ࣒', null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('309', '42', 'G01_016', '1', '2003欧州高血压学会，心脏学会高血压防治指南', '2003 European society of hypertension European society of cardiology guidelines for the management of arterial hypertension', '欧洲高血压学会/欧洲心脏学会', '2003', 'http://www.doc88.com/p-1847569062436.html', '英文', '1.理想血压<br />&nbsp;&nbsp;2.正常血压<br />&nbsp;&nbsp;3.正常高值血压<br />&nbsp;&nbsp;4.高血压1级<br />&nbsp;&nbsp;5.高血压2级<br />&nbsp;&nbsp;6.高血压3级<br />&nbsp;&nbsp;6.单纯收缩期高血压', '高血压；Hypertension ；Blood Pressure, High', null, null, '血压分类基本沿用（WHO/ISH0999年）的分类，但去掉临界高血压的部分。其特点分为7档：理想血压、正常血压、正常高值血压、高血压1级、2级、3级及单纯收缩期高血压。理想血压 收缩压＜120 和 舒张压＜80正常血压收缩压 120～129 和（或）舒张压 80～84\n正常高值 收缩压130～139 和（或）舒张压 85～891级高血压收缩压 140～159 和（或）舒张压 90～99\n2级高血压 收缩压160～179 和（或） 舒张压100～109\n3级高血压收缩压 ≥180 和（或） 舒张压≥110\n畻坴畿\0\0\0\0醼畻聱盯\n\0\0', null, null, null, '特别指出正常高危这组“高血压”治 疗，而 对 低 危 者 则 没 有 使 用 降 压 药 的 指 征。并取消了“临界”高血压亚组，分别合并为１级（轻度）高血压和单纯收缩期高血压。欧洲指南中强调，JNC7中的“高血压前期”对于糖尿病、脑卒中或心肌梗死后的患者可能是高血压，正常高值血压划分有利于糖尿病患者的血压控制，同时，欧洲指南根据此分类决定进行危险分层以决定治疗强度及治疗手段。ESH高血压指南强调了危险分层和量化预后，且对正常血压、正常高值也作了危险分层。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('31', '33', 'T02_003', '0', 'ZYYXH/T 120-2008 痛风和高尿酸血症', '无', '中华中医药学会', '2008', null, '中文', '无症状期；<br />&nbsp;&nbsp;急性痛风性关节炎期；<br />&nbsp;&nbsp;慢性关节炎期；<br />&nbsp;&nbsp;痛风性肾病<br />&nbsp;&nbsp;', '痛风;高尿酸血症', null, '2.1肝肾阴虚证<br />&nbsp;&nbsp;\n2.2脾肾阳虚证<br />&nbsp;&nbsp;\n2.3气阴两虚证<br />&nbsp;&nbsp;\n2.4阴阳两虚证<br />&nbsp;&nbsp;\n2.5兼夹证<br />&nbsp;&nbsp;\n夹湿热<br />&nbsp;&nbsp;\n夹寒湿<br />&nbsp;&nbsp;\n夹水湿<br />&nbsp;&nbsp;\n夹湿浊<br />&nbsp;&nbsp;\n夹瘀血<br />&nbsp;&nbsp;\n', '1诊断依据<br />&nbsp;&nbsp;\n临床表现根据临床表现分为四期：<br />&nbsp;&nbsp;\n1.1.1无症状期：仅有高尿酸血症；随病程年限的增高症状出现率增高,但也有终身仅为此期而无症状者。<br />&nbsp;&nbsp;\n1.1.2急性痛风性关节炎期：患者往往在夜间突然发病,以拇趾及第一踢趾关节为主,多见关节红、肿、热、痛,关节腔可有渗液。常伴有发热、畏寒、头痛、乏力等全身症状。急性关节病变亦可见于躁、膝、足跟等下肢关节,而腕、肘、肩、指、胸、锁、脊椎、髓、骸骼关节则较少累及。在发作时血白细胞增高,红细胞沉降率增高。经:1~2日或1~2周后可自行缓解,病变部位皮肤留有色素沉着。在缓解期无任何症状,间歇期长短不一,多数患者于半年后再复发,亦可有发作次后终生不再发作者。<br />&nbsp;&nbsp;\n受凉、劳累、饮酒、进食高嘌呤类食物,创伤、手术及服用影响尿酸排泄的药物等均可诱发急性痛风性关节炎的发作。<br />&nbsp;&nbsp;\n1.1.3慢性关节炎期：急性痛风性关节炎的反复发作可发展为多关节受累,并从急性期的关节局部肿胀发展为慢性期的关节畸形、局部骨质缺损。尿酸盐结晶沉积于关节附近的肌键、腿鞘及皮肤结缔组织中,形成大小不一的痛风石,多见于肠趾、手指、肘部、耳轮、对耳轮等处。痛风石沉着处皮肤可破溃,形成痰管流出白色粉样尿酸盐结晶。受累关节在X片上可见到骨软骨缘的骨质缺损,骨关节间隙变宽,痛风石还可沉着于主动脉、主动脉瓣、二尖瓣、心肌、声带、舌、鼻软骨等处,但较少见。<br />&nbsp;&nbsp;\n1.1.4痛风性肾病：早期可仅有间歇性蛋白尿,尿比重降低。病情进展可持续出现蛋白尿,高血压疾病缓慢发展进而血尿素氮、血肌醉增高,\'肾功能不全而危及生命。<br />&nbsp;&nbsp;\n尿酸盐通过尿路排出量增多,可发生尿路尿酸结石而致肾绞痛、血尿排出结石等。尿酸结石如无钙化形成复合结石时,在线检查时不能被发现。<br />&nbsp;&nbsp;\n1.2理化检查<br />&nbsp;&nbsp;\n1.2.1血尿酸测定：用尿酸氧化酶法所测得的血清尿酸正常范围：150~380μmol/L（2.4~6.4mg/dl）男性和100~300μmol/L（1.6~3.2 mg/dl）女性。男性高尿酸血症者一般血一般血尿酸值>420μmol/L,女性>300μmol/L。急性痛风性关节炎发作前的高尿酸血症对发作有一定的预测及诊断价值,但急性发作期血尿酸增高的程度与临床症状的轻重程度不一定平行,少数患者在急性发作期时的血尿酸水平正常急性期过后,往往发现血尿酸增高。<br />&nbsp;&nbsp;\n1.2.2尿尿酸测定痛风患者在限制嘿吟饮食后尿尿酸仍,提示尿酸生成增多。<br />&nbsp;&nbsp;\n1.2.3滑囊液检查：急性痛风性关节炎时,关节滑囊空刺液内可发现白细胞内有双折光性针形尿酸盐结晶,常伴多形核白细胞增多。<br />&nbsp;&nbsp;\n1.2.4痛风结节内容物检查：痛风结节破溃物或穿刺液内可发现尿酸结晶。尿道排出的结石,经分析其成分,可证实为尿酸盐。<br />&nbsp;&nbsp;\n1.2.5特殊检查线：<br />&nbsp;&nbsp;\nX线检查可发现受累关节的骨软骨缘邻近关节的骨质可有圆形或不整齐、穿凿样透亮缺损,系尿酸盐侵蚀骨质所致,为痛风的线特征。受累的关节,早期仅有软组织肿胀。部分患者可见到的骨质缺损。随病程进展,病情加重,可见到痛风结节附近骨质不规则或分叶状凹陷。在慢性关节炎期骨软骨缘邻近的骨质有圆形或不规则的凿样透亮缺损,骨关节间隙狭窄。<br />&nbsp;&nbsp;\n1.3诊断要点<br />&nbsp;&nbsp;\n依据2005年中华医学会《临床诊疗指南•内分泌及代谢性疾病分册》典型的痛风性关节炎发作表现、特殊的诱发因素、家族史、好发年龄,以及尿酸结石病史等,可疑及痛风。以下为诊断依据,尤以前三点最为重要：<br />&nbsp;&nbsp;\n1.3.1血尿酸增高。<br />&nbsp;&nbsp;\n1.3.2关节腔穿刺取滑囊液,证实存在尿酸盐结晶。<br />&nbsp;&nbsp;\n1.3.3痛风石活检或穿刺内容物,证实为尿酸盐结晶。<br />&nbsp;&nbsp;\n1.3.4受累X关节线检查,呈痛风的X线特征。<br />&nbsp;&nbsp;\n急性关节炎期确诊有困难时,可试用秋水仙碱作诊断性治疗,如为痛风,服秋水仙碱后症状迅速缓解,具有诊断意义。<br />&nbsp;&nbsp;\n', '2.1肝肾阴虚证<br />&nbsp;&nbsp;\n证候：腰膝酸痛,双目干涩,五心烦热,口干喜饮,大便干结,尿赤或沙石尿,舌淡红或舌红少苔,脉弦细。<br />&nbsp;&nbsp;\n2.2脾肾阳虚证<br />&nbsp;&nbsp;\n证候：气短乏力,纳少腹胀,四肢不温,腰膝酸软,夜尿多且清长,大便塘,舌体胖大,舌质淡,舌边有齿痕,脉沉细。<br />&nbsp;&nbsp;\n2.3气阴两虚证<br />&nbsp;&nbsp;\n证候：神疲乏力,自汗气短,手足心热,咽干口燥,口渴喜饮或饮水不多,大便或干或稀,舌质淡红边有齿痕,脉沉细。此为临床最常见证候。<br />&nbsp;&nbsp;\n2.4阴阳两虚证<br />&nbsp;&nbsp;\n证候：面色少华,畏寒肢冷,腰酸腰痛,口干欲饮,或有水肿,大便或干或稀,舌胖而质淡,脉沉细或沉弱。多见于痛风末期。<br />&nbsp;&nbsp;\n2.5兼夹证<br />&nbsp;&nbsp;\n夹湿热：兼关节肿痛发热,口渴烦躁,尿黄赤,舌红苔黄腻。<br />&nbsp;&nbsp;\n夹寒湿：兼关节疼痛,遇寒加重,得温痛减。<br />&nbsp;&nbsp;\n夹水湿：主要表现为水肿。<br />&nbsp;&nbsp;\n夹湿浊：湿浊阻滞中焦者。<br />&nbsp;&nbsp;\n夹瘀血：常有肢痛肢麻,关节不利,唇暗,舌质暗或有癖斑痛点。<br />&nbsp;&nbsp;\n', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('310', '42', 'G01_017', '1', '2007欧州高血压学会，心脏学会高血压防治指南', null, '欧洲高血压学会/欧洲心脏学会', '2007', '陈建华, 宋和平, 陆瑾. 国内外高血压诊断标准比较[J]. 中西医结合心脑血管病杂志, 2014(5):527-528.', '英文', '1.理想血压<br />&nbsp;&nbsp;2.正常血压<br />&nbsp;&nbsp;3.正常高值血压<br />&nbsp;&nbsp;4.高血压1级<br />&nbsp;&nbsp;5.高血压2级<br />&nbsp;&nbsp;6.高血压3级<br />&nbsp;&nbsp;6.单纯收缩期高血压', '高血压；Hypertension ；Blood Pressure, High', null, null, '血压水平的定义和分类a（mmHg）\n理想血压 收缩压＜120 和 舒张压＜80正常血压收缩压 120～129 和（或）舒张压 80～84\n正常高值 收缩压130～139 和（或）舒张压 85～891级高血压收缩压 140～159 和（或）舒张压 90～99\n2级高血压 收缩压160～179 和（或） 舒张压100～109\n3级高血压收缩压 ≥180 和（或） 舒张压≥110\n单纯收缩期高血压 收缩压≥140 和舒张压 ＜90', null, null, null, '新版指南强调了高血压的真正阈值是灵活的，而应根据总的心血管危险因素的高低决定。血压水平分为１、２、３级取消了轻、中、重度之分。当收缩压和舒张压分属不同级别时则以较高的分级为准。单纯收缩期高血压应根据收缩压的数值进行分级。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('311', '42', 'G01_018', '1', '2013年欧洲高血压学会（ESH）/ESC 动脉高血压指南', null, '欧洲高血压学会', '2013', 'European Heart Journal，2013-06-14', '英文', '3', '高血压；Hypertension ；Blood Pressure, High', null, null, '血压分类推荐与2003版及2007版ESH/ESC指南相同。理想血压:收缩压＜120 和 舒张压＜80正常血压收缩压 120～129 和（或）舒张压 80～84;正常高值 收缩压130～139 和（或）舒张压 85～891级高血压收缩压 140～159 和（或）舒张压 90～99;2级高血压 收缩压160～179 和（或） 舒张压100～109;3级高血压收缩压 ≥180 和（或） 舒张压≥110;单纯收缩期高血压 收缩压≥140 和舒张压 ＜90', null, '高血压患者的降压目标是收缩压＜140mmHg,且舒张压＜90mmHg.此标准适用于以下人群，伴有低危或中危心血管风险，既往脑卒中或短暂性脑缺血发作，冠状动脉性疾病，慢性肾脏疾病，糖尿病或非糖尿病肾病。对于糖尿病患者，其血压目标值收缩压＜140且舒张压80-85mmHg，＜80岁且收缩压≥160mmHg的老年高血压患者，其收缩压应该控制在140-150mmHg.＞80岁收缩压≥160mmHg且健康状况良好的老年高血压患者，也建议将收缩压控制在140-150mmHg；收缩压≥160mmHg的老年高血压患者需要畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭혨ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭', null, '如果双上臂血压差持续＞１０ｍｍ　Ｈｇ（１ｍｍ　Ｈｇ＝０．１３３ｋＰａ），这种情况意味着心血管风险增加；利尿剂与 ACEI、ARB 或 CCB 联用为理想的治疗方案；新指南进一步强调动态血压检测和家庭自测血压的重要性', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('312', '42', 'G01_019', '1', '2009ESH 欧洲儿童和青少年高血压指南', '2009ESH Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension', 'ESH\n欧洲高血压学会(ESH,European Society of Hypertension)', '2009', 'J Hypertens. 2009 Sep;27(9):1719-42.', '英文', null, '高血压；Hypertension ；Blood Pressure, High', 'This provides a rationale fortargeting children and adolescents with essential hypertension to a BP below the 95th age, sex and heightspecific percentiles, but it is probably wiser and saferto aim at a BP below the 90th percentile.', null, '见word\n\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('313', '42', 'G01_021', '1', '日本高血压指南', null, '日本高血压学会', '2001', '何吟绵, 何熹延. 高血压诊断标准进展[J]. 医学信息, 2001, 14(11):773-776.', '英文', '3', '高血压；Hypertension ；Blood Pressure, High', null, '1.将高血压危险分层定为低、中、高三级;2.日本废除了临界性高血压;3.在危险分层的RF中,男>60岁(WHO/ISH为>55),女子仍为>65;4.提高了老人降压目标值: 60～ 69岁≤ 140 /<90,70～79岁≤ 150～ 160 /<90, 80～ 89岁为≤ 160～ 170 /<90。而WHO/ISH均为140 /90以下。', '将高血压危险分层定为低、中、高三级', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('314', '42', 'G01_022', '1', '日本高血压指南', null, '日本高血压学会', '2009', 'Hypertens Res. 2009 Jan;32(1):3-107.', '英文', null, '高血压；Hypertension ；Blood Pressure, High', null, null, '对家庭自测血压高血压的诊断标准设定在≥135/85 mmHg（1 mmHg= 0.133 k Pa），较诊室血压低5 mmHg。\n诊室血压 收缩压140舒张压 90家庭血压收缩压 135舒张压 85动态血压24小时平均值收缩压130舒张压80白天收缩压135舒张压85夜间收缩压120舒张压70', null, null, '青年、中年 诊室血压＜130/85 家庭血压＜125/80老年人诊室血压 ＜140/90家庭血压 ＜135/85糖尿病、慢性肾病、心肌梗死后诊室血压 ＜130/80 家庭血压＜125/75脑血管疾病 诊室血压＜140/90 家庭血压＜135/85', 'JSH2009对老年高血压目标值设定在140/90 mm Hg，但是在65岁前即开始降压治疗的患者，并将血压已经降到130/85 mm Hg以下，到了65岁以后，没有必要缓和降压目标和程度。对年龄较高（＞75岁）的收缩压在2、3级以上的患者，降压目标虽然还是140/90 mm Hg，但是第一步降到150/90 mm Hg这一中间值也可以。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('315', '42', 'G01_023', '1', '日本高血压指南', 'JSH2009', '日本高血压学会', '2014', 'Hypertens Res. 2014 Apr;37(4):253-387.', '英文', null, '高血压；Hypertension ；Blood Pressure, High', null, null, '\n诊室血压收缩压 140mmHg，舒张压90mmHg；家庭血压收缩压 135mmHg  舒张压85mmHg；动态血压 24小时平均值 130mmHg  80mmHg ；白天 收缩压135mmHg  舒张压85mmHg ；夜间 收缩压120mmHg  舒张压70mmHg \n', null, null, '降压目标值:一般患者<140/90mmHg，75岁以上患者<150/90mmHg，若能耐受可降至<140/90mmHg，糖尿病患者<130/80mmHg。', '1.降压药物的心血管保护作用主要取决于血压下降本身而非药物类别。\n2.应根据患者具体情况以及药物的强制性适应证与禁忌证选择降压药物。\n3.对于无强制性适应证的高血压患者，可首选CCB、ARB、ACEI或利尿剂，不建议将β-受体阻滞剂作为一线降压药物。\n4.长效降压药物一般每日服用一次。但为达到全天24小时平稳控制血压，有些患者可能需要分两次用药。\n5.应将高血压患者的血压逐渐降至目标值以下(数月内)。对于高危患者(如合并多种心血管危险因素的3级高血压)应在数周内使其血压达标。\n6.为使血压达标，多数患者需畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽㤤ఆ亴ఆ彿㎽亨ఆ塚㎽亴ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂圔㎽ﺼఅ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0턀ਘ䐺盭暼痭턀ਘༀƙ \0턀ਘĀ\0\0㺣盭턀ਘ\0ﱔ턄ਘ\0팃目턄ਘ࣒턄ਘ큁目턄ਘﻰఅ﫬\0Item\0\0伸ఆ\0\0\0\0\0\0Count\0\0ﱬﬄ턴ਘ㳜੪\0\0턄ਘ\0\0\0\0੪寶目㳠੪矵䥷㎽㤤ఆ\0\0伸ఆ�㏂亨ఆ\0\0\0੪\0\0\0謁ﱔ\0\0㎾٨\0ﱜ\0\0x�㏂亨ఆ\0\0隲W伸ఆ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\0霪W露W\0\0ﱴxt\0Љ\0\0\0௱鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0쓠ఌ쓠ఌ\0\0\0寶目㲈੪ﷰఅi\0\0ﱄ﷜ﱴﲔ먙㎼ﷰఅ㲈੪i\0\0ﱄ﷜ﱴ먰㎼﷜ﷰఅ�㏂ﵠఅ\0\0릎㎼ﷰఅi\0╪췬目╾췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒௱竗௱目W\0竗\0\0\0賓器目\0\0\0\0ﻰఅ\0目瑉浥目\0\0\0\0ﻰఅ\0目潃湵t\0\0\0\0̷\0\0ဠ\0\0侠̓', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('316', '42', 'G01_024', '1', '英国高血压防治指南', 'The clinical management of primary hypertension in adults', '英国高血压学会', '1999', '冯宁. 英国高血压学会1999年高血压治疗指南:概要[J]. 英国医学杂志:中文版, 2000(2):90-94.', '英文', null, '高血压；Hypertension ；Blood Pressure, High', null, null, null, null, null, null, '英国《指南》与WHO/ISH《指南》大同小异,其要点大致有:1.对SP持续≥ 160或DP≥ 100患者,就开始抗高血压、药物治疗。2.　对Ⅰ级高血压,根据是否有TOD、心血管病、 DM、或10年期间冠心病危险是否≥ 15% ,决定是否给予抗高血压药物治疗。亦体现了从预后、多危险因素角度制定治疗策略的思想。3.血压理想靶值: SP<140、DP<85,并建议最低可接受水平为SP<150、 DP<90 (audit标准)。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('317', '42', 'G01_025', '1', '英国成人原发性高血压临床管理指南', 'The clinical management of primary hypertension in adults(CG127)', '英国国家卫生与临床优化研究所 (NICE,National Institute for Health and Clinical Excellence)', '2011', '郭艺芳, 张靖. 2011英国成人原发性高血压管理指南介绍[J]. 中国医学前沿杂志:电子版, 2011, 03(05):94-96.', '英文', null, '高血压；Hypertension ；Blood Pressure, High', null, null, ' 如果诊室血压为140/90 mmHg或更高，应提供动态血压监测（ABPM）以证实高血压的诊断。当使用ABPM来证实高血压的诊断时，应保证在受检者平常清醒时间（如08:00 -22:00时之间）每小时至少测量2次。应用受检者平常清醒时间至少14次测量的平均值来证实高血压的诊断。', null, null, '对于检出有“白大衣效应”的人，可考虑用ABPM或HBPM辅助诊室血压测量，监测用生活方式改变或药物降压治疗的反应。（新，2011）<br />&nbsp;&nbsp;对年龄80岁以下治疗高血压的患者，目标诊室血压低于140/90 mmHg。（新，2011）<br />&nbsp;&nbsp;对年龄80岁及以上治疗高血压的患者，目标诊室血压低于150/90 mmHg。（新，2011）<br />&nbsp;&nbsp;当用ABPM或HBPM监测治疗反应（如认定有“白大衣效应”和选择在家中监测其血压的患者）时，受检者平常清醒时间的目标平均血压：\n• 80岁以下的人低于135/85；\n• 80畻坴畿\0\0\0\0醼畻聱盯', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('318', '42', 'G01_026', '1', '高血压诊断标准', null, '世界卫生组织', '1978', null, '英文', null, '高血压；Hypertension ；Blood Pressure, High', null, null, '3次检查核实后，按血压值的高低分为正常血压、临界高血压和诊断高血压。 (1)正常血压:收缩压在18.7kPa(140mmHg)或以下，舒张压12.0kPa(90mmHg)或以下，而又非低血压者，应视为正常血压。 (2)临界高血压:收缩压在8.8~21.2kPa(141~159mmHg)和舒张压在12.1~12.5kPa(91 ~95mmHg)之间者为是。 (3)确诊高血压:收缩压达到或超过21.3kPa(160mmHg)和舒张压达到或超过12.7kPa(95mmHg)者为是。', null, null, '所有高血压患者的血压均应降至＜140／90mmHg，≤138／83mmHg更为理想。轻度患者以控制在120／80mmHg为好。中青年应降至＜130／85mmHg，老年患者以控制在＜140／90mmHg为宜，单纯收缩压高者亦应将收缩压控制在140mmHg以下。若合并糖尿病或心、脑、肾等脏器损害时，应尽量将血压降至＜130／85mmHg或达到理想水平。', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('319', '42', 'G01_027', '1', '高血压诊断标准', null, '世界卫生组织', '1998', null, '英文', null, '高血压；Hypertension ；Blood Pressure, High', null, null, '在未使用抗高血压药物的情况下，收缩压大于、等于140mmHg，舒张压大于、等于90mmHg;既往有高血压史，目前正在使用抗高血压药物，现血压虽未达到上述水平，亦应诊断为高血压。 ', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('32', '33', 'T02_004', '1', '高尿酸血症和痛风治疗中国专家共识', '无', '中华医学会内分泌学分会(CSE,Chinese Society of Endocrinology)\n', '2013', '中华医学会内分泌学分会.高尿酸血症和痛风治疗的中国专家共识[J].中华内分泌代谢杂志,2013,29(11):913-920.\n', '中文', '二、HUA 的诊断标准和分型<br />&nbsp;&nbsp;\n国际上将HUA 的诊断定义为:正常嘌呤饮食状态下,非同日2 次空腹血尿酸水平:男性>420μmol/ L,女性>360μmol/ L。<br />&nbsp;&nbsp;\n分型诊断:HUA 患者低嘌呤饮食5 d 后,留取24 h尿检测尿尿酸水平。根据血尿酸水平和尿尿酸排泄情况分为以下三型:(1) 尿酸排泄不良型:尿酸排泄<0. 48 mg•kg-1•h-1,尿酸清除率<6. 2 ml/ min。(2) 尿酸生成过多型:尿酸排泄>0. 51mg•kg-1•h-1,尿酸清除率逸6. 2 ml/ min。(3) 混合型:尿酸排泄>0. 51mg•kg-1•h-1,尿酸清除率<6. 2 ml/ min。[注:尿酸清除率(Cua)= 尿尿酸*每分钟尿量/ 血尿酸] <br />&nbsp;&nbsp;\n考虑到肾功能对尿酸排泄的影响,以肌酐清除率(Ccr) 校正,根据Cua/ Ccr 比值对HUA 分型如下:>10%为尿酸生成过多型,<5% 为尿酸排泄不良型,5% ~10%为混合型。<br />&nbsp;&nbsp;\n临床研究结果显示,90%的原发性HUA 属于尿酸排泄不良型<br />&nbsp;&nbsp;\n', '痛风；高尿酸血症', null, null, '二、HUA 的诊断标准和分型<br />&nbsp;&nbsp;\n国际上将HUA 的诊断定义为:正常嘌呤饮食状态下,非同日2 次空腹血尿酸水平:男性>420μmol/ L,女性>360μmol/ L。<br />&nbsp;&nbsp;\n分型诊断:HUA 患者低嘌呤饮食5 d 后,留取24 h尿检测尿尿酸水平。根据血尿酸水平和尿尿酸排泄情况分为以下三型:(1) 尿酸排泄不良型:尿酸排泄<0. 48 mg•kg-1•h-1,尿酸清除率<6. 2 ml/ min。(2) 尿酸生成过多型:尿酸排泄>0. 51mg•kg-1•h-1,尿酸清除率逸6. 2 ml/ min。(3) 混合型:尿酸排泄>0. 51mg•kg-1•h-1,尿酸清除率<6. 2 ml/ min。[注:尿酸清除率(Cua)= 尿尿酸*每分钟尿量/ 血尿酸] <br />&nbsp;&nbsp;\n考虑到肾功能对尿酸排泄的影响,以肌酐清除率(Ccr) 校正,根据Cua/ Ccr 比值对HUA 分型如下:>10%为尿酸生成过多型,<5% 为尿酸排泄不良型,5% ~10%为混合型。<br />&nbsp;&nbsp;\n临床研究结果显示,90%的原发性HUA 属于尿酸排泄不良型<br />&nbsp;&nbsp;\n干预治疗切点：血尿酸>420μmol/ L(男性),>360μmol/ L(女性)。$$$', null, '血尿酸（SUA）；', '控制目标:血尿酸<360μmol/ L(对于有痛风发作的患者,血尿酸宜<300μmol/ L)。<br />&nbsp;&nbsp;\n确诊痛风后血尿酸的控制目标要低于诊断标准,即均要长期控制到<360μmol/ L,以维持在尿酸单钠的饱和点之下,而且有证据显示血尿酸<300μmol/ L 将防止痛风反复发作。<br />&nbsp;&nbsp;\n\n', '【共识要点】目前中国高尿酸血症(HUA)呈现高流行、年轻化、男性高于女性、沿海高于内地的趋势。HUA 是多种心血管危险因素及相关疾病(代谢综合征、2型糖尿病、高血压、心血管事件及死亡、慢性肾病等)的独立危险因素。HUA 治疗前建议进行分型诊断,以利于治疗药物的选择。生活方式指导、避免引起HUA 的因素是预防HUA 的核心策略。痛风作为与HUA 直接因果相关的疾病,应严格控制血尿酸在360 μmol/L 以下,最好达300μmol/L,并长期维持。对于无症状的HUA,也应予以积极地分层治疗。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('320', '42', 'G01_028', '1', '高血压诊断标准', null, '世界卫生组织', '1995', '陈建华, 宋和平, 陆瑾. 国内外高血压诊断标准比较[J]. 中西医结合心脑血管病杂志, 2014(5):527-528.', '英文', null, '高血压；Hypertension ；Blood Pressure, High', null, null, '在未服药物的情况下，收缩压≥140mmHg和舒张压≥90mmHg。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('321', '42', 'G01_029', '1', '高血压诊断标准', null, 'WHO/ISH', '1999', 'http://www.doc88.com/p-019708209269.html\n余振球,马长生,赵连友等.实用高血压病学.北京:科学出版社,1993,6～9', '英文', '1级高血压.<br />&nbsp;&nbsp;2.级高血压<br />&nbsp;&nbsp;3.级高血压<br />&nbsp;&nbsp;4.单纯收缩期高血压', '高血压；Hypertension ；Blood Pressure, High', null, null, '①理想血压：收缩压＜120mmHg，舒张压＜80mmHg；②正常血压：收缩压＜130 mmHg，舒张压 ＜80 mmHg；③ 正常高值：收缩压（130～139）mmHg，舒张压（85～89）mmHg；③ 高 血压：按血压升高的程度又分为：1级高血压（轻度）：收缩压（140～159）mmHg，舒 张 压（90～99）mmHg。亚 组 临 界 高 血 压：收缩压（140～149）mmHg，舒 张 压 （90～94）mmHg。2 级 高 血 压（中度）：收缩压（160～179）mmHg，舒 张 压（100～10畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭턀ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽⩐ఆ䥠ఆ彿㎽䥔ఆ塚㎽䥠ఆꍈ㏂\0\0ﺼఅ學㎽漸', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('322', '42', 'G01_030', '1', '高血压诊断标准', null, 'WHO', '2003', null, '英文', '1级高血压.<br />&nbsp;&nbsp;2.级高血压<br />&nbsp;&nbsp;3.级高血压<br />&nbsp;&nbsp;4.单纯收缩期高血压', '高血压；Hypertension ；Blood Pressure, High', null, null, '①理想血压：收缩压＜120mmHg，舒张压＜80mmHg；②正常血压：收缩压＜130 mmHg，舒张压 ＜80 mmHg；③ 正常高值：收缩压（130～139）mmHg，舒张 压（85～89）mmHg；③ 高 血压：按血压升高的程度又分为：1级高血压（轻度）：收缩压（140～159）mmHg，舒 张 压（90～99）mmHg。亚 组 临 界 高 血 压：收缩压（140～149）mmHg，舒 张 压 （90～94）mmHg。2 级 高 血 压（中度）：收缩压（160～179）mmHg，舒 张 压（100～1畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭혨ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽⩐ఆ䥠ఆ彿㎽䥔ఆ塚㎽䥠ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂', null, null, null, '与1999年指南相比，确定根据多重危险因素来决定血压界限和治疗目标，提出了治疗策略，考虑到经济效益问题。没有采用JNC7的高血压前期的内容。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('323', '42', 'G01_031', '1', '2015 CHEP高血压管理建议：血压的测量、诊断、风险评估、预防和治疗', 'The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension', '加拿大高血压教育计划委员会(CHEP,Canadian Hypertension Education Program)', '2015', 'Canadian Journal of Cardiology 31 (2015) 549-568.', '英文', null, '高血压；Hypertension ；Blood Pressure, High', null, null, 'SBP ≥ 140 mmHg 或DBP ≥ 90mmHg 时，患者可诊断为高血压 ；SBP在 130 ～ 139 mmHg 和（ 或 ）DBP 在 85 ～ 89 mmHg，患者可诊断为血压正常高值（C 级）。②自动化诊室血压测量 ：平均 SBP ≥ 135 mmHg 或DBP ≥ 85  mmHg， 即 可 诊 断 为 高 血 压（D 级 ）。③动态血压监测 ：在清醒状态下平均 SBP ≥ 135 mmHg 或 DBP ≥ 85  mmHg ； 或 24 小 时 平 均SBP ≥ 130  mmHg 或畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭턀ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽⩐ఆ䥠ఆ彿㎽䥔ఆ塚㎽䥠ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂圔㎽ﺼఅ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0턀ਘ䐺盭暼痭턀ਘༀƙ \0턀ਘĀ\0\0㺣盭턀ਘ\0ﱔ턄ਘ\0팃目턄ਘ࣒턄ਘ큁目턄ਘﻰఅ﫬\0Item\0\0䧤ఆ\0\0\0\0\0\0Count', null, null, null, '①推荐使用经过验证的电子（示波法）血压计测量上臂血压，认为准确度优于听诊法测量的诊室血压 ；②如果第一次就诊测得的平均血压升高但低于 180/110 mm Hg，建议在第二次就诊前使用诊室外的动态血压监测（最好）或者家庭血压监测以排除白大衣性高血压，因为白大衣性高血压无需进行药物治疗。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('324', '42', 'G01_032', '1', '2014加拿大高血压教育计划', 'The 2014 Canadian Hypertension Education Program (CHEP) Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention and Treatment of Hypertension', '加拿大高血压教育计划委员会(CHEP,Canadian Hypertension Education Program)', '2014', 'Can J Cardiol. 22 February 2014.', '英文', null, '高血压；Hypertension ；Blood Pressure, High', null, null, '使用适当的自动血压测量设备，诊室测量的血压值 SBP ≥ 135 mmHg 或 DBP ≥ 85 mmHg可以作为日间动态血压的相应值（D 级）。如果 SBP ≥ 140 mmHg 和（或）DBP ≥ 90 mmHg，应定期进行高血压评估（D 级）。血压为正常高值的 [SBP：130 ～ 139 mmHg和（或）DBP：85～89mmHg]，要求每年随访 1 次（C 级）；对 于 初 次 就 诊，SBP ≥ 140 mmHg和（ 或 ）DBP ≥ 90mmHg 的患者，评估时要用经过验证的设备按照规定的测畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽⩐ఆ䥠ఆ彿㎽䥔ఆ塚㎽䥠ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂圔㎽ﺼఅ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0턀ਘ䐺盭暼痭턀ਘༀƙ \0턀ਘĀ\0\0㺣盭턀ਘ\0ﱔ턄ਘ\0팃目턄ਘ࣒턄ਘ큁目턄ਘﻰఅ﫬\0Item\0\0䧤ఆ\0\0\0\0\0\0Count\0\0ﱬﬄ턴ਘ㳜੪\0\0턄ਘ\0\0\0\0੪寶目㳠੪矵䥷㎽⩐ఆ\0\0䧤ఆ�㏂䥔ఆ\0\0\0੪', null, null, null, '对于已患有冠心病且舒张压（DBP）≤ 60 mm Hg 的患者，在降低收缩压（SBP）达标时需要谨慎，可能加重心肌缺血 ；②新诊断的高血压患者应检测糖化血红蛋白', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('325', '42', 'G01_033', '1', '2013年CHEP 加拿大高血压管理推荐', '2013 Canadian Recommendations for the Management of Hypertension', '加拿大高血压教育计划委员会(CHEP,Canadian Hypertension Education Program)', '2013', 'http://www.hypertension.ca/resources', '英文', null, '高血压；Hypertension ；Blood Pressure, High', null, null, null, null, null, '80岁以上人群的降压目标＜150mmhg', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('326', '42', 'G01_034', '1', '2012年CHEP 加拿大高血压教育计划', 'The 2012 Canadian Hypertension Education Program - Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy', '加拿大高血压教育计划委员会(CHEP,Canadian Hypertension Education Program)', '2012', 'Can J Cardiol. 2012 May;28(3):270-87.', '英文', null, '高血压；Hypertension ；Blood Pressure, High', null, null, '① OBPM ：采用人工诊室血压检测方法，若3次随访的血压平均值 SBP ≥ 160 mmHg 和（或）DBP ≥ 100 mmHg，或 5 次随访的血压平均值SBP ≥ 140 mmHg 和（ 或 ）DBP ≥ 90 mmHg，则可明确诊断高血压（Grade D）。②动态血压监测（ABPM）：若清醒状态下平均SBP ≥ 135 mmHg 和（或）DBP ≥ 85 mmHg，或 24 小时平均 SBP ≥ 130 mmHg 和（或）DBP ≥ 80 mmHg，可诊断为高血压（Grade C）。③ HBPM畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭혨ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ', null, null, '①急性卒中期间（症状发生至 72 小时）：缺血性卒中不溶栓治疗的患者，不常规采用降压治疗（Grade D）。SBP ＞ 220 mmHg 或 DBP ＞ 120 mmHg 者 可 谨 慎 降 压，24 小时内逐步下降 15%，不超过 25%（Grade D）。缺血性卒中可行溶栓治疗者，若 BP ＞ 185/110 mmHg，必须在溶栓治疗同时降低血压，以避免颅内出血（Grade B）。②卒中后血压治疗 ：卒中急性阶段降压治疗必须十分谨慎，急性期后，血压控制的靶目标为＜ 140/90 mmHg（Grade 畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭혨ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽㑄ఆ䷸ఆ彿㎽䷬ఆ塚㎽䷸ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂圔㎽ﺼఅ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0쳠ਘ䐺盭暼痭쳠ਘༀƙ \0쳠ਘĀ\0\0㺣盭쳠ਘ\0ﱔ쳤ਘ\0팃目쳤ਘ࣒쳤ਘ큁目쳤ਘﻰఅ﫬\0Item\0\0乼ఆ\0\0\0\0\0\0Count\0\0ﱬﬄ촔ਘ㳜੪\0\0쳤ਘ\0\0\0\0੪寶', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('327', '42', 'G01_035', '1', '2011加拿大高血压教育计划', 'The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy', '加拿大高血压教育计划委员会(CHEP,Canadian Hypertension Education Program)', '2011', 'Can J Cardiol. 2011 Jul-Aug;27(4):415-433.e1-2.', null, null, '高血压；Hypertension ；Blood Pressure, High', null, null, '初次就诊表现有高血压危象或高血压急诊者即刻诊断高血压病，并立即给予治疗（级别D）。2.2　对SBP≥140 mmHg和（或）DBP≥90 mmHg者，必须安排再次随访就诊，对血压正常高值者[SBP为130～139 mmHg和（或）DBP为85～89 mmHg]推荐每年随访1次（级别D）。2.3　初次就诊发现SBP≥140  mmHg和（或）DBP≥90 mmHg者，应去除第1次检测值，取后两次检测血压的平均值。并积极检查了解危险因素及靶器官损害情况。1月内安排第2次随访（级别D）。2.4　第2次随访，若S畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭쳠ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽⩐ఆ䥠ఆ彿㎽䥔ఆ塚㎽䥠ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂圔㎽ﺼఅ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0ਘ䐺盭暼痭ਘༀƙ \0ਘĀ\0\0㺣盭ਘ\0ﱔਘ\0팃目ਘ࣒ਘ큁目ਘﻰఅ﫬\0Item\0\0䧤ఆ\0\0\0\0\0\0Count\0\0ﱬﬄਘ㳜੪\0\0ਘ\0\0\0\0੪寶目㳠੪矵䥷㎽⩐ఆ\0\0䧤ఆ�㏂䥔ఆ\0\0\0੪\0\0\0謁ﱔ\0\0㎾Ծ\0ﱜ\0\0x�㏂䥔ఆ\0\0隲W䧤ఆ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\n\0霪W露W\0\0ﱴxt\0Љ\0\0\0௱鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0쓠ఌ쓠ఌ\0\0\0寶目㲈੪ﷰఅi\0\0ﱄ﷜ﱴ', null, null, '对SBP≥160 mmHg和（或）DBP≥100  mm  Hg者，或SBP≥140  mm  Hg和（或）DBP≥90 mmHg且伴靶器官损害或心血管危险因素者需采用药物治疗（级别A）。对无明显靶器官损害的患者，降压目标仍为SBP≤140 mmHg及DBP≤90 mmHg。\n故本指南仍推荐糖尿病患者应保持SBP＜130 mm H g（级别C）和DBP＜80 mmHg（级别A）', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('328', '42', 'G01_036', '1', '2015年中国台湾地区高血压管理指南', '2015 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension', '中国台湾地区心脏病学会（taiwan society of cardiology,TSOC)与中国台湾地区高血压学会（Taiwan hypertension society ,THS)', '2015', 'J Chin Med Assoc. 2014 Dec 26.', null, null, '高血压；Hypertension ；Blood Pressure, High', null, null, '收缩压 ≥140和（或）舒张压≥90mmHg诊断为高血压。此外，对于糖尿病、冠心病、伴 蛋 白 尿 的 慢 性 肾 脏 病 患 者，当 血 压 ＞130／80mmHg时，即视为血压升高。', null, null, '同2013年欧洲心脏学会／欧洲高血压学会高血压管理指南一般人群血压的控制目标＜140／90mmHg；但不支持2014年美国成人高血压循证管理指南中将60-80 岁老年人血压目标放宽至 ＜150／90 mmHg糖尿病、冠心病、蛋白尿性慢性肾脏病及正在接受脑卒中预防抗凝治疗者，推荐血压目标＜130／80 mmHg；对于≥80岁 老年人，推荐 ＜150／90 mmHg。推荐降压目标与2014年日本高血压指南相同', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('329', '42', 'G01_038', '1', '2010 ISHB 黑人高血压指南管理共识', 'International Society on Hypertension in Blacks. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement.', '\n黑人高血压国际学会(ISHIB,International Society on Hypertension in Blacks)', '2010', 'Hypertension. 2010;56(5):780-800.', null, null, '高血压；Hypertension ；Blood Pressure, High', null, null, null, null, null, 'Risk Category Recommended Treatment Goal BP, mmHg\nPrimary preventionBP≥135/85 mmHg withouttarget-organ damage,†preclinical CVD,‡ or CVD§( Lifestyle modification*≤ 3 months withoutdrugs) Drugtherapy ＜135/85\nSecondary prevention/target-organ damage†‡§BP  13畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭쳠ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽㑄ఆ䷸ఆ彿㎽䷬ఆ塚㎽䷸ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂圔㎽ﺼఅ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0혨ਘ䐺盭暼痭혨ਘༀƙ \0혨ਘĀ\0\0㺣盭혨ਘ\0ﱔ혬ਘ\0팃目혬ਘ࣒혬ਘ큁目혬ਘﻰఅ﫬\0Item\0\0乼ఆ\0\0\0\0\0\0Count\0\0ﱬﬄ활ਘ㳜੪\0\0혬ਘ\0\0\0\0੪寶目㳠੪矵䥷㎽㑄ఆ\0\0乼ఆ�㏂䷬ఆ\0\0\0੪\0\0\0謁ﱔ\0\0㎾؄\0ﱜ\0\0x�㏂䷬ఆ\0\0隲W乼ఆ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\0霪W露W\0\0ﱴxt\0Љ\0\0\0௱鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0쓠ఌ쓠ఌ\0\0\0寶目㲈੪ﷰఅi\0\0ﱄ﷜ﱴﲔ먙㎼ﷰఅ㲈੪i\0\0ﱄ﷜ﱴ먰㎼﷜ﷰఅ�㏂ﵠఅ\0\0릎㎼ﷰఅi\0╪췬目╾췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒௱竗௱目W\0竗\0\0\0賓器目', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('33', '33', 'T02_005', '1', '痛风诊断与管理的多国证据推荐意见：源自文献系统回顾整合及风湿专家\"3e\"方案意见', 'Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative', '国外风湿免疫科相关专家小组\n', '2013', 'http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913257/pdf/annrheumdis-2013-203325.pdf', '英文', null, '痛风', null, null, '为确定诊断痛风，应对尿酸钠结晶进行鉴别；当无法鉴别时，若患者存在典型临床表现（如足痛风、痛风石、对秋水仙碱治疗反应快）和（或）特征性影像学发现时，也可支待痛风的诊断。临床或影像学表现可以支持诊断。<br />&nbsp;&nbsp;\nit was felt that clinical or imaging findings could support a diagnosis. The presence of hyperuricaemia on its own is insufficient to establish a diagnosis of gout. Response of acute arthritis to colchicine could support a clinical diagnosis of gout, but was felt unhelpful in differentiating types of crystal arthritis (eg, gout and acute calcium pyrophosphate arthritis).<br />&nbsp;&nbsp;\n', null, '血尿酸（SUA）', ' 治疗的靶目标是血清尿酸低于0.36mmol/lL(6mg/L)、无痛风发作和痛风石溶解；监测血清尿酸水平、痛风发作次数和痛风石大小。', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('330', '42', 'G01_039', '1', '2011年南非高血压指南', 'South African Hypertension Guideline 2011', '南非高血压学会', '2011', 'S Afr Med J 2012;102:57-84.', '英文', '1级高血压.<br />&nbsp;&nbsp;2.级高血压<br />&nbsp;&nbsp;3.级高血压', '高血压；Hypertension ；Blood Pressure, High', null, null, '正常SBP120 ～ 129mmHg 或DBP 80 ～ 84mmHg；正常高值SBP130 ～ 139mmHg 或DBP85 ～ 89mmHg； 1 级SBP140 ～ 159mmHg 或DBP 90 ～ 99mmHg；高血压 2 级SBP160 ～ 179 mmHg或DBP100 ～ 109mmHg；高血压 3 级高血压SBP ＞ 180 mmHg或DBP ＞ 110mmHg', null, null, '降压目标 ：一般高血压患者降压目标值为＜ 140/90 mmHg，高危病人如伴有糖尿病、肾病（微量蛋白尿和 / 或肌酐水平升高）、充血性心力衰竭患者降压目标值为＜ 130/80 mmHg。当孕妇血压达到 SBP ≥ 160 mmHg或 DBP ≥ 110 mmHg 时应立即开始降压治疗。', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('331', '42', 'G01_040', '1', '2014南非高血压指南', 'South African hypertension practice guideline 2014', '南非', '2014', 'Cardiovasc J Afr. 2014 Nov-Dec;25(6):288-94.', '英文', '1级高血压.<br />&nbsp;&nbsp;2.级高血压<br />&nbsp;&nbsp;3.级高血压<br />&nbsp;&nbsp;单纯收缩期高血压', '高血压；Hypertension ；Blood Pressure, High', null, null, 'Stage SystolicBP(mmHg) DiastolicBP(mmHg)\nNormal <120 <80\nOptimal 120–129 80–84\nHighnormal 130–139 85–89\nGrade1 140–159 90–99\nGrade2 160–179 100–109\nGrade3 ≥180 ≥110\nIsolated systolic ≥140 <90\n', null, null, 'does not support the JNC-8 committee recommendations of  a  goalBP ＜150/90  mmHg  for  persons  over  60  years  without diabetes and CKD不支持JNC8中关于六十岁以上没有糖尿病和心血管疾病的 人血压范围是150-90的范围', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('332', '42', 'G01_041', '1', '2013 年法国高血压学会成人高血压治疗指南', 'Management of arterial hypertension in adults: 2013 guidelines of the French Society of Arterial Hypertension', '法国高血压学会', '2013', 'Ann Cardiol Angeiol (Paris). 2013 Jun;62(3):132-8.', '英文', null, '高血压；Hypertension ；Blood Pressure, High', null, null, '血压的高值≥ 140 mmHg 和（或）低值≥ 90 mmHg。血压应在静息状态下多次测量以确诊高血压。', null, null, '患者需每月到医院随诊，直至达到目标血压值，即包括糖尿病及肾病患者在内，自测血压收缩压 130 ～ 139 mm  Hg，舒张压低于 90  mmHg。年龄大于 80 岁的患者推荐（1）收缩压目标值低于 150 mmHg，无体位性低血压 ；', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('333', '42', 'G01_042', '1', '2009拉丁美洲高血压指南', 'Latin American guidelines on hypertension. Latin American Expert Group.', '拉丁美洲专家组(Latin American Expert Group)', '2009', 'J Hypertens. 2009 May;27(5):905-22.', '英文', '1级高血压.<br />&nbsp;&nbsp;2.级高血压<br />&nbsp;&nbsp;3.级高血压<br />&nbsp;&nbsp;单纯收缩期高血压', '高血压；Hypertension ；Blood Pressure, High', null, null, '正常血压 120/80 mmHg ～ 129/84 mmHg；正常高值 130/85 mmHg ～ 139/89 mmHg；高血压1 级 140 ～ 159/90 ～ 99 mmHg；2 级 160 ～ 179/100 ～ 109 mmHg；3 级 ≥ 180/110 mmHg；单纯收缩期高血压 ≥ 140/ ＜ 90 mmHg；如果收缩压和舒张压分属不同级别，以较高的级别定义；<br />&nbsp;&nbsp;儿童高血压定义为不同时间至少 3 次测量平均 SBP 和（或）平均 DBP 高于相应年龄、性别和身高第 95 百分位血压畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭ਘༀƙ\0ਘĀ\0\n\0㺣盭', null, null, null, '本指南还对社会底层人员给予了最大的关注，在分层的危险因素中增加了社会经济因素，在治疗部分明确提出低危的高血压患者如果社会风险大也应考虑启动治疗并强制密切监测。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('334', '42', 'G01_043', '1', '2013年印度高血压指南', 'Indian guidelines on hypertension (I.G.H.) - III. 2013.', '印度医学学会(API,The Association of Physicians of India)', '2013', 'J Assoc Physicians India. 2013 Feb;61(2 Suppl):6-36.', '英文', '1级高血压.<br />&nbsp;&nbsp;2.级高血压<br />&nbsp;&nbsp;3.级高血压<br />&nbsp;&nbsp;4.单纯收缩期高血压', '高血压；Hypertension ；Blood Pressure, High', null, null, '18 岁以上的成年人，如收缩压（SBP）≥ 140 mmHg 和（或）舒张压（DBP）≥ 90 mmHg，诊断为高血压。或患者既往有高血压史，目前正在使用降压药物，血压虽低于 140/90 mmHg，也诊断为高血压.\n理想血压，收缩压＜ 120 和 舒张压＜ 80正常血压 收缩压＜ 130 和 舒张压＜ 85正常高值血压收缩压 130 ～ 139 或舒张压 85 ～ 89高血压；1 级高血压收缩压 140 ～ 159 或舒张压 90 ～ 99；2 级高血压 收缩压160 ～ 179 或舒张压 100 ～ 畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭쳠ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫', null, null, '除 3 级高血压患者，应逐步降压达标。中青年高血压患者理想或正常血压应降至＜ 140/90 mmHg。糖尿病患者血压应降至＜ 140/80 mmHg。脑卒中后的高血压患者一般血压目标为 130/85 mmHg 以下。老年患者血压应控制在 140 ～ 145/90 mmHg 以下', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('335', '42', 'G01_044', '1', '澳大利亚成人高血压管理指南（修订版）2010NHFA 成人高血压管理指南', 'Guide to management of hypertension 2008. Updated December 2010', '澳大利亚国家心脏基金会(NHFA,National Heart Foundation of Australia)', '2010', 'NHFA官网', '英文', '1级高血压.<br />&nbsp;&nbsp;2.级高血压<br />&nbsp;&nbsp;3.级高血压<br />&nbsp;&nbsp;4.宽脉压的收缩性高血压', '高血压；Hypertension ；Blood Pressure, High', null, null, '白天血压≤135/85  mmHg（1 mmHg= 0.133 k Pa），夜间血压≤120/70 mmHg，平均血压≤130/80 mmHg。平均动态血压超过白天/夜间血压标准值或动态血压超过参考值的20%都支持高血压的诊断。夜间平均血压基线应该至少低于白天血压基线的10%，夜间血压不低者的心血管危险度显著增加。高血压分类 收缩压（mmHg） 舒张压（mmHg） 随访\n正常 ＜120 ＜80  2年内复查\n正常高限 120～139 80～89 1年内复查\n1级高血压 140～159 90～99 2月内确畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭혨ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽⩐ఆ䥠ఆ彿㎽䥔ఆ塚㎽䥠ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂', null, null, '①尿蛋白＞1 g/d（无论是否有糖尿病），血压目标＜125/75 mmHg；②具有冠心病、糖尿病、慢性肾脏病、蛋白尿＞300  mg/d、卒中/短暂性脑缺血发作（TIA）合并症的患者，血压目标＜130/80 mmHg；③无以上任何合并症的患者，血压目标＜140/90 mmHg或可耐受的情况下更低。', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('336', '42', 'G01_045', '1', '2008 NHFA 成人高血压管理指南', 'Guide to management of hypertension 2008. Updated December 2010', '\n澳大利亚国家心脏基金会(NHFA,National Heart Foundation of Australia)', '2008', 'NHFA官网', '英文', '1级高血压.<br />&nbsp;&nbsp;2.级高血压<br />&nbsp;&nbsp;3.级高血压<br />&nbsp;&nbsp;单纯收缩期高血压', '高血压；Hypertension ；Blood Pressure, High', null, null, '标准血压，白天＜135/85,晚上睡着后，＜120/70，24h平均，＜130/80diagnosticcategory* Systolic(mmHg) Diastolic(mmHg) Followup\nNormal ＜120 <80 Recheck in 2 years(or earlier as guided by patient’s absolute cardiovascular risk).†\nHigh-normal 120–139 80–89 Recheck in1year(or earlier畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭턀ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽⩐ఆ䥠ఆ彿㎽䥔ఆ塚㎽䥠ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂圔㎽ﺼఅ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0턀ਘ䐺盭暼痭턀ਘༀƙ \0턀ਘĀ\0\0㺣盭턀ਘ\0ﱔ턄ਘ\0팃目턄ਘ࣒턄ਘ큁目턄ਘﻰఅ﫬\0Item\0\0䧤ఆ\0\0\0\0\0\0Count\0\0ﱬﬄ턴ਘ㳜੪\0\0턄ਘ\0\0\0\0੪寶目㳠੪矵䥷㎽⩐ఆ\0\0䧤ఆ�㏂䥔ఆ\0\0\0੪\0\0\0謁ﱔ\0\0㎾ت\0ﱜ\0\0x�㏂䥔ఆ\0\0隲W䧤ఆ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\n\0霪W露W\0\0ﱴxt\0Љ\0\0\0௱鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0쓠ఌ쓠ఌ\0\0\0寶目㲈੪ﷰఅi\0\0ﱄ﷜ﱴﲔ먙㎼ﷰఅ㲈੪i\0\0ﱄ﷜ﱴ먰㎼﷜ﷰఅ�㏂ﵠఅ\0\0릎㎼ﷰఅi\0╪췬目╾췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒௱竗௱目W\0竗\0\0\0賓器目\0\0\0\0ﻰఅ\0目瑉浥目', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('337', '42', 'G01_046', '0', '中医病证诊断疗效标准', ' ', ' 国家中医药管理局', '1994', 'ZY/T 001.1-94, 中医内科病证诊断疗效标准[S].', '中文', null, null, '头风；眩晕', '1.头风的证候分类1.1肝阳上亢：头痛而胀，或抽掣而痛。痛时常有烘热，面红目赤，耳鸣如蝉，心烦口干。舌红，苔黄，脉弦。 1.2痰浊上扰：头痛胀重，或兼目眩。胸闷脘胀，恶心食少，痰多粘白。舌苔白腻，脉弦滑。1.3瘀阻脑络：头痛反复，经久不愈，痛处固定，痛如锥刺。舌紫暗或有瘀斑，苔薄白，脉细弦或细涩。 1.4气血亏虚：头痛绵绵。两目畏光，午后更甚，神疲乏力，面色huang(恍）白，心悸寐少。舌淡，苔薄，脉弱。1.5肝肾阴虚：头痛眩晕，时轻时重。视物模糊，五心烦热，口干，腰酸腿软。舌红少苔，脉细弦。2.眩晕的证畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭쳠ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽ⷈఆ䫘ఆ彿㎽䫌ఆ塚㎽䫘ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂圔㎽ﺼఅ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0혨ਘ䐺盭暼痭혨ਘༀƙ \0혨ਘĀ\0\0㺣盭혨ਘ\0ﱔ', null, '头风的诊断依据\n 1. 1头痛部位多在头部一侧额颞、前额、颠顶，或左或右辗转发作，或呈全头痛。头痛的性质多为跳痛、刺痛、胀痛、昏痛、隐痛，或头痛如裂等。头痛每次发作可持续数分钟、数小时、数天，也有持续数周者。 1. 2隐袭起病，逐渐加重或反复发作。 1. 3应查血常规，测血压，必要时做腰穿、骨穿，脑电图。有条件时做经颅多普勒、CT、磁共振等检查，以明确头痛的病因，排除器质性疾病。<br />&nbsp;&nbsp;眩晕的诊断依据1.1头晕目眩，视物旋转，轻者闭目即止，重者如坐车船，甚则仆倒。1.2可伴恶心呕吐，眼球震颤，耳鸣耳聋，汗畻坴畿\0\0\0\0醼畻聱盯\r\0\0\0痭쳠ਘༀƙ\0ਘĀ\0\r\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽「ఆ䮔ఆ彿㎽䮈ఆ塚㎽䮔', null, '头风的疗效评定：治愈：头痛消失，各项实验室检查正常。好转：头痛减轻，发作时间缩短或周期延长，实验室检查有改善。未愈：头痛症状及血压等无变化。<br />&nbsp;&nbsp;眩晕的疗效判定治愈：症状、体征及有关实验室检查基本正常。好转：症状及体征减轻，实验室检查有改善。未愈：症状无改变。\n\n', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('338', '42', 'G01_047', '1', '临床诊疗指南心血管分册', null, '中华医学会', '2009', '中华医学会.临床诊疗指南心血管分册[M].人民卫生出版社.2009', '中文', '1级高血压.<br />&nbsp;&nbsp;2.级高血压<br />&nbsp;&nbsp;3.级高血压<br />&nbsp;&nbsp;单纯收缩期高血压', null, null, null, '目前，我国采用国际上统一的标准，即收缩压≥140和（或）舒张压≥90即可诊断为高血压，根据血压增高水平，可进一步将高血压分为1、2、3级。正常血压收缩压＜120，舒张压＜80，正常高值，收缩压120-139，舒张压80-89高血压收缩压≥140，舒张压≥90,1级高血压（轻度）收缩压140-159,90-99；2级高血压（中度）收缩压160-179舒张压100-109；3级高血压（重度）收缩压≥180舒张压≥110单纯收缩期高血压收缩压≥140舒张压＜90<br />&nbsp;&nbsp;原发性高血压危险度的分层：原发性高血压的严畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭쳠ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽⩐ఆ䥠ఆ彿㎽䥔ఆ塚㎽䥠ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂圔㎽ﺼఅ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0쳠ਘ䐺盭暼痭쳠ਘༀƙ \0쳠ਘĀ\0\0㺣盭쳠ਘ\0ﱔ쳤ਘ\0팃目쳤ਘ࣒쳤ਘ큁目쳤ਘﻰఅ﫬\0Item\0\0䧤ఆ\0\0\0\0\0\0Count\0\0ﱬﬄ촔ਘ㳜੪\0\0쳤ਘ\0\0\0\0੪寶目㳠੪矵䥷㎽⩐ఆ\0\0䧤ఆ�㏂䥔ఆ\0\0\0੪\0\0\0謁ﱔ\0\0㎾۬\0ﱜ\0\0x�㏂䥔ఆ\0\0隲W䧤ఆ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\n\0霪W露W\0\0ﱴxt\0Љ\0\0\0௱鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0쓠ఌ쓠ఌ\0\0\0寶目㲈੪ﷰఅi\0\0ﱄ﷜ﱴﲔ먙㎼ﷰఅ㲈੪i\0\0ﱄ﷜ﱴ먰㎼﷜ﷰఅ�㏂ﵠఅ\0\0릎㎼ﷰఅi\0╪췬目╾췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒௱竗௱目W\0竗\0\0\0賓器目\0\0\0\0ﻰఅ\0目瑉浥目\0\0\0\0ﻰఅ\0目潃湵t\0\0\0\0̷\0\0ဠ\0\0侠̓ﯬ侠̓̙\0\0\0\0\0\0\0̙῰̓\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0῰̓\0\0\0\0̙ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚ', null, null, '1.原发性高血压的治疗目标，降低血压，使血压恢复至正常（＜140/90mmhg）或理想水平（＜120/80mmhg），对中青年患者（＜60岁），高血压合并肾病患者应使血压降至130/80mmhg一下，老年人尽量降至150/90mmhg.<br />&nbsp;&nbsp;继发性高血压的治疗目标，肾实质性高血压降压目标值为＜130/80mmhg，24小时尿蛋白＞1g者，降压目标值应＜125/75mmhg。', '若患者的收缩压与舒张压分属不同的级别时，则以较高的分级为准，单纯收缩期高血压也可按照书哦索亚水平分为123级。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('339', '42', 'G01_048', '0', '中医内科常见病诊疗指南中医疾病部分', null, '中华中医药学会', '2008', '中华中医药学会.中医内科常见病诊疗指南中医疾病部分[M].北京：中国中医药出版社.2008', '中文', null, null, null, '1.肝阳上亢证：眩晕，头部跳痛，耳鸣如潮，心烦易怒，失眠多梦，舌质红，苔薄黄，脉弦滑。2.气血亏虚证：头目眩晕，劳则加剧，神疲健忘，声低气短，面白少华或萎黄，或心悸失眠，舌质淡，苔薄白，脉细弱。3.痰浊内蕴证：头重如蒙，头目不清，胸闷少食，嗜睡，时吐痰涎，舌苔腻，脉滑或弦滑。4.瘀血阻络证：眩晕日久，头痛明显，失眠健忘，心悸怔仲，唇舌色暗，舌有瘀点或瘀斑，脉涩。5.肾精不足证：眩晕耳鸣，精神萎靡，腰膝酸软。偏于阴虚者兼见咽干，形瘦，五心烦热，舌嫩红，苔少或光剥，脉细数；偏于阳虚者兼见面色光白或黧黑，形寒肢畻坴畿\0\0\0\0醼畻聱盯', null, '眩晕的诊断要点：头晕目眩，视物旋转，轻则闭目可止，重者如坐舟车，甚则昏仆；可伴恶心呕吐，眼球震颤，耳鸣耳聋，汗出，面色苍白等。虚证者可见沉细弱脉，实证者以弦滑脉多见。1.2鉴别诊断1.2.1中风：中风是以卒然昏仆、不省人事，伴有口舌歪斜、语言謇涩、半身不遂为主症的一种疾病；或不经昏仆而仅以僻不遂为特征。眩晕发作严重者，有突然昏仆的现象，但神志清醒，且无口舌歪斜、半身不遂等症状；中年以上患者，肝阳上亢之眩晕极易化风而演变为中风。1.2.2厥证：厥证以突然昏倒、不省人事或伴有四肢逆冷为主，患者短时间内逐渐苏畻坴畿\0\0\0\0醼畻聱盯\r\0\0\0痭쳠ਘༀƙ\0ਘĀ\0\r\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽「ఆ䮔ఆ彿㎽䮈ఆ塚㎽䮔ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂圔㎽ﺼఅ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0쳠ਘ䐺盭暼痭쳠ਘༀƙ \0쳠ਘĀ\0\0㺣盭쳠ਘ\0ﱔ쳤ਘ\0팃', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('34', '33', 'T02_006', '1', '2012 ACR 痛风管理指南第1部分:高尿酸血非药物和药物的系统治疗方法', '2012 American College of Rheumatology Guidelines for Management of Gout. Part 1:Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia', '美国风湿病学会(ACR,American College of Rheumatology)', '2012', 'http://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines/Gout', '英文', 'T02_006_01_慢性沙粒状痛风性关节炎分度.docx', '痛风', null, null, ' T02_006_02图解慢性痛风石慢性痛风关节炎.docx', null, '血尿酸（SUA）', '痛风患者ULT目标为SUA＜6 mg/dl；对于痛风性关节炎症状长期不缓解或有痛风石的患者，SUA应＜5 mg/dl。<br />&nbsp;&nbsp;\nThe TFP recommended that the goal of ULT is to achieve a serum urate level target at a minimum of  6 mg/dl in all gout case scenarios (evidence A). Moreover, the TFP recommended that the target serum urate level should be lowered sufficiently to durably improve signs and symptoms of gout, including palpable and visible tophi detected by physical examination, and that this may involve therapeutic serum urate level lowering to below 5 mg/dl (evidence B).<br />&nbsp;&nbsp;', '痛风性关节炎的发病率逐年增高，关于高尿酸血症及痛风性关节炎的规范治疗越来越受到人们的视。2012年美国风湿病学会（ACR）在2011年推出诊治共识的基础上，制定了最新的痛风治疗指南，该指南分为两部分：第一部分是痛风的系统治疗指南，第二部分是急性痛风性关节炎的治疗与预防性抗炎治疗，均发表于《关节炎护理与研究》[Arthritis Care Res 2012，64（10）：1431和1447]杂志。此次治疗指南对过去各国治疗指南进行了总结更新，结合最新的文献证据和专家共识，制定出了不同证据级别的治疗方案。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('340', '42', 'G01_049', '1', '中医内科常见病诊疗指南西医疾病部分', '诊断标准采用1999年WHO/ISH', '中华中医药学会', '2008', '中华中医药学会.中医内科常见病诊疗指南西医疾病部分[M].北京：中国中医药出版社.2008', '中文', '3', null, null, '1.肝火上炎证：以头晕胀痛、面红目赤、烦躁易怒为主症，兼见耳鸣如潮、胁痛口苦、便秘溲黄等症，舌红，苔黄，脉弦数。2.痰湿内阻证：以头重如裹为主症，兼见胸脘痞闷、纳呆恶心、呕吐痰涎、身重困倦、少食多寐等症，苔腻，脉滑。3.瘀血内阻证：以头痛如刺、痛有定处为主症，兼见胸闷心悸、手足麻木、夜间尤甚等症，舌质暗，脉弦涩。4.阴虚阳亢证：以眩晕、耳鸣、腰酸膝软、五心烦热为主症，兼见头重脚轻、口燥咽干、两目干涩等症，舌红，少苔，脉细数。5.肾精不足证：以心烦不寐、耳鸣腰酸为主症，兼见心悸健忘、失眠梦遗、口干口渴等症，畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭쳠ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽ⷈఆ䫘ఆ彿㎽䫌ఆ塚㎽䫘ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂圔㎽ﺼఅ圞㎽\0\0圭㎽', '1诊断依据1.1临床表现1.1.1缓进型高血压：多数患者无症状，有些伴有头痛头晕、头胀耳鸣、眼花健忘、注意力不集中、失眠烦闷、心悸乏力、四肢麻木等症状。若血压长期高，则可出现脑、心、肾、眼底等器质性损害和功能障碍，并出现相应的临床表现。甚至发生脑卒中、心肌梗死。1.1.2急进型高血压：其表现基本上与缓进型高血压病相似，但症状明显，如头痛剧烈病情严重，发展迅速，视网膜病变和肾功能很快衰竭，血压迅速升高，常于数月至1 ～2年内出现严重的脑、心、肾损害，发生脑血管意外、心力衰竭和尿毒症；并常有视力模糊和失明，最畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭쳠ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽⩐ఆ䥠ఆ彿㎽䥔ఆ塚㎽䥠ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂圔㎽ﺼఅ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0턀ਘ䐺盭暼痭턀ਘༀƙ \0턀ਘĀ\0\0㺣盭턀ਘ\0ﱔ턄ਘ\0팃目턄ਘ࣒턄ਘ큁目턄ਘﻰఅ﫬\0Item\0\0䧤ఆ\0\0\0\0\0\0Count\0\0ﱬﬄ턴ਘ㳜੪\0\0턄ਘ\0\0\0\0੪寶目㳠੪矵䥷㎽⩐ఆ\0\0䧤ఆ�㏂䥔ఆ\0\0\0੪\0\0\0謁ﱔ\0\0㎾ࠆ\0ﱜ\0\0x�㏂䥔ఆ\0\0隲W䧤ఆ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\n\0霪W露W\0\0ﱴxt\0Љ\0\0\0௱鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0쓠ఌ쓠ఌ\0\0\0寶目㲈੪ﷰఅi\0\0ﱄ﷜ﱴﲔ먙㎼ﷰఅ㲈੪i\0\0ﱄ﷜ﱴ먰㎼﷜ﷰఅ�㏂ﵠఅ\0\0릎㎼ﷰఅi\0╪췬目╾췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒௱竗௱目W\0竗\0\0\0賓器目\0\0\0\0ﻰఅ\0目瑉浥目\0\0\0\0ﻰఅ\0目潃湵t\0\0\0\0̷\0\0ဠ\0\0侠̓ﯬ侠̓̙\0\0\0\0\0\0\0̙῰̓\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0῰̓\0\0\0\0̙ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚ￞\0\0⟒췬⟚췬目Љ\0鲸࣒\0￿￿目Љ\0鲬࣒௱觴௱目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨﷰఅ目潅f䓾瑤\0\0豸ࢋ\0\0核ʊ\0\0䒛瑤䕢瑤ꂸ瑧\0䔯瑤䑩瑤ʊ䀷瑤選ਟᛒ瑤\0㽺瑤\0\0㿣瑤選ਟ\0\0￿￿￿￿㯄瑽嵞盡㨣瑽Д', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('341', '42', 'G01_050', '1', '常见疾病的诊断与疗效判断标准', null, '中国中医药出版社', '1999', '吴少祯，吴敏.常见疾病的诊断与疗效判断标准[M].北京：中国中医药出版社.1999', '中文', null, null, null, null, null, null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('342', '42', 'G01_053', '1', '2006年加拿大高血压教育计划: 高血压治疗部份', null, '加拿大高血压教育计划委员会(CHEP,Canadian Hypertension Education Program)', '2006', '罗雪琚. 2006年加拿大高血压教育计划:高血压治疗部份[J]. 心血管病学进展, 2007(4):653-654.', '中文', null, null, null, null, null, null, null, '所有的患者血压应 <140/90 mmHg ( 1mmHg=0. 1333kPa) , 糖尿病或慢性肾脏病患者血压应 <130/80 mmHg( 无论其蛋白尿程度如何 ) 。', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('343', '42', 'G01_054', '1', '中国脑血管病一级预防指南', null, '中华医学会神经病学分会', '2015', '中华医学会神经病学分会. 中国脑血管病一级预防指南2015[J]. 中华医学信息导报, 2015, 30(17):8-8.', null, null, null, null, null, null, null, null, '高血压的治疗目标主要是提高控制率以减少脑卒中等合并症的发生。患者收缩压与舒张压的达标同等重要，但重点应放在收缩压的达标上。降压目标：普通高血压患者应将血压降至<140／90\nmmHg；伴糖尿病或肾病的高血压患者依据其危险分层及耐受性还可进一步降低(I级推荐，A级证据)。老年人(≥65岁)收缩压可根据具体情况降至<150mHg(I级推荐，A级证据)；但如能耐受，应进一步降低(I级推荐)。', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('344', '42', 'G01_055', '1', '2004英国高血压学会高血压治疗指南(BHS-IV):概要', 'Btriish Hypertension Socetiy guideileins for Hypertension managemet 2004(BHS-IV)', '英国高血压学会', '2004', 'Bryan Williams, Neil R Poulter, Peter S Sever,等. 2004英国高血压学会高血压治疗指南(BHS-IV):概要[J]. 英国医学杂志:中文版, 2004(5):273-279.', '英文', '1.高血压一级(轻度)<br />&nbsp;&nbsp; 2.二级(中度) <br />&nbsp;&nbsp; 3.三级(重度) <br />&nbsp;&nbsp; 4.单纯收缩期高血压一级收缩压', null, null, null, '英国高血压学会血压水平分类：收缩压(mmHg)舒张压(mmHg)血压理想收缩压<120mmHg舒张压<80mmHg正常收缩压<130mmHg舒张压<85mmHg正常高值收缩压130-139mmHg舒张压85-89mmHg高血压一级(轻度) 收缩压140-159mmHg舒张压90-99mmHg二级(中度) 收缩压160-179mmHg舒张压100-109mmHg三级(重度) 收缩压≥180mmHg舒张压≥110mmHg单纯收缩期高血压一级收缩压140-159舒张压<90mmHg二级≥160mmHg舒张压<9畻坴畿', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('345', '42', 'G01_056', '1', '2013 KSH指南：高血压的管理', '2013 Korean Society of Hypertension guidelines for the management of hypertension', '\n韩国高血压学会(KSH,Korean Society of Hypertension)', '2013', 'Clin Hypertens. 2015 Mar 19;21:1.2.3.', '英文', '1级高血压.<br />&nbsp;&nbsp;2.级高血压<br />&nbsp;&nbsp;3.单纯收缩期高血压', null, null, null, 'Hypertension (HTN) is defined as systolic blood pressure (SBP) or diastolic blood pressure (DBP) greaterthan or equal to 140 or 90 mm Hg, respectively (Table 1).Normal blood pressure (BP) is defined only as both SBPless than 120 mm Hg and DBP less than 80畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఅਘĀ\0అ彿㎽奋㎽巫㎽⩐ఆ䥠ఆ彿㎽䥔ఆ塚㎽䥠ఆꍈ㏂\0\0ﺼఅ學㎽漸㏂圔㎽ﺼఅ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0쳠ਘ䐺盭暼痭쳠ਘༀƙ \0쳠ਘĀ\0\0㺣盭쳠ਘ\0ﱔ쳤ਘ\0팃目쳤ਘ࣒쳤ਘ큁目쳤ਘﻰఅ﫬\0Item\0\0䧤ఆ\0\0\0\0\0\0Count\0\0ﱬﬄ촔ਘ㳜੪\0\0쳤ਘ\0\0\0\0੪寶目㳠੪矵䥷㎽⩐ఆ\0\0䧤ఆ�㏂䥔ఆ\0\0\0੪\0\0\0謁ﱔ\0\0㎾ࢲ\0ﱜ\0\0x�㏂䥔ఆ\0\0隲W䧤ఆ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\n\0霪W露W\0\0ﱴxt\0Љ\0\0\0௱鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0쓠ఌ쓠ఌ\0\0\0寶目㲈੪ﷰఅi\0\0ﱄ﷜ﱴﲔ먙㎼ﷰఅ㲈੪i\0\0ﱄ﷜ﱴ먰㎼﷜ﷰఅ�㏂ﵠఅ\0\0릎㎼ﷰఅi\0╪췬目╾췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒௱竗௱目W\0竗\0\0\0賓器目\0\0\0\0ﻰఅ\0目瑉浥目\0\0\0\0ﻰఅ\0目潃湵t\0\0\0\0̷\0\0ဠ\0\0侠̓ﯬ侠̓̙\0\0\0\0\0\0\0̙῰̓\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0῰̓\0\0\0\0̙ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚ￞\0\0⟒췬⟚췬目Љ\0鲸࣒\0￿￿目Љ\0鲬࣒௱觴௱目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨﷰఅ目潅f䓾瑤\0\0豸ࢋ\0\0核ʊ\0\0䒛瑤䕢瑤ꂸ瑧\0䔯瑤䑩瑤ʊ䀷瑤選ਟᛒ瑤\0㽺瑤\0\0㿣瑤選ਟ\0\0￿￿￿￿㯄瑽嵞盡㨣瑽Д輀ਟ\0\0鍈盠僦璅Д\0輀ਟ鰈瑼ἢ㌁\0\0㲺췭뀒\0ᢰ氁\0\0\0\0\0\0Ĺ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0㷤췭骶瑼輀ਟ\0\0\0\0\0磻\0\0磻\0\0\0磻', null, null, 'G01_056_表2', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('346', '42', 'G01_057', '1', '2016年加拿大高血压指南', 'HypertensionCanada’s2016CHEPGuidelinesforBloodPressureMeasurement,Diagnosis,AssessmentofRisk,PreventionandTreatmentofHypertension', '加拿大高血压教育计划委员会(CHEP,CanadianHypertensionEducationProgram)', '2016', 'CanadianJournalofCardiology(2016)', '英文', null, null, null, null, null, null, 'BP', 'Furthermore,inselectedhigh-riskpatients,intensivebloodpressurereductiontoatargetsystolicbloodpressure≤120mmHgshouldbeconsideredtolowertheriskofcardiovascularevents.<br />&nbsp;&nbsp;TargetBPforage<80is<140/90mmHg;forage≥80:targetSBPis<150mmHg', '1.血压测量工具首选全自动血压计；<br />&nbsp;&nbsp;2.检测血脂参数不再强调空腹采血；<br />&nbsp;&nbsp;3.对于不具有高血钾危险因素的患者，增加饮食中钾摄入有助于降低血压；<br />&nbsp;&nbsp;4.伴稳定性心绞痛的高血压患者（无心衰、心梗或冠脉旁路手术病史者），β受体阻滞剂或钙通道阻滞剂均可作为初始治疗选择；<br />&nbsp;&nbsp;5.新指南中最值得关注的是将不久前结束的SPRINT研究结论引入该指南，推荐将≤120mmHg作为部分高危患者（如年龄≥75岁者）的降压目标值。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('347', '48', 'Y04_001', '0', '中医病证诊断疗效标准', ' ', ' 国家中医药管理局', '1994', '国家中医药管理局.ZY／T001.8-94中医病证诊断疗效标准·中医皮肤科病证诊断疗效标准[S].南京：南京大学出版社，1994.', null, null, '银屑病', '白疕', '1.风热血燥<br />&nbsp;&nbsp;2.血虚风燥<br />&nbsp;&nbsp;3.瘀滞肌肤\n', '诊断依据：皮损初为针尖至扁豆大的炎性红色丘疹，常呈点滴状分布，迅速增大，表面覆盖银白色多层性鳞屑，状如云母。鳞屑剥离后，可见薄膜现象及筛状出血，基底浸润，可有同形反应。陈旧皮疹可呈钱币状、盘状、地图状等。 好发于头皮、四肢伸侧，以肘关节面多见，常泛发全身。部分病人可见指甲病变，轻者呈点状凹陷，重者甲板增厚，光泽消失。或可见于口腔、阴部粘膜。发于头皮者可见束状毛发。起病缓慢，易于复发。有明显季节性，一般冬重夏轻。可有家族史。 组织病理检查示表皮角化过度、角化不全。角层内有中性多形核白细胞堆积，棘层增厚。表皮突呈规则性向下延伸，真皮乳头水肿呈棒状，乳头内血管扩张，血管周围有炎性细胞浸润。', '风热血燥：皮损鲜红，皮疹不断出现，红斑增多，刮去鳞屑可见发亮薄膜，点状出血，有同形反应。伴心烦口渴，大便干，尿黄。舌质红，舌苔黄或腻，脉弦滑或数。血虚风燥：皮损色淡，部分消退，鳞屑较多。伴口干，便干。舌质淡红，苔薄白，脉细缓。 瘀滞肌肤：皮损肥厚浸润，颜色暗红，经久不退。舌质紫暗或见瘀斑、瘀点，脉涩或细缓。\n', null, '治愈：皮损完全消退，或消退95％以上。好转：皮损消退50％以上。未愈：皮损消退不足50％。\n', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('348', '48', 'Y04_002', '1', '临床诊疗指南皮肤病与性病分册', null, '中华医学会', '2010', '中华医学会. 临床诊疗指南(皮肤病与性病分册)[M]. 人民卫生, 2010.', null, '寻常型、脓疱型、关节病型和红皮病型', '银屑病', null, null, '1、寻常型银屑病，此型最多见，多急性发病。（1）多青壮年发病。部分发病或加重常由扁桃体炎或上呼吸道感染诱发。（2）好发于头皮、躯干和四肢伸侧，常对称分布，亦有仅局限于某一部位者。（3）典型皮疹为粟粒至绿豆大红色丘疹、斑丘疹或斑块，可融合成片，边界清楚，周围有炎性红晕，浸润显著，表面覆盖厚积的银白色鳞屑。轻轻刮除鳞屑，可见一层淡红色半透明薄膜（薄膜现象)；刮除薄膜后出现点状出血（Auspitz征）白色鳞屑，薄膜现象和点状出血是本病的临床特征。皮疹形态多样，可为点滴状，钱币状，地图状，蛎壳状等。（4）发生于头皮者，发呈束状。指趾甲受累，可见甲板上出现顶针样点状凹陷，纵嵴，横沟，游离端与甲床剥离以及混浊肥厚等。（5）粘膜损害：多见于龟头，口唇以及颊粘膜。龟头为边缘清楚的红色斑片，无鳞屑。上唇可有银白色鳞屑。颊粘膜有灰黄色或白色的环性斑片。（6）临床表现，可以分为三期。进行期：新皮疹不断发生，旧皮疹不断扩大，验证明显，常伴同形反应。静止期：病情稳定，基本上无新皮疹出现，亦不见旧皮损消退。消退期：皮损逐渐减小，消退，遗留暂时性色素减退或色素沉着斑片。（7）慢性病程：可持续十余年或数十年，甚至终身迁延不愈。常冬季复发或加重，春夏季减轻或消失，亦有与此相反者。（8）组织病理：表皮改变出现较早，主要为角化不全，有时角层内或其下方可见Munro微脓肿。颗粒层变薄或消失。棘层沸后，表皮嵴演唱。真皮乳头部血管扭曲扩张，轻度增厚。乳头上方表皮变薄，真皮上部有轻度至中度炎细胞浸润。2.脓疱型银屑病，临床较少见。分为掌跖脓疱性与泛发型脓疱型银屑病。（1）掌跖脓疱性银屑病：为掌跖的红色斑片上出现针头、粟粒大脓疱。又是在肘膝伸侧、胫前出现寻常型银屑病皮疹（鳞屑性红斑）（2）泛发型脓疱型银屑病：临床较少见。1）常因寻常型银屑病患者内用皮质类固醇，或外用强效皮质类固醇后突然减量或停药，或外用强刺激性药物，或内用砷剂，内服蟾皮后引起。2）常伴高热，关节肿痛，全身不适等。3）皮损为密集，针头至粟粒大小，浅在性无菌性小脓疱，表面覆有鳞屑，脓疱可以逐渐融合成大片脓湖，破溃后局部米兰，渗液，结黄痂。4）甲受累变形。常由沟状舌，地图舌，病情反复发作。好转时可出现典型的淫邪病皮损。5）组织病理，基本与寻常型银屑病相同。棘层上部出现Kogoj海绵状脓疱，疱内主要为中性粒细胞，真皮层主要为淋巴细胞和组织细胞浸润。6）实验室检查：多数白细胞增高，血沉增快，可有低蛋白血症和血钙降低。3.关节病型银屑病，（1）关节炎症状多发生于寻常型银屑病之后，或与脓疱型或红皮病型银屑病并发。偶有关节炎症状出现于寻常型银屑病之前者。（2）可同时侵犯大小关节，但以手、腕以及足等小关节受累多见。（3）关节炎症状一般与皮肤症状同时减轻或加重，临床表现类似类风湿性关节炎，为远端指趾间关节肿胀、疼痛，久病则出现关节畸形、僵硬，严重者多个大、小关节及脊柱受累，发生骶髂关节炎和强直性脊柱炎。（4）慢性病程（5）实验室检查：类风湿因子常阴性，可有血沉增快。X线检查显示受累关节边缘轻度肥厚，无普遍脱钙，亦有呈类风湿性关节炎改变者。4.红皮病型银屑病，是一种较少见的严重银屑病。（1）常因在银屑病急性进行期应用刺激性较强的活不适当的药物引起的，亦有因长期大量内服或外用皮质类固醇突然停药或减量过快所致，脓疱型银屑病在脓疱消退过程中可出现红皮病改变，少数由寻常型银屑病发展而来，极少数患者（儿童多见）初次发病即为本型。（3）临床表现：基本与剥脱性皮炎相同（4）寻常型银屑病特征性皮损常常消失，红皮病控制后可出现寻常型银屑病皮疹。（5）病程长，易复发，常数月或数年不愈。（6）组织病理：具有寻常型银屑病的病例特点，其他变化类似慢性皮炎。【诊断要点】根据临床表现，皮疹特点，好发部位，发病与季节的关系等。【鉴别诊断】1、玫瑰糠疹2.脂溢性皮炎3.副银屑病4。扁平.癣5.二期梅毒疹6.毛发红糠疹7.掌跖脓疱病8.疱疹样脓疱病9.连续性肢端皮炎10.类风湿性关节炎11.红皮病。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('349', '48', 'Y04_003', '1', '常见疾病的诊断与疗效判断标准', null, '中国中医药出版社', '1999', '吴少祯，吴敏.常见疾病的诊断与疗效判断标准[M].北京：中国中医药出版社.1999', '中文', '4', '银屑病', null, null, '【诊断标准】症状1.原发疹为帽针头至扁豆大小的红色炎性丘疹或斑丘疹，迅速增大，扩延全身，呈特有的淡红色，境界明显，表面覆盖银白色鳞屑， 皮损可表现各种形态，如点滴状，钱币状，地图状，花瓣状，带状，蛎壳状等。2.剥去鳞屑可漏出半透明膜（薄膜现象）剥去薄膜则见有小的出血点。成为Auspitz征。3。皮疹可发生于全身各处，但以四肢伸侧，特别是肘膝部好发，呈对称性。其此次是头发，腰骶部，少数可见于腹股沟，也过，掌跖，指（趾）甲及粘膜部。发于指（趾）甲者，甲根有顶针状小凹陷。临床称“顶针甲”.【分型】1.寻常型，根据病程分为三期。（1）进行期，皮损浸润明显，鳞屑较厚，皮损周围红晕，受机械性刺激如针刺，搔抓或用刺激性较强的外用药物，常在所刺激部引起新的皮损，称同形反应，亦称Kocbher征。（2）稳定器或静止期，病情稳定，暂停止发展，炎症减轻，无新皮疹发生。（3）退行期或恢复期，验证基本消退，皮疹缩小变平，周围出现色晕，色晕扩大，皮疹消退。2.脓疱型，以掌跖部多见，重者泛发全身，皮疹为在红斑基础上出现针头到粟米大小脓疱，或反复发作，常伴发热，关节痛等，疱液细菌培养呈阴性。3.关节型，出游寻常型典型皮损外，伴有关节痛，大小关节均可受累，可致骨质破坏，少数伴有发热等全身症状。4.红皮病型，常由不适当治疗及外用刺激性较强的药物而致，皮损呈弥漫性潮红，紫红，甚至肿胀浸润，大量脱屑，常伴有发热，寒战等全身症状。', null, null, '治愈，皮疹消退95%以上，好转，皮疹消退50%以上，未愈，皮疹消退不足50%。', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('34b2eca42c8740ad99341d639238d209', '4', 'fadfadsfa', '0', 'fasdfasdf', '', 'adfadsfadsfasdfd&amp;amp;amp;lt;/br&amp;amp;amp;gt;dafdfadsf&amp;amp;amp;lt;/br&amp;amp;amp;gt;adsfadfasdf', null, '', '中文', '', '', '', '', '', '', '', '', '', '3', '0', 'admin', '2016-05-12 16:10:47', 'admin', '2016-05-13 14:01:48');
INSERT INTO `biz_standard` VALUES ('35', '33', 'T02_007', '1', '2012 ACR 痛风管理指南第2部分:急性痛风性关节炎治疗和抗炎预防', '2012 American College of Rheumatology Guidelines for Management of Gout. Part 2: Therapy and Antiinflammatory Prophylaxis of Acute Gouty Arthritis', '美国风湿病学会(ACR,American College of Rheumatology)', '2012', 'http://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines/Gout', '英文', 'T02_007_01_急性痛风关节炎分度诊断.docx', '急性痛风性关节炎', null, null, ' T02_007_01_急性痛风关节炎分度诊断.docx', null, '血尿酸（SUA）', '症状消失', '痛风性关节炎的发病率逐年增高，关于高尿酸血症及痛风性关节炎的规范治疗越来越受到人们的视。2012年美国风湿病学会（ACR）在2011年推出诊治共识的基础上，制定了最新的痛风治疗指南，该指南分为两部分：第一部分是痛风的系统治疗指南，第二部分是急性痛风性关节炎的治疗与预防性抗炎治疗，均发表于《关节炎护理与研究》[Arthritis Care Res 2012，64（10）：1431和1447]杂志。此次治疗指南对过去各国治疗指南进行了总结更新，结合最新的文献证据和专家共识，制定出了不同证据级别的治疗方案。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('350', '48', 'Y04_004', '1', '牛皮癣：儿童牛皮癣', 'Psoriasis: childhood psoriasis', 'British Association of Dermatologists and Primary Care Dermatology Society', '2012', 'http://www.pcds.org.uk/clinical-guidance/psoriasis-in-children', null, null, '银屑病', null, null, 'Clinical findings<br />&nbsp;&nbsp;The following are more common findings in children compared with adults:<br />&nbsp;&nbsp;Distribution <br />&nbsp;&nbsp;Face, especially eyes and ears <br />&nbsp;&nbsp;Scalp - may be the only presenting feature <br />&nbsp;&nbsp;Distal limbs One digit - often associated with paronychia and nail changes. Often recalcitrant to treatment, but many improve with time <br />&nbsp;&nbsp;Guttate psoriasis - some patients get one or two outbreaks and do not go on to develop psoriasis in adult life. In others the psoriasis persists<br />&nbsp;&nbsp;\'Nappy rash\' / genital involvement - it may that some infants diagnosed as having seborrhoeic dermatitis of the nappy area may instead have psoriasis <br />&nbsp;&nbsp;An eczematised form of psoriasis - the two problems may co-exist<br />&nbsp;&nbsp; Chronic plaque psoriasis tends to be paler with less scale, although lesions are still well demarcated', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('351', '48', 'Y04_006', '1', '银屑病面积和严重程度指数(PASI)工作表', 'PSORIASIS AREA AND SEVERITY INDEX (PASI) WORKSHEET', 'British Association of Dermatologists', null, 'http://www.bad.org.uk/shared/get-file.ashx?id=1654&itemtype=document', null, null, '银屑病', null, null, 'Y04_006_01表1-3', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('352', '48', 'Y04_007', '1', '中国银屑病治疗指南', null, '中华医学会皮肤性病分会银屑病学组', '2008', '中华医学会皮肤性病分会银屑病学组. 中国银屑病治疗指南（2008版）[J]. 中华皮肤科杂志, 2009, 42(3):213-214.', null, '1.轻度<br />&nbsp;&nbsp;2.中度<br />&nbsp;&nbsp;3.重度', '银屑病', null, null, '一个简单界定银屑病严重程度的方法称为十分规则，即体表受累面积（BSA）DAYU510%(10个手掌的面积)或银屑病面积与严重程度指数（PASI）＞10或皮肤病生活质量指数（DLQI）＞10即为重度银屑病。BSA＜3%为轻度，3%-10%为中度。还要考虑皮损范围，部位，对生活质量的影响等诸多因素。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('353', '48', 'Y04_008', '1', '寻常型银屑病的系统性治疗指南', 'Systemic Treatment of Psoriasis vulgaris.\nDeveloped by the Guideline Subcommittee of the\nEuropean Dermatology Forum', 'European Dermatology Forum', '2009', 'http://www.euroderm.org/edf/images/stories/guidelines/guideline_on_psoriasis-version1b-2009-10-.pdf', '英文', null, '银屑病；Psoriasis', null, null, 'The diagnosis of psoriasis vulgaris is based almost exclusively on the clinical appearance ofthe lesions. Auspitz’s sign (i.e. multiple fine bleeding points when psoriatic scale is removed) may be elicited in scaly plaques. Involvement of predilection sites and the presence of nail psoriasis contribute to the diagnosis. Occasionally, psoriasis is difficult to distinguish from nummular eczema, tinea, or cutaneous lupus. Guttate psoriasis may resemble pityriasis rosea. In rare cases, mycosis fungoides must be excluded. If the skin changes are located in the intertriginous areas, intertrigo and candidiasis must be considered. In some cases, histological examination of biopsies taken from the border of representative lesions is needed to confirm the clinical diagnosis.<br />&nbsp;&nbsp;Tools for assessing the severity of symptoms are available for plaque psoriasis. The most widely used measure is the Psoriasis Area and Severity Index (PASI). According to recent guidelines, moderate to severe disease is defined as a PASI score >10 32. PASI 75 and PASI Tools for assessing the severity of symptoms are available for plaque psoriasis. The most widely used measure is the Psoriasis Area and Severity Index (PASI). According to recent guidelines, moderate to severe disease is defined as a PASI score >10 32. PASI 75 and PASI', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('354', '48', 'Y04_009', '1', '2005 英国皮肤医师协会(BAD)《 银屑病生物制剂干预指南》', 'British Association of Dermatologists guidelines for use of\nbiological interventions in psoriasis 2005', 'British Association of Dermatologists', '2005', 'British Journal of Dermatology 2005 153, pp486–497', '英文', null, '银屑病；Psoriasis', null, null, 'To be considered eligible for treatment, patients must have severedisease as defined in (a) and fulfil one of the clinical categories<br />&nbsp;&nbsp;outlined in (b):<br />&nbsp;&nbsp;(a) Severe disease is defined as a PASI score of 10 or more (or aBSA of 10% or greater where PASI is not applicable) and a DLQI >10. Disease should have been severe for 6 months, resistant totreatment and the patient should be a candidate for systemic therapy. In exceptional circumstances (for example, disabling acraldisease), patients with severe disease may fall outside this definition but may be considered for treatment. (Strength of recommendationD, level of evidence 3).<br />&nbsp;&nbsp;AND<br />&nbsp;&nbsp;(b) fulfil at least one of the following clinical categories (Strengthof recommendation B, level of evidence 1++ and formal consensus):<br />&nbsp;&nbsp;(i) have developed or are at higher than average risk of developing clinically important drug-related toxicity and where alternative standard therapya cannot be used<br />&nbsp;&nbsp;(ii) are or have become intolerant to or cannot receive standardsystemic therapy<br />&nbsp;&nbsp;(iii) are or have become unresponsive to standard therapyb<br />&nbsp;&nbsp;(iv) have disease that is only controlled by repeated inpatientmanagement<br />&nbsp;&nbsp;(v) have significant, coexistent, unrelated comorbidity whichprecludes use of systemic agents such as ciclosporin or methotrexate<br />&nbsp;&nbsp;(vi) have severe, unstable, life-threatening disease (erythrodermic or pustular psoriasis)<br />&nbsp;&nbsp;(vii) have psoriatic arthritis fulfilling the British Society forRheumatology (BSR) eligibility criteria for treatment with antiTNF agents,11 in association with skin disease<br />&nbsp;&nbsp;astandard systemic therapy includes acitretin, ciclosporin, methotrexate, narrowband ultraviolet (UV) B and psoralen + UVAphotochemotherapy (PUVA)<br />&nbsp;&nbsp;bunresponsive to standard therapy is defined as an unsatisfactoryclinical response (a less than 50% improvement in baseline PASIscore or percentage BSA where the PASI is not applicable, and aless than 5-point improvement in DLQI) to at least 3 months oftreatment in the therapeutic dose range to the following treatments: ciclosporin 2Æ5–5 mg kg)1 daily; methotrexate singleweekly dose (oral, subcutaneous, intramuscular) 15 mg, max 25–30 mg; acitretin 25–50 mg daily; narrowband UVB or psoralenphotochemotherapy (nonresponse, rapid relapse or exceedingrecommended maximum doses) 150–200 treatments for PUVA,350 treatments for narrowband UVB.12,13', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('355', '48', 'Y04_010', '0', '寻常型银屑病（白疕）中医药循证实践指南（2013年版）', null, '中华中医药学会皮肤科分会，北京中医药学会皮肤病专业委员会，北京中西医结合学会皮肤性病专业委员会', '2013', '寻常型银屑病(白疕)中医药循证临床实践指南(2013版)[J]. 中医杂志.2004.55(1):76-82.', '中文', null, '寻常型银屑病', '白疕', '1.血热证<br />&nbsp;&nbsp; 2.血燥证<br />&nbsp;&nbsp; 3.血瘀证', null, '1.血热证<br />&nbsp;&nbsp;本证相关类型包括风热血燥证、风热证和血热内蕴证。<br />&nbsp;&nbsp;主症:①皮损鲜红;②新出皮疹不断增多或迅速扩大。<br />&nbsp;&nbsp;次症:①心烦易怒;②小便黄;③舌质红或绛;④脉弦滑或数。<br />&nbsp;&nbsp;证候确定:具备全部主症和1项以上次症。<br />&nbsp;&nbsp;2.血燥证<br />&nbsp;&nbsp;本证相关类型包括血虚风燥证。<br />&nbsp;&nbsp;主症:①皮损淡红;②鳞屑干燥。<br />&nbsp;&nbsp;次症:①口干咽燥;②舌质淡，舌苔少或薄白;③脉细或细数。<br />&nbsp;&nbsp;证候确定:具备全部主症和1项以上次症。<br />&nbsp;&nbsp;3.血瘀证<br />&nbsp;&nbsp;本证相关类型包括瘀滞肌肤证和气滞血瘀证。<br />&nbsp;&nbsp;主畻坴畿\0\0\0\0醼畻聱盯\r\0\0\0痭⿈ఌༀƙ\0ఌĀ\0\r\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄ᡸఅఌĀ\0ఄ彿㎽奋㎽巫㎽毜అ讬అ彿㎽讠అ塚㎽讬అꍈ㏂\0\0ᡸఅ學㎽漸㏂圔㎽ᡸఅ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0㿰੟䐺盭暼痭㿰੟ༀƙ \0㿰੟ð\0\0㺣盭㿰੟\0𢡄㿴੟\0팃目㿴੟࣒㿴੟큁目㿴੟᢬అ泌\0Item\0\0谰అ\0\0\0\0\0\0Count\0\0﫨呂䀤੟㳜੪\0\0㿴੟\0\0\0\0੪寶目㳠੪楱䥷㎽毜అ\0\0谰అ�㏂讠అ\0\0\0੪\0\0\0露𢡄\0\0㎾ќ\0齃\0\0x�㏂讠అ', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('356', '48', 'Y04_011', '1', '银屑病和银屑病关节炎的管理指南', 'Guidelines of care for the management of\npsoriasis and psoriatic arthritis', 'American Academy of Dermatology', '2008', 'J Am Acad Dermatol 2008;58:826-50.', null, '1.Plaque psoriasis<br />&nbsp;&nbsp;2.Inverse psoriasis<br />&nbsp;&nbsp;3.Erythrodermic psoriasis <br />&nbsp;&nbsp;4.Pustular<br />&nbsp;&nbsp;5.Guttate<br />&nbsp;&nbsp;6.Nail disease<br />&nbsp;&nbsp;7.Nail disease', null, null, null, null, null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('357', '48', 'Y04_012', '1', '临床指南：牛皮癣', 'GUIDELINE TITLE\nPsoriasis', 'Finnish Medical Society Duodecim - Professional Association', '2002', 'National Guideline Clearinghouse', '英文', null, null, null, null, '1. Assessment of clinical features and patterns of cutaneous lesions\n2. Assessment for family history of psoriasis\n3. Biopsy, if needed<br />&nbsp;&nbsp;Characteristic cutaneous lesions facilitate diagnosis.· The plaques are sharply demarcated, slightly elevated, and covered with silvery scales (see pictures 1, 3, and 2*).\n· Gentle scraping of the scales reveals minute capillary bleeding points\n(Auspitz sign) (see picture 4*).\n· The elbows (see picture 5*), knees (see picture 6*), legs, lower back,scalp (see pictures 7 and 8*), and glans penis (see picture 9*) are the sites of predilection.\n· Involvement of the nails is common.\n· Pitting\n· Separation of the distal nail plate from the nail bed (onycholysis),yellowish flecks beneath the nail plate (\"oily macules\"), and subungualhyperkeratosis (see pictures 11, 12, and 10*).\n· Acrodermatitis continua of Hallopeau is a painful, localized pustularform of psoriasis which often leads to nail deformity (see pictures 14and 13*).<br />&nbsp;&nbsp;Common Manifestations of Psoriasis<br />&nbsp;&nbsp;· The most common type is plaque psoriasis, which is a stationary form of the disease with the lesions often covered with thick silvery scales.<br />&nbsp;&nbsp;· Guttate psoriasis is often triggered by tonsillitis. It is widely distributed throughout the body.<br />&nbsp;&nbsp;· Flexural psoriasis is localized within the main skin folds (genitocrural area [see picture 15*], navel, axillae, submammary region).<br />&nbsp;&nbsp;· Erythrodermic psoriasis (see picture 16*) is a generalized form of the disease and is most refractory to treatment. It may also appear in a pustular form(pustular psoriasis).<br />&nbsp;&nbsp;· Psoriasis may also affect joints in 5 to 10% of cases.<br />&nbsp;&nbsp;Differential Diagnosis<br />&nbsp;&nbsp;· Diagnosis is based on the clinical picture (Lebwohl, 2003).<br />&nbsp;&nbsp;· A biopsy may exclude some other skin diseases resembling psoriasis, but itrarely is pathognomic (Lebwohl, 2003).<br />&nbsp;&nbsp;· A family history of psoriasis may help in diagnosis: up to 50% of patients report an affected relative (Swanbeck et al., 1997).<br />&nbsp;&nbsp;Scalp<br />&nbsp;&nbsp;· In seborrhoeic dermatitis (see the Finnish Medical Society Duodecim guideline \"Seborrhoeic dermatitis\" (see picture 17*) the flakes are thinner, \"greasier,\" and the condition responds better to treatment. It is often difficult to differentiate seborrhoeic dermatitis from psoriasis unless other skin areas offer additional information.<br />&nbsp;&nbsp;· Fungal infection of the scalp (see the Finnish Medical Society Duodecim guideline \"Dermatomycoses\") is uncommon in the Western populations. It mostly affects children. This diagnosis can be excluded by microscopy and negative culture for fungi.<br />&nbsp;&nbsp;· Neurodermatitis of the neck (lichen simplex nuchae) is characterised by an isolated, itchy plaque covered with thin scales.<br />&nbsp;&nbsp;Flexures<br />&nbsp;&nbsp;· Seborrhoeic dermatitis may resemble flexural psoriasis. Examine other skin areas. It is not necessary to differentiate between these two conditions, as the treatment is the same.<br />&nbsp;&nbsp;· Fungal infection (tinea) (see the Finnish Medical Society Duodecim guideline \"Dermatomycoses\") may resemble psoriasis; however, it usually heals in the centre and expands peripherally. Potassium hydroxide (KOH) and fungal culture are diagnostic.<br />&nbsp;&nbsp;· Candidiasis is not often seen in the young and middle-aged patients. It presents as a moist area of erythema and maceration with outlying \"satellite eruptions.\"<br />&nbsp;&nbsp;· Erythrasma is a macular brown area with few symptoms, most often found<br />&nbsp;&nbsp;in the armpits or groin. It is caused by overgrowth of diphtheroids of the normal skin flora. These areas fluoresce coral pink under long-wave ultraviolet radiation (Wood\'s light).<br />&nbsp;&nbsp;Hands, Feet<br />&nbsp;&nbsp;· Hyperkeratotic eczema of the palms and palmoplantar pustulosis may be difficult to differentiate from psoriasis (see picture 18*). Examine theentire skin.<br />&nbsp;&nbsp;· Fungal infection (see the Finnish Medical Society Duodecim guideline \"Dermatomycoses\") can easily be diagnosed with microscopic examination and culture.\n', null, 'Psoriasis clearance rate\n· Remission rate\n· Adverse effects of (tolerance to) treatment', null, 'Psoriasis is a chronic disease of the skin caused by genetic and environmental\nfactors. It is characterized by well-defined plaques bearing adherent, silvery\nscales.', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('358', '48', 'Y04_013', '1', '依那西普和依法利珠治疗成人银屑病指南', 'Etanercept and efalizumab\nfor the treatment of adults\nwith psoriasis', 'National Institute for Health and Clinical Excellence', '2006', 'www.nice.org.uk/TA103', '英文', ' 1.mild<br />&nbsp;&nbsp;2. moderate <br />&nbsp;&nbsp;3. severe', 'psoriasis', null, null, 'Psoriasis is generally graded as mild, moderate or severe. Several different\nscales for measuring the severity of psoriasis are also used, which are\nvariably based on the following criteria: the proportion of body surface area\naffected; the disease activity (degree of plaque redness, thickness and\nscaling); the response to previous therapies; and the impact of the disease on\nthe person.<br />&nbsp;&nbsp;‘Severe’ psoriasis means a total Psoriasis Area Severity Index (PASI)≥ 10 and a Dermatology LifeQuality Index (DLQI) >10.Clinicians will need toagree locally on how todefine ‘failed torespond to’ and‘intolerance to’standard systemictherapies, for auditpurposes.‘Standard systemictherapies’ includeciclosporin,methotrexate andPUVA (psoralen andlong-wave ultravioletradiation).(As a guide fordesigning the audit,see the BritishAssociation ofDermatologistsGuidelines for use ofbiological interventionsin psoriasis for moredetail related todefinitions.)See the summaries ofproduct characteristicsfor contraindications tostandard systemictherapies in routineuse', null, 'PASI score;DLQI', 'It was aware that the EMEA recognises that reduction of baseline PASI score by 75% (PASI 75) is an indicator that severe psoriasis has responded to treatment. Additionally the British Society for Rheumatology guidelines on the use of these agents in PsA a畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭㿰੟ༀƙ\0੟ð\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄ᡸఅ੟ð\0ఄ彿㎽奋㎽巫㎽瀔అ贤అ彿㎽贘అ塚㎽贤అꍈ㏂\0\0ᡸఅ學㎽漸㏂圔㎽ᡸఅ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0駠ƞ䐺盭暼痭駠ƞༀƙ \0駠ƞð\0\0㺣盭駠ƞ\0𢡄駤ƞ\0팃目駤ƞ࣒駤ƞ큁目駤ƞ᢬అ泌\0Item\0\0趨అ\0\0\0\0\0\0Count\0\0﫨呂騔ƞ㳜੪\0\0駤ƞ\0\0\0\0੪寶目㳠੪楱䥷㎽瀔అ\0\0趨అ�㏂贘అ\0\0\0੪\0\0\0露𢡄\0\0㎾Ⴒ\0齃\0\0x�㏂贘అ\0\0隲W趨అ\0\0�Ĳ\0\0\0鹿齃殺\0\0霈W戀醙霫W戀ꊠऺ齃x\0霪W露Wꊠऺ﫰xt\0Љ\0\0\0൐௲鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0⑰ਫ਼⑰ਫ਼㲈੪ឬఅ寶目㲈੪ឬఅi\0\0變ﱘ﫰﬐먙㎼ឬఅ㲈੪i\0\0變ﱘ﫰먰㎼ﱘឬఅ�㏂᜜అ\0\0릎㎼ឬఅi\0⓮췬目⓲췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒൐௲竗൐௲目W\0竗\0\0\0目\0\0\0\0᢬అ\0目瑉浥目\0\0\0\0᢬అ\0目潃湵t\0\0\0Ƕ\0\0ဠ\0\0侠̓賓侠̓̙\0\0\0\0\0\0\0̙῰̓\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0῰̓\0\0\0\0̙華뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚ目\0\0륿ရ╖췬╞췬目Љ\0鲸࣒\0￿￿目Љ\0鲬࣒൐௲觴൐௲目t\0觴\0\0\0梅礼目\0\0\0\0﫤ឬఅ目潅f摲敳t盡옎盡㊊췭\0\0ό2\0$\0\0\0\0\0\0p\0￿￿￿￿얠盡왑盡↢쬁\0\0\0\0\0翽捥盦Ȓ묞￾￿옎盡伛盡\0\0٣դό2đ\0ϐ̀ϐ ƭ伦盡㋪췭ƭđ\0\0\0\0\0\0\0\0\0\0捥盦謺묞￾￿템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂瞒⫠\0\0\0瞒⪌쀕瞒〠\0䪔㏂\0T\0\0⪌쀕\0\0ꀀ翽翽瞒鸞䪔㏂\0邰ƙ\0\0ࠀ᎖眊\0\0䪔㏂鸞\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ菱ឬఅﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀﬘眿ฒ趨అ磻ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿菱￿￿\0\0異\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ\0\0\0\0\0奰畿⡥췬焚畻邰ƙࠀ菱￿￿㏂￿￿\0\0\0\0滑煔畻:\0菱￿￿㏂￿￿奰畿\0\0\0\0璉㎾ࠄ\0\0菱￿￿㏂㎾x\0\0�㏂贘అ\0\0頲W怜\0\0\0\0ࠄ\0顇WValu\0\0菱令趨అ齃\0\0\0\0\0\0菱\0磻\0窱餀W齃ﬄ	\0ﭴ\0\0ੴ\0.\0\0\0\0\0ᇜੵ\0\0識⤖췬識뜩@﷩\0\0\0\0靖䗧@林蕶@ੴ﫬煮\0뮩@館믆@믎@﫬﷩\0釚@﫬﫬﷩\0ༀƙ﫰ༀƙ社戤痝\0Ɨ\0\0䈸੏並ఄఄ忉㎽豜అ奁㎽ఄ	\0豨అ贤అ彿㎽﫠䦕盭贤అ	\0贤అ忉㎽𢡄䥷盭贤అꊠऺ	\0﫨趨అ﫰馘B齃ﭴxﬄﬄ駰B﫰蠸ঽ兰৺\0అ\0\0𢡄ﲘ齃xﲘxﲀﭴx﬐xﲘ﬜xﲘﲴxﲘꊠऺ蠸ঽ뿄x\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0ꊠऺ᢬అ䗆@	ऺ᢬అ趨అ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0ʎC᢬అﲘC᢬అ\0\0\0\0\0అ\0\0\0\0అﱘ￿\0\0\0\0\0\0￿\0\0\0\0\0台৺\0\0\0ﴀ\0\0ﴄ稐ɪఅ\0\0ῄ੟ﲘ\0\0뤬ॕﴌ嵿{ﳴ\0\0\0\0\0ﴀﳀ庱{ﴌﴔ彨{ﴌꊠऺ\0ﺰੂৄϐ Â\0\0\0표৻\0\0ɯ\0\0\0稐ɪ\0\0㡬੷\0\0ﵤⰛEﴠⰺEﵤﴬⱹEﵤﴸⳗEﵤﵬ⳶Eﵤꊠऺ\0\0\0਌\0\0帠ঽﺀੂĀ﷌㘣Tﹸ㘶T﷌﹠\0\0\0\0崈盡ﶠ갦盠쾐ƫ\0\0ﹸ\0\0ﷀ駅Éॹˢ\0\0\0ﹸ翽ﹸ﷜﷔츐ɳ﷤刞E\0\0\0\0\0\0\0\0︐쓷盡਌\0\0\0\0\0\0\0\0ꯍ�\0\0﹠\0\0ﺈ엷盡࿢Ԗ਌\0\0\0\0\0\0㪂췭Ｈ＠쬠ƫ$\0\0\0\0\0\00\0￿￿￿￿얠盡\0\0ｄ\0\0\0\0\0︬Ꝥɹﻜ捥盦Ȓ묞\0\0ﻬ찰盡\0\0࿢Ԗ਌\0\0\0\0\0\0쬴ƫ\0㫦췭츐ɳ＠\0\0\0\0\0\0\0\0ﺼﺰｄｄ捥盦ࡒ묞￾￿ﻼ첈盡࿢Ԗ\0\0਌㺖T＠ｬ\0\0\0\0츐ɳ㻛T਌\0\0\0\0\0\0�ğǶ\0ǋ\0ꋴĵ䈆Tｐ䈐', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('359', '48', 'Y04_014', '1', '牛皮癣患者管理指南', 'Guidelines for management of patients with psoriasis', 'British Association of Dermatologists', '1991', 'Dermatologists B A O. Guidelines for management of patients with psoriasis[J]. Bmj British Medical Journal, 1991, 303(6806):829-835.', '英文', null, null, null, null, 'The diagnosis of psoriasis is clinical and mostdoctors should have few problems in diagnosing mostcases. Laboratory investigations are rarely helpful.There are several clinical forms of psoriasis, and aperson may, during a lifetime, move from one type toanother. The body surface area affected can range froma small area to almost total coverage. Psoriasis canchange qualitatively from stable plaque lesions toan unstable form typified by eruptive inflammatorylesions that are easily irritated by topical treatment.Drugs thought to precipitate or worsen psoriasisinclude alcohol and, in some patients, -3 blockers andnon-steroidal anti-inflammatory agents. Lithium,chloroquine, and mepacrine may be associated withsevere, even life threatening, deterioration ofpsoriasis.<br />&nbsp;&nbsp;The assessment of severity should include twodifferent components: firstly, the patient\'s own perception of disability -that is, the \"need for treatment\"-and, secondly, an objective assessment of the extentand severity of body involvement.<br />&nbsp;&nbsp;\nFor family doctors most information will be obtainedfrom the patient\'s need for treatment. Many dermatologists use measures such as body mapping or thepsoriasis area and severity index to give a roughguide of objective improvement with treatment.Measurements of percentage area affected alone,however, are not sufficient as similar extents ofcoverage at different sites, such as the trunk and hands,create different degrees of disability and distress.Furthermore, the degree of disability experienced bydifferent people with the same amount of psoriasisvaries greatly. Because of this the aim of managementshould always be determined in close association withthe individual patient\'s views. It is good practice torecord in the clinical notes what patients thinkis the most upsetting aspect of their psoriasis. Manage ment aims can then be directed appropriately within therapeutic limitations and judgments based on therisk: benefit ratio.\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('36', '33', 'T02_008', '1', '痛风的管理指南', 'Managmeng of Gout', '马来西亚卫生部(MOH,Ministry of Health Malaysia)', '2008', null, '英文', '痛风性关节炎<br />&nbsp;&nbsp;痛风的进展通过几个临床阶段,即急性痛风,临界区痛风,慢性痛风。<br />&nbsp;&nbsp;\n\n', '痛风', null, null, ' 1.急性痛风通常表现为急性、自限性,大约90%的患者的关节炎性关节炎。下肢关节的影响往往比上肢。<br />&nbsp;&nbsp;关节一般影响是: <br />&nbsp;&nbsp;——第一跖趾关节(临床也称为足痛风) <br />&nbsp;&nbsp;——前脚/脚背<br />&nbsp;&nbsp;——踝关节<br />&nbsp;&nbsp;——膝关节<br />&nbsp;&nbsp;——腕关节<br />&nbsp;&nbsp;——肘关节<br />&nbsp;&nbsp;——手指关节<br />&nbsp;&nbsp;急性痛风还涉及关节外部位尤其是鹰嘴囊和跟腱。<br />&nbsp;&nbsp;在检查,可能有红斑,温暖和涉及关节肿胀,与极端的温柔。随后,病人可能皮肤脱屑覆盖受影响的联合。发烧可能存在。<br />&nbsp;&nbsp;攻击痛风通常持续几天至2 - 3周,逐步完成决议的炎症的迹象。<br />&nbsp;&nbsp;痛风是一种间歇性的常规攻击和缓解,紧随其后的是一种慢性阶段。大约有60%的病人在第一年内第二次攻击,和78%在两年内第二次袭击。只有7%的患者在10年期间没有复发。<br />&nbsp;&nbsp;2.临界区痛风<br />&nbsp;&nbsp;当病人发作与无症状之间的时期。<br />&nbsp;&nbsp;3.慢性痛风<br />&nbsp;&nbsp;慢性痛风是由多关节关节炎和痛风石的形成。<br />&nbsp;&nbsp;慢性痛风诊断要点<br />&nbsp;&nbsp;\n--急性发作> 3 /年<br />&nbsp;&nbsp;\n--慢性tophaceous痛风<br />&nbsp;&nbsp;\n--出现尿酸盐的肾病<br />&nbsp;&nbsp;\n--出现尿酸盐肾脏结石<br />&nbsp;&nbsp;<br />&nbsp;&nbsp;\n4.痛风诊断标准<br />&nbsp;&nbsp;临床诊断需满足两个以下标准:<br />&nbsp;&nbsp;1）病史，至少两次明显的发作痛苦的关节肿胀，2周内完全缓解。<br />&nbsp;&nbsp;2）一个清晰的病史或观察痛风。<br />&nbsp;&nbsp;3）存在痛风结节。<br />&nbsp;&nbsp;4）秋水仙碱开始治疗在48小时内有快速反应。<br />&nbsp;&nbsp;如果在滑液或组织可见单钠尿酸盐晶体，可明确的诊断。<br />&nbsp;&nbsp;\n1.Acute gout<br />&nbsp;&nbsp;Acute gout commonly presents as an acute, self-limiting, monoarticular inflammatory arthritis in approximately 90% of patients. Joints of the lower limbs are affected more often than those of the upper limbs.<br />&nbsp;&nbsp;The joints commonly affected are:<br />&nbsp;&nbsp;--1st metatarsophalangeal joint (clinically also known as podagra)<br />&nbsp;&nbsp;--forefoot / instep<br />&nbsp;&nbsp;--ankle joint<br />&nbsp;&nbsp;--knee joint<br />&nbsp;&nbsp;--wrist joint<br />&nbsp;&nbsp;--elbow joint<br />&nbsp;&nbsp;--finger joints<br />&nbsp;&nbsp;Acute gout also involves extra-articular sites particularly the olecranon bursa and Achilles tendon. <br />&nbsp;&nbsp;On examination, there may be erythema, warmth and swelling over the involved joint, associated with extreme tenderness. Subsequently, the patient may have skin desquamation overlying the affected joint. Fever may be present.<br />&nbsp;&nbsp;Attacks of gout usually last from a few days to 2 - 3 weeks, with a gradual complete resolution of all inflammatory signs. <br />&nbsp;&nbsp;The usual course of gout is one of intermittent attacks and remissions, followed by a chronic phase. Approximately 60% of patients have a second attack within the first year, and 78% have a second attack within two years. Only 7% of patients do not have a recurrence within a 10-year period. <br />&nbsp;&nbsp;2.Intercritical gout<br />&nbsp;&nbsp;These are periods in between attacks when the patient is asymptomatic. <br />&nbsp;&nbsp;3.Chronic gout<br />&nbsp;&nbsp;Chronic gout is marked by polyarticular arthritis and the formation of tophi. <br />&nbsp;&nbsp;\nChronic Gout<br />&nbsp;&nbsp;\n-- >3 acute attacks/year<br />&nbsp;&nbsp;\n-- Chronic tophaceous gout<br />&nbsp;&nbsp;\n-- Presence of urate nephropathy<br />&nbsp;&nbsp;\n-- Urate renal calculi<br />&nbsp;&nbsp;\nDIAGNOSTIC GRITERIA FOR GOUT<br />&nbsp;&nbsp;Two of the following criteria are required for a clinical diagnosis:<br />&nbsp;&nbsp;   1） Presence of a clear history of at least two attacks of painful joint swelling with complete resolution within 2 weeks.<br />&nbsp;&nbsp;   2） A clear history or observation of podagra.<br />&nbsp;&nbsp;   3） Presence of a tophus.<br />&nbsp;&nbsp;   4） Rapid response to colchicine within 48 hours of starting treatment.<br />&nbsp;&nbsp;A definitive diagnosis can be made if crystals of monosodium urate are seen in the synovial fluid or in the tissues.<br />&nbsp;&nbsp;\nT02_008_01_基线调查关节肿X光图.docx', null, '血尿酸（SUA）', 'SUA<360mmol/L ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('360', '48', 'Y04_015', '1', '2009BAD/PCDS 银屑病的初始管理的建议', 'Recommendations for the initial management\nof psoriasis\n', 'British Association of Dermatologists & Primary Care Dermatology Society', '2009', 'http://guide.medlive.cn/guideline/preview/1/1464?token=8f7acdfea90116be7f24a77d20b4a258', '英文', null, 'psoriasis', null, null, 'Clinical features<br />&nbsp;&nbsp;• The diagnosis of psoriasis is clinical, and laboratory investigations are unhelpful <br />&nbsp;&nbsp;• There are several forms of psoriasis, and the type affecting an individual may change over time. The sites and extent of involvement can range from trivial to almost total coverage <br />&nbsp;&nbsp;• Psoriasis can change from stable plaques to an unstable form, typified by eruptive inflammatory lesions that are easily irritated by topical treatment <br />&nbsp;&nbsp;• Drugs thought to precipitate or worsen psoriasis include beta-adrenoceptor blocking drugs and NSAIDs. Oral administration of lithium, chloroquine or mepacrine may be associated with severe deterioration of psoriasis. Alcohol may worsen psoriasis and may interfere with treatment in various ways <br />&nbsp;&nbsp; Assessment of severity should include the patient\'s own perception of disability, the need for treatment, and an objective assessment of the extent and severity of the disease <br />&nbsp;&nbsp;o the total area of involvement is a factor in assessing severity, but is difficult to estimate accurately<br />&nbsp;&nbsp;', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('361', '48', 'Y04_016', '1', '中国银屑病治疗指南2013', null, '中华医学会皮肤性病分会银屑病学组', '2013', '中华医学会皮肤性病分会银屑病学组. 中国银屑病治疗指南（2008版）[J]. 中华皮肤科杂志, 2009, 42(3):213-214.', null, null, '银屑病', null, '1.血热风盛型<br />&nbsp;&nbsp;2.血瘀肌肤型<br />&nbsp;&nbsp;3.血虚风燥型<br />&nbsp;&nbsp;4.湿热蕴藉型<br />&nbsp;&nbsp;5.火毒炽盛型<br />&nbsp;&nbsp;6.风湿寒痹型<br />&nbsp;&nbsp;7.热毒伤阴型<br />&nbsp;&nbsp;8.肝肾阴虚型', '银屑病的分类<br />&nbsp;&nbsp;1.寻常型银屑病 此型约占银屑病患者的90%以上，原发性皮疹是红色丘疹或斑块, 表面覆有多层疏松的银白色鳞屑, 刮除鳞屑后,出现薄膜现象和点状出血。皮损可局限亦可累及全身；好发于头皮、躯干和四肢关节伸侧；伴有不同程度的瘙痒；病情冬重夏轻。<br />&nbsp;&nbsp;点滴状银屑病  皮损为广泛或散在分布的红色鳞屑性丘疹，经常是疾病最早的皮损表现，尤其是链球菌感染激发的病例，后期皮疹多转变为斑块状。<br />&nbsp;&nbsp;斑块状银屑病  寻常型中最常见的类型，鳞屑性红色斑块大小不一，边界清楚；掌跖部斑块鳞屑粘着，常伴有皲裂疼痛。瘙痒明显的皮损会呈现疣状改变；伴有严重炎症时，鳞屑为黄色疏松的痂片，伴有少量渗出的皮损成蛎壳状外观。<br />&nbsp;&nbsp;反向性银屑病  皮损分布与通常银屑病皮损的部位相反，限局于屈侧的皱褶部位（腋下、乳房下、腹股沟、外阴和肛周等）。由于局部潮湿，皮损为红斑而少有鳞屑。<br />&nbsp;&nbsp;2.脓疱型银屑病  银屑病角层中的中性粒细胞微脓疡增大到表现出肉眼可见的脓疱时，称之为脓疱型银屑病。<br />&nbsp;&nbsp;（1）泛发性脓疱型银屑病  严重时可伴有皮肤疼痛和发热等全身症状；脓疱发生的前后，或同时可具有寻常型银屑病皮损特点。<br />&nbsp;&nbsp;（2）局限性脓疱型银屑病  包括掌跖脓疱病和连续性肢端皮炎；前者皮疹限于手掌足底，可伴发或不伴发典型的寻常型银屑病。连续性肢端皮炎的皮疹发生于指趾端，引起甲及其下骨质的损伤，是脓疱型银屑病中少见的类型。<br />&nbsp;&nbsp;3.红皮病型银屑病  可从斑块状银屑病或脓疱型银屑病发展而来，皮损累及整个体表面积的90%以上，伴有大量的鳞屑脱落。皮肤广泛毛细血管扩张的体温调节作用可引起脱水、寒战和低体温；同时脱屑的丢失和消化系统的吸收不良，可导致高输出量的心衰、低蛋白血症和感染等其他系统疾病。<br />&nbsp;&nbsp;4.关节病型银屑病  银屑病患者中6-42%转变成关节病型银屑病，尤其是严重的银屑病发生关节炎比率较高。银屑病性关节炎病谱宽广，从脊柱到外周指趾远端关节均可累及，可出现关节滑膜和邻近软组织的炎症、肌腱端炎、骨炎，严重的骨质溶解和新骨形成，指骨呈笔套样畸形；受累关节多为非对称性，常先有单个关节的肿胀疼痛，关节症状与皮损的严重程度不一定相关；病程缓慢，加重和缓解交替发生，不可逆的破坏使正常功能逐渐丧失。<br />&nbsp;&nbsp;5. 其它<br />&nbsp;&nbsp;各型银屑病均可累及皮肤附属器。指趾甲表现为甲板顶针状凹点、甲下“油滴”状斑点、甲板增厚、甲下角化过度、甲分离和甲破坏；在头皮皮损处头发呈束状,通常不会导致毛发脱落。<br />&nbsp;&nbsp;银屑病皮损可累及粘膜，包括眼结膜、口腔粘膜、外阴部黏膜、外耳道等。在脓疱型银屑病常可见有沟纹舌、地图舌。<br />&nbsp;&nbsp;（二） 检查<br />&nbsp;&nbsp;1.病理检查：皮肤组织病理检查有助于银屑病的诊断，但若病理结果不符合银屑病的特征,临床上也不能除外银屑病的可能。<br />&nbsp;&nbsp;2.影像学检查：可用于关节病型银屑病的诊断。CT对微小病变比X线敏感，核磁共振可较早诊断关节周围软组织的病变。临床无症状的银屑病常有肌腱端的改变，超声波可以为疾病早期的异常提供识别。<br />&nbsp;&nbsp;3.实验室检查：HLA分型可作为关节病型与脓疱型银屑病的参考指标；类风湿因子的检测可作为类风关和关节病型银屑病的鉴别的依据；严重的银屑病发生全身症状时，必须进行相应的常规和生化检测。<br />&nbsp;&nbsp;（三） 鉴别诊断<br />&nbsp;&nbsp;1.寻常型银屑病需与下列疾病相鉴别：慢性湿疹、神经性皮炎、痒疹、药疹、浅部真菌感染、皮肤型红斑狼疮、扁平苔藓、二期梅毒疹、蕈样肉芽肿、毛发红糠疹、副银屑病、疣状痣、脂溢性皮炎、玫瑰糠疹等。反向性银屑病应与间擦症、念珠菌感染等项鉴别。<br />&nbsp;&nbsp;2.甲病变需与下列疾病相鉴别：甲真菌病、甲营养不良。<br />&nbsp;&nbsp;3.头皮病变需与下列疾病相鉴别：石棉状糠疹、头癣、脂溢性皮炎。<br />&nbsp;&nbsp;4.关节病型银屑病需与下列疾病相鉴别：类风关、Reiter病、强直性脊柱炎、骨关节炎。<br />&nbsp;&nbsp;5.红皮病型银屑病需与下列疾病相鉴别：各种原因引起的剥脱性皮炎，如毛发红糠疹、湿疹、皮肤淋巴瘤等。<br />&nbsp;&nbsp;6.脓疱型银屑病需与下列疾病相鉴别：角层下脓疱性皮病、反应性关节炎综合征、天疱疮、急性泛发性发疹性脓疱病、坏死松解性游走性红斑等。<br />&nbsp;&nbsp;一个简单界定银屑病严重程度的方法称为十分规则，即体表受累面积（BSA）DAYU510%(10个手掌的面积)或银屑病面积与严重程度指数（PASI）＞10或皮肤病生活质量指数（DLQI）＞10即为重度银屑病。BSA＜3%为轻度，3%-10%为中度。还要考虑皮损范围，部位，对生活质量的影响等诸多因素。', '1.血热风盛型：本型相当于寻常型进行期，皮损为点滴状或钱币状，皮色鲜红，皮疹进行性增加，伴有瘙痒。可伴有咽痛等上呼吸道感染症状。<br />&nbsp;&nbsp;2.血瘀肌肤型：本型相当于寻常型静止期，皮损为钱币状或地图状，鳞屑较厚的斑块，皮色暗红，皮疹反复不愈，冬季可病情加重。<br />&nbsp;&nbsp;3.血虚风燥型：本型相当于寻常型消退期，皮损为环状或边缘消退状，鳞屑容易脱落，皮色淡红或暗红，病情稳定，无新发皮疹。<br />&nbsp;&nbsp;4.湿热蕴藉型：本型相当于局限或掌跖脓疱型，皮损为四肢或掌跖红斑上针头或米粒大小脓疱，反复发生；或腋窝、腹股沟等皱褶部位红斑畻坴畿\0\0\0\0醼畻聱盯\r\0\0\0痭㿰੟ༀƙ\0੟ð\0\r\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄ᡸఅ੟ð\0ఄ彿㎽奋㎽巫㎽毜అ讬అ彿㎽讠అ塚㎽讬అꍈ㏂\0\0ᡸఅ學㎽漸㏂圔㎽ᡸఅ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0⿈ఌ䐺盭暼痭⿈ఌༀƙ \0⿈ఌð\0\0㺣盭⿈ఌ\0𢡄⿌ఌ\0팃目⿌ఌ࣒⿌ఌ큁目⿌ఌ᢬అ泌\0Item\0\0谰అ\0\0\0\0\0\0Count\0\0﫨呂⿼ఌ㳜੪\0\0⿌ఌ\0\0\0\0੪寶目㳠੪楱䥷㎽毜అ\0\0谰అ�㏂讠అ\0\0\0੪\0\0\0露𢡄\0\0㎾Ҭ\0齃\0\0x�㏂讠అ\0\0隲W谰అ\0\0�Ĳ\0\0\0鹿齃殺\0\0霈W戀醙霫W戀ꊠऺ齃x\r', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('362', '48', 'Y04_017', '1', '2012 NPF共识指南：斑块状银屑病的管理', 'Consensus guidelines for the management of plaque psoriasis.', '\n国家银屑病基金会(NPF,National Psoriasis Foundation)', '2012', 'Arch Dermatol. 2012 Jan;148(1):95-102.', '英文', null, null, null, null, 'Moderate psoriasis is commonly distinguished from milder forms of the disease on the basis of scores on 1 or more clinical metrics, such as the Psoriasis Area and Severity Index (PASI); the percentage of the body surface area affected; and the Dermatological Life Quality Index (eAppendix, chapter 3, Table 2; http://www.archdermatol.com)', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('363', '48', 'Y04_018', '1', '维吾尔医常见病诊疗指南', null, '中国民族医药学会', '2015', '中国民族医药学会.T/ZGMZYYXH001-007-2015，维吾尔医常见病诊疗指南[S].北京：中国中医药出版社，2015.', '中文', '寻常型<br />&nbsp;&nbsp;红皮病型<br />&nbsp;&nbsp;脓疱病型<br />&nbsp;&nbsp;关节病型<br />&nbsp;&nbsp;\n进行期<br />&nbsp;&nbsp;静止期<br />&nbsp;&nbsp;消退期', '鳞屑癣；寻常型银屑病', null, '1. 异常血液质型鳞屑癣<br />&nbsp;&nbsp;异常胆液质型鳞屑癣<br />&nbsp;&nbsp;异常成性黏液质型鳞屑癣<br />&nbsp;&nbsp;异常黑胆液质型鳞屑癣', '临床表现：多青壮年发病，部分发病或加重常由扁桃体炎或上呼吸道感染诱发。好发于头皮、躯-和四肢伸侧，常对称分布，亦有仅局限于某一部位者。典型皮疹为粟粒至绿豆大红色丘疹、斑丘疹或斑块，可融合成片，边界清楚，周围有炎性红晕，浸润湿著，表面覆盖厚积的银白色鳞屑。轻轻刮除鳞屑，可见一层淡红色半透明薄膜（薄膜现象）；刮除薄膜后．出现点状出血（Auspitz征）。白色鳞屑、薄膜现象和点状出血是本病的临床特征。皮疹形态多样，可为点滴状、钱币状、地图状、蛎壳状等。发生于头皮者，呈束状。可有指（趾）甲受累，黏膜损害。慢性病程，甚至终生迁延不愈‘常冬季复发或加重，春夏减轻或消失，亦有与此相反者。<br />&nbsp;&nbsp;组织病理：表皮改变出现较早．主要为角化不全，有时角质层内或其下发可见Munro微脓肿；颗粒层变薄或消失；棘层肥厚，表皮嵴延长；真皮乳头部血管扭曲扩张，轻度增厚；乳头上方表皮变薄；真皮上部有轻度至中度炎细胞浸润。<br />&nbsp;&nbsp;诊断要点:根据临床表现、皮疹特点、好发部位、发病与季节的关系等综合诊断。<br />&nbsp;&nbsp;鉴别诊断:本病应与玫瑰糠疹、脂溢性皮炎、副银屑病、扁平苔癣、二期梅毒疹、毛发红糠疹、掌跖脓疱病、疱疹样脓疱病、连续性肢端皮炎、类风湿性关节炎等鉴别诊断。', '1. 异常血液质型鳞屑癣（相当于寻常型银屑病进行期）<br />&nbsp;&nbsp;主症：银白色鳞屑，可见薄膜现象、点状出血点。<br />&nbsp;&nbsp;次症：皮疹不断出现和扩大，皮损颜色红，鳞屑厚积，周围有红晕，痒感较烈；舌红，苔黄，脉搏为硬波浪形，少数出现上呼吸道感染症状，小便颜色黄。<br />&nbsp;&nbsp;2.异常胆液质型鳞屑癣（相当于寻常型银屑病进行期）<br />&nbsp;&nbsp;主症：银白色鳞屑，可见薄膜现象一点状出血点。<br />&nbsp;&nbsp;次症：皮疹多为点滴或片状，基底潮红，表面覆盖银白色麟屑，瘙痒；夏季加重伴有口渴咽干，便秘，苔薄黄，脉搏硬且快，小便颜色黄，皮损灼热。<br />&nbsp;&nbsp;3.畻坴畿\0\0\0\0醼畻聱盯\r\0\0\0痭駠ƞༀƙ\0ƞĀ\0\r\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄ᡸఅƞĀ\0ఄ彿㎽奋㎽巫㎽毜అ讬అ彿㎽讠అ塚㎽讬అꍈ㏂\0\0ᡸఅ學㎽漸㏂圔㎽ᡸఅ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0駠ƞ䐺盭暼痭駠ƞༀƙ \0駠ƞð\0\0㺣盭駠ƞ\0𢡄駤ƞ\0팃目駤ƞ࣒駤ƞ큁目駤ƞ᢬అ泌\0Item', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('364', '48', 'Y04_001', '0', '中医病证诊断疗效标准', ' ', ' 国家中医药管理局', '1994', '国家中医药管理局.ZY／T001.8-94中医病证诊断疗效标准·中医皮肤科病证诊断疗效标准[S].南京：南京大学出版社，1994.', null, null, '银屑病', '白疕', '1.风热血燥<br />&nbsp;&nbsp;2.血虚风燥<br />&nbsp;&nbsp;3.瘀滞肌肤\n', '诊断依据：皮损初为针尖至扁豆大的炎性红色丘疹，常呈点滴状分布，迅速增大，表面覆盖银白色多层性鳞屑，状如云母。鳞屑剥离后，可见薄膜现象及筛状出血，基底浸润，可有同形反应。陈旧皮疹可呈钱币状、盘状、地图状等。 好发于头皮、四肢伸侧，以肘关节面多见，常泛发全身。部分病人可见指甲病变，轻者呈点状凹陷，重者甲板增厚，光泽消失。或可见于口腔、阴部粘膜。发于头皮者可见束状毛发。起病缓慢，易于复发。有明显季节性，一般冬重夏轻。可有家族史。 组织病理检查示表皮角化过度、角化不全。角层内有中性多形核白细胞堆积，棘层增厚。表皮突呈规则性向下延伸，真皮乳头水肿呈棒状，乳头内血管扩张，血管周围有炎性细胞浸润。', '风热血燥：皮损鲜红，皮疹不断出现，红斑增多，刮去鳞屑可见发亮薄膜，点状出血，有同形反应。伴心烦口渴，大便干，尿黄。舌质红，舌苔黄或腻，脉弦滑或数。血虚风燥：皮损色淡，部分消退，鳞屑较多。伴口干，便干。舌质淡红，苔薄白，脉细缓。 瘀滞肌肤：皮损肥厚浸润，颜色暗红，经久不退。舌质紫暗或见瘀斑、瘀点，脉涩或细缓。\n', null, '治愈：皮损完全消退，或消退95％以上。好转：皮损消退50％以上。未愈：皮损消退不足50％。\n', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('365', '48', 'Y04_002', '1', '临床诊疗指南皮肤病与性病分册', null, '中华医学会', '2010', '中华医学会. 临床诊疗指南(皮肤病与性病分册)[M]. 人民卫生, 2010.', null, '寻常型、脓疱型、关节病型和红皮病型', '银屑病', null, null, '1、寻常型银屑病，此型最多见，多急性发病。（1）多青壮年发病。部分发病或加重常由扁桃体炎或上呼吸道感染诱发。（2）好发于头皮、躯干和四肢伸侧，常对称分布，亦有仅局限于某一部位者。（3）典型皮疹为粟粒至绿豆大红色丘疹、斑丘疹或斑块，可融合成片，边界清楚，周围有炎性红晕，浸润显著，表面覆盖厚积的银白色鳞屑。轻轻刮除鳞屑，可见一层淡红色半透明薄膜（薄膜现象)；刮除薄膜后出现点状出血（Auspitz征）白色鳞屑，薄膜现象和点状出血是本病的临床特征。皮疹形态多样，可为点滴状，钱币状，地图状，蛎壳状等。（4）发生于头皮者，发呈束状。指趾甲受累，可见甲板上出现顶针样点状凹陷，纵嵴，横沟，游离端与甲床剥离以及混浊肥厚等。（5）粘膜损害：多见于龟头，口唇以及颊粘膜。龟头为边缘清楚的红色斑片，无鳞屑。上唇可有银白色鳞屑。颊粘膜有灰黄色或白色的环性斑片。（6）临床表现，可以分为三期。进行期：新皮疹不断发生，旧皮疹不断扩大，验证明显，常伴同形反应。静止期：病情稳定，基本上无新皮疹出现，亦不见旧皮损消退。消退期：皮损逐渐减小，消退，遗留暂时性色素减退或色素沉着斑片。（7）慢性病程：可持续十余年或数十年，甚至终身迁延不愈。常冬季复发或加重，春夏季减轻或消失，亦有与此相反者。（8）组织病理：表皮改变出现较早，主要为角化不全，有时角层内或其下方可见Munro微脓肿。颗粒层变薄或消失。棘层沸后，表皮嵴演唱。真皮乳头部血管扭曲扩张，轻度增厚。乳头上方表皮变薄，真皮上部有轻度至中度炎细胞浸润。2.脓疱型银屑病，临床较少见。分为掌跖脓疱性与泛发型脓疱型银屑病。（1）掌跖脓疱性银屑病：为掌跖的红色斑片上出现针头、粟粒大脓疱。又是在肘膝伸侧、胫前出现寻常型银屑病皮疹（鳞屑性红斑）（2）泛发型脓疱型银屑病：临床较少见。1）常因寻常型银屑病患者内用皮质类固醇，或外用强效皮质类固醇后突然减量或停药，或外用强刺激性药物，或内用砷剂，内服蟾皮后引起。2）常伴高热，关节肿痛，全身不适等。3）皮损为密集，针头至粟粒大小，浅在性无菌性小脓疱，表面覆有鳞屑，脓疱可以逐渐融合成大片脓湖，破溃后局部米兰，渗液，结黄痂。4）甲受累变形。常由沟状舌，地图舌，病情反复发作。好转时可出现典型的淫邪病皮损。5）组织病理，基本与寻常型银屑病相同。棘层上部出现Kogoj海绵状脓疱，疱内主要为中性粒细胞，真皮层主要为淋巴细胞和组织细胞浸润。6）实验室检查：多数白细胞增高，血沉增快，可有低蛋白血症和血钙降低。3.关节病型银屑病，（1）关节炎症状多发生于寻常型银屑病之后，或与脓疱型或红皮病型银屑病并发。偶有关节炎症状出现于寻常型银屑病之前者。（2）可同时侵犯大小关节，但以手、腕以及足等小关节受累多见。（3）关节炎症状一般与皮肤症状同时减轻或加重，临床表现类似类风湿性关节炎，为远端指趾间关节肿胀、疼痛，久病则出现关节畸形、僵硬，严重者多个大、小关节及脊柱受累，发生骶髂关节炎和强直性脊柱炎。（4）慢性病程（5）实验室检查：类风湿因子常阴性，可有血沉增快。X线检查显示受累关节边缘轻度肥厚，无普遍脱钙，亦有呈类风湿性关节炎改变者。4.红皮病型银屑病，是一种较少见的严重银屑病。（1）常因在银屑病急性进行期应用刺激性较强的活不适当的药物引起的，亦有因长期大量内服或外用皮质类固醇突然停药或减量过快所致，脓疱型银屑病在脓疱消退过程中可出现红皮病改变，少数由寻常型银屑病发展而来，极少数患者（儿童多见）初次发病即为本型。（3）临床表现：基本与剥脱性皮炎相同（4）寻常型银屑病特征性皮损常常消失，红皮病控制后可出现寻常型银屑病皮疹。（5）病程长，易复发，常数月或数年不愈。（6）组织病理：具有寻常型银屑病的病例特点，其他变化类似慢性皮炎。【诊断要点】根据临床表现，皮疹特点，好发部位，发病与季节的关系等。【鉴别诊断】1、玫瑰糠疹2.脂溢性皮炎3.副银屑病4。扁平.癣5.二期梅毒疹6.毛发红糠疹7.掌跖脓疱病8.疱疹样脓疱病9.连续性肢端皮炎10.类风湿性关节炎11.红皮病。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('366', '48', 'Y04_003', '1', '常见疾病的诊断与疗效判断标准', null, '中国中医药出版社', '1999', '吴少祯，吴敏.常见疾病的诊断与疗效判断标准[M].北京：中国中医药出版社.1999', '中文', '4', '银屑病', null, null, '【诊断标准】症状1.原发疹为帽针头至扁豆大小的红色炎性丘疹或斑丘疹，迅速增大，扩延全身，呈特有的淡红色，境界明显，表面覆盖银白色鳞屑， 皮损可表现各种形态，如点滴状，钱币状，地图状，花瓣状，带状，蛎壳状等。2.剥去鳞屑可漏出半透明膜（薄膜现象）剥去薄膜则见有小的出血点。成为Auspitz征。3。皮疹可发生于全身各处，但以四肢伸侧，特别是肘膝部好发，呈对称性。其此次是头发，腰骶部，少数可见于腹股沟，也过，掌跖，指（趾）甲及粘膜部。发于指（趾）甲者，甲根有顶针状小凹陷。临床称“顶针甲”.【分型】1.寻常型，根据病程分为三期。（1）进行期，皮损浸润明显，鳞屑较厚，皮损周围红晕，受机械性刺激如针刺，搔抓或用刺激性较强的外用药物，常在所刺激部引起新的皮损，称同形反应，亦称Kocbher征。（2）稳定器或静止期，病情稳定，暂停止发展，炎症减轻，无新皮疹发生。（3）退行期或恢复期，验证基本消退，皮疹缩小变平，周围出现色晕，色晕扩大，皮疹消退。2.脓疱型，以掌跖部多见，重者泛发全身，皮疹为在红斑基础上出现针头到粟米大小脓疱，或反复发作，常伴发热，关节痛等，疱液细菌培养呈阴性。3.关节型，出游寻常型典型皮损外，伴有关节痛，大小关节均可受累，可致骨质破坏，少数伴有发热等全身症状。4.红皮病型，常由不适当治疗及外用刺激性较强的药物而致，皮损呈弥漫性潮红，紫红，甚至肿胀浸润，大量脱屑，常伴有发热，寒战等全身症状。', null, null, '治愈，皮疹消退95%以上，好转，皮疹消退50%以上，未愈，皮疹消退不足50%。', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('367', '48', 'Y04_004', '1', '牛皮癣：儿童牛皮癣', 'Psoriasis: childhood psoriasis', 'British Association of Dermatologists and Primary Care Dermatology Society', '2012', 'http://www.pcds.org.uk/clinical-guidance/psoriasis-in-children', null, null, '银屑病', null, null, 'Clinical findings<br />&nbsp;&nbsp;The following are more common findings in children compared with adults:<br />&nbsp;&nbsp;Distribution <br />&nbsp;&nbsp;Face, especially eyes and ears <br />&nbsp;&nbsp;Scalp - may be the only presenting feature <br />&nbsp;&nbsp;Distal limbs One digit - often associated with paronychia and nail changes. Often recalcitrant to treatment, but many improve with time <br />&nbsp;&nbsp;Guttate psoriasis - some patients get one or two outbreaks and do not go on to develop psoriasis in adult life. In others the psoriasis persists<br />&nbsp;&nbsp;\'Nappy rash\' / genital involvement - it may that some infants diagnosed as having seborrhoeic dermatitis of the nappy area may instead have psoriasis <br />&nbsp;&nbsp;An eczematised form of psoriasis - the two problems may co-exist<br />&nbsp;&nbsp; Chronic plaque psoriasis tends to be paler with less scale, although lesions are still well demarcated', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('368', '48', 'Y04_006', '1', '银屑病面积和严重程度指数(PASI)工作表', 'PSORIASIS AREA AND SEVERITY INDEX (PASI) WORKSHEET', 'British Association of Dermatologists', null, 'http://www.bad.org.uk/shared/get-file.ashx?id=1654&itemtype=document', null, null, '银屑病', null, null, 'Y04_006_01表1-3', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('369', '48', 'Y04_007', '1', '中国银屑病治疗指南', null, '中华医学会皮肤性病分会银屑病学组', '2008', '中华医学会皮肤性病分会银屑病学组. 中国银屑病治疗指南（2008版）[J]. 中华皮肤科杂志, 2009, 42(3):213-214.', null, '1.轻度<br />&nbsp;&nbsp;2.中度<br />&nbsp;&nbsp;3.重度', '银屑病', null, null, '一个简单界定银屑病严重程度的方法称为十分规则，即体表受累面积（BSA）DAYU510%(10个手掌的面积)或银屑病面积与严重程度指数（PASI）＞10或皮肤病生活质量指数（DLQI）＞10即为重度银屑病。BSA＜3%为轻度，3%-10%为中度。还要考虑皮损范围，部位，对生活质量的影响等诸多因素。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('37', '34', 'M03_001', '1', '慢性肾功能衰竭', null, '中华中医药学会', '2008', 'ZYYXH/T106-2008, 慢性肾衰竭[S].', '中文', '临床分期标准<br />&nbsp;&nbsp;肾功能不全代偿期：Ccr80~50ml/min，Scr<133μmol/L。<br />&nbsp;&nbsp;肾功能不全失代偿期：：Ccr50~25ml/min，Scr133~221μmol/L。<br />&nbsp;&nbsp;肾功能衰竭期：：Ccr<10ml/min，Scr>442μmol/L。<br />&nbsp;&nbsp;', '慢性肾衰竭', null, '1.脾肾气虚证<br />&nbsp;&nbsp;2.脾肾阳虚证<br />&nbsp;&nbsp;3.脾肾气阴两虚证<br />&nbsp;&nbsp;4.肝肾阴虚证<br />&nbsp;&nbsp;5.阴阳两虚证<br />&nbsp;&nbsp;', '诊断依据<br />&nbsp;&nbsp;1.临床表现<br />&nbsp;&nbsp;1.1症状：临床表现十分复杂，基本可以分为代谢紊乱和各系统症状两大组。但两者亦互为因果，许多代谢紊乱可以是系统症状的基本原因，反过来，各系统脏器因代谢异常而导致毒性代谢产物储留，影响脏器功能，从而加剧代谢紊乱。体征慢性肾衰竭患者无明显特异性的1.2体征：主要根据患者的原发病及控制情况、肾功能损害、并发症、生活方式的调节等不同而表现各异，如水肿、高血压、皮肤改变等。<br />&nbsp;&nbsp;2.理化检查<br />&nbsp;&nbsp;2.1 尿常规检查：可有程度不等的蛋白尿、血尿、管型尿，也可无明显尿检异常，以24小时尿肌酐计算肌酐清除率，有明显下降。<br />&nbsp;&nbsp;2.2血常规检查：有红细胞、血红蛋白、红细胞压积的明显下降，部分患者可有白细胞和血小板的减少肾功能有尿素氮及血肌配的明显升高，达到失代偿指标早期患者可呈低钙高磷，在合并甲状旁腺功能亢进时可呈高钙高磷，慢性肾功能不全患者应注意血钾水平的变化及酸中毒状态的纠正血脂水平为甘油三醋的中度升高及胆固醇在不同脂蛋白的分布异常血β-微球水平可反映肾小球的滤过功能通常可升高，血碱性磷酸酶升高，钙磷乘积升高。病因诊断时还可以检查血糖、血尿酸、免疫指标等项目。<br />&nbsp;&nbsp;2.3 影像学检查：包括B超、ECT、心脏超声、X线摄片等。<br />&nbsp;&nbsp;2.4 肾活检：一般来说，慢性肾衰竭不是肾活检的适应证。<br />&nbsp;&nbsp;3. 诊断要点<br />&nbsp;&nbsp;参照中华内科杂志编委会肾脏病专业组年拟定标准制定。①内生肌配清除率Ccr<80ml/min;②血肌酐Scr>133μmol/L；③有慢性肾脏疾病或累及肾脏的系统性疾病病史。<br />&nbsp;&nbsp;', '1.脾肾气虚证<br />&nbsp;&nbsp;证候：倦怠乏力，气短懒言，食少纳呆，腰酸膝软，脘腹胀满，大便不实，口淡不渴，舌淡有齿痕，脉沉细。<br />&nbsp;&nbsp;2.脾肾阳虚证<br />&nbsp;&nbsp;证候：倦怠乏力，气短懒言，食少纳呆，腰酸膝软，脘腹胀满，大便不实，口淡不渴，舌淡有齿痕，脉沉细。<br />&nbsp;&nbsp;3.脾肾气阴两虚证<br />&nbsp;&nbsp;证候：倦怠乏力，气短懒言，食少纳呆，腰酸膝软，脘腹胀满，大便不实，口淡不渴，舌淡有齿痕，脉沉细。<br />&nbsp;&nbsp;4.肝肾阴虚证<br />&nbsp;&nbsp;证候：倦怠乏力，气短懒言，食少纳呆，腰酸膝软，脘腹胀满，大便不实，口淡不渴，舌淡有齿痕，脉沉细。<br />&nbsp;&nbsp;5.阴阳两虚证<br />&nbsp;&nbsp;证候：倦怠乏力，气短懒言，食少纳呆，腰酸膝软，脘腹胀满，大便不实，口淡不渴，舌淡有齿痕，脉沉细。<br />&nbsp;&nbsp;', null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('370', '48', 'Y04_008', '1', '寻常型银屑病的系统性治疗指南', 'Systemic Treatment of Psoriasis vulgaris.\nDeveloped by the Guideline Subcommittee of the\nEuropean Dermatology Forum', 'European Dermatology Forum', '2009', 'http://www.euroderm.org/edf/images/stories/guidelines/guideline_on_psoriasis-version1b-2009-10-.pdf', '英文', null, '银屑病；Psoriasis', null, null, 'The diagnosis of psoriasis vulgaris is based almost exclusively on the clinical appearance ofthe lesions. Auspitz’s sign (i.e. multiple fine bleeding points when psoriatic scale is removed) may be elicited in scaly plaques. Involvement of predilection sites and the presence of nail psoriasis contribute to the diagnosis. Occasionally, psoriasis is difficult to distinguish from nummular eczema, tinea, or cutaneous lupus. Guttate psoriasis may resemble pityriasis rosea. In rare cases, mycosis fungoides must be excluded. If the skin changes are located in the intertriginous areas, intertrigo and candidiasis must be considered. In some cases, histological examination of biopsies taken from the border of representative lesions is needed to confirm the clinical diagnosis.<br />&nbsp;&nbsp;Tools for assessing the severity of symptoms are available for plaque psoriasis. The most widely used measure is the Psoriasis Area and Severity Index (PASI). According to recent guidelines, moderate to severe disease is defined as a PASI score >10 32. PASI 75 and PASI Tools for assessing the severity of symptoms are available for plaque psoriasis. The most widely used measure is the Psoriasis Area and Severity Index (PASI). According to recent guidelines, moderate to severe disease is defined as a PASI score >10 32. PASI 75 and PASI', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('371', '48', 'Y04_009', '1', '2005 英国皮肤医师协会(BAD)《 银屑病生物制剂干预指南》', 'British Association of Dermatologists guidelines for use of\nbiological interventions in psoriasis 2005', 'British Association of Dermatologists', '2005', 'British Journal of Dermatology 2005 153, pp486–497', '英文', null, '银屑病；Psoriasis', null, null, 'To be considered eligible for treatment, patients must have severedisease as defined in (a) and fulfil one of the clinical categories<br />&nbsp;&nbsp;outlined in (b):<br />&nbsp;&nbsp;(a) Severe disease is defined as a PASI score of 10 or more (or aBSA of 10% or greater where PASI is not applicable) and a DLQI >10. Disease should have been severe for 6 months, resistant totreatment and the patient should be a candidate for systemic therapy. In exceptional circumstances (for example, disabling acraldisease), patients with severe disease may fall outside this definition but may be considered for treatment. (Strength of recommendationD, level of evidence 3).<br />&nbsp;&nbsp;AND<br />&nbsp;&nbsp;(b) fulfil at least one of the following clinical categories (Strengthof recommendation B, level of evidence 1++ and formal consensus):<br />&nbsp;&nbsp;(i) have developed or are at higher than average risk of developing clinically important drug-related toxicity and where alternative standard therapya cannot be used<br />&nbsp;&nbsp;(ii) are or have become intolerant to or cannot receive standardsystemic therapy<br />&nbsp;&nbsp;(iii) are or have become unresponsive to standard therapyb<br />&nbsp;&nbsp;(iv) have disease that is only controlled by repeated inpatientmanagement<br />&nbsp;&nbsp;(v) have significant, coexistent, unrelated comorbidity whichprecludes use of systemic agents such as ciclosporin or methotrexate<br />&nbsp;&nbsp;(vi) have severe, unstable, life-threatening disease (erythrodermic or pustular psoriasis)<br />&nbsp;&nbsp;(vii) have psoriatic arthritis fulfilling the British Society forRheumatology (BSR) eligibility criteria for treatment with antiTNF agents,11 in association with skin disease<br />&nbsp;&nbsp;astandard systemic therapy includes acitretin, ciclosporin, methotrexate, narrowband ultraviolet (UV) B and psoralen + UVAphotochemotherapy (PUVA)<br />&nbsp;&nbsp;bunresponsive to standard therapy is defined as an unsatisfactoryclinical response (a less than 50% improvement in baseline PASIscore or percentage BSA where the PASI is not applicable, and aless than 5-point improvement in DLQI) to at least 3 months oftreatment in the therapeutic dose range to the following treatments: ciclosporin 2Æ5–5 mg kg)1 daily; methotrexate singleweekly dose (oral, subcutaneous, intramuscular) 15 mg, max 25–30 mg; acitretin 25–50 mg daily; narrowband UVB or psoralenphotochemotherapy (nonresponse, rapid relapse or exceedingrecommended maximum doses) 150–200 treatments for PUVA,350 treatments for narrowband UVB.12,13', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('372', '48', 'Y04_010', '0', '寻常型银屑病（白疕）中医药循证实践指南（2013年版）', null, '中华中医药学会皮肤科分会，北京中医药学会皮肤病专业委员会，北京中西医结合学会皮肤性病专业委员会', '2013', '寻常型银屑病(白疕)中医药循证临床实践指南(2013版)[J]. 中医杂志.2004.55(1):76-82.', '中文', null, '寻常型银屑病', '白疕', '1.血热证<br />&nbsp;&nbsp; 2.血燥证<br />&nbsp;&nbsp; 3.血瘀证', null, '1.血热证<br />&nbsp;&nbsp;本证相关类型包括风热血燥证、风热证和血热内蕴证。<br />&nbsp;&nbsp;主症:①皮损鲜红;②新出皮疹不断增多或迅速扩大。<br />&nbsp;&nbsp;次症:①心烦易怒;②小便黄;③舌质红或绛;④脉弦滑或数。<br />&nbsp;&nbsp;证候确定:具备全部主症和1项以上次症。<br />&nbsp;&nbsp;2.血燥证<br />&nbsp;&nbsp;本证相关类型包括血虚风燥证。<br />&nbsp;&nbsp;主症:①皮损淡红;②鳞屑干燥。<br />&nbsp;&nbsp;次症:①口干咽燥;②舌质淡，舌苔少或薄白;③脉细或细数。<br />&nbsp;&nbsp;证候确定:具备全部主症和1项以上次症。<br />&nbsp;&nbsp;3.血瘀证<br />&nbsp;&nbsp;本证相关类型包括瘀滞肌肤证和气滞血瘀证。<br />&nbsp;&nbsp;主畻坴畿\0\0\0\0醼畻聱盯\r\0\0\0痭駠ƞༀƙ\0ƞĀ\0\r\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఄƞĀ\0ఄ彿㎽奋㎽巫㎽「అ䮔అ彿㎽䮈అ塚㎽䮔అꍈ㏂\0\0ﺼఄ學㎽漸㏂圔㎽ﺼఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0バఌ䐺盭暼痭バఌༀƙ \0バఌĀ\0\0㺣盭バఌ\0ﱔピఌ\0팃目ピఌ࣒ピఌ큁目ピఌﻰఄ﫬\0Item\0\0䰘అ\0\0\0\0\0\0Count\0\0ﱬﬄ㄄ఌ㳜੪\0\0ピఌ\0\0\0\0੪寶目㳠੪矵䥷㎽「అ\0\0䰘అ�㏂䮈అ\0\0\0੪\0\0\0謁ﱔ\0\0㎾ќ\0ﱜ\0\0x�㏂䮈అ', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('373', '48', 'Y04_011', '1', '银屑病和银屑病关节炎的管理指南', 'Guidelines of care for the management of\npsoriasis and psoriatic arthritis', 'American Academy of Dermatology', '2008', 'J Am Acad Dermatol 2008;58:826-50.', null, '1.Plaque psoriasis<br />&nbsp;&nbsp;2.Inverse psoriasis<br />&nbsp;&nbsp;3.Erythrodermic psoriasis <br />&nbsp;&nbsp;4.Pustular<br />&nbsp;&nbsp;5.Guttate<br />&nbsp;&nbsp;6.Nail disease<br />&nbsp;&nbsp;7.Nail disease', null, null, null, null, null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('374', '48', 'Y04_012', '1', '临床指南：牛皮癣', 'GUIDELINE TITLE\nPsoriasis', 'Finnish Medical Society Duodecim - Professional Association', '2002', 'National Guideline Clearinghouse', '英文', null, null, null, null, '1. Assessment of clinical features and patterns of cutaneous lesions\n2. Assessment for family history of psoriasis\n3. Biopsy, if needed<br />&nbsp;&nbsp;Characteristic cutaneous lesions facilitate diagnosis.· The plaques are sharply demarcated, slightly elevated, and covered with silvery scales (see pictures 1, 3, and 2*).\n· Gentle scraping of the scales reveals minute capillary bleeding points\n(Auspitz sign) (see picture 4*).\n· The elbows (see picture 5*), knees (see picture 6*), legs, lower back,scalp (see pictures 7 and 8*), and glans penis (see picture 9*) are the sites of predilection.\n· Involvement of the nails is common.\n· Pitting\n· Separation of the distal nail plate from the nail bed (onycholysis),yellowish flecks beneath the nail plate (\"oily macules\"), and subungualhyperkeratosis (see pictures 11, 12, and 10*).\n· Acrodermatitis continua of Hallopeau is a painful, localized pustularform of psoriasis which often leads to nail deformity (see pictures 14and 13*).<br />&nbsp;&nbsp;Common Manifestations of Psoriasis<br />&nbsp;&nbsp;· The most common type is plaque psoriasis, which is a stationary form of the disease with the lesions often covered with thick silvery scales.<br />&nbsp;&nbsp;· Guttate psoriasis is often triggered by tonsillitis. It is widely distributed throughout the body.<br />&nbsp;&nbsp;· Flexural psoriasis is localized within the main skin folds (genitocrural area [see picture 15*], navel, axillae, submammary region).<br />&nbsp;&nbsp;· Erythrodermic psoriasis (see picture 16*) is a generalized form of the disease and is most refractory to treatment. It may also appear in a pustular form(pustular psoriasis).<br />&nbsp;&nbsp;· Psoriasis may also affect joints in 5 to 10% of cases.<br />&nbsp;&nbsp;Differential Diagnosis<br />&nbsp;&nbsp;· Diagnosis is based on the clinical picture (Lebwohl, 2003).<br />&nbsp;&nbsp;· A biopsy may exclude some other skin diseases resembling psoriasis, but itrarely is pathognomic (Lebwohl, 2003).<br />&nbsp;&nbsp;· A family history of psoriasis may help in diagnosis: up to 50% of patients report an affected relative (Swanbeck et al., 1997).<br />&nbsp;&nbsp;Scalp<br />&nbsp;&nbsp;· In seborrhoeic dermatitis (see the Finnish Medical Society Duodecim guideline \"Seborrhoeic dermatitis\" (see picture 17*) the flakes are thinner, \"greasier,\" and the condition responds better to treatment. It is often difficult to differentiate seborrhoeic dermatitis from psoriasis unless other skin areas offer additional information.<br />&nbsp;&nbsp;· Fungal infection of the scalp (see the Finnish Medical Society Duodecim guideline \"Dermatomycoses\") is uncommon in the Western populations. It mostly affects children. This diagnosis can be excluded by microscopy and negative culture for fungi.<br />&nbsp;&nbsp;· Neurodermatitis of the neck (lichen simplex nuchae) is characterised by an isolated, itchy plaque covered with thin scales.<br />&nbsp;&nbsp;Flexures<br />&nbsp;&nbsp;· Seborrhoeic dermatitis may resemble flexural psoriasis. Examine other skin areas. It is not necessary to differentiate between these two conditions, as the treatment is the same.<br />&nbsp;&nbsp;· Fungal infection (tinea) (see the Finnish Medical Society Duodecim guideline \"Dermatomycoses\") may resemble psoriasis; however, it usually heals in the centre and expands peripherally. Potassium hydroxide (KOH) and fungal culture are diagnostic.<br />&nbsp;&nbsp;· Candidiasis is not often seen in the young and middle-aged patients. It presents as a moist area of erythema and maceration with outlying \"satellite eruptions.\"<br />&nbsp;&nbsp;· Erythrasma is a macular brown area with few symptoms, most often found<br />&nbsp;&nbsp;in the armpits or groin. It is caused by overgrowth of diphtheroids of the normal skin flora. These areas fluoresce coral pink under long-wave ultraviolet radiation (Wood\'s light).<br />&nbsp;&nbsp;Hands, Feet<br />&nbsp;&nbsp;· Hyperkeratotic eczema of the palms and palmoplantar pustulosis may be difficult to differentiate from psoriasis (see picture 18*). Examine theentire skin.<br />&nbsp;&nbsp;· Fungal infection (see the Finnish Medical Society Duodecim guideline \"Dermatomycoses\") can easily be diagnosed with microscopic examination and culture.\n', null, 'Psoriasis clearance rate\n· Remission rate\n· Adverse effects of (tolerance to) treatment', null, 'Psoriasis is a chronic disease of the skin caused by genetic and environmental\nfactors. It is characterized by well-defined plaques bearing adherent, silvery\nscales.', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('375', '48', 'Y04_013', '1', '依那西普和依法利珠治疗成人银屑病指南', 'Etanercept and efalizumab\nfor the treatment of adults\nwith psoriasis', 'National Institute for Health and Clinical Excellence', '2006', 'www.nice.org.uk/TA103', '英文', ' 1.mild<br />&nbsp;&nbsp;2. moderate <br />&nbsp;&nbsp;3. severe', 'psoriasis', null, null, 'Psoriasis is generally graded as mild, moderate or severe. Several different\nscales for measuring the severity of psoriasis are also used, which are\nvariably based on the following criteria: the proportion of body surface area\naffected; the disease activity (degree of plaque redness, thickness and\nscaling); the response to previous therapies; and the impact of the disease on\nthe person.<br />&nbsp;&nbsp;‘Severe’ psoriasis means a total Psoriasis Area Severity Index (PASI)≥ 10 and a Dermatology LifeQuality Index (DLQI) >10.Clinicians will need toagree locally on how todefine ‘failed torespond to’ and‘intolerance to’standard systemictherapies, for auditpurposes.‘Standard systemictherapies’ includeciclosporin,methotrexate andPUVA (psoralen andlong-wave ultravioletradiation).(As a guide fordesigning the audit,see the BritishAssociation ofDermatologistsGuidelines for use ofbiological interventionsin psoriasis for moredetail related todefinitions.)See the summaries ofproduct characteristicsfor contraindications tostandard systemictherapies in routineuse', null, 'PASI score;DLQI', 'It was aware that the EMEA recognises that reduction of baseline PASI score by 75% (PASI 75) is an indicator that severe psoriasis has responded to treatment. Additionally the British Society for Rheumatology guidelines on the use of these agents in PsA a畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭バఌༀƙ\0ఌĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఄఌĀ\0ఄ彿㎽奋㎽巫㎽㑄అ䷸అ彿㎽䷬అ塚㎽䷸అꍈ㏂\0\0ﺼఄ學㎽漸㏂圔㎽ﺼఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0턀ਘ䐺盭暼痭턀ਘༀƙ \0턀ਘĀ\0\0㺣盭턀ਘ\0ﱔ턄ਘ\0팃目턄ਘ࣒턄ਘ큁目턄ਘﻰఄ﫬\0Item\0\0乼అ\0\0\0\0\0\0Count\0\0ﱬﬄ턴ਘ㳜੪\0\0턄ਘ\0\0\0\0੪寶目㳠੪矵䥷㎽㑄అ\0\0乼అ�㏂䷬అ\0\0\0੪\0\0\0謁ﱔ\0\0㎾Ⴒ\0ﱜ\0\0x�㏂䷬అ\0\0隲W乼అ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\0霪W露W\0\0ﱴxt\0Љ\0\0\0൐௲鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0⑰ਫ਼⑰ਫ਼㲈੪ﷰఄ寶目㲈੪ﷰఄi\0\0ﱄ﷜ﱴﲔ먙㎼ﷰఄ㲈੪i\0\0ﱄ﷜ﱴ먰㎼﷜ﷰఄ�㏂ﵠఄ\0\0릎㎼ﷰఄi\0╪췬目╾췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒൐௲竗൐௲目W\0竗\0\0\0賓器目\0\0\0\0ﻰఄ\0目瑉浥目\0\0\0\0ﻰఄ\0目潃湵t\0\0\0\0Ơ\0\0ဠ\0\0侠̓ﯬ侠̓̙\0\0\0\0\0\0\0̙῰̓\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0῰̓\0\0\0\0̙ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚЉ\0\0\0⟒췬⟚췬目Љ\0鲸࣒\0￿￿目Љ\0鲬࣒൐௲觴൐௲目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨﷰఄ目潅f摲敳t ㋬췭쓷盡ϐ Â\0\0\0태৻Â\0ꯍ�\0\0Â\0飘盦아췿왑盡䛌E\0덐ɫ‾Q岛@\0䛌E\0덐ɫ‾Q岛@\0⎐ۓ﮵S豀ɳ\0덐ɫ\0﯏S臀ɳ\0豀ɳ\0䛌E\0템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂奈瞒⫠\0\0\0瞒⪌쀕瞒若〠\0䪔㏂\0T\0\0⪌쀕\0\0ꀀ翽翽凜瞒郎瘝䪔㏂\0邰ƙ\0\0ࠀᴒ眊\0\0䪔㏂瘝\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ﫜ﷰఄﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀勤﬘眿捻ฒ乼అ﫨ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿﫜￿￿\0\0﫦\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ\0\0\0\0\0奰畿⫡췬臭焚畻邰ƙࠀ﫜￿￿㏂￿￿\0\0\0\0愈煔畻:\0﫜￿￿㏂￿￿奰畿\0\0\0\0﬘㎾ࠄ\0\0﫜￿￿㏂㎾x\0\0�㏂䷬అ\0\0頲Wאּ\0\0\0\0ࠄ\0顇WValu\0\0﫜שּׁ乼అﱜ\0\0\0\0\0\0﫜\0﫨\0ﰰ餀Wﱜﲈ	\0ﳸ\0\0ᇜੵ\0.\0\0\0\0\0ኜੵ\0\0ﮀ⮒췬ﮀ뜩@﷩\0\0\0\0ﮠ䗧@ﭸ蕶@ᇐੵﱰ﯌\0뮩@ﮰ믆@믎@ﱰ﷩\0釚@ﱰﱰ﷩\0ༀƙﱴༀƙ﯐戤痝\0Ɨ\0\0퀰੧ﯴఄఄ忉㎽䱄అ奁㎽ఄ	\0䱐అ䷸అ彿㎽ﱤ䦕盭䷸అ	\0䷸అ忉㎽ﱔ䥷盭䷸అ\0\0	\0ﱬ乼అﱴ馘Bﱜﳸxﲈﲈ駰Bﱴ驨ঽ兰৺\0అ\0\0ﱔ︜ﱜx︜x︄ﳸxﲔx︜ﲠx︜︸x︜\0\0驨ঽ뿄x\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0\0\0ﻰఄ䗆@	\0ﻰఄ乼అ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0ʎCﻰఄ︜Cﻰఄ\0\0\0\0\0ఄ\0\0\0\0ఄ﷜￿\0\0\0\0\0\0￿\0\0\0\0\0台৺\0\0\0ﺄ\0\0ﺈ稐ɪఅ\0\0큼੧︜\0\0쌄ॕﺐ嵿{ﹸ\0\0\0\0\0ﺄ﹄庱{ﺐﺘ彨{ﺐ\0\0\0\0ﺰੂৄﹼ邏S\0\0ㄐ঵\0\0ɯ\0\0\0稐ɪ\0\0㡬੷\0\0ﻨⰛEﺤⰺEﻨﺰⱹEﻨﺼⳗEﻨﻰ⳶Eﻨ\0\0\0\0槠৬\0\0\0\0蠸ঽﺀੂﻰĒ８䳫Tｄ䴙T８\0\0\0\0츐ɳ\0\0\0\0\0Ā츐ɳｬ㻨T਌\0\0\0\0\0\0￶ğƠ\0Ǎ\0ꋴĵ䈆Tｐ䈐Tｬｸ䉉Tｬ\0\0\0\0ꋴĵ츐ɳﾈ잜Ĳꀀ翽ￄ枴@ﾈ\0\0ﾔ眿ꀀ翽ￔ㭓瞖ꀀ翽ᮒ眊\0\0\0\0ꀀ翽\0\0\0\0\0\0ﾠ\0\0￿￿瞑\0\0￬㬦瞖얼Ĳꀀ翽\0\0\0\0\0\0\0\0얼Ĳꀀ翽\0\0譕召�䖋倌䶋謈ᢑ＀菒ӄ䶋༈醷ش\0숻Ѵ쀳⏫䖋倌䶋脈ⳁ儀喋謈ᒂ＀菐ࣄ�쀛삃嬁쉝쳌쳌쳌쳌쳌쳌삋鱠è\0堀%￰￿⑴倨탿삅ᕵ憝è\0堀%￰诿Ҁ＀㏠觀⑄鴠쉡쳌쳌쳌邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('376', '48', 'Y04_014', '1', '牛皮癣患者管理指南', 'Guidelines for management of patients with psoriasis', 'British Association of Dermatologists', '1991', 'Dermatologists B A O. Guidelines for management of patients with psoriasis[J]. Bmj British Medical Journal, 1991, 303(6806):829-835.', '英文', null, null, null, null, 'The diagnosis of psoriasis is clinical and mostdoctors should have few problems in diagnosing mostcases. Laboratory investigations are rarely helpful.There are several clinical forms of psoriasis, and aperson may, during a lifetime, move from one type toanother. The body surface area affected can range froma small area to almost total coverage. Psoriasis canchange qualitatively from stable plaque lesions toan unstable form typified by eruptive inflammatorylesions that are easily irritated by topical treatment.Drugs thought to precipitate or worsen psoriasisinclude alcohol and, in some patients, -3 blockers andnon-steroidal anti-inflammatory agents. Lithium,chloroquine, and mepacrine may be associated withsevere, even life threatening, deterioration ofpsoriasis.<br />&nbsp;&nbsp;The assessment of severity should include twodifferent components: firstly, the patient\'s own perception of disability -that is, the \"need for treatment\"-and, secondly, an objective assessment of the extentand severity of body involvement.<br />&nbsp;&nbsp;\nFor family doctors most information will be obtainedfrom the patient\'s need for treatment. Many dermatologists use measures such as body mapping or thepsoriasis area and severity index to give a roughguide of objective improvement with treatment.Measurements of percentage area affected alone,however, are not sufficient as similar extents ofcoverage at different sites, such as the trunk and hands,create different degrees of disability and distress.Furthermore, the degree of disability experienced bydifferent people with the same amount of psoriasisvaries greatly. Because of this the aim of managementshould always be determined in close association withthe individual patient\'s views. It is good practice torecord in the clinical notes what patients thinkis the most upsetting aspect of their psoriasis. Manage ment aims can then be directed appropriately within therapeutic limitations and judgments based on therisk: benefit ratio.\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('377', '48', 'Y04_015', '1', '2009BAD/PCDS 银屑病的初始管理的建议', 'Recommendations for the initial management\nof psoriasis\n', 'British Association of Dermatologists & Primary Care Dermatology Society', '2009', 'http://guide.medlive.cn/guideline/preview/1/1464?token=8f7acdfea90116be7f24a77d20b4a258', '英文', null, 'psoriasis', null, null, 'Clinical features<br />&nbsp;&nbsp;• The diagnosis of psoriasis is clinical, and laboratory investigations are unhelpful <br />&nbsp;&nbsp;• There are several forms of psoriasis, and the type affecting an individual may change over time. The sites and extent of involvement can range from trivial to almost total coverage <br />&nbsp;&nbsp;• Psoriasis can change from stable plaques to an unstable form, typified by eruptive inflammatory lesions that are easily irritated by topical treatment <br />&nbsp;&nbsp;• Drugs thought to precipitate or worsen psoriasis include beta-adrenoceptor blocking drugs and NSAIDs. Oral administration of lithium, chloroquine or mepacrine may be associated with severe deterioration of psoriasis. Alcohol may worsen psoriasis and may interfere with treatment in various ways <br />&nbsp;&nbsp; Assessment of severity should include the patient\'s own perception of disability, the need for treatment, and an objective assessment of the extent and severity of the disease <br />&nbsp;&nbsp;o the total area of involvement is a factor in assessing severity, but is difficult to estimate accurately<br />&nbsp;&nbsp;', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('378', '48', 'Y04_016', '1', '中国银屑病治疗指南2013', null, '中华医学会皮肤性病分会银屑病学组', '2013', '中华医学会皮肤性病分会银屑病学组. 中国银屑病治疗指南（2008版）[J]. 中华皮肤科杂志, 2009, 42(3):213-214.', null, null, '银屑病', null, '1.血热风盛型<br />&nbsp;&nbsp;2.血瘀肌肤型<br />&nbsp;&nbsp;3.血虚风燥型<br />&nbsp;&nbsp;4.湿热蕴藉型<br />&nbsp;&nbsp;5.火毒炽盛型<br />&nbsp;&nbsp;6.风湿寒痹型<br />&nbsp;&nbsp;7.热毒伤阴型<br />&nbsp;&nbsp;8.肝肾阴虚型', '银屑病的分类<br />&nbsp;&nbsp;1.寻常型银屑病 此型约占银屑病患者的90%以上，原发性皮疹是红色丘疹或斑块, 表面覆有多层疏松的银白色鳞屑, 刮除鳞屑后,出现薄膜现象和点状出血。皮损可局限亦可累及全身；好发于头皮、躯干和四肢关节伸侧；伴有不同程度的瘙痒；病情冬重夏轻。<br />&nbsp;&nbsp;点滴状银屑病  皮损为广泛或散在分布的红色鳞屑性丘疹，经常是疾病最早的皮损表现，尤其是链球菌感染激发的病例，后期皮疹多转变为斑块状。<br />&nbsp;&nbsp;斑块状银屑病  寻常型中最常见的类型，鳞屑性红色斑块大小不一，边界清楚；掌跖部斑块鳞屑粘着，常伴有皲裂疼痛。瘙痒明显的皮损会呈现疣状改变；伴有严重炎症时，鳞屑为黄色疏松的痂片，伴有少量渗出的皮损成蛎壳状外观。<br />&nbsp;&nbsp;反向性银屑病  皮损分布与通常银屑病皮损的部位相反，限局于屈侧的皱褶部位（腋下、乳房下、腹股沟、外阴和肛周等）。由于局部潮湿，皮损为红斑而少有鳞屑。<br />&nbsp;&nbsp;2.脓疱型银屑病  银屑病角层中的中性粒细胞微脓疡增大到表现出肉眼可见的脓疱时，称之为脓疱型银屑病。<br />&nbsp;&nbsp;（1）泛发性脓疱型银屑病  严重时可伴有皮肤疼痛和发热等全身症状；脓疱发生的前后，或同时可具有寻常型银屑病皮损特点。<br />&nbsp;&nbsp;（2）局限性脓疱型银屑病  包括掌跖脓疱病和连续性肢端皮炎；前者皮疹限于手掌足底，可伴发或不伴发典型的寻常型银屑病。连续性肢端皮炎的皮疹发生于指趾端，引起甲及其下骨质的损伤，是脓疱型银屑病中少见的类型。<br />&nbsp;&nbsp;3.红皮病型银屑病  可从斑块状银屑病或脓疱型银屑病发展而来，皮损累及整个体表面积的90%以上，伴有大量的鳞屑脱落。皮肤广泛毛细血管扩张的体温调节作用可引起脱水、寒战和低体温；同时脱屑的丢失和消化系统的吸收不良，可导致高输出量的心衰、低蛋白血症和感染等其他系统疾病。<br />&nbsp;&nbsp;4.关节病型银屑病  银屑病患者中6-42%转变成关节病型银屑病，尤其是严重的银屑病发生关节炎比率较高。银屑病性关节炎病谱宽广，从脊柱到外周指趾远端关节均可累及，可出现关节滑膜和邻近软组织的炎症、肌腱端炎、骨炎，严重的骨质溶解和新骨形成，指骨呈笔套样畸形；受累关节多为非对称性，常先有单个关节的肿胀疼痛，关节症状与皮损的严重程度不一定相关；病程缓慢，加重和缓解交替发生，不可逆的破坏使正常功能逐渐丧失。<br />&nbsp;&nbsp;5. 其它<br />&nbsp;&nbsp;各型银屑病均可累及皮肤附属器。指趾甲表现为甲板顶针状凹点、甲下“油滴”状斑点、甲板增厚、甲下角化过度、甲分离和甲破坏；在头皮皮损处头发呈束状,通常不会导致毛发脱落。<br />&nbsp;&nbsp;银屑病皮损可累及粘膜，包括眼结膜、口腔粘膜、外阴部黏膜、外耳道等。在脓疱型银屑病常可见有沟纹舌、地图舌。<br />&nbsp;&nbsp;（二） 检查<br />&nbsp;&nbsp;1.病理检查：皮肤组织病理检查有助于银屑病的诊断，但若病理结果不符合银屑病的特征,临床上也不能除外银屑病的可能。<br />&nbsp;&nbsp;2.影像学检查：可用于关节病型银屑病的诊断。CT对微小病变比X线敏感，核磁共振可较早诊断关节周围软组织的病变。临床无症状的银屑病常有肌腱端的改变，超声波可以为疾病早期的异常提供识别。<br />&nbsp;&nbsp;3.实验室检查：HLA分型可作为关节病型与脓疱型银屑病的参考指标；类风湿因子的检测可作为类风关和关节病型银屑病的鉴别的依据；严重的银屑病发生全身症状时，必须进行相应的常规和生化检测。<br />&nbsp;&nbsp;（三） 鉴别诊断<br />&nbsp;&nbsp;1.寻常型银屑病需与下列疾病相鉴别：慢性湿疹、神经性皮炎、痒疹、药疹、浅部真菌感染、皮肤型红斑狼疮、扁平苔藓、二期梅毒疹、蕈样肉芽肿、毛发红糠疹、副银屑病、疣状痣、脂溢性皮炎、玫瑰糠疹等。反向性银屑病应与间擦症、念珠菌感染等项鉴别。<br />&nbsp;&nbsp;2.甲病变需与下列疾病相鉴别：甲真菌病、甲营养不良。<br />&nbsp;&nbsp;3.头皮病变需与下列疾病相鉴别：石棉状糠疹、头癣、脂溢性皮炎。<br />&nbsp;&nbsp;4.关节病型银屑病需与下列疾病相鉴别：类风关、Reiter病、强直性脊柱炎、骨关节炎。<br />&nbsp;&nbsp;5.红皮病型银屑病需与下列疾病相鉴别：各种原因引起的剥脱性皮炎，如毛发红糠疹、湿疹、皮肤淋巴瘤等。<br />&nbsp;&nbsp;6.脓疱型银屑病需与下列疾病相鉴别：角层下脓疱性皮病、反应性关节炎综合征、天疱疮、急性泛发性发疹性脓疱病、坏死松解性游走性红斑等。<br />&nbsp;&nbsp;一个简单界定银屑病严重程度的方法称为十分规则，即体表受累面积（BSA）DAYU510%(10个手掌的面积)或银屑病面积与严重程度指数（PASI）＞10或皮肤病生活质量指数（DLQI）＞10即为重度银屑病。BSA＜3%为轻度，3%-10%为中度。还要考虑皮损范围，部位，对生活质量的影响等诸多因素。', '1.血热风盛型：本型相当于寻常型进行期，皮损为点滴状或钱币状，皮色鲜红，皮疹进行性增加，伴有瘙痒。可伴有咽痛等上呼吸道感染症状。<br />&nbsp;&nbsp;2.血瘀肌肤型：本型相当于寻常型静止期，皮损为钱币状或地图状，鳞屑较厚的斑块，皮色暗红，皮疹反复不愈，冬季可病情加重。<br />&nbsp;&nbsp;3.血虚风燥型：本型相当于寻常型消退期，皮损为环状或边缘消退状，鳞屑容易脱落，皮色淡红或暗红，病情稳定，无新发皮疹。<br />&nbsp;&nbsp;4.湿热蕴藉型：本型相当于局限或掌跖脓疱型，皮损为四肢或掌跖红斑上针头或米粒大小脓疱，反复发生；或腋窝、腹股沟等皱褶部位红斑畻坴畿\0\0\0\0醼畻聱盯\r\0\0\0痭バఌༀƙ\0ఌĀ\0\r\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఄఌĀ\0ఄ彿㎽奋㎽巫㎽「అ䮔అ彿㎽䮈అ塚㎽䮔అꍈ㏂\0\0ﺼఄ學㎽漸㏂圔㎽ﺼఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0駠ƞ䐺盭暼痭駠ƞༀƙ \0駠ƞĀ\0\0㺣盭駠ƞ\0ﱔ駤ƞ\0팃目駤ƞ࣒駤ƞ큁目駤ƞﻰఄ﫬\0Item\0\0䰘అ\0\0\0\0\0\0Count\0\0ﱬﬄ騔ƞ㳜੪\0\0駤ƞ\0\0\0\0੪寶目㳠੪矵䥷㎽「అ\0\0䰘అ�㏂䮈అ\0\0\0੪\0\0\0謁ﱔ\0\0㎾Ҭ\0ﱜ\0\0x�㏂䮈అ\0\0隲W䰘అ\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\r', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('379', '48', 'Y04_017', '1', '2012 NPF共识指南：斑块状银屑病的管理', 'Consensus guidelines for the management of plaque psoriasis.', '\n国家银屑病基金会(NPF,National Psoriasis Foundation)', '2012', 'Arch Dermatol. 2012 Jan;148(1):95-102.', '英文', null, null, null, null, 'Moderate psoriasis is commonly distinguished from milder forms of the disease on the basis of scores on 1 or more clinical metrics, such as the Psoriasis Area and Severity Index (PASI); the percentage of the body surface area affected; and the Dermatological Life Quality Index (eAppendix, chapter 3, Table 2; http://www.archdermatol.com)', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('38', '34', 'M03_002', '1', '临床诊疗指南肾脏病学分册', ' ', '中华医学会', '2011', '中华医学会.临床诊疗指南(肾脏病学分册)[M].北京：人民卫生出版社，2011', '中文', '慢性肾衰可分为以下四个阶段：（1）肾功能代偿期；（2）肾功能失代偿期；（3）肾功能衰竭期（尿毒症前期）；（4）尿毒症期<br />&nbsp;&nbsp;\nM03_002_01_我国CRF的分期方法.docx', '慢性肾衰竭', null, null, '临床表现<br />&nbsp;&nbsp;   在CRF的不同阶段，其临床表现也各不相同。在CRF的代偿期和失代偿早期，病人可以无任何症状，或仅有乏力、腰酸、夜尿增多等轻度不适；少数病人可有食欲减退、代谢性酸中毒及轻度贫血。CRF中期以后，上述症状更趋明显。在尿毒症期，可出现急性心衰、严重高钾血症、消化道出血、中枢神经系统障碍等严重并发症，甚至有生命危险。<br />&nbsp;&nbsp;    1．水、电解质代谢紊乱  慢性肾衰时，酸碱平衡失调和各种电解质代谢紊乱相当常见。在这类代谢紊乱中，以代谢性酸中毒和水钠平衡紊乱最为常见。<br />&nbsp;&nbsp;    1.1 代谢性酸中毒：在部分轻中度慢性肾衰（GFR>25 ml/min，或血肌酐<350 μmol/l）患者中，部分患者由于肾小管分泌氢离子障碍或肾小管HC03- ，的重吸收能力下降，因而可发生正常阴离子间隙的高氯血症性代谢性酸中毒，即肾小管性酸中毒。当GFR降低至<25 ml/min（血肌酐>350 μmol/l）时，肾衰时代谢产物如磷酸、硫酸等酸性物质因肾的排泄障碍而潴留，可发生高氯血症性（或正氯血症性）高阴离子间隙性代谢性酸中毒，即“尿毒症性酸中毒”。轻度慢性酸中毒时，多数患者症状较少，但如动脉血HCO3-<15 mmol/L，则可出现明显食欲不振、呕吐、虚弱无力、呼吸深长等。<br />&nbsp;&nbsp;    1.2水钠代谢紊乱：主要表现为水钠潴留，或低血容量和低钠血症。肾功能不全时，肾脏对钠负荷过多或容量过多，适应能力逐渐下降。水钠潴留可表现为不同程度的皮下水肿或／和体腔积液，这在临床相当常见；此时易出现血压升高、左心功能不全和脑水肿。低血容量主要表现为低血压和脱水。低钠血症的原因，既可因缺钠引起（真性低钠血症），也可因水过多或其它因素所引起（假性低钠血症），而以后者更为多见。<br />&nbsp;&nbsp;    1.3 钾代谢紊乱：当GFR降至20-25ml/min或更低时，肾脏排钾能力逐渐下降，此时易于出现高钾血症；尤其当钾摄入过多、酸中毒、感染、创伤、消化道出血等情况发生时，更易出现高钾血症。严重高钾血症(血清钾>6.5mmol/l)有一定危险，需及时治疗抢救。有时由于钾摄入不足、胃肠道丢失过多、应用排钾利尿剂等因素，也可出现低钾血症。<br />&nbsp;&nbsp;    1.4 钙磷代谢紊乱：主要表现为磷过多和钙缺乏。钙缺乏主要与钙摄入不足、活性维生素D缺乏、高磷血症、代谢性酸中毒等多种因素有关，明显钙缺乏时可出现低钙血症。<br />&nbsp;&nbsp;血磷浓度由肠道对磷的吸收及肾的排泄来调节。当肾小球滤过率下降、尿内排出减少，血磷浓度逐渐升高。在肾衰的早期，血钙、磷仍能维持在正常范围，且通常不引起临床症状，只在肾衰的中、晚期( GFR<20ml/min)时才会出现高磷血症、低钙血症。低钙血症、高磷血w症、活性维生素D缺乏等可诱发甲状旁腺激素(PTH)升高，即继发性甲状旁腺功能亢进（简称甲旁亢）和肾性骨营养不良。<br />&nbsp;&nbsp;    1.5 镁代谢紊乱：当GFR<20ml/min时，由于肾排镁减少，常有轻度高镁血症。患者常无任何症状：如使用含镁的药物（抗酸药、泻药等），则更易于发生。低镁血症也偶可出现，与镁摄入不足或过多应用利尿剂有关。<br />&nbsp;&nbsp;    2．蛋白质、糖类、脂肪和维生素的代谢紊乱<br />&nbsp;&nbsp;    CRF病人蛋白质代谢紊乱一般表现为蛋白质代谢产物蓄积（氮质血症），也可有血清白蛋白水平下降、血浆和组织必需氨基酸水平下降等。上述代谢紊乱主要与蛋白质分解增多或／和合成减少、负氮平衡、肾脏排出障碍等因素有关。<br />&nbsp;&nbsp;    糖代谢异常主要表现为糖耐量减低和低血糖两种情况，前者多见，后者少见。高脂血症相当常见，其中多数病人表现为轻到中度高甘油三脂血症，少数病人表现为轻度高胆固醇血症，或二者兼有。维生素代谢紊乱相当常见，如血清维生素A水平增高、维生素B6及叶酸缺乏等。<br />&nbsp;&nbsp;    3．心血管系统表现<br />&nbsp;&nbsp;    心血管病变是CKD患者患者的主要并发症之一和最常见的死因。尤其是进入终末期肾病阶段，则死亡率进一步增高（占尿毒症死因的45%-60%）。近期研究发现，尿毒症患者心血管不良事件及动脉粥样硬化性心血管病比普通人群约高15-20倍。<br />&nbsp;&nbsp;    较常见的心血管病变主要有高血压和左心室肥厚、心力衰竭、尿毒症性心肌病、心包积液、心包炎、血管钙化和动脉粥样硬化等。近年发现，由于高磷血症、钙分布异常和“血管保护性蛋白”（如胎球蛋白A）缺乏而引起的血管钙化，在心血管病变中亦起着重要作用。<br />&nbsp;&nbsp;    4．呼吸系统症状体液过多或酸中毒时均可出现气短、气促，严重酸中毒可致呼吸深长。体液过多、心功能不全可引起肺水肿或胸腔积液。由尿毒症毒素诱发的肺泡毛细血管渗透性增加、肺充血可引起“尿毒症肺水肿”，此时肺部X线检查可出现“蝴蝶翼”征，及时利尿或透析上述症状可迅速改善。<br />&nbsp;&nbsp;    5．胃肠道症状  主要表现有食欲不振、恶心、呕吐、口腔有尿味。消化道出血也较常见，其发生率比正常人明显增高，多是由于胃粘膜糜烂或消化性溃疡，尤以前者为最常见。<br />&nbsp;&nbsp;    6．血液系统表现CRF病人血液系统异常主要表现为肾性贫血和出血倾向。大多数患者一般均有轻、中度贫血，其原因主要由于红细脆生成素缺乏，故称为肾性贫血；如同时伴有缺铁、营养不良、出血等因素，可加重贫血程度。晚期CRF病人有出血倾向，如皮下或粘膜出血点、瘀斑、胃肠道出血、脑出血等。<br />&nbsp;&nbsp;    7．神经肌肉系统症状早期症状可有失眠、注意力不集中、记忆力减退等。尿毒症时可有反应淡漠、谵妄、惊厥、幻觉、昏迷、精神异常等。周围神经病变也很常见，感觉神经障碍更为显著，最常见的是肢端袜套样分布的感觉丧失，也可有肢体麻木、烧灼感或疼痛感、深反射迟钝或消失，并可有神经肌肉兴奋性增加，如肌肉震颤、痉挛、不宁腿综合征等。初次透析患者可能发生透析失衡综合征，出现恶心、呕吐、头痛、惊厥等，主要由于血透后细胞内外液渗透压失衡和脑水肿、颅内压增高所致。<br />&nbsp;&nbsp;    8．内分泌功能紊乱主要表现有：①肾脏本身内分泌功能紊乱：如1，25(OH)。维生素D3、红细胞生成素不足和肾内肾素-血管紧张素II过多；②下丘脑-垂体内分泌功能紊乱：如泌乳素、促黑色素激素(MSH)、促黄体生成激素(FSH)、促卵泡激素(LH)、促肾上腺皮质激素(ACTH)等水平增高；③外周内分泌腺功能紊乱：大多数病人均有血PTH升高，部分病人（大约四分之一）有轻度甲状腺素水平降低；以及胰岛素受体障碍、性腺功能减退等。<br />&nbsp;&nbsp;    9．骨骼病变肾性骨营养不良（即肾性骨病）相当常见，包括纤维囊性骨炎（高周转性骨病）、骨生成不良(adynamic bone disease)、骨软化症（低周转性骨病）及骨质疏松症。在透析前患者中骨骼X线发现异常者约35%，但出现骨痛、行走不便和自发性骨折相当少见（少于10%）。而骨活体组织检查（骨活检）约90%可发现异常，故早期诊断要靠骨活检。<br />&nbsp;&nbsp;    纤维囊性骨炎主要由于PTH过高引起，易发生骨盐溶化、肋骨骨折。X线检查可见骨骼<br />&nbsp;&nbsp;囊样缺损（如指骨、肋骨）及骨质疏松（如脊柱、骨盆、股骨等）的表现。<br />&nbsp;&nbsp;    骨生成不良的发生，主要与血PTH浓度相对偏低、某些成骨因子不足有关，因而不足以维持骨的再生；透析患者如长期过量应用活性维生素D、钙剂等药或透析液钙含量偏高，则可能使血PTH浓度相对偏低。<br />&nbsp;&nbsp;    【诊断要点】<br />&nbsp;&nbsp;    1．诊断要点：<br />&nbsp;&nbsp;    (1)慢性肾脏病史超过3个月。所谓慢性肾脏病，是指各种原因引起的慢性肾脏结构和功能障碍，包括病理损伤、血液或尿液成分异常及影像学检查异常。<br />&nbsp;&nbsp;    (2)不明原因的或单纯的GFR下降<60ml/min（老年人GFR<50ml/min）超过3个月。<br />&nbsp;&nbsp;    (3)在GFR下降过程中出现与肾衰竭相关的各种代谢紊乱和临床症状。<br />&nbsp;&nbsp;    以上三条中，第一条是诊断的主要依据。根据第二条做诊断时宜慎重或从严掌握。如第三条同时具备，则诊断依据更为充分。<br />&nbsp;&nbsp;    临床医师应仔细询问病史和查体，而且应当及时做必要的实验室检查，包括肾功能的检查，以及血电解质（K，Na，CI，Ca，P等）、动脉血气分析、影像学等。要重视CRF的定期筛查（普通人群一般每年一次），努力做到早期诊断。<br />&nbsp;&nbsp;    2．鉴别诊断：<br />&nbsp;&nbsp;    (1)CRF与与肾前性氮质血症的鉴别：在有效血容量补足24-72小时后肾前性氮质血症患者肾功能即可恢复，而CRF则肾功能难以恢复。<br />&nbsp;&nbsp;    (2) CRF与急性肾衰的鉴别：往往根据患者的病史即可作出鉴别。在患者病史欠详时，可借助于影像学检查（如B超，CT等）或肾图检查结果进行分析，如双肾明显缩小，或肾图提示慢性病变，则支持CRF的诊断。<br />&nbsp;&nbsp;    (3)慢性肾衰伴发急性肾衰：如果慢性肾衰较轻，而急性肾衰相对突出，且其病程发展符合急性肾衰演变过程，则可称为“慢性肾衰合并急性肾衰”(acute on chronic renal failure)，其处理原则基本上与急性肾衰相同。如慢性肾衰本身己相对较重，或其病程加重过程未能反映急性肾衰演变特点，则称之为“慢性肾衰急性加重”(acute progression of CRF)。<br />&nbsp;&nbsp;\n', null, '血压、蛋白尿', ' M03_002_02_CKD-CRF患者血压血糖HbA1C蛋白质GFR变化的治疗目标.docx', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('380', '48', 'Y04_018', '1', '维吾尔医常见病诊疗指南', null, '中国民族医药学会', '2015', '中国民族医药学会.T/ZGMZYYXH001-007-2015，维吾尔医常见病诊疗指南[S].北京：中国中医药出版社，2015.', '中文', '寻常型<br />&nbsp;&nbsp;红皮病型<br />&nbsp;&nbsp;脓疱病型<br />&nbsp;&nbsp;关节病型<br />&nbsp;&nbsp;\n进行期<br />&nbsp;&nbsp;静止期<br />&nbsp;&nbsp;消退期', '鳞屑癣；寻常型银屑病', null, '1. 异常血液质型鳞屑癣<br />&nbsp;&nbsp;异常胆液质型鳞屑癣<br />&nbsp;&nbsp;异常成性黏液质型鳞屑癣<br />&nbsp;&nbsp;异常黑胆液质型鳞屑癣', '临床表现：多青壮年发病，部分发病或加重常由扁桃体炎或上呼吸道感染诱发。好发于头皮、躯-和四肢伸侧，常对称分布，亦有仅局限于某一部位者。典型皮疹为粟粒至绿豆大红色丘疹、斑丘疹或斑块，可融合成片，边界清楚，周围有炎性红晕，浸润湿著，表面覆盖厚积的银白色鳞屑。轻轻刮除鳞屑，可见一层淡红色半透明薄膜（薄膜现象）；刮除薄膜后．出现点状出血（Auspitz征）。白色鳞屑、薄膜现象和点状出血是本病的临床特征。皮疹形态多样，可为点滴状、钱币状、地图状、蛎壳状等。发生于头皮者，呈束状。可有指（趾）甲受累，黏膜损害。慢性病程，甚至终生迁延不愈‘常冬季复发或加重，春夏减轻或消失，亦有与此相反者。<br />&nbsp;&nbsp;组织病理：表皮改变出现较早．主要为角化不全，有时角质层内或其下发可见Munro微脓肿；颗粒层变薄或消失；棘层肥厚，表皮嵴延长；真皮乳头部血管扭曲扩张，轻度增厚；乳头上方表皮变薄；真皮上部有轻度至中度炎细胞浸润。<br />&nbsp;&nbsp;诊断要点:根据临床表现、皮疹特点、好发部位、发病与季节的关系等综合诊断。<br />&nbsp;&nbsp;鉴别诊断:本病应与玫瑰糠疹、脂溢性皮炎、副银屑病、扁平苔癣、二期梅毒疹、毛发红糠疹、掌跖脓疱病、疱疹样脓疱病、连续性肢端皮炎、类风湿性关节炎等鉴别诊断。', '1. 异常血液质型鳞屑癣（相当于寻常型银屑病进行期）<br />&nbsp;&nbsp;主症：银白色鳞屑，可见薄膜现象、点状出血点。<br />&nbsp;&nbsp;次症：皮疹不断出现和扩大，皮损颜色红，鳞屑厚积，周围有红晕，痒感较烈；舌红，苔黄，脉搏为硬波浪形，少数出现上呼吸道感染症状，小便颜色黄。<br />&nbsp;&nbsp;2.异常胆液质型鳞屑癣（相当于寻常型银屑病进行期）<br />&nbsp;&nbsp;主症：银白色鳞屑，可见薄膜现象一点状出血点。<br />&nbsp;&nbsp;次症：皮疹多为点滴或片状，基底潮红，表面覆盖银白色麟屑，瘙痒；夏季加重伴有口渴咽干，便秘，苔薄黄，脉搏硬且快，小便颜色黄，皮损灼热。<br />&nbsp;&nbsp;3.畻坴畿\0\0\0\0醼畻聱盯\r\0\0\0痭턀ਘༀƙ\0ਘĀ\0\r\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔﺼఄਘĀ\0ఄ彿㎽奋㎽巫㎽「అ䮔అ彿㎽䮈అ塚㎽䮔అꍈ㏂\0\0ﺼఄ學㎽漸㏂圔㎽ﺼఄ圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0턀ਘ䐺盭暼痭턀ਘༀƙ \0턀ਘĀ\0\0㺣盭턀ਘ\0ﱔ턄ਘ\0팃目턄ਘ࣒턄ਘ큁目턄ਘﻰఄ﫬\0Item', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('381', '22', 'G06_001', '0', '临床诊疗指南·消化系统疾病分册', null, '中华医学会', '2010', '临床诊疗指南·消化系统疾病分册,2004,北京：人民卫生出版社.', '中文', '1.溃疡样型<br />&nbsp;&nbsp;2.运动障碍型<br />&nbsp;&nbsp;3.反流样型<br />&nbsp;&nbsp;4.复合型', '功能性消化不良', '未提及', '未提及', '1.上腹部胀痛、早饱、嗳气、反酸、恶心等症状持续4周以上，或在近一年内有上述症状至少3个月（但不一定持续）<br />&nbsp;&nbsp;2.内镜或钡餐检查未发现胃、十二指肠溃疡、糜烂、肿瘤等器质性病变<br />&nbsp;&nbsp;3.实验室、B超及X线检查排除肝、胆、胰及肠道器质性病变<br />&nbsp;&nbsp;4.无糖尿病、风湿病及精神、神经性等全身性疾病<br />&nbsp;&nbsp;5.无腹部手术史<br />&nbsp;&nbsp;6.症状与排便无关<br />&nbsp;&nbsp;7.有条件单位可结合胃电图、胃排空功能等测定做出诊断<br />&nbsp;&nbsp;1.溃疡样型:表现为局限性上腹痛，疼痛可呈节律性，有时有饥饿痛，常伴有嗳气、反酸等症状<br />&nbsp;&nbsp;2.运动障碍型：表现为上腹饱胀、餐后早饱感、嗳气、反酸、恶心、呕吐、食欲不佳等<br />&nbsp;&nbsp;3.反流样型：表现为剑突下及胸骨后疼痛、嗳气、反酸、烧心感<br />&nbsp;&nbsp;4.复合型：表现症状为非特异性', '未提及', '未提及', '未提及', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('382', '22', 'G06_002', '1', '亚洲功能性消化不良共识意见', 'Asian Consensus Report on Functional Dyspepsia ', '亚太胃肠病学会(Asian Pacific Association of Gastroenterology) 亚洲神经胃肠病学与动力学协会(Asian Neurogastroenterology and Motility Association)', '2011', 'http://d.dxy.cn/preview/2436883', '英文', '1.餐后不适综合征 meal-induced dyspeptic symptoms (PDS)<br />&nbsp;&nbsp;2.上腹疼痛综合征 epigastric pain (EPS)', '功能性消化不良', '未提及', '未提及', '1.症状：上腹疼痛,上腹部燃烧,餐后饱胀感,早饱感、上腹部肿胀,恶心、呕吐、嗳气（Dyspepsia refers to a symptom or set of symptoms：epigastric pain, epigastric burning, postprandial fullness, early satiation, bloating in the upper abdomen, nausea, vomiting, and belching.）<br />&nbsp;&nbsp;2.慢性症状，无器质性病变（Functional dyspepsia is a condition characterized by chronic dyspeptic symptoms in the absence of organic, systemic or metabolic condition(s) that is (are) likely to explain the symptoms.）<br />&nbsp;&nbsp;3.上消化道内窥镜检查(upper gastrointestinal endoscopy)<br />&nbsp;&nbsp;4.全血细胞计数和血液生化检查（complete blood cell count and blood biochemistry tests）', '未提及', '症状和体征  ', '1.缓解症状：烧心、（symptom relieve:heartburn ）<br />&nbsp;&nbsp;2.改善胃酸分泌过多(acid secretion become normal)<br />&nbsp;&nbsp;3.催乳素分泌增多（enhanced prolactin release in FD patients）', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('383', '22', 'G06_003', '1', '功能性胃肠病诊断标准', 'Functional Gastroduodenal Disorders', '美国胃肠病学会(American Gastroenterological Association Institute)', '2006', 'Gastroenterology.2006,130:1466–1479.', '英文', '1.餐后不适综合征 meal-induced dyspeptic symptoms (PDS)<br />&nbsp;&nbsp;2.上腹疼痛综合征 epigastric pain (EPS)', '功能性消化不良', '未提及', '未提及', '1.症状：以下1条或多条：餐后饱胀不适、早饱感、上腹痛、上腹烧灼感<br />&nbsp;&nbsp;2.没有可以解释上述症状的器质性疾病（One or more of:a. Bothersome postprandial fullness；b. Early satiation c. Epigastric pain；d. Epigastric burning AND 2. No evidence of structural disease (including at upper endoscopy) that is likely to explain the symptoms. Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis)参见G06-003-图表1<br />&nbsp;&nbsp;1.餐后不适综合征：必须包括以下1条或2条：进食正常食量后出现的餐后饱胀不适感，每周至少发生数次；早饱感，抑制了正常进食，每周至少发生数次（meal-induced dyspeptic symptoms (PDS)：Must include one or both of the following:\n1. Bothersome postprandial fullness, occurring after ordinary sized meals, at least several times per week 2. Early satiation that prevents finishing a regular meal, at least several times per week）<br />&nbsp;&nbsp;3.上腹疼痛综合征：必须包括以下所有条件：中等程度以上的上腹部疼痛或烧灼感，每周至少1次；间断性疼痛；不是全腹痛，不位于腹部其他部位或胸部；排便或排气后不能缓解；不符合胆囊或Oddi括约肌疾病的诊断标准（epigastric pain (EPS)：Must include all of the following:1. Pain or burning localized to the epigastrium of at least moderate severity at least once per week 2. The pain is intermittent 3. Not generalized or localized to other abdominal or chest regions 4. Not relieved by defecation or passage of flatus 5. Not fulfilling criteria for gallbladder andsphincter of Oddi disorders）参见G06-003-图表2', '未提及', '未提及', '未提及', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('384', '22', 'G06_004', '1', '成人消化不良初级保健管理', 'Dyspepsia: Managing dyspepsia in adults in primary care', '英格兰、威尔士国家公共医疗卫生服务(National Health Service in England and Wales)', '2006', 'http://guide.medlive.cn/guideline/1581', '英文', '未提及', '消化不良', '未提及', '未提及', '症状：上腹痛或不适，烧心，反酸，恶心，呕吐等持续一个月以上（upper abdominal pain or discomfort, heartburn, acid reflux, nausea, or vomiting present for four weeks or more）', '未提及', '未提及', '未提及', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('385', '22', 'G06_006', '1', '消化不良和胃食管返流性疾病。调查和管理消化不良或胃食管返流疾病或两者兼而有之。', 'Dyspepsia and gastro-oesophageal reflux disease. Investigation and management of dyspepsia, symptoms suggestive of gastro-oesophageal reflux\ndisease, or both.', '美国国家健康研究所和护理机构(NICE)', '2014', 'National Institute for Health and Care Excellence (NICE). Dyspepsia and gastro-oesophageal reflux disease. Investigation and management of dyspepsia, symptoms suggestive\nof gastro-oesophageal reflux disease, or both. London (UK): National Institute for Health and C are Excellence (NIC E); 2014 Sep. 43 p. (C linical guideline; no. 184).', '英文', '未报告', '消化不良', '未报告', '未报告', '未报告', '未报告', '减少症状(严重性/频率)、活组织检查结果(病理)、内镜食管的出现、健康相关的生活质量(测量使用EQ-5D和/或疾病特性工具)、减少药物需求(频率和剂量)、不利影响的干预(诊断或治疗)、资源利用和成本、巴雷斯特食道症和腺癌的发生', 'Meta分析结果及GRADE评价结果', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('386', '22', 'G06_007', '1', '中国儿童功能性消化不良诊断和治疗共识', '无', '中华医学会儿科学分会消化学组', '2012', '中华医学会儿科学分会消化学组.中国儿童功能性消化不良诊断和治疗共识.中华儿科杂志', '中文', '餐后不适综合征(表现为餐后饱胀或早饱)和上腹痛综合征(表现为上腹痛或烧灼感)', '儿童功能性消化不良', '未报告', '未报告', '1．对消化不良症状的评估：临床症状包括上腹痛、腹胀、早饱、暖气、厌食、烧心、反酸、恶心和呕吐。症状可反复发作，也可在相当一段时间内无症状；可以某一症状为主，也可多个症状叠加。症状的评估为是否进行相关检查以及后续治疗的选择提供重要依据。2．辅助检查：对初诊的消化不良患儿应在采集病史与体检基础上有针对性选择辅助检查：①血常规；②粪便隐血试验；③上消化道内彩胃肠钡餐检查；④肝胆胰腺B超；⑤肝肾功能；⑥空腹血糖；⑦甲状腺功能；⑧胸部x线检查。其中①～④为第一线检查，⑤～⑧为可选择性检查。多数根据第一线检查即可基本确定FD的诊断。对经验治疗或常规治疗无效的FD患儿可行幽门螺杆菌(Hp)等检查。3．胃功能检查：对症状严重或常规治疗效果不佳的FD患儿，可进行胃电图、胃排空、胃肠道压力检测等胃肠功能性检查，对其胃动力及感知功能进行评估，指导调整治疗方案。4．儿童FD诊断标准：有消化不良症状至少2个月，每周至少出现1次，并符合以下3项条件：(1)持续或反复发作的上腹部(脐上)疼痛或不适、早饱、嗳气、恶心、呕吐、反酸；(2)症状在排便后不能缓解，或症状发作与排便频率或粪便性状的改变无关(即除外肠易激综合征)；(3)无炎症性、解剖学、代谢性或肿瘤性疾病的证据可以解释患儿的症状。', '未报告', '未报告', '未报告', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('387', '22', 'G06_008', '1', '中国消化不良的诊治指南', '无', '中华医学会消化病学分会胃肠动力学组', '2008', '中华医学会消化病学分会胃肠动力学组.中国消化不良的诊治指南(2007大连).胃肠病学.2008.13（2）:114-117', '中文', '餐后不适综合征( postprandial distress syndrome, PDS) 和上腹痛综合征( epigastric pain syndrome, EPS)', '消化不良', '未报告', '未报告', '(一)、对消化不良以及相关症状的评估对消化不良症状的评估可为是否进行相关检查以及选择治疗方案提供重要线索。罗马Ⅲ诊断标准对消化不良的主要症状给予的定义[3]如下: ①餐后饱胀: 食物长时间存留于胃内引起的不适感; ②早饱感: 指进食少许食物即感胃部饱满, 不能继续进餐; ③上腹痛: 位于胸骨剑突下与脐水平以上、两侧锁骨中线之间区域的疼痛; ④上腹烧灼感: 局部的灼热感, 与烧心不同。烧心是指胸骨后烧灼样疼痛或不适, 是GERD 的特征性症状。询问病史时需了解: ①消化不良症状及其程度和频度; ②症状的发生与进餐的关系, 有无夜间出现症状以及症状与体位、排便的关系; ③进食量有无改变, 有无体质量下降以及营养状况; ④患者的进食行为、心理状态以及是否影响生活质量; ⑤有无重叠症状, 如烧心、反酸、腹泻或便秘等; ⑥引起消化不良的可能病因, 注意有无警报征象。消化不良的警报征象包括: 消瘦、贫血、上腹包块、频繁呕吐、呕血或黑便、年龄>40 岁的初发病者、有肿瘤家族史等。对有警报征象者建议及时行相关检查。对有精神心理障碍者, 也建议及时进行检查, 明确排除器质性疾病对解释病情更为有利。\n(二)、相关检查\n对初诊的消化不良患者应在详细采集病史和进行体格检查的基础上有针对性地选择辅助检查。我国胃镜检查已很普及,建议将胃镜检查作为消化不良诊断的主要手段。其他辅助检查包括肝、肾功能以及血糖等生化检查、腹部超声检查和消化系统肿瘤标志物检测,必要时行腹部CT扫描。对经验性治疗或常规治疗无效的FD 患者可行H.pylori检查。对怀疑胃肠外疾病引起的消化不良患者,应选择相应的检查以利病因诊断。\n(三)、胃功能检查\n对症状严重或对常规治疗效果不明显的FD患者,可行胃电图、胃排空、胃容纳功能和感知功能检查,对其动力和感知功能进行评估,指导调整治疗方案。上述检查也可用于对其他动力相关疾病所致的消化不良的评估, 如糖尿病性消化不良等。', '未报告', '未报告', '未报告', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('388', '22', 'G06_009', '1', '功能性消化不良的中西医结合诊疗共识意见', '无', '中国中西医结合学会消化系统疾病专业委员会', '2011', '中国中西医结合学会消化系统疾病专业委员会.功能性消化不良的中西医结合诊疗共识意见(2010).中国中西医结合杂志.2011.31(11):1545-1549', '中文', '餐后不适综合征( postprandial distress syndrome, PDS) 和上腹痛综合征( epigastric pain syndrome, EPS)', '功能性消化不良', '“痞满”、“胃脘痛”、“积滞”', '1.肝气郁结 2.肝气犯胃证 3.脾胃气虚证 4.湿热滞胃证 5.寒热错杂证', '罗马Ⅲ诊断标准\n1 FD 诊断标准必须包括以下1条或多条: (1) 餐后饱胀不适; (2) 早饱感; (3) 上腹痛; (4) 上腹烧灼感; 并且没有可解释症状的器质性疾病(包括胃镜检查) 的证据。诊断前症状出现至少6个月，近3个月满足以上标准。\n2 FD 分型诊断标准(1) EPS诊断标准，必须符合以下所有条件: ①至少为中等程度的上腹部疼痛或烧灼感，至少每周发生1次; ②疼痛呈间断性; ③疼痛非全腹性，不放射或不在腹部其他区域/胸部出现; ④排便或排气不能缓解; ⑤不符合胆囊或Oddi括约肌功能障碍诊断标准。支持诊断的条件有: ①疼痛可为烧灼样，但不向胸骨后传导; ②疼痛常由进餐诱发或缓解，但也可发生于空腹状态; ③可能同时存在\nPDS。(2) PDS 诊断标准，必须包括以下1 条或2 条:①正常量进食后出现餐后饱胀不适感，每周至少发生数次; ②早饱感阻碍正常进食，每周至少发生数次。支持诊断的条件有: ①上腹胀或餐后恶心或过度嗳气;②可同时存在EPS。以上2型可有重叠。', '1 肝气郁结证主症: (1) 脘胁胀痛，痛无定处; (2) 脘闷嗳气; (3) 急躁易怒; (4) 脉弦。次症:(1) 口苦; (2) 精神抑郁，善太息; (3) 咽部异物感; (4)烧心或泛酸; (5) 腹胀纳呆或呕吐; (6) 舌淡红或尖边红，苔薄黄。证型确定: 具备主症2 项加次症1 项，或主症第1项加次症2项。\n2 肝气犯胃证主症: (1) 胃脘痞满，闷胀不舒，胀及两胁，情志不遂易诱发或加重; (2) 嗳气、呃逆; (3) 烧心泛酸; (4) 心烦急躁; (5) 脉弦或弦细。次症: (1) 两胁气畻坴畿\0\0\0\0醼畻聱盯\r\0\0\0痭�ਘༀƙ\0ਘĀ\0\r\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄ᓶఄਘĀ\0ః彿㎽奋㎽巫㎽桚ఄ蠪ఄ彿㎽蠞ఄ塚㎽蠪ఄꍈ㏂\0\0ᓶఄ學㎽漸㏂圔㎽ᓶఄ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0�ਘ䐺盭暼痭�ਘༀƙ \0�ਘĀ\0\0㺣盭�ਘ\0𢡄�ਘ\0팃目�ਘ࣒�ਘ큁目�ਘᔪఄ泌\0Item\0\0袮ఄ\0\0\0\0\0\0Count\0\0﫨呂�ਘ㳜੪\0\0�ਘ\0\0\0\0੪寶目㳠੪楱䥷㎽桚ఄ\0\0袮ఄ�㏂蠞ఄ\0\0\0੪\0\0\0露𢡄\0\0㎾ذ\0齃\0\0x�㏂蠞ఄ\0\0隲W袮ఄ\0\0�Ĳ\0\0\0鹿齃殺\0\0霈W戀醙霫W戀ꊠऺ齃x\r\0霪W露Wꊠऺ﫰xt\0Љ\0\0\0൐௲鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0⑰ਫ਼⑰ਫ਼㲈੪ᐪఄ寶目㲈੪ᐪఄi\0\0變ﱘ﫰﬐먙㎼ᐪఄ㲈੪i\0\0變ﱘ﫰먰㎼ﱘᐪఄ�㏂᎚ఄ\0\0릎㎼ᐪఄi\0⓮췬目⓲췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒൐௲竗൐௲目W\0竗\0\0\0目\0\0\0\0ᔪఄ\0目瑉浥目\0\0\0\0ᔪఄ', '证候', '疗效指数计算: 疗效指数= (治疗前证候总分－治疗后证候总分) /治疗前证候总分×100%。疗效指数＜30%为无效; 30%～70%(含30%) 为好转; 70%～95%(含70%)为显效;≥95%为临床治愈', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('389', '22', 'G06_010', '0', '消化不良中医诊疗共识意见(2009)', '无', '中华中医药学会脾胃病分会', '2010', '中华中医药学会脾胃病分会.消化不良中医诊疗共识意见(2009).中国中西医结合杂志.2010.30(5):533-537', '中文', '餐后不适综合征( postprandial distress syndrome, PDS) 和上腹痛综合征( epigastric pain syndrome, EPS)', '消化不良', '(1)以餐后饱胀不适、早饱为主症者,应属于中医\"痞满\"、\"积滞\"的范畴; (2)以上腹痛、上腹烧灼感为主症者, 应属于中医\"胃痛\"范畴', '(1)脾虚气滞证(2)肝胃不和证(3)脾胃湿热证(4)脾胃虚寒证(5)寒热错杂证', '参照罗马Ⅲ标准', '(1)脾虚气滞证。主症: 胃脘痞闷或胀痛; 食少纳呆。次症: 纳少泛恶;嗳气呃逆; 疲乏无力;舌淡,苔薄白;脉细弦。(2)肝胃不和证。主症:胃部胀痛;两胁胀满。次症:每因情志不畅而发作或加重;痞塞不舒;心烦易怒;善太息;舌淡红,苔薄白;脉弦。(3)脾胃湿热证。主症:脘腹痞满或疼痛;舌苔黄厚腻。次症:口干口苦;身重困倦;恶心呕吐;小便短黄;食少纳呆;脉滑。(4)脾胃虚寒证。主症:胃寒隐痛或痞满;喜温喜按。次症:泛吐清水;食少纳呆;神疲倦怠;手足不温;大便溏薄;舌淡苔白;脉细弱。(5)寒热错杂证。主症:胃脘痞畻坴畿\0\0\0\0醼畻聱盯\r\0\0\0痭㽸ਠༀƙ\0ਠà\0\r', '症状积分、证候积分、胃内容标记物含量、胃容纳功能和感知功能、生活质量量表', '1.主要症状总体疗效评定标准: 按改善百分率=(治疗前总积分-治疗后总积分)/治疗前总积分*100% ,计算症状总体改善百分率。症状消失为痊愈, 症状改善百分率>=80% 为显效, 50%<=症状改善百分率<80% 为进步, 症状改善百分率<50% 为无效,症状改善百分率负值时为恶化。痊愈和显效病例数计算总有效率。2.证候疗效评定标准:采用尼莫地平法计算。疗效指数=(治疗前积分-治疗后积分)/治疗前积分*100% 。(1)临床痊愈: 主要症状、体征消失或基本消失, 疗效指数>=95% 。(2)显效: 主要畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭㽸ਠༀƙ\0ਠà\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄ᓶఄਠà\0ః彿㎽奋㎽巫㎽沒ఄ覢ఄ彿㎽視ఄ塚㎽覢ఄꍈ㏂\0\0ᓶఄ學㎽漸㏂圔㎽ᓶఄ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0ਘ䐺盭暼痭ਘༀƙ \0ਘà\0\0㺣盭ਘ\0𢡄ਘ\0팃目ਘ࣒ਘ큁目ਘᔪఄ泌\0It', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('39', '34', 'M03_003', '1', '慢性肾衰竭中西医结合诊疗指南', ' ', '中国中西医结合学会肾脏疾病专业委员会', '2015', '中国中西医结合学会肾脏疾病专业委员会.慢性肾衰竭中西医结合诊疗指南[J].中国中西医结合杂志.2015,35(9):1029-1033.', '中文', '慢性肾功能衰竭早期、中期、晚期，分别相当于慢性肾脏病（CKD）的3期[GFR30~59mL/(min*1.73m2)]、4期[GFR15~29mL/( min*1.73m2)]和5期[GFR<15ml/( min*1.73m2) 的非透析患者]。', '慢性肾衰竭', null, '1.正虚证型<br />&nbsp;&nbsp;1.1气虚证<br />&nbsp;&nbsp;1.2血虚证<br />&nbsp;&nbsp;1.3阴虚证<br />&nbsp;&nbsp;1.4阳虚证<br />&nbsp;&nbsp;2.标实证型<br />&nbsp;&nbsp;2.1 水湿证<br />&nbsp;&nbsp;2.2湿热证<br />&nbsp;&nbsp;2.3血瘀证<br />&nbsp;&nbsp;2.4溺毒证<br />&nbsp;&nbsp;3.复合证型<br />&nbsp;&nbsp;3.1 气虚证、阴虚证和阳虚证夹杂水湿证<br />&nbsp;&nbsp;3.2 气阴两虚证、阴阳两虚证夹杂湿热证和血瘀证<br />&nbsp;&nbsp;3.3 气血阴阳俱虚证夹杂溺毒证<br />&nbsp;&nbsp;', ' ', null, null, 'CKD患者高血压控制靶目标：CKD患者无论是否伴有糖尿病，若尿蛋白<30mg/24h,建议控制血压<140/90mmHg;若尿白蛋白≥30mg/24h,建议控制血压应更低。', ' 本指南以成人CRF患者为对象，从临床诊疗的实际出发，坚持科学、实用的原则，提出中医、西医和中西医结合医师易懂，适用的CRF中西医相关概念，西医诊断与治疗、中医基本辨证分型及治法方案，力求突出中西医结合诊疗CRF的特色。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('390', '50', 'Y01_001', '0', '中医病证诊断疗效标准', '无', '国家中医药管理局', '1994', '国家中医药管理局.ZY／T001.1～001.9-94，中医病证诊断疗效标准[S].南京：南京大学出版社，1994.', '中文', '1单侧椎间盘突出：下腰痛伴一侧下肢放射痛，脊柱侧弯，腰生理前凸减小或消失，病变椎间盘患侧椎旁压涌，可沿坐骨神经向下肢放射，直腿抬高试验阳性。 cT检查：椎间盘向椎管一侧突出。<br />&nbsp;&nbsp;2双侧椎间盘脱出：下腰痛，伴双侧下肢放射痛，腰生理前凸减少或消失，病变椎间盘两侧椎旁均有压痛，可沿坐骨神经向下肢放射，双下肢直腿抬高试验阳性。cT检查：椎间盘肉左右突出，并可见游离块。<br />&nbsp;&nbsp;3中央型椎间盘脱出：除出现腰腿痛的症状外，还可出现会阴部麻木和大小便功能障碍等马尾神经压迫症。CT检查：椎间盘向正中方向突出。<br />&nbsp;&nbsp;4上下型椎间盘脱出：大部分患者仅有腰痛症状，X光检查病变椎间盘可见Schmori结节。<br />&nbsp;&nbsp;', null, '腰椎间盘突出症', '1血瘀证：腰腿痛如刺，痛有定处，日轻夜重，腰部板硬，俯仰旋转受限，痛处拒按。舌质暗紫，或有瘀斑，脉弦紧或涩。<br />&nbsp;&nbsp;2寒湿证：腰腿冷痛重着，转侧不利，静卧痛不减，受寒及阴雨加重，肢体发凉。舌质淡，苔白或腻，脉沉紧或濡缓。<br />&nbsp;&nbsp;3湿热证：腰部疼痛，腿软无力，痛处伴有热感，遇热或雨天痛增，活动后痛减，恶热口渴，小便短赤。苔黄腻，脉濡数或弦数。<br />&nbsp;&nbsp;4肝肾亏虚：腰酸痛，腿膝乏力，劳累更甚，卧则减轻。偏阳虚者面色恍白，手足不温，少气懒言，腰腿发凉，或有阳萎、早泄，妇女带下清稀，舌质淡，脉沉细。偏阴虚者，咽干口渴，面色潮红，倦怠乏力，心烦失眠，多梦或有遗精，妇女带下色黄味臭，舌红少苔，脉弦细数。<br />&nbsp;&nbsp;', null, '1有腰部外伤、慢性劳损或受寒湿史。大部分患者在发病前有慢性腰痛史。<br />&nbsp;&nbsp;2常发生于青壮年。<br />&nbsp;&nbsp;3腰痛向臀部及下肢放射，腹压增加（如咳嗽、喷嚏）时疼痛加重。<br />&nbsp;&nbsp;4脊柱侧弯，腰生理孤度消失，病变部位椎旁有压痛，并向下肢放射，腰活动受限。<br />&nbsp;&nbsp;5下肢受累神经支配区有感觉过敏或迟钝，病程长者可出现肌肉萎缩。直腿抬高或加强试验阳性，膝、跟腱反射减弱或消失，拇趾背伸力减弱。<br />&nbsp;&nbsp;6 X线摄片检查：脊柱侧弯，腰生理前凸消失，病变椎间盘可能变窄，相邻边缘有骨赘增生。CT检查可显示椎间盘突出的部位及程度。<br />&nbsp;&nbsp;', '腰腿痛；直腿抬高', '1治愈：腰腿痛消失，直腿抬高70°以上，能恢复原工作。<br />&nbsp;&nbsp;2好转：腰腿痛减轻，腰部活动功能改善。<br />&nbsp;&nbsp;3未愈：症状、体征无改善。<br />&nbsp;&nbsp;<br />&nbsp;&nbsp;', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('391', '50', 'Y01_002', '1', '神经根型腰椎间盘突出症临床指南', 'Clinical guidelines for diagnosis and treatment of lumbar disc herniation with radiculopathy. ', '北美脊柱学会', '2013', 'https://www.spine.org/Portals/0/Documents/ResearchClinicalCare/Guidelines/LumbarDiscHerniation.pdf', '英文', null, '神经根型腰椎间盘突出症', null, null, null, null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('392', '50', 'Y01_003', '1', '临床诊疗指南·骨科分册', '无 ', '中华医学会', '2009', '中华医学会.临床诊疗指南·骨科分册.北京：人民卫生出版社，2009.', '中文', null, '腰椎间盘突出症', null, null, '一、临床表现<br />&nbsp;&nbsp;1．腰痛和一侧下肢放射痛是该病的主要症状。腰痛常发生于腿痛之前，也可两者同时发生；大多有外伤史，也可无明确诱因。疼痛具有以下特点：<br />&nbsp;&nbsp;放射痛沿坐骨神经传导，直达小腿外侧、足背或足趾。如为L3.L4间隙突出，因L4神经根受压迫，产生向大腿前方的放射痛。<br />&nbsp;&nbsp;一切使脑脊液压力增高的动作，如咳嗽、，喷嚏和排便等，都可加重腰痛和放射痛。<br />&nbsp;&nbsp;活动时疼痛加剧，休息后减轻。卧床体位：多数患者采用侧卧位，并屈曲患肢；个别严重病例在各种体位均疼痛，只能屈髋屈膝跪在床上以缓解症状。合并腰椎管狭窄者，常有间歇性跛行。<br />&nbsp;&nbsp;2．脊柱侧凸畸形  主要弯曲在下腰部，前屈时更为明显。侧凸的方向取决于突出髓核与神经根的关系：如突出位于神经根的前方，躯干一般向患侧弯。例如，髓核突出位于神经根内前方，脊柱向患侧弯曲，如向健侧的弯曲则疼痛加剧。<br />&nbsp;&nbsp;3．脊柱活动受限  髓核突出，压迫神经根，使腰肌呈保护性紧张，可发生于单侧或双侧。由于腰肌紧张，腰椎生理性前凸消失。脊柱前屈后伸活动受限制，前屈或后伸时可出现向一侧下肢的放射痛。侧弯受限往往只有一侧，据此可与腰椎结核或肿瘤鉴别。<br />&nbsp;&nbsp;4．腰部压痛伴放射痛  椎间盘突出部位的患侧棘突旁有局限的压痛点，并伴有向小腿或足部的放射痛，此点对诊断有重要意义。<br />&nbsp;&nbsp;5．直腿抬高试验阳性  由于个人体质的差异，该试验阳性无统一的度数标准，应注意两侧对比。患侧抬腿受限，并感到向小腿或足的放射痛即为阳性。有时抬高健肢而患侧腿发生麻痛，系因患侧神经受牵拉引起，此点对诊断有较大价值。<br />&nbsp;&nbsp;6．神经系统检查  L4、L5突出（L4神经根受压）时，可有膝反射减退或消失，小腿内侧感觉减退；L4、L5突出（L5神经根受压）时，小腿前外侧足背感觉减退，伸拇及第2趾肌力常有减退；L5、S1间突出（S1神经根受压）时，小腿外后及足外侧感觉减退，第3、4、5趾肌力减退，跟腱反射减退或消失。神经压迫症状严重者患肢可有肌肉萎缩。如突出较大，或为中央型突出，或纤维环破裂髓核碎片突出至椎管者，可出现较广泛的神经根或马尾神经损害症状，患侧麻木区常较广泛，可包括髓核突出平面以下患侧臀部、股外侧、小腿及足部。中央型突出往往两下肢均有神经损伤症状，但一侧较重；应注意检查鞍区感觉，常有一侧减退，有时两侧减退，常有小便失控、湿裤尿床、大便秘结、性功能障碍，甚至两下肢部分或大部分瘫痪。<br />&nbsp;&nbsp;二、诊断  <br />&nbsp;&nbsp;大多数腰椎间盘突出症患者，根据临床症状或体征即可做出正确的诊断。主要的症状和体征是：<br />&nbsp;&nbsp;(1)腰痛合并“坐骨神经痛”，放射至小腿或足部，直腿抬高试验阳性；<br />&nbsp;&nbsp;(2)在L4、L5或L5、Sl棘间韧带侧方有明显的压痛点，同时有至小腿或足部的放射性痛；<br />&nbsp;&nbsp; (3)小腿前外或后外侧皮肤感觉减退，趾肌力减退，患侧跟腱反射减退或消失。<br />&nbsp;&nbsp;X线片可排除其他骨性病变。<br />&nbsp;&nbsp;三、鉴别诊断<br />&nbsp;&nbsp;1．腰椎小关节紊乱  相邻椎体的上下关节突构成腰椎小关节，为滑膜关节，有神经分布。当小关节上、下关节突的关系不正常时，急性期可因滑膜嵌顿产生疼痛，慢性病例可产生后关节创伤性关节炎，出现腰痛。此种疼痛多发生于棘突旁1. 5cm处，可有向同侧臀部或大腿后的放射痛，易与腰椎间盘突出症相混。该病的放射痛一般不超过膝关节，且不伴有感觉、肌力减退及反射消失等神经根受损之体征。对鉴别困难的病例，可在病变的关节突附近局部封闭，如症状消失，可排除腰椎间盘突出症。<br />&nbsp;&nbsp;2．腰椎椎管狭窄症  间歇性跛行是最突出的症状，患者自诉步行一段距离后，下肢酸困、麻木、无力，必须蹲下休息后方能继续行走。骑自行车可无症状。患者主诉多而体征少，也是重要特点。少数患者有根性神经损伤的表现。严重的中央型狭窄可出现大小便失禁，脊髓造影和CT扫描等特殊检查可进一步确诊。<br />&nbsp;&nbsp;3．腰椎结核早期局限性腰椎结核可刺激邻近的神经根，造成腰痛及下肢放射痛D腰椎结核有结核病的全身反应，腰痛较剧烈，x线片上可见椎体或椎弓根的破坏o CT扫描对x线片不能显示的椎体早期局限性结核病灶有独特诊断价值。<br />&nbsp;&nbsp;4．椎体转移瘤  疼痛加剧，夜间加重，患者体质衰弱，可查到原发肿瘤。X线平片可见椎体溶骨性破坏。<br />&nbsp;&nbsp;5．脊膜瘤及马尾神经瘤  为慢性进行性疾患，无间歇好转或自愈现象，常有大小便失禁。脑脊液蛋白增高，奎氏试验显示梗阻。脊髓造影检查可明确诊断。<br />&nbsp;&nbsp; ', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('393', '50', 'Y01_004', '0', '中医整脊常见病诊疗指南', ' 无', ' 中华中医药学会', '2012', '中华中医药学会.ZYYXH/T417~441-2012，中医整脊常见病诊疗指南[S].北京：中国中医药出版社，2012.', '中文', '腰椎间盘突出症的分型方法较多，目前尚无统一的分类。而对整脊学治疗较具指导意义的分型方法为整脊学分型法。<br />&nbsp;&nbsp;1.3.1  椎间孔型<br />&nbsp;&nbsp;3.2  退化刺激型', '腰椎间盘突出症', null, '1血瘀证<br />&nbsp;&nbsp;    腰腿疼痛如刺，痛有定处，日轻夜重，俯仰不便，转侧不能，咳嗽时加重，间有便结溺清，烦躁口干。舌质紫暗或有瘀斑，脉沉涩。<br />&nbsp;&nbsp;2寒湿证<br />&nbsp;&nbsp;    腰脊冷痛，肢冷无力，按有定处，有时觉下肢麻木重着，得寒痛剧．遇热痛减，溲溺清长。舌质淡，苔薄白或腻，脉沉紧。<br />&nbsp;&nbsp;3风湿证<br />&nbsp;&nbsp;    腰脊疼痛，痛引下肢，肌肤麻木，痛无定处，走窜不定，与天气变化有关，伴有微恶风寒-，舌质淡，苔薄白或薄黄，脉虚细。<br />&nbsp;&nbsp;4  肾阳虚证<br />&nbsp;&nbsp;    腰痛绵绵酸软，肢冷麻木无力，久治不愈，喜按喜揉，遇劳尤甚。常伴少腹拘急，面色白，畏寒，少气乏力。舌质淡，苔薄润，脉沉弱。<br />&nbsp;&nbsp;5  肾阴虚证<br />&nbsp;&nbsp;腰痛绵绵，酸软无力，久治不愈，遇劳则甚。常伴心烦不眠，口燥咽干，面色潮红，手足心热，舌红少苔，脉弦细数。', ' 1.  诊断要点<br />&nbsp;&nbsp;1.1病史<br />&nbsp;&nbsp;    本病多发于青壮年，中老年人多为反复发病，往往有腰部外伤、积累性损伤或外感风寒湿邪等病史。<br />&nbsp;&nbsp;1.2  临床表现<br />&nbsp;&nbsp;1.2.1  症状<br />&nbsp;&nbsp;腰腿痛或单纯性腰痛或下肢放射痛。腰部活动受限、侧弯，站立．行走疼痛加重。<br />&nbsp;&nbsp;1.2.2  体征<br />&nbsp;&nbsp;患者常出现脊柱姿势的异常改变，如腰椎过度前屈、腰椎生理曲度平直或反张、腰椎侧凸。患者的脊柱前屈、后伸、侧屈及旋转等运动均可有不同程度的受限，尤以后伸疼痛最明显。一般在病变棘突间隙及椎旁l ~2cm处，有明显压痛点，常引起下肢放射性疼痛。直腿抬高试验及加强试验阳性多提示腰3—4、腰4—5或腰5骶l椎间盘突出，但阴性不能排除腰3—4节段以上的椎间盘突出。股神经牵拉试验阳性多提示腰2—3椎间盘突出。受压节段神经根所支配的皮肤会出现感觉的改变。先为感觉过敏，后为感觉迟钝或消失。股神经受压，则膝腱反射减低；骶l神经根受压，则跟腱反射减低。某些病程长、反复发作的患者常出现患侧股四头肌及小腿肌萎缩，．<br />&nbsp;&nbsp;1.2.3  影像学检查<br />&nbsp;&nbsp;1.2.3.1   X线检查<br />&nbsp;&nbsp;常规拍摄腰椎正侧位片。正位片可见椎体旋转、侧弯；侧位片可显示椎间隙变窄，椎曲变小甚至反弓。中老年患者多并有椎间盘退化、骨质增生．X线检查还可以除外骨关节的破坏、转移癌、骨结核、肿瘤、脊柱的先天畸形等。<br />&nbsp;&nbsp;1.2.3.2   CT检查<br />&nbsp;&nbsp;    可观察到突出物的直接影像及与神经根、硬膜囊的相邻关系，并可了解椎管容积、黄韧带、神经根管等情况。同时，还可从横断面图像测量椎管和侧隐窝的容积，<br />&nbsp;&nbsp;1.2.3.3  MRI检查<br />&nbsp;&nbsp;    可判断椎间盘突出的大小和硬膜囊与神经根受压的程度。<br />&nbsp;&nbsp;1.2.4辅助检查<br />&nbsp;&nbsp;    主要为肌电图检查，它可对受损神经根进行定位。部分患者病程较长时，可出现相应节段受损神经支配的肌肉部分失神经征象。<br />&nbsp;&nbsp;2鉴别诊断<br />&nbsp;&nbsp;2.1  退变性腰椎管狭窄症<br />&nbsp;&nbsp;    该症多发于中年人，起病缓慢，主要症状为腰痛、腿痛及间歇性跛行，站立行走时症状加重，休息、下蹲时症状可减轻。一般x线摄片、脊髓造影或CT检查可明确诊断。<br />&nbsp;&nbsp;  2.2  腰椎结核<br />&nbsp;&nbsp;    部分腰椎结核患者可出现以腰痛或坐骨神经痛为主的临床表现，易与腰椎间盘突出症相混淆。但结核常为缓慢发病，进行性加重，无间歇期，多伴有午后潮热、全身乏力，身体逐渐消瘦，且实验室检查多有血沉加快，肺部多有原发病灶。X线摄片可发现椎间隙变窄，椎体边缘模糊不清，相应节段多有骨质破坏及寒性脓肿，有时可见腰椎小关节的破坏。<br />&nbsp;&nbsp; 2.3  梨状肌综合征<br />&nbsp;&nbsp;    其症状与腰椎间盘突出症很相似，但患者多无腰痛及脊柱体征，在梨状肌处有明显压痛及放射痛。直腿抬高试验抬腿60o以下疼痛明显，但超过60o疼痛减轻。梨状肌局部痛点封闭可使症状减轻或消失，此乃与腰椎间盘突出症的鉴别要点。<br />&nbsp;&nbsp;2.4  骶髂关节炎<br />&nbsp;&nbsp;    其压痛在髂后上下嵴及骶髂关节处，骨瓮分离、挤压试验均为阳性。X线摄片显示骶髂关节间隙模糊、硬化或狭窄。<br />&nbsp;&nbsp;2.5  马尾神经肿瘤<br />&nbsp;&nbsp;    马尾神经肿瘤初期因侵及一条神经根，可出现根性痛，表现为腰痛、腿痛或腰腿痛，类似椎间盘突出症的神经功能障碍。但肿瘤的生长是持续发展的，故其症状多呈渐发的持续性加重，无间歇，不因卧床休息而减轻。后期因肿瘤增大侵及多个神经根，故症状由一腿扩展到另一腿，出现双下肢自下而上的疼痛麻木，最终导致马鞍区麻木，直肠膀胱功能障碍，这与中央型椎间盘突出所出现的马尾神经障碍是不同的。马尾神经肿瘤患者腰穿多显示不完全或完全梗阻，且脑脊液检查蛋白含量增高，脊髓造影或磁共振检查可明确病变部位。<br />&nbsp;&nbsp;2.6骶髂关节错缝症<br />&nbsp;&nbsp;    多有骶尾部损伤史或生育后发病史，其压痛在骼后上下嵴及骶髂关节处，骨盆分离、挤压试验及”4\"试验均为阳性。X线摄片显示骶髂关节间隙可不对称。<br />&nbsp;&nbsp;2.7腰椎后关节错缝症<br />&nbsp;&nbsp;    多有腰部扭转、闪腰或弯腰后立即直腰的病史，发病较急，伤后以腰部剧痛伴活动受限为主要症状一般无神经刺激体征。 x线摄片可见腰椎后关节排列不对称，腰椎侧弯或后凸，椎间隙左右不等宽等，但主要依据临床症状及体征。1.3  诊断分型<br />&nbsp;&nbsp;腰椎间盘突出症的分型方法较多，目前尚无统一的分类。而对整脊学治疗较具指导意义的分型方法为整脊学分型法。<br />&nbsp;&nbsp;1.3.1  椎间孔型<br />&nbsp;&nbsp;指椎间盘突出于后外侧椎间孔部位，压迫神经根。症见单下肢放射性疼痛、麻痹。直腿抬高试验阳性。 CT检查可显示椎间盘突出压迫椎间孔。<br />&nbsp;&nbsp;3.2  退化刺激型<br />&nbsp;&nbsp;指椎间盘退化，自身的炎症刺激脊神经，引起以腰痛，并单下肢放射性麻痹。直腿抬高试验阳性或弱阳性，此类型往往反复发作，x线摄片椎曲轻度改变，侧弯不明显；有唇样增生，CT、MRI检查可显示突出的椎间盘是否破坏或有囊性气泡。<br />&nbsp;&nbsp;', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('394', '51', 'Y02_001', '0', '中医妇科病证诊断疗效标准', '无', '国家中医药管理局', '1994', 'ZY／T001.3-94，中医妇科病证诊断疗效标准[S].南京：南京大学出版社，1994.', '中文', null, null, '月经先期', '气不摄血；血热内扰；', '1. 月经周期提前7天以上，甚至半月余一行，连续2次以上。<br />&nbsp;&nbsp;　2. 月经周期提前半月，应与经间期出血、青春期、更年期月经先期相鉴别。<br />&nbsp;&nbsp;', '1 气不摄血：月经提前，质稀色淡，神疲乏力，气短懒言，小腹空坠，纳少便溏。舌质淡，脉弱。<br />&nbsp;&nbsp;　2 血热内扰：月经提前，量多，色红质粘，夹有小血块，烦热口干，尿黄便艰。舌质红，苔黄，脉滑数。<br />&nbsp;&nbsp;', '月经周期；', '治愈：月经周期恢复正常能维持3个月以上。<br />&nbsp;&nbsp;好转：月经周期恢复正常，但不能维持3个月以上。<br />&nbsp;&nbsp;未愈：月经周期末见变化。<br />&nbsp;&nbsp;', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('395', '51', 'Y02_002', '0', '中医妇科病证诊断疗效标准', '无', '国家中医药管理局', '1994', 'ZY／T001.3-94，中医妇科病证诊断疗效标准[S].南京：南京大学出版社，1994.', '中文', null, null, '月经后期', '血寒凝滞；肝血亏虚；', '1. 月经周期超过35天，连续2个月经周期以上。<br />&nbsp;&nbsp;2. 育龄妇女周期延后，应与妊娠、青青期、更年期月经后期相鉴别。<br />&nbsp;&nbsp;3. 妇科检查，B超或气腹造影，以排除子宫及卵巢器质性疾病。<br />&nbsp;&nbsp;', '1 血寒凝滞：月经周期延后，量少，色黯有血块，小腹冷痛，得热减轻，畏寒肢冷。苔白，脉沉紧。<br />&nbsp;&nbsp;2 肝血亏虚：月经周期延后，量少，色淡无块，小腹隐涌，头晕眼花，心悸少寐，面色苍白或萎黄。舌质淡红，脉细弱。<br />&nbsp;&nbsp;3 肝气郁滞：月经周期延后，量少，色黯红或有小血块，小腹胀痛或胸腹、两胁、乳房胀痛。舌苔正常，脉弦。<br />&nbsp;&nbsp;', '月经周期；', '治愈：月经周期恢复正常，维持3个月以上。<br />&nbsp;&nbsp; 好转：月经周期恢复正常，但不能维持3个月以上。<br />&nbsp;&nbsp;未愈：月经周期末见好转。<br />&nbsp;&nbsp;', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('396', '51', 'Y02_003', '0', '中医妇科病证诊断疗效标准', '无', '国家中医药管理局', '1994', 'ZY／T001.3-94，中医妇科病证诊断疗效标准[S].南京：南京大学出版社，1994.', '中文', null, null, '月经先后无定期', '肝气郁滞；肾气不足；', '1. 月经周期或前或后，均逾7天以上，并连续2个月经周期以上。<br />&nbsp;&nbsp;2. 月经周期紊乱应与青春期、更年期月经紊乱相区别。<br />&nbsp;&nbsp;3.  妇科检查及B超等排除器质性病变。测基础体温，阴道涂片、宫颈粘液结晶检查以了解卵巢功能情况。<br />&nbsp;&nbsp;　', '1 肝气郁滞：月经周期不定，经量或多或少，色紫红有块，经行不畅，胸胁、乳房以及小腹胀痛，脘闷不舒，时叹息。苔薄白或薄黄，脉弦。<br />&nbsp;&nbsp;2 肾气不足：月经周期不定，量少，色淡黯，质稀，神疲乏力，腰骶酸痛，头晕耳鸣。舌淡苔少，脉细尺弱。<br />&nbsp;&nbsp;', '月经周期；', '治愈：月经周期恢复正常，维持3个月以上。<br />&nbsp;&nbsp;好转：月经周期恢复正常，但不能维持3个月以上。<br />&nbsp;&nbsp;未愈：月经周期末见变化。<br />&nbsp;&nbsp;', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('397', '51', 'Y02_004', '0', '中医妇科病证诊断疗效标准', '无', '国家中医药管理局', '1994', 'ZY／T001.3-94，中医妇科病证诊断疗效标准[S].南京：南京大学出版社，1994.', '中文', null, null, '月经过多', '气不摄血；血热内扰；瘀滞胞宫；', '1. 月经周期基本正常，经量明显增多，在50ml以上，或时间超过7天。<br />&nbsp;&nbsp;2. 妇科检查及B超检查，排除子宫肌瘤等器质性疾病。<br />&nbsp;&nbsp;3. 排除血小板减少症及凝血机制障碍所致月经过多。<br />&nbsp;&nbsp;', '1 气不摄血：经来量多，色淡红，质清稀。或面色苍白，气短懒言，肢软无力，或小腹空坠。舌淡，脉细。<br />&nbsp;&nbsp;2 血热内扰：经来量多，色鲜红或深红，质稠粘，或有小血块。常伴心烦口渴，尿黄便秘。舌质红，苔黄，脉滑数。<br />&nbsp;&nbsp;3 瘀滞胞宫：经来量多，或多时不净，色紫黑，有血块或伴小腹疼痛拒按。舌质紫暗或有瘀点,脉细涩。<br />&nbsp;&nbsp;', '月经量；', '治愈：经量恢复正常，能维持3个月以上。<br />&nbsp;&nbsp;好转：经量明显减少或行经期正常，但不能维持3个月以上。<br />&nbsp;&nbsp;未愈：月经周期、经量无变化。<br />&nbsp;&nbsp;', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('398', '51', 'Y02_005', '0', '中医妇科病证诊断疗效标准', '无', '国家中医药管理局', '1994', 'ZY／T001.3-94，中医妇科病证诊断疗效标准[S].南京：南京大学出版社，1994.', '中文', null, null, '月经过少', '肝血亏虚；肾阳亏虚；瘀滞胞宫；痰湿阻滞；', '1. 月经周期基本正常，经量很少，不足30ml，甚或点滴即净。<br />&nbsp;&nbsp;2. 本病应与早孕激经相鉴别。<br />&nbsp;&nbsp;3. 排除因结核病引起的月经过少。<br />&nbsp;&nbsp;', '1. 肝血亏虚：月经量少或点滴即净，色淡无块，或伴头晕眼花，心悸怔忡，面色萎黄，小腹空坠，舌质淡红，脉细。<br />&nbsp;&nbsp;2. 肾阳亏虚：月经量少，色淡红或黯红，质稀，腰脊酸软，头晕耳鸣，或小腹冷，夜尿多。舌质淡，脉弱或沉迟。<br />&nbsp;&nbsp;3. 瘀滞胞宫：月经量少，色紫黑，有血块，小腹胀痛，拒按，血块排出后胀痛减轻。舌正常或紫黯，或有瘀点，脉细弦涩。<br />&nbsp;&nbsp;4. 痰湿阻滞：月经量少，色淡红，质粘腻，形体肥胖，胸闷呕恶，或带多粘稠。苔白腻，脉滑。<br />&nbsp;&nbsp;', '月经量；', '治愈：经量恢复正常，维持3个月以上。<br />&nbsp;&nbsp;好转：经量明显增多。或经量恢复正常，但不能维持3个月以上。<br />&nbsp;&nbsp;未愈：经周期、经量无变化。<br />&nbsp;&nbsp;', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('399', '51', 'Y02_006', '0', '中医妇科病证诊断疗效标准', '无', '国家中医药管理局', '1994', 'ZY／T001.3-94，中医妇科病证诊断疗效标准[S].南京：南京大学出版社，1994.', '中文', null, null, '经期延长', '瘀滞胞宫；阴虚血热；气不摄血；湿热下注；', '1. 月经周期基本正常，行经时间超过7天，甚至淋漓半月始净。<br />&nbsp;&nbsp;2. 应与漏下和赤带相鉴别。<br />&nbsp;&nbsp;3. 必要时作妇科检查或B超检查，排除宫颈息肉、宫颈炎或子宫器质性病变。<br />&nbsp;&nbsp;', '1. 瘀滞胞宫：经行淋漓8－9日或10余日始净，量少，色黯有块，小腹疼痛拒按。舌质紫黯或有瘀点，脉弦涩。<br />&nbsp;&nbsp;2. 阴虚血热：月经持续8－10天，量少色红质稠，咽干口燥，或有颧红，潮热，或见手心灼热。舌质红少津，苔少或无苔，脉细数。<br />&nbsp;&nbsp;3.气不摄血：月经持续8－l0天始净，量少，色淡，质清稀。伴神疲乏力，或头晕眼花，心悸少寐，或纳少便溏。舌质淡，苔薄白，脉弱或虚细。<br />&nbsp;&nbsp;4.湿热下注：经行8～10天始净，量少，色黯如酱，混杂粘液，气味秽臭，腰腹胀痛。平素带多色黄、有臭味。舌正常或偏红，苔黄腻，脉濡数。<br />&nbsp;&nbsp;', '行经期；', '治愈：行经期恢复正常3个月以上。<br />&nbsp;&nbsp;好转：行经期缩短，但未恢复正常。<br />&nbsp;&nbsp;未愈：行经时间无变化。<br />&nbsp;&nbsp;', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('4', '10', 'D02_004', '1', '中国2型糖尿病防治指南（2010年版）', '无', '中华医学会糖尿病学分会', '2010', '中国2型糖尿病防治指南(2010年版)[J].中国糖尿病杂志,2012,20(1):S1-S37', '中文', null, '代谢综合征', null, null, ' ', null, '1.体重减轻降低、BMI、腰围；<br />&nbsp;&nbsp;2.血压；<br />&nbsp;&nbsp;3.LDL-C、甘油三酯、HDL-C；<br />&nbsp;&nbsp;4.空腹血糖、负荷后2hPG、HbA1c。', '针对各种危险因素如糖尿病或糖调节受损、高血压、血脂紊乱以及肥胖等的药物治疗，治疗目标如下：<br />&nbsp;&nbsp;1.体重在一年内减轻降低7%~10%,争取达到BMI和腰围正常化；<br />&nbsp;&nbsp;2.血压：糖尿病患者<130/80mmHg，非糖尿病患者<40/90mmHg；<br />&nbsp;&nbsp;3.LDL-C<2.6mmol/L（100mg/dl）、甘油三酯<1.7mmol/L（150mg/dl）、HDL-C>1.04mmol/L（40mg/dl）（男）或>1.3mmol/L（50mg/dl）（女）；<br />&nbsp;&nbsp;4.空腹血糖<6.1mmol/L（110mg/dl）、负荷后2hPG<7.8mmol/L（140mg/dl）及HbA1c<7.0％。', '与2007年版相比：1.体重降低由5%变成7%~10%；2.增加BMI、腰围；3.增加非糖尿病患者血压标准；4.HbA1c<7.0％，2007版为6.5%.', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('40', '34', 'M03_004', '1', 'KDIGO 2012年临床实践指南的慢性肾脏疾病的评估和管理', ' KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.', ' 国际肾脏病学会（International Society of Nephrology）', '2012', 'KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013 Jan;3(1):1-150.$$$$\nhttp://www.guideline.gov/content.aspx?id=46510&search=kidney+failure', '英文', null, '肾衰', null, null, '年轻人的正常肾小球滤过率(GFR)大约是125毫升/分钟/ 1.73平方米。肾小球滤过率(GFR)< 15毫升/分钟/ 1.73平方米(肾小球滤过率(GFR)类别G5)被定义为肾功能衰竭.<br />&nbsp;&nbsp;\nThe normal GFR in young adults is approximately 125 ml/min/1.73m2. GFR <15 ml/min/1.73m2(GFR category G5) is defined as kidney failure.<br />&nbsp;&nbsp;\n M03_004_01_CKD的分类.docx', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('400', '51', 'Y02_007', '0', '中医妇科病证诊断疗效标准', '无', '国家中医药管理局', '1994', 'ZY／T001.3-94，中医妇科病证诊断疗效标准[S].南京：南京大学出版社，1994.', '中文', null, null, '痛经', '气血瘀滞；寒湿凝滞；肝郁湿热；气血亏虚；肝肾亏损；', '1. 经期或经行前后小腹疼痛，痛及腰骶，甚则昏厥。呈周期性发作。<br />&nbsp;&nbsp;2. 好发于青年未婚女子。<br />&nbsp;&nbsp;3. 排除盆腔器质性疾病所致腹痛。<br />&nbsp;&nbsp;', '1. 气血瘀滞：经前或经期小腹胀痛拒按，或伴乳胁胀痛。经行量少不畅，色紫黑有块，块下痛减。舌质紫黯或有瘀点，脉沉弦或涩。<br />&nbsp;&nbsp;2. 寒湿凝滞：经行小腹冷痛，得热则舒，经量少，色紫黯有块。伴形寒肢冷，小便清长。苔白，脉细或沉紧。<br />&nbsp;&nbsp;3. 肝郁湿热：经前或经期小腹疼痛，或痛及腰骶，或感腹内灼热。经行量多质稠，色鲜或紫，有小血块。时伴乳胁胀痛，大便干结，小便短赤，平素带下黄稠。舌质红，苔黄腻，脉弦数。<br />&nbsp;&nbsp;4. 气血亏虚：经期或经后小腹隐痛喜按，经行量少质稀。形寒肢疲，头晕目花，心悸气短.舌质淡，苔薄，脉细弦。<br />&nbsp;&nbsp;5. 肝肾亏损：经期或经后小腹绵绵作痛，经行量少，色红无块。腰膝酸软，头晕耳鸣。舌淡红，苔薄，脉细弦。<br />&nbsp;&nbsp;', '疼痛；', '治愈：疼痛消失，连续3个月经周期末见复发。<br />&nbsp;&nbsp;好转：疼痛减轻或疼痛消失，但不能维持3个月以上。<br />&nbsp;&nbsp;未愈：疼痛未见改善。<br />&nbsp;&nbsp;', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('401', '51', 'Y02_008', '0', '中医妇科病证诊断疗效标准', '无', '国家中医药管理局', '1994', 'ZY／T001.3-94，中医妇科病证诊断疗效标准[S].南京：南京大学出版社，1994.', '中文', null, null, '闭经', '肾气不足；气血亏虚；痰湿阻滞；阴虚内热；血寒凝滞；血瘀气滞；', '1. 年逾18周岁女子，月经尚未初潮者，属原发性闭经。<br />&nbsp;&nbsp;2. 女子已行经而又中断3个月以上者，属继发性闭经。<br />&nbsp;&nbsp;3. 须与妊娠期、哺乳期、绝经期等生理性停经相鉴别。<br />&nbsp;&nbsp;', '1. 肾气不足：年逾18周岁，月经未至或来潮后复闭。素体虚弱，头晕耳鸣，第二性征不足，腰腿酸软，腹无胀痛，小便频数。舌淡红，脉沉细。<br />&nbsp;&nbsp;2. 气血亏虚：月经周期后延，经量偏少，继而闭经。面色不荣，头晕目眩，心悸气短，神疲乏力。舌淡边有齿印，苔薄，脉细无力。<br />&nbsp;&nbsp;3. 痰湿阻滞：月经停闭，形体肥胖，神疲嗜睡，头晕目眩，胸闷泛恶多痰，带下量多。苔白腻，脉濡或滑。<br />&nbsp;&nbsp;4. 阴虚内热：月经先多后少，渐致闭经。五心烦热，颧红升火，潮热盗汗，口干舌燥。舌质红或有裂纹，脉细数。<br />&nbsp;&nbsp;5. 血寒凝滞：经闭不行，小腹冷痛，得热痛减，四肢欠温，大便不实。苔白，脉沉紧。<br />&nbsp;&nbsp;6. 血瘀气滞：月经闭止，胸胁胀满，小腹胀痛，精神抑郁。舌质紫黯，边有瘀点，苔薄，脉沉涩或沉弦。<br />&nbsp;&nbsp;', '月经来潮；', '治愈：月经来潮，连续3次以上正常行经。<br />&nbsp;&nbsp;好转：月经恢复来潮。但月经周期未正常。<br />&nbsp;&nbsp;未愈：月经仍未来潮。<br />&nbsp;&nbsp;', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('402', '51', 'Y02_009', '0', '中医妇科病证诊断疗效标准', '无', '国家中医药管理局', '1994', 'ZY／T001.3-94，中医妇科病证诊断疗效标准[S].南京：南京大学出版社，1994.', '中文', null, null, '崩漏', '血热内扰；气不摄血；肾阳亏虚；肾阴亏虚；瘀滞胞宫；', '1. 经血无周期可循。<br />&nbsp;&nbsp;2. 经量或暴下如注，或漏下不止，或两者交替出现。<br />&nbsp;&nbsp;3. 须与胎漏、异位妊娠、产后出血、赤带以及症瘕、外伤引起的阴道出血相鉴别。<br />&nbsp;&nbsp;', '1. 血热内扰：经血量多，或淋漓不净，色深红或紫红，质粘稠，夹有少量血块。面赤头晕，烦躁易怒，口干喜饮，便秘尿赤。舌质红，苔黄，脉弦数或滑数。<br />&nbsp;&nbsp;2. 气不摄血：经血量多，或淋漓不净，色淡质稀。神疲懒言，面色萎黄，动则气促，头晕心悸，纳呆便溏。舌质淡胖或边有齿印，舌苔薄润，脉芤或细无力。<br />&nbsp;&nbsp;3. 肾阳亏虚：经血量多，或淋漓不净，色淡质稀。精神不振，面色晦暗，肢冷畏寒，腰膝酸软，小便清长。舌质淡，苔薄润，脉沉细无力，尺部尤弱。<br />&nbsp;&nbsp;4. 肾阴亏虚：经血时多时少，色鲜红。头晕耳鸣，五心烦热，夜寐不安。舌质红或有裂纹，苔少或无苔，脉细数。<br />&nbsp;&nbsp;5. 瘀滞胞宫：经漏淋漓不绝，或骤然暴下，色暗或黑，夹有瘀块，小腹疼痛，块下痛减。舌质紫暗或边有瘀斑，脉沉涩或弦紧。<br />&nbsp;&nbsp;', '经量；经期；周期；', '治愈：经量、经期、周期恢复正常，能维持3个月经周期以上。或更年期妇女血止绝经者。<br />&nbsp;&nbsp;好转：经量、经期、周期虽恢复正常，但不能维持3个月经周期。或经量减少，或经期缩短。<br />&nbsp;&nbsp;未愈：阴道出血无变化。<br />&nbsp;&nbsp;', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('403', '51', 'Y02_010', '1', '原发性痛经诊疗共识指南', 'Primary Dysmenorrhea Consensus Guideline', '加拿大妇产科医生协会(SOGC,Society of Obstetricians and Gynaecologists of Canada)', '2005', 'http://sogc.org/guidelines/primary-dysmenorrhea-consensus-guideline/ ；http://sogc.org/wp-content/uploads/2013/01/169E-CPG-December2005.pdf', '英文', null, '痛经', null, null, '1. 初潮前6个月痛经的青少年，及无卵性痛经的病人，诊断为生殖器畸形引起的。\n2. 继发性痛经为经过很多年无痛经的经历后，出现痛经症状。\n3. 痛经的高患病率表明，许多妇女在这个问题上不寻求医疗关注，卫生保健提供者应在获得妇女病史时，关注痛经的具体问题。\n4. 如果一个青少年没有性行为，且痛经为轻中度，则不必要进行盆腔检查。\n5. 在所有病人中，盆腔检查用于提示不适用于传统治疗的痛经或者病理检查可疑时。\n1. In adolescents experiencing dysmenorrhea in the 畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭치੣ༀƙ\0੣°\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అ੣°\0ఄ彿㎽奋㎽巫㎽橔అᯀఅ彿㎽᮴అ塚㎽ᯀఅꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0᜘੏䐺盭暼痭᜘੏ༀƙ \0᜘੏\0\0㺣盭᜘੏\0𢡄᜜੏\0팃目᜜੏࣒᜜੏큁目᜜੏匰అ泌\0Item\0\0᱄అ\0\0\0\0\0\0Count\0\0﫨呂ᝌ੏㳜੪\0\0᜜੏\0\0\0\0੪寶目㳠੪楱䥷㎽橔అ\0\0᱄అ�㏂᮴అ\0\0\0੪\0\0\0露𢡄\0\0㎾ऒ\0齃\0\0x�㏂᮴అ\0\0隲W᱄అ\0\0�Ĳ\0\0\0鹿齃殺\0\0霈W戀醙霫W戀ꊠऺ齃x\n\0霪W露Wꊠऺ﫰xt\0Љ\0\0\0൐௲鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0⑰ਫ਼⑰ਫ਼㲈੪到అ寶目㲈੪到అi\0\0變ﱘ﫰﬐먙㎼到అ㲈੪i\0\0變ﱘ﫰먰㎼ﱘ到అ�㏂冠అ\0\0릎㎼到అi\0⓮췬目⓲췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒൐௲竗൐௲目W\0竗\0\0\0目\0\0\0\0匰అ\0目瑉浥目\0\0\0\0匰అ\0目潃湵tƢ\0愢睉뮴ơࣴշ\0\0\0ઔշผշ,\0ဈշ\0\0慰睉ߐշ\0\0\0ೂᰁࣴշผշ,\0\0\0崹睊ೂᰁࣴշ\0\0㞍Qđ\0ᠠ৸,\0ผշ\0\0▪췬目Љ\0►췬目Љ\0╖췬╞췬目Љ\0鲸࣒\0￿￿目Љ\0鲬࣒൐௲觴൐௲目t\0觴\0\0\0梅礼目\0\0\0\0﫤到అ目潅f摲敳t盡옎盡㊊췭\0\0ࣾ}\0$\0\0\0\0\0\0p\0￿￿￿￿얠盡왑盡ೂᰁ\0\0\0\0\0翽捥盦Ȓ묞￾￿옎盡伛盡\0\0ɭդࣾ}đ\0ࣸ̀ࣸEꊌƩ伦盡㋪췭ꉸƩđ\0\0\0\0\0\0\0\0\0\0捥盦謺묞￾￿템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂瞒⫠\0\0\0瞒⪌쀕瞒〠\0䪔㏂\0T\0\0⪌쀕\0\0ꀀ翽翽瞒鸞䪔㏂\0邰ƙ\0\0ࠀ᎖', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('404', '51', 'Y02_011', '1', '月经过多临床指南', 'Heavy menstrual bleeding', '英国国家卫生与临床优化研究所 (NICE,National Institute for Health and Clinical Excellence)', '2007', 'http://guide.medlive.cn/guideline/3029', '英文', null, '月经过多', null, null, null, null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('405', '51', 'Y02_012', '1', '月经过多临床指南', 'Heavy menstrual bleeding', '英国国家卫生与临床优化研究所 (NICE,National Institute for Health and Clinical Excellence)', '2013', 'http://www.nice.org.uk/guidance/qs47/resources/heavy-menstrual-bleeding-2098671748549', '英文', null, '月经过多', null, null, null, null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('406', '51', 'Y02_013', '1', '临床诊疗指南·妇产科学分册', null, '中华医学会', '2007', '中华医学会.临床诊疗指南·妇产科学分册.北京：人民卫生出版社，2007.', '中文', '1.无排卵性功血；2.有排卵型功血；', '功能失调性子宫出血', null, null, '（一）无排卵型功血<br />&nbsp;&nbsp;   1. 临床表现<br />&nbsp;&nbsp;  1.1常见于青春期及绝经过渡期妇女。月经周期及经期长短不一，可间隔数天或数月后出现阴道流血，出血时间可为数天或数十天不等。出血量时多时少，甚至大出血。同时可有乏力、头晕、心悸等症状。病程很长。<br />&nbsp;&nbsp;  1.2体征：程度不等的贫血貌，可有多毛、肥胖、泌乳。妇科检查正常，子宫可稍软及饱满。<br />&nbsp;&nbsp;  1.3辅助检查：基础体温测定多数为单相型，也可偶有双相。盆腔B超检查生殖器官未见病变，子宫内膜厚度不定。诊断性刮宫所得子宫内膜病理检查可为增殖期、不同程畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭치੣ༀƙ\0੣°\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అ੣°\0ఄ彿㎽奋㎽巫㎽橔అᯀఅ彿㎽᮴అ塚㎽ᯀఅꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0턀ਘ䐺盭暼痭턀ਘༀƙ \0턀ਘ\0\0㺣盭턀ਘ\0𢡄턄ਘ\0팃目턄ਘ࣒턄ਘ큁目턄ਘ匰అ泌\0Item\0\0᱄అ\0\0\0\0\0\0Count\0\0﫨呂턴ਘ㳜੪\0\0턄ਘ\0\0\0\0੪寶目㳠੪楱䥷㎽橔అ\0\0᱄అ�㏂᮴అ\0\0\0੪\0\0\0露𢡄\0\0㎾ྦ\0齃\0\0x�㏂᮴అ\0\0隲W᱄అ\0\0�Ĳ\0\0\0鹿齃殺\0\0霈W戀醙霫W戀ꊠऺ齃x\n\0霪W露Wꊠऺ﫰xt\0Љ\0\0\0൐௲鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0⑰ਫ਼⑰ਫ਼㲈੪到అ寶目㲈੪到అi\0\0變ﱘ﫰﬐먙㎼到అ㲈੪i\0\0變ﱘ﫰먰㎼ﱘ到అ�㏂冠అ\0\0릎㎼到అi\0⓮췬目⓲췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒൐௲竗൐௲目W\0竗\0\0\0目\0\0\0\0匰అ\0目瑉浥目\0\0\0\0匰అ\0目潃湵tƢ\0愢睉뮴ơࣴշ\0\0\0ઔշผշ,\0ဈշ\0\0慰睉ߐշ\0\0\0ೂᰁࣴշผշ,\0\0\0崹睊ೂᰁࣴշ\0\0㞍Qđ\0ᠠ৸,\0ผշ\0\0▪췬目Љ\0►췬目Љ\0╖췬╞췬目Љ\0鲸࣒\0￿￿目Љ\0鲬࣒൐௲觴൐௲目t\0觴\0\0\0梅礼目\0\0\0\0﫤到అ目潅f摲敳t盡옎盡㊊췭\0\0ࣾ}\0$\0\0\0\0\0\0p\0￿￿￿￿얠盡왑盡ೂᰁ\0\0\0\0\0翽捥盦Ȓ묞￾￿옎盡伛盡\0\0ɭդࣾ}đ\0ࣸ̀ࣸEꊌƩ伦盡㋪췭ꉸƩđ\0\0\0\0\0\0\0\0\0\0捥盦謺묞￾￿템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂瞒⫠\0\0\0瞒⪌쀕瞒〠\0䪔㏂\0T\0\0⪌쀕\0\0ꀀ翽翽瞒鸞䪔㏂\0邰ƙ\0\0ࠀ᎖眊\0\0䪔㏂鸞\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ菱到అﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀﬘眿ฒ᱄అ磻ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿菱￿￿\0\0異\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ\0\0\0\0\0奰畿⡥췬焚畻邰ƙࠀ菱￿￿㏂￿￿\0\0\0\0滑煔畻:\0菱￿￿㏂￿￿奰畿\0\0\0\0璉㎾ࠄ\0\0菱￿￿㏂㎾x\0\0�㏂᮴అ\0\0頲W怜\0\0\0\0ࠄ\0顇WValu\0\0菱令᱄అ齃\0\0\0\0\0\0菱\0磻\0窱餀W齃ﬄ	\0ﭴ\0\0৻.\07\0\0\0\0\0븴ॕ\0\0識⤖췬識뜩@﷩\0\0\0\0靖䗧@林蕶@৻﫬煮\0뮩@館믆@믎@﫬﷩\0釚@﫬﫬﷩\0ༀƙ﫰ༀƙ社戤痝\0Ɨ\0\0슘ơ並ఄఄ忉㎽᫸అ奁㎽ఄ	\0ᬄఅᯀఅ彿㎽﫠䦕盭ᯀఅ	\0ᯀఅ忉㎽𢡄䥷盭ᯀఅꊠऺ	\0﫨᱄అ﫰馘B齃ﭴxﬄﬄ駰B﫰惈ੴ嬀৹\0అ\0\0𢡄ﲘ齃xﲘxﲀﭴx﬐xﲘ﬜xﲘﲴxﲘꊠऺ惈ੴ뿄x\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0ꊠऺ匰అ䗆@	ऺ匰అ᱄అ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0ʎC匰అﲘC匰అ\0\0\0\0\0అ\0\0\0\0అﱘ￿\0\0\0\0\0\0￿\0\0\0\0\0偠৹\0\0\n\0ﴀ\0\0ﴄ疐ɪఅ\0\0싔ơﲘ\0\0柌॑ﴌ嵿{ﳴ\0\0\0\0\0ﴀﳀ庱{ﴌﴔ彨{ﴌꊠऺ\0ﺰ஑ৄࣸEÂ\0\0\0৻\0\0쥈ɯ\0\0\0疐ɪ\0\0జੳ\0\0ﵤⰛEﴠⰺEﵤﴬⱹEﵤﴸⳗEﵤﵬ⳶Eﵤꊠऺ\0\0\0਌\0\0悰ੴﺀ஑Ā﷌㘣Tﹸ㘶T﷌﹠\0\0\0\0崈盡ﶠ갦盠쾐ƫ\0\0ﹸ\0\0ﷀ駅Éॹˢ\0\0\0ﹸ翽ﹸ﷜﷔츐ɳ﷤刞E\0\0\0\0\0\0\0\0︐쓷盡਌\0\0\0\0\0\0\0\0ꯍ�\0\0﹠\0\0ﺈ엷盡࿢Ԗ਌\0\0\0\0\0\0㪂췭Ｈ＠쬠ƫ$', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('407', '51', 'Y02_014', '1', '临床诊疗指南·妇产科学分册', null, '中华医学会', '2007', '中华医学会.临床诊疗指南·妇产科学分册.北京：人民卫生出版社，2007.', '中文', null, '原发性痛经', null, null, '临床表现<br />&nbsp;&nbsp;    年轻女性从初潮后6～12个月开始，在月经来潮前数小时或来潮后出现下腹部持续性或阵发性疼痛，可放射至腰骶部和大腿内侧，历时1～3日，自行缓解。重者而色发白，出冷汗，畏寒，恶心，呕吐或腹泻。有时四肢厥冷、尿频和全身乏力。妇科检查无异常发现，有时可有子宫轻度压痛。症状在结婚、分娩后可自行减轻或消失。<br />&nbsp;&nbsp;诊断要点<br />&nbsp;&nbsp;    有上述临床表现的患者，除外器质性疾病（子宫内膜异位症、子宫腺肌症、盆腔炎）引起的继发性痛经后即可诊断。除典型症状及查体外，可行盆腔超声检查除外子宫、卵巢明显的器畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭치੣ༀƙ\0੣°\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('408', '51', 'Y02_015', '1', '临床诊疗指南·妇产科学分册', null, '中华医学会', '2007', '中华医学会.临床诊疗指南·妇产科学分册.北京：人民卫生出版社，2007.', '中文', '1.子宫性闭经；2.卵巢性闭经；3.垂体性闭经；4.下丘脑性闭经；', '闭经', null, null, '1. 临床表现<br />&nbsp;&nbsp;1.1卵巢轴异常<br />&nbsp;&nbsp;1.1.1子宫性闭经：先天性疾病有先天性无阴道、无子宫(Rokitansky Kuster Hauscr综合征)、始基子宫、睾丸女性化等；后天性疾病可为子宫内膜结核、严重的产后盆腔感染、多次宫腔手术后所引起。宫腔粘连（Asherman综合征）除有闭经外，还有周期性下腹痛。<br />&nbsp;&nbsp;1.1.2卵巢性闭经：先天性疾病有先天性卵巢（性腺）发育不全，如Turner综合征、单纯性性腺发育不全（46，XX型、46，XY型即Swyer综合征）、XO/XY性腺发育不全、17a-畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭치੣ༀƙ\0੣°\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అ੣°\0ఄ彿㎽奋㎽巫㎽橔అᯀఅ彿㎽᮴అ塚㎽ᯀఅꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0치੣䐺盭暼痭치੣ༀƙ \0치੣\0\0㺣盭치੣\0𢡄친੣\0팃目친੣࣒친੣큁目친੣匰అ泌\0Item\0\0᱄అ\0\0\0\0\0\0Count\0\0﫨呂캌੣㳜੪\0\0친੣\0\0\0\0੪寶目㳠੪楱䥷㎽橔అ\0\0᱄అ�㏂᮴అ\0\0\0੪\0\0\0露𢡄\0\0㎾႒\0齃\0\0x�㏂᮴అ\0\0隲W᱄అ\0\0�Ĳ\0\0\0鹿齃殺\0\0霈W戀醙霫W戀ꊠऺ齃x\n\0霪W露Wꊠऺ﫰xt\0Љ\0\0\0൐௲鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0⑰ਫ਼⑰ਫ਼㲈੪到అ寶目㲈੪到అi\0\0變ﱘ﫰﬐먙㎼到అ㲈੪i\0\0變ﱘ﫰먰㎼ﱘ到అ�㏂冠అ\0\0릎㎼到అi\0⓮췬目⓲췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒൐௲竗൐௲目W\0竗\0\0\0目\0\0\0\0匰అ\0目瑉浥目\0\0\0\0匰అ\0目潃湵tƢ\0愢睉뮴ơࣴշ\0\0\0ઔշผշ,\0ဈշ\0\0慰睉ߐշ\0\0\0ೂᰁࣴշผշ,\0\0\0崹睊ೂᰁࣴշ\0\0㞍Qđ\0ᠠ৸,\0ผշ\0\0▪췬目Љ\0►췬目Љ\0╖췬╞췬目Љ\0鲸࣒\0￿￿目Љ\0鲬࣒൐௲觴൐௲目t\0觴\0\0\0梅礼目\0\0\0\0﫤到అ目潅f摲敳t盡옎盡㊊췭\0\0ࣾ}\0$\0\0\0\0\0\0p\0￿￿￿￿얠盡왑盡ೂᰁ\0\0\0\0\0翽捥盦Ȓ묞￾￿옎盡伛盡\0\0ɭդࣾ}đ\0ࣸ̀ࣸEꊌƩ伦盡㋪췭ꉸƩđ\0\0\0\0\0\0\0\0\0\0捥盦謺묞￾￿템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂瞒⫠\0\0\0瞒⪌쀕瞒〠\0䪔㏂\0T\0\0⪌쀕\0\0ꀀ翽翽瞒鸞䪔㏂\0邰ƙ\0\0ࠀ᎖眊\0\0䪔㏂鸞\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ菱到అﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀﬘眿ฒ᱄అ磻ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿菱￿￿\0\0異\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ\0\0\0\0\0奰畿⡥췬焚畻邰ƙࠀ菱￿￿㏂￿￿\0\0\0\0滑煔畻:\0菱￿￿㏂￿￿奰畿\0\0\0\0璉㎾ࠄ\0\0菱￿￿㏂㎾x\0\0�㏂᮴అ\0\0頲W怜\0\0\0\0ࠄ\0顇WValu\0\0菱令᱄అ齃\0\0\0\0\0\0菱\0磻\0窱餀W齃ﬄ	\0ﭴ\0\0㵌੯S\0d\0\0\0\0\0쳄ॏ\0\0識⤖췬識뜩@﷩\0\0\0!\0靖䗧@林蕶@㵀੯﫬煮\"\0뮩@館믆@믎@﫬﷩\0釚@﫬﫬﷩\0ༀƙ﫰ༀƙ社戤痝\0Ɨ\0\0䢀ਕ並ఄఄ忉㎽᫸అ奁㎽ఄ	\0ᬄఅᯀఅ彿㎽﫠䦕盭ᯀఅ	\0ᯀఅ忉㎽𢡄䥷盭ᯀఅꊠऺ	\0﫨᱄అ﫰馘B齃ﭴxﬄﬄ駰B﫰悀ੴ嬀৹\0అ\0\0𢡄ﲘ齃xﲘxﲀﭴx﬐xﲘ﬜xﲘﲴxﲘꊠऺ悀ੴ뿄x\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0ꊠऺ匰అ䗆@	ऺ匰అ᱄అ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0ʎC匰అﲘC匰అ\0\0\0\0\0అ\0\0\0\0అﱘ￿\0\0\0\0\0\0￿\0\0\0\0\0偠৹\0\0\n\0ﴀ\0\0ﴄ疐ɪఅ\0\0᜜੏ﲘ\0\0더ॏﴌ嵿{ﳴ\0\0\0\0\0ﴀﳀ庱{ﴌﴔ彨{ﴌꊠऺ\0ﺰ஑ৄࣸEÂ\0\0\0৻\0\0쥈ɯ\0\0\0疐ɪ\0\0జੳ\0\0ﵤⰛEﴠⰺEﵤﴬⱹEﵤﴸⳗEﵤﵬ⳶Eﵤꊠऺ\0\0\0਌\0\0悰ੴﺀ஑Ā﷌㘣Tﹸ㘶T﷌﹠\0\0\0\0崈盡ﶠ갦盠쾐ƫ\0\0ﹸ\0\0ﷀ駅Éॹˢ\0\0\0ﹸ翽ﹸ﷜﷔츐ɳ﷤刞E\0\0\0\0\0\0\0\0︐쓷盡਌\0\0\0\0\0\0\0\0ꯍ�\0\0﹠\0\0ﺈ엷盡࿢Ԗ਌\0\0\0\0\0\0㪂췭Ｈ＠쬠ƫ$\0\0\0\0\0\00\0￿￿￿￿얠盡\0\0ｄ\0\0\0\0\0︬Ꝥɹﻜ捥盦Ȓ묞\0\0ﻬ찰盡\0\0࿢Ԗ਌\0\0\0\0\0\0쬴ƫ\0㫦췭츐ɳ＠\0\0\0\0\0\0\0\0ﺼﺰｄｄ捥盦ࡒ묞￾￿ﻼ첈盡࿢Ԗ\0\0਌㺖T＠ｬ\0\0\0\0츐ɳ㻛T਌', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('409', '51', 'Y02_016', '1', '闭经诊断与治疗指南（试行）', null, '中华医学会妇产科学分会内分泌学组', '2011', '中华妇产科杂志，2011,:46（9）：712-716.', '中文', '(一)1.原发性闭经；2.继发性闭经<br />&nbsp;&nbsp;（二）1.下丘脑性闭经；2.垂体性闭经；3.卵巢性闭经；4.子宫性闭经；5.生殖道发育异常性闭经；<br />&nbsp;&nbsp;（三）Ⅰ型；Ⅱ型；Ⅲ型；<br />&nbsp;&nbsp; ', '闭经', null, null, '1.诊断：<br />&nbsp;&nbsp;1.1病史<br />&nbsp;&nbsp;包括月经史、婚育史、服药史、子宫手术史、家族史以及发病的可能起因和伴随症状，如环境变化、精神生理创伤、情感应激、运动性职业或过强运动、营养状况及有无头痛、溢乳等；对原发性闭经者应了解青春期生长和发育进程。<br />&nbsp;&nbsp;表1<br />&nbsp;&nbsp;1.2体格检查<br />&nbsp;&nbsp;包括智力、身高、体质量、第二性征发育情况、有无发育畸形，有无甲状腺肿大，有无乳房溢乳，皮肤色泽及毛发分布。对原发性闭经、性征幼稚者还应检查嗅觉有无缺失。<br />&nbsp;&nbsp;1.3妇科检查<br />&nbsp;&nbsp;内、外科生殖器发育情况及有无畸形；已婚妇女可通畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭턀ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అਘĀ\0ఄ彿㎽奋㎽巫㎽橔అᯀఅ彿㎽᮴అ塚㎽ᯀఅꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0媈ఉ䐺盭暼痭媈ఉༀƙ \0媈ఉ\0\0㺣盭媈ఉ\0𢡄媌ఉ\0팃目媌ఉ࣒媌ఉ큁目媌ఉ匰అ泌\0Item\0\0᱄అ\0\0\0\0\0\0Count\0\0﫨呂媼ఉ㳜੪\0\0媌ఉ\0\0\0\0੪寶目㳠੪楱䥷㎽橔అ\0\0᱄అ�㏂᮴అ\0\0\0੪\0\0\0露𢡄\0\0㎾র\0齃\0\0x�㏂᮴అ\0\0隲W᱄అ\0\0�Ĳ\0\0\0鹿齃殺\0\0霈W戀醙霫W戀ꊠऺ齃x\n\0霪W露Wꊠऺ﫰xt\0Љ\0\0\0൐௲鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0⑰ਫ਼⑰ਫ਼㲈੪到అ寶目㲈੪到అi\0\0變ﱘ﫰﬐먙㎼到అ㲈੪i\0\0變ﱘ﫰먰㎼ﱘ到అ�㏂冠అ\0\0릎㎼到అi\0⓮췬目⓲췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒൐௲竗൐௲目W\0竗\0\0\0目\0\0\0\0匰అ\0目瑉浥目\0\0\0\0匰అ\0目潃湵tƢ\0愢睉뮴ơࣴշ\0\0\0ઔշผշ,\0ဈշ\0\0慰睉ߐշ\0\0\0ೂᰁࣴշผշ,\0\0\0崹睊ೂᰁࣴշ\0\0㞍Qđ\0ᠠ৸,\0ผշ\0\0▪췬目Љ\0►췬目Љ\0╖췬╞췬目Љ\0鲸࣒\0￿￿目Љ\0鲬࣒൐௲觴൐௲目t\0觴\0\0\0梅礼目\0\0\0\0﫤到అ目潅f摲敳t盡옎盡㊊췭\0\0ࣾ}\0$\0\0\0\0\0\0p\0￿￿￿￿얠盡왑盡ೂᰁ\0\0\0\0\0翽捥盦Ȓ묞￾￿옎盡伛盡\0\0ɭդࣾ}đ\0ࣸ̀ࣸEꊌƩ伦盡㋪췭ꉸƩđ\0\0\0\0\0\0\0\0\0\0捥盦謺묞￾￿템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂瞒⫠\0\0\0瞒⪌쀕瞒〠\0䪔㏂\0T\0\0⪌쀕\0\0ꀀ翽翽瞒鸞䪔㏂\0邰ƙ\0\0ࠀ᎖眊\0\0䪔㏂鸞\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ菱到అﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀﬘眿ฒ᱄అ磻ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('41', '34', 'M03_005', '1', 'ACR肾功能衰竭适当性标准', 'ACR Appropriateness Criteria renal failure. ', '美国放射学会(ACR,American College of Radiology)', '2008', 'Remer EM, Papanicolaou N, Casalino DD, Bishoff JT, Blaufox MD, Coursey CA, Dighe M, Eberhardt SC, Goldfarb S, Harvin HJ, Heilbrun ME, Leyendecker JR, Nikolaidis P, Oto A, Preminger GM, Raman SS, Sheth S, Vikram R, Weinfeld RM, Expert Panel on Urologic Imaging. ACR Appropriateness Criteria® renal failure. [online publication]. Reston (VA): American College of Radiology (ACR); 2013. 12 p. $$$$\nhttp://www.guideline.gov/content.aspx?id=47681&search=urolithiasis', '英文', null, '慢性肾衰 (Chronic Kidney Disease)', null, null, 'Chronic Kidney Disease<br />&nbsp;&nbsp;\nCKD often presents insidiously and is characterized by a steady decrease in GFR. The most common causes of C KD are diabetic nephropathy and hypertensive nephropathy. The causes of C KD that lead to ESRD and result in transplantation are (in order of decreasing frequency): chronic glomerulonephritis, diabetic nephropathy, hypertensive nephropathy, polycystic renal disease, chronic pyelonephritis, and renal calculi. Hypertensive nephropathy in one study accounted for 25% of all patients with ESRD. The most common causes of C KD in children are chronic glomerulonephritis and pyelonephritis. US best differentiates between obstruction and intrinsic parenchymal disease. In children with small-scarred kidneys, voiding cystourethrography (VC UG) is performed to exclude vesicoureteral reflux. For adults with ESRD and urinary tract infection or calculi, evaluation with VC UG, urodynamics, and retrograde pyelography is also advised. The National Kidney Foundation has defined the five stages of C KD based on GFR calculations. <br />&nbsp;&nbsp;\nPatients with C RF, especially those on dialysis, frequently develop multiple cysts. If a patient develops ≥4 cysts in each kidney, a diagnosis of acquired cystic renal disease is made. The duration and severity of C KD is a major risk factor in cyst development, as is the length of time a patient has received dialysis. A complication of acquired cystic renal disease is the development of renal cell carcinoma (RC C ). RC C in this population is estimated to be 30 times more common than in the general population. The timing of screening for RC C and the modality used are somewhat controversial, as the rate of death related to RC C in C KD patients is low. Initial screening is recommended after patients are on dialysis 3 to 5 years. One strategy is to first evaluate for cysts using US; if cysts are encountered, then C T can be performed yearly. Early enhanced C T (40-second [s] scan delay) is recommended rather than a later delay (120 s) to better detect tumors. Alternatively, MRI and US can be used. Patients with C KD on temporary dialysis should not be given intravascular iodinated contrast media. The administration of gadolinium-based MR intravascular agents in patients with C KD is also restricted (see \"Anticipated Exceptions\" below). <br />&nbsp;&nbsp;\nIn one study, atherosclerotic renal artery stenosis (RAS) presenting as C KD occurred in 14% of patients >50 years old. Reports on the ability of duplex Doppler US to detect RAS vary widely; some reports have shown it to be as high as 90%, whereas others have shown poor results. Over one-third of patients evaluated with earlier Doppler methodology had an unsatisfactory examination. With use of a posterior or posterolateral translumbar approach and analysis of intrarenal vessel waveforms, duplex Doppler US has been reported to detect significant (>70%) RAS as a cause of renal failure, with a sensitivity of 95% and specificity of 97%. Examinations were almost always technically feasible and accomplished within 30 minutes. One study found it effective in evaluating RAS, but only when the RAS was ≥80%. Usually, high-grade stenoses are associated with renal failure. <br />&nbsp;&nbsp;\nA subsequent study was not able to reproduce results adequately to support the use of duplex Doppler US as a screening test for RAS. Duplex Doppler US for diagnosis of RAS is very operator-dependent. <br />&nbsp;&nbsp;\nRenal scintigraphy with Tc-99m DTPA and an angiotensin-converting enzyme inhibitor (AC EI) has high sensitivity and specificity in detecting RAS in patients with normal or nearnormal renal function. Its use is also reported in patients with renal insufficiency. However, it becomes less accurate in patients with C KD, because DTPA is a pure glomerular agent and there is a variable response to AC EI in patients with low baseline renal (e.g., GFR <15 mL/min). It is of value to only a subset of all potential renovascular patients and is of limited value in patients with significant azotemia, bilateral RAS, or RAS to a single, functioning kidney. Therefore, it is no longer recommended by the American C ollege of C ardiology/American Heart Association guidelines.\nMRA is able to demonstrate, with high sensitivity and specificity, atherosclerotic narrowing of the orifice and proximal renal artery. Aortic or proximal renal artery disease is the usual culprit when atherosclerosis causes renal failure, making MRA a helpful imaging modality. Newer, ultrafast MRA techniques using intravenous gadolinium agents during breath-held imaging provide excellent images of the entire renal artery and often the segmental branches. Gadolinium agents have less nephrotoxicity than conventional iodinated contrast media and, therefore, may be used in cases of mild renal insufficiency when contrast-enhanced imaging is necessary. Furthermore, several nonenhanced MRA techniques are available and can be used to evaluate the renal arteries in patients with severe renal insufficiency without the risk of NSF. <br />&nbsp;&nbsp;\nFollowing recent advances in multidetector C T (MDC T) technology, C T angiography (C TA) has emerged as an effective alternative to MRA and duplex US for evaluating RAS, if the intravascular administration of contrast media is not contraindicated. Both MRA and C TA, although not as sensitive as digital subtraction angiography (DSA), have been shown to be better than duplex US and radionuclide captopril renography. C urrently, C TA has better spatial resolution and shorter examination times than MRA. It can also determine the extent of calcified atheromatous plaques that are not seen on MRA. The disadvantages of C TA include the radiation exposure and risk for renal damage in patients with compromised renal function. <br />&nbsp;&nbsp;\nConventional angiography with iodinated contrast material and DSA technique should be carefully considered because of the risk of contrast nephrotoxicity. Some institutions use carbon dioxide as the contrast agent, and thereby avoid nephrotoxicity. If intra-arterial contrast is used judiciously, the ability to treat any encountered stenosis with balloon angioplasty or renal artery stent placement at the time of diagnosis makes angiography an option in patients with a high clinical suspicion for RAS. However, this approach may be appropriate in a limited number of patients, as revascularization was found to impart substantial risks but no worthwhile clinical benefit in 806 patients; in 140 patients randomized to medication only or medication with stenting, there was no statistically significant difference in the progression of renal failure over 2 years. <br />&nbsp;&nbsp;\nUrinary obstruction as a cause of C KD is being evaluated by US. If azotemia is secondary to obstructive uropathy, hydronephrosis will almost always be demonstrable. US has sensitivity approaching 100% in moderate to severe hydronephrosis. There may be a false-positive rate ≤26%, caused by such entities as vesicoureteral reflux, full bladder, renal sinus cysts, and normal vessels in the renal sinus; however, vascular structures causing confusion can be resolved with duplex Doppler US or color Doppler US. When the kidneys fail secondary to a chronic obstruction, resistive indexes may return to normal. <br />&nbsp;&nbsp;\nNewer and future techniques for detecting renal function in patients with renal failure include determining the clearance of small doses (10 mL) of low osmolar contrast media and dynamic MRI with gadolinium DTPA. <br />&nbsp;&nbsp;\nThe nephrology literature contains several reports stressing the importance of preserving residual renal function (RRF) in patients on peritoneal dialysis or hemodialysis, who may require intravascular administration of contrast media for diagnostic purposes. The preservation of RRF, even after initiating dialysis, has been shown to result in better survival, electrolyte and fluid balance, nutritional status, and quality of life and has shown a decrease in morbidity and the need for fewer dialysis sessions (fewer or shorter dialysis sessions are cost effective). The recommendation is to continue to protect the RRF in patients on peritoneal dialysis or hemodialysis by balancing the risks versus benefits derived from using intravascular contrast media. It should be emphasized that if a patient is on temporary (on demand) dialysis, the use of such contrast media is usually withheld. The standard of practice is to administer intravascular contrast media to patients on permanent dialysis only when indicated. This is supported by evidence that no accelerated loss of RRF was observed after the administration of intravascular contrast media in peritoneal dialysis patients undergoing diagnostic studies. <br />&nbsp;&nbsp;\nRenal Biopsy<br />&nbsp;&nbsp;\nA percutaneous renal biopsy is used to diagnose renal dysfunction when pre- and postrenal causes have been excluded. It is essential in the diagnosis of glomerular, vascular, and tubulointerstitial diseases of the kidney. Indications for native renal biopsy include further evaluation of proteinuria, microscopic hematuria, renal manifestations of systemic disease, and unexplained renal failure. Biopsies are performed using real-time US guidance and a 16- or 18-gauge automated biopsy device. Specimens are obtained from the lower pole of the kidney with the biopsy device directed to traverse the renal cortex. Perinephric hemorrhage is the most common complication and is typically self-limited and subclinical. Gross hematuria has been reported to be as common as 5% to 7%, but in a series of 8,573 renal biopsies in adults it occurred in only 1.9% of patients. Other complications include pseudoaneurysm and arteriovenous fistula. Patients with increased serum creatinine are at an increased risk for bleeding complications. It has also been reported that an age >60 years, systolic blood pressure >160 mm Hg, and ARF can increase complication rates. <br />&nbsp;&nbsp;\n', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('410', '51', 'Y02_017', '0', '中医妇科常见病诊疗指南', null, '中华中医药学会', '2012', '中华中医药学会.ZYYXH/T203~246-2012，中医妇科常见病诊疗指南[S].北京：中国中医药出版社，2012.', '中文', '脾虚证；肾气虚证；肾阴虚证；肾阳虚证；虚热证；实热证；血瘀证；', null, '崩漏', '1脾虚证<br />&nbsp;&nbsp;经血非时暴下不止，或淋漓日久不尽，色淡，质稀；神疲乏力，气短懒言，面色白，倦怠嗜卧，小腹空坠，面浮肢肿，纳呆便溏；舌淡胖，边有齿痕，苔薄白，脉细弱或缓弱。<br />&nbsp;&nbsp;2肾气虚证<br />&nbsp;&nbsp;经血非时而下，量乡或淋漓日久不尽，色淡红或淡暗，质清稀；面色晦暗，目眶暗黑，腰膝酸软，头晕耳鸣，精神不振，小便频数；舌淡暗，苔白润，脉沉弱。<br />&nbsp;&nbsp;3肾阴虚证<br />&nbsp;&nbsp;经乱无期，量多或淋漓日久不尽，色鲜红，质稍稠；头晕耳鸣，五心烦热，腰膝酸痛，潮热颧红，夜寐不安；舌红，少苔，脉细数。<br />&nbsp;&nbsp;4肾阳虚证<br />&nbsp;&nbsp;经血非畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭치੣ༀƙ\0੣°\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అ੣°\0ఄ彿㎽奋㎽巫㎽溌అ躤అ彿㎽躘అ塚㎽躤అꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0치੣䐺盭暼痭치੣ༀƙ \0치੣\0\0㺣盭치੣\0𢡄친੣\0팃目친੣࣒친੣큁目친੣匰అ泌\0Item\0\0輨అ\0\0\0\0\0\0Count\0\0﫨呂캌੣㳜੪\0\0친੣\0\0\0\0੪寶目㳠੪楱䥷㎽溌అ\0\0輨అ�㏂躘అ\0\0\0੪\0\0\0露𢡄\0\0', '1诊断要点<br />&nbsp;&nbsp;1.1病史<br />&nbsp;&nbsp;详细了解发病时间、阴道出血类型、病程、出血前有无停经史。注意年龄、月经史、产育史、避孕措施、激素类药物使用史、七情内伤史、生活失度史及全身有无相关疾病史等。1.2症状<br />&nbsp;&nbsp;月经周期紊乱，出血时间长短不定，血量或多或少，行经时间超过半月以上，甚或数月不止，亦有停闭数月突然暴下不止或淋漓不尽者，可伴有不同程度贫血。<br />&nbsp;&nbsp;1.3体征<br />&nbsp;&nbsp;妇科检查无明显器质性病变。<br />&nbsp;&nbsp;1.4辅助检查<br />&nbsp;&nbsp;1.4.1诊断性刮宫<br />&nbsp;&nbsp;根据病情需要选做，以明确子宫内膜病理诊断。<br />&nbsp;&nbsp;畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭치੣ༀƙ\0੣°\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అ੣°\0ఄ彿㎽奋㎽巫㎽橔అᯀఅ彿㎽᮴అ塚㎽ᯀఅꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0치੣䐺盭暼痭치੣ༀƙ \0치੣\0\0㺣盭치੣\0𢡄친੣\0팃目친੣࣒친੣큁目친੣匰అ泌\0Item\0\0᱄అ\0\0\0\0\0\0Count\0\0﫨呂캌੣㳜੪\0\0친੣\0\0\0\0੪寶目㳠੪楱䥷㎽橔అ\0\0᱄అ�㏂᮴అ\0\0\0੪\0\0\0露𢡄\0\0㎾۠\0齃\0\0x�㏂᮴అ\0\0隲W᱄అ\0\0�Ĳ\0\0\0鹿齃殺\0\0霈W戀醙霫W戀ꊠऺ齃x\n\0霪W露Wꊠऺ﫰xt\0Љ\0\0\0൐௲鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0⑰ਫ਼⑰ਫ਼㲈੪到అ寶目㲈੪到అi\0\0變ﱘ﫰﬐먙㎼到అ㲈੪i\0\0變ﱘ﫰먰㎼ﱘ到అ�㏂冠అ\0\0릎㎼到అi\0⓮췬目⓲췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒൐௲竗൐௲目W\0竗\0\0\0目\0\0\0\0匰అ\0目瑉浥目\0\0\0\0匰అ\0目潃湵tƢ\0愢睉뮴ơࣴշ\0\0\0ઔշผշ,\0ဈշ\0\0慰睉ߐշ\0\0\0ೂᰁࣴշผշ,\0\0\0崹睊ೂᰁࣴշ\0\0㞍Qđ\0ᠠ৸,\0ผշ\0\0▪췬目Љ', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('411', '51', 'Y02_018', '0', '中医妇科常见病诊疗指南', null, '中华中医药学会', '2012', '中华中医药学会.ZYYXH/T203~246-2012，中医妇科常见病诊疗指南[S].北京：中国中医药出版社，2012.', '中文', '(一)1.原发性闭经；2.继发性闭经<br />&nbsp;&nbsp;（二）1.肾气亏损证；肝肾阴虚证；气血虚弱证；阴虚血燥证；痰湿阻滞证；寒凝血瘀证；', null, '闭经', '1  肾气亏损证<br />&nbsp;&nbsp;女子年逾16岁尚未行经，或月经初潮偏迟，时有月经停闭，或月经周期建立后，出现月经周期延后、经量减少渐至月经停阔；全身发育欠佳，第二性征发育不良，腰腿酸软，头晕耳鸣，倦怠乏力，夜尿频多，性欲淡漠，面色晦暗，眼眶暗黑；舌淡润，苔薄白，脉沉弱。<br />&nbsp;&nbsp;2肝肾阴虚证<br />&nbsp;&nbsp;经量减少，色鲜红，质黏稠，经期逐渐延后以致停闭不行；腰膝酸软，神疲倦怠，头晕耳鸣，两目干涩，面色少华；舌暗淡，苔薄白或薄黄，脉弦细而数或沉细无力。<br />&nbsp;&nbsp;3气血虚弱证<br />&nbsp;&nbsp;月经周期延迟，量少，色淡红，质稀薄，渐至经闭不畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭䢀ਕༀƙ\0ਕ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అਕ\0ఄ彿㎽奋㎽巫㎽溌అ躤అ彿㎽躘అ塚㎽躤అꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0䢀ਕ䐺盭暼痭䢀ਕༀƙ \0䢀ਕ\0\0㺣盭䢀ਕ\0𢡄䢄ਕ\0팃目䢄ਕ࣒䢄ਕ큁目䢄ਕ匰అ泌\0Item\0\0輨అ\0\0\0\0\0\0Count\0\0﫨呂䢴ਕ㳜੪\0\0䢄ਕ\0\0\0\0੪寶目㳠੪楱䥷㎽溌అ\0\0輨అ�㏂躘అ\0\0\0੪\0\0\0露𢡄\0\0㎾Ҏ\0齃\0\0x�㏂躘అ\0\0隲W輨అ\0\0�Ĳ\0\0\0鹿齃殺\0\0霈W戀', '1诊断要点<br />&nbsp;&nbsp;1.1病史<br />&nbsp;&nbsp;对于原发性闭经患者，应详细了解先天身体状况及后天生长发育过程中健康状况，有无严重慢性消耗性疾病、营养不良、甲状腺疾病、肾上腺疾病、结核病及家族遗传同类疾病等。<br />&nbsp;&nbsp;对于继发性闭经者，应询问闭经前的月经情况，是否服用避孕药物，或接触化学药物，有无精神过度刺激或生活环境改变，有无产后出血、多次流产、反复刮宫及放化疗等病史。<br />&nbsp;&nbsp;1.2症状<br />&nbsp;&nbsp;女子年逾16周岁月经尚未来潮，或已建立正常月经周期后又停经6个月以上，或停闭超过既往月经3个周期以上。<br />&nbsp;&nbsp;1.3体征$$$畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭䢀ਕༀƙ\0ਕ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అਕ\0ఄ彿㎽奋㎽巫㎽橔అᯀఅ彿㎽᮴అ塚㎽ᯀఅꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0䢀ਕ䐺盭暼痭䢀ਕༀƙ \0䢀ਕ\0\0㺣盭䢀ਕ\0𢡄䢄ਕ\0팃目䢄ਕ࣒䢄ਕ큁目䢄ਕ匰అ泌\0Item\0\0᱄అ\0\0\0\0\0\0Count\0\0﫨呂䢴ਕ㳜੪\0\0䢄ਕ\0\0\0\0੪寶目㳠੪楱䥷㎽橔అ\0\0᱄అ�㏂᮴అ\0\0\0੪\0\0\0露𢡄\0\0㎾ࢂ\0齃\0\0x�㏂᮴అ\0\0隲W᱄అ\0\0�Ĳ\0\0\0鹿齃殺\0\0霈W戀醙霫W戀ꊠऺ齃x\n\0霪W露Wꊠऺ﫰xt\0Љ\0\0\0൐௲鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0⑰ਫ਼⑰ਫ਼㲈੪到అ寶目㲈੪到అi\0\0變ﱘ﫰﬐먙㎼到అ㲈੪i\0\0變ﱘ﫰먰㎼ﱘ到అ�㏂冠అ\0\0릎㎼到అi\0⓮췬目⓲췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒൐௲竗൐௲目W\0竗\0\0\0目\0\0\0\0匰అ\0目瑉浥目\0\0\0\0匰అ\0目潃湵tƢ\0愢睉뮴ơࣴշ\0\0\0ઔշผշ,\0ဈշ\0\0慰睉ߐշ\0\0\0ೂᰁࣴշผշ,\0\0\0崹睊ೂᰁࣴշ\0\0㞍Qđ\0ᠠ৸,\0ผշ\0\0▪췬目Љ\0►췬目Љ\0╖췬╞췬目Љ\0鲸࣒\0￿￿目Љ\0鲬࣒൐௲觴൐௲目t\0觴\0\0\0梅礼目\0\0\0\0﫤到అ目潅f摲敳t盡옎盡㊊췭\0\0ࣾ}\0$\0\0\0\0\0\0p\0￿￿￿￿얠盡왑盡ೂᰁ\0\0\0\0\0翽捥盦Ȓ묞￾￿옎盡伛盡\0\0ɭդࣾ}đ\0ࣸ̀ࣸEꊌƩ伦盡㋪췭ꉸƩđ\0\0\0\0\0\0\0\0\0\0捥盦謺묞￾￿템瞕풒瞕(\0픔瞕\0⫠⫠픔', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('412', '51', 'Y02_019', '0', '中医妇科常见病诊疗指南', null, '中华中医药学会', '2012', '中华中医药学会.ZYYXH/T203~246-2012，中医妇科常见病诊疗指南[S].北京：中国中医药出版社，2012.', '中文', '肾阴虚证；湿热证；血瘀证；', null, '经间期出血', '1肾阴虚证<br />&nbsp;&nbsp;经间期出血，量少或稍多，色红无血块；头昏腰酸，夜寐不宁，便艰溲黄；舌质偏红，脉细数。<br />&nbsp;&nbsp;2湿热证<br />&nbsp;&nbsp;经间期出血，量稍多，色红质黏稠，或赤白带下，质黏腻，或有臭气；神疲乏力，周身酸楚，胸闷烦躁，纳食较差，小便短赤，少腹胀痛；舌质红，苔黄白厚腻，脉细弦数。<br />&nbsp;&nbsp;3血瘀证<br />&nbsp;&nbsp;经间期出血，量多少不一，色紫暗有血块；少腹胀痛或刺痛，胸闷烦躁，口渴不欲饮；舌质暗红，边有瘀点，脉细弦。<br />&nbsp;&nbsp;', '1诊断要点<br />&nbsp;&nbsp;1.1病史<br />&nbsp;&nbsp;月经不调史；手术流产史。<br />&nbsp;&nbsp;1.2症状<br />&nbsp;&nbsp;两次月经中间，出现规律的阴道出血，其量少于经量，出血持续数小时或2—3天，呈周期性发作。有的伴有明显的腰酸，少腹作胀作痛，带下增多，色白质黏如蛋清，或呈赤白带下。<br />&nbsp;&nbsp;1.3体征<br />&nbsp;&nbsp;妇科检查常无明显阳性体征，宫颈黏液透明呈拉丝状夹有血丝。<br />&nbsp;&nbsp;1.4辅助检查<br />&nbsp;&nbsp;1.4.1  BBT测定<br />&nbsp;&nbsp;多见低、高相交替时出血。<br />&nbsp;&nbsp;1.4.2生殖内分泌激素测定<br />&nbsp;&nbsp;月经中期血清E2、P测定水平偏低。<br />&nbsp;&nbsp;1.4.畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭턀ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అਘĀ\0ఄ彿㎽奋㎽巫㎽橔అᯀఅ彿㎽᮴అ塚㎽ᯀఅꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0치੣䐺盭暼痭치੣ༀƙ \0치੣\0\0㺣盭치੣\0𢡄친੣', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('413', '51', 'Y02_020', '0', '中医妇科常见病诊疗指南', null, '中华中医药学会', '2012', '中华中医药学会.ZYYXH/T203~246-2012，中医妇科常见病诊疗指南[S].北京：中国中医药出版社，2012.', '中文', '气虚证；阴虚血热证；湿热蕴结证；血瘀证；', null, '经期延长', '1气虚证<br />&nbsp;&nbsp;行经时间延长，量多，色淡，质清稀；神倦嗜卧，气短懒言，肢软无力，小腹空坠，头昏眼花，面色白，纳少便溏，心悸少寐；舌质偏淡，苔薄白，脉缓弱。<br />&nbsp;&nbsp;2阴虚血热证<br />&nbsp;&nbsp;行经时间延长，量少，色鲜红，质稍稠；咽干口燥，手心灼热，潮热颧红，大便燥结；舌质红，少津少苔，脉细数。<br />&nbsp;&nbsp;3湿热蕴结证<br />&nbsp;&nbsp;行经时间延长，量多，色深红，混杂黏液，阴中灼热，或伴有阴痒，平素带下量多，色黄臭秽；腰腹胀痛，四肢沉重，全身乏力；舌质偏红，苔黄腻，脉滑数。<br />&nbsp;&nbsp;4血瘀证<br />&nbsp;&nbsp;月经淋漓延期不净，经量时多时少，色畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭턀ਘༀƙ\0ਘĀ\0\0㺣盭\0\0', '1  诊断要点<br />&nbsp;&nbsp;1.1病史<br />&nbsp;&nbsp;饮食、起居、情志失调史；盆腔炎性疾病史；官内节育器避孕史。<br />&nbsp;&nbsp;1.2症状<br />&nbsp;&nbsp;行经时间超过7天，甚至淋漓2周；月经周期正常，或伴有经量增多。<br />&nbsp;&nbsp;1.3体征<br />&nbsp;&nbsp;妇科检查功能失调性子宫出血者盆腔多无明显器质性病变。盆腔炎性疾病引起者，子宫等可有触痛。<br />&nbsp;&nbsp;1.4辅助检查<br />&nbsp;&nbsp;1.4.1   BBT测定<br />&nbsp;&nbsp;BBT呈双相型，但下降缓慢。<br />&nbsp;&nbsp;1.4.2 B型超声检查<br />&nbsp;&nbsp;了解子宫有无器质性病变。<br />&nbsp;&nbsp;1.4.3诊断性刮宫<br />&nbsp;&nbsp;功能失调性子宫出血畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭턀ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అਘĀ\0ఄ彿㎽奋㎽巫㎽橔అᯀఅ彿㎽᮴అ塚㎽ᯀఅꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞㎽\0\0圭㎽𢡄', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('414', '51', 'Y02_021', '0', '中医妇科常见病诊疗指南', null, '中华中医药学会', '2012', '中华中医药学会.ZYYXH/T203~246-2012，中医妇科常见病诊疗指南[S].北京：中国中医药出版社，2012.', '中文', '气滞血瘀质证；寒凝血瘀证；湿热瘀阻证；气血虚弱证；肝肾亏损证；', null, '痛经', '1气滞血瘀证<br />&nbsp;&nbsp;经前或经期小腹胀痛拒按，经行不畅，色紫暗，有血块，块下痛减；经前乳房胀痛；舌暗红或有瘀点、瘀斑，苔薄白，脉弦。<br />&nbsp;&nbsp;2寒凝血瘀证<br />&nbsp;&nbsp;经前或经期小腹冷痛，得热痛减，色暗，有血块；平素带下量多，质清稀，畏寒肢冷；舌暗或有瘀点、瘀斑，苔白或腻，脉沉紧。<br />&nbsp;&nbsp;3湿热瘀阻证<br />&nbsp;&nbsp;经前或经期小腹疼痛或胀痛拒按，有灼热感，或痛连腰骶，色暗红，质稠，或夹较多黏液；平素带下量多，色黄，质稠，有味，或低热起伏，小便黄赤；舌红，苔黄腻，脉弦数或滑数。<br />&nbsp;&nbsp;4气血虚弱证<br />&nbsp;&nbsp;经期或经后小腹隐隐坠畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭턀ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అਘĀ\0ఄ彿㎽奋㎽巫㎽溌అ躤అ彿㎽躘అ塚㎽躤అꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞', '1诊断要点<br />&nbsp;&nbsp;1.1症状<br />&nbsp;&nbsp;原发性痛经多见于青春期少女，初潮后1~2年内发病。继发性痛经多见于育龄期妇女。<br />&nbsp;&nbsp;正值经期或经期前后7天内下腹疼痛明显，以致影响正常工作、生活。疼痛多呈阵发性、痉挛性，或呈胀痛或伴下坠感。疼痛常可放射至腰骶部、肛门、阴道及大腿内侧。痛甚者可伴面色苍白，出冷汗，手足发凉，恶心呕吐，甚至昏厥等。<br />&nbsp;&nbsp;疼痛程度的判定方法：视觉模拟标度尺（VAS法）。<br />&nbsp;&nbsp;用0– 100mm的刻度尺，量化患者的主观疼痛程度，VAS指数0mm代表无痛，10mm代表无法忍受的剧痛。VAS指畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭턀ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అਘĀ\0ఄ彿㎽奋㎽巫㎽橔అᯀఅ彿㎽᮴అ塚㎽ᯀఅꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0턀ਘ䐺盭暼痭턀ਘༀƙ \0턀ਘ\0\0㺣盭턀ਘ\0𢡄턄ਘ\0팃目턄ਘ࣒턄ਘ큁目턄ਘ匰అ泌\0Item\0\0᱄అ\0\0\0\0\0\0Count\0\0﫨呂턴ਘ㳜੪\0\0턄ਘ\0\0\0\0੪寶目㳠੪楱䥷㎽橔అ\0\0᱄అ�㏂᮴అ\0\0\0੪\0\0\0露𢡄\0\0㎾؈\0齃\0\0x�㏂᮴అ\0\0隲W᱄అ\0\0�Ĳ\0\0\0鹿齃殺\0\0霈W戀醙霫W戀ꊠऺ齃x\n\0霪W露Wꊠऺ﫰xt\0Љ\0\0\0൐௲鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0⑰ਫ਼⑰ਫ਼㲈੪到అ寶目㲈੪到అi\0\0變ﱘ﫰﬐먙㎼到అ㲈੪i\0\0變ﱘ﫰먰㎼ﱘ到అ�㏂冠అ\0\0릎㎼到అi\0⓮췬目⓲췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒൐௲竗൐௲目W\0竗\0\0\0目', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('415', '51', 'Y02_022', '0', '中医妇科常见病诊疗指南', null, '中华中医药学会', '2012', '中华中医药学会.ZYYXH/T203~246-2012，中医妇科常见病诊疗指南[S].北京：中国中医药出版社，2012.', '中文', '1.气虚证；<br />&nbsp;&nbsp;2.血热证；<br />&nbsp;&nbsp;2.1实热证；<br />&nbsp;&nbsp;2.2虚热证；<br />&nbsp;&nbsp;3.血瘀证；<br />&nbsp;&nbsp;\n', null, '月经过多', '1气虚证<br />&nbsp;&nbsp;月经量多，色淡红，质清稀；面色白，气短懒言，肢软无力，精神倦怠，小腹空坠，动则汗出，食少腹胀；舌质淡，苔薄白，脉细弱。<br />&nbsp;&nbsp;2血热证<br />&nbsp;&nbsp;2.1实热证<br />&nbsp;&nbsp;经来甚多，色深红，质黏稠；口渴，心烦，面赤唇干，小溲短黄，大便燥结；舌红，苔黄，脉滑数。<br />&nbsp;&nbsp;2.2虚热证<br />&nbsp;&nbsp;经行量多，色鲜红，质稍稠；颧红，潮热，咽干口燥，盗汗，腰膝酸软，心烦不寐，小便短赤；舌质红，少苔，脉细数。<br />&nbsp;&nbsp;3血瘀证<br />&nbsp;&nbsp;经行量多，色紫黑，有血块，经行不畅，小腹疼痛拒按，血块排出后疼痛减轻；可无明显全身症状畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭치੣ༀƙ\0੣°\0\0', '1诊断要点<br />&nbsp;&nbsp;1.1病史<br />&nbsp;&nbsp;大病久病、精神刺激、饮食不节史；经期、产后感邪或不禁房事史；宫内节育器避孕史。<br />&nbsp;&nbsp;1.2症状<br />&nbsp;&nbsp;月经量明显增多，周期、经期正常。<br />&nbsp;&nbsp;1.3体征<br />&nbsp;&nbsp;妇科检查多无明显器质性病变。<br />&nbsp;&nbsp;1.4辅助检查<br />&nbsp;&nbsp;1.4.1 B型超声检查<br />&nbsp;&nbsp;排除子宫器质性病变。<br />&nbsp;&nbsp;1.4.2官腔镜检查<br />&nbsp;&nbsp;了解子宫内膜情况，排除子宫器质性病变。<br />&nbsp;&nbsp;1.4.3诊断性刮宫<br />&nbsp;&nbsp;了解子宫内膜情况。<br />&nbsp;&nbsp;1.4.4血液学检查<br />&nbsp;&nbsp;排除凝血功能障碍。<br />&nbsp;&nbsp;2鉴别诊断$畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭치੣ༀƙ\0੣°\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('416', '51', 'Y02_023', '0', '中医妇科常见病诊疗指南', null, '中华中医药学会', '2012', '中华中医药学会.ZYYXH/T203~246-2012，中医妇科常见病诊疗指南[S].北京：中国中医药出版社，2012.', '中文', '肾虚证；血虚证；血瘀证；痰湿证；', null, '月经过少', '1肾虚证<br />&nbsp;&nbsp;经量渐少，甚至点滴即净，色淡暗，质稀薄；面色晦暗或有暗斑，头晕耳鸣，腰膝酸软，小便频数；舌淡，苔薄，脉沉弱。<br />&nbsp;&nbsp;2血虚证<br />&nbsp;&nbsp;月经量少，色淡，质稀；面色萎黄，皮肤不润，头晕眼花，心悸失眠，小腹绵绵作痛；舌质淡，苔薄白，脉细无力。<br />&nbsp;&nbsp;3血瘀证<br />&nbsp;&nbsp;月经量少，色紫暗，夹有血块；小腹刺痛拒按，血块排出腹痛减轻，胸胁胀痛；舌紫暗，有瘀点或瘀斑，脉弦涩。<br />&nbsp;&nbsp;4痰湿证<br />&nbsp;&nbsp;月经量少，质黏稠；平素带下量多，色白质稠，形体肥胖，胸脘满闷，呕恶痰多；舌淡胖，苔白腻，脉滑。<br />&nbsp;&nbsp;', '1诊断要点<br />&nbsp;&nbsp;1.1病史<br />&nbsp;&nbsp;口服避孕药史；人工或药物流产史；宫内节育器的取放史；宫腔内冷冻、电凝术史；工作压力大或精神过度紧张；结核病及与其患者接触史等。<br />&nbsp;&nbsp;1.2症状<br />&nbsp;&nbsp;月经周期正常，月经量较常量明显减少；行经时间缩短，甚至点滴即净。<br />&nbsp;&nbsp;1.3体征<br />&nbsp;&nbsp;妇科检查  了解子宫大小及排除妊娠等。<br />&nbsp;&nbsp;1.4辅助检查<br />&nbsp;&nbsp;1.4.1 BBT测定<br />&nbsp;&nbsp;了解卵巢功能。<br />&nbsp;&nbsp;1.4.2  B型超声检查<br />&nbsp;&nbsp;了解子宫情况。<br />&nbsp;&nbsp;1.4.3 生殖内分泌激素测定<br />&nbsp;&nbsp;测定血清E2、P、畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭䢀ਕༀƙ\0ਕ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అਕ\0ఄ彿㎽奋㎽巫㎽橔అᯀఅ彿㎽᮴అ塚㎽ᯀఅꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0턀ਘ䐺盭暼痭턀ਘༀƙ \0턀ਘ\0\0㺣盭턀ਘ\0𢡄턄ਘ\0팃目턄ਘ࣒턄ਘ큁目턄ਘ匰అ泌\0Item\0\0᱄అ\0\0\0\0\0\0Coun', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('417', '51', 'Y02_024', '0', '中医妇科常见病诊疗指南', null, '中华中医药学会', '2012', '中华中医药学会.ZYYXH/T203~246-2012，中医妇科常见病诊疗指南[S].北京：中国中医药出版社，2012.', '中文', '1肾虚证；<br />&nbsp;&nbsp;2血虚证；<br />&nbsp;&nbsp;3血寒证；<br />&nbsp;&nbsp;3.1虚寒证；<br />&nbsp;&nbsp;3.2实寒证；<br />&nbsp;&nbsp;4痰湿证；<br />&nbsp;&nbsp;5气滞证；<br />&nbsp;&nbsp;', null, '月经后期', '1肾虚证<br />&nbsp;&nbsp;月经周期延后，量少，色淡暗，质清稀；面色晦暗或有暗斑，头晕耳鸣，腰膝酸软，夜尿频多；舌淡暗，苔薄白，脉沉细。<br />&nbsp;&nbsp;2血虚证<br />&nbsp;&nbsp;月经周期延后，量少，色淡红，质稀；面色苍白或萎黄，头晕眼花，心悸失眠，小腹绵绵作痛；舌淡红，苔薄，脉细弱。<br />&nbsp;&nbsp;3血寒证<br />&nbsp;&nbsp;3.1虚寒证<br />&nbsp;&nbsp;月经周期延后，量少，色淡，质清稀；小腹冷痛，喜暖喜按，腰酸无力，小便清长，大便溏薄；舌淡，苔白，脉沉迟无力。<br />&nbsp;&nbsp;3.2实寒证<br />&nbsp;&nbsp;月经周期延后，量少，色暗黑，夹有血块；小腹冷痛拒按，畏寒肢冷；舌暗，苔白，脉畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭䢀ਕༀƙ\0ਕ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అਕ\0ఄ彿㎽奋㎽巫㎽溌అ躤అ彿㎽躘అ塚㎽躤అꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞㎽', '1.诊断要点<br />&nbsp;&nbsp;1.1病史<br />&nbsp;&nbsp;先天禀赋不足；工作压力较大或精神过度紧张；人工或药物流产史；减肥史；感寒饮冷等。<br />&nbsp;&nbsp;1.2症状<br />&nbsp;&nbsp;月经周期延后7天以上，甚至3~5个月一行，周期延后连续出现2个周期以上。<br />&nbsp;&nbsp;1.3体征<br />&nbsp;&nbsp;妇科检查了解子宫大小及排除妊娠等。<br />&nbsp;&nbsp;1.4辅助检查<br />&nbsp;&nbsp;1.4.1 BBT测定<br />&nbsp;&nbsp;了解卵巢功能。<br />&nbsp;&nbsp;1.4.2  B型超声检查<br />&nbsp;&nbsp;了解子宫情况。<br />&nbsp;&nbsp;1.4.3生殖内分泌激素测定<br />&nbsp;&nbsp;测定血清E2、P、卵泡刺激素(FSH)、黄体生成激素(LH)畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭䢀ਕༀƙ\0ਕ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అਕ\0ఄ彿㎽奋㎽巫㎽橔అᯀఅ彿㎽᮴అ塚㎽ᯀఅꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0䢀ਕ䐺盭暼痭䢀ਕༀƙ \0䢀ਕ\0\0㺣盭䢀ਕ\0𢡄䢄ਕ\0팃目', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('418', '51', 'Y02_025', '0', '中医妇科常见病诊疗指南', null, '中华中医药学会', '2012', '中华中医药学会.ZYYXH/T203~246-2012，中医妇科常见病诊疗指南[S].北京：中国中医药出版社，2012.', '中文', '脾气虚证；肾气虚证；阴虚血热证；肝郁血热证；阳盛血热证；', null, '月经先期', '1脾气虚证<br />&nbsp;&nbsp;月经周期提前，经量或多或少，色淡红，质清稀；神疲乏力，面色萎黄，气短懒言，倦怠嗜卧，小腹空坠，纳少便溏，语声低微，脘闷腹胀；舌淡胖，边有齿痕，苔薄白，脉缓弱。<br />&nbsp;&nbsp;2肾气虚证<br />&nbsp;&nbsp;月经周期提前，量或多或少，色淡暗，质清稀；腰膝酸软，头晕耳鸣，面色晦暗或有暗斑，精神不振，夜尿频多，小便清长；舌淡暗，苔薄白，脉沉细。<br />&nbsp;&nbsp;3阴虚血热证<br />&nbsp;&nbsp;月经周期提前，量少，色鲜红，质稠；手足心热，咽干口燥，两颧潮红，潮热盗汗，心烦不寐，口舌糜烂；舌质红，少苔，脉细数。<br />&nbsp;&nbsp;4肝郁血热证<br />&nbsp;&nbsp;月畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭치੣ༀƙ\0੣°\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అ੣°\0ఄ彿㎽奋㎽巫㎽溌అ躤అ彿㎽躘అ塚㎽躤అꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞㎽\0\0圭㎽𢡄霪Wༀƙ ', '1诊断要点<br />&nbsp;&nbsp;1.1症状<br />&nbsp;&nbsp;月经周期提前l~2周，连续出现2个月经周期以上，经期基本正常。<br />&nbsp;&nbsp;1.2体征<br />&nbsp;&nbsp;妇科检查盆腔无明显器质性病变。<br />&nbsp;&nbsp;1.3辅助检查<br />&nbsp;&nbsp;1.3.1基础体温BBT测定<br />&nbsp;&nbsp;黄体功能不足者，BBT呈双相型，但黄体期少于11天，或排卵后体温上升缓慢，上升幅度<0.3℃。<br />&nbsp;&nbsp;1.3.2诊断性刮宫<br />&nbsp;&nbsp;经前或月经来潮6小时内诊刮，子宫内膜病理检查呈分泌反应不良。<br />&nbsp;&nbsp;1.3.3生殖内分泌激素测定<br />&nbsp;&nbsp;测定血清雌二醇(E2)、孕酮(P)，以了解卵巢功能。$$畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭치੣ༀƙ\0੣°\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అ੣°\0ఄ彿㎽奋㎽巫㎽橔అᯀఅ彿㎽᮴అ塚㎽ᯀఅꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0턀ਘ䐺盭暼痭턀ਘༀƙ \0턀ਘ\0\0㺣盭턀ਘ\0𢡄턄ਘ\0팃目턄ਘ࣒턄ਘ큁目턄ਘ匰అ泌\0I', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('419', '51', 'Y02_026', '0', '中医妇科常见病诊疗指南', null, '中华中医药学会', '2012', '中华中医药学会.ZYYXH/T203~246-2012，中医妇科常见病诊疗指南[S].北京：中国中医药出版社，2012.', '中文', '肾虚证；肝郁证；', null, '月经先后不定期', '1肾虚证<br />&nbsp;&nbsp;周经周期先后不定，量少，色淡暗，质清稀；头晕耳鸣，腰膝酸软，小便清长，夜尿频多；舌淡，苔白，脉沉细。<br />&nbsp;&nbsp;2肝郁证<br />&nbsp;&nbsp;月经周期先后不定，经量或多或少，色暗红，有块，经行不畅；胸胁、乳房、少腹胀痛，脘闷不舒，时欲叹息；舌质正常，苔薄白或薄黄，脉弦。<br />&nbsp;&nbsp;', '1诊断要点<br />&nbsp;&nbsp;1.1病史<br />&nbsp;&nbsp;七情内伤史；房劳多产史。<br />&nbsp;&nbsp;1.2症状<br />&nbsp;&nbsp;月经周期提前或延后1-2周，经期、经量正常，连续出现3个周期以上。<br />&nbsp;&nbsp;1.3体征<br />&nbsp;&nbsp;妇科检查  了解子宫大小及排除妊娠等。<br />&nbsp;&nbsp;1.4辅助检查<br />&nbsp;&nbsp;1.4.1  BBT测定<br />&nbsp;&nbsp;了解卵巢功能。<br />&nbsp;&nbsp;1.4.2   B型超声检查<br />&nbsp;&nbsp;排除子宫器质性病变。<br />&nbsp;&nbsp;1.4.3生殖内分泌激素测定<br />&nbsp;&nbsp;测定血清E2.P、FSH、LH、PRL、T，以了解生殖内分泌功能。<br />&nbsp;&nbsp;1.4.4妊娠试验<br />&nbsp;&nbsp;排除妊娠。畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭치੣ༀƙ\0੣°\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అ੣°\0ఄ彿㎽奋㎽巫㎽橔అᯀఅ彿㎽᮴అ塚㎽ᯀఅꍈ㏂\0\0勼అ', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('42', '34', 'M03_006', '1', 'ACR肾功能衰竭适当性标准', 'ACR Appropriateness Criteria renal failure. ', '美国放射学会(ACR,American College of Radiology)', '2008', 'Remer EM, Papanicolaou N, Casalino DD, Bishoff JT, Blaufox MD, Coursey CA, Dighe M, Eberhardt SC, Goldfarb S, Harvin HJ, Heilbrun ME, Leyendecker JR, Nikolaidis P, Oto A, Preminger GM, Raman SS, Sheth S, Vikram R, Weinfeld RM, Expert Panel on Urologic Imaging. ACR Appropriateness Criteria® renal failure. [online publication]. Reston (VA): American College of Radiology (ACR); 2013. 12 p. $$$$\nhttp://www.guideline.gov/content.aspx?id=47681&search=urolithiasis', '英文', null, '急性肾衰（Acute Kidney Injury）', null, null, '急性肾衰<br />&nbsp;&nbsp;AKI可以广义地定义为肾功能突然下降，导致氮质血症。AKI的定义仍有争论。最近的一个共识认为突变（48小时内）肾功能降低，目前定义为血清肌酐大于0.3 mg/dL的绝对增长（> 25μM / L），尿量增加或减少50%（记录少尿＜0.5毫升/公斤/小时> 6 h），构成AKI（看到AKI的标准和阶段的原始文件附录1）。它可以发展于预先存在的肾功能不全，或以前正常的肾脏的病人。<br />&nbsp;&nbsp;\nAcute Kidney Injury<br />&nbsp;&nbsp;\nAKI can be broadly defined as a sudden decrease in renal function resulting in azotemia. The definition of AKI is still under some debate. A recent consensus considers an abrupt (within 48 h) reduction in kidney function, currently defined as an absolute increase in serum creatinine >0.3 mg/dL (>25 μM/L), and a 50% increase or reduction in urine output (documented oliguria <0.5 mL/kg/h for >6 h) to constitute AKI (see Appendix 1 in the original guideline document for criteria and stages of AKI). It can develop in the setting of pre-existing renal insufficiency or can develop in a patient with previously normal kidneys.<br />&nbsp;&nbsp;\nOver 75% of patients with AKI will have either prerenal azotemia (PRA) or ATN (a parenchymal, intrarenal process) as the cause. Prerenal causes of AKI relate to hypoperfusion or hypovolemia. A clinical suspicion of AKI usually leads to a fluid challenge with central monitoring and correction of the hypovolemic state, which corrects the renal failure. A common exception to this approach is the patient with heart failure or liver failure. A high ratio of blood urea nitrogen to creatinine has long been considered a marker of PRA. In addition, a characteristic laboratory finding in PRA is avid sodium retention, with a urine sodium concentration <20 mEq/L. A meta-analysis of various laboratory studies in an attempt to differentiate PRA from ATN revealed that most determinations (urine/plasma creatinine index, urine/plasma urea, or urinary sodium) are often nonspecific or unreliable. Still, most experienced clinicians find that when urine output is <500 mL for 24 hours, a determination of urinary fractional excretion of sodium is helpful. .<br />&nbsp;&nbsp;\nIn a patient with previously undiagnosed renal failure, the most helpful initial diagnostic test is to evaluate renal size using grayscale ultrasonography (US). If the kidneys are small and echogenic, the process is long-standing and unlikely to improve. Renal size is commonly determined from a measurement of renal length. Renal volume calculated by US provides a better measure of functioning renal parenchyma; however, it is an imperfect measure because it includes the renal central sinus fat. In patients with C RF, the renal cortical thickness measured by US appears to be more closely related to the estimated glomerular filtration rate (eGFR) than renal length. .<br />&nbsp;&nbsp;\nSometimes, evaluation by US helps to identify a correctable cause of renal failure, such as obstruction, which is a postrenal cause of AKI. However, a number of studies have evaluated the use of US in the setting of acute renal insufficiency and have found it is generally unnecessary to exclude an obstruction unless 1) there is a clinical history that strongly supports an obstruction, such as flank pain, urolithiasis, or pelvic mass; 2) the patient is deemed at high risk for obstruction; or 3) if specific clinical factors stratify the patient into a high-risk group. This applies irrespective of whether the patient requires treatment in an intensive care setting. If hydronephrosis is present, retrograde or antegrade relief of the obstruction is usually performed. If there is no hydronephrosis and the patient does not have hypertension or other history to suggest RAS, then further workup of the small, echogenic kidneys is not warranted. .<br />&nbsp;&nbsp;\nObstruction may occur in the oncologic patient, the trauma patient, or the patient with a solitary kidney. Bilateral, obstructing ureteral calculi are rare. More often in the older male patient, a bilateral ureteral obstruction may occur in a chronic bladder outlet obstruction by an enlarged prostate. In such cases, the patient may appear to be suffering from new onset renal failure; however, the deterioration in renal function has been ongoing but has remained clinically occult. Grayscale US is the most effective way to exclude a subacute or chronic obstruction. Regular grayscale US is not accurate in the minimally dilated obstructive situation, such as with retroperitoneal metastatic tumor or idiopathic retroperitoneal fibrosis, in which the ureter encasement interferes with peristalsis; in 1 series, 4% to 5% of patients with an obstruction showed minimal or no upper-tract dilation. .<br />&nbsp;&nbsp;\nColor Doppler US of the bladder can assist in detecting a urinary obstruction. Ureteral jets are streams of urine entering the bladder that can be detected with color Doppler US. .<br />&nbsp;&nbsp;\nThe unilateral absence of a renal jet after 10 minutes of observation has an approximately 90% positive predictive value for a complete obstruction. The bilateral absence of ureteral jets, however, is a normal finding. Also, in a partial obstruction, the ureteral jets can still be seen; a continuous low-level jet on the partially obstructed side is common. .<br />&nbsp;&nbsp;\nThe patient with an obstructed renal transplant can present with acute failure. One study found an elevated resistive index (RI) in 85% of transplanted kidneys with obstruction; a normal RI should argue strongly against an obstruction, unless a ureteral leak is also present. In addition to obstruction, an elevated RI can also be found in rejection and ATN; therefore, RI measurements are not reliable in the differential diagnosis of these entities. If US cannot determine the cause of the obstruction, MRI or nonenhanced CT can be obtained (retroperitoneal mass, lymphadenopathy, fibrosis, calculi, etc.). .<br />&nbsp;&nbsp;\nRAS and thrombosis are prerenal causes of AKI, but they are uncommon. The multicenter Program to Improve Care in Acute Renal Disease Study found that renal artery thrombosis, stenosis, or trauma accounted for 1% of the causes of AKI in 618 critically ill patients. US can provide a measure of renal perfusion. Some have suggested that duplex Doppler US can supplant radionuclide scintigraphy, magnetic resonance angiography (MRA), or contrast angiography in evaluating the renal arteries; however, these results have not been reproduced in many centers. Newer MRA techniques offer improved images of the main and segmental renal arteries. .<br />&nbsp;&nbsp;\nMRI can also provide direct assessment of renal blood flow. Patients with normal or mildly decreased renal function may undergo contrast-enhanced MRA. However, if there is a risk for nephrogenic systemic fibrosis (NSF) among patients with reduced renal reserves, effective nonenhanced MRA techniques for evaluating the renal arteries are also available (e.g., steady-state free precession using inflow inversion recovery or 3-D phase contrast). One caveat for patients with AKI is that eGFR or creatinine levels are unreliable when non–steady-state conditions exist. An MRI with contrast should be pursued with caution in any patient with AKI until it is clear that the kidney function is stable. .<br />&nbsp;&nbsp;\nBilateral renal vein thrombosis is another vascular cause of AKI that can be diagnosed using Doppler US or MRI with vascular imaging techniques. However, it, too, is an uncommon cause of AKI; no cases were found in 748 AKI episodes in a prospective, multicenter epidemiological study from Spain. Trauma presents a unique constellation of possible causes of AKI, such as renal artery occlusion, severe kidney trauma, and renal vein thrombosis occurring bilaterally or in a solitary kidney. Renal trauma is more fully addressed as a separate topic (see the National Guideline C learinghouse [NGC ] summary AC R Appropriateness C riteria® renal trauma.) .<br />&nbsp;&nbsp;\nIf the kidneys are of normal size on the initial US examination, with or without increased echogenicity, this may represent reversible renal failure, most often AKI. A number of publications from the late 1980s and early 1990s suggested the potential of Doppler US to improve the assessment of renal intrinsic dysfunction. C hanges in intrarenal arterial waveforms were shown to be associated with urinary obstruction, several intrinsic renal disorders, and renal vascular disease. One example is the use of Doppler imaging to distinguish acute prerenal failure from ATN (intrarenal failure). Unlike traditional grayscale US, which shows normal kidneys in most patients with ATN, duplex Doppler US shows an elevated RI ([peak systolic velocity – end diastolic velocity]/peak systolic velocity], abnormal >0.7) in 96% of patients with ATN. However, false-negative examinations can occur with nephrotoxic drug-induced ATN. Also, ATN has a higher RI than prerenal ARF, but there is some overlap as 20% of patients with prerenal ARF had resistive indexes >0.75. These inconsistent findings and discouraging clinical experiences prompted most radiologists to abandon the RI, and renal biopsy remains important for evaluating intrinsic renal dysfunction. .<br />&nbsp;&nbsp;\nNephrotoxic drugs and ATN following prolonged shock, with the precipitation of hemoglobin and/or myoglobin in the tubules, are other causes of AKI that may lead to abnormal C T findings.\nIf prerenal and postrenal causes of AKI have been excluded, then an intrarenal cause is likely. Radionuclide scintigraphy with technetium (Tc)-labeled mercaptoacetyltriglycine (MAG3) has been studied in this setting, but it is currently not commonly performed. A progressive parenchymal accumulation without significant excretion is suggestive of ATN. .<br />&nbsp;&nbsp;\nAn absent uptake suggests more serious conditions, such as acute cortical necrosis and acute glomerulonephritis. In AKI, GFR is more affected than renal blood flow; hence, Tc-99m diethylene-triamine-penta-acetic acid (DTPA) accumulation is decreased, and this agent is less able to distinguish acute from chronic renal disease. However, quantitative studies with the renal tubular agents, such as Tc-99m MAG3, can be used. These methods assess the effective renal plasma flow (ERPF) and the degree of renal function, and they also have prognostic significance. Patients with an ERPF >125 mL/min and good uptake usually recover completely or improve markedly. ATN, hepatorenal syndrome, and acute interstitial nephritis belong in the category of good prognosis. Patients with low uptake have a poor prognosis and eventually require dialysis or transplantation. .<br />&nbsp;&nbsp;\nCT is used to evaluate the trauma patient and supplement technically unsatisfactory or equivocal US findings. Excretory urography has no role in investigating AKI.<br />&nbsp;&nbsp;\nRenal Biopsy<br />&nbsp;&nbsp;\nA percutaneous renal biopsy is used to diagnose renal dysfunction when pre- and postrenal causes have been excluded. It is essential in the diagnosis of glomerular, vascular, and tubulointerstitial diseases of the kidney. Indications for native renal biopsy include further evaluation of proteinuria, microscopic hematuria, renal manifestations of systemic disease, and unexplained renal failure. Biopsies are performed using real-time US guidance and a 16- or 18-gauge automated biopsy device. Specimens are obtained from the lower pole of the kidney with the biopsy device directed to traverse the renal cortex. Perinephric hemorrhage is the most common complication and is typically self-limited and subclinical. Gross hematuria has been reported to be as common as 5% to 7%, but in a series of 8,573 renal biopsies in adults it occurred in only 1.9% of patients. Other complications include pseudoaneurysm and arteriovenous fistula. Patients with increased serum creatinine are at an increased risk for bleeding complications. It has also been reported that an age >60 years, systolic blood pressure >160 mm Hg, and ARF can increase complication rates. <br />&nbsp;&nbsp;\n\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('420', '51', 'Y02_027', '1', '异常子宫出血管理指南', 'GUIDELINES FOR THE MANAGEMENT OF ABNORMAL UTERINE BLEEDING', '加拿大妇产科医生协会(SOGC,Society of Obstetricians and Gynaecologists of Canada)', '2001', 'http://sogc.org/wp-content/uploads/2013/01/106E-CPG-August2001.pdf', '英文', null, '异常子宫出血', null, null, null, null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('421', '51', 'Y02_028', '1', '绝经期前异常子宫出血', 'Abnormal Uterine Bleeding in Pre-menopausal Women', '加拿大妇产科医生协会(SOGC,Society of Obstetricians and Gynaecologists of Canada)', '2013', 'http://sogc.org/wp-content/uploads/2013/07/gui292CPG1305E.pdf', '英文', null, '异常子宫出血', null, null, null, null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('422', '51', 'Y02_029', '1', '异常子宫出血诊断与治疗指南', null, '中华医学会妇产科学分会内分泌学组', '2014', '中华妇产科杂志，2014，49（11）:801-806', '中文', '子宫内膜息肉(polyp)所致AUB(简称：AUB-P)；<br />&nbsp;&nbsp;子宫腺肌病(adenomyosis)所致AUB(简称：AUB-A)；<br />&nbsp;&nbsp;子宫平滑肌瘤(1eiomyoma)所致AUB(简称：AUB-L)；<br />&nbsp;&nbsp;子宫内膜恶变和不典型增生(malignancy and hyperplasia)所致AUB(简称：AUB-M)； <br />&nbsp;&nbsp;全身凝血相关疾病(coagulopathy)所致AUB(简称：AUB-C)；<br />&nbsp;&nbsp;排卵障碍(ovulatory dysfunction)相关的AUB(简称：AUB-O)；畻坴畿\0\0\0\0醼畻聱盯	\0\0\0痭媈ఉༀƙ\0ఉĀ\0	\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అఉĀ\0ఄ彿㎽奋㎽巫㎽核అᬄఅ彿㎽᫸అ塚㎽ᬄఅꍈ㏂\0\0勼అ學㎽漸', '异常子宫出血', null, null, '一、AUB病因诊断流程<br />&nbsp;&nbsp;对AUB(即月经失调)患者，首先要通过详细询问月经改变的历史，确认其特异的出血模式，也就是患者就诊的主要问题(即主诉)。应注意询问性生活情况和避孕措施以除外妊娠或产褥期相关的出血(必要时测定血HCG水平)，应注意区别酷似正常月经的出血和异常出血，并以近1～3次出血的具体日期进行核对，重点关注的应是自然月经而非药物诱发的人工月经。<br />&nbsp;&nbsp;初诊时全身检查及妇科检查不可或缺，可及时发现相关体征，如性征、身高、泌乳、体质量、体毛、腹部包块等，有助于确定出血来源，排除子宫颈、阴道病变，畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭媈ఉༀƙ\0ఉĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అఉĀ\0ఄ彿㎽奋㎽巫㎽橔అᯀఅ彿㎽᮴అ塚㎽ᯀఅꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0媈ఉ䐺盭暼痭媈ఉༀƙ \0媈ఉ\0\0㺣盭媈ఉ\0𢡄媌ఉ\0팃目媌ఉ࣒媌ఉ큁目媌ఉ匰అ泌\0Item\0\0᱄అ\0\0\0\0\0\0Count\0\0﫨呂媼ఉ㳜੪\0\0媌ఉ\0\0\0\0੪寶目㳠੪楱䥷㎽橔అ\0\0᱄అ�㏂᮴అ\0\0\0੪\0\0\0露𢡄\0\0㎾ᕢ\0齃\0\0x�㏂᮴అ\0\0隲W᱄అ\0\0�Ĳ\0\0\0鹿齃殺\0\0霈W戀醙霫W戀ꊠऺ齃x\n\0霪W露Wꊠऺ﫰xt\0Љ\0\0\0൐௲鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0⑰ਫ਼⑰ਫ਼㲈੪到అ寶目㲈੪到అi\0\0變ﱘ﫰﬐먙㎼到అ㲈੪i\0\0變ﱘ﫰먰㎼ﱘ到అ�㏂冠అ\0\0릎㎼到అi\0⓮췬目⓲췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒൐௲竗൐௲目W\0竗\0\0\0目\0\0\0\0匰అ\0目瑉浥目\0\0\0\0匰అ\0目潃湵tƢ\0愢睉뮴ơࣴշ\0\0\0ઔշผշ,\0ဈշ\0\0慰睉ߐշ\0\0\0ೂᰁࣴշผշ,\0\0\0崹睊ೂᰁࣴշ\0\0㞍Qđ\0ᠠ৸,\0ผշ\0\0▪췬目Љ\0►췬目Љ\0╖췬╞췬目Љ\0鲸࣒\0￿￿目Љ\0鲬࣒൐௲觴൐௲目t\0觴\0\0\0梅礼目\0\0\0\0﫤到అ目潅f摲敳t盡옎盡㊊췭\0\0ࣾ}\0$\0\0\0\0\0\0p\0￿￿￿￿얠盡왑盡ೂᰁ\0\0\0\0\0翽捥盦Ȓ묞￾￿옎盡伛盡\0\0ɭդࣾ}đ\0ࣸ̀ࣸEꊌƩ伦盡㋪췭ꉸƩđ\0\0\0\0\0\0\0\0\0\0捥盦謺묞￾￿템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂瞒⫠\0\0\0瞒⪌쀕瞒〠\0䪔㏂\0T\0\0⪌쀕\0\0ꀀ翽翽瞒鸞䪔㏂\0邰ƙ\0\0ࠀ᎖眊\0\0䪔㏂鸞\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ菱到అﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀﬘眿ฒ᱄అ磻ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿菱￿￿\0\0異\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ\0\0\0\0\0奰畿⡥췬焚畻邰ƙࠀ菱￿￿㏂￿￿\0\0\0\0滑煔畻:\0菱￿￿㏂￿￿奰畿\0\0\0\0璉㎾ࠄ\0\0菱￿￿㏂㎾x\0\0�㏂᮴అ\0\0頲W怜\0\0\0\0ࠄ\0顇WValu\0\0菱令᱄అ齃\0\0\0\0\0\0菱\0磻\0窱餀W齃ﬄ	\0ﭴ\0\0戌ۇʪ\0њ\0\0\0\0\0鯬৬\0\0識⤖췬識뜩@﷩\0\0\0ƌ\0靖䗧@林蕶@戀ۇ﫬煮ƍ\0뮩@館믆@믎@﫬﷩\0釚@﫬﫬﷩\0ༀƙ﫰ༀƙ社戤痝\0Ɨ\0\0䁠௦並ఄఄ忉㎽᫸అ奁㎽ఄ	\0ᬄఅᯀఅ彿㎽﫠䦕盭ᯀఅ	\0ᯀఅ忉㎽𢡄䥷盭ᯀఅꊠऺ	\0﫨᱄అ﫰馘B齃ﭴxﬄﬄ駰B﫰憸ੴ嬀৹\0అ\0\0𢡄ﲘ齃xﲘxﲀﭴx﬐xﲘ﬜xﲘﲴxﲘꊠऺ憸ੴ뿄x\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0ꊠऺ匰అ䗆@	ऺ匰అ᱄అ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0ʎC匰అﲘC匰అ\0\0\0\0\0అ\0\0\0\0అﱘ￿\0\0\0\0\0\0￿\0\0\0\0\0偠৹\0\0\n\0ﴀ\0\0ﴄ疐ɪఅ\0\0앬ఉﲘ\0\0ꘌ੽ﴌ嵿{ﳴ\0\0\0\0\0ﴀﳀ庱{ﴌﴔ彨{ﴌꊠऺ\0ﺰ஑ৄࣸEÂ\0\0\0৻\0\0쥈ɯ\0\0\0疐ɪ\0\0鞼੾\0\0ﵤⰛEﴠⰺEﵤﴬⱹEﵤﴸⳗEﵤﵬ⳶Eﵤꊠऺ\0\0\0਌\0\0悰ੴﺀ஑Ā﷌㘣Tﹸ㘶T﷌﹠\0\0\0\0崈盡ﶠ갦盠쾐ƫ\0\0ﹸ\0\0ﷀ駅Éॹˢ\0\0\0ﹸ翽ﹸ﷜﷔츐ɳ﷤刞E\0\0\0\0\0\0\0\0︐쓷盡਌\0\0\0\0\0\0\0\0ꯍ�\0\0﹠\0\0ﺈ엷盡࿢Ԗ਌\0\0\0\0\0\0㪂췭Ｈ＠쬠ƫ$\0\0\0\0\0\00\0￿￿￿￿얠盡\0\0ｄ\0\0\0\0\0︬Ꝥɹﻜ捥盦Ȓ묞\0\0ﻬ찰盡\0\0࿢Ԗ਌\0\0\0\0\0\0쬴ƫ\0㫦췭츐ɳ＠\0\0\0\0\0\0\0\0ﺼﺰｄｄ捥盦ࡒ묞￾￿ﻼ첈盡࿢Ԗ\0\0਌㺖T＠ｬ\0\0\0\0츐ɳ㻛T਌\0\0\0\0\0\0㙡įѲ\0ɢ\0ꋴĵ䈆Tｐ䈐Tｬｸ䉉Tｬ\0\0\0\0ꋴĵ츐ɳﾈ잜Ĳꀀ翽ￄ枴@ﾈ\0\0ﾔ眿ꀀ翽ￔ㭓瞖ꀀ翽ᮒ眊\0\0\0\0ꀀ翽\0\0\0\0\0\0ﾠ\0\0￿￿瞑\0\0￬㬦瞖얼Ĳꀀ翽\0\0\0\0\0\0\0\0얼Ĳꀀ翽\0\0譕召�䖋倌䶋謈ᢑ＀菒ӄ䶋༈醷ش\0숻Ѵ쀳⏫䖋倌䶋脈ⳁ儀喋謈ᒂ＀菐ࣄ�쀛삃嬁쉝쳌쳌쳌쳌쳌쳌삋鱠è\0堀%￰￿⑴倨탿삅ᕵ憝è\0堀%￰诿Ҁ＀㏠觀⑄鴠쉡쳌쳌쳌邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐譕臬⣬였웿옒웂온贀�觿��诿櫒栀Ȑ\0趍﷠￿橑謁ౕ譒ࡅ袋М\0퇿삅մ跩\0ༀ閷﷠￿䖋༈袷࠾\0턻ɴ盫喋脈㛂刀薋﷤￿譐ࡍ醋Д\0틿쒃蔈痀譓ࡅ褀��跿ﱍ橑贄��勿䖋謈⒈儀ｪ喋謈₂＀跐ﱍ橑贅譒ࡅ袋Ш\0橑诿ࡕ芋Р\0탿쉝쳌쳌쳌쳌쳌즋譐⑄茌￸⍵ｘ倒䒋ࠤ鱠è\0嬀￿卐￾鷿塡⣂堀ዿ⣂찀쳌쳌쳌쳌쳌邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐', null, null, null, '本指南中提出废用“功血”一词。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('423', '51', 'Y02_030', '1', '生殖期妇女异常子宫出血诊断', 'Diagnosis of abnormal uterine bleeding in reproductive-aged women', '美国妇产科医生学会（ACOG,The American College of Obstetricians and Gynecologists）', '2012', 'http://www.guideline.gov/content.aspx?id=38623', '英文', '图1', '异常子宫出血', null, null, null, null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('424', '51', 'Y02_031', '1', '育龄女性非妊娠急性异常子宫出血的管理', 'Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women', '美国妇产科医生学会（ACOG,The American College of Obstetricians and Gynecologists）', '2013', 'http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/Management-of-Acute-Abnormal-Uterine-Bleeding-in-Nonpregnant-Reproductive-Aged-Women ', '英文', '图1', '异常子宫出血', null, null, '1．病史<br />&nbsp;&nbsp;以PALM–COEIN 系统为指南，采集完整的病史，主要集中在出血的情况，相关的症状、过去的月经史、妇科病以及其它病史。可能的话，结合适当的实验室检查和影像学检查。超过13%的月经过多的患者有血管性血友病史。超过20%的妇女可能有潜在的凝血功能障碍。其它的凝血因子缺乏、血友病、血小板功能异常可能与任何年龄组的急性异常出血相关。应用方框1 的筛选工具有助于临床医生通过实验室检查判断患者的凝血异常。另外全身性疾病如白血病、肝功能衰竭及某些药物（如抗凝血药、化疗药）可损害凝血功能而导致急性异常出畻坴畿\0\0\0\0醼畻聱盯\n\0\0\0痭턀ਘༀƙ\0ਘĀ\0\n\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄勼అਘĀ\0ఄ彿㎽奋㎽巫㎽橔అᯀఅ彿㎽᮴అ塚㎽ᯀఅꍈ㏂\0\0勼అ學㎽漸㏂圔㎽勼అ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0턀ਘ䐺盭暼痭턀ਘༀƙ \0턀ਘ\0\0㺣盭턀ਘ\0𢡄턄ਘ\0팃目턄ਘ࣒턄ਘ큁目턄ਘ匰అ泌\0Item\0\0᱄అ\0\0\0\0\0\0Count\0\0﫨呂턴ਘ㳜੪\0\0턄ਘ\0\0\0\0੪寶目㳠੪楱䥷㎽橔అ\0\0᱄అ�㏂᮴అ\0\0\0੪\0\0\0露𢡄\0\0㎾ᱢ\0齃\0\0x�㏂᮴అ\0\0隲W᱄అ\0\0�Ĳ\0\0\0鹿齃殺\0\0霈W戀醙霫W戀ꊠऺ齃x\n\0霪W露Wꊠऺ﫰xt\0Љ\0\0\0൐௲鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0⑰ਫ਼⑰ਫ਼㲈੪到అ寶目㲈੪到అi\0\0變ﱘ﫰﬐먙㎼到అ㲈੪i\0\0變ﱘ﫰먰㎼ﱘ到అ�㏂冠అ\0\0릎㎼到అi\0⓮췬目⓲췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒൐௲竗൐௲目W\0竗\0\0\0目\0\0\0\0匰అ\0目瑉浥目\0\0\0\0匰అ\0目潃湵tƢ\0愢睉뮴ơࣴշ\0\0\0ઔշผշ,\0ဈշ\0\0慰睉ߐշ\0\0\0ೂᰁࣴշผշ,\0\0\0崹睊ೂᰁࣴշ\0\0㞍Qđ\0ᠠ৸,\0ผշ\0\0▪췬目Љ\0►췬目Љ\0╖췬╞췬目Љ\0鲸࣒\0￿￿目Љ\0鲬࣒൐௲觴൐௲目t\0觴\0\0\0梅礼目\0\0\0\0﫤到అ目潅f摲敳t盡옎盡㊊췭\0\0ࣾ}\0$\0\0\0\0\0\0p\0￿￿￿￿얠盡왑盡ೂᰁ\0\0\0\0\0翽捥盦Ȓ묞￾￿옎盡伛盡\0\0ɭդࣾ}đ\0ࣸ̀ࣸEꊌƩ伦盡㋪췭ꉸƩđ\0\0\0\0\0\0\0\0\0\0捥盦謺묞￾￿템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂瞒⫠\0\0\0瞒⪌쀕瞒〠\0䪔㏂\0T\0\0⪌쀕\0\0ꀀ翽翽瞒鸞䪔㏂\0邰ƙ\0\0ࠀ᎖眊\0\0䪔㏂鸞\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ菱到అﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀﬘眿ฒ᱄అ磻ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿菱￿￿\0\0異\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ\0\0\0\0\0奰畿⡥췬焚畻邰ƙࠀ菱￿￿㏂￿￿\0\0\0\0滑煔畻:\0菱￿￿㏂￿￿奰畿\0\0\0\0璉㎾ࠄ\0\0菱￿￿㏂㎾x\0\0�㏂᮴అ\0\0頲W怜\0\0\0\0ࠄ\0顇WValu\0\0菱令᱄అ齃\0\0\0\0\0\0菱\0磻\0窱餀W齃ﬄ	\0ﭴ\0\0ꐌॉ\0\0\0\0\0\0慤ੴ\0\0識⤖췬識뜩@﷩\0\0\0\0靖䗧@林蕶@ꐀॉ﫬煮\0뮩@館믆@믎@﫬﷩\0釚@﫬﫬﷩\0ༀƙ﫰ༀƙ社戤痝\0Ɨ\0\0੫並ఄఄ忉㎽᫸అ奁㎽ఄ	\0ᬄఅᯀఅ彿㎽﫠䦕盭ᯀఅ	\0ᯀఅ忉㎽𢡄䥷盭ᯀఅꊠऺ	\0﫨᱄అ﫰馘B齃ﭴxﬄﬄ駰B﫰慰ੴ嬀৹\0అ\0\0𢡄ﲘ齃xﲘxﲀﭴx﬐xﲘ﬜xﲘﲴxﲘꊠऺ慰ੴ뿄x\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0ꊠऺ匰అ䗆@	ऺ匰అ᱄అ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0ʎC匰అﲘC匰అ\0\0\0\0\0అ\0\0\0\0అﱘ￿\0\0\0\0\0\0￿\0\0\0\0\0偠৹\0\0\n\0ﴀ\0\0ﴄ疐ɪ\0\0\0�੫\0\0\0\0鿌ॉﴌ嵿{ﳴ\0\0\0\0\0ﴀﳀ庱{ﴌﴔ彨{ﴌꊠऺ\0ﺰ஑ৄࣸEÂ\0\0\0৻\0\0쥈ɯ\0\0\0疐ɪ\0\0ꘌ੽\0\0ﵤⰛEﴠⰺEﵤﴬⱹEﵤﴸⳗEﵤﵬ⳶Eﵤꊠऺ\0\0\0਌\0\0悰ੴﺀ஑Ā﷌㘣Tﹸ㘶T﷌﹠\0\0\0\0崈盡ﶠ갦盠쾐ƫ\0\0ﹸ\0\0ﷀ駅Éॹˢ\0\0\0ﹸ翽ﹸ﷜﷔츐ɳ﷤刞E\0\0\0\0\0\0\0\0︐쓷盡਌\0\0\0\0\0\0\0\0ꯍ�\0\0﹠\0\0ﺈ엷盡࿢Ԗ਌\0\0\0\0\0\0㪂췭Ｈ＠쬠ƫ$\0\0\0\0\0\00\0￿￿￿￿얠盡\0\0ｄ\0\0\0\0\0︬Ꝥɹﻜ捥盦Ȓ묞\0\0ﻬ찰盡\0\0࿢Ԗ਌\0\0\0\0\0\0쬴ƫ\0㫦췭츐ɳ＠\0\0\0\0\0\0\0\0ﺼﺰｄｄ捥盦ࡒ묞￾￿ﻼ첈盡࿢Ԗ\0\0਌㺖T＠ｬ\0\0\0\0츐ɳ㻛T਌\0\0\0\0\0\0㙡įѲ\0ɢ\0ꋴĵ䈆Tｐ䈐Tｬｸ䉉Tｬ\0\0\0\0ꋴĵ츐ɳﾈ잜Ĳꀀ翽ￄ枴@ﾈ\0\0ﾔ眿ꀀ翽ￔ㭓瞖ꀀ翽ᮒ眊\0\0\0\0ꀀ翽\0\0\0\0\0\0ﾠ\0\0￿￿瞑\0\0￬㬦瞖얼Ĳꀀ翽\0\0\0\0\0\0\0\0얼Ĳꀀ翽\0\0譕召�䖋倌䶋謈ᢑ＀菒ӄ䶋༈醷ش\0숻Ѵ쀳⏫䖋倌䶋脈ⳁ儀喋謈ᒂ＀菐ࣄ�쀛삃嬁쉝쳌쳌쳌쳌쳌쳌삋鱠è\0堀%￰￿⑴倨탿삅ᕵ憝è\0堀%￰诿Ҁ＀㏠觀⑄鴠쉡쳌쳌쳌邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐譕臬⣬였웿옒웂온贀�觿��诿櫒栀Ȑ\0趍﷠￿橑謁ౕ譒ࡅ袋М\0퇿삅մ跩\0ༀ閷﷠￿䖋༈袷࠾\0턻ɴ盫喋脈㛂刀薋﷤￿譐ࡍ醋Д\0틿쒃蔈痀譓ࡅ褀��跿ﱍ橑贄��勿䖋謈⒈儀ｪ喋謈₂＀跐ﱍ橑贅譒ࡅ袋Ш\0橑诿ࡕ芋Р\0탿쉝쳌쳌쳌쳌쳌즋譐⑄茌￸⍵ｘ倒䒋ࠤ鱠è\0嬀￿卐￾鷿塡⣂堀ዿ⣂찀쳌쳌쳌쳌쳌邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐`劁眿邐邐邐邐邐邐犡瞕⍤瞓慌瞔靷睁盠屖瞔C:\\Program Files\\360\\360safe\\safemon\\safemon.dll\0邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐`\\KnownDlls\\user32.dll\0\\邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐*邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('425', '51', 'Y02_032', '1', '与妊娠无关的急性子宫出血', 'Acute Uterine Bleeding Unrelated to Pregnancy:A Southern California Permanente Medical Group Practice Guideline', 'The Southern California Permanente Medical Group’s Abnormal Uterine Bleeding Working Group', '2013', 'http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3783080/', '英文', null, '异常子宫出血', null, null, null, null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('426', '52', 'M04_001', '1', '前列腺炎诊断治疗指南', '无', '中华医学会泌尿外科学分会 (CUA)', '2014', '那彦群，叶章群，孙颖浩等,中国泌尿外科疾病诊断治疗指南（2014版）[M].北京：人民卫生出版社，2014.', '中文', '1.传统分类方法：<br />&nbsp;&nbsp;1.1急性细菌性前列腺炎；<br />&nbsp;&nbsp;1.2慢性细菌性前列腺炎；<br />&nbsp;&nbsp;1.3慢性非细菌性前列腺炎；<br />&nbsp;&nbsp;1.4前列腺痛；<br />&nbsp;&nbsp;2. 新的分类方法：<br />&nbsp;&nbsp;   2.1 Ⅰ型；<br />&nbsp;&nbsp;2.2 Ⅱ型；<br />&nbsp;&nbsp;2.3 Ⅲ型；<br />&nbsp;&nbsp;2.4 Ⅳ型；<br />&nbsp;&nbsp;', '前列腺炎', null, null, '1.诊断原则<br />&nbsp;&nbsp;推荐按照MH分型诊断前列腺炎。以患者临床表现为诊断的起点，I型为急性病程，多具有典型临床表现；Ⅱ型和Ⅲ型为慢性病程，临床表现类似。<br />&nbsp;&nbsp;I型：诊断主要依靠病史、体格检查和血、尿的细菌培养结果。常规对患者进行直肠指检，但禁忌进行前列腺按摩。在应用抗生素治疗前，应进行中段尿培养或血培养。经36小时规范处理，患者病情未改善时，建议进行经直肠B超等检查，全面评估下尿路病变，明确有无前列腺脓肿。<br />&nbsp;&nbsp;Ⅱ型和Ⅲ型（慢性前列腺炎）：须详细询问病史（尤其是反复下泌尿道感染史）、全面体格检查（包括直肠指检）、尿液和前列腺按摩液常规检查。推荐应用NIH慢性前列腺炎症状评分(NIH chronic prostatitis symptom index, NIH-CPSI，见附录一）进行症状评分。临床表现的UPOllNT(S)分型有助于进行以症状为导向的个体化综合治疗（见附录二）。推荐“两杯法”或“四杯法”进行病原体定位试验。详见表1。为明确诊断需对类似症状的疾病进行鉴别。<br />&nbsp;&nbsp;插入表1<br />&nbsp;&nbsp;Ⅳ型：无临床症状，在前列腺按摩液(EPS)、精液、前列腺按摩后尿液、前列腺组织活检及前列腺切除标本的病理检查时被发现。<br />&nbsp;&nbsp;2.诊断方法<br />&nbsp;&nbsp;前列腺炎具体诊断方法包括：<br />&nbsp;&nbsp;2.1临床症状诊断前列腺炎时，应详细询问病史，了解发病原因或诱因；询问疼痛性质、特点、部位、程度和排尿异常等症状；了解治疗经过和复发情况；评价疾病对生活质量的影响；了解既往史、个人史和性生活情况。<br />&nbsp;&nbsp;Ⅰ型：常突然发病，表现为寒战、发热、疲乏无力等全身症状，伴有会阴部和耻骨上疼痛，尿路刺激症状和排尿困难，甚至急性尿潴留。<br />&nbsp;&nbsp;Ⅱ和Ⅲ型：临床症状类似，多有疼痛和排尿异常等。Ⅱ型可表现为反复发作的下尿路感染。Ⅲ型主要表现为骨盆区域疼痛，可见于会阴、阴茎、肛周部、尿道、耻骨部或腰骶部等部位，尤以射精痛更为影响患者。排尿异常可表现为尿急、尿频、尿痛和夜尿增多等。由于慢性疼痛久治不愈，患者生活质量下降，并可能有性功能障碍、焦虑、抑郁、失眠、记忆力下降等。<br />&nbsp;&nbsp;Ⅳ型：无临床症状。<br />&nbsp;&nbsp;慢性前列腺炎症状评分由于诊断慢性前列腺炎的客观指标相对缺乏并存在诸多争议。因此，推荐应用NIH-CPSI进行症状评估。NIH-CPSl主要包括3部分内容，有9个问题(0-43分)。第一部分评估疼痛部位、频率和严重程度，由问题1-4组成(0-21分)；第二部分为排尿症状，评估排尿不尽感和尿频的严重程度，由问题5～6组成(0-10分)；第三部分评估对生活质量的影响，由问题7～9组成(0-12分)。目前已被翻译成多种语言，广泛应用于慢性前列腺炎的症状和疗效评估。<br />&nbsp;&nbsp;2.2 体格检查  诊断前列腺炎，应进行全面体格检查，重点是泌尿生殖系统。检查患者下腹部、腰骶部、会阴部、阴茎、尿道外口、睾丸、附睾和精索等有无异常，有助予进行诊断和鉴别诊断。直肠指检对前列腺炎的诊断非常重要，且有助于鉴别会阴、直肠、神经病变或前列腺其他疾病，同时通过前列腺按摩获得EPS。<br />&nbsp;&nbsp;Ⅰ型：体检时可发现耻骨上压痛、不适感，有尿潴留者可触及耻骨上膨隆的膀胱。直肠指检可发现前列腺肿大、触痛、局部温度升高和外形不规则等。禁忌进行前列腺按摩。 <br />&nbsp;&nbsp;Ⅱ型和Ⅲ型：直肠指检可了解前列腺大小、质地、有无结节、有无压痛及其范围与程度，盆底肌肉的紧张度、盆壁有无压痛，按摩前列腺获得EPS。直肠指检前，建议留取尿液进行常规分析和尿液细菌培养。<br />&nbsp;&nbsp;2.3 实验室检查<br />&nbsp;&nbsp;2.3.1 EPS常规检查：EPS常规检查通常采用湿涂片法和血细胞计数板法镜检，后者具有更好的精确度。<br />&nbsp;&nbsp;正常的EPS中白细胞<10个/HP，卵磷脂小体均匀分布于整个视野，pH 6.3-6.5，红细胞和上皮细胞不存在或偶见。当白细胞>10个／HP，卵磷脂小体数量减少，有诊断意义。白细胞的多少与症状的严重程度不相关。胞质内含有吞噬的卵磷脂小体或细胞碎片等成分的巨噬细胞，也是前列腺炎的特有表现。当前列腺有细菌、真菌及滴虫等病原体感染时，可在EPS中检测出这些病原体。<br />&nbsp;&nbsp;此外，为了明确区分EPS中白细胞等成分，可对EPS采用革兰染色等方法进行鉴别。<br />&nbsp;&nbsp;如前列腺按摩后收集不到EPS，不宜多次重复按摩，可让患者留取前列腺按摩后尿液进行分析。<br />&nbsp;&nbsp;2.3.2尿常规分析及尿沉渣检查：尿常规分析及尿沉渣检查是排除尿路感染、诊断前列腺炎的辅助方法。<br />&nbsp;&nbsp;2.3.3 细菌学检查<br />&nbsp;&nbsp;2.3.3.1 Ⅰ型：应进行中段尿的染色镜检、细菌培养与药敏试验，以及血培养与药敏试验。<br />&nbsp;&nbsp;2.3.3.2 Ⅱ型和Ⅲ型：推荐“两杯法”或“四杯法”病原体定位试验。<br />&nbsp;&nbsp;A．“四杯法”：1968年，Meares和Stamey提出采用依次收集患者的分段尿液和EPS分别进行分离培养的方法（简称“四杯法”），区分男性尿道、膀胱和前列腺感染(表2)。<br />&nbsp;&nbsp;表2  “四杯法”（Meares-Stamey试验）诊断    前列腺炎结果分析<br />&nbsp;&nbsp;B．“两杯法”：“四杯法”操作复杂、耗时、费用高，在实际临床工作中推荐“两杯法”。“两杯法”是通道获取前列腺按摩前、后的尿液，进行显微镜检查和细菌培养(表3) 。<br />&nbsp;&nbsp;表3“两杯法”诊断前列腺炎结果分析<br />&nbsp;&nbsp;Ⅱ型和Ⅲ型患者如有淋病感染史，可选择进行EPS淋球菌检测。<br />&nbsp;&nbsp;2.3.4 其他病原体检查<br />&nbsp;&nbsp;2.3.4.1 沙眼衣原体：沙眼衣原体( Chlamydia trachomatis，Ct)检测方法有培养法、免疫荧光法、斑点金免疫渗滤法、聚合酶链反应(polymerase chain reaction，PCR)和连接酶链反应(ligase chain reaction，LCR)等。培养法仅检测活的Ct，且因费用、时间及技术水平等原因，不推荐临床应用。目前主要采用灵敏度高、特异性强的PCR和LCR技术检测Ct的核酸成分。<br />&nbsp;&nbsp;2.3.4.2 支原体：可能引起前列腺感染的支原体主要为溶脲脲原体(Ureaplasma urealyticum，Uu)和人型支原体(mycoplasma hominis，Mh)。培养法是Uu和Mh检测的金标准，结合药敏试验可为临床诊断与治疗提供帮助；免疫学检测和核酸扩增技术等也应用于支原体检测。<br />&nbsp;&nbsp;由于以上病原体也可能存在于男性尿道中，建议先取尿道拭子检测，在排除尿道感染后，再进行EPS检测，以进一步明确是否为前列腺感染。<br />&nbsp;&nbsp;此外，对于EPS中其他病原体，如真菌的检测方法主要为直接涂片染色镜检和分离培养；病毒检测通常采用前列腺组织培养或PCR技术。<br />&nbsp;&nbsp;2.3.5其他实验室检查：前列腺炎患者可能出现精液质量异常，如白细胞增多、精液不液化、血精和精子活力下降等改变。有生育要求的前列腺炎患者可进行精液检查。在部分慢性前列腺炎患者中也会出现PSA升高的情况。建议年龄>50岁的患者常规进行血清PSA检测。尿细胞学检查在与膀胱原位癌等鉴别方面具有一定价值。<br />&nbsp;&nbsp;2.4器械检查<br />&nbsp;&nbsp;2.4.1尿流率：可以大致了解患者排尿状况，有助于前列腺炎与排尿障碍相关疾病进行鉴别。<br />&nbsp;&nbsp;2.4.2尿动力学检查：研究表明，前列腺炎患者尿动力学检查可以发现膀胱出口梗阻、尿道功能性梗阻、膀胱逼尿肌收缩力减退或逼尿肌无反射和逼尿肌不稳定等膀胱尿道功能障碍。在临床怀疑有上述排尿功能障碍，或尿流率及残余尿有明显异常时，可选择尿动力学检查以明确诊断。<br />&nbsp;&nbsp;2.4.3 膀胱尿道镜：为有创性检查，不推荐前列腺炎患者常规进行此项检查。在某些情况下，如患者有血尿，尿液分析明显异常，其他检查提示有膀胱尿道病变时可选择膀胱尿道镜检查以明确诊断。<br />&nbsp;&nbsp;2.5影像学检查<br />&nbsp;&nbsp;2.5.1 B超：前列腺炎患者的前列腺超声表现易出现前列腺结石或钙化，且其大小与症状成正相关。且B超检查还可以发现前列腺回声不均、前列腺周围静脉丛扩张等表现，但各型之间无特异性表现，仍无法利用B超对前列腺炎进行分型。此外，B超可以较准确地了解前列腺炎患者肾脏、膀胱以及残余尿等情况，对于除外尿路器质性病变有一定帮助。经直肠B超对于鉴别前列腺、精囊和射精管病变以及诊断和引流前列腺脓肿有价值。<br />&nbsp;&nbsp;2.5.2 CT和MRI:对除外泌尿系统其它器质性病变，鉴别精囊、射精管等盆腔器官病变有潜在应用价值，对于持续发热或药物治疗效果不佳的前列腺炎患者，CT或MRI有助于诊断前列腺脓肿，但对于前列腺炎本身的诊断价值仍不清楚。<br />&nbsp;&nbsp;3. 鉴别诊断<br />&nbsp;&nbsp;需要鉴别的疾病包括：良性前列腺增生、睾丸附睾和精索疾病、膀胱过度活动症、神经源性膀胱、间质性膀胱炎、腺性膀胱炎、性传播疾病、原位癌等膀胱肿瘤、前列腺癌、泌尿男生殖系结核、肛门直肠疾病、腰椎疾病、中枢和外周神经病变等。主要依靠详细病史、体格检查及选择相应辅助检查明确鉴别诊断。<br />&nbsp;&nbsp;Ⅲ型前列腺炎（尤其是ⅢB型）缺乏客观的、特异性的诊断依据，临床诊断时应与可能导致骨盆区域疼痛和排尿异常的疾病进行鉴别诊断。<br />&nbsp;&nbsp;附录一<br />&nbsp;&nbsp;附录二<br />&nbsp;&nbsp;', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('427', '52', 'M04_002', '1', '慢性前列腺中西医结合诊疗专家共识', '无', '中国中西医结合学会男科专业委员会', '2015', '中国中西医结合杂志，2015，3（8）：933-941.', '中文', '前列腺炎分类方法:<br />&nbsp;&nbsp;1.Ⅰ型：急性细菌性前列腺炎( acute bacterial prostatitis，ABP)；<br />&nbsp;&nbsp;2.Ⅱ型：慢性细菌性前列腺炎(chronic bacterial prostatitis，CBP)；<br />&nbsp;&nbsp;3.Ⅲ型：慢性前列腺炎/熳性盆腔疼痛综合征(chronic prostatitis/chronic pelvic pain syndrome，CP/CPPS)；<br />&nbsp;&nbsp;3.1 ⅢA型（炎症性CPPS）；<br />&nbsp;&nbsp;3.2ⅢB型（非炎症性CPPS）；<br />&nbsp;&nbsp;4.Ⅳ型：无症状性前列腺炎；', '慢性前列腺炎', null, '1.基本证型：<br />&nbsp;&nbsp;1.1湿热下注；<br />&nbsp;&nbsp;1.2气滞血瘀；<br />&nbsp;&nbsp;1.3肝气郁结；<br />&nbsp;&nbsp;1.4肾阳不足；<br />&nbsp;&nbsp;1.5肾阴亏虚；<br />&nbsp;&nbsp;2.复合证型：<br />&nbsp;&nbsp;湿热瘀滞、肾虚湿热、脾肾两虚、中气亏虚、肝郁脾虚、肝郁化火、寒凝肝脉等。<br />&nbsp;&nbsp;', '1. 前列腺炎分类<br />&nbsp;&nbsp;1995年美国国立卫生研究院( National Institutes of Health，NIH)根据当时对前列腺炎的基础和临床研究情况，制定了前列腺炎分类方法。<br />&nbsp;&nbsp; I型：急性细菌性前列腺炎( acute bacterial prostatitis，ABP)。Ⅱ型：慢性细菌性前列腺炎(chronic bacterial prostatitis，CBP)。Ⅲ型：慢性前列腺炎/熳性盆腔疼痛综合征(chronic prostatitis/chronic pelvic pain syndrome，CP/CPPS)，根据前列腺按摩液( expressed prostatic secretion，EPS)或精液或第三份膀胱中段尿标本(third midstream bladder specimen，VB3)常规显微镜检查，该型又分为ⅢA（炎症性CPPS）和ⅢB型（非炎症性CPPS）两种亚型，即ⅢA患者的EPS或精液或VB3中WBC数量升高，ⅢB型患者的EPS或糟液或VB3中WBC在正常范围。Ⅳ型：无症状性前列腺炎( asymptoma-tory inflammatory prostatitis，AIP)，无主观症状，仅在有关前列腺方面的检查（EPS、精液、前列腺组织活检及前列腺切除标本的病理检查等）时发现炎症证据。<br />&nbsp;&nbsp;前列腺炎常见的类型主要是Ⅱ型、ⅢA型和ⅢB型，Ⅳ型前列腺炎由于缺乏明显症状而少有就诊者，但报道显示在男性不育患者中有较高的发病率。<br />&nbsp;&nbsp;2. 临床症状<br />&nbsp;&nbsp;患者表现为不同程度的下尿路症状(lower urinary tract symptoms，LUTS)，如尿频、尿急、尿痛、尿不尽感、尿道灼热；于晨起、尿末或排便时尿道有少量白色分泌物流出；会阴部、外生殖器区、下腹部、耻骨区、腰骶及肛周坠胀疼痛不适；还可有排尿等待、排尿无力、尿线变细、尿分叉或中断及排尿时间延长等。部分患者还可出现头晕、乏力、记忆力减退、性功能异常、射精不适或疼痛和精神抑郁、焦虑等症状。在诊断CP时，推荐应用NIH的CP症状指数( National Institutes of Health - chronic prostatitis symptom index，NIH-CPSI)进行基础评估和治疗监测。心理状况的评估可以通过患者健康问卷( patient health questionnaire，PHQ)及疼痛灾难化评分( pain  catastrophizing  scale，PCS)等测量工具来实现。<br />&nbsp;&nbsp;3 .体格检查  <br />&nbsp;&nbsp;包括直肠在内的泌尿生殖系统检查和局部神经肌肉系统检查。<br />&nbsp;&nbsp;3.1  局部体检  检查患者下腹部、腰骶部、会阴部、阴茎、阴囊、尿道外口、睾丸、附睾、精索等有无异常，有助于进行鉴别诊断。<br />&nbsp;&nbsp;3.2前列腺指检  包括大小（增大或正常）；边界（清或不清）；质地（腺体饱满，或软硬不匀，或有结节，或质地较硬）；中央沟（存在、变浅、消失）；前列腺局部温度（增高、正常）；压痛（有无局限性压痛）；盆底肌肉的压痛和触发点以及肛门直肠本身的病变。建议在进行前列腺指检前先留取尿液做尿液分析。<br />&nbsp;&nbsp;4. 实验室检查<br />&nbsp;&nbsp;4.1  尿常规分析及尿沉渣检查  前列腺按摩前留取尿液进行尿液分析是排除尿路感染和诊断前列腺炎的辅助方法，可发现或排除部分相关疾病如细菌感染、泌尿生殖系统恶性肿瘤等。<br />&nbsp;&nbsp;4.2前列腺按摩液检查  一般认为在Ⅱ型、ⅢA型前列腺炎患者EPS中WBC数目增加，而ⅢB型WBC不增加。WBC计数与症状严重程度相关性尚不明确。EPS中巨噬细胞的胞质内含有被吞噬的卵磷脂小体或细胞碎片等成分，为前列腺炎的特有表现。<br />&nbsp;&nbsp;4.3病原学定位检查   (1)四杯法为经典方法，但试验繁杂，可操作性有限，本共识不推荐应用于日常的诊疗工作中； (2)推荐使用两杯法或按摩前后试验(pre and post massage test，PPMT)，后者诊断准确率大于96%。仅有8%的CP/CPPS患者前列腺细菌定位培养阳性，这一比例与无症状者无显著差异，因此，病原学定位检查对于CP/CPPS的诊断价值有限，并非必需。<br />&nbsp;&nbsp;5. 辅助检查  主要有B超、尿流率、尿动力学、膀胱尿道镜、血清PSA、CT和MRI检查、前列腺穿刺等。B超检查可见前列腺回声不均匀、钙化、结石、腺管扩张、精囊改变、盆腔静脉充血改变等，但不推荐单一使用B超检查结果作为诊断依据。上述各项辅助检查主要用于排除泌尿生殖系统以及盆腔脏器可能存在的其他疾病。<br />&nbsp;&nbsp;6. 鉴别诊断  本病需要与良性前列腺增生、睾丸附睾和精索疾病、膀胱过度活动症、神经源性膀胱、间质性膀胱炎、腺性膀胱炎、泌尿生殖系统结核、泌尿生殖系统结石、性传播疾病、膀胱肿瘤、前列腺癌、肛门直肠疾病、腰椎疾病、中枢和外周神经病变等可能导致盆腔区域疼痛和排尿异常的疾病进行鉴别。 <br />&nbsp;&nbsp;7.  CP/CPPS临床表型分类系统（表1、2）前列腺炎的NIH分类法和NIH-CPSI症状评分体系的建立，以改善症状作为前列腺炎的治疗目的，已经基本达成共识。但是，多项基于此的多中心临床试验结果并不十分令人满意。Nickel JC等于2009年提出并初步验证了可用于指导CP/CPPS诊断和治疗的表型分类系统( phenotypic classification system)和建议的治疗方法。该系统将CP/CPPS的临床表现（表型）细分为六类，即排尿症状(urinary symptoms)、社会心理障碍(psychosocial dysfunction)、器官特异性表现( organ-specific  findings)，感染( infection)、神经系统，全身性状况(neurological/systemic conditions)和盆底肌肉触痛(tenderness of pelvic floor skeletal muscles)，简称为UPOINT。并建议使用评估步骤和项目对CP/CPPS进行UPOINT表型分类。这一分类方法倡导对于造成CP的几个因素进行综合干预，可有效缓解症状，达到临床治愈的目标。<br />&nbsp;&nbsp;尽管仍需更多的临床实践和研究对其进行验证，但UPOINT表型分类系统对于CP/CPPS诊断、治疗和临床研究的指导价值已获得较广泛肯定，是继NIH分类系统和NIH-CPSI之后的又一重大进展，与中医强调整体观念的辨证治疗方法也有相通之处。<br />&nbsp;&nbsp;', '1.湿热下注。主症：尿频尿急，灼热涩痛。次症：小便黄浊，尿后滴白，阴囊潮湿，心烦气急，口苦口干。舌脉：舌苔黄腻，脉滑实或弦数。<br />&nbsp;&nbsp;2.气滞血瘀。主症：会阴部、或外生殖器区、或小腹、或耻骨区、或腰骶及肛周疼痛或坠胀，尿后滴沥。次症：排尿刺痛，淋漓不畅，血精或血尿。舌脉：舌质紫黯或有瘀点、瘀斑，苔白或黄，脉弦或涩。<br />&nbsp;&nbsp;3.肝气郁结。主症：会阴部、或外生殖器区、或少腹、或耻骨区、或腰骶及肛周坠胀不适，似痛非痛，小便淋漓。次症：胸闷心烦，排尿无力，余沥不尽，疑病恐病。舌脉：舌淡红，脉弦细。<br />&nbsp;&nbsp;5.肾阳不足。主症：尿后滴沥，劳后白浊。次症：畏寒肢泠，腰膝酸软，精神萎靡，阳痿早泄或性欲低下。舌脉：舌淡胖苔白，脉沉迟或无力。<br />&nbsp;&nbsp;6.肾阴亏虚。主症：尿频尿急，尿黄尿热。次症：五心烦热，失眠多梦，头晕眼花，遗精早泄、性欲亢进或阳强。舌脉：舌红少苔，脉沉细或弦细。<br />&nbsp;&nbsp;7.湿热瘀滞。主症：小便频急，灼热涩痛，排尿困难，余沥不尽，会阴胀痛或下腹、耻部、腰骶及腹股沟等部位不适或疼痛。次症：小便黄浊，尿道滴白，口苦口干，阴囊潮湿。舌脉：舌红，苔黄腻，脉弦数或弦滑。<br />&nbsp;&nbsp;', '尿道灼热；尿道涩痛；尿频；尿急；排尿刺痛；尿后滴沥；尿短赤；尿道白浊；尿细；尿不尽；尿等待；尿无力；夜尿增多；会阴等坠胀、似痛非痛；会阴等局部刺痛；会阴部冷痛、遇寒加重；会阴部隐痛；腰膝酸软而痛；早泄；阳痿；遗精；阴囊潮湿；精神抑郁；胸闷善太息；神疲乏力；便泄稀溏；五心烦热；潮热盗汗；眩晕耳鸣；失眠健忘；口咽干燥；', '中医、中西医结合治疗CP疗效研究必须经过至少1个月以上的严格临床试验，并与阳性对照药物或安慰剂比较，记录全部症状、体征的变化和不良反应，进行动态观测。<br />&nbsp;&nbsp;EPS WBC计数与NIH-CPSI评分，症状的严重程度无相关性，作为临床诊断、选择治疗、预测疗效等工具的价值有限。因此，临床评价以NIH-CPSI评分、中医辨证评分为主要指标，EPS中的各参数作为次要指标，并不以消除前列腺局部的炎症为主。<br />&nbsp;&nbsp;表3 慢性前列腺炎中医辨证评分参考表<br />&nbsp;&nbsp;研究结果的有效性和安全性参数应清楚和简明，避免2个或2个以上的参数组合成“总指数”，评估结果应该展示NIH-CPSI评分表、中医辨证评分表参数变化的绝对值和百分数。<br />&nbsp;&nbsp;安全性评价：血、尿、大便常规检查；心电图、肝功能、肾功能检查；可能出现的不良反应及临床表现、严重程度、发生和持续时间及消除方法。<br />&nbsp;&nbsp;', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('428', '52', 'M04_003', '1', '慢性前列腺炎中西医结合诊疗指南', '无', '中国中西医结合学会男科专业委员会', '2007', '中国中西医结合杂志，2007,27（11）:1052-1056', '中文', '前列腺炎分类方法:<br />&nbsp;&nbsp;1.Ⅰ型：急性细菌性前列腺炎( acute bacterial prostatitis，ABP)；<br />&nbsp;&nbsp;2.Ⅱ型：慢性细菌性前列腺炎(chronic bacterial prostatitis，CBP)；<br />&nbsp;&nbsp;3.Ⅲ型：慢性前列腺炎/熳性盆腔疼痛综合征(chronic prostatitis/chronic pelvic pain syndrome，CP/CPPS)；<br />&nbsp;&nbsp;3.1 ⅢA型（炎症性CPPS）；<br />&nbsp;&nbsp;3.2ⅢB型（非炎症性CPPS）；<br />&nbsp;&nbsp;4.Ⅳ型：无症状性前列腺炎；', '慢性前列腺炎', null, '1.基本证型<br />&nbsp;&nbsp;1.1湿热下注;  <br />&nbsp;&nbsp;1.2气滞血瘀；<br />&nbsp;&nbsp;1.3肝气郁结;  <br />&nbsp;&nbsp;1.4肾阳亏虚; <br />&nbsp;&nbsp;2.复合证型<br />&nbsp;&nbsp;2.1湿热瘀滞、肝肾阴虚、寒凝肝脉、肝郁化火、肝郁脾虚、脾肾阳虚、中气亏虚；<br />&nbsp;&nbsp;', '1. 前列腺炎新的分类  Ⅰ型：即为急性前列腺炎( acute bacterial prostatitis，ABP)．起病急，伴有持续和明显的下尿路感染症状，尿液中自细胞数量升高，血液和（或）尿液中的细菌培养阳性。Ⅱ型：即为慢性细菌性前列腺炎( chronic bacterial prostatitis，CBP)，有反复发作的下尿路感染症状，前列腺液(EPS)或精液或按摩后尿液( VB3)中白细胞数量升高，细菌培养结果阳性。Ⅲ型：即为慢性前列腺炎／慢性盆腔疼痛综合征( chronic prostatitis chronic pelvic pain syndromes，CP/CPPS)，相当于传统分类方法中的慢性非细菌性前列腺炎(chronic nonbacterial prostatitis，CNP)和前列腺痛(prostatodynia，PD)，主要表现为长期、反复的骨盆区域疼痛或不适，持续时间超过3个月，EPS或精液或VB3细菌培养阴性；根据EPS或棺浪或VB3常规显微镜检查，该型又分为ⅢA（炎症性CPPS）和ⅢB型(非炎症性CPPS)两种亚型，即ⅢA患者的EPS或精液或VB3中白细胞数量升高，ⅢB型患者的EPS或精液或VB3中白细胞在正常范围。Ⅳ型：无症状性前列腺炎(asymptomatory inflammatory prostatitis，AIP)，无主观症状，仅在有关前列腺方面的检查时发现炎症证据。<br />&nbsp;&nbsp;2.临床症状  患者表现为不同程度的尿频、尿急，尿痛，尿不尽感，尿道灼热，于晨起、尿末或排便时尿道有少量白色分泌物流出：会阴部、外生殖器区、下腹部、耻骨上区、腰骶及肛周坠胀疼痛不适。还可有排尿等待、排尿无力、尿线变细或中断及排尿时间延长等。部分患者还可出现头晕、乏力、记忆力减退、性功能异常、射精不适或疼痛和精神郁抑等症状，在诊断慢性前列腺炎时，推荐应用NIH-CPSI进行症状评估。NIH-CPSI主要包括三部分内容，有9个问题（0 - 43分）。第一部分评估疼痛部位、频率和严重程度，由问题1-4组成（0-21分）；第二部分为排尿症状，评估排尿不尽感和尿频的严重程度，由问题5-6组成(0-10分)；第三部分评估对生活质量的影响，由问题7-9组成（0-12分）。<br />&nbsp;&nbsp;3体格检查  (1)局部体检：检查患者下腹部、腰骶部、会阴部、阴茎、尿道外口、睾丸、附睾、精索等有无异常，有助于进行鉴别诊断。 (2)前列腺指诊：质地：腺体饱满，或软硬不匀，或有结节，或质地较硬；压痛：可有局限性压痛；大小：可轻度增大或正常。<br />&nbsp;&nbsp;4实验室检查<br />&nbsp;&nbsp;4.1尿常规分析及尿沉渣检查    尿常规及尿沉渣检查是排除尿路感染和诊断前列腺炎的辅助方法。<br />&nbsp;&nbsp;4.2前列腺液(EPS)检查    EPS中WBC数正常值<10个/HP．WBC≥10个/HP和卵磷脂小体消失或减少为异常。EPS中WBC数量的多少尚有争议，但一般认为在Ⅱ型、ⅢA型前列腺炎患者EPS中WBC数增加，而ⅢB型则WBC不增多。WBC计数与症状严重程度不一定相关。EPS中巨噬细胞的胞质内含有被吞噬的卵磷脂小体或细胞碎片等成分是前列腺炎的特有表现。<br />&nbsp;&nbsp;4.3病原学检查    当前列腺有细菌、霉菌及滴虫等病原体感染时，可在EPS中检测出这些病原体。样本的采集方法有：(1)四杯法：VB1和VB2为初段尿和中段尿，对尿道和膀胱感染有定位意义，VB 3和EPS定位前列腺。但因其操作复杂、耗时、费用高，一般较少采用。(2)推荐选用二杯法：只取前列腺按摩前中段尿(VB2)和按摩后尿液(VB3)，可获得与四杯法相似结果。<br />&nbsp;&nbsp;5辅助检查   主要有B超、尿流率、尿动力学、膀胱镜、尿道镜、CT和MRI检查等。B超检查可见前列腺回声不均匀，钙化，结石，腺管扩张，精囊改变，盆腔静脉充血改变等，但不推荐单一使用B超检查结果作为诊断依据。上述各项辅助检查主要用于排除泌尿生殖系统以及盆腔脏器可能存在的其他疾病。<br />&nbsp;&nbsp;6鉴别诊断    Ⅲ型前列腺炎需要与良性前列腺增生、睾丸附睾和精索疾病、膀胱过度活动症、神经原性膀胱、间质性膀胱炎，腺性膀胱炎、性传播疾病、膀胱肿瘤、前列腺癌、肛门直肠疾病、腰椎疾病、中枢和外周神经病变等可能导致骨盆区域疼痛和排尿异常的疾病进行鉴别。<br />&nbsp;&nbsp;', '1.湿热下注  主症：小便灼热涩痛，尿频尿急。次症：尿黄短赤、尿后滴沥，小便白浊，阴囊潮湿，心烦口干，口臭脘痞。舌脉：舌苔黄腻，脉滑实或弦数。<br />&nbsp;&nbsp;2气滞血瘀  主症：会阴部、或外生殖器区、或下腹部、或耻骨上区、或腰骶及肛周疼痛，以上部位坠胀。次症；尿后滴沥，尿刺痛，小便淋漓不畅。舌脉：舌质黯或有瘀点、瘀斑，脉弦或涩。<br />&nbsp;&nbsp;3肝气郁结  主症：会阴部、或外生殖器区、或下腹部、或耻骨上区、或腰骶及肛周坠胀不适，以上部位似痛非痛，精神抑郁。次症：小便淋漓不畅，胸闷善太息，性情急躁焦虑，疑病恐病。舌脉：舌淡红，脉弦。<br />&nbsp;&nbsp;4肾阳亏虚  主症：畏寒怕冷+腰膝酸软或酸痛。次症：尿后滴沥，精神萎靡，阳痿或性欲低下。舌脉：舌淡苔薄白，脉沉迟或无力。<br />&nbsp;&nbsp;5.湿热瘀滞  主症：尿频、尿急、尿痛，排尿困难，会阴、或肛门坠胀不适或疼痛，尿道口有乳白色分泌物。次症：尿不尽，尿有余沥、尿黄、尿道有灼热感；口苦口干，阴囊潮湿。舌脉：舌红，苔黄腻，脉弦数或弦滑。<br />&nbsp;&nbsp;6.肝肾阴虚  主症：腰膝酸软或酸痛，五心烦热，失眠多梦。次症：小便白浊如米泔样或短赤，遗精、早泄、性欲亢进或阳强。舌脉：舌红少苔，脉沉细或弦细。<br />&nbsp;&nbsp;', '尿道灼热；尿道涩痛；尿频；尿急；排尿刺痛；尿后滴沥；尿短赤；尿道白浊；尿细；尿不尽；尿等待；尿无力；夜尿增多；会阴等坠胀、似痛非痛；会阴等局部刺痛；会阴部冷痛、遇寒加重；会阴部隐痛；腰膝酸软而痛；早泄；阳痿；遗精；阴囊潮湿；精神抑郁；胸闷善太息；神疲乏力；便泄稀溏；五心烦热；潮热盗汗；眩晕耳鸣；失眠健忘；口咽干燥；', '中医、西医结合慢性前列腺炎疗效研究必须经过至少1个月以上的严格临床试验，并与阳性对照药或安慰剂比较，记录全部症状、体征的变化和不良反应，进行动态观测。临床评价以NIH-CPSI评分、中医辨证评分为主要指标（见表1），EPS中的各参数作为次要指标。研究结果的有效性和安全性参数应清楚和简明，避免2个或2个以上的参数组合成“总指数”，苹果结果应该展示NIH-CPSI评分表、中医辨证评分表参数变化的绝对值和百分数。<br />&nbsp;&nbsp;安全性评价：血、尿、粪常规检查；心电图、肝功能、肾功能检查；可能出现的不良反应及出现不良反应的临床表现、严重程度、发生时间、持续时间及消除的方法。<br />&nbsp;&nbsp;无症状型前列腺炎（IV型）：无主观症状，仅在有关前列腺方面的检查（EPS、精液、前列腺组织活检及前列腺切除标本的病理检查等）时发现炎症证据。对此型前列腺炎一般暂不治疗，应注意观察，只有当合并男性不育或有特异性病因时才推荐治疗。<br />&nbsp;&nbsp;', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('429', '52', 'M04_004', '1', '慢性细菌性前列腺炎和慢性前列腺炎/慢性盆腔综合征诊断治疗指南', 'Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline', '英国前列腺炎专家组(PERG,The Prostatitis Expert Reference Group)', '2015', '医脉通？', '英文', null, '慢性细菌性前列腺炎；慢性前列腺炎', null, null, 'Table 3 summarizes the investigations and physical examinations that should be considered during initial clinical assessment. Differential diagnosis is important, given the significant overlap of symptoms of CBP and CP/CPPS with those of other conditions ：investigations to rule these out are detailed in Table 3, with specific recommendations regarding prostate-specific antigen (PSA) testing in Box 2.\nA definitive diagnosis of CBP requires the presence of (typically recurrent) UTI and isolation of an aetiologically recognised organism from prostatic fluid or urine. There is no gold standard for a definitive diagnosis of CP/CPPS, which is typically based on patient history, symptoms and exclusion of other causes . Referral to specialist care should be considered at initial presentation if there is uncertainty regarding the possible differential diagnosis, or if severe symptoms that require immediate specialist attention are present.\n', null, null, 'Validated symptom-scoring instruments for CBP and CP/CPPS (Table 4) include: the NIH Chronic Prostatitis Symptom Index (NIH-CPSI; evaluating pain, voiding and impact on QoL); the International Prostate Symptom Score (IPSS; urinary symptoms and impact on QoL); and the more recent Urinary, Psychosocial, Organ-specific, Infection, Neurological/systemic, and Tenderness (UPOINT) classification, that aims to stratify patients into specific symptomled phenotypes. The International Index of Erectile Function (IIEF-5) or Sexual Health Inventory for Men (SHIM) specifically evaluates erectile dysfunction (ED).', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('43', '34', 'M03_007', '1', 'ACR适当性标准', 'ACR Appropriateness Criteria', '美国放射学会(ACR,American College of Radiology)', '2013', null, '英文', null, '急性肾衰（Acute Kidney Injury）', null, null, 'Acute Kidney Injury<br />&nbsp;&nbsp;\nAKI can be broadly defined as a sudden decrease in renal function resulting in azotemia. The definition of AKI is still under some debate. A recent consensus considers an abrupt (within 48 h) reduction in kidney function, currently defined as an absolute increase in serum creatinine >0.3 mg/dL (>25 μM/L), and a 50% increase or reduction in urine output (documented oliguria <0.5 mL/kg/h for >6 h) to constitute AKI (see Appendix 1 for criteria and stages of AKI) [9]. It can develop in the setting of pre-existing renal insufficiency or can develop in a patient with previously normal kidneys [10]. <br />&nbsp;&nbsp;\nOver 75% of patients with AKI will have either prerenal azotemia (PRA) or ATN (a parenchymal, intrarenal process) as the cause [4]. Prerenal causes of AKI relate to hypoperfusion or hypovolemia. A clinical suspicion of AKI usually leads to a fluid challenge with central monitoring and correction of the hypovolemic state, which corrects the renal failure. A common exception to this approach is the patient with heart failure or liver failure. A high ratio of blood urea nitrogen to creatinine has long been considered a marker of PRA. In addition, a characteristic laboratory finding in PRA is avid sodium retention, with a urine sodium concentration <20 mEq/L [11]. A meta-analysis of various laboratory studies in an attempt to differentiate PRA from ATN revealed that most determinations (urine/plasma creatinine index, urine/plasma urea, or urinary sodium) are often nonspecific or unreliable [10]. Still, most experienced clinicians find that when urine output is <500 mL for 24 hours, a determination of urinary fractional excretion of sodium is helpful. <br />&nbsp;&nbsp;\nIn a patient with previously undiagnosed renal failure, the most helpful initial diagnostic test is to evaluate renal size using grayscale ultrasonography (US). If the kidneys are small and echogenic, the process is long-standing and unlikely to improve. Renal size is commonly determined from a measurement of renal length. Renal volume calculated by US provides a better measure of functioning renal parenchyma [12]; however, it is an imperfect measure because it includes the renal central sinus fat. In patients with CRF, the renal cortical thickness measured by US appears to be more closely related to the estimated glomerular filtration rate (eGFR) than renal length [13]. <br />&nbsp;&nbsp;\nSometimes, evaluation by US helps to identify a correctable cause of renal failure, such as obstruction, which is a postrenal cause of AKI. However, a number of studies have evaluated the use of US in the setting of acute renal insufficiency and have found it is generally unnecessary to exclude an obstruction unless 1) there is a clinical history that strongly supports an obstruction [14], such as flank pain, urolithiasis, or pelvic mass [15]; 2) the patient is deemed at high risk for obstruction [16]; or 3) if specific clinical factors stratify the patient into a highrisk group [17]. This applies irrespective of whether the patient requires treatment in an intensive care setting [18]. If hydronephrosis is present, retrograde or antegrade relief of the obstruction is usually performed. If there is no hydronephrosis and the patient does not have hypertension or other history to suggest RAS, then further workup of the small, echogenic kidneys is not warranted. Obstruction may occur in the oncologic patient, the trauma patient, or the patient with a solitary kidney [19,20]. <br />&nbsp;&nbsp;\nBilateral, obstructing ureteral calculi are rare. More often in the older male patient, a bilateral ureteral obstruction may occur in a chronic bladder outlet obstruction by an enlarged prostate. In such cases, the patient may appear to be suffering from new onset renal failure; however, the deterioration in renal function has been ongoing but has remained clinically occult. Grayscale US is the most effective way to exclude a subacute or chronic obstruction. <br />&nbsp;&nbsp;\nRegular grayscale US is not accurate in the minimally dilated obstructive situation, such as with retroperitoneal metastatic tumor or idiopathic retroperitoneal fibrosis, in which the ureter encasement interferes with peristalsis; in 1 series, 4%–5% of patients with an obstruction showed minimal or no upper-tract dilation [21]. Color Doppler US of the bladder can assist in detecting a urinary obstruction. Ureteral jets are streams of urine entering the bladder that can be detected with color Doppler US. The unilateral absence of a renal jet after 10 minutes of observation has an approximately 90% positive predictive value for a complete obstruction [22]. The bilateral absence of ureteral jets, however, is a normal finding. Also, in a partial obstruction, the ureteral jets can still be seen; a continuous low-level jet on the partially obstructed side is common [22].\nThe patient with an obstructed renal transplant can present with acute failure. Platt et al [23] found an elevated resistive index (RI) in 85% of transplanted kidneys with obstruction; a normal RI should argue strongly against an obstruction, unless a ureteral leak is also present. In addition to obstruction, an elevated RI can also be found in rejection and ATN; therefore, RI measurements are not reliable in the differential diagnosis of these entities. If US cannot determine the cause of the obstruction, MRI or nonenhanced CT can be obtained (retroperitoneal mass, lymphadenopathy, fibrosis, calculi, etc.). <br />&nbsp;&nbsp;\nRAS and thrombosis are prerenal causes of AKI, but they are uncommon. The multicenter Program to Improve Care in Acute Renal Disease Study found that renal artery thrombosis, stenosis, or trauma accounted for 1% of the causes of AKI in 618 critically ill patients [24]. US can provide a measure of renal perfusion. Some have suggested that duplex Doppler US can supplant radionuclide scintigraphy, magnetic resonance angiography (MRA), or contrast angiography in evaluating the renal arteries; however, these results have not been reproduced in many centers. Newer MRA techniques offer improved images of the main and segmental renal arteries [25]. <br />&nbsp;&nbsp;\nMRI can also provide direct assessment of renal blood flow [26]. Patients with normal or mildly decreased renal function may undergo contrast-enhanced MRA. However, if there is a risk for nephrogenic systemic fibrosis (NSF) among patients with reduced renal reserves, effective nonenhanced MRA techniques for evaluating the renal arteries are also available (eg, steady-state free precession using inflow inversion recovery or 3-D phase contrast) [27]. One caveat for patients with AKI is that eGFR or creatinine levels are unreliable when non–steadystate\nconditions exist. An MRI with contrast should be pursued with caution in any patient with AKI until it is clear that the kidney function is stable. Bilateral renal vein thrombosis is another vascular cause of AKI that can be diagnosed using Doppler US or MRI with vascular imaging techniques. However, it, too, is an uncommon cause of AKI; no cases were found in 748 AKI episodes in a prospective, multicenter epidemiological study from Spain [28]. Trauma presents a unique constellation of possible causes of AKI, such as renal artery occlusion, severe kidney trauma, and renal vein thrombosis occurring bilaterally or in a solitary kidney. Renal trauma is more fully addressed as a separate topic. (See the ACR Appropriateness Criteria® topic on “Renal Trauma.”) <br />&nbsp;&nbsp;\nIf the kidneys are of normal size on the initial US examination, with or without increased echogenicity, this may represent reversible renal failure, most often AKI. A number of publications from the late 1980s and early 1990s suggested the potential of Doppler US to improve the assessment of renal intrinsic dysfunction [29]. Changes in intrarenal arterial waveforms were shown to be associated with urinary obstruction, several intrinsic renal disorders, and renal vascular disease. One example is the use of Doppler imaging to distinguish acute prerenal failure from ATN (intrarenal failure). Unlike traditional grayscale US, which shows normal kidneys in most patients with ATN, duplex Doppler US shows an elevated RI ([peak systolic velocity – end diastolic velocity]/peak systolic velocity], abnormal >0.7) in 96% of patients with ATN. However, false-negative examinations can occur with nephrotoxic drug-induced ATN [20]. Also, ATN has a higher RI than prerenal ARF, but there is some overlap as 20% of patients with prerenal ARF had resistive indexes >0.75. These inconsistent findings and discouraging clinical experiences prompted most radiologists to abandon the RI [29], and renal biopsy remains important for evaluating intrinsic renal dysfunction. <br />&nbsp;&nbsp;\nNephrotoxic drugs and ATN following prolonged shock, with the precipitation of hemoglobin and/or myoglobin in the tubules, are other causes of AKI that may lead to abnormal CT findings [2]. <br />&nbsp;&nbsp;\nIf prerenal and postrenal causes of AKI have been excluded, then an intrarenal cause is likely. Radionuclide scintigraphy with technetium-labeled mercaptoacetyltriglycine (MAG-3) has been studied in this setting, but it is currently not commonly performed. A progressive parenchymal accumulation without significant excretion is suggestive of ATN. An absent uptake suggests more serious conditions, such as acute cortical necrosis and acute glomerulonephritis. In AKI, GFR is more affected than renal blood flow; hence, Tc-99m diethylene-triaminepenta- acetic acid (DTPA) accumulation is decreased, and this agent is less able to distinguish acute from chronic renal disease. However, quantitative studies with the renal tubular agents, such as Tc-99m MAG-3, can be used [30,31]. These methods assess the effective renal plasma flow (ERPF) and the degree of renal function, and they also have prognostic significance. Patients with an ERPF >125 mL/min and good uptake usually recover completely or improve markedly. ATN, hepatorenal syndrome, and acute interstitial nephritis belong in the category of good prognosis. Patients with low uptake have a poor prognosis and eventually require dialysis or transplantation. <br />&nbsp;&nbsp;\nCT is used to evaluate the trauma patient and supplement technically unsatisfactory or equivocal US findings. Excretory urography has no role in investigating AKI. <br />&nbsp;&nbsp;\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('430', '52', 'M04_005', '1', '前列腺炎诊断治疗指南', '无', '中华医学会泌尿外科学分会 (CUA)', '2011', '那彦群，叶章群，孙光等,2011版中国泌尿外科疾病诊断治疗指南[M].北京：人民卫生出版社，2011.', '中文', '1.传统分类方法：<br />&nbsp;&nbsp;1.1急性细菌性前列腺炎；<br />&nbsp;&nbsp;1.2慢性细菌性前列腺炎；<br />&nbsp;&nbsp;1.3慢性非细菌性前列腺炎；<br />&nbsp;&nbsp;1.4前列腺痛；<br />&nbsp;&nbsp;2. 新的分类方法：<br />&nbsp;&nbsp;   2.1 Ⅰ型；<br />&nbsp;&nbsp;2.2 Ⅱ型；<br />&nbsp;&nbsp;2.3 Ⅲ型；<br />&nbsp;&nbsp;2.4 Ⅳ型；<br />&nbsp;&nbsp;', '前列腺炎', null, null, '1．诊断原则<br />&nbsp;&nbsp;推荐按照NIH分型诊断前列腺炎。<br />&nbsp;&nbsp;Ⅰ型：诊断主要依靠病史、体格检查和血、尿的细菌培养结果。对患者进行直肠指检是必须的，但禁忌进行前列腺按摩。在应用抗生素治疗前，应进行中段尿培养或血培养。经36小时规范处理，患者病情未改善时，建议进行经直肠B超等检查，全面评估下尿路病变，明确有无前列腺脓肿。<br />&nbsp;&nbsp;Ⅱ型和Ⅲ型（慢性前列腺炎）：须详细询问病史、全面体格检查（包括直肠指检）、尿液和前列腺按摩液常规检查。推荐应用NIH慢性前列腺炎症状指数（NIH chronic prostatitis symptom index，NIH-CPSI，见附录一）进行症状评分。推荐“两杯法”或“四杯法”进行病原体定位试验。<br />&nbsp;&nbsp;为明确诊断及鉴别诊断，可选择的检查有：精液分析或细菌培养、前列腺特异性抗原（prostate-specific antigen，PSA）、尿细胞学、经腹或经直肠B超（包括残余尿测定）、尿流率、尿动力学、CT、MRI、尿道膀胱镜检查和前列腺穿刺活检等（表1）。<br />&nbsp;&nbsp;Ⅳ型：无症状，在前列腺按摩液（EPS）、精液、前列腺按摩后尿液、前列腺组织活检及前列腺切除标本的病理检查时被发现。<br />&nbsp;&nbsp;  2.诊断方法<br />&nbsp;&nbsp;前列腺炎具体诊断方法包括：<br />&nbsp;&nbsp;2.1临床症状  诊断前列腺炎时，应详细询问病史，了解发病原因或诱因；询问疼痛性质、特点、部位、程度和排尿异常等症状；了解治疗经过和复发情况；评价疾病对生活质量的影响；了解既往史、个人史和性生活情况。<br />&nbsp;&nbsp;Ⅰ型：常突然发病，表现为寒战、发热、疲乏无力等全身症状，伴有会阴部和耻骨上疼痛，尿路刺激症状和排尿困难，甚至急性尿潴留。<br />&nbsp;&nbsp;Ⅱ和Ⅲ型：临床症状类似，多有疼痛和排尿异常等。Ⅱ型可表现为反复发作的下尿路感染。Ⅲ型主要表现为骨盆区域疼痛，可见于会阴、阴茎、肛周部、尿道、耻骨部或腰骶部等部位。排尿异常可表现为尿急、尿频、尿痛和夜尿增多等。由于慢性疼痛久治不愈，患者生活质量下降，并可能有性功能障碍、焦虑、抑郁、失眠、记忆力下降等。<br />&nbsp;&nbsp;Ⅳ型：无临床症状。<br />&nbsp;&nbsp;慢性前列腺炎症状评分<br />&nbsp;&nbsp;由于诊断慢性前列腺炎的客观指标相对缺乏并存在诸多争议。因此，推荐应用NIH-CPSI进行症状评估[2]。NIH-CPSI主要包括3部分内容，有9个问题（0～43分）。第一部分评估疼痛部位、频率和严重程度，由问题1～4组成（0～21分）；第二部分为排尿症状，评估排尿不尽感和尿频的严重程度，由问题5～6组成（0～10分）；第三部分评估对生活质量的影响，由问题7～9组成（0～12分）。目前已被翻译成多种语言，广泛应用于慢性前列腺炎的症状和疗效评估。<br />&nbsp;&nbsp;2.2体格检查  诊断前列腺炎，应进行全面体格检查，重点是泌尿生殖系统。检查患者下腹部、腰骶部、会阴部、阴茎、尿道外口、睾丸、附睾和精索等有无异常，有助于进行诊断和鉴别诊断。直肠指检对前列腺炎的诊断非常重要，且有助于鉴别会阴、直肠、神经病变或前列腺其他疾病，同时通过前列腺按摩获得EPS。<br />&nbsp;&nbsp;Ⅰ型：体检时可发现耻骨上压痛、不适感，有尿潴留者可触及耻骨上膨隆的膀胱。直肠指检可发现前列腺肿大、触痛、局部温度升高和外形不规则等。禁忌进行前列腺按摩。<br />&nbsp;&nbsp;Ⅱ型和Ⅲ型：直肠指检可了解前列腺大小、质地、有无结节、有无压痛及其范围与程度，盆底肌肉的紧张度、盆壁有无压痛，按摩前列腺获得EPS。直肠指检前，建议留取尿液进行常规分析和尿液细菌培养。<br />&nbsp;&nbsp;2.3实验室检查<br />&nbsp;&nbsp;2.3.1EPS常规检查：EPS常规检查通常采用湿涂片法和血细胞计数板法镜检，后者具有更好的精确度。<br />&nbsp;&nbsp;正常的EPS中白细胞<10个/HP，卵磷脂小体均匀分布于整个视野，pH 6.3～6.5，红细胞和上皮细胞不存在或偶见。当白细胞>10个/HP，卵磷脂小体数量减少，有诊断意义。白细胞的多少与症状的严重程度不相关。胞质内含有吞噬的卵磷脂小体或细胞碎片等成分的巨噬细胞，也是前列腺炎的特有表现。当前列腺有细菌、真菌及滴虫等病原体感染时，可在EPS中检测出这些病原体。<br />&nbsp;&nbsp;此外，为了明确区分EPS中白细胞等成分，可对EPS采用革兰染色等方法进行鉴。<br />&nbsp;&nbsp;如前列腺按摩后收集不到EPS，不宜多次重复按摩，可让患者留取前列腺按摩后尿液进行分析。<br />&nbsp;&nbsp;2.3.2尿常规分析及尿沉渣检查：尿常规分析及尿沉渣检查是排除尿路感染、诊断前列腺炎的辅助方法。<br />&nbsp;&nbsp;2.3.3细菌学检查<br />&nbsp;&nbsp;1）Ⅰ型：应进行中段尿的染色镜检、细菌培养与药敏试验，以及血培养与药敏试验。<br />&nbsp;&nbsp;2） 慢性前列腺炎（Ⅱ型和Ⅲ型）：推荐“两杯法”或“四杯法”病原体定位试验。<br />&nbsp;&nbsp;A. “四杯法”：1968年，Meares和Stamey提出采用依次收集患者的分段尿液和EPS分别进行分离培养的方法（简称“四杯法”），区分男性尿道、膀胱和前列腺感染（表2）。<br />&nbsp;&nbsp;B. “两杯法”：“四杯法”操作复杂、耗时、费用高，在实际临床工作中通常推荐“两杯法”。“两杯法”是通过获取前列腺按摩前、后的尿液，进行显微镜检查和细菌培养（表3）。<br />&nbsp;&nbsp;2.3.4其他病原体检查 <br />&nbsp;&nbsp;1） 沙眼衣原体检测：沙眼衣原体（Chlamydia trachomatis，Ct）检测方法有培养法、免疫荧光法、斑点金免疫渗滤法、聚合酶链反应(polymerase chain reaction，PCR)和连接酶链反应(ligase chain reaction，LCR)等。培养法仅检测活的Ct，且因费用、时间及技术水平等原因，不推荐临床应用。目前主要采用灵敏度高、特异性强的PCR 和LCR 技术检测Ct的核酸成分。<br />&nbsp;&nbsp;2）支原体检测：可能引起前列腺感染的支原体主要为溶脲脲原体（Ureaplasma urealyticum，Uu）和人型支原体（mycoplasma hominis，Mh）。培养法是Uu和Mh检测的金标准，结合药敏试验可为临床诊断与治疗提供帮助；免疫学检测和核酸扩增技术等也应用于支原体检测。<br />&nbsp;&nbsp;由于沙眼衣原体和支原体也可能存在于男性尿道中，建议先取尿道拭子检测，在排除尿道感染后，再进行EPS检测，以进一步明确是否为前列腺感染。<br />&nbsp;&nbsp;此外，对于EPS中其他病原体，如真菌的检测方法主要为直接涂片染色镜检和分离培养；病毒检测通常采用前列腺组织培养或PCR技术 。<br />&nbsp;&nbsp;（5）其他实验室检查：前列腺炎患者可能出现精液质量异常，如白细胞增多、精液不液化、血精和精子质量下降等改变。在部分慢性前列腺炎患者中也会出现PSA升高的情况。尿细胞学检查在与膀胱原位癌等鉴别方面具有一定价值。<br />&nbsp;&nbsp;2.4器械检查<br />&nbsp;&nbsp;2.4.1 B超：尽管前列腺炎患者B超检查可以发现前列腺回声不均，前列腺结石或钙化，前列腺周围静脉丛扩张等表现，但目前仍然缺乏B超诊断前列腺炎的特异性表现，也无法利用B超对前列腺炎进行分型。但B超可以较准确地了解前列腺炎患者肾脏、膀胱以及残余尿等情况，对于除外尿路器质性病变有一定帮助。经直肠B超对于鉴别前列腺、精囊和射精管病变以及诊断和引流前列腺脓肿有价值。<br />&nbsp;&nbsp;2.4.2尿动力学：①尿流率，尿流率检查可以大致了解患者排尿状况，有助于前列腺炎与排尿障碍相关疾病进行鉴别；② 侵入性尿动力学检查， 研究表明，前列腺炎患者侵入性尿动力学检查可以发现膀胱出口梗阻、尿道功能性梗阻、膀胱逼尿肌收缩力减退或逼尿肌无反射和逼尿肌不稳定等膀胱尿道功能障碍。在临床怀疑有上述排尿功能障碍，或尿流率及残余尿有明显异常时，可选择侵入性尿动力学检查以明确诊断。<br />&nbsp;&nbsp;2.4.3膀胱尿道镜：膀胱尿道镜为有创性检查，不推荐前列腺炎患者常规进行此项检查。在某些情况下，如患者有血尿，尿液分析明显异常，其他检查提示有膀胱尿道病变时可选择膀胱尿道镜检查以明确诊断。<br />&nbsp;&nbsp;2.4.4 CT和MRI  对鉴别精囊、射精管等盆腔器官病变有潜在应用价值，但对于前列腺炎本身的诊断价值仍不清楚。<br />&nbsp;&nbsp;3. 鉴别诊断<br />&nbsp;&nbsp;Ⅲ型前列腺炎缺乏客观的、特异性的诊断依据，临床诊断时应与可能导致骨盆区域疼痛和排尿异常的疾病进行鉴别诊断，以排尿异常为主的患者应明确有无膀胱出口梗阻和膀胱功能异常。需要鉴别的疾病包括：良性前列腺增生、睾丸附睾和精索疾病、膀胱过度活动症、神经源性膀胱、间质性膀胱炎、腺性膀胱炎、性传播疾病、膀胱肿瘤、前列腺癌、肛门直肠疾病、腰椎疾病、中枢和外周神经病变等。<br />&nbsp;&nbsp;III型前列腺炎患者经治疗后症状无缓解，应根据具体情况，选择进一步的检查，除外上述疾病。<br />&nbsp;&nbsp;<br />&nbsp;&nbsp;', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('431', '27', 'C01_001', '0', 'ZY／T001.8-94，中医病证诊断疗效标准·中医皮肤科病证诊断疗效标准', 'Criteria of diagnosis and therapeutic effect of skin diseases and syndromes in traditional Chinese medicine', '国家中医药管理局', '1994', '国家中医药管理局.ZY／T001.8-94，中医病证诊断疗效标准·中医皮肤科病证诊断疗效标准[S].南京：南京大学出版社，1994.', '中文', null, null, '粉刺', '1.肺经风热：丘疹色红，或有痒痛。舌红，苔薄黄，脉浮数。<br />&nbsp;&nbsp;2.湿热蕴结：皮疹红肿疼痛，或有脓疱，口臭，便秘，尿黄。舌红，苔黄腻，脉滑数。<br />&nbsp;&nbsp;3.痰湿凝结：皮疹结成囊肿，或有纳呆，便溏。舌淡胖，苔薄，脉滑。', '粉刺多发于面部，以丘疹、脓疱、结节有时可挤出白色碎米样粉汁为特征的一种皮肤病。相当于寻常性痤疮。<br />&nbsp;&nbsp;1. 初起在毛囊口，呈现小米粒大小红色丘疹，亦可演变为脓疱。此后可形成硬结样白头粉刺或黑头粉刺，严重病例可形成硬结性囊肿。<br />&nbsp;&nbsp;2. 多发于男女青春期之面部及胸背部，常伴有皮脂溢出。<br />&nbsp;&nbsp;3. 多有饮食不节，过食肥甘厚味，或感外邪等诱发。<br />&nbsp;&nbsp;4. 青春期过后，多数可自然减轻。<br />&nbsp;&nbsp;5. 妇女多伴有月经不调。', null, '皮损、自觉症状', '1.治愈：皮肤损害消退，自觉症状消失。<br />&nbsp;&nbsp;2.好转：自觉症状明显减轻，皮损消退30％以上。<br />&nbsp;&nbsp;3.未愈：皮损及症状均无变化或消退不足30％。', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('432', '27', 'C01_002', '1', 'GB17149.3-1997化妆品痤疮诊断标准及处理原则', 'Diagnostic criteria and principles of management of acne induced by cosmetics', '国家技术监督局，中华人民共和国卫生部', '1997', '国家技术监督局，中华人民共和国卫生部.GB17149.3-1997，化妆品痤疮诊断标准及处理原则[S].北京：中国标准出版社，1997', '中文', null, '化妆品痤疮', null, null, '化妆品痤疮是指由化妆品引起的面部痤疮样皮疹。<br />&nbsp;&nbsp;有明确的化妆品接触史，在接触部位出现与毛孔一致的黑头粉刺、炎性丘疹及脓疱等。除外非化妆品引起的痤疮，必要时对患者所用化妆品做质量鉴定。 <br />&nbsp;&nbsp;1.发病前有明确的化妆品接触史。 <br />&nbsp;&nbsp;2.皮损仅局限于接触化妆品的部位。 <br />&nbsp;&nbsp;3.化妆品痤疮一般表现为黑头粉刺、炎性丘疹，脓疱等。 <br />&nbsp;&nbsp;4.若原先已有寻常痤疮存在，则症状会明显加重。 <br />&nbsp;&nbsp;5.停用可疑化妆品后，痤疮样皮损可明显改善或消退。 <br />&nbsp;&nbsp;6.排除非化妆品引起的其他一切痤疮。 ', null, null, null, ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('433', '27', 'C01_003', '1', 'GB16375-1996 职业性痤疮诊断标准及处理原则', 'Diagnostic criteria and principles of management of occupational acne', '国家技术监督局，中华人民共和国卫生部', '1996', '国家技术监督局，中华人民共和国卫生部.GB16375-1996，职业性痤疮诊断标准及处理原则[S].北京：中国标准出版社，1996', '中文', '油痤疮；氯痤疮', '职业性痤疮', null, null, '1.油座疮<br />&nbsp;&nbsp;接触部位发生多数毛囊性损害，表现为毛孔扩张、毛囊口角化、毳毛折断及黑头粉刺。常有炎性丘疹、毛囊炎、结节及囊肿。较大的黑头粉刺挤出黑头脂质栓塞物后，常留有凹陷性疤痕。皮损一般无自觉症状或有轻度痒感或刺痛。多发生于眼睑、耳廓、四肢伸侧，特别是与油类浸渍的衣服摩擦的部位，而不限于面颈、胸、背、肩等寻常座疮的好发部位。2.氯座疮<br />&nbsp;&nbsp;接触部位发生成片的毛囊性皮损，表现以黑头粉刺为主。初发时常在眼外下方及颧部出现密集的针尖大的小黑点，日久则于耳廓周围、腹部、臀部及阴囊等处出现较大的黑头粉刺，伴有毛囊口角化，间有粟丘疹样皮损，炎性丘疹较少见。耳廓周围及阴囊等处常有草黄色囊肿。<br />&nbsp;&nbsp;表C01_003_001', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('434', '27', 'C01_004', '1', 'GBZ 55-2002 职业性座疮诊断标准', 'Diagnostic Criteria of Occupational Acne', '中华人民共和国卫生部', '2002', '中华人民共和国卫生部.GBZ55-2002，职业性痤疮诊断标准[S].北京：中国标准出版社，2002', '中文', '油痤疮；氯痤疮', '职业性痤疮', null, null, '1.油痤疮：接触部位发生多数毛囊性损害，表现为毛孔扩张、毛囊口角化、毳毛折断及黑头粉刺。常有炎性丘疹、毛囊炎、结节及囊肿。较大的黑头粉刺挤出黑头脂质栓塞物后，常留有凹陷性疤痕。皮损一般无自觉症状或有轻度痒感或刺痛。多发生于眼睑、耳廓、四肢伸侧，特别是与油类浸渍的衣服摩擦的部位，而不限于面颈、胸、背、肩等寻常痤疮的好发部位。<br />&nbsp;&nbsp;2.氯痤疮：接触部位发生成片的毛囊性皮损，表现以黑头粉刺为主。初发时常在眼外下方及颧部出现密集的针尖大的小黑点，日久则于耳廓周围、腹部、臀部及阴囊等处出现较大的黑头粉刺，伴有毛囊口角化，间有粟丘疹样皮损，炎性丘疹较少见。耳廓周围及阴囊等处常有草黄色囊肿。<br />&nbsp;&nbsp;表C01_004_001\n', null, null, ' ', ' 诊断标准与1996版基本一致。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('435', '27', 'C01_005', '1', '儿科痤疮诊断和治疗循证推荐', 'Evidence-Based Recommendations for the Diagnosis and Treatment of Pediatric Acne', '美国痤疮和酒糟鼻学会(AARS,American Acne and Rosacea Society)', '2013', 'http://pediatrics.aappublications.org/content/131/Supplement_3/S163.full.html', '英文', '（一）按年龄分类：新生儿痤疮；婴儿痤疮；儿童中期痤疮；青春期前痤疮；青春期痤疮。<br />&nbsp;&nbsp;（二）按严重度分：轻度；中度；严重。', '儿科痤疮', null, null, '表C01_005_001', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('436', '27', 'C01_006', '1', '寻常痤疮分级和疗效标准初步制定', '无', '中华医学美学与美容分会皮肤美容学组', '1998', '寻常痤疮分级和疗效标准初步制定.中华医学美容杂志 1998，4（1）：41.', '中文', '（一）3度：轻度；中度；重度。<br />&nbsp;&nbsp;（二）9组：1级；2级；3级；4级；5级；6级；7级；8级；9级。', '寻常痤疮', null, null, '表C01_006_001', null, '疗效指数', '（一）评分: ①治疗前( 3)度9级，每1级评为1分；②治疗后，每降低1级减去1分，若全部消失则为0分；③疗效指数=(疗前分数-疗后分数)/疗前指数×100%；④举例：若一患者在治疗前为5级，计为5分，治疗后降为2级，则为2分；指数=(5-2)/5×100%=60% ；⑤若治疗后仍为原级，但有所减轻，则可计算小分，每好转10%可减去0. 1分。<br />&nbsp;&nbsp;（二）疗效标准：分为4级<br />&nbsp;&nbsp;临床治愈：疗效指数达95%以上；显效：疗效指数60～ 95%；有效：疗效指数20～ 59%；无效：疗效指数< 20% 。<br />&nbsp;&nbsp;（三）注释：①皮损计数部位：选右或左侧面部，以中心线划界,包括半侧额部、颧部、颊部、颏部和颌部总和计算；②非活动性病变，包括色素沉着，坑点状瘢痕，碎冰锥样瘢痕，不作评分指数；③疗效判定时间：第一次判定：按治疗方案所选定的疗程结束时即可判定疗效；第二次判定：指疗程结束后4周再做第二次判定。', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('437', '27', 'C01_007', '0', 'ZYYXH/T342～361-2012中医皮肤科常见病诊疗指南', 'Guidlines for Diagnosis and Treatment of Commom Diseases of Dermatology in Traditional Chinese Medicine', '中华中医药学会', '2012', '中华中医药学会.ZYYXH/T342～361-2012，中医皮肤科常见病诊疗指南[S].北京：中国中医药出版社，2012.', '中文', '寻常性痤疮；聚合性痤疮；迟发性痤疮（成人痤疮或青春期后痤疮）；其他类型痤疮', null, '肺风粉刺', '肺经风热证；胃肠湿热证；肝经郁热证；热毒夹瘀证；痰瘀聚结证', '1.寻常性痤疮：寻常性痤疮多见于青少年，皮损好发面部，其次是胸部及上背部。常见皮损为白头粉刺（闭合性粉刺）和黑头粉刺（开放性粉刺），为非炎症性皮损，进一步发展为炎性皮疹。部分顶端出现脓疱，愈后局部留有色素沉着或小凹陷性瘢痕。严重时，炎症继续扩大及深入皮下，出现花生到蚕豆大小的炎性结节或囊肿。\n2.聚合性痤疮：聚合性痤疮是痤疮中较重的类型。临床表现为面、颈、背部、腰臀等部位出现多数的大粉刺、丘疹、脓疱、囊肿、有窦道的脓疡等，流出恶臭的脓性分泌物。脓疡破溃后可以形成深', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('438', '27', 'C01_008', '1', '临床诊疗指南·皮肤病与性病分册', '无', '中华医学会', '2006', '中华医学会.临床诊疗指南·皮肤病与性病分册.北京：人民卫生出版社，2006.', '中文', 'Ⅰ度（轻度）：散发至多发的黑头粉刺，可伴散在分布的炎性丘疹。<br />&nbsp;&nbsp;Ⅱ度（中等度）：Ⅰ度+炎症性皮损数目增加，出现浅在性脓疱，但局限于颜面。<br />&nbsp;&nbsp;Ⅲ度（重度）：Ⅱ度+深在性脓疱，分布于颜面、颈部和胸背部。<br />&nbsp;&nbsp;Ⅳ度（重度-集簇性）：Ⅲ度+结节、囊肿，伴瘢痕形成，发生于上半身。', '痤疮', null, null, '1.诊断<br />&nbsp;&nbsp;1.1多发于青年男女。<br />&nbsp;&nbsp;1.2主要见于面、额部，其次是胸、背及肩部等皮脂溢出部位。<br />&nbsp;&nbsp;1.3皮损初起为与毛囊一致的圆锥形丘疹称粉刺，分为开放性的黑头粉刺和闭合性的白头粉刺，同时伴有炎症损害如炎性丘疹、脓丘疹、脓疱、结节、囊肿等。<br />&nbsp;&nbsp;1.4临床上根据病情的严重程度，采用Pillsbury分类法将痤疮分为Ⅰ-Ⅳ度。<br />&nbsp;&nbsp;Ⅰ度（轻度）：散发至多发的黑头粉刺，可伴散在分布的炎性丘疹。<br />&nbsp;&nbsp;Ⅱ度（中等度）：Ⅰ度+炎症性皮损数目增加，出现浅在性脓疱，但局限于颜面。<br />&nbsp;&nbsp;Ⅲ度（重度）：Ⅱ度+深在性脓疱，分布于颜面、颈部和胸背部。<br />&nbsp;&nbsp;Ⅳ度（重度-集簇性）：Ⅲ度+结节、囊肿，伴瘢痕形成，发生于上半身。<br />&nbsp;&nbsp;1.5特殊类型的痤疮：如聚合性痤疮、暴发性痤疮、药物性痤疮、婴儿痤疮、月经前痤疮、职业性痤疮、化妆品痤疮等。<br />&nbsp;&nbsp;1.6一般无自觉症状，可有轻微痒、痛。<br />&nbsp;&nbsp;1.7病程慢性，时轻时重，多数至青春期渐缓解，少数患者至中年期方愈，可遗留色素沉着、瘢痕。<br />&nbsp;&nbsp;2.鉴别诊断：<br />&nbsp;&nbsp;2.1酒渣鼻<br />&nbsp;&nbsp;2.颜面播散性粟粒性狼疮。', null, null, null, ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('439', '28', 'Z03_001', '0', 'ZY／T001.7-94，中医病证诊断疗效标准·中医肛肠科病证诊断疗效标准', 'Criteria of diagnosis and therapeutic effect of anorectal diseases and syndromes in traditional Chinese medicine', '国家中医药管理局', '1994', '国家中医药管理局.ZY／T001.7-94，中医病证诊断疗效标准·中医肛肠科病证诊断疗效标准[S].南京：南京大学出版社，1994.\n\n', '中文', '1.一期；2.二期；3.三期', null, '内痔', '风伤肠络；湿热下注；气滞血瘀；脾虚气陷', '1.便血，色鲜红，或无症状。肛门镜检查：齿线上方粘膜隆起，表面色淡红。多见于一期内痔。<br />&nbsp;&nbsp;2.便血，色鲜红，伴有肿物脱出肛外，便后可自行复位。肛门镜检查：齿线上方粘膜隆起，表面色暗红。多见于二期内痔。<br />&nbsp;&nbsp;3.排便或增加腹压时，肛内肿物脱出，不能自行复位，需休息后或手法复位，甚者可发生嵌顿，伴有剧烈疼痛，便血少见或无。肛门镜检查：齿线上方有粘膜隆起，表面多有纤维化。多见于三期内痔。\n', '1.风伤肠络：大便带血、滴血或喷射状出血，血色鲜红，或有肛门瘙痒。舌红，苔薄白或薄黄，脉浮数。<br />&nbsp;&nbsp;2.湿热下注：便血色鲜，量较多，肛内肿物外脱，可自行回缩，肛门灼热。舌红，苔黄腻，脉滑数。<br />&nbsp;&nbsp;3.气滞血瘀：肛内肿物脱出，甚或嵌顿，肛管紧缩，坠胀疼痛。甚则肛缘有血栓，水肿，触痛明显。舌质暗红，苔白或黄，脉弦细涩。<br />&nbsp;&nbsp;4.脾虚气陷：肛门坠胀，肛内肿物外脱，需手法复位。便血色鲜或淡，可出现贫血，面色少华，头昏神疲，少气懒言，纳少便溏。舌淡胖，边有齿痕，舌苔薄白，脉弱。\n', '自觉症状、痔核', '1.治愈：症状消失，痔核消失或全部萎缩。<br />&nbsp;&nbsp;2.好转：症状改善，痔核缩小或萎缩不全。<br />&nbsp;&nbsp;3.未愈：症状和体征均无变化。\n', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('44', '34', 'M03_008', '1', 'ACR适当性标准', 'ACR Appropriateness Criteria', '美国放射学会(ACR,American College of Radiology)', '2013', null, '英文', null, '慢性肾衰 (Chronic Kidney Disease)', null, null, null, null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('440', '28', 'Z03_002', '0', 'ZY／T001.7-94，中医病证诊断疗效标准·中医肛肠科病证诊断疗效标准', 'Criteria of diagnosis and therapeutic effect of anorectal diseases and syndromes in traditional Chinese medicine', '国家中医药管理局', '1994', '国家中医药管理局.ZY／T001.7-94，中医病证诊断疗效标准·中医肛肠科病证诊断疗效标准[S].南京：南京大学出版社，1994.\n\n', '中文', '1.炎性外痔；2.血栓性外痔；3.静脉曲张性外痔', null, '外痔', '气滞血瘀；湿热下注；脾虚气陷', '1.肛缘皮肤损伤或感染，呈红肿或破溃成脓，疼痛明显。多见于炎性外痔。<br />&nbsp;&nbsp;2.肛缘皮下突发青紫色肿块，局部皮肤水肿，肿块初起尚软，疼痛剧烈，渐变硬，可活动，触痛明显。多见于血栓性外痔。<br />&nbsp;&nbsp;3.排便时或久蹲，肛缘皮有柔软青紫色团块隆起（静脉曲张团），可伴有坠胀感，团块按压后可消失。多见于静脉曲张性外痔。', '1.气滞血瘀：肛缘肿物突起，排便时可增大，有异物感，可有胀痛或坠痛，局部可触及硬性结节。舌紫，苔淡黄，脉弦涩。<br />&nbsp;&nbsp;2.湿热下注：肛缘肿物隆起，灼热疼痛或有滋水，便干或溏。舌红，苔黄腻，脉滑数。<br />&nbsp;&nbsp;3.脾虚气陷：肛缘肿物隆起，肛门坠胀，似有便意，神疲乏力，纳少便溏。舌淡胖，苔薄白，脉细无力。多见于经产妇、老弱体虚者。\n', '自觉症状；痔\n', '1.治愈：症状消失，痔消失。<br />&nbsp;&nbsp;2.好转：症状改善，痔缩小。<br />&nbsp;&nbsp;3.未愈：症状及体征均无变化。\n', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('441', '28', 'Z03_003', '0', 'ZY／T001.7-94，中医病证诊断疗效标准·中医肛肠科病证诊断疗效标准', 'Criteria of diagnosis and therapeutic effect of anorectal diseases and syndromes in traditional Chinese medicine', '国家中医药管理局', '1994', '国家中医药管理局.ZY／T001.7-94，中医病证诊断疗效标准·中医肛肠科病证诊断疗效标准[S].南京：南京大学出版社，1994.\n\n', '中文', null, null, '混合痔', null, '1.便血及肛门部肿物，可有肛门坠胀、异物感或疼痛。<br />&nbsp;&nbsp;2.可伴有局部分泌物或瘙痒。<br />&nbsp;&nbsp;3.肛管内齿线上下同一方位出现肿物（齿线下亦可为赘皮）。', '参照内痔、外痔。', '自觉症状；痔\n', '1.治愈：症状消失，痔消失。<br />&nbsp;&nbsp;2.好转：症状改善，痔缩小。<br />&nbsp;&nbsp;4.未愈：症状及体征均无变化。\n', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('442', '28', 'Z03_004', '0', 'ZYYXH/T322～341-2012，中医肛肠科常见病诊疗指南', 'Guidelines for Diagnosis and Treatment of Commom Diseases of Coloproctology in Traditional Chinese Medicine', '中华中医药学会', '2012', '中华中医药学会.ZYYXH/T322～341-2012，中医肛肠科常见病诊疗指南[S].北京：中国中医药出版社，2012', '中文', '1.内痔：Ⅰ度；Ⅱ度；Ⅲ度；Ⅳ度。<br />&nbsp;&nbsp;2.外痔。<br />&nbsp;&nbsp;3.混合痔。', null, '痔', '风伤肠络；湿热下注；气滞血瘀；脾虚气陷', '1.分类：痔分为内痔、外痔、混合痔。<br />&nbsp;&nbsp;2.临床症状：<br />&nbsp;&nbsp;内痔的主要症状是出血和脱出，可并发血栓、嵌顿、绞窄及排便困难。根据内痔的症状，其严重程度分为4度。<br />&nbsp;&nbsp;Ⅰ度：便时带血、滴血，便后出血可自行停止；无痔脱出。<br />&nbsp;&nbsp;Ⅱ度：常有便血；排便时有痔脱出，便后可自行还纳。<br />&nbsp;&nbsp;Ⅲ度：可有便血；排便或久站及咳嗽、劳累、负重时有痔脱出，需用手还纳。<br />&nbsp;&nbsp;Ⅳ度：可有便血；痔持续脱出或还纳后易脱出。<br />&nbsp;&nbsp;外痔的主要症状是肛门部有软组织团块，可有肛门不适、潮湿、瘙痒或异物感，如发生血栓及炎症，可有疼痛。<br />&nbsp;&nbsp;混合痔主要表现为内痔和外痔的症状同时存在，严重时表现为环状痔脱出。<br />&nbsp;&nbsp;3.体征<br />&nbsp;&nbsp;肛门视诊：肛门视诊可检查有无内痔脱出，肛门周围有无静脉曲张性外痔、血栓性外痔及皮赘。必要时可行蹲位检查，观察脱出内痔的部位、大小和有无出血以及痔黏膜有无充血水肿、糜烂和溃疡。<br />&nbsp;&nbsp;肛管直肠指诊：肛管直肠指诊是重要的检查方法。Ⅰ、Ⅱ度内痔指检时多无异常；对反复脱出的Ⅲ、Ⅳ度内痔，指检有时可触及齿状线上的纤维化痔组织。肛管直肠指诊还可以排除肛管直肠肿瘤和其他疾病。<br />&nbsp;&nbsp;肛门直肠镜：肛门直肠镜可以明确内痔的部位、大小、数目和内痔表面黏膜有无出血、水肿、糜烂等。<br />&nbsp;&nbsp;4.实验室检查：<br />&nbsp;&nbsp;大便隐血试验：这是排除全消化道肿瘤的常用筛查手段。<br />&nbsp;&nbsp;全结肠镜检查：以便血就诊者，有消化道肿瘤家族史或本人有息肉病史者，年龄超过50岁者，大便隐血试验阳性以及缺铁性贫血的痔患者，建议行全结肠镜检查。<br />&nbsp;&nbsp;', '1.风伤肠络证：大便滴血、射血或带血，血色鲜红，大便干结，肛门瘙痒，口干咽燥，舌红，苔黄，脉浮数。<br />&nbsp;&nbsp;2.湿热下注证：便血色鲜红，量较多，肛门肿物外脱、肿胀、灼热疼痛或有滋水，便干或溏，小便短赤，舌质红，苔黄腻，脉浮数。<br />&nbsp;&nbsp;3.气滞血瘀证：肿物脱出肛外、水肿，内有血栓形成，或有嵌顿，表面紫暗、糜烂、渗液，疼痛剧烈，触痛明显，肛管紧缩，大便秘结，小便不利，舌质紫暗或有瘀斑，脉弦或涩。<br />&nbsp;&nbsp;4.脾虚气陷证：肿物脱出肛外，不易复位，肛门坠胀，排便乏力，便血色淡，面色少华，头晕神疲，食少乏力，少气懒言，舌淡胖，苔薄白，脉细弱。', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('443', '28', 'Z03_005', '1', '痔诊治暂行标准', 'Diagnostic criteria and principles of management of occupational acne', '《中华外科杂志》编委会；中华医学会外科学分会肛肠外科学组', '2001', '中华医学会第六回中日大肠肛门病学术交流会.痔诊治暂行标准.第六回中日大肠肛门病学术交流会论文汇编.中国西安.2001,5', '中文', '1.内痔：Ⅰ度；Ⅱ度；Ⅲ度；Ⅳ度。<br />&nbsp;&nbsp;2.外痔。<br />&nbsp;&nbsp;3.混合痔。', '痔', null, null, '1.内痔的分度及临床表现。I度: 便时带血、滴血或喷射状出血，无内痔脱出，便后出血可自行停止。Ⅱ度: 便时带血、滴血或喷射状出血，伴内痔脱出，便后可自行回纳。Ⅲ度: 便时带血、滴血, 伴内痔脱出或久站、咳嗽、劳累、负重时内痔脱出，需用手回纳。Ⅳ度: 内痔脱出，不能回纳，内痔可伴发绞窄、嵌顿。<br />&nbsp;&nbsp;2.外痔的临床表现。肛门不适、潮湿不洁，可伴发血栓形成及皮下血肿。<br />&nbsp;&nbsp;3.混合痔的临床表现。内痔和外痔的症状可同时存在。<br />&nbsp;&nbsp;4.依据病史和肛门物理检查、肛管直肠指检和肛门镜检, 参照痔的分类和内痔分度做出诊断。如稍有可疑应进一步检查；以除外结、直肠、肛管的良、恶性肿瘤及炎性疾病。', null, null, null, ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('444', '28', 'Z03_006', '1', '痔诊治暂行标准2002', '无', '中华医学会外科学分会肛肠外科学组', '2003', '修订痔诊治暂行标准会议纪要.中华外科杂志，2003，41(9):698-699.', '中文', '1.内痔：Ⅰ度；Ⅱ度；Ⅲ度；Ⅳ度。<br />&nbsp;&nbsp;2.外痔。<br />&nbsp;&nbsp;3.混合痔。', '痔', null, null, '1.内痔的主要临床表现是出血和脱出，可伴发血栓、绞窄、嵌顿以及排便困难。内痔的分度:Ⅰ度：便时带血、滴血或喷射状出血，便后出血可自行停止；无痔脱出。Ⅱ度：常有便血；排便时有痔脱出，便后可自行还纳。Ⅲ度：偶有便血；排便或久站、咳嗽、劳累、负重时痔脱出，需用手还纳。Ⅳ度：偶有便血；痔脱出不能还纳。<br />&nbsp;&nbsp;2.外痔的主要临床表现是肛门不适、潮湿不洁，如发生血栓及皮下血肿有剧痛。<br />&nbsp;&nbsp;3.混合痔的主要临床表现是内痔和外痔的症状可同时存在，严重时表现为环状痔脱出。', null, null, ' ', '进一步明确了内痔、外痔和混合痔的概念, 强调了肛垫对内痔发病的作用, 维持原有的内痔的4度分期方法。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('445', '28', 'Z03_007', '1', '痔临床诊治指南（2006版）', '无', '中华医学会外科学分会结直肠肛门外科学组；中华中医药学会肛肠病专业委员会；中国中西医结合学会结直肠肛门病专业委员会', '2006', '痔临床诊治指南（2006版）.中华胃肠外科杂志，2006,9（5）：461-463.', '中文', '1.内痔：Ⅰ度；Ⅱ度；Ⅲ度；Ⅳ度。<br />&nbsp;&nbsp;2.外痔。<br />&nbsp;&nbsp;3.混合痔。', '痔', null, '风伤肠络；湿热下注；气滞血瘀；脾虚气陷', '1.临床表现：<br />&nbsp;&nbsp;1.1内痔：的主要症状是出血和脱出，可并发血栓、嵌顿、绞窄及排便困难。根据内痔的症状，其严重程度分为4度。Ⅰ度：便时带血、滴血，便后出血可自行停止；无痔脱出。Ⅱ度：常有便血；排便时有痔脱出，便后可自行还纳。Ⅲ度：可有便血；排便或久站及咳嗽、劳累、负重时有痔脱出，需用手还纳。Ⅳ度：可有便血；痔持续脱出或还纳后易脱出。<br />&nbsp;&nbsp;1.2外痔：主要临床表现为肛门部软组织团块，有肛门不适、潮湿瘙痒或异物感，如发生血栓及炎症，可有疼痛。<br />&nbsp;&nbsp;1.3混合痔：主要临床表现为内痔和外痔的症状同时存在，严重时表现为环状痔脱出。<br />&nbsp;&nbsp;2.检查方法<br />&nbsp;&nbsp;2.1肛门视诊：检查有无内痔脱出，肛门周围有无静脉曲张性外痔、血栓性外痔及皮赘。必要时可行蹲位检查，观察脱出内痔的部位、大小和有无出血以及痔黏膜有无充血水肿、糜烂和溃疡。<br />&nbsp;&nbsp;2.2肛管直肠指诊：是重要的检查方法。Ⅰ、Ⅱ度内痔指检时多无异常；对反复脱出的Ⅲ、Ⅳ度内痔，指检有时可触及齿状线上的纤维化痔组织。肛管直肠指诊还可以排除肛管直肠肿瘤和其他疾病。<br />&nbsp;&nbsp;2.3肛门直肠镜：可以明确内痔的部位、大小、数目和内痔表面黏膜有无出血、水肿、糜烂等。<br />&nbsp;&nbsp;2.4大便隐血试验：是排除全消化道肿瘤的常用筛查手段。<br />&nbsp;&nbsp;2.5全结肠镜检查：以便血就诊者，有消化道肿瘤家族史或本人有息肉病史者，年龄超过50岁者，大便隐血试验阳性以及缺铁性贫血的痔患者，建议行全结肠镜检查。', '1.风伤肠络证：大便滴血、射血或带血，血色鲜红，大便干结，肛门瘙痒，口干咽燥，舌红，苔黄，脉浮数。<br />&nbsp;&nbsp;2.湿热下注证：便血色鲜红，量较多，肛门肿物外脱、肿胀、灼热疼痛或有滋水，便干或溏，小便短赤，舌质红，苔黄腻，脉浮数。<br />&nbsp;&nbsp;3.气滞血瘀证：肿物脱出肛外、水肿，内有血栓形成，或有嵌顿，表面紫暗、糜烂、渗液，疼痛剧烈，触痛明显，肛管紧缩，大便秘结，小便不利，舌质紫暗或有瘀斑，脉弦或涩。<br />&nbsp;&nbsp;4.脾虚气陷证：肿物脱出肛外，不易复位，肛门坠胀，排便乏力，便血色淡，面色少华，头晕神疲，食少乏力，少气懒言，舌淡胖，苔薄白，脉细弱。', null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('446', '28', 'Z03_008', '1', '痔诊断和治疗指南（2010修订版）', 'Practice Parameters for the Management of Hemorrhoids (Revised 2010)', '美国结直肠外科医师协会标准化工作委员会（The American Society of Colon and Rectal Surgeons,ASCRS）', '2010', '美国结直肠外科医师协会标准化工作委员会.痔诊断和治疗指南（2010修订版）.中华消化外科杂志，2012,11（3）：243-247.$$$$《Diseases of the Colon ＆ Rectum》，2011，54（9）：1059-1064.', '英文', '1.内痔：Ⅰ期；Ⅱ期；Ⅲ期；Ⅳ期。', '痔', null, null, '1.初步诊断<br />&nbsp;&nbsp;痔的诊断主要依靠临床症状和体征。痔的初步诊断应包括有针对性地询问病史和体格检查，重点询问病变范围、严重程度及症状持续时间，如：出血、脱垂、卫生问题及疼痛、纤维素和水的摄入情况。另外，大便习惯，包括大便频率、性状及排便的难易程度也应问及。直肠出血患者，应仔细询问家族史，重点询问肠道病史。有恶性肿瘤的患者需要进一步评估，以确定是否存在偶发或继发性的结直肠癌，是否需要对结肠进行进一步评估。<br />&nbsp;&nbsp;典型的体格检查包括：肛门望诊、指检以及肛门镜或直肠镜，检查是否有血栓形成或其他伴发的肛门、直肠病变，如肛裂、肛瘘、肛周脓肿或克罗恩病。内痔，位于齿状线以上，按照表予以分期。这对治疗方法的选择有指导意义。而实验室检查并非必需。<br />&nbsp;&nbsp;表Z03_009_001<br />&nbsp;&nbsp;2.结肠镜检查<br />&nbsp;&nbsp;有直肠出血的痔患者有必要行结肠镜检查。直肠出血通常由痔引起，但也可能是其他疾病所致，如结直肠肿瘤、炎性肠病、其他类型结肠炎、憩室病和血管发育异常。完整的个人史，详细的家族史，以及包括直肠镜和（或）软性乙状结肠镜在内的体格检查，可识别出高危患者（需要进一步检查）。纳入高危范围的患者，需行全结肠镜检查。无法耐受者，可用软的乙状结肠镜检查，并结合钡灌肠或指南中相应的其他诊断手段。', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('447', '28', 'Z03_009', '0', '痔疮的诊疗标准（试行）', '无', '中国中西医结合学会大肠肛门病专业委员会', '2004', '痔疮的诊疗标准（试行）.《中西医结合大肠肛门病研究新进展——第十届中国中西医结合学会大肠肛门病学术研讨会论文集》2004年：1-3.', '中文', '1.内痔：Ⅰ度；Ⅱ度；Ⅲ度；Ⅳ度。<br />&nbsp;&nbsp;2.外痔：静脉曲张性外痔；血栓性外痔；炎性外痔；结缔组织外痔。<br />&nbsp;&nbsp;3.混合痔。', '痔疮', '痔疮', '1.内痔：风伤肠络；湿热下注；气滞血瘀；大肠实热；脾虚气陷；阴虚肠燥<br />&nbsp;&nbsp;2.外痔<br />&nbsp;&nbsp;大肠实热；湿热下注；气滞血瘀；脾虚气陷<br />&nbsp;&nbsp;3.混合痔<br />&nbsp;&nbsp;风伤肠络、大肠实热、气滞血瘀血、湿热下注、脾虚气陷、阴虚肠燥。', '1.内痔<br />&nbsp;&nbsp;1.1Ⅰ期内痔：主证：偶发便鲜血，可无其他症状。肛镜检查见肛垫充血肿胀、黏膜表面轻度糜烂，局部可有出血点或出血倾向，痔核呈血管肿型，痔核大约1cm 左右。指诊肛垫肿胀，柔软。<br />&nbsp;&nbsp;1.2Ⅱ期内痔：主证：便血，色鲜红，伴有肛垫脱垂，便后可自行回纳。肛镜检查见肛垫肿胀明显，黏膜粗糙色暗或糜烂，其表面局部或有出血点或有出血倾向，痔核呈血管肿型伴纤维化，痔核大于1cm。指诊肥大肛垫可扪及，质软。<br />&nbsp;&nbsp;1.3Ⅲ期内痔：主证：排便或增加腹压时肛垫下移脱出，不能自行回纳，需休息后或手法复位。次证：便血少或无，可发生嵌顿，可伴有肛门胀痛不适等症。肛镜检查肛垫肿胀，隆突显著，痔核较大，界线尚存。其黏膜表面纤维化，伴静脉曲张，肛垫间沟变浅，痔核呈纤维化型伴静脉曲张。指诊可扪及肛垫肥大隆突的团块，质柔软，局部可有硬结。<br />&nbsp;&nbsp;1.4Ⅳ期内痔：主证：站久坐久或负重咳嗽肥大肛垫即行脱出，复位困难。次证：肛垫肿胀肥人明显，常污内裤，在肛外常可见肥大肛垫。肛镜下见黏膜色紫暗，表面常糜烂，伴发血栓，可有血性黏液覆盖，肛垫间沟消失，内痔呈环状，为静脉瘤型伴血栓。指诊肛门一般较松弛，常可扪及血栓小硬结。<br />&nbsp;&nbsp;2.外痔<br />&nbsp;&nbsp;2.1 静脉曲张外痔：久蹲或腹压增大时肛缘皮下有青紫色团块隆起，压之柔软，压处可消失，轻者无症状，重者可有肛坠胀不适感为静脉曲张外痔。<br />&nbsp;&nbsp;2.2 血栓性外痔：肛缘曲张静脉因腹压增加、用力努挣等致血液滞留于内凝结为块，或血管破裂出血而瘀积形成暗紫色硬节发生肿胀疼痛，触之压痛质硬，为血栓性外痔。<br />&nbsp;&nbsp;2.3 炎性外痔：肛缘皮肤破损感染发炎，或过食辛辣、酗酒、腹泻致皮皱充血水肿发炎形成炎性肿块，发生疼痛、灼热或湿痒不适为炎性外痔。<br />&nbsp;&nbsp;2.4 结缔组织外痔：肛缘皮肤皱襞因反复刺激或发炎，致结缔组织增生肿大形成皮垂，称为结缔组织外痔。一般无症状，或偶有湿痒，异物不适感。<br />&nbsp;&nbsp;3.混合痔：根据混合痔临床体征和病理变化可分为静脉曲张型混合痔、结缔组织型混合痔和环状混合痔。<br />&nbsp;&nbsp;3.1临床症状<br />&nbsp;&nbsp;主证：便血，肛坠，肛门异物感，肛门潮湿或伴瘙痒。<br />&nbsp;&nbsp;次证：肛门肿痛，灼热，或少气懒言，面色无华，或头昏心烦，纳少便塘，或大便干结。<br />&nbsp;&nbsp;舌脉：舌红或淡，苔白或黄，脉细数或弦滑数。<br />&nbsp;&nbsp;3.2体征<br />&nbsp;&nbsp;静脉曲张型混合痔：肛缘静脉丛瘀血曲张隆突与内痔相融，齿线消失形成一肿块脱于肛外，肛门潮湿、瘙痒，回纳困难，甚者嵌顿。指诊肿块柔软，压之局部可消失。<br />&nbsp;&nbsp;结缔组织型混合痔：肛缘结缔组织增生高突与内痔相融，齿线消失形成一肿块脱于肛外，不能回纳。指诊有肿物，可有小结节压痛。<br />&nbsp;&nbsp;环状混合痔：肛周静脉丛瘀血曲张伴结缔组织增生与内痔融合形成外脱之环状肿块( 或占据肛周2/3之上者) ，其表面多糜烂，静脉屈曲而伴发血栓。指诊压痛，有硬结。', '1.内痔<br />&nbsp;&nbsp;1.1风伤肠络<br />&nbsp;&nbsp;主证：大便带血，滴血或射血，血色鲜红。<br />&nbsp;&nbsp;次证：肛门瘙痒，大便干结。<br />&nbsp;&nbsp;舌脉：舌红，苔薄白或薄黄，脉浮数或数。<br />&nbsp;&nbsp;1.2湿热下注<br />&nbsp;&nbsp;主证：便血量多色鲜，肛坠，肥大肛垫外脱，肛门灼热。<br />&nbsp;&nbsp;次证：肛门湿痒，大便干结或塘，或小便频数。<br />&nbsp;&nbsp;舌脉：舌红苔黄腻或苔黄白腻，脉滑数。<br />&nbsp;&nbsp;1.3气滞血瘀<br />&nbsp;&nbsp;主证：肥大肛垫外脱不能回纳，或肛缘血肿疼痛。<br />&nbsp;&nbsp;次证：肛门紧缩，肛坠胀疼痛，水肿，大便干结。<br />&nbsp;&nbsp;舌脉：舌暗红或有瘀斑，苔白或黄，脉弦细涩。<br />&nbsp;&nbsp;1.4大肠实热<br />&nbsp;&nbsp;主证：便血量多，色鲜，肥大肛垫脱垂不能回纳，糜烂、灼痛。<br />&nbsp;&nbsp;次证：口渴喜饮，唇燥咽干。<br />&nbsp;&nbsp;舌脉：舌红，苔黄，或苔燥，脉洪数。<br />&nbsp;&nbsp;1.5脾虚气陷<br />&nbsp;&nbsp;主证：便血色淡或鲜红，肛门坠胀，肥大肛垫外脱难于自回纳、神疲乏力，面色少华。<br />&nbsp;&nbsp;次证：少气懒言，纳少便溏。<br />&nbsp;&nbsp;舌脉：舌淡或胖，边有齿痕，苔薄白，脉细弱。<br />&nbsp;&nbsp;1.6阴虚肠燥<br />&nbsp;&nbsp;主证：便血鲜红，形体消瘦，五心烦热，大便燥结。<br />&nbsp;&nbsp;次证：头昏咽干，盗汗，便时肛门疼痛，肥大肛垫下脱。<br />&nbsp;&nbsp;舌脉：舌红，少苔，或苔薄黄，脉细数无力等。<br />&nbsp;&nbsp;2.外痔<br />&nbsp;&nbsp;2.1大肠实热<br />&nbsp;&nbsp;主证：肛缘肿物高突，红肿灼热疼痛或有血栓硬结。<br />&nbsp;&nbsp;次证：大便燥结，小便短赤，口渴喜饮。<br />&nbsp;&nbsp;舌脉：舌质红，苔黄脉洪数。<br />&nbsp;&nbsp;2.2湿热下注<br />&nbsp;&nbsp;主证：肛缘肿物突起，灼热疼痛，渗液或糜烂出血。<br />&nbsp;&nbsp;次证：大便溏或干，或小便灼热频数。<br />&nbsp;&nbsp;舌脉：舌红，苔黄腻或苔白厚腻，脉滑数。<br />&nbsp;&nbsp;2.3气滞血瘀<br />&nbsp;&nbsp;主证：肛缘肿物隆突，用力时增大，或伴有血栓肿痛。<br />&nbsp;&nbsp;次证：肛门部异物感，或胀痛灼痛肛坠不适。<br />&nbsp;&nbsp;舌脉：舌红紫斑，苔淡黄，脉弦涩。<br />&nbsp;&nbsp;2.4脾虚气陷<br />&nbsp;&nbsp;主证：肛缘肿物隆起，肛门坠胀，欲便不出，神疲乏力，面色少华。<br />&nbsp;&nbsp;次证：少气懒言，纳少便塘。<br />&nbsp;&nbsp;舌脉：舌质淡胖，边有齿痕，苔薄白，脉细弱。<br />&nbsp;&nbsp;3.混合痔<br />&nbsp;&nbsp;参照内痔、外痔的证候进行分型，仍分五型，即风伤肠络、大肠实热、气滞血瘀血、湿热下注、脾虚气陷、阴虚肠燥进行辨证。', '症状、体征', '（一）内痔<br />&nbsp;&nbsp;1. 治愈：症状消失，肛镜下见肛垫发炎水肿消失，肛垫形态大小、黏膜色泽正常。<br />&nbsp;&nbsp;2.好转：症状改善，肛镜下见肛垫肿胀明显减轻缩小，或向外脱出减轻，黏膜色泽趋于正常。<br />&nbsp;&nbsp;3 .未愈：症状和体征均无变化。<br />&nbsp;&nbsp;（二）外痔<br />&nbsp;&nbsp;1.治愈：症状消失，痔核消除<br />&nbsp;&nbsp;2.好转：症状缓解，痔核变小或炎症消除。<br />&nbsp;&nbsp;3.未愈：症状与体征均无改善。（三）混合痔<br />&nbsp;&nbsp;1.治愈：症状消失，脱出痔块消除，肛门功能正常。<br />&nbsp;&nbsp;2.好转：症状改善，脱出痔块缩小。<br />&nbsp;&nbsp;3.未愈：症状、体征均无改畻坴畿', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('448', '28', 'Z03_010', '0', '痔、肛瘘、肛裂、直肠脱垂的诊断标准(试行草案)', '无', '中华中医药学会肛肠专业委员会', '2003', '痔、肛瘘、肛裂、直肠脱垂的诊断标准(试行草案).中医杂志，2003,44（增刊）：313-314.', '中文', '1.内痔：Ⅰ度；Ⅱ度；Ⅲ度；Ⅳ度。<br />&nbsp;&nbsp;2.外痔：结缔组织性外痔；血栓性外痔；静脉曲张性外痔；炎性外痔。<br />&nbsp;&nbsp;3.混合痔。', '痔', '内外痔', '风伤肠络；湿热下注；气滞血瘀；脾虚气陷', '1.内痔：内痔是指发生于肛管齿线以上，直肠粘膜下的血管性衬垫病理性扩张或增生形成的隆起性组织，又称“里痔”。<br />&nbsp;&nbsp;诊断标准：I期内痔：便血，色鲜红或无症状。肛门镜检查见齿线上直肠粘膜隆起，直径超过两个钟点位置，粘膜表面色淡红。Ⅱ期内痔：便血，色鲜红，大便时伴有肿物脱出肛外，便后可自行还纳复位。肛门镜检查见齿线上直肠粘膜隆起，粘膜表面色暗红。Ⅲ期内痔：排便或其他原因增加腹压时，肛内肿物脱出，需休息或手推方能还纳复位，粘膜表面暗红。Ⅳ期内痔：肛内肿物脱出，无论休息或手推均不能复位，粘膜表面糜烂。<br />&nbsp;&nbsp;2.外痔：外痔是指发生于肛管齿线以下，肛管部隆起性组织。根据组织的病理特点，又分为结缔组织性外痔、血栓性外痔、静脉曲张性外痔、炎性外痔四类。<br />&nbsp;&nbsp;诊断标准：结缔组织性外痔：齿线以下有柔软的隆起性组织，表面覆盖皮肤，无疼痛，无红肿，又称皮赘。血栓性外痔：齿线以下突发性红肿包块．疼痛明显，皮下可触及硬结。静脉曲张性外痔：增加腹压时齿线以下形成隆起性包块，质地柔软，无压痛，皮下可见扩张的血管团。炎性外痔：齿线以下发生的红肿包块，起病较急，包块皮肤水肿潮红，压痛明显。<br />&nbsp;&nbsp;3.混合痔：混合痔是指齿线上下互相融合的隆起性组织，它具有内痔和外痔的临床特征。在诊断混合痔时，应注明内痔的分期和外痔的分类。\n', '1.风伤肠络证：大便滴血、射血或带血，血色鲜红，大便干结，肛门瘙痒，口干咽燥，舌红，苔黄，脉浮数。<br />&nbsp;&nbsp;2.湿热下注证：便血色鲜红，量较多，肛门肿物外脱、肿胀、灼热疼痛或有滋水，便干或溏，小便短赤，舌质红，苔黄腻，脉浮数。<br />&nbsp;&nbsp;3.气滞血瘀证：肿物脱出肛外、水肿，内有血栓形成，或有嵌顿，表面紫暗、糜烂、渗液，疼痛剧烈，触痛明显，肛管紧缩，大便秘结，小便不利，舌质紫暗或有瘀斑，脉弦或涩。<br />&nbsp;&nbsp;4.脾虚气陷证：肿物脱出肛外，不易复位，肛门坠胀，排便乏力，便血色淡，面色少华，头晕神疲，食少乏力，少气懒言，舌淡胖，苔薄白，脉细弱。', null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('449', '28', 'Z03_011', '1', '痔的诊疗指南(初稿)', '无', '中华中医药学会肛肠专业委员会；中国中西医结合学会肛肠专业委员会；世界中医药联合会肛肠专业委员会；中医药高等教育学会临床教育研究会肛肠分会', '2011', '痔的诊疗指南（初稿）.中国肛肠病研究心得集2011：77-80.', '中文', '1.内痔：Ⅰ度；Ⅱ度；Ⅲ度；Ⅳ度。<br />&nbsp;&nbsp;2.外痔：血栓性外痔；静脉曲张性外痔；炎性外痔；结缔组织性外痔。<br />&nbsp;&nbsp;3.混合痔。', '痔', null, '风伤肠络；湿热下注；气滞血瘀；脾虚气陷', '1.分类<br />&nbsp;&nbsp;痔分为内痔、外痔、混合痔。<br />&nbsp;&nbsp;2.临床症状<br />&nbsp;&nbsp;内痔的主要症状是出血和脱出，可并发血栓、嵌顿、绞窄及排便困难。根据内痔的症状，其严重程度分为4度。<br />&nbsp;&nbsp;Ⅰ度：便时带血、滴血，血色鲜红，便后出血可自行停止；无痔脱出。<br />&nbsp;&nbsp;Ⅱ度：常有排便时出血，血色鲜红；排便时有痔脱出，便后可自行还纳。<br />&nbsp;&nbsp;Ⅲ度：可有便血；排便或久站及咳嗽、劳累、负重时有痔脱出，需用手还纳。<br />&nbsp;&nbsp;Ⅳ度：偶有便血；痔核脱出不能还纳，或还纳后易脱出。<br />&nbsp;&nbsp;外痔的主要症状是肛门部有软组织团块，可有肛门不适、潮湿瘙痒或异物感，如发生血栓及炎症，可有疼痛。根据外痔的特点分为血栓性外痔，静脉曲张性外痔，炎性外痔，结缔组织性外痔四型。<br />&nbsp;&nbsp;混合痔主要表现为内痔和外痔的症状同时存在，严重时表现为环状痔脱出。<br />&nbsp;&nbsp;3.体征<br />&nbsp;&nbsp;3.1肛门视诊<br />&nbsp;&nbsp;肛门视诊可检查有无内痔脱出，肛门周围有无静脉曲张性外痔、血栓性外痔及皮赘。必要时可行蹲位检查，观察脱出内痔的部位、大小和有无出血以及痔黏膜有无充血水肿、糜烂和溃疡。<br />&nbsp;&nbsp;3.2肛管直肠指诊<br />&nbsp;&nbsp;肛管直肠指诊是重要的检查方法。Ⅰ、Ⅱ度内痔指检时多无异常；对反复脱出的Ⅲ、Ⅳ度内痔，指检有时可触及齿状线上的纤维化痔组织。肛管直肠指诊还可以排除肛管直肠肿瘤和其他疾病。<br />&nbsp;&nbsp;3.3肛门直肠镜<br />&nbsp;&nbsp;：肛门直肠镜可以明确内痔的部位、大小、数目和内痔表面黏膜有无出血、水肿、糜烂等。<br />&nbsp;&nbsp;4.实验室检查<br />&nbsp;&nbsp;4.1大便隐血试验<br />&nbsp;&nbsp;这是排除全消化道肿瘤的常用筛查手段。<br />&nbsp;&nbsp;4.2全结肠镜检查<br />&nbsp;&nbsp;以便血就诊者，有消化道肿瘤家族史或本人有息肉病史者，年龄超过50岁者，大便隐血试验阳性以及缺铁性贫血的痔患者，建议行全结肠镜检查。', '1.风伤肠络证：大便滴血、射血或带血，血色鲜红，大便干结，肛门瘙痒，口干咽燥，舌红，苔黄，脉浮数。<br />&nbsp;&nbsp;2.湿热下注证：便血色鲜红，量较多，肛门肿物外脱、肿胀、灼热疼痛或有滋水，便干或溏，小便短赤，舌质红，苔黄腻，脉浮数。<br />&nbsp;&nbsp;3.气滞血瘀证：肿物脱出肛外、水肿，内有血栓形成，或有嵌顿，表面紫暗、糜烂、渗液，疼痛剧烈，触痛明显，肛管紧缩，大便秘结，小便不利，舌质紫暗或有瘀斑，脉弦或涩。<br />&nbsp;&nbsp;4.脾虚气陷证：肿物脱出肛外，不易复位，肛门坠胀，排便乏力，便血色淡，面色少华，头晕神疲，食少乏力，少气懒言，舌淡胖，苔薄白，脉细弱。', null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('45', '34', 'M03_009', '1', '筛查、监测和治疗慢性肾病1到3阶段:美国医师学会临床实践指南委员临床指南', ' Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the Clinical Guidelines Committee of the American College of Physicians.', ' 美国医师学会', '2013', 'Qaseem A, Hopkins RH, Sweet DE, Starkey M, Shekelle P. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013 Dec 17;159(12):835-47. $$$$\n', '英文', null, '慢性肾病(chronic kidney disease)', null, null, '1. Screening for chronic kidney disease based (CKD) on symptoms and risk factors<br />&nbsp;&nbsp;\n2. Testing for proteinuria<br />&nbsp;&nbsp;\n3. Angiotensin-converting enzyme (AC E) inhibitor or an angiotensin II-receptor blocker (ARB) <br />&nbsp;&nbsp;\n4. Statin therapy<br />&nbsp;&nbsp;\n1．筛查慢性肾脏病的基础（CKD）的症状和危险因素<br />&nbsp;&nbsp;\n2．检测尿蛋白<br />&nbsp;&nbsp;\n3．血管紧张素转换酶（ACE）抑制剂或血管紧张素II受体拮抗剂（ARB）<br />&nbsp;&nbsp;\n4．他汀类药物治疗<br />&nbsp;&nbsp;\n', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('450', '28', 'Z03_012', '1', '临床诊疗指南·外科学分册', '无', '中华医学会', '2006', '中华医学会.临床诊疗指南·外科学分册.北京：人民卫生出版社，2006.', '中文', '1.内痔：Ⅰ级；Ⅱ级；Ⅲ级；Ⅳ级。<br />&nbsp;&nbsp;2.外痔。', '痔', null, null, '1.概述<br />&nbsp;&nbsp; 痔是外科常见的多发病。内痔是肛垫（肛管血管垫）支持结构、血管丛及动静脉吻合支发生的病理改变和（或）异常移位。<br />&nbsp;&nbsp;    内痔的主要临床表现是出血和脱出，可伴发排便困难，可发生血栓、绞窄、嵌顿。内痔的分度：<br />&nbsp;&nbsp;    1.1Ⅰ度  便时带血、滴血或喷射状出血，便后出血可自行停止，无痔脱出。<br />&nbsp;&nbsp;    1.2Ⅱ度  常有便血，排便时有痔脱出，便后可自行还纳。<br />&nbsp;&nbsp;    1.3Ⅲ度  偶有便血；排便或久站、咳嗽、劳累、负重时痔脱出，需用手还纳。<br />&nbsp;&nbsp;    1.4Ⅳ度  偶有便血；痔脱出，不能还纳。<br />&nbsp;&nbsp;    外痔是直肠下静脉属支在齿状线远侧表皮下静脉丛病理性扩张和血栓形成，外痔的主要临床表现是肛门不适、潮湿不洁，如发生血栓形成及皮下血肿有剧痛。<br />&nbsp;&nbsp;    混合痔是内痔通过丰富的静脉丛吻合支和相应部位的外痔静脉丛相互融合。混合痔的主要临床表现是内痔和外痔的症状可同时存在，严重时表现为环状痔脱出。<br />&nbsp;&nbsp;   2.临床表现<br />&nbsp;&nbsp;    2.1便血  是内痔及混合痔最常见的症状。便血一般发生于排便过程中，无疼痛感，血色鲜红，可呈滴血、喷射状或便纸上染血，与粪便不相混，便后出血自行停止。常因粪便干燥、饮酒、进食刺激性食物及劳累而诱发便血。反复便血有时可引起贫血。<br />&nbsp;&nbsp;    2.2内痔脱出  Ⅱ、Ⅲ、Ⅳ度内痔可脱出肛门外。<br />&nbsp;&nbsp;   2.3疼痛或不适  是外痔和混合痔的常见症状，血栓性外痔伴有剧烈疼痛。内痔一般无疼痛，但伴有感染、糜烂和血栓形成或绞窄、嵌顿时，即可出现疼痛或不适。<br />&nbsp;&nbsp;    2.4瘙痒、溢液  由于内痔脱出及括约肌功能减退，黏液溢出至肛门刺激周围皮肤，引起瘙痒甚至肛门周围皮肤湿疹。<br />&nbsp;&nbsp;  3.诊断要点<br />&nbsp;&nbsp;   3.1肛门视诊  有无内痔脱出，肛门周围有无湿疹，有无静脉曲张性外痔、血栓性外痔及赘皮。<br />&nbsp;&nbsp;    3.2蹲位检  对有内痔脱出的病人，应在排便后立即观察脱出的内痔，并记录脱出内痔的部位、大小和有无出血、痔黏膜有无糜烂、溃疡。<br />&nbsp;&nbsp;   3.3肛门镜检查  可以看清内痔的部位、大小、数目和内痔表面黏膜有无出血、糜烂。<br />&nbsp;&nbsp;    3.4鉴别诊断  重要的是与直肠占位性病变鉴别，因两者临床表现相似，也可同时发生。因此必须常规行直肠指检，必要时行直肠、乙状结肠硬镜或纤维肠镜检查，以免漏诊。<br />&nbsp;&nbsp;', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('451', '28', 'Z03_013', '1', 'SICCR共识声明：痔疮的评估和管理', ' Evaluation and management of hemorrhoids: Italian society of colorectal surgery (SICCR) consensus statement', '意大利结直肠外科学会(Italian society of colorectal surgery，SICCR)', '2015', 'guide.medlive.cn', '英文', '1.内痔：Ⅰ度；Ⅱ度；Ⅲ度；Ⅳ度。<br />&nbsp;&nbsp;2.外痔；<br />&nbsp;&nbsp;4.混合痔。', '痔疮', null, null, ' 痔通常根据其位置和脱垂的严重程度进行分类。<br />&nbsp;&nbsp;通过位置区分内痔和外痔：内痔发生在齿状线与粘膜的顶部，而外痔发生在齿状线以下，鳞状上皮所覆盖。<br />&nbsp;&nbsp;最常见的分类法是Goligher分类：出血但没有脱垂（I级）。<br />&nbsp;&nbsp;排便时脱垂，可自行还纳。（II级）<br />&nbsp;&nbsp;排便时脱垂，需用手还纳。（III级）<br />&nbsp;&nbsp;脱垂，不能还纳。（Ⅳ级）<br />&nbsp;&nbsp;由于Goligher分类不考虑具体的临床情况，如环状脱垂和可能出现的并发症如血栓等。为了进一步满足痔的临床治疗新技术的应用需求，一些作者提出了新的分类系统，然而，也许因为太过复杂，都没有被广泛使用。<br />&nbsp;&nbsp;痔疮诊断首先要考虑病史，确定有痔病及危险因素如便秘，其次是体检。<br />&nbsp;&nbsp;体格检查应包括腹部检查，对肛周组织检查，肛门直肠指检，肛门直肠镜检查。<br />&nbsp;&nbsp;即使痔疮可见，有结肠直肠症状的患者也应进行结肠镜检查，以排除其他病变（推荐级：B）。<br />&nbsp;&nbsp;50岁以下的低风险患者，乙状结肠镜检查可以作为初步诊断（推荐级：B）。<br />&nbsp;&nbsp;老年患者，有结肠直肠肿瘤病史/家族史，炎症性肠疾病，排便习惯改变，严重消瘦以及缺铁性贫血等情况时，应强制进行全结肠镜检查。（推荐级：B）。<br />&nbsp;&nbsp;乙状结肠镜检查、结肠镜检查应与肛门镜或可视肛门镜检查相结合，这种方法已被证实对肛周疾病有较高确诊率。（推荐级：B）。<br />&nbsp;&nbsp;肛门静止状态压力增强常见于非脱垂型痔疮，但测压并不是常规诊断方法。测压可以用于复发病例的术前准备，如果肛门压低，也可用于质疑体检结果。<br />&nbsp;&nbsp;直肠超声检查通常不用于痔的诊断，但可用于确诊痔合并了粘膜下组织还是肛门内括约肌、外括约肌。', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('452', '31', 'S02_001', '0', 'ZYYXH/T50～135-2008，中医内科常见病诊疗指南西医疾病部分', 'Guidelines for Diagnosis and Treatment of Common Internal Diseases in Chinese Medicine Diseases of Modern Medicine', '中华中医药学会', '2008', '中华中医药学会.ZYYXH/T50～135-2008，中医内科常见病诊疗指南西医疾病部分[S].北京：中国中医药出版社，2008.', '中文', null, '原发性肾病综合征', null, '1.风水泛滥证；2.湿热蕴结证；3.肾络瘀阻证；4.脾肾阳虚证；5.肝肾阴虚证', '1.临床表现<br />&nbsp;&nbsp;1.1症状<br />&nbsp;&nbsp;水肿：以全身性为多。严重者可以出现胸腔、腹腔、阴囊等积液，甚至心包腔大量积液。<br />&nbsp;&nbsp;蛋白尿：尿液中含有大量泡沫，消散缓慢。1日流失蛋白3.5~20g，亦有多达40~60g。<br />&nbsp;&nbsp;低蛋白血症：血清白蛋白水平在30g/L以下。<br />&nbsp;&nbsp;高脂血症：血浆胆固醇、甘油三酯均明显增加，血清中低密度及极低密度脂蛋白浓度增加，高密度脂蛋白正常或稍下降。<br />&nbsp;&nbsp;消化道功能障碍：因胃肠道水肿，可见厌食、恶心、呕吐、腹泻、腹痛等。<br />&nbsp;&nbsp;1.2体征：眼睑、颜面及双下肢不同程度的水肿，严重者可有胸水、腹水，肾区叩击痛。<br />&nbsp;&nbsp;2.理化检查<br />&nbsp;&nbsp;2.1尿液生化检查：尿常规中尿蛋白定性多（+++）~（++++），24小时尿蛋白量＞3.5g/24h。<br />&nbsp;&nbsp;2.2血液生化检查：①血清白蛋白＜30g/L；②血清胆固醇、甘油三酯及低密度脂蛋白升高；③血清免疫球蛋白以IgG下降为主；④血清补体C3含量测定对膜增殖性病变的鉴别有意义，约68%病例在病初即见持续下降；⑤肾功能多数正常，但肾炎性的肾病综合征可见不同程度的肾损害。<br />&nbsp;&nbsp;2.3血或尿的FDP（纤维蛋白降解产物）检测：其含量增加。<br />&nbsp;&nbsp;2.4选择性蛋白尿：如尿中出现的是大分子、中分子蛋白质则提示病变在肾小球；如是小分子蛋白质则提示病变在肾小管及间质；如为混合性蛋白质则提示病变累及肾小球、肾小管及间质；如尿中主要是中分子蛋白质，则为选择性蛋白尿，说明损害较轻；如有大分子蛋白漏出，则选择性差，肾损害较严重。<br />&nbsp;&nbsp;2.5肾活检：这是确定临床病理类型的唯一手段，且对明确诊断、制定治疗方案及判断预后有帮助。<br />&nbsp;&nbsp;3.诊断要点<br />&nbsp;&nbsp;3.1临床诊断：①大量蛋白尿；②低蛋白血症；③明显水肿；④高脂血症。<br />&nbsp;&nbsp;其中①、②两项必备。如发生可疑，可以取任意尿测定其蛋白浓度及肌酐浓度及其两者比率。若尿蛋白与尿肌酐比率＞3.5即为肾病综合征范围的蛋白尿。<br />&nbsp;&nbsp;3.2病理诊断：主要病理类型有微小病变肾病、系膜增生性肾炎、局灶性节段性肾小球硬化、膜性肾病、膜增生性肾炎。微小病变以儿童多见，预后好；膜性肾病在成人多见。各病理类型之间可以转化。<br />&nbsp;&nbsp;', '1.风水泛滥证<br />&nbsp;&nbsp;    证候：颜面、眼睑浮肿，很快累及全身，肢节酸重，小便不利，有的兼见恶风寒、鼻塞、咳嗽、舌苔薄白、脉浮而紧，有的兼见咽红而痛、舌质红、脉浮数。    <br />&nbsp;&nbsp;2.湿热蕴结证<br />&nbsp;&nbsp;    证候：全身浮肿，皮色光亮，胸痞腹胀，烦热口渴，大便秘结，小便短赤，或皮肤有疮疡疖肿，舌红，苔滑或腻，脉滑数。<br />&nbsp;&nbsp;3.肾络瘀阻证<br />&nbsp;&nbsp;    证候：面目、四肢浮肿，迁延日久，皮肤甲错，或见红丝赤缕，瘀点瘀斑，或者腰痛尿赤，舌质淡或暗红，边有瘀点，舌下脉络瘀紫，苔薄黄或腻，脉细涩。<br />&nbsp;&nbsp;4.脾肾阳虚证<br />&nbsp;&nbsp;      证候：面色光白，形寒肢冷，遍体浮肿，按之没指，甚则伴有胸水、腹水，乃至胸闷气急，小溲短少，大便溏薄，舌淡体胖，苔薄腻或白腻，脉沉细滑。<br />&nbsp;&nbsp;5.肝肾阴虚证<br />&nbsp;&nbsp;    证候：面目四肢浮肿不甚，眩晕口干，咽喉干痛反复不已，心烦急躁，腰酸，时见盗汗，小便短赤，舌质红，脉细弦数。<br />&nbsp;&nbsp;', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('453', '31', 'S02_002', '1', '儿童常见肾脏疾病诊治循证指南（试行）(三)：激素敏感耐药型肾病综合征诊治循证指南', '无', '中华医学会儿科学分会肾脏病学组', '2009', '儿童常见肾脏疾病诊治循证指南(一)：激素敏感、复发/依赖肾病综合征诊治循证指南(试行).中华儿科杂志，2009,47（3）：167-170.', '中文', '1．依据临床表现可分为以下两型：<br />&nbsp;&nbsp;1.1单纯型NS(simple type NS)：只有上述表现者。<br />&nbsp;&nbsp;1.2肾炎型NS(nephritic type NS)：除以上表现外。尚具有以下4项之1或多项者：(2周内分别3次以上离心尿检查RBC≥10个/高倍镜视野(HPF)，并证实为肾小球源性血尿者；②反复或持续高血压(学龄儿童≥130/90mmHg，学龄前儿童≥120/80mmHg；1mmHg=0.133 kPa)，并除外使用GC等原因所致；③肾功能不全，并排除由于血容量不足等所致；④持续低补体血症。<br />&nbsp;&nbsp;2．按糖皮质激素(简称激素)反应可分以下3型：<br />&nbsp;&nbsp;2.1激素敏感型NS(Steroid-sensitive NS，SSNS)：以泼尼松足量[2mg/(kg.d)或60mg/(m2.d)]治疗≤4周尿蛋白转阴者。<br />&nbsp;&nbsp;2.2激素耐药型NS(Steroid-resistant NS，SRNS)：以泼尼松足量治疗>4周尿蛋白仍阳性者。<br />&nbsp;&nbsp;2.3激素依赖型NS(Steroid-dependent NS，SDNS)：指对激素敏感，但连续两次减量或停药2周内复发者。\n', '激素敏感、复发/依赖肾病综合征', null, null, '1.原发性肾病综合征诊断标准：<br />&nbsp;&nbsp;1.1大量蛋白尿：1周内3次尿蛋白定性(+++)～(++++)，或随机或晨尿尿蛋白/肌酐(mg/mg)≥2.0；24 h尿蛋白定量≥50 mg/kg。<br />&nbsp;&nbsp;1.2低蛋白血症：血浆白蛋白低于25g/L。<br />&nbsp;&nbsp;1.3高脂血症：血浆胆固醇高于5.7 mmol/L。<br />&nbsp;&nbsp;1.4不同程度的水肿。<br />&nbsp;&nbsp;以上4项中以1和2为诊断的必要条件。<br />&nbsp;&nbsp;2.复发和频复发：<br />&nbsp;&nbsp;2.1复发(Relaps)：连续3d，晨尿蛋白由阴性转为(+++)或(++++)，或24h尿蛋白定量≥50 mg/kg或尿蛋白/肌酐(mg/mg)≥2.0。<br />&nbsp;&nbsp;2.2频复发(Frequently relaps，FR)：指肾病病程中半年内复发≥2次，或1年内复发≥3次。\n', null, '血生化；尿蛋白', '1．临床治愈：完全缓解，停止治疗>3年无复发。<br />&nbsp;&nbsp;2．完全缓解(CR)：血生化及尿检查完全正常。<br />&nbsp;&nbsp;3．部分缓解(PR)：尿蛋白阳性<(+++)。<br />&nbsp;&nbsp;4．未缓解：尿蛋白≥(+++)。\n', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('454', '31', 'S02_003', '1', '儿童常见肾脏疾病诊治循证指南(一)：激素敏感、复发/依赖肾病综合征诊治循证指南(试行)', '无', '中华医学会儿科学分会肾脏病学组', '2010', '儿童常见肾脏疾病诊治循证指南（试行）(三)：激素耐药型肾病综合征诊治指南.中华儿科杂志，2010,48（1）：72-74.', '中文', '常见病理类型：以非微小病变为主包括局灶节段性肾小球硬化(FSGS)；系膜增生性肾小球肾炎(MsPGN)；膜增生性肾小球肾炎(MPGN)；膜性肾病(MN)。', '激素耐药型肾病综合征', null, null, '以泼尼松足量治疗＞4周尿蛋白仍阳性，除外感染、遗传等因素所致者。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('455', '31', 'S02_004', '1', '肾病综合征', '无', '中华医学会肾脏病学分会', '2011', '中华医学会.临床诊疗指南·肾脏病学分册.北京：人民卫生出版社，2011', '中文', '1.肾病综合征可为原发性和继发性。如考虑为继发性应积极寻找病因，在排除继发性NS,如糖尿病肾病、紫癜性肾炎、狼疮性肾炎、乙肝相关性肾炎、肾淀粉样变等之后才能诊断为原发性NS。<br />&nbsp;&nbsp;2.原发性肾小球肾炎所致的肾病综合征常见的病理类型分为：<br />&nbsp;&nbsp;2.1微小病变型（MCD）：光镜下肾小球基本正常，近端肾小管上皮细胞可见脂肪变性，故又被称为“类脂性肾病”。免疫荧光阴性，电镜下特征性表现为弥漫性足突融合，肾小球内一般无电子致密物沉积。<br />&nbsp;&nbsp;2.2系膜增生性肾小球肾炎（MsPGN）：光镜可见肾小球弥漫性系膜细胞增生伴系膜基质增多，而肾小球毛细血管壁和基底膜正常。按免疫荧光结果可分为IgA 肾病（单纯IgA 或以IgA 沉积为主）和非IgA 系膜增生性肾小球肾炎（以IgG 或IgM 沉积为主）。<br />&nbsp;&nbsp;2.3局灶节段性硬化（FSGS）：其病理特征为局灶损害。病变以系膜基质增多、血浆蛋白沉积、球囊粘连、玻璃样变性为特征，伴或不伴球性硬化。电镜可见弥漫性足细胞足突消失，免疫荧光呈现IgM 和C3 沉积。<br />&nbsp;&nbsp;2.4膜性肾病（MN）：以局限于肾小球基膜的免疫复合物沿肾小球基底膜外侧（上皮下）沉积，刺激基底膜增殖，致使“钉突”形成、基底膜弥漫增厚为特征的一种疾病。<br />&nbsp;&nbsp;2.5膜增生性肾小球肾炎（MPGN）：其共同特点为肾小球基底膜增厚、系膜细胞增生及系膜基质扩张，毛细血管袢呈“双轨征”为其典型特征性病理改变。<br />&nbsp;&nbsp;3.难治性肾病综合征是指部分患者表现为对激素依赖或激素抵抗。<br />&nbsp;&nbsp;3.1激素依赖是指激素治疗有效，激素减量或停药后2 周内复发。<br />&nbsp;&nbsp;3.2激素抵抗是指使用足量泼尼松（龙）1mg/(kg·d)或甲泼尼龙0.8mg/(kg·d)，8～12 周无效，局灶节段肾小球硬化的判断时间应延长为16 周。', '肾病综合征（nephrotic syndrom,NS）', null, null, '1．症状和体征:可发生于任何年龄，发病前可有职业病史、有毒有害物接触史、服用药物或食物过敏史等情况；可继发于呼吸道、皮肤的感染、病毒性肝炎、肿瘤、糖尿病、系统性疾病等，起病可急骤也可隐匿，患者可有乏力、恶心、腰酸、食欲下降等，部分患者可无明显临床症状。除水肿、蛋白尿外，临床还可表现为血尿、高血压及不同程度肾功能减退。其主要症状为水肿，特点是水肿首先出现于皮下组织较疏松部位，如眼睑、颜面等处，然后出现于下肢（常从踝部开始），多为指压凹陷性水肿，严重的可发展至全身，引起胸水、腹水、心包积液。水肿与体位有明显的关系，如出现一侧下肢与体位无关的固定性水肿时应怀疑下肢深静脉血栓形成。但也有部分患者可水肿不明显。<br />&nbsp;&nbsp;2．实验室检查:典型的肾病综合征实验室检查表现为：<br />&nbsp;&nbsp;2.1大量蛋白尿（尿蛋白定量>3.5g/d）；2.2低白蛋白血症（血浆白蛋白<30g/L）；<br />&nbsp;&nbsp;2.3高脂血症。此外，尿沉渣镜检红细胞可增多，可见管型，肾功能正常或受损（GFR 下降），可伴免疫指标（抗核抗体、抗双链DNA、ANCA、免疫球蛋白等）、肿瘤指标（CEA、AFP、PSA 等）、病毒指标（HBV、HCV、HIV 等）、骨髓穿刺活检异常。肾穿刺活检可明确病理分型。<br />&nbsp;&nbsp;3.诊断要点:<br />&nbsp;&nbsp;3.1大量蛋白尿（尿蛋白定量>3.5g/d）<br />&nbsp;&nbsp;3.2 低白蛋白血症（血浆白蛋白<30g/L）<br />&nbsp;&nbsp; 3.3 高度水肿<br />&nbsp;&nbsp; 3.4 高脂血症（血浆胆固醇、甘油三酯均明显增高） <br />&nbsp;&nbsp; 3.5前两项是诊断肾病综合征的必要条件，后两项为次要条件。临床上只要满足上述2项必要条件，肾病综合征的诊断即成立。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('456', '31', 'S02_005', '1', '小儿肾小球疾病的临床分类、诊断及治疗', '无', '中华医学会儿科学分会肾脏病学组', '2001', '小儿肾小球疾病的临床分类、诊断及治疗.中华儿科杂志，2001,39（12）：746-749.', '中文', '1.依临床表现分为两型:<br />&nbsp;&nbsp;1.1单纯型NS (Simple Type NS)。<br />&nbsp;&nbsp;1.2肾炎型NS (Nephrotic Type NS)。凡具有以下四项之一或多项者属于肾炎型NS：(1)2周内分别3次以上离心尿检查RBC≥10个/HPF，并证实为肾小球源性血尿者。(2)反复或持续高血压(学龄儿童≥130/90mmHg，学龄前儿童≥120/80mmHg；1mmHg=0.133kPa)并除外使用糖皮质激素等原因所致。(3)肾功能不全，并排除由于血容量不足等所致。(4)持续低补体血症。<br />&nbsp;&nbsp;2.按糖皮质激素(简称激素)反应分为:<br />&nbsp;&nbsp;2.1激素敏感型NS(Steroid-responsive NS):以泼尼松足量治疗≤8周尿蛋白转阴者。<br />&nbsp;&nbsp;2.2激素耐药型NS(Steroid-resistant NS):以泼尼松足量治疗8周尿蛋白仍阳性者。<br />&nbsp;&nbsp;2.3激素依赖型NS(Steroid-dependent NS):对激素敏感，但减量或停药1个月内复发，重复2次以上者。【注】NS复发与频复发(Relaps and Frequently Relaps)复发(包括反复)是指尿蛋白由阴转阳＞2周。频复发是指肾病病程中半年内复发≥2次;或1年内复发≥3次。', '肾病综合征', null, null, '诊断标准：大量蛋白尿[尿蛋白(+++)～ (++++)；1周内3次，24h尿蛋白定量≥50mg/kg]；血浆白蛋白低于30g/L；血浆胆固醇高于5.7mmol/L；不同程度的水肿。以上四项中以大量蛋白尿和低白蛋白血症为必要条件。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('457', '31', 'S02_006', '1', '激素敏感型肾病综合征治疗的修订指南', 'Management of Steroid Sensitive Nephrotic Syndrome: Revised Guidelines', '印度儿科学会儿童肾脏病学组', '2008', 'Indian Pediatric Nephrology Group， Indian Academy of Pediatrics，Bagga A，et al．Management of steroid sensitive nephrotic syndrome: Revised guidelines．Indian Pediatr，2008，45(3):203－214．', '英文', null, '激素敏感型肾病综合征(SSNS)', null, null, 'Nephrotic syndrome characerized by heavy proteinuria,hypoalbuminemia (serum albumin＜2.5g/dL),hyperlipidemia (serum cholesterol＞200mg/dL)and edema(1,2).Nephrotic range proteinuria is present if early morning urine protein is 3+/4+(on dipstick or boiling test),spot protein/creatinine ratio＞2mg/mg,or urine albumin excretion＞40mg/m2 per hr (on a timed-sample).Precise quantitative assessment of proteinuria,including 24-hr urine protein measurement is seldom necessary .Definitions for clarifying the course of nephrotic syndrome are shown in Table Ⅱ.<br />&nbsp;&nbsp;1.肾病综合征的诊断：1.1大量蛋白尿：晨尿尿蛋白+++或++++(试纸或煮沸试验)，尿蛋白/肌酐＞200mg/mg，或尿清蛋白排出量＞40mg/m2/h（定时采样）。<br />&nbsp;&nbsp;1.2低清蛋白血症：血清白蛋白＜25g/dl。<br />&nbsp;&nbsp;1.3高脂血症：血清胆固醇＞200mg/dl。<br />&nbsp;&nbsp;1.4水肿。<br />&nbsp;&nbsp;很少需要测量24小时尿蛋白总量。<br />&nbsp;&nbsp;表S02_006_001', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('458', '31', 'S02_007', '1', '儿童激素耐药型肾病综合征治疗指南', 'Management of Steroid Resistant Nephrotic Syndrome', '印度儿童肾脏病协会', '2009', 'Indian Society of Pediatric Nephrology，Gulati A，Bagga A， et al． Management of steroid resistant nephrotic syndrome．Indian Pediatr，2009，46(1):35－47．', '英文', null, '激素耐药型肾病综合征', null, null, 'A patient is diagnosed to have steroid resistance if there is lack of remission despite treatment with prednisolone at a dose of 2mg/kg/day(60mg/m2/day)for 4 weeks.Remission is defined as absence of proteinuria(urine albumin nil or trace for three consecutive days by dipstick or boiling test)<br />&nbsp;&nbsp;患儿应用泼尼松2mg/kg/day(60mg/m2/day)治疗4周仍未缓解，缓解是指尿蛋白转阴(尿中清蛋白消失或连续3天试纸或煮沸检查阴性) 。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('459', '31', 'S02_008', '1', '肾病综合征管理指南', 'Guideline for the Management of Nephrotic Syndrome', 'Scottish Paediatric Renal and Urology Network (SPRUN)苏格兰儿科肾脏泌尿科网', '2014', 'http://www.sprun.scot.nhs.uk/', '英文', 'S02_008_001', '肾病综合征', null, null, 'S02_008_002', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('46', '34', 'M06_001', '0', 'ZYYXH/T 107-2008 泌尿系统结石', null, '中华中医药学会 ', '2008', 'ZYYXH/T 107-2008 泌尿系统结石[S]', '中文', null, '泌尿系统结石', null, '1.虚证或虚实夹杂证<br />&nbsp;&nbsp;2.肝经气滞证<br />&nbsp;&nbsp;3.瘀血内阻证<br />&nbsp;&nbsp;4.脾肾两虚证<br />&nbsp;&nbsp;5.气阴不足证', '1.临床表现<br />&nbsp;&nbsp;1.1症状：泌尿系统结石的临床症状与结石所在部位、大小、性质、有无感染等诸多因素有重要关系。<br />&nbsp;&nbsp;无症状结石：见于表面光滑的小结石,能自动排出而不引起明显症状。此外,固定在肾盂或下肾盏内不移动而又无感染的结石,可长期存在而不引起症状,或仅有轻度腰部不适或酸胀感,在拍摄腹部线平片或型超声检查时偶然发现。<br />&nbsp;&nbsp;疼痛：肾和输尿管结石的疼痛部位常位于腰腹部,为钝痛、隐痛或绞痛,以间歇发作性疼痛为特点。典型的肾绞痛常在夜间或清晨突然发作,患者表现为腰腹部急剧疼痛,并向同侧腹股沟、攀丸、大阴唇等处放射,常伴有恶心、呕吐、腹胀、尿少。输尿管下段的结石疼痛发作时,可伴有尿频、尿急、尿痛等症状。<br />&nbsp;&nbsp;血尿：肾绞痛时,多伴有肉眼血尿或镜下血尿,以后者为多见。偶有无痛性血尿,活动后血尿加重。<br />&nbsp;&nbsp;排沙石：患者可从尿中排出沙石,特别在疼痛及血尿发作后,尿中可检出沙粒或小结石。结石在排出过程中可出现尿道刺痛或发生尿中断阻塞现象。<br />&nbsp;&nbsp;尿路梗阻和尿路感染：肾结石较常见的并发症是梗阻和感染,梗阻可引起肾积水,易发生尿路感染,可为无症状性细菌尿或有明显的尿路感染症状。梗阻再加上感染,会较快地导致肾实质损害,发生肾功能衰竭。双肾结石或孤立肾结石梗阻可出现无尿而致急性肾衰竭。<br />&nbsp;&nbsp;1.2体征：无并发症的肾结石患者在发作间歇期体检可无任何阳性体征。在肾绞痛发作时可有肾区压痛和肋脊角叩击痛、沿输尿管走行压痛。合并有肾积水时可触及肿大的肾脏合并慢性肾功能衰竭的患者可有不同程度的贫血。<br />&nbsp;&nbsp;\n2.理化检查<br />&nbsp;&nbsp;2.1 尿液检查<br />&nbsp;&nbsp;尿常规：镜下或肉眼血尿。并发感染时,尿中血细胞或脓细胞增多。新鲜层液有时可见结石。24小时尿定量分析测定钙、磷、草酸、胧氨酸、钠、镁、氯化物、构椽酸等。<br />&nbsp;&nbsp;2.2血液生化检查<br />&nbsp;&nbsp;并发肾功能衰竭时,血肌配、尿素氮升高,二氧化碳结合力降低,高钾或低钾血症。<br />&nbsp;&nbsp;血清钙、磷、尿酸的测定,对于明确结石成因及性质有重要意义。<br />&nbsp;&nbsp;X线腹平片约90%的泌尿系统结石可在X线腹平片上显影。结石在X线腹平片上显影密度的高低和结石成分有关,依次为草酸钙、磷酸盐、含钙的尿酸盐和胧氨酸,而纯尿酸和胧氨酸石可不显影。<br />&nbsp;&nbsp;静脉肾盂造影能明确显示结石的位置和整个泌尿道的情况。腹部平片未显示的肾结石,通过静脉肾盂造影,可见肾结石区充盈缺损。<br />&nbsp;&nbsp;B型超声波检查：可发现肾积水,结石强回声和声影,能诊断出X线阴性结石,当结石直径时即可显示。<br />&nbsp;&nbsp;逆行肾盂造影对于静脉肾孟造影显像不理想的患者可采取该方法。肾盂注气造影适用于阴性结石患者。<br />&nbsp;&nbsp;核素肾图和肾扫描放射性核素扫描不仅可以显示结石,而且也能表明梗阻和肾功能损害程度,肾图可提示有无梗阻。<br />&nbsp;&nbsp;CT和MRI和可鉴别结石、血块或肿瘤。<br />&nbsp;&nbsp;结石定性分析：对排出或取出的结石,在可能条件下应进行化学分析,并结合尿液、血液等检查,探讨结石形成的原因,以便提出针对性防治措施。<br />&nbsp;&nbsp;偏光显微镜检查：将取出结石磨成薄片,进行镜下观察,可直接鉴定结石的成分和结构,对结石的治疗和防治有指导意义。<br />&nbsp;&nbsp;\n3.诊断要点<br />&nbsp;&nbsp;\n腰部或上腹部持续钝痛或阵发性剧烈绞痛,常放射至同侧下腹部或外阴。<br />&nbsp;&nbsp;\n肉眼或镜下血尿,绞痛发作时血尿加重。<br />&nbsp;&nbsp;\nX线腹部尿路平片大多可见阳性结石影。<br />&nbsp;&nbsp;\n肾盂造影可进一步确定腹部平片中钙化影是否与泌尿系有关,可明确结石部位、有无梗阻,并可显示X线阴性的结石。<br />&nbsp;&nbsp;\n核素肾图及B超、对诊断有一定帮助。<br />&nbsp;&nbsp;\n', '1.虚证或虚实夹杂证<br />&nbsp;&nbsp;证候：腰部疼痛,少腹胀满,小便涩滞不畅,或尿中时夹沙石,灼热刺痛,尿色黄赤,或尿血鲜红,有的兼有寒热,口苦,呕恶,大便秘结,舌质红,苔黄腻,脉滑数。治法清热利湿,通淋排石。<br />&nbsp;&nbsp;2.肝经气滞证<br />&nbsp;&nbsp;证候：腰胁胀痛,小便涩滞,淋漓不尽,或腰痛引及少腹阴股,或尿流突然中断,点滴而出,小腹膨隆,窘迫难忍,暖气,胸腹胀满,舌苔薄黄或薄白,脉弦滑。<br />&nbsp;&nbsp;3.瘀血内阻证<br />&nbsp;&nbsp;证候：腰腹疼痛,固定不移,或可触及肿块,按之痛甚,尿血紫暗,反复不已,或夹有血块,尿出茎中涩痛,少腹硬满,舌质紫暗或有痪斑,脉弦涩。<br />&nbsp;&nbsp;4.脾肾两虚证<br />&nbsp;&nbsp;证候：腰酸乏力,不耐劳累,肾区喜揉喜按,小便涩滞不甚,少腹坠胀,伴见腰酸乏力,面色萎黄,舌质淡胖,苔薄,脉细弱无力。<br />&nbsp;&nbsp;5.气阴不足证<br />&nbsp;&nbsp;证候：结石日久不消,头晕耳鸣,腰痛绵绵,时轻时重,小便微涩,或带血丝,可伴口干咽燥,心烦失眠,手足心热,舌质红少苔,脉弦细带数。<br />&nbsp;&nbsp;', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('460', '31', 'S02_009', '0', 'ZYYXH/T247～286-2012，中医儿科科常见病诊疗指南', null, '中华中医药学会', '2012', '中华中医药学会.ZYYXH/T247～286-2012，中医儿科常见病诊疗指南[S].北京：中国中医药出版社，2012', '中文', null, '1.临床表现$$$$    主症表现：浮肿，身体困重，小便短少，尿浊或血尿。$$$$    次症表现：面色白，恶心，呕吐，食欲不振，腹胀，腹痛，泄泻。$$$$    重症表现：面色紫暗或黧黑，无尿，口有秽味，或伴胸水、腹水；频繁呕吐，四肢厥冷，面色白或口唇青紫；头痛，抽搐，谵语，嗜睡，昏迷。$$$$2.实验室检查$$$$    尿蛋白检查：尿常规检查蛋白定性在(+++)以上，24小时尿蛋白定量在50mg/ (kg•d)以$$$$上，并持续2周以上。$$$$    血生化检查：低蛋白血症，血浆白蛋白< 30畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭㸀੟ༀƙ\0੟ð\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄Ὰఅ੟ð\0ఄ彿㎽奋㎽巫㎽枢అ諺అ彿㎽諮అ塚㎽諺అꍈ㏂\0\0Ὰఅ學㎽漸㏂圔㎽Ὰఅ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0䃨੟䐺盭暼痭䃨੟ༀƙ \0䃨੟`\0\0㺣盭䃨੟\0𢡄䃬੟', null, '1.本证：肺脾气虚证；脾虚湿困证；脾肾阳虚证；肝肾阴虚证；气阴两虚证。<br />&nbsp;&nbsp;2.标证：外感风邪证；水湿内停证；湿热内蕴证；瘀血阻滞证；湿浊停聚证。<br />&nbsp;&nbsp;3.变证：邪陷心肝证；水毒内闭证。', '1.临床表现<br />&nbsp;&nbsp;    主症表现：浮肿，身体困重，小便短少，尿浊或血尿。<br />&nbsp;&nbsp;    次症表现：面色白，恶心，呕吐，食欲不振，腹胀，腹痛，泄泻。<br />&nbsp;&nbsp;    重症表现：面色紫暗或黧黑，无尿，口有秽味，或伴胸水、腹水；频繁呕吐，四肢厥冷，面色白或口唇青紫；头痛，抽搐，谵语，嗜睡，昏迷。<br />&nbsp;&nbsp;2.实验室检查<br />&nbsp;&nbsp;    尿蛋白检查：尿常规检查蛋白定性在(+++)以上，24小时尿蛋白定量在50mg/ (kg•d)以<br />&nbsp;&nbsp;上，并持续2周以上。<br />&nbsp;&nbsp;    血生化检查：低蛋白血症，血浆白蛋白< 30g/L；高脂血症，血浆胆固醇>5.7mmol/L。<br />&nbsp;&nbsp;    高凝状态检查：大多数患儿存在不同程度的高凝状态，血小板增高，血小板凝聚率增加，血浆纤维蛋白原增加，尿纤维蛋白降解产物增高。<br />&nbsp;&nbsp;    肾穿刺活检：有条件者可以做，以确定病理诊断。<br />&nbsp;&nbsp;3.需与肾病综合征鉴别的病种 <br />&nbsp;&nbsp;急性肾小球肾炎，泌尿道感染，营养性水肿，肝性水肿，急性肾盂肾炎等。', '1.本证<br />&nbsp;&nbsp;1.1肺脾气虚证<br />&nbsp;&nbsp;    全身浮肿，颜面为著，面色苍白或萎黄，身重困倦，气短乏力，声低懒言，自汗，纳呆，便溏，小便短少，平素易感冒，舌淡或淡胖，苔白或白滑，脉浮细，指纹淡红。<br />&nbsp;&nbsp;1.2脾虚湿困证<br />&nbsp;&nbsp;    全身浮肿，肢体为著，按之凹陷，面色萎黄，身体困重，倦怠乏力，或兼胸闷，腹胀，纳少，便溏，小便短少，舌淡胖，舌边有齿痕，苔厚腻，脉沉缓，指纹淡红。<br />&nbsp;&nbsp;1.3脾肾阳虚证<br />&nbsp;&nbsp;    全身明显浮肿，按之深陷难起，腰腹下肢尤甚，或伴胸水、腹水，畏寒肢冷，身体重着，神疲倦卧，脘腹胀满，腰膝酸软，恶心，呕吐，纳少，便溏，小便短少不利，面色白，舌淡胖，舌边有齿痕，苔白滑，脉沉细无力，指纹淡红。<br />&nbsp;&nbsp;1.4肝肾阴虚证<br />&nbsp;&nbsp;    浮肿较轻或无浮肿，头痛，头晕耳鸣，面色潮红，五心烦热，盗汗，失眠多梦，口干咽燥，咽部暗红，腰膝酸软，或伴痤疮，舌红，苔少，脉细数，指纹淡。<br />&nbsp;&nbsp;1.5气阴两虚证<br />&nbsp;&nbsp;    浮肿较轻或无浮肿，面色无华，神疲乏力，自汗、盗汗或午后低热，手足心热，头晕，耳鸣，口干咽燥或长期咽痛，咽部暗红，易感冒，舌红少津，苔少，脉细弱，指纹淡。<br />&nbsp;&nbsp;2.标证<br />&nbsp;&nbsp;2.1外感风邪证<br />&nbsp;&nbsp;    恶寒，发热，头身疼痛，咳嗽，喷嚏，流涕，无汗或有汗，或喘咳气急，或咽红、喉核肿痛，舌红，苔薄白，脉浮，指纹浮红。<br />&nbsp;&nbsp;2.2水湿内停证<br />&nbsp;&nbsp;    全身明显浮肿，皮肤光亮，按之深陷难起，腹水明显，或伴胸水，或见胸闷、气短喘咳，身体困重，腹满泛恶，便溏或泄泻，尿少，舌淡，苔白，脉滑，指纹紫滞。<br />&nbsp;&nbsp;2.3湿热内蕴证<br />&nbsp;&nbsp;    身体困重，身热不扬，皮肤疮疡疖肿；恶心欲呕，口黏口苦，口干不欲饮，脘腹胀满，纳呆，大便不调，腰痛，小腹坠胀，小便频数短黄，或灼热刺痛，舌红，苔黄腻，脉滑数，指纹紫滞。<br />&nbsp;&nbsp;2.4瘀血阻滞证<br />&nbsp;&nbsp;    颜面浮肿，面色紫暗或晦暗，眼睑下发青，唇舌紫暗，皮肤粗糙或肌肤甲错，有紫纹或血缕，或胁下痞块，腰痛，舌质紫暗有瘀点瘀斑，苔少，脉涩，指纹紫滞。<br />&nbsp;&nbsp;2.5湿浊停聚证<br />&nbsp;&nbsp;    身重困倦，精神委靡，头痛，眩晕，胸闷，腹胀，纳呆，恶心，呕吐，大便黏腻，小便短黄，口黏腻，舌淡，苔厚腻，脉滑，指纹紫。<br />&nbsp;&nbsp;3.变证<br />&nbsp;&nbsp;3.1邪陷心肝证<br />&nbsp;&nbsp;    浮肿尿少，头痛头晕，视物模糊，恶心呕吐，烦躁不安，谵语，肢体震颤，重则抽搐，昏迷，舌红绛，苔黄燥，脉弦数，指纹紫滞。<br />&nbsp;&nbsp;3.2水毒内闭证<br />&nbsp;&nbsp;    全身浮肿或伴胸水、腹水，少尿或无尿，面色晦暗，头晕头痛，恶心呕吐，口有秽味，重则神昏谵语，抽搐昏迷，舌质暗，苔白厚腻，脉沉细或滑数，指纹紫滞。', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('461', '31', 'S02_010', '1', 'KDIGO肾小球肾炎指南-内固醇敏感儿童肾病综合症', 'KDIGO Clinical Practice Guideline for Glomerulonephritis-Steroid-sensitive nephrotic syndrome in children\n', '改善全球肾脏病预后组织（Kidney Disease: Improving Global Outcomes，KDIGO）', '2012', 'http://kdigo.org/home/glomerulonephritis-gn/;$$$$\nKidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for\nGlomerulonephritis. Kidney inter., Suppl. 2012; 2: 139–274.', '英文', null, '激素敏感型儿童肾病综合症；Steroid-sensitive nephrotic syndrome in children\n', null, null, 'S02_010_001儿童肾病综合征定义.docx<br />&nbsp;&nbsp;\n水肿, uPCR ≥2000 mg/g (≥200 mg/mmol), or≥300 mg/dl, or 3+ 尿液试纸蛋白, 低蛋白血症 ≤2.5 g/dl (≤25 g/l)<br />&nbsp;&nbsp;Edema, uPCR ≥2000 mg/g (≥200 mg/mmol), or≥300 mg/dl, or 3+ protein on urine dipstick, hypoalbuminaemia ≤2.5 g/dl (≤25 g/l)', null, '尿蛋白清除率urine protein:creatinine ratio.', '1.完全缓解：连续3天uPCR＜200mg/g（＜20mg/mmol）或尿试纸蛋白＜1+  <br />&nbsp;&nbsp;2.部分缓解：尿蛋白减少50%以上，并且uPCR在200-2000mg/g之间（20-200mg/mmol）；3.没有缓解：尿蛋白减少不到50%，或uPCR＞2000mg/g(＞200mg/mmol)', '本章是针对内固醇治疗有效的1到18岁儿童。This chapter makes treatment recommendations for children aged 1 to 18 years with nephrotic syndrome, who respond to corticosteroid therapy by achieving complete remission (SSNS). The cost implications for global application of this g畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭㠰੟ༀƙ\0੟ð\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄Ὰఅ੟ð\0ఄ彿㎽奋㎽巫㎽簶అ锢అ彿㎽锖అ塚㎽锢అꍈ㏂\0\0Ὰఅ學㎽漸㏂圔㎽Ὰఅ圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0㤨੟䐺盭暼痭㤨੟ༀƙ \0㤨੟à\0\0㺣盭㤨੟\0𢡄㤬੟\0팃目㤬੟࣒㤬੟큁目㤬੟΅అ泌', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('462', '31', 'S02_011', '1', 'KDIGO肾小球肾炎指南-激素抵抗型儿童肾病综合症', 'KDIGO Clinical Practice Guideline for Glomerulonephritis-Steroid-resistant nephrotic syndrome in children\n', '改善全球肾脏病预后组织（Kidney Disease: Improving Global Outcomes，KDIGO）', '2012', 'http://kdigo.org/home/glomerulonephritis-gn/;$$$$\nKidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for\nGlomerulonephritis. Kidney inter., Suppl. 2012; 2: 139–274.', '英文', null, '激素抵抗型儿童肾病综合症；Steroid-resistant nephrotic syndrome in children\n', null, null, '以下评估的SRNS患儿<br />&nbsp;&nbsp;4.4.1:我们建议至少8周治疗定义类固醇皮质激素抵抗。(2 d) <br />&nbsp;&nbsp;4.1.2:以下是评估儿童所需SRNS(不计入分数): <br />&nbsp;&nbsp;--诊断肾活检; <br />&nbsp;&nbsp;--评价肾功能的肾小球滤过率(GFR)和表皮生长因子受体; <br />&nbsp;&nbsp;--定量尿蛋白排泄。<br />&nbsp;&nbsp;\nEvaluation of children with SRNS<br />&nbsp;&nbsp;4.1.1: We suggest a minimum of 8 weeks treatment with corticosteroids to define steroid resistance. (2D) <br />&nbsp;&nbsp;4.1.2: The following are required to evaluate the child with SRNS (Not Graded): <br />&nbsp;&nbsp;K a diagnostic kidney biopsy; <br />&nbsp;&nbsp;K evaluation of kidney function by GFR or eGFR; <br />&nbsp;&nbsp;K quantitation of urine protein excretion. <br />&nbsp;&nbsp;\n', null, '尿蛋白清除率urine protein:creatinine ratio.', null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('464', '29', 'M05_001', '0', 'ZYYXH/T64-2008心力衰竭', 'Guidelines for Diagnosis and Treatment of Common Internal Diseases in Chinese Medicine Diseases of Modern Medicine', '中华中医药学会', '2008', '中华中医药学会.ZYYXH/T50～135-2008中医内科常见病诊疗指南西医疾病部分[S].北京：中国中医药出版社，2008', '中文', '1.急性左心衰竭分级<br />&nbsp;&nbsp;1.1Killip分级：Ⅰ级、Ⅱ级、Ⅲ级、Ⅳ级；<br />&nbsp;&nbsp;1.2Forrester分型：Ⅰ级、Ⅱ级、Ⅲ级、Ⅳ级；<br />&nbsp;&nbsp;2.\n心力衰竭的分类：<br />&nbsp;&nbsp;2.1根据心力衰竭进展的快慢:急性心力衰竭、慢性心力衰竭；<br />&nbsp;&nbsp;2.2根据心力衰竭发生的解剖部位：左心衰竭、右心衰竭、全心衰竭；<br />&nbsp;&nbsp;2.3根据心力衰竭时心排血量的高低：高排血量心衰、低排血量心衰；<br />&nbsp;&nbsp;2.4根据心力衰竭时收缩功能和舒张功能的改变：收缩功能障碍性心力衰竭、舒张功能障碍性心力衰竭；<br />&nbsp;&nbsp;2.5根据心力衰竭时血流动力学变化特征：后向性心力衰竭、前向性心力衰竭；<br />&nbsp;&nbsp;2.6根据临床症状的有无：无症状性心力衰竭、显性心力衰竭。', '心力衰竭', null, '1.心肺气虚证；2.气阴两虚证；3.气虚血瘀证；4.阳虚水停证；5.热痰壅肺证；6.寒痰阻肺证；7.阴竭阳脱证', '1.临床表现<br />&nbsp;&nbsp;充血性心力衰竭临床上习惯分为左心衰竭、右心衰竭和全心衰竭。心力衰竭开始发生在左侧心脏和以肺充血为主的称为左心衰竭；开始发生在右侧心脏并以肝、肾等器官和周围静脉淤血为主的,称为右心衰竭。两者同时存在的称全心衰竭。以左心衰竭开始的情况较多见,大多经过一定时期发展为肺动脉高压而引起右心衰竭。单独的右心衰竭较少见。<br />&nbsp;&nbsp;1.1左心衰竭<br />&nbsp;&nbsp;症状：表现为劳力性呼吸困难,阵发性夜间呼吸困难,倦怠乏力,活动后加重,咳嗽咳痰,浮肿,小便，量少,严重者呈端坐呼吸,咳嗽及咳粉红色泡沫样痰,呼吸频率增快,鼻翼煽动,大汗淋漓,面色苍白或晦暗。<br />&nbsp;&nbsp;体征：原有心脏病的体征,左心室增大,心尖搏动向左下移位,心率增快,心尖区有舒张期奔马律,肺动脉瓣区第二心音亢进,其中舒张期奔马律最有诊断价值,在患者心率增快或左侧卧位并作深呼气时更容易听到。左室扩大还可形成相对性二尖瓣关闭不全,产生心尖区收缩期杂音。交替脉,两肺底部有中小水泡音,急性肺水肿时可有粗大湿锣音,满布两肺,并可伴有哮鸣音。胸水可局限于肺叶间,也可呈单侧或双侧胸腔积液。<br />&nbsp;&nbsp;1.2右心衰竭<br />&nbsp;&nbsp;症状：主要有食欲不振,恶心呕吐,上腹饱胀,甚至剧烈腹痛,黄疸,尿量减少、夜尿增多等。<br />&nbsp;&nbsp;体征：原有心脏病的体征,以右心室增大为主者可伴有心前区抬举性搏动。心率增快,部分患者可在胸骨左缘相当于右心室表面处听到舒张早期奔马律。右心室明显扩大可形成功能性三尖瓣关闭不全,产生三尖瓣区收缩期杂音,吸气时杂音增强。颈静脉充盈,肝肿大和压痛,肝颈静脉反流现象阳性。水肿最早出现在身体的下垂部位,起床活动者以脚、踝内侧和胫前较明显,仰卧者骶部水肿。右心衰竭时,可有双侧或单侧胸水,甚至腹水。心包积液,呼吸急促,不能平卧,紫绀。晚期患者可有明显营养不良、消瘦甚至恶病质。<br />&nbsp;&nbsp;1.3全心衰竭：左、右心衰竭同时存在,但患者或以左心衰竭的临床表现为主,或以右心衰竭的临床表现为主。左心衰竭的临床表现可因右心衰竭的发生而减轻。<br />&nbsp;&nbsp;2.理化检查<br />&nbsp;&nbsp;2.1心电图（ECG）：窦性心动过速；可见二尖瓣P波、V1导联P波终末电势增大和左室肥大劳损等反映左心房、室肥大,以及与所患心脏病相应的变化；可有急性、陈旧性心肌梗死或心肌缺血,以及多种心律失常等表现。<br />&nbsp;&nbsp;2.2胸部X线检查：心影增大,右心房、室增大,心胸比例增大可见上腔静脉增宽及搏动,肺门血管影增粗、模糊不清,肺血管分支增粗,或肺叶间淋巴管扩张可见密度增高的云雾状阴影,有时还可见到局限性肺叶间、单侧或双侧胸水。<br />&nbsp;&nbsp;2.3二维超声心动图及彩色多普勒超声检查：可见左或右心房、室扩大或全心扩大,或有室壁瘤存在；心脏收缩及舒张功能降低并可见原发基础心脏病的表现。<br />&nbsp;&nbsp;2.4 6分钟步行试验：在特定的情况下,测量在规定的时间内步行的距离,不仅是评价心力衰竭患者运动耐力的客观指标,而且是判断患者预后的良好指标之一。<br />&nbsp;&nbsp;2.5运动试验：左室功能衰竭时,运动时左室舒张末压增加,超过1.60kPa（12cmH2O）,而射血量不变或下降,心排血量的增加与氧耗量的增加不成正常比例。总的心肺系统的功能还可用平板运动时最大氧耗量（VmaxO2）表示。<br />&nbsp;&nbsp;2.6心导管检查术：静脉压增高,血流动力学监测示中心静脉压、右房压增高,肺源性心脏病患者肺动脉压增高,合并左心衰竭时,肺毛细血管楔压多正常。静脉压增高,肘静脉压超过1.4kPa(14cmH2O)或重压肝脏0.5-1分钟后上升0.1-0.2kPa(1-2cmH2O)以上的,提示有右心衰竭。<br />&nbsp;&nbsp;2.7核素心室造影及核素心肌灌注显像：可准确测定心室容量、左室射血分数及室壁运动。<br />&nbsp;&nbsp;2.8血常规及生化检查：患者血常规可见白细胞升高,中性粒细胞比例增加生化正常或出现电解质紊乱、肝肾功能异常。<br />&nbsp;&nbsp;2.9血气分析检查：血气分析可见低氧血症、二氧化碳潴留或伴发酸碱代谢紊乱。<br />&nbsp;&nbsp;2.10血脑钠素（BNP）水平：可反映心衰的程度。<br />&nbsp;&nbsp;3.诊断要点<br />&nbsp;&nbsp;左心衰竭的诊断依据为原有心脏病的体征和肺循环充血的表现。右心衰竭的诊断依据为原有心脏病的体征和体循环淤血的表现,且患者大多有左心衰竭的病史。<br />&nbsp;&nbsp;3.1慢性充血性心力衰竭：临床慢性充血性心力衰竭的诊断多采用Framingham诊断要点。<br />&nbsp;&nbsp;主要标准：夜间阵发性呼吸困难或端坐呼吸；颈静脉怒张；肺部啰音；胸片显示心脏增大；急性肺水肿；第三心音奔马律；静脉压增高＞16mmHg；循环时间延长≥25秒；肝颈回流征阳性。<br />&nbsp;&nbsp;次要标准：双侧踝部水肿；夜间咳嗽；日常劳动时发生呼吸困难；肝脏增大；胸腔积液；肺活量较既往最大测值降低1/3；心动过速（120次/分）。<br />&nbsp;&nbsp;主要或次要标准：治疗5日以上时间,体重减轻≥4.5kg。<br />&nbsp;&nbsp;同时存在以上2项主要指标或1项主要指标加2项次要指标；次要指标只有在不能用其他疾病解释时才可作为心衰的诊断要点。<br />&nbsp;&nbsp;3.2急性左心衰竭<br />&nbsp;&nbsp;症状：突发重度呼吸困难,端坐呼吸,吸气时肋间隙和锁骨上窝内陷,呼吸频率增快,烦躁不安,大汗淋漓,皮肤湿冷,面色灰白,紫绀,阵发性咳嗽伴哮鸣音,常咳大量白色或粉红色泡沫痰。<br />&nbsp;&nbsp;体征：呼吸频率增快,口唇紫绀,颈静脉怒张,双肺满布湿哆音及哮鸣音,亢进,心率增快,心尖部可听到舒张期奔马律,心音低钝,心律不齐。开始血压升高,随病情进展,血压常下降,严重者可有心源性休克及阿-斯综合征。<br />&nbsp;&nbsp;辅助检查：心电图可见心率快或慢,或伴有心律失常,如有心肌缺血或心肌梗死,同时可见相应改变。X线片可见上肺静脉充盈、肺门增宽呈蝶翼状或大片云雾样阴影,肺纹理增粗和肺小叶间隔增厚。心脏超声可见心脏增大,收缩或舒张功能不全,同时伴见心脏原发病的表现。肺毛细血管楔压＞36mmHg(4.8kPa)提示即将出现急性肺水肿。<br />&nbsp;&nbsp;结合患者的病史、典型症状、体征及实验室检查,即可明确诊断。<br />&nbsp;&nbsp;3.3心力衰竭的分级<br />&nbsp;&nbsp;3.3.1慢性充血性心力衰竭分级采用纽约NYHA心脏病协会心功能分级及客观评价表。<br />&nbsp;&nbsp;表M05_001_001<br />&nbsp;&nbsp;3.3.2急性左心衰竭分级<br />&nbsp;&nbsp;Killip分级：Ⅰ级：无心力衰竭,体检肺部无啰音,无S3,及心功能不全症状。Ⅱ级：有轻度至中度的心力衰竭,体检肺部啰音占肺野50%以下,有S3。Ⅲ级：有严重的心力衰竭、肺水肿,湿性啰音占50%肺野以上。Ⅳ级：心源性休克。用于心肌梗死急性期的心功能分级。<br />&nbsp;&nbsp;Forrester分型：Ⅰ级：无肺淤血又无周围灌注不足,心功能处于代偿状态；无泵衰竭的临床症状及体征,心脏指数（CI）＞2.2L/（min• m2），肺毛细血管楔压（PCWP）≤18mmHg(2.4kPa)；心力衰竭,体检肺部无啰音,无S3及心功能不全症状。Ⅱ级：有肺淤血,没有周围灌注不足症状,为常见的临床类型。此型早期也可无明显的临床表现；CI＞2.2L/（min•m2），PCWP＞18mmHg(2.4kPa)。Ⅲ级：无肺淤血,有周围灌注不足症状；该型多见于右室梗死,亦可见于血容量不足患者；此型早期也可无明显的临床表现；CI≤2.2L/（min•m2），PCWP＞18mmHg(2.4kPa)。Ⅳ级：此型兼有肺淤血与周围灌注不足症状,为严重类型；见于大面积急性心肌梗死；CI≤2.2L/（min•m2），PCWP＞18mmHg(2.4kPa)。', '1.心肺气虚证<br />&nbsp;&nbsp;证候：以气短喘促、心悸咳嗽为主症,可兼见胸闷乏力、动则加剧、面色灰青等症,舌淡,苔薄白,脉沉弱。<br />&nbsp;&nbsp;2.气阴两虚证<br />&nbsp;&nbsp;证候：以心悸气短、五心烦热为主症,可兼见失眠多梦、目眩乏力、口干舌燥等症,舌红,苔少或无苔,脉细数。<br />&nbsp;&nbsp;3.气虚血瘀证<br />&nbsp;&nbsp;证候：以心悸怔忡、胸胁作痛、状若针刺、浮肿尿少为主症,可兼见腹胀痞满、口唇紫绀等症，舌质紫暗或有癖点、疲斑,脉涩或结代。<br />&nbsp;&nbsp;4.阳虚水停证<br />&nbsp;&nbsp;证候：以怔忡喘促、尿少浮肿为主症,可兼见恶寒肢冷、或夜尿频数、神志恍惚、面色苍白等症,舌淡,苔薄白滑,脉沉细。<br />&nbsp;&nbsp;5.热痰壅肺证<br />&nbsp;&nbsp;证候：以心悸咳喘、发热口渴、咳痰黏稠为主症,或兼神昏澹语,舌红,苔黄,脉滑数。<br />&nbsp;&nbsp;6.寒痰阻肺证<br />&nbsp;&nbsp;证候：以心悸咳喘、尿少浮肿、痰多质稀或泡沫样痰为主症,舌淡暗,苔白滑,脉弦滑。<br />&nbsp;&nbsp;7.阴竭阳脱证<br />&nbsp;&nbsp;证候：以呼吸喘促、呼多吸少、烦躁不安、张口抬肩、汗出如油为主症,可兼见四肢厥逆或昏厥谵语等症,舌质紫暗,苔少或无苔,脉微细欲绝。<br />&nbsp;&nbsp;', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('465', '29', 'M05_002', '1', '中国心力衰竭诊断和治疗指南2014', '无', '中华医学会心血管病学分会；中华心血管病杂志编辑委员会', '2014', '中华心血管病杂志，2014，42（2）：98-122.', '中文', '1.依据左心室射血分数(LVEF)，心衰可分为LVEF降低的心衰(heart failure with reduced left ventricular ejection\nfraction，HF-REF)和LVEF保留的心衰(heart failure with preserved left ventricu]ar ejection fraction，HF-PEF)。HF-REF指传统概念上的收缩性心衰，而HF-PEF指舒张性心衰。LVEF保留或正常的情况下收缩功能仍可能是异常的，部分心衰患者收缩功能异常和舒张功能异常可以共存。2.根据心衰发生的时间、速度、严重程度可分为慢性心衰和急性心衰。在原有慢性心脏疾病基础上逐渐出现心衰症状、体征的为慢性心衰。慢性心衰症状、体征稳定1个月以上称为稳定性心衰。慢性稳定性心衰恶化称为失代偿性心衰，如失代偿突然发生则称为急性心衰。急性心衰的另一种形式为心脏急性病变导致的新发心衰。<br />&nbsp;&nbsp;3.心衰发生发展的各阶段<br />&nbsp;&nbsp;表M05_002_001<br />&nbsp;&nbsp;4.心衰的程度<br />&nbsp;&nbsp;4.1NYHA心功能分级：心衰症状严重程度与心室功能的相关性较差，但与生存率明确相关，而轻度症状的患者仍可能有较高的住院和死亡的绝对风险。<br />&nbsp;&nbsp;表M05_002_002<br />&nbsp;&nbsp;4.2  6 min步行试验：用于评定患者的运动耐力。6min步行距离<150m为重度心衰，150～450m为中度心衰，>450m为轻度心衰。<br />&nbsp;&nbsp;5.急性左心衰竭严重程度分级<br />&nbsp;&nbsp;主要有Killip法、Forrester法和临床程度床边分级3种。Killip法主要用于AMI患者，根据临床和血液动力学状态分级。Forrester法适用于监护病房，及有血液动力学监测条件的病房、手术室。临床程度床边分级根据Forrester法修改而来，主要根据末稍循环的观察和肺部听诊，无需特殊的监测条件，适用于一般的门诊和住院患者。<br />&nbsp;&nbsp;表M05_002_003<br />&nbsp;&nbsp;\n\n', '心力衰竭', null, null, '1.HF-PEF(舒张性心衰)的诊断标准<br />&nbsp;&nbsp;1.1主要临床表现：①有典型心衰的症状和体征；②LVEF正常或轻度下降(≥45％)，且左心室不大；③有相关结构性心脏病存在的证据(如左心室肥厚、左心房扩大)和(或)舒张功能不全；④超声心动图检查无心瓣膜病，并可排除心包疾病、肥厚型心肌病、限制型(浸润性)心肌病等。本病的LVEF标准尚未统一。LVEF在4l％-49％被称为临界HF-PEF，其人群特征、治疗及预后均与HF-REF类似，这提示将LVEF>50％作为临床诊断标准可能更好。此外，有的患者既往出现过LVEF下降至≤40％，其临床预后与LVEF持续性保留的患者可能也不同。<br />&nbsp;&nbsp;1.2其他需要考虑的因素：①应符合本病的流行病学特征：大多为老年患者、女性，心衰的病因为高血压或既往有长期高血压史，部分患者可伴糖尿病、肥胖、房颤等。②BNP和(或)NT-proBNP测定有参考价值，但尚有争论。如测定值呈轻至中度升高，或至少在“灰区值”之间，有助于诊断。<br />&nbsp;&nbsp;1.3辅助检查：超声心动图参数诊断左心室舒张功能不全准确性不够、重复性较差，应结合所有相关的二维超声参数和多普勒参数，综合评估心脏结构和功能。二尖瓣环舒张早期心肌速度(e’)可用于评估心肌的松弛功能，E/e’值则与左心室充盈压有关。左心室舒张功能不全的超声心动图证据可能包括e’减少(e’平均<9 cm/s)，E/e 7值增加(>15)，E/A异常(>2或<1)，或这些参数的组合。至少2个指标异常和(或)存在房颤，增加左心室舒张功能不全诊断的可能性。<br />&nbsp;&nbsp;2.急性心衰<br />&nbsp;&nbsp;2.1临床表现急性心衰发作迅速，可以在几分钟到几小时(如AMI引起的急性心衰)，或数天至数周内恶化。患者的症状也可有所不同，从呼吸困难、外周水肿加重到威胁生命的肺水肿或心原性休克，均可出现。急性心衰症状也可因不同病因和伴随临床情况而不同。<br />&nbsp;&nbsp;2.1基础心血管疾病的病史和表现：大多数患者有各种心脏疾病史，存在引起急性心衰的各种病因。老年人中主要病因为冠心病、高血压和老年性退行性心瓣膜病，年轻人中多由风湿性心瓣膜病、扩张型心肌病、急性重症心肌炎等所致。<br />&nbsp;&nbsp;2.2早期表现：原来心功能正常的患者出现原因不明的疲乏或运动耐力明显减低，以及心率增加15～20次/min，可能是左心功能降低的最早期征兆。继续发展可出现劳力性呼吸困难、夜问阵发性呼吸困难、不能平卧等；检查可发现左心室增大、舒张早期或中期奔马律、P2亢进、两肺尤其肺底部有湿性啰音，还可有干啰音和哮鸣音，提示已有左心功能障碍。<br />&nbsp;&nbsp;2.3急性肺水肿：起病急骤，病情可迅速发展至危重状态。突发严重呼吸困难、端坐呼吸、喘息不止、烦躁不安，并有恐惧感，呼吸频率可达30～50次/min；频繁咳嗽并咯出大量粉红色泡沫样血痰；听诊心率快，心尖部常可闻及奔马律；两肺满布湿啰音和哮鸣音。<br />&nbsp;&nbsp;2.4心原性休克：主要表现为：(1)持续性低血压，收缩压降至90mmHg以下，且持续30min以上，需要循环支持。(2)血液动力学障碍：肺毛细血管楔压(PCWP)≥18mmHg，心脏指数≤2.2L•min-1•m-2(有循环支持时)或1.8 L•min-1•m-2(无循环支持时)。(3)组织低灌注状态，可有皮肤湿冷、苍白和紫绀；尿量显著减少(<30ml/h)，甚至无尿；意识障碍；代谢性酸中毒。<br />&nbsp;&nbsp;3.右心衰竭诊断标准：(1)存在可能导致有心衰竭的病因。其中最重要的是存在左心衰竭、肺动脉高压(包括COPD所致)、右室心肌病变[包括右心室梗死，限制性病变和致心律失常性右室心肌病(ARVC)等]、右侧瓣膜病变，以及某些先天性心脏病。(2)存在右心衰竭的症状和体征。主要由于体循环静脉淤血和右心排血量减少。症状主要有活动耐量下降，乏力以及呼吸困难。体征主要包括颈静脉压增高的征象，肝脏增大，中心性水肿(如胸腔积液、腹水、心包积液)和外周水肿，以及这些体征的组合。(3)存在右心结构和(或)功能异常和心腔内压力增高的客观证据。主要来自影像学检查，包括超声心动图、核素、磁共振等。右心导管可提供心腔内压力增高和功能异常的证据。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('466', '29', 'M05_003', '0', '慢性心力衰竭中医诊疗专家共识', '无', '冠心病中医临床研究联盟；中国中西医结合学会心血管疾病专业委员会；中华中医药学会心病分会；中国医师协会中西医结合医师分会心血管病学专家委员会', '2014', '中医杂志，2014，55（14）：1258-1260.', '中文', null, '慢性心力衰竭', null, '1.气虚血瘀证；2.气阴两虚血瘀证；3.阳气亏虚血瘀证；4.兼证：痰饮证。', '参照2014年中华医学会心血管病学分会发布的《中国心力衰竭诊断和治疗指南2014》', '1.气虚血瘀证<br />&nbsp;&nbsp;主症: 气短/喘息、乏力、心悸。<br />&nbsp;&nbsp;次症: ①倦怠懒言，活动易劳累; ②自汗; ③语声低微; ④面色/口唇紫暗。<br />&nbsp;&nbsp;舌脉: 舌质紫暗( 或有瘀斑、瘀点或舌下脉络迂曲青紫)，舌体不胖不瘦，苔白，脉沉、细或虚无力。<br />&nbsp;&nbsp;2.气阴两虚血瘀证<br />&nbsp;&nbsp;主症: 气短/喘息、乏力、心悸。<br />&nbsp;&nbsp;次症: ①口渴/咽干; ②自汗/盗汗; ③手足心热; ④面色/口唇紫暗。<br />&nbsp;&nbsp;舌脉: 舌质暗红或紫暗( 或有瘀斑、瘀点或舌下脉络迂曲青紫)，舌体瘦，少苔，或无苔，或剥苔，或有裂纹，脉细数无力或结代。<br />&nbsp;&nbsp;3.阳气亏虚血瘀证<br />&nbsp;&nbsp;主症: 气短/喘息、乏力、心悸。<br />&nbsp;&nbsp;次症: ①怕冷和/ ( 或) 喜温; ②胃脘/腹/腰/肢体冷感; ③冷汗; ④面色/口唇紫暗。<br />&nbsp;&nbsp;舌脉: 舌质紫暗( 或有瘀斑、瘀点或舌下脉络迂曲青紫)，舌体胖大，或有齿痕，脉细、沉、迟无力。<br />&nbsp;&nbsp;具备主症2 项，次症2 项，结合舌脉，即可诊断。<br />&nbsp;&nbsp;4.兼证<br />&nbsp;&nbsp;痰饮证: 咳嗽/咯痰、胸满/腹胀、面浮/肢肿、小便不利。<br />&nbsp;&nbsp;舌脉: 舌苔润滑，或腻，或有滑脉。<br />&nbsp;&nbsp;具有兼证1 项，结合舌脉，即可诊断。<br />&nbsp;&nbsp;', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('467', '29', 'M05_004', '1', '慢性心力衰竭诊断治疗指南', '无', '中华医学会心血管病学分会；中华心血管病杂志编辑委员会', '2007', '中华心血管病杂志，2007，35（12）：1076-1095.', '中文', '1.根据心衰发生发展的过程，从心衰的高发危险人群进展成器质性心脏病，出现心衰症状直至难治性终末期心衰，可分成A、B、C、D四个阶段。<br />&nbsp;&nbsp;1.1阶段A：为“前心衰阶段”（pre-heart failure），包括心衰的高发危险人群，但目前尚无心脏的结构或功能异常，也无心衰的症状和（或）体征。这一人群主要指高血压病、冠心病、糖尿病等，也包括肥胖、代谢综合征等最终可累及心脏的近年流行病，此外还有应用心脏毒性药物的病史、酗酒史、风湿热史或心肌病家族史等患者。<br />&nbsp;&nbsp;1.2阶段B：属“前临床心衰阶段”（pre-clinical heart failure）。患者从无心衰的症状和（或）体征，但已发展成结构性心脏病，例如左室肥厚、无症状瓣膜性心脏病、以往有心肌梗死史等。这一阶段相当于无症状性心衰，或NYHA心功能Ⅰ级。由于心衰是一种进行性的病变，心肌重构可自身不断地发展，因此，这一阶段患者的积极治疗极其重要，而治疗的关键是阻断或延缓心肌重构。<br />&nbsp;&nbsp;1.3阶段C：为临床心衰阶段。患者已有基础的结构性心脏病，以往或目前有心衰的症状和（或）体征；或目前虽无心衰的症状和（或）体征，但以往曾因此治疗过。这一阶段包括NYHA心功能Ⅱ、Ⅲ级和部分Ⅳ级心功能患者。<br />&nbsp;&nbsp;1.4阶段D：为难治性终末期心衰阶段。患者有进行性结构性心脏病，虽经积极的内科治疗，休息时仍有症状，且需要特殊干预（例如：因心衰需反复住院且不能安全出院、需长期在家静脉用药、等待心脏移植、应用心脏机械辅助装置者，也包括部分NYHA心功能Ⅳ级）的患者。这一阶段患者预后极差，平均生存时间仅3.4个月。', '慢性心力衰竭', null, null, '1.心脏病性质及程度判断：收缩性心衰的临床表现为：（1）左室增大、左室收缩末期容量增加及LVEF≤40%；（2）有基础心脏病的病史、症状及体征；（3）有或无呼吸困难、乏力和液体储留水肿等。<br />&nbsp;&nbsp;1.1病史及体格检查：可提供各种心脏病的病因线索，如冠心病、瓣膜性心脏病、高血压、心肌病和先天性心脏病。应询问吸烟、血脂异常、睡眠呼吸障碍、胸部放射史、接触心脏毒性药物（包括抗肿瘤药物, 例如蒽环类抗生素或大剂量环磷酰胺等）病史。询问有关违禁药物使用史和酒精摄入量。应特别关注非心脏疾病，例如结缔组织病、细菌性或寄生虫感染、肥胖、甲状腺机能亢进或减退、淀粉样变以及嗜铬细胞瘤等病史。根据临床症状及体征可判断左心衰竭、右心衰竭或全心衰竭。<br />&nbsp;&nbsp;1.2二维超声心动图及多普勒超声：可用于（1）诊断心包、心肌或瓣膜疾病；（2）定量或定性房室内径、心脏几何形状、室壁厚度、室壁运动以及心包、瓣膜和血管结构，定量瓣膜狭窄、关闭不全程度，测量LVEF、左室舒张末期和收缩末期容量；（3）区别舒张功能不全和收缩功能不全；（4）估测肺动脉压；（5）为评价治疗效果提供客观指标。<br />&nbsp;&nbsp;推荐采用二维超声心动图的改良Simpson法测量左室容量及LVEF，与造影或尸检比较其相关性较好。由于超声检查简便、价廉、便于床旁检查及重复检查，故左室功能的测定还是以此法最为普遍。<br />&nbsp;&nbsp;1.3核素心室造影及核素心肌灌注显像：前者可准确测定左室容量、LVEF及室壁运动。后者可诊断心肌缺血和心肌梗死，并对鉴别扩张型心肌病或缺血性心肌病有一定帮助。<br />&nbsp;&nbsp;1.4 X线胸片：提供心脏增大、肺淤血、肺水肿及原有肺部疾病的信息。<br />&nbsp;&nbsp;1.5心电图：提供既往心肌梗死、左室肥厚、广泛心肌损害及心律失常信息。有心律失常时应作24小时动态心电图记录。<br />&nbsp;&nbsp;1.6冠状动脉造影适用于有心绞痛或心肌梗死、需血管重建或临床怀疑冠心病的患者，也可鉴别缺血性或非缺血性心肌病，但不能用来判断是否有存活心肌。<br />&nbsp;&nbsp;1.7心肌活检：对不明原因的心肌病诊断价值有限，但有助于明确心肌炎症性或浸润性病变的诊断。<br />&nbsp;&nbsp;2.心功能不全的程度判断<br />&nbsp;&nbsp;2.1 NYHA心功能分级：Ⅰ级，日常活动无心衰症状；Ⅱ级，日常活动出现心衰症状（呼吸困难、乏力）；Ⅲ级，低于日常活动出现心衰症状；Ⅳ级，在休息时出现心衰症状。反映左室收缩功能的与心功能分级症状并非完全一致。<br />&nbsp;&nbsp;2.2 6分钟步行试验：不但能评定患者的运动耐力，而且可预测患者预后。6分钟步行距离＜300m，提示预后不良。根据美国的卡维地洛研究设定的标准：6分钟步行距离＜150m为重度心衰；150-450m为中度心衰；＞450m为轻度心衰。<br />&nbsp;&nbsp;3.液体潴留及其严重程度判断<br />&nbsp;&nbsp;液体潴留对决定利尿剂治疗十分重要。短时间内体重增加是液体潴留的可靠指标。每次随诊应记录体重，注意颈静脉充盈程度、肝颈静脉回流征、肺和肝充血的程度（有无肺部啰音、肝脏肿大），检查下肢和骶部水肿、腹部移动性浊音，以发现腹水。<br />&nbsp;&nbsp;4.其他生理功能评价<br />&nbsp;&nbsp;4.1有创性血流动力学检查：主要用于严重威胁生命并对治疗无反应的泵衰竭患者，或需对呼吸困难和低血压休克作鉴别诊断的患者。<br />&nbsp;&nbsp;4.2血浆脑利钠肽（BNP）测定：BNP测定有助于心衰诊断和预后判断。慢性心衰包括症状性和无症状性左室功能障碍患者血浆BNP水平均升高。伦敦一项心衰研究证实，BNP诊断心衰的敏感性、特异性、阴性预测值和阳性预测值分别为97%、84%、97%和70%。血浆BNP可用于鉴别心原性和肺原性呼吸困难，BNP正常的呼吸困难基本可除外心原性。血浆高水平BNP预示严重心血管事件，包括死亡的发生。心衰经治疗，血浆BNP水平下降提示预后改善。大多数心衰导致呼吸困难患者的BNP在400ng/L以上。BNP＜100ng/L时不支持心衰的诊断；BNP在100-400ng/L之间还应考虑其他原因，如肺栓塞、慢性阻塞性肺部疾病、心衰代偿期等。<br />&nbsp;&nbsp;NT-proBNP是BNP激素原分裂后没有活性的N-末端片段，比半衰期更长、更稳定，其浓度可反映短暂时间内新合成的而不是贮存的BNP释放，因此更能反映BNP通路的激活。正常人血浆BNP和NT-proBNP的浓度相似。在左室功能障碍时，血浆NT-proBNP的水平超过BNP水平可达4倍。血浆NT-proBNP水平与年龄、性别和体重有关，老龄和女性升高，肥胖者降低，肾功能不全时升高。血浆NT-proBNP水平也随心衰程度加重而升高，在伴急性冠状动脉综合征、慢性肺部疾病、肺动脉高压、高血压、心房颤动（房颤）时也会升高。BNP亦有类似改变。50岁以下的成人血浆NT-proBNP浓度450ng/L诊断急性心衰的敏感性和特异性分别为93%和95%；50岁以上者的血浆浓度900ng/L诊断心衰的敏感性和特异性分别为91%和80%。NT-proBNP＜300ng/L为正常，可排除心衰，其阴性预测值为99%。心衰治疗后NT-proBNP＜200ng/L提示预后良好。肾功能不全、肾小球滤过率＜60ml/min时，NT-proBNP 1200ng/L诊断心衰的敏感性和特异性分别为85%和88%。<br />&nbsp;&nbsp;4.3心脏不同步：心衰常合并传导异常，导致房室、室间和（或）室内运动不同步。房室不同步表现为心电图中PR间期延长，使左室充盈减少；左右心室间不同步表现为左束支传导阻滞，使右室收缩早于左室；室内传导阻滞在心电图上表现为QRS时限延长（＞120ms）。以上不同步现象均严重影响左室收缩功能。', null, 'NYHA心功能分级；6分钟步行试验', '1.治疗效果的评估<br />&nbsp;&nbsp;1.1 NYHA心功能分级：可用来评价心衰治疗后症状的变化。<br />&nbsp;&nbsp;1.2  6分钟步行试验：可作为评估运动耐力的客观指标，或评价药物治疗效果。<br />&nbsp;&nbsp;2.疾病进展的评估<br />&nbsp;&nbsp;综合评价疾病进展包括以下方面：（1）症状恶化（NYHA心功能分级加重）；（2）因心衰加重需要增加药物剂量或增加新药治疗；（3）因心衰或其他原因需住院治疗；（4）死亡。其中，住院事件在临床和经济效益方面最有意义。死亡率是临床预后的主要指标，大型临床试验设计均以存活率来评价治疗效果，已对临床实践产生重要影响。猝死是心衰死亡的常见原因。<br />&nbsp;&nbsp;3.预后的评定<br />&nbsp;&nbsp;多变量分析表明，以下临床参数有助于判断心衰的预后和存活：LVEF下降、NYHA分级恶化、低钠血症的程度、运动峰耗氧量减少、血球压积容积降低、心电图12导联QRS增宽、慢性低血压、静息心动过速、肾功能不全（血肌酐升高、估计肾小球滤过率降低）、不能耐受常规治疗以及难治性容量超负荷均是公认的关键性预后参数。<br />&nbsp;&nbsp;4.根据循证医学, 对于初诊和随访时临床评价的分类和证据等级，建议如下。<br />&nbsp;&nbsp;4.1初诊时的临床评价：（1）采集完整的病史和进行全面体格检查，以评价导致心衰发生和发展的心原性和非心原性疾病或诱因（Ⅰ类，C级）；（2）仔细询问饮酒史、违禁药物或化疗药物应用史（Ⅰ类，C级）；（3）评估心衰患者耐受日常生活和运动的能力（Ⅰ类，C级）；（4）所有患者检测血和尿常规、肝和肾功能、血清电解质、空腹血糖、血脂，检查甲状腺功能、12导联心电图及X线胸片（Ⅰ类，C级）；（5）所有患者行二维和多普勒超声心动图检查，评价心脏大小、室壁厚度、LVEF和瓣膜功能（Ⅰ类，C级）；（6）有心绞痛和心肌缺血的患者行冠状动脉造影检查（Ⅰ类，C级）。<br />&nbsp;&nbsp;4.2随访时的临床评价：（1）日常生活和运动能力（Ⅰ类，C级）；（2）容量负荷状况并测量体重（Ⅰ类，C级）；（3）饮酒、违禁药物及化疗药物应用情况（Ⅰ类，C级）。', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('468', '29', 'M05_005', '1', '急性心力衰竭诊断和治疗指南', '无', '中华医学会心血管病学分会；中华心血管病杂志编辑委员会', '2010', '中华心血管病杂志，2010，38（3）：195-208.', '中文', '1．急性心衰分类<br />&nbsp;&nbsp;1.1急性左心衰竭：(1)慢性心衰急性失代偿，(2)急性冠状动脉综合征，(3)高血压急症，(4)急性心瓣膜功能障碍，(5)急性重症心肌炎和围生期心肌病，(6)严重心律失常。\n1.2急性右心衰竭。<br />&nbsp;&nbsp;1.3非心原性急性心衰：(1)高心排血量综合征，(2)严重肾脏疾病(心肾综合征)，(3)严重肺动脉高压，(4)大块肺栓塞等。<br />&nbsp;&nbsp;2.急性左心衰竭严重程度分级主要有Killip法、Forrester法和临床程度分级三种。Killip法主要用于急性心肌梗死患者，根据临床和血流动力学状态来分级。Forrester法可用于急性心肌梗死或其他原因所致的急性心衰，其分级的依据为血流动力学指标如PCWP、CI以及外周组织低灌注状态，故适用于心脏监护室、重症监护室和有血流动力学监测条件的病房、手术室内。临床程度分级根据Forrester法修改而来，其各个级别可以与Forrester法一一对应，由此可以推测患者的血流动力学状态；由于分级的标准主要根据末梢循环的望诊观察和肺部听诊，无须特殊的监测条件，适合用于一般的门诊和住院患者。这三种分级法均以I级病情最轻，逐级加重，Ⅳ级为最重。以Forrester法和临床程度分级为例，由Ⅰ级至Ⅳ级的病死率分别为2.2％、10.1％、22.4％和55.5％。表M05_005_001<br />&nbsp;&nbsp;\n', '急性心力衰竭', null, null, '1.急性左心衰竭<br />&nbsp;&nbsp;1.1临床表现<br />&nbsp;&nbsp;1.1.1基础心血管疾病的病史和表现：大多数患者有各种心脏病的病史，存在引起急性心衰的各种病因。老年人中的主要病因为冠心病、高血压和老年性退行性心瓣膜病，而在年轻人中多由风湿性心瓣膜病、扩张型心肌病、急性重症心肌炎等所致。<br />&nbsp;&nbsp;1.1.2诱发因素：常见的诱因有：(1)慢性心衰药物治疗缺乏依从性；(2)心脏容量超负荷；(3)严重感染，尤其肺炎和败血症；(4)严重颅脑损害或剧烈的精神心理紧张与波动；(5)大手术后；(6)肾功能减退；(7)急性心律失常如室性心动过速(室速)、心室颤动(室颤)、心房颤动(房颤)或心房扑动伴快速心室率、室上性心动过速以及严重的心动过缓等；(8)支气管哮喘发作；(9)肺栓塞；(10)高心排血量综合征如甲状腺机能亢进危象、严重贫血等；(11)应用负性肌力药物如维拉帕米、地尔硫、β受体阻滞剂等；(12)应用非甾体类抗炎药；(13)心肌缺血(通常无症状)；(14)老年急性舒张功能减退；(15)吸毒；(16)酗酒；(17)嗜铬细胞瘤。这些诱因使心功能原来尚可代偿的患者骤发心衰，或者使已有心衰的患者病情加重。<br />&nbsp;&nbsp;1.1.3早期表现：原来心功能正常的患者出现原因不明的疲乏或运动耐力明显降低以及心率增加15-20次/min，可能是左心功能降低的最早期征兆。继续发展可出现劳力性呼吸困难、夜间阵发性呼吸困难、睡觉需用枕头抬高头部等；检查可发现左心室增大、闻及舒张早期或中期奔马律、P2亢进、两肺尤其肺底部有细湿性啰音，还可有干性啰音和哮鸣音，提示已有左心功能障碍。<br />&nbsp;&nbsp;1.1.4急性肺水肿：起病急骤，病情可迅速发展至危重状态。突发的严重呼吸困难、端坐呼吸、喘息不止、烦躁不安并有恐惧感，呼吸频率可达30～50次/min；频繁咳嗽并咯出大量粉红色泡沫样血痰；听诊心率快，心尖部常可闻及奔马律；两肺满布湿性啰音和哮鸣音。<br />&nbsp;&nbsp;1.1.5心原性休克：主要表现为：(1)持续低血压，收缩压降至90mmHg(1mmHg=0.133 kPa)以下，或原有高血压的患者收缩压降幅≥60mmHg，且持续30min以上。(2)组织低灌注状态，可有：①皮肤湿冷、苍白和紫绀，出现紫色条纹；②心动过速>110次/min；③尿量显著减少(<20 ml/h)，甚至无尿；④意识障碍，常有烦躁不安、激动焦虑、恐惧和濒死感；收缩压低于70 mmHg，可出现抑制症状如神志恍惚、表情淡漠、反应迟钝，逐渐发展至意识模糊甚至昏迷。(3)血流动力学障碍：PCWP≥18mmHg，心脏排血指数(CI)≤36.7ml•s-1•m-2(≤2.2 L•min-1•m-1)。(4)低氧血症和代谢性酸中毒。<br />&nbsp;&nbsp;1.2急性左心衰竭的实验室和辅助检查<br />&nbsp;&nbsp;1.2.1心电图：能提供许多重要信息，包括心率、心脏节律、传导，以及某些病因依据如心肌缺血性改变、ST段抬高或非ST段抬高心肌梗死以及陈旧性心肌梗死的病理性Q波等。还可检测出心肌肥厚、心房或心室扩大、束支传导阻滞、心律失常的类型及其严重程度如各种房性或室性心律失常(房颤、心房扑动伴快速性心室率、室速)、QT间期延长等。<br />&nbsp;&nbsp;1.2.2胸部X线检查：可显示肺淤血的程度和肺水肿，如出现肺门血管影模糊、蝶形肺门，甚至弥漫性肺内大片阴影等。还可根据心影增大及其形态改变，评估基础的或伴发的心脏和(或)肺部疾病以及气胸等。<br />&nbsp;&nbsp;1.2.3超声心动图：可用以了解心脏的结构和功能、心瓣膜状况、是否存在心包病变、急性心肌梗死的机械并发症以及室壁运动失调；可测定左室射血分数(LVEF)，检测急性心衰时的心脏收缩/舒张功能相关的数据。超声多普勒成像可间接测量肺动脉压、左右心室充盈压等。此法为无创性，应用方便，有助于快速诊断和评价急性心衰，还可用来监测患者病情的动态变化，对于急性心衰是不可或缺的监测方法。一般采用经胸超声心动图，如患者疑为感染性心内膜炎，尤为人工瓣膜心内膜炎，在心衰病情稳定后还可采用经食管超声心动图，能够更清晰显示赘生物和瓣膜周围的脓肿等。<br />&nbsp;&nbsp;1.2.4动脉血气分析：急性左心衰竭常伴低氧血症，肺淤血明显者可影响肺泡氧气交换。应检测动脉氧分压(PaO2)、二氧化碳分压(PaCO2)和氧饱和度，以评价氧含量(氧合)和肺通气功能。还应检测酸碱平衡状况，本症患者常有酸中毒，与组织灌注不足、二氧化碳潴留有关，且可能与预后相关，及时处理纠正很重要。无创测定血氧饱和度可用作长时间、持续和动态监测，由于使用简便，一定程度上可以代替动脉血气分析而得到广泛应用，但不能提供PaCO2和酸碱平衡状态的信息。<br />&nbsp;&nbsp;1.2.5常规实验室检查：包括血常规和血生化检查，如电解质(钠、钾、氯等)、肝功能、血糖、白蛋白及高敏C反应蛋白(hs-CRP)。研究表明，hs-CRP对评价急性心衰患者的严重程度和预后有一定的价值。<br />&nbsp;&nbsp;1.2.6心衰标志物：B型利钠肽(BNP)及其N末端B型利钠肽原(NT-proBNP)的浓度增高已成为公认诊断心衰的客观指标，也是心衰临床诊断上近几年的一个重大进展。其临床意义如下：(1)心衰的诊断和鉴别诊断：如BNP<100ng/L或NT-proBNP<400 ng/L，心衰可能性很小，其阴性预测值为90％；如BNP>400ng/L或NT-proBNP>1500 ng/L，心衰可能性很大，其阳性预测值为90％。急诊就医的明显气急患者，如BNP/NT-proBNP水平正常或偏低，几乎可以除外急性心衰的可能性。(2)心衰的危险分层：有心衰临床表现、BNP/NT-proBNP水平又显著增高者属高危人群。(3)评估心衰的预后：临床过程中这一标志物持续走高，提示预后不良。<br />&nbsp;&nbsp;1.2.7心肌坏死标志物：旨在评价是否存在心肌损伤或坏死及其严重程度。(1)心肌肌钙蛋白T或I(cTnT或cTnI)：其检测心肌受损的特异性和敏感性均较高。急性心肌梗死时可升高3-5倍以上，不稳定性心绞痛和急性心肌炎也会显著升高；慢性心衰可出现低水平升高；重症有症状心衰存在心肌细胞坏死、肌原纤维不断崩解，血清中cTn水平可持续升高。(2)肌酸磷酸激酶同工酶(CK-MB)：一般在发病后3-8h升高，9-30h达高峰，48-72h恢复正常；其动态升高可列为急性心肌梗死的确诊指标之一，高峰出现时间与预后有关，出现早者预后较好。(3)肌红蛋白：其分子质量小，心肌损伤后即释出，故在急性心肌梗死后0.5-2h便明显升高，5-12h达高峰，18-30h恢复，作为早期诊断的指标优于CK-MB，但特异性较差。伴急性或慢性肾功能损伤者肌红蛋白可持续升高，此时血肌酐水平也会明显增高。<br />&nbsp;&nbsp;1.3急性左心衰竭的监测方法<br />&nbsp;&nbsp;1.3.1无创性监测(Ⅰ类，B级)<br />&nbsp;&nbsp;每个急性心衰患者均需应用床边监护仪持续测量体温、心率、呼吸频率、血压、心电图和血氧饱和度等。<br />&nbsp;&nbsp;1.3.2血流动力学监测<br />&nbsp;&nbsp;1.3.2.1适应证：适用于血流动力学状态不稳定、病情严重且治疗效果不理想的患者，如伴肺水肿和(或)心原性休克的患者。<br />&nbsp;&nbsp;1.3.2.2方法：(1)床边漂浮导管(Ⅰ类，B级)：可用来测定主要的血流动力学指标如右心房压力(反映中心静脉压)、肺动脉压力(PAP)、PCWP，应用热稀释法可测定CO。可以持续监测上述各种指标的动态变化，酌情选择适当的药物，评估治疗的效果；(2)外周动脉插管(Ⅱa类，B级)：可持续监测动脉血压，还可抽取动脉血样标本检查；(3)肺动脉插管(Ⅱa类，B级)：不常规应用。对于病情复杂、合并心脏或肺部疾病者、其他检查难以确定时，可用来鉴别心原性或非心原性(例如肺原性)病因；对于病情极其严重，例如心原性休克的患者，可提供更多的血流动力学信息。<br />&nbsp;&nbsp;1.3.3注意：(1)在二尖瓣狭窄、主动脉瓣反流、肺动脉闭塞病变以及左心室顺应性不良等情况下，PCWP往往不能准确反映左心室舒张末压。对于伴严重三尖瓣反流的患者，热稀释法测定CO也不可靠。(2)插入导管的各种并发症如感染、血栓形成或栓塞以及血管损伤等随导管留置时间延长而发生率明显增高。<br />&nbsp;&nbsp;1.4急性左心衰竭的诊断步骤<br />&nbsp;&nbsp;可疑的急性左心衰竭患者应根据临床表现和辅助性检查作出诊断评估。图M05_005_002<br />&nbsp;&nbsp;1.5急性左心衰竭的鉴别诊断<br />&nbsp;&nbsp;急性左心衰竭应与可引起明显呼吸困难的疾病如支气管哮喘发作和哮喘持续状态、急性大块肺栓塞、肺炎、严重的慢性阻塞性肺病(COPD)尤其伴感染等相鉴别，还应与其他原因所致的非心原性肺水肿(如急性呼吸窘迫综合征)以及非心原性休克等疾病相鉴别。<br />&nbsp;&nbsp;2.急性右心衰竭的临床表现、诊断和鉴别诊断<br />&nbsp;&nbsp;急性右心衰竭的诊断需根据病因。<br />&nbsp;&nbsp;2.1右心室梗死伴急性右心衰竭：如心肌梗死时出现V1、V2导联ST段压低，应考虑右心室梗死，当然也有可能为后壁梗死，而非室间隔和心内膜下心肌缺血。下壁ST段抬高心肌梗死伴血流动力学障碍者应观察心电图V4R导联，并作经胸壁超声心动图检查，后者发现右心室扩大伴活动减弱可以确诊右心室梗死。右心室梗死伴急性右心衰竭典型者可出现低血压、颈静脉显著充盈和肺部呼吸音清晰的三联症。<br />&nbsp;&nbsp;2.2急性大块肺栓塞伴急性右心衰竭：典型表现为突发呼吸困难、剧烈胸痛、有濒死感，还有咳嗽、咯血痰、明显发绀、皮肤湿冷、休克和晕厥，伴颈静脉怒张、肝肿大、肺梗死区呼吸音减低、肺动脉瓣区杂音。如有导致本病的基础病因及诱因，出现不明原因的发作性呼吸困难、紫绀、休克，无心肺疾病史而突发的明显右心负荷过重和心衰，都应考虑肺栓塞。<br />&nbsp;&nbsp;2.3右侧心瓣膜病伴急性右心衰竭：主要为右心衰竭的临床表现，有颈静脉充盈、下肢水肿、肝脏淤血等。<br />&nbsp;&nbsp;急性右心衰竭临床上应注意与急性心肌梗死、肺不张、急性呼吸窘迫综合征、主动脉夹层、心包压塞、心包缩窄等疾病相鉴别。<br />&nbsp;&nbsp;3.急性心衰诊断和评估要点<br />&nbsp;&nbsp;3.1应根据基础心血管疾病、诱因、临床表现(病史、症状和体征)以及各种检查(心电图、胸部X线检查、超声心动图和BNP/NT-proBNP)作出急性心衰的诊断。并做临床评估包括病情的分级、严重程度和预后。<br />&nbsp;&nbsp;3.2常见的临床表现是急性左心衰竭所致的呼吸困难。系由肺淤血所致。严重患者可出现急性肺水肿和心原性休克。<br />&nbsp;&nbsp;3.3BNP/NT-proBNP作为心衰的生物学标志物。对急性左心衰竭的诊断和鉴别诊断有肯定的价值，对患者的危险分层和预后评估有一定的临床价值。<br />&nbsp;&nbsp;3.4急性左心衰竭病情严重程度分级有不同的方法。Killip法适用于基础病因为急性心肌梗死的患者：Forrester法多用于心脏监护室、重症监护室及有血流动力学监测条件的场合；临床程度分级则可用于一般的门诊和住院患者。<br />&nbsp;&nbsp;3.5急性右心衰竭主要常见病因为右心室梗死和急性大块肺栓塞。根据病史、临床表现如突发的呼吸困难、低血压、颈静脉怒张等，结合心电图和超声心动图检查，可以作出诊断。\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('469', '29', 'M05_006', '1', '慢性收缩性心力衰竭治疗建议', null, '中华医学会心血管病学分会；中华心血管病杂志编辑委员会', null, '中华心血管病杂志，2002，30（1）：7-23.', null, 'NYHA心功能分级：Ⅰ级：日常活动无心力衰竭症状；Ⅱ级：日常活动出现心力衰竭症状(呼吸困难、乏力)；Ⅲ级：低于日常活动出现心力衰竭症状；Ⅳ级：在休息时出现心力衰竭症状。', '慢性收缩性心力衰竭', null, null, '1.心脏病性质及程度判断<br />&nbsp;&nbsp;收缩期心力衰竭的临床表现为：(1)左心室增大、左心室收缩末期容量增加及LVEF≤40 %。(2)有基础心脏病的病史、症状及体征。(3)有或无呼吸困难、乏力和液体潴留(水肿)等症状。<br />&nbsp;&nbsp;1.1根据病史及体格检查, 提供各种心脏病的病因线索, 如冠心病、心脏瓣膜病、高血压、心肌病和先天性心脏病。根据临床症状及体征判断左心衰竭、右心衰竭或全心衰竭。<br />&nbsp;&nbsp;1.2二维超声心动图(2DE)及多普勒超声检查:(1)诊断心包、心肌或心脏瓣膜疾病。(2)定量或定性房室内径, 心脏几何形状, 室壁厚度, 室壁运动, 心包、瓣膜及血管结构, 瓣膜狭窄定量、关闭不全程度,测量LVEF , 左室舒张末期容量(LVEDV)和收缩末期容量(LVESV)。(3)区别舒张功能不全和收缩功能不全, LVEF≤40 %为左室收缩功能不全。LVEF 还能鉴别收缩功能不全或其他原因引起的心力衰竭。(4)LVEF 及LVESV 是判断收缩功能和预后的最有价值的指标。左室收缩末期容量指数(LVESVI =LVESV/体表面积)达45 ml/m2的冠心病患者, 其死亡率增加3 倍。(5)为评价治疗效果提供客观指标。<br />&nbsp;&nbsp;在左室扩大、呈球形及左室短径已大于长径的1/2 时, 通过M 型超声心动图左室短径的测量, 用立方法计算左室容量及LVEF 显然有很大的局限性,尤其当存在节段性室壁运动异常时,M 型心脏超声测量会产生误差, 故推荐采用2DE 的改良Simpson法测量左室容量及LVEF。2DE与造影或尸检比较,测量左室容量和LVEF 相关较好, 但准确数据的采集取决于心室图像内膜的清晰度, 并要求有较好的重复性。在某些老龄、肥胖和肺气肿患者, 获得满意的2DE 图像较为困难, 故临床应用受到一定的限制。由于超声检查简便、价廉、便于床旁检查及重复检查, 故左室功能的测定还是以2DE 最为普遍。<br />&nbsp;&nbsp;1.3核素心室造影及核素心肌灌注显像：核素心室造影可准确测定左室容量、LVEF 及室壁运动。核素心肌灌注显像可诊断心肌缺血和心肌梗死, 对鉴别扩张型心肌病和缺血性心肌病有一定帮助。<br />&nbsp;&nbsp;1.4  X线胸像：提供心脏增大, 肺淤血、肺水肿及原有肺部疾病信息。<br />&nbsp;&nbsp;1.5心电图：提供既往心肌梗死, 左室肥厚, 广泛心肌损害及心律失常信息。<br />&nbsp;&nbsp;1.6冠状动脉造影：有心绞痛或既往有心肌梗死, 需血管重建者或临床怀疑冠心病者应行冠状动脉造影, 也可鉴别缺血性和非缺血性心肌病。但冠状动脉造影不能判断存活心肌。存活心肌的评估对陈旧性心肌梗死患者血管重建的必要性至关重要。有心肌存活的患者, 血管重建可有效改善左室功能。<br />&nbsp;&nbsp;1.7目前应用于临床判断存活心肌的方法有：(1)刺激心肌收缩力储备的小剂量多巴酚丁胺超声心动图负荷试验(DSE)。(2)核素心肌灌注显像(201Tl和99Tcm-MIBI SPECT)及代谢示踪剂氟脱氧葡萄糖(FDG)判断心肌活性的正电子发射断层摄影(PET)。<br />&nbsp;&nbsp;小剂量多巴酚丁胺超声心动图负荷试验评估存活心肌的临床应用价值已为临床所公认, 其诊断存活心肌的敏感性为80 %～85 %, 特异性为85 %。由于方法简便、安全、价格低廉, 可作为评估存活心肌的首选方法。201TI再注射心肌显像是一种比较可靠的评价存活心肌的方法。硝酸酯99Tcm-MIBI 心肌显像可提高评价存活心肌的准确性。核素诊断心肌存活性的敏感性为90 %, 特异性70 %。PET 灌注、代谢显像是评价存活心肌的最可靠的无创方法, 但价格昂贵, 技术复杂, 目前尚不能成为常规检查手段。<br />&nbsp;&nbsp;1.8心肌活检：对不明原因的心肌病诊断价值有限, 有助于明确心肌炎症性或浸润性病变的诊断。<br />&nbsp;&nbsp;2.心功能不全的程度判断<br />&nbsp;&nbsp;2.1 NYHA心功能分级：Ⅰ级：日常活动无心力衰竭症状。Ⅱ级：日常活动出现心力衰竭症状(呼吸困难、乏力)。Ⅲ级：低于日常活动出现心力衰竭症状。Ⅳ级：在休息时出现心力衰竭症状。心力衰竭患者的LVEF 与心功能分级症状并非完全一致。<br />&nbsp;&nbsp;2.2  6 min步行试验：在特定的情况下, 测量在规定的时间内步行的距离。虽然心力衰竭患者在6min内步行的距离可能受到医师诱导或患者的主观能动性的影响, 但此方法安全、简便、易行, 已逐渐在临床应用。6 min步行距离不但能评定患者的运动耐力, 而且可预测患者预后。SOLVD(Studies Of Left Ventricular Dysfunction)试验亚组分析显示, 6 min 步行距离短的与距离长的患者比较, 在8 个月的随诊期间, 死亡率前者为10.23 %, 后者为2.99 %(P =0.01);心力衰竭的住院率, 前者为22.16 %, 后者为1.99 %(P <0.0001), 提示6 min 步行距离短的患者预后差。<br />&nbsp;&nbsp;3.液体潴留及其严重程度判断<br />&nbsp;&nbsp;每次随诊时应记录患者的体重, 注意颈静脉充盈的程度及肝颈静脉回流征, 并注意肺和肝充血的程度(肺部啰音, 肝脏肿大), 检查下肢和骶部水肿,腹部移动性浊音以发现腹水。液体潴留的判断对决定是否需要利尿剂治疗十分重要, 短时间内体重增加是液体潴留的可靠指标, 故体重测量是有用的判断液体潴留的方法。<br />&nbsp;&nbsp;4.其他生理功能评价<br />&nbsp;&nbsp;有创性血液动力学检查主要用于严重威胁生命, 并对治疗无反应的泵衰竭或需对呼吸困难和低血压休克作鉴别诊断时。有心律失常时可作24 h动态心电图记录。', null, '临床状况；疾病进展', '1.临床状况的评估<br />&nbsp;&nbsp;1.1数十年来, 临床一直普遍沿用NYHA 心功能分级来评价心力衰竭治疗后症状的变化。<br />&nbsp;&nbsp;1.2  6 min步行试验作为心力衰竭患者运动耐力的客观指标, 可用来评价药物治疗效果。<br />&nbsp;&nbsp;2.疾病进展的评估<br />&nbsp;&nbsp;2.1死亡率：死亡率是临床预后的主要指标, 为此, 大系列临床试验设计以存活率来评价治疗效果已对临床实践产生重要影响。但是, 死亡率并不能完全评价疾病的进展, 不少心力衰竭患者虽然存活但症状恶化, 需多次反复住院, 并且需要强化和昂贵的治疗。因此, 需要结合疾病进展情况来综合评定。<br />&nbsp;&nbsp;2.2综合评价疾病进展包括以下方面：(1)死亡。(2)猝死。(3)症状恶化(NYHA 心功能分级加重)。(4)因心力衰竭加重需要增加药物剂量或增加新药治疗。(5)因心力衰竭或其他原因需住院治疗, 其中住院事件在临床和经济效益方面最有意义。', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('47', '34', 'M06_002', '1', '尿石症诊断治疗指南(2007)', null, '中华医学会泌尿外科学分会;中国泌尿外科疾病诊断治疗指南编辑委员会', '2007', ' 中国泌尿外科疾病诊断治疗指南[M].北京：人民卫生出版社,2007\n', '中文', null, '泌尿系结石', null, null, '4.诊断<br />&nbsp;&nbsp;4.1影像学检查<br />&nbsp;&nbsp;对所有具有泌尿系结石临床症状的患者都应该做影像学检查，其结果对于结石的进一步检查和治疗具有重要的价值。<br />&nbsp;&nbsp;4.1.1.B超（推荐）<br />&nbsp;&nbsp;超声波检查简便、经济、无创伤，可以发现2毫米以上不透和透过mm以上不透和透过X线阳性及阴性的结石。此外，超声波检查还可以了解结石以上尿路的扩张程度，间接了解肾实质和集合系统的情况。对膀胱结石，超声检查能够同时观察膀胱和前列腺，寻找结石形成的诱因和并发症。但是，由于受肠道内容物的影响，因而超声波检查诊断输尿管中下段结石的敏感性较低。<br />&nbsp;&nbsp;超声可作为泌尿系结石的常规的检查方法，尤其是在肾绞痛时，可以作为首选方法的检查方法供临床应用。<br />&nbsp;&nbsp;4.1.2.尿路平片（KUB平片）（推荐）<br />&nbsp;&nbsp;尿路平片可以发现90%左右不透过X线阳性的结石，能够大致地确定结石的位置、形态、大小和数量，并且初步地提示结石的化学性质。因此，可以作为结石检查的常规方法。在尿路平片上，不同成分的结石显影程度依次为：草酸钙、磷酸钙和磷酸镁铵、胱氨酸、含尿酸盐结石。单纯性尿酸结石和黄嘌呤结石能够透过X线（X线阴性）石，胱氨酸结石的密度低，后者在尿路平片上的显影比较淡。<br />&nbsp;&nbsp;4.1.3..静脉尿路造影（IVU）（推荐）<br />&nbsp;&nbsp;静脉尿路造影应该在尿路平片的基础上进行，其价值在于了解尿路的解剖，确定结石在尿路的位置，发现尿路平片上不能显示的透过X线阴性的结石，鉴别平片上可疑的钙化灶。此外，还可以了解分侧肾脏的功能，确定肾积水程度。在一侧肾脏功能严重受损或者使用普通剂量造影剂而肾脏不显影的情况下，采用加大造影剂剂量（双剂量或大剂量）或者延迟拍片的方法往往可以达到肾脏显影的目的。肾绞痛发作时，由于急性尿路的梗阻往往会导致尿路不显影或显影不良，因此对结石的诊断会带来困难。<br />&nbsp;&nbsp;4.1.4.CT扫描（可选择）<br />&nbsp;&nbsp;泌尿系结石的诊断通常不需要做CT检查。但是，由于CT扫描不受结石成分、肾功能和呼吸运动的影响，而且螺旋CT还能够同时对所获取的图像进行二维及三维重建，因此，能够检出其他常规影像学检查中容易遗漏的小结石。ＣＴCT诊断结石的敏感性比尿路平片及静脉尿路造影高，尤其适用于急性肾绞痛患者的诊断，可以作为X线检查的重要补充。另外，结石的成分及脆性可以通过不同的CT值改变来进行初步的评估，从而对治疗方法的选择提供参考。增强CT能够显示肾脏积水的程度和肾实质的厚度，从而反映了肾功能的改变情况。<br />&nbsp;&nbsp;4.1.5.5.逆行或经皮肾穿刺造影（可选择）<br />&nbsp;&nbsp;属于创伤的检查方法，不作为常规检查手段，仅在静脉尿路造影不显影或显影不良以及怀疑是透过X线的结石X线阴性结石、需要作进一步的鉴别诊断时应用。<br />&nbsp;&nbsp;4.1.6..磁共振水成像（MRU）（可选择）<br />&nbsp;&nbsp;磁共振对尿路结石的诊断效果极差，因而一般不用于结石的检查。但是，磁共振水成像（MRU）能够了解上尿路梗阻的情况，而且不需要造影剂即可获得与静脉尿路造影同样的效果，不受肾功能改变的影响。因此，对于不适合做静脉尿路造影的患者（例如造影剂过敏、严重肾功能损害、儿童和孕妇等）可考虑采用。<br />&nbsp;&nbsp;4.1.7.放射性核素（可选择）<br />&nbsp;&nbsp;放射性核素检查不能直接显示泌尿系结石，但是，它可以显示泌尿系统的形态，提供肾脏血流灌注、肾功能及尿路梗阻情况等信息，因此对手术方案的选择以及手术疗效的评价具有一定价值。此外，肾动态显影还可以用于评估体外冲击波碎石对肾功能的影响情况。<br />&nbsp;&nbsp;4.2.实验室检查<br />&nbsp;&nbsp;4.2.1.常规检查<br />&nbsp;&nbsp;结石患者的实验室检查应包括血液分析、尿液分析和结石分析,见表Ⅶ-4表3。<br />&nbsp;&nbsp;表Ⅶ-4表3结石患者的常规实验室检查<br />&nbsp;&nbsp;结石分析血液分析尿液分析<br />&nbsp;&nbsp;每个患者至少分析一颗结石每个患者至少分析1颗结石钙禁食、清晨、新鲜尿液<br />&nbsp;&nbsp;白蛋白1试纸法检测<br />&nbsp;&nbsp;肌酐pH<br />&nbsp;&nbsp;尿酸2白细胞/细菌3<br />&nbsp;&nbsp;胱氨酸检查4<br />&nbsp;&nbsp;1检测白蛋白＋钙以矫正白蛋白结合钙的对血钙浓度的影响，或者直接检测离子钙浓度。<br />&nbsp;&nbsp;2可供选择的分析，考虑尿酸/尿酸盐结石时选择。<br />&nbsp;&nbsp;3存在泌尿系感染则行尿液培养。<br />&nbsp;&nbsp;4如果通过其他手段不能排除胱氨酸尿症则行尿胱氨酸检查<br />&nbsp;&nbsp;4.2.2..复杂性肾结石的尿液分析<br />&nbsp;&nbsp;复杂性肾结石患者（指结石反复复发、有或无肾内残石和特别的危险因素的患者）可选择进一步的尿液分析,（见表Ⅶ-5）见表4。<br />&nbsp;&nbsp;表Ⅶ-5表4复杂性肾结石患者的尿液分析<br />&nbsp;&nbsp;收集24小时尿液分析<br />&nbsp;&nbsp;钙、草酸、枸橼酸、尿酸、镁、磷酸、尿素、钠、钾、肌酐、尿量<br />&nbsp;&nbsp;1测定镁和磷酸以评估计算草酸钙（CaOx）和磷酸钙（CaP）离子活度积，如AP（CaOx）指数和AP（CaP）指数。<br />&nbsp;&nbsp;2尿素、磷酸盐、钠、钾的测定用于评估患者的饮食习惯。<br />&nbsp;&nbsp;4.2.3..尿液采集方案（表Ⅶ-6）<br />&nbsp;&nbsp;表Ⅶ-6尿液采集方案<br />&nbsp;&nbsp;采集24小时<br />&nbsp;&nbsp;尿液2份尿液1存于含有30ml6mmol/L盐酸的标本瓶中<br />&nbsp;&nbsp;尿液2存于含有30ml0.3mmol/L叠氮化钠的标本瓶中。<br />&nbsp;&nbsp;1用于分析草酸、枸橼酸、磷酸的尿液必须先用盐酸酸化：①可预防贮存的尿液析出草酸钙和磷酸钙沉淀。②消除了维生素C对草酸盐的氧化作用。③预防尿液中细菌生长。<br />&nbsp;&nbsp;2如果需要检查尿酸盐的排泄，则必须碱化尿液使尿酸盐沉淀溶解。添加了叠氮化钠的尿液可以进行尿酸盐分析。<br />&nbsp;&nbsp;3用于测定pH值的尿液不宜加入盐酸，可用叠氮化钠保存的尿液进行测定；由于尿液存放一段时间后其pH值可能发生改变，故对于夜间采集的尿液必须在收集后立即检测。<br />&nbsp;&nbsp;4.2.4..检查结果评价<br />&nbsp;&nbsp;4.2.4.1.测定血清/血浆钙有助于甲状旁腺功能亢进（HPT）或其他与高钙血症有关疾病的诊断。若血钙浓度高（>>2.60mmol/L），则应测定甲状旁腺激素水平，以确诊或排除HPT。<br />&nbsp;&nbsp;4.2.4.2.透X线阴性结石伴有高尿酸血症者应考虑尿酸结石，但CT片上可显示。<br />&nbsp;&nbsp;4.2.4.3.禁食晨尿pH>高于5.8可考虑为完全性或不完全性肾小管性酸中毒（RTA），应同时作酸负荷试验及血液pH、钾、碳酸氢盐和氯化物测定。<br />&nbsp;&nbsp;', null, null, null, '2007 版《指南》增加了膀胱癌、 泌尿系结石、 前列腺炎和压力性尿失禁四种泌尿外科常见疾病。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('470', '30', 'X03_001', '0', '中医病证诊断疗效标准·中医内科病证诊断疗效标准', 'Guidelines for Diagnosis and Treatment of Common Internal Diseases in Chinese Medicine Diseases of Modern Medicine', '国家中医药管理局', '1994', '国家中医药管理局.ZY／T001.1-94，中医病证诊断疗效标准·中医内科病证诊断疗效标准[S].南京：南京大学出版社，1994.', '中文', null, null, '骨痹', '肾虚髓亏；阳虚寒凝；瘀血阻滞', '1.初起多见腰腿、腰脊、膝关节等隐隐作痛，屈伸、俯仰、转侧不利，轻微活动稍缓解，气候变化加重，反复缠绵不愈。<br />&nbsp;&nbsp;2.起病隐袭，发病缓慢，多见于中老年。<br />&nbsp;&nbsp;3.局部关节可轻度肿胀，活动时关节常有喀刺声或摩擦声。严重者可见肌肉萎缩。关节畸形，腰弯背驼。<br />&nbsp;&nbsp; 4. X线摄片检查：示骨质疏松，关节面不规则，关节间隙狭窄，软骨下骨质硬化，以及边缘唇样改变，骨赘形成。<br />&nbsp;&nbsp;5.查血沉、抗“O”、粘蛋白、类风湿因子等与风湿痹、尫痹相鉴别。', '1.肾虚髓亏：关节隐隐作痛，腰膝酸软，腰腿不利，俯仰转侧不利。伴有头晕，耳鸣，耳聋，目眩。舌淡红、苔薄白，脉细。<br />&nbsp;&nbsp;2.阳虚寒凝：肢体关节疼痛，重著，屈伸不利，天气变化加重，昼轻夜重，遇寒痛增，得热稍减。舌淡，苔白，脉沉细缓。<br />&nbsp;&nbsp;3.瘀血阻滞：关节刺痛，痛处固定，关节畸形，活动不利，或腰弯背驼，面色晦暗。唇舌紫暗，脉沉或细涩。\n', '症状；活动功能；实验室检查', '1.治愈：消失，活动功能恢复正常，实验室检查正常。<br />&nbsp;&nbsp;2.好转：关节疼痛、肿胀减轻，活动功能好转。<br />&nbsp;&nbsp;3.未愈：关节疼痛及肿胀无变化。\n', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('471', '30', 'X03_002', '1', '临床诊疗指南·骨科分册', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南·骨科分册.北京：人民卫生出版社，2009.', '中文', '1.原发性；<br />&nbsp;&nbsp;2.继发性:机械性、失用性、先天性和遗传性等。', '骨关节炎', null, null, '1．典型表现：<br />&nbsp;&nbsp;1.1多见于50岁以上女性，65岁以上男性；为退行性病变；好发于负重大、活动多的关节，如髋、膝、踝、颈椎、腰椎等关节。<br />&nbsp;&nbsp;1.2发病缓慢，早期表现为关节疼痛和发僵，刚开始活动时较明显，活动后减轻，活动多时又加重，休息后症状缓解。晚期疼痛持续，并可出现活动受限、特别是上下楼梯困难，伴有关节积液、畸形和关节内游离体，但关节强直较少见。脊椎骨关节炎除有局部疼痛和活动受限外，有时因骨赘压迫神经根、脊髓而引起肢体感觉和运动障碍。<br />&nbsp;&nbsp;2．体格检查：关节肿胀、压痛，浮髌征阳性；关节活动度降低；晚期关节畸形。<br />&nbsp;&nbsp;3．辅助检查：<br />&nbsp;&nbsp;3.1 X线：关节间隙不对称，患侧变窄，软骨下骨质致密，骨小梁断裂，随之囊性变，关节缘呈唇样骨质增生，可见关节内游离体。<br />&nbsp;&nbsp;3.2关节镜检：可见关节软骨剥脱，关节内游离体。<br />&nbsp;&nbsp;3.3同位素检查：如99m锝磷酸盐，可以对软骨活性进行正确评价，对退行性骨关节炎的早期诊断是有帮助的。<br />&nbsp;&nbsp;3.4 MRI检查：磁共振可以用来观察软骨的退行性改变，而且对关节液和软组织的变化是很敏感的，但费用比较昂贵，难以普及。<br />&nbsp;&nbsp;4.鉴别诊断：骨关节炎需要与类风湿性关节炎进行鉴别诊断，有时两者也可以同时存在；另外也要注意与痛风性关节炎、结核及神经性关节炎相鉴别。', '疼痛症状；关节功能；关节结构', '治疗目标：①解除疼痛症状；②维持或改善关节功能；③保护关节结构。', null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('472', '49', 'Y05_001', '1', '临床诊疗指南消化系统疾病分册', null, '中华医学会', '2004', '中华医学会.临床诊疗指南消化系统疾病分册[M].人民卫生出版社.2004', '中文', '1.急性胰腺炎<br />&nbsp;&nbsp;2.慢性胰腺炎', '急性胰腺炎', null, null, '1．急性轻型胰腺炎：腹痛为本病的主要表现，常发生在饱餐、高脂餐及饮酒后，同时伴有恶心、呕吐后腹痛不缓解。多数患者可出现中等程度的发热，少数可有轻度黄疸。一般3～5天症状可以缓解。<br />&nbsp;&nbsp;2．重症胰腺炎：如果腹痛、发热症状持续不缓解，应警惕重症胰腺炎的发生。患者随病情加重，可出现腹水、麻痹性肠梗阻、消化道出血、血压下降乃至休克。还可以出现各种局部及全身并发症，局部并发症包括胰内或胰周积液、胰腺脓肿、胰腺假性囊肿形成、胰性腹膜炎等口并发症可累及全身各脏器。(l)神经系统：重症胰腺炎可出现神经精神症状，称为“胰性脑病”。主要表现为烦躁、谵妄、幻觉、定向障碍、甚至昏迷。(2)呼吸系统：急性胰腺炎的肺和胸膜病变表现多样，患者可因痛导致呼吸变浅、膈肌抬高，还可出现胸痛、气急、咳嗽等症状。胸腔积液又称胰性胸水’’，两侧均可见，但左侧居多。严重者发生重度呼吸困难，导致成人呼吸窘迫综合征。(3)循环系统：重症胰腺炎时心脏并发症很多，包括充血性心衰、心肌梗死、心律失常、心源性休克以及心包积液，甚至造成猝死。(4)肾脏表现：急性胰腺炎可以导致肾脏损害，表现为少尿、血尿、蛋白尿和管型尿，肾功能衰竭则少见。(5)其他：急性胰腺炎可以引起一过性血糖升高及糖耐量异常，随病情好转可以恢复。还可出现脾静脉血栓形成、脾包膜下血肿等。皮肤表现常发生在少数无痛性胰腺炎，可以作为首发症状，主要为脂肪坏死，见于皮下脂肪、腹膜后组织、胸膜、纵隔、心包等处。<br />&nbsp;&nbsp;【诊断要点】<br />&nbsp;&nbsp;1．症状：急性起病，突发上腹痛伴恶心、呕吐、发热等，多与酗酒或饱餐有<br />&nbsp;&nbsp;关。<br />&nbsp;&nbsp;2．体征：腹部体征主要是上腹压痛，多位于左上腹，也可为全腹深压痛。重<br />&nbsp;&nbsp;症‘町出现明显肌紧张。有胰性腹水时腹水征阳性，并可出现明显腹膜刺激征<br />&nbsp;&nbsp;胰周积液、胰腺脓肿、假性囊肿形成时上腹可扪及包块c麻痹性肠梗阻者可出现<br />&nbsp;&nbsp;腹部膨隆、肠鸣音减弱或消失。腰部皮肤蓝棕色斑“（．Grey-\'Furner征”及脐周蓝<br />&nbsp;&nbsp;色斑“CulLen征”，仅见于病情严重患者，发生率极低。<br />&nbsp;&nbsp;3．辅助检查<br />&nbsp;&nbsp;(1)实验室检查<br />&nbsp;&nbsp;①血淀粉酶升高：对诊断很有意义，但其水平高低与病情轻重并不平行。<br />&nbsp;&nbsp;②血脂肪酶升高：敏感性与淀粉酶相当，但特异性优于淀粉酶，其临床应用<br />&nbsp;&nbsp;逐渐普及。<br />&nbsp;&nbsp;③白细胞计数：急性胰腺炎患者白细胞计数可增高，并可出现核左移。<br />&nbsp;&nbsp;④其他：血糖升高、血钙降低等，持久的高血糖和低血钙往往提示预后不良。<br />&nbsp;&nbsp;转氨酶、碱性磷酸酶及胆红素水平均可出现异常。<br />&nbsp;&nbsp;⑤尿淀粉酶：作为急性胰腺炎辅助检查项日c<br />&nbsp;&nbsp;(2)影像学检查<br />&nbsp;&nbsp;①X线：胸片检查可有膈肌抬高、肺不张、胸腔积液及肺实质病变。腹部平<br />&nbsp;&nbsp;片可有肠梗阻的表现。<br />&nbsp;&nbsp;②超声：腹部B超常常由于气体干扰使胰腺显示不清，但有助于判断是否<br />&nbsp;&nbsp;有胆结石、胰管扩张、腹水。<br />&nbsp;&nbsp;③腹部CT：CT检查对胰腺病变程度（特别是重症胰腺炎）的判定、并发症<br />&nbsp;&nbsp;的出现及鉴别诊断均有意义<br />&nbsp;&nbsp;2.慢性胰腺炎【临床表现】<br />&nbsp;&nbsp;慢性胰腺炎的临床表现轻重不一，早期可无症状，胰腺功能正常；中期以腹痛为主要表现，胰腺功能不全处于代偿期；晚期因胰腺广泛纤维化而出现胰腺功能失代偿表现：腹泻、吸收不良、消瘦和糖尿病。<br />&nbsp;&nbsp;1．腹痛：腹痛是慢性胰腺炎最主要的症状，90%-ioo%的患者均有不同程度的腹痛口疼痛多位于上腹部，病变在胰头以右上腹为主，在胰尾以左上腹为主，可放射至肩、背、胸及下腹部，伴恶心呕吐c头前倾膝曲位、俯卧位和坐位可缓解疼痛，仰卧位和进食后疼痛可加重。疼痛的原因可能是炎性产物对腹腔感觉神经纤维的刺激或梗阻所致的胰管内压力增高。<br />&nbsp;&nbsp;2．腹泻：通常仅在胰腺外分泌功能丧失90%以上才出现蛋白质、脂肪及糖的吸收不良，主要表现为脂肪泻。每日排便次数增多，大便量多、稀软而酸臭，外观呈现泡沫，表面油腻并有油漂浮。严重时可伴有脂溶性维生素缺乏症。<br />&nbsp;&nbsp;3．体重下降：一方面是由于吸收不良导致营养障碍，另一方面是因为恐惧进食后腹痛加重而厌食。大部分患者体重减轻。<br />&nbsp;&nbsp;4．糖尿病：糖尿病是慢性胰腺炎最常见的并发症，多发生在腹痛持续数年之后，较少发生酮症昏迷。大约1/3的慢性胰腺炎患者为显性糖尿病，另l/3为糖耐量异常。一般至少80%的胰腺组织破坏才会出现糖尿病或糖耐量异常。<br />&nbsp;&nbsp;5．其他并发症：慢性胰腺炎还可出现梗阻性黄疸、十二指肠狭窄、胰腺假性囊肿、胰源性胸腹水和脾静脉血栓形成等并发症。<br />&nbsp;&nbsp;【诊断要点】<br />&nbsp;&nbsp;症状：上腹痛、腹泻（脂肪泻）及消瘦。<br />&nbsp;&nbsp;2．体征：上腹压痛、体重下降。<br />&nbsp;&nbsp;3．基本实验室检查：(1)粪苏丹Ⅲ染色：阳性者为脂肪滴。显微镜下粪巾脂肪滴>lo。个／高倍视野或肌肉纤维>-10个／低倍视野c(2)粪便弹力蛋白酶：正常值200μg/g，慢性胰腺炎<200wμg／g。(3)血与尿淀粉酶：慢性胰腺炎可伴有血、尿淀粉酶升高，急性发作时血、尿淀粉酶明显升高。单一的尿淀粉酶升高仅作为辅助指标。(4)空腹血糖升高或糖耐量异常。(5)血清胆囊收缩素明显升高，血浆胰多肽明显下降。<br />&nbsp;&nbsp;2．体征：上腹压痛、体重下降。<br />&nbsp;&nbsp;3．基本实验室检查：<br />&nbsp;&nbsp;(1)粪苏丹Ⅲ染色：阳性者为脂肪滴。显微镜下粪巾脂肪滴>lo。个／高倍<br />&nbsp;&nbsp;视野或肌肉纤维>-10个／低倍视野c<br />&nbsp;&nbsp;(2)粪便弹力蛋白酶：正常值200μg/g，慢性胰腺炎<200μg／g。<br />&nbsp;&nbsp;(3)血与尿淀粉酶：慢性胰腺炎可伴有血、尿淀粉酶升高，急性发作时血、尿<br />&nbsp;&nbsp;淀粉酶明显升高。单一的尿淀粉酶升高仅作为辅助指标。<br />&nbsp;&nbsp;(4)空腹血糖升高或糖耐量异常。<br />&nbsp;&nbsp;(5)血清胆囊收缩素明显升高，血浆胰多肽明显下降。<br />&nbsp;&nbsp;4．胰腺外分泌功能检查<br />&nbsp;&nbsp;(1)直接测定法：胰泌素一促胰酶素试验：本试验是诊断胰腺外分泌功能不全的金标准，敏感性为74%～90%，特异性为80%～90%脉注射胰泌素(lu／kg)和促胰酶素(lu/kg)，60min内胰液分泌量<15lml，碳酸氢盐浓度<70mmol/L，碳酸氢盐排出量<11.3mmol;30min内淀粉酶排出量<131u/L，提<br />&nbsp;&nbsp;示胰腺外分泌功能不全。<br />&nbsp;&nbsp;(2)间接测定法<br />&nbsp;&nbsp;①Lundh试验（试餐试验）：口服标准餐后十二指肠液中胰蛋白酶浓度<61u/L为功能不全，在慢性胰腺炎患者中的阳性率达80%～900/。<br />&nbsp;&nbsp;②BT-PABA试验（苯甲酰一酪氨酰一耐氨基苯甲酸试验）：口服BT--PABA500mg,6h尿PABA排出率>60%为正常，<50%提示功能不全；或口服BT—PABA1000mg后2h血PABA浓度<20μmol/L也有意义。其对中重度慢性胰腺炎患者的敏感性达80%～90%，但对轻度或早期患者的敏感性很低。<br />&nbsp;&nbsp;③胰月桂酸试验：U服月桂酸荧光素，lOh时尿荧光素浓度<30%为异常，本试验的敏感性及特异性略高于BT-PABA试验。<br />&nbsp;&nbsp;④呼气实验：13标记的混合甘油三酯呼气实验是一种诊断胰腺外分泌功<br />&nbsp;&nbsp;能不全敏感性89%特异性91%的方法。本病患者呼气中13CO2含量降低。<br />&nbsp;&nbsp;(3)粪便检验：72h粪脂肪定量>6g/d（每天进食含100G脂肪的食物）、粪氯排出量>2g/d（每天进食含709蛋白质的食物）、粪糜蛋白酶<5.6IU/g粪便或粪弹性蛋白酶<IOOFilg粪便均提示胰腺外分泌功能不全。其中粪糜蛋白酶测定敏感性为40%～90%，粪弹性蛋白酶敏感性及特异性均>90%.<br />&nbsp;&nbsp;5．影像学检查<br />&nbsp;&nbsp;(l)x线：30%～60%的慢性胰腺炎患者腹部平片可见胰腺钙化或胰管结石.低张。卜二指肠造影可见胃向前移位、十二指肠肠圈增大、十二指肠内侧壁黏膜呈针剌状改变以及乳头肿大.<br />&nbsp;&nbsp;', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('473', '49', 'Y05_002', '1', '中医内科常见病诊疗指南西医疾病部分', null, '中华中医药学会', '2008', 'ZYYXH/T50～135—2008，中医内科常见病诊疗指南[M].中国中医药出版社，2008', '中文', '1.轻症急性胰腺炎（MAP);<br />&nbsp;&nbsp;2.重症急性胰腺炎（SAP)<br />&nbsp;&nbsp;3.暴发性胰腺炎', '急性胰腺炎', null, '1.肝胆湿热证<br />&nbsp;&nbsp;2.胃肠热结证<br />&nbsp;&nbsp;3.实热结胸证<br />&nbsp;&nbsp;4.瘀热互结证5.腑闭血瘀证<br />&nbsp;&nbsp;6.内闭外脱证<br />&nbsp;&nbsp;7.肝脾失调证<br />&nbsp;&nbsp;8.气阴两虚证', '1诊断依据<br />&nbsp;&nbsp;1.1临床表现<br />&nbsp;&nbsp;1.1.1症状<br />&nbsp;&nbsp;腹痛：95％急性胰腺炎患者有腹痛，多突然发作，呈持续刀割样，以上腹部多见。约一半患者腹痛可向左背部放射。腹痛通常持续48小时，偶可超过1周。<br />&nbsp;&nbsp;恶心、呕吐：呕吐物多为胃内容物，重者可混有胆汁，甚至血液。呕吐后患者症状无减轻。<br />&nbsp;&nbsp;发热：多为中度发热，偶有高热，一般持续3～5日。如发热不退或逐日升高，尤其持续2～3周以上者，要警惕胰腺脓肿的可能。<br />&nbsp;&nbsp;黄疽：一般情况下，急性胰腺炎患者可无黄疽。若因胆道因素发病，或因胰头肿大、假性囊肿、脓肿压迫胆总管或合并肝脏损害等可出现黄疽。<br />&nbsp;&nbsp;腹胀、休克：多发生于重症急性胰腺炎。<br />&nbsp;&nbsp;1.1.2体征<br />&nbsp;&nbsp;腹部体征：轻症者仅为轻压痛，重症者可出现腹膜刺激征，胰源性腹水征，Grey-Tuner征，Cullen征。部分患者因脾静脉栓塞出现门静脉高压体征。腹部因液体积聚或假性囊肿形成可触及肿块。<br />&nbsp;&nbsp;全身体征：与病变的严重程度有关。黄疽可在胆石性胰腺炎见到，提示可能有远端胆总管胆石性梗阻水肿的胰头压迫胆总管所致。重症胰腺炎患者多有循环系统、呼吸系统、泌尿系统、血液系统等异常改变。<br />&nbsp;&nbsp;1.2理化检查<br />&nbsp;&nbsp;1.2.1血常规：白细胞总数和中性粒细胞分类可以增高。<br />&nbsp;&nbsp;1.2.2酶学检查<br />&nbsp;&nbsp;血清淀粉酶：急性胰腺炎起病6小时后，血清淀粉酶>500U/L(Somogyi单位）可确诊<br />&nbsp;&nbsp;尿淀粉酶：急性胰腺炎起病8～12小时后开始升高，常可＞1000U/L(Somogyi单位）。若仅尿淀粉酶升高，尚不能诊断胰腺炎，但应继续动态监测血尿淀粉酶变化。<br />&nbsp;&nbsp;另外，血脂肪酶、血胰蛋白酶原、尿胰蛋白酶原、胰蛋白酶抑制物（PSTI）对诊断急性胰腺炎均有一定意义。<br />&nbsp;&nbsp;1.2.3血钙：急性胰腺炎时，血钙的明显下降提示胰腺广泛坏死。当血钙＜1.75mmol/L(7mg/dl)时，提示患者预后不良。<br />&nbsp;&nbsp;1.2.4血糖：可呈暂时性升高。空腹血糖水平持续升高，提示广泛胰腺坏死，预后不良。<br />&nbsp;&nbsp;1.2.5C反应蛋白（CRP)：当CRP>200mg/L时，提示急性重症胰腺炎；当CRP>279mg/L时，提示胰腺坏死的风险显著增加。<br />&nbsp;&nbsp;1.2.6X线检查：腹平片可见肠麻痹。胸片可表现为双肺底和胸膜腔改变。<br />&nbsp;&nbsp;1.2.7B超检查：轻症者胰腺呈均匀性增大，回声减低，胰腺界线不清；重症者胰腺呈普遍增大，回声不均匀，或有散在回声，胰腺表面不光滑，有渗液。B超可清晰显示结石、假性囊肿和脓肿。1.2.8CT/MRI检查：CT严重程度指数（CTSI）评分≥Ⅱ级作为重症标准。CT将胰腺炎症的严重程度分为A～E级（表84-1)：<br />&nbsp;&nbsp;A级：影像学为正常胰腺。<br />&nbsp;&nbsp;B级：胰腺实质改变，包括胰腺局部或弥漫性肿大，胰腺内小范围的积液（侧支胰管或直径＜3cm的胰腺坏死所致）。<br />&nbsp;&nbsp;C级：胰腺实质及周围炎症改变，除B级所述胰腺实质的变化外，胰腺周围软组织也有炎症改变。<br />&nbsp;&nbsp;D级：胰腺外的炎症改变，以胰腺周围改变为突出表现而不是单纯的液体积聚。<br />&nbsp;&nbsp;E级：广泛的胰腺外积液和脓肿，包括胰腺内显著的积液坏死，胰腺周围的积液和脂肪坏死，胰腺脓肿。<br />&nbsp;&nbsp;表84-1急性胰腺炎分级和CT严重指数(CTSI)CTSI＝CT分级积分＋坏死积分（Ⅰ级0～3分，Ⅱ级4～6分，Ⅲ级7～10分）<br />&nbsp;&nbsp;1.3诊断要点<br />&nbsp;&nbsp;急性胰腺炎在临床上表现为急性、持续性腹痛，血清淀粉酶活性增高达正常值上限3倍，影像学提示胰腺有或无形态改变，排除其他疾病者。可有或无其他器官功能障碍。少数病例血清淀粉酶活性正常或轻度增高。临床上又分轻症急性胰腺炎（MAP)、重症急性胰腺炎（SAP)和暴发性胰腺炎（又称早期重症急性胰腺炎）。<br />&nbsp;&nbsp;1.3.1轻症急性胰腺炎：应具备AP的临床表现和生化改变，而无器官功能障碍或局部并发症，对液体补充治疗反应良好，Ranson评分＜3分，或CT分级为A、B、C。<br />&nbsp;&nbsp;1.3.2重症急性胰腺炎：应具备AP的临床表现和生化改变，且应具备下列之一者：局部并发症<br />&nbsp;&nbsp;（胰腺坏死、假性囊肿、胰腺脓肿）；其他脏器功能损伤；Ranson评分≥3分；CT分级为D、E级。1.3.3暴发性胰腺炎：是SAP患者中病情极其凶险者，指SAP患者发病后72小时内即出现器官功能衰竭、休克、血功能障碍、败血症、全身炎症反应综合征等严重并发症者。', '1.急性期<br />&nbsp;&nbsp;1.1肝胆湿热证<br />&nbsp;&nbsp;证候：上腹部胀痛拒按，胁痛，或呃逆，发热，倦怠，大便不畅或干结，小便短赤，目黄身黄，舌质红，苔薄黄或黄腻，脉弦数。\n1.2胃肠热结证<br />&nbsp;&nbsp;证候：腹痛剧烈，由上腹至脐腹部，甚者从心下至少腹满痛不可近，有痞满燥实坚征象，伴有腹胀，恶心呕吐，口干渴，尿短赤，日哺潮热，舌红，苔黄厚腻或燥，脉洪数或弦数。<br />&nbsp;&nbsp;1.3实热结胸证<br />&nbsp;&nbsp;证候：胸腹痛，胁痛，心下满硬，痛不可近，发热畏寒，口苦纳呆，气息短促，苔薄黄，脉弦数或滑数。<br />&nbsp;&nbsp;1.4瘀热互结证<br />&nbsp;&nbsp;证候：腹部刺痛拒按，痛有定处，或有包块，或皮肤青紫有瘀斑，发热夜甚，口干不渴，小便短赤，大便燥结，舌质红或有瘀斑，脉弦数或涩。<br />&nbsp;&nbsp;1.5腑闭血瘀证<br />&nbsp;&nbsp;证候：脘腹疼痛如锥如割，呕吐剧烈，高热不退，或兼黄疽，腹水，小便如茶，大便秘结，舌质绛或紫，苔黄燥或灰黑，脉弦数而微涩。<br />&nbsp;&nbsp;1.6内闭外脱证<br />&nbsp;&nbsp;证候：脐周剧痛，呕恶身热，烦渴多汗，面色苍白，肢冷搐搦，舌质干绛，苔灰黑而燥，脉沉细而弱。<br />&nbsp;&nbsp;2恢复期<br />&nbsp;&nbsp;1肝脾失调证<br />&nbsp;&nbsp;证候：上腹部不适或上腹部、胁部微感胀满，进食后明显，纳食不香，或轻微恶心，舌苔白或白腻，脉弦缓。<br />&nbsp;&nbsp;2气阴两虚证<br />&nbsp;&nbsp;证候：精神疲倦，少气懒言，纳呆食少，口干，或饥而不欲食，脘痞不舒，大便干，舌淡红少苔或无苔，脉沉细数。<br />&nbsp;&nbsp;\n', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('474', '49', 'Y05_003', '1', '中医内科常见病诊疗指南中医病证部分', null, '中国中医药出版社', '2008', 'ZYYXH/T28-2008，中医内科常见病诊疗指南[M].中国中医药出版社，2008', '中文', null, null, '腹痛', '1.寒邪内阻证<br />&nbsp;&nbsp;2.湿热壅滞证<br />&nbsp;&nbsp;3.中虚脏寒证<br />&nbsp;&nbsp;4.饮食停滞证<br />&nbsp;&nbsp;5.肝郁气滞证<br />&nbsp;&nbsp;6.瘀血阻滞证', null, '腹痛是指以胃脘以下、耻骨毛际以上的部位发生疼痛为主要表现的病证。脏腑气机不利，经脉气血阻滞，不通则痛或不荣则痛为基本病机。病变的脏腑涉及肝、胆、脾、肾、膀胱、大小肠等。临床实证多，虚证少，亦可见虚实夹杂、寒热错杂者。常见于西医的急慢性胰腺炎、胃肠痉挛、肠梗阻、腹膜炎等多种疾病。<br />&nbsp;&nbsp;1诊断与鉴别诊断<br />&nbsp;&nbsp;1.1诊断要点<br />&nbsp;&nbsp;1.1.1以胃脘以下、耻骨毛际以上部位疼痛为特征。<br />&nbsp;&nbsp;1.1.2常伴有恶心呕吐、泄泻或便秘、纳呆等兼症。<br />&nbsp;&nbsp;1.1.3病性属急性发作，亦有久痛反复发作者。<br />&nbsp;&nbsp;1.2鉴别诊断<br />&nbsp;&nbsp;1.2.1胃痛：胃痛部位在上腹近心窝处，常伴脘腹胀满、呕恶泛酸、嗳气嘈杂等症，病变以胃为主。腹痛的部位是在胃脘以下、耻骨毛际以上，常伴有便秘、泄泻等肠道症状，病变范围较广，凡腹内脏腑及有关经脉受病，均可引起腹痛。<br />&nbsp;&nbsp;1.2.2干霍乱：干霍乱除有腹中绞痛外，以欲吐不得吐、欲泻不得泻为特点。<br />&nbsp;&nbsp;1.2.3妇科腹痛：妇科腹痛部位多在小腹，与经、带、胎、产有关。<br />&nbsp;&nbsp;1.2.4外科腹痛：外科腹痛多先腹痛后发热，疼痛剧烈，痛有定处，压痛明显，伴有肌紧张和反跳痛；内科腹痛常先发热后腹痛，疼痛不剧，压痛不明显，腹部柔软，痛无定处。<br />&nbsp;&nbsp;2辨证论治2.1寒邪内阻证<br />&nbsp;&nbsp;证候：腹痛急剧，得温则减，遇冷更甚，多有受寒病史，口和不渴，小便清长，舌苔白腻，脉沉紧。<br />&nbsp;&nbsp;2.2湿热壅滞证<br />&nbsp;&nbsp;证候：腹痛拒按，胀满不舒，大便秘结或黏滞不爽，烦渴引饮，自汗，小便短赤，舌苔黄腻，脉滑数。<br />&nbsp;&nbsp;\n2.3中虚脏寒证<br />&nbsp;&nbsp;证候：腹痛绵绵，时作时止，喜热恶冷，痛时喜按，饥饿及劳累后加重，神疲气短，怯寒肢冷，大便溏薄，舌淡苔白，脉沉细。<br />&nbsp;&nbsp;2.4饮食停滞证<br />&nbsp;&nbsp;证候：脘腹胀满，疼痛拒按，恶食，嗳腐吞酸，大便泄泻或秘结，舌苔垢腻，脉滑实。<br />&nbsp;&nbsp;2.5肝郁气滞证<br />&nbsp;&nbsp;证候：脘腹疼痛，胀满不舒，攻窜两胁，痛引少腹，得嗳气、矢气后减轻，遇情绪激动或郁怒则重，胸闷善太息，舌苔薄白，脉弦。<br />&nbsp;&nbsp;2.6瘀血阻滞证<br />&nbsp;&nbsp;证候：腹中刺痛，痛势较剧，固定不移，拒按，面色晦暗，唇暗，舌质紫暗或瘀斑，脉细涩。\n', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('475', '49', 'Y05_004', '1', '急性胰腺炎诊治指南（2014）', null, '\n中华医学会外科学分会胰腺外科学组', '2015', '中国实用外科杂志.2015,35(1):4-7.', '中文', '间质水肿型胰腺炎；坏死型胰腺炎；<br />&nbsp;&nbsp;急性期；演进期；感染期<br />&nbsp;&nbsp;轻症急性胰腺炎;中重症急性胰腺炎；重症急性胰腺炎', '急性胰腺炎；acute pancreatitis', null, null, '临床表现AP的主要症状多为急性发作的持续性上腹部剧烈疼痛，常向背部放射，常伴有腹胀及恶心呕吐。临床体征轻者仅表现为轻压痛，重者可出现腹膜刺激征、腹水，偶见腰肋部皮下淤斑征（Grey-Turner征）和脐周皮下淤斑征（Cullen征）。腹部因液体积聚或假性囊肿形成可触及肿块。可以并发一个或多个脏器功能障碍，也可伴有严重的代谢功能紊乱。<br />&nbsp;&nbsp;增强CT为诊断AP有效检查方法，BalthazarCT评级（表1）、改良的CT严重指数评分（modifiedCTseverityindex，MCTSI）（表2）常用于炎症反应及坏死程度的判断。B超及腹腔穿刺对AP诊断有一定帮助。<br />&nbsp;&nbsp;表1BalthazarCT评级\nBalthazarCT分级CT表现\nA级胰腺正常\nB级胰腺局部或弥漫性肿大，但胰周正常\nC级胰腺局部或弥漫性肿大，胰周脂肪结缔组织炎症性改变\nD级胰腺局部或弥漫性肿大，胰周脂肪结缔组织炎症性改变，胰腺实质内或胰周单发性积液\nE级广泛的胰腺内、外积液，包括胰腺和脂肪坏死，胰腺脓肿\n注：MRI分级同CT分级<br />&nbsp;&nbsp;表2改良的CT严重指数评分（MCTSI）标准\n特征评分\n胰腺炎症反应\n正常胰腺0\n胰腺和（或）胰周炎性改变2\n单发或多个积液区或胰周脂肪坏死4\n胰腺坏死\n无胰腺坏死0\n坏死范围≤30%2\n坏死范围＞30%4\n胰外并发症，包括胸腔积液、腹水、血管或胃肠道受累等2\n注：MCTSI评分为炎性反应与坏死评分之和<br />&nbsp;&nbsp;诊断AP：（1）与AP相符合的腹痛；（2）血清淀粉酶和（或）脂肪酶活性至少高于正常上限值3倍；（3）腹部影像学检查符合AP影像学改变。<br />&nbsp;&nbsp;2AP的病理分型及严重度分级<br />&nbsp;&nbsp;2.1病理分型<br />&nbsp;&nbsp;2.1.1间质水肿型胰腺炎（interstitialedematouspancreatitis）多数AP病人由于炎性水肿引起弥漫性或局限性胰腺肿大，CT表现为胰腺实质均匀强化，但胰周脂肪间隙模糊，可伴有胰周积液。2.1.2坏死型胰腺炎（necrotizingpancreatitis）部分AP病人伴有胰腺实质和（或）胰周组织坏死。胰腺灌注损伤和胰周坏死的演变需要数天，早期增强CT有可能低估胰腺及胰周坏死的程度，起病1周后的增强CT更有价值。<br />&nbsp;&nbsp;2.2严重程度分级<br />&nbsp;&nbsp;2.2.1轻症急性胰腺炎（mildacutepancreatitis，MAP）占AP的多数，不伴有器官功能衰竭及局部或全身并发症，通常在1～2周内恢复，病死率极低。<br />&nbsp;&nbsp;2.2.2中重症急性胰腺炎（moderatelysevereacutepancreatitis，MSAP）伴有一过性（≤48h）的器官功能障碍。早期病死率低，后期如坏死组织合并感染，病死率增高。<br />&nbsp;&nbsp;2.2.3重症急性胰腺炎（severeacutepancreatitis，SAP）约占AP的5%~10%，伴有持续（>48h）的器官功能衰竭。SAP早期病死率高，如后期合并感染则病死率更高。器官功能衰竭的诊断标准依据改良Marshall评分系统，任何器官评分≥2分可定义存在器官功能衰竭（表3）\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('476', '49', 'Y05_005', '1', '中国急性胰腺炎诊治指南', null, '中华医学会消化病学分会', '2013', '中华医学会消化病学分会', '中文', '轻度；中度；重度', '急性胰腺炎', null, null, '轻度：具备的临床表现和生物化学改变，不伴有器官功能衰竭及局部或全身并发症，通常在1-2周内恢复，病死率极低。中度：具备的临床表现和生物化学改变，伴有一过性的器官功能衰竭内可自行恢复，或伴有局部或全身并发症而不存在持续性的器官功能衰竭48h内不能自行恢复。对于有重症倾向的患者，要定期监测各项生命体征并持续评估。重度：具备的临床表现和生物化学改变，须伴有持续的器官功能衰竭持续48h以上、不能自行恢复的呼吸系统、心血管或肾脏功能衰竭，可累及一个或多个脏器，病死率较高，为36%-50%，如后期合并感染则病死率极高。<br />&nbsp;&nbsp;影像学诊断<br />&nbsp;&nbsp;2013指南：仍然推荐CT扫描作为AP诊断的标准影像学方法，且发病1周左右的增强CT诊断价值更高，可有效区分液体积聚和坏死的范围。在SAP的病程中，应强调密切随访CT检查，建议按病情需要，平均每周次。按照改良CT严重指数(MCTSI)，胰腺炎性反应分级为，正常胰腺0分，胰腺和或胰周炎性改变2分，单发或多个积液区或胰周脂肪坏死4分；胰腺坏死分级为，无胰腺坏死0分，坏死范围≤30%2分，坏死范围＞30%4分；胰腺外并发症，包括胸腔积液、腹水，血管或胃肠道等2分。评分≥4分可诊断为MSAP或SAP。此外，MRI也可以辅助诊断。<br />&nbsp;&nbsp;七、AP的诊断体系<br />&nbsp;&nbsp;AP的诊断标准：临床上符合以下3项特征中的2项，即可诊断为AP。①与符合的腹痛急性、突发、持续、剧烈的上腹部疼痛，常向背部放射；②血清淀粉酶和或脂肪酶活性至少倍正常上限值；③增强CT/MRI或腹部超声呈AP影像学改变。', null, null, null, '2013指南：由指南中定义的中划分出来，符合原“SAP”的条件。但不伴有持续的器官功能衰竭。不建议使用“暴发性胰腺炎”，因该术语提及的起病时间72h之内”不能反映预后。并且其诊断标准之一的全身炎性反应综合征。只是部分的临床表现，不能反映病情的严重度。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('477', '49', 'Y05_006', '1', '美国AP指南', 'American College of Gastroenterology Guideline:\nManagement of Acute Pancreatitis', '美国胃肠病学会', '2013', 'http://gi.org/clinical-guidelines/', '英文', '轻症急性胰腺炎；中度急性胰腺炎；重症急性胰腺炎', 'AP', null, null, 'DIAGNOSISRecommendations1. The diagnosis of AP is most often established by thepresence of 2 of the 3 following criteria: (i) abdominal painconsistent with the disease, (ii) serum amylase and / or lipasegreater than three times the upper limit of normal, and / or (iii) characteristic findings from abdominal imaging (strongrecommendation, moderate quality of evidence).2. Contrast-enhanced computed tomography (CECT) and / ormagnetic resonance imaging (MRI) of the pancreas shouldbe reserved for patients in whom the diagnosis is unclear orwho fail to improve clinically within the first 48 – 72 h afterhospital admission or to evaluate complications (strongrecommendation, low quality of evidence) <br />&nbsp;&nbsp;DIAGNOSIS: CLINICAL PRESENTATIONPatients with AP typically present with epigastric or left upperquadrant pain. The pain is usually described as constant withradiation to the back, chest, or flanks, but this description is nonspecific. The intensity of the pain is usually severe, but can be variable. The intensity and location of the pain do not correlate withseverity. Pain described as dull, colicky, or located in the lowerabdominal region is not consistent with AP and suggests an alternative etiology. Abdominal imaging may be helpful to determinethe diagnosis of AP in patients with atypical presentations.<br />&nbsp;&nbsp;DIAGNOSIS: LABORATORY PARAMETERSBecause of limitations in sensitivity, specificity, and positive andnegative predictive value, serum amylase alone cannot be usedreliably for the diagnosis of AP and serum lipase is preferred.Serum amylase in AP patients generally rises within a few hoursafter the onset of symptoms and returns to normal values within3 – 5 days; however, it may remain within the normal range onadmission in as many as one-fifth of patients ( 12,13 ). Comparedwith lipase, serum amylase returns more quickly to values belowthe upper limit of normal. Serum amylase concentrations maybe normal in alcohol-induced AP and hypertriglyceridemia.Serum amylase concentrations might be high in the absenceof AP in macroamylasaemia (a syndrome characterized bythe formation of large molecular complexes between amylaseand abnormal immunoglobulins), in patients with decreasedglomerular filtration rate, in diseases of the salivary glands,and in extrapancreatic abdominal diseases associated withinflammation, including acute appendicitis, cholecystitis, intestinal obstruction or ischemia, peptic ulcer, and gynecologicaldiseases. Serum lipase appears to be more specific and remains elevated longer than amylase after disease presentation. Despiterecommendations of previous investigators ( 14 ) and guidelinesfor the management of AP ( 15 ) that emphasize the advantageof serum lipase, similar problems with the predictive valueremain in certain patient populations, including the existenceof macro lipasemia. Lipase is also found to be elevated in a variety of nonpancreatic diseases, such as renal disease, appendicitis, cholecystitis, and so on. In addition, an upper limit ofnormal greater than 3 – 5 times may be needed in diabetics whoappear to have higher median lipase compared with nondiabeticpatients for unclear reasons ( 16,17 ). A Japanese consensus conference to determine appropriate “ cutoff ” values for amylase and lipase could not reach consensus on appropriate upper limits ofnormal ( 18 ). Assays of many other pancreatic enzymes havebeen assessed during the past 15 years, but none seems tooffer better diagnostic value than those of serum amylase andlipase ( 19 ). Although most studies show a diagnostic efficacy ofgreater than 3 – 5 times the upper limit of normal, clinicians mustconsider the clinical condition of the patient when evaluating amylase and lipase elevations. When a doubt regarding thediagnosis of AP exists, abdominal imaging, such as CECT, isrecommended<br />&nbsp;&nbsp;DIAGNOSIS: ABDOMINAL IMAGINGAbdominal imaging is useful to confirm the diagnosis of AP.CECT provides over 90 % sensitivity and specificity for the diagnosis of AP ( 20 ). Routine use of CECT in patients with AP isunwarranted, as the diagnosis is apparent in many patients andmost have a mild, uncomplicated course. However, in a patientfailing to improve after 48 – 72 (e.g., persistent pain, fever, nausea,unable to begin oral feeding), CECT or MRI imaging is recommended to assess local complications such as pancreatic necrosis( 21 – 23 ). Computed tomography (CT) and MRI are comparablein the early assessment of AP ( 24 ). MRI, by employing magneticresonance cholangiopancreatography (MRCP), has the advantage of detecting choledocholithiasis down to 3 mm diameter and pancreatic duct disruption while providing high-quality imaging fordiagnostic and / or severity purposes. MRI is helpful in patientswith a contrast allergy and renal insufficiency where T2-weightedimages without gadolinium contrast can diagnose pancreaticnecrosis ( 24 ).<br />&nbsp;&nbsp;Table 2. Summary of recommendationsDiagnosis1. The diagnosis of AP is most often established by the presence of two of the three following criteria: (i) abdominal pain consistent with the disease,(ii) serum amylase and/or lipase greater than three times the upper limit of normal, and/or (iii) characteristic fi ndings from abdominal imaging(strong recommendation, moderate quality of evidence).2. Contrast-enhanced computed tomographic (CECT) and/or magnetic resonance imaging (MRI) of the pancreas should be reserved for patients inwhom the diagnosis is unclear or who fail to improve clinically within the fi rst 48–72h after hospital admission (strong recommendation, low quality ofevidence).<br />&nbsp;&nbsp;1.诊断急性胰腺炎一般需以下3个标准中的2条：①具有急性胰腺炎特征性腹痛；②血清淀粉酶和（或）脂肪酶大于正常值上限3倍；③急性胰腺炎特征的腹部影像学特征性表现。（强烈推荐，中级证据）2.对诊断不明或在临床症状无改善的患者，应在入院后内完善胰腺对比增强和或磁共振成像（检査。（强烈推荐，低级证据）2.AP的分级诊断：①MAP为符合AP诊断标准，满足以下情况之一，无脏器衰竭、无局部或全身并发症，Ranson评分＜3分，急性生理功能和慢性健康状况评分系统（APACHE）Ⅱ评分＜8分，AP严重程度床边指数（BISAP）评分＜3分，修正CT严重指数(MCTSI)评分＜4分。②MSAP为符合AP诊断标准急性期满足下列情况之一，Ranson评分≥3分，APACHEⅡ评分≥8分，BISAP评分≥3分，MCTSI评分≥4分，可有一过性（＜48h的器官功能障碍。恢复期出现需要干预的假性囊肿、胰瘘或胰周脓肿等。③SAP为符合AP诊断标准，伴有持续性器官功能障碍单器官或多器官），改良评分（见表2）', null, null, null, 'Y05_006_biao1', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('478', '49', 'Y05_007', '1', '慢性胰腺炎诊治指南 （2014）', null, '中华医学会外科学分会胰腺外科学组', '2014', '中国实用外科杂志.2015,35(3):277-282.', '中文', '1.慢性钙化性胰腺炎<br />&nbsp;&nbsp;2.慢性阻塞性胰腺炎<br />&nbsp;&nbsp;3.慢性炎症性胰腺炎<br />&nbsp;&nbsp;\n4.自身免疫性胰腺炎<br />&nbsp;&nbsp;早期；进展期；并发症期；终末期', '慢性胰腺炎', null, null, 'CP的诊断主要依据临床表现和影像学检查，胰腺内外分泌功能检测可以作为诊断的补充。病理学诊断是CP诊断的确定标准。3.1临床表现腹痛是CP病人主要临床症状，典型表现为发作性上腹部疼痛，常因高脂饮食或饮酒诱发，随着胰腺外分泌功能不断下降，疼痛程度会减轻，甚至消失。外分泌功能不全病人早期无特殊症状，后期可出现脂肪泻、消瘦及营养不良表现。内分泌功能不全病人早期可出现糖耐量异常，后期表现为糖尿病症状。如合并胆道梗阻、十二指肠梗阻、胰腺假性囊肿、胰源性门静脉高压及胰源性胸腹水等并发症，则有相应的临床表现。<br />&nbsp;&nbsp;3.2影像学检查<br />&nbsp;&nbsp;3.2.1X线胰腺区域可见钙化灶或结石影。<br />&nbsp;&nbsp;3.2.2超声与内镜超声（EUS）超声检查通常作为CP的初筛检查，可显示胰腺形态改变，胰管狭窄、扩张、结石或钙化及囊肿等征象，但敏感度和特异度较差。EUS除显示形态特征外，还可以辅助穿刺活检组织学诊断。<br />&nbsp;&nbsp;3.2.3CT是CP诊断首选检查方法。对中晚期病变诊断准确度较高，对早期病变诊断价值有限。可见胰腺实质增大或萎缩、胰腺钙化、结石形成、主胰管扩张及假性囊肿形成等征象。<br />&nbsp;&nbsp;3.2.4磁共振成像（MRI）和磁共振胆胰管成像（MRCP）MRI诊断价值与CT相似。MRCP可以清晰显示胰管病变的部位、程度和范围。胰泌素增强MRCP（secretin-enhancedMRCP）能间接反映胰腺的外分泌功能，有助于CP的早期诊断。<br />&nbsp;&nbsp;3.2.5ERCP主要显示胰管形态改变，以往是诊断CP的重要依据。但作为有创性检查，目前多被MRCP和EUS替代，仅在诊断困难或需要治疗操作时选用。<br />&nbsp;&nbsp;3.2.6胰管镜可直接观察胰管内病变，同时能收集胰液、细胞刷片及组织活检等检查，对CP早期诊断及胰腺癌鉴别诊断有意义，有条件的单位可开展。<br />&nbsp;&nbsp;3.3胰腺功能检查<br />&nbsp;&nbsp;3.3.1胰腺外分泌功能检查分为直接外分泌功能和间接低，仅在胰腺功能严重受损时才有阳性结果，临床应用和诊断价值有限，不常规开展。<br />&nbsp;&nbsp;3.3.2胰腺内分泌功能检查继发于CP的糖尿病现归类为IIIC型，诊断标准为糖化血红蛋白（HbA1c）≥6.5%，空腹血糖（FBG）≥7mmol/L，其他指标包括血清胰岛素及C肽等。这些指标通常在胰腺内分泌功能损失90%以上才出现变化，敏感度低。<br />&nbsp;&nbsp;3.4其他实验室检查CP急性发作时血清淀粉酶、脂肪酶可升高；胰源性胸腹水中淀粉酶明显升高。血清CA19-9值可以增高，通常升幅较小，如明显升高应警惕合并胰腺癌可能。其他指标如IgG4、血钙、血脂、甲状旁腺素的检测有助于CP的病因诊断。<br />&nbsp;&nbsp;3.5胰腺活检组织活检是CP诊断的确定性标准，但其操作和临床开展受技术条件限制，不推荐常规使用。主要用于临床上与胰腺癌鉴别诊断时。方法包括CT或超声引导下经皮胰腺穿刺活检；EUS引导下胰腺活检，包括细针穿刺抽吸（EUS-FNA）及活检（EUS-FNB），较经皮穿刺安全，但取材组织量较少；手术或腹腔镜下胰腺活检，其中胰头部病变建议经十二指肠组织芯穿刺活检（corebiopsy）。3.6CP的诊断标准诊断条件包括：（1）1种及1种以上影像学检查显示CP特征性形态改变；（2）组织病理学检查显示CP特征性改变；（3）病人有典型上腹部疼痛，或其他疾病病人，需要进一步临床观察和评估。（4）血清或尿胰酶水平异常；（5） 胰腺外分泌功能异常 （见Y05_007_表1）。（1） 或 （2） 任何1项典型表现， 或者（1）或（2）疑似表现加（3）、（4）和（5）中任何两项可以确诊。（1）或（2）任何1项疑似表现考虑为可疑病人， 需要进一步临床观察和评估', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('479', '49', 'Y05_008', '1', '2006ACG急性胰腺炎诊疗指南 ', null, '美国胃肠病学院(ACG,American College of Gastroenterology)', '2006', '中国消化内镜,2007,(10):37-48.', '中文', '第 1 期 , 胰腺腺泡细胞内胰蛋白酶过早活化。<br />&nbsp;&nbsp;第 2 期 , 经由不同的机制和途径发生胰腺内炎症。<br />&nbsp;&nbsp;第 3 期 , 发生胰腺外炎症 , 包括急性呼吸窘迫综合征 (ARDS)。', '急性胰腺炎', null, null, '大部分急性胰腺炎患者出现上腹痛 , 其中近半数放射至背部 , 起病迅速 ,30 分钟内疼痛达到高峰 , 通常难以耐受 , 持续 24 小时以上不缓解。疼痛常伴随有恶心和呕吐。体格检查往往显不剧烈的上腹部压痛及肌卫。诊断急性胰腺炎一般需以下 3 点中的 2条 :(1) 具有急性胰腺炎特征性腹痛 ;(2) 血清淀粉酶和 ( 或 ) 脂肪酶≥正常值上限 3 倍 ;(3) 急性胰腺炎特征性的 CT 表现。本定义允许淀粉酶和 ( 或 ) 脂肪酶 < 正常值上限 3 倍而诊断急性胰腺炎的可能性。如果患者具备急性胰腺炎特征性的腹痛 , 血清酶水平低于正常值上限 3 倍 , 必须行 CT 检查以确诊急性胰腺炎。此外 , 本定义尚允许患者因急性或慢性疾病致严重神志失常而使腹痛无法评估的可能性。急性胰腺炎病程中淀粉酶及脂肪酶水平一般均升高。血清脂肪酶升高持续时间可能稍长于淀粉酶。淀粉酶和 ( 或 ) 脂肪酶升高的程度与急性胰腺炎的轻重并不直接相关。同时检测血清淀粉酶和脂肪酶往往无必要。血清脂肪酶应优选 , 因为在可能导致淀粉酶升高的非胰腺疾病, 如巨淀粉酶血症、腮腺炎和某些肿瘤 , 血清脂肪酶仍保持正常。血清脂肪酶诊断急性胰腺炎的敏感性和特异性一般优于淀粉酶。确诊急性胰腺炎之后仍每日监测血清淀粉酶或脂肪酶对评估疾病进程或预后的价值有限。如果血清淀粉酶和 ( 或 ) 脂肪酶升高持续数周 , 提示持续的胰腺 / 胰周炎症、胰管阻塞或假性囊肿形成等可能性。急性胰腺炎的鉴别诊断范围较广, 包括肠系膜缺血或梗塞、 胃、 十二指肠溃疡穿孔、胆绞痛、主动脉夹层、肠梗阻、下壁心肌梗死。<br />&nbsp;&nbsp;增强 CT( 尤其是增强薄层多排 CT) 是排除疑似胰腺炎病例、判断急性胰腺炎严重程度及确认胰腺炎并发症的最佳影像学检查。确定诊断胰腺炎的 CT 表现包括胰腺肿大伴弥漫性水肿、胰腺实质密度不均、胰腺边缘模糊及胰周积液。通过静脉注射造影剂 , 可确诊胰腺坏死。此外 ,增强 CT 可提供病因诊断线索 : 如偶尔直接观察到胆总管结石,胰腺钙化提示饮酒或其他原因所致的慢性胰腺炎 , 胰腺肿块提示恶性病变 , 弥漫性胰管扩张或囊性变提示胰管内乳头状黏液瘤或囊性新生物。磁共振成像 (MRI) 和 MRCP 诊断胰腺管结石方面优于 CT<br />&nbsp;&nbsp;入院时或 48 小时内实验室检查确定严重程度APACHE II 评分和红细胞压积有助于区别轻度与重症急性胰腺炎。推荐在住院 3 天内及之后按需计算 APACHE II 以利于两者鉴别', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('48', '34', 'M06_003', '1', '尿石症诊断治疗指南 (2010)', ' ', '中华医学会泌尿外科学分会;中国泌尿外科疾病诊断治疗指南编辑委员会', '2010', null, '中文', 'M06_003_01泌尿系结石分类.docx', '泌尿系结石', null, null, '1.影像学检查<br />&nbsp;&nbsp;对所有具有泌尿系结石临床症状的患者都应该做影像学检查，其结果对于结石的进一步检查和治疗具有重要的价值。<br />&nbsp;&nbsp;1.1B 超（推荐）超声波检查简便、经济、无创伤，可以发现2mm以上X线阳性及阴性结石。此外，超声波检查还可以了解结石以上尿路的扩张程度，间接了解肾实质和集合系统的情况。对膀胱结石，超声检查能够同时观察膀胱和前列腺，寻找结石形成的诱因和并发症。但是，由于受肠道内容物的影响，超声波检查诊断输尿管中下段结石的敏感性较低。<br />&nbsp;&nbsp;超声可作为泌尿系结石的常规检查方法，尤其是在肾绞痛时作为首选方法。<br />&nbsp;&nbsp;1.2. 尿路平片（KUB平片）（推荐）尿路平片可以发现90%左右X线阳性结石，能够大致地确定结石的位置、形态、大小和数量，并且初步地提示结石的化学性质。因此，可以作为结石检查的常规方法。在尿路平片上，不同成分的结石显影程度依次为：草酸钙、磷酸钙和磷酸镁铵、胱氨酸、含尿酸盐结石。单纯性尿酸结石和黄嘌呤结石能够透过X线（X线阴性），胱氨酸结石的密度低，后者在尿路平片上的显影比较淡。<br />&nbsp;&nbsp;1.3. 静脉尿路造影（IVU）（推荐）静脉尿路造影应该在尿路平片的基础上进行，其价值在于了解尿路的解剖，确定结石在尿路的位置，发现尿路平片上不能显示的X线阴性结石，鉴别平片上可疑的钙化灶。此外，还可以了解分侧肾脏的功能，确定肾积水程度。在一侧肾脏功能严重受损或者使用普通剂量造影剂而肾脏不显影的情况下，采用加大造影剂剂量（双剂量或大剂量）或者延迟拍片的方法往往可以达到肾脏显影的目的。肾绞痛发作时，由于急性尿路梗阻往往会导致尿路不显影或显影不良，因此对结石的诊断会带来困难。<br />&nbsp;&nbsp;1.4.  CT扫描（可选择）泌尿系结石的诊断通常不需要做CT检查。但是，由于CT扫描不受结石成分、肾功能和呼吸运动的影响，而且螺旋CT还能够同时对所获取的图像进行二维及三维重建，因此，能够检出其他常规影像学检查中容易遗漏的小结石。CT 诊断结石的敏感性比尿路平片及静脉尿路造影高，尤其适用于急性肾绞痛患者的诊断，可以作为X线检查的重要补充。另外，结石的成分及脆性可以通过不同的CT值改变来进行初步的评估，从而对治疗方法的选择提供参考。增强CT能够显示肾脏积水的程度和肾实质的厚度，从而反映了肾功能的改变情况。<br />&nbsp;&nbsp;1.5. 逆行或经皮肾穿刺造影（可选择）属于创伤的检查方法，不作为常规检查手段，仅在静脉尿路造影不显影或显影不良以及怀疑是X线阴性结石、需要作进一步的鉴别诊断时应用。<br />&nbsp;&nbsp;1.6.磁共振水成像（MRU）（可选择）磁共振对尿路结石的诊断效果极差，因而一般不用于结石的检查。但是，磁共振水成像（MRU）能够了解上尿路梗阻的情况，而且不需要造影剂即可获得与静脉尿路造影同样的效果，不受肾功能改变的影响。因此，对于不适合做静脉尿路造影的患者（例如造影剂过敏、严重肾功能损害、儿童和孕妇等）可考虑采用。<br />&nbsp;&nbsp;1.7. 放射性核素（可选择）放射性核素检查不能直接显示泌尿系结石，但是，它可以显示泌尿系统的形态，提供肾脏血流灌注、肾功能及尿路梗阻情况等信息，因此对手术方案的选择以及手术疗效的评价具有一定价值。此外，肾动态显影还可以用于评估体外冲击波碎石对肾功能的影响情况。<br />&nbsp;&nbsp;\n2.实验室检查<br />&nbsp;&nbsp;2.1.常规检查  结石患者的实验室检查应包括血液分析、尿液分析和结石分析,见表4。<br />&nbsp;&nbsp;\nM06_003_02结石患者的常规实验室检查.docx<br />&nbsp;&nbsp;\n2.2复杂性肾结石的尿液分析  复杂性肾结石患者（指结石反复复发、有或无肾内残石和特别的危险因素的患者）可选择进一步的尿液分析（表5）。<br />&nbsp;&nbsp;M06_003_03复杂性肾结石患者的尿液分析.docx<br />&nbsp;&nbsp;\n2.3尿液采集方案（表6）<br />&nbsp;&nbsp;\nM06_003_04尿液采集方案.docx<br />&nbsp;&nbsp;\n2.4.检查结果评价  测定血清/血浆钙有助于甲状旁腺功能亢进（HPT）或其他与高钙血症有关疾病的诊断。若血钙浓度高（>2.60 mmol/L），则应测定甲状旁腺激素水平，以确诊或排除HPT 。<br />&nbsp;&nbsp;X线阴性结石伴有高尿酸血症者应考虑尿酸结石，但CT片上可显示。<br />&nbsp;&nbsp;禁食晨尿pH>5.8可考虑为完全性或不完全性肾小管性酸中毒，应同时作酸负荷试验及血液pH、钾、碳酸氢盐和氯化物测定。<br />&nbsp;&nbsp;\n', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('480', '49', 'Y05_009', '1', '重症急性胰腺炎诊治指南', null, '\n中华医学会外科学分会胰腺外科学组', '2007', '中华医学会外科学分会胰腺外科学组. 重症急性胰腺炎诊治指南[J]. 中华外科杂志, 2007, 45(11):727-729.', '中文', '1．急性反应期<br />&nbsp;&nbsp;2．全身感染期<br />&nbsp;&nbsp;3．残余感染期症急性胰腺炎', '重症急性胰腺炎；暴发性急性胰腺炎', null, null, '重症急性胰腺炎急性胰腺炎伴有脏器功能障碍，或出现坏死、脓肿或假性囊肿等局部并发症者，或两者兼有。常见腹部体征有上腹部明显的压痛、反跳痛、肌紧张、腹胀、肠鸣音减弱或消失等。可以有腹部包块，偶见腰肋部皮下淤斑征(Grey—Tumer征)和脐周皮下淤斑征(cullen征)。可以并发一个或多个脏器功能障碍，也町伴有严重的代谢功能紊乱，包括低钙血症(血钙<1．87 mmoL／L)．增强cT为诊断胰腺坏死的最有效方法，B超及腹腔穿刺对诊断有一定帮助。APAcHEⅡ评分≥8分。B althazarCT分级系统≥Ⅱ级。<br />&nbsp;&nbsp;暴发性急性胰腺炎在重症急性胰腺炎患者中，凡存起病72 h内经正规非手术治疗(包括充分液体复苏)仍出现脏器功能障碍者，可诊断为暴发性急性胰腺炎。暴发性急性胰腺炎病情闪险，非手术治疗常不能奏效，常继发腹腔间隔搴综合征。<br />&nbsp;&nbsp;严重程度分级<br />&nbsp;&nbsp;重症急性胰腺炎无脏器功能障碍者为I级，伴有脏器功能障碍者为Ⅱ级，其中72 h内经充分的液体复苏，仍出现脏哭功能障碍的Ⅱ级重症急性胰腺炎患者属于暴发性急性胰腺炎。病程分期全病程大体可以分为三期，但不是所有患者都有三期病程，有的只有第一期，有的有二期，有的有三期。1．急性反应期：自发病至2周，可有休克、呼吸功能障碍、肾功能障碍和脑病等并发症。2．全身感染期：发病2周～2个月，以全身细菌感染、深部真菌感染或双重感染为其主要临床表现。3．残余感染期：时间为发病2—3个月以后，主要临床表现为全身营养不良，存在后腹膜或腹腔内<br />&nbsp;&nbsp;', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('481', '49', 'Y05_010', '1', ' APA循证诊断报告指南：慢性胰腺炎', 'American Pancreatic Association practice guidelines in chronic pancreatitis: evidence-based report on diagnostic guidelines', '\n美国胰腺协会(APA,American Pancreatic Association)', '2014', 'Pancreas. 2014 Nov;43(8):1143-62.', '英文', null, '慢性胰腺炎；chronic pancreatitis', null, null, 'EVIDENCE-BASED REPORT ONDIAGNOSTIC GUIDELINESChronic pancreatitis should be in the differential diagnosis of a patient with typical features of epigastric pain withradiation to the back, steatorrhea, weight loss, or recurrentAP. Patients generally have known risk factors for CP such asmoderate to heavy alcohol or tobacco exposure. Because thedisease is irreversible and carries a social stigma, the diagnosisneeds to be certain (ie, definitive, probable) before labeling apatient with this chronic illness. Furthermore, clinical evaluation is warranted in patients with a high suspicion of diseaseto rule out pancreas carcinoma that can mimic both its clinicaland imaging presentation.<br />&nbsp;&nbsp;In general, the radiologic and endoscopic evaluation of apatient with suspected CP should progress from a least invasiveto more invasive approach to establish a diagnosis. A computedtomography (CT) scan of the pancreas is usually the initial imaging modality of choice. Patients with equivocal or mild CTimaging findings or refractory symptoms may be referred tospecialized centers for additional studies such as magnetic resonance imaging (MRI)/secretin-enhanced magnetic resonancecholangiopancreatography (MRCP) or endoscopic proceduressuch as endoscopic ultrasound (EUS), endoscopic retrograde cholangiopancreatography (ERCP), and pancreas function testing.<br />&nbsp;&nbsp;The posttest probability of chronic pancreatic disease ismarkedly influenced by the clinical history, physical examination, etiologic risk factor profile, and results of radiologic andendoscopic imaging tests. Despite exhaustive attempts at diagnosis, up to 5% to 10% of patients cannot be clearly diagnosedwith certainty because of disagreement or discordance betweenimaging and endoscopic findings.<br />&nbsp;&nbsp;This article is the first of a 3-part guideline proposed by theAPA to assist physicians caring for individuals with suspectedCP. We review the current epidemiology, pathology, radiology, endoscopy, and physiologic testing methods and procedures that arecurrently utilized in the evaluation of suspected CP. We present evidence to support a definitive diagnosis and propose a nomenclature that can be used at academic centers to standardize clinicalresearch reporting of data.<br />&nbsp;&nbsp;It is our hope that this initial document will serve as an initialplatform on which to build further evidence-based recommendations as more knowledge becomes available and as our understanding of CP pathophysiology improves.<br />&nbsp;&nbsp;具体见Y05_010_word和Y05_010_biao1', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('482', '49', 'Y05_011', '1', '2015 JSHBPS指南：日本急性胰腺炎的管理', 'Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015', '\n日本肝胆胰腺外科学会(JSHBPS,Japanese Society of Hepato-Biliary-Pancreatic Surgery)', '2015', 'J Hepatobiliary Pancreat Sci. 2015 May 13.', '英文', null, '急性胰腺炎；acute pancreatitis', null, null, 'The measurement of serum lipase is recommended for the diagnosis of acute pancreatitis.However, when the measurement of lipase is difficult, serum amylase (pancreatic amylase) should be measured.(1B)<Comment> The detection of elevated levels of bloodpancreatic enzymes is crucial in the diagnosis of acutepancreatitis [4, 13, 21, 45–52]. When the diagnosis acute pancreatitis cannot be differentiated from other diseases, serum lipase is superior to any other pancreatic enzymes, includingserum amylase [53] (Table 3).<br />&nbsp;&nbsp;When acute pancreatitis is suspected, ultrasonography isrecommended.(1C)<Comment> Ultrasonography, which enables the visualization of findings associated with acute pancreatitis such aspancreatic enlargement and inflammatory changes aroundthe pancreas, is useful in diagnosing acute pancreatitis[57, 58]. It can also visualize causes and abnormal findings associated with the pathological conditions of acute pancreatitissuch as ascites, bile duct stones and bile duct dilatation(Fig. 1). Color Doppler ultrasonography is useful in the diagnosis of pseudoaneurysm developing inside the pseudocyst [59].CQ4 Is computed tomography (CT) recommended in the diagnosis of acute pancreatitis?CT is recommended for the diagnosis of acute pancreatitis.(1C)<Comment> When a definitive diagnosis of acute pancreatitis is not possible based on clinical findings,blood/urine tests or ultrasonography, or where the etiologyof pancreatitis is uncertain, contrast-enhanced dynamic CTshould be actively used as long as no renal function problemsare observed. Particularly in acute pancreatitis caused by pancreatic ductal stenosis due to pancreas tumors such as cancer,a simple CT alone is very likely to overlook the causative pancreatic cancer [60–62].<br />&nbsp;&nbsp;Table 2 Summary of recommendationA. Diagnosis1 The measurement of serum lipase is recommended for the diagnosis of acute pancreatitis. However, when the measurement of lipase isdifficult, serum amylase (pancreatic amylase) should be measured. (1B)<br />&nbsp;&nbsp;2 Urinary trypsinogen-2 dipstick may be useful for minimally invasive method and rapid diagnosis of acute pancreatitis. However, this isnot commercially available in Japan and therefore it cannot be recommended at this time. (ungraded B)B. Diagnostic imaging<br />&nbsp;&nbsp;3 When acute pancreatitis is suspected, ultrasonography is recommended. (1C)<br />&nbsp;&nbsp;4 CT is recommended for the diagnosis of acute pancreatitis. (1C)<br />&nbsp;&nbsp;5 MRI is more useful than CT in diagnosing bile duct stones causing pancreatitis and hemorrhagic necrotizing pancreatitis. (2C)<br />&nbsp;&nbsp;6 Contrast-enhanced CT is useful for the diagnosis of active hemorrhage and thrombosis associated with pancreatitis. (1C)', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('483', '49', 'Y05_012', '0', '2013 急性胰腺炎中医诊疗专家共识意见', null, '\n中华中医药学会脾胃病分会', '2013', '中华中医药杂志(原中国医药学报).2013,28(6):1836-1831.', '中文', null, '急性胰腺炎', '腹痛', '1.肝郁气滞证 <br />&nbsp;&nbsp;2.肝胆湿热证<br />&nbsp;&nbsp;3.腑实热结证<br />&nbsp;&nbsp;4.瘀热（毒）互结证<br />&nbsp;&nbsp;5.内闭外脱证 ', null, '肝郁气滞证 主症：①中上腹阵痛或窜痛， 或向左季肋部、左背部窜痛；②腹胀、矢气则舒， 可无发热。 次症：①情志抑郁， 急躁易怒， 善太息； ②恶心或呕吐； ③嗳气呃逆； ④舌淡红， 苔薄白或薄黄；⑤脉弦紧或弦数。主症2项加次症2项即可诊断。<br />&nbsp;&nbsp;肝胆湿热证 主症：①上腹胀痛拒按或腹满胁痛；②舌质红， 苔黄腻或薄黄。 次症：①发热口渴， 口干口苦；②身目色， 小便短黄； ⑤倦怠乏力； ⑥脉弦数。 主症2项加次症2项即可诊断。<br />&nbsp;&nbsp;1.3 腑实热结证 主症： ①腹痛剧烈， 甚至从心下至少腹痛满不可近； ②有痞满燥实坚征象。 次症： ①恶心呕吐； ②日晡潮热； ③口干口渴； ④小便短赤； ⑤舌质红， 苔黄厚腻或燥； ⑥脉洪大或滑数。 主症2项加次症2项即可诊断。<br />&nbsp;&nbsp;1.4 瘀热（毒）互结证 主症：①腹部刺痛拒按，痛处不移； ②或可扪及包块； 或见出血， 皮肤青紫有瘀斑。 次症： ①发热夜甚； ②口干不渴； ③小便短赤， 大便燥结； ④舌质红或有瘀斑； ⑤脉弦数或涩。 主症2项加次症2项即可诊断。<br />&nbsp;&nbsp;1.5 内闭外脱证 主症： ①脐周剧痛； ②呼吸喘促、 面色苍白， 肢冷抽搦。 次症： ①恶心呕吐； ②身热烦渴多汗， 皮肤可见花斑； ③神志不清； ④大便不通， 小便量少甚或无尿； ⑤舌质干<br />&nbsp;&nbsp;', null, '疗效判定标准痊愈：轻症，5d内症状及体征消失，且实验室指标[血清淀粉酶、CT评分标准（见Y05_012表1）或B超检查]恢复正常；重症，10d内达到上述标准。显效：轻症，5d内症状及体征消失，实验室指标明显改善；重症，10d内达到上述标准，合并症未完全消失，或APACHE分数（见Y05_012表2）降低50％以上。有效：轻症，5d内症状及体征好转，实验室指标改善；重症，10d较入院时有些恢复，但未恢复正常，或APACHE分数（见Y05_012表2）降低未达50％。无效：轻症，5d内临床症状及体征无改变或加畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭㤨੟ༀƙ\0੟ð\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄톎఑੟ð\0ꐘ఑彿㎽奋㎽巫㎽⤪ఒ䘺ఒ彿㎽䘮ఒ塚㎽䘺ఒꍈ㏂\0\0톎఑學㎽漸㏂圔㎽톎఑圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0촠੝䐺盭暼痭촠੝ༀƙ \0촠੝À\0\0㺣盭촠੝\0𢡄촤੝\0팃目촤੝࣒촤੝큁目촤੝퇂఑泌\0Item\0\0䚾ఒ\0\0\0\0\0\0Count\0\0﫨呂쵔੝㳜੪\0\0촤੝\0\0\0\0੪寶目㳠੪楱䥷㎽⤪ఒ\0\0䚾ఒ�㏂䘮ఒ\0\0\0੪\0\0\0露𢡄\0\0㎾Ӷ\0齃\0\0x�㏂䘮ఒ\0\0隲W䚾ఒ\0\0�Ĳ\0\0\0鹿齃殺\0\0霈W戀醙霫W戀ꊠऺ齃x\0霪W露Wꊠऺ﫰xt\0Љ\0\0\0൐௲鲬࣒菮畻\0\0\0\0', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('484', '49', 'Y05_013', '1', '慢性胰腺炎诊治指南（2012，上海）', null, '\n中华胰腺病杂志编委会\n中华医学会内镜学分会(CSDE,Chinese Society of Digestive Endoscopy)', '2012', '中华消化内镜杂志2012年6月第29卷第6期', '中文', '1.Ⅰ型（急性发作型）<br />&nbsp;&nbsp;2.Ⅱ型（慢性腹痛型）<br />&nbsp;&nbsp;3.Ⅲ型（局部并发症型）<br />&nbsp;&nbsp;4.Ⅳ（外、内分泌功能不全型）', '慢性胰腺炎', null, null, '（二）体征<br />&nbsp;&nbsp;上腹部压痛， 急性发作时可有腹膜刺激征。 当并发巨大假性囊肿时可扪及包块。当胰头显著纤维化或假性囊肿压迫胆总管下段， 可出现黄疸。 由于消化吸收功能障碍可导致消瘦，亦可出现其他并发症相关的体征。（三）影像诊断X线：部分患者可见胰腺区域的钙化灶、阳性结石影。腹部超声：根据胰腺形态、回声和胰管变化可作为CP的初筛检查，但诊断的敏感度不高。CT/MRI/MRCP:CT显示胰腺增大或缩小、轮廓不规则、胰腺钙化、胰管不规则扩张或胰腺假性囊肿等改变。 MRI对CP的诊断价值与CT相似，但对钙化和结石的显示不如CT。MRCP可显示胰管扩张的程度和结石位置，并能明确部分CP的病因。<br />&nbsp;&nbsp;内镜超声(EUS)：对CP的诊断优于腹部超声，诊断敏感度约80%。主要表现为胰实质回声增强、主胰管狭窄或不规则扩张及分支胰管扩张、胰管结石、假性囊肿等。内镜逆行胰胆管造影术( ERCP)：是诊断CP的重要依据，可见胰管狭窄及扩张、 结石。轻度CP:胰管侧支扩张或阻塞（超过3个） ，主胰管正常；中度CP:主胰管狭窄及扩张；重度CP:主胰管阻塞、 狭窄、 结石、 钙化， 有假性囊肿形成。<br />&nbsp;&nbsp;（四）实验室检查<br />&nbsp;&nbsp;急性发作期可见血清淀粉酶升高， 如合并胸、 腹水， 胸、腹水中的淀粉酶含量往往明显升高。血糖测定及糖耐量试验可反映胰腺内分泌功能。 CP也可出现血清CA19-9增高，如明显升高，应警惕合并胰腺癌的可能。胰腺外分泌功能试验： 胰腺外分泌功能检查多为无创性检查， 是诊断的参考依据， 但目前开展的试验敏感度较差。其他相关检查： 有条件可行IgG4、 血钙、 血脂、 甲状旁腺素、病毒等检查以明确CP的病因。<br />&nbsp;&nbsp;（五） CP的病理变化<br />&nbsp;&nbsp;CP的基本病理变化包括不同程度的腺泡破坏、胰腺间质纤维化、 导管扩张和囊肿形成等。 按其病理变化可分为慢性钙化性胰腺炎、 慢性梗阻性胰腺炎和慢性炎症性胰腺炎。慢性钙化性胰腺炎最多见， 表现为散发性间质纤维化及腺管内蛋白栓子、 结石形成及腺管的损伤； 慢性阻塞性胰腺炎因主胰管局部阻塞、 导管狭窄导致近端扩张和腺泡细胞萎缩，由纤维组织取代； 慢性炎症性胰腺炎主要表现为胰腺组织纤维化和萎缩及单核细胞浸润。 出现并发症时， 也可见胰腺外器官的病理变化， 如胆管梗阻、 门静脉受压、 血栓形成等胰腺标本的获取： 手术活检是理想的标本， 也可经EUS、CT或腹部超声引导下的穿刺活检获得。<br />&nbsp;&nbsp;四、 CP的诊断标准和分期<br />&nbsp;&nbsp;（一）诊断标准<br />&nbsp;&nbsp;主要诊断依据：<br />&nbsp;&nbsp;①典型的临床表现（反复发作上腹痛或急性胰腺炎等）；<br />&nbsp;&nbsp;②影像学检查提示胰腺钙化、 胰管结石、 胰管狭窄或扩张等；<br />&nbsp;&nbsp;③病理学特征性改变；<br />&nbsp;&nbsp;④胰腺外分泌功能不全表现。<br />&nbsp;&nbsp;②或③可确诊；①+④拟诊。<br />&nbsp;&nbsp;（二）临床分期<br />&nbsp;&nbsp;根据CP的临床表现和合并症进行分期（表2），对治疗选择具有指导意义。<br />&nbsp;&nbsp;表2慢性胰腺炎的临床分期\n临床分期 临床表现\nl期 仅有I型或Ⅱ型临床表现\n2期 出现Ⅲ型临床表现\n3期 出现Ⅳ型临床表现\n\n<br />&nbsp;&nbsp;分型 主要表现\nⅠ型（急性发作型） 急性上腹痛，伴血淀胰酶升高和影像学急性炎症改变<br />&nbsp;&nbsp;\nⅡ型（慢性腹痛型） 间歇性或持续性上腹部疼痛\nⅢ型（局部并发症型） 假性囊肿、消化道梗阻、左侧门脉高压症、腹水、胰痿等并发症<br />&nbsp;&nbsp;\nⅣ（外、内分泌功能不全型） 消化吸收不良、脂肪泻、糖尿病和体重减轻等症状<br />&nbsp;&nbsp;\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('485', '49', 'Y05_014', '1', '2005BSG英国急性胰腺炎的管理指南', 'UK guidelines for the management of acute pancreatitis.', null, '2005', 'Gut. 2005 May;54 Suppl 3:iii1-9.', '英文', null, '急性胰腺炎', null, null, '*The correct diagnosis of acute pancreatitisshould be made in all patients within48 hours of admission (recommendationgrade C).<br />&nbsp;&nbsp;The aetiology of acute pancreatitis should bedetermined in at least 80% of cases and nomore than 20% should be classified as idiopathic (recommendation grade B).<br />&nbsp;&nbsp;Although amylase is widely available andprovides acceptable accuracy of diagnosis,where lipase estimation is available it ispreferred for the diagnosis of acute pancreatitis (recommendation grade A).<br />&nbsp;&nbsp;Where doubt exists, imaging may be used:ultrasonography is often unhelpful and pancreatic imaging by contrast enhanced computed tomography provides good evidence forthe presence or absence of pancreatitis(recommendation grade C).<br />&nbsp;&nbsp;Clinical features (abdominal pain and vomiting) togetherwith elevation of plasma concentrations of pancreaticenzymes are the cornerstones of diagnosis. Pancreaticenzymes are released into the circulation during an acuteattack. Levels peak early, and decline over 3–4 days. ‘‘Animportant concept derives from this: the diagnosis of acutepancreatitis should not rely on arbitrary limits of values 3 or 4times greater than normal, but values should be interpretedin light of the time since the onset of abdominal pain’’.4The half life of elevated amylase is shorter than that oflipase. Because it persists longer after the onset of the attackand because the pancreas is the only source of lipase,estimation of plasma lipase has slightly superior sensitivityand specificity and greater overall accuracy than amylase.<br />&nbsp;&nbsp;Plain radiographs contribute little to the diagnosis of acutepancreatitis. Ultrasound may show pancreatic swelling butthe pancreas is visualised in only 25–50% of patients withacute pancreatitis. The value of ultrasonography lies in itsability to demonstrate gall bladder stones and dilatation ofthe common bile duct, as well as other pathology unrelated tothe pancreas such as abdominal aortic aneurysm. CT isoccasionally indicated for diagnosis, if clinical and biochemical findings are inconclusive, especially when abdominalsigns raise the possibility of an alternative abdominalemergency, such as a perforation or infarction of the bowel.\nRecommendations<br />&nbsp;&nbsp;Although amylase is widely available and providesacceptable accuracy of diagnosis, where lipase isavailable it is preferred for the diagnosis of acutepancreatitis (recommendation grade A).<br />&nbsp;&nbsp;Where doubt exists, imaging may be used: ultrasonography is often unhelpful and pancreatic imaging bycontrast enhanced CT provides good evidence for thepresence or absence of pancreatitis (recommendationgrade C).\n', null, null, null, 'Recommendations 2003(*Unchanged\nfrom the 1998recommendations)', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('486', '49', 'Y05_015', '1', '慢性胰腺炎诊治指南（2005，南京）', null, '\n中华医学会消化病学分会(CSGE,Chinese Society Of Gastroenterology)', '2005', '中华内科杂志2005年44卷8期', '中文', null, '慢性胰腺炎', null, null, '1. 临床表现 :临床症状仍是诊断 CP的重要依据 ,轻度CP无明显特异性临床表现 。 中 、重度 CP临床表现包括 :(1) 腹痛 、腹胀 、黄疸等 。 腹痛是 CP的主要临床症状 ,初为间歇性 ,后转为持续性 ,多位于上腹部 ,可放射至背部或两肋 。 腹痛常因饮酒 、饱食 、高脂肪餐或劳累而诱发 。 ( 2)消化吸收不良 、脂肪泻 、体重减轻等症状 。 ( 3)并发症可有糖尿病 、胰腺假性囊肿 、腹水 、胰瘘 、消化道梗阻及胰源性门脉高压症等 。<br />&nbsp;&nbsp;2.体征 :可有轻度压痛 。 当并发巨大假性囊肿时可扪及包块 。 当胰头显著纤维化或假性囊肿压迫胆总管下段 ,可出现黄疸 。 由于消化吸收功能障碍导致消瘦 ,亦可出现并发症有关的体征 。<br />&nbsp;&nbsp;3. 影像诊断 : (1) 腹部 X线片可有胰腺钙化 。 ( 2) 腹部 B超 :根据胰腺形态与回声及胰管变化可作为 CP的初筛检查 ,但诊断的敏感性不高 。 (3) 超声内镜 ( EUS) :对 CP的诊断优于腹部 B 超 ,诊断敏感性达 80%。 声像图表现主要有胰实质回声增强 、主胰管狭窄或不规则扩张及分支胰管扩张 、胰管结石 、假性囊肿等 。 (4) CT/MR I检查 : CT显示胰腺增大或缩小 、轮廓不规则 、胰腺钙化 、胰管不规则扩张或胰周胰腺假性囊肿等改变 。 MR I对 CP的诊断价值与 CT相似 ,但对钙化和结石逊于 CT。 ( 5) 胰胆管影像学检查 :是诊断CP的重要依据 。 轻度 CP:胰管侧支扩张 /阻塞 (超过 3个 ) ,主胰管正常 ;中度 CP:主胰管狭窄及扩张 ;重度 CP:主胰管阻塞 ,狭窄 ,钙化 ,有假性囊肿形成 。 胰胆管影像检查主要方法有内镜逆行胰胆管造影术 ( ERCP)和磁共振胰胆管成像术(MRCP) 。<br />&nbsp;&nbsp;4. 实验室检查 : (1)急性发作期可见血清淀粉酶升高 ,如合并胸 、腹水 ,其胸 、腹水中的淀粉酶含量往往明显升高 。血糖测定及糖耐量试验可反映胰腺内分泌功能。 CP也可出现血清 CA1929增高 ,但升高幅度一般较小 ,如明显升高 ,应警惕合并胰腺癌的可能 。 (2) 胰腺外分泌功能试验 。 胰腺外分泌功能检查理论上是诊断 CP的重要依据 ,但目前国内外开展的各种试验敏感性较差 ,仅在中 、重度 CP才有变化 ,因而临床价值有限 ,仅有胰腺外分泌功能改变 ,不能诊断为CP。 有条件的单位应尽可能开展此项工作并寻找更为敏感 、特异的胰外分泌功能检查方法 。<br />&nbsp;&nbsp;5.病理变化 : CP的病理改变 :早期可见散在的灶状脂肪坏死 ,小叶及导管周围纤维化 ,胰管分支内有蛋白栓及结石形成 。 在进展期 ,胰管可有狭窄 、扩张改变 ,主胰管内可见嗜酸性蛋白栓和结石 。 导管上皮萎缩 、化生乃至消失 ,并可见大小不等的囊肿形成 ,甚至出现小脓肿 。 随着纤维化的发展 ,可累及小叶周围并将实质小叶分割成不规则结节状 ,而被纤维组织包裹的胰岛体积和数量甚至会有所增加 ,偶尔会见到残留导管细胞芽生所形成的类似于胚胎发生时的胰岛细胞样组织 ,类似于肝硬化时假小叶的形成 。 晚期 ,病变累及胰腺内分泌组织 ,导致大部内分泌细胞减少 ,少数细胞如A细胞和 PP细胞相对增生 ,随着病变的进一步发展 ,多数胰岛消失 ,少数病例胰岛细胞显著增生 ,呈条索状和丛状 。 胰腺标本的获取 :手术活检是最理想的标本 ,但通常难以获得 ;经超声 (腹部 、 EUS)或 CT引导下的穿刺活检是最常用的方法 。<br />&nbsp;&nbsp;三 、CP的诊断标准在排除胰腺癌的基础上 ,建议将下述 4项作为 CP的主要诊断依据 : (1) 典型的临床表现 (腹痛 、胰腺外分泌功能不全症状 ) ; (2) 病理学检查 ; (3) 影像学上有 CP的胰胆改变征象 ; (4) 实验室检查有胰腺外分泌功能不全依据。 第1项为诊断所必须 ,第 2项阳性可确诊 , 1 + 3可基本确诊 , 1 + 4为疑似病人 。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('487', '49', 'Y05_016', '1', '2015 JSGE循证临床实践指南：慢性胰腺炎', 'Evidence-based clinical practice guidelines for chronic pancreatitis 2015.', '\n日本胃肠病学会(JSGE,Japanese Society of Gastroenterology)', '2015', 'J Gastroenterol. 2016 Jan 4.', '英文', null, '慢性胰腺炎；chronic pancreatitis', null, null, 'Diagnosis<br />&nbsp;&nbsp;The definitive diagnosis of chronic pancreatitis is sometimesdifficult, especially if the disease is not considered by thephysicians treating the patient. This chapter describes howchronic pancreatitis is suspected, based on signs, symptoms,and laboratory results, and how the diagnosis is developed.The CQ are very detailed and consist of 12 items, includinghistory taking, physical examination, determination methodsfor pancreatic enzymes in the blood and urine [5, 6], significance of various imaging methods [chest and abdominalradiography, abdominal ultrasonography, computedtomography (CT), magnetic resonance imaging (MRI),endoscopic ultrasound, and pancreatography] in the diagnosis of chronic pancreatitis [7–15], exocrine pancreaticfunction testing, pathological diagnosis, differential diagnosis from pancreatic cancer and intraductal papillarymucinous neoplasm (IPMN), and genetic testing [16–20].<br />&nbsp;&nbsp;In order to facilitate understanding the path to diagnosis,flow diagram 1 (Fig. 1) was prepared. When chronic pancreatitis is suspected, a diagnosis should be made accordingto the criteria for the diagnosis of chronic pancreatitisrevised in 2009 [1]. Definitive and probable diagnosis ofchronic pancreatitis can be made by imaging alone. Of thecases in which findings for probable diagnosis are present,those that satisfy two or more items among repeated attacksof upper abdominal pain, abnormalities in blood/urinepancreatic enzymes, and exocrine pancreatic dysfunctionare definitively diagnosed as chronic pancreatitis. However, the concept of early chronic pancreatitis has beenadopted. Cases that do not qualify for definitive or probablediagnosis but which satisfy two or more items from theabove three findings in addition to persistent drinkinghistory (80 g/day), and show appropriate imaging findingsas well (Table 1), are diagnosed as early chronicpancreatitis.<br />&nbsp;&nbsp;Staging<br />&nbsp;&nbsp;Chronic pancreatitis generally first presents with repeatedupper abdominal and back pain, and endocrine and exocrine pancreatic function gradually deteriorates [21, 22]. InJapan, the disease is classified into three phases: compensated, transitional, and uncompensated, depending on thestage; however, an early chronic pancreatitis category hasbeen added before the compensated phase in this revision[1]. Exocrine pancreatic disorder (that includes digestiveand absorptive disorders) and abnormal glucose tolerance(pancreatic diabetes) occur as chronic pancreatitis progresses; therefore, to improve prognosis, pharmacologicaland nutritional therapies should be given in accordancewith the stage of the disease. In this regard, staging ofchronic pancreatitis is important. The CQ in this chapter comprise eight items, and clinical signs, blood and urinepancreatic enzyme levels, imaging, exocrine pancreaticfunction tests, and abnormal glucose tolerance tests, as wellas the significance of scoring of these factors, are allimportant in determining the severity, staging, and treatment of chronic pancreatitis [23–32].', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('488', '49', 'Y05_017', '1', '2012版急性胰腺炎分类-亚特兰大国际共识的分类和定义的修订', 'Classification of acute pancreatitis-2012：revision of the Atlanta classification and definitions by international consensus．', '\n美国哈佛医学院等国际胰腺研究组织', '2012', 'Gut 2013;62:102–111.', '英文', '1.interstitial\noedematous pancreatitis<br />&nbsp;&nbsp;2. necrotising pancreatitis.<br />&nbsp;&nbsp;Mild acute pancreatitis<br />&nbsp;&nbsp;Moderately severe acute pancreatitis<br />&nbsp;&nbsp;Moderately severe acute pancreatitis(Y05_017表1)', '急性胰腺炎', null, null, 'The diagnosis of acute pancreatitis requires two of the followingthree features: (1) abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epigastric pain often radiating to the back); (2) serum lipase activity (or amylase activity) atleast three times greater than the upper limit of normal; and (3) characteristic findings of acute pancreatitis on contrast-enhancedcomputed tomography (CECT) and less commonly magnetic resonance imaging (MRI) or transabdominal ultrasonography.9–13\nIf abdominal pain suggests strongly that acute pancreatitis ispresent, but the serum amylase and/or lipase activity is less thanthree times the upper limit of normal, as may be the case withdelayed presentation, imaging will be required to confirm thediagnosis.13 14 If the diagnosis of acute pancreatitis is establishedby abdominal pain and by increases in the serum pancreaticenzyme activities, a CECT is not usually required for diagnosisin the emergency room or on admission to the hospital.<br />&nbsp;&nbsp;Definition of severity of acute pancreatitis<br />&nbsp;&nbsp;There are important reasons to define and stratify the severityof acute pancreatitis. First, on admission, it is important toidentify patients with potentially severe acute pancreatitis whorequire aggressive early treatment. Second, in a secondary caresetting, clinicians need to identify such patients for possibletransfer to specialist care. Third, for specialists who receivesuch referrals, there are advantages to stratifying these patientsinto subgroups based on the presence of persistent organ failureand local or systemic complications.<br />&nbsp;&nbsp;This classification defines three degrees of severity: mildacute pancreatitis, moderately severe acute pancreatitis, andsevere acute pancreatitis.32 33 Terminology that is important inthis classification includes transient organ failure, persistentorgan failure, and local or systemic complications (boxes 1and 3). Transient organ failure is organ failure that is presentfor <48 h. Persistent organ failure is defined as organ failurethat persists for >48 h. Local complications include peripancreatic fluid collections and acute necrotic collections13 14 39 41(box 1), while systemic complications can be related to exacerbations of underlying co-morbidities related to the acutepancreatitis\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('489', '49', 'Y05_018', '1', '2006JPN 日本急性胰腺炎管理指南：诊断标准', '2006JPN Guidelines for the management of acute pancreatitis: diagnostic criteria for acute pancreatitis', '\n日本肝胆胰腺外科学会(JSHBPS,Japanese Society of Hepato-Biliary-Pancreatic Surgery)', '2006', 'J Hepatobiliary Pancreat Surg (2006) 13:25–32', '英文', null, '急性胰腺炎', null, null, 'Diagnostic criteria<br />&nbsp;&nbsp;Clinical symptoms and signs<br />&nbsp;&nbsp;Clinical question (CQ) 1. Are clinical symptoms andsigns useful in diagnosing acute pancreatitis?It is essential to interview all patients (including thosewith consciousness disorders or who are in a state ofshock), take their medical histories, and perform aphysical examination (Recommendation A)<br />&nbsp;&nbsp;Abdominal pain, pain radiating to the back, anorexia,fever, nausea and vomiting, and decreased bowel soundsare frequent manifestations of acute pancreatitis (Tables1 and 2) (Level 4).1,2 However, these features are notspecific to acute pancreatitis, and when a patient presents with these manifestations, acute pancreatitis mustbe differentiated from other acute abdominal diseases.Acute pancreatitis accounts for 2% to 3% of all acuteabdominal diseases (Level 2b, unknown)3,4 and in a veryfew patients there is no abdominal pain (Level 2b).5<br />&nbsp;&nbsp;Acute pancreatitis is sometimes manifested bydiscoloration of the skin, such as Grey Turner’s sign (onthe lateral abdominal wall), Cullen’s sign (around thenavel), and Fox’s sign (over the lower portion of theinguinal ligament). However, because these signs appear in only 3% (Level 2b)6 of patients, and becausethey are also observed in patients with other diseases(Level 4)7 and are often seen 48 to 72h after the onset ofpancreatitis, their diagnostic significance is low.<br />&nbsp;&nbsp;Blood and urine tests<br />&nbsp;&nbsp;Blood lipase<br />&nbsp;&nbsp;CQ2. Which pancreatic enzymes should be measured to diagnose acute pancreatitis?<br />&nbsp;&nbsp;When making a diagnosis of acute pancreatitis or a<br />&nbsp;&nbsp;differential diagnosis from other diseases, the blood<br />&nbsp;&nbsp;lipase level is the best pancreatic enzyme parameter,<br />&nbsp;&nbsp;even better than the total blood amylase level (Recommendation A)<br />&nbsp;&nbsp;Comparisons of measurements of various pancreaticenzymes to detect the presence of acute pancreatitis(Level 2a)8 have shown that the blood lipase level isalmost as sensitive as the total blood amylase level andhas better specificity (Tables 3 and 4).9,10<br />&nbsp;&nbsp;According to Apple et al.,8 the sensitivity and specificity of blood lipase in the diagnosis of acute pancreati tis are 85% to 100% and 84.7% to 99.0% (Level 2a),8respectively. The blood lipase value is more sensitivethan blood amylase (Levels 2b-4)11–13 and provides diagnostic capability similar to that of blood P-amylase(Level 2b).13 Blood lipase is considered a valuable diagnostic tool, because abnormally high values persist forlonger than abnormal blood amylase levels (Level 2b),14and it is more sensitive in terms of detecting the presence of acute alcohol-induced pancreatitis. The combined use of blood amylase and blood lipase levels(Level 2a)8 does not facilitate the diagnosis of acute<br />&nbsp;&nbsp;pancreatitis.<br />&nbsp;&nbsp;The above findings lead to the conclusion that theblood lipase level is an important indicator in the diagnosis of acute pancreatitis and that the measurement ofthe blood lipase level should be given top priority. Measurement of the lipase level is of primary importancewhen the blood amylase level of a patient suspected ofhaving acute pancreatitis is normal Blood amylase (blood total amylase)<br />&nbsp;&nbsp;CQ3. What is the optimal examination for diagnosing acute pancreatitis?<br />&nbsp;&nbsp;Identifying an increase in the level of pancreatic enzymes in the blood is a pivotal factor in the diagnosis<br />&nbsp;&nbsp;of acute pancreatitis (Recommendation A)<br />&nbsp;&nbsp;When the cutoff blood amylase level is set at the upperlimit of normal, it has a sensitivity of 91.7% to 100% anda specificity of 71.6% to 97.6% for the diagnosis of acutepancreatitis. If the cutoff level is set higher, specificity<br />&nbsp;&nbsp;Table 2. Symptoms and signs at onset of acute pancreatitisaSymptoms and signs No. of cases (%)improves, but sensitivity declines. When the cutoff levelis set at 1000 IU/l, specificity improves to 100%, butsensitivity declines to 60.9% (Levels 2a-4; Table 5).9,11,16–19 Sensitivity declines because (1) the blood amylaselevel does not rise as much in many patients withchronic alcoholic pancreatitis with acute exacerbationsas it does in patients with acute pancreatitis (Level2b)12,20 and (2) since the elevated blood amylase leveldeclines almost immediately and is maintained for a shorter time than are other elevated pancreatic enzymelevels, the level must be measured soon after the onset(Levels 3b-4).21,22 The blood amylase level seldom risesin acute pancreatitis caused by hyperlipidemia (Level3b).23 Because many other diseases besides pancreatitisare associated with hyperamylasemia (Table 6; Level2a),8 it is necessary to measure extrapancreatic enzymeswith high specificity for pancreatitis in order to make aproper differential diagnosis of pancreatitis. If the blood enzyme value and/or imaging findings do not allow for adiagnosis of acute pancreatitis in a patient with ascites,the amylase level in the ascitic fluid may be useful in making the diagnosis. However, it is not usually very useful, because the amylase level in the ascitic fluid<br />&nbsp;&nbsp;sometimes increases in other diseases, including alimentary tract perforation.<br />&nbsp;&nbsp;P-amylase (amylase isozyme)<br />&nbsp;&nbsp;The blood P-amylase level is considered useful in thedifferential diagnosis of hyperamylasemia, and, whileone report claimed it could identify 83% of patients (19/23) with hyperamylasemia independent of pancreaticdisease (Level 4),24 others suggest a capability of only20% to 44% (Levels 3b-4).16,19 There is a report describing the blood P-amylase level as a useful indicator, because the abnormally high level is maintained for longerthan are the abnormal blood amylase levels in acutepancreatitis (Levels 3b),25 but another report showedthat the blood P-amylase level did not improve sensitivity or specificity (Level 2b).17 The diagnostic value of theP-amylase level for acute pancreatitis requires furtherstudy.<br />&nbsp;&nbsp;Blood elastase-1 and other pancreatic enzymes<br />&nbsp;&nbsp;Clinically measurable extrapancreatic enzymes can beroughly classified into blood and urine amylase, Pamylase (amylase isozyme), and serum lipase, whoseenzymatic activity is measured by an enzyme-chemicalmethod; and serum elastase-1, serum trypsin, and serumphospholipase A2 (PLA2), whose antigen levels aremeasured immunologically. Because the immunologicalmeasurements require a lot of time, it is difficult to usethem as a routine procedure for the diagnosis of acutepancreatitis. A latex agglutination method has enabledthe rapid, convenient measurement of the serumelastase-1 level. Elastase-1 has the advantage of maintaining an abnormally high value for longer than thelevels of other pancreatic enzymes (Level 3b),26,27 although the ability to diagnose or assess the severity ofacute pancreatitis (Level 2b)28 was not improved by thecombined use of the serum elastase-1 and blood amylase levels.<br />&nbsp;&nbsp;Trypsin is a key enzyme present at the onset of acutepancreatitis, but its activity cannot be measured, because it is too rapidly inactivated by protease inhibitorsin the blood, and therefore the quantity of the antigenshould be measured immunologically. Blood trypsin hashigh sensitivity for the diagnosis of acute pancreatitis(Level 2b).23,29 The blood PLA2 level rises markedly inacute pancreatitis and is correlated with the severity(Levels 3b-4).30,31 Qualitative evaluation of urine trypsinogen-2 with test paper to determine its rate of positiv ity in acute pancreatitis has shown that it has a diagnostic ability similar to that of lipase, and it is expected tobe useful in early diagnosis (Levels 3b-4).32,33<br />&nbsp;&nbsp;Imaging examinations<br />&nbsp;&nbsp;Ultrasonography (US)<br />&nbsp;&nbsp;CQ4. Is US effective in diagnosing acute<br />&nbsp;&nbsp;pancreatitis?<br />&nbsp;&nbsp;Ultrasonography (US) is one of the diagnostic<br />&nbsp;&nbsp;procedures that should be performed first in all<br />&nbsp;&nbsp;patients suspected of having acute pancreatitis (Recommendation A)<br />&nbsp;&nbsp;Ultrasonography (US) is capable of identifying pancreatic enlargement and inflammatory changes near thepancreas, and it may be useful in diagnosing acute pancreatitis. Although, in severe cases, visualization of thepancreas and peripancreatic tissue may be impaired bygas in the intestinal tract (Levels 1b-2b),34,35 the visualization rate is 62% to 90% for the pancreas, 100% forthe peripancreatic tissue in the anterior paranephriccavity, 90% in the cavity of the lesser omentum, and65% in the mesentery (Levels 1b-2b).34,35 Ultrasonography may also visualize abnormal findings associatedwith the etiology and morbidity of acute pancreatitis,such as ascites, gallstones, and cholangiectasis. It isparticularly important to check for the presence ofcholecholithiasis and cholangiectasis when judgingwhether endoscopic sphincterotomy for gallstone pancreatitis is required. It is desirable to examine patientsrepeatedly, using US, even when no gallstones are detected by the initial examination. US is also useful forscreening for comorbidities such as aneurysms.<br />&nbsp;&nbsp;Magnetic resonance imaging (MRI)<br />&nbsp;&nbsp;CQ5. Is MRI effective in diagnosing acute pancreatitis?<br />&nbsp;&nbsp;MRI is one of the most important imaging procedures<br />&nbsp;&nbsp;for the diagnosis of acute pancreatitis and its<br />&nbsp;&nbsp;intraabdominal complications (Recommendation B)<br />&nbsp;&nbsp;MRI scanning visualizes pancreatic enlargement andthe inflammatory changes around the pancreas (Level2c)37 and can distinguish the intestinal tract from thenecrotic part of the pancreas. Gadolinium-DTPA (GdDTPA)-enhanced MRI can visualize foci of pancreaticnecrosis (Level 2b).38 MRI accurately depicts the stateof necrosis, the main pancreatic ducts, and the extent ofinflammation, and it has more value than CT (Levels2b-3c).39,40 MRI scanning has the advantage of no X-ray exposure. However, because MRI takes much longerthan CT scanning and requires the removal of all metalobjects (such as respirators and transfusion pumps) before the examination, it is not routinely used to diagnoseacute pancreatitis in Japan, where the system for MRIuse is not yet adequate. However, magnetic resonancecholangiopancreatography (MRCP) is often required toidentify the etiology of acute pancreatitis, such ascholecholithiasis (Level 4)41 and abnormal pancreaticocholedochal junction (abnormal junction of thepancreatobiliary ducts; Level 4).42 MRI scanning can beperformed earlier than CT, because it requires nooperation of the duodenal papilla and there is no riskof aggravating acute pancreatitis. Although MRCP isnoninvasive, it has the disadvantages of less clear imaging than endoscopic retrograde cholangiopancreatography (ERCP) and impaired visualization due toperipancreatic fluid collection.<br />&nbsp;&nbsp;Computed tomography (CT)<br />&nbsp;&nbsp;CQ6. Is CT effective in diagnosing acutepancreatitis?CT is one of the most important imaging proceduresfor the diagnosis of acute pancreatitis and its intraabdominal complications. CT should be performed whenthe diagnosis of acute pancreatitis cannot be established on the basis of the clinical findings and theresults of blood and urine tests and US, or when theetiology of the pancreatitis is unknown (Recommendation B)CT is unaffected by the adipose tissue in the abdominalwall and inside the abdominal cavity, and it provides clear local images (Level 1b).34 CT findings useful forthe diagnosis of acute pancreatitis include an enlargedpancreas, inflammatory change around the pancreas,fluid collections, uneven density of the pancreatic parenchyma, and traumatic disruption of the pancreas<br />&nbsp;&nbsp;(Figs. 1, 2, and 3). Gas patterns visualized inside andaround the pancreas are often due to fistula formationwith the intestinal tract and infection by gas-forminganaerobes (Level 1c).36<br />&nbsp;&nbsp;CT scanning allows for the differentiation ofacute pancreatitis from other intraabdominal diseases,such as perforation caused by a gastroduodenal ulcer,and it allows the diagnosis of comorbidities in intraabdominal organs and complications of pancreatitis; it isalso an important procedure for assessing the severity of acute pancreatitis and selecting a treatment plan. CTscanning is especially needed in severe acute pancreatitis, where adequate information cannot be obtained byUS because of abdominal pain and the complication ofileus.<br />&nbsp;&nbsp;Plain X-rays<br />&nbsp;&nbsp;CQ7. Are plain X-ray examinations useful in diagnosing acute pancreatitis?When acute pancreatitis is suspected, chest and abdominal X-ray examinations should be performed tocheck for the presence of any abnormal findings causedby acute pancreatitis (Recommendation A)Abdominal X-ray examinations in acute pancreatitisvisualize ileus, localized sentinel loop signs in the leftupper abdomen, enlarged duodenal loops and gascollections, colon cutoff signs in the right colon, retroperitoneal gas collection, calcified gallstones, andpancreatolithiasis.Chest X-rays visualize pleural effusion, acute respiratory distress syndrome (ARDS), and pneumonia. Noneof these findings, however, are specific enough to makea diagnosis of acute pancreatitis (level 4).44 X-ray examinations are necessary, however, to evaluate the clinicalcourse of acute pancreatitis and to differentiate acutepancreatitis from other diseases, such as alimentarytract perforation.', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('49', '34', 'M06_004', '1', '鹿角形肾结石评估(2011)', null, '中华医学会泌尿外科学分会(CUA)', '2011', '那彦群, 叶章群, 孙光.中国泌尿外科疾病诊断治疗指南[M].北京：人民卫生出版社，2011.', '中文', null, '鹿角形肾结石', null, null, null, null, '无石率', '“无石率”（stone free rates）是指在某一组研究对象中，在结石治疗后的特定阶段内复查 X 线照片、B超或者CT扫描，将之与术前对比，确认为“无石”的患者的数量占所有研究对象的比率。由于鹿角形肾结石需要多次的系列治疗，因此，无石率的评价可分为三个阶段：①首次治疗后的无石率；②所有主要治疗后的无石率（主要是指用同一种方法进行完全治疗后，如SWL）；③所有治疗后的无石率。因此，对比不同治疗方法的无石率时，应注意区分评价时不同的治疗方法所处的治疗阶段是否相同。目前大部分学者所统计的无石率均是指首次治疗后的无石率，如果用这些数据来评估所有治疗后的无石率就会出现偏低的结果。', '本指南的制定原则以循证医学为基础，同时广泛征求专家意见，因此属于循证医学指南与专家共识的结合。自2006年出版以来，已经做过三次更新，从最初的4个疾病“指南”扩增到现在的23个“指南”。我们相信，随着《中国泌尿外科疾病诊断治疗指南》不断地更新和推广，必将对中国泌尿外科疾病诊断治疗的规范化和合理化起到巨大的推动作用。\n本书是《2011版中国泌尿外科疾病诊断治疗指南》，由那彦群、叶章群和孙光主编。介绍了23个泌尿外科疾病的诊断治疗，包括：肾细胞癌、膀胱癌、睾丸肿瘤、阴茎癌、良性前列腺增生、前列腺炎、膀胱过度活动症、女性压力性尿失禁、神经源性膀胱、尿石症等。\n', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('490', '49', 'Y05_019', '1', 'AGA研究所急性胰腺炎声明', 'AGA Institute Medical Position Statement on Acute Pancreatitis', 'AGA Institute', '2007', 'http://www.gastro.org/guidelines/2014/03/04/acute-pancreatitis', '英文', null, 'Acute Pancreatitis', null, null, 'Diagnosis<br />&nbsp;&nbsp;● The diagnosis of acute pancreatitis should be established within 48 hours of admission. The diagnosisshould be based on compatible clinical features andelevations in amylase or lipase levels. Elevations inamylase or lipase levels greater than 3 times theupper limit of normal, in the absence of renal failure,are most consistent with acute pancreatitis. Elevations in amylase or lipase levels less than 3 times theupper limit of normal have low specificity for acutepancreatitis and hence are consistent with, but notdiagnostic of, acute pancreatitis. Elevation of lipaselevels is somewhat more specific and is thus preferred.<br />&nbsp;&nbsp;● Acute pancreatitis should be considered among thedifferential diagnoses in patients admitted with unexplained multiorgan failure or the systemic inflammatory response syndrome.<br />&nbsp;&nbsp;● Confirmation of the diagnosis, if required, is bestachieved by computed tomography (CT) of the abdomen using intravenous contrast enhancement.Clinicians should be aware that an early CT (within72 hours of illness onset) might underestimate theamount of pancreatic necrosis.<br />&nbsp;&nbsp;Assessment of Severity<br />&nbsp;&nbsp;● Clinicians should define severe disease by mortalityor by the presence of organ failure and/or localpancreatic complications including pseudocyst, necrosis, or abscess. Multiorgan system failure andpersistent or progressive organ failure are mostclosely predictive of mortality and are the most reliable markers of severe disease.<br />&nbsp;&nbsp;● The prediction of severe disease, before its onset, isbest achieved by careful ongoing clinical assessmentcoupled with the use of a multiple factor scoringsystem and imaging studies. The Acute Physiologyand Chronic Health Evaluation (APACHE) II systemis preferred, utilizing a cutoff of 8. Those withpredicted or actual severe disease, and those with© 2007 by the AGA Institute0016-5085/07/$32.00doi:10.1053/j.gastro.2007.03.066<br />&nbsp;&nbsp;AGA<br />&nbsp;&nbsp;INSTITUTE<br />&nbsp;&nbsp;GASTROENTEROLOGY 2007;132:2019 –2021other severe comorbid medical conditions, should bestrongly considered for triage to an intensive careunit or intermediate medical care unit.<br />&nbsp;&nbsp;● Rapid-bolus contrast-enhanced CT should be performed after 72 hours of illness to assess the degreeof pancreatic necrosis in patients with predictedsevere disease (APACHE II score 8) and in thosewith evidence of organ failure during the initial 72hours. CT should be used selectively based on clinical features in those patients not satisfying thesecriteria.<br />&nbsp;&nbsp;● Laboratory tests may be used as an adjunct toclinical judgment, multiple factor scoring systems,and CT to guide clinical triage decisions. A serumC-reactive protein level 150 mg/L at 48 hoursafter disease onset is preferred.', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('491', '49', 'Y05_020', '1', 'IAP/APA急性胰腺炎的循证管理指南', 'IAP/APA evidence-based guidelines for the management of acute\npancreatitis', 'Working Group IAP/APA Acute Pancreatitis Guidelines', '2013', 'http://www.internationalpancreatology.org/', '英文', null, 'Acute Pancreatitis', null, null, 'A. Diagnosis of acute pancreatitis and etiology<br />&nbsp;&nbsp;1. The definition of acute pancreatitis is based on the fulfillment of ‘2 out of 3’ of the following criteria: clinical (upper abdominal pain), laboratory (serum amylase or lipase>3x upper limit of normal) and/or imaging (CT, MRI, ultrasonography) criteria.(GRADE 1B, strong agreement)<br />&nbsp;&nbsp;2. On admission, the etiology of acute pancreatitis should be determined using detailed personal (i.e. previous acute pancreatitis, known gallstone disease, alcohol intake,medication and drug intake, known hyperlipidemia, trauma, recent invasive procedures such as ERCP) and family history of pancreatic disease, physical examination,laboratory serum tests (i.e. liver enzymes, calcium, triglycerides), and imaging (i.e. right upper quadrant ultrasonography).(GRADE 1B, strong agreement)<br />&nbsp;&nbsp;3. In patients considered to have idiopathic acute pancreatitis, after negative routine work-up for biliary etiology, endoscopic ultrasonography (EUS) is recommended asthe first step to assess for occult microlithiasis, neoplasms and chronic pancreatitis. If EUS is negative, (secretin-stimulated) MRCP is advised as a second step to identifyrare morphologic abnormalities. CT of the abdomen should be performed. If etiology remains unidentified, especially after a second attack of idiopathic pancreatitis,genetic counseling (not necessarily genetic testing) should be considered.(GRADE 2C, weak agreement)', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('492', '49', 'Y05_022', '1', 'Rosemont诊断分层', null, null, '2009', 'Catalano et al, Gastrointest Endosc 2009;69:1251-61.', '英文', null, 'chronic Pancreatitis ', null, null, null, null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('493', '49', 'Y05_023', '1', '急性胰腺炎的新的诊断标准JPN Guidelines 2010', 'New diagnostic criteria of acute pancreatitis', 'Japanese Society of Hepato-Biliary-Pancreatic Surgery and Springer 2009', '2010', 'http://www.jshbps.jp/en/guideline/jpn-guideline2010.html', '英文', null, 'Acute Pancreatitis', null, null, 'Acute abdominal pain and tenderness in the upperabdomen.2. Elevated levels of pancreatic enzymes in the blood orurine.3. Abnormal findings of acute pancreatitis detected by US,CT or MRI.<br />&nbsp;&nbsp;Patients who present with at least two of the abovethree manifestations and in whom other pancreatic diseases and acute abdomen have been ruled out are diagnosed as having acute pancreatitis. However, acuteaggravation in chronic pancreatitis should be included asthe category of acute pancreatitis.<br />&nbsp;&nbsp;Note: Measurement of pancreatic enzymes (such aspancreatic amylase and lipase) with high specificity forthe pancreas is desirable.<br />&nbsp;&nbsp;In the diagnostic criteria of acute pancreatitis establishedby the Japanese Ministry of Health, Labour, and Welfare2008 [1], a diagnosis of acute pancreatitis is made if thepatient presents with at least two of the following threemanifestations: acute attack of abdominal pain and tenderness in the upper abdomen, elevated levels of pancreaticleaking enzymes and findings of the pancreas detected byUS, CT or MRI. Because individual cut-off levels differdepending upon reports (Table 1) [2–13], at present there isneither sufficient evidence nor consensus to support thesetting of cut-off levels.<br />&nbsp;&nbsp;Indicated for differential diagnosis is acute abdomencausing abdominal pain, which also arises from perforationof the alimentary tract, acute cholecystitis, ileus, mesenteric artery occlusion and acute aortic dissection.Clinical symptoms and signs<br />&nbsp;&nbsp;CQ2 What are clinical symptoms and signs in patients inwhom acute pancreatitis is suspected?Acute pancreatitis should be differentiated from otherabdominal diseases in patients who have acute onset ofabdominal pain and tenderness mainly in the upperabdomen (Recommendation A)It is reported that more than 90% of patients with acutepancreatitis complain of abdominal pain (Y05_023_biao1) (Level3b–5) [14–16]. Clinical symptoms and signs most characteristic of acute pancreatitis are acute attack ofabdominal pain and tenderness in the upper abdomen. Itis reported that abdominal pain occurs most frequently inthe upper abdomen followed by the whole abdomen,while tenderness occurs most frequently in the wholeabdomen followed by the upper abdomen and the right upper abdomen (Table 3) (Level 4) [17]. There are cases<br />&nbsp;&nbsp;in which acute pancreatitis is not accompanied byabdominal pain, although this occurs very rarely (Level2b) [18]. Of all the patients with abdominal pain, therate of acute pancreatitis is reported to be 0.9%(n = 1000) (Level 2b) [19] and that the rate of acutepancreatitis is 1.6% (n = 6317) when there is abdominalpain of acute onset in patients under 50 years of age and7.3% (n = 2406) in patients over 50 years of age (Level4) [20]. On the other hand, it is reported that the rate is2–3% in the case of acute abdomen (Level 2b, 5) [21,22]. Except for abdominal pain, symptoms and signsobserved frequently include pain radiating to the back,anorexia, fever, nausea and vomiting, and decreasedbowel sound (Table VI-1, 2) (Level 3b–5) [14–16].Hematological examination and urinalysis<br />&nbsp;&nbsp;CQ3 Which pancreatic enzyme measurements are important<br />&nbsp;&nbsp;in making a diagnosis of acute pancreatitis?<br />&nbsp;&nbsp;Measurement of blood lipase is most useful for thediagnosis of acute pancreatitis (Recommendation A) When the measurement of blood lipase is difficult, bloodamylase (pancreatic amylase) should be measured (Recommendation A)Detection of elevated levels of blood pancreaticenzymes is crucial in the diagnosis of acute pancreatitis.The diagnostic ability of measurements of various types ofpancreatic enzymes is listed in Table 1.Among several pancreatic enzymes, blood amylase isused most widely because it can be measured rapidly.However, blood lipase is reported to be superior to bloodamylase in terms of sensitivity and specificity [23–27](Level 3b, 5). By comparison of values of various pancreatic enzymes for diagnosing acute pancreatitis (Level2a) [28, 29], blood lipase has similar sensitivity to bloodamylase but with superior specificity (Tables 4, 5), someasurement of blood lipase is recommended rather thanblood amylase for the diagnosis of acute pancreatitis.Addition of measurements of blood amylase to blood lipaseresulted in no improvement in the diagnostic ability ofacute pancreatitis [30].<br />&nbsp;&nbsp;Blood lipase<br />&nbsp;&nbsp;The sensitivity and specificity of blood lipase in adiagnosis of acute pancreatitis are reported to be 85–100and 84.7–99.0%, respectively (Level 2a) [28] and bloodlipase is shown to be more sensitive than blood amylase(Level 2b–3b) [4, 31, 32] (Table 1). Abnormal values ofblood lipase last longer than those of blood amylase(Level 2b) [33], so blood lipase is useful in a diagnosisof acute pancreatitis when blood amylase level is normal.Also, blood lipase has almost equal diagnostic value asthat of blood p-amylase (Level 2b) [32]. Blood lipase isalso reported to be useful because of its high sensitivityin a diagnosis of alcohol-induced acute pancreatitis(Level 2b) [34].<br />&nbsp;&nbsp;Blood amylase (total blood amylase)The sensitivity and specificity of blood amylase in adiagnosis of acute pancreatitis are not constant because ofthe difference in the diagnostic grounds of acute pancreatitis and the cutoff level that has been set. When the cutoffblood amylase level is set at the upper limit of normal, itssensitivity and specificity are 91.7–100 and 71.6–97.6%,respectively. On the other hand, when the cutoff level is sethigher, specificity improves but sensitivity decreases. It isshown that at the cutoff level of 1000 IU/L, specificity risesup to 100% while sensitivity goes down to 60.9% (Level2a–3b) [2, 3, 8–11, 13, 25, 28, 35] (Table 1).<br />&nbsp;&nbsp;There are the following factors contributing to decreasedblood amylase sensitivity. Blood amylase levels do notincrease in many cases of alcohol-induced acute pancreatitis, especially when chronic pancreatitis is present in thebackground (Level 2b) [31, 36]. Compared with otherpancreatic enzymes, blood amylase levels decrease soonafter the onset of the disease and an abnormal high levellasts for only a short time. Therefore, if the passage of timefrom the onset of the disease to the hospital visit is long,the level may return to normal (Level 3b) [37, 38]. There isalso a report showing that blood amylase levels seldom risein the case of acute pancreatitis caused by hyperlipidemia(Level 3b) [39] A hole regarding blood amylase levels in a diagnosis ofacute pancreatitis is that an abnormal high level is oftendetected in diseases other than pancreatic diseases(Table 6) and that blood amylase has poor specificity fordiagnosis (Level 2a) [30].<br />&nbsp;&nbsp;p-Amylase (amylase isozyme)<br />&nbsp;&nbsp;There is a study reporting that, by measuring the blood pamylase level, a differential diagnosis of hyperamylasemianot associated with pancreatic diseases was made in 83%(19/23 cases) of patients with hyperamylasemia (Level 4)[40]. On the other hand, there are reports showing that thedifferential ability of measurements of blood p-amylasewas 20–44% (Level 3b) [11, 13]. According to anotherreport, no improvement was observed in sensitivity andspecificity compared with blood amylase and other bloodpancreatic enzymes (Level 2b) [2] (Table 1). The usefulness of blood p-amylase in making a diagnosis of acutepancreatitis is therefore not certain. Urine amylase<br />&nbsp;&nbsp;Urine amylase has shown high sensitivity in a diagnosis ofacute pancreatitis in the past (Level 2b) [41]. However,comparison with blood amylase and other blood pancreaticenzymes found that, at present, measurements of urineamylase have no superiority in diagnostic ability to measurements of other blood pancreatic enzymes (Level 2b–3b)<br />&nbsp;&nbsp;[42, 43].<br />&nbsp;&nbsp;Blood esterase 1<br />&nbsp;&nbsp;Esterase 1 is characterized by keeping an abnormal highlevel longer than any other pancreatic enzymes (Level2b–3b) [44, 45], so its measurement is considered usefulwhen medical examination is conducted after a long timehas passed since the onset of the disease. A study reportsthat blood esterase 1 has no additional value in thediagnosis of acute pancreatitis and severity assessment(Level 2b) [46]. However, it is also reported that esterase1 is as suitable as amylase and lipase in terms of clinicalusefulness including sensitivity and specificity becauserapid and simple measurement has recently become possible (Table 1) [10].<br />&nbsp;&nbsp;Other blood pancreatic enzymes<br />&nbsp;&nbsp;Trypsin is a key enzyme involved in the onset of acutepancreatitis and is inactivated rapidly by protease inhibitorsin the blood, so determination of its enzymatic activity isdifficult. However, it is determined as an antigen quantityby an immunological method. Measurement of the bloodtrypsin level in acute pancreatitis shows that it has highsensitivity for acute pancreatitis (Level 2b–3b) [39, 47].Furthermore, there are reports that blood phospholipase A2(PLA2) increases remarkably in acute pancreatitis and itslevel is correlated with the severity of the disease (Level3b) [48, 49]. However, determination of both enzymesdepends upon the immunological method, which makesrapid determination difficult. Therefore, their measurementis not suitable for making a diagnosis of acute pancreatitisin clinical settings.<br />&nbsp;&nbsp;Other urine pancreatic enzymes<br />&nbsp;&nbsp;Trypsinogen-2, one of the precursors of trypsin, belongs tothe group of pancreatic enzymes and is excreted into theurine in the early phase of acute pancreatitis. Recently,there are several studies that reported a method that uses astick resembling test paper to examine the presence orabsence of an elevated level of urine trypsinogen-2 within5 min or so (Level 2b) [5, 7–9, 35, 50, 51]. Clinical valueof this method including its sensitivity and specificity is ashigh as that of amylase and lipase (Table 7). Particularly,recent studies report that sensitivity and negative predictivevalue (NPV) are both 100% [5, 12, 50]. This is a rapid andsimple method, so its measurement is also a promisingprocedure for general clinicians.<br />&nbsp;&nbsp;Diagnostic imaging<br />&nbsp;&nbsp;Plain chest-abdominal roentgenography<br />&nbsp;&nbsp;CQ4 Is plain chest-abdominal roentgenography necessary<br />&nbsp;&nbsp;for the diagnosis of acute pancreatitis?<br />&nbsp;&nbsp;Plain chest-abdominal roentgenography is necessarywhen acute pancreatitis is suspected (Recommendation A)Because both plain chest and abdominal roentgenographicfindings associated with acute pancreatitis are not specific,it is impossible to make a diagnosis of acute pancreatitisusing this method (Level 4) [52]. However, plain chest andabdominal roentgenography is a crucial test in patients withacute pancreatitis for the differential diagnosis from otherdiseases such as alimentary tract perforation as well as forassessing the clinical course.<br />&nbsp;&nbsp;Findings in acute pancreatitis detected by plain X-rayexaminations include images of ileus, colon cut-off signs,images of localized sentinel loop signs in the left upperabdomen, images of dilated duodenal loops and gas collection, and images of retroperitoneal gas collection. Coloncut-off signs are reported to be a result that the narrowingof the inner spaces of colon by the spread of inflammationarises from the extension of fluid collection and fat necrosisas far as the transverse mesocolon, phrenicocolic ligamentsand the left or right anterior paranephric cavities, causesthe dilatation of the mouth side of the colon [53–55] (Level4). Most of the colon cut-off signs are observed in thesplenic flexura or descending colon, followed by thetransverse colon. Findings detected by plain chest andabdominal X-ray examinations include images suggestingthe presence of such conditions as collection of pleuraleffusion, acute respiratory distress syndrome (ARDS) andpneumonia. Ultrasonography, which enables visualization of findingsassociated with acute pancreatitis such as pancreaticenlargement, inflammatory changes around the pancreasand ascites, is useful in making a diagnosis of acutepancreatitis. It is reported that the visualization rate ofthe pancreas by US is 62–90% and that of inflammatorychanges around the pancreas are 62–90% for the anteriorparaphrenic cavity, 90% for the lesser momentum, and65% for the mesentery, respectively (Level 1b–2b) [56,57]. Visualization of the pancreas and parapancreatictissues may be poor in severe cases under the influenceof images of intra-intestinal retention of gas bubbles(Level 1b–2b) [56, 57]. US is also effective in detectingbiliary lithiasis responsible for acute pancreatitis anddifferentiating acute pancreatitis from other abdominaldiseases.<br />&nbsp;&nbsp;CT<br />&nbsp;&nbsp;CQ6 Is CT useful in making a diagnosis of acute pancreatitis?<br />&nbsp;&nbsp;CT is useful when acute pancreatitis is suspected (Recommendation A)CT should be performed aggressively when a definitivediagnosis of acute pancreatitis on the basis of clinicalmanifestations, hematological examination, urinalysisand US is impossible. CT enables visualization ofobjective local images of the pancreas free from theinfluence of gas bubbles in the alimentary tract and fattytissues in the abdominal wall and cavity (Level 1b) [56,58, 59], so it is the most useful imaging examination formaking a diagnosis of acute pancreatitis. It is also usefulin a differential diagnosis from other intra-abdominaldiseases such as perforation associated with gastroduodenal ulcer.<br />&nbsp;&nbsp;CT findings useful in a diagnosis of acute pancreatitisinclude the enlargement of the pancreas, increased concentrations of adipose tissue in the parapancreatic andretroperitoneal cavities (mainly in an anterior pararenalspace) and mesocolon and mesenteriolum, fluid collection,pseudocyst formation, uneven density of the pancreaticparenchyma, pancreatic necrosis, fatty necrosis in the retroperitoneal space and mesentery, hematoma, images ofpancreatic fissure associated with trauma [60] (Figs. 1, 2,3). Gas images in and around the pancreas are often causedby fistula formation between the intestinal tract andinfections with gas-forming bacteria (Level 1c) (Fig. 4)<br />&nbsp;&nbsp;[61].<br />&nbsp;&nbsp;CT also helps in assessing the severity of acute pancreatitis because a diagnosis that is important in decidingtreatment policy has been made possible concerning complications accompanying pancreatitis and comorbidities inthe intra-abdominal organs.Ultrasonography<br />&nbsp;&nbsp;CQ5 Is ultrasonography necessary for the diagnosis of acutepancreatitis?When acute pancreatitis is suspected, ultrasonography isnecessary (Recommendation A)Ultrasonography is one of the tests to be performed atfirst in every patient in whom acute pancreatitis issuspected. <br />&nbsp;&nbsp;MRI is useful in making a diagnosis of biliary stones<br />&nbsp;&nbsp;causing pancreatitis and hemorrhagic pancreatic necrosis<br />&nbsp;&nbsp;(Recommendation B)<br />&nbsp;&nbsp;A diagnosis of edematous pancreatitis by CT is difficultwhen it is not accompanied by enlargement of the pancreasbut T2-enhanced MRI imaging enables visualization of thepancreas clearly in accordance with the severity of edema.Also, MRI has diagnostic ability similar to that of CT inmaking a diagnosis of parapancreatic fluid collection andhypertrophy of the anterior renal fascia [62, 63] (Fig. 5).Although differentiation by CT of parapancreatic fattynecrosis from fluid collection may be difficult in somecases, MRI enables clear differentiation of fatty necrosisfrom fluid according to signal strength (compared withfluid, fatty necrosis presents higher signals in T1-enhancedimaging and mildly low signals in T2-enhanced imaging)[62, 64, 65]. Hemorrhagic fatty necrosis that presents ahigh signal particularly in fat-saturation T1-enhancedimaging can be diagnosed relatively easily (Fig. 6). GdDTPA dynamic MRI imaging is able to depict foci ofpancreatic necrosis as a hyperchromatic area<br />&nbsp;&nbsp;', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('494', '49', 'Y05_024', '1', '\n急性胰腺炎:日本2015年指南', 'Japanese guidelines for the management of\nacute pancreatitis: Japanese Guidelines 2015', 'Hepato-Biliary-Pancreatic Sciences', '2015', 'http://www.jshbps.jp/en/guideline/jpn-guideline2015.html', '英文', null, 'Acute Pancreatitis', null, null, 'CQ1 Which pancreatic enzyme measurements are important<br />&nbsp;&nbsp;when diagnosing acute pancreatitis?<br />&nbsp;&nbsp;The measurement of serum lipase is recommended for the diagnosis of acute pancreatitis.However, when the measurement of lipase is difficult, serum amylase (pancreatic amylase) should be measured.(1B)<br />&nbsp;&nbsp;<Comment> The detection of elevated levels of bloodpancreatic enzymes is crucial in the diagnosis of acute pancreatitis [4, 13, 21, 45–52]. When the diagnosis acute pancreatitis cannot be differentiated from other diseases, serum lipase is superior to any other pancreatic enzymes, includingserum amylase [53] (Table 3).<br />&nbsp;&nbsp;CQ2 Is a urinary trypsinogen-2 dipstick useful in diagnosing<br />&nbsp;&nbsp;acute pancreatitis?<br />&nbsp;&nbsp;Urinary trypsinogen-2 dipstick may be useful for minimallyinvasive method and rapid diagnosis of acute pancreatitis.However, this is not commercially available in Japan andtherefore it cannot be recommended at this time.(ungraded B)<br />&nbsp;&nbsp;<Comment> The diagnosis of acute pancreatitis using aurinary trypsinogen-2 dipstick is highly effective in medicalinstitutions where a blood test cannot be examined, notrequiring blood sample, given the short time (5min) requiredfor the test, its diagnostic ability, and the fact that it is roughlyequivalent to serum pancreatic enzymes [54–56].<br />&nbsp;&nbsp;Diagnostic imaging<br />&nbsp;&nbsp;CQ3 Is ultrasonography recommended for the diagnosis of<br />&nbsp;&nbsp;acute pancreatitis?<br />&nbsp;&nbsp;When acute pancreatitis is suspected, ultrasonography is<br />&nbsp;&nbsp;recommended.<br />&nbsp;&nbsp;(1C)<br />&nbsp;&nbsp;<Comment> Ultrasonography, which enables the visualization of findings associated with acute pancreatitis such aspancreatic enlargement and inflammatory changes aroundthe pancreas, is useful in diagnosing acute pancreatitis[57, 58]. It can also visualize causes and abnormal findings associated with the pathological conditions of acute pancreatitissuch as ascites, bile duct stones and bile duct dilatation(Fig. 1). Color Doppler ultrasonography is useful in the diagnosis of pseudoaneurysm developing inside the pseudocyst [59].<br />&nbsp;&nbsp;CQ4 Is computed tomography (CT) recommended in the diagnosis of acute pancreatitis?<br />&nbsp;&nbsp;CT is recommended for the diagnosis of acute pancreatitis.(1C)<br />&nbsp;&nbsp;<Comment> When a definitive diagnosis of acute pancreatitis is not possible based on clinical findings,blood/urine tests or ultrasonography, or where the etiologyof pancreatitis is uncertain, contrast-enhanced dynamic CTshould be actively used as long as no renal function problemsare observed. Particularly in acute pancreatitis caused by pancreatic ductal stenosis due to pancreas tumors such as cancer,a simple CT alone is very likely to overlook the causative pancreatic cancer [60–62].<br />&nbsp;&nbsp;Summary of recommendation<br />&nbsp;&nbsp;A. Diagnosis<br />&nbsp;&nbsp;1 The measurement of serum lipase is recommended for the diagnosis of acute pancreatitis. However, when the measurement of lipase isdifficult, serum amylase (pancreatic amylase) should be measured. (1B)<br />&nbsp;&nbsp;2 Urinary trypsinogen-2 dipstick may be useful for minimally invasive method and rapid diagnosis of acute pancreatitis. However, this isnot commercially available in Japan and therefore it cannot be recommended at this time. (ungraded B)B. Diagnostic imaging<br />&nbsp;&nbsp;3 When acute pancreatitis is suspected, ultrasonography is recommended. (1C)<br />&nbsp;&nbsp;4 CT is recommended for the diagnosis of acute pancreatitis. (1C)<br />&nbsp;&nbsp;5 MRI is more useful than CT in diagnosing bile duct stones causing pancreatitis and hemorrhagic necrotizing pancreatitis. (2C)<br />&nbsp;&nbsp;6 Contrast-enhanced CT is useful for the diagnosis of active hemorrhage and thrombosis associated with pancreatitis. (1C)', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('495', '47', 'X02_001', '0', '中医病证诊断疗效标准', ' ', ' 国家中医药管理局', '1994', '国家中医药管理局.ZY／T001.8-94中医病证诊断疗效标准·中医内科病证诊断疗效标准[S].南京：南京大学出版社，1994.', '中文', null, '消化性溃疡；Peptic Ulcer ；Gastroduodenal Ulcer； Marginal Ulcer', '胃脘痛', '1.肝胃气滞<br />&nbsp;&nbsp;2.寒邪犯胃<br />&nbsp;&nbsp;3.胃热炽盛<br />&nbsp;&nbsp;4.食滞胃肠<br />&nbsp;&nbsp;5.瘀阻胃络<br />&nbsp;&nbsp;6.胃阴亏虚<br />&nbsp;&nbsp;7.脾胃虚寒', '胃脘痛的诊断依据胃脘部疼痛，常伴痞闷或胀满、嗳气、泛酸、嘈杂、恶心呕吐等症。发病常与情志不畅、饮食不节、劳累、受寒等因素有关。上消化道钡餐X线检查、纤维胃镜及组织病理活检等，可见胃、十二指肠粘膜炎症、溃疡等病变。大便或呕吐物隐血试验强阳性者，提示并发消化道出血。B超、肝功能、胆道X线造影有助于鉴别诊断。', '1.肝胃气滞：胃脘痞胀疼痛或攻窜胁背，嗳气频作。苔薄白，脉弦。<br />&nbsp;&nbsp;2.寒邪犯胃：胃脘冷痛暴作，呕吐清水痰涎，畏寒喜暖，口不渴。苔白，脉弦紧。<br />&nbsp;&nbsp;3.胃热炽盛：胃痛急迫或痞满胀痛，嘈杂吐酸，心烦，口苦或粘。舌质红，苔黄或腻，脉数。<br />&nbsp;&nbsp;4.食滞胃肠：胃脘胀痛，嗳腐吞酸或呕吐不消化食物，吐后痛缓。苔厚腻，脉滑或实。<br />&nbsp;&nbsp;5.瘀阻胃络：胃痛较剧，痛如针刺或刀割，痛有定处，拒按，或大便色黑。舌质紫暗，脉涩。<br />&nbsp;&nbsp;6.胃阴亏虚：胃痛隐作，灼热不适，嘈杂似饥，食少口干，大便干燥。舌红少津，脉细数。<br />&nbsp;&nbsp;7.脾胃虚寒：胃痛绵绵，空腹为甚，得食则缓，喜热喜按，泛吐清水，神倦乏力，手足不温，大便多溏。舌质淡，脉沉细。\n', null, '治愈：胃脘痛及其它症状消失，X线钡餐造影或胃镜检查正常。\n好转：胃痛缓解，发作次数减少，其他症状减轻，X线钡餐造影或胃镜检查有好转。\n未愈：症状无改善，X线钡餐造影或胃镜检查无变化。\n', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('496', '47', 'X02_002', '1', '临床诊疗指南消化系统疾病分册', null, '中华医学会', '2004', null, '中文', null, null, null, null, '疼痛性质及时间：空腹痛、灼痛、胀痛、隐痛。十二指肠溃疡有空腹痛、半夜痛，进食可以缓解。胃溃疡饭后半小时后痛，至下餐前缓解。（3）患病的周期性和疼痛的节律性：每年春秋季节变换时发病。（4）诱因：饮食不当或精神紧张等。2.其他症状：可以伴有反酸、烧心、嗳气等消化不良症状。3.体征（1）上腹部压痛：十二指肠溃疡压痛偏右上腹，胃溃疡偏左上腹。（2）其他体征取决于溃疡并发症，幽门梗阻时可见胃型及胃蠕动波，溃疡穿孔时有局限性或弥漫性腹膜炎的体征。4.特殊类型的溃疡：包括胃及十二指肠复合溃疡、幽门管溃疡、球后溃疡、老年性溃疡及胃泌素瘤。特殊类型的溃疡不具备典型溃疡的疼痛特点，往往缺乏疼痛的节律性。胃泌素瘤患者多有顽固性症状和多发性难治性溃疡，手术后近期多复发，有的伴有水泻或脂肪泻。<br />&nbsp;&nbsp;诊断要点1、临床表现：消化性溃疡往往具有典型的临床症状，但要注意特殊类型溃疡症状往往不典型。还有极少数患者无症状，甚至以消化性溃疡的并发症如穿孔、上消化道出血为首发症状。2.体征：消化性溃疡除在相应部位有压痛之外，无其他对诊断有意义的体征。但要注意，如患者出现胃型及胃蠕动波揭示有幽门梗阻，如患者出现局限性或弥漫性腹膜炎体征，则提示溃疡穿孔。3.胃镜检查：胃镜可对消化性溃疡进行最直接的检查，而且还可以取活体组织作病理和幽门螺杆菌检查。内镜检查应该包括溃疡的部位、大小、数目以及溃疡的分期：活动期（A1，A2)、愈合期（H1，H2)、瘢痕期（S1，S2）。对胃溃疡应常规取活体组织作病理检查。4、X线钡餐检查：气钡双重对比可以显示X线的直接征象（具有诊断意义的龛影）和间接征象（对诊断有参考价值的局部痉挛、激惹及十二指肠球部变形）。5.幽门螺杆菌检查：通过胃镜可以取胃窦粘膜作快速尿素酶试验、组织学检查或者作HP培养。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('497', '47', 'X02_003', '1', '中医内科常见病诊疗指南西医疾病部分', null, '中华中医药学会', '2008', 'ZYYXH/T50～135—2008，中医内科常见病诊疗指南[M].中国中医药出版社，2008', '中文', null, null, null, '1.肝胃不和证<br />&nbsp;&nbsp;2.肝胃郁热证<br />&nbsp;&nbsp;3.脾胃虚寒证<br />&nbsp;&nbsp;4.脾胃湿热证<br />&nbsp;&nbsp;5.胃阴不足证<br />&nbsp;&nbsp;6.胃络瘀阻证', '1诊断依据1.1临床表现1.1.1症状：上腹部疼痛是溃疡病最常见的症状之一，常呈节律性、周期性和长期性的特点，每年春秋季节变化时易发病。疼痛的性质常为空腹痛、隐痛、灼痛、胀痛。胃溃疡疼痛发生于进餐半小时后，至下餐前缓解。如发生在幽门管的溃疡则上腹痛的节律性不明显。十二指肠溃疡疼痛为空腹痛、半夜痛，进食后可以缓解。发生在十二指肠球部以下的球后溃疡，多表现为夜间痛及背部放射痛。胃溃疡的疼痛部位在上腹部偏左，十二指肠溃疡在上腹部或偏右，后壁穿透性溃疡疼痛可放射至背部7～12胸椎区。消化性溃疡的发作可伴有嗳气、烧心、反酸、恶心、呕吐等症状。9％～25％的患者，尤其是老年人常无上腹部疼痛等典型症状，而是以上消化道出血或急性穿孔等并发症为首发症状就诊。1.1.2体征：溃疡病在缓解期体征可不明显，病情发作期可有上腹部压痛，多和溃疡存在部位相一致，如胃溃疡的压痛多在剑突下左方，幽门前区溃疡多在上腹正中或稍偏右，十二指肠溃疡压痛偏右上腹。1.2理化检查\n1.2.1胃镜检查：是确诊消化性溃疡的主要方法。1.2.2X线钡餐检查：气钡双层造影可以显示X线的直接征象和间接征象。龛影是直接征象，有诊断意义。\n1.2.3幽门螺杆菌检测：按检测方法分为侵入性和非侵入性两大类。前者需通过胃镜检查取胃黏膜活组织进行检测，主要包括快速尿素酶试验、组织学检查、幽门螺杆菌培养和聚合酶链反应等；后者主要有13C或14C尿素呼气试验、粪便幽门螺杆菌抗原检测及血清学检查。1.2.4隐血检查：经3天素食后，如粪便隐血阳性，提示溃疡有活动性。1.2.5胃液分析和血清胃泌素测定：一般作为胃泌素瘤的鉴别诊断之用。1.3诊断要点1.3.1长期反复发作的周期性、节律性的上腹部疼痛，应用制酸和碱性药物可缓解。1.3.2上腹部有局限性压痛。1.3.3胃镜检查：可见到溃疡。1.3.4X线钡餐造影：见溃疡龛影。\n', '1.肝胃不和证：胃脘胀痛，连及两胁，遇情志不遂加重，嗳气或矢气则舒，嘈杂泛酸，口苦，胸闷食少，性急易怒，喜叹息，舌苔薄白，脉弦。<br />&nbsp;&nbsp;2.肝胃郁热证：胃脘灼痛，痛势急迫，泛酸嘈杂，口干口苦，喜冷饮，情绪烦躁易怒，大便干结，舌质红，苔黄，脉弦或弦数。<br />&nbsp;&nbsp;3.脾胃虚寒证：胃脘隐痛，喜温喜按，每遇冷或劳累易发作和加重，空腹痛重，得食痛减，食后腹胀，泛吐清水，畏寒肢冷，倦怠乏力，神疲懒言，大便溏薄，舌质淡嫩，边有齿印，苔薄白，脉细弱或沉细。<br />&nbsp;&nbsp;4.脾胃湿热证：胃脘疼痛，痞胀不适，纳谷不香，恶心欲吐，口苦口黏，口干不欲饮，肢重困倦，小便黄，大便溏而不爽，舌质红，苔黄腻，脉滑或滑数。<br />&nbsp;&nbsp;5.胃阴不足证：胃脘隐隐灼痛，空腹时加重，嘈杂，似饥而不欲食，口干舌燥而不欲饮，大便干结，手足心热，舌红少津、有裂纹，少苔或花剥苔，脉细数。<br />&nbsp;&nbsp;6.胃络瘀阻证：胃脘刺痛，痛处不移，入夜尤甚，胃痛剧烈，可痛彻胸背，肢冷，汗出，有呕血或黑便史，舌质紫暗或有瘀点、瘀斑，脉弦或涩。', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('498', '47', 'X02_004', '1', '常见疾病的诊断与疗效判断标准', null, '中国中医药出版社', '1999', null, '中文', null, null, null, null, '1.慢性病程，周期性发作，常与季节，精神因素，饮食不当有关，发作时有上腹灼痛，钝痛，胀痛或隐痛，服碱性药物后可缓解。典型胃溃疡疼痛部位在剑突下偏左，好发于餐后半小时到2小时，十二指肠溃疡疼痛位于上中腹偏右，好发于餐后3-4小时或半夜，进食后可缓解，常伴嗳气，反酸。2.X线钡餐检查可见龛影及你暗牧皱襞集中征象，单纯局部压痛，激惹或变形为间接征象，仅供诊断参考。3.内镜检查，可在胃、十二指肠发现圆形，椭圆形，线形，不整形或霜降样溃疡，底部平整，覆有白色或灰白色苔，边缘多整齐，无结节状隆起，周围粘膜充血水肿，有时可见皱襞向溃疡集中，活检及细胞组织学检查可排除恶性病变。具备以上1、2或1、3项可以确诊。', null, null, '1.治愈，临床症状消失，食欲正常，胃酸分泌正常，胃镜所见溃疡愈合及粘膜组织学改变基本恢复正常。2.好转，症状基本消失或减轻，胃酸分泌接近正常，胃镜所见溃疡及粘膜组织学改变减轻，或溃疡范围缩小达50%以上。', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('499', '47', 'X02_005', '1', '2002 AIHA 成人消化性溃疡的诊断与治疗草案', 'protocol for diagnosis and treatment of peptic ulcer in adults', '\n美国国际健康联盟(AIHA,American International Health Alliance)', '2002', 'Clinical Practice Guidelines for General Practitioners', '英文', '1. Gastric ulcer, including peptic ulcer of the pyloricand other parts of the stomach (CODE K-25)<br />&nbsp;&nbsp;2. Duodenal ulcer, including peptic ulcer of allparts of the duodenum (CODE K-26) <br />&nbsp;&nbsp;3. Gastrojejunal ulcer, including peptic ulcer ofgastric anastomoses, afferent and efferent intestinal loops, gastroenterostomy excluding theprimary intestinal ulcer (CODE K-28)', 'Peptic Ulcer', null, null, 'Complaintsincaseofuncomplicatedulcer:•Aching,burninglocalizedpaininepigastrium(pepticulcerdiagnosisisconfirmedinlessthan50%ofthepatientswiththementionedcomplaints)•Antacidsalleviatepain•Nocturnalpain(midnight–3A.M.)orduringintervalsbetweenmeals(painfromhunger).Thisistheleadingcomplaintfor2/3ofpatientswithduodenalulcerand1/3ofpatientswithgastriculcer.Howeverthesamecomplaintispredominatein1/3ofpatientswithdyspepsianotassociatedwithulcer.<br />&nbsp;&nbsp;•Belchingasadominatingsymptomischaracteristicforesophagealreflux,butnotforthepepticulcer.Signsofthecomplicatedulcer:•Gastrointestinalbleeding(melena,hematemesis,positivefecalbloodtest).Themostcommoncomplicationsencounteredin15-20%ofcases.•Obstruction(vomitingprecededbynausea).•Penetration,perforatedulcer(acuteabdominalpain).•Gastriccancer(weightloss,lossofappetite).Chancesfordevelopmentofgastriccancerincreasewithage.Patientsolderthan45withrecentonsetofcomplaintsrequireearlyconsultationbygastroenterologist.', null, null, 'In absence of symptoms, diagnostic procedures to confirm successful eradication may be omitted. In case of complicated ulcer, endoscopy is indicated to confirm the success of the therapy.', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('5', '10', 'D02_005', '1', '中国2型糖尿病防治指南（2013年版）', '无', '中华医学会糖尿病学分会', '2013', '中国2型糖尿病防治指南(2013年版)[J].中华糖尿病杂志;2014;6(7):447-498', '中文', null, '代谢综合征', null, null, '1.腹型肥胖：腰围男性≥90cm，女性≥85cm｡<br />&nbsp;&nbsp;2.高血糖：空腹血糖≥6.1mmol/L或糖负荷后2h血糖≥7.8mmol/L和(或)已确诊为糖尿病并治疗者｡<br />&nbsp;&nbsp;3.高血压：血压≥130/85mmHg及(或)已确认为高血压并治疗者｡<br />&nbsp;&nbsp;4.空腹TG≥1.70mmol/L｡<br />&nbsp;&nbsp;5.空腹HDL-C<1.04mmol/L｡<br />&nbsp;&nbsp;以上具备三项或更多项即可诊断｡', null, '1.体重减轻降低、BMI、腰围；<br />&nbsp;&nbsp;2.血压；<br />&nbsp;&nbsp;3.LDL-C、甘油三酯、HDL-C；<br />&nbsp;&nbsp;4.空腹血糖、负荷后2hPG、HbA1c。', '针对各种危险因素如糖尿病或糖调节受损、高血压、血脂紊乱以及肥胖等的药物治疗，治疗目标如下：<br />&nbsp;&nbsp;1.体重在一年内减轻降低7%~10%,争取达到BMI和腰围正常化；<br />&nbsp;&nbsp;2.血压：糖尿病患者<130/80mmHg，非糖尿病患者<40/90mmHg；<br />&nbsp;&nbsp;3.LDL-C<2.60mmol/L（100mg/dl）、甘油三酯<1.70mmol/L（150mg/dl）、HDL-C>1.04mmol/L（40mg/dl）（男）或>1.3mmol/L（50mg/dl）（女）；<br />&nbsp;&nbsp;4.空腹血糖<6.1mmol/L（110mg/dl）、负荷后2hPG<7.8mmol/L（140mg/dl）及HbA1c<7.0％。', '本指南在2004年CDS建议基础上，对代谢综合征的组分量化指标进行修订', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('50', '34', 'M06_005', '1', '尿路结石', null, '中华医学会肾脏病学分会', '2009', '临床诊疗指南肾脏病学分册[M].北京：人民卫生出版社,2009', '中文', null, '尿路结石', null, null, '【临床表现】<br />&nbsp;&nbsp;\n1. 症状：主要取决于结石的大小、形状、所在部位和结石对尿路的刺激和损伤，梗阻及继发感染等。<br />&nbsp;&nbsp;1.1无症状结石：肾结石可以完全无症状，甚至发生梗阻时亦无症状，而因其他原因做X 线腹部照片或B 超时偶然发现。有些病例则可能有镜下血尿，有些病例因为存在原发疾病（如甲状旁腺功能亢进或痛风）检查时发现结石。<br />&nbsp;&nbsp;1.2疼痛：患侧的腰部和上腹部隐痛、钝痛甚至绞痛，少数患者表现为对侧腰痛，多为阵发性。开始时是腰部或上腹部隐痛，逐渐加强至剧痛，疼痛常放射下腹部、腹股沟、大腿内侧或外阴部。绞痛发作时可伴有出冷汗、恶心或呕吐。肾绞痛往往在剧烈运动和旅行颠簸后发作、加剧，也可在夜间或清晨突然发生。随着结石的排出，疼痛可立即消失。<br />&nbsp;&nbsp;1.3 血尿：近75％的病人在疼痛发作时出现肉眼或镜下血尿，或从尿中排出结石。在无症状的肾结石，如有血尿，则多为轻度镜下血尿，如结石有移动，则有肉眼血尿。<br />&nbsp;&nbsp;1.4 尿路梗阻和尿路感染：结石病人由于可能引起尿路梗阻，易于发生尿路感染，可为无症状性细菌尿或有明显的尿路感染症状。梗阻再加上感染，可导致肾盏积液或积脓，进一步引起肾实质感染、疤痕形成，可发展为肾周感染。<br />&nbsp;&nbsp;1.5肾功能衰竭：独肾病人因结石堵塞输尿管，造成急性梗阻，偶亦可发生双侧输尿管堵塞造成急性肾功能衰竭。结石引起的慢性肾脏感染或梗阻性肾病均可发展为慢性肾衰竭。<br />&nbsp;&nbsp;2. 体征 体格检查可无明显阳性体征。部分患者患侧肾区可有叩击痛。输尿管走行区结石相应部位有压痛。肾绞痛发作时，病人往往大汗淋漓、面色苍白、辗转不安，在床上来回滚动，难以静卧。结石梗阻引起严重肾积水时，可在上腹部触及增大的肾脏。<br />&nbsp;&nbsp;3. 并发症 尿路结石常见并发症有尿路感染、尿路梗阻、梗阻性肾病、脓肾、肾功能衰竭。<br />&nbsp;&nbsp;\n【诊断要点】<br />&nbsp;&nbsp;1. 诊断原则<br />&nbsp;&nbsp;除确定患者结石的存在外，还应了解结石的部位、大小、数目及结石对肾脏所造成的影响，判断肾功能并加以保护。有无感染存在对尿石症的治疗和防治有重要意义。明确结石的病因，以防治结石的发展及复发。<br />&nbsp;&nbsp;$【诊断依据】<br />&nbsp;&nbsp;1. 病史和体检：病史中多有典型的腰痛、肾绞痛和血尿，或曾从尿道排出过结石。体格检查可无明显阳性体征；部分患者患侧肾区可有叩击痛。结石梗阻引起严重肾积水时，可在上腹部触及增大的肾脏；输尿管走行区结石相应部位有压痛。对于反复发生肾结石的患者，要检查颈部，注意有无肿大的甲状旁腺。<br />&nbsp;&nbsp;2. 化验检查：尿液常规检查可见红细胞、白细胞或结晶；尿pH 在草酸盐及尿酸盐结石患者常为酸性；磷酸盐结石常为硷性。合并感染时尿中出现较多的脓细胞，尿细菌学培养常为阳性，计数大于10 万/ml 以上。并发急性感染及感染较重时，血常规检查可见白细胞总数及中性粒细胞升高。多发性和复发性结石的病人，应寻找尿路结石形成的代谢因素。查血尿酸、甲状旁腺激素（iPTH）、血钙、血胱氨酸，草酸浓度。查尿钙、草酸、枸橼酸水平等。<br />&nbsp;&nbsp;3.影像学检查：对所有具有泌尿系结石临床症状的患者都应该做影像学检查，其结果对于结石的进一步检查和治疗具有重要的价值。<br />&nbsp;&nbsp;3.1.B 超检查：可以发现4mm 以上X 线阳性及阴性结石，并了解结石以上尿路的扩张程度，间接反应肾实质和集合系统的情况。超声可作为泌尿系结石的常规检查方法,尤其是在肾绞痛时作为首选方法。<br />&nbsp;&nbsp;3.2尿路平片：尿路平片可以发现大部分X 线阳性结石，能大致地确定结石的位置、形态、大小和数量。<br />&nbsp;&nbsp;3.3静脉尿路造影(IVU)：可了解尿路有无解剖异常，确定结石位置，发现尿路平片上不能显示的X 线阴性结石。还可以了解分侧肾脏的功能，确定肾积水程度。在一侧肾脏功能严重受损或者使用普通剂量造影剂而肾脏不显影的情况下，采用加大造影剂剂量(双剂量或大剂量)或者延迟拍片的方法往往可以达到肾脏显影的目的。肾绞痛发作时，由于急性尿路梗阻往往会导致尿路不显影或显影不良，因此对结石的诊断会带来困难。<br />&nbsp;&nbsp;3.4CT 扫描：尽管尿路结石诊断通常不需要CT 检查，但螺旋CT 能够检出其他常规影像学检查中容易遗漏的小结石，尤其适合急性肾绞痛患者。<br />&nbsp;&nbsp;3.5逆行或经皮肾穿刺造影：不作为常规检查手段，仅在静脉尿路造影不显影或显影不良以及怀疑是X 线阴性结石，需要作进一步的鉴别诊断时应用。<br />&nbsp;&nbsp;\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('500', '47', 'X02_006', '1', '2015 JSGE循证临床实践指南：消化性溃疡', 'Evidence-based clinical practice guidelines for peptic ulcer disease 2015.', '\n日本胃肠病学会(JSGE,Japanese Society of Gastroenterology)', '2016', 'J Gastroenterol. 2016 Feb 15.', '英文', null, 'gastric ulcers；peptic ulcer', null, null, null, null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('501', '47', 'X02_007', '1', '2002 小儿慢性胃炎、消化性溃疡胃镜诊断标准', null, '\n《中华儿科杂志》编辑委员会<br />&nbsp;&nbsp;中华医学会儿科学分会感染消化学组', '2001', '中华儿科杂志，2003,41（3）：189', '中文', '1.胃溃疡<br />&nbsp;&nbsp;2.十二指肠球部溃疡<br />&nbsp;&nbsp;3.复合性溃疡：胃溃疡和十二指肠球部溃疡并存。<br />&nbsp;&nbsp;1.活动期<br />&nbsp;&nbsp;2.愈合期<br />&nbsp;&nbsp;3.瘢痕期', null, null, null, '消化性溃疡主要指发生于胃和十二指肠的慢性溃疡。胃镜下见粘膜缺损呈圆形、椭圆形、线形、不规则形，底部平坦，边缘整齐，为白苔或灰白苔覆盖。或为一片充血粘膜上散在小白苔，形如霜斑，称“霜斑样溃疡”。<br />&nbsp;&nbsp;根据部位分型：1.胃溃疡<br />&nbsp;&nbsp;2.十二指肠球部溃疡<br />&nbsp;&nbsp;3.复合性溃疡：胃溃疡和十二指肠球部溃疡并存。<br />&nbsp;&nbsp;根据胃镜下所见分期：1.活动期：溃疡基底部有白色或灰白色厚苔，边缘整齐，周围粘膜充血、水肿、有时易出血；水肿消退，呈粘膜向溃疡集中。十二指肠溃疡有时表现为一片充血粘膜上散在小白苔，即霜斑样溃疡。2.愈合期：溃疡变浅，周围粘膜充血水肿消退，基底出现薄苔；薄苔是愈合期的标志。3.瘢痕期：溃疡基底部白苔消失，遗下红色瘢痕，以后红色瘢痕转为白色瘢痕，其四周粘膜呈辐射状，表示溃疡完全愈合，但仍可遗留轻微凹陷。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('502', '47', 'X02_008', '1', '2011 消化性溃疡中西医结合诊疗共识意见（2011年天津）', null, '中国中西医结合学会消化系统疾病专业委员会', '2011', '中国中西医结合杂志2012年6月第32卷第6期', '中文', '三期六级: 活 动 期 ( A 期、A1A2) <br />&nbsp;&nbsp;愈合期( H 期、 H1H2) <br />&nbsp;&nbsp;瘢痕期( S 期、 S1S2)', null, null, '肝气犯胃证<br />&nbsp;&nbsp;寒热错杂证<br />&nbsp;&nbsp;瘀血阻络证<br />&nbsp;&nbsp;胃阴不足<br />&nbsp;&nbsp;脾胃虚寒证', '(1)初步诊断:慢性、周期性、节律性上腹痛伴反酸者。(2)基本诊断:伴有上消化道出血、穿孔史或现症者。(3)确定诊断:胃镜发现消化性溃疡病灶(兼查Hp，方法如快速尿素酶实验或13C、14C-UBT)者。', '1.肝气犯胃证主症:(1)胃脘胀痛，窜及两胁;(2)胸闷喜叹息，遇情志不遂胃痛加重;(3)嗳气频繁;(4)脉弦。次症:(1)烦躁易怒;(2)嘈杂反酸;(3)口苦纳差;(4)舌质淡红，苔薄白或薄黄。胃镜象:(1)蠕动活跃或亢进;(2)溃疡呈圆形或椭圆形，中心覆盖黄苔或白苔较薄，周围黏膜轻度充血水肿;(3)或白苔消失呈现红色新生黏膜者。证型确定:具备主症2项加次症1项，或主症第1项加次症2项，并结合胃镜象。<br />&nbsp;&nbsp;2.寒热错杂证主症:(1)胃脘灼痛，喜温喜按;(2)口干苦或吐酸水;(3)舌淡或淡红，体胖有齿痕，苔黄白相间或苔黄腻。次症:(1)嗳气时作;(2)嘈杂泛酸;(3)四肢不温;(4)大便时干时稀。⑤脉弦细。胃镜象:溃疡覆盖黄色或白色厚苔，可溢出溃疡边缘，周围黏膜充血水肿明显。证型确定:具备主症2项加次症1项，或主症第1项加次症2项，并结合胃镜象。<br />&nbsp;&nbsp;3.瘀血阻络证主症:(1)胃脘疼痛如针刺或如刀割，痛处不移;(2)胃痛拒按，食后胃痛加重;(3)舌质紫暗或见瘀斑。次症:(1)疼痛晚间发作，或夜间痛甚;(2)呕血或黑便;(3)脉涩或沉弦。胃镜象:溃疡呈圆形或椭圆形，中心覆盖黄苔或白苔，可伴有渗血或出血或血痂，周围黏膜充血水肿明显。证型确定:具备主症2项加次症1项，或主症第1项加次症2项，并结合胃镜象。<br />&nbsp;&nbsp;4.胃阴不足证主症:(1)胃脘隐痛或灼痛;(2)嘈杂似饥，饥不欲食;(3)舌红少津裂纹、少苔、无苔或剥苔。次症:(1)口干不欲饮;(2)纳呆食少;(3)干呕;(4)大便干结;(5)脉细数。胃镜象:(1)黏液量少黏稠;(2)溃疡黄苔或白苔变薄，周围充血水肿减轻，或出现红色新生黏膜。证型确定:具备主症2项加次症1项，或主症第1项加次症2项，并结合胃镜象。<br />&nbsp;&nbsp;5.脾胃虚寒证主症:(1)胃脘隐痛，喜温喜按;(2)空腹痛重，得食痛减;(3)舌体胖，边有齿痕，苔薄白。次症:(1)面色无华;(2)神疲肢怠;(3)纳呆食少;(4)泛吐清水。(4)四肢不温;', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('502dcfc4e01c4b2c81b391b772eb6b1a', '57', 'addd', '0', 'adddaddd', '', 'adddadddadddaddd', null, '', '中文', '', '', 'adddadddaddd', '', '', '', '', '', '', '1', '0', 'admin', '2016-05-10 18:52:30', 'admin', '2016-05-10 18:52:30');
INSERT INTO `biz_standard` VALUES ('503', '47', 'X02_009', '1', '消化性溃疡病诊断与治疗规范建议(2008，黄山)', null, null, '2008', '中华消化杂志编委会. 消化性溃疡病诊断与治疗规范建议(2008,黄山)[J]. 中华消化杂志, 2008, 28(7):447-450.', '中文', null, null, null, null, '胃溃疡的腹痛多发生在餐后半小时左右，而十二指肠溃疡则常发生在空腹时，近年来，由于抗酸剂、抑酸剂等药物广泛使用，症状不典型的患者日益增多。由于NsAID有较强的镇痛作用，NSAID溃疡临床上无症状者居多，部分以上消化道出血为首发症状，也有表现为恶心、厌食、纳差、腹胀等消化道非特异性症状。<br />&nbsp;&nbsp;胃镜检查过程中应注意溃疡的部位、形态、大小、深度、病期以及溃疡周围黏膜的情况。胃镜检查对鉴别良、恶性溃疡具有重要价值。必须指出，溃疡的形态改变对病变性质的鉴别都没有绝对界限。因此，对胃溃疡应常规行活组织检查，对不典型或难愈合溃疡，要分析其原因，必要时行超声内镜检查或黏膜大块活检，以明确诊断。NSAID溃疡以胃部多见，分布在近幽门、胃窦和胃底部，溃疡形态多样，大小从0.2～3.0cm不等，呈多发、浅表性溃疡。<br />&nbsp;&nbsp;对消化性溃疡病鼓励常规进行尿素酶试验或核素标记C呼气等试验，以明确是否存在幽门螺杆菌感染。<br />&nbsp;&nbsp;13．消化性溃疡病须与克罗恩病、结核、淋巴瘤、巨细胞病毒等继发性上消化道的溃疡相鉴别。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('504', '47', 'X02_010', '1', '消化性溃疡中医诊疗共识意见(2009,深圳)', null, '中华中医药学会脾胃病分会', '2009', '中华中医药学会脾胃病分会. 消化性溃疡中医诊疗共识意见(2009,深圳)[J]. 中医杂志, 2010, 51(10):941-944.', '中文', '活动期(A1、A2)<br />&nbsp;&nbsp;愈合期(H1、H2) <br />&nbsp;&nbsp;瘢痕期(S1、S2)', '消化性溃疡', null, null, '初步诊断:慢性、周期性、节律性上腹痛伴反酸者。基本诊断:伴有上消化道出血、穿孔史或现症者。确定诊断:胃镜发现消化性溃疡病灶(尿素酶实验或13C或14C标记的尿素呼吸试验等兼查Hp),或上消化道气钡双重造影检查见胃或十二指肠有龛影或球部变形者。良性溃疡内镜下分三期六段:活动期(A1、A2)、愈合期(H1、H2)和瘢痕期(S1、S2)。A1期:溃疡呈圆形或椭圆形,中心覆盖厚白苔,可伴有渗血或血痂,周围潮红,充血水肿明显;A2期:溃疡覆盖黄色或白色苔,无出血,周围充血水肿减轻。一些十二指肠溃疡表现为多个散在、浅表溃疡,斑点状或小片状,内镜下酷似白霜覆盖在充血、水肿黏膜上,称为“霜斑样溃疡”,可能是溃疡处于A期进展过程或愈合中的一种表现。H1期:溃疡处于愈合中,其周围充血、水肿消失,溃疡苔变薄、消退,伴有新生毛细血管;H2期:溃疡继续变浅、变小,周围黏膜皱襞向溃疡集中。S1期:溃疡白苔消失,呈现红色新生黏膜,称红色瘢痕期;S2期:溃疡的新生黏膜由红色转为白色,有时不易与周围黏膜区别,称白色瘢痕期。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('504c17409e934a358507741011c5a0e6', '4', 'a_b', '0', 'adfd', '', 'adfadsf', null, '', '中文', '<img src=\"/bzpt/images/2016/5/13/e7630eb467e641c997bfe63c0be7013c.jpg\" alt=\"\" />', '', '', '<img src=\"/bzpt/images/2016/5/13/980621e26d3f47be88b62c7942eb74c4.jpg\" alt=\"\" />ad', '<img src=\"http://localhost:18080/bzpt/images/2016/5/13/1238fb464e7d4e24ade15bf94ef4224c.jpg\" alt=\"\" />', '<img src=\"http://localhost:18080/bzpt/images/2016/5/13/1238fb464e7d4e24ade15bf94ef4224c.jpg\" alt=\"\" />', '<img src=\"/bzpt/images/2016/5/13/9ea5a6f90c724dd5a73726110d8662a4.jpg\" alt=\"\" />', '<img src=\"http://localhost:18080/bzpt/images/2016/5/13/1238fb464e7d4e24ade15bf94ef4224c.jpg\" alt=\"\" />', '<img src=\"/bzpt/images/2016/5/13/1238fb464e7d4e24ade15bf94ef4224c.jpg\" alt=\"\" />', '4', '0', 'admin', '2016-05-12 20:21:43', 'admin', '2016-05-17 16:38:48');
INSERT INTO `biz_standard` VALUES ('505', '47', 'X02_011', '1', '十二指肠溃疡诊断标准', 'Diagnostic Criteria of Duodenal Ulcer', '\n中华人民共和国卫生部(MINISTRY OF HEALTH OF THE PEOPLE`S REPUBLIC OF CHINA)', '2010', 'WS 317-2010, 十二指肠溃疡诊断标准[S].', '中文', '活动期（A期）<br />&nbsp;&nbsp;愈合期（H期）<br />&nbsp;&nbsp;瘢痕期（S期）', '十二指肠溃疡', null, null, '1诊断依据<br />&nbsp;&nbsp;1.1危险因素：Hp感染；服用NSAIDs;吸烟、饮食、精神压力、劳累及遗传等因素均与十二指肠溃<br />&nbsp;&nbsp;疡发病有关。<br />&nbsp;&nbsp;1.2症状：表现多样，典型表现为反复发作的规律性上腹痛，为“饥饿痛”和（或）“夜间痛”，疼痛性<br />&nbsp;&nbsp;质可多样，有时甚至无痛。<br />&nbsp;&nbsp;1.3体征：无特异性，可有上腹部的固定压痛点。<br />&nbsp;&nbsp;1.1内镜检查：内镜是诊断十二指肠溃疡的主要手段，具体方法参见附录A。<br />&nbsp;&nbsp;1.2上消化道钡餐检查：龛影为诊断十二指肠溃疡的直接征象。对于较小的、浅表或接近愈合期的溃<br />&nbsp;&nbsp;疡，钡餐难于诊断。<br />&nbsp;&nbsp;2诊断<br />&nbsp;&nbsp;2.1临床诊断：具备上述危险因素及典型症状、体征者，可拟诊十二指肠溃疡。<br />&nbsp;&nbsp;2.2确定诊断：应通过内镜检查或上消化道钡餐检查，其中内镜检查更为准确可靠。<br />&nbsp;&nbsp;.3Hp诊断：Hp为十二指肠溃疡重要病因，应常规对十二指肠溃疡患者进行幽门螺杆菌检测，具体方法参见附录B。<br />&nbsp;&nbsp;4并发症诊断：诊断十二指肠溃疡应同时通过问诊和查体，必要时进行粪便隐血试验及其它相关检查，以评估是否存在上消化道出血、幽门梗阻、消化道穿孔等并发症。<br />&nbsp;&nbsp;4.1出血：临床表现取决于出血量和出血速度，可表现为黑便和（或）呕血。出血量少时，仅粪便潜血呈阳性；急性大量出血时，表现为呕血和（或）柏油便，可危及生命。<br />&nbsp;&nbsp;4.2穿孔：急性穿孔可表现为突发剧烈上腹痛，迅速波及全腹。体检可出现腹式呼吸减弱或消失，全腹压痛、反跳痛，腹肌紧张呈“板样”强直，尤以右上腹明显，肝浊音界缩小或消失，可有移动性浊音。慢性穿孔可以穿透胰腺或其他邻近组织，形成包裹，出现相应部位的疼痛。<br />&nbsp;&nbsp;4.3幽门梗阻：典型症状为发生呕吐宿食，可有胃型及蠕动波、振水音。分为水肿型和瘢痕型：<br />&nbsp;&nbsp;a)水肿型：活动期溃疡，由于幽门痉挛和（或）溃疡周围炎症水肿引起可逆性梗阻；<br />&nbsp;&nbsp;b)瘢痕型：长期反复发作的溃疡，由于溃疡瘢痕形成，可以造成十二指肠变形和狭窄，导致药物治疗不能缓解的持续性梗阻。<br />&nbsp;&nbsp;4.4癌变：十二指肠溃疡罕见癌变。<br />&nbsp;&nbsp;6鉴别诊断：十二指肠溃疡应与其它会引起上腹部疼痛的疾病相鉴别，包括功能性消化不良、胃食管反流病、胃溃疡、上消化道肿瘤、胆道及胰腺疾病、肠道血管疾病以及心血管疾病等。还应与Zollinger-Ellison综合征及十二指肠癌等进行鉴别。<br />&nbsp;&nbsp;十二指肠溃疡的内镜下诊断及分期方法见X02_011_表1', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('506', '47', 'X02_019', '1', '难治性消化性溃疡的诊断和治疗方法', 'Diagnostic and Treatment Approaches for Refractory Peptic Ulcers', null, '2015', 'Kim H U. Diagnostic and Treatment Approaches for Refractory Peptic Ulcers.[J]. Clinical Endoscopy, 2015, 48(4):285-90.', '英文', null, 'Refractory Peptic Ulcers', null, null, 'Korean diagnostic guidelinesRecent Korean guidelines for treatment of non-bleedingpeptic ulcer disease recommend the following steps for treatment of refractory ulcers.2 The first is drug compliance. If anulcer fails to heal with a standard dose of an anti-secretorydrug, the dose should be doubled and treatment should becontinued for an additional 6 to 8 weeks. Second, H. pylori status should be evaluated. False-negative results should be suspected when ulcers test negative for H. pylori infection. Third,clinicians should confirm that patients have discontinued useof NSAIDs. Many patients do not realize that cold remediesor headache medicines contain NSAIDs, so it is important to confirm that they are not inadvertently taking medicinescontaining NSAIDs. Fourth, clinicians should check that patients have quit smoking. Fifth, it is important to determineif there is a family history of gastrinoma, Zollinger-Ellisonsyndrome (ZES), or type I multiple endocrine neoplasia;their secondary symptoms, including chronic diarrheaor hypercalcemia due to hyperparathyroidism, should beinvestigated for acid hypersecretion. Sixth, the possibilityof primary or metastatic malignancies, infectious diseasessuch as cytomegalovirus infection, crack cocaine use, andgastroduodenal involvement of inflammatory bowel diseaseshould be considered. About 90% of refractory ulcers healafter 8 weeks of PPI treatment; however, additional or continuous treatment may be necessary in 10% of cases, andsurgical treatment may also be considered.', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('507', '46', 'Y03_002', '1', '2006 CMA抑郁障碍防治指南（中国精神障碍分类与诊断标准）', ' ', ' \n中华医学会', '2006', '中国精神障碍防治指南丛书', '中文', null, '抑郁', null, null, '以心境低落为主，并至少有下列4项：（1）兴趣丧失、无愉快感；（2）精力减退或疲乏感；（3）精神运动性迟滞或激越；（4）自我评价过低、自责，或有内疚感；（5）联想困难或自觉思考能力下降；（6）反复出现想死的念头或有自杀、自伤行为；（7）睡眠障碍，如失眠、早醒，或睡眠过多；（8）食欲降低或体重明显减轻；（9）性欲减退。【严重标准】社会功能受损，给本人造成痛苦或不良后果。【病程标准】（1）符合症状标准和严重标准至少已持续2周。（2）可存在某些分裂性症状，但不符合分裂症的诊断。若同时符合分裂症的症状标准，分裂症状缓解后，满足抑郁发作标准至少2周。【排除标准】排除器质性精神障碍，或精神活性物质和非成瘾物质所致抑郁。<br />&nbsp;&nbsp;无精神病性症状的抑郁症，除了在32抑郁发作的症状标准中，增加“无幻觉、妄想，或紧张综合征等精神病性症状”之外，其余均符合该标准。<br />&nbsp;&nbsp;复发性抑郁症：【诊断标准】（1）目前发作符合某一型抑郁标准，并在间隔至少2个月前，有过另一次发作符合某一抑郁标准；（2）以前从未有符合任何一型躁狂、双柑隋感障碍，或环性情感障碍标准；（3）排除器质性精神障碍，或精神活性物质和非成瘾物质所致的抑郁发作。<br />&nbsp;&nbsp;环性心境障碍【症状标准】反复出现心境高涨或低落，值禾符合躁狂或抑郁发作症状标准。【严重标准】社会功能受损较轻。【病程标准】符合症状标准和严重程度标准至少2年，但这2年中，可有数月心境正常间歇期。【排除标准】（1）心境变化并非躯体病或精神活性物质的直接后果，也非分裂症及其他精神病性障碍的附加症状；<br />&nbsp;&nbsp;恶劣心境：【症状标准】持续存在心境低落，但不符合任何一型抑郁的症状标准。【严重标准】社会功能受损较轻，自知力完整或较完整。【病程标准】符合症状标准和严重程度标准至少已2年，但这2年中，很少有持续2个月的心境正常间歇期。【排除标准】（1）心境变化并非躯体病或精神活性物质的直接后果，也非分裂症及其他精神病性障碍的附加症状；（2）排除各型抑郁，一旦符合相应的其他类型情感障碍标准，则应作出相应的其他类型诊断。', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('508', '46', 'Y03_004', '1', '2010 APA 重性抑郁障碍的治疗指南（第三版）', 'Treatment of Patients With Major Depressive Disorder, Third Edition', ' 美国精神病学会（APA,American Psychiatric Associatio）', '2010', 'http://psychiatryonline.org/guidelines', '英文', '\n急性期、巩固期、维持期、停药期', 'Post-schizophrenic depression；Neonatal cerebral depression；Bipolar affective disorder, current episode mild or moderate depression；Bipolar affective disorder, current episode severe depression without psychotic symptoms；Bipolar affective disorder, current episode severe depression with psychotic symptoms', null, null, ' Patients with symptoms of depression should receive athorough biopsychosocial assessment, both to determine whether a diagnosis of major depressive disorder is warranted and to identify the presence of other psychiatric orgeneral medical conditions. The general principles andcomponents of a complete psychiatric evaluation have beenoutlined in APA’s Practice Guideline for Psychiatric Evaluation of Adults, Second Edition In establishing a diagnosis of major depressive disorderas part of the initial assessment, other differential diagnostic possibilities are important to consider. An initialconsideration in the differential diagnosis is mood disorderdue to a general medical condition. Specific medical conditions that are important to consider and that may be associated with a major depressive episode include neurologicalconditions (e.g., stroke, Parkinson’s disease, dementia,multiple sclerosis), thyroid disorders, metabolic conditions(e.g., hypercalcemia), malignancy, and infectious diseases(13–15). Depressive symptoms that would otherwise bediagnosable as major depressive disorder are diagnosedinstead as a mood disorder due to a general medical condition if the mood disturbance is judged to be the directphysiological consequence of a specific general medical condition. Similarly, medications used to treat general medicalconditions may induce depressive syndromes. Such medications include transplant anti-rejection agents, chemotherapy agents, interferon, steroids, some antibiotics, andothers. Depression caused by medications is classified inthe DSM-IV-TR as other (or unknown) substanceinduced mood disorder (DSM-IV-TR code 292.84)', null, null, '新指南强调急性期疗程至少需要6周～12周，治疗目标为\n临床治愈(remission)，完全恢复到患者病前功能水平。 ', ' 第2版指南相比，新版推荐选择抗抑郁药时需要考虑的因素更多，新加入了“伴发躯体疾病，潜在的药物相互作用和药物的半衰期”条款，并指出抗抑郁药对细胞色素P450酶的抑制作用是初始选药需要考虑的因素之一。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('509', '46', 'Y03_005', '1', '2010英属哥伦比亚卫生部儿童和青少年焦虑和抑郁的诊断和治疗指南', 'Anxiety and Depression in Children and Youth - Diagnosis and Treatment ', ' \n英属哥伦比亚卫生部(Ministry of Health (British Columbia))', '2010', 'Anxiety and Depression in Children and Youth – Diagnosis and Treatment\nEffective Date: January 1, 2010', '英文', null, 'Post-schizophrenic depression；Neonatal cerebral depression；Bipolar affective disorder, current episode mild or moderate depression；Bipolar affective disorder, current episode severe depression without psychotic symptoms；Bipolar affective disorder, current episode severe depression with psychotic symptoms', null, null, ' Take a medical history and do a physical examination with attention to conditions that may mimic anxiety or depressive disorders. Consider indications for diagnostic tests such as TSH. Consider the family situation and social stressors.', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('51', '34', 'M06_006', '1', '尿石症诊断治疗指南（2014）', null, '中华医学会泌尿外科分会', '2014', '那彦群, 叶章群, 孙光.中国泌尿外科疾病诊断治疗指南[M].北京：人民卫生出版社，2014.', '中文', 'M06_006_01泌尿系结石分类.docx', '尿石症', null, null, '1.影像学检查<br />&nbsp;&nbsp;具有泌尿系结石临床症状的所有患者都应该做影像学检查，其结果对于结石的进一步检查和治疗具有重要的价值。<br />&nbsp;&nbsp;1.1. B 超(雄荐)超声波检查简便、经济、无创伤，可以发现2mm 以上X 线阳性及阴性结石。<br />&nbsp;&nbsp;此外，超声波检查还可以了解结石以上尿路的扩张程度，间接了解肾实质和集合系统的情况。对膀脱结石，超声检查能够同时观察膀脱和前列腺，寻找结石形成的诱因和并发症。但是，由于受肠道内容物的影响，超声波检查诊断输尿管中下段结石的敏感性较低。<br />&nbsp;&nbsp;超声可作为泌尿系结石的常规检查方法，尤其是在肾绞痛时作为首选方法。<br />&nbsp;&nbsp;1.2. 尿路平片(KUB 平片) (推荐)尿路平片以发现90% 左右X 线阳性结石，能够大致地确定结石的位置、形态、大小和数量，并且初步地提示结石的化学性质。因此，可以作为结石检查的常规方法。在尿路平片上，不同成分的结石显影程度依次为:草酸钙、磷酸钙和磷酸镁铵、脱氨酸、含尿酸盐结石。单纯性尿酸结石和黄嘌呤结石能够透过X 线(X 线阴性)，脱氨酸结石的密度低，后者在尿路平片上的显影比较淡。<br />&nbsp;&nbsp;1.3. 静脉尿路造影(IVU) (推荐)静脉尿路造影应该在尿路平片的基础上进行，其价值在于了解尿路的解剖，确定结石在尿路的位置，发现尿路平片上不能显示的X 线阴性结石，鉴别平片上可疑的钙化灶。此外，还可以了解分侧肾脏的功能，确定肾积水程度。在一侧肾脏功能严重受损或者使用普通剂量造影剂而肾脏不显影的情况下，采用加大造影剂剂量(双剂量或大剂量)或者延迟拍片的方法往往可以达到肾脏显影的目的。肾绞痛发作时，由于急性尿路梗阻往往会导致尿路不显影或显影不良，因此对结石的诊断会带来困难。<br />&nbsp;&nbsp;1.4. 非增强CT 扫描( Non-contrast CT, NCCT)或者C丁KUB (Unenhanced CT of the kidneys ,ureters and bladder) (推荐) CT 检查分辨率较KUB 高，可发现lmm 的结石解决了KUB 成像的组织重叠问题，不易受肠道内气体干扰，不受结石成分、肾功能和呼吸运动的影响，而且螺旋CT 能够同时对所获得的图像进行二维或三维重建，将横切面图像转换成类似IVU 图像，可以清楚地显示包括阴性结石在内的结石的形态和大小。此外，还可以通过结石的CT 值来初步判断结石的成分，通过增强CT 显示肾积水的程度和肾实质的厚度，同时还能评估肾脏炎症情况。螺旋CT 进行三维建可以更准确地估计出结石体积，术前准确判断结石负荷(stone burden)，从而对治疗方法的选择提供重要的参考价值。 由于CT 检查不需要做肠道准备，不受肾功能限制，检查所需时间短，对结石的显示非常敏感，可以明确梗阻部位及梗阻原因，对肾绞痛患者的病因诊断具有重要意义。所以，对肾绞痛患者，可首选CT 平扫，再依据CT 结果适当选择其他影像学检查，以提高诊断准确率。<br />&nbsp;&nbsp;研究显示，以前采用的单层螺旋CT 诊断结石的敏感度和特异度达到96%~100% 和92%~100% ，对于微小结石会漏诊。多层图像质量优于单层CT 相同扫描层厚的图像， 16 层螺旋CT 行5mm 层厚扫描相当于直接薄层0.625mm 扫描效果，对结石诊断特异度及敏感度接近100%。 在国外，目前提出了CTKUB (Unenhanced CT of the kidneys , uretersand bladder) 的概念，即全泌尿系CT 平扫，国外一医疗机构已经开始用CT 代替传统的KUB 和IVU 作为诊断泌尿系结石的金标准。<br />&nbsp;&nbsp;1.5. CT 增强+三维重建(CTU)( 可选择) CTU是将螺旋CT 扫描与IVU 检查相结合的一种检查方法，可以准确判断结石的有元、大小、多少、部位及梗阻、积水的情况。对于合并有肾结石且需要同时治疗的患者可行CTU 检查评估肾脏情况，可作为IVU 的替代检查。但CTU 的价格较昂贵，并且较IVU 需要接受更高的放射剂量。<br />&nbsp;&nbsp;1.6. 逆行或经皮肾穿刺造影(可选择)属于创伤的检查方法，不作为常规检查手段，仅在静脉尿路造影不显影或显影不良以及怀疑是X 线阴性结石、需要作进一步的鉴别诊断时应用。<br />&nbsp;&nbsp;1.7. 磁共振水成像(MRU) (可选择)磁共振对尿路结石的诊断效果极差，因而一般不用于结石的检查。但是，磁共振水成像(MRU) 能够了解上尿路梗阻的情况，而且不需要造影剂即可获得与静脉尿路造影同样的效果，不受肾功能改变的影响。因此，对于不适合做静脉尿路造影的患者(例如选影剂过敏、严重肾功能损害、儿童和孕妇等)可考虑采用。<br />&nbsp;&nbsp;1.8. 放射性核素(可选择)放射性核素检查不能直接显示泌尿系结石，但是，它可以显示泌尿系统的形态，提供肾脏血流灌注、肾功能及尿路梗阻情况等信息，因此对手术方案的选择以及手术疗效的评价具有一定价值。此外，肾动态显影还可以用于评估体外冲击波碎石对肾功能的影响情况。<br />&nbsp;&nbsp;2.实验室检查<br />&nbsp;&nbsp;2.1. 常规检查结石患者的实验室检查应包括血液分析、尿液分析和结石分析，见表6-4 。<br />&nbsp;&nbsp;M06_006_02结石患者常规实验室检查.docx<br />&nbsp;&nbsp;2.2. 复杂性肾结石的尿液分析复杂性肾结<br />&nbsp;&nbsp;石患者(指结石反复复发、有或无肾内残石和特别的危险因素的患者)可选择进一步的尿液分析(表6-5)。<br />&nbsp;&nbsp;M06_006_03复杂性肾结石患者的尿液分析.docx<br />&nbsp;&nbsp;2.3. 尿液采集方案(表6-6)<br />&nbsp;&nbsp;M06_006_04尿液采集方案.docx<br />&nbsp;&nbsp;2.4. 检查结果评价测定血清/血浆钙有助于甲状旁腺功能亢进(到PT) 或其他与高钙血症有关疾病的诊断。若血钙浓度高(>2.60mmol/L) ，则应测定甲状旁腺激素水平，以确诊或排除HPT 。X 线阴性结石伴有高尿酸血症者应考虑尿酸结石，但CT 片上可显示。禁食晨尿pH>5.8 可考虑为完全性或不完全性肾小管性酸中毒，应同时作酸负荷试验及血液pH 、钾、碳酸氢盐和氯化物测定。<br />&nbsp;&nbsp;', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('510', '46', 'Y03_011', '1', '精神障碍诊断与统计手册-IV ', 'Diagnostic and Statistical Manual of Mental Disorders(DSM-IV )', '\n美国精神病学会(APA,American Psychiatric Association)', '1994', 'http://allpsych.com/disorders/dsm/', '中文', null, null, '郁证', null, '重性抑郁发作A在同一个2周时期内，出现与以往功能不同的明显改变，表现为下列5项以上，其中至少1项是（1）心境抑郁，或（2）丧失兴趣或乐趣。注：不包括明显是由于一般躯体情况，或者与心境协调的妄想幻觉所致的症状。（1）几乎每天的一天中大部分时间都心境抑郁，这或者是主观的体验（例如，感到悲伤或空虚），或者是他人的观察（例如，看来在流泪）；注：儿童或青少年，可能是心境激惹；（2）几乎每天的一天中大部分时间，对于所有（或几乎所有）活动的兴趣都显著减低；（3）显著的体重减轻（未节食）或体重增加（一月内体重变化超过原体重的5％），或几乎每天食欲减退或增加；注：儿童则为未达到应增体重；（4）几乎每天失眠或嗜睡；（5）几乎每天精神运动性激越或迟缓（由他人观察到的情况，不仅是主观体验到坐之不安或缓慢下来）；（6）几乎每天疲倦乏力或缺乏精力；（7）几乎每天感到生活没有价值，或过分的不合适的自责自罪（可以是妄想性的程度，不仅限于责备自己患了病）；（8）几乎天天感到思考或集中思想的能力减退，或者犹豫不决（或为自我体验，或为他人观察）；（9）反复想到死亡（不只是怕死），想到没有特殊计划的自杀意念，或者想到某种自杀企图或一种特殊计划以期实行自杀。D.这些症状并不符合混合发作的标准。C.这些症状产生了临床上明显的痛苦烦恼，或在社交、职业、或其他重要方面的功能缺损。D.这些症状并非由于某种物质（例如某种滥用药物；某种治疗药品）或由于一般躯体性情况例如甲亢所致之直接生理性效应。E这些症状不可能归于离丧；后者即，在失去所爱者后出现这些症状并持续2月以上，其特点为显著的功能缺损、病态地沉湎于生活无价值、自杀意念、精神病性症状、或精神运动性迟缓。重性抑郁障碍，单次发作296.2XA.呈现一个单次的重性抑郁发作。B．此重性抑郁发作不可能归于分裂情感性障碍，也不是叠加于精神分裂症、精神分裂样障碍、妄想性精神障碍、或他处来注明的精神病性障碍。C.从来没有过躁狂发作、混合性发作、或轻躁狂发作。注：这一条排除标准不适用于所有因物质或治疗所致躁狂样、混合样、或轻躁狂样发作，也不适用于一般躯体情况所致之直接生理性效应。<br />&nbsp;&nbsp;重性抑郁障碍，反复发作296.3XA.呈现2次以上重性抑郁发作。注：作为2次单独的发作，其间期至少为连续2月，在此期间的表现不符合重性抑郁发作的标准。B．此重性抑郁发作不可能归于分裂情感性障碍，也不是叠加于精神分裂症、精神分裂样障碍、妄想性精神障碍、或他处来注明的精神病性障碍。C.从来没有过躁狂发作、混合性发作、或轻躁狂发作。注：这一条排除标准不适用于所有因物质或治疗所致躁狂样、混合样、或轻躁狂样发作，也不适用于一般躯体情况所致直接生理性效应。<br />&nbsp;&nbsp;双相I型障碍，单次躁狂发作296.0XA.呈现仅只一次的躁狂发作，而无重性抑郁发作的历史。注：复发是指至少在没有从躁狂相转为抑郁根或没有躁狂症状之后2月才出现的发作。B.此跟狂发作不可能归于分裂性情感样精神障碍，也不是叠加于精神分裂症、精神分裂样精神障碍、妄想性精神障碍、或他处未注明的病性障碍。<br />&nbsp;&nbsp;双相I型障碍，最近一次为轻躁狂发作296.40A.当前（或最近一次）为轻躁狂发作。B.以前至少曾有一次躁狂发作或混合性发作。C.此心境障碍产生了临床上明显的痛苦烦恼，或在社交、职业、或其他重要方面的功能缺损。D.A及B的发作都不可能归于分裂情感性障碍，也不是叠加于精神分裂症、精神分裂样精神障碍、妄想性精神障碍、或他处未注明的精神病性障碍。<br />&nbsp;&nbsp;双相I型障碍，最近一次为躁狂发作296.4XA．当前（或最近一次）为躁狂发作。B.以前至少曾有一次重性抑郁发作、躁狂发作、或混合性发作。C.上述A及B的发作都不可能归于分裂情感性障碍，也不是叠加于精神分裂症、精神分裂样精神障碍、妄想性精神障碍、或他处未注明的精神病性障碍。双相I型障碍，最近一次为混合性发作296.6XA.当前（或最近一次）为混合性发作。B.C.均同上一节。双相I型障碍，最近一次重性抑郁发作296.SXA.当前（可最近一次）为重性抑郁发作。B.以前至少曾有一次躁狂发作或混合性发作。C.同上一节。<br />&nbsp;&nbsp;双相I型障碍，最近一次发作未注明296.7A.除了病期外，当前（或最近一次）发作符合躁狂、轻躁狂、混合性、或重性抑郁发作。B.以前至少曾有一次躁狂发作或混合性发作。C.D.同双相I型障碍，最近一次为轻躁狂发作一节的C与D。E.上述A及B中的心境症状并非由于某种物质（例如，滥用药物，治疗药品，或其他治疗），或由于一般躯体情况（例如，甲亢）所致之直接生理性效应。<br />&nbsp;&nbsp;双相II型障碍296.89A.呈现（或曾有）一次以上重性抑郁障碍。B.呈现（或曾有）至少一次轻躁狂发作。C.从未有过躁狂发作或混合性发作。D.A及B的心境症状都不可能归于分裂情感性障碍，也不是叠加于精神分裂症、精神分裂样精神障碍、妄想性精神障碍、或地处未注明的精神病性障碍。E.此障碍产生了临床上明显的痛苦烦恼，或在社交、职业、或其他重要方面的功能缺损。抑郁发作患者心境低落，与所处的境遇不相称，可以从闷闷不乐到悲痛欲绝，甚至发生木僵状态。严重者可出现妄想、幻觉等精神病性症状，某些病例中焦虑与运动性激越比抑郁更为显著。【抑郁发作诊断标准】一、症状标准，以心境低落为主要特征且持续至少二周，在此期间至少有下述症状中的四项：1.对日常活动丧失兴趣，无愉快感；2.精力明显减退，无原因的持续疲乏感；3.精神运动性迟滞或激越；4.自我评价过低，或自责，或有内疚感，可达妄想程度；5.联想困难，或自觉思考能力显著下降；6.反复出现想死的念头，或有自杀行为；7.失眠，或早醒，或睡眠过多；8.食欲不振，或体重明显减轻；9.性欲明显减退。二、严重程度标准，精神障碍至少造成下述情况之一：1.社会功能受损；2.给本人造成痛苦或不良后果。32)抑郁发作32F32抑郁发作抑郁发作以心境低落为主，与其处境不相称，可以从闷闷不乐到悲痛欲绝，甚至发生木僵。严重者可出现幻觉、妄想等精神病性症状。某些病例的焦虑与运动性激越很显著。【症状标准】以心境低落为主，并至少有下列4项：(1)兴趣丧失、无愉快感；(2)精力减退或疲乏感；(3)精神运动性迟滞或激越；(4)自我评价过低、自责，或有内疚感；(5)联想困难或自觉思考能力下降；(6)反复出现想死的念头或有自杀、自伤行为；(7)睡眠障碍，如失眠、早醒，或睡眠过多；(8)食欲降低或体重明显减轻；(9)性欲减退。【严重标准】社会功能受损，给本人造成痛苦或不良后果。【病程标准】(1)符合症状标准和严重标准至少已持续2周。(2)可存在某些分裂性症状，但不符合分裂症的诊断。若同时符合分裂症的症状标准，在分裂症状缓解后，满足抑郁发作标准至少2周。【排除标准】排除器质性精神障碍，或精神活性物质和非成瘾物质所致抑郁。【说明】本抑郁发作标准仅适用于单次发作的诊断。<br />&nbsp;&nbsp;抑郁发作32.1F32.0轻性抑郁症(轻抑郁)除了社会功能无损害或仅轻度损害外，发作符合32抑郁发作的全部标准。(32)抑郁发作32.2F32.1无精神病性症状的抑郁症除了在32抑郁发作的症状标准中，增加“无幻觉、妄想，或紧张综合征等精神病性症状”之外，其余均符合该标准。<br />&nbsp;&nbsp;抑郁发作32.3F32.2有精神病性症状的抑郁症除了在32抑郁发作的症状标准中，增加“有幻觉、妄想，或紧张综合征等精神病性症状”之外，其余均符合该标准。<br />&nbsp;&nbsp;抑郁发作32.4F33复发性抑郁症【诊断标准】(1)目前发作符合某一型抑郁标准，并在间隔至少2个月前，有过另1次发作符合某一型抑郁标准；(2)以前从未有躁狂符合任何一型躁狂、双相情感障碍，或环性情感障碍标准；(3)排除器质性精神障碍，或精神活性物质和非成瘾物质所致的抑郁发作。(32)抑郁发作32.41F33.0复发性抑郁症>>复发性抑郁症，目前为轻抑郁符合32.4复发性抑郁的诊断标准，目前发作符合32.1轻抑郁标准(32)抑郁发作32.42F33.2复发性抑郁症>>复发性抑郁症，目前为无精神病性症状的抑郁符合32.4复发性抑郁的诊断标准，目前发作符合32.2无精神病性症状的抑郁标准。(32)抑郁发作32.43F33.3复发性抑郁症>>复发性抑郁症，目前为有精神病性症状的抑郁符合32.4复发性抑郁的诊断标准，目前发作符合32.3有精神病性症状的抑郁标准。(32)抑郁发作32.9F32.8；F32.9；F33.8；F33.9其他或待分类的抑郁症(33)持续性心境障碍33F34持续性心境障碍(33)持续性心境障碍33.1F34.0环性心境障碍【症状标准】反复出现心境高涨或低落，但不符合躁狂或抑郁发作症状标准。【严重标准】社会功能受损较轻。【病程标准】符合症状标准和严重标准至少已2年，但这2年中，可有数月心境正常间歇期。【排除标准】(1)心境变化并非躯体病或精神活性物质的直接后果，也非分裂症及其他精神病性障碍的附加症状；(2)排除躁狂或抑郁发作，一旦符合相应标准即诊断为其他类型情感障碍。(33)持续性心境障碍33.2F34.1恶劣心境【症状标准】持续存在心境低落，但不符合任何一型抑郁的症状标准，同时无躁狂症状。【严重标准】社会功能受损较轻，自知力完整或较完整。【病程标准】符合症状标准和严重标准至少已2年，在这2年中，很少有持续2个月的心境正常间歇期。【排除标准】(1)心境变化并非躯体病（如甲状腺机能亢进症），或精神活性物质导致的直接后果，也非分裂症及其他精神病性障碍的附加症状；(2)排除各型抑郁（包括慢性抑郁或环性情感障碍），一旦符合相应的其他类型情感障碍标准，则应作出相应的其他类型诊断；(3)排除抑郁性人格障碍。(33)持续性心境障碍33.9F34.8；F34.9其他或待分类的持续性心境障碍(39)其他或待分类的心境障碍39F38；F39其他或待分类的心境障碍心境障碍的第5位编码3x.xx1F38意识障碍（如谵妄）严重躁狂发作可出现意识障碍（如谵妄），可称谵妄性躁狂等。<br />&nbsp;&nbsp;心境障碍的第5位编码3x.xx2F38伴躯体症状【说明】在抑郁发作中，有显著的躯体症状与自主神经症状，而无相应的躯体疾病可以解释，有时甚至掩盖了抑郁症状，有人称为“隐匿性抑郁症”，这一名称未获国际公认，本分类系统亦不列入。心境障碍的第5位编码3x.xx3F38慢性一次抑郁或躁狂发作的病程至少持续2年。心境障碍的第5位编码3x.xx4F38缓解期曾有1次以上情感性精神障碍发作史，目前已完全缓解至少2个月。<br />&nbsp;&nbsp;月经前心境恶劣障碍（研究标准）A.过去几年中大多数月经周期时，在黄体期的这本一星期的大多数时间呈现以下5项以上症状，而在卵泡期一开始的几天之内开始缓解，在此后一直表现正常以至下一周期。5项症状必须包括（l）、（2）、（3）、（4）中的任1项：（l）显著的心境抑郁、绝望感、或自我懊悔的想法；（2）显著的焦虑、紧张、“不耐烦”感；（3）显著的感情脆弱（例如，感到突然悲伤或眼泪汪汪，或对被拒绝十分敏感）；（4）持久显著的愤怒或激惹，或人际关系矛盾冲突加重；（5）对日常活动兴趣减低（例如，工作、学习、朋友、爱好）；（6）主观感觉思想难以集中；（7）倦睡、易疲倦、或显著缺乏精力；（8）食欲显著改变，吃得过多，或挑食；（9）睡眠过多或失眠；（10）主观感觉到即将崩溃或失去控制；（11）其他躯体症状，例如乳房胀痛、头痛、关节肌肉疼痛、“发胀”感、体重增加。B.明显影响工作或学习，或影响日常社交活动及与他人关系（例如，回避社交活动，工作或学习的效率及成绩减退）。C.并不只是其他精神障碍的症状的恶化加重，例如重性抑郁障碍、惊恐障碍、心境恶劣障碍、或某种人格障碍（虽然可以叠加于任一种障碍之上）。D.标准A、B、及C应在至少2个连续周期，予以逐日观察记录，并加以肯定（在肯定之前可以暂作出诊断）。<br />&nbsp;&nbsp;A、在连续两周的时间里，病人表现出下列九个症状中的五个以上。这些症状必须是病人以前没有的、或者极轻的。并且至少包括症状(1)和(2)中的一个。\n1.每天的大部分时间心情抑郁，或者是由病人自我报告(例如，感到伤心，心理空空的)，或者是通过旁人的观察(例如，暗暗流泪)。注意:在儿童和青少年中，可以表现为易激惹，而不是明显的心情抑郁。2.在每天大部分时间，对所有或者大多数平时感兴趣的活动失去了兴趣。或者通过病人自我报告，或者通过旁人的观察。3.体重显著减轻或增加(正常体重的5%)，食欲显著降低或增加。注意:在儿童中，考虑缺乏正常的体重增加。4.每天失眠或者睡眠过多。5.每天精神运动亢进或减少(不止是自我主观感觉到的坐立不安或者不想动，旁人都可以观察得到)。6.每天感到疲劳，缺乏精力。7.每天感到自己没有价值，或者自罪自贬(可能出现妄想)。这不仅是普通的自责，或只是对自己的抑郁感到丢脸。8.每天注意力和思考能力下降，做决定时犹豫不决。(自我报告或者是旁人的观察)。9.常常想到死(不只是惧怕死亡)，或者常常有自杀的念头但没有具体的计划，或者是有自杀的具体计划，甚至有自杀行为。B、排除双向燥郁。C、上述症状对病人的生活工作或其他重要方面造成严重影响。D、上述症状不是由于药物的生理作用(例如，服药、吸毒、酗酒)或者躯体疾病所引起(例如，甲状腺分泌降低)。E、上述症状不能仅仅由丧失亲友等应激事件来解释。(如果有丧失亲友的事件发生，那么上述症状必须在事件发生后的两个月后仍存在，而且伴随着显著的生活工作方面的功能缺损、病态的自罪自责，自杀观念，精神症状，或精神运动迟滞。<br />&nbsp;&nbsp;\n', null, null, null, 'Numerous changes were made to the classification (e.g., disorders were added, deleted, and reorganized), to the diagnostic criteria sets, and to the descriptive text. Developers of DSM-IV and the 10th edition of the ICD worked closely to coordinate their efforts, resulting in increased congruence between the two systems and fewer meaningless differences in wording. ICD-10 was published in 1992.抑郁症诊断标准中有一个排除标准应用于丧失亲人以后抑郁症状持续不足2个月的患者，即排除居丧反应。有“兴趣丧失、无愉快感,,在内的5一8个抑郁症状但无“情绪低落,时能否被诊断为抑郁上的差异是与CCMD-3在抑郁诊断上不一致的主要原因。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('511', '46', 'Y03_012', '1', '精神障碍诊断与统计手册-IV-TR', 'Diagnostic and Statistical Manual of Mental Disorders(DSM-IV-TR)', '\n美国精神病学会(APA,American Psychiatric Association)', '2000', 'th. Diagnostic and statistical manual of mental disorders : DSM-IV-TR[J]. Corsini Encyclopedia of Psychology, 2000(2001).', '英文', '1.mild<br />&nbsp;&nbsp;2.moderate<br />&nbsp;&nbsp;3.severe<br />&nbsp;&nbsp;4.in partial remission<br />&nbsp;&nbsp;5.in full remission<br />&nbsp;&nbsp;6. prior history', null, null, null, 'most of the criteria sets prisented in this manual include exclusion criteria that are necessary to establish boundaries between disorders and to clarify differential diagnoses.The several different wordings of exclusion criteria in the criteria sets throughout DSM-IV reflect the different types of possible relationships among disorders:<br />&nbsp;&nbsp;Criteria have never been met for^this exclusion criterion is used to define alifetime hierarchy between disorders.for example,a diagnosis of a Major Depressive Disorder can no longer be given once a Manic Episode has occured and must be changed to a diagnosis of Bipolar I Disorder.\nA Five (or more) of the following symptoms have been present during the same 2-week period and represent achange from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interestor pleasure.Note: Do not include symptoms that are clearly due to a general medical condition, or mood-incongruentdelusions or hallucinations.\n1. Depressed mood most of the day, nearly every day, as indicated by either subjective report (e.g. feels sad or\nempty) or observation made by others (e.g. appears tearful). Note: In children and adolescents, can be irritable\nmood.\n2. Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day (as indicated by either subjective account or observation made by others).3. Significant weight loss when not dieting or weight gain (e.g. a change of more than 5% of body weight in a month), or decrease or increase in appetite nearly every day. Note: In children, consider failure to make expected weight gains.4. Insomnia or hypersomnia nearly every day.5. Psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down).6. Fatigue or loss of energy nearly every day.7. Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick).8. Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective account or as observed by others).9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide.B The symptoms do not meet criteria for a Mixed Episode (see Criteria for Mixed Episode).\nC The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.\nD The symptoms are not due to the direct physiological effects of a substance (e.g. a drug of abuse, a medication) or a general medical condition (e.g. hypothyroidism).\nE The symptoms are not better accounted for by Bereavement (i.e. after the loss of a loved one), the symptoms persist for longer than 2 months or are characterised by marked functional impairment, morbid preoccupation with worthlessness, suicidal ideation, psychotic symptoms, or psychomotor retardation.<br />&nbsp;&nbsp;Diagnostic criteria for 296.3x Major Depressive Disorder, Recurrent\nA Presence of two or more Major Depressive Episodes (see Criteria for Major Depressive Episode). Note: To be considered separate episodes, there must be an interval of at least 2 consecutive months in which criteria are not met for a Major Depressive Episode.\nB The Major Depressive Episodes are not better accounted for by Schizoaffective Disorder and are not superimposed on Schizophrenia, Schizophreniform Disorder, Delusional Disorder, or Psychotic Disorder Not Otherwise Specified.\nC There has never been a Manic Episode (see Criteria for Manic Episode), a Mixed Episode (see Criteria for Mixed Episode), or a Hypomanic Episode (see Criteria for Hypomanic Episode). Note: This exclusion does not apply if all of the manic-like, mixed-like, or hypomanic-like episodes are substance or treatment induced or are due to the direct physiological effects of a general medical condition.\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('512', '46', 'Y03_013', '1', '精神障碍诊断与统计手册-5', 'Diagnostic and Statistical Manual of Mental Disorders FIFTH EDITION（DSM-5） ', '\n美国精神病学会(APA,American Psychiatric Association)', '2013', 'https://www.psychiatry.org/psychiatrists/practice/dsm/history-of-the-dsm', '英文', null, 'Disruptive Mood Dysregulation Disorder', '郁证', null, ' Disruptive Mood Dysregulation Disorder Diagnostic CriteriaA.Severe recurrent temper outbursts manifested verbally (e.g., verbal rages) and/or behaviorally (e.g., physical aggression toward people or property) that are grossly out ofproportion in intensity or duration to the situation or provocation.<br />&nbsp;&nbsp;B. The temper outbursts are inconsistent with developmental level. $C. The temper outbursts occur, on average, three or more times per week. <br />&nbsp;&nbsp;D. The mood between temper outbursts is persistently irritable or angry most of the day,nearly every day, and is observable by others (e.g., parents, teachers, peers). <br />&nbsp;&nbsp;E. Criteria A-D have been present for 12 or more months. Throughout that time, the individual has not had a period lasting 3 or more consecutive months without all of thesymptoms in Criteria A-D. <br />&nbsp;&nbsp;F. Criteria A and D are present in at least two of three settings (i.e., at home, at school,with peers) and are severe in at least one of these. <br />&nbsp;&nbsp;G. The diagnosis should not be made for the first time before age 6 years or after age 18years. <br />&nbsp;&nbsp;H. By history or observation, the age at onset of Criteria A-E is before 10 years. <br />&nbsp;&nbsp;I. There has never been a distinct period lasting more than 1 day during which the fullsymptom criteria, except duration, for a manic or hypomanie episode have been met.Note: Developmentally appropriate mood elevation, such as occurs in the context of ahighly positive event or its anticipation, should not be considered as a symptom of mania or hypomania. <br />&nbsp;&nbsp;J. The behaviors do not occur exclusively during an episode of major depressive disorderand are not better explained by another mental disorder (e.g., autism spectrum disorder, posttraumatic stress disorder, separation anxiety disorder, persistent depressivedisorder [dysthymia]).Note: This diagnosis cannot coexist with oppositional defiant disorder, intermittent explosive disorder, or bipolar disorder, though it can coexist with others, including majordepressive disorder, attention-deficit/hyperactivity disorder, conduct disorder, andsubstance use disorders. Individuals whose symptoms meet criteria for both disruptivemood dysregulation disorder and oppositional defiant disorder should only be given thediagnosis of disruptive mood dysregulation disorder. If an individual has ever experienced a manic or hypomanie episode, the diagnosis of disruptive mood dysregulationdisorder should not be assigned. <br />&nbsp;&nbsp;K. The symptoms are not attributable to the physiological effects of a substance or to another medical or neurological condition. <br />&nbsp;&nbsp;Differential Diagnosis<br />&nbsp;&nbsp;Because chronically irritable children and adolescents typically present with complex histories, the diagnosis of disruptive mood dysregulation disorder must be made while considering the presence or absence of multiple other conditions. Despite the need to consider many other syndromes, differentiation of disruptive mood dysregulation disorder from bipolar disorder and oppositional defiant disorder requires particularly careful assessment.<br />&nbsp;&nbsp;$Diagnostic FeaturesThe core feature of disruptive mood dysregulation disorder is chronic, severe persistent irritabihty. This severe irritability has two prominent clinical manifestations, the first ofwhich is frequent temper outbursts. These outbursts typically occur in response to frustration and can be verbal or behavioral (the latter in the form of aggression against property, self, or others). They must occur frequently (i.e., on average, three or more times perweek) (Criterion C) over at least 1 year in at least two settings (Criteria E and F), such as inthe home and at school, and they must be developmentally inappropriate (Criterion B).The second manifestation of severe irritability consists of chronic, persistently irritable orangry mood that is present between the severe temper outbursts. This irritable or angrymood must be characteristic of the child, being present most of the day, nearly every day,and noticeable by others in the child\'s environment (Criterion D).The clinical presentation of disruptive mood dysregulation disorder must be carefullydistinguished from presentations of other, related conditions, particularly pediatric bipolar disorder. In fact, disruptive mood dysregulation disorder was added to DSM-5 toaddress the considerable concern about the appropriate classification and treatment of\nchildren who present with chronic, persistent irritability relative to children who present\nwith classic (i.e., episodic) bipolar disorder.Some researchers view severe, non-episodic irritability as characteristic of bipolar disorder in children, although both DSM-IV and DSM-5 require that both children and adultshave distinct episodes of mania or hypomania to qualify for the diagnosis of bipolar I disorder. During the latter decades of the 20th century, this contention by researchers thatsevere, nonepisodic irritability is a manifestation of pediatric mania coincided with an upsurge in the rates at which clinicians assigned the diagnosis of bipolar disorder to theirpediatric patients. This sharp increase in rates appears to be attributable to clinicians combining at least two clinical presentations into a single category. That is, both classic, episodic presentations of mania and non-episodic presentations of severe irritability havebeen labeled as bipolar disorder in children. In DSM-5, the term bipolar disorder is explicitlyreserved for episodic presentations of bipolar symptoms. DSM-IV did not include a diagnosis designed to capture youths whose hallmark symptoms consisted of very severe, nonepisodic irritability, whereas DSM-5, with the inclusion of disruptive mood dysregulationdisorder, provides a distinct category for such presentations.\n\n', null, null, ' ', 'To address concerns about potential overdiagnosis and overtreatment of bipolar disorder inchildren, a new diagnosis, disruptive mood dysregulation disorder, is included for childrenup to age 18 years who exhibit persistent irritability and frequent episodes of extreme behavioral dyscontrol. Premenstrual dysphoric disorder is now promoted from Appendix B, \"Criteria Sets and Axes Provided for Further Study,\" in DSM-IV to the main body of DSM-5. Whatwas referred to as dysthymia in DSM-IV now falls under the category of persistent depressivedisorder, which includes both chronic major depressive disorder and the previous dysthymicdisorder. The coexistence within a major depressive episode of at least three manic symptoms (insufficient to satisfy criteria for a manic episode) is now acknowledged by the specifier \"with mixed features.\" In DSM-IV, there was an exclusion criterion for a major depressive episode that was applied to depressive symptoms lasting less than 2months following the deathof a loved one (i.e., the bereavement exclusion). This exclusion is omitted in DSM-5 for severalreasons, including the recognition that bereavement is a severe psychosocial stressor that canprecipitate a major depressive episode in a vulnerable individual, generally beginning soonafter the loss, and can add an additional risk for suffering, feelings of worthlessness, suicidalideation, poorer medical health, and worse interpersonal and work functioning. It was criticalto remove the implication that bereavement typically lasts only 2months, when both physicians and grief counselors recognize that the duration is more commonly 1-2 years. A detailedfootnote has replaced the more simplistic DSM-IV exclusion to aid clinicians in making thecritical distinction between the symptoms characteristic of bereavement and those of a majordepressive disorder. Finally, a new specifier to indicate the presence of mixed symptoms hasbeen added across both the bipolar and the depressive disorders. <br />&nbsp;&nbsp;取消排除居丧反应，与DSM-4简单的排除不同，DSM-5抑郁症的诊断标准中有非常详细的脚注，帮助医生区分居丧的特征性症状与抑郁发作症状。<br />&nbsp;&nbsp;将DSM-IV中双相障碍的“混合发作”，改为“混合性发作特征”，如果在躁狂或者轻躁狂发作的基础上呈现抑郁的特征，或者在抑郁症或双相障碍抑郁发作的基础上呈现躁狂/轻躁狂的特征，即添加“混合性发作特征”的标注。抑郁症的诊断标准中“混合性发作特征”即满足抑郁症的标准并且合并出现至少3种躁狂症状。<br />&nbsp;&nbsp;添加“伴焦虑困扰”标注，使得医生对所有双相障碍或抑郁障碍患者的焦虑严重程度进行评估。<br />&nbsp;&nbsp;推荐PHQ-9评估抑郁严重程度。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('513', '46', 'Y03_013', '1', '精神障碍诊断与统计手册-5', ' DSM-5', '\n美国精神病学会(APA,American Psychiatric Association)', '2013', 'https://www.psychiatry.org/psychiatrists/practice/dsm/history-of-the-dsm', '英文', null, 'major depressive disorder', '郁证', null, 'major depressive disorderDiagnostic CriteriaA. Five (or more) of the following symptoms have been present during the same 2-weekperiod and represent a change from previous functioning: at least one of the symptomsis either (1) depressed mood or (2) loss of interest or pleasure.Note: Do not include symptoms that are clearly attributable to another medical condition.1. Depressed mood most of the day, nearly every day, as indicated by either subjective report (e.g., feels sad, empty, hopeless) or observation made by others (e.g.,appears tearful). (Note: In children and adolescents, can be irritable mood.)2. Markedly diminished interest or pleasure in all, or almost all, activities most of theday, nearly every day (as indicated by either subjective account or observation).3. Significant weight loss when not dieting or weight gain (e.g., a change of more than5% of body weight in a month), or decrease or increase in appetite nearly every day.(Note: In children, consider failure to make expected weight gain.)4. Insomnia or hypersomnia nearly every day.5. Psychomotor agitation or retardation nearly every day (observable by others, notmerely subjective feelings of restlessness or being slowed down).6. Fatigue or loss of energy nearly every day.7. Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick).8. Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective account or as observed by others).9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide.B. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.C. The episode is not attributable to the physiological effects of a substance or to anothermedical condition.Note: Criteria A-C represent a major depressive episode.Note: Responses to a significant loss (e.g., bereavement, financial ruin, losses from a natural disaster, a serious medical illness or disability) may include the feelings of intense sadness, rumination about the loss, insomnia, poor appetite, and weight loss noted in Criterion A,which may resemble a depressive episode. Although such symptoms may be understandable or considered appropriate to the loss, the presence of a major depressive episode inaddition to the normal response to a significant loss should also be carefully considered. Thisdecision inevitably requires the exercise of clinical judgment based on the individual’s historyand the cultural norms for the expression of distress in the context of loss.^D. The occurrence of the major depressive episode is not better explained by schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, orother specified and unspecified schizophrenia spectrum and other psychotic disorders.E. There has never been a manic episode or a hypomanie episode.Note: This exclusion does not apply if all of the manic-like or hypomanic-like episodesare substance-induced or are attributable to the physiological effects of another medical condition.Coding and Recording ProceduresThe diagnostic code for major depressive disorder is based on whether this is a single orrecurrent episode, current severity, presence of psychotic features, and remission status.Current severity and psychotic features are only indicated if full criteria are currently metfor a major depressive episode. Remission specifiers are only indicated if the full criteriaare not currently met for a major depressive episode. Codes are as follows:见DSM-5表1\nSeverity/course specifier Single episode Recurrent episode*\nMild(p.188) 296.21(F32.0) 296.31(F33.0)\nModerate(p.188) 296.22(F32.1) 296.32(F33.1)\nSevere(p.188) 296.23(F32.2) 296.33(F33.2)\nWithpsychoticfeatures**(p.186) 296.24(F32.3) 296.34(F33.3)\nInpartialremission(p.188) 296.25(F32.4) 296.35(F33.41)\nInfullremission(p.188) 296.26(F32.5) 296.36(F33.42)\nUnspecified 296.20(F32.9) 296.30(F33.9)\n<br />&nbsp;&nbsp;Diagnostic FeaturesThe criterion symptoms for major depressive disorder must be present nearly every day tobe considered present, with the exception of weight change and suicidal ideation. Depressed mood must be present for most of the day, in addition to being present nearly every day. Often insomnia or fatigue is the presenting complaint, and failure to probe foraccompanying depressive symptoms will result in underdiagnosis. Sadness may be denied at first but may be elicited through interview or inferred from facial expression anddemeanor. With individuals who focus on a somatic complaint, clinicians should determine whether the distress from that complaint is associated with specific depressivesymptoms. Fatigue and sleep disturbance are present in a high proportion of cases; psychomotor disturbances are much less common but are indicative of greater overall severity, as is the presence of delusional or near-delusional guilt.<br />&nbsp;&nbsp;Associated Features Supporting DiagnosisMajor depressive disorder is associated with high mortality, much of which is accountedfor by suicide; however, it is not the only cause. For example, depressed individuals admitted to nursing homes have a markedly increased likelihood of death in the first year. Individuals frequently present with tearfulness, irritability, brooding, obsessive rumination,anxiety, phobias, excessive worry over physical health, and complaints of pain (e.g., headaches; joint, abdominal, or other pains). In children, separation anxiety may occur.<br />&nbsp;&nbsp;Differential Diagnosis Manic episodes with irritable mood or mixed episodes. Major depressive episodeswith prominent irritable mood may be difficult to distinguish from manic episodes withirritable mood or from mixed episodes. This distinction requires a careful clinical evaluation of the presence of manic symptoms.Mood disorder due to another medical condition. A major depressive episode is theappropriate diagnosis if the mood disturbance is not judged, based on individual history,physical examination, and laboratory findings, to be the direct pathophysiological consequence of a specific medical condition (e.g., multiple sclerosis, stroke, hypothyroidism).Substance/medication-induced depressive or bipolar disorder. This disorder is distinguished from major depressive disorder by the fact that a substance (e.g., a drug of abuse,a medication, a toxin) appears to be etiologically related to the mood disturbance. For example, depressed mood that occurs only in the context of withdrawal from cocaine wouldbe diagnosed as cocaine-induced depressive disorder.Attention-deficit/hyperactivity disorder. Distractibility and low frustration tolerancecan occur in both attention-deficit/ hyperactivity disorder and a major depressive episode; if the criteria are met for both, attention-deficit/hyperactivity disorder may be diagnosed in addition to the mood disorder. However, the clinician must be cautious not tooverdiagnose a major depressive episode in children with attention-deficit/hyperactivitydisorder whose disturbance in mood is characterized by irritability rather than by sadnessor loss of interest.Adjustment disorder with depressed mood. A major depressive episode that occurs inresponse to a psychosocial stressor is distinguished from adjustment disorder w^ith depressed mood by the fact that the full criteria for a major depressive episode are not met inadjustment disorder.Sadness. Finally, periods of sadness are inherent aspects of the human experience.These periods should not be diagnosed as a major depressive episode unless criteria aremet for severity (i.e., five out of nine symptoms), duration (i.e., most of the day, nearly every day for at least 2 w^eeks), and clinically significant distress or impairment. The diagnosis other specified depressive disorder may be appropriate for presentations of depressedmood wiih clinically significant impairment that do not meet criteria for duration or severity.', null, null, ' ', ' Depressive Disorders<br />&nbsp;&nbsp;DSM-5 contains several new depressive disorders, including disruptive mood dysregulation disorderand premenstrual dysphoric disorder. To address concerns about potential overdiagnosis and overtreatment of bipolar disorder in children, a new diagnosis, disruptive mood dysregulation disorder, is included for children up to age 18 years who exhibit persistent irritability and frequent episodes of extremebehavioral dyscontrol. Based on strong scientific evidence, premenstrual dysphoric disorder has beenmoved from DSM-IV Appendix B, “Criteria Sets and Axes Provided for Further Study,” to the main bodyof DSM-5. Finally, DSM-5 conceptualizes chronic forms of depression in a somewhat modified way.What was referred to as dysthymia in DSM-IV now falls under the category of persistent depressive disorder, which includes both chronic major depressive disorder and the previous dysthymic disorder. Aninability to find scientifically meaningful differences between these two conditions led to their combination with specifiers included to identify different pathways to the diagnosis and to provide continuitywith DSM-IV.<br />&nbsp;&nbsp;Major Depressive DisorderNeither the core criterion symptoms applied to the diagnosis of major depressive episode nor the requisite duration of at least 2 weeks has changed from DSM-IV. Criterion A for a major depressive episodein DSM-5 is identical to that of DSM-IV, as is the requirement for clinically significant distress or impairment in social, occupational, or other important areas of life, although this is now listed as CriterionB rather than Criterion C. The coexistence within a major depressive episode of at least three manicsymptoms (insufficient to satisfy criteria for a manic episode) is now acknowledged by the specifier“with mixed features.” The presence of mixed features in an episode of major depressive disorder in- creases the likelihood that the illness exists in a bipolar spectrum; however, if the individual concernedhas never met criteria for a manic or hypomanic episode, the diagnosis of major depressive disorder isretained.', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('514', '46', 'Y03_013', '1', '精神障碍诊断与统计手册-5', 'DSM-5 ', '\n美国精神病学会(APA,American Psychiatric Association)', '2013', 'https://www.psychiatry.org/psychiatrists/practice/dsm/history-of-the-dsm', '英文', null, 'Persistent Depressive Disorder (Dysthymia)', '郁证', null, ' Persistent Depressive Disorder (Dysthymia)Diagnostic Criteria 300.4 (F34.1)This disorder represents a consolidation of DSM-lV-defined chronic major depressive disorder and dysthymic disorder.A. Depressed mood for most of the day, for more days than not, as indicated by eithersubjective account or observation by others, for at least 2 years.Note: In children and adolescents, mood can be irritable and duration must be at least1 year.B. Presence, while depressed, of two (or more) of the following:1. Poor appetite or overeating.2. Insomnia or hypersomnia.3. Low energy or fatigue.4. Low self-esteem.5. Poor concentration or difficulty making decisions.6. Feelings of hopelessness.C. During the 2-year period (1 year for children or adolescents) of the disturbance, the individual has never been without the symptoms in Criteria A and B for more than 2 months at atime.D. Criteria for a major depressive disorder may be continuously present for 2 years.E. There has never been a manic episode or a hypomanie episode, and criteria havenever been met for cyclothymic disorder.F. The disturbance is not better explained by a persistent schizoaffective disorder,schizophrenia, delusional disorder, or other specified or unspecified schizophreniaspectrum and other psychotic disorder.G. The symptoms are not attributable to the physiological effects of a substance (e.g., adrug of abuse, a medication) or another medical condition (e.g. hypothyroidism).H. The symptoms cause clinically significant distress or impairment in social, occupational,or other important areas of functioning.Note: Because the criteria for a major depressive episode include four symptoms that areabsent from the symptom list for persistent depressive disorder (dysthymia), a very limited number of individuals will have depressive symptoms that have persisted longer than 2 yearsbut will not mee| criteria for persistent depressive disorder. If full criteria for a major depressive episode have been met at some point during the current episode of illness, theyshould be given a diagnosis of major depressive disorder. Othenwise, a diagnosis of otherspecified depressive disorder or unspecified depressive disorder is warranted.Specify if:With anxious distress (p. 184)With mixed features (pp. 184-185)With melancholic features (p. 185)With atypical features (pp. 185-186)With mood-congruent psychotic features (p. 186)With mood-incongruent psychotic features (p. 186)With péripartum onset (pp. 186-187)Specify if:In partial remission (p. 188)In full remission (p. 188)Specify if:Early onset: If onset is before age 21 years.Late onset: If onset is at age 21 years or older.Specify if (for most recent 2 years of persistent depressive disorder):With pure dysthymic syndrome: Full criteria for a major depressive episode have notbeen met in at least the preceding 2 years.With persistent major depressive episode: Full criteria for a major depressive episode have been met throughout the preceding 2-year period.With intermittent major depressive episodes, with current episode: Full criteria fora major depressive episode are currently met, but there have been periods of at least8 weeks in at least the preceding 2 years with symptoms below the threshold for a fullmajor depressive episode.With intermittent major depressive episodes, without current episode: Full criteria for a major depressive episode are not currently met, but there has been one ormore major depressive episodes in at least the preceding 2 years.Specify current severity:Mild (p. 188)Moderate (p. 188)Severe (p. 188)<br />&nbsp;&nbsp;Diagnostic FeaturesThe essential feature of persistent depressive disorder (dysthymia) is a depressed moodthat occurs for most of the day, for more days than not, for at least 2 years, or at least 1 yearfor children and adolescents (Criterion A). This disorder represents a consolidation ofDSM-IV-defined chronic major depressive disorder and dysthymic disorder. Major depression may precede persistent depressive disorder, and major depressive episodes mayoccur during persistent depressive disorder. Individuals whose symptoms meet major depressive disorder criteria for 2 years should be given a diagnosis of persistent depressivedisorder as well as major depressive disorder.Individuals with persistent depressive disorder describe their mood as sad or \"downin the dumps.\" During periods of depressed mood, at least two of the six symptoms fromCriterion B are present. Because these symptoms have become a part of the individual\'sday-to-day experience, particularly in the case of early onset (e.g., \"I\'ve always been this way\"), they may not be reported unless the individual is directly prompted. E>uring the 2-yearperiod (1 year for children or adolescents), any symptom-free intervals last no longer than2 months (Criterion C).<br />&nbsp;&nbsp;Differential DiagnosisMajor depressive disorder. If there is a depressed mood plus two or more symptomsmeeting criteria for a persistent depressive episode for 2 years or more, then the diagnosis ofpersistent depressive disorder is made. The diagnosis depends on the 2-year duration,which distinguishes it from episodes of depression that do not last 2 years. If the symptomcriteria are sufficient for a diagnosis of a major depressive episode at any time during this period, then the diagnosis of major depression should be noted, but it is coded not as a separatediagnosis but rather as a specifier with the diagnosis of persistent depressive disorder. If theindividual\'s symptoms currently meet full criteria for a major depressive episode, then thespecifier of \"with intermittent major depressive episodes, with current episode\" would bemade. If the major depressive episode has persisted for at least a 2-year duration and remains present, then the specifier \"with persistent major depressive episode\" is used. Whenfull major depressive episode criteria are not currently met but there has been at least oneprevious episode of major depression in the context of at least 2 years of persistent depressive symptoms, then the specifier of \"with intermittent major depressive episodes, withoutcurrent episode\" is used. If the individual has not experienced an episode of major depression in the last 2 years, then the specifier \"with pure dysthymic syndrome\" is used.Psychotic disorders. Depressive symptoms are a common associated feature of chronicpsychotic disorders (e.g., schizoaffective disorder, schizophrenia, delusional disorder). Aseparate diagnosis of persistent depressive disorder is not made if the symptoms occuronly during the course of the psychotic disorder (including residual phases).Depressive or bipolar and related disorder due to another medical condition. Persistentdepressive disorder must be distinguished from a depressive or bipolar and related disorder due to another medical condition. The diagnosis is depressive or bipolar and relateddisorder due to another medical condition if the mood disturbance is judged, based on history, physical examination, or laboratory findings, to be attributable to the direct pathophysiological effects of a specific, usually chronic, medical condition (e.g., multiplesclerosis). If it is judged that the depressive symptoms are not attributable to the physiological effects of another medical condition, then the primary mental disorder (e.g., persistentdepressive disorder) is recorded, and the medical condition is noted as a concomitant medical condition (e.g., diabetes mellitus).Substance/medication-induced depressive or bipolar disorder. A substance/medication-induced depressive or bipolar and related disorder is distinguished from persistent depressive disorder when a substance (e.g., a drug of abuse, a medication, a toxin) isjudged to be etiologically related to the mood disturbance.Personality disorders. Often, there is evidence of a coexisting personality disturbance.When an individual\'s presentation meets the criteria for both persistent depressive disorder and a personality disorder, both diagnoses are given.', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('515', '46', 'Y03_013', '1', '精神障碍诊断与统计手册-5', 'DSM-5 ', '\n美国精神病学会(APA,American Psychiatric Association)', '2013', 'https://www.psychiatry.org/psychiatrists/practice/dsm/history-of-the-dsm', '英文', null, ' Premenstrual Dysphoric Disorder', '郁证', null, ' Premenstrual Dysphoric Disorder Diagnostic Criteria A. In the majority of menstrual cycles, at least five symptoms must be present in the finalweek before the onset of menses, start to improve within a few days after the onset ofmenses, and become minimal or absent in the week postmenses.B. One (or more) of the following symptoms must be present:1. Marked affective lability (e.g., mood swings: feeling suddenly sad or tearful, or increased sensitivity to rejection). 2. Marked irritability or anger or increased interpersonal conflicts.3. Marked depressed mood, feelings of hopelessness, or self-deprecating thoughts.4. Marked anxiety, tension, and/or feelings of being keyed up or on edge.C. One (or more) of the following symptoms must additionally be present, to reach a totalof five symptoms when combined with symptoms from Criterion B above.1. Decreased interest in usual activities (e.g., work, school, friends, hobbies).2. Subjective difficulty in concentration.3. Lethargy, easy fatigability, or marked lack of energy.4. Marked change in appetite; overeating; or specific food cravings.5. Hypersomnia or insomnia.6. A sense of being ovenwhelmed or out of control.7. Physical symptoms such as breast tenderness or swelling, joint or muscle pain, asensation of “bloating,” or weight gain.Note: The symptoms in Criteria A-C must have been met for most menstrual cycles thatoccurred in the preceding year.D. The symptoms are associated with clinically significant distress or interference withwork, school, usual social activities, or relationships with others (e.g., avoidance of social activities; decreased productivity and efficiency at work, school, or home).E. The disturbance is not merely an exacerbation of the symptoms of another disorder,such as major depressive disorder, panic disorder, persistent depressive disorder(dysthymia), or a personality disorder (although it may co-occur with any of these disorders).F. Criterion A should be confirmed by prospective daily ratings during at least two symptomatic cycles. (Note: The diagnosis may be made provisionally prior to this confirmation.)G. The symptoms are not attributable to the physiological effects of a substance (e.g., adrug of abuse, a medication, other treatment) or another medical condition (e.g., hyperthyroidism).<br />&nbsp;&nbsp;Diagnostic FeaturesThe essential features of premenstrual dysphoric disorder are the expression of mood lability, irritability, dysphoria, and anxiety symptoms that occur repeatedly during the premenstrual phase of the cycle and remit around the onset of menses or shortly thereafter.These symptoms may be accompanied by behavioral and physical symptoms. Symptomsmust have occurred in most of the menstrual cycles during the past year and must have anadverse effect on work or social functioning. The intensity and/or expressivity of the accompanying symptoms may be closely related to social and cultural background characteristics of the affected female, family perspectives, and more specific factors such asreligious beliefs, social tolerance, and female gender role issues.Typically, symptoms peak around the time of the onset of menses. Although it is notuncommon for symptoms to linger into the first few days of menses, the individual musthave a symptom-free period in the follicular phase after the menstrual period begins.While the core symptoms include mood and anxiety symptoms, behavioral and somaticsymptoms commonly also occur. However, the presence of physical and/or behavioralsymptoms in the absence of mood and/or anxious symptoms is not sufficient for a diag nosis. Symptoms are of comparable severity (but not duration) to those of another mentaldisorder, such a^ a major depressive episode or generalized anxiety disorder. In order toconfirm a provisional diagnosis, daily prospective symptom ratings are required for atleast two symptomatic cycles.<br />&nbsp;&nbsp;Associated Features Supporting DiagnosisDelusions and hallucinations have been described in the late luteal phase of the menstrualcycle but are rare. The premenstrual phase has been considered by some to be a risk periodfor suicide.<br />&nbsp;&nbsp;Diagnostic MarkersAs indicated earlier, the diagnosis of premenstrual dysphoric disorder is appropriatelyconfirmed by 2 months of prospective symptom ratings. A number of scales, including the Daily Rating of Severity of Problems and the Visual Analogue Scales for PremenstrualMood Symptoms, have undergone validation and are commonly used in clinical trials forpremenstrual dysphoric disorder. The Premenstrual Tension Syndrome Rating Scale has aself-report and an observer version, both of v^hich have been validated and used widely tomeasure illness severity in women who have premenstrual dysphoric disorder. <br />&nbsp;&nbsp;Differential DiagnosisPremenstrual syndrome. Premenstrual syndrome differs from premenstrual dysphoricdisorder in that a minimum of five symptoms is not required, and there is no stipulation ofaffective symptoms for individuals who have premenstrual syndrome. This conditionmay be more common than premenstrual dysphoric disorder, although the estimatedprevalence of premenstrual syndrome varies. While premenstrual syndrome shares thefeature of symptom expression during the premenstrual phase of the menstrual cycle, it isgenerally considered to be less severe than premenstrual dysphoric disorder. The presence of physical or behavioral symptoms in the premenstruum, without the requiredaffective symptoms, likely meets criteria for premenstrual syndrome and not for premenstrual dysphoric disorder.Dysmenorrhea. Dysmenorrhea is a syndrome of painful menses, but this is distinct from asyndrome characterized by affective changes. Moreover, symptoms of dysmenorrhea beginwith the onset of menses, whereas symptoms of premenstrual dysphoric disorder, by definition, begin before the onset of menses, even if they linger into the first few days of menses.Bipolar disorder, major depressive disorder, and persistent depressive disorder(dysthymia). Many women with (either naturally occurring or substance/medicationinduced) bipolar or major depressive disorder or persistent depressive disorder believethat they have premenstrual dysphoric disorder. However, when they chart symptoms,they realize that the symptoms do not follow a premenstrual pattern. Women with another mental disorder may experience chronic symptoms or intermittent symptoms thatare unrelated to menstrual cycle phase. However, because the onset of menses constitutesa memorable event, they may report that symptoms occur only during the premenstruumor that symptoms worsen premenstrually. This is one of the rationales for the requirementthat symptoms be confirmed by daily prospective ratings. The process of <br />&nbsp;&nbsp;Differential Diagnosis, particularly if the clinician relies on retrospective symptoms only, is made moredifficult because of the overlap between symptoms of premenstrual dysphoric disorderand some other diagnoses. The overlap of symptoms is particularly salient for differentiating premenstrual dysphoric disorder from major depressive episodes, persistent depressive disorder, bipolar disorders, and borderline personality disorder. However, therate of personality disorders is no higher in individuals with premenstrual dysphoric disorder than in those without the disorder.Use of hormonal treatments. Some women who present with moderate to severe premenstrual symptoms may be using hormonal treatments, including hormonal contraceptives. If such symptoms occur after initiation of exogenous hormone use, the symptoms may be due to the use of hormones rather than to the underlying condition of premenstrual dysphoriq disorder. If the woman stops hormones and the symptoms disappear,this is consistent with substance/medication-induced depressive disorder.', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('516', '46', 'Y03_013', '1', '精神障碍诊断与统计手册-5', ' DSM-5', '\n美国精神病学会(APA,American Psychiatric Association)', '2013', 'https://www.psychiatry.org/psychiatrists/practice/dsm/history-of-the-dsm', '英文', null, 'Substance/Medication-InducedDepressive Disorder', '郁证', null, ' Substance/Medication-InducedDepressive DisorderDiagnostic CriteriaA. A prominent and persistent disturbance in mood that predominates in the clinical picture and is characterized by depressed mood or markedly diminished interest or pleasure in all, or almost all, activities.B. There is evidence from the history, physical examination, or laboratory findings of both(1)and(2):1. The symptoms in Criterion A developed during or soon after substance intoxicationor withdrawal or after exposure to a medication.2. The involved substance/medication is capable of producing the symptoms in Criterion A.C. The disturbance is not better explained by a depressive disorder that is not substance/medication-induced. Such evidence of an independent depressive disorder could include the following:The symptoms preceded the onset of the substance/medication use; the symptomspersist for a substantial period of time (e.g., about 1 month) after the cessation of acutewithdrawal or severe intoxication; or there is other evidence suggesting the existenceof an independent non-substance/medication-induced depressive disorder (e.g., a history of recurrent non-substance/medication-related episodes).D. The disturbance does not occur exclusively during the course of a delirium.E. The disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.Note: This diagnosis should be made instead of a diagnosis of substance intoxication orsubstance withdrawal only when the symptoms in Criterion A predominate in the clinicalpicture and when they are sufficiently severe to warrant clinical attention.Coding note: The ICD-9-CM and ICD-10-CM codes for the [specific substance/medication]-induced depressive disorders are indicated in the table below. Note that the ICD-10- CM code depends on wliether or not there is a comorbid substance use disorder present forthe same class of substance. If a mild substance use disorder is comorbid with the substanceinduced depressive disorder, the 4th position character is“1 and the clinician should record“mild [substance] use disorder” before the substance-induced depressive disorder (e.g.,“mild cocaine use disorder with cocaine-induced depressive disorder”). If a moderate or severe substance use disorder is comorbid with the substance-induced depressive disorder,the 4th position character is “2,” and the clinician should record “moderate [substance] usedisorder” or “severe [substance] use disorder,” depending on the severity of the comorbidsubstance use disorder. If there is no comorbid substance use disorder (e.g., after a onetime heavy use of the substance), then the 4th position character is “9,” and the clinician shouldrecord only the substance-induced depressive disorder.\n  ICD-10-CM\n ICD-9-CM Withuse disorder,mild Withuse disorder,moderate orsevere Without use disorder \nAlcohol 291.89 F10.14 F10.24 FI0.94\nPhencyclidine 292.84 F16.14 F16.24 F16.94\nOtherhallucinogen 292.84 F16.14 F16.24 FI6.94\nInhalant 292.84 F18.14 F18.24 FI8.94\nOpioid 292.84 F11.14 F11.24 F11.94\nSedative,hypnotic,oranxiolytic 292.84 F13.14 FI3.24 FI3.94\nAmphetamine(orotherstimulant) 292.84 F15.14 FI5.24 FI5.94\nCocaine 292.84 F14.14 FI4.24 FI4.94\nOther(orunknown)substance 292.84 F19.14 F19.24 FI9.94\n<br />&nbsp;&nbsp;Diagnostic FeaturesThe Diagnostic Features of substance/medication-induced depressive disorder include thesymptoms of a depressive disorder, such as major depressive disorder; however, the depressive symptoms are associated with the ingestion, injection, or inhalation of a substance (e.g., drug of abuse, toxin, psychotropic medication, other medication), and thedepressive symptoms persist beyond the expected length of physiological effects, intoxication, or withdrawal period. As evidenced by clinical history, physical examination, orlaboratory findings, the relevant depressive disorder should have developed during orwithin 1 month after use of a substance that is capable of producing the depressive disorder (Criterion Bl). In addition, the diagnosis is not better explained by an independentdepressive disorder. Evidence of an independent depressive disorder includes the depressive disorder preceded the onset of ingestion or withdrawal from the substance; thedepressive disorder persists beyond a substantial period of time after the cessation of substance use; or other evidence suggests the existence of an independent non-substance/medication-induced depressive disorder (Criterion C). This diagnosis should not be madewhen symptoms occur exclusively during the course of a delirium (Criterion D). The depressive disorder associated with the substance use, intoxication, or withdrawal mustcause clinically significant distress or impairment in social, occupational, or other important areas of functioning to qualify for this diagnosis (Criterion E).Some medications (e.g., stimulants, steroids, L-dopa, antibiotics, central nervoussystem drugs, dermatological agents, chemotherapeutic drugs, immunological agents) can induce depressive mood disturbances. Clinical judgment is essential to determinewhether the medication is truly associated with inducing the depressive disorder orwhether a primary depressive disorder happened to have its onset while the person wasreceiving the treatment. For example, a depressive episode that developed within the firstseveral weeks of beginning alpha-methyldopa (an antihypertensive agent) in an individual with no history of major depressive disorder would qualify for the diagnosis of medication-induced depressive disorder. In some cases, a previously established condition(e.g., major depressive disorder, recurrent) can recur while the individual is coincidentallytaking a medication that has the capacity to cause depressive symptoms (e.g., L-dopa, oralcontraceptives). In such cases, the clinician must make a judgment as to whether the medication is causative in this particular situation.A substance/medication-induced depressive disorder is distinguished from a primarydepressive disorder by considering the onset, course, and other factors associated with thesubstance use. There must be evidence from the history, physical examination, or laboratory findings of substance use, abuse, intoxication, or withdrawal prior to the onset of thedepressive disorder. The withdrawal state for some substances can be relatively protracted, and thus intense depressive symptoms can last for a long period after the cessationof substance use. <br />&nbsp;&nbsp;Diagnostic makersDetermination of the substance of use can sometimes be made through laboratory assaysof the suspected substance in the blood or urine to corroborate the diagnosis. <br />&nbsp;&nbsp;Differential Diagnosis Substance intoxication and withdrawal. Depressive symptoms occur commonly in substance intoxicahon and substance withdrawal, and the diagnosis of the substance-specificintoxication or withdrawal will usually suffice to categorize the symptom presentation. Adiagnosis of substance-induced depressive disorder should be made instead of a diagnosis of substance intoxication or substance withdrawal when the mood symptoms aresufficiently severe to warrant independent clinical attention. For example, dysphoricmood is a characteristic feature of cocaine withdrawal. Substance/medication-induceddepressive disorder should be diagnosed instead of cocaine withdrawal only if the mooddisturbance is substantially more intense or longer lasting than what is usually encounteredwith cocaine withdrawal and is sufficiently severe to be a separate focus of attention andtreatment. Primary depressive disorder. A substance/medication-induced depressive disorder isdistinguished from a primary depressive disorder by the fact that a substance is judged tobe etiologically related to the symptoms, as described earlier (see section \"Developmentand Course\" for this disorder).Depressive disorder due to another medical condition. Because individuals with othermedical conditions often take medications for those conditions, the clinician must consider thepossibility that the mood symptoms are caused by the physiological consequences of the medical condition rather than the medication, in which case depressive disorder due to anothermedical condition is diagnosed. The history often provides Üie primary basis for such a judgment. At times, a change in the treatment for the other medical condition (e.g., medication substitution or discontinuation) may be needed to determine empirically whether the medicationis the causative agent. If the clinician has ascertained that the disturbance is a function of bothanother medical condition and substance use or withdrawal, both diagnoses (i.e., depressivedisorder due to another medical condition and substance/medication-induced depressivedisorder) may be given. When there is insufficient evidence to determine whether the depressive symptoms are associated with substance (including a medication) ingestion or withdrawal or with another medical condition or are primary (i.e., not a function of either asubstance or another medical condition), a diagnosis of other specified depressive disorder orunspecified depressive disorder would be indicated. ', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('517', '46', 'Y03_013', '1', '精神障碍诊断与统计手册-5', 'DSM-5 ', '\n美国精神病学会(APA,American Psychiatric Association)', '2013', 'https://www.psychiatry.org/psychiatrists/practice/dsm/history-of-the-dsm', '英文', null, ' Depressive Disorder Due to Another Medical Condition', '郁证', null, ' Depressive Disorder Due to Another Medical Condition Diagnostic Criteria A. A prominent and persistent period of depressed mood or markedly diminished interestor pleasure in all, or almost all, activities that predominates in the clinical picture.B. There is evidence from the history, physical examination, or laboratory findings that thedisturbance is the direct pathophysiological consequence of another medical condition.C. The disturbance is not better explained by another mental disorder (e.g., adjustmentdisorder, with depressed mood, in which the stressor is a serious medical condition).D. The disturbance does not occur exclusively during the course of a delirium.E. The disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning. Coding note: The ICD-9-CM code for depressive disorder due to another medical condition is 293.83, which is assigned regardless of the specifier. The ICD-10-CM code depends on the specifier (see below). Specify if:(F06.31) With depressive features: Full criteria are not met for a major depressiveepisode. \'(F06.32) Witli major depressive-iilce episode: Full criteria are met (except CriterionC) for a major depressive episode.(F06.34) With mixed features: Symptoms of mania or hypomania are also present butdo not predominate in the clinical picture.Coding note: Include the name of the other medical condition in the name of the mental disorder (e.g., 293.83 [F06.31] depressive disorder due to hypothyroidism, with depressive features). The other medical condition should also be coded and listed separately immediatelybefore the depressive disorder due to the medical condition (e.g., 244.9 [E03.9] hypothyroidism; 293.83 [F06.31] depressive disorder due to hypothyroidism, with depressive features).<br />&nbsp;&nbsp;Diagnostic FeaturesThe essential feature of depressive disorder due to another medical condition is a prominent and persistent period of depressed mood or markedly diminished interest or pleasure in all, or almost all, activities that predominates in the clinical picture (Criterion A)and that is thought to be related to the direct physiological effects of another medical condition (Criterion B). In determining whether the mood disturbance is due to a generalmedical condition, the clinician must first establish the presence of a general medical condition. Further, the clinician must establish that the mood disturbance is etiologically related to the general medical condition through a physiological mechanism. A careful andcomprehensive assessment of multiple factors is necessary to make this judgment. Although there are no infallible guidelines for determining whether the relationshipbetween the mood disturbance and the general medical condition is etiological, severalconsiderations provide some guidance in this area. One consideration is the presence of atemporal association between the onset, exacerbation, or remission of the general medicalcondition and that of the mood disturbance. A second consideration is the presence of features that are atypical of primary Mood Disorders (e.g., atypical age at onset or course orabsence of family history). Evidence from the literature that suggests that there can be a direct association between the general medical condition in question and the developmentof mood symptoms can provide a useful context in the assessment of a particular situation.<br />&nbsp;&nbsp;Associated Features Supporting DiagnosisEtiology (i.e., a causal relationship to another medical condition based on best clinical evidence) is the key variable in depressive disorder due to another medical condition. Thelisting of the medical conditions that are said to be able to induce major depression is nevercomplete, and the clinician\'s best judgment is the essence of this diagnosis.There are clear associations, as well as some neuroanatomical correlates, of depressionwith stroke, Huntington\'s disease, Parkinson\'s disease, and traumatic brain injury. Amongthe neuroendocrine conditions most closely associated with depression are Cushing\'s disease and hypothyroidism. There are numerous other conditions thought to be associatedwith depression, such as multiple sclerosis. However, the literature\'s support for a causalassociation is greater with some conditions, such as Parkinson\'s disease and Huntington\'sdisease, than with others, for which the <br />&nbsp;&nbsp;Differential Diagnosis may be adjustment disorder,with depressed mood. <br />&nbsp;&nbsp;DiagnosticMakersDiagnostic markers pertain to those associated with the medical condition (e.g., steroidlevels in blood or urine to help corroborate the diagnosis of Cushing\'s disease, which canbe associated with manic or depressive syndromes). <br />&nbsp;&nbsp;Differential DiagnosisDepressive disorders not due to another medical condition. Determination of whethera medical condition accompanying a depressive disorder is causing the disorder dependson a) the absence of an episode(s) of depressive episodes prior to the onset of the medical condition, b) the probability that the associated medical condition has a potential to promote or cause a depressive disorder, and c) a course of the depressive symptoms shortlyafter the onset oi^ worsening of the medical condition, especially if the depressive symptoms remit near the time that the medical disorder is effectively treated or remits.Medication-induced depressive disorder. An important caveat is that some medical conditions are treated with medications (e.g., steroids or alpha-interferon) that can induce depressive or manic symptoms. In these cases, clinical judgment, based on all the evidence in hand, isthe best way to try to separate the most likely and/or the most important of two etiological factors (i.e., association with the medical condition vs. a substance-induced syndrome).Adjustment disorders. It is important to differentiate a depressive episode from an adjustment disorder, as the onset of the medical condition is in itself a life stressor that couldbring on either an adjustment disorder or an episode of major depression. The major differentiating elements are the pervasiveness the depressive picture and the number andquality of the depressive symptoms that the patient reports or demonstrates on the mentalstatus examination. The <br />&nbsp;&nbsp;Differential Diagnosis of the associated medical conditions is relevant but largely beyond the scope of the present manual.', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('518', '46', 'Y03_014', '1', '临床诊疗指南——精神病学分册', ' ', ' 中华医学会', '2006', '中华医学会. 临床诊疗指南(精神病学分册)[M]. 人民卫生出版社, 2012.', '中文', null, null, null, null, ' 主要依据病史和精神检查，必要时作人格、智能等心理测验，脑CT或磁共振，脑电图或脑地形图等检查，以排除器质性精神障碍、精神活性物质和非成瘾物质所致抑郁。<br />&nbsp;&nbsp;1.临床上以持久的心境低落为主，主要表现思维缓慢、言语和动作减少；病程至少已持续2周；伴有社会功能受损，或给本人造成痛苦或不良后果。2.部分病例可有生物学特征性症状，如食欲降低、体重下降、星域减退、早醒、以及心境低落呈晨重夕轻的节律改变。3.反复出现相想死的念头或有自杀、自伤行为。4.可存在某些精神病性症状，但不符合精神分裂症的诊断。若同时符合精神分裂症的症状标准，在精神病性症状缓解后，满足抑郁发作标准至少2周。5.抑郁症的病程特点大多都具有发作性病程，而在发作间歇期精神状态可恢复病前水平。既往有类似的发作，或家族中有抑郁症遗传史，对诊断均有帮助。6.老年抑郁症除有抑郁心境外，多数患者有明显的焦虑烦躁情绪，也可以表现为易激惹和敌意。精神运动性迟缓和躯体不适主诉较年轻患者更为明显。7.地塞米松抑制试验（DST）、促甲状腺素激发试验和睡眠脑电图检查等，有时也有助于诊断。', null, null, ' 倡导全程治疗，应保证足量、足疗程，包括急性治疗、巩固治疗和维持治疗三期。急性期治疗6-8周，巩固期治疗4-6个月，维持治疗时间因人而异，第一次发作主张维持治疗6-12个月，第二次发作3-5年，第三次发作，应长期维持治疗。', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('519', '46', 'Y03_015', '0', '中医病证诊断疗效标准', ' ', ' 中华中医药学会', '1994', 'ZY/T 001.1-94, 中医内科病证诊断疗效标准[S].', '中文', null, null, '郁病', '1.肝气郁结<br />&nbsp;&nbsp;2.气郁化火<br />&nbsp;&nbsp;3.忧郁伤神<br />&nbsp;&nbsp;4.心脾两虚<br />&nbsp;&nbsp;5.阴虚火旺', '1 忧郁不畅，精神不振，胸闷胁胀，善太息。或不思饮食，失眠多梦，易怒善哭等症。2 有郁怒、多虑、悲哀、忧愁等情志所伤史。 3 经各系统检查和实验室检查可排除器质性疾病。4 应与癫病、狂病鉴别。 ', '1.肝气郁结：精神抑郁，胸胁作胀，或脘痞，嗳气频作，善太息，月经不调。\n舌苔薄白，脉弦。2 气郁化火：急躁易怒，胸闷胁胀，头痛目赤，口苦，嘈杂泛酸，便结尿黄。\n舌红，苔黄，脉弦数。3 忧郁伤神：神志恍惚不安，心胸烦闷，多梦易醒，悲忧善哭。舌尖红苔\n薄白，脉弦细。4 心脾两虚：善思多虑不解，胸闷心悸，失眠健忘，面色萎黄，头晕，神疲倦怠，易汗，纳谷不馨。舌淡，苔薄白，脉弦细或细数。5 阴虚火旺：病久虚烦少寐，烦躁易怒，头晕心悸，颧红，手足心热，口干\n咽燥，或见盗汗。舌红，苔薄，脉弦细或细数。', null, '治愈：症状消失，情绪正常。<br />&nbsp;&nbsp;好转：症状减轻，情绪基本稳定。\n<br />&nbsp;&nbsp;᳾愈：症状、情绪均无改善。 ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('52', '34', 'M06_007', '1', '鹿角形肾结石诊断治疗指南（2014）', null, '中华医学会泌尿外科分会', '2014', '那彦群, 叶章群, 孙光.中国泌尿外科疾病诊断治疗指南[M].北京：人民卫生出版社，2014.', '中文', null, '鹿角形肾结石', null, null, '1.影像学位查<br />&nbsp;&nbsp;1.1. 推荐的检查<br />&nbsp;&nbsp;1.1.1 x 线检查:90% 以上的尿路结石含有钙盐，在X 线尿路平片(KUB) 上可以显示其致密影。不同成分的结石在KUB 上的显影程度依次为草酸钙、磷酸钙和磷酸筷钱、脱氨酸、含尿酸盐结石。单纯性尿酸结石和黄晾口令结石能透过X 线，为X 线阴性结石。脱氨酸结石的密度低，在KUB上的显影比较淡(表7-1)0 KUB 可以发现90% 左右的X 线阳性结石能够大致地确定结石的位置、形态、大小和数量并且初步地确定结石的化学性质，是结石检查的常规方法。<br />&nbsp;&nbsp;M06_007_01不同成分X线特点.docx<br />&nbsp;&nbsp;静脉尿路造影(IVU) 简单易行，也是泌尿系结石的基本检查之一。应该在KUB 的基础上进行IVU 检查，其价值在于了解尿路的结构，确定结石的位置。此外，还可以了解分肾功能，确定肾积水的程度。在一侧肾脏功能严重受损或者使用普通造影剂量不显影的情况下，采用加大造影剂量(双剂量或大剂量)或者延迟拍片的方法往往可以达到肾脏显影的目的。<br />&nbsp;&nbsp;典型的鸟粪石结石在出现症状之前生长迅速，可充满整个集合系统，形成\"鹿角\"状外观。大多数感染性结石为X 线阳性结石，但由于其矿物质的含量较低故在KUB 上的密度显示比含钙结石低。<br />&nbsp;&nbsp;输尿管逆行插管造影或经皮肾穿刺造影属于有创的检查方法，不作为常规检查手段，仅在IVU不显影或显影不良、怀疑X 线阴性结石及需要作进一步的鉴别诊断时才选择使用。<br />&nbsp;&nbsp;1.1.2  B 超:B 超检查简便、快捷、经济、无创伤，元痛苦、无放射性、无需特殊造影剂、不受肾脏功能好坏的影响，是安全、理想的检查方式，最适合于对结石患者的筛选和随诊，可作为常规检查的项目。<br />&nbsp;&nbsp;1.1.3  CT: 多数情况下泌尿系结石的诊断需要做CT 检查。CT 诊断结石的敏感性和特异性均高于KUB 及IV它，而且能直观地显示结石与周边组织的关系，并可鉴别X 线阴性结石及其他原因引起的不显影。随着多层螺旋CT 在临床中的应用，泌尿系统影像的纵向空间分辨率大大提高， CT 泌尿系成像(CTU) 也正在逐步取代传统的KUB 、IVU及大部分的磁共振泌尿系成像(MRU)。<br />&nbsp;&nbsp;多层螺旋CT 具有较高的密度分辨率，能显示在KUB 上不易显示的含钙量低的结石和不显影的X 线阴性结石，同时可以发现是否合并肾囊肿、肾积水等，以便进行鉴别诊断。利用超薄层横断面图像进行二维及三维重建，如最大密度投影(maxium intensity projection , MIP)、多平部重建(multi -planar reformation , MPR)、容积重建( volumerending , VR) 等多种技术后处理，形成3D 图像，可任意方向旋转和观察，立体地显示结石和集合系统的全貌以及并发症的情况。通过MIP 、MPR 及VR 技术，在手术前对结石和肾脏的王维结构进行分析，可以发现鹿角状结石的各个分支以及各分支连接处所在的狭窄部位，判断其在肾脏的投影及其周围的肾实质厚度，显示肾孟肾盏的结构及其与结石的关系，测量肾盏颈的宽度及目标肾盏与相邻肾盏的角度，了解肾脏功能及肾周脏器的情况，对选择穿刺通道或肾皮质切口、指导手术或碎石治疗均具有重要的作用。<br />&nbsp;&nbsp;1.2  可选择的检查<br />&nbsp;&nbsp;1.2.1 同位素扫描(ECT): 对于需要外科干预的病例，肾功能的测定是必要的。虽然根据血清肌断或肌酐清除率即可明确总肾功能，但如果IVU或CTU 提示某一侧肾功能有可能异常，则应做ECT 来评估分肾功能。测定分肾功能对于判断保留肾脏还是切除肾脏是很有必要的。<br />&nbsp;&nbsp;ECT 放射性核素检查不能直接显示结石，但可以显示泌尿系统的形态提供肾脏血流灌注、肾功能及尿路梗阻等信息。因此，对手术方案的选择及手术疗效的评价具有一定的价值。此外，肾动态显影还用于评估SWL 对肾功能的影响。<br />&nbsp;&nbsp;1.2.2  磁共振水成像(MRU): 磁共振对尿路结石的诊断效果极差，一般不用于结石的检查。但，MRU 能够了解上尿路梗阻的情况，不需要造影剂即可获得与IVU 同样的效果，而且不受肾功能的影响。由于MRU 是一种非侵袭性、无需对比剂且无辐射损伤的检查方法，因此，对于造影剂过敏、严重肾功能损害、儿童和孕妇等不适合做IVU的患者可考虑采用。<br />&nbsp;&nbsp;2. 实验室检查<br />&nbsp;&nbsp;2.1. 血液分析血清肌酐的升高提示肾功能下降，通常是由于结石长期造成引流系统的梗阻、或者反复发生的肾孟肾炎最终导致肾实质的破坏所致。<br />&nbsp;&nbsp;检测血清白蛋白及钙可矫正白蛋白结合钙对血钙浓度的影响，亦可直接测定离子钙浓度。测定血清/血浆钙有助于甲状旁腺功能亢进(HPT)或其他与高钙血症有关疾病的诊断。若血钙浓度高(>2.6mmol/L) ，则应测定甲状旁腺激素水平，以确诊或排除HPT。 检测血尿酸可供考虑尿酸/尿酸盐结石时作选择分析，高尿酸血症患者的X 线阴性结石应考虑尿酸结石。<br />&nbsp;&nbsp;2.2. 尿液分析尿液标本必须是禁食的清晨新鲜尿，分析内容包括尿pH 、白细胞、菌尿检测、尿液培养等，其他方法不能排除脱氨酸尿症时行尿脱氨酸检查。<br />&nbsp;&nbsp;试图从感染性结石中根除细菌几乎是不可能的，患者通常表现为菌尿或版尿。所有准备行取石手术的患者都必须行菌尿的检查，对于病情并不复杂的病例，进行试纸法筛查是行之有效的，部分存在泌尿系感染的患者则需作尿细菌培养。脲酶阳性细菌的感染与碱性尿、镜检发现细菌、白细胞和\"同型异构形\"晶体密切相关。<br />&nbsp;&nbsp;尿液培养鉴定产生脲酶的细菌及抗生素敏感测试是指导术前治疗必不可少的。如果尿液细菌培养阴性，但高度怀疑磷酸铵镁结石，应考虑非典型微生物如解脲支原体、解脲棒杆菌或真菌的感染对于结石反复复发、有肾内残石和特别危险。<br />&nbsp;&nbsp;因素的复杂性肾结石患者，可选择24 小时尿液分析，包括尿钙、草酸、枸橼酸、尿酸、镁、磷酸、尿素、<br />&nbsp;&nbsp;钠、钾、肌酐及尿量等。测定镁和磷酸可估算草酸钙和磷酸钙离子活度积，测定尿素、磷酸盐、钠及钾可评估患者的饮食习惯。禁食晨尿pH 值>5.85才可考虑为完全性或不完全性肾小管酸中毒，应同时作酸负荷试验，并且进行血液pH 值、钾、碳酸氢盐和氯化物测定。<br />&nbsp;&nbsp;', null, '无石率,残余结石 ', '1. 无石率(stone free rates) 完全清除结石是治疗鹿角形结石的根本目标，以达到彻底消除致病微生物、预防结石再生长和伴发的感染以及保护肾功能的目的。因此，大多数学者认为，无石率是评价鹿角形结石治疗效果的一个最重要的指标元石\" (stone free , SF) 的定义为:X 线照片、B 超或者CT 扫描检查无残留结石的证据。\"无石率\" (stone free rates) 是指在某一组研究对象中，在结石治疗后的特定阶段内复查X 线照片、B 超或者CT 扫描，将之与术前对比，确认为\"无石\"的患者的数量占所有研究对象的比率。由于鹿角形肾结石需要多次的系列治疗，因此，无石率的评价可分为三个阶段:①首次治疗后的元石率;②所有主要治疗后的无石率(主要是指用同一种方法进行完全治疗后，如SWL); ③所有治疗后的无石率(主要指应用一种以上所有治疗方法后，如:SWL+PNL ，等)。因此，对比不同治疗方法的元石率时，应注意区分评价时不同的治疗方法所处的治疗阶段是否相同。目前大部分学者所统计的无石率均是指首次治疗后的无石率，如果用这些数据来评估所有治疗后的无石率就会出现偏低的结果。<br />&nbsp;&nbsp;在判断鹿角形结石治疗效果的指标中，无石率是最重要的指标。无石率与结石的大小、部位、复杂程度和医师经验等诸多的因素有关。目前国内外对完全性鹿角形结石采用联合治疗的无石率可达到87% 以上。<br />&nbsp;&nbsp;2. 残余结石(residual stones) 治疗后直径≥5mm 的结石称为残余结石。残余结石多发生于SWL 或其他体内碎石术后，且多见于肾下盏。<br />&nbsp;&nbsp;文献报道残余结石的发生率因检测方法的不同而有差异。残余结石的临床危害性在于:①以残余结石为核心，形成新的结石;②使尿路感染持续存在;③残余结石位置的移动可能会导致梗阻，引发症状。<br />&nbsp;&nbsp;临床无意义残石(clinically insignificant residualfragments , CIRF): 传统上，对于治疗后直径≤4mm的结石残余物，定义为残余碎片。临床无意义残石( CIRF) 是指治疗后残石直径≤4mm 的草酸钙或磷酸钙结石、上尿路解剖正常、无尿路感染或者其他任何症状者。目前，对于检测非常细小的残余碎片的临床价值尚存在争议。<br />&nbsp;&nbsp;一般来说，对于无症状的CIRF 可以不继续临床处理，密切随访观察;而对于有症状的CIRF ，应积极去除结石。<br />&nbsp;&nbsp;对于直径≥5mm 或者有临床症状的残余结石，即临床有意义残石(significant residual fragments ，SIRF) 则需要积极处理。有资料表明，随着时间的延长，残余结石会逐渐增大，结石的复发率随之增加，部分患者需要重复进行取石治疗。感染性结石治疗后如有结石残留，则其复发率较其他类型的结石明显增加。就所有类型结石而言， 21%-59%伴有残余结石的患者在5 年内需要再次治疗。因此，目前认为，对于所有的残留结石都应该积极处理。处理原则和治疗方法的选择，与治疗前的原发性结石相同或再次SWL。PNL 后1-3 天，<br />&nbsp;&nbsp;利用原通道再次观察，如发现有结石残留，及时进行处理，可避免残余结石的发生。<br />&nbsp;&nbsp;', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('520', '46', 'Y03_017', '0', '中医内科常见病诊疗指南 中医病证部分', ' ', ' 中国中医药出版社', '2008', 'ZYYXH/T 49-2008, 郁病[S].', '中文', null, null, null, '1.肝气郁结证<br />&nbsp;&nbsp;2.血行郁滞证<br />&nbsp;&nbsp;3.肝郁脾虚证<br />&nbsp;&nbsp;4.肝胆湿热证<br />&nbsp;&nbsp;5.忧郁伤神证<br />&nbsp;&nbsp;6.肾虚肝郁证\n', ' ', '1诊断要点1.1以忧郁不畅，情绪不宁，胸胁胀满疼痛，或者易哭善怒，情绪多变，或者咽中如有物阻为主要临床症状。1.2多有忧愁、焦虑、悲哀、恐惧、愤怒等情志内伤史，且病情的反复常与各种因素导致的情绪变化相关。1.3各系统检查和理化检查正常，可以除外器质性疾病。2鉴别诊断2.1癫证：郁病者可见神志恍惚、悲忧善哭、喜怒无常等表现，应与癫证相鉴别。癫者多发青壮年，男女发病率没有显著性差别，病程较长，病证难以自愈，较少自行缓解；郁病为女性多见，受精神刺激可间歇性发作，停则如常人。2.2阴虚喉痹：郁病中有梅核气症状者多畻坴畿\0\0\0\0醼畻聱盯\r\0\0\0痭ᦠ੏ༀƙ\0੏Ð\0\r\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄돀఑੏Ð\0ꐘ఑彿㎽奋㎽巫㎽఑ࡸఒ彿㎽࡬ఒ塚㎽ࡸఒꍈ㏂\0\0돀఑學㎽漸㏂圔㎽돀఑圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0柰ఉ䐺盭暼痭柰ఉༀƙ \0柰ఉĀ\0\0㺣盭柰ఉ\0𢡄柴ఉ\0팃目柴ఉ࣒柴ఉ큁目柴ఉ돴఑泌\0Item\0\0ࣼఒ\0\0\0\0\0\0Count\0\0﫨呂栤ఉ㳜੪\0\0柴ఉ\0\0\0\0੪寶目㳠੪楱䥷㎽఑\0\0ࣼఒ�㏂࡬ఒ\0\0\0੪\0\0\0露𢡄\0\0㎾ଂ\0齃\0\0x�㏂࡬ఒ\0\0隲Wࣼఒ\0\0�Ĳ\0\0\0鹿齃殺\0\0霈W戀醙霫W戀ꊠऺ齃x\r\0霪W露Wꊠऺ﫰xt\0Љ\0\0\0൐௲鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0⑰ਫ਼⑰ਫ਼\0\0寶目㲈੪담఑i\0\0變ﱘ﫰﬐먙㎼담఑㲈੪i\0\0變ﱘ﫰먰㎼ﱘ담఑�㏂뉤఑\0\0릎㎼담఑i\0⓮췬目⓲췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒൐௲竗൐௲目W\0竗\0\0\0目\0\0\0\0돴఑\0目瑉浥目\0\0\0\0돴఑\0目潃湵t\0\0\0ɩ\0\0ဠ\0\0̨賓̨̙\0\0\0\0\0\0\0̙῰̓\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0῰̓\0\0\0\0̙華뎥ဆ\0ē\0錠ƚ錠ƚ룤ဆ돜်錠ƚ瞑\0\0륿ရ╖췬╞췬目Љ\0鲸࣒\0￿￿目Љ\0鲬࣒൐௲觴൐௲目t\0觴\0\0\0梅礼目\0\0\0\0﫤담఑目潅f䓾瑤\0\0豸ࢋ\0\0核ʊ\0\0䒛瑤䕢瑤ꂸ瑧\0䔯瑤䑩瑤굨ʌ䀷瑤檨ਗ਼ᛒ瑤\0㽺瑤\0\0㿣瑤檨ਗ਼\0\0￿￿￿￿㯄瑽嵞盡㨣瑽Ә´椰ਗ਼\0\0鍈盠僦璅Ә´\0椰ਗ਼鰈瑼∘䬁\0\0難$\0ු⬁\0\0\0\0\0\0Ĺ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0㉘췭骶瑼椰ਗ਼\0\0\0\0\0\0\0\0\0\0\0᭟盡@Ә´㈠췭쓷盡Ә´\0\0\0\0\0\0ꯍ�\0\0\0\0邰ƙ\0\0ࠀ옎盡㰂췭\0駨瑼\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ菱담఑ﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀﬘眿ฒࣼఒ磻ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿菱￿￿\0\0異\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ\0\0\0\0\0奰畿⡥췬焚畻邰ƙࠀ菱￿￿㏂￿￿\0\0\0\0滑煔畻:\0菱￿￿㏂￿￿奰畿\0\0\0\0璉㎾ࠄ\0\0菱￿￿㏂㎾x\0\0�㏂࡬ఒ\0\0頲W怜\0\0\0\0ࠄ\0顇WValu\0\0菱令ࣼఒ齃\0\0\0\0\0\0菱\0磻\0窱餀W齃', null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('521', '46', 'Y03_018', '1', '中国精神障碍分类与诊断标准CCMD-3', 'CCMD-3 ', '《中国精神障碍分类与诊断标准第3版(CCMD-3)》工作组 ', '2001', 'http://www.doc88.com/p-49613027594.html', '中文', null, null, null, null, ' 抑郁发作以心境低落为主，与其处境不相称，可以从闷闷不乐到悲痛欲绝，甚至发生木僵，严重者可出现幻觉、妄想等精神病性症状。某些病例的焦虑与运动性激越很显著。症状标准，以心境低落为主，并至少有下列4项：（1）兴趣丧失、无愉快感，（2）精力减退或疲乏感（3）精神运动性迟滞或激越（4）自我评价过低、自责，或有内疚感（5）联想困难或自觉思考能力下降，（6）反复出现相死的念头或有自杀、自伤行为（7）睡眠障碍，如失眠、早醒，或睡眠过多（8）食欲降低或体重明显减轻（9）性欲减退<br />&nbsp;&nbsp;严重标准，社会功能受损，给本人造成痛苦或不良后果。<br />&nbsp;&nbsp;病程标准（1）符合症状标准和严重标准至少已持续2周。（2）可存在某些分裂性症状，但不符合分裂症的诊断。若同时符合分裂症的症状标准，分裂症状缓解后，满足抑郁发作标准至少2周。<br />&nbsp;&nbsp;排除标准，排除器质性精神障碍，或精神活性物质和非成瘾物质所致抑郁。<br />&nbsp;&nbsp;轻性抑郁症，除了社会功能无损害或仅轻度损害外，发作符合32抑郁发作的全部标准。<br />&nbsp;&nbsp;无精神病性症状的抑郁症，除了在32抑郁发作的症状标准中，增加“无幻觉、妄想，或紧张综合征等精神病性症状”之外，其余均符合标准。<br />&nbsp;&nbsp;有精神病性症状的抑郁症，除了在抑郁发作 的症状标准中，增加了“有幻觉、妄想，或紧张综合征等精神病性症状”之外，其余均符合该标准。<br />&nbsp;&nbsp;发作性抑郁症【诊断标准】（1）目前发作符合某一型抑郁标准，并在间隔至少2个月前，有过另一次发作符合某一抑郁标准。（2）以前从未有符合任何一型躁狂、双相惰感障碍，或环性情感障碍标准，（3）排除器质性精神障碍，或精神活性物质和非成瘾物质所致的抑郁发作。<br />&nbsp;&nbsp;复发性抑郁症，目前为轻抑郁，符合复发性抑郁的诊断标准，目前发作符合轻抑郁标准。<br />&nbsp;&nbsp;复发性抑郁症，目前为无精神病性症状的抑郁，符合复发性抑郁的诊断标准，目前发作符合无精神病性症状的抑郁标准。<br />&nbsp;&nbsp;复发性抑郁症，目前为有精神病性症状的抑郁，符合复发性抑郁的诊断标准，目前发作符合有精神病性症状的抑郁标准。<br />&nbsp;&nbsp;其他或待分类的抑郁症。', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('522', '46', 'Y03_020', '1', '中国精神障碍分类与诊断标准CCMD-4（征询意见稿）', 'CCMD-4', '中华精神科学会', null, 'http://www.doc88.com/p-637728725911.html', '中文', null, null, null, null, ' 32 抑郁发作[F32] 32.1  轻抑郁[F32.0] 32.2  无精神病性症状的抑郁[F32.1] 32.3  有精神病性症状的抑郁[F32.2] 32.4  复发性抑郁[F33] 32.41 复发性抑郁，目前为轻抑郁[F33.0] 32.42 复发性抑郁，目前为无精神病性症状的抑郁[33.2] 32.43 复发性抑郁，目前为有精神病性症状的抑郁[33.3] 32.9  其它或待分类的抑郁[F32.8; F32.9]【诊断标准】32抑郁发作[F32] 以心境低落为主，与其处境不相称，可以从闷闷不乐到悲痛欲绝，甚至发生木僵。严重者 可出现幻觉、妄想等精神病性症状。某些病例的焦虑与运动性激越很显著。一、症状标准：以心境低落为主，并至少有下列 4项： 1.兴趣丧失、无愉快感； 2.精力减退或疲乏感； 3.精神运动性迟滞或激越； 4.自我评价过低、自责，或有内疚感； 5.联想困难或自觉思考能力下降； 6.反复出现想死的念头或有自杀、自伤行为； 7.睡眠障碍，如失眠、早醒，或睡眠过多； 8.食欲降低或体重明显减轻； 9.性欲减退。 二、严重标准：社会功能受损，或给本人造成痛苦或不良后果。 三、病程标准： 1.符合症状标准和严重标准至少已持续 2周。 2.可存在某些分裂性症状，但不符合分裂症的诊断。若同时符合分裂症的症状标准，在分 裂症状缓解后，满足抑郁发作标准至少 2周。 四、排除标准：排除器质性精神障碍，或精神活性物质和非成瘾物质所致抑郁。 说明：本抑郁发作标准仅适用于单次发作的诊断。  32.1轻抑郁[F32.0] 除了社会功能无损害或仅轻度损害外，发作符合32抑郁发作的全部标准。  32.2无精神病性症状的抑郁[F32.1] 除了在32抑郁发作的症状标准中，增加“无幻觉、妄想，或紧张综合征等精神病性症状” 之外，其余均符合该标准。  32.3有精神病性症状的抑郁[F32.2] 除了在32抑郁发作的症状标准中，增加“有幻觉、妄想，或紧张综合征等精神病性症状” 之外，其余均符合该标准。  32.4复发性抑郁[F33] 1.目前发作符合某一型抑郁标准，并在间隔至少 2个月前，有过另 1次发作符合某一型抑 郁标准； 2.以前从未有躁狂符合任何一型躁狂、双相情感障碍，或环性情感障碍标准； 3.排除器质性精神障碍，或精神活性物质和非成瘾物质所致的抑郁发作。  32.41 复发性抑郁，目前为轻抑郁[F33.0] 符合32.4复发性抑郁的诊断标准，目前发作符合32.1轻抑郁标准。  32.42 复发性抑郁，目前为无精神病性症状的抑郁[33.2] 符合32.4复发性抑郁的诊断标准，目前发作符合32.2无精神病性症状的抑郁标准。  32.43 复发性抑郁，目前为有精神病性症状的抑郁[33.3] 符合32.4复发性抑郁的诊断标准，目前发作符合32.3有精神病性症状的抑郁标准。  32.9其它或待分类的抑郁[F32.8; F32.9]  ', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('523', '46', 'Y03_022', '1', '疾病和有关健康问题的国际统计分类', 'ICD-10（International Statistical Classification of Diseases and Related Health Problems 10th Revision） ', ' WHO', '2016', 'http://apps.who.int/classifications/icd10/browse/2016/en', '英文', null, null, null, null, ' Depressive episode\nIn typical mild, moderate, or severe depressive episodes, the patient suffers from lowering of mood,reduction of energy, and decrease in activity. Capacity for enjoyment, interest, and concentration is reduced, and marked tiredness after even minimum effort is common. Sleep is usually disturbed and appetite diminished. Self-esteem and self-confidence are almost always reduced and, even in the mild form, some ideas of guilt or worthlessness are often present. The lowered mood varies little from day to day, is unresponsive to circumstances and may be accompanied by so-called ‘somatic’ symptoms, such as loss of interest and pleasurable feelings, waking in the morning several hours before the usual time, depression worst in the morning, marked psychomotor retardation, agitation, loss of appetite, weight loss, and loss of libido. Depending upon the number and severity of the symptoms, a depressive episode may be specified as mild, moderate or severe.\nIncludes: single episodes of:\n– depressive reaction\n– psychogenic depression\n– reactive depression\nExcludes: adjustment disorder (F43.2)\nrecurrent depressive disorder (F33.-)\nwhen associated with conduct disorders in F91.- (F92.0)\nF32.0 Mild depressive episode\nTwo or three of the above symptoms are usually present. The patient is usually distressed by these but will probably be able to continue with most activities.\nF32.1 Moderate depressive episode\nFour or more of the above symptoms are usually present and the patient is likely to have great difficulty in continuing with ordinary activities.\nF32.2 Severe depressive episode without psychotic symptoms\nAn episode of depression in which several of the above symptoms are marked and distressing, typically loss of self-esteem and ideas of worthlessness or guilt. Suicidal thinking and acts are common and a number of ‘somatic’ symptoms are usually present.\nAgitated depression } Major depression } single episode without psychotic symptoms\nVital depression }\nF32.3 Severe depressive episode with psychotic symptoms\nAn episode of depression as described in F32.2, but with the presence of hallucinations, delusions,psychomotor retardation, or stupor so severe that ordinary social activities are impossible; there may be danger to life from suicide, dehydration, or starvation. The hallucinations and delusions may or may not be mood-congruent.\nSingle episodes of: – major depression with psychotic symptoms – psychogenic depressive psychosis\n– psychotic depression\n– reactive depressive psychosis\nF32.8 Other depressive episodes\nAtypical depression\nSingle episodes of ‘masked’ depression not otherwise specified\nF32.9 Depressive episode, unspecified\nDepression not otherwise specified\nDepressive disorder not otherwise specified\nF33 Recurrent depressive disorder\nA disorder characterised by repeated episodes of depression as described for depressive episode\n(F32.-), without any history of independent episodes of mood elevation and increased energy (mania).\nThere may, however, be brief episodes of mild mood elevation and overactivity (hypomania) immediately\nafter a depressive episode, sometimes precipitated by antidepressant treatment. The more severe forms\nof recurrent depressive disorder (F33.2 and F33.3) have much in common with earlier concepts such\nas manic-depressive depression, melancholia, vital depression and endogenous depression. The first\nepisode may occur at any age from childhood to old age, the onset may be either acute or insidious, and\nthe duration varies from a few weeks to many months. The risk that a patient with recurrent depressive\ndisorder will have an episode of mania never disappears completely, however many depressive episodes\nhave been experienced. If such an episode does occur, the diagnosis should be changed to bipolar\naffective disorder (F31.-).\nIncludes: recurrent episodes of:\n– depressive reaction\n– psychogenic depression\n– reactive depression\nseasonal depressive disorder\nExcludes: recurrent brief depressive episodes (F38.1)\n', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('524', '46', 'Y03_024', '1', '成人抑郁症临床实践指南', 'Clinical practice guideline on the management of depression in adults.', null, '2008', null, '英文', null, 'depression', null, null, ' Evaluation and Screening for Depression<br />&nbsp;&nbsp;Evaluation of Depression<br />&nbsp;&nbsp;How should depression be evaluated?<br />&nbsp;&nbsp;√: The clinical interview is the essential procedure for the diagnosis of depression. The International Classification of Diseases (ICD) and Diagnostic and Statistical Manual ofMental Disorders (DSM) provide a set of agreed criteria to rely on.<br />&nbsp;&nbsp;C: Due to the existence of different factors that may affect the progress, course and severity of depression, it is recommended to evaluate the following areas:Features of the episode: duration, number and intensity of symptoms, comorbidityPsychosocial assessment (social support and interpersonal relationships)Degree of associated dysfunction and/or disabilitiesRisk of suicide Response to previous treatment<br />&nbsp;&nbsp;C: It is recommended to assess the risk of suicide in patients with depression, considering the following factors:Presence of previous suicide attempts, other comorbid mental disorders and substance abuseSpecific symptoms such as hopelessness, anxiety, agitation or suicidal ideationOther risk factors such as physical illness, chronicity, pain or disability, family history of suicide, social factors and a history of suicide in the environment<br />&nbsp;&nbsp;Q: When assessing depression, it is recommended to consider the heterogeneity of its presentation as well as the perception patients have about their symptoms and thedisorder.<br />&nbsp;&nbsp;Q: It is recommended to pay special attention to issues that affect the daily lives of patients with depression which may have a greater functional impact.<br />&nbsp;&nbsp;Q: The assessment should consider the sociodemographic and cultural factors that may affect the development or maintenance of depressive symptoms and influence treatment,such as sex, family, social network and perceived stigma.<br />&nbsp;&nbsp;Q: The meaning and impact of depression on the patient\'s family and any needs that may arise should be explored; especially regarding children, adolescents and familydependent upon the depressed patient.<br />&nbsp;&nbsp;Q: It is recommended to encourage the communication of feelings and emotions in an empathetic and respectful environment.<br />&nbsp;&nbsp;Q: When a diagnosis of depression is made, all the necessary information about the disorder and treatment options, as well as explanations to reduce the guilt and stigmaattached, must be promoted and provided.<br />&nbsp;&nbsp;Assessment Instruments<br />&nbsp;&nbsp;Which scales have the best psychometric properties for the assessment of depression in adults?√: The scales provide additional information in the evaluation, but cannot replace the clinical interview.<br />&nbsp;&nbsp;D: Some of the scales that may be useful in assessing depression are the Hamilton Rating Scale for Depression (HRSD), the Montgomery Asberg Depression Rating Scale(MADRS), the 9-item (Brief) Patient Health Questionnaire (PHQ-9) and the Beck Depression Inventory (BDI).<br />&nbsp;&nbsp;Depression Screening<br />&nbsp;&nbsp;Does screening improve health outcomes in depression?<br />&nbsp;&nbsp;B: Routine screening for depression is not recommended for the general population, as there are reasonable doubts about its effectiveness.<br />&nbsp;&nbsp;B: Clinicians should be alert to the possibility of depression, especially in patients with risk factors who also have symptoms such as insomnia, low mood, anhedonia and suicidalideation.<br />&nbsp;&nbsp;B: In primary care, when an indicator for depression is observed in a routine examination, it is recommended to use two questions about mood and the ability to enjoy to assessfor the presence of depressive disorders. If the response is positive, an appropriate psychopathological assessment is recommended.', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('525', '46', 'Y03_025', '1', '中国精神障碍分类与诊断标准CCMD-2R', null, '中华精神科学会精神疾病分类方案与诊断修订小组', '1994', 'http://www.docin.com/p-127823319.html', '中文', null, '抑郁症', null, null, ' 抑郁症总论（296.1；F32，F33） <br />&nbsp;&nbsp;以心境显著而持久的改变——低落为基本临床表现， 伴有相应的思维和行为改变， 有反复发作的倾向，间歇期完全缓解。发作症状较轻者可达不到精神病的程度。本病发作可表现为抑郁相，其含义和诊断标准为：患者心境低落，与所处的境遇不相称，可以从闷闷不乐到悲痛欲绝，甚至发生木僵状态。严重者可出现妄想、幻觉等精神病性症状，某些病例中焦虑与运动性激越比抑郁更为显著。<br />&nbsp;&nbsp;【抑郁发作诊断标准】<br />&nbsp;&nbsp;一、症状标准，以心境低落为主要特征且持续至少二周，在此期间至少有下述症状中的四项：<br />&nbsp;&nbsp;1.对日常活动丧失兴趣，无愉快感；<br />&nbsp;&nbsp;2.精力明显减退，无原因的持续疲乏感；<br />&nbsp;&nbsp;3.精神运动性迟滞或激越；<br />&nbsp;&nbsp;4.自我评价过低，或自责，或有内疚感，可达妄想程度；<br />&nbsp;&nbsp;5.联想困难，或自觉思考能力显著下降；<br />&nbsp;&nbsp;6.反复出现想死的念头，或有自杀行为；<br />&nbsp;&nbsp;7. 失眠，或早醒，或睡眠过多；<br />&nbsp;&nbsp;8.食欲不振，或体重明显减轻；<br />&nbsp;&nbsp;9.性欲明显减退。<br />&nbsp;&nbsp;二、严重程度标准，精神障碍至少造成下述情况之一：<br />&nbsp;&nbsp;1.社会功能受损；<br />&nbsp;&nbsp;2.给本人造成痛苦或不良后果。<br />&nbsp;&nbsp;五、 排除标准：与躁狂发作所列内容相同。<br />&nbsp;&nbsp;【抑郁症诊断标准】<br />&nbsp;&nbsp;一、符合抑郁发作的诊断标准。<br />&nbsp;&nbsp;二、过去无躁狂发作的依据。<br />&nbsp;&nbsp;32.0 单次发作抑郁症（296.1；F32） <br />&nbsp;&nbsp;【诊断标准】<br />&nbsp;&nbsp;一、符合抑郁症的诊断标准。<br />&nbsp;&nbsp;二、过去从无躁狂发作或抑郁发作的依据。<br />&nbsp;&nbsp;32.l 反复发作抑郁症（296.1；F33） <br />&nbsp;&nbsp;【诊断标准】<br />&nbsp;&nbsp;一、本次发作符合抑郁症的诊断标准。<br />&nbsp;&nbsp;二、过去有抑郁发作史，但无躁狂发作史。', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('526', '46', 'Y03_026', '1', '中医神志病临床诊疗指南', null, '中华中医药学会', '2015', '中国中医药学会.ZYYXH/T442-471-2015，中医生治病临床诊疗指南[S].北京：中国中医药出版社，2015.', '中文', null, null, '悲病', '心肺气虚证；肝脾失调证；痰浊内盛证', ' ', '诊断要点1.临床表现：情绪低落，无故悲伤，悲痛欲哭，平素遇事易激动流泪，易悲伤，不能自控。2.辅助检查：头颅CT/MRI检查排除其他器质性病变，汉密尔顿抑郁量表，汉密尔顿焦虑量表及明尼苏达多项人格测验对本病的诊断有参考作用。3.鉴别诊断，悲病当与卑惵、脏燥、郁病作出鉴别。<br />&nbsp;&nbsp;1.心肺气虚证：善悲欲哭，情绪低沉，心悸气短，失眠多梦，舌质红，苔白，脉象沉细。2.肝脾失调证：善悲欲哭，以哭为快，甚则大哭倒地，或悲而易怒，心烦不寐，坐卧不宁，腹胀便溏，舌质红，苔白或少津，脉沉细。3.痰浊内盛证：善悲欲哭，表情畻坴畿\0\0\0\0醼畻聱盯\r\0\0\0痭柰ఉༀƙ\0ఉĀ\0\r\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0', null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('527', '56', 'Z02_007', '1', '自发性脑出血诊疗指南', ' ', '美国心脏协会(AHA,American Heart Association); 美国卒中协会(ASA,American Stroke Association)', '2010', '杜伟, 范存刚, 张庆俊. 解读2010年美国心脏协会／美国中风协会《自发性脑出血诊疗指南》[J]. 中华神经外科杂志, 2011, 27(10):1074-1076.', '英文', '', '自发性脑出血intracerebral hemorrhage, ICH', '', '', 'Emergency Diagnosis and Assessment of ICHand Its Causes<br />\r\n&nbsp;&nbsp;ICH is a medical emergency. Rapid diagnosis and attentivemanagement of patients with ICH is crucial because early deterioration is common in the first few hours after ICHonset. More than 20% of patients will experience a decreasein the Glasgow Coma Scale (GCS) score of 2 pointsbetween the prehospital emergency medical services assessment and the initial evaluation in the emergency department(ED).7 Among those patients with prehospital neurologicaldecline, the GCS score decreases by an average of 6 pointsand the mortality rate is 75%. Further, within the first hourof presentation to a hospital, 15% of patients demonstrate adecrease in the GCS score of 2 points.8 The risk for earlyneurological deterioration and the high rate of poor long-termoutcomes underscores the need for aggressive earlymanagement.<br />\r\n&nbsp;&nbsp;Neuroimaging<br />\r\n&nbsp;&nbsp;The abrupt onset of focal neurological symptoms is presumed tobe vascular in origin until proven otherwise. However, it isimpossible to know whether symptoms are due to ischemia orhemorrhage based on clinical characteristics alone. Vomiting,systolic BP 220 mm Hg, severe headache, coma or decreasedlevel of consciousness, and progression over minutes or hours allsuggest ICH, although none of these findings are specific; neuroimaging is thus mandatory.19 CT and magnetic resonanceimaging (MRI) are both reasonable for initial evaluation. CT isvery sensitive for identifying acute hemorrhage and is considered the gold standard; gradient echo and T2*susceptibilityweighted MRI are as sensitive as CT for detection of acute bloodand are more sensitive for identification of prior hemorrhage.20,21Time, cost, proximity to the ED, patient tolerance, clinical status,and MRI availability may, however, preclude emergent MRI ina sizeable proportion of cases.22<br />\r\n&nbsp;&nbsp;The high rate of early neurological deterioration after ICH isin part related to active bleeding that may proceed for hours aftersymptom onset. The earlier time from symptom onset to firstneuroimage, the more likely subsequent neuroimages willdemonstrate hematoma expansion.15,23,24 Among patientsundergoing head CT within 3 hours of ICH onset, 28% to38% have hematoma expansion of greater than one third on follow-up CT.8,25 Hematoma expansion is predictive ofclinical deterioration and increased morbidity and mortality.8,10,15,25 As such, identifying patients at risk for hematomaexpansion is an active area of research. CT angiography andcontrast-enhanced CT may identify patients at high risk ofICH expansion based on the presence of contrast extravasation within the hematoma.26–30 MRI/angiogram/venogramand CT angiogram/venogram are reasonably sensitive atidentifying secondary causes of hemorrhage, including arteriovenous malformations, tumors, moyamoya, and cerebralvein thrombosis.31–33 A catheter angiogram may be considered if clinical suspicion is high or noninvasive studies aresuggestive of an underlying vascular cause. Clinical suspicionof a secondary cause of ICH may include a prodrome ofheadache, neurological, or constitutional symptoms. Radiological suspicions of secondary causes of ICH should be invoked by the presence of subarachnoid hemorrhage, unusual (noncircular) hematoma shape, the presence of edemaout of proportion to the early time an ICH is first imaged, anunusual location for hemorrhage, and the presence of otherabnormal structures in the brain like a mass. An MR or CTvenogram should be performed if hemorrhage location, relative edema volume, or abnormal signal in the cerebral sinuseson routine neuroimaging suggest cerebral vein thrombosis.In summary, ICH is a medical emergency, characterized by highmorbidity and mortality, which should be promptly diagnosed andaggressively managed. Hematoma expansion and early deterioration are common within the first few hours after onset. <br />\r\n&nbsp;&nbsp;Recommendations<br />\r\n&nbsp;&nbsp;1. Rapid neuroimaging with CT or MRI is recommendedto distinguish ischemic stroke from ICH (Class I; Levelof Evidence: A). (Unchanged from the previous guideline)<br />\r\n&nbsp;&nbsp;2. CT angiography and contrast-enhanced CT may beconsidered to help identify patients at risk for hematoma expansion (Class IIb; Level of Evidence: B), andCT angiography, CT venography, contrast-enhancedCT, contrast-enhanced MRI, magnetic resonance angiography, and magnetic resonance venography can be useful to evaluate for underlying structural lesions,including vascular malformations and tumors whenthere is clinical or radiological suspicion (Class IIa;Level of Evidence: B). (New recommendation)对突然出现的局灶神经症状，伴有呕吐、收缩压＞220mmHg、剧烈头痛或意识障碍进行性加重者，应当首先考虑ICH的可能，在影像学检查方面，CT 依然是诊断急性ICH的金标准。复查CT时血肿增大，强大CT可见造影剂自血肿周围外渗均提示存在活动性出血，与不良预后有关（2类证据）对疑为动静脉畸形，肿瘤，烟雾病或颅内静脉血栓等引起ICH者，可以根据情况行MRI/MRA/MRV/CTA/CTV等检查以明确诊断（2类证据）MRI诊断价值与CT相似（1类证据），在发现陈旧出血灶方面优于CT，但远不如CT快捷简便。', '', '', '', ' ', '5', '0', null, null, 'admin', '2016-05-06 15:08:32');
INSERT INTO `biz_standard` VALUES ('528', '56', 'Z02_008', '1', '成人自发性脑出血诊疗指南', 'Guidelines for the management of spontaneous intracerebral hemorrhage in adults ', '美国心脏协会(AHA,American Heart Association); 美国卒中协会(ASA,American Stroke Association)', '2007', null, '英文', '1.Class I Conditions for which there is evidence for and/or general agreement that the procedure or treatment is useful andeffective<br />&nbsp;&nbsp;2.Class II Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of aprocedure or treatmentClass IIa The weight of evidence or opinion is in favor of the procedure or treatmentClass IIb Usefulness/efficacy is less well established by evidence or opinion<br />&nbsp;&nbsp;3.3Class III Conditions for which there is evidence and/or general agreement that the procedure or treatment is notuseful/effective and in some cases may be harmful）', '自发性脑出血', null, null, 'Rapid recognition and diagnosis of ICH are essential becauseof its frequently rapid progression during the first severalhours. The classic clinical presentation includes the onset ofa sudden focal neurological deficit while the patient is active,which progresses over minutes to hours. This smooth symptomatic progression of a focal deficit over a few hours isuncommon in ischemic stroke and rare in subarachnoidhemorrhage. Headache is more common with ICH than withischemic stroke, although less common than in subarachnoidhemorrhage.9\nVomiting is more common with ICH than with eitherischemic stroke or subarachnoid hemorrhage. Increased bloodpressure and impaired level of consciousness are common.9However, clinical presentation alone, although helpful, isinsufficient to reliably differentiate ICH from other strokesubtypes.\nThe early risk of neurological deterioration and cardiopulmonary instability in ICH is high. Identification of prognostic indicators during the first several hours is very important forplanning the level of care in patients with ICH. The volumeof ICH and grade on the Glasgow Coma Scale (GCS) onadmission are the most powerful predictors of death by 30days.10 Hydrocephalus was an independent indicator of 30-day death in another study.11 Conversely, cortical location,mild neurological dysfunction, and low fibrinogen levelshave been associated with good outcomes in medium to largeICH.\nBecause of the difficulty in differentiating ICH fromischemic stroke by clinical measures, emergency medicinepersonnel triage and transport patients with ICH and ischemicstroke to hospitals similarly. As described below, patientswith ICH often have greater neurological instability and riskof very early neurological deterioration than do patients withischemic stroke and will have a greater need for neurocriticalcare, monitoring of increased intracranial pressure (ICP), andeven neurosurgical intervention. This level of care mayexceed that available at some hospitals, even those that meetthe criteria for primary stroke centers. Thus, each hospitalthat evaluates and treats stroke patients should determinewhether the institution has the infrastructure and physiciansupport to manage patients with moderate-sized or large ICHsor has a plan to transfer these patients to a tertiary hospitalwith the appropriate resources.\nInitial clinical diagnostic evaluation of ICH at the hospitalinvolves assessment of the patient’s presenting symptoms andassociated activities at onset, time of stroke onset, age, andother risk factors. The patient or witnesses are questionedabout trauma; hypertension; prior ischemic stroke, diabetesmellitus, smoking, use of alcohol and prescription, over-thecounter, or recreational drugs such as cocaine; use of warfarinand aspirin or other antithrombotic therapy; and hematologicdisorders or other medical disorders that predispose to bleeding, such as severe liver disease.<br />&nbsp;&nbsp;The physical examination focuses on level of consciousness and degree of neurological deficit after assessment of airway, breathing, circulation, and vital signs. In severalretrospective studies, elevated systolic blood pressure160 mm Hg on admission has been associated with growthof the hematoma, but this has not been demonstrated inprospective studies of ICH growth.13–16 Fever 37.5°C thatpersists for 24 hours is found in 83% of patients with pooroutcomes and correlates with ventricular extension of thehemorrhage.<br />&nbsp;&nbsp;Brain imaging is a crucial part of the emergent evaluation.Computed tomography (CT) and magnetic resonance scansshow equal ability to identify the presence of acute ICH, itssize and location, and hematoma enlargement. Deep hemorrhages in hypertensive patients are often due to hypertension,whereas lobar hemorrhages in nonhypertensive elderly patients are often due to cerebral amyloid angiopathy; however,a substantial number of lobar hemorrhages in hypertensivepatients may be due to hypertension, and both deep andsuperficial hemorrhages may be caused by vascular abnormalities and other nonhypertensive causes\nCT may be superior at demonstrating associated ventricular extension, whereas magnetic resonance imaging (MRI) issuperior at detecting underlying structural lesions and delineating the amount of perihematomal edema and herniation. ACT scan with contrast may identify an associated aneurysm,arteriovenous malformation, or tumor. CT angiography mayprovide additional detail in patients with suspected aneurysmor arteriovenous malformation\nCT has also clarified the natural history of ICH. Oneprospective study of spontaneous ICH in the mid-1990sdemonstrated that an increase in volume of 33% is detectable on repeated CT examination in 38% of patients initiallyscanned within 3 hours after onset. In two thirds of cases withgrowth in volume of ICH, this increase was evident within 1hour. Growth of the volume of ICH was associated with earlyneurological deterioration.15 Hematoma growth is associatedwith a nearly 5-fold increase in clinical deterioration, pooroutcome, and death.18 The lobar location of ICH increases therisk of long-term recurrence by a factor of 3.8.1\nMRI performs as well as CT in identifying ICH. In onemulticenter study of acute stroke within 6 hours of onset,gradient-echo MRI was as accurate as CT for the identification of acute hemorrhage and more accurate for identificationof chronic hemorrhage.20 In another under-6-hour multicenterdiagnostic trial, MRI showed equivalent performance to CT in ICH identification.21 MRI is also superior to CT for theidentification of associated vascular malformations, especially cavernoma. MRI, however, is not as practical as CT forall presenting patients. One study found that MRI was notfeasible in 20% of acute stroke patients because of contraindications to MRI or impaired consciousness, hemodynamiccompromise, vomiting, or agitation. Of the patients withacute stroke ineligible for MRI, 73% had an ICH\nIndications for catheter angiography include subarachnoidhemorrhage, abnormal calcifications, obvious vascular abnormalities, and blood in unusual locations, such as the sylvianfissure. Angiography may also be indicated in patients withno obvious cause of bleeding, such as those subjects withisolated IVH.23 The yield of angiography declines in elderlypatients with hypertension and a deep hematoma. The timing\nof the angiogram balances the need for a diagnosis with thecondition of the patient and the potential timing of anysurgical intervention. A critically ill patient with hemorrhageand herniation may require urgent surgery before angiography, whereas the stable patient with imaging features of ananeurysm or arteriovenous malformation should undergoangiography before any intervention.\nRoutine laboratory tests performed in patients with ICHinclude complete blood count; electrolytes; blood urea nitrogen and creatinine; glucose; electrocardiogram; chest radiography; prothrombin time or international normalized ratio(INR); and activated partial thromboplastin time. A toxicology screen in young or middle-aged persons to rule outcocaine use and a pregnancy test in a woman of childbearingage should also be obtained.\nElevated serum glucose is likely a response to the stressand severity of ICH and is a marker for death, with an oddsratio (OR) of 1.2.24 Warfarin use, reflected in an elevatedprothrombin time or INR, is a risk factor for hematomaexpansion (OR 6.2), with expansion continuing longer than inpatients not taking warfarin.25\n \n1. ICH is a medical emergency, with frequent early,\nongoing bleeding and progressive deterioration, severe\nclinical deficits, and subsequent high mortality and\nmorbidity rates, and it should be promptly recognized\nand diagnosed (Class I, Level of Evidence A).\n2. CT and magnetic resonance are each first-choice initial\nimaging options (Class I, Level of Evidence A); in\npatients with contraindications to magnetic resonance,\nCT should be obtained (Class I, Level of Evidence A).', null, null, ' estimate of certainty(Precision)of treatment effect (见表Z02_008_01)', ' ', '5', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('529', '56', 'Z02_012', '0', '脑出血中医诊疗指南', ' ', '  中华中医药学会', '2011', '中华中医药学会. 脑出血中医诊疗指南[J]. 中国中医药现代远程教育, 2011, 09(23):110-112.', '中文', '', '脑出血', '', '1.肝阳暴亢，风火上扰证<br />&nbsp;&nbsp;2.阴虚风动证<br />&nbsp;&nbsp;3.痰热内闭清窍证<br />&nbsp;&nbsp;4.痰湿蒙塞清窍证<br />&nbsp;&nbsp;5.气虚血瘀证', '诊断依据1.1 临床表现1.1.1 症状 突发性偏瘫、偏身感觉障碍、失语等局灶性神经功能缺损症状，常伴有头痛、呕吐、意识水平下降，重症者起病即表现为意识障1.1.2 体征 可有偏瘫、偏身感觉障碍、偏盲、失语、空间构象障碍、精神症状、凝视麻痹、共济失调、眼震、复视、眼睑下垂、痫性发作、四肢瘫、去脑强直、意识障碍和脑膜刺激征等。1.2 理化检查1.2.1 血液检查 可有白细胞增高，血糖升高等。1.2.2 影像学检查 头颅 CT：是诊断脑出血安全有效的首选方法，可准确、清楚地显示脑出血的部位、出血量、占位效应、 是否破人脑室或蛛网膜下腔及周围脑组织受压的情况。头颅 CT 扫描示血肿灶为高密度影，边界清楚，CT 值为 75～80Hu，在血肿被吸收后显示为低密度影。头颅 MRI： 脑出血后的不同时期血肿的 MRI 表现各异。急性期脑出血的诊断 CT 优于 MRI，但 MRI 检查能更准确地显示血肿演变过程，对某些脑出血患者的病因探讨会有所帮助，如能较好地鉴别瘤卒中，发现脑动静脉畸形及动脉瘤等。脑血管造影：中青年非高血压性脑出血或者 CT 和MRI 检查怀疑有血管异常时，应进行脑血管造影检查。脑血管造影可清楚地显示异常血管及显示出造影剂外漏的破裂血管和部位。可检出脑动脉瘤、脑动静脉畸形、可进行腰穿检查以协助诊断脑出血。对大量的脑出血、小脑出血或脑疝早期，腰穿应慎重，以免诱发脑疝。', '肝阳暴亢，风火上扰证证候：半身不遂，口舌歪斜，言语謇涩或不语，偏身麻木，头晕头痛，面红目赤，口苦咽干，心烦易怒，尿赤便干，舌质红或红绛，舌苔薄黄，脉弦有力。<br />\r\n&nbsp;&nbsp;痰热腑实，风痰上扰证证候：半身不遂，口舌歪斜，言语謇涩或不语，偏身麻木，腹胀，便干便秘，头晕目眩，咯痰或痰多，舌质暗红或暗淡，苔黄或黄腻，脉弦滑或偏瘫侧脉弦滑而大。<br />\r\n&nbsp;&nbsp;阴虚风动证证候：半身不遂，口舌歪斜，言语謇涩或不语，偏身麻木，烦躁失眠，头晕耳鸣，手足心热，咽干口燥，舌质红绛或暗红，或舌红瘦，少苔或无苔，脉弦细或弦细数。<br />\r\n&nbsp;&nbsp;痰热内闭清窍证证候：神昏，半身不遂，鼻鼾痰鸣，项强身热，气粗口臭，躁扰不宁，甚则手足厥冷，频繁抽搐，偶见呕血，舌质红绛，舌苔黄腻或干腻，脉弦滑数。<br />\r\n&nbsp;&nbsp;痰湿蒙塞清窍证证候：神志昏蒙，半身不遂，口舌歪斜，痰鸣漉漉，面白唇暗，肢体松懈，瘫软不温，静卧不烦，二便自遗，或周身湿冷，舌质紫暗，苔白腻，脉沉滑缓。痰湿蒙塞清窍证证候：神志昏蒙，半身不遂，口舌歪斜，痰鸣漉漉，面白唇暗，肢体松懈，瘫软不温，静卧不烦，二便自遗，或周身湿冷，舌质紫暗，苔白腻，脉沉滑缓。<br />\r\n&nbsp;&nbsp;气虚血瘀证证候：半身不遂，口舌歪斜，言语謇涩或不语，偏身麻木，面色白，气短乏力，口角流涎，自汗出，心悸便溏，手足肿胀，舌质暗淡，或舌边有齿痕，舌苔薄白或白腻，脉沉细、细缓或细弦。本证多见于恢复期。', '', '111', ' ', '5', '0', 'admin', null, 'admin', '2016-05-09 16:57:40');
INSERT INTO `biz_standard` VALUES ('53', '34', 'M06_008', '1', '输尿管结石', null, '中华医学会泌尿外科分会', '2014', '那彦群, 叶章群, 孙光.中国泌尿外科疾病诊断治疗指南[M].北京：人民卫生出版社，2014.', '中文', '1.按结石大小输尿管结石分为三类:直径<5mm 的结石、直径为5~10mm 的结石以及直径>10mm 的结石。<br />&nbsp;&nbsp;\n2.x 光平片上的结石影像：X线阳性结石和阴性结石两种。', '输尿管结石', null, null, '1.超声(推荐)<br />&nbsp;&nbsp;超声检查简便、经济、无创伤，可以发现2mm 以上的输尿管结石(包括阴性结石)，了解结石的位置和大小、集合系统的扩张程度、肾皮质厚度等，为治疗方法的选择提供参考。因此，可以作为输尿管结石的常规检查方法。对肾绞痛、腆造影剂过敏、妇女辰合并结石、无尿、慢性肾功能不全等不能行静脉尿路造影或CT 增强检查者，可首选超声检查。由于腹腔脏器的干扰，超声诊断输尿管中下段结石或较小的上段结石敏感性较低，对于>5mm 的上尿路结石，超声诊断的敏感度为96% ，特异度接近100% ，而对于所有部位的结石，其敏感度和特异度分别为78% 和31%。此时，需结合病史或其他检查方法以明确诊断。经直肠或阴道的腔内超声检查诊断输尿管下段结石的敏感性和特异性几乎达到100% 。<br />&nbsp;&nbsp;2.非增强CT 扫描( Non-contrast CT, NCC丁)或者C丁KUB (Unenhanced C丁of the kidneys ,ureters and bladder)  (推荐)<br />&nbsp;&nbsp;CT 检查分辨率比KUB 高，可发现1 mm 以上的结石，解决了KUB 成像的组织重叠问题，不易受肠道内气体干扰，不受结石成分、肾功能和呼吸运动的影响，而且螺旋CT 能够同时对所获得的图像进行二维或三维重建，将横切面图像转换成类似IVU 图像，可以清楚地显示包括阴性结石在内的结石的形态和大小。输尿管阴性结石在CT 上的主要表现为: (1)高密度影; (2) 结石以上输尿管扩张积水; (3) 较小结石(直径<0.6cm) 可见输尿管结石周围有轮缘征出现。此外，还可以通过结石的CT 值来初步判断结石的成分，通过增强CT 显示肾积水的程度和肾实质的厚度，同时还能评估肾脏炎症情况。螺旋CT 进行三维重建可以更准确地估计出结石体积，术前准确判断结石负荷(stone burden) ，对治疗方法的选择提供重要的依据。由于CT 检查不需要做肠道准备，不受肾功能限制，检查所需时间短，对结石的显示非常敏感，可以明确梗阻部位及梗阻原因，对肾绞痛患者的病因诊断具有重要意义。所以，对肾绞痛患者，首选CT 平扫再依据CT 结果适当选择其他影像学检查，以提高诊断准确率。研究显示，以前采用的单层螺旋CT 诊断结石的敏感度和特异度达到96% 和92% ，对于微小的结石容易出现漏诊。多层图像质量优于单层CT 相同扫描层厚的图像， 16 层螺旋CT 行5mm 层厚扫描石相当于直接薄层0.625mm 扫描效果，对结石诊断186特异度及敏感度接近100%。国外文献中提出了CTKUB (Unenhanced CT of the kidneys , ureters and bladder) 的概念，即全泌尿系CT 平扫，国外一些医疗机构已经开始用CT 代替传统的KUB 和IVU作为诊断泌尿系结石的标准， CTKUB 可作为输尿管结石的首选确诊方法。<br />&nbsp;&nbsp;3. 腹部平片(KUB) (推荐)<br />&nbsp;&nbsp;90% 以上的输尿管结石可以在KUB 上显影。通过KUB 检查，可以大致确定结石的位置、形态、大小和数量。根据结石在平片上的密度，可以初步判定结石的成分。各种成分的结石在平片上的显影程度依次为:草酸钙结石、磷酸钙和磷酸镁铵结石、脱氨酸结石、尿酸盐结石;单纯尿酸结石和基质结石能透过X 线，不能在KUB 上显示，称为透光结石或阴性结石。但是，临床上单一成分的结石很少见，多数是以某一种成分为主的混合型结石。因此，在KUB 上结石的密度并不一定均匀一致。<br />&nbsp;&nbsp;肠道内容、软组织钙化、结石X 线阻光性差以及患者过度肥胖等因素，常常会影响KUB 对输尿管诊断的准确性，文献报道， KUB 对泌尿系结石敏感度和特异度分别为44%~77% 和80%-87% ，明显低于CT。因此，如果有条件应选用CT 检查确诊输尿管结石。但是KUB 有助于X 线阳性或者阴性结石的鉴别。<br />&nbsp;&nbsp;KUB 上的高密度影有时需与腹腔内的一些钙化影如胆囊结石、肠系膜淋巴结钙化、静脉石等相鉴别，此时可加行侧位片、IVU ，或者CT 检查。<br />&nbsp;&nbsp;4. 静脉尿路造影(lVU) (推荐)<br />&nbsp;&nbsp;IVU 一般应结合KUB 检查进行分析，可以了解尿路的解剖结构，进一步明确结石在输尿管的位置、结石引起的尿路梗阻情况以及对肾功能的影响。此外， IVU 还可以发现KUB 上不能显示的阴性结石，并能与腹腔内的钙化影相鉴别。常规剂量显影不良时，可行大剂量造影剂IVU 检查以了解患侧肾功能情况，对治疗方法的选择有一定的参考价值。<br />&nbsp;&nbsp;5. CT 增强十三维重建(CTU) (可选择)<br />&nbsp;&nbsp;CTU 是将螺旋CT 扫描与IVU 检查相结合的一种检查方法，可以准确判断结石的有元、大小、多少、部位及梗阻、积水的情况。对于输尿管结石合并有肾结石并且需要同时治疗的患者，可行CTU 检查评估肾脏情况，可以作为IVU 的替代检查。由于造影剂的存在会影响结石的观察，因此，一般情况下不应该把CT 增强作为常规检查。此外， CTU 的价格比较高，并且比IVU 需要接受更高的放射剂量。<br />&nbsp;&nbsp;6. 逆行肾孟造影(RGP) (可选择)<br />&nbsp;&nbsp;属于有创检查旦不能了解肾功能情况，不作为常规检查方法，仅用于不宜行IVU 或IVU 显影不满意者。其优点是显影清楚，不受肾功能的影响，可以显示X 线不显影的阴性结石，了解结石的位置及其引起的尿路梗阻程度，排除结石下方输尿管梗阻和狭窄。<br />&nbsp;&nbsp;7. 磁共振尿路成像(MRU) (可选择)<br />&nbsp;&nbsp;由于成像原理及空间分辨率的限制， MRU 难以直接显示结石，一般不用于输尿管结石的检查。但是，由于MRU 不受肾功能改变的影响，不需造影剂即可获得与IVU 类似的图像，能够了解输尿管结石所引起的尿路梗阻情况。因此，对孕妇、严肾功能损害或对造影剂过敏等不适合行X 线检查(Ivu 或CT) 的患者可考虑采用。<br />&nbsp;&nbsp;8. 输尿管镜检查(可选择)<br />&nbsp;&nbsp;属于有创检查，常需在麻醉下进行，为非常规检查方法。仅在以上方法检查不能确诊的情况下采用，如发现结石可以行一期碎石或取石。输尿管镜技术可以用于诊断娃振期输尿管结石，与超声检查比较，输尿管镜技术对输尿管结石诊断准确率可达100% ，同时可避免X 线对胎儿可能造成的辐射危害。<br />&nbsp;&nbsp;9. 放射性核素(可选择)<br />&nbsp;&nbsp;放射性核素检查不能直接显示输尿管结石，但是可以提供肾脏血流灌注、肾功能及尿路梗阻情况等信息，对治疗方法的选择和疗效的评估具有一定的价值。<br />&nbsp;&nbsp;排石治疗的适应证:<br />&nbsp;&nbsp;\n(1) 2013 年EAU 建议直径0.5cm~ 1.0cm 的结石可以作为药物治疗的初选指证，国内的多数意见认为药物治疗时结石的直径以0.6cm 左右为宜;<br />&nbsp;&nbsp;\n(2) 结石表明光滑，无明显的嵌顿或梗阻，停留于局部少于2 周;<br />&nbsp;&nbsp;\n(3) 结石以下输尿管无梗阻;<br />&nbsp;&nbsp;\n(4) 经皮肾镜、输尿管镜碎石术后及SWL 后的辅助治疗。<br />&nbsp;&nbsp;\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('530', '56', 'Z02_027', '1', '脑出血诊断标准（自拟 ）', '', '第二次全国脑血管学术会议', '1986', '常见疾病的诊断与疗效判断标准', '1', '', '高血压性脑出血', '', '', '高血压性脑出血的诊断要点1.常于体力或情绪激动时发病。2.发作时常有反复呕吐，头痛，血压升高。3.一般意识清楚或有意识障碍，可伴有精神症状。4.病情紧张迅速，常出现意识障碍，偏瘫和其他神经系统局灶症状。5.多有高血压病史。6.腰穿脑脊液多含血和压力增高（其中20%左右可不含血）7.脑超声波检查多有中线波移位。8.鉴别诊断有困难时若有条件可作CT检查。', '', '', '', '', '7', '0', 'admin', null, 'admin', '2016-05-09 17:15:07');
INSERT INTO `biz_standard` VALUES ('531', '56', 'Z02_028', '1', '脑出血诊断标准（自拟 ）', '', '美国国家神经及神经系统关联病和卒中研究中心', '1982', '常见疾病的诊断与疗效判断标准', '英文', '', '脑出血', '', '', '1.CT扫描见到颅内血肿者。2.有下述一项以上且症状持续24小时以上（1）意识障碍（2）视力及视野损害（3）不完全和完全性偏瘫，以及双肢体瘫（特别是脑干损伤时）（4）半球感觉障碍（5）言语障碍（6）吞咽困难（7）共济失调（8）急剧头痛。3.血性或黄色脑脊液。4.脑血管造影见到动脉瘤或动静脉畸形之无血管区。确定诊断1或2，高度怀疑2或3.', '', '', '', '', '1', '0', 'admin', null, 'admin', '2016-05-09 17:15:18');
INSERT INTO `biz_standard` VALUES ('532', '56', 'Z02_030', '1', '脑蛛网膜下腔出血诊断标准（自拟 ）', '', '第二次全国脑血管学术会议', '1986', '常见疾病的诊断与疗效判断标准', '英文', '', '脑蛛网膜下腔出血', '', '', '主要是指先天性脑动脉瘤破裂，脑血管畸形和脑动脉樱花出血引起。1.发病急骤，2.常伴有剧烈头痛，呕吐。3.一般意识清楚或有意识障碍，可伴有精神症状。4.多有脑膜刺激征，少数可伴有路神经及轻偏瘫等局灶体征。5.腰穿脑脊液呈血性。6.脑血管造影可帮助明确病因。7.有条件时可进行CT检查。', '', '', '', '', '2', '0', 'admin', null, 'admin', '2016-05-09 17:17:03');
INSERT INTO `biz_standard` VALUES ('533', '56', 'Z02_031', '1', '脑蛛网膜下腔出血诊断标准（自拟 ）', null, '美国国家神经及神经系统关联病和卒中研究中心', '1982', '常见疾病的诊断与疗效判断标准', '中文', null, '脑蛛网膜下腔出血', null, null, '1.在脑血管造影上找到动脉瘤或血管畸形等出血源者（动脉瘤或动脉畸形附近有血肿乃至血管痉挛者）2.在CT片上于大脑外侧裂，半球间裂，脑底池，脑室内有动脉瘤破裂产生的血肿存在者。3.从起病后数分钟到数小时内，出现下述两个以上的症状者（1）发病及入院时有剧烈头痛（2）意识障碍（3）脑膜刺激体征（4）眼底有网膜前出血（5）偏瘫（6）动脉神经损伤所致之眼球运动障碍。4.血性脑脊液或呈黄变。确定诊断，1或2或1、2。高度怀疑3、4.', null, null, '治愈，症状及体征消失，脑脊液恢复正常。好转，症状及体征改善。', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('534', '56', 'Z02_032', '1', '欧州中风协会自发性脑出血管理指南', 'European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage', 'European Stroke Organisation (ESO) ', '2014', 'http://www.eso-stroke.org/fileadmin/files/2013/eso-stroke/ESO_Guidelines_10_1111_IJS_12309_2014_03.pdf', '英文', null, '自发性脑出血', null, null, 'Table 1 Criteria for assigning grade of evidence (12)\nGrade of evidence Criteria\nHigh quality Further research is very unlikely to change our conﬁdence in the estimate of effect\nModerate quality Further research is likely to have an important impact on our conﬁdence in the estimate of effect and may change\nthe estimate\nLow quality Further research is very likely to have an important impact on our conﬁdence in the estimate of effect and is likely to\nchange the estimate\nVery low quality Any estimate of effect is very uncertain\nGuidelines T. Steiner et al.\n© 2014 World Stroke Organization Vol ••, •• 2014, ••–•• 3Summary of recommendations related to functional outcome and mortality (with exemption to 13a, 14b)\nQuality of\nevidence\nStrength of\nrecommendation\n1. Acute stroke unit care reduces both death and dependency for patients with ICH in comparison with\ncare on a general ward.\nHigh Strong\n2. In acute ICH within 6 h of onset, intensive blood pressure reduction (systolic target <140 mmHg in <1 h)\nis safe and may be superior to a systolic target <180 mmHg. No speciﬁc agent can be recommended.\nModerate Weak\n3. We do not recommend the use of rFVIIa for adults with acute spontaneous ICH not associated with\nantithrombotic drug use outside RCTs.\nHigh Strong\n4. In the absence of RCTs, we cannot make strong recommendations about how, when, and for whom to\nnormalize clotting for patients with acute spontaneous ICH who had been on antiplatelet drugs.\nVery low None\n5. In the absence of RCTs, we cannot make strong recommendations about how, when, and for whom to\nnormalize coagulation for patients with acute spontaneous ICH who had been on anticoagulant drugs.Very low None6. There is no evidence to support surgical intervention on a routine basis to improve outcome aftersupratentorial ICH in comparison with conservative management, but early surgery may be of value forpatients with a GCS score 9–12.Moderate Weak7. In the absence of RCTs, we cannot make strong recommendations about how, when, and for whom toplace an EVD in patients with acute spontaneous ICH.Very low None8. In the absence of RCTs, we cannot make strong recommendations about how, when, and for whom touse EVD combined with intrathecal thrombolysis in spontaneous ICH.Very low None9. There is insufﬁcient evidence from RCTs to make strong recommendations about how, when, and forwhom to perform surgical evacuation in adults with infratentorial ICH.Low Weak10. In the absence of RCTs we cannot not make strong recommendations about how, when, and for whominvasive monitoring of intracranial pressure should be performed for patients with acute ICH.\nVery low None11. There is insufﬁcient evidence from RCTs to make strong recommendations on measures to lower\nintracranial pressure for adults with acute ICH.Low Weak12. There is insufﬁcient evidence from RCTs to make strong recommendations on whether, when, and for\nwhom preventive or early fever treatment should be given after acute ICH.\nLow Weak13a. We do not recommend short or long graduated compression stockings for the prevention of DVT. Werecommend intermittent pneumatic compression to improve outcome and reduce the risk of DVT in\nimmobile patients with ICH.Moderate Strong\n13b. There is insufﬁcient evidence from RCTs to make strong recommendations about how, when, and forwhom anticoagulation should be given to prevent DVT or improve outcome.Low Weak14a. There is insufﬁcient evidence from RCTs to make strong recommendations on whether preventive\nantiepileptic treatment should be used after ICH for the prevention of seizures or improvement of\noutcome in the long term.\nLow Weak\n14b. There is insufﬁcient evidence from RCTs to make strong recommendations about how, when, and for\nwhom AEDs should be given to reduce the risk of epilepsy after ICH.\nLow Weak\n15. We do not recommend the use of dexamethasone in patients with acute ICH outside RCTs. Moderate Weak\n16. In the absence of RCTs, we cannot make strong recommendations about how, when, and for whom\ndo-not-attempt-resuscitation or withdrawal-of-care orders should be used to reduce suffering after ICH.\nVery low None\n17. We recommend lowering blood pressure for secondary prevention after ICH. Moderate Strong\n18. In the absence of RCTs, we cannot make strong recommendations about whether and when to resume\nantithrombotic drugs after ICH.\nVery low None\nTable 2 Factors that affect the strength of a recommendation (12)\nFactor Examples of strong recommendations Examples of weak recommendations\nQuality of evidence Many high-quality randomized trials have shown\nthe beneﬁt of inhaled steroids in asthma\nOnly case series have examined the utility of\npleurodesis in pneumothorax\nUncertainty about the balance between\ndesirable and undesirable effects\nAspirin in myocardial infarction reduces mortality\nwith minimal toxicity, inconvenience, and cost\nWarfarin in low-risk patients with atrial\nﬁbrillation results in small stroke reduction\nbut increased bleeding risk and substantial\ninconvenience\nUncertainty or variability in values and\npreferences\nYoung patients with lymphoma will invariably place\na higher value on the life-prolonging effects of\nchemotherapy than on treatment toxicity\nOlder patients with lymphoma may not place a\nhigher value on the life-prolonging effects of\nchemotherapy than on treatment toxicity\nUncertainty about whether the intervention\nrepresents a wise use of resources\nThe low cost of aspirin as prophylaxis against\nstroke in patients with transient ischemic attacks\nThe high cost of clopidogrel and of\ncombination dipyridamole and aspirin as\nprophylaxis against stroke in patients with\ntransient ischemic attacks', null, null, 'In acute ICH within 6 h of onset, intensive blood pressure\nreduction (systolic target <140 mmHg in <1 h) is safe and\nmay be superior to a systolic target <180 mmHg. No speciﬁc\nagent can be recommended.', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('535', '56', 'Z02_037', '1', '颅内动脉瘤和蛛网膜下腔出血欧州中风协会管理指南', 'European Stroke Organization Guidelines for \nthe Management of Intracranial Aneurysms \nand Subarachnoid Haemorrhage', 'European Stroke Organization', '2013', 'http://www.congrex-switzerland.com/fileadmin/files/2013/eso-stroke/pdf/ESO_SAH_Guideline_CVD.pdf', '英文', null, 'Intracranial Aneurysms \n；Subarachnoid Haemorrhage颅内动脉瘤；蛛网膜下腔出血', null, null, null, null, null, 'Until coiling or clipping, systolic blood pressure should be \nkept below 180 mm Hg; this may be already achieved by \n applying analgetics and nimodipine (GCP)', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('536', '56', 'Z02_038', '1', ' AHA/ASA 自发性脑出血管理指南', 'Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association', '\n美国心脏协会(AHA,American Heart ssociation)\n美国卒中协会(ASA,American Stroke Association)', '2015', null, '英文', null, '自发性脑出血', null, null, 'Emergency Diagnosis and Assessment A baseline severity score should be performed as part of the initial evaluation of patients with ICH (Class I; Level of Evidence B).(New recommendation)Rapid neuroimaging with CT or MRI is recommended to distinguish ischemic stroke from ICH (Class I; Level of Evidence A).\n(Unchanged from the previous guideline)', null, null, 'For ICH patients presenting with SBP between 150 and 220 mm Hg and without contraindication to acute BP treatment,\nacute lowering of SBP to 140 mm Hg is safe (Class I; Level of Evidence A) and can be effective for improving functional\noutcome (Class IIa; 畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭㻸੟ༀƙ\0੟ð\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄祰௸੟ð\0ᅸ௸彿㎽奋㎽巫㎽鯜௸띌௸彿㎽띀௸塚㎽띌௸ꍈ㏂\0\0祰௸學㎽漸㏂圔㎽祰௸圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('537', '56', 'Z02_046', '1', '短暂性脑出血的诊断与初步治疗', 'Diagnosis and initial management of transient ischaemic attack', '皇家医师学院royal college of physicians', '2010', 'http://www.stroke.org.nz/stroke-health-professionals', '英文', null, 'transient ischaemic attack短暂性脑缺血发作', null, null, 'A Prompt recognition of symptoms and correct diagnosis of transient ischaemic\nattack (TIA)\nPatients with transient neurological dysfunction often fail to recognise the significance of their symptoms and delay seeking medical attention. The transient nature of TIA symptoms does not reduce the importance of an immediate response.\n1 In people with sudden onset of neurological symptoms:\n• a validated tool such as the FAST (Box 1) should be used outside hospital to screen for a diagnosis of a stroke or TIA\n• hypoglycaemia should be excluded as the cause of these symptoms.\n2 In people who are admitted to accident and emergency (A&E) with a suspected stroke or TIA:\n• the diagnosis should be established rapidly using a validated tool such as the Recognition of Stroke in the Emergency Room (ROSIER) (Z02_046_图1).<br />&nbsp;&nbsp;B Assessment and early management of TIA\nTIA is an important predictor of subsequent stroke. All patients who have had a suspected TIA should be assessed as soon\nas possible for their risk of subsequent stroke.\n1 A validated scoring system, such as ABCD2 (Box 2), should be used to assess the risk of stroke following a suspected TIA:An ABCD2 score of:\n• 4 or above represents a high risk of subsequent stroke\n• 3 or below represents a lower risk of subsequent stroke.\nPeople with crescendo TIA (2 TIAs in a week) should be treated as being at high risk of stroke, even if their ABCD2 score is 3.\nPeople who have had a TIA, but who present late (more than one week after their last symptom has resolved), should be treated as though they are at lower risk of stroke.\n\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('538', '56', 'Z02_061', '1', '短暂性脑出血病人的评估和管理', 'FOR THE ASSESSMENT AND MANAGEMENT OF PEOPLE WITH RECENT\nTRANSIENT ISCHAEMIC ATTACK (TIA)', '新西兰中风基金会', '2008', 'http://www.strokesociety.com.au/index.php?option=com_docman&Itemid=176', '英文', null, 'TRANSIENT ISCHAEMIC ATTACK (TIA)', null, null, 'Diagnosis of TIA is more likely to be correct if the history confirms;• Sudden onset of symptoms, with maximal neurological deficit at onset• Symptoms typical of focal loss of brain function such as unilateral weakness orspeech disturbance• Rapid recovery of symptoms, usually within 30-60 minutes.', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('539', '56', 'Z02_052', '1', '临床诊疗指南神经病学分册', null, '中华医学会', '2004', '中华医学会. 临床诊疗指南(神经病学分册)[M]. 人民卫生, 2010.', '中文', null, '蛛网膜下腔出血', null, null, '【蛛网膜下腔出血】突然发生的剧烈头痛和呕吐，脑膜刺激征阳性，癫痫发作，颅神经损害特别是动眼神经麻痹，或轻偏瘫等局限性体征，若眼底检查发现玻璃体下出血即可诊断SAH。辅助检查1.脑脊液检查，均匀血性脑脊液是 蛛网膜下腔出血的特征性表现，起病1天后红细胞开始破坏，脑脊液逐步变黄，持续2-3周，故脑脊液黄变提示蛛网膜下腔陈旧性出血的可能。脑脊液压力增高，白细胞计数轻度增高。2.影像学检查，（1）CT检查，可以显示蛛网膜下腔，脑池，脑沟内高密度影的蛛网膜下腔出血，以及继发颅内血肿，脑室出血，脑积水，脑水肿，脑梗死等，颅底，鞍上池，侧裂等处可见高密度影，在发病开始后5天内阳性率较高。MRI诊断蛛网膜下腔出血的实用价值没有CT高，但磁共振血管造影MRA可发现动脉瘤等。CT和MRI也可 排除非动脉瘤的病因，如肿瘤或血管畸形等。（2）脑血管造影，数字减影动脉造影和磁共振血管造影已广为应用，是确定蛛网膜下腔出血病因的重要手段，可确定出血的病因，部位，性质，如动脉瘤，动静脉畸形及血管痉挛等。MRA可以在任何时候进行，DSA选择出血3天内或3周后进行为宜。【鉴别诊断】包括脑膜炎，偏头痛急性发作，高血压脑病，脑实质出血，脑室出血，颅内肿瘤等。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('54', '34', 'M06_009', '1', 'EAU尿路结石诊疗指南', 'Guidelines on Urolithiasis ', '欧洲泌尿外科学会(EAU,European Association of Urology)', '2012', null, '英文', '1.结石的分类<br />&nbsp;&nbsp;尿结石可根据大小、位置、x线特点、病因学的形成、组成和复发的风险来分类。<br />&nbsp;&nbsp;1.1结石大小<br />&nbsp;&nbsp;结石的大小通常是在一个或两个维度,和分层测量5,> 5 - 10,> 10 - 20,最大直径> 20毫米。<br />&nbsp;&nbsp;1.2结石的位置<br />&nbsp;&nbsp;结石可以分类根据解剖位置:上、中等或较低的肾盏;肾盂;上部,中部或远端输尿管,膀胱。这里不讨论膀胱结石治疗。<br />&nbsp;&nbsp;1.3 x射线特征<br />&nbsp;&nbsp;结石可根据普通x光外观(肾输尿管膀胱摄影，KUB)(表3),根据矿物成分变化分类。磁共振计算机断层摄影(畻坴畿\0\0\0\0醼畻聱盯	\0\0\0痭駠ƞༀƙ\0ƞĀ\0	\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᓸ௢ƞĀ\0è௢彿㎽奋㎽巫㎽놲௢퍞௢彿㎽퍒௢塚㎽퍞௢ꍈ㏂\0\0ᓸ௢學㎽漸㏂圔㎽ᓸ௢圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0衘ƞ䐺盭暼痭衘ƞༀƙ \0衘ƞà\0\0㺣盭衘ƞ\0ﱔ衜ƞ\0팃目衜ƞࡳ衜ƞ큁目衜ƞᔬ௢﫬\0Item\0\0폢௢\0\0\0\0\0\0Count\0\0ﱬﬄ袌ƞኜੑ\0\0衜ƞ\0\0\0\0ੑ寶目አੑ矵䥷㎽놲௢\0\0폢௢�㏂퍒௢\0\0\0ੑ\0\0\0謁ﱔ\0\0㎾ਊ\0ﱜ\0\0x�㏂퍒௢\0\0隲W폢௢\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx	\0霪W露W\0\0ﱴxt\0Љ\0\0\0注ƚ鲬ࡳ菮畻\0\0\0\0ᇰੑEo\0\0ቄੑ\0\0ᲈ੓ᲈ੓\0\0\0寶目ቈੑᐬ௢i\0\0ﱄ﷜ﱴﲔ먙㎼ᐬ௢ቈੑi\0\0ﱄ﷜ﱴ먰㎼﷜ᐬ௢�㏂᎜௢\0\0릎㎼ᐬ௢i\0╪췬目╾췬目Љ\0镴ࡳ\0￿￿目Љ\0镨ࡳ注ƚ竗注ƚ目W\0竗\0\0\0賓器目\0\0\0\0ᔬ௢\0目瑉浥目\0\0\0\0ᔬ௢\0目潃湵t\0\0\0\0ʃ\0\0ဠ\0\0ꯈʩﯬꯈʩච̓\0\0\0\0\0\0\0ච̓꒠̑\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0꒠̑\0\0\0\0ච̓ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚ￞\0\0⟒췬⟚췬目Љ\0鲸ࡳ\0￿￿目Љ\0鲬ࡳ注ƚ觴注ƚ目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨᐬ௢目潅f䓾瑤\0\0豸ࢋ\0\0核ʊ\0\0䒛瑤䕢瑤ꂸ瑧\0䔯瑤䑩瑤釨ࢋ䀷瑤੒ᛒ瑤\0㽺瑤\0\0㿣瑤੒\0\0￿￿￿￿㯄瑽嵞盡㨣瑽Ә੒\0\0鍈盠僦璅Ә\0੒鰈瑼ྭࠁ\0\0ﯬ$\0᳅愁\0\0\0\0\0\0Ĺ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0㷤췭骶瑼੒\0\0\0\0\0磻\0\0磻\0\0\0磻\0᭟盡@Ә㶬췭樂쓷盡Ә\0\0\0\0\0\0ꯍ�\0\0磻\0襤鹿\0邰ƙ\0\0ࠀ옎盡㶆췭\0駨瑼\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ﫜ᐬ௢ﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀勤﬘眿捻ฒ폢௢﫨ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿﫜￿￿\0\0﫦\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ', '尿路结石；Urolithiasis ', null, null, '1.诊断成像<br />&nbsp;&nbsp;尿路结石患者通常表现为腰痛,呕吐,有时发热,但也可无症状。标准评价包括详细的病史和体格检查。临床诊断应由适当的成像。<br />&nbsp;&nbsp;如果可行的话,应该使用超声作为主要诊断成像工具，虽然缓解疼痛,或任何其他紧急措施不应推迟了成像评估。它是安全的(没有辐射的风险),可再生的和便宜的。它可以识别石头位于凹洼,骨盆,肾盂-输尿管-膀胱连接,以及上尿路扩张。结石> 5毫米,超声的敏感性为96%,特异性100%。所有结石点,超声检查的敏感性和特异性分别为降低到78%和31%,。KUB的敏感性和特异性44 - 77%和80 - 77%。如NCCT KUB认为不应该执行,然而,它有助于区分射线可透过的和不透射线的结石和随访期间进行比较。<br />&nbsp;&nbsp;发烧或孤独的肾脏,当诊断怀疑,建议直接成像。<br />&nbsp;&nbsp;2.诊断——代谢相关<br />&nbsp;&nbsp;每个紧急病人尿石病需要一个简洁的尿液和血液生化检查除了成像。在这一点上,高和低风险的患者之间没有区别。<br />&nbsp;&nbsp;1.Diagnostic imaging<br />&nbsp;&nbsp;Patients with urinary stones usually present with loin pain, vomiting, and sometimes fever, but may also be asymptomatic. Standard evaluation includes detailed medical history and physical examination. Clinical diagnosis should be supported by appropriate imaging.<br />&nbsp;&nbsp;If available, ultrasonography should be used as the primary diagnostic imaging tool although pain relief, or any other emergency measures should not be delayed by imaging assessments. It is safe (no risk of radiation), reproducible and inexpensive. It can identify stones located in the calices, pelvis, and pyelo-ureteric and vesicoureteric junctions, as well as upper urinary tract dilatation. For stones > 5 mm, ultrasound has a sensitivity of 96% and specificity of nearly 100% (1). For all stone locations, sensitivity and specificity of ultrasound reduces to 78% and 31%, respectively (1).<br />&nbsp;&nbsp;The sensitivity and specificity of KUB is 44-77% and 80-87%, respectively (2). KUB should not be performed if NCCT is considered (3), however, it is helpful in differentiating between radiolucent and radiopaque stones and for comparison during follow-up.<br />&nbsp;&nbsp;With fever or solitary kidney, and when diagnosis is doubtful, immediate imaging is indicated.<br />&nbsp;&nbsp;2. Diagnostics - metabolism-related<br />&nbsp;&nbsp;Each emergency patient with urolithiasis needs a succinct biochemical work-up of urine and blood besides imaging. At that point, no distinction is made between high- and low-risk patients.<br />&nbsp;&nbsp;\nM06_009_02急性结石痛基础分析.docx\n', null, '结石通过率（Stone-passage rates）', ' 1.观察输尿管结石<br />&nbsp;&nbsp;1.1 结石通过率<br />&nbsp;&nbsp;自发的结石通道根据大小只有有限的数据。Meta-分析328例隐藏输尿管结石< 10毫米的可能输尿管结石通过。<br />&nbsp;&nbsp;这些研究的局限性包括非标准化的结石大小测量,以及缺乏分析,结石的位置,结石通过时间。<br />&nbsp;&nbsp;1.Observation of ureteral stones<br />&nbsp;&nbsp;1.1 Stone-passage rates<br />&nbsp;&nbsp;There are only limited data about spontaneous stone passage according to size . A meta-analysis of 328 patients harbouring ureteral stones < 10 mm investigated the likelihood of ureteral stone passage.<br />&nbsp;&nbsp;These studies had limitations including non-standardisation of stone size measurement, and lack of analysis of stone position, stone-passage history, and time to stone passage.<br />&nbsp;&nbsp;\nM06_009_03输尿管结石通过率.docx', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('540', '56', 'Z02_017', '1', '临床诊疗指南神经病学分册', null, '中华医学会', '2004', '中华医学会. 临床诊疗指南(神经病学分册)[M]. 人民卫生, 2010.', '中文', null, '脑出血', null, null, '【脑出血】50岁以上的高血压患者，急性发病和病情进展迅速，除伴随头痛、意识障碍外，还有局灶症状和体征者。影像学检查，头颅CT可见出血改变。早期CT检查即可显示密度增高，可确定出血的大小、部位，出血周围水肿呈低密度改变，以排除非出血性疾患，病情需要和有条件时可作MRI检查。小脑出血者应定期做CT检查，至少1周复查一次，病情变化时随时复查，除注意观察血肿本身的变化外，应特别注意观察有无脑室对称性扩大等脑积水征象，以指导治疗。3.辅助检查，CT检查能诊断。在没有条件时可进行腰椎穿刺协助诊断，但脑脊液正常者不能否定脑出血的诊断。颅内压增高，脑干受压者禁忌腰椎穿刺。非高血压性脑出血，应注意血液学、免疫学及颅内血管的检查，以明确病因。', null, '一般对原血压正常又无严重颅内压增高的患者，将血压控制在出血前原有水平或略高，原有高血压者将血压控制在150-160mmHg/90-100mmHg为宜。', null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('541', '56', 'Z02_029', '1', '中风病疗效评定标准', null, null, '1986', '常见疾病的诊断与疗效判断标准', '中文', null, '脑出血', null, null, null, null, null, '1.神志状态：神志清醒4分，神志恍惚（思睡、唤醒后能与人言3分，神智迷蒙（嗜睡，呼之回答不确切）2分，神昏1分，昏愦（神昏同时兼脱证）0分。2.语言表达：正常4分，表达一般，命名不能3分，说话成句但表达不全2分，不能说单词，词组1分，语言不能或基本不能0分。3.上肢肩关节，正常4分，上举全而肌力差3分，上举平肩或略过肩2分，上举不到肩1分，不能动或前后略摆动0分。4.上肢指关节，正常4分，手指分别动作有效而肌力差者3分，握拳伸指2分，屈指而握不成拳，不能伸1分，能活动0分。5.下肢髋关节，正常4分，太高4畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭虈ƞༀƙ\0ƞĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄祰௸ƞĀ\0ᅸ௸彿㎽奋㎽巫㎽鯜௸띌௸彿㎽띀௸塚㎽띌௸ꍈ㏂\0\0祰௸學㎽漸㏂圔㎽祰௸圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0駠ƞ䐺盭暼痭駠ƞༀƙ \0駠ƞĀ\0\0㺣盭駠ƞ\0𢡄駤ƞ\0팃目駤ƞ࣒駤ƞ큁目駤ƞ禤௸泌\0Item\0\0럐௸\0\0\0\0\0\0Count\0\0﫨呂騔ƞ㳜੪\0\0駤ƞ\0\0\0\0੪寶目㳠', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('542', '56', 'Z02_004', '1', '中医内科常见病诊疗指南西医疾病部分\n', ' ', ' 中华中医药学会', '2008', 'ZYYXH/T50～135—2008，中医内科常见病诊疗指南[M].中国中医药出版社，2008', '中文', null, '脑出血', null, '1.肝阳暴亢，风火上扰证<br />&nbsp;&nbsp;2.痰热腑实，风痰上扰证<br />&nbsp;&nbsp;3.阴虚风动证<br />&nbsp;&nbsp;4.痰热内闭清窍证<br />&nbsp;&nbsp;5.痰湿蒙塞清窍证<br />&nbsp;&nbsp;6.元气败脱，神明散乱证', '脑出血的1诊断依据<br />&nbsp;&nbsp;1.1临床表现<br />&nbsp;&nbsp;1.1.1症状：突发性偏瘫、偏身感觉障碍、失语等局灶性神经功能缺损症状，常伴有头痛、呕吐、意识水平下降，重症者起病即表现为意识障碍。<br />&nbsp;&nbsp;1.1.2体征：可有偏瘫、偏身感觉障碍、偏盲、失语、空间构象障碍、精神症状、凝视麻痹、共济失调、眼震、复视、眼睑下垂、痫性发作、四肢瘫、去脑强直、意识障碍和脑膜刺激征等。<br />&nbsp;&nbsp;1.2理化检查<br />&nbsp;&nbsp;1.2.1血液检查：可有白细胞增高，血糖升高等。<br />&nbsp;&nbsp;1.2.2影像学检查<br />&nbsp;&nbsp;头颅CT：是诊断脑出血安全有效的首选方法，可准确、清楚地显示脑出血的部位、出血量、占位效应、是否破入脑室或蛛网膜下腔及周围脑组织受压的情况。头颅CT扫描示血肿灶为高密度影，边界清楚，CT值为75～80Hu，在血肿被吸收后显示为低密度影。<br />&nbsp;&nbsp;头颅MRI：脑出血后的不同时期血肿的MRI表现各异。急性期脑出血的诊断CT优于MRI，但<br />&nbsp;&nbsp;MRI检查能更准确地显示血肿演变过程，对某些脑出血患者的病因探讨会有所帮助，如能较好地鉴别瘤卒中，发现脑动静脉畸形及动脉瘤等。<br />&nbsp;&nbsp;脑血管造影：中青年非高血压性脑出血或者CT和MRI检查怀疑有血管异常时，应进行脑血管造影检查。脑血管造影可清楚地显示异常血管及显示出造影剂外漏的破裂血管和部位。可检出脑动脉瘤、脑动静脉畸形、烟雾病（moyamoyadisease）和血管炎等。<br />&nbsp;&nbsp;腰穿检查：在没有条件或不能进行CT扫描者，可进行腰穿检查以协助诊断脑出血。对大量的脑出血、小脑出血或脑疝早期，腰穿应慎重，以免诱发脑疝。<br />&nbsp;&nbsp;1.3诊断要点<br />&nbsp;&nbsp;参照1995年中华医学会第四次全国脑血管病学术会议修订的《各类脑血管疾病诊断要点》：好发部位为壳核、丘脑、尾状核头部、中脑、桥脑、小脑、皮质下白质，即脑叶、脑室及其他。主要是高血压性脑出血，也包括其他病因的非外伤性脑内出血。高血压性脑出血的诊断要点如下：<br />&nbsp;&nbsp;1.3.1常于体力活动或情绪激动时发病。<br />&nbsp;&nbsp;1.3.2发作时常有反复呕吐、头痛和血压升高。<br />&nbsp;&nbsp;1.3.3病情进展迅速，常出现意识障碍、偏瘫和其他神经系统局灶症状。<br />&nbsp;&nbsp;1.3.4多有高血压病史。<br />&nbsp;&nbsp;1.3.5腰穿脑脊液多含血和压力增高（其中20％左右可不含血）。<br />&nbsp;&nbsp;1.3.6脑超声波检查多有中线波移位。<br />&nbsp;&nbsp;1.3.7鉴别诊断有困难时可做CT检查。<br />&nbsp;&nbsp;脑梗死1诊断依据1.1临床表现1.1.1发病形式：大部分患者静态下急性起病，动态起病者以心源性脑梗死多见，部分病例在发病前可有TIA发作，如短暂的肢体麻木、无力等。病情一般在数小时或数日内达到高峰，也可能症状进行性加重或病情波动。1.1.2症状体征：取决于梗死病灶的部位和大小，主要表现为局灶性神经功能缺损的症状和体征，如偏瘫、偏身感觉障碍、认知功能障碍、颅神经麻痹、共济失调等，部分可出现全脑症状和体征，如头痛、恶心呕吐、昏迷和生命体征异常等。1.2理化检查<br />&nbsp;&nbsp;1.2.1血液检查：血小板、凝血功能、血糖等。有条件的医脘可以进行血浆同型半胱氨酸等检查。1.2.2影像学检查头颅CT：头颅CT检查应常规进行，对于脑梗死和脑出血的鉴别有重要价值。但是对于超早期（发病6小时以内）缺血性病变和皮质或皮质下小的梗死灶不敏感，不能显示脑干和小脑较小梗死灶。多数病例在发病24小时后逐渐显影，大面积脑梗死可以较早显示病灶。主要表现为低密度灶，大面积梗死可以伴有脑水肿和占位效应，出血性梗死呈现混杂密度。超早期阶段可以有微小改变，如大脑中动脉高密度征、皮质边缘（尤其岛叶）及豆状核区灰白质分界不清、脑沟消失等。头颅MRI：可以清晰地显示早期缺血性梗死灶，对脑干和小脑梗死显示清楚，主要表现为T1低信号、T2高信号病灶，出血性梗死显示其中混杂T1高信号。对于超早期脑梗死和脑出血则难以鉴别。弥散加权成像（DWI)在发病2小时即可显示病变，对早期梗死敏感，为早期治疗提供重要信息。灌注加权成像（PWI)显示的病灶区域较弥散加权范围大，目前认为弥散-灌注不匹配区域为半暗带，为溶栓治疗提供信息。经颅彩色多普勒超声（TCD)：有利于判断颅内外血管狭窄、闭塞和侧支循环建立程度。<br />&nbsp;&nbsp;血管造影：磁共振血管成像（MRA)、CT血管成像（CTA）等属于无创检查，可以了解血管情况及疗效等。数字减影血管造影（DSA）在进行血管内介入治疗、动脉溶栓时有意义，但有一定的风险。其他：正电子发射断层扫描（PET)、单光子发射计算机断层扫描（SPECT）等在有条件的单位用于临床研究。', '1.1肝阳暴亢，风火上扰证：半身不遂，口舌歪斜，言语謇涩或不语，偏身麻木，头晕头痛，面红目赤，口苦咽干，心烦易怒，尿赤便干，舌质红或红绛，舌苔薄黄，脉弦有力。<br />&nbsp;&nbsp;1.2痰热腑实，风痰上扰证：半身不遂，口舌歪斜，言语謇涩或不语，偏身麻木，腹胀，便干便秘，头晕目眩，咯痰或痰多，舌质暗红或暗淡，苔黄或黄腻，脉弦滑或偏瘫侧脉弦滑而大。<br />&nbsp;&nbsp;1.3阴虚风动证：半身不遂，口舌歪斜，言语謇涩或不语，偏身麻木，烦躁失眠，头晕耳鸣，手足心热，咽干口燥，舌质红绛或暗红，或舌红瘦，少苔或无苔，脉弦细或弦细数。<br />&nbsp;&nbsp;1.4痰热内闭清窍证：神昏，半身不遂，鼻鼾痰鸣，项强身热，气粗口臭，躁扰不宁，甚则手足厥冷，频繁抽搐，偶见呕血，舌质红绛，舌苔黄腻或干腻，脉弦滑数。<br />&nbsp;&nbsp;1.5痰湿蒙塞清窍证：神志昏蒙，半身不遂，口舌歪斜，痰鸣漉漉，面白唇暗，肢体松懈，瘫软不温，静卧不烦，二便自遗，或周身湿冷，舌质紫暗，苔白腻，脉沉滑缓。<br />&nbsp;&nbsp;1.6元气败脱，神明散乱证：神昏，肢体瘫软，目合口张，呼吸微弱，手撒肢冷，汗多，重则周身湿冷，二便失禁，舌痿不伸，舌质紫暗，苔白腻，脉沉缓或沉微。<br />&nbsp;&nbsp;1.7气虚血瘀证：半身不遂，口舌歪斜，言语謇涩或不语，偏身麻木，面色光白，气短乏力，口角流涎，自汗出，心悸便溏，手足肿胀，舌质暗淡，或舌边有齿痕，舌苔薄白或白腻，脉沉细、细缓或细弦。本证多见于恢复期。', null, ' ', '脑梗死的病程急性期：发病1～2周<br />&nbsp;&nbsp;恢复期：发病2周～6个月<br />&nbsp;&nbsp;后遗症期：发病6个月以后\n', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('543', '56', 'Z02_003', '1', '各类脑血管疾病诊断要点及疗效评定标准', ' ', '中华医学会第四次全国脑血管病学术会议', '1995', null, '中文', null, '脑出血；', null, null, '【高血压性脑出血】的诊断要点如下：1.3.1常于体力活动或情绪激动时发病。1.3.2发作时常有反复呕吐、头痛和血压升高。1.3.3病情进展迅速，常出现意识障碍、偏瘫和其他神经系统局灶症状。1.3.4多有高血压病史。<br />&nbsp;&nbsp;1.3.1.1动脉粥样硬化性血栓性脑梗死。常于安静状态下发病。大多数发病时无明显头痛和呕吐。发病较缓慢，多逐渐进展，或呈阶段性进行，多与脑动脉粥样硬化有关，也可见于动脉炎、血液病等。一般发病后1～2日内意识清楚或轻度障碍。有颈内动脉系统和（或）椎-基底动脉系统症状和体征。应做CT或MRI检查。腰穿脑脊液一般不应含血。', null, null, '（1） 神经功能缺损积分值的减少（功能改善）（2）患者总的生活能力状态（评定时的病残程度）<br />&nbsp;&nbsp;0级，能回复工作或操持家务。1级，生活自理，独立生活，部分工作。2级，基本独立生活，小部分需人帮助。3级，部分生活活动可自理，大部分需人帮助。4级，可站立步行，但需人随时照料。5级，卧床，能做，各项生活需人照料。6级，卧床，有部分意识活动，可喂食。7级，植物人状态。<br />&nbsp;&nbsp;临床疗效评定分级标准（1）基本痊愈，功能缺损评分减少90%~100%，病残程度0级（2）显著进步功能缺损评分减少46%~89%，病残程度1畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭㬘੟ༀƙ\0੟ð\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄祰௸੟ð\0ᅸ௸彿㎽奋㎽巫㎽鯜௸띌௸彿㎽띀௸塚㎽띌௸ꍈ㏂\0\0祰௸學㎽漸㏂圔㎽祰௸圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0㻸੟䐺盭暼痭㻸੟ༀƙ \0㻸੟ð\0\0㺣盭㻸੟\0𢡄㻼੟\0팃目㻼੟࣒㻼੟큁目㻼੟禤௸泌\0Item', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('544', '53', 'P01_001', '0', '中华中医药学会标准-头痛', '无', '中华中医药学会', '2008', 'ZYYXH/T 43-2008, 头痛[S].', '中文', null, null, '头痛', '1.外感头痛；1.1风寒证；1.2风热证；1.3风湿头痛证；2.内伤头痛；2.1肝阳化风证；2.2气血亏虚证；2.3痰浊阻络证；2.4瘀血阻络证', '1.诊断要点<br />&nbsp;&nbsp;1.1头部疼痛：疼痛的部位为前额、额顾、颞顶、顶枕或全头部疼痛，性质多为跳痛、刺痛、胀痛、昏痛、隐痛等；头痛可突然发作，或缓慢起病，或反复发作，时痛时止；头痛持续时间不一，可数分钟、数小时或数天、数周不等。<br />&nbsp;&nbsp;1.2发作诱因：本病常有一定诱因，外感头痛多因感受外邪或起居不慎，内伤头痛常有饮食、劳倦、病后体虚或房事不节等诱因。<br />&nbsp;&nbsp;2.鉴别诊断<br />&nbsp;&nbsp;2.1类中风：多见于45岁以上，眩晕反复发作、头痛突然加重时，常由风痰壅盛引起。常兼偏侧肢体括动不灵，或舌蹇语涩。<br />&nbsp;&nbsp;2.2真头痛：多突然剧烈头痛，持续痛而阵发加重，甚至喷射状呕吐、手足逆冷以至肢体痉厥、抽搐。真头痛病情凶险，与一般头痛不难区别。<br />&nbsp;&nbsp;2.3眩晕：头痛与瞎晕可单独出现，也可同时出现。头痛的病因有内伤与外感两个方面，表现为头部疼痛；眩晕则以内伤为主，表现为目眩和头晕。', '1.外感头痛<br />&nbsp;&nbsp;1.1风寒证：头痛起病急，痛连项背，恶风晨寒，遇风尤剧，口不渴，苔薄白，脉浮紧。<br />&nbsp;&nbsp;1.2风热证：头胀痛，甚则头痛如裂，发热或恶风，面红目赤，口渴欲饮，便秘尿黄，舌质红，苔黄，脉浮数。<br />&nbsp;&nbsp;1.3风湿头痛证：头痛如裹，肢体困重，胸闷纳呆，大便或溏，苔白腻，脉濡或滑。<br />&nbsp;&nbsp;2.内伤头痛<br />&nbsp;&nbsp;2.1肝阳化风证：头胀痛，心烦易怒，夜眠不宁，口苦面红，或兼胁痛，舌红苔黄，脉弦。<br />&nbsp;&nbsp;2.2气血亏虚证：头痛隐隐，或伴头晕，心悸不宁，面色少华，神疲乏力，遇劳加重，休息减轻，舌质淡，苔薄白，脉细弱。<br />&nbsp;&nbsp;2.3痰浊阻络证：头痛昏蒙，脘闷纳差，呕恶纳呆，舌胖大边有齿痕，苔白腻，脉滑或弦滑。<br />&nbsp;&nbsp;2.4瘀血阻络证：头痛经久不愈，痛处固定不移，痛如锥刺，或有头部外伤史，舌紫暗，或有瘀斑、瘀点，苔薄白，脉细或细涩。', null, null, '为中医标准。有详细诊断及中医辨证分型，并附针刺、推拿等其它治法。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('545', '53', 'P01_002', '0', '中华中医药学会标准-偏头痛', '无', '中华中医药学会', '2008', 'ZYYXH/T 128-2008, 偏头痛[S].', '中文', null, '偏头痛', null, '1.寒凝肝脉证；2.肝阳上亢证；3.风痰上扰证；4.瘀血阻络证；5.气血不足证；6.肝肾亏虚证', '1临床表现<br />&nbsp;&nbsp;1.1症状<br />&nbsp;&nbsp;    一般情况与病史：具有明显的发作-缓解特点，详细地询问病史对于诊断偏头痛具有重要的意义。偏头痛女性多于男性，以青年和成年人较为常见，首次发病多在50岁以前，病程一般比较长。部分偏头痛患者有明显的家族遗传史。<br />&nbsp;&nbsp;    头痛特点：头痛的程度、发作时间、持续时间、性质、部位、频率、严重程度、缓解和加重因素，是诊断偏头痛的重要依据。偏头痛发作前数小时到l—2日，可出现前驱症状，包括疲倦、注意力难以集中、颈部僵硬、对光或声音敏感、恶心、视觉模糊、打呵欠及脸色苍白等。偏头痛一次发作时间可持续4 -72小时，多为搏动性头痛或胀痛，可以一侧也可以双侧，多于活动或劳累时诱发或加重，休息后减轻或缓解。<br />&nbsp;&nbsp;    先兆症状：是区别有先兆偏头痛与无先兆偏头痛的重要依据，典型先兆包括完全可逆的视觉症状，包括正向特征（如：闪烁的光、点或线）及（或）负向特征（即视力丧失）：完全可逆的感觉症状，包括正向特征（即针刺感）及（或）负向特征（即麻木感），以及完全可逆的失语性语言障碍等。先兆症状一般持续_5—60分钟。<br />&nbsp;&nbsp;    伴随症状：伴随症状是诊断偏头痛的依据之一，主要有视觉症状（眼前闪光，亮点、线或失明）；感觉症状（针刺感、麻木）；言语障碍；恶心、呕吐、畏声、畏光等。<br />&nbsp;&nbsp;    精神心境和睡眠状况：对于病程较长的患者，多伴有精神心境的改变和睡眠障碍，要详细询问患者的心境和睡眠状况，以提高诊断准确性，并指导治疗。<br />&nbsp;&nbsp;1.2体征<br />&nbsp;&nbsp;    在偏头痛发作间期，体格检查无阳性体征，在发作过程中不同类型的偏头痛具有各自的体征。<br />&nbsp;&nbsp;    对于有先兆的偏头痛，经常伴有眼肌麻痹、偏身麻木、偏瘫或失语等神经系统局灶体征，但这些症状通常在5 -20分钟内逐渐产生，持续不超过60分钟，且反复发作。如果体征持续超过60分钟，则应考虑是否为短暂性脑缺血发作、脑梗死或脑出血等脑血管疾病。如果症状持续且逐渐加重，要注意除外颅内肿瘤。<br />&nbsp;&nbsp;    偏头痛的诊断需要除外其他疾患引起的头痛，因此建议时就诊的患者进行详细而全面的体格检查和神经系统查体。<br />&nbsp;&nbsp;2理化检查<br />&nbsp;&nbsp;2.1影像学检查：除外颅内器质性疾患，对诊断提供依据。建议参照美国国家头痛基金会编写颁布的《影像学检查指南》：<br />&nbsp;&nbsp;    若头痛患者有下述任何1项者，应做神经影像学检查：意识水平下降或认知功能受损；用力、性交、咳嗽、喷嚏等情况下疼痛加重；疼痛、病情进行性加重；颈项强直；局灶性神经体征；50岁以上首次发生头痛的患者；最严重的头痛；头痛不具原发性头痛的特定形式。<br />&nbsp;&nbsp;    若头痛患者同时满足下述中的5项者，可不做神经影像学检查：过去有类似头痛史；生命体征正常；意识和认知功能正常；无脑膜刺激征；无阳性神经体征；头痛自发缓解。<br />&nbsp;&nbsp;2.2经颅彩色多普勒(TCD)：可表现为血流速度的改变，多见于两侧或单侧大脑中动脉和（或）大脑前动脉流速轻度增高，间歇期平均流速多小于150cm/s，两侧血流速度不对称，两侧相对应动脉的流差大于20cm/s。还可能有血管杂音。建议对拟诊的偏头痛患者进行TCD的检查。<br />&nbsp;&nbsp;2.3脑电图：文献报道偏头痛患者有11%—14%脑电图不正常。<br />&nbsp;&nbsp;3.诊断要点<br />&nbsp;&nbsp;    推荐使用2004年1月国际头痛协会推出的《国际头痛疾病分类（第二版）》。<br />&nbsp;&nbsp;    该标准将偏头痛归属于原发性头痛的一种，又将偏头痛分为无先兆偏头痛、有先兆偏头痛、通常为偏头痛前驱症状的儿童周期性症候群、视网膜偏头痛、偏头痛并发症和可能是偏头痛等六种。<br />&nbsp;&nbsp;由于偏头痛的诊断是依据头痛的发作特点、伴随症状等，缺乏客观的体征和理化检查结果，故一个人可以有不同类型头痛的发作。', '1.寒凝肝脉证：多见于发作期，常因感受寒邪诱发，头痛较剧，呈掣痛，多位于巅顶，面色发青，呕吐清水疲涎，甚至四肢厥冷，或兼口唇青紫或紫暗，舌质淡暗或青紫，苔薄白，脉沉细弦。<br />&nbsp;&nbsp;2.肝阳上亢证：多见于发作期，常因情志过激、劳累过度等诱发。头痛常于大怒或劳累后突然出现，一侧尤甚或两侧跳痛或胀痛；伴头晕或目眩，常波及巅顶，颜面潮红，眼目抽痛，心烦易怒，夜眠不宁；或兼胁痛，口干口苦，尿赤，便秘；舌红或绛，苔薄黄，脉弦或弦数。<br />&nbsp;&nbsp;3.风痰上扰证：多见于发作期，常因情志不遂、劳逸过度或饮食不节等诱发。头痛突然出现，起止无常，头部昏痛或胀痛，头重如裹，胸脘满闷，恶心、呕吐痰涎，口淡食少；或口中黏腻，口苦，大便不爽；舌胖大，苔白腻或黄腻，脉弦滑或弦滑数。<br />&nbsp;&nbsp;4.瘀血阻络证：发作期和缓解期均可见到。多为病程日久患者，头痛反复，痛如锥刺，或左或右，固定不移，经久不愈，面色晦滞，妇女行经色暗或夹血块，唇舌紫暗或见瘀斑，舌紫暗，有瘀点或瘀斑，脉细涩。<br />&nbsp;&nbsp;5.气血不足证：多见于缓解期，患者多为脑力劳动，饮食作息无常。头痛隐隐，反复发作，遇劳加重，心悸，食少纳呆，瘦眠易醒或多梦，神疲乏力，或自汗气短，面色苍白，舌质淡，苫薄白，脉沉细而弱。<br />&nbsp;&nbsp;6.肝肾亏虚证：多见于缓解期，头痛隐隐且空，每兼眩晕，时轻时重，腰膝酸软，遗精带下，视物模糊，耳鸣少寐，五心烦热，口干，舌红少苔，脉弦细或细数。', null, null, '为中医标准。有详细诊断及中医辨证分型，并附针刺、推拿等其它治法。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('546', '53', 'P01_003', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会.临床诊疗指南神经病学分册[M].北京：人民卫生出版社，2009.', '中文', '1.先兆偏头痛<br />&nbsp;&nbsp;    以青春期发病，25～29岁患病率最高，10岁以下少见，60岁以上发作减少。发作次数以2～3次居多。约30. 6%的患着有家族史，遗传因素常来自母亲。先兆头痛约占偏头痛患者的10%左右。<br />&nbsp;&nbsp;    在头痛发作前20～30分钟出现先兆，多为视觉先兆。典型的视觉先兆开始为一中央旁视觉盲点，缓慢向视野边缘扩展呈“C\"形，在扩展过程中，扩展边缘出现闪光角，使边缘呈锯齿状并有颜色，持续20～25分钟后消失在视野周围，这种视觉先兆被称作“堡垒幻影”( fortification  spectrum)。其他先兆有：偏身感觉异常或麻木，偏身力弱或失语或难以分类的语言障碍少见。这些症状通常持续不超过30分钟，于头痛开始前消失，少数可贯穿于整个头痛期，偶尔头痛缓解后仍持续几天。无论先兆是否确切，几乎所有的患者都有畏光和畏声症状。<br />&nbsp;&nbsp;    头痛部位以眶上、眶后、额颞部最常见，偶尔可出现在顶部、枕部。疼痛起先为钝痛，继而转为剧烈的搏动性疼痛，头痛程度达到顶峰，最后呈持续性头痛。可以单侧或双侧性，约10%的患者固定在一侧发作。在未治疗的情况下头痛可持续数小时至2～3天。<br />&nbsp;&nbsp;    头痛发作时，常伴恶心、呕吐、面色苍白、出汗、有排便感，少数可出现面部潮红、腹痛、腹泻等。头痛常为睡眠所终止，醒后头痛完全缓解。头痛消失后1～2天之内，常表现有身体及精神的疲劳感、虚弱感、抑郁感、头沉、头重等残留症状。<br />&nbsp;&nbsp;    部分先兆性头痛在头痛出现前1～2天，出现情绪不稳定、食欲增加、口渴、嗜睡、欣快或抑郁、颈肩部感觉异常等先驱症状。<br />&nbsp;&nbsp;    头痛发作的诱因有：精神疲劳，紧张，月经期，食韧（如各种酒类、巧克力、坚果、奶酪）及某些药物（血管扩张剂、抗高血压药、5-羟色胺释放剂、雌激素和口服避孕药等）。<br />&nbsp;&nbsp;    若头痛持续数天不缓解，称为偏头痛持续状态。<br />&nbsp;&nbsp;2.无先兆偏头痛<br />&nbsp;&nbsp;    无先兆偏头痛是常见的偏头痛类型，约占偏头痛的2/3，常开始于儿童期，女多于男，约70%的患者有家族史，除了没有先兆以外，头痛发作和先兆偏头痛相似，但发作较频繁，持续时间也比先兆偏头痛长，可达1～3天。在头痛前数小时或数天可以有一些非特异性前驱症状，如胃肠道症状恶心、呕吐、身体不适、精神障碍、畏光和畏声等。<br />&nbsp;&nbsp;3.家族性偏瘫型偏头痛(FHM)<br />&nbsp;&nbsp;    家族性偏瘫型偏头痛系常染色体显性遗传性疾患，临床表现为以偏瘫为先兆的偏头痛发作为特征的综合征。FHM有很强的遗传基础，其遗传异质性至少涉及3个染色体19p、lq21-23和lp31，50%的FHM家族其基因连锁至染色体19p13。FHM是因CACNAIA基因突变所致，CACNAIA是颅神经元P／Q型钙通道d/A亚单位的基因编码，其错义突变造成FHM。<br />&nbsp;&nbsp;    FHM的临床特征是：其先兆表现为程度轻重不等的轻偏瘫和偏瘫，按先兆持续时间可分为有先兆型偏头痛或先兆延长型偏头痛（可长达数天或数周），受累侧左右不定，常以一侧发生为主，并可伴有其他神经系统功能障碍症状，如视觉盲点，偏身感觉丧失，失语，意识障碍从精神混乱到昏迷，发热，脑脊液白细胞增多和脑膜刺激征等假性脑膜炎的症状和体征，脑水肿和脑电图表现为慢波活动，持续数日或数周。当这些症状出现时多被误诊为颅内感染等其他疾病。一些家族还可有小脑受累症状，如眼球震颤和进行性共济失调或发作性<br />&nbsp;&nbsp;共济失调，MRI可见小脑萎缩。小脑症状可先于偏瘫型偏头痛发作出现。一些家族还可有特发性震颤和癫痫发作。乙酰唑胺对FHM发作效果明显，但对进行性共济失调无效。<br />&nbsp;&nbsp;4.儿童期偏头痛<br />&nbsp;&nbsp;    儿童期偏头痛的临床表现和成人偏头痛差别极大，诊断和处理时应予特别注意和对待。儿童期偏头痛的特点有：<br />&nbsp;&nbsp;    4.1儿童偏头痛患病率国外约为5%，我国大陆10岁以下男女患病率只有18.7/10万和66.5/10万。<br />&nbsp;&nbsp;    4.2 40%的患儿成人期后不再有头痛发作。<br />&nbsp;&nbsp;    4.3头痛发作持续时间短暂，多不超过1小时。<br />&nbsp;&nbsp;    4.4头痛发作轻重不等，但更易表现为严重的胃肠道紊乱，神经功能紊乱症状。<br />&nbsp;&nbsp;    4.5先兆多奇异怪诞，如为视觉先兆可表现为视物变小症、视物交大症和视物变形症，被称为爱丽丝漫游奇境综合征。<br />&nbsp;&nbsp;    4.6罕见的偏头痛形式更多见于儿童，如精神混乱型偏头痛、基底动脉型偏头痛、FHM和眼型偏头痛。<br />&nbsp;&nbsp;    4.7儿童期偏头痛更常表现为发作性非头痛的其他周期性症状综合征，如周期性呕吐、复发性腹痛、阵发性眩晕和交替性偏瘫。<br />&nbsp;&nbsp;    4.8睡眠与儿童期偏头痛关系密切。多数儿童于头痛发作后不久即入睡，醒后多数头痛明显好转，部分患儿头痛消失。睡眠持续时间0～5小时至16小时不等。<br />&nbsp;&nbsp;    4.9儿童期偏头痛急性发作的治疗以使用一般止痛药为宜，扑热息痛为首选，不宜使用阿司匹林，因有引发Reye综合征的危险。止吐药不宜选用胃复安( metoclopramide)．儿童使用该药更宜诱发肌张力障碍(dystonia)、麦角胺和traiptans对儿童偏头痛治疗的疗效和不良反应尚未确定，预防治疗和成年人相同。<br />&nbsp;&nbsp;5.基底型偏头痛<br />&nbsp;&nbsp;    极罕见，主要发生在少年或青年女性，与月经周期密切相关。先兆症状包括双侧视觉障碍，如闪光、暗点、双侧视力模糊或全盲、短暂性眩晕、讷吃、复视、耳呜、口周和肢体远端麻木或感觉异常、共济失调，也可有嗜睡状态和跌倒发作。先兆期平均持续10～30分钟，继而出现搏动性头痛，常位于枕部，可向后颈部放射，伴恶心、呕吐，近1/4的患者头痛发作的高峰期可有意识不清，头痛可持续数小时至1天，常在睡眠后缓解，恢复完全，间歇期亦正常，偶尔多次发作后可导致基底动脉或大脑后动脉血栓形成。该型与椎一基底动脉系统缺血疾病难以鉴别。', '偏头痛', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1先兆偏头痛<br />&nbsp;&nbsp;    以青春期发病，25～29岁患病率最高，10岁以下少见，60岁以上发作减少。发作次数以2～3次居多。约30. 6%的患着有家族史，遗传因素常来自母亲。先兆头痛约占偏头痛患者的10%左右。<br />&nbsp;&nbsp;    在头痛发作前20～30分钟出现先兆，多为视觉先兆。典型的视觉先兆开始为一中央旁视觉盲点，缓慢向视野边缘扩展呈“C\"形，在扩展过程中，扩展边缘出现闪光角，使边缘呈锯齿状并有颜色，持续20～25分钟后消失在视野周围，这种视觉先兆被称作“堡垒幻影”( fortification  spectrum)。其他先兆有：偏身感觉异常或麻木，偏身力弱或失语或难以分类的语言障碍少见。这些症状通常持续不超过30分钟，于头痛开始前消失，少数可贯穿于整个头痛期，偶尔头痛缓解后仍持续几天。无论先兆是否确切，几乎所有的患者都有畏光和畏声症状。<br />&nbsp;&nbsp;    头痛部位以眶上、眶后、额颞部最常见，偶尔可出现在顶部、枕部。疼痛起先为钝痛，继而转为剧烈的搏动性疼痛，头痛程度达到顶峰，最后呈持续性头痛。可以单侧或双侧性，约10%的患者固定在一侧发作。在未治疗的情况下头痛可持续数小时至2～3天。<br />&nbsp;&nbsp;    头痛发作时，常伴恶心、呕吐、面色苍白、出汗、有排便感，少数可出现面部潮红、腹痛、腹泻等。头痛常为睡眠所终止，醒后头痛完全缓解。头痛消失后1～2天之内，常表现有身体及精神的疲劳感、虚弱感、抑郁感、头沉、头重等残留症状。<br />&nbsp;&nbsp;    部分先兆性头痛在头痛出现前1～2天，出现情绪不稳定、食欲增加、口渴、嗜睡、欣快或抑郁、颈肩部感觉异常等先驱症状。<br />&nbsp;&nbsp;    头痛发作的诱因有：精神疲劳，紧张，月经期，食韧（如各种酒类、巧克力、坚果、奶酪）及某些药物（血管扩张剂、抗高血压药、5-羟色胺释放剂、雌激素和口服避孕药等）。<br />&nbsp;&nbsp;    若头痛持续数天不缓解，称为偏头痛持续状态。<br />&nbsp;&nbsp;1.2无先兆偏头痛<br />&nbsp;&nbsp;    无先兆偏头痛是常见的偏头痛类型，约占偏头痛的2/3，常开始于儿童期，女多于男，约70%的患者有家族史，除了没有先兆以外，头痛发作和先兆偏头痛相似，但发作较频繁，持续时间也比先兆偏头痛长，可达1～3天。在头痛前数小时或数天可以有一些非特异性前驱症状，如胃肠道症状恶心、呕吐、身体不适、精神障碍、畏光和畏声等。<br />&nbsp;&nbsp;1.3家族性偏瘫型偏头痛(FHM)<br />&nbsp;&nbsp;    家族性偏瘫型偏头痛系常染色体显性遗传性疾患，临床表现为以偏瘫为先兆的偏头痛发作为特征的综合征。FHM有很强的遗传基础，其遗传异质性至少涉及3个染色体19p、lq21-23和lp31，50%的FHM家族其基因连锁至染色体19p13。FHM是因CACNAIA基因突变所致，CACNAIA是颅神经元P／Q型钙通道d/A亚单位的基因编码，其错义突变造成FHM。<br />&nbsp;&nbsp;    FHM的临床特征是：其先兆表现为程度轻重不等的轻偏瘫和偏瘫，按先兆持续时间可分为有先兆型偏头痛或先兆延长型偏头痛（可长达数天或数周），受累侧左右不定，常以一侧发生为主，并可伴有其他神经系统功能障碍症状，如视觉盲点，偏身感觉丧失，失语，意识障碍从精神混乱到昏迷，发热，脑脊液白细胞增多和脑膜刺激征等假性脑膜炎的症状和体征，脑水肿和脑电图表现为慢波活动，持续数日或数周。当这些症状出现时多被误诊为颅内感染等其他疾病。一些家族还可有小脑受累症状，如眼球震颤和进行性共济失调或发作性<br />&nbsp;&nbsp;共济失调，MRI可见小脑萎缩。小脑症状可先于偏瘫型偏头痛发作出现。一些家族还可有特发性震颤和癫痫发作。乙酰唑胺对FHM发作效果明显，但对进行性共济失调无效。<br />&nbsp;&nbsp;1.4儿童期偏头痛<br />&nbsp;&nbsp;    儿童期偏头痛的临床表现和成人偏头痛差别极大，诊断和处理时应予特别注意和对待。儿童期偏头痛的特点有：<br />&nbsp;&nbsp;    1.4.1儿童偏头痛患病率国外约为5%，我国大陆10岁以下男女患病率只有18.7/10万和66.5/10万。<br />&nbsp;&nbsp;    1.4.2 40%的患儿成人期后不再有头痛发作。<br />&nbsp;&nbsp;    1.4.3头痛发作持续时间短暂，多不超过1小时。<br />&nbsp;&nbsp;    1.4.4头痛发作轻重不等，但更易表现为严重的胃肠道紊乱，神经功能紊乱症状。<br />&nbsp;&nbsp;    1.4.5先兆多奇异怪诞，如为视觉先兆可表现为视物变小症、视物交大症和视物变形症，被称为爱丽丝漫游奇境综合征。<br />&nbsp;&nbsp;    1.4.6罕见的偏头痛形式更多见于儿童，如精神混乱型偏头痛、基底动脉型偏头痛、FHM和眼型偏头痛。<br />&nbsp;&nbsp;    1.4.7儿童期偏头痛更常表现为发作性非头痛的其他周期性症状综合征，如周期性呕吐、复发性腹痛、阵发性眩晕和交替性偏瘫。<br />&nbsp;&nbsp;    1.4.8睡眠与儿童期偏头痛关系密切。多数儿童于头痛发作后不久即入睡，醒后多数头痛明显好转，部分患儿头痛消失。睡眠持续时间0～5小时至16小时不等。<br />&nbsp;&nbsp;    1.4.9儿童期偏头痛急性发作的治疗以使用一般止痛药为宜，扑热息痛为首选，不宜使用阿司匹林，因有引发Reye综合征的危险。止吐药不宜选用胃复安( metoclopramide)．儿童使用该药更宜诱发肌张力障碍(dystonia)、麦角胺和traiptans对儿童偏头痛治疗的疗效和不良反应尚未确定，预防治疗和成年人相同。<br />&nbsp;&nbsp;1.5基底型偏头痛<br />&nbsp;&nbsp;    极罕见，主要发生在少年或青年女性，与月经周期密切相关。先兆症状包括双侧视觉障碍，如闪光、暗点、双侧视力模糊或全盲、短暂性眩晕、讷吃、复视、耳呜、口周和肢体远端麻木或感觉异常、共济失调，也可有嗜睡状态和跌倒发作。先兆期平均持续10～30分钟，继而出现搏动性头痛，常位于枕部，可向后颈部放射，伴恶心、呕吐，近1/4的患者头痛发作的高峰期可有意识不清，头痛可持续数小时至1天，常在睡眠后缓解，恢复完全，间歇期亦正常，偶尔多次发作后可导致基底动脉或大脑后动脉血栓形成。该型与椎一基底动脉系统缺血疾病难以鉴别。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1头痛的诊断<br />&nbsp;&nbsp;2.1.1病史采集。<br />&nbsp;&nbsp;2.1.2应进行全面的体格检查和神经系统检查，排除继发性头痛。<br />&nbsp;&nbsp;2.1.3进行必要的实验室检查和特殊的辅助检查，如头颅CT和MRI等，以及腰椎穿刺。<br />&nbsp;&nbsp;2.2原发性头痛的诊断<br />&nbsp;&nbsp;    在排除继发性头痛的基础上，按IHS的诊断标准进行诊断。<br />&nbsp;&nbsp;2.3偏头痛的诊断标准<br />&nbsp;&nbsp;P01_003图1<br />&nbsp;&nbsp; P01_003图2', null, null, null, '为西医标准。明确各类偏头痛诊断标准、评估以及相应治疗。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('547', '53', 'P01_004', '1', '中国偏头痛诊断治疗指南', '无', '中华医学会疼痛学分会头面痛学组', '2011', '舜伟,李焰生,刘若卓,等. 中国偏头痛诊断治疗指南[J]. 中国疼痛医学杂志,2011,17（2）:65-86.', '中文', null, '偏头痛', null, null, '1.无先兆和有先兆偏头痛诊断标准P01_004表1<br />&nbsp;&nbsp;2.有先兆偏头痛的诊断标准：有先兆偏头痛的诊断主要根据先兆特征，需要有2次以上的先兆发作并排除继发性头痛的可能。符合表2中B-D特征的先兆为典型先兆，如果典型先兆后1小时内出现偏头痛性头痛发作，即可诊断为伴典型先兆的偏头痛性头痛（见表2）。如果典型先兆后的头痛不符合偏头痛性头痛的特点。则诊断为伴典型先兆的非偏头痛性头痛（见表3）。典型先兆后也可以没有头痛发作，此时诊断为典型先兆不伴头痛（见表4）。一旦先兆期出现肢体无力表现，须考虑偏瘫性偏头痛，若患者的一、二级亲属中有类似发作。则诊断为家族性偏瘫性偏头痛（见表5），否则诊断为散发性偏瘫性偏头痛（见表6）。如果先兆明显地表现出起源于脑干和（或）双侧大脑半球同时受累的症状，且不伴肢体无力时，诊断为基底型偏头痛（见表7），确诊需要下列2项以上的症状：构音障碍、眩晕、耳鸣、听力下降、复视、双鼻侧或双颞侧视野同时出现的视觉症状、共济失调、意识改变、双侧感觉异常等。偏瘫性偏头痛和基底型偏头痛在先兆症状同时或在先兆出现的60分钟内有偏头痛性头痛发作。P01_004表2<br />&nbsp;&nbsp;P01_004表3<br />&nbsp;&nbsp;P01_004表4<br />&nbsp;&nbsp;P01_004表5<br />&nbsp;&nbsp;P01_004表6<br />&nbsp;&nbsp;P01_004表7<br />&nbsp;&nbsp;3.辅助检查与鉴别继发性头痛  目前尚缺乏偏头痛特异性诊断手段。辅助检查的目的是为了排除继发性头痛或了解偏头痛患者合并的其他疾病。<br />&nbsp;&nbsp;3.1血液检查：血液检查主要用于排除颅内或系统性感染、结缔组织疾病、内环境紊乱、遗传代谢性疾病等引起的头痛，如对50岁后新发头痛，需排除巨细胞动脉炎。则应进行红细胞沉降率和C-反应蛋白的检查。<br />&nbsp;&nbsp;3.2脑电图：偏头痛患者发作间期脑电图可有轻度异常。15%的患者可有局灶性慢波，0.2%-9%的患者可见棘波活动，但明确的异常脑电活动发生率不高，与正常人相当。<br />&nbsp;&nbsp;    推荐：脑电图无助于头痛的日常评估。但是可用于头痛伴有意识障碍或不典型先兆疑为痫性发作的情况。<br />&nbsp;&nbsp;3.3经颅多普勒超声：经颅多普勒超声在偏头痛发作时可以观察到血流速度增快或减慢、血流速度不稳定、血流速度两侧不对称等种种表现。各个研究的报道结果相当不一致。<br />&nbsp;&nbsp;    推荐：经颅多普勒超声检查不能帮助偏头痛的诊断。<br />&nbsp;&nbsp;3.4腰椎穿刺：腰椎穿刺主要用于排除蛛网膜下腔出血、颅内感染、脑膜癌病及异常颅压所导致的头痛。突然发生的严重头痛，如果CT正常。仍应进一步行腰椎穿刺以排除蛛网膜下腔出血的可能。<br />&nbsp;&nbsp;3.5CT和MRI检查：CT和MRI检查是了解头痛是否源于颅内器质性病变的主要手段。对1876例连续到神经科就诊的病程超过4周的非急性患者进行CT或MRI检查，结果仅l2%患者的存在“有意义”的影像学发现，神经系统检查正常者的”有意义”的影像学异常率为0.9%。而临床符合偏头痛表现的患者仅为0.4%。系统分析11项研究发现，偏头痛或神经系统检查正常的非急性患者的“有意义”的影像学异常仅占0.27%。我国一项研究回顾性调查338例无神经功能异常、病程超过3月的患者，MRI发现重要异常仅7例(21%)，而在偏头痛及合并紧张型头痛的患者中未发现重要异常。一些研究表明，偏头痛患者MRI上出现白质异常信号的风险高，但其临床意义有待进一步研究。<br />&nbsp;&nbsp;    许多情况下，MRI较CT有更高的敏感性，然而尚无证据表明MRI较CT能检测到更多的有意义的影像学发现。如再考虑经济因素，CT和MRI在头痛诊断中孰优孰劣更无定论。临床中可以根据具体情况加以选择：CT在急性颅内出血、脑外伤、颅骨病变方面有优势。MRI则在后颅窝及颅颈交界病变、垂体病变、白质病变、缺血性病变、静脉窦血栓形成、动静脉畸形、硬膜外及硬膜下血肿、肿瘤、脑腆病变（包括低颅压引起的弥漫性脑膜增强）、小脑炎症、脑脓肿等方面更胜一筹。疑有静脉窦血栓时还应行DSA检查或磁共振静脉血管造影检查。<br />&nbsp;&nbsp;    凡具有典型的偏头痛症状、长期头痛发作基本相似且神经系统体检正常的患者，不推荐常规进行CT或MRI检查。<br />&nbsp;&nbsp;4.与其他原发性头痛的鉴别诊断  如果病史典型。多数患者在首次就诊时就能得到确诊。但仅根据1、2次的发作则难以与紧张型头痛或丛集性头痛相鉴别，但多次发作则易于诊断(见表8)。临床上。患者同时具有偏头痛与紧张型头痛的情况不少见。可以同时诊断。P01_004表8<br />&nbsp;&nbsp;5.其它类型偏头痛的诊断  临床上还存在一些偏头痛类型，如儿童偏头痛、月经性偏头痛等，只被纳入ICHD-II的附录中。<br />&nbsp;&nbsp;5.1儿童偏头痛：儿童偏头痛具有一些特点：多为无先兆偏头痛发作类型：头痛的持续时间短。可仅数十分钟；头痛位于双侧较单侧常见：畏光或畏声情况多于成人：约20%的患儿在头痛之前或头痛时，逐渐出现视觉先兆，表现为双眼经常可见到光点、色彩、亮点或光线。偶尔也可发生在单眼。通常视觉症状持续不超过30分钟。<br />&nbsp;&nbsp;    可能为偏头痛前驱的儿童周期综合征包括：<br />&nbsp;&nbsp;    （1）周期性呕吐：呈反复发作性的刻板性症状，恶心和剧烈呕吐，发作时伴有面色苍白和嗜睡，发作间期症状完全缓解。此综合征的临床特点与偏头痛头痛的伴随症状相似。<br />&nbsp;&nbsp;    （2）腹型偏头痛：反复发作性腹部中线处疼痛，发怍持续1- 72小时，发作间期正常。腹痛程度为中重度，常伴恶心和呕吐。腹痛具有以下特征：位于中线、脐周或难以定位：性质为钝痛或“就是痛”：程度为中重度。腹痛期间。至少伴随2项其他症状，如食欲减退、恶心、呕吐或面色苍白。诊断须排除其它疾病。<br />&nbsp;&nbsp;    （3）儿童期良性发作性眩晕：反复短暂性眩晕发作。眩晕可突然发生和迅速缓解。神经系统检查、听力检查和前庭功能检查均正常。眩晕持续时间短暂，可伴有眼震或呕吐。有些患儿可伴单侧博动性头痛。<br />&nbsp;&nbsp;5.2月经性偏头痛：多为无先兆偏头痛。发作通常持续时间较长，可达4-5天，与月经持续时间相当。可分为单纯性月经性无先兆偏头痛和月经相关性无先兆偏头痛。<br />&nbsp;&nbsp;    (1)单纯性月经性无先兆偏头痛：偏头痛发作发生于月经期女性，符合无先兆偏头痛的诊断标准。头痛发作应该在3个月经周期中至少有2个周期头痛发作，而且，仅仅发生在月经第1±2天，即月经期的一2到+3天。而在月经周期的其它时间不发生。<br />&nbsp;&nbsp;    (2)月经相关性无先兆偏头痛：发生于月经期女性。头痛发作在月经第1±2天。即月经期的一2到+3天。并且这种情况在3个月经周期中至少有2个周期发生，在月经周期的其他时间亦有发作。也就是说，这些患者既有围月经期偏头痫，又有月经周期其他时间的偏头痛。<br />&nbsp;&nbsp;5.3慢性偏头痛：根据EHD-II的定义。慢性偏头痛是指在没有药物过度使用的情况下。至少3个月偏头痛发作每月达到或超过15天。<br />&nbsp;&nbsp;    由于对慢性偏头痛的界定存在较大争议，2006年国际头痛分类委员会对慢性偏头痛的诊断标准进行了修改(见表9)，并将其放入ICH D-II的附录以备进一步的研究完善。P01_004表9<br />&nbsp;&nbsp;5.4偏头痛持续状态：偏头痛持续状态是指一次使人心力交瘁的偏头痛发作持续72小时以上，具体诊断标准见表10。P01_004表10<br />&nbsp;&nbsp;', null, null, null, '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('548', '53', 'P01_005', '1', '偏头痛、紧张型头痛、丛集性头痛、药物过度使用头痛的所有医疗专业人员的诊治指南', 'Guidelines for All Healthcare Professionals in the Diagnosis and Management of Migraine Tension-Type Headache Cluster Headache Medication-Overuse Headache', '英国头痛研究学会（BASH,British Association for the study of Headache）', '2010', 'http://guide.medlive.cn/guideline/1456', '英文', null, '偏头痛', null, null, '1.Taking a history<br />&nbsp;&nbsp;There are no diagnostic tests for any of the primary headache disorders, or for medication-overuse headache. The history is all-important. A headache history requires time to elicit, and not ﬁ  nding the time to take it fully is the probable cause of most misdiagnosis. A simple and helpful ploy when the patient ﬁ  rst presents in a busy clinic is to request the keeping of a diary over a few weeks. The pattern of attacks is a very helpful pointer to the right diagnosis, and review can be arranged at a time less rushed. First, of course, it must be ascertained that a condition requiring more urgent intervention is not present (see 5.0).<br />&nbsp;&nbsp; P01_005表1<br />&nbsp;&nbsp;In children, distinctions between headache types, particularly migraine and tension-type headache, are often less clear than in adults.<br />&nbsp;&nbsp;Different headache types are not mutually exclusive. Patients are often aware of more than one headache type, and a separate history should be taken for each. The crucial elements of a headache history are set out in table I.<br />&nbsp;&nbsp;2. Migraine<br />&nbsp;&nbsp;Patients with migraine typically give an account of recurrent episodic moderate or severe headaches (which may be unilateral and/or pulsating) lasting part of a day or up to 3 days, associated with gastrointestinal symptoms, during which they limit activity and prefer dark and quiet. They are free from symptoms between attacks.<br />&nbsp;&nbsp;Diagnostic criteria for migraine without aura are shown in table III. It is easy to regard these as a check-list, sufﬁcient if ticked by a nurse or even the patient, but they require clinical interpretation. One of the weaknesses of the diagnostic criteria of ICHD-II is that they focus on symptoms, not patients. For migraine, therefore, they do not describe the all-important patterns of occurrence of attacks. Nevertheless, if used as they are meant to be, supplementary to normal <br />&nbsp;&nbsp;enquiry practice, they distinguish effectively between migraine without aura and its principal differential diagnosis, tension-type headache.<br />&nbsp;&nbsp; P01_005表2<br />&nbsp;&nbsp;Migraine with aura, which affects about one third of migraine sufferers, is diagnosed relatively easily. The occurrence of typical aura clinches it, but beware of patients who bring “visual disturbance” into their accounts because of what they have read about migraine. Visual blurring and “spots” are not diagnostic. Symptoms of typical aura are progressive, last 5-60 minutes prior to headache and are visual, consisting of transient hemianopic disturbance or a spreading scintillating scotoma (patients may draw a jagged crescent if asked). In some cases visual symptoms occur together or in sequence with other reversible focal neurological disturbances such as unilateral paraesthesia of hand, arm or face (the leg is rarely affected) and/or dysphasia, all manifestations of functional cortical disturbance of one cerebral hemisphere.<br />&nbsp;&nbsp;Particularly in older patients, typical visual migrainous aura may occur without any further development of a migraine attack. When there is a clear history of earlier migraine with aura, and the description of aura remains similar, this is not alarming. Otherwise it should be remembered that transient ischaemic attack is in the differential diagnosis for older patients.<br />&nbsp;&nbsp;Patients may, at different times, have attacks of migraine with and migraine without aura. They may, over a lifetime, change from a predominance of one subtype to the other.<br />&nbsp;&nbsp;Prolonged aura, especially aura persisting after resolution of the headache, and aura involving motor weakness, require referral to specialists for exclusion of other disease. Amongst these cases are a very small number of families expressing recognized genes for familial hemiplegic migraine.<br />&nbsp;&nbsp;Migrainous headache occurring every day (chronic migraine) is classiﬁ  ed as a complication of migraine; it requires specialist referral because diagnosis and management are difﬁcult.<br />&nbsp;&nbsp;“Diagnosis” by treatment It is tempting to use anti-migraine drugs as a diagnostic test for migraine. This is a condition where an empirical approach to management (“Try this and see how it works”) is not always unreasonable. However, triptans, despite being the most speciﬁ  c and effective drugs currently available, are at best effective in three quarters of attacks. As a diagnostic test they have rather low sensitivity so this approach is likely to mislead.<br />&nbsp;&nbsp;3.Tension-type headache (TTH)<br />&nbsp;&nbsp;Episodic tension-type headache also occurs in attack-like episodes, with variable and often very low frequency and mostly short-lasting – no more than several hours. Headache can be unilateral but is more often generalised. It is typically described as pressure or tightness, like a vice or tight band around the head, and commonly spreads into or arises from the neck. Whilst it can be disabling for a few hours, it lacks the speciﬁ  c features and associated symptom complex of migraine (although photophobia and exacerbation by movement are common to many headaches).<br />&nbsp;&nbsp;TTH may be stress-related or associated with functional or structural cervical or cranial musculoskeletal abnormality, and these are not mutually exclusive. Patients may admit or deny stress. Clinically, there are cases where stress is obvious and likely to be aetiologically implicated (often in headache that becomes worse during the day) and others where it is not apparent. Equally there are cases with musculoskeletal involvement evident in the history (or on examination) and others where this is not a factor.<br />&nbsp;&nbsp;What causes people with TTH to consult healthcare professionals is that it is becoming frequent, in which case it may no longer be responding to painkillers. Chronic tension-type headache occurs by deﬁ  nition on >15 days a month, and may be daily. This condition is disabling.<br />&nbsp;&nbsp;Both migraine and TTH are aggravated by stress and, in practice, there are occasions when the distinction is not easily made. Where this is so, especially in patients with frequent headache, the two may co-exist. In such cases, unless both conditions are recognised and dealt with individually, management is unlikely to be successful (see 10.0).<br />&nbsp;&nbsp;4. Cluster headache (CH)<br />&nbsp;&nbsp;There is another group of disorders, the trigeminal autonomic cephalalgias, where daily occurrence of headache (often several attacks daily) is usual. The most common is cluster headache.<br />&nbsp;&nbsp;CH affects mostly men (male to female ratio about 6:1) in their 20s or older (very rarely children) and very often smokers. The condition has its name because, typically (although there is a less common chronic subtype), headaches occur in bouts for 6-12 weeks, once a year or two years, often at the same time each year.<br />&nbsp;&nbsp;The pain of CH is intense, probably as severe as that of renal colic, and strictly unilateral. Although most often focused in one or other eye, it can spread over a larger area of the head, which sometimes misleads the diagnosis. There may, also, be a continuous background headache. The other features should leave no diagnostic doubt, although unusual patterns do occur, especially in women. Typically CH occurs daily, at a similar time each day, and usually but far from always at night, 1-2 hours after falling asleep. The wakened patient, unable to stay in bed, agitatedly paces the room, even going outdoors. He may beat his head on the wall or ﬂoor until the pain diminishes, usually after 30-60 minutes. The associated autonomic features of ipsilateral conjunctival injection and lacrimation, rhinorrhoea or nasal blockage, and ptosis as the most obvious feature of a partial Horner’s syndrome, may not all be present but almost invariably at least one or two secure the diagnosis. (There are other rare causes of painful Horner’s syndrome; referral to specialists is appropriate where doubt occurs.)<br />&nbsp;&nbsp;5.Medication overuse headache (MOH)<br />&nbsp;&nbsp;This term has displaced the pejorative alternatives of drug, analgesic or medication abuse or misuse headache. It is estimated that 1 in 50 adults suffer from MOH, 5 women to each man, and some children.<br />&nbsp;&nbsp;Headache secondary to overuse of medication intended for the treatment of headache was ﬁrst noted with phenacetin. It became more apparent in patients overusing ergotamine prescribed for migraine.<br />&nbsp;&nbsp;Increasingly in evidence is MOH occurring with triptan overuse. These drugs do not accumulate, but all of them are associated with headache relapse after acute therapy, through mechanisms not yet clear, whilst chronic usage probably results in down-regulation of 5-HT receptors.<br />&nbsp;&nbsp;MOH results also, and much more commonly, from chronic overuse of analgesics to treat headache. Combination analgesics containing barbiturates, caffeine, and codeine are the prime candidates for the development of medication overuse headache. This may be a consequence of the addictive properties of these drugs. However, even simple analgesics such as aspirin and paracetamol are implicated in MOH. Whilst the mechanism is again unclear, it is different from those of ergotamine intoxication and triptan-induced MOH, probably involving changes in neural pain pathways. Consequently, it may take a long time (weeks to months) for the headache to resolve after withdrawal.<br />&nbsp;&nbsp;Many patients with MOH use very large quantities of medication: 35 doses a week on average in one study, and six different agents. Much smaller amounts are sufﬁcient to induce MOH: the regular intake of simple analgesics on 15 or more days a month or of codeine-containing analgesics, ergot or triptans on 10 or more days a month. <br />&nbsp;&nbsp;Frequency is important: low doses daily carry greater risk than larger doses weekly.<br />&nbsp;&nbsp;MOH is highly variable but often oppressive, present and often at its worst – on awakening in the morning. It increases after physical exertion. Associated nausea and vomiting are rarely pronounced. A typical history begins with episodic headache up to years earlier, more commonly migraine than TTH, treated with an analgesic or other acute medication. Over time, headache episodes become more frequent, as does medication intake, until both are daily. Often what brings patients to the GP’s attention is that they seek prescriptions for “something stronger”. A common and probably key factor in the development of MOH is a switch to pre-emptive use of medication, in anticipation of rather than for headache. In the end-stage, which not all patients <br />&nbsp;&nbsp;reach, headache persists all day, ﬂ  uctuating with medication use repeated every few hours. This evolution occurs over a few weeks or much, much longer, depending largely but not solely on the medication taken. MOH rarely develops when analgesics are regularly taken for another indication, such as chronic backache or rheumatic disease, except in the presence of primary headache.<br />&nbsp;&nbsp;Prophylactic medication added to medication overuse is generally ineffective and can only aggravate the condition, which therefore must be recognised. Any patient complaining of frequently-recurring headache should give a detailed account of medication use (including, and particularly, OTC medications). If they cannot, or are suspected of having unreliable recall, they should keep a prospective diary over two weeks. Some patients who do not reveal their true extent of medication use need an understanding approach if a practice of which they may be ashamed is to be brought into the open.<br />&nbsp;&nbsp;The diagnosis of MOH based on symptoms and drug use is initially presumptive. It is conﬁ  rmed only when symptoms improve after medication is withdrawn. Sometimes the diagnosis turns out to have been wrong. It is very difﬁ  cult to diagnose any other headache in the presence of medication overuse which, in any event, must be detected and dealt with lest there be some other condition lurking beneath.<br />&nbsp;&nbsp;6.Differential diagnosis<br />&nbsp;&nbsp;Headache in almost any site, but often posterior, may arise from functional or structural derangement of the neck (cervicogenic headache), precipitated or aggravated by particular neck movements or positioning and associated with altered neck posture, movement, muscle tone, contour and/or muscle tenderness.<br />&nbsp;&nbsp;Headache, whether episodic or chronic, should not be attributed to sinus disease in the absence of other symptoms suggestive of it. Chronic sinusitis is not a validated cause of headache unless there is an acute exacerbation. Errors of refraction may be associated with migraine  but are generally widely overestimated as a cause of headache which, if it does occur, is mild, frontal and in the eyes themselves, and absent on waking. Headache should not be considered secondary to conditions affecting the ears, temporomandibular joints or teeth unless other symptoms are indicative of these.A number of serious secondary headache disorders should always be kept in mind during diagnostic enquiry (see 5.0).<br />&nbsp;&nbsp;6.1 Warning features in the history<br />&nbsp;&nbsp;Headache that is new or unexpected in an individual patient<br />&nbsp;&nbsp;Thunderclap headache (intense headache with abrupt or “explosive” onset)<br />&nbsp;&nbsp;Headache with atypical aura (duration >1 hour, or including motor weakness)<br />&nbsp;&nbsp;Aura occurring for the ﬁ  rst time in a patient during use of combined oral contraceptives<br />&nbsp;&nbsp;New onset headache in a patient older than 50 years<br />&nbsp;&nbsp;New onset headache in a patient younger than 10 years<br />&nbsp;&nbsp;Persistent morning headache with nausea<br />&nbsp;&nbsp;Progressive headache, worsening over weeks or longer<br />&nbsp;&nbsp;Headache associated with postural change<br />&nbsp;&nbsp;New onset headache in a patient with a history of cancer<br />&nbsp;&nbsp;New onset headache in a patient with a history of HIV infection.<br />&nbsp;&nbsp;7. Undiagnosed headache<br />&nbsp;&nbsp;A small minority of headaches do not meet recognised criteria and even after the keeping of a diary cannot reliably be diagnosed. The most important requirement in such cases is to exclude (or detect) serious causes (see 5.0).<br />&nbsp;&nbsp;8.Physical examination of headache patients<br />&nbsp;&nbsp;All of the headaches so far discussed are diagnosed solely on history, with signs present in cluster headache patients if seen during attacks (occasionally, ptosis may persist between). The purpose of physical examination is sometimes debated but, for reasons given below, the optic fundi should always be examined during the diagnostic consultation. Blood pressure measurement is recommended: raised blood pressure is very rarely a cause of headache but patients often think it may be. Several drugs used for migraine prophylaxis affect blood pressure so it is important to have a baseline measurement. Drugs used for headache, especially migraine and cluster headache, affect blood pressure and vice versa.<br />&nbsp;&nbsp;Examination of the head and neck for muscle tenderness (generalised or with tender “nodules”), stiffness, limitation in range of movement and crepitation is often revealing, especially in TTH. Positive ﬁ  ndings may suggest a need for physical forms of treatment but not necessarily headache causation. It is uncertain whether routine examination of the jaw and bite contribute to headache diagnosis but may reveal incidental abnormalities.<br />&nbsp;&nbsp;In children, some paediatricians recommend that head circumference is measured at the diagnostic visit, and plotted on a centile chart.<br />&nbsp;&nbsp;For many people with troublesome but benign headache, reassurance is very much part of successful management. The physical examination adds to the perceived value of reassurance and, within limits, the more thorough the examination the better. The time spent will likely be saved several times over, obviating many future consultations by a still-worried patient.<br />&nbsp;&nbsp;A recent outpatient study found only 0.9% of consecutive headache patients without neurological signs had signiﬁ cant pathology. This reinforces the importance of physical examination in diagnosing serious causes of headache such as tumour (see 5.0), although the history would probably be revealing in these cases. A prospective study has suggested that isolated headache for longer than ten weeks after initial presentation will only exceptionally be due to a tumour.', null, null, null, '系统的偏头痛、紧张型头痛、丛集性头痛、药物过度使用头痛的诊断和治疗', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('549', '53', 'P01_006', '1', '2012NICE 青少年和成年患者头痛诊断和管理指南', 'Diagnosis and management of headaches in young people and adults', '英国国家卫生与临床优化研究所（NICE,National Institute for Health and Clinical Excellence）', '2012', 'http://guide.medlive.cn/guideline/3808', '英文', null, '偏头痛', null, null, 'P01_006表1', null, null, null, '英国国立健康与临床优化研究所（NICE）发布青少年和成年患者头痛诊断和管理指南，其摘要9月19日在线发表于《英国医学杂志》（BMJ）。在排除感染、肿瘤、出血及动脉炎等严重病因所引起的头痛后，原发性头痛包括丛集性头痛、偏头痛和紧张性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('55', '34', 'M06_010', '1', 'EAU尿路结石诊疗指南', 'Guidelines on Urolithiasis', '欧洲泌尿外科学会(EAU,European Association of Urology)', '2011', null, '英文', '结石的分类<br />&nbsp;&nbsp;尿结石可根据结石大小,结石的位置,x光结石的特点,形成结石的病因学,结石组合(矿物学)和复发风险来分类。<br />&nbsp;&nbsp;2.1结石大小<br />&nbsp;&nbsp;石头的大小通常以毫米计,使用一个或两个维度。结石也可以将进一步分成：5毫米, > 5 - 10毫米,> 10 - 20毫米,> 20毫米。<br />&nbsp;&nbsp;2.2结石的位置<br />&nbsp;&nbsp;结石可以分类根据解剖位置:上,中，下肾盏，肾盂、输尿管, 上部,中部或远端输尿管和膀胱。然而, 这里不讨论膀胱结石治疗。<br />&nbsp;&nbsp;2.3 x射线特征<br />&nbsp;&nbsp;结石可根据普通x光外观(肾输尿管膀畻坴畿\0\0\0\0醼畻聱盯	\0\0\0痭衘ƞༀƙ\0ƞĀ\0	\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᓸ௢ƞĀ\0è௢彿㎽奋㎽巫㎽놲௢퍞௢彿㎽퍒௢塚㎽퍞௢ꍈ㏂\0\0ᓸ௢學㎽漸㏂圔㎽ᓸ௢圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0衘ƞ䐺盭暼痭衘ƞༀƙ \0衘ƞĀ\0\0㺣盭衘ƞ\0ﱔ衜ƞ\0팃目衜ƞࡳ衜ƞ큁目衜ƞᔬ௢﫬\0Item\0\0폢௢\0\0\0\0\0\0Count\0\0ﱬﬄ袌ƞኜੑ\0\0衜ƞ\0\0\0\0ੑ寶目አੑ矵䥷㎽놲௢\0\0폢௢�㏂퍒௢\0\0\0ੑ\0\0\0謁ﱔ\0\0㎾സ\0ﱜ\0\0x�㏂퍒௢\0\0隲W폢௢\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx	\0霪W露W\0\0ﱴxt\0Љ\0\0\0注ƚ鲬ࡳ菮畻\0\0\0\0ᇰੑEo\0\0ቄੑ\0\0ᲈ੓ᲈ੓\0\0\0寶目ቈੑᐬ௢i\0\0ﱄ﷜ﱴﲔ먙㎼ᐬ௢ቈੑi\0\0ﱄ﷜ﱴ먰㎼﷜ᐬ௢�㏂᎜௢\0\0릎㎼ᐬ௢i\0╪췬目╾췬目Љ\0镴ࡳ\0￿￿目Љ\0镨ࡳ注ƚ竗注ƚ目W\0竗\0\0\0賓器目\0\0\0\0ᔬ௢\0目瑉浥目\0\0\0\0ᔬ௢\0目潃湵t\0\0\0\0ʃ\0\0ဠ\0\0ꯈʩﯬꯈʩච̓\0\0\0\0\0\0\0ච̓꒠̑\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0꒠̑\0\0\0\0ච̓ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚ￞\0\0⟒췬⟚췬目Љ\0鲸ࡳ\0￿￿目Љ\0鲬ࡳ注ƚ觴注ƚ目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨᐬ௢目潅f䓾瑤\0\0豸ࢋ\0\0核ʊ\0\0䒛瑤䕢瑤ꂸ瑧\0䔯瑤䑩瑤釨ࢋ䀷瑤੒ᛒ瑤\0㽺瑤\0\0㿣瑤੒\0\0￿￿￿￿㯄瑽嵞盡㨣瑽Ә੒\0\0鍈盠僦璅Ә\0੒鰈瑼ྭࠁ\0\0ﯬ$\0᳅愁\0\0\0\0\0\0Ĺ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0㷤췭骶瑼੒\0\0\0\0\0磻\0\0磻\0\0\0磻\0᭟盡@Ә㶬췭樂쓷盡Ә\0\0\0\0\0\0ꯍ�\0\0磻\0襤鹿\0邰ƙ\0\0ࠀ옎盡㶆췭\0駨瑼\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ﫜ᐬ௢ﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀勤﬘眿捻ฒ폢௢﫨ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿﫜￿￿\0\0﫦\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ\0\0\0\0\0奰畿⫡췬臭焚畻邰ƙࠀ﫜￿￿㏂￿￿\0\0\0\0愈煔畻:\0﫜￿￿㏂￿￿奰畿\0\0\0\0﬘㎾ࠄ\0\0﫜￿￿㏂㎾x\0\0�㏂퍒௢\0\0頲Wאּ\0\0\0\0ࠄ\0顇WValu\0\0﫜שּׁ폢௢ﱜ\0\0\0\0\0\0﫜\0﫨\0ﰰ餀Wﱜﲈ	\0ﳸ\0\0ꑬी\07\0\0\0\0\0䗼ष\0\0ﮀ⮒췬ﮀ뜩@﷩\0\0\0\0ﮠ䗧@ﭸ蕶@ꑠीﱰ﯌\0뮩@ﮰ믆@믎@ﱰ﷩\0釚@ﱰﱰ﷩\0ༀƙﱴༀƙ﯐戤痝\0Ɨ\0\0퀈ਟﯴÜ௢è௢忉㎽튖௢奁㎽è௢	\0튢௢퍞௢彿㎽ﱤ䦕盭퍞௢	\0퍞௢忉㎽ﱔ䥷盭퍞௢\0\0	\0ﱬ폢௢ﱴ馘Bﱜﳸxﲈﲈ駰Bﱴ़限ी\0௢\0\0ﱔ︜ﱜx︜x︄ﳸxﲔx︜ﲠx︜︸x︜\0\0़뿄x\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0\0\0ᔬ௢䗆@	\0ᔬ௢폢௢\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0', '尿路结石；Urolithiasis ', null, null, 'M06_010_02诊断.docx', null, '结石通过率（Stone-passage rates）', '1.观察输尿管结石<br />&nbsp;&nbsp;结石通过率<br />&nbsp;&nbsp;自发的结石通道根据大小只有有限的数据(1、2)。五个病人组的Meta-分析包括328名患者隐藏输尿管结石< 10毫米输尿管结石的可能性通过调查(表11)(1)。这些研究的局限性包括非标准化的结石大小测量,以及缺乏分析,结石的位置,结石通过时间。<br />&nbsp;&nbsp;2.观察的肾结石<br />&nbsp;&nbsp;肾结石的观察,特别是位于狭窄的部分,取决于他们的自然历史,6.2.1节中讨论。<br />&nbsp;&nbsp;1. Observation of ureteral stones<br />&nbsp;&nbsp;Stone-passage rates<br />&nbsp;&nbsp;Only limited data are available on the topic of spontaneous passage by stone size (1,2). A meta-analysis of five patient groups including 328 patients harbouring ureteral stones < 10 mm investigated the likelihood of ureteral stone passage (Table 11) (1). The Panel recognised that these studies had certain limitations including nonstandardisation of the stone size measurement methods and lack of analysis of stone position, stone-passage history, and time to stone passage in some.<br />&nbsp;&nbsp;2.Observation of kidney stones<br />&nbsp;&nbsp;Observation of kidney stones, especially when located in calices, depend on their natural history, which is discussed in Section 6.2.1.<br />&nbsp;&nbsp;', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('550', '53', 'P01_007', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 3rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/9.toc', '英文', null, '无先兆偏头痛', null, null, 'A. At least ﬁve attacks fulﬁlling criteria B–D<br />&nbsp;&nbsp;B. Headache attacks lasting 4-72 hours (untreated orunsuccessfully treated)<br />&nbsp;&nbsp;C. Headache has at least two of the following four characteristics:<br />&nbsp;&nbsp;1. unilateral location<br />&nbsp;&nbsp;2. pulsating quality<br />&nbsp;&nbsp;3. moderate or severe pain intensity<br />&nbsp;&nbsp;4. aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs)<br />&nbsp;&nbsp;D. During headache at least one of the following:<br />&nbsp;&nbsp;1. nausea and/or vomiting<br />&nbsp;&nbsp;2. photophobia and phonophobia<br />&nbsp;&nbsp;E. Not better accounted for by another ICHD-3 diagnosis.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生3个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('551', '53', 'P01_008', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 4rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/9.toc', '英文', null, '先兆偏头痛', null, null, 'A. At least two attacks fulﬁlling criteria B and C<br />&nbsp;&nbsp;B. One or more of the following fully reversible aura symptoms:<br />&nbsp;&nbsp;1. visual<br />&nbsp;&nbsp;2. sensory<br />&nbsp;&nbsp;3. speech and/or language<br />&nbsp;&nbsp;4. motor<br />&nbsp;&nbsp;5. brainstem<br />&nbsp;&nbsp;6. retinal<br />&nbsp;&nbsp;C. At least two of the following four characteristics:<br />&nbsp;&nbsp;1. at least one aura symptom spreads gradually over  5 minutes, and/or two or more symptoms occur in succession<br />&nbsp;&nbsp;2. each individual aura symptomlasts 5-60minutes<br />&nbsp;&nbsp;3. at least one aura symptom is unilateral<br />&nbsp;&nbsp;4. the aura is accompanied, or followed within 60 minutes, by headache<br />&nbsp;&nbsp;D. Not better accounted for by another ICHD-3 diagnosis, and transient ischaemic attack has been excluded.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生4个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('552', '53', 'P01_009', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 5rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/9.toc', '英文', null, '典型偏头痛', null, null, 'A. At least two attacks fulﬁlling criteria B and C<br />&nbsp;&nbsp;B. Aura consisting of visual, sensory and/or speech/language symptoms, each fully reversible, but no motor, brainstem or retinal symptoms<br />&nbsp;&nbsp;C. At least two of the following four characteristics:<br />&nbsp;&nbsp;1. at least one aura symptom spreads gradually over≥5 minutes, and/or two or more symptoms occur in succession<br />&nbsp;&nbsp;2. each individual aura symptom lasts 5-60minutes<br />&nbsp;&nbsp;3. at least one aura symptom is unilateral<br />&nbsp;&nbsp;4. the aura is accompanied, or followed within 60 minutes, by headache<br />&nbsp;&nbsp;D. Not better accounted for by another ICHD-3 diagnosis, and transient ischaemic attack has been excluded.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生5个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('553', '53', 'P01_010', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 6rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/9.toc', '英文', null, '头痛典型先兆Typical aura with headache\n', null, null, 'A. Fulﬁls criteria for Migraine with typical aura <br />&nbsp;&nbsp;B. Headache, with or without migraine characteristics, accompanies or follows the aura within 60 minutes.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生6个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('554', '53', 'P01_011', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 7rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/9.toc', '英文', null, '无头痛典型先兆Typical aura with headache', null, null, 'A. Fulﬁls criteria for Migraine with typical aura <br />&nbsp;&nbsp;B. Headache, with or without migraine characteristics, accompanies or follows the aura within 60 minutes.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生7个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('555', '53', 'P01_012', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 8rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/9.toc', '英文', null, '脑干先兆偏头痛Migraine with brainstem aura', null, null, 'A. At least two attacks fulﬁlling criteria B-D<br />&nbsp;&nbsp;B. Aura consisting of visual, sensory and/or speech/language symptoms, each fully reversible, but no motor or retinal symptoms<br />&nbsp;&nbsp;C. At least two of the following brainstem symptoms:<br />&nbsp;&nbsp;1. dysarthria<br />&nbsp;&nbsp;2. vertigo<br />&nbsp;&nbsp;3. tinnitus<br />&nbsp;&nbsp;4. hypacusis<br />&nbsp;&nbsp;5. diplopia<br />&nbsp;&nbsp;6. ataxia<br />&nbsp;&nbsp;7. decreased level of consciousness<br />&nbsp;&nbsp;D. At least two of the following four characteristics:<br />&nbsp;&nbsp;1. at least one aura symptom spreads gradually over≥5 minutes, and/or two or more symptoms<br />&nbsp;&nbsp;occur in succession<br />&nbsp;&nbsp;2. each individual aura symptom lasts 5-60 minutes<br />&nbsp;&nbsp;3. at least one aura symptom is unilateral<br />&nbsp;&nbsp;4. the aura is accompanied, or followed within 60 minutes, by headache<br />&nbsp;&nbsp;E. Not better accounted for by another ICHD-3 diagnosis, and transient ischaemic attack has been excluded.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生8个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('556', '53', 'P01_013', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 9rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/9.toc', '英文', null, '偏瘫型偏头痛', null, null, 'A. At least two attacks fulﬁlling criteria B and C<br />&nbsp;&nbsp;B. Aura consisting of both of the following:<br />&nbsp;&nbsp;1. fully reversible motor weakness<br />&nbsp;&nbsp;2. fully reversible visual, sensory and/or speech/language symptoms<br />&nbsp;&nbsp;C. At least two of the following four characteristics:<br />&nbsp;&nbsp;1. at least one aura symptom spreads gradually over≥5 minutes, and/or two or more symptoms<br />&nbsp;&nbsp;occur in succession<br />&nbsp;&nbsp;2. each individual non-motor aura symptom lasts 5–60 minutes, and motor symptoms last <72 hours<br />&nbsp;&nbsp;3. at least one aura symptom is unilateral<br />&nbsp;&nbsp;4. the aura is accompanied, or followed within 60 minutes, by headache<br />&nbsp;&nbsp;D. Not better accounted for by another ICHD-3 diagnosis, and transient ischaemic attack and stroke have been excluded.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生9个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('557', '53', 'P01_014', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 10rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/10.toc', '英文', null, '家族性偏瘫型偏头痛', null, null, 'A. Fulﬁls criteria for Hemiplegic migraine<br />&nbsp;&nbsp;B. At least one ﬁrst- or second-degree relative has had attacks fulﬁlling criteria for 1.2.3 Hemiplegic migraine.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生10个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('558', '53', 'P01_015', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 11rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/11.toc', '英文', null, 'Ⅰ型家族性偏瘫型偏头痛', null, null, 'A. Fulﬁls criteria for Familial hemiplegic migraine<br />&nbsp;&nbsp;B. A causative mutation on the CACNA1A gene has been demonstrated.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生11个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('559', '53', 'P01_016', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 12rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/12.toc', '英文', null, 'Ⅱ型家族性偏瘫型偏头痛', null, null, 'A. Fulﬁls criteria for Familial hemiplegic migraine<br />&nbsp;&nbsp;B. A causative mutation on the ATP1A2 gene has been demonstrated.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生12个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('56', '34', 'M06_011', '1', 'EAU尿路结石诊疗指南', 'Guidelines on Urolithiasis ', '欧洲泌尿外科学会(EAU,European Association of Urology)', '2013', null, '英文', '1结石的分类<br />&nbsp;&nbsp;尿结石可根据结石大小,结石的位置,x光结石的特点,形成结石的病因学,结石组合(矿物学)和复发风险来分类。<br />&nbsp;&nbsp;1.1结石大小<br />&nbsp;&nbsp;石头的大小通常以毫米计,通常一个或两个维度测量，结石也可以将进一步分成：5毫米, > 5 - 10毫米,> 10 - 20毫米,> 20毫米。<br />&nbsp;&nbsp;1.2结石的位置<br />&nbsp;&nbsp;结石可以分类根据解剖位置:上,中，下肾盏，肾盂、输尿管, 上部,中部或远端输尿管和膀胱。然而, 这里不讨论膀胱结石治疗。<br />&nbsp;&nbsp;1.3 x射线特征<br />&nbsp;&nbsp;结石可根据普通x光表现[肾输畻坴畿\0\0\0\0醼畻聱盯	\0\0\0痭衘ƞༀƙ\0ƞĀ\0	\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᓸ௢ƞĀ\0è௢彿㎽奋㎽巫㎽놲௢퍞௢彿㎽퍒௢塚㎽퍞௢ꍈ㏂\0\0ᓸ௢學㎽漸㏂圔㎽ᓸ௢圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0衘ƞ䐺盭暼痭衘ƞༀƙ \0衘ƞà\0\0㺣盭衘ƞ\0ﱔ衜ƞ\0팃目衜ƞࡳ衜ƞ큁目衜ƞᔬ௢﫬\0Item\0\0폢௢\0\0\0\0\0\0Count\0\0ﱬﬄ袌ƞኜੑ\0\0衜ƞ\0\0\0\0ੑ寶目አੑ矵䥷㎽놲௢\0\0폢௢�㏂퍒௢\0\0\0ੑ\0\0\0謁ﱔ\0\0㎾ઞ\0ﱜ\0\0x�㏂퍒௢\0\0隲W폢௢\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx	\0霪W露W\0\0ﱴxt\0Љ\0\0\0注ƚ鲬ࡳ菮畻\0\0\0\0ᇰੑEo\0\0ቄੑ\0\0ᲈ੓ᲈ੓\0\0\0寶目ቈੑᐬ௢i\0\0ﱄ﷜ﱴﲔ먙㎼ᐬ௢ቈੑi\0\0ﱄ﷜ﱴ먰㎼﷜ᐬ௢�㏂᎜௢\0\0릎㎼ᐬ௢i\0╪췬目╾췬目Љ\0镴ࡳ\0￿￿目Љ\0镨ࡳ注ƚ竗注ƚ目W\0竗\0\0\0賓器目\0\0\0\0ᔬ௢\0目瑉浥目\0\0\0\0ᔬ௢\0目潃湵t\0\0\0\0ʃ\0\0ဠ\0\0ꯈʩﯬꯈʩච̓\0\0\0\0\0\0\0ච̓꒠̑\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0꒠̑\0\0\0\0ච̓ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚ￞\0\0⟒췬⟚췬目Љ\0鲸ࡳ\0￿￿目Љ\0鲬ࡳ注ƚ觴注ƚ目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨᐬ௢目潅f䓾瑤\0\0豸ࢋ\0\0核ʊ\0\0䒛瑤䕢瑤ꂸ瑧\0䔯瑤䑩瑤釨ࢋ䀷瑤੒ᛒ瑤\0㽺瑤\0\0㿣瑤੒\0\0￿￿￿￿㯄瑽嵞盡㨣瑽Ә੒\0\0鍈盠僦璅Ә\0੒鰈瑼ྭࠁ\0\0ﯬ$\0᳅愁\0\0\0\0\0\0Ĺ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0㷤췭骶瑼੒\0\0\0\0\0磻\0\0磻\0\0\0磻\0᭟盡@Ә㶬췭樂쓷盡Ә\0\0\0\0\0\0ꯍ�\0\0磻\0襤鹿\0邰ƙ\0\0ࠀ옎盡㶆췭\0駨瑼\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ﫜ᐬ௢ﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀勤﬘眿捻ฒ폢௢﫨ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿﫜￿￿\0\0﫦\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ\0\0\0\0\0奰畿⫡췬臭焚畻邰ƙࠀ﫜￿￿㏂￿￿\0\0\0\0愈煔畻:\0﫜￿￿㏂￿￿奰畿\0\0\0\0﬘㎾ࠄ\0\0﫜￿￿㏂㎾x\0\0�㏂퍒', '尿路结石；Urolithiasis ', null, null, 'M06_011_02诊断.docx', null, '结石通过率（Stone-passage rates）', ' 1.观察输尿管结石<br />&nbsp;&nbsp;1.1结石通过率<br />&nbsp;&nbsp;自发的结石通道根据大小只有有限的数据(1、2)。五个病人组的Meta-分析包括328名患者隐藏输尿管结石< 10毫米输尿管结石通道的可能性分析（表10）（2）。这些研究的局限性包括，石径测量的非标准化,以及缺乏结石的位置分析,结石通道历史，结石通过时间。<br />&nbsp;&nbsp;2.观察的肾结石<br />&nbsp;&nbsp;肾结石的观察,特别是位于狭窄的部分,取决于他们的自然历史。<br />&nbsp;&nbsp;\n1.Observation of ureteral stones<br />&nbsp;&nbsp;\n1.1Stone-passage rates<br />&nbsp;&nbsp;\nThere are only limited data about spontaneous stone passage according to size (2,3). A meta-analysis of 328 patients harbouring ureteral stones < 10 mm investigated the likelihood of ureteral stone passage (Table 10) (2). <br />&nbsp;&nbsp;\nThese studies had limitations including non-standardisation of stone size measurement, and lack of analysis of stone position, stone-passage history, and time to stone passage. <br />&nbsp;&nbsp;\n2.Observation of kidney stones<br />&nbsp;&nbsp;\nObservation of kidney stones, especially in calices, depends on their natural history (Section 6.2.1). <br />&nbsp;&nbsp;\n\n', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('560', '53', 'P01_017', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 13rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/13.toc', '英文', null, '其他基因位点家族性偏瘫型偏头痛Familial hemiplegic migraine, other loci', null, null, 'A. Fulﬁls criteria for 1.2.3.1 Familial hemiplegic migraine<br />&nbsp;&nbsp;B. Genetic testing has demonstrated no mutation on the CACNA1A, ATP1A2 or SCN1A genes.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生13个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('561', '53', 'P01_018', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 14rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/14.toc', '英文', null, '散发性偏瘫型偏头痛Sporadic hemiplegic migraine', null, null, 'A. Fulﬁls criteria for Hemiplegic migraine<br />&nbsp;&nbsp;B. No ﬁrst- or second-degree relative fulﬁls criteria for Hemiplegic migraine.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生14个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('562', '53', 'P01_019', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 15rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/15.toc', '英文', null, '视网膜型偏头痛', null, null, 'A. At least two attacks fulﬁlling criteria B and C<br />&nbsp;&nbsp;B. Aura consisting of fully reversible monocular positive and/or negative visual phenomena (e.g. scintillations, scotomata or blindness) conﬁrmed during an attack by either or both of the following:<br />&nbsp;&nbsp;1. clinical visual ﬁeld examination<br />&nbsp;&nbsp;2. the patient’s drawing (made after clear instruction) of a monocular ﬁeld defect<br />&nbsp;&nbsp;C. At least two of the following three characteristics<br />&nbsp;&nbsp;1. the aura spreads gradually over≥5 minutes<br />&nbsp;&nbsp;2. aura symptoms last 5-60 minutes<br />&nbsp;&nbsp;3. the aura is accompanied, or followed within 60 minutes, by headache<br />&nbsp;&nbsp;D. Not better accounted for by another ICHD-3 diagnosis, and other causes of amaurosis fugax have been excluded.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生15个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('563', '53', 'P01_020', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 16rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/16.toc', '英文', null, '慢性偏头痛', null, null, 'A. Headache (tension-type-like and/or migraine-like) on≥15 days per month for >3 months and fulﬁlling criteria B and C<br />&nbsp;&nbsp;B. Occurring in a patient who has had at least ﬁve attacks fulﬁlling criteria B-D for 1.1 Migraine with-out aura and/or criteria B and C for 1.2 Migraine with aura<br />&nbsp;&nbsp;C. On≥8 days per month for >3 months, fulﬁlling any of the following3:<br />&nbsp;&nbsp;1. criteria C and D for 1.1 Migraine without aura<br />&nbsp;&nbsp;2. criteria B and C for 1.2 Migraine with aura<br />&nbsp;&nbsp;3. believed by the patient to be migraine at onset and relieved by a triptan or ergot derivative<br />&nbsp;&nbsp;D. Not better accounted for by another ICHD-3 diagnosis.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生16个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('564', '53', 'P01_021', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 17rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/17.toc', '英文', null, '偏头痛持续状态', null, null, 'A. A headache attack fulﬁlling criteria B and C<br />&nbsp;&nbsp;B. Occurring in a patient with 1.1 Migraine without aura and/or 1.2 Migraine with aura, and typical of previous attacks except for its duration and severity<br />&nbsp;&nbsp;C. Both of the following characteristics:<br />&nbsp;&nbsp;1. unremitting for >72 hours<br />&nbsp;&nbsp;2. pain and/or associated symptoms are debilitating<br />&nbsp;&nbsp;D. Not better accounted for by another ICHD-3 diagnosis.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生17个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('565', '53', 'P01_022', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 18rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/18.toc', '英文', null, '无梗死持续状态Persistent aura without infarction\n', null, null, 'A. Aura fulﬁlling criterion B<br />&nbsp;&nbsp;B. Occurring in a patient with 1.2 Migraine with aura and typical of previous auras except that one or more aura symptoms persists for≥1week<br />&nbsp;&nbsp;C. Neuroimaging shows no evidence of infarction<br />&nbsp;&nbsp;D. Not better accounted for by another ICHD-3 diagnosis.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生18个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('566', '53', 'P01_023', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 19rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/19.toc', '英文', null, '偏头痛性脑梗死Migrainous infarction', null, null, 'A. A migraine attack fulﬁlling criteria B and C<br />&nbsp;&nbsp;B. Occurring in a patient with 1.2 Migraine with aura and typical of previous attacks except that one or more aura symptoms persists for >60 minutes<br />&nbsp;&nbsp;C. Neuroimaging demonstrates ischaemic infarction in a relevant area<br />&nbsp;&nbsp;D. Not better accounted for by another diagnosis.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生19个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('567', '53', 'P01_024', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 20rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/20.toc', '英文', null, '可能的偏头痛Probable migraine', null, null, 'A. Attacks fulﬁlling all but one of criteria A-D for 1.1 Migraine without aura, or all but one of criteria A-Cfor 1.2 Migraine with aura<br />&nbsp;&nbsp;B. Not fulﬁlling ICHD-3 criteria for any other headache disorder<br />&nbsp;&nbsp;C. Not better accounted for by another ICHD-3 diagnosis.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生20个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('568', '53', 'P01_025', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 21rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/21.toc', '英文', null, '可能的无先兆偏头痛Probable migraine without aura', null, null, 'A. Attacks fulﬁlling all but one of criteria A–D for 1.1Migraine without aura<br />&nbsp;&nbsp;B. Not fulﬁlling ICHD-3 criteria for any other headache disorder<br />&nbsp;&nbsp;C. Not better accounted for by another ICHD-3 diagnosis.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生21个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('569', '53', 'P01_026', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 22rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/22.toc', '英文', null, '可能的有先兆偏头痛Probable migraine with aura', null, null, 'A. Attacks fulﬁlling all but one of criteria A–C for 1.2 Migraine with aura or any of its subforms<br />&nbsp;&nbsp;B. Not fulﬁlling ICHD-3 criteria for any other headache disorder<br />&nbsp;&nbsp;C. Not better accounted for by another ICHD-3 diagnosis.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生22个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('57', '34', 'M06_012', '1', 'EAU尿路结石诊疗指南', 'Guidelines on Urolithiasis', '欧洲泌尿外科学会(EAU,European Association of Urology)', '2015', 'http://uroweb.org/guideline/urolithiasis/', '英文', '1.结石分类<br />&nbsp;&nbsp;\n尿路结石可根据大小、分类定位，X线特点，形成、组成病因和复发的风险[ 6，18-20 ]。<br />&nbsp;&nbsp;\n1.1结石大小<br />&nbsp;&nbsp;\n石头的大小通常是在一个或两个维度测量最大直径5，5-10，10-20，和> 20毫米。<br />&nbsp;&nbsp;\n1.2结石位置<br />&nbsp;&nbsp;\n结石可根据解剖位置分类：上、中、下盏、肾盏、上、中、下段输尿管及膀胱。在这里没有讨论膀胱结石的治疗。<br />&nbsp;&nbsp;\n1.3 X线特点<br />&nbsp;&nbsp;\n结石可以根据不同的矿物成分X线表现[肾输尿管膀胱分类（KUB）摄影]（表3.2.1）[ 20 ]。使用非强化畻坴畿\0\0\0\0醼畻聱盯	\0\0\0痭衘ƞༀƙ\0ƞĀ\0	\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔᓸ௢ƞĀ\0è௢彿㎽奋㎽巫㎽놲௢퍞௢彿㎽퍒௢塚㎽퍞௢ꍈ㏂\0\0ᓸ௢學㎽漸㏂圔㎽ᓸ௢圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0쫐ਘ䐺盭暼痭쫐ਘༀƙ \0쫐ਘp\0\0㺣盭쫐ਘ\0ﱔ쫔ਘ\0팃目쫔ਘࡳ쫔ਘ큁目쫔ਘᔬ௢﫬\0Item\0\0폢௢\0\0\0\0\0\0Count\0\0ﱬﬄ쬄ਘኜੑ\0\0쫔ਘ\0\0\0\0ੑ寶目አੑ矵䥷㎽놲௢\0\0폢௢�㏂퍒௢\0\0\0ੑ\0\0\0謁ﱔ\0\0㎾੪\0ﱜ\0\0x�㏂퍒௢\0\0隲W폢௢\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx	\0霪W露W\0\0ﱴxt\0Љ\0\0\0注ƚ鲬ࡳ菮畻\0\0\0\0ᇰੑEo\0\0ቄੑ\0\0ᲈ੓ᲈ੓\0\0\0寶目ቈੑᐬ௢i\0\0ﱄ﷜ﱴﲔ먙㎼ᐬ௢ቈੑi\0\0ﱄ﷜ﱴ먰㎼﷜ᐬ௢�㏂᎜௢\0\0릎㎼ᐬ௢i\0╪췬目╾췬目Љ\0镴ࡳ\0￿￿目Љ\0镨ࡳ注ƚ竗注ƚ目W\0竗\0\0\0賓器目\0\0\0\0ᔬ௢\0目瑉浥目\0\0\0\0ᔬ௢\0目潃湵t\0\0\0\0ʃ\0\0ဠ\0\0ꯈʩﯬꯈʩච̓\0\0\0\0\0\0\0ච̓꒠̑\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0꒠̑\0\0\0\0ච̓ﰼ뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚ￞\0\0⟒췬⟚췬目Љ\0鲸ࡳ\0￿￿目Љ\0鲬ࡳ注ƚ觴注ƚ目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨᐬ௢目潅f䓾瑤\0\0豸ࢋ\0\0核ʊ\0\0䒛瑤䕢瑤ꂸ瑧\0䔯瑤䑩瑤釨ࢋ䀷瑤੒ᛒ瑤\0㽺瑤\0\0㿣瑤੒\0\0￿￿￿￿㯄瑽嵞盡㨣瑽Ә੒\0\0鍈盠僦璅Ә\0੒鰈瑼ྭࠁ\0\0ﯬ$\0᳅愁\0\0\0\0\0\0Ĺ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0㷤췭骶瑼੒\0\0\0\0\0磻\0\0磻\0\0\0磻\0᭟盡@Ә㶬췭樂쓷盡Ә\0\0\0\0\0\0ꯍ�\0\0磻\0襤鹿\0邰ƙ\0\0ࠀ옎盡㶆췭\0駨瑼\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ﫜ᐬ௢ﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀勤﬘眿捻ฒ폢௢﫨ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿﫜￿￿\0\0﫦\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ\0\0\0\0\0奰畿⫡췬臭焚畻邰ƙࠀ﫜￿￿㏂￿￿\0\0\0\0愈煔畻:\0﫜￿￿㏂￿￿奰畿', '尿路结石；Urolithiasis ', null, null, 'M06_012_02诊断.docx<br />&nbsp;&nbsp;\n1.草酸钙结石<br />&nbsp;&nbsp;诊断<br />&nbsp;&nbsp;血液分析需要肌酐、钠、钾、氯离子测定，钙离子（或总钙+白蛋白），尿酸，和甲状旁腺激素（PTH）（维生素D）在钙水平升高的情况。<br />&nbsp;&nbsp;验尿要求尿量测量、尿pH曲线、比重、钙、草酸、尿酸、柠檬酸钠、镁。<br />&nbsp;&nbsp;2.磷酸钙结石<br />&nbsp;&nbsp;诊断<br />&nbsp;&nbsp;诊断需要分析：肌酐、血钠、钾、氯、钙离子（或总钙+白蛋白），PTH（增加钙含量的情况下）。尿液分析包括：测量体积、尿PH、比重、钙、磷酸盐和柠檬酸盐。<br />&nbsp;&nbsp;1.Calcium oxalate stones<br />&nbsp;&nbsp;Diagnosis<br />&nbsp;&nbsp;Blood analysis requires measurement of creatinine, sodium, potassium, chloride, ionised calcium (or total calcium + albumin), uric acid, and parathyroid hormone (PTH) (and vitamin D) in the case of increased calcium levels. <br />&nbsp;&nbsp;Urinalysis requires measurement of urine volume, urine pH profile, specific weight, calcium, oxalate, uric acid, citrate, sodium and magnesium. <br />&nbsp;&nbsp;2.Calcium phosphate stones<br />&nbsp;&nbsp;Diagnosis<br />&nbsp;&nbsp;Diagnosis requires blood analysis for: creatinine, sodium, potassium, chloride, ionised calcium (or total calcium + albumin), and PTH (in the case of increased calcium levels). Urinalysis includes measurement of: volume, urine pH profile, specific weight, calcium, phosphate and citrate. <br />&nbsp;&nbsp;', null, '结石清除率（stone-free rates）；缓解疼痛（Pain relief）', '1、肾或输尿管结石患者的管理<br />&nbsp;&nbsp;肾绞痛<br />&nbsp;&nbsp;缓解疼痛<br />&nbsp;&nbsp;缓解疼痛是急性结石性发作患者的首选治疗步骤<br />&nbsp;&nbsp;\n2、脓毒症的治疗<br />&nbsp;&nbsp;梗阻肾的所有迹象泌尿道感染（UTI）是一种外科急救。紧急减压是必要的，预防感染的肾积水继发结石导致进一步的并发症，单侧或双侧肾梗阻。<br />&nbsp;&nbsp;1.Management of patients with renal or ureteral stones<br />&nbsp;&nbsp;Renal colic<br />&nbsp;&nbsp;Pain relief<br />&nbsp;&nbsp;Pain relief is the first therapeutic step in patients with an acute stone episode<br />&nbsp;&nbsp;2.Management of sepsis in obstructed kidney<br />&nbsp;&nbsp;The obstructed kidney with all signs of urinary tract infection (UTI) is a urological emergency. Urgent decompression is often necessary to prevent further complications in infected hydronephrosis secondary to stone-induced, unilateral or bilateral renal obstruction. <br />&nbsp;&nbsp;\n', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('570', '53', 'P01_027', '1', 'IHS 国际头痛分类第三版（beta版）', 'The International Classification of Headache Disorders, 23rd edition (beta version)', '国际头痛协会（IHS,International Headache society）', '2013', 'http://cep.sagepub.com/content/33/23.toc', '英文', null, '腹型偏头痛Abdominal migraine', null, null, 'A. At least ﬁve attacks of abdominal pain, fulﬁlling criteria B–D<br />&nbsp;&nbsp;B. Pain has at least two of the following three characteristics:<br />&nbsp;&nbsp;1. midline location, periumbilical or poorly localized<br />&nbsp;&nbsp;2. dull or ‘just sore’ quality<br />&nbsp;&nbsp;3. moderate or severe intensity<br />&nbsp;&nbsp;C. During attacks, at least two of the following:<br />&nbsp;&nbsp;1. anorexia<br />&nbsp;&nbsp;2. nausea<br />&nbsp;&nbsp;3. vomiting<br />&nbsp;&nbsp;4. pallor<br />&nbsp;&nbsp;D. Attacks last 2-72 hours when untreated or unsuccessfully treated<br />&nbsp;&nbsp;E. Complete freedom from symptoms between attacks<br />&nbsp;&nbsp;F. Not attributed to another disorder.', null, null, null, '在ICHD-III版本中的一个最大的变化是对慢性偏头痛内容的定义，新版本定义慢性偏头痛每月至少发生15天并持续发生23个月以上。新的分类方法能够区分原发性头痛和由其他原因引起的继发性头痛。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('571', '53', 'P01_028', '1', '2012 Barany学会/IHS共识：前庭性偏头痛诊断标准', 'Vestibular migraine: diagnostic criteria', 'Barany学会(Bárány Society)；国际头痛协会(IHS,International Headache society)', '2012', 'Thomas Lempert, Jes Olesen, Joseph Furman，etc.Vestibular migraine: diagnostic criteria.J Vestib Res. 2012，22(4):167-172.', '英文', null, '前庭性偏头痛', null, null, '1.前庭性偏头痛的诊断标准<br />&nbsp;&nbsp;曾用术语: 偏头痛关联性眩晕/头晕、偏头痛相关性前庭病、偏头痛性眩晕。<br />&nbsp;&nbsp;2.其他鉴别诊断<br />&nbsp;&nbsp;2.1良性发作性位置性眩晕( BPPV)<br />&nbsp;&nbsp;前庭性偏头痛可表现为纯粹的位置性眩晕，类似BPPV在急性期对眼震的直接观察对鉴别诊断是需要的 在前庭性偏头痛中，位置性眼震常常呈持续性，不符合单一半规管诱发的眼震 前庭性偏头痛的症状阵发时间更短( 数分钟至数日，而不是数周)且更频繁( 前庭性偏头痛每年数次，而BPPV数年1次)<br />&nbsp;&nbsp;2.2短暂性缺血发作(TIA)<br />&nbsp;&nbsp;在老年患者，椎基底动脉TIA的鉴别诊断必须考虑提示性特征包括血管危险因素、突发起病发作史＜1年以及血管造影术或多普勒超声提示椎动脉或基底动脉近端存在血管病变。<br />&nbsp;&nbsp;2.3前庭阵发症<br />&nbsp;&nbsp;前庭阵发症是一种有争议的疾病，推测由前庭神经被血管压迫所致。表现为短暂眩晕发作，持续1至数秒，每日多次发作若卡马西平能成功阻断发作则支持这一诊断。<br />&nbsp;&nbsp;2.4精神性头晕<br />&nbsp;&nbsp;焦虑和抑郁可致头晕，同样可使前庭疾病复杂化。焦虑相关性头晕的特征是情境激发，强烈的自主神经激活，灾难思维以及回避行为。超过50%的前庭性偏头痛患者合并精神疾病。<br />&nbsp;&nbsp;1. Diagnostic criteria for vestibular migraine<br />&nbsp;&nbsp;Previously used terms: migraine-associated vertigo dizziness, migraine-related vestibulopathy,migrainou vertigo.<br />&nbsp;&nbsp;(For the relationship between vestibular migraine and basilar-typemigraine (migrainewith brainstemaura according to ICHD-3) and the relationship between vestibular migraine and benign paroxysmal vertigo of childhood, please see comments.)P01_028表1<br />&nbsp;&nbsp;2. Other differential diagnoses<br />&nbsp;&nbsp;2.1 Benign paroxysmal positional vertigo (BPPV)Vestibular migraine may present with purely positional vertigo, thusmimickingBPPV.Direct nystagmus observation during the acute phase may be required for differentiation. In vestibular migraine, positional nystagmus is usually persistent and not aligned with a single semicircular canal. Symptomatic episodes tend to be shorter with vestibular migraine (minutes to days rather thanweeks) andmore frequent (several times per year with vestibular migraine rather than once every few years with BPPV).<br />&nbsp;&nbsp;2.2 Transient ischemic attacks (TIAs)<br />&nbsp;&nbsp;Adifferential diagnosis of vertebrobasilarTIAsmust be considered particularly in elderly patients. Suggestive features include vascular risk factors, sudden onset of symptoms, total history of attacks of less than one year, and angiographic or Doppler ultrasound evidence for vascular pathology in the vertebral or proximal basilar artery.<br />&nbsp;&nbsp;2.3 Vestibular paroxysmia<br />&nbsp;&nbsp;Vestibular paroxysmia is a controversial disorder, presumably caused by vascular compression of the vestibular nerve. The presenting feature is brief attacks of vertigo, lasting from one to several seconds, which recur many times per day. Successful prevention of attacks with carbamazepine supports the diagnosis.<br />&nbsp;&nbsp;2.4 Psychiatric dizziness<br />&nbsp;&nbsp;Anxiety and depression may cause dizziness and likewise complicate a vestibular disorder. Anxiety-related dizziness is characterized by situational provocation, intense autonomic activation, catastrophic thinking and avoidance behaviour. More than 50% of patients with vestibular migraine have comorbid psychiatric disorders . Caloric stimulation often triggers migraine attacks within 24 hours in patients with migraine , which shows that migraine attacks can be a secondary effect of vestibular activation rather than its cause in susceptible individuals. Possibly, the high rate of headaches and other migraine symptoms during Meni` ere attacks can be explained by this mechanism. Thus, migraine symptoms during vertigo attacks do not prove a diagnosis of vestibular migraine and consideration of other potential causes remains mandatory.', null, null, null, 'Barany 学会( 从事前庭研究的基础科学家、耳鼻喉学家及神经病学家组成的国际组织) 授权了一个分类小组以研究前庭性偏头痛的诊断标准。分类的形式按照国际头痛疾患分类的形式 Barany学会分类委员会之前发布过前庭症状定义的专家共\n识，作为对前庭疾患分类的首次尝试及准备。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('572', '54', 'M09_001', '1', '泌尿系感染诊断治疗指南', null, '中华医学会泌尿外科分会', '2014', '那彦群, 叶章群, 孙光.中国泌尿外科疾病诊断治疗指南[M].北京：人民卫生出版社，2011.', '中文', '尿路感染按感染部位可分为上尿路感染和下尿路感染。<br />&nbsp;&nbsp;依据两次感染之间的关系可以分为孤立或散发感染(isolated or sporadic infection) 和反复发作性感染(recurrent infection) ，反复发作性感染可以进一步分为再感染( reinfection) 和细菌持续存在(bacterial persistence)，细菌持续存在也称为复发(relapse)。<br />&nbsp;&nbsp;按感染发生时的尿路状态分类: <br />&nbsp;&nbsp;单纯性尿路感染(单纯下尿路感染和单纯上尿路感染)。<br />&nbsp;&nbsp;复杂性尿路感染(包括导管相关的感染等)尿服毒血症。<br />&nbsp;&nbsp;男性生殖系统感染:前列腺炎、附辜炎、辜丸炎、精囊炎等(不在本指南中)。<br />&nbsp;&nbsp;', '尿路感染', null, null, '1.症状 对尿路感染有诊断意义的症状和体征为尿频、尿急、尿痛、血尿、背部疼痛和肋脊角压痛，如果女性患者同时存在尿痛和尿频，则尿路感染的可能性为90% 。<br />&nbsp;&nbsp;2.体检 急性膀脱炎患者可有耻骨上区压痛，但缺乏特异性。发热、心动过速、肋脊角压痛对肾孟肾炎的诊断特异性高。<br />&nbsp;&nbsp;3.实验室检查<br />&nbsp;&nbsp;3.1尿常规检查：包括尿液物理学检查、尿生化检查和尿沉渣检查。应用最普遍的是尿液的干化学分析仪检查和尿沉渣人工镜检。<br />&nbsp;&nbsp;3.1.1尿生化检查：其中与尿路感染相关的常用指标包括：亚硝酸盐(nitrite，NIT)： 阳性见于大肠埃希菌等革兰阴性杆菌引起的尿路感染，尿液中细菌数>105/ml 时多数呈阳性反应，阳性反应程度与尿液中细菌数成正比。白细胞醋酶（leukocyteesterase , LEU)：正常值为阴性，尿路感染时为阳性。<br />&nbsp;&nbsp;3.1.2尿沉渣显微镜检：有症状的女性患者尿沉渣显微镜检诊断细菌感染的敏感性60%～100% ，特异性49%～100% 。应注意，尿检没有WBC不能除外上尿路感染，同时尿WBC也可见于非感染性肾疾病。<br />&nbsp;&nbsp;3.2尿培养：治疗前的中段尿标本培养是诊断尿路感染最可靠的指标。<br />&nbsp;&nbsp;3.2.1尿标本收集<br />&nbsp;&nbsp;排尿标本：大多数患者可以通过排尿的方式取得合格的尿标本。<br />&nbsp;&nbsp;导尿标本：如果患者元法自行排尿，应行导尿留取标本。<br />&nbsp;&nbsp;耻骨上穿刺拍吸尿标本：仅限于不能按要求排尿(如脊髓损伤)的患者，在新生儿和截瘫患者也可以使用。<br />&nbsp;&nbsp;3.2.2关于尿培养细菌菌落计数数量的说明：美国感染疾病学会(IDSA) 和欧洲临床微生物学和感染疾病学会(ESCMID) 规定的尿路感染细菌培养标准为：急性非复杂性膀脱炎中段尿培养≥103CFU/ml；急性非复杂性肾孟肾炎中段尿培养≥l04CFU/ml；女性中段尿培养≥l05CFU/ml； 男性中段尿培养或女性复杂性尿路感染导尿标系本主≥104CFU/ml。<br />&nbsp;&nbsp;', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('573', '54', 'M09_002', '1', '泌尿系感染诊断治疗指南', null, '中华医学会泌尿外科分会', '2014', '那彦群, 叶章群, 孙光.中国泌尿外科疾病诊断治疗指南[M].北京：人民卫生出版社，2011.', '中文', null, '单纯性尿路感染', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1 急性单纯性膀脱炎临床表现为尿频、尿急、尿痛、耻骨上膀脱区或会阴部不适、尿道烧灼感。常见终末血尿，体温正常或仅有低热。<br />&nbsp;&nbsp;1.2. 急性单纯性肾孟肾炎患者同时具有尿路剌激征、患侧或双侧腰部胀痛等泌尿系统症状和全身症状。2诊断<br />&nbsp;&nbsp;通过病史询问、体格检查和实验室检查获得诊断。<br />&nbsp;&nbsp;', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('574', '54', 'M09_003', '1', '泌尿系感染诊断治疗指南', null, '中华医学会泌尿外科分会', '2014', '那彦群, 叶章群, 孙光.中国泌尿外科疾病诊断治疗指南[M].北京：人民卫生出版社，2011.', '中文', null, '复杂性尿路感染', null, null, '1.临床症状：复杂性尿路感染可伴或不伴有临床症状(如尿急、尿频、尿痛、排尿困难、腰背部疼痛、肋脊角压痛、耻骨上疼痛和发热)。除了泌尿系疾病之外，复杂性尿路感染常伴随其他疾病，如糖尿病(10%) 和肾功能衰竭。复杂性尿路感染的后遗症较多，最严重和致命的情况一是尿服毒症，二是肾功能衰竭。<br />&nbsp;&nbsp;1.1病史采集(推荐)复杂性UTI 的病史采集包括：①尿路感染症状：如尿频、尿急、尿痛、等下尿路刺激症状，及腰痛和(或)下腹部痛等；②全身感染症状：如寒战、发热、头痛、恶心、呕吐、食欲不振等；③伴随疾病本身引起的症状：如尿路结石、糖尿病引起的症状；④先前的治疗史，尤其是抗菌药物的应用史。<br />&nbsp;&nbsp;2. 体格检查(推荐) <br />&nbsp;&nbsp;3.辅助检查<br />&nbsp;&nbsp;3.1尿常规(推荐)；<br />&nbsp;&nbsp;3.2 尿培养(推荐)；<br />&nbsp;&nbsp;3.3血液检查(可选)：血液白细胞计数和中性粒细胞升高，血沉增快。若怀疑伴有肾功能不全、糖尿病、免疫缺陷等潜在性疾病，必须进行相关的血液学检查。当患者出现除毒血症先兆症状时，还需进行血液细菌培养和药敏试验。<br />&nbsp;&nbsp;3.4影像学检查(可选)。<br />&nbsp;&nbsp;', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('575', '54', 'M09_004', '1', '泌尿系感染诊断治疗指南', null, '中华医学会泌尿外科分会', '2014', '那彦群, 叶章群, 孙光.中国泌尿外科疾病诊断治疗指南[M].北京：人民卫生出版社，2011.', '中文', null, '导尿管相关尿路感染', null, null, '1.症状和体征 超过90%的院内导尿管相关感染菌尿是无症状的，有症状的感染中常见的症状是发热。<br />&nbsp;&nbsp;2.菌尿和脓尿不推荐单纯根据菌尿和脓尿的情况对可能发生的有症状感染进行预测。<br />&nbsp;&nbsp;', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('576', '54', 'M09_005', '1', '泌尿系感染诊断治疗指南', null, '中华医学会泌尿外科分会', '2014', '那彦群, 叶章群, 孙光.中国泌尿外科疾病诊断治疗指南[M].北京：人民卫生出版社，2011.', '中文', null, '尿脓毒血症', null, null, '1.临床表现<br />&nbsp;&nbsp;包括尿路感染、伴随的其他潜在疾病和感染性休克三方面。<br />&nbsp;&nbsp;2.诊断<br />&nbsp;&nbsp;当尿路感染出现临床感染症状并且伴有全身炎症反应征象(SIRS) 即可诊断为尿版毒血症。<br />&nbsp;&nbsp;', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('577', '54', 'M09_006', '1', '中国儿童常见肾脏疾病诊治循证指南(试行)(七)：泌尿系感染诊断治疗指南', null, '中华医学会儿科学分会肾脏病学组', '2010', '中华医学会儿科学分会肾脏病学组.中国儿童常见肾脏疾病诊治循证指南(试行)(七)：泌尿系感染诊断治疗指南[J].中华儿科杂志,2010,48(11):814-816.\n', '中文', null, '泌尿系感染', null, null, '1.临床症状：急性UTI症状随患儿年龄的不同存在着较大的差异。婴幼儿UTI临床症状缺乏特异性，需给予高度关注，3月龄以下婴幼儿的临床症状可包括：发热、呕吐、哭吵、嗜睡、喂养困难、发育落后、黄疸、血尿或脓尿等；3月龄以上儿童的临床症状可包括：发热、纳差、腹痛、呕吐、腰酸、尿频、排尿困难、血尿、脓血尿、尿液混浊等[c/I]。<br />&nbsp;&nbsp;在检查和诊断过程中还需注意是否存在女婴外阴炎、男婴包茎合并感染等情况。<br />&nbsp;&nbsp;2．实验室检查：(1)尿液分析：①尿常规检查：清洁中段尿离心沉渣中自细胞≥5个／HPF，即可怀疑为UTI[A／I]。血尿也很常见，肾盂肾炎患儿还可出现中等蛋白尿、白细胞管型尿及晨尿的比重和渗透压减低。②试纸条亚硝酸盐试验和尿白细胞酯酶检测：试纸条亚硝酸盐试验对诊断UTI的特异度高(75．6％-100％)而敏感度较低(16．2％一88．1％)，若采用晨尿进行检测可提高其阳性率[A／I]。尿白细胞酯酶检测对诊断UTI的特异度和敏感度分别为69．3％-97．8％和37．5％-100％[A／I]。两者联合检测对诊断UTI的特异度和敏感度分别为89．2％-100％和30．O％-89．2％[A／I]。<br />&nbsp;&nbsp;(2)尿培养细菌学检查：尿细菌培养及菌落计数是诊断UTI的主要依据，而尿细菌培养结果的诊断意义与恰当的尿液标本收集方法相关。通常认为清洁中段尿培养菌落数>105／ml可确诊，104-105／ml为可疑，<104／ml系污染。但结果分析应结合患儿性别、尿液收集方法、细菌种类及繁殖力综合评价其临床意义，具体见表2[A／I]。对临床高度怀疑UTI而尿普通细菌培养阴性者，应作L-型细菌和厌氧菌培养。<br />&nbsp;&nbsp;3．影像学检查：目的在于：①辅助UTI定位；②检查泌尿系有无先天性或获得性畸形；③了解慢性肾损害或瘢痕进展情况。<br />&nbsp;&nbsp;常用的影像学检查有B超、排泄性膀胱尿路造影(MCU)、静态核素肾扫描等。<br />&nbsp;&nbsp;(1)B超：建议伴有发热症状的UTI者均行B超检查[A／I]。B超检查主要是发现和诊断泌尿系统发育畸形。<br />&nbsp;&nbsp;(2)核素肾静态扫描(99mTc-DMSA)：①诊断急性肾盂肾炎(APN)的金标准：APN时，由于肾实质局部缺血及肾小管功能障碍致对DMSA摄取减少。典型表现呈肾单个或多个局灶放射性减低或缺损，但无容量丢失，也可呈弥漫的放射性稀疏伴外形肿大。其诊断该病的敏感性与特异性分别为96％和98％[B／I]。但由于价格昂贵，多用于特殊需要时。②肾瘢痕的发现：国内外学者均发现首次UTI的患儿在DMSA无异常发现情况下罕见VUR存在，而在DMSA发现肾瘢痕的患儿中VUR的阳性率相当高。推荐在急性感染后3—6个月行99mTc-DMSA以评估肾瘢痕[A／II a]。<br />&nbsp;&nbsp;(3)排泄性膀胱尿路造影(MCU)：系确诊VUR的基本方法及分级的“金标准”。MCU常用检查方法：通过导尿管将稀释后的造影剂(目前常用碘普胺，用0．9％生理盐水以l：3的比例进行稀释)注入膀胱至患儿有排尿感(≤2岁注入30—50 ml，3—6岁50—100 m1)，然后拔出导尿管并嘱患儿排尿，同时进行摄片。<br />&nbsp;&nbsp;①<2岁的患儿：UTI伴有发热症状者，无论男女，在行尿路B超检查后无论超声检查是否异常，均建议在感染控制后行MCU检查。如说服后家属对MCU仍有顾虑者，宜尽早行DMSA检查：(a)如DMSA肾实质损害较严重或合并双侧肾实质损害，需尽早行MCU检查；(b)如DMSA肾实质损害较轻，也可在交代可能性后暂缓MCU检查，且在3个月后随访DMSA(其间建议应用预防量抗生素即1／3治疗量睡前顿服)；(c)B超显像泌尿系异常者需在感染控制后立即行MCU检查[A／I]。②>4岁的患儿：B超显像泌尿系异常者需在感染控制后进行MCU检查[B／I]。③2-4岁可根据病情而定。<br />&nbsp;&nbsp;4．上／下泌尿道感染的鉴别：上泌尿道感染又称急性肾盂肾炎主要指菌尿并有发热(≥38℃)，伴有腰酸、激惹等不适。下泌尿道感染或称膀胱炎有菌尿，但无全身症状和体征。c反应蛋白在临床上无鉴别作用。<br />&nbsp;&nbsp;如果患儿有明确的尿液检查异常。UTI的诊断即可初步建立，在进一步取得尿液细菌学培养结果的同时可以开始临床抗生素治疗。<br />&nbsp;&nbsp;M06_006_01尿液标本收集方法与菌落技术判断标准.docx', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('578', '54', 'M09_007', '1', '尿路感染诊断与治疗中国专家共识（2015版）—复杂性尿路感染', null, '尿路感染诊断与治疗中国专家共识编写组\n', '2015', '尿路感染诊断与治疗中国专家共识编写组.尿路感染诊断与治疗中国专家共识（2015版）—复杂性尿路感染[J].中华泌尿外科杂志.2015,36(4):241-244.', '中文', null, '复杂性尿路感染', null, null, '诊断复杂性尿路感染有2条标准，尿培养阳性以及包括以下至少1条合并因素：留置导尿管、支架管或间歇性膀胱导尿；残余尿>100 ml；任何原因引起的梗阻性尿路疾病，如膀胱出口梗阻、神经源性膀胱、结石和肿瘤；膀胱输尿管反流或其他功能异常；尿流改道；化疗或放疗损伤尿路上皮；围手术期和术后尿路感染：肾功能不全、移植肾、糖尿病和免疫缺陷等。<br />&nbsp;&nbsp;临床评估<br />&nbsp;&nbsp;下尿路感染常见症状为尿频、尿急、尿痛等，上尿路感染则以肾区疼痛、发热较为多见。泌尿生殖道结构、功能异常或者其他存在易发感染的原发病所引起的临床症状多种多样。<br />&nbsp;&nbsp;尿培养：对于复杂性尿路感染，清洁中段尿培养菌落计数女性>105 cfu／ml、男性>104 cfu／ml，或所有患者导尿留取的尿标本细菌菌落计数>104 cfu／ml具有诊断价值。<br />&nbsp;&nbsp;其他相关检查：影像学检查如超声、腹部平片、尿路造影和泌尿系CT主要目的是寻找泌尿生殖道结构、功能异常或者其他存在易发感染的疾病。<br />&nbsp;&nbsp;\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('579', '54', 'M09_008', '1', '尿路感染诊断与治疗中国专家共识(2015版)--尿路感染抗菌药物选择策略及特殊类型尿路感染的治疗建议', null, '尿路感染诊断与治疗中国专家共识编写组', '2015', '尿路感染诊断与治疗中国专家共识编写组.尿路感染诊断与治疗中国专家共识(2015版)--尿路感染抗菌药物选择策略及特殊类型尿路感染的治疗建议[J].中华泌尿外科杂志.2015,36(04):245-244.', '中文', '反复发作性尿路感染分类<br />&nbsp;&nbsp;(1)细菌持续存在：由同一种细菌引起．并且在较短的期间内再次复发，患者在使用敏感性抗菌药物治疗2周后，尿中仍可培养出同种细菌即可诊断。这种情况常见于合并泌尿系统解剖或功能异常．属于复杂性尿路感染。<br />&nbsp;&nbsp;(2)再感染：是指患者由不同种类的微生物引起的再次感染。患者属于非复杂性尿路感染，感染的原因是自身抵抗力低下出现的新的感染而不是首次感染治疗的失败。<br />&nbsp;&nbsp;', '无症状尿路感染', null, null, '对无症状女性患者或留置尿路导管的患者。尿培养细菌菌落计数≥105 CFU／ml；男性患者清洁尿标本培养出1种菌株菌落计数≥103 CFU／ml：男性或女性患者的导尿标本，1次菌落计数≥102 CFU／ml。<br />&nbsp;&nbsp;', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('58', '34', 'M06_013', '1', 'EAU指南：尿路结石的诊断和保守治疗', 'EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis\n', '欧洲泌尿外科学会(EAU,European Association of Urology)', '2015', null, '英文', 'M06_013_01病因结石分类.docx', '尿路结石（Urolithiasis）', null, null, 'M06_013_02结石分类.docx<br />&nbsp;&nbsp;\n1.诊断性评价<br />&nbsp;&nbsp;评价包括详细的病史、体格检查、适当的影像学检查和基本评价。输尿管结石常伴有腰痛、呕吐的患者，有时发热，而肾结石可无症状。<br />&nbsp;&nbsp;1.1diagnostic成像<br />&nbsp;&nbsp;超声（美国）应该作为主要的诊断影像工具，虽然疼痛缓解和其他紧急措施不应该被成像评估（表3）推迟。我们可以识别位于肾输尿管及膀胱输尿管连接处和结石，但经常无法检测输尿管结石。输尿管结石患者的上尿路常扩张。对于所有的结石，我们的敏感性为19-93%，特异性为84-100%[14]。<br />&nbsp;&nbsp;结石识别的敏感性和特异性分别为44–KUB片77%和80–87%，分别为[15]。KUB造影可鉴别阴性和阳性结石，比较随访之间是有帮助的。磁共振成像不能用于检测尿路结石[16]。NCCT已成为诊断急性腰痛的标准，并已取代静脉尿路造影似乎是更准确的[17]。当结石不存在时，应确定引起腹痛的原因。<br />&nbsp;&nbsp;NCCT能够检测尿酸和黄嘌呤结石，这是透亮的平片，但不是茚地那韦和基质结石[18]。NCCT能够确定结石密度（Hounsfield单位，HU）和皮肤的石头距离（表4），影响体外冲击波碎石术（SWL），结果[11,19,20]。非对比造影的优点是不需要平衡的，防止肾功能和解剖的泌尿系统（表3）的信息丢失。<br />&nbsp;&nbsp;低剂量的放射能降低辐射风险。在患者的身体质量指数（BMI）＜30公斤/平方米，低剂量CT检测灵敏度86%输尿管结石结石小于3毫米和3毫米100% > [22]。一个荟萃分析显示，低剂量CT准确率97%，结石方法[23,24]患者特异性95%混合灵敏度。<br />&nbsp;&nbsp;1.2。基本的实验室分析：非急救尿石症患者<br />&nbsp;&nbsp;生化检查是相似的所有结石患者，包括血细胞计数、电解质、肌酐、钙、尿酸和尿路感染，如果存在，C反应蛋白。干预前应评估凝血状态。试纸分析是足够的常规筛查，以有迹象显示，尿培养。在结石复发高危患者应进行更具体的分析根据指南对代谢评价[ 4 ]。结石分析是进一步代谢评价的基础（表5）。应告知患者筛选药物的有效治疗急性结石绞痛有较好的镇痛疗效优于阿片类药物[ 32 ]。日常a-阻断剂减少复发性疝气。<br />&nbsp;&nbsp;如果不充分的医疗镇痛，应进行引流或除石术（表10）。<br />&nbsp;&nbsp;一个肾与尿路感染的迹象是泌尿系统的急救，以防止进一步的并发症，需要紧急减压。目前，有紧急减压梗阻收集系统两种选择：一种留置输尿管导管和一个肾造瘘管置入位置（表11）。很少有证据支持在其他[等]的一个优势。最终结石清除应推迟直到感染被清除后，一个完整的抗菌药物治疗（表12）。<br />&nbsp;&nbsp;1.Diagnostic evaluation<br />&nbsp;&nbsp;Evaluation includes a detailed medical history, physical examination, appropriate imaging, and basic evaluation. Patients with ureteral stones usually present with loin pain, vomiting, and sometimes fever, whereas renal stones may be asymptomatic. <br />&nbsp;&nbsp;1.1Diagnostic imaging<br />&nbsp;&nbsp;Ultrasound (US) should be used as the primary diagnostic imaging tool, although pain relief and other emergency measures should not be delayed by imaging assessments (Table 3). US can identify stones located in the kidney and pyeloureteral and vesicoureteric junctions, but frequently fails to detect ureteral calculi. The upper urinary tract is usually dilated in patients with ureteral stones. For all stones, US has sensitivity of 19–93% and specificity of 84–100% [14]. <br />&nbsp;&nbsp;The sensitivity and specificity of KUB radiography for stone identification are 44–77% and 80–87%, respectively [15]. KUB radiography may be helpful in differentiating between radiolucent and radiopaque stones and for comparison during follow-up. Magnetic resonance urography cannot be used to detect urinary stones [16]. NCCT has become the standard for diagnosing acute flank pain, and has replaced intravenous urography as it seems to be more accurate [17]. When stones are absent, the cause of abdominal pain should be identified. <br />&nbsp;&nbsp;NCCT can detect uric acid and xanthine stones, which are radiolucent on plain films, but not indinavir and matrix stones [18]. NCCT can determine stone density (Hounsfield units, HU) and skin-to-stone distance (Table 4), which affect extracorporeal shockwave lithotripsy (SWL) outcome [11,19,20]. The advantage of non-contrast imaging must be balanced against loss of information about renal function and anatomy of the urinary collecting system (Table 3). <br />&nbsp;&nbsp;Radiation risk can be reduced by low-dose CT [21]. In patients with body mass index (BMI) <30 kg/m2, low-dose CT has sensitivity of 86% for detecting ureteric stones <3 mm and 100% for calculi >3 mm [22]. A meta-analysis of low-dose CT accuracy revealed pooled sensitivity of 97% and specificity of 95% in patients with urolithiasis [23,24]. <br />&nbsp;&nbsp;1.2. Basic laboratory analysis: non-emergency urolithiasis patients<br />&nbsp;&nbsp;Biochemical work-up is similar for all stone patients and includes blood cell count, electrolytes, creatinine, calcium, uric acid and, if UTI is present, C-reactive protein. Blood coagulation status should be assessed before intervention. Dipstick analysis is sufficient for routine screening, withurine culture in cases with signs of UTI. Patients at high-risk of stone recurrence should undergo more specific analysis according to the EAU guidelines on metabolic evaluation [4]. Stone analysis is fundamental for further metabolic evaluation (Table 5). Patients should be instructed to filter drugs are effective in patients with acute stone colic and have better analgesic efficacy than opioids [5,32]. Daily a-blockers reduce recurrent colic. <br />&nbsp;&nbsp;If medical analgesia is insufficient, drainage or stone removal should be performed (Table 10). <br />&nbsp;&nbsp;An obstructed kidney with signs of a UTI is a urologic emergency that requires urgent decompression to prevent further complications. Currently, there are two options for urgent decompression of obstructed collecting systems: placement of an indwelling ureteral catheter and percutaneous placement of a nephrostomy tube (Table 11). There is little evidence to support the superiority of one over the other [33,34]. Definitive stone removal should be delayed until the infection is cleared following a complete course of antimicrobial therapy (Table 12). <br />&nbsp;&nbsp;', null, '缓解疼痛（Pain relief）；结石清除率（stone-free rate）', ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('580', '54', 'M09_009', '1', '尿路感染诊断与治疗中国专家共识(2016版)--尿路感染抗菌药物选择策略及特殊类型尿路感染的治疗建议', null, '尿路感染诊断与治疗中国专家共识编写组', '2015', '尿路感染诊断与治疗中国专家共识编写组.尿路感染诊断与治疗中国专家共识(2015版)--尿路感染抗菌药物选择策略及特殊类型尿路感染的治疗建议[J].中华泌尿外科杂志.2015,36(04):245-245.', '中文', null, '反复发作性尿路感染', null, null, '诊断反复发作尿路感染最为重要的是其发病的次数必须满足诊断标准。发作时的症状、体征和实验室检查均与二般尿路感染类似。影像学检查主要包括腹部x线平片、静脉尿路造影、膀胱尿道造影、泌尿系B超、CT、MRI等。其目的是发现泌尿系统可能存在的解剖结构异常和／或合并疾病。女性患者要行妇科检查，排除妇科畸形及妇科生殖道感染等疾病。<br />&nbsp;&nbsp;', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('581', '54', 'M09_010', '1', '尿路感染诊断与治疗中国专家共识(2017版)--尿路感染抗菌药物选择策略及特殊类型尿路感染的治疗建议', null, '尿路感染诊断与治疗中国专家共识编写组', '2015', '尿路感染诊断与治疗中国专家共识编写组.尿路感染诊断与治疗中国专家共识(2015版)--尿路感染抗菌药物选择策略及特殊类型尿路感染的治疗建议[J].中华泌尿外科杂志.2015,36(04):245-246.', '中文', null, '泌尿生殖系真菌感染', null, null, '临床评估：膀胱和前列腺真菌感染多无症状，仅4％的患者会出现尿频、排尿困难、血尿等症状，膀胱镜检查可发现膀胱壁白色斑片、黏膜水肿和红色斑点等；肾脏是念珠菌血症侵犯的主要靶器官。肾脏念珠菌感染表现为肾盂肾炎的症状，有腰部疼痛和发热，并可能产生输尿管梗阻，形成念珠菌感染性肾周脓肿或脓肾等。<br />&nbsp;&nbsp;念珠菌尿的诊断主要依据尿液真菌涂片及尿液真菌培养，但标本易污染。B超和CT检查有可能发现集合系统的真菌感染相关变化．并对尿路梗阻进行评估。<br />&nbsp;&nbsp;', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('582', '54', 'M09_011', '1', 'EAU泌尿系感染诊疗指南', 'Guidelines on Urological Infections', '欧洲泌尿外科学会(EAU,European Association of Urology)', '2015', 'European Association of Urology', '英文', null, '成人无症状菌尿', null, null, 'ABU is defined by a mid-stream sample of urine (MSU) showing bacterial growth >105 cfu/ml in twoconsecutive samples in women and in one single sample in men, in an individual without symptomsfrom the urinary tract. In a single catheterised sample, bacterial growth may be as low as 102 cfu/ml to beconsidered representing true bacteriuria in both men and women. Diagnostic work-up should includemeasurement of residual urine while cystoscopy and/or imaging of the upper urinary tract is not mandatoryif the medical history is otherwise without remarks (LE: 4; GR: A). If persistent growth of urease producingbacteria, i.e. Proteus mirabilis, is detected, stone formation in the urinary tract must be excluded. In men,a DRE of the prostate has to be performed to rule out prostate diseases, including chronic bacterial prostatitis(Chapter 3I).', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('583', '55', 'M08_001', '0', '中医内科常见病诊疗指南西医疾病部分', 'Guidelines for Diagnosis and Treatment of Common Internal Diseases in Chinese Medicine Diseases of Modern Medicine', '中华中医药学会', '2008', '中华中医药学会.ZYYXH/T50～135-2008，中医内科常见病诊疗指南西医疾病部分[S].北京：中国中医药出版社，2008.', '中文', '1.类型：慢性复发型、慢性持续型、暴发型、初发型。<br />&nbsp;&nbsp;2.临床严重程度分级：轻度、中度、重度。<br />&nbsp;&nbsp;3.病情分期：活动期、缓解期。\n', '溃疡性结肠炎', null, '1.大肠湿热证；2.脾胃气虚证；3.脾肾阳虚证；4.肝郁脾虚证；5.阴虚肠燥证；6.血瘀肠络证\n', '1.临床表现<br />&nbsp;&nbsp;1.1症状：起病多缓慢，少数急骤，偶有呈暴发性者。病程多迁延，呈发作与缓解期交替，少数可持续并逐渐加重。<br />&nbsp;&nbsp;    消化系统表现：腹泻、便血和腹痛为最主要症状，直肠受累明显者可有里急后重。重者可见腹胀、纳差、恶心呕吐。<br />&nbsp;&nbsp;    全身表现：可有发热、贫血、消瘦和低蛋白血症等。<br />&nbsp;&nbsp;    肠外表现：可有关节炎、结节性红斑、坏疽性脓皮病、口腔黏膜溃疡，以及眼部、肝胆等系统受累。<br />&nbsp;&nbsp;1.2体征：部分患者有腹部压痛，轻者除下腹稍有压痛外，多无其他体征。重型和暴发型病例可见腹胀、腹部压痛、反跳痛及肌紧张。部分患者左下腹可触及条索状物。<br />&nbsp;&nbsp;2.理化检查<br />&nbsp;&nbsp;2.1结肠镜检查：为确定诊断的最可靠方法，可见病变呈连续性、弥漫性分布，黏膜充血、水肿、脆性增加，易出血及脓性分泌物附着等炎症表现。重者有多发性糜烂或溃疡，慢性者结肠袋形变浅或消失，可有假息肉或桥形黏膜等。<br />&nbsp;&nbsp;2.2黏膜病理学检查：有活动期与缓解期的不同表现：<br />&nbsp;&nbsp;    活动期：固有膜内弥漫性、慢性炎细胞及中性粒细胞、嗜酸性粒细胞浸润；隐窝急性炎细胞浸润，尤其上皮细胞及中性粒细胞浸润、隐窝炎，甚至形成隐窝脓肿，可有脓肿溃入固有膜；隐窝上皮增生，杯状细胞减少；黏膜表层糜烂，溃疡形成，肉芽组织增生。<br />&nbsp;&nbsp;    缓解期：中性粒细胞消失，慢性炎细胞减少；隐窝大小形态不规则，排列紊乱；腺上皮与黏膜肌层间隙增大；潘氏细胞化生。<br />&nbsp;&nbsp;2.3钡剂灌肠检查：可见黏膜粗乱及（或）颗粒样改变；肠管边缘呈锯齿状或毛刺样，肠壁有多发性小充盈缺损；肠管短缩，袋形消失呈铅管样。<br />&nbsp;&nbsp;2.4实验室检查<br />&nbsp;&nbsp;    粪便常规检查：活动期有脓血。镜检有大量红、白细胞和黏液，在急性发作期粪便涂片中常见有大量多核的巨噬细胞。溶组织阿米巴滋养体、包囊、血吸虫卵及大便孵化，细菌培养（沙门菌、痢疾杆菌、空肠弯曲杆菌、需氧及厌氧菌）及真菌培养阴性。<br />&nbsp;&nbsp;    血常规：急性活动期白细胞可以增多，伴有发热者多见。重症患者可高达30 × 109/L，中性粒细胞可左移并有中毒颗粒，偶见嗜酸细胞增多。50％～60％的患者可有不同程度的低色素性贫血。<br />&nbsp;&nbsp;血沉：轻度或中度增快，多见于较重病例。在病情演变中，常把红细胞沉降率作为观察指标。<br />&nbsp;&nbsp;3.诊断要点<br />&nbsp;&nbsp;    诊断本病需先排除细菌性痢疾、阿米巴性结肠炎、血吸虫病、肠结核、Crohn病、放射性肠炎等原因明确的结肠炎症；具有典型的临床表现，并至少有内镜或钡剂灌肠的特征性改变中的一项可以确诊；临床症状不典型，但有典型肠镜或钡剂灌肠表现或病理活检证实亦可确诊。临床上有典型症状或典型既往史，而目前结肠镜或钡灌肠检查并无典型改变者，应列为疑诊随访。<br />&nbsp;&nbsp;一个完整的诊断应包括临床类型、病变范围、严重程度、病情分期及并发症。<br />&nbsp;&nbsp;3.1类型：慢性复发型、慢性持续型、暴发型、初发型。初发型指无既往史而首次发作；暴发型症状严重伴全身中毒性症状，可伴中毒性巨结肠、肠穿孔、脓毒血症等并发症。除暴发型外，各型可相互转化。<br />&nbsp;&nbsp;3.2临床严重程度分级：轻度：患者腹泻1日4次以下，便血轻或无，无发热、脉搏加快或贫血，血沉正常。中度：介于轻度和重度之间。重度：腹泻1日6次以上，明显黏液血便，体温在37.5℃以上，脉搏在90次／分以上，血红蛋白＜10g/L，血沉＞300mm/h<br />&nbsp;&nbsp;3.3病变范围：可为直肠、直肠乙状结肠、左半结肠、右半结肠全结肠、区域性结肠受累。<br />&nbsp;&nbsp;3.4病情分期：活动期、缓解期。<br />&nbsp;&nbsp;3.5肠外表现及并发症：如前所述。', '1.大肠湿热证<br />&nbsp;&nbsp;证候：腹痛，腹泻黏膜脓血便，里急后重，肛门灼热，口苦，小便短赤，舌质红，苔黄腻，脉滑数或濡数。<br />&nbsp;&nbsp;2.脾胃气虚证<br />&nbsp;&nbsp;证候：腹泻便溏，有黏液或少量脓血，食少纳差，食后腹胀，腹部隐痛喜按，肢倦乏力，面色萎黄，舌质淡或体胖有齿痕，苔薄白，脉细弱或濡缓。<br />&nbsp;&nbsp;3.脾肾阳虚证<br />&nbsp;&nbsp;证候：久泻不愈，大便清稀或伴有完谷不化，或黎明前泻，脐中腹痛，喜温喜按，腰膝酸软，形寒肢冷，食少神疲，面色光白，舌质淡，舌体胖有齿痕，苔白润，脉沉细或尺脉弱。<br />&nbsp;&nbsp;4.肝郁脾虚证<br />&nbsp;&nbsp;证候：腹痛则泻，泻后痛减，腹泻发作常与情志因素有关，黏液便，胸胁胀闷，喜叹息，纳差腹胀，矢气较频，舌质淡红，苔薄白，脉弦或弦细。<br />&nbsp;&nbsp;5.阴虚肠燥证<br />&nbsp;&nbsp;证候：大便秘结或带少量脓血，虚坐努责，腹痛绵绵，心烦易怒，午后低热，形瘦乏力，口燥咽干，舌质红，苔燥少津，脉细数。<br />&nbsp;&nbsp;6.血瘀肠络证<br />&nbsp;&nbsp;证候：泻下不爽，下利脓血或黑便，腹痛拒按，痛有定处，腹部或有痞块，面色晦暗，舌质紫暗或有瘀点、瘀斑，脉沉涩。', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('584', '55', 'M08_002', '0', '溃疡性结肠炎中医诊疗共识意见', '无', '中华中医药学会脾胃病分会', '2010', '中华中医药杂志，2010,25（6）：891-895.', '中文', '1.临床类型:初发型、慢性复发型、慢性持续型和暴发型。<br />&nbsp;&nbsp;2.严重程度：轻度、中度和重度。<br />&nbsp;&nbsp;3.病情分期：活动期、缓解期。', '溃疡性结肠炎', '可归属于“休息痢”、“久痢”和“肠澼”。\n', '1.大肠湿热证；2.脾虚湿蕴证；3.寒热错杂证；4.肝郁脾虚证；5.脾肾阳虚证；6.阴血亏虚证\n', '1.临床表现：有持续或反复发作的腹泻，黏液脓血便伴腹痛、里急后重和不同程度的全身症状。病程多在6周以上。可有关节、皮肤、眼，口腔及肝胆等肠道外表现。<br />&nbsp;&nbsp;2．相关检查：（1）结肠镜检查：病变多从直肠开始，呈连续性、弥漫性分布。表现为：①黏膜血管纹理模糊、紊乱或消失、充血、水肿、质脆、出血，脓血性分泌物附着，亦常见黏膜粗糙、呈细颗粒状；②病变明显处可见弥漫性、多发性糜烂或溃疡；③缓解期患者可见结肠袋囊变浅、变钝或消失，假息肉及桥形黏膜等。（2）钡剂灌肠检查：①黏膜粗乱和（或）颗粒样改变；②肠管边缘呈锯齿状或毛刺样，肠壁有多发性小充盈缺损；③肠管短缩，袋囊消失呈铅管样。（3）黏膜组织学检查：活动期和缓解期有不同表现。活动期：①固有膜内有弥漫性慢性炎性细胞、中性粒细胞、嗜酸性粒细胞浸润；②隐窝内有急性炎性细胞浸润，尤其是上皮细胞间有中性粒细胞浸润及隐窝炎，甚至形成隐窝脓肿，脓肿可溃入固有膜；③隐窝上皮增生，杯状细胞减少；④可见黏膜表层糜烂、溃疡形成和肉芽组织增生。缓解期：①中性粒细胞消失，慢性炎性细胞减少；②隐窝大小、形态不规则，排列紊乱；③腺上皮与黏膜肌层间隙增宽；④潘氏细胞化生。<br />&nbsp;&nbsp;3．诊断标准：排除细菌性痢疾、阿米巴痢疾、慢性血吸虫病、肠结核等感染性结肠炎以及缺血性结肠炎、放射性结肠炎、孤立性直肠溃疡、结肠克罗恩病后，可按下列标准诊断：（1）确诊：①腹泻或便血6周以上，结肠镜检查发现一个以上的下述表现：黏膜易脆、点状出血、弥漫性炎性糜烂、溃疡；或钡剂检查发现溃疡、肠腔狭窄或结肠短缩。同时伴有明确的黏膜组织学改变：活动期炎性细胞浸润、隐窝脓肿、杯状细胞缺失。缓解期隐窝结构异常（扭曲分枝）、隐窝萎缩。②手术切除或活检标本在显微镜下有特征性改变。（2）疑诊：①病史不典型，结肠镜或钡剂灌肠检查有相应表现；或有相应病史，伴可疑的结肠镜检查表现，无钡剂灌肠检查；或有典型病史，伴可疑的钡剂灌肠发现，无结肠镜检查报告。均缺乏组织学证据。②手术标本大体表现典型，但组织学检查不肯定。（3）诊断内容：完整的诊断应包括疾病的临床类型（初发型、慢性复发型、慢性持续型和暴发型）、严重程度（轻度、中度和重度）、病情分期（活动期、缓解期）、病变范围（直肠炎、左半结肠和广泛结肠）、肠外表现和并发症（大出血、穿孔、中毒性巨结肠和癌变等）。如溃疡性结肠炎初发型、中度、活动期、左半结肠受累。', '1.大肠湿热证<br />&nbsp;&nbsp;主症：①腹痛，腹泻，便下黏液脓血；②舌质红，苔黄腻。次症：①肛门灼热；②里急后重；③身热，小便短赤；④口干口苦，口臭；⑤脉滑数。<br />&nbsp;&nbsp;2.脾虚湿蕴证<br />&nbsp;&nbsp;主症：①大便溏薄，黏液白多赤少，或为白冻；②舌质淡红，边有齿痕，苔白腻。次症：①腹痛隐隐；②脘腹胀满，食少纳差；③肢体倦怠，神疲懒言；④脉细弱或细滑。<br />&nbsp;&nbsp;3.寒热错杂证<br />&nbsp;&nbsp;主症：①下痢稀薄，夹有黏冻，反复发作；②舌质红，或舌淡红，苔薄黄。次症：①腹痛绵绵；②四肢不温；③腹部有灼热感，烦渴；④脉弦，或细弦。<br />&nbsp;&nbsp;4.肝郁脾虚证<br />&nbsp;&nbsp;主症：①腹痛即泻，泻后痛减；②常因情志或饮食因素诱发大便次数增多。次症：①大便稀溏，或黏液便；②情绪抑郁或焦虑不安；③嗳气不爽，食少腹胀；④舌质淡红，苔薄白；⑤脉弦或弦细。<br />&nbsp;&nbsp;5.脾肾阳虚证<br />&nbsp;&nbsp;主症：①久泻不止，夹有白冻，甚则完谷不化，滑脱不禁；②形寒肢冷。次症：①腹痛喜温喜按；②腹胀，食少纳差；③腰酸膝软；④舌质淡胖，或有齿痕，苔薄白润；⑤脉沉细。<br />&nbsp;&nbsp;6.阴血亏虚证<br />&nbsp;&nbsp;主症：①排便困难，粪夹少量黏液脓血；②舌红少津，少苔或无苔。次症：①腹中隐隐灼痛；②午后低热，盗汗；③口燥咽干；④头晕目眩，心烦不安；⑤脉细数。<br />&nbsp;&nbsp;上述证候确定：主症必备，加次症2项以上即可诊断。<br />&nbsp;&nbsp; M08_002_001诊治流程', '症状；证候；结肠镜；黏膜组织学；生活质量。', ' 1．症状疗效评价标准（1）主要症状单项的记录与评价：主要症状指腹痛、腹泻、黏液脓血便。①临床控制：症状消失；②显效：症状分级减少2级；③有效：症状分级减少1级；④无效：达不到以上标准者（主要症状分级记录：0级：没有症状，积0分；Ⅰ级：症状轻微，不影响日常生活，积1分；Ⅱ级：症状中等，部分影响日常生活，积2分；Ⅲ级：症状严重，影响到日常生活，难以坚持工作，积3分）。（2）主要症状综合疗效评定标准：按改善百分率=[（治疗前总积分－治疗后总积分）÷治疗前总积分]×100%，计算主要症状改善百分率。症状消失为痊愈，症状改善百分率≥80%为显效，50%≤症状改善百分率＜80%为进步，症状改善百分率＜50%为无效，症状改善百分率负值时为恶化。痊愈和显效病例数计算总有效率。<br />&nbsp;&nbsp;2．证候疗效评价标准：按照尼莫地平法计算公式：疗效指数=[（治疗前积分－治疗后积分）÷治疗前积分]×100%，计算疗效指数。①临床缓解：症状、体征明显改善，疗效指数≥95%；②显效：症状、体征明显改善，70%≤疗效指数＜95%；③有效：症状、体征有改善，30%≤疗效指数＜70%；④无效：症状、体征无明显减轻或加重者，疗效指数＜30%。<br />&nbsp;&nbsp;3．结肠镜评分标准：内镜下黏膜愈合已成为目前溃疡性结肠炎治疗的目标之一，内镜评分具有重要作用。目前Baron内镜评分应用最广，其标准为：①正常黏膜图像记0分；②轻度病变（血管纹理模糊，黏膜充血但无出血）记1分；③中度病变（黏膜呈颗粒样变化，中度接触性出血）记2分；④重度病变（黏膜溃疡并自发性出血）记3分。观察并评价治疗前后记分变化。<br />&nbsp;&nbsp;4．黏膜组织学评分标准见  表M08_002_002 ；肠黏膜组织学与内镜评分结合可准确评价溃疡性结肠炎黏膜愈合情况，Geboes指数描述详细，可重复性好，效度高，是溃疡性结肠炎理想的组织学评分指数，已被用于许多临床试验，作为药效评估的终点指标之一。<br />&nbsp;&nbsp;5．疾病严重度与活动度评估：见 表M08_002_003  。1987年Schroeder将Powell-Tuck指数简化为改良的Mayo活动指数。该指数吸收了Truelove-Witts严重度指标和Baron内镜评分的优点，简便易行，目前已被广泛应用于临床试验，是欧洲克罗恩病和结肠炎组织（Ecco）推荐的理想疗效观察指数。并被亚太地区炎症性肠病处理共识意见和中华医学会消化病分会对我国炎症性肠病诊断治疗规范的共识意见所采纳。<br />&nbsp;&nbsp;6．生活质量评分标准：IBD多发于青年人，病程冗长，长期的肠道和全身症状势必影响到患者的情感和社会能力。目前多采用Guyatt编制的IBDQ炎症性肠病的评价量表进行生存质量分析。IBDQ量表包括32个定性和半定量的问题，测量IBD患者生活的4个方面：肠道症状[B]（10个问题）、全身症状[S]（5个问题）、情感能力畦[E]（10个问题）、社会能力[SF]（5个问题），范围32-224分，准确性、可信度和反应度良好。', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('584a1c2a835a40ccad58ff670e1ee41c', '4', 'adfa', '0', 'adf', '', 'adfa', null, '', '中文', '', '', '', '', '', '', '', '', '', '1', '0', 'admin', '2016-05-13 09:58:03', 'admin', '2016-05-13 09:58:03');
INSERT INTO `biz_standard` VALUES ('585', '55', 'M08_003', '1', '对我国炎症性肠病诊断治疗规范的共识意见', '无', '中华医学会消化病学分会炎症性肠病协作组', '2007', '中华消化杂志，2007，27（8）：545-550.', '中文', '1．临床类型：可分为慢性复发型、慢性持续型、暴发型和初发型。初发型指无既往史、首次发作；暴发型指症状严重，每日解血便10次以上，伴全身中毒性症状，可伴中毒性巨结肠、肠穿孔、脓毒血症等并发症。除暴发型外，各型可相互转化。<br />&nbsp;&nbsp;2．临床严重程度：可分为轻度、中度和重度。轻度：患者每日腹泻4次以下，便血轻或无，无发热、脉搏加快或贫血，红细胞沉降率正常。重度：腹泻每日6次以上，伴明显黏液血便，体温＞37.5℃，脉搏＞9O次/min，血红蛋白(Hb)＜100g/L，红细胞沉降率＞30mm/1h，详细Truelove分度见表M08_003_001。中度：介于轻度和重度之间。<br />&nbsp;&nbsp;3．病情分期：可分为活动期和缓解期。South-erland疾病活动指数（DAI），也称Mayo指数，较为简单实用，见表M08_003_002。慢性活动性或顽固性UC指诱导或维持缓解治疗失败，通常为糖皮质激素抵抗或依赖病例。前者指泼尼松龙足量应用4周不缓解，后者为泼尼松龙减量至10mg/d即无法控制发作或停药后3个月内复发者。<br />&nbsp;&nbsp;4．病变范围：分为直肠、直乙状结肠、左半结肠(脾曲以远)、广泛结肠(脾曲以近)、全结肠。<br />&nbsp;&nbsp;5．肠外表现及并发症：肠外可有关节、皮肤、眼部、肝胆等系统受累；并发症可有大出血、穿孔、中毒性巨结肠及癌变等。', '溃疡性结肠炎', null, null, '1．临床表现：有持续或反复发作的腹泻、黏液脓血便伴腹痛、里急后重和不同程度的全身症状。病程多在4～6周以上。可有关节、皮肤、眼、口及肝胆等肠外表现。<br />&nbsp;&nbsp;2．结肠镜检查：病变多从直肠开始，呈连续性、弥漫性分布。表现为：①黏膜血管纹理模糊、紊乱或消失、充血、水肿、质脆、出血、脓性分泌物附着，亦常见黏膜粗糙，呈细颗粒状；②病变明显处可见弥漫性、多发性糜烂或溃疡；③缓解期患者可见结肠袋囊变浅、变钝或消失，假息肉及桥形黏膜等。<br />&nbsp;&nbsp;3．钡剂灌肠检查：主要改变如下。①黏膜粗乱和(或)颗粒样改变；②肠管边缘呈锯齿状或毛刺样，肠壁有多发性小充盈缺损；③肠管短缩，袋囊消失呈铅管样。<br />&nbsp;&nbsp;4．黏膜组织学检查：活动期和缓解期有不同表现。活动期：① 固有膜内有弥漫性慢性炎性细胞、中性粒细胞、嗜酸粒细胞浸润；②隐窝有急性炎性细胞浸润，尤其是上皮细胞间有中性粒细胞浸润及隐窝炎，甚至形成隐窝脓肿，脓肿可溃入固有膜；③隐窝上皮增生，杯状细胞减少；④可见黏膜表层糜烂、溃疡形成和肉芽组织增生。缓解期：①中性粒细胞消失，慢性炎性细胞减少；②隐窝大小、形态不规则，排列紊乱；③腺上皮与黏膜肌层间隙增宽；④潘氏细胞化生。<br />&nbsp;&nbsp;5．手术切除标本病理检查：肉眼及组织学上可见上述UC特点。<br />&nbsp;&nbsp;在排除细菌性痢疾、阿米巴痢疾、慢性血吸虫病、肠结核等感染性结肠炎及结肠CD、缺血性结肠炎、放射性结肠炎等疾病基础上，可按下列标准诊断。①具有上述典型临床表现者为临床疑诊，安排进一步检查。②同时具备上述第1、2、3项中之任何一项，可拟诊为本病。③如再加上第4或第5项中病理检查的特征性表现，则可确诊。④初发病例、临床表现和结肠镜改变均不典型者，暂不诊断UC，但须随访3～6个月，观察发作情况。⑤结肠镜检查发现的轻度慢性直、乙状结肠炎不能与UC等同，应观察病情变化，认真寻找病因。', null, '临床症状；结肠镜检查', '1．完全缓解：临床症状消失，结肠镜复查发现黏膜大致正常。<br />&nbsp;&nbsp;2．有效：临床症状基本消失，结肠镜复查黏膜轻度炎症或假息肉形成。<br />&nbsp;&nbsp;3．无效：经治疗后临床症状、内镜及病理检查结果均无改善。', 'M08_003 2007CSGE+对我国炎症性肠病诊断治疗规范的共识意见(2007.济南).pdf', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('586', '55', 'M08_004', '1', '多伦多共识：非住院性溃疡性结肠炎的医学管理指南', 'Clinical Practice Guidelines for the Medical Management of Non-Hospitalized Ulcerative Colitis: The Toronto Consensus', '多伦多溃疡性结肠炎共识组（Toronto Ulcerative Colitis Consensus Group）', '2015', 'Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI,Panaccione R, Steinhart AH, Tse F, Feagan B, on behalf of the Toronto Ulcerative Colitis Consensus Group, Afif W,Bernard E-J, Borgaonkar M, Devlin S, Fedorak R, Nguyen GC, Penner R, Peyrin-Biroulet L,Reinisch W, Seow CH, Sy R, Targownik L, Thomson P, Van Assche G, Williams C, Clinical Practice Guidelines for the Medical Management of Non-Hospitalized Ulcerative Colitis: The Toronto Consensus,Gastroenterology (2015), doi: 10.1053/j.gastro.2015.03.001', '英文', 'The extent of endoscopic disease was categorized as: a) proctitis (distal to the rectosigmoid junction or within 18 cm of the anal verge); b) left sided colitis (extending anywhere from the sigmoid to the splenic flexure); or c) extensive colitis (extending beyond the splenic flexure).\n内镜下病变程度分为：a）直肠炎（直肠末梢到直肠乙状结肠连接处，或肛门边缘向内18cm）；b）左半结肠炎（延伸的地方从乙状结肠到脾曲）；c）广泛性结肠炎（延伸至脾曲）。', '溃疡性结肠炎', null, null, 'M08_004_002评分量表', null, '症状；内窥镜', 'M08_004_001', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('587', '55', 'M08_005', '0', 'T/ZGMZYYXH001-007-2015维吾尔医常见病诊疗指南', 'Guidelines for Diagnosis and Treatment of Common Diseases in Uighur Medicine', '中国民族医药学会', '2015', '中国民族医药学会.T/ZGMZYYXH001-007-2015，维吾尔医常见病诊疗指南[S].北京：中国中医药出版社，2015.', '中文', '1.按临床类型分类：初发型；慢性复发性；慢性持续型；急性暴发型。<br />&nbsp;&nbsp;2.按病情程度分类：轻度；中度；重度。<br />&nbsp;&nbsp;3.按临床分期：活动期；缓解期。<br />&nbsp;&nbsp;4.结肠镜黏膜病变分级：Ⅰ级；Ⅱ级；Ⅲ级。<br />&nbsp;&nbsp;5.按病变范围：直肠；直乙状结肠；左半结肠（脾曲以远）；广泛结肠（脾曲以近）；全结肠。\n', null, '肠溃疡', '1.活动期:数量过多的胆液质型；蓝色胆液质型；腐败血液质型。<br />&nbsp;&nbsp;2.缓解朝:异常黏液质型；异常黑胆质型。', '1.临床表现<br />&nbsp;&nbsp;1.1临床症状<br />&nbsp;&nbsp;有持续或反复发作的腹泻，黏液脓血便伴腹痛、里急后重和不同程度的全身症状，病程多在4-6周以上，可有关节、皮肤、眼、口腔及肝胆等肠道外表现。<br />&nbsp;&nbsp;1.2结肠镜检查<br />&nbsp;&nbsp;    病变多从直肠开始，呈连续性、弥漫性分布，表现为：<br />&nbsp;&nbsp;1.2.1黏膜血管纹理模糊、紊乱，或消失、充血、水肿、质脆、出血、脓血性分泌物附着，亦常见黏膜粗糙呈细颗粒状。<br />&nbsp;&nbsp;1.2.2病变明显处可见弥漫性、多发性糜烂或溃疡。<br />&nbsp;&nbsp;1.2.3缓解期可见结肠带囊变浅、变钝或消失，以及假息肉和桥形黏膜等。<br />&nbsp;&nbsp;1.3钡剂灌肠检查<br />&nbsp;&nbsp;1.3.1  黏膜粗乱和，（或）颗粒样改变。<br />&nbsp;&nbsp;1.3.2肠管边缘呈锯齿状或毛刺样，肠壁有多发性小充盈缺损<br />&nbsp;&nbsp;1.3.3肠管短缩，袋囊小时呈铅管样。<br />&nbsp;&nbsp;1.4黏膜组织学检查<br />&nbsp;&nbsp;1.4.1活动期<br />&nbsp;&nbsp;    ①固有膜内有弥漫性慢性炎性细胞、中性粒细胞、嗜酸性粒细胞浸润；②隐窝内有急性炎性细胞浸润，尤其是上皮细胞间有中性粒细胞浸润及隐窝炎，甚至形成隐窝脓肿，可有脓肿溃入固有膜；③隐窝上皮增生，杯状细胞减少；④可见黏膜表层糜烂、溃疡形成和肉芽组织增生。<br />&nbsp;&nbsp;1.4.2缓解期<br />&nbsp;&nbsp;    ①中性粒细胞消失，慢性炎性细胞减少；②隐窝大小、形态不规则，排列紊乱；③腺上皮与黏膜肌层间隙增宽；④潘氏细胞化生。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;在排除细菌性痢疾、阿米巴痢疾、慢性血吸虫病、肠结核等感染性结肠炎及结肠CD、缺血性结肠炎、放射性结肠炎等疾病基础上，可按下列标准诊断：<br />&nbsp;&nbsp;2.1 具有上述典型临床表现者为临床疑诊，安排进一步检查。<br />&nbsp;&nbsp;2.2同时具备以上条件4.1和4.2或4.3项中任何一项，可拟诊本病。<br />&nbsp;&nbsp;2.3如再加上3.1. 4项中病理检查的特征性表现，可以确诊。<br />&nbsp;&nbsp;2.4初发病例、临床表现和结肠镜改变均不典型者，暂不诊断UC，需随访3-6个月，观察发作情况。<br />&nbsp;&nbsp;2.5结肠镜检查发现的轻度慢性直、乙状结肠炎不能与UC等同，应观察病情变化，认真寻找病因。<br />&nbsp;&nbsp;完整的诊断应包括疾病的临床类型、病情程度、临床分期、病变分级、病变范围及并发症。<br />&nbsp;&nbsp;2.5. 1按临床类型分类<br />&nbsp;&nbsp;初发型：无既往史而首次发病。<br />&nbsp;&nbsp;慢性复发性：病变范围小，症状较轻，往往有缓解期，但易复发。<br />&nbsp;&nbsp;慢性持续型：病变范围较广，症状持续半年以上。<br />&nbsp;&nbsp;急性暴发型：起病急骤，症状严重，伴全身中毒症状，或伴中毒性结肠扩张、肠穿孔、败血症等并发症。<br />&nbsp;&nbsp;2.5.2按病情程度分类<br />&nbsp;&nbsp;轻度：腹泻每日3次以下，便血轻或无，无发热、脉搏加快或贫血，血沉正常。<br />&nbsp;&nbsp;中度：介于轻度和重度之间。<br />&nbsp;&nbsp;    重度：腹泻每日6次以上，明显黏液血便，体温＞37.5℃，脉搏＞90次/分，血红蛋白＜100g/L，血沉＞30mm/h。<br />&nbsp;&nbsp;2.5.3按临床分期<br />&nbsp;&nbsp;活动期：有明显症状和体征，结肠镜观察为炎症活动期表现。<br />&nbsp;&nbsp;缓解期：无明星症状体症，结肠镜观察为炎症缓解静止期表现。<br />&nbsp;&nbsp;2.5.4结肠镜黏膜病变分级<br />&nbsp;&nbsp;Ⅰ级：肠黏膜轻度充血水肿，轻度糜烂或无，溃疡无或散在分布数量少于3个，周边轻度红肿。<br />&nbsp;&nbsp;Ⅱ级：肠黏膜中度充血水肿，中度糜烂伴有出血，溃疡散在分布数量多于3个，周边明显红肿。<br />&nbsp;&nbsp;Ⅲ级：肠黏膜重度充皿水肿，重度糜烂伴有明显出血，溃疡分布多，表面布满脓苔，周边显著红肿。<br />&nbsp;&nbsp;2.5.5按病变范围<br />&nbsp;&nbsp;分为直肠、直乙状结肠、左半结肠（脾曲以远）、广泛结肠（脾曲以近）、全结肠。<br />&nbsp;&nbsp;2.5.6肠外表现及并发症<br />&nbsp;&nbsp;肠外可有关节、皮肤、眼部，肝胆等系统受累；并发症可有大出血、穿孔、中毒性巨结肠和癌变等。<br />&nbsp;&nbsp;3.鉴别诊断<br />&nbsp;&nbsp;本病应与细菌性痢疾、阿米巴痢疾、慢性血吸虫病、肠结核等感染性结肠炎及结肠CD、缺血性结肠炎、放射性结肠炎等鉴别诊断。', '维吾尔医辨证论治<br />&nbsp;&nbsp;1.活动期<br />&nbsp;&nbsp;1.1 数量过多的胆液质型<br />&nbsp;&nbsp;主症：腹泻，脓血便，腹痛，发热。<br />&nbsp;&nbsp;次症：肛门灼热，脉细、较快，舌苔黄，舌干易裂，晨起时口苦，皮肤粗糙、干热，面部发黄。<br />&nbsp;&nbsp;1.2蓝色胆液质型<br />&nbsp;&nbsp;主症：腹泻，脓血便，腹痛，腹胀与发热。<br />&nbsp;&nbsp;次症：嗳气，脉细、快，舌苔黄，舌干，晨起时口苦涩，皮肤干热，面部发黄。<br />&nbsp;&nbsp;1.3腐败血液质型<br />&nbsp;&nbsp;    主症：腹泻，脓血便，腹痛，腹胀，腰酸，食少。<br />&nbsp;&nbsp;次症：头晕眼花，脉粗缓呈波浪状，无舌苔，晨起口甜，面部发红，乏力，皮肤热湿。<br />&nbsp;&nbsp;2.缓解朝<br />&nbsp;&nbsp;2.1异常黏液质型<br />&nbsp;&nbsp;主症：腹泻，腹痛，脓血便较少，无发热。<br />&nbsp;&nbsp;次症：头晕眼花，脉粗、较慢弱，舌苔白，晨起口黏，舌体相对较大，面部暗淡无光，皮快寒湿：<br />&nbsp;&nbsp;2.2异常黑胆质型<br />&nbsp;&nbsp;主症：腹泻，轻度腹痛，脓血便较少或无脓血便，无发热。<br />&nbsp;&nbsp;次症：头晕眼花，脉细较慢弱，舌干，舌苔黑色或灰色，晨起口苦涩，消瘦。<br />&nbsp;&nbsp;', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('588', '55', 'M08_006', '1', '儿童炎症性肠病诊断规范共识意见', '无', '中华医学会儿科学会消化学组儿童炎症性肠病协作组', '2010', '中国实用儿科杂志，2010，25（4）：263-265.', '中文', '1.按临床类型：初发型；慢性复发型；慢性持续型；暴发型。<br />&nbsp;&nbsp;2.按病变范围：直肠型；直肠乙状结肠型；左半结肠型；全结肠型。<br />&nbsp;&nbsp;3.按病情程度：轻度；中度；重度。<br />&nbsp;&nbsp;4.按活动性：活动期；缓慢期。', '溃疡性结肠炎（ulcerative colitis，UC）', null, null, '1. 临床依据：根据以下临床表现和检查结果诊断UC，确诊UC 应符合（1）+［（2）或（3）］+（4）；拟诊UC 应符合（1）+（2）或（3）。（1）临床表现：持续4 周以上或反复发作的腹泻，为血便或黏液脓血便，伴明显体重减轻。其他临床表现包括腹痛、里急后重和发热、贫血等不同程度的全身症状，可有关节、皮肤、眼、口及肝胆等肠外表现。（2）结肠镜检查：病变从直肠开始，连续性近端发展，呈弥漫性黏膜炎症，血管网纹消失、黏膜易脆（接触性出血）、伴颗粒状外观、多发性糜烂或溃疡、结肠袋囊变浅、变钝或消失（铅管状），假息肉及桥形黏膜、肠腔狭窄、肠管变短等。（3）钡灌肠检查：肠壁多发性小充盈缺损，肠腔狭窄，袋囊消失呈铅管样，肠管短缩。（4）活检组织标本或手术标本病理学检查：①活动性：固有膜内弥漫性、慢性炎性细胞及中性粒细胞、嗜酸粒细胞浸润、隐窝炎或形成隐窝脓肿；隐窝上皮增生，同时杯状细胞减少；黏膜表层糜烂、溃疡形成。②缓解期：中性粒细胞消失，慢性炎性细胞减少；隐窝不规则，排列紊乱；腺上皮与黏膜肌层间隙增大，潘氏细胞化生。<br />&nbsp;&nbsp;2. 诊断内容：诊断应包括其临床类型、病变范围、严重程度以及活动性等。（1）临床类型：初发型、慢性复发型、慢性持续型、暴发型。①初发型：既往无病史首次发作；②慢性复发型：病情缓解后复发；③慢性持续型：首次发作后可持续有轻度不等的腹泻、便血，常持续半年以上，可有急性发作；④暴发型：症状严重，血便每日10 次以上，伴中毒性巨结肠、肠穿孔、脓毒血症等并发症。（2）病变范围：直肠型、直肠乙状结肠型、左半结肠型、全结肠型。病变范围参考结肠镜检查结果确定。（3）病情程度：轻度、中度、重度。①轻度：患儿腹泻每日4次以下，便血轻或无，无发热、脉搏加快、贫血，血沉正常；②中度：介于轻度与重度之间；③重度：腹泻每日6次以上，伴明显黏液血便、体温37.5℃以上、脉搏加快、血红蛋白＜100g/L、血沉＞30mm/h。（4）活动性：活动期、缓慢期。①活动期：患儿有典型临床表现，结肠镜下黏膜呈炎症性改变，病理学检查显示黏膜呈活动期表现；②缓解期：临床表现缓解，结肠黏膜病理检查呈缓解期表现。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('589', '55', 'M08_007', '1', '炎症性肠病诊断与治疗的共识意见（2012年·广州）', '无', '中华医学会消化病学分会炎症性肠病学组', '2012', '胃肠病学，2012，17（12）：763-781.', '中文', '1.疾病活动性的严重程度：<br />&nbsp;&nbsp;1.1活动期：轻度；中度；重度。<br />&nbsp;&nbsp;1.2缓解期。<br />&nbsp;&nbsp;2.临床类型：初发型；慢性复发型。<br />&nbsp;&nbsp;3.病变范围：E1；E2；E3。', '溃疡性结肠炎（ulcerative colitis，UC）', null, null, '1.诊断标准<br />&nbsp;&nbsp;UC 缺乏诊断的金标准，主要结合临床、内镜和组织病理学表现进行综合分析，在排除感染性和其他非感染性结肠炎的基础上作出诊断。<br />&nbsp;&nbsp;1.1临床表现<br />&nbsp;&nbsp;UC 最常发生于青壮年期，根据我国资料统计，发病高峰年龄为20-49岁，男女性别差异不明显（男: 女比约为1.0：1—1.3：1）。临床表现为持续或反复发作的腹泻、黏液脓血便伴腹痛、里急后重和不同程度的全身症状，病程多在4-6周以上。可有皮肤、黏膜、关节、眼、肝胆等肠外表现。<br />&nbsp;&nbsp;黏液脓血便是UC最常见的症状。超过6周的腹泻病程可与多数感染性肠炎鉴别。<br />&nbsp;&nbsp;1.2结肠镜检查<br />&nbsp;&nbsp;结肠镜检查并活检是UC 诊断的主要依据。结肠镜下UC 病变多从直肠开始，呈连续性、弥漫性分布，表现为: ①黏膜血管纹理模糊、紊乱或消失、充血、水肿、质脆、自发性或接触性出血和脓性分泌物附着，亦常见黏膜粗糙、呈细颗粒状; ②病变明显处可见弥漫性、多发性糜烂或溃疡; ③可见结肠袋变浅、变钝或消失以及假息肉、黏膜桥等。<br />&nbsp;&nbsp;内镜下黏膜染色技术能提高内镜对黏膜病变的识别能力，结合放大内镜技术通过对黏膜微细结构的观察和病变特征的判别，有助UC 诊断，有条件的单位可开展。<br />&nbsp;&nbsp;1.3黏膜活检组织学检查<br />&nbsp;&nbsp;建议多段、多点取材。组织学上可见以下主要改变。活动期:①固有膜内弥漫性、急性、慢性炎性细胞浸润，包括中性粒细胞、淋巴细胞、浆细胞、嗜酸性粒细胞等，尤其是上皮细胞间有中性粒细胞浸润和隐窝炎，乃至形成隐窝脓肿; ②隐窝结构改变: 隐窝大小、形态不规则，排列紊乱，杯状细胞减少等; ③可见黏膜表面糜烂、浅溃疡形成和肉芽组织增生。缓解期: ①黏膜糜烂或溃疡愈合;②固有膜内中性粒细胞浸润减少或消失，慢性炎性细胞浸润减少; ③隐窝结构改变:隐窝结构改变可加重，如隐窝减少、萎缩，可见Paneth细胞化生(结肠脾曲以远) 。<br />&nbsp;&nbsp;UC 活检标本的病理诊断: 活检病变符合上述活动期或缓解期改变，结合临床，可报告符合UC 病理改变。宜注明为活动期或缓解期。如有隐窝上皮异型增生(上皮内瘤变) 或癌变，应予注明。<br />&nbsp;&nbsp;1.4其他检查<br />&nbsp;&nbsp;结肠镜检查可以取代钡剂灌肠检查。无条件行结肠镜检查的单位可行钡剂灌肠检查。检查所见的主要改变为: ①黏膜粗乱和(或)颗粒样改变;②肠管边缘呈锯齿状或毛刺样改变，肠壁有多发性小充盈缺损; ③肠管短缩，袋囊消失呈铅管样。<br />&nbsp;&nbsp;结肠镜检查遇肠腔狭窄镜端无法通过时，可应用钡剂灌肠检查、CT 或MRI 结肠显像显示结肠镜检查未及部位。<br />&nbsp;&nbsp;1.5手术切除标本病理检查<br />&nbsp;&nbsp;大体和组织学改变见上述UC 的特点。<br />&nbsp;&nbsp;诊断要点在排除其他疾病(详见“三、鉴别诊断”部分)基础上，可按下列要点诊断: ①具有上述典型临床表现者为临床疑诊，安排进一步检查; ②同时具备上述结肠镜和(或)放射影像学特征者，可临床拟诊; ③如再具备上述黏膜活检和(或)手术切除标本组织病理学特征者，可以确诊; ④初发病例如临床表现、结肠镜以及活检组织学改变不典型者，暂不确诊UC，应予随访。<br />&nbsp;&nbsp;2.疾病评估<br />&nbsp;&nbsp;UC 诊断成立后，需进行疾病评估，以利于全面估计病情和预后，制定治疗方案。<br />&nbsp;&nbsp;2.1临床类型: 可简单分为初发型和慢性复发型。初发型指无既往病史而首次发作，该类型在鉴别诊断中应予特别注意，亦涉及缓解后如何进行维持治疗的考虑。慢性复发型指临床缓解期再次出现症状，临床上最常见。以往所称之暴发型结肠炎( fulminant colitis) ，因概念不统一而易造成认识的混乱，本共识建议弃用，将其归入重度UC 中。<br />&nbsp;&nbsp;2.2病变范围: 推荐采用蒙特利尔分型(见表M08_007_001)。该分型特别有助于癌变危险性的估计和监测策略的制定，亦有助于治疗方案的选择。<br />&nbsp;&nbsp;2.3疾病活动性的严重程度: UC病情分为活动期和缓解期，活动期疾病按严重程度分为轻、中、重度。改良Truelove和Witts疾病严重程度分型标准(见表M08_007_002) 易于掌握，临床上实用。改良Mayo评分更多用于临床研究的疗效评估(见表M08_007_003)。<br />&nbsp;&nbsp;2.4肠外表现和并发症:①肠外表现: 包括皮肤黏膜表现(如口腔溃疡、结节性红斑和坏疽性脓皮病) 、关节损害(如外周关节炎、脊柱关节炎等) 、眼部病变(如虹膜炎、巩膜炎、葡萄膜炎等) 、肝胆疾病(如脂肪肝、原发性硬化性胆管炎、胆石症等)、血栓栓塞性疾病等。②并发症: 包括中毒性巨结肠、肠穿孔、下消化道大出血、上皮内瘤变以及癌变。<br />&nbsp;&nbsp;3.鉴别诊断<br />&nbsp;&nbsp;3.1 急性感染性肠炎: 各种细菌感染，如志贺菌、空肠弯曲杆菌、沙门菌、产气单胞菌、大肠杆菌、耶尔森菌等。常有流行病学特点(如不洁食物史或疫区接触史) ，急性起病常伴发热和腹痛，具有自限性(病程一般数天至1 周，不超过6 周) ; 抗菌药物治疗有效; 粪便检出病原体可确诊。<br />&nbsp;&nbsp;3.2阿米巴肠病: 有流行病学特征，果酱样大便，结肠镜下见溃疡较深、边缘潜行，间以外观正常的黏膜，确诊有赖于粪便或组织中找到病原体，非流行区患者血清阿米巴抗体阳性有助诊断。高度疑诊病例抗阿米巴治疗有效。<br />&nbsp;&nbsp;3.3 肠道血吸虫病: 有疫水接触史，常有肝脾肿大。确诊有赖粪便检查见血吸虫卵或孵化毛蚴阳性。急性期结肠镜下可见直肠、乙状结肠黏膜黄褐色颗粒，活检黏膜压片或组织病理学检查见血吸虫卵。免疫学检查有助鉴别。<br />&nbsp;&nbsp;3.4其他: 肠结核、真菌性肠炎、抗菌药物相关性肠炎(包括假膜性肠炎)、缺血性结肠炎、放射性肠炎、嗜酸粒细胞性肠炎、过敏性紫癜、胶原性结肠炎、白塞病、结肠息肉病、结肠憩室炎以及人类免疫缺陷病毒( HIV) 感染合并的结肠病变应与本病鉴别。还需注意，结肠镜检查发现的直肠轻度炎症改变，如不符合UC 的其他诊断要点，常为非特异性，应认真寻找病因，观察病情变化。<br />&nbsp;&nbsp;3.5 UC 合并艰难梭菌或巨细胞病毒( CMV) 感染:重度UC 或在免疫抑制剂维持治疗病情处于缓解期患者出现难以解释的症状恶化时，应考虑到合并艰难梭菌或CMV感染的可能。确诊艰难梭菌感染可行粪便艰难梭菌毒素试验(酶联免疫测定ToxinA/B)。<br />&nbsp;&nbsp;确诊CMV 感染可行结肠镜下活检HE染色找巨细胞包涵体以及免疫组化染色和血CMV-DNA 定量。<br />&nbsp;&nbsp;3.6 UC与CD鉴别: 详见CD 鉴别诊断部分。<br />&nbsp;&nbsp;4.诊断步骤<br />&nbsp;&nbsp;4.1病史和体检: 详细的病史询问应包括从首发症状开始的各项细节，特别注意腹泻和便血的病程; 近期旅游史、用药史［特别是非甾体消炎药( NSAIDs) 和抗菌药物］、阑尾手术切除史、吸烟、家族史; 口、皮肤、关节、眼等肠外表现和肛周情况。体检应特别注意患者一般状况和营养状态，并进行细致的腹部、肛周、会阴检查和直肠指检。<br />&nbsp;&nbsp;4.2 常规实验室检查: 强调粪便常规检查和培养不少于3 次。根据流行病学特点，进行排除阿米巴肠病、血吸虫病等的相关检查。常规检查包括血常规、血清白蛋白、电解质、ESR、CRP 等。有条件的单位可行粪便钙卫蛋白和血清乳铁蛋白等检查作为辅助指标。<br />&nbsp;&nbsp;4.3结肠镜检查(应进入末端回肠) 并活检: 是建立诊断的关键。结肠镜检查遇肠腔狭窄镜端无法通过时，可应用钡剂灌肠检查、CT或MRI 结肠显像显示结肠镜检查未及部位。<br />&nbsp;&nbsp;4.4 下列情况考虑行小肠检查: 病变不累及直肠(未经药物治疗者)、倒灌性回肠炎(盲肠至回肠末端的连续性炎症) 以及其他难以与CD鉴别的情况。小肠检查方法详见CD诊断部分。左半结肠炎伴阑尾开口炎症改变或盲肠红斑改变在UC 常见，因此一般无需进一步行小肠检查。<br />&nbsp;&nbsp;4.5 重度活动期患者检查的特殊性: 以常规腹部X 线平片了解结肠情况。缓行全结肠检查，以策安全。但为诊断和鉴别诊断，可行不做常规肠道准备的直肠、乙状结肠有限检查和活检，操作应轻柔，少注气。为了解有无合并艰难梭菌和(或) CMV 感染，行有关检查。', null, '临床症状；结肠镜检查', '结合临床症状和内镜检查作为疗效判断标准。<br />&nbsp;&nbsp;1.缓解的定义<br />&nbsp;&nbsp;完全缓解是指完全无症状(排便次数正常且无血便和里急后重)伴内镜复查见黏膜愈合(肠黏膜正常或无活动性炎症)。关于UC患者黏膜愈合的定义，目前尚未达成共识。<br />&nbsp;&nbsp;2.疗效评定<br />&nbsp;&nbsp;2.1临床疗效评定: 适用于临床工作，但因无量化标准，不适用于科研。①缓解: 临床症状消失，结肠镜复查见黏膜大致正常或无活动性炎症。②有效: 临床症状基本消失，结肠镜复查见黏膜轻度炎症。③无效: 临床症状、结肠镜复查均无改善。<br />&nbsp;&nbsp;2.2改良Mayo评分(见表M08_007_003) : 适用于科研，亦可用于临床。<br />&nbsp;&nbsp;3.复发的定义<br />&nbsp;&nbsp;自然或经药物治疗进入缓解期后，UC 症状再发，最常见的是便血，腹泻亦多见。可通过结肠镜检查证实。临床研究应选取某一评分系统进行定义。<br />&nbsp;&nbsp;3.1复发的类型: 复发可分为偶发(≤1次/年) 、频发(≥2次/年) 和持续型(UC症状持续活动，不能缓解) 。<br />&nbsp;&nbsp;3.2早期复发: 经先前治疗进入缓解期的时间＜3个月。<br />&nbsp;&nbsp;4.与糖皮质激素(后文简称激素)治疗相关的特定疗效评价<br />&nbsp;&nbsp;4.1激素无效: 经相当于泼尼松0.75mg•kg－1•d－1治疗超过4 周，疾病仍处于活动期。<br />&nbsp;&nbsp;4.2激素依赖: ①虽能维持缓解，但激素治疗3个月后，泼尼松仍不能减量至10 mg /d; ②在停用激素3 个月内复发。', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('59', '36', 'S01_001', '1', 'ZYYXH/T 97-2008慢性肾小球肾炎', null, '中华中医药学会 ', '2008', '中华中医药学会.ZYYXH/T 97-2008慢性肾小球肾炎[S]', '中文', null, '慢性肾小球肾炎', null, '1.实证：脾肾气虚证、肺肾气虚证、脾肾阳虚证、肝肾阴虚证、气阴两虚证。<br />&nbsp;&nbsp;\n2.标证：水湿证、湿热证、血瘀证、湿浊证。<br />&nbsp;&nbsp;\n', '1临床表现<br />&nbsp;&nbsp;1.1症状<br />&nbsp;&nbsp;水肿：在慢性肾炎的整个疾病过程中,多数患者有不同程度的水肿,轻者仅见于面部、眼睑等组织疏松部位,晨起比较明显,进而发展至足躁、下肢重者全身水肿,并可有腹胸水。<br />&nbsp;&nbsp;高血压：部分患者以高血压为首发症状,高血压的程度差异较大,轻者仅140~160/95~100mmHg,重者达到或超过200/110mmHg。持续高血压容易导致心功能受损、加速肾功能恶化,其程度与预后关系密切。高血压在临床上常表现为头胀,头痛,眩晕,眼花,耳鸣,失眠多梦,记忆力减退等症状。<br />&nbsp;&nbsp;尿异常改变：是慢性肾炎的基本标志。水肿期间尿量减少,无水肿者,尿量接近正常常有夜尿及低比重尿,尿比重(禁水1~2小时)不超过1.020;至尿毒症期即可出现少尿(<400ml/d)或无尿(<100ml/d);有不同程度的尿蛋白,一般在1~3d/d,也可呈大量蛋白尿(>3.5g/d);蛋白尿多呈非选择性;尿沉渣可见颗粒管型和透明管型;不同程度的血尿,在急性发作期可出现镜下血尿甚至肉眼血尿。<br />&nbsp;&nbsp;贫血：患者呈现中度以上贫血,表明肾单位损坏及肾功能损害已很严重,发展到终末期出现严重贫血。如果患者无明显营养不良,其贫血多属正细胞、正色素型。患者可有头晕,乏力,心悸,面色苍白,唇甲色淡等症状体征。<br />&nbsp;&nbsp;肾功能不全：主要表现为肾小球滤过率（GFR）下降,肌酐清除率（Ccr）降低。轻中度肾功能受损患者可无任何临床症状,当Ccr低于10ml/min,临床上可见少尿或者无尿,恶心呕吐,纳呆,乏力,嗜睡,皮肤瘙痒等症。<br />&nbsp;&nbsp;1.2体征患者具有贫血貌,唇甲苍白,眼睑及颜面甚至双下肢浮肿,严重者可有胸水、腹水。<br />&nbsp;&nbsp;2.理化检查<br />&nbsp;&nbsp;2.1实验室检查<br />&nbsp;&nbsp;尿液检查：尿常规检查有尿蛋白,镜下血尿及或管型尿尿比重降低,圆盘电泳为中分子型蛋白尿为主,红细胞形态为变畸形红细胞。<br />&nbsp;&nbsp;血常规检查：轻度贫血常见,肾功能衰竭时出现较严重贫血。<br />&nbsp;&nbsp;肾功能测定：肾功能不同程度受损,血尿素氮、血肌配升高,内生配清除率下降,浓缩稀释功能异常。<br />&nbsp;&nbsp;2.2影像学检查<br />&nbsp;&nbsp;B超：双肾可缩小,双肾实质病变。<br />&nbsp;&nbsp;肾活检病理检查：诊断不明确时,可行肾活检确诊。<br />&nbsp;&nbsp;3.诊断要点<br />&nbsp;&nbsp;3.1 起病缓慢,病情迁延,时轻时重,肾功能逐步减退,后期出现贫血、电解质紊乱,血尿素氮、血肌配升高等。<br />&nbsp;&nbsp;3.2 有不同程度的水肿、蛋白尿、血尿、管型尿、贫血及高血压等表现。<br />&nbsp;&nbsp;3.3 病程中可因呼吸道感染等原因诱发急性发作, 出现类似急性肾炎的表现。<br />&nbsp;&nbsp;\n3分级标准<br />&nbsp;&nbsp;病情的轻重主要从尿蛋白、肾功能、水肿、高血压、血瘀证等方面判断。凡具备下列任何项即可确定。<br />&nbsp;&nbsp;3.1.重度<br />&nbsp;&nbsp;尿蛋白检查持续（+++）~（++++）,或24小时尿蛋白定量在2.1~3.5g之间,血清白蛋白低于30g/L。<br />&nbsp;&nbsp;肾功能不正常(血肌酐≥133~442μmol)。<br />&nbsp;&nbsp;明显浮肿及高血压。<br />&nbsp;&nbsp;有明显血瘀证表现①面色黧黑或晦暗②腰痛固定或呈刺痛,肌肤甲错或肢体麻木③舌色紫暗或有瘀点、瘀斑④脉象细涩⑤尿纤维蛋白降解产物含量增高⑥血液流变学检测全血黏度、血浆黏度升高。凡具备上述项表现者即可确定血瘀证。<br />&nbsp;&nbsp;3.2.中度<br />&nbsp;&nbsp;尿蛋白检查持续（++）~（+++）,或24小时尿蛋白定量持续在1~2g之间,肾功能正常。<br />&nbsp;&nbsp;浮肿可轻可重,可有高血压。<br />&nbsp;&nbsp;有血瘀证的临床表现。凡具备上述项血瘀证表现者即可确定。<br />&nbsp;&nbsp;3.3.轻度<br />&nbsp;&nbsp;尿蛋白持续（+）~（++）,或24小时尿蛋白定量持续在1g以下,肾功能正常。<br />&nbsp;&nbsp;浮肿不明显或无,血压正常。<br />&nbsp;&nbsp;有或无血瘀证的临床表现。<br />&nbsp;&nbsp;\n', '1.实证<br />&nbsp;&nbsp;1.1脾肾气虚证<br />&nbsp;&nbsp;证候：腰脊酸痛,疲倦乏力,或浮肿,纳少或脱腹胀满,大便塘薄,尿频或夜尿多,舌质淡红、有齿痕,苔薄白,脉细。<br />&nbsp;&nbsp;1.2肺肾气虚证<br />&nbsp;&nbsp;证候：颜面浮肿或肢体肿胀,疲倦乏力,少气懒言,易感冒,腰脊酸痛,面色萎黄,舌淡、苔白润,有齿痕,脉细弱。<br />&nbsp;&nbsp;1.3脾肾阳虚证<br />&nbsp;&nbsp;证候：全身浮肿,面色苍白,畏寒肢冷,腰脊冷痛或酸痛,纳少或便塘或泄泻或五更泄泻,胫酸腿软,食少纳呆,精神倦怠,足跟作痛,大便溏薄,舌质淡胖,边有齿痕,脉沉偏细或沉迟无力。<br />&nbsp;&nbsp;1.4肝肾阴虚证<br />&nbsp;&nbsp;证候：目睛干涩或视物模糊,头晕耳鸣,五心烦热,或手足心热,口干咽燥,腰脊酸痛,遗精,滑精,或月经失调,舌红少苔,脉弦细或细数。<br />&nbsp;&nbsp;1.5气阴两虚证<br />&nbsp;&nbsp;证候：面色无华,少气乏力,或易感冒,午后低热,手足心热,腰痛或浮肿,口干咽燥或咽部暗红,咽痛,舌质红或偏红,少苔,脉细或弱。<br />&nbsp;&nbsp;2标证<br />&nbsp;&nbsp;2.1水湿证<br />&nbsp;&nbsp;证候：颜面或肢体浮肿,口淡乏味,胸痞腹胀,小便不利,舌苔白或白腻,脉细或沉细。<br />&nbsp;&nbsp;2.2湿热证<br />&nbsp;&nbsp;证候：皮肤疖肿、疮疡,咽喉肿痛,小便黄赤、灼热或涩痛不利,面目或肢体浮肿,口苦或口干口黏,胸闷纳呆,口干喜热饮,舌苔黄腻,脉濡数或滑数。<br />&nbsp;&nbsp;2.3血瘀证<br />&nbsp;&nbsp;证候：面色黧黑或晦暗,腰痛固定或呈刺痛,肌肤甲错或肢体麻木,舌色紫暗或有瘀点瘀斑,脉细涩。<br />&nbsp;&nbsp;2.4湿浊证<br />&nbsp;&nbsp;证候：纳呆,恶心或呕吐,口中黏腻,脘胀或腹胀,身重困倦,精神萎靡,舌苔腻,脉缓。<br />&nbsp;&nbsp;', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('590', '45', 'Z02_018', '1', '短暂性脑缺血发作诊断标准（自拟）', null, '中华医学会第二次全国脑血管学术会议第三次修订', '1986', '常见疾病的诊断与疗效判断标准', '中文', null, '短暂性脑缺血发作', null, null, '1.为短暂的、可逆的、局部的脑血液循环障碍，可反复发作，少者1-2次，多至数10次，多与动脉粥样硬化有关，也可以是脑梗塞的前驱发作。2.可表现为颈内动脉系统和/或椎基底动脉系统的症状和体征。3.每次发作持续时间通常在数分钟至1h左右，症状和体征应该在24h内完全消失。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('591', '45', 'Z02_019', '1', '短暂性脑缺血发作诊断标准（自拟）', null, '美国卒中对策协作委员会（JCSF）', '1975', '常见疾病的诊断与疗效判断标准http://med.39.net/cds/jbzd/8-114-28526.shtml', '中文', null, '短暂性脑缺血发作', null, null, '各种原因引起发作性短暂的脑血流减低，出现一过性（24h内）消失的脑缺血局部症状，称一过性脑缺血发作。1.颈内动脉系统症状：运动障碍（单肢或同侧上、下肢）感觉障碍（单肢或同侧上、下肢）失语（自轻度至高度不等，也可伴读书及写字障碍）一过性单眼失明。同向偏盲。上述五项的组合。2.椎基底动脉系统症状：运动障碍（（单肢或同侧上、下肢，对侧肢、四肢。有时在几次发作中，可由一侧转至另一侧。））感觉障碍（单肢或同侧上、下肢，对侧肢、四肢感觉钝木或消失，有时在几次发作中，可由一侧转至另一侧。）同向偏盲。1/4偏盲。不伴眩晕的共济失调，平衡障碍。上述1-+4并有眩晕，复视，吞咽困难、构音障碍。3.需要注意的症状，（不能单独成立诊断）（1）单独眩晕（2）单独构音障碍（3）单独吞咽困难（4）单独复视（5）意识障碍或眩晕发作（6）强直-阵挛性痉挛（7）进行扩展性的运动，感觉障碍（8）大小便失禁（9）意识障碍伴视力障碍（10）伴有局灶症状的偏头痛（11）闪光暗点（）（12）单独精神错乱（13）单独健忘（14）单独头晕感，伴或不伴恶心呕吐等其他症状。（15）单独雾视4.其他（1）椎基底动脉一过性脑缺血发作，有时可表现为一侧性运动，感觉或视力障碍，因此不能仅凭一侧性局灶症状否定椎基底动脉病变而肯定为颈内动脉病变（2）本病约1/4有头痛症状，一般颈内动脉在额部，椎基底动脉在顶枕部比较多（3）倾倒发作，是椎基底动脉病变的主要症状之一，但须与多见于中年妇女的隐源性猝倒发作区别。（4）锁骨下动脉-盗血综合征可引起同侧椎动脉血流逆行，出现脑干一过性缺血发作。', null, null, '治愈：临床症状和神经系统体征消失，短期内不再发作。', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('592', '45', 'Z02_013', '1', '短暂性脑缺血发作与轻型卒中抗血小板治疗中国专家共识', ' ', ' \n短暂性脑缺血发作中国专家共识组', '2014', '中华医学杂志.2014,94(27):2092-2096.', '中文', null, '短暂性脑缺血发作 ( TIA) ；急性缺血性轻型卒中', null, null, ' ( 1) TIA 和轻型卒中是最为重要的脑血管病急症， 越早期卒中复发风险越高， 应该引起高度重视 (Ⅰ类、C 级证据) 。( 2) 推荐使用 ABCD2 等卒中危险分层工具，尽快识别 TIA 或轻型卒中高危患者， 尽早启动如血管评价、抗栓、稳定斑块和血压管理等综合干预措施 ( Ⅰ类、C 级证据) 。', null, null, ' ', '首都医科大学附属北京天坛医院王拥军教授、赵性泉教授、暨南大学附属华侨医院徐安定教授、香港中文大学威尔士亲王医院黄家星教授、美国伊利诺伊大学医学院伊利诺伊神经研究所卒中中心David Wan教授等国内外著名脑血管病专家组成的“短暂性脑缺血发作中国专家共识组”制定了《短暂性脑缺血发作与轻型卒中抗血小板治疗中国专家共识（2014年）》 ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('593', '45', 'Z02_039', '1', ' AHA/ASA 早期急性缺血性中风患者的管理', 'Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.', 'the American Heart Association/American\nStroke Association', '2013', 'Jauch E C, Saver J L, Adams H P, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.[J]. Stroke, 2013, 44(3):870-947.', '英文', null, 'acute ischemic stroke急性缺血性中风', null, null, 'Diagnostic Testing During the Acute Phase<br />&nbsp;&nbsp;Overview of Neuroimaging in StrokeDiagnostic imaging techniques include CT, MRI, magneticresonance angiography, CT angiography, conventional angiography, and carotid and transcranial ultrasound of thecervical and cephalic arteries.13 Imaging of extracranial andintracranial cerebral blood vessels may be essential forunderstanding the mechanism of AIS. The presence of ahigh-grade stenosis, occlusion, dissection, or vascular anomaly indicates the events that led to the stroke. The nurse willneed to educate the patient and family regarding each test andwhat to expect.<br />&nbsp;&nbsp;Computed Tomography<br />&nbsp;&nbsp;Imaging in the hyperacute phase was discussed above. Arepeat CT or MRI brain scan should be done 24 hours afterthe initial stroke event in patients treated with thrombolysis orin any situation in which the patient is clinically deterioratingto assess hemorrhagic transformation and infarct progression.The CT scan is still considered the gold standard in AIS treatment, although recent technology has led to more sophisticated multimodal approaches in stroke imaging with CTevaluation. CT perfusion and CT angiography provide a mapof cerebral blood volume, cerebral blood flow, and meantransit time. These studies identify the ischemic core andpneumbra regions that can guide the decision for furtherinterventional treatment.<br />&nbsp;&nbsp;Magnetic Resonance Imaging<br />&nbsp;&nbsp;MRI demonstrates evidence of ischemic injury to the brainearlier than CT for all ischemic stroke subtypes. Magneticresonance angiography is a useful noninvasive procedure forevaluating extracranial and intracranial vessels. Newer multimodal techniques (eg, diffusion-weighted imaging andperfusion-weighted imaging) have further increased the sensitivity of MRI. The advantage of diffusion-weighted imagingis early identification of the ischemic area within minutesof onset of acute stroke. Perfusion-weighted imagingindicates the hemodynamic status of cerebral blood flow.A diffusion-perfusion mismatch shows an ischemic penumbra change in perfusion without a diffusion abnormality. This is an opportunity to identify irreversible versusreversible cerebral tissue. If there is no mismatch, the hopeof salvageable tissue is less. Treatment modalities and timeto treatment may change as more is learned about theischemic penumbra.13,206 –208<br />&nbsp;&nbsp;Ultrasonography<br />&nbsp;&nbsp;Carotid duplex scanning is the standard ultrasound testinitially used to screen for cervical internal carotid stenosis.Demonstration of stenosis 60% is highly accurate; however, differentiation between severe (95% to 99%) stenosisand 100% occlusion is not completely reliable. <br />&nbsp;&nbsp;Cerebral Angiography<br />&nbsp;&nbsp;Cerebral angiography is the best tool to accurately evaluatethe surface characteristics of a stenosed artery and is considered the “gold standard” for measuring the degree of stenosisof a cervical or cephalic artery. After the procedure, the nursewill perform frequent measurement of vital signs, neurological assessment, femoral and pedal pulse checks, and groinchecks. The radiologist should be notified if a groin hematoma or change in velocity of the pedal pulse develops.Postprocedure activity is restricted according to the closuredevice used and the patient’s status.<br />&nbsp;&nbsp;Transesophageal and Transthoracic Echocardiography<br />&nbsp;&nbsp;All patients with ischemic stroke or transient ischemic attackshould undergo a comprehensive assessment of cardiovascular risk to identify those with the highest likelihood ofmorbidity and mortality due to unrecognized coronary heartdisease or the presence of a cardioembolic source ofstroke.13,209,210 Transthoracic echocardiography is excellentfor identifying ventricular sources, such as a dyskineticventricular wall segment, whereas transesophageal echocardiography excels at identifying atrial and aortic sources, suchas patent foramen ovale or aortic arch atherosclerosis. Atransesophageal echocardiogram is sensitive for detectingapical thrombi and atrial septal defects or patent foramenovale Transthoracic echocardiography is the less invasive of the2 procedures and is the most commonly ordered initial test toevaluate for a cardioembolic source of stroke. During atransesophageal echocardiogram, the nurse must monitor thepatient closely and position the patient to decrease risk ofaspiration if nausea or vomiting occurs.210,211<br />&nbsp;&nbsp;Chest Radiograph<br />&nbsp;&nbsp;A chest radiograph is no longer routinely recommendedduring the ED evaluation of stroke unless an underlyingpulmonary or cardiac problem is suspected. Obtaining a chestradiograph may take valuable time that is needed to administer rtPA within the 3-hour window. Therefore, a chestradiograph is not a high priority in the ED but is done duringthe acute phase of hospitalization.', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('594', '45', 'Z02_064', '1', '南非缺血性中风和短暂性缺血性发作管理2010', 'South African guideline for management of ischaemic stroke and transient ischaemic attack 2010', 'the South African Stroke Society\n(SASS) and the SASS Writing Committee', '2010', 'http://www.sastrokesociety.org.za/', '英文', null, 'ischaemic stroke and transient ischaemic attack', null, null, 'Pre-hospital diagnosis of stroke •<br />&nbsp;&nbsp; Inaccurate initial diagnosis by professional groups represents a major problem.11,12 •<br />&nbsp;&nbsp; EMS should have validated algorithm of questions to diagnose stroke during the phone interview. •<br />&nbsp;&nbsp; There should be in-house training of all paramedics, particularly pertaining to diagnosis and pre-hospital care of stroke patients. •<br />&nbsp;&nbsp; Paramedics should be able to recognise symptoms and signs of stroke and diagnose stroke using simple instruments such as the Face-Arm-Speech-Test.1<br />&nbsp;&nbsp;8.3 Diagnostic tests Several tests should be done routinely on patients with suspected ischaemic stroke to identify conditions that may cause or mimic stroke or that may influence therapeutic options. 8.3.1 All patients •<br />&nbsp;&nbsp; blood glucose •<br />&nbsp;&nbsp; full blood count •<br />&nbsp;&nbsp; urea, creatinine, electrolytes •<br />&nbsp;&nbsp; ESR or CRP •<br />&nbsp;&nbsp; ECG •<br />&nbsp;&nbsp; chest X-ray •<br />&nbsp;&nbsp; oxygen saturation. 8.3.2 Investigations that may be required on selected patients •<br />&nbsp;&nbsp; INR if patient suspected or known to be on warfarin •<br />&nbsp;&nbsp; fasting serum lipids •<br />&nbsp;&nbsp; serological test for syphilis (RPR or VDRL) •<br />&nbsp;&nbsp; lumbar puncture •<br />&nbsp;&nbsp; echocardiogram: transthoracic or transoesophageal •<br />&nbsp;&nbsp; 24-hour cardiac Holter •<br />&nbsp;&nbsp; full hypercoagulation screen •<br />&nbsp;&nbsp; anticardiolipin antibody (both IgG and IgM), thrombophilia screen •<br />&nbsp;&nbsp; collagen screen •<br />&nbsp;&nbsp; hepatic function tests •<br />&nbsp;&nbsp; toxicology screen •<br />&nbsp;&nbsp; MRI/MRA scan (diffusion and perfusion sequences), MR venogram •<br />&nbsp;&nbsp; CT angiogram •<br />&nbsp;&nbsp; cerebral angiography •<br />&nbsp;&nbsp; carotid duplex Doppler ultrasonography of neck<br />&nbsp;&nbsp;8.3.3 Brain imaging •<br />&nbsp;&nbsp; Brain imaging distinguishes ischaemic stroke from intracranial haemorrhage (haemorrhage v. infarct cannot be reliably predicted on clinical grounds, and management differs) and identifies other stroke mimics (e.g. neoplasm). •<br />&nbsp;&nbsp; Non-contrast CT scan of the brain distinguishes reliably between haemorrhagic and ischaemic stroke and is the most cost-effective strategy for imaging acute stroke patients.4 Non-haemorrhagic infarcts (ischaemic strokes) may not be apparent on CT scan within the first 6 hours of onset. •<br />&nbsp;&nbsp; Ideally, all stroke patients should have CT brain scan to accurately determine accurately the type of stroke and the anatomy of the stroke (an important clue to aetiology). In reality, this not always feasible because of logistical reasons and resource constraints in many parts of the country. However, under certain circumstances, patients may well be required to be referred to another centre for an urgent CT or MRI scan of the brain (see 5.3.2 for indications for urgent CT scan). •<br />&nbsp;&nbsp; Diagnostic brain imaging must be performed immediately on arrival at the hospital for stroke patients who are potential candidates for thrombolysis, to facilitate prompt treatment. •<br />&nbsp;&nbsp; The brain imaging study (CT or MRI) should be interpreted by a physician with expertise in reading CT or MRI studies of the brain. Some centres prefer to use MRI scan as first-line routine investigation for acute stroke. •<br />&nbsp;&nbsp; Diffusion-weighted MRI (DWI) is more sensitive than CT for detection of early ischaemic changes, and is particularly useful in the diagnosis of posterior circulation stroke and lacunar or small cortical infarctions. A DWI MRI can be negative in patients with definite stroke.5 •<br />&nbsp;&nbsp; MRI can also detect small and old haemorrhages for a prolonged period with T2 gradient echo sequences.6 •<br />&nbsp;&nbsp; MRI is particularly useful in acute stroke patients with unusual presentations and uncommon aetiologies, or in whom a stroke mimic is suspected but not clarified on CT. •<br />&nbsp;&nbsp; MRI is less suited for agitated patients or for those who may vomit and aspirate. •<br />&nbsp;&nbsp; Vascular imaging may identify the site and cause of arterial obstruction, and identifies patients at high risk of stroke recurrence. •<br />&nbsp;&nbsp; Vascular imaging may be necessary to identify patients with tight symptomatic arterial stenosis who could benefit from carotid endarterectomy or, in highly selected individuals, cerebral artery angioplasty. •<br />&nbsp;&nbsp; Non-invasive imaging with colour-coded duplex imaging of the extracranial arteries, CT angiography (CTA) or contrastenhanced MR angiography (CE-MRA) should be available at level 3 hospitals. •<br />&nbsp;&nbsp; Carotid Doppler studies are an important tool in evaluating patients with ischaemic stroke, and should be available at level 2 and level 3 hospitals. •<br />&nbsp;&nbsp; Non-invasive approaches to visualising the vasculature are associated with less risk than intra-arterial angiography, which has a 1 - 3% risk of causing stroke in patients with symptomatic carotid lesions.7 •<br />&nbsp;&nbsp; Digital subtraction angiography (DSA) may be needed in some circumstances, e.g. when other tests have been inconclusive. •<br />&nbsp;&nbsp; Transcranial Doppler ultrasound (TCD) is not routine and is currently available at only a few centres in South Africa. •<br />&nbsp;&nbsp; TCD may be useful for the diagnosis of abnormalities in the large cerebral arteries at the base of the skull, and can be used to identify right-to-left cardiac shunts.<br />&nbsp;&nbsp;', null, null, 'Patients with markedly elevated BP above these levels may have their BP lowered; a reasonable goal would be to lower the BP by 15% in the first 24 hours after stroke. • Avoid drastic rapid reduction in BP. • Upper level of systolic BP in patients undergoing thrombolytic therapy is 180 mmHg. • Avoid and treat hypotension.', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('595', '45', 'Z02_040', '1', '急性缺血性卒中血管内治疗中国指南2015', null, '\n中国卒中学会(CSA,Chinese Stroke Association)\n中国卒中学会神经介入分会\n中华预防医学会卒中预防与控制专业委员会介入学组', '2015', '中国卒中杂志.2015,10(7):590-606.', '中文', null, '急性缺血性卒中', null, null, null, null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('596', '45', 'Z02_041', '1', '诊断和初始管理的急性中风和短暂性缺血性发作(TIA)', 'Stroke. Diagnosis and initial management of acute stroke and transient ischaemic attack (TIA)', 'National Institute for Health and Clinical Excellence (NICE)', '2008', 'http://www.guideline.gov/content.aspx?id=14328&search=stroke\nNational Collaborating Centre for Chronic Conditions. Stroke. Diagnosis and initial management of acute stroke and transient ischaemic attack (TIA). London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 Jul. 37 p. (Clinical guideline; no. 68). ', '英文', null, 'acute stroke； transient ischaemic attack急性中风；短暂脑缺血发作', null, null, '1.Prompt recognition of symptoms of stroke and transient ischemic attack (TIA) using validated tools such as FAST (Face Arm Speech Test) or ROSIER (Recognition of Stroke in the Emergency Room)<br />&nbsp;&nbsp;2.Assessment of people with suspected TIA for risk of subsequent stroke using a validated scoring system such as ABCD2<br />&nbsp;&nbsp;3.Brain imaging (diffusion-weighted magnetic resonance imaging or computed tomography) <br />&nbsp;&nbsp;4.Carotid imaging<br />&nbsp;&nbsp;<br />&nbsp;&nbsp;5.Specialist assessment and investigation within 24 hours of symptom onset', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('597', '45', 'Z02_042', '1', '缺血性中风的诊断和初始治疗', 'Diagnosis and initial treatment of ischemic stroke.', null, '2012', 'Anderson D, Larson D, Bluhm J, Charipar R, Fiscus L, Hanson M, Larson J, Rabinstein A, Wallace G, Zinkel A. Diagnosis and initial treatment of ischemic stroke. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2012 Jul. 122 p. [238 references]', '英文', null, 'Ischemic stroke缺血性中风；Transient ischemic attack (TIA)短暂脑缺血发作', null, null, 'prothrombin time/international normalized ratio [INR], activated partial thromboplastin time [aPTT], hemoglobin A1c, fasting lipid profile, troponin, aspartate aminotransferase [AST], urine or serum pregnancy testing), electrocardiogram, echocardiogram, brain and vascular imaging (e.g., computed tomography [CT] of the head without contrast, CT angiography of head and neck, magnetic resonance imaging [MRI], diffusion-weighted MRI, magnetic resonance angiography [MRA], CT or carotid ultrasound), cardiac monitoring<br />&nbsp;&nbsp;Other cardiac assessment (telemetry) as appropriate<br />&nbsp;&nbsp;Considering if intra-arterial recanalization is appropriate<br />&nbsp;&nbsp;', null, null, null, 'ICSI scientific documents are revised every 12 to 36 months as indicated by changes in clinical practice and literature. ICSI checks with every work group 6 months before the schedule revision to determine if there have been changes in the literature sign畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭೸੏ༀƙ\0੏Ð\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄祰௸੏Ð\0ᅸ௸彿㎽奋㎽巫㎽ꂼ௸레௸彿㎽럼௸塚㎽레௸ꍈ㏂\0\0祰௸學㎽漸㏂圔㎽祰௸圞㎽\0\0圭㎽𢡄霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0蕀ƞ䐺盭暼痭蕀ƞༀƙ \0蕀ƞÐ\0\0㺣盭蕀ƞ\0𢡄蕄ƞ\0팃目蕄ƞ࣒蕄ƞ큁目蕄ƞ禤௸泌\0Item\0\0뢌௸\0\0\0\0\0\0Count\0\0﫨呂蕴ƞ㳜੪\0\0蕄ƞ\0\0\0\0੪寶目㳠੪楱䥷㎽ꂼ௸\0\0뢌௸�㏂럼௸\0\0\0੪\0\0\0露𢡄\0\0㎾߬\0齃\0\0x�㏂럼௸\0\0隲W뢌௸\0\0�Ĳ\0\0\0鹿齃殺\0\0霈W戀醙霫W戀ꊠऺ齃x\0霪W露Wꊠऺ﫰xt\0Љ\0\0\0൐௲鲬࣒菮畻\0\0\0\0㰰੪Eo\0\0㲄੪\0\0⑰ਫ਼⑰ਫ਼密盡彪盡寶目㲈੪碤௸i\0\0變ﱘ﫰﬐먙㎼碤௸㲈੪i\0\0變ﱘ﫰먰㎼ﱘ碤௸�㏂研௸\0\0릎㎼碤௸i\0⓮췬目⓲췬目Љ\0镴࣒\0￿￿目Љ\0镨࣒൐௲竗൐௲目W\0竗\0\0\0目\0\0\0\0禤௸\0目瑉浥目\0\0\0\0禤௸\0目潃湵t\0\0\0̖\0\0ဠ\0\0̨賓̨̙\0\0\0\0\0\0\0̙\0\0\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0\0\0\0\0\0\0̙華뎥ဆ\0ē\0錠ƚ뢼ဆ돜်錠ƚ옎盡\0\0륿ရ╖췬╞췬目Љ\0鲸࣒\0￿￿目Љ\0鲬࣒൐௲觴൐௲目t\0觴\0\0\0梅礼目\0\0\0\0﫤碤௸目潅fo\0兜盡僶盡㉒췭\0\0\0\0\0捥盦锊묞￾￿僶盡쓷盡ؖ8\0\0\0̖o\0ꯍ�\0\0', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('598', '45', 'Z02_069', '1', '急性缺血性中风患者的早期管理', 'Guidelines for the Early Management of Patients With Acute Ischemic Stroke : AGuideline for Healthcare Professionals From the American Heart Association/AmericanStroke Association', null, '2013', null, '英文', null, 'Acute Ischemic Stroke', null, null, 'Diagnostic Tests<br />&nbsp;&nbsp;Several tests should be routinely emergently performed asindicated in patients with suspected ischemic stroke, primarily to exclude important alternative diagnoses (especiallyICH), assess for serious comorbid diseases, aid in treatmentselection, and search for acute medical or neurological complications of stroke (Table 8). Laboratory tests to considerin all patients include blood glucose, electrolytes with renalfunction studies, complete blood count with platelet count,cardiac markers, prothrombin time (PT), international normalized ratio (INR), and activated partial thromboplastin time (aPTT). Hypoglycemia may cause focal signs and symptomsthat mimic stroke, and hyperglycemia is associated with unfavorable outcomes. Determination of the platelet count and, inpatients taking warfarin or with liver dysfunction, the PT/INRis important. Cardiac markers are frequently elevated in acuteischemic stroke, with elevations occurring in 5% to 34% ofpatients, and these elevations have prognostic significance.123Elevation of cardiac troponin T is associated with increasedstroke severity and mortality risk, as well as worse clinicaloutcomes.124–127<br />&nbsp;&nbsp;Certain laboratory tests should be considered in selectpatients. As the use of direct thrombin inhibitors, such asdabigatran, and direct factor Xa inhibitors, such as rivaroxaban and apixaban, becomes more prevalent, it is important tounderstand what studies may assist in determining qualitatively whether an anticoagulant effect is present. The PT/INRis not helpful in determining whether an anticoagulant effectfrom dabigatran is present. A patient may have significantconcentrations without alterations in PT/INR. A thrombintime (TT) is a sensitive indicator to the presence of dabigatranactivity, and a normal TT excludes the presence of significantactivity; however, it may be influenced by the use of otheranticoagulants. The ecarin clotting time (ECT) demonstrates alinear relationship with direct thrombin inhibitor levels, and anormal ECT generally excludes a significant direct thrombininhibitor effect and is not influenced by other anticoagulants;however, this test may not be available at all hospitals.128 Asnewer anticoagulation agents become available, for instance,direct factor Xa inhibitors, specific assays of activity may berequired.<br />&nbsp;&nbsp;Beyond new anticoagulants, specific laboratory tests maybe helpful when there is a suspicion of drug abuse, particularlyin cases of stroke in young adults. In this instance, toxicological screens for sympathomimetic use (cocaine, methamphetamine, etc) may identify the underlying cause of the stroke.129Although uncommon, women of childbearing age with acutestroke may be pregnant, and results from pregnancy testingmay impact the patient’s overall management. Examination ofthe cerebrospinal fluid has a limited role in the acute evaluation of patients with suspected stroke, unless there is a strongsuspicion for subarachnoid hemorrhage or acute central nervous system infections.<br />&nbsp;&nbsp;Because time is critical, fibrinolytic therapy should not bedelayed while awaiting the results of the PT, aPTT, or plateletcount unless a bleeding abnormality or thrombocytopenia issuspected, the patient has been taking warfarin and heparin,or anticoagulation use is uncertain. Retrospective reviews ofpatients who received intravenous fibrinolysis demonstratedvery low rates of unsuspected coagulopathies and thrombocytopenia that would have constituted a contraindication tofibrinolysis.130,131 The only laboratory result required in allpatients before fibrinolytic therapy is initiated is a glucosedetermination; use of finger-stick measurement devices isacceptable.<br />&nbsp;&nbsp;Chest radiography is often performed in patients with acutestroke; however, only limited observational data are available to guide decision making regarding its utility. One studythat evaluated chest radiographs obtained 12 to 24 hours afteradmission for stroke found clinical management was altered in 3.8% of cases.132 A different study found 3.8% of routinechest radiographs obtained during a code stroke activation(within 6 hours of symptom onset) had a potentially relevantabnormality, with 1 film showing a possibly wide mediastinum (subsequently determined to be normal) and 1.8% having confirmed pulmonary opacities. Thus, the utility of routinechest radiography is debatable in the absence of clinical suspicion of underlying pulmonary, cardiac, or vascular disease.133As with diagnostic laboratory tests, chest radiography shouldnot delay administration of intravenous rtPA unless there arespecific concerns about intrathoracic issues, such as aorticdissection.<br />&nbsp;&nbsp;All acute stroke patients should undergo cardiovascularevaluation, both for determination of the cause of the strokeand to optimize immediate and long-term management. Thiscardiac assessment should not delay reperfusion strategies.Atrial fibrillation may be seen on an admission electrocardiogram; however, its absence does not exclude the possibilityof atrial fibrillation as the cause of the event. Thus, ongoingmonitoring of cardiac rhythm on telemetry or by Holter monitoring may detect atrial fibrillation or other serious arrhythmias.134,135 Acute stroke and acute myocardial infarction canpresent contemporaneously, with one precipitating the other.Ischemic stroke can also cause electrocardiogram abnormalities and, occasionally, cardiac decompensation (cardiomyopathy) via neurohormonal pathways.136–139<br />&nbsp;&nbsp;Because of the close association between stroke and cardiac abnormalities, it is important to assess the cardiovascularstatus of patients presenting with acute stroke. Baseline electrocardiogram and cardiac biomarkers may identify concurrent myocardial ischemia or cardiac arrhythmias. Troponin ispreferred because of its increased sensitivity and specificityover creatine phosphokinase or creatine phosphokinase–MB.Repeat electrocardiogram and serial cardiac enzymes mayidentify developing silent ischemia or paroxysmal arrhythmias not detected on initial studies', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('599', '45', 'Z02_064', '1', '小脑缺血性中风:瑞士建议', 'Decompressive craniectomy for space occupying\nhemispheric and cerebellar ischemic strokes: Swiss\nrecommendations', ' the Swiss Neurological Society,the Swiss Society of Neurosurgery and the Swiss Society of Intensive Care\nMedicine.', '2009', 'Michel et.al. Decompressive craniectomy for space occupying hemispheric cerebellar ischemic\nstrokes: Swiss recommendations. International Journal of Stroke, 2009;4:218-223.', null, null, null, null, null, null, null, ' hypertension', 'In case of complications due to hypertension such asmyocardial infarction, heart failure, aortic aneurysm, etc.,the BP should be reduced slowly and cautiously to thefollowing target values:<br />&nbsp;&nbsp;& Systolic BP 140–160 mmHg<br />&nbsp;&nbsp;& Diastolic BP 80–90 mmHg<br />&nbsp;&nbsp;& MAP 90–120 mmHg.<br />&nbsp;&nbsp;J In case of cardiac complications due to hypertension, BPreduction should be achieved by means of a short-acting,intravenously administered b-blocker (e.g. esmolol)J An arterial hypotension or a cerebral hypoperfusion (CPPo60 mmHg) should be avoided in any case.<br />&nbsp;&nbsp;', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('5fdcd0b62cf24d6894c253b05edb6bae', '4', 'adf', '0', 'fadfa', '', 'adfadf', null, '', '中文', '', '', '', '<img src=\"/bzpt/images/2016/5/13/f2dc7e5787944b019aec746b028c6cf1.jpg\" alt=\"\" />', '', '', '', '', '', '1', '0', 'admin', '2016-05-13 16:28:43', 'admin', '2016-05-13 19:14:50');
INSERT INTO `biz_standard` VALUES ('6', '10', 'D02_006', '1', '中国成人血脂异常防治指南', '无', '中国成人血脂异常防治指南制订联合委员会', '2007', '中国成人血脂异常防治指南[J].中华心血管病杂志;2007;35(5):390-419', '中文', null, '代谢综合征', null, null, '1.腹型肥胖：腰围男性≥90cm，女性≥85cm｡<br />&nbsp;&nbsp;2.血TG≥1.70mmol/L｡<br />&nbsp;&nbsp;3.血HDL-C<1.04mmol/L｡<br />&nbsp;&nbsp;4.血压≥130/85mmHg｡<br />&nbsp;&nbsp;5.空腹血糖≥6.1mmol/L（110mg/dl）或糖负荷后2h血糖≥7.8mmol/L（140mg/dl）或有糖尿病史｡', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('60', '36', 'S01_002', '1', '慢性肾小球肾炎诊疗指南', null, '中华中医药学会 ', '2011', '王小琴,邵朝弟,巴元明. 慢性肾小球肾炎诊疗指南[J]. 中国中医药现代远程教育,2011,9（09）:129-132.', '中文', null, '慢性肾小球肾炎', null, '1.本证：脾肾气虚证、肾气虚证、肾阳虚证、肾阴虚证、气阴两虚证.<br />&nbsp;&nbsp;\n2.标证：水湿证、湿热证、血瘀证、湿浊证.<br />&nbsp;&nbsp;\n', '1.临床表现<br />&nbsp;&nbsp;1.1 症状 水肿：在慢性肾炎的整个疾病过程中，多数患者有不同程度的水肿，轻者仅见于面部、眼睑等组织疏松部位，晨起比较明显，进而发展至足踝、下肢；重者全身水肿，并可有腹（胸）水。<br />&nbsp;&nbsp;高血压：部分患者以高血压为首发症状，高血压的程度差异较大，轻者仅140～160／95～100mmHg，重者达到或超过200／110mmHg。持续高血压容易导致心功能受损、加速肾功能恶化，其程度与预后关系密切。高血压在临床上常表现为头胀，头痛，眩晕，眼花，耳鸣，失眠多梦，记忆力减退等症状。<br />&nbsp;&nbsp;尿异常改变：是慢性肾炎的基本标志。水肿期间尿量减少，无水肿者，尿量接近正常；常有夜尿及低比重尿，尿比重（禁水1～2h）不超过1.020；至尿毒症期即可出现少尿（＜400ml／d）或无尿（＜100ml／d）；有不同程度的尿蛋白，一般在1～3g／d，也可呈大量蛋白尿（＞3.5g／d）；蛋白尿多呈非选择性；尿沉渣可见颗粒管型和透明管型；不同程度的血尿，在急性发作期可出现镜下血尿甚至肉眼血尿。<br />&nbsp;&nbsp;贫血：患者呈现中度以上贫血，表明肾单位损坏及肾功能损害已很严重，发展到终末期出现严重贫血。如果患者无明显营养不良，其贫血多属正细胞、正色素型。患者可有头晕，乏力，心悸，面色苍白，唇甲色淡等症状体征。<br />&nbsp;&nbsp;肾功能不全：主要表现为肾小球滤过率（GFR）下降，肌酐清除率（Ccr）降低。轻中度肾功能受损患者可无任何临床症状，当Ccr 低于10ml／min，临床上可见少尿或者无尿，恶心呕吐，纳呆，乏力，嗜睡，皮肤瘙痒等症。<br />&nbsp;&nbsp;1.2 体征 患者具有贫血貌，唇甲苍白，眼睑及颜面甚至双下肢浮肿，严重者可有胸水、腹水。<br />&nbsp;&nbsp;2.理化检查<br />&nbsp;&nbsp;2.1 实验室检查 尿液检查：尿常规检查有尿蛋白，镜下血尿及（或）管型尿；尿比重降低，圆盘电泳为中分子型蛋白尿为主，红细胞形态为变（畸）形红细胞。<br />&nbsp;&nbsp;血常规检查：轻度贫血常见，肾功能衰竭时出现较严重贫血。<br />&nbsp;&nbsp;肾功能测定：肾功能不同程度受损，血尿素氮、血肌酐升高，内生酐清除率下降，浓缩稀释功能异常。<br />&nbsp;&nbsp;2.2 影像学检查 B 超：双肾可缩小，双肾实质病变。<br />&nbsp;&nbsp;肾活检病理检查：诊断不明确时，可行肾活检确诊。<br />&nbsp;&nbsp;3 诊断要点<br />&nbsp;&nbsp;3.1 起病缓慢，病情迁延，时轻时重，肾功能逐步减退，后期出现贫血、电解质紊乱，血尿素氮、血肌酐升高等。<br />&nbsp;&nbsp;3.2 有不同程度的水肿、蛋白尿、血尿、管型尿、贫血及高血压等表现。<br />&nbsp;&nbsp;3.3 病程中可因呼吸道感染等原因诱发急性发作，出现类似急性肾炎的表现。<br />&nbsp;&nbsp;4 分级标准 病情的轻重主要从尿蛋白、肾功能、水肿、高血压、血瘀证等方面判断。凡具备下列任何1 项即可确定。<br />&nbsp;&nbsp;4.1 重度 尿蛋白检查持续（＋＋＋）—（＋＋＋＋），或24h 尿蛋白定量在2.1～3.5g 之间，血清白蛋白低于30g／L。<br />&nbsp;&nbsp;肾功能不正常（血肌酐≥133～442μmol／L）。<br />&nbsp;&nbsp;明显浮肿及高血压。<br />&nbsp;&nbsp;有明显血瘀证表现：①面色黧黑或晦暗；②腰痛固定或呈刺痛，肌肤甲错或肢体麻木；③舌色紫暗或有瘀点、瘀斑；④脉象细涩；⑤尿纤维蛋白降解产物（FDP）含量增高；⑥血液流变学检测全血黏度、血浆黏度升高。凡具备上述3 项表现者即可确定血瘀证。<br />&nbsp;&nbsp;4.2 中度：<br />&nbsp;&nbsp;尿蛋白检查持续（＋＋）～（＋＋＋），或24h 尿蛋白定量持续在1～2g 之间，肾功能正常。<br />&nbsp;&nbsp;浮肿可轻可重，可有高血压。<br />&nbsp;&nbsp;有血瘀证的临床表现。凡具备上述2 项血瘀证表现者即可确定。<br />&nbsp;&nbsp;4.3 轻度 尿蛋白持续（＋）～（＋＋），或24h 尿蛋白定量持续在1g 以下，肾功能正常。<br />&nbsp;&nbsp;浮肿不明显或无，血压正常。有或无血瘀证的临床表现。<br />&nbsp;&nbsp;', '1.本证<br />&nbsp;&nbsp;1.2 脾肾气虚证 证候：腰脊酸痛，疲倦乏力，或浮肿，纳少或脘腹胀满，大便溏薄，尿频或夜尿多，舌质淡红、有齿痕，舌苔薄白，脉细。<br />&nbsp;&nbsp;1.3肺肾气虚证 证候：颜面浮肿或肢体肿胀，疲倦乏力，少气懒言，易感冒，腰脊酸痛，面色萎黄，舌淡、苍白润，有齿痕，脉细弱。<br />&nbsp;&nbsp;1.4脾肾阳虚证 证候：全身浮肿，面色苍白，畏寒肢冷，腰脊冷痛或酸痛，纳少或便溏或泄泻或五更泄泻，胫酸腿软，食少纳呆，精神倦怠，足跟作痛，大便溏薄，舌质淡胖，边有齿痕，脉沉偏细或沉迟无力。<br />&nbsp;&nbsp;1.5肝肾阴虚证 证候：目睛干涩或视物模糊，头晕耳鸣，五心烦热，或手足心热，口干咽燥，腰脊酸痛，遗精，滑精，或月经失调，舌红少苔，脉弦细或细数。<br />&nbsp;&nbsp;1.6气阴两虚证 证候：面色无华，少气乏力，或易感冒，午后低热，手足心热，腰痛或浮肿，口干咽燥或咽部暗红，咽痛，舌质红或偏红，少苔，脉细或弱。<br />&nbsp;&nbsp;2.标证<br />&nbsp;&nbsp;2.1 水湿证 证候：颜面或肢体浮肿，口淡乏味，胸痞腹胀，小便不利，舌苔白或白腻，脉细或沉细。<br />&nbsp;&nbsp;2.2 湿热证 证候：皮肤疖肿、疮疡，咽喉肿痛，小便黄赤、灼热或涩痛不利，面目或肢体浮肿，口苦或口子口黏，胸闷纳呆，口干喜热饮，舌苔黄腻，脉濡数或滑数。<br />&nbsp;&nbsp;2.3 血瘀证 证候：面色黧黑或晦暗，腰痛固定或呈刺痛，肌肤甲错或肢体麻木舌色紫暗或有瘀点瘀斑，脉细涩。<br />&nbsp;&nbsp;2.4 湿浊证 证候：纳呆，恶心或呕吐，口中黏腻，脘胀或腹胀，身重困倦，精神萎靡，舌苔腻，脉缓。<br />&nbsp;&nbsp;', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('600', '45', 'Z02_063', '1', '缺血性中风和短暂性缺血性发作管理指南\n', 'Guidelines for Management of Ischaemic Stroke and\nTransient Ischaemic Attack 2008', 'The European Stroke Organization (ESO)', '2008', 'http://www.strokesociety.com.au/index.php?option=com_docman&Itemid=176', '英文', null, 'Ischaemic Stroke；Transient Ischaemic Attack', null, null, 'medical assessment and diagnosis, including imaging (CT, magnetic resonance imaging [MRI]), and early assessment of nursing and therapy needs<br />&nbsp;&nbsp;•<br />&nbsp;&nbsp; early management, consisting of early mobilization, prevention of complications, and treatment of hypoxia, hyperglycaemia, pyrexia and dehydration<br />&nbsp;&nbsp; Diagnostic imaging<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp; In patients with suspected TIA or stroke, urgent cranial CT (Class I), or alternatively MRI (Class II), is recommended (Level A)<br />&nbsp;&nbsp; If MRI is used, the inclusion of diffusion weighted imaging (DWI) and T2*- weighted gradient echo sequences is recommended (Class II, Level A)<br />&nbsp;&nbsp; In patients with TIA, minor stroke or early spontaneous recovery immediate diagnostic work-up, including urgent vascular imaging (ultrasound, CTangiography, or MR angiography) is recommended (Class I, Level A) Imaging of the brain and supplying vessels is crucial in the assessment of patients with stroke and TIA. Brain imaging distinguishes ischaemic stroke from intracranial haemorrhage and stroke mimics, and identifies the type and often also the cause of stroke; it may also help to differentiate irreversibly damaged tissue from areas that may recover, thus guiding emergency and subsequent treatment and may help to predict outcome. Vascular imaging may identify the site and cause of arterial obstruction, and identifies patients at high risk of stroke recurrence.<br />&nbsp;&nbsp;General principles Stroke victims should have clear priority over other patients for brain imaging, because time is crucial. In patients with suspected TIA or stroke, general and neurological examination followed by diagnostic brain imaging must be performed immediately on arrival at the hospital so that treatment can be started promptly. Investigation of TIA is equally urgent, because up to 10% of these patients will suffer stroke within the next 48 hours. Immediate access to imaging is facilitated by prehospital notification and good communication with the imaging facility: stroke services should work closely with the imaging department to plan the best use of resources. Diagnostic imaging must be sensitive and specific in detecting stroke pathology, particularly in the early phase of stroke. It should provide reliable images, and should be technically feasible in acute stroke patients. Rapid, focused neurological assessment is helpful to determine which imaging technique should be used. Imaging tests should take into account the patient’s condition [121]; for example, up to 45% of patients with severe stroke may not tolerate MR examination because of their medical condition and contraindications [122-124].<br />&nbsp;&nbsp;Imaging in patients with acute stroke Patients admitted within 3 hours of stroke onset may be candidates for intravenous thrombolysis [125]; CT is usually sufficient to guide routine thrombolysis. Patients arriving later may be candidates for trials testing extended time windows for thrombolysis or other experimental reperfusion strategies. Plain CT is widely available, reliably identifies most stroke mimics, and distinguishes acute ischaemic from haemorrhagic stroke within the first 5-7 days [126-128]. Immediate CT scanning is the most cost-effective strategy for imaging acute stroke patients [129], but is not sensitive for old haemorrhage. Overall, CT is less sensitive than MRI, but equally specific, for early ischaemic changes [130]. Two thirds of patients with moderate to severe stroke have visible ischaemic changes within the first few hours [130-134], but no more than 50% of patients with minor stroke have a visible relevant ischaemic lesion on CT, especially within the first few hours of stroke [135]. Training in identification of early ischaemic changes on CT [134, 136, 137], and the use of scoring systems [133], improve detection of early ischaemic changes. Early CT changes in ischaemic stroke include decreases in tissue x-ray attenuation, tissue swelling with effacement of cerebrospinal fluid spaces, and arterial hyperattenuation, which indicates the presence of intraluminal thrombus with high specificity [138]. CT is highly specific for the early identification of ischaemic brain damage [131, 139, 140]. The presence of early signs of ischaemia on CT should not exclude patients from thrombolysis within the first 3 hours, though patients with a hypoattenuating ischaemic lesion which exceeds one third of the middle cerebral artery (MCA) territory may benefit less from thrombolysis [125, 133, 134, 141, 142]. Some centres prefer to use MRI as first line routine investigation for acute stroke. MRI with diffusion-weighted imaging (DWI) has the advantage of higher sensitivity for early ischaemic changes than CT [130]. This higher sensitivity is particularly useful in the diagnosis of posterior circulation stroke and lacunar or small cortical infarctions. MRI can also detect small and old haemorrhages for a prolonged period with T2* (gradient echo) sequences [143]. However, DWI can be negative in patients with definite stroke [144]. Restricted diffusion on DWI, measured by the apparent diffusion coefficient (ADC), is not 100% specific for ischaemic brain damage. Although abnormal tissue on DWI often proceeds to infarction it can recover, which indicates that DWI does not show only permanently damaged tissue [145, 146]. Tissue with only modestly reduced ADC values may be permanently damaged; there is as yet no reliable ADC threshold to differentiate dead from still viable tissue [147, 148]. Other MRI sequences (T2, FLAIR, T1) are less sensitive in the early detection of ischaemic brain damage. MRI is particularly important in acute stroke patients with unusual presentations, stroke varieties, and uncommon aetiologies, or in whom a stroke mimic is suspected but not clarified on CT. If arterial dissection is suspected, MRI of the neck with fat suppressed T1-weighted sequences is required to detect intramural haematoma. MRI is less suited for agitated patients or for those who may vomit and aspirate. If necessary, emergency life support should be continued while the patient is being imaged, as patients (especially those with severe stroke) may become hypoxic while supine during imaging [124]. The risk of aspiration is increased in the substantial proportion of patients who are unable to protect their airway. Perfusion imaging with CT or MRI and angiography may be used in selected patients with ischaemic stroke (e.g. unclear time window, late admission) to aid the decision on whether to use thrombolysis, although there is no clear evidence that patients with particular perfusion patterns are more or less likely to benefit from thrombolysis [149- 152]. Selected patients with intracranial arterial occlusion may be candidates for intra-arterial thrombolysis, although there is only limited evidence to support this [153, 154]. Patients with combined obstructions of the internal carotid artery (ICA) and MCA have less chance of recovering with intravenous thrombolysis than patients with isolated MCA obstructions [155]. In patients with MCA trunk occlusions, the frequency of severe extracranial occlusive disease in the carotid distribution is high [156, 157]. Mismatch between the volume of brain tissue with critical hypoperfusion (which can recover after reperfusion) and the volume of infarcted tissue (which does not recover even with reperfusion) can be detected with MR diffusion/perfusion imaging with moderate reliability [158], but this is not yet a proven strategy for improving the response to thrombolysis up to 9 hours [159]. There is disagreement on how to best identify irreversible ischaemic brain injury and to define critically impaired blood flow [149, 152, 160]. Quantification of MR perfusion is problematic [161], and there are widely differing associations between perfusion parameters and clinical and radiological outcomes [149]. Decreases in cerebral blood flow on CT are associated with subsequent tissue damage [150, 151], but the therapeutic value of CT perfusion imaging is not yet established. Although infarct expansion may occur in a high proportion of patients with mismatch, up to 50% of patients without mismatch may also have infarct growth and so might benefit from tissue salvage [152, 162]. The “imaging/clinical” mismatch, i.e. the mismatch between the extent of the lesion seen on DWI or CT and the extent of the lesion as expected from the severity of the neurological deficit, has produced mixed results [163, 164]. Hence, neither perfusion imaging with CT or MRI nor the mismatch concept can be recommended for routine treatment decisions. Microhaemorrhages are present on T2* MRI in up to 60% of patients with haemorrhagic stroke, and are associated with older age, hypertension, diabetes, leukoaraiosis, lacunar stroke, and amyloid angiopathy [165]. The incidence of symptomatic intracranial haemorrhage following thrombolysis in ischaemic stroke patients was not increased in those having cerebral microbleeds on pre-treatment T2*-weighted MRI [166]. Vascular imaging should be performed rapidly to identify patients with tight symptomatic arterial stenosis who could benefit from endarterectomy or angioplasty. Non-invasive imaging with colour-coded duplex imaging of the extracranial and intracranial arteries, CT angiography (CTA), or contrast-enhanced MR angiography (CE-MRA) is widely available. These approaches are relatively risk-free, whereas intra-arterial angiography has a 1-3% risk of causing stroke in patients with symptomatic carotid lesions [167, 168]. Digital subtraction angiography (DSA) may be needed in some circumstances, for example when other tests have been inconclusive. Carotid ultrasound, MRA and CTA visualise carotid stenosis. Systematic reviews and individual patient data meta-analysis indicate that contrast-enhanced MRA (CE-MRA) is the most sensitive and specific non-invasive imaging modality for carotid artery stenosis, closely followed by Doppler ultrasound and CTA, with non-contrast MRA being the least reliable [169, 170]. Some data suggest that vertebrobasilar TIA and minor stroke is associated with a high risk of recurrent stroke [171]. Extracranial vertebral ultrasound diagnosis is useful, but intracranial ultrasound of the vertebrobasilar system can be misleading due to low specificity. Limited data suggest that contrast-enhanced MRA and CTA offer better non-invasive imaging of the intracranial vertebral and basilar arteries [172]. Unlike other imaging modalities ultrasound is fast, non-invasive and can be administered using portable machines. It is therefore applicable to patients unable to co-operate with MRA or CTA [157]. However, Doppler-studies alone often provide only limited information, are investigator-dependant and require skilled operators, although they allow repeated measurements at the bedside.\nTranscranial Doppler ultrasound (TCD) is useful for the diagnosis of abnormalities in the large cerebral arteries at the base of the skull. However, between 7% and 20% of acute stroke patients, particularly elderly individuals and those from certain ethnic groups do not have an adequate acoustic window [173, 174]. This problem can be considerably reduced by using ultrasound contrast agents, which also allow perfusion studies in the acute phase [175-177] and continuous monitoring of cerebral haemodynamic responses [178]. The combination of ultrasound imaging techniques and MRA reveals excellent results equal to DSA [179]. Cerebral reactivity and cerebral autoregulation are impaired in patients with occlusive extracerebral arterial disease (particularly carotid stenosis and occlusion) and inadequate collateral supply, who are at increased risk of recurrent stroke [180, 181]. TCD is the only technique that detects circulating intracranial emboli [182], which are particularly common in patients with large artery disease. In patients with symptomatic carotid artery stenoses they are a strong independent predictor of early recurrent stroke and TIA [183], and have been used as a surrogate marker to evaluate antiplatelet agents [184]. TCD microbubble detection can be used to identify a right-to-left shunt which mainly results from a patent foramen ovale (PFO) [185].<br />&nbsp;&nbsp;Imaging in patients with TIA, minor non-disabling stroke, and stroke with<br />&nbsp;&nbsp;spontaneous recovery Patients presenting with TIA are at high risk of early recurrent stroke (up to 10% in the first 48 hours) [186]. They therefore need urgent clinical diagnosis to treat associated general abnormalities, modify active risk factors and identify specific treatable causes, particularly arterial stenosis and other embolic sources. Vascular imaging is a priority in those patients with TIA or minor stroke, more than in those with major stroke in whom surgery is not going to be of benefit in the short term. Immediate preventive treatment will reduce stroke, disability and death [86, 187]. Simple clinical scoring systems can be used to identify patients at particularly high risk [186]. Patients with minor non-disabling stroke and rapid spontaneous clinical recovery are also at high risk of recurrent stroke [58].\nPatients with widely varying brain pathology may present with transient neurological deficits indistinguishable from TIA. CT reliably detects some of these pathologies (e.g. intracerebral haemorrhage, subdural haematoma, tumours) [129], but others (e.g. multiple sclerosis, encephalitis, hypoxic brain damage, etc.) are better identified on MRI, while others (e.g. acute metabolic disturbances) are not visible at all. Intracranial haemorrhage is a rare cause of TIA. Between 20-50% of patients with TIAs may have acute ischaemic lesions on DWI [144, 188, 189]. These patients are at increased risk of early recurrent disabling stroke [189]. However, there is currently no evidence that DWI provides better stroke prediction than clinical risk scores [190]. The risk of recurrent disabling stroke is also increased in patients with TIA and an infarct on CT [191]. The ability of DWI to identify very small ischaemic lesions may be particularly helpful in patients presenting late or in patients with mild non-disabling stroke, in whom the diagnosis may be difficult to establish on clinical grounds [130]. T2*-MRI is the only reliable method to identify haemorrhages after the acute phase, when blood is no longer visible on CT [143].<br />&nbsp;&nbsp;Other diagnostic tests<br />&nbsp;&nbsp;Recommendations<br />&nbsp;&nbsp; In patients with acute stroke and TIA, early clinical evaluation, including physiological parameters and routine blood tests, is recommended (Class I,<br />&nbsp;&nbsp;Level A)<br />&nbsp;&nbsp; For all stroke and TIA patients, a sequence of blood tests is recommended (Table 3, Table 5)<br />&nbsp;&nbsp; It is recommended that all acute stroke and TIA patients should have a 12-lead ECG. In addition continuous ECG recording is recommended for ischaemic stroke and TIA patients (Class I, Level A)  It is recommended that for stroke and TIA patients seen after the acute phase, 24-hour Holter ECG monitoring should be performed when arrhythmias are suspected and no other causes of stroke are found (Class I, Level A)<br />&nbsp;&nbsp; Echocardiography is recommended in selected patients (Class III, Level B)\nCardiac evaluation Cardiac and ECG abnormalities are common in acute stroke patients [192]. In particular, prolonged QTc, ST depression, and T wave inversion are prevalent in acute ischaemic stroke, especially if the insular cortex is involved [193, 194]. Hence, all acute stroke and TIA patients should have a 12-channel ECG. Cardiac monitoring should be conducted routinely after an acute cerebrovascular event to screen for serious cardiac arrhythmias. It is unclear whether continuous ECG recording at the bedside is equivalent to Holter monitoring for the detection of atrial fibrillation (AF) in acute stroke patients. Holter monitoring is superior to routine ECG for the detection of AF in patients anticipated to have thromboembolic stroke with sinus rhythm [195]; however, serial 12-channel ECG might be sufficient to detect new AF in a stroke unit setting [196]. A recent systematic review found that new AF was detected by Holter ECG in 4.6% of patients with recent ischaemic stroke or TIA, irrespective of baseline ECG and clinical examination [197]. Extended duration of monitoring, prolonged event loop recording, and confining Holter monitoring to patients with non-lacunar stroke, may improve detection rates [198]. Echocardiography can detect many potential causes of stroke [199], but there is controversy about the indications for, and type of, echocardiography in stroke and TIA patients. Transoesophageal echocardiography (TOE) has been claimed to be superior to transthoracic echocardiography (TTE) for the detection of potential cardiac sources of embolism [200], independent of age [201]. Echocardiography is particularly required in patients with: •<br />&nbsp;&nbsp; evidence of cardiac disease on history, examination, or ECG •<br />&nbsp;&nbsp; suspected cardiac source of embolism (e. g. infarctions in multiple cerebral or systemic arterial territories) •<br />&nbsp;&nbsp; suspected aortic disease •<br />&nbsp;&nbsp; suspected paradoxical embolism •<br />&nbsp;&nbsp; no other identifiable causes of stroke. TTE is sufficient for evaluation of mural thrombi, particularly in the apex of the left ventricle; this technique has >90% sensitivity and specificity for ventricular thrombi after myocardial infarction [202]. TOE is superior for evaluation of the aortic arch, left atrium, and atrial septum [199]. It also allows risk stratification for further thromboembolic events in patients with AF [203]. The role of cardiac CT and cardiac MRI in the detection of embolic sources in stroke patients has not been evaluated systematically.<br />&nbsp;&nbsp;Blood tests Blood tests required on emergency admission are listed in Table 3. Subsequent tests depend on the type of stroke and suspected aetiology (Z02_063_biao1).<br />&nbsp;&nbsp;诊断影像学\n建议\n建议对疑似 TIA 或卒中的患者急诊行头颅 CT（I 类证据，A 级建议）或 MRI (II类证据，A 级建议)检查如果进行 MRI 检查，要包括弥散加权成像(DWI)以及 T2*-加权梯度回波序列（T2*MRI）（II 类证据，A 级建议）建议给 TIA、轻微卒中或早期自发恢复的患者立即进行紧急血管影像检查，包括超声、CT 血管成像（CTA）或 MR 血管成像（MRA）在内的诊断性筛查（I 类证据，A 级建议）\n脑和其供血动脉影像为判断卒中及 TIA 提供了至关重要的证据。头颅影像将缺血性卒中与颅内出血和卒中模拟病区分开来，帮助鉴别卒中类型，通常也能够区分卒中病因；同时也将不可逆性损伤区域与可恢复区域分开，指导急诊及后续治疗，并有助于判断临床转归。血管影像学有助于识别动脉闭塞的部位和原因，利于确定卒中再发高危患者。一般原则由于时间至关重要，疑似卒中患者应优先得到脑影像学检查。为能迅速开展治疗，疑诊 TIA 或卒中患者到院后应立即完成一般检查和神经科检查，随后要快速进行诊断性脑影像学检查。由于 TIA 患者中 10%在随后的 48 小时内会发生卒中，因此其诊断和评估同样紧急。院前通知影像小组，并与其保持良好沟通保证了即刻影像学评价：卒中服务设施应该靠近影像科，保证资源的最好利用。诊断性影像学在确定卒中病理类型方面必须具有敏感性和特异性，尤其是卒中的早期阶段。应确保影像可靠，且对急性卒中患者可行。快速并定位准确的神经系统检查有助于选择合适的影像学检查方法。影像学检查应该考虑到患者情况[122]；例如，严重卒中患者由于疾病状况不允许或存在禁忌症，45%无法承受MR 检查[123-125].\n急性卒中患者的影像学\n卒中发生 3 小时内入院的患者有机会进行静脉溶栓治疗[126]；CT 通常足够指导常规溶栓治疗。超过 3 小时入院的患者有机会加入扩大溶栓时间窗试验或其他试验性再灌注治疗。CT 平扫广泛应用，可有效鉴别大部分卒中模拟病, 并区分发生 5-7 天内的急性缺血性和出血性卒中[127-129]。对急性卒中患者，立即进行 CT 扫描是效价比最高的方法[130]，但 CT 对陈旧性出血不敏感。总体来说，对早期缺血性改变 CT的敏感性不如 MRI，但具有相同的特异性[131]。发病数小时内，CT 能检查到中重度卒中患者的 2/3 有缺血性改变[131-135]，而轻度卒中患者 CT 可见的缺血性改变不超过 50%[136]。培训识别缺血性卒中 CT 早期改变[135, 137, 138]，使用评分系统能够提高对早期缺血性改变的识别[134]。\n缺血性卒中的早期 CT 改变包括脑组织密度降低，组织肿胀脑脊液空间减小和高度提示腔内血栓形成的动脉高密度征[139]。CT 对缺血性脑损伤的早期识别具有高度特异性[132, 140, 141]。发病 3 小时内 CT 出现缺血改变早期征象的患者，并不意味着不能溶栓，但是低密度缺血性损伤范围超过大脑中动脉供血区 1/3 的患者，可能很少获益[126, 134, 135, 142, 143]。有些中心更倾向于使用 MRI 作为急性卒中常规一线检查。与 CT 相比，DWI 对\n早期缺血性改变具有更高的敏感性[131]，尤其有助于诊断后循环卒中、腔隙性\n或小的皮层梗死。T2*MRI [144]能够发现微小和陈旧性出血。但是，DWI 在确诊\n的卒中患者可能出现阴性结果[145]。\n通过测量表观弥散系数(ADC)获得的 DWI 弥散受限, 使其对缺血性损害并非100%特异。DWI 显示的异常组织经常超过梗死灶，超出梗死灶部分的异常组织是可复的，这提示 DWI 并不只是显示存在永久性损害的组织[146，147]。ADC值中度降低的组织可能存在永久性损害；目前还没有一个可信的 ADC 阈值用于区分死亡和存活的组织[148, 149]。其他 MRI 序列(T2, FLAIR, T1)在早期缺血性脑损害的识别中，敏感性相对较差。对于出现不寻常表现，卒中多样以及非常见病因的急性卒中患者，或者疑似卒中模拟病但 CT 检查未明确的患者，MRI 尤其重要。如果怀疑动脉夹层，需要行颈部脂肪抑制 T1 加权序列的 MRI 检查来发现腔内血肿。\nMRI 并不适用于躁动患者或是那些可能出现呕吐并误吸的患者。当患者进行影像学检查时，必要时应继续进行急诊生命支持。当患者（尤其是严重卒中患者）仰卧位进行影像学检查时，可能出现低氧血症[125]。在不能保护气道的患者中，误吸的危险有所增加。\n尽管没有明确的证据表明特殊灌注类型的患者溶栓治疗可能是更有益的，但灌注CT（CTP），灌注 MRI（PWI）以及血管造影可用于筛选缺血性卒中患者（例如时间窗不明，入院时间晚），帮助确定是否能够进行溶栓治疗[150-153]。尽管证据有限，颅内动脉闭塞的患者可能适宜动脉溶栓[154, 155]。颈内动脉（ICA）和 MCA 均闭塞的患者与单独 MCA 闭塞的患者相比，静脉溶栓再通的机会更小[156]。MCA 主干闭塞的患者中，发生严重颈动脉颅外段闭塞的几率较高[157,158]。\n严重低灌注脑组织（再灌注后可恢复）和梗死脑组织（及时再灌注后仍不能恢复）容量之间的不匹配可以通过 DWI/PWI 检查获得，具有中等可信度[159]，但这并不是将溶栓时间窗延长到 9 小时的可信策略[160]。关于如何精确识别不可逆性缺血性脑损伤和定义严重脑血流灌注不足，尚未达成一致意见[150, 153, 161]。PWI 定量仍存疑问[162]，在灌注参数和临床及影像结果之间有很大差别[150]。CTP 脑血流量的下降与随后的组织损伤有关[151，152]，但是 CTP 的治疗作用还未建立。尽管出现灌注和梗死不匹配的很多患者可能发生梗死扩大，但不存在不匹配的患者中也有 50%可能出现梗死扩大，因此同样有可能从挽救组织中获益[153, 163]。“影像/临床”也存在不匹配，例如 DWI 或 CT 所显示的范围与根据神经功能损伤严重程度确定的范围之间的不匹配，产生复杂的结果[164，165]。因此，无论 CT 或 MR 灌注成像，还是不匹配概念，都不建议作为常规治疗的决\n策方法。\n出血性卒中患者中有 60%通过 T2*MRI 能观察到微出血，与高龄、高血压、糖尿病、脑白质疏松、腔隙性梗死、淀粉样变性等因素相关[166]。治疗前 T2*MRI上有微出血并不增加缺血性卒中患者溶栓后症状性颅内出血的风险[167]应快速进行血管影像评估，将那些可能从颈动脉内膜剥脱术（CEA）或血管成形术（CAS）中获益的症状性颈动脉狭窄患者识别出来。无创性血管影像技术，如颈动脉超声和 TCD，CTA 或增强 MRA（CE-MRA）可广泛应用。上述方法相对无风险，而数字减影血管造影（DSA）在症状性颈动脉病变患者中，1-3%有卒中的风险[168，169]。当其他方法得不出结论时，需要进行 DSA 检查。\n颈动脉超声、MRA 和 CTA 等都可以直观地看到颈动脉狭窄。系统回顾和个例病人资料的 meta 分析显示，无创颈动脉狭窄诊断方法依据可靠性的排列顺序是：CE-MRA、颈动脉超声、CTA 和非增强 MRA [170, 171]。有资料表明椎基底动脉系统 TIA 和轻微卒中有较高的卒中再发风险[172]。椎动脉颅外段超声有助于诊断，但是椎动脉颅内段超声由于其特异性差可能误导。增强 MRA 和 CTA 可能是更理想的检查椎动脉颅内段和基底动脉病变的无创诊断方法[173]。\n不同于其他影像学检查，超声是一种快速、无创并可便携的方法。因此，可适用于那些不能配合 MRA 或 CTA 检查的患者[158]。虽然超声多普勒可床旁重复检查，但其单项检查所提供的信息有限，结果还在很大程度上依赖于操作者的技术水平和熟练程度。\n经颅多普勒超声（TCD）可以检查颅底脑动脉异常。但是有 7%-20%的急性卒中患者，尤其是老年患者和某些种族的人群（黑人和亚裔），声窗不良[174, 175]。应用超声增强剂可以明显改善这一情况，并用来研究急性期脑灌注[176-178]，TCD 也可以持续监测脑血流动力学反应[179]。联合超声影像和 MRA 技术，可以获得等同于 DSA 检查的理想结果[180]。存在颅外动脉闭塞性疾病（尤其是颈动脉狭窄和闭塞）且侧枝代偿不好的患者，脑血管反应性和脑动脉自动调节功能受损，将增加卒中再发的风险[181，182]。TCD 是唯一能够探查到循环中颅内动脉栓子的检查[183]，这些栓子在伴有大动脉病变的患者中尤其常见。对于存在症状性大动脉狭窄的患者，它是早期再发卒中和 TIA 的独立预测因子[184]，并且是评价抗血小板药物的一个标志[185]。TCD 微栓子的监测可用于识别源于卵圆孔未闭(PFO)所致的右－左分流[186]。\nTIA、轻微非致残性卒中和自发缓解卒中患者的影像检查出现 TIA 的患者有高度再发卒中的风险(首个 48 小时内达到 10%) [187]。因此需立即进行临床诊断、治疗相关的全身异常情况、控制危险因素和寻找可治的特殊病因，尤其是动脉狭窄和其他栓子源。与在短期内手术治疗没有益处的大卒中患者相比，发生 TIA 或轻微卒中的患者要优先进行血管影像检查。即刻预防性治疗可以减少卒中、致残和死亡[86, 188]。简单的临床评分系统尤其有助于识别高危患者[187]。轻微非致残性卒中和迅速自发临床缓解的患者同样是卒中再发的高危人群[58]。\n多种不同脑病理改变都有可能出现与 TIA 难以区分的短暂性神经功能缺失。CT能识别颅内出血、硬膜下出血和肿瘤等病变[130]，但多发性硬化、脑炎和缺氧脑损害等则要借助 MRI，也有某些情况（如急性代谢性脑病）则 CT 或 MRI 等影像可能不会有特别的发现。颅内出血极少引起 TIA。\n大约 20-50%TIA 患者的 DWI 上有急性缺血性损伤[145, 189, 190]。这些患者早期再发致残性卒中的风险增加[190]。但是，目前没有证据证实 DWI 比临床危险度评分能更好地预测卒中[191]。CT 上有梗死灶的 TIA 患者再发致残性卒中的风险也增加[192]。\nDWI 能识别微小缺血灶的优点尤其适用于 TIA 或轻微非致残性卒中的患者，仅依赖临床资料诊断往往较困难[131]。急性期过后头颅 CT 不再能看到的脑出血唯有 T2*MRI 能诊断[143]。\n其他诊断试验\n建议\n建议对急性卒中或TIA患者进行早期临床评估，包括生理参数和常规血液检查(I类证据，A级建议)建议对所有急性卒中和TIA患者进行系列血液检查(表3，表5)建议对所有急性卒中和TIA患者进行12-导联心电图(ECG)检查。此外，建议对缺血性卒中和TIA患者进行连续心电图记录(I类证据，A级建议)\n急性期后发现的卒中和TIA患者，如果怀疑心律失常并且未发现其他病因，建议进行24-小时Holter心电图监测(I类证据，A级建议)建议有选择地进行超声心动图检查(III 类证据，B 级建议)心脏评价急性卒中患者常出现心功能和心电图异常[193]。急性缺血性卒中，尤其是岛叶皮层受损时，常可见到 QTc 延长、ST 段压低以及 T 波倒置等情况 [194，195]。因此，所有急性卒中和 TIA 患者都应进行 12-导联心电图检查。急性脑血管事件后应常规进行心电监测筛查严重心律失常。对于心房颤动（AF）的检测来说，急性卒中患者持续床旁心电监测效果是否等同于 Holter 尚不清楚。在临床考虑血栓栓塞事件但窦性心律的患者，Holter 较常规 ECG 更能发现 AF。[196]；但最新研究发现连续 12-导联 ECG 足够用于监测卒中单元内新发 AF 事件[197]。近来的一项系统性回顾研究发现，不计 ECG 基线及临床检查情况，缺血性卒中或 TIA 患者由 Holter 监测到的新发 AF 事件为 4.6%[198]。非腔隙性梗死患者，常规 ECG 和 Holter 均正常的病人，通过进一步采用事件环形记录仪（event-loop-recording）和延长监测时间，还能再提高检出率[199]。超声心动图能够检测出许多潜在的卒中病因[200]，但卒中和 TIA 患者行超声心动图检查的适应症，即卒中类型，仍有争议。经食道超声心动图（TOE）对任何年龄潜在心源性栓塞的检出均优于经胸超声心动图（TTE）[201，202]，。患者伴随以下情况时，需行超声心动图检查 ：病史、查体或 ECG 提示有心脏病疑诊心源性栓塞（例如多处脑组织或多个系统动脉供血区脑梗死）疑诊主动脉弓病变疑诊反常栓塞未发现其他明确卒中原因TTE 能很好地检测到附壁血栓，尤其位于左室心尖部；对心肌梗死后室性附壁血栓的患者，该检查敏感性和特异性均>90%[203]。TOE 更适于评价主动脉弓、左心房和房间隔[200]，也有助于对 AF 患者未来是否容易发生血栓栓塞性事件进行危险分层[204]。心脏 CT 和心脏 MRI 在检测卒中患者栓子来源方面的应用，尚未得到系统评价。血液检查急诊需要进行的血液检查在表 3 中列出。随后的检查依赖于卒中类型和疑似病因\n\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('601', '45', 'Z02_060', '1', '新西兰短暂性脑缺血的评估管理', 'New Zealand Guideline for the Assessment and Management of\nTransient Ischaemic Attack (TIA)', '新西兰中风基金会', '2008', 'http://www.strokesociety.com.au/index.php?option=com_docman&Itemid=176', '英文', null, 'Transient Ischaemic Attack (TIA)', null, null, 'Diagnosis of TIA is more likely to be correct if thehistory confirms;•<br />&nbsp;&nbsp; Sudden onset of symptoms, with maximal neurological deficitat onset•<br />&nbsp;&nbsp; Symptoms typical of focal loss of brain function such asunilateral weakness or speech disturbance•<br />&nbsp;&nbsp; Rapid recovery of symptoms, usually within 30-60 minutes.<br />&nbsp;&nbsp;A diagnosis of TIA is likely to be correct if history confirms;•<br />&nbsp;&nbsp; Sudden onset of symptoms. Usually people (or observers)can describe what they were doing at the time. If they areuncertain, TIA is less likely.•<br />&nbsp;&nbsp; Maximal neurological deficit occurs at onset. A progressiveonset or a march of symptoms from one part of the body toanother is more suggestive of epilepsy (if fast, over secondsto 1-2 minutes) or migraine (if slow, over several minutes).•<br />&nbsp;&nbsp; Focal symptoms consistent with vascular cause. Disruptionof blood supply to a part of the cerebral circulation resultsin focal symptoms. Symptoms of generalised disturbance ofneurological function such as confusion (unless mistakenfor dysphasia), faints, generalised weakness or numbness,bilateral blurred vision, isolated dizziness and ‘funny turns’are rarely due to TIA unless also accompanied by focalsymptoms. (see TIA symptoms table).•<br />&nbsp;&nbsp; Loss of function. Typical symptoms of TIA are ‘negative’ dueto loss of focal neurological function such as unilateral lossof movement or sensation, or loss of speech or vision. TIAsrarely cause positive symptoms such as pins and needles,limb shaking or scintillating visual field abnormalities.•<br />&nbsp;&nbsp; Rapid recovery. Most TIAs resolve within 30 minutes. Ifsymptoms are still present beyond one hour then assumelikely acute stroke.', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('602', '45', 'Z02_053', '1', '临床诊疗指南神经病学分册', null, '中华医学会', '2004', '中华医学会. 临床诊疗指南(神经病学分册)[M]. 人民卫生, 2010.', '中文', null, '短暂性脑缺血发作TIA', null, null, '【短暂性脑缺血发作TIA】TIA的临床表现随着受累的血管不通而表现不同，1.短暂性单眼盲，又称发作性黑矇，短暂的单眼失明是颈内动脉分支眼动脉缺血的特征性症状。2.颈动脉系统TIA，以偏侧肢体或单肢的发作性轻瘫最常见，通常以上肢和面部较重，主侧半球的颈动脉系统缺血可表现为失语，偏瘫，偏身感觉障碍和偏盲。3.椎基底动脉系统TIA常见症状有眩晕和共济失调，复视，构音障碍，吞咽困难，交叉性或双侧肢体瘫痪，或感觉障碍，皮质性盲和视野缺损。另外，还可以出现猝倒症。1.临床诊断，TIA患者就医时多发作已过，因此，诊断只能那个依靠病史，在对TIA患者作出临床诊断之后，应同时对患者进行神经影像学检查，以排除可导致短暂性神经功能缺损的肺血液循环障碍性疾病。2.病因诊断（1）血液成分，包括血常规，血沉，凝血象，血生化等。（2）心脏，心电图，超声心动图检查，有必要时可作24小时心电监测，以了解心脏节律的变化，有条件时也可考虑作经食管超声心动图检查（3）供应脑的大动脉和脑动脉检查，颈部多普勒超声，经颅多普勒超声，有条件和必要时可作磁共振血管造影等。以及数字减影动脉血管造影检查（4）血流动力学变化，主要是寻找可以导致脑血流量下降的因素，如低血压，脱水，心脏功能差，大动脉狭窄或阻塞导致供血区的血流量下降等。3.鉴别诊断，TIA应与可以导致短暂性神经功能障碍发作的疾病相鉴别，如伴先兆的偏头痛，部分性癫痫，颅内结构性损伤，多发性硬化，迷路病变，代谢性疾病，心理障碍等，发作性黑矇应与青光眼等眼科疾病相鉴别。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('603', '45', 'Z02_002', '1', '中医内科常见病诊疗指南(西医疾病部分)\n', ' ', ' 中华中医药学会', '2008', 'ZYYXH/T50～135—2008，中医内科常见病诊疗指南[M].中国中医药出版社，2008', '中文', null, '短暂性脑缺血发作；', '中风先兆；小中风', '1.肝阳上亢证<br />&nbsp;&nbsp;2.痰浊壅滞证<br />&nbsp;&nbsp;3.气虚血瘀证<br />&nbsp;&nbsp;4.肾虚血阻证\n', 'TIA1诊断依据1.1临床表现1.1.1症状：具有突发性、短暂性、反复性和恢复较完全，常不遗留神经功能缺损体征的临床特点。常见一过性一侧肢体无力、偏身或麻或木、失语、黑矇、雾视或眼前阴影晃动，光线减少；或表现为眩晕、复视、偏盲或双侧视觉丧失，共济失调、构音障碍，面部口周麻木；TIA较少出现晕厥、头痛、单纯尿便失禁、嗜睡、记忆缺失或癫痫症状。1.1.2体征：缺血症状与体征主要取决于受累血管的分布。发作时通常存在如下体征：颈内动脉系统TIA：轻偏瘫，偏身感觉减退，可伴有偏瘫同侧的中枢性面瘫，言语困难或失语；单眼一过性黑矇、视野模糊及自发性闪光，同时可伴有对侧偏瘫及（或）感觉障碍。椎-基底动脉系统TIA：眩晕，复视，平衡障碍，异常的眼球运动，构音障碍，单侧或双侧面部、口周麻木，交叉性运动或感觉障碍，偏盲或双侧视力丧失，跌倒发作。1.2理化检查检查主要目的在于确定TIA发生的病因，特别针对可能需要特殊治疗的TIA的病因，并寻找可改善的危险因素及判断预后。临床上没有常规标准化的评估顺序和固定的辅助诊断检查项目，常需要根据个体病情而定。1.2.1CT和MRI:CT有助于排除与TIA类似的颅内病变。MRI的阳性率更高，但一般不常规应用于筛查。1.2.2超声检查\n颈动脉超声检查：是TIA患者的一个基本检查手段，可显示颈动脉、椎动脉颅外段、锁骨下动脉等血管狭窄情况，血管管腔内径、动脉粥样硬化斑的形态、大小、部位及斑块的稳定性。经颅彩色多普勒超声（TCD）检查：是发现颅内大血管狭窄的有力手段，有助于发现严重的颅内血管痉挛或狭窄，了解侧支循环情况。超声心动及经食道超声心动检查：可确定血栓栓塞源或左心室收缩功能障碍，二者都是常见的缺血性卒中的预测因素。1.2.3脑血管造影检查选择性动脉导管脑血管造影（数字减影血管造影DSA):DSA是颅内外血管检查的金标准，但造影价格昂贵又是有创性技术，具有一定风险。严重并发症的发生率为0.5％～1.0%。不作为TIA常规检查手段使用。计算机成像血管造影（CTA）和磁共振显像血管造影（MRA)：是评价颅内外血管的无创方法。可以识别颅内一、二级血管（主干血管）或颈部血管的动脉狭窄闭塞情况，但易导致动脉狭窄程度的判断过度，是TIA非常规检查手段。1.2.4实验室检查：主要是针对血栓前状态的进一步检查，新近发生的TIA除进行全面细致的体格检查外，应尽快了解血小板计数、血红蛋白、红细胞压积、凝血酶原时间、纤维蛋白原含量及其他的血凝指标。对于有明确卒中危险因素的患者，应进行高凝状态评价。此外，血常规及生化检查有一定的鉴别意义。<br />&nbsp;&nbsp;诊断要点：采用1995年中华医学会第四次全国脑血管病学术会议修订的《各类脑血管疾病诊断要点》：1.3.1为短暂的、可逆的、局部的脑血液循环障碍，可反复发作，少者1～2次，多至数十次。多与动脉硬化有关，也可以是脑梗死的前驱症状。1.3.2表现为颈内动脉系统和（或）椎-基底动脉系统的症状和体征。1.3.3一次发作时间通常在数分钟至1小时左右，症状和体征在24小时内完全消失。\n\n', '1.肝阳上亢证：阵发性眩晕，发作性偏身麻木，短暂性言语謇涩，一过性偏身瘫软，瞬时性视歧昏瞀，面色发红，头脑胀痛，目赤口苦，急躁易怒，手足颤抖，尿黄赤，舌红，苔薄黄或黄干，脉弦数。<br />&nbsp;&nbsp;2痰浊壅滞证：阵发性眩晕，发作性偏身麻木，短暂性言语謇涩，一过性偏身瘫软，瞬时性视歧昏瞀，头沉重感，或伴有胸闷痰多，纳呆多寐，肢体困重，舌质淡红或暗红，舌体胖大或有齿痕，苔白腻或黄腻，脉弦滑或濡数。<br />&nbsp;&nbsp;3.气虚血瘀证：阵发性眩晕，发作性偏身麻木，短暂性言语謇涩，一过性偏身瘫软，瞬时性视歧昏瞀，面色无华，心悸气短，自汗乏畻坴畿\0\0\0\0醼畻聱盯\r\0\0\0痭ᒐ੏ༀƙ\0੏Ð\0\r\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0𢡄祰௸੏Ð\0ᅸ௸彿㎽奋㎽巫㎽鞤௸뗔௸彿㎽뗈௸塚㎽뗔௸ꍈ㏂', null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('604', '45', 'Z02_003', '1', '各类脑血管疾病诊断要点及疗效评定标准', ' ', '中华医学会第四次全国脑血管病学术会议', '1995', null, '中文', null, '短暂性脑缺血发作', null, null, '【短暂性脑缺血发作】1.3.1为短暂的、可逆的、局部的脑血液循环障碍，可反复发作，少者1～2次，多至数十次。多与动脉硬化有关，也可以是脑梗死的前驱症状。1.3.2表现为颈内动脉系统和（或）椎-基底动脉系统的症状和体征。1.3.3一次发作时间通常在数分钟至1小时左右，症状和体征在24小时内完全消失。\n', null, null, '（1） 神经功能缺损积分值的减少（功能改善）（2）患者总的生活能力状态（评定时的病残程度）<br />&nbsp;&nbsp;0级，能回复工作或操持家务。1级，生活自理，独立生活，部分工作。2级，基本独立生活，小部分需人帮助。3级，部分生活活动可自理，大部分需人帮助。4级，可站立步行，但需人随时照料。5级，卧床，能做，各项生活需人照料。6级，卧床，有部分意识活动，可喂食。7级，植物人状态。<br />&nbsp;&nbsp;临床疗效评定分级标准（1）基本痊愈，功能缺损评分减少90%~100%，病残程度0级（2）显著进步功能缺损评分减少46%~89%，病残程度1-3级（3）进步，功能缺损评分减少18%~45%（4）无变化功能缺损评分减少或增加在18%以内。（5）恶化，功能缺损评分增加18%以上。<br />&nbsp;&nbsp;中医证侯疗效判定，（1）临床痊愈，中医临床症状、体征消失，证候积分减少≥95%（2）显效，中医临床症状、体征明显改善，证候积分减少≥70%（3）有效，中医临床症状、体征均有好转，证候积分减少≥30%。（4）无效，中医临床症状、体征均无明显改善，甚或加重，证候积分减少不足30% ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('605', '57', 'Z02_003', '1', '各类脑血管疾病诊断要点及疗效评定标准', ' ', '中华医学会第四次全国脑血管病学术会议', '1995', null, '中文', null, '脑栓塞', null, null, '【脑栓塞】多为急骤发病。多数无前驱症状。 一般意识清楚或有短暂性意识障碍。有颈内动脉系统和（或）椎-基底动脉系统症状和体征。腰穿脑脊液一般不含血，若有红细胞可考虑出血性脑梗死。栓子的来源可为心源性或非心源性，也可同时伴有其他脏器、皮肤、黏膜等栓塞症状。\n', null, null, '（1） 神经功能缺损积分值的减少（功能改善）（2）患者总的生活能力状态（评定时的病残程度）<br />&nbsp;&nbsp;0级，能回复工作或操持家务。1级，生活自理，独立生活，部分工作。2级，基本独立生活，小部分需人帮助。3级，部分生活活动可自理，大部分需人帮助。4级，可站立步行，但需人随时照料。5级，卧床，能做，各项生活需人照料。6级，卧床，有部分意识活动，可喂食。7级，植物人状态。<br />&nbsp;&nbsp;临床疗效评定分级标准（1）基本痊愈，功能缺损评分减少90%~100%，病残程度0级（2）显著进步功能缺损评分减少46%~89%，病残程度1-3级（3）进步，功能缺损评分减少18%~45%（4）无变化功能缺损评分减少或增加在18%以内。（5）恶化，功能缺损评分增加18%以上。<br />&nbsp;&nbsp;中医证侯疗效判定，（1）临床痊愈，中医临床症状、体征消失，证候积分减少≥95%（2）显效，中医临床症状、体征明显改善，证候积分减少≥70%（3）有效，中医临床症状、体征均有好转，证候积分减少≥30%。（4）无效，中医临床症状、体征均无明显改善，甚或加重，证候积分减少不足30% ', ' ', '2', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('606', '57', 'Z02_024', '1', '脑栓塞诊断标准（自拟）', null, '第二次全国脑血管学术会议', '1986', '常见疾病的诊断与疗效判断标准', '中文', null, '脑栓塞', null, null, '1.多为急性发病。2.多数无前驱症状。3.一般意识清楚或有短暂性意识障碍。4.有颈动脉系统和或椎基底动脉系统的症状和体征。5.腰穿脑脊液一般不含血，若有红细胞可考虑出血性脑栓塞。6.栓子的来源可谓心源性或非心源性，也可同时伴有其他脏器，皮肤，黏膜等栓塞症候。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('607', '57', 'Z02_025', '1', '脑栓塞诊断标准（自拟）', '', '美国国家神经及神经系统关联病和卒中研究中心', '1982', '常见疾病的诊断与疗效判断标准', '中文', 'bb', '脑栓塞', '', 'aa', '1.下述两项以上，急性起病且症状持续24小时以上者1-7与脑血栓之1-7相同，8为抽搐（指24小时内抽1次或1词以上者。）<br />\r\n&nbsp;&nbsp;2.可能有下述栓子源存在时（1）心脏瓣膜病（2）心房纤颤（3）有附壁血栓的心肌梗塞（4）心脏手术（5）空气栓塞（6）脂肪栓赛（7）心脏粘液瘤（8）颈动脉溃疡性动脉硬化斑块（9）细菌性心内膜炎。<br />\r\n&nbsp;&nbsp;3.脑脊液呈血性或清亮透明（可能检查时）<br />\r\n&nbsp;&nbsp;4.辅助检查同脑血栓，至少有一项为阳性（即CT显示出血性梗塞，脑血管造影显示过度关注。另外，必须用脑闪烁扫描除外脑肿瘤）确定诊断：1-4.高度怀疑1、2、3或4。', 'dd', 'cc', 'ee', 'ff', '3', '0', 'admin', null, 'admin', '2016-05-10 18:06:40');
INSERT INTO `biz_standard` VALUES ('6073fb408b854b9b9fd4a1eb3a387487', '3', 'bbb', '0', 'bbb', '', 'bbbb', null, '', '中文', '', '', '', '', '', '', '', '', '', '1', '0', 'admin', '2016-05-11 16:07:32', 'admin', '2016-05-11 16:07:32');
INSERT INTO `biz_standard` VALUES ('608', '57', 'Z02_021', '1', '脑血栓诊断标准（自拟）', null, '中华医学会第二次全国脑血管学术会议第三次修订', '1986', '常见疾病的诊断与疗效判断标准', '中文', null, '脑血栓', null, null, '1.常于安静状态下发病。<br />&nbsp;&nbsp;2.大多数无明显头痛和呕吐。<br />&nbsp;&nbsp;3.发病可较缓慢，多逐渐发展或成阶段性进行，多与脑动脉粥样硬化有关，也可见于动脉炎，血液病等。<br />&nbsp;&nbsp;4.一般发病后1-2天内意识清楚或轻度障碍。<br />&nbsp;&nbsp;5.有颈部动脉系统和或椎基底动脉系统症状和体征。<br />&nbsp;&nbsp;6.腰穿脑脊液一般不应含血。<br />&nbsp;&nbsp;7.鉴别诊断困难时如有条件可作CT检查。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('609', '57', 'Z02_022', '1', '脑血栓诊断标准（自拟）', null, '国际神经系传染病及卒中协会', '1982', '常见疾病的诊断与疗效判断标准', '中文', null, '脑血栓', null, null, '1.具备下列1项以上神经症状或体征，且至少持续24h（1）意识障碍（2）视力视野障碍（3）轻瘫或偏瘫，或两侧瘫痪（尤其于脑干损害时）（4）偏侧感觉障碍（5）言语障碍（6）吞咽困难（7）运动失调。2.脑脊液五色透明。3.至少可见一下1项以上辅助检查有阳性改变（1）CT扫描可见提示脑水肿，脑缺血病变的低密度区域，无出血性改变。（2）脑血管造影发现1支或1支以上主干动脉高度狭窄或闭塞改变。（3）脑扫描提示脑梗塞而除外脑肿瘤。完全具备以上1、3两项（倘已行2项检查时）者，可以确诊，具备1、2及3中（3）项者，为高度可能。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('61', '36', 'S01_003', '0', 'IgＡ肾病西医诊断和中医辨证分型的实践指南', null, '中国中西医结合学会肾脏疾病专业委员会', '2013', '中国中西医结合学会肾脏疾病专业委员会.IgＡ肾病西医诊断和中医辨证分型的实践指南[J].中国中西医结合杂志,2013,33(５):583-585.', '中文', null, ' IgA肾病', 'IgA肾病无特定的中医病名，大多归属于“血尿”、“水肿”、“腰痛”、“肾风”、“虚劳”等范畴中.', '1.急性发作期:<br />&nbsp;&nbsp;1.1 外感风热证<br />&nbsp;&nbsp;1.2 下焦湿热证<br />&nbsp;&nbsp;2. 慢性持续期<br />&nbsp;&nbsp;2.1 肺脾气虚证<br />&nbsp;&nbsp;2.2 气阴两虚证<br />&nbsp;&nbsp;2.3 肝肾阴虚证<br />&nbsp;&nbsp;2.4 脾肾阳虚证<br />&nbsp;&nbsp;３ 特殊辨证<br />&nbsp;&nbsp;3.1 IgA肾病在使用大剂量激素或配合免疫抑制剂治疗时多表现为：（１）阴虚火旺证,（２）热毒炽盛证。<br />&nbsp;&nbsp;3.2 IgA肾病在使用激素配合免疫抑制剂治疗的减量期多表现为：（１）气阴两虚证；（２）肝肾阴虚证；（３）脾肾阳虚证,易夹兼证：湿热、血瘀。<br />&nbsp;&nbsp;4 兼证辨证<br />&nbsp;&nbsp;4.1 水湿。<br />&nbsp;&nbsp;4.2 痰湿。<br />&nbsp;&nbsp;4.3 湿热。<br />&nbsp;&nbsp;4.4 寒湿。<br />&nbsp;&nbsp;4.5 血瘀。<br />&nbsp;&nbsp;4.6 肝郁。<br />&nbsp;&nbsp;4.7 浊毒。<br />&nbsp;&nbsp;', '１. IgA肾病的临床诊断线索<br />&nbsp;&nbsp;临床上有下列线索应考虑IgA 肾病的诊断：（１）上呼吸道感染或扁桃体炎发作后出现肉眼血尿或尿检异常加重；（２）典型的畸形红细胞尿合并不同程度蛋白尿；（３）血清IgA值增高。<br />&nbsp;&nbsp;２　IgA肾病的病理诊断<br />&nbsp;&nbsp;IgA 肾病的确诊依赖于肾活检免疫病理检查。IgA肾病的光镜切片以２μｍ 左右为好，常规４种染色：（１）ＨＥ染色，主要观察肾组织的基本结构，分辨细胞种类；（２）ＰＡＳ染色，主要观察细胞的位置和细胞外基质的多少；（３）ＰＡＭ 染色，观察肾小球和肾小管基底膜较清楚；（４）Ｍａｓｓｏｎ染色，易于观察细胞核、免疫复合物和纤维化的程度。IgA肾病的光镜下改变通常是多种多样的，可以表现为几乎正常的“轻微病变”，也可表现为肾小球系膜或毛细血管内、外不同程度的增殖、硬化，最常见的表现为系膜增殖。部分典型病例ＰＡＳ染色后观察，在肾小球系膜区和（或）旁系膜区有均质的嗜复红免疫复合物沉积。在肉眼血尿伴快速进展性肾功能不全的肾活检标本中常常有新月体形成。肾小管间质损害多继发于肾小球病变，在病变或硬化的小球周围，表现为肾小管萎缩、间质炎细胞浸润和间质纤维化。IgA肾病血管病变的发生率高于非IgA系膜增生性肾炎和特发性膜性肾病，而且肾小动脉的病变重、玻璃样变的发生率高。<br />&nbsp;&nbsp;IgA肾病的诊断必须依赖免疫病理检查，推荐使用免疫荧光直接法检查。常用的抗体包括：ＩｇＧ、IgA、ＩｇＭ、Ｃ３、Ｃ４、Ｃ１ｑ、Ｆｉｂｒｉｎ，必要时可进行免疫球蛋白轻链κ和λ以及ＨｂｓＡｇ和ＨｂｃＡｇ染色以鉴别诊断。以IgA为主的免疫球蛋白在肾小球系膜区呈团块状或颗粒状弥漫性沉积是IgA 肾病诊断必备的条件。绝大多数IgA肾病患者合并Ｃ３的沉积，并与IgA 的分布一致；约半数患者同时合并ＩｇＧ 、ＩｇＭ 的沉积；原发性IgA肾病很少有Ｃ１ｑ和Ｃ４的沉积。<br />&nbsp;&nbsp;IgA肾病的电镜表现为系膜区和旁系膜区电子致密物沉积。<br />&nbsp;&nbsp;长期以来，IgA肾病病理分类多采取Ｌｅｅ氏分级、Ｈａａｓ氏分级、参照狼疮性肾炎ＷＨＯ病理形态学分类的分级以及Ｋａｔａｆｕｃｈｉ半定量积分，但均有一定的局限性。２００９年国际IgA 肾病协作组和美国肾脏病理协会的专家们在IgA 肾病的病理组织学分类上达成一个国际共识（IgA肾病的牛津病理分类），提出４种病理组织学改变可以作为IgA 肾病预后的预测指标：（１）系膜细胞增多；（２）节段硬化或粘连；（３）毛细血管内细胞增多；（４）肾小管萎缩／间质纤维化。建议IgA肾病的肾活检报告，应该详细描述这些病理特征在光镜、免疫荧光及电镜下的表现，给出诊断并对所见的特征进行量化评分：系膜细胞增殖评分≤０.５（Ｍ０），＞０.５（Ｍ１）；节段硬化或粘连，无（Ｓ０），有（Ｓ１）；毛细血管内细胞增多，无（Ｅ０），有（Ｅ１）；肾小管萎缩／间质纤维化，≤２５％（Ｔ０），２６％～５０％（Ｔ１），＞５０％（Ｔ２）。<br />&nbsp;&nbsp;还需描述肾小球的总数目及毛细血管内增殖、坏死、细胞性／纤维细胞性新月体、球性肾小球硬化及节段肾小球硬化的肾小球数目。例如：IgA 肾病：系膜增殖、节段硬化、４０％肾小管萎缩／间质纤维化（Ｍ１、Ｅ０、Ｓ１、Ｔ１）。<br />&nbsp;&nbsp;３　IgA肾病的鉴别诊断<br />&nbsp;&nbsp;由于上述病理表现不是原发性IgA肾病特有的，因此必须除外各种继发性IgA肾病才能诊断原发性IgA肾病。原发性和继发性IgA肾病的鉴别主要依靠病史和辅助检查。一般情况下，只要有继发因素存在，首先考虑继发性IgA肾病，尤其是IgA的沉积是局灶或节段性的或不很明显以及组织病理表现的程度和类型很不均一时，更应考虑继发性IgA肾病。常见继发性IgA肾病的原发病有:过敏性紫癜、病毒性肝炎、肝硬化、系统性红斑狼疮、类风湿关节炎、银屑病等。<br />&nbsp;&nbsp;', '1.急性发作期<br />&nbsp;&nbsp;1.1 外感风热证<br />&nbsp;&nbsp;主症：发热或微恶风寒，咽喉肿痛，小便红赤或镜下血尿，泡沫尿，诱发因素多为上呼吸道感染。<br />&nbsp;&nbsp;次症：咳嗽，头痛。<br />&nbsp;&nbsp;舌脉：舌红或舌边尖红，苔薄黄，脉浮数。<br />&nbsp;&nbsp;1.2 下焦湿热证<br />&nbsp;&nbsp;主症：小便短赤或镜下血尿，小便频数灼热，大便腥臭稀溏。<br />&nbsp;&nbsp;次症：口干、口苦，脘腹胀闷，腰部疼痛。<br />&nbsp;&nbsp;舌脉：舌红，苔黄腻，脉滑数。<br />&nbsp;&nbsp;2. 慢性持续期<br />&nbsp;&nbsp;2.1 肺脾气虚证<br />&nbsp;&nbsp;主症：面色苍白或萎黄，神疲懒言，纳少、腹胀，颜面或肢体水肿，易感冒。<br />&nbsp;&nbsp;次症：口淡不渴，自汗，大便溏薄。<br />&nbsp;&nbsp;舌脉：舌淡红，质胖大边有齿痕，苔薄白，脉细弱。<br />&nbsp;&nbsp;易夹兼证：水湿，痰湿，血瘀，浊毒。<br />&nbsp;&nbsp;2.2 气阴两虚证<br />&nbsp;&nbsp;主症：气短乏力，盗汗、自汗，腰膝酸软，手足心热。<br />&nbsp;&nbsp;次症：口干、神疲。<br />&nbsp;&nbsp;舌脉：舌淡或淡红，质胖大边有齿痕，少苔偏干，脉沉细或细数而无力。<br />&nbsp;&nbsp;易夹兼证：血瘀，湿热。<br />&nbsp;&nbsp;2.3 肝肾阴虚证<br />&nbsp;&nbsp;主症：目睛干涩或视物模糊，耳鸣、腰痛，头目眩晕，潮热盗汗，五心烦热。<br />&nbsp;&nbsp;次症：口干、口苦，失眠多梦，梦遗或月经失调。<br />&nbsp;&nbsp;舌脉：舌红，苔薄黄而干或少苔偏干，脉细数或细弦数。<br />&nbsp;&nbsp;易夹兼证：肝郁，血瘀，湿热。<br />&nbsp;&nbsp;2.4 脾肾阳虚证<br />&nbsp;&nbsp;主症：面色白或黧黑，神疲乏力，畏寒肢冷，肢体水肿，夜尿增多。<br />&nbsp;&nbsp;次症：口淡不渴、或喜热饮，纳少，腹胀，小便清长或尿少，大便溏薄。<br />&nbsp;&nbsp;舌脉：舌淡，质胖边有齿痕，苔薄白，脉沉弱或沉细。<br />&nbsp;&nbsp;３ 特殊辨证<br />&nbsp;&nbsp;3.1 IgA肾病在使用大剂量激素或配合免疫抑制剂治疗时多表现为：（１）阴虚火旺证：主症：潮热盗汗，心烦失眠，颧红耳鸣，咽痛口干；次症：腰膝酸软，口干唇燥，大便干结，小便短赤；舌脉：舌红少苔、脉细数。<br />&nbsp;&nbsp;（２）热毒炽盛证：主症：口渴欲饮，咽干咽痛，皮肤痤疮，大便秘结；次症：小便短赤，口腔溃疡，血尿；舌脉：舌红或红赤起刺，苔黄厚腻，脉数。<br />&nbsp;&nbsp;3.2 IgA肾病在使用激素配合免疫抑制剂治疗的减量期多表现为：（１）气阴两虚证；（２）肝肾阴虚证；<br />&nbsp;&nbsp;（３）脾肾阳虚证。主、次症及舌脉同慢性持续期的表现。易夹兼证：湿热、血瘀。<br />&nbsp;&nbsp;4 兼证辨证<br />&nbsp;&nbsp;4.1 水湿 主要表现为肢体、颜面水肿，肢体困重，纳差，腹胀，舌淡润苔白，脉沉。<br />&nbsp;&nbsp;4.2 痰湿 主要表现为体形肥胖，口黏口腻，胸闷痰多，眩晕困倦，舌体胖大，苔白腻，脉滑。<br />&nbsp;&nbsp;4.3 湿热 主要表现为小便短赤，大便溏臭，口干口苦，脘腹胀闷，舌红苔黄腻，脉滑数。<br />&nbsp;&nbsp;4.4 寒湿 主要表现为腰骶部及四肢关节酸冷，肢体困重疼痛。<br />&nbsp;&nbsp;4.5 血瘀 主要表现为面色黎黑，唇色紫暗或有瘀斑，定位刺痛、夜间加重，腰痛，肢体麻木，肌肤甲错，经色暗，多血块，舌淡黯、舌有瘀点、瘀斑，舌下脉络瘀紫，脉细涩或涩。<br />&nbsp;&nbsp;4.6 肝郁 主要表现为胁肋胀满，口苦，郁郁寡欢，善太息，月经失调。<br />&nbsp;&nbsp;4.7 浊毒 主要表现为恶心呕吐，头晕、头痛，口有尿味，小便量少，胸闷气促，皮肤瘙痒。<br />&nbsp;&nbsp;', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('62', '36', 'S01_004', '1', 'KDIGO肾小球肾炎指南-内固醇敏感儿童肾病综合症', 'KDIGO Clinical Practice Guideline for Glomerulonephritis-Steroid-sensitive nephrotic syndrome in children\n', ' 改善全球肾脏病预后组织(KDIGO)', '2012', 'http://kdigo.org/home/glomerulonephritis-gn/;$$$$\nKidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for\nGlomerulonephritis. Kidney inter., Suppl. 2012; 2: 139–274.', '英文', null, '内固醇敏感儿童肾病综合症；Steroid-sensitive nephrotic syndrome in children\n', null, null, 'S01_004_01儿童肾病综合征定义.docx<br />&nbsp;&nbsp;\n水肿, uPCR ≥2000 mg/g (≥200 mg/mmol), or≥300 mg/dl, or 3+ 尿液试纸蛋白, 低蛋白血症 ≤2.5 g/dl (≤25 g/l)<br />&nbsp;&nbsp;Edema, uPCR ≥2000 mg/g (≥200 mg/mmol), or≥300 mg/dl, or 3+ protein on urine dipstick, hypoalbuminaemia ≤2.5 g/dl (≤25 g/l)', null, '尿蛋白清除率urine protein:creatinine ratio.', ' ', '本章是针对内固醇治疗有效的1到18岁儿童。This chapter makes treatment recommendations for children aged 1 to 18 years with nephrotic syndrome, who respond to corticosteroid therapy by achieving complete remission (SSNS). The cost implications for global application of this guideline are addressed in Chapter 2. This chapter does not apply to children under 1 year of age in whom nephrotic syndrome is often associated with gene mutations and with histologies other than MCD.\n', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('63', '36', 'S01_005', '1', 'KDIGO肾小球肾炎指南-激素抵抗型儿童肾病综合症', 'KDIGO Clinical Practice Guideline for Glomerulonephritis-Steroid-resistant nephrotic syndrome in children\n', ' 改善全球肾脏病预后组织', '2012', 'http://kdigo.org/home/glomerulonephritis-gn/;$$$$\nKidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for\nGlomerulonephritis. Kidney inter., Suppl. 2012; 2: 139–274.', '英文', null, '激素抵抗型儿童肾病综合症；Steroid-resistant nephrotic syndrome in children\n', null, null, '以下评估的SRNS患儿<br />&nbsp;&nbsp;4.4.1:我们建议至少8周治疗定义类固醇皮质激素抵抗。(2 d) <br />&nbsp;&nbsp;4.1.2:以下是评估儿童所需SRNS(不计入分数): <br />&nbsp;&nbsp;--诊断肾活检; <br />&nbsp;&nbsp;--评价肾功能的肾小球滤过率(GFR)和表皮生长因子受体; <br />&nbsp;&nbsp;--定量尿蛋白排泄。<br />&nbsp;&nbsp;\nEvaluation of children with SRNS<br />&nbsp;&nbsp;4.1.1: We suggest a minimum of 8 weeks treatment with corticosteroids to define steroid resistance. (2D) <br />&nbsp;&nbsp;4.1.2: The following are required to evaluate the child with SRNS (Not Graded): <br />&nbsp;&nbsp;K a diagnostic kidney biopsy; <br />&nbsp;&nbsp;K evaluation of kidney function by GFR or eGFR; <br />&nbsp;&nbsp;K quantitation of urine protein excretion. <br />&nbsp;&nbsp;\n', null, '尿蛋白清除率urine protein:creatinine ratio.', null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('64', '36', 'S01_006', '1', 'KDIGO肾小球肾炎指南-成人特发性局灶节段性肾小球硬化症', 'KDIGO Clinical Practice Guideline for Glomerulonephritis-Idiopathic focal segmental glomerulosclerosis in adults', ' 改善全球肾脏病预后组织', '2012', 'http://kdigo.org/home/glomerulonephritis-gn/;$$$$\nKidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for\nGlomerulonephritis. Kidney inter., Suppl. 2012; 2: 139–274.', '英文', null, '成人特发性局灶节段性肾小球硬化症；Idiopathic focal segmental glomerulosclerosis in adults', null, null, 'S01_006_01成人局灶性节段性肾小球硬化症的肾病综合征.docx', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('65', '36', 'S01_007', '1', 'KDIGO肾小球肾炎指南-特发性膜性肾病', 'KDIGO Clinical Practice Guideline for Glomerulonephritis- Idiopathic membranous nephropathy', ' 改善全球肾脏病预后组织', '2012', 'http://kdigo.org/home/glomerulonephritis-gn/;$$$$\nKidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for\nGlomerulonephritis. Kidney inter., Suppl. 2012; 2: 139–274.', '英文', null, '特发性膜性肾病；Idiopathic membranous nephropathy', null, null, '1.建议只有在当至少满足下列条件之一,启动初始治疗肾病综合症患者:<br />&nbsp;&nbsp;——尿蛋白排泄持续超过4g / d和仍然超过50%的基线值,并且不显示逐步下降,在抗高血压和抗蛋白尿治疗(见第1章)在至少6个月的观察期;(1 b)<br />&nbsp;&nbsp;——存在严重、禁用或致命性的肾病综合征相关症状;(1 c)<br />&nbsp;&nbsp;-- 从诊断6至12个月内 SCr已上涨30%或更多的,但表皮生长因子受体不小于25 - 30 ml/min每1.73平方米,这种变化不是解释为叠加的并发症。(2 c)<br />&nbsp;&nbsp;2.不使用免疫抑制治疗的患者一个可控SCr持续>3.5 mg / dl(>309 μmol / l)(或一个eGFR o30毫升/每分钟1.73平方米)和对超声肾脏大小减少(如, <8厘米长)或伴随严重或潜在致命性的感染。(未分级)1.We recommend that initial therapy be started only in patients with nephrotic syndrome AND when at least one of the following conditions is met:<br />&nbsp;&nbsp;-- urinary protein excretion persistently exceeds 4 g/d AND remains at over 50% of the baseline value, AND does not show progressive decline, during antihypertensive and antiproteinuric therapy (see Chapter 1) during an observation period of at least 6 months; (1B)<br />&nbsp;&nbsp;-- the presence of severe, disabling, or lifethreatening symptoms related to the nephrotic syndrome; (1C)<br />&nbsp;&nbsp;\n--SCr has risen by 30% or more within 6 to 12 months from the time of diagnosis but the eGFR is not less than 25–30 ml/min per 1.73m2 AND this change is not explained by superimposed complications. (2C) <br />&nbsp;&nbsp;2: Do not use immunosuppressive therapy in patients with a SCr persistently >3.5 mg/dl (>309 μmol/l) (or an eGFR <30 ml/min per 1.73m2) AND reduction of kidney size on ultrasound (e.g., <8 cm in length) OR those with concomitant severe or potentially lifethreatening infections. (Not Graded) <br />&nbsp;&nbsp;\n', null, '尿蛋白排泄Urinary protein excretion', 'S01_007_01缓解.docx', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('66', '36', 'S01_008', '1', 'KDIGO肾小球肾炎指南', 'KDIGO Clinical Practice Guideline for Glomerulonephritis', ' 改善全球肾脏病预后组织', '2012', 'http://kdigo.org/home/glomerulonephritis-gn/;$$$$\nKidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for\nGlomerulonephritis. Kidney inter., Suppl. 2012; 2: 139–274.', '英文', null, '肾小球肾炎', null, null, '1.评估肾脏功能<br />&nbsp;&nbsp;肾小球肾炎的关键结果管理办法包括评估肾脏功能,尤其是测量蛋白尿和肾小球滤过率(GFR)。<br />&nbsp;&nbsp;肾病综合症在发表文献的传统定义是每24小时蛋白尿43.5 g(儿童440 mg / m2 /hr或PCR 42000 mg / g(4200mg/mmol)或4300 mg / dl或3 t尿液试纸)+低白蛋白血症和水肿。Nephrotic-range蛋白尿几乎总是任意定义为蛋白尿每24小时(43.5 g uPCR 42000mg/ g(4200mg/mmol)儿童)在缺乏临床明显的肾病综合症。通过定义没有临床症状,无症状性蛋白尿变量的蛋白尿水平的范围0.3-1.5 g / 24小时(或同等)。<br />&nbsp;&nbsp;2.肾小球滤过率<br />&nbsp;&nbsp;大部分的现有证据治疗GN的基于估计使用血清肌酐的排泄肾功能(SCr)或肌酐清除率(CrCl)，需要24小时尿液收集。<br />&nbsp;&nbsp;\n1.Assessment of Kidney Function<br />&nbsp;&nbsp;Key outcome measures for the management of GN include assessment of kidney function, particularly measurement of proteinuria and glomerular filtration rate (GFR).<br />&nbsp;&nbsp;The conventional definition of nephrotic syndrome in the published literature is proteinuria 43.5 g per 24 hours (in children, 440 mg/m2/hr or PCR 42000 mg/g [4200 mg/ mmol] or 4300 mg/dl or 3t on urine dipstick) plus hypoalbuminemia and edema. Nephrotic-range proteinuria is nearly always arbitrarily defined as proteinuria 43.5 g per 24 hours [uPCR 42000 mg/g [4200 mg/mmol] in children)<br />&nbsp;&nbsp;in the absence of clinically overt nephrotic syndrome. Asymptomatic proteinuria, by definition without clinical symptoms, has variable levels of proteinuria in the range of 0.3–1.5 g per 24 hours (or equivalent).<br />&nbsp;&nbsp;2.Estimation of GFR<br />&nbsp;&nbsp;Most of the available evidence for  treatment of GN has been based on estimations of excretory kidney function using serum creatinine (SCr) or creatinine clearance (CrCl) requiring a 24-hour urine collection. <br />&nbsp;&nbsp;\n', null, '主要结果是：<br />&nbsp;&nbsp;--蛋白尿的变化<br />&nbsp;&nbsp;--肾小球滤过率<br />&nbsp;&nbsp;--血清肌酐水平<br />&nbsp;&nbsp;--完全或部分缓解<br />&nbsp;&nbsp;--复发率<br />&nbsp;&nbsp;--肾脏疾病的进展<br />&nbsp;&nbsp;--终末期肾脏疾病<br />&nbsp;&nbsp;--死亡/死亡率/生存<br />&nbsp;&nbsp;--生活质量<br />&nbsp;&nbsp;--协议驱动额外治疗肾小球肾炎<br />&nbsp;&nbsp;--药物不良发生率的影响<br />&nbsp;&nbsp;Major Outcomes Considered：<br />&nbsp;&nbsp;--Changes in proteinuria<br />&nbsp;&nbsp;--Glomerular filtration rate<br />&nbsp;&nbsp;--Serum cre畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭잸ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔ햞௤ਘĀ\0ꃨ௤彿㎽奋㎽巫㎽⬞௥䦎௥彿㎽䦂௥塚㎽䦎௥ꍈ㏂\0\0햞௤學㎽漸㏂圔㎽햞௤圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0잸ਘ䐺盭暼痭잸ਘༀƙ \0잸ਘð\0\0㺣盭잸ਘ\0ﱔ잼ਘ\0팃目잼ਘࡻ잼ਘ큁目잼ਘ헒௤﫬\0Item\0\0䨒௥\0\0\0\0\0\0Count\0\0ﱬﬄ쟬ਘ쭼ਢ\0\0잼ਘ\0\0\0\0ਢ寶目쮀ਢ矵䥷㎽⬞௥\0\0䨒௥�㏂䦂௥\0\0\0ਢ\0\0\0謁ﱔ\0\0㎾ц\0ﱜ', '1.Complete remission, ESRD, mortality<br />&nbsp;&nbsp;A definitive assessment of the efficacy of a treatment for GN requires the demonstration that end-stage renal disease (ESRD) has been prevented, and mortality reduced. Very few studies in GN have been of sufficient畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭잸ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔ햞௤ਘĀ\0ꃨ௤彿㎽奋㎽巫㎽ⴺ௥䩊௥彿㎽䨾௥塚㎽䩊௥ꍈ㏂\0\0햞௤學㎽漸㏂圔㎽햞௤圞㎽\0\0圭㎽ﱔ霪Wༀƙ \0ༀƙ戤痝\0Ɨ\0\0㠰੟䐺盭暼痭㠰੟ༀƙ \0㠰੟ð\0\0㺣盭㠰੟\0ﱔ㠴੟\0팃目㠴੟ࡻ㠴੟큁目㠴੟헒௤﫬\0Item\0\0䫎௥\0\0\0\0\0\0Count\0\0ﱬﬄ㡤੟쭼ਢ\0\0㠴੟\0\0\0\0ਢ寶目쮀ਢ矵䥷㎽ⴺ௥\0\0䫎௥�㏂䨾௥\0\0\0ਢ\0\0\0謁ﱔ\0\0㎾ᐐ\0ﱜ\0\0x�㏂䨾௥\0\0隲W䫎௥\0\0�Ĳ\0\0\0醙ﱜ﫴\0\0霈Wﬔﱈ霫Wﬔ\0\0ﱜx\0霪W露W\0\0ﱴxt\0Љ\0\0\0宨ƚ鲬ࡻ菮畻\0\0\0\0쫐ਢEo\0\0쬤ਢ\0\0저੐저੐쬨ਢ퓒௤寶目쬨ਢ퓒௤i\0\0ﱄ﷜ﱴﲔ먙㎼퓒௤쬨ਢi\0\0ﱄ﷜ﱴ먰㎼﷜퓒௤�㏂푂௤\0\0릎㎼퓒௤i\0╪췬目╾췬目Љ\0镴ࡻ\0￿￿目Љ\0镨ࡻ宨ƚ竗宨ƚ目W\0竗\0\0\0賓器目\0\0\0\0헒௤\0目瑉浥目\0\0\0\0헒௤\0目潃湵t\0\0\0\0ǒ\0\0ဠ\0\0ꯈʩﯬꯈʩච̓\0\0\0\0\0\0\0ච̓꒠̑\0\0\0\0\0\0\0$\0\0轖ဖ໘̉\0\0꒠̑\0\0\0\0ච̓ﰼ뎥ဆ\0ē\0錠ƚ錠ƚ룤ဆ돜်錠ƚЉ\0\0\0⟒췬⟚췬目Љ\0鲸ࡻ\0￿￿目Љ\0鲬ࡻ宨ƚ觴宨ƚ目t\0觴\0\0\0﯈ﮜ目\0\0\0\0ﱨ퓒௤目潅f摲敳t盡燎捥盦通묞￾￿吊盡璀Ӯ3뜐੎ཬब璀綻眶E\0Ӯ3\0\0ℇ鈁.\0\0\0\0䛌E\0덐ɫ‾Q岛@\0䛌E\0덐ɫ‾Q岛@\0⎐ۓ﮵S豀ɳ\0덐ɫ\0﯏S臀ɳ\0豀ɳ\0䛌E\0템瞕풒瞕(\0픔瞕\0⫠⫠픔瞕⫠⪌䪤㏂奈瞒⫠\0\0\0瞒⪌쀕瞒若〠\0䪔㏂\0T\0\0⪌쀕\0\0ꀀ翽翽凜瞒郎瘝䪔㏂\0邰ƙ\0\0ࠀᴒ眊\0\0䪔㏂瘝\0邰ƙ\0\0ࠀ\0\0\0邰ƙ\0\0ࠀ﫜퓒௤ﬥ眿䊘㏂邰ƙ\0\0\0\0\0\0\0\0\0฀勤﬘眿捻ฒ䫎௥﫨ﬥ眿㏂邰ƙ\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0￿﫜￿￿\0\0﫦\0\0￿￿\0\0\0㏂￿￿\0\0\0㏂\0\0￿￿\0\0\0õ\0\0\0\0\0奰畿⫡췬臭焚畻邰ƙࠀ﫜￿￿㏂￿￿\0\0\0\0愈煔畻:\0﫜￿￿㏂￿￿奰畿\0\0\0\0﬘㎾ࠄ\0\0﫜￿￿㏂㎾x\0\0�㏂䨾௥\0\0頲Wאּ\0\0\0\0ࠄ\0顇WValu\0\0﫜שּׁ䫎௥ﱜ\0\0\0\0\0\0﫜\0﫨\0ﰰ餀Wﱜﲈ	\0ﳸ\0\0ᘼۊэ\0٪\0\0\0\0\0駌঍\0\0ﮀ⮒췬ﮀ뜩@﷩\0\0\0ɣ\0ﮠ䗧@ﭸ蕶@ᘰۊﱰ﯌ɤ\0뮩@ﮰ믆@믎@ﱰ﷩\0釚@ﱰﱰ﷩\0ༀƙﱴༀƙ﯐戤痝\0Ɨ\0\0荀ੑﯴꃜ௤ꃨ௤忉㎽䦂௥奁㎽ꃨ௤	\0䦎௥䩊௥彿㎽ﱤ䦕盭䩊௥	\0䩊௥忉㎽ﱔ䥷盭䩊௥\0\0	\0ﱬ䫎௥ﱴ馘Bﱜﳸxﲈﲈ駰Bﱴ虘ह몐ी\0௥\0\0ﱔ︜ﱜx︜x︄ﳸxﲔx︜ﲠx︜︸x︜\0\0虘ह뿄x\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0\0\0헒௤䗆@	\0헒௤䫎௥\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0\0	\0ʎC헒௤︜C헒௤\0\0\0\0\0௤\0\0\0\0௤﷜￿\0\0\0\0\0\0￿\0\0\0\0\0꒰ी\0\0\0ﺄ\0\0ﺈ尐ɪ௥\0\0맜੪︜\0\0醬ֱﺐ嵿{ﹸ\0\0\0\0\0ﺄ﹄庱{ﺐﺘ彨{ﺐ\0\0\0\0ﺰࣚ栌֬ﹼ邏S\0\0ㄐ঵\0\0쌰ɯ\0\0\0尐ɪ\0\0঻\0\0ﻨⰛEﺤⰺEﻨﺰⱹEﻨﺼⳗEﻨﻰ⳶Eﻨ\0\0\0\0Რम\0\0\0\0蝸हﺀࣚﻰĒ８䳫Tｄ䴙T８\0\0\0\0츐ɳ\0\0\0\0\0Ā츐ɳｬ㻨T਌\0\0\0\0\0\0싳ǒ\0Ƨ\0ꋴĵ䈆Tｐ䈐Tｬｸ䉉Tｬ\0\0\0\0ꋴĵ츐ɳﾈ잜Ĳꀀ翽ￄ枴@ﾈ\0\0ﾔ眿ꀀ翽ￔ㭓瞖ꀀ翽ᮒ眊\0\0\0\0ꀀ翽\0\0\0\0\0\0ﾠ\0\0￿￿瞑\0\0￬㬦瞖얼Ĳꀀ翽\0\0\0\0\0\0\0\0얼Ĳꀀ翽\0\0譕召�䖋倌䶋謈ᢑ＀菒ӄ䶋༈醷ش\0숻Ѵ쀳⏫䖋倌䶋脈ⳁ儀喋謈ᒂ＀菐ࣄ�쀛삃嬁쉝쳌쳌쳌쳌쳌쳌삋鱠è\0堀%￰￿⑴倨탿삅ᕵ憝è\0堀%￰诿Ҁ＀㏠觀⑄鴠쉡쳌쳌쳌邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐譕臬⣬였웿옒웂온贀�觿��诿櫒栀Ȑ\0趍﷠￿橑謁ౕ譒ࡅ袋М\0퇿삅մ跩\0ༀ閷﷠￿䖋༈袷࠾\0턻ɴ盫喋脈㛂刀薋﷤￿譐ࡍ醋Д\0틿쒃蔈痀譓ࡅ褀��跿ﱍ橑贄��勿䖋謈⒈儀ｪ喋謈₂＀跐ﱍ橑贅譒ࡅ袋Ш\0橑诿ࡕ芋Р\0탿쉝쳌쳌쳌쳌쳌즋譐⑄茌￸⍵ｘ倒䒋ࠤ鱠è\0嬀￿卐￾鷿塡⣂堀ዿ⣂찀쳌쳌쳌쳌쳌邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐邐`劁眿邐邐邐邐邐邐犡瞕⍤瞓慌瞔靷睁盠屖瞔', '本指南包括的肾小球疾病有:儿童激素敏感型肾病综合征、儿童激素抵抗型肾病综合征、微小病变、特发性局灶节段性肾小球硬化、特发性膜性肾病、膜增生性肾小球肾炎、感染相关性肾小球肾炎、IgA肾病、过敏紫癜性肾炎、狼疮性肾炎、寡免疫复合物局灶节段坏死性肾小球肾炎和抗肾小球基膜肾炎。指南推荐的治疗方法是基于系统回顾及相关的临床试验证据。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('67', '36', 'S01_009', '1', '肾小球肾炎', 'Glomerulonephritis', '新加坡卫生部', '2007', 'Singapore Ministry of Health; 2007 Mar. 130 p. [234 references]', '英文', null, '肾小球肾炎', null, null, '1.血尿管理的诊断评估<br />&nbsp;&nbsp;1.1 验尿<br />&nbsp;&nbsp;1.2 详细的历史包括尿症状的描述,最近的病史,既往史、药物史和家族史<br />&nbsp;&nbsp;1.3 体格检查包括血压测量,检查皮肤紫癜和数字血管炎,咽喉、扁桃体检查,心脏听诊杂音,液体超负荷的迹象,腹部检查扩大,ballotable 肾脏或其他器官巨大症, 男性前列腺直肠指诊。<br />&nbsp;&nbsp;1.4 实验室评价包括全血细胞计数,肾脏功能测试,尿液文化、尿液相衬显微镜和尿蛋白测量。<br />&nbsp;&nbsp;1.5 必需的神经病学l转诊。<br />&nbsp;&nbsp;1.6 超声成像研究,包括静脉尿路造影术,灵活的膀胱尿道镜检查。<br />&nbsp;&nbsp;2.管理蛋白尿的诊断评估<br />&nbsp;&nbsp;2.1 详细的历史包括描述尿症状,既往史和药物的历史。<br />&nbsp;&nbsp;2.2 体检包括血压,最终器官损伤的迹象，因高血压、肾功能衰竭的迹象,糖尿病或自身免疫性疾病的迹象,水肿。<br />&nbsp;&nbsp;2.3 实验室评价包括尿液、尿液文化;血清尿素、肌酐、空腹血糖、血清白蛋白;24小时尿液收集量化(24小时尿蛋白总量)或随机或者发现尿蛋白和肌酸酐测量。<br />&nbsp;&nbsp;2.4 神经病学评价包括肾脏超声;尿液相衬显微镜;24小时尿肌酐清除率。<br />&nbsp;&nbsp;2.5 肾活检。<br />&nbsp;&nbsp;1.Management of Haematuria -- Diagnostic Assessment<br />&nbsp;&nbsp;1.1. Urinalysis<br />&nbsp;&nbsp;1.2. Detailed history including description of urinary symptoms, recent medical history, past medical history, drug history and family history<br />&nbsp;&nbsp;1.3. Physical examination including blood pressure measurement, skin examination for purpura and digital vasculitis, throat/ tonsil inspection, cardiac auscultation for murmurs, signs of fluid overload, abdominal examination for enlarged, ballotable kidneys or other organomegaly, digital rectal examination of the prostate in males<br />&nbsp;&nbsp;1.4. Laboratory evaluation including full blood count, renal function tests, urine culture, urine phase contrast microscopy, and urine protein measurement<br />&nbsp;&nbsp;1.5. Nephrological referral, as required<br />&nbsp;&nbsp;1.6. Imaging studies, including intravenous urography, ultrasonography, flexible cystourethroscopy<br />&nbsp;&nbsp;2.Management of Proteinuria -- Diagnostic Assessment<br />&nbsp;&nbsp;2.1. Detailed history including description of urinary symptoms, past medical history and drug history<br />&nbsp;&nbsp;2.2. Physical examination including blood pressure, signs of end organ damage due to hypertension, signs of renal failure, signs of diabetes or auto-immune disease, oedema<br />&nbsp;&nbsp;2.3. Laboratory evaluation including urinalysis; urine culture; serum urea, creatinine and fasting glucose; serum albumin; 24-hour urine collection for quantification (24-hour total urinary protein) OR random or spot urinary protein and creatinine measurement<br />&nbsp;&nbsp;2.4. Nephrological evaluation including ultrasound of the kidneys; urine phase contrast microscopy; 24-hour urinary creatinine clearance<br />&nbsp;&nbsp;2.5. Renal biopsy<br />&nbsp;&nbsp;S01_009_01.docx', null, null, '\n', null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('68', '36', 'S01_010', '1', '急性肾小球肾炎的循证诊治指南', null, '中国人民解放军医学会儿科分会肾脏病学组', '2013', '中国人民解放军医学会儿科分会肾脏病学组.急性肾小球肾炎的循证诊治指南[J]. 临床儿科杂志,2013,31（06）:561-564.', '中文', '原发性急性肾小球肾炎根据致病的病原菌不同，可分为急性链球菌感染后肾小球肾炎（acute poststreptococcal glomerulnephrius，APSGN）和非链球菌感染后急性肾小球肾炎（non-poststreptococcal acute glomerulonephritis）。', '急性肾小球肾炎；原发性急性肾小球肾炎；急性链球菌感染后肾小球肾炎；acute\npoststreptococcal glomerulnephrius；APSGN', null, null, '1.APSGN的临床表现<br />&nbsp;&nbsp;\nAPSGN 常表现为水肿、血尿、少尿或无尿、高血压，也可出现一系列少见复杂的临床如呼吸窘迫、肺水肿和脑病可作为APSGN 首发临床表现，先于尿检异常出现。<br />&nbsp;&nbsp;\n2.APSGN的诊断<br />&nbsp;&nbsp;\nAPSGN 满足以下第①、④、⑤三条即可诊断，如伴有②、③、⑥的任一条或多条则诊断依据更加充分：①血尿伴（或不伴）蛋白尿伴（或不伴）管型尿；②水肿，70%患儿有水肿，一般先累及眼睑及颜面部，继呈下行性累及躯干和双下肢，呈非凹陷性；③高血压，30%~80%患儿出现血压增高；④血清C3 短暂性降低，到病程第8 周94% 的患者恢复正常；⑤ 3 个月内链球菌感染证据（感染部位细菌培养）或链球菌感染后的血清学证据（抗链球菌溶血素O，或抗双磷酸吡啶核苷酸酶，或抗脱氧核糖核酸酶B，或抗透明质酸酶滴度增加），疑似APSGN 的患儿应该完善链球菌血清学检查（敏感性94.6%），其敏感性高于有明确的感染史（敏感性75.7%）和链球菌培养阳性（24.3%）者[10]；⑥临床考虑不典型的急性肾炎，或临床表现或检验不典型，或病情迁延者应考虑行肾组织病理检查，典型病理表现为毛细血管内增生性肾小球肾炎。<br />&nbsp;&nbsp;\n', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('69', '36', 'S01_011', '1', '中国儿童常见肾脏疾病诊治循证指南(试行)(四):原发性IgA肾病诊断治疗指南', 'Evidence-based guidelines on diagnosis and treatment of childhood common renal diseases (Ⅳ) : IgA nephropathy\n', '中华医学会儿科学分会肾脏病学组', '2010', '中华医学会儿科学分会肾脏病学组.中国儿童常见肾脏疾病诊治循证指南(试行)(四):原发性IgA肾病诊断治疗指南[J].2010,48(5):355-357.', '中文', '1.临床分型<br />&nbsp;&nbsp;本指南建议将我国儿童原发性IgA肾病临床表现分为以下7种类型：(1)孤立性血尿型(包括复发性肉眼血尿型和孤立性镜下血尿型)；(2)孤立性蛋白尿型(24 h尿蛋白定量<50 mg／kg)；(3)血尿和蛋白尿型(24 h尿蛋白定量<50 mg/kg)；(4)急性肾炎型；(5)肾病综合征型；(6)急进性肾炎型；(7)慢性肾炎型。<br />&nbsp;&nbsp;2.病理分型<br />&nbsp;&nbsp;I级：绝大多数肾小球正常，偶见轻度系膜增宽(节段)伴／不伴细胞增殖；Ⅱ级：半数以下肾小球局灶节段性系膜增殖或硬化，罕见小的新月体；Ⅲ级：轻畻坴畿\0\0\0\0醼畻聱盯	\0\0\0痭픠ਘༀƙ\0ਘĀ\0	\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔ햞௤ਘĀ\0ꃨ௤彿㎽奋㎽巫㎽ ௥䆚௥彿㎽䆎௥塚㎽䆚௥ꍈ㏂', '原发性IgA肾病', null, null, '诊断标准：IgA肾病是免疫病理诊断名称，其免疫荧光特征为在肾小球系膜区和(或)毛细血管襻有以IgA为主的免疫球蛋白沉积，并排除过敏性紫癜、系统性红斑狼疮、慢性肝病等疾病所致IgA在肾组织沉积者。', null, null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('7', '10', 'D02_007', '1', '糖尿病及其并发症的定义、诊断与分类', 'Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications', '世界卫生组织慢性非传染性疾病监测部（World Health Organization\nDepartment of Noncommunicable Disease Surveillance）', '1998', 'http://apps.who.int/iris/bitstream/10665/66040/1/WHO_NCD_NCS_99.2.pdf', '英文', null, 'Metabolic Syndrome', null, null, '1.Impaired glucose regulation or diabetes (see Table 1) D02_007_图表1<br />&nbsp;&nbsp;2.Insulin resistance (under hyperinsulinaemic, euglycaemic conditions, glucose uptake below lowest quartile for background population under investigation)<br />&nbsp;&nbsp;3.Raised arterial pressure≥140/90 mmHg<br />&nbsp;&nbsp;4.Raised plasma triglycerides (≥1.7mmol l–1; 150 mg dl–1) and/or low HDL–cholesterol (< 0.9 mmol l–1, 35 mg dl–1 men; < 1.0 mmol l–1, 39 mg dl–1 women)<br />&nbsp;&nbsp;5.Central obesity (males: waist to hip ratio > 0.90; females: waist to hip ratio > 0.85) and/or BMI > 30 kg m–2<br />&nbsp;&nbsp;6.Microalbuminuria (urinary albumin excretion rate≥20g min–1 or albumin: creatinine ratio≥30 mg g–1) <br />&nbsp;&nbsp;Several other components of the Metabolic Syndrome have been described (e.g. hyperuricaemia, coagulation disorders, raised PAI–1, etc.) but they are not necessary for the recognition of the condition.<br />&nbsp;&nbsp;A clear description of the essential components of the syndrome is needed together with data to support the relative importance of each component. Internationally agreed criteria for central obesity, insulin resistance and hyperinsulinaemia would be of major assistance.', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('70', '36', 'S01_012', '1', '2014 JSN临床实践指南：IgA肾病', 'Evidence-based clinical practice guidelines for IgA nephropathy 2014', ' \n\n日本肾脏病学会(JSN,Japanese Society of Nephrology)\n', '2016', 'http://link.springer.com/article/10.1007%2Fs10157-015-1223-y;$$$$ Yuzawa Y, Yamamoto R, Takahashi K, Katafuchi R, Tomita M, Fujigaki Y, Kitamura H, Goto M, Yasuda T, Sato M, Urushihara M, Kondo S, Kagami S, Yasuda Y, Komatsu H, Takahara M, Harabuchi Y, Ki畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭੧ༀƙ\0੧`\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔ햞௤੧`\0ꃨ௤彿㎽奋㎽巫㎽᥂௥㽦௥彿㎽㽚௥塚㎽㽦௥ꍈ㏂\0\0햞௤學㎽漸', '英文', null, 'IgA肾病', null, null, 'S01_012_01_诊断标准.docx', null, null, null, '2016年4月，日本肾脏病学会(JSN)发布了IgA肾病指南2014年版，旨在为日本IgA肾病的临床管理提供循证指导，文章主要包括3大部分内容，分别为：概念，诊断，流行病学。指南针对这些内容个提出14个临床问题，并针对这些临床问题提出推荐意见。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('71', '36', 'S01_013', '1', '2009 IgA肾病-牛津分类：原理，临床病理相关性以及分类', 'The Oxford classification of IgA nephropathy:rationale, clinicopathological correlations, and classification', '国际IgA 肾病协作组(IIgANN,The International IgA Nephropathy Network);\n肾脏病理学会(RPS,Renal Pathology Society)\n', '2009', 'A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Daniel C. Cattran, Rosanna Coppo, H. Terence Cook, John Feehally, Ian S.D. Roberts, Stéphan Troyanov, Charles E. Alpers, and others.The Oxford classification of 畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭㜸੟ༀƙ\0੟ð\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔ햞௤੟ð\0ꃨ௤彿㎽奋㎽巫㎽᥂௥㽦௥彿㎽㽚௥塚㎽㽦௥ꍈ㏂\0\0햞௤學㎽漸㏂圔㎽햞௤圞㎽\0\0圭㎽ﱔ霪Wༀƙ ', '英文', 'S01_013_01_分类.docx', 'IgA肾病', null, null, null, null, null, null, '2009年，由国际lgA肾病协作组（International IgA Nephropathy Network）和肾脏病理协会（Renal Pathology Society）组成的工作组发表了lgA肾病新的分类共识，这一新的分类共识被称为“lgA肾病牛津分类法（The Oxford classification of IgA nephropathy）。牛津分类法较以往的分类有了一些实质性变化，表现在定义与病理相关术语、组织学积分方法及病理诊断报告模式等方面。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('72', '36', 'S01_014', '1', '2009 IgA肾病-牛津分类：病理学定义，相互关系以及复现\n', 'The Oxford classification of IgA nephropathy:pathology definitions, correlations, and reproducibility', '国际IgA 肾病协作组(IIgANN,The International IgA Nephropathy Network);\n肾脏病理学会(RPS,Renal Pathology Society)\n', '2009', 'A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Ian S.D. Roberts, H. Terence Cook, Stéphan Troyanov, Charles E. Alpers, Alessandro Amore, Jonathan Barratt, Francois Berthoux, and others.\nThe Oxford classificat畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭툈ਘༀƙ\0ਘĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖㎼\0\0\0ﱔ햞௤ਘĀ\0ꃨ௤彿㎽奋㎽巫㎽᥂௥㽦௥彿㎽㽚௥塚㎽㽦௥ꍈ㏂\0\0햞௤學㎽漸㏂圔㎽햞௤圞㎽\0\0圭㎽ﱔ霪Wༀ', '英文', null, 'IgA肾病', null, null, 'IgA肾病：IgA肾病的肾脏被定义为显性或显性的染色与IgA在肾小球免疫荧光或免疫过氧化物酶。不是所有需要显示阳性肾小球。系统性红斑狼疮肾炎应排除相关。IgA染色强度应大于微量。分布于肾小球系膜IgA染色应包括存在，伴或不伴毛细血管襻染色，不含纯质，弥漫，全球颗粒GBM染色模式或线性GBM染色模式。IgG和IgM可能是存在的，但不是在更大的强度比IgA、IgM可能除了硬化区突出。补体3（C3）可能存在。C1q染色强度超过微量的存在带来了狼疮性肾炎的思考。<br />&nbsp;&nbsp;\n肾小球的定义<br />&nbsp;&nbsp;\n弥漫型：病变累及大部分（≥50%）肾小球<br />&nbsp;&nbsp;\n焦点：病变累及肾小球＜50%<br />&nbsp;&nbsp;\n全球：病变累及肾小球超过一半（见下面的节段性和全球硬化的定义）<br />&nbsp;&nbsp;\n节段型：病变累及少于一半（即肾小球，至少一半的肾小球是幸免）。见下面的节段性和全球硬化的定义<br />&nbsp;&nbsp;\n内皮细胞增生：由于细胞数量的增加肾小球毛细血管内皮细胞增生，使管腔狭窄<br />&nbsp;&nbsp;\n核碎裂：凋亡、固缩和核碎片的存在，<br />&nbsp;&nbsp;\n坏死是由（我）与肾小球基底膜破坏（II）纤维蛋白渗出和（iii）碎裂。至少2这三个病灶需要符合坏死的标准。（2008修正案：坏死不应该在PAS染色部分单独评分；纤维蛋白更容易识别H＆E或MSB染色切片，并在肾小球基底膜断裂是在银更容易识别染色切片。对坏死性病变的定义的最低要求是弥漫性渗出。）<br />&nbsp;&nbsp;\nGBM复制：双轮廓或GBM无内皮细胞增生<br />&nbsp;&nbsp;\n系膜基质增多：在这样的间隙的宽度至少在两个肾小球系膜细胞小叶超过两个核的细胞外物质的增加<br />&nbsp;&nbsp;\n硬化：通过增加细胞外基质的毛细血管腔闭塞，伴或不伴透明变性或泡沫细胞<br />&nbsp;&nbsp;\n粘附：肾小球和肾小囊单独从弥漫病变或节段硬化的区域之间的连续性的一个地区<br />&nbsp;&nbsp;\n节段性硬化：硬化涉及任何数量的簇，但不涉及整个簇<br />&nbsp;&nbsp;\n全球硬化：硬化涉及整个肾小球丛<br />&nbsp;&nbsp;\n崩溃/缺血性肾小球：肾小球毛细血管袢呈现或崩溃不增厚和纤维化肾小囊鲍曼的空间<br />&nbsp;&nbsp;\n弥漫病变分为：<br />&nbsp;&nbsp;\n弥漫增殖或细胞性新月体：占两根以上细胞病变>50%层细胞外细胞增殖。按比例分为<10，10，25，26，50，和>50%<br />&nbsp;&nbsp;\n外肌纤维增生或纤维细胞新月体：一个弥漫病变，包括细胞和细胞外基质，用> 50%细胞＜90%矩阵。这是进一步分为，<10，25 - 26，10 - 50，和>50%<br />&nbsp;&nbsp;\n弥漫纤维化或纤维性新月体：肾小囊的覆盖由≥90%基质病变周长>10%。它是由肾小球周围参与率进一步分类：10–25%、26–50%到>50 %。肾小球缺血，应排除适用<br />&nbsp;&nbsp;\n新月是一个弥漫病变涉及>的肾小囊的周长10%<br />&nbsp;&nbsp;\n系膜细胞过多细分如下：<br />&nbsp;&nbsp;\n如果< 4系膜细胞/系膜面积=正常，<br />&nbsp;&nbsp;\n4–5肾小球系膜细胞、肾小球系膜区=轻度系膜细胞增生，<br />&nbsp;&nbsp;\n6–7肾小球系膜细胞、系膜区=中度系膜细胞增生，并<br />&nbsp;&nbsp;\n8个或更多的肾小球系膜细胞、肾小球系膜区=重度系膜细胞增生。<br />&nbsp;&nbsp;\n注：这是在每个肾小球通过评估大多数细胞系膜区。立即相邻的血管蒂的肾小球系膜区不应该被评分。个别肾小球系膜区显示细胞过多受到地区缩小到<2系膜细胞核分离的宽度（即，数簇，不系膜细胞核文件）<br />&nbsp;&nbsp;\n肾小管间质的定义<br />&nbsp;&nbsp;\n管式萎缩是指直径较低的管基底膜厚的不规则。它是根据皮质区参与的百分比得分，与1至5%的5%和其他值为10%和<br />&nbsp;&nbsp;\n间质纤维化被定义为增加细胞外基质分离管的皮质区。这是得分为百分比的参与，有1个5%个圆形到5%个和其他价值观的最接近10%。<br />&nbsp;&nbsp;\n间质炎症是指炎症细胞在皮质间质过度。这是得分为百分比的参与，有1个5%个圆形到5%个和其他价值观的最接近10%。应该注意的是，炎症是否局限于间质纤维化的领域<br />&nbsp;&nbsp;\n其他肾小管病变的注意如下：存在大量的红血细胞，定义为肾小管完全充满了红血细胞<br />&nbsp;&nbsp;\n或不投，以病变时涉及≥20%小管<br />&nbsp;&nbsp;\n对近端肾小管上皮细胞进行了简化，定义了无肾小管基底膜增厚<br />&nbsp;&nbsp;\n血管的定义<br />&nbsp;&nbsp;\n在最严重的病变的基础上，对动脉病变进行评分。小叶和大动脉分别进球。一个小叶间动脉是一个包围皮质；弓形动脉是一个在皮髓质交界处。内膜增厚是通过比较在同一段的容器中的介质的内膜的厚度。将内膜的不同程度分为正常的，增厚到更多或小于媒体的厚度。<br />&nbsp;&nbsp;\n小动脉透明指出动脉影响的比例（0，1–25%、26–50%，＞50%）。<br />&nbsp;&nbsp;\nIgA nephropathy: IgA nephropathy in the native kidney is defined as dominant or codominant staining with IgA in glomeruli by immunofluorescence or immunoperoxidase. Not all glomeruli need show this positivity. SLE-related nephritis should be excluded. The intensity of IgA staining should be more than trace. The distribution of IgA staining should include presence in the mesangium, with or without capillary loop staining, excluding a pure membranous, diffuse, global granular GBM staining pattern or a linear GBM staining pattern. IgG and IgM may be present, but not in greater intensity than IgA, except that IgM may be prominent in sclerotic areas. Complement 3 (C3) may be present. The presence of C1q staining in more than trace intensity should bring up consideration of lupus nephritis. <br />&nbsp;&nbsp;\nGlomerular definitions<br />&nbsp;&nbsp;\nDiffuse: A lesion involving most (≥50%) glomeruli<br />&nbsp;&nbsp;\nFocal: A lesion involving <50% of glomeruli<br />&nbsp;&nbsp;\nGlobal: A lesion involving more than half of the glomerular tuft (See below for definitions of segmental and global sclerosis) <br />&nbsp;&nbsp;\nSegmental: A lesion involving less than half of the glomerular tuft (i.e., at least half of the glomerular tuft is spared). See below for definitions of segmental and global sclerosis<br />&nbsp;&nbsp;\nEndocapillary hypercellularity: Hypercellularity due to increased number of cells within glomerular capillary lumina, causing narrowing of the lumina<br />&nbsp;&nbsp;\nKaryorrhexis: Presence of apoptotic, pyknotic, and fragmented nuclei<br />&nbsp;&nbsp;\nNecrosis is defined by (i) disruption of the glomerular basement membrane with (ii) fibrin exudation and (iii) karyorrhexis. At least two of these three lesions need to be present to meet the criteria for necrosis. (2008 Amendment: Necrosis should not be scored on the PAS-stained section alone; fibrin is more easily identified on H&E or MSB-stained sections, and breaks in the glomerular basement membrane are more easily identified on silver-stained sections. A minimum requirement for the definition of a necrotizing lesion is extracapillary fibrin exudation.) <br />&nbsp;&nbsp;\nGBM duplication: A double contour of the GBM with or without endocapillary hypercellularity<br />&nbsp;&nbsp;\nIncreased mesangial matrix: An increase in the extracellular material in the mesangium such that the width of the interspace exceeds two mesangial cell nuclei in at least two glomerular lobules<br />&nbsp;&nbsp;\nSclerosis: Obliteration of the capillary lumen by increased extracellular matrix, with or without hyalinosis or foam cells\nAn adhesion: An area of continuity between the glomerular tuft and Bowman’s capsule separate from an extracapillary lesion or from an area of segmental sclerosis<br />&nbsp;&nbsp;\nSegmental sclerosis: Any amount of the tuft involved with sclerosis, but not involving the whole tuft<br />&nbsp;&nbsp;\nGlobal sclerosis: The entire glomerular tuft involved with sclerosis<br />&nbsp;&nbsp;\nCollapsed/ischemic glomerulus: A glomerulus showing collapse of the capillary tuft with or without thickening of Bowman’s capsule and fibrosis in the Bowman’s space<br />&nbsp;&nbsp;\nExtracapillary lesions are subclassified as follows: <br />&nbsp;&nbsp;\nExtracapillary proliferation or cellular crescent: Extracapillary cell proliferation of more than two cell layers with >50% of the lesion occupied by cells. It is further classified by the percentage of glomerular circumference involved: <10, 10–25, 26–50, and >50%<br />&nbsp;&nbsp;\nExtracapillary fibrocellular proliferation or fibrocellular crescent: An extracapillary lesion comprising cells and extracellular matrix, with >50% cells and <90% matrix. This is further classified by the percentage of the glomerular circumference involved:<10, 10–25, 26–50, and >50%<br />&nbsp;&nbsp;\nExtracapillary fibrosis or fibrous crescent: >10% of the circumference of Bowman’s capsule covered by a lesion composed of ≥90% matrix. It is further classified by the percentage of the glomerular circumference involved: 10–25%, 26–50%, and>50%. Ischemic, obsolescent glomeruli should be excluded<br />&nbsp;&nbsp;\nA crescent is one of these extracapillary lesions that involves >10% of the circumference of Bowman’s capsule<br />&nbsp;&nbsp;\nMesangial hypercellularity is subclassified as follows: <br />&nbsp;&nbsp;\nIf <4 mesangial cells/mesangial area=normal, <br />&nbsp;&nbsp;\n4–5 mesangial cells/mesangial area=mild mesangial hypercellularity, <br />&nbsp;&nbsp;\n6–7 mesangial cells/mesangial area=moderate mesangial hypercellularity, and<br />&nbsp;&nbsp;\n8 or more mesangial cells/mesangial area=severe mesangial hypercellularity. <br />&nbsp;&nbsp;\nNote: This is scored for each glomerulus by assessing the most cellular mesangial area. Mesangial areas immediately adjacent to the vascular stalk should not be scored. Individual mesangial areas showing hypercellularity are separated by areas narrowing to the width of <2 mesangial cell nuclei (i.e., count clusters, not files of mesangial cell nuclei) <br />&nbsp;&nbsp;\nTubulointerstitial definitions<br />&nbsp;&nbsp;\nTubular atrophy is defined by thick irregular tubular basement membranes with decreased diameter of tubules. It is scored according to the percentage of cortical area involvement, with 1–5% rounded to 5% and other values rounded to the closest 10%<br />&nbsp;&nbsp;\nInterstitial fibrosis is defined as increased extracellular matrix separating tubules in the cortical area. It is scored as percentage involvement, with 1–5% rounded to 5% and other values rounded to the closest 10%.<br />&nbsp;&nbsp;\nInterstitial inflammation is defined as inflammatory cells within the cortical interstitium in excess. It is scored as percentage involvement, with 1–5% rounded to 5% and other values rounded to the closest 10%. It should be noted whether the inflammation is confined to the areas of interstitial fibrosis or not<br />&nbsp;&nbsp;\nAdditional tubular lesions are noted as follows: The presence of numerous red blood cells, defined as tubules completely filled with red blood cells with<br />&nbsp;&nbsp;\nor without casts, is noted as a lesion when it involves ≥20% of tubules<br />&nbsp;&nbsp;\nAcute tubular injury of the proximal tubular epithelium is defined by simplification of the epithelium without tubular basement membrane thickening<br />&nbsp;&nbsp;\nVascular definitions<br />&nbsp;&nbsp;\nArterial lesions are scored based on the most severe lesions. Interlobular and larger arteries are scored separately. An interlobular artery is one surrounded by the cortex; an arcuate artery is one at the corticomedullary junction. Intimal thickening is scored by comparing the thickness of the intima to that of the media in the same segment of vessel. Score the intima variously as normal, and thickened to more or less than the thickness of the media. <br />&nbsp;&nbsp;\nArteriolar hyaline is noted as the proportion of arterioles affected (0, 1–25%, 26–50%, >50%).<br />&nbsp;&nbsp;\n', null, null, null, '2009年，由国际lgA肾病协作组（International IgA Nephropathy Network）和肾脏病理协会（Renal Pathology Society）组成的工作组发表了lgA肾病新的分类共识，这一新的分类共识被称为“lgA肾病牛津分类法（The Oxford classification of IgA nephropathy）。牛津分类法较以往的分类有了一些实质性变化，表现在定义与病理相关术语、组织学积分方法及病理诊断报告模式等方面。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('73', '17', 'F04_001', '1', '慢性肺原性心脏病诊断标准', '无', '全国肺心病专业会议', '1977', '慢性肺原性心脏病诊断标准[J]. 新医学,1978,9(1):51-52.', '中文', null, '肺原性心脏病', null, null, '1.慢性肺胸疾病或肺血管病变主要根据病史、体征、X线。并可参考放射性同位素、超声心动图、心电向量图、肺功能或其他检查判定。<br />&nbsp;&nbsp;2.右心功能不全主要表现为颈静脉怒张、肝肿大压痛、肝颈反流征阳性、下肢浮肿及静脉压增高等。<br />&nbsp;&nbsp;3.肺动脉高压、右心室增大的诊断依据：<br />&nbsp;&nbsp;3.1体征：剑突下出现收缩期搏动，肺动脉瓣区第二音亢进，三尖瓣区心音较心尖部明显增强或出现收缩期杂音。<br />&nbsp;&nbsp;3.2X线征象和诊断标准（见附件一）<br />&nbsp;&nbsp;3.3心电图诊断标准（见附件二）<br />&nbsp;&nbsp;3.4超声心动图诊断标准（见附件三）<br />&nbsp;&nbsp;3.5心电向量图诊断标准（见附件四）<br />&nbsp;&nbsp;3.6放射性同位素：肺灌注扫描肺上部血流增加下部减少，即表示可能有肺动脉高压。<br />&nbsp;&nbsp;注：3.4、3.5、3.6项有条件的单位可作诊断参考。本标准在高原地区仅供参考。<br />&nbsp;&nbsp;附件一：慢性肺原性心脏病X线诊断标准<br />&nbsp;&nbsp;1.右肺下动脉干扩张：①横径≥15毫米；或②右肺下动脉横径与气管横径比值)≥1.07，或③经动态观察较原右肺下动脉干增宽2毫米以上。<br />&nbsp;&nbsp;2.肺动脉段中度凸出或其高度≥3毫米。<br />&nbsp;&nbsp;三、中心肺动脉扩张和外围分支纤细两者形成鲜明对比。<br />&nbsp;&nbsp;四、圆锥部显著凸出（右前斜位45°）或“锥高”≥7毫米。<br />&nbsp;&nbsp;五、右心室增大（结合不同体位判断）。<br />&nbsp;&nbsp;具有上述一-四项中的一项可提示，两项或以上者可以诊断，具有五项一项者则可诊断。<br />&nbsp;&nbsp;附件二：慢性肺原性心脏病心电图诊断标准<br />&nbsp;&nbsp;1.主要条件<br />&nbsp;&nbsp;1.1额面平均电轴≥+90°。<br />&nbsp;&nbsp;1.2V1R/S≥1。<br />&nbsp;&nbsp;1.3重度顺钟向转位（V5导联R/S≤1）。<br />&nbsp;&nbsp;1.4RV1+SV5>1.05mV。<br />&nbsp;&nbsp;1.5aVRR/S或R/Q≥1。<br />&nbsp;&nbsp;1.6 V1-3呈QS、Qr、qr（需除外心肌梗塞）。<br />&nbsp;&nbsp;1.7 肺型P波：①P电压≥0.22毫伏，或②电压>0.2mV呈尖峰型，结合P电轴>+80°，或③当低电压时P电压>1/2R，呈尖峰型，结合电轴>+80°。<br />&nbsp;&nbsp;2.次要条件<br />&nbsp;&nbsp;2.1肢导联低电压。<br />&nbsp;&nbsp;（二）右束枝传导阻滞（不完全性或完全性）。<br />&nbsp;&nbsp;具有一条主要的即可诊断，二条次要的为可疑肺心病的心电图表现。<br />&nbsp;&nbsp;附件三：慢性肺原性心脏病超声心动图诊断标准（试行草案）<br />&nbsp;&nbsp;1.心底波群中显示有右心室流出道增宽，其内径>30毫米。<br />&nbsp;&nbsp;2.从各种不同部位探查均显示有右心室增大，其内径值>20毫米，左/右心室内径的比值<2，或有右心室前壁搏幅增强，有增厚征象者。<br />&nbsp;&nbsp;3.胸骨上窝探及右肺动脉内径增大，超过18毫米者。<br />&nbsp;&nbsp;4.心室波群显示有室间隔增厚（大于15毫米），搏幅减低（<6毫米）伴有右心室容量负荷过重时，室间隔搏动曲线与左心室后壁呈同向搏动。<br />&nbsp;&nbsp;5.剑突下探及三尖瓣曲线DE、EF速度增快，E峰尖高，AC间期延长等改变者，或有右心房增大征象者。<br />&nbsp;&nbsp;6.二尖瓣前叶曲线幅度低，CD段上升缓慢，多呈水平位，AE峰改变者。<br />&nbsp;&nbsp;以上1-4项为主要诊断条件，5、6项为参考条件。凡有二项主要条件或一项主要条件和一项参考条件者均可提示肺心病。<br />&nbsp;&nbsp;附件四：慢性肺原性心脏病心电向最图诊断标准（试行草案）<br />&nbsp;&nbsp;1.肺心病：心电向量图具有右心房及/或右心室增大指征者均符合诊断。<br />&nbsp;&nbsp;1.1右心室增大：<br />&nbsp;&nbsp;1.1.1轻度右心室增大：<br />&nbsp;&nbsp;①横面QRS环呈狭长形，逆钟向运行，自左前转向右后方，其S/R>1或X轴右/左向量比值>0.58或S向量角>-110°。<br />&nbsp;&nbsp;②横面QRS环呈逆钟向运行，其右后占总面积20%以上或额面QRS环呈顺钟向运行，其右下或右上占面积20%以上。<br />&nbsp;&nbsp;以上两条具有一条并结合额面平均电轴>+70°即可诊断。<br />&nbsp;&nbsp;1.1.2中度右心室增大：<br />&nbsp;&nbsp;①横面环呈逆钟向运行，其向前加右后占总面积70%以上。<br />&nbsp;&nbsp;②横面QRS环呈“8”字形，其主体及终末部均向右后。<br />&nbsp;&nbsp;以上两条具有一条即可诊断。<br />&nbsp;&nbsp;1.1.3重度右心室增大：<br />&nbsp;&nbsp;横面QRS环呈钟向运行，向前向右。T环向右后。<br />&nbsp;&nbsp;1.2右心房增大：P环振幅≥0.2mV，P向量环角度>+75°，可符合诊断。<br />&nbsp;&nbsp;2.可疑肺心病：<br />&nbsp;&nbsp;横面QRS环呈肺气肿图形（其环体向后，最大QRS向量沿270°轴向后，环体幅度减低和变窄），其额面平均电轴>+70°或肺气肿图形在右后面积占总面积的15%以上。<br />&nbsp;&nbsp;合并右束枝传导阻滞或终未传导延缓作为参考条件。', null, null, null, '1977年修订。相比1973年版本，1.增加了肺动脉高压诊断；2.X线与心电图诊断修改补充；3.增加了超声心动图、心电向量图、放射性同位素诊断标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('74', '17', 'F04_002', '1', '慢性肺原性心脏病诊断标准', '无', '全国肺心病专业会议', '1980', '慢性肺原性心脏病诊断标准(1977年全国第二次肺心病专业会议修订)[J]. 山西医药杂志,1982,11（1）:35-39.', '中文', null, '肺源性心脏病', null, null, '1.慢性肺胸疾病或肺血管病变主要根据病史、体征、X线。并可参考放射性同位素、超声心动图、心电向量图、肺功能或其他检查判定。<br />&nbsp;&nbsp;2.右心功能不全主要表现为颈静脉怒张、肝肿大压痛、肝颈反流征阳性、下肢浮肿及静脉压增高等。<br />&nbsp;&nbsp;3.肺动脉高压、右心室增大的诊断依据：<br />&nbsp;&nbsp;3.1体征：剑突下出现收缩期搏动，肺动脉瓣区第二音亢进，三尖瓣区心音较心尖部明显增强或出现收缩期杂音。<br />&nbsp;&nbsp;3.2 X线征象和诊断标准（见附件一）<br />&nbsp;&nbsp;3.3心电图诊断标准（见附件二）<br />&nbsp;&nbsp;3.4超声心动图诊断标准（见附件三）<br />&nbsp;&nbsp;3.5心电向量图诊断标准（见附件四）<br />&nbsp;&nbsp;3.6放射性同位素：肺灌注扫描肺上部血流增加下部减少，即表示可能有肺动脉高压。<br />&nbsp;&nbsp;注：3.4、3.5、3.6项有条件的单位可作诊断参考。本标准在高原地区仅供参考。<br />&nbsp;&nbsp;附件一：慢性肺原性心脏病X线诊断标准<br />&nbsp;&nbsp;1.右肺下动脉干扩张：①横径≥15毫米；或②右肺下动脉横径与气管横径比值)≥1.07，或③经动态观察较原右肺下动脉干增宽2毫米以上。<br />&nbsp;&nbsp;2.肺动脉段中度凸出或其高度≥3毫米。<br />&nbsp;&nbsp;三、中心肺动脉扩张和外围分支纤细两者形成鲜明对比。<br />&nbsp;&nbsp;四、圆锥部显著凸出（右前斜位45°）或“锥高”≥7毫米。<br />&nbsp;&nbsp;五、右心室增大（结合不同体位判断）。<br />&nbsp;&nbsp;具有上述一-四项中的一项可提示，两项或以上者可以诊断，具有五项一项者则可诊断。<br />&nbsp;&nbsp;附件二：慢性肺原性心脏病心电图诊断标准<br />&nbsp;&nbsp;1.主要条件<br />&nbsp;&nbsp;1.1额面平均电轴≥+90°。<br />&nbsp;&nbsp;1.2 V1R/S≥1。<br />&nbsp;&nbsp;1.3重度顺钟向转位（V5导联R/S≤1）。<br />&nbsp;&nbsp;1.4 RV1+SV5>1.05mV。<br />&nbsp;&nbsp;1.5 aVRR/S或R/Q≥1。<br />&nbsp;&nbsp;1.6 V1-3呈QS、Qr、qr（需除外心肌梗塞）。<br />&nbsp;&nbsp;1.7 肺型P波：①P电压≥0.22毫伏，或②电压>0.2mV呈尖峰型，结合P电轴>+80°，或③当低电压时P电压>1/2R，呈尖峰型，结合电轴>+80°。<br />&nbsp;&nbsp;2.次要条件<br />&nbsp;&nbsp;2.1肢导联低电压。<br />&nbsp;&nbsp;2.2右束枝传导阻滞（不完全性或完全性）。<br />&nbsp;&nbsp;具有一条主要的即可诊断，二条次要的为可疑肺心病的心电图表现。<br />&nbsp;&nbsp;附件三：慢性肺原性心脏病超声心动图诊断标准<br />&nbsp;&nbsp;主要条件<br />&nbsp;&nbsp;1.右心室流出道内径≥30mm。<br />&nbsp;&nbsp;2.右心室内径≥20mm。<br />&nbsp;&nbsp;3.右心室前壁的厚度≥5.0mm，或有前壁搏动幅度增强者。<br />&nbsp;&nbsp;4.左/右心室内径比值<2.<br />&nbsp;&nbsp;5.右肺动脉内径≥18mm，或肺动脉干≥20mm。<br />&nbsp;&nbsp;6.右心室流出道/左心房内径比值>1.4。<br />&nbsp;&nbsp;7.肺动脉办曲线出现肺动脉高压征象者（a波低平或<2mm，有收缩中期关闭征等）。<br />&nbsp;&nbsp;参考条件<br />&nbsp;&nbsp;1.室间隔厚度≥12mm，搏幅<5mm，或呈矛盾运动征象者。<br />&nbsp;&nbsp;2.右心房增大，≥2mm（剑突下区）<br />&nbsp;&nbsp;3.三尖瓣前叶曲线DE、EF速度增快，E峰呈尖高型，或有AC间期延长者。<br />&nbsp;&nbsp;4.二尖瓣前叶曲线幅度低，CE<18mm，CD段上升缓慢，延长，呈水平位或有EF下降缓慢，<19mm/秒。<br />&nbsp;&nbsp;说明<br />&nbsp;&nbsp;①凡有胸肺疾病的患者，具有上述二项条件者（其中必具一项主要条件）均可诊断肺心病。<br />&nbsp;&nbsp;②上述标准仅适用于心前区探测部位<br />&nbsp;&nbsp;附件四：慢性肺原性心脏病心电向最图诊断标准<br />&nbsp;&nbsp;肺心病：<br />&nbsp;&nbsp;在胸肺疾病基础上，心电向量图具有右心室及/或右心房增大指征者均符合诊断。<br />&nbsp;&nbsp;1.右心室肥厚<br />&nbsp;&nbsp;1.1轻度右心室肥厚：<br />&nbsp;&nbsp;（1）①横面QRS环呈狭长形，逆钟向运行，自左前转向右后方，其S/R>1.2或②X轴（额面或横面）右/左向量比值>0.58或③S向量角<-110°伴S向量电压>0.6mV。<br />&nbsp;&nbsp;（2）①横面QRS环呈逆钟向运行，其右后面积占总面积的20%以上伴额面QRS环呈顺钟向运行，最大向量方位>+60°或②右下或③右上面积占面积20%以上。<br />&nbsp;&nbsp;上述三条（六项）中具有一项即可诊断。<br />&nbsp;&nbsp;2.中度右心室增大：<br />&nbsp;&nbsp;（1）横面QRS环呈逆钟向运行，其向前+右后面积>总面积70%以上且右后向量>0.6mV。<br />&nbsp;&nbsp;（2）横面QRS环呈8字形，主体及终末部均向右后方位。<br />&nbsp;&nbsp;以上二条具有一条即可诊断。<br />&nbsp;&nbsp;3.重度右心室肥厚：横面QRS环呈顺钟向运行，向前向右，T环向右后。<br />&nbsp;&nbsp;二、右心房增大<br />&nbsp;&nbsp;1.额面或侧面最大P向量电压>0.18mV。<br />&nbsp;&nbsp;2.横面P环呈顺钟向运行。<br />&nbsp;&nbsp;3.横面向前P向量>0.06mV。<br />&nbsp;&nbsp;以上三条符合一条即可诊断，额面最大P向量>+75°作为参考条件。<br />&nbsp;&nbsp;可疑肺心病：<br />&nbsp;&nbsp;横面QRS环呈肺气肿图形（其环体向后，最大QRS向量沿270°轴向后伸，环体幅度减低和变窄），其额面最大QRS向量方位>+60°或肺气肿图形其右后面积占总面积的15%以上。<br />&nbsp;&nbsp;合并右束支传导阻滞或终未传导延缓作为参考条件。', null, null, ' ', '1980年第三次修订。相比1977年版本，超声心动图、心电向量图诊断标准进行最新修改。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('75', '17', 'F04_003', '0', '慢性肺原性心脏病中西医结合辨证分型和治疗原则', '无', '全国肺心病专业会议', '1977', '慢性肺原性心脏病诊断标准(1977年全国第二次肺心病专业会议修订)[J]. 山西医药杂志,1982,11（1）:35-39.', '中文', null, null, '肺源性心脏病', '1.缓解期；<br />&nbsp;&nbsp;1.1肺肾气（阳）虚；<br />&nbsp;&nbsp;2.急性发作期；<br />&nbsp;&nbsp;2.1肺肾气虚外感偏寒型；<br />&nbsp;&nbsp;2.2肺肾气虚外感偏热型；<br />&nbsp;&nbsp;2.3心脾肾阳虚水泛；<br />&nbsp;&nbsp;2.4痰浊蔽窍；<br />&nbsp;&nbsp;2.5元阳欲绝；<br />&nbsp;&nbsp;2.6热淤伤络<br />&nbsp;&nbsp;', ' ', '1.缓解期<br />&nbsp;&nbsp;肺肾气（阳）虚型（以肺功能不全为主）。<br />&nbsp;&nbsp;主证：咳嗽、气短，活动后加重，或有少量泡沫痰，腰酸腿软，或畏寒肢冷，舌质淡，苔薄白，脉沉细。<br />&nbsp;&nbsp;兼证：<br />&nbsp;&nbsp;1.兼脾虚湿痰症：痰稀白量少、少食、乏力、苔白腻，脉滑或细而无力。<br />&nbsp;&nbsp;2.偏阴虚症：口干、心烦、手足心热、舌质红、脉细数。<br />&nbsp;&nbsp;3.兼心气虚症：除肺肾气虚主症外，心悸明显，脉沉细或有结代。<br />&nbsp;&nbsp;2.急性发作期<br />&nbsp;&nbsp;2.1肺肾气虚外感型（肺功能不全合并呼吸道感染）<br />&nbsp;&nbsp;2.1.1偏寒型（早期呼吸道感染）<br />&nbsp;&nbsp;主证：咳喘、气短、咳白痰、或恶寒、周身不适、苔白、脉浮紧。<br />&nbsp;&nbsp;2.1.2偏热型（呼吸道感染）<br />&nbsp;&nbsp;主证：咳嗽喘促或不能平卧，痰黄粘稠，或发热、苔黄、脉滑数。<br />&nbsp;&nbsp;2.2心脾肾阳虚水泛型（以心功能不全为主）<br />&nbsp;&nbsp;主证：浮肿、心悸、气短不能平卧，尿少，口唇紫绀，舌质紫绛，苔白腻，脉沉虚数或结代。<br />&nbsp;&nbsp;2.3痰浊蔽窍型（肺性脑病）<br />&nbsp;&nbsp;主证：意识朦胧，神志澹语，甚致昏迷，呼吸急促或伴痰鸣，舌质紫，脉滑数。<br />&nbsp;&nbsp;兼证：兼肝风内动证，除上述主证外，兼有烦燥不安、抽搐。<br />&nbsp;&nbsp;2.4元阳欲绝型（休克）<br />&nbsp;&nbsp;主证：面色晦暗，汗出，肢冷，脉沉细而数，甚至脉微欲绝。<br />&nbsp;&nbsp;2.5热淤伤络型（伴有出血倾向）<br />&nbsp;&nbsp;主证：皮肤淤斑或有出血倾向，舌紫绛，脉细数或涩数。<br />&nbsp;&nbsp;', null, ' ', '1977年修订。相比1973年版本，1.修改为疾病分期下的辨证。2.增加热淤伤络等证型。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('76', '17', 'F04_004', '0', '中华人民共和国中医药行业标准-中医病证诊断疗效标准', '无', '国家中医药管理局', '1994', 'ZY/T001.1～001.9-94,中华人民共和国中医药行业标准-中医病证诊断疗效标准[S].', '中文', null, null, '喘病', '1.风寒束肺；<br />&nbsp;&nbsp;2.风热犯肺；<br />&nbsp;&nbsp;3.痰湿蕴肺；<br />&nbsp;&nbsp;4.水气凌心；<br />&nbsp;&nbsp;5.肺脾两虚；<br />&nbsp;&nbsp;6.肺肾两虚<br />&nbsp;&nbsp;', ' ', '1.以气短喘促，呼吸困难，甚至张口抬肩，鼻翼煽动，不能平卧，口唇发绀为特征。<br />&nbsp;&nbsp;2.多有慢性咳嗽，哮病，肺痨，心悸等疾病史，每遇外感及劳累而诱发。<br />&nbsp;&nbsp;3.呈桶状胸。叩诊胸部呈过清音，心浊音界缩小或消失，肝浊音界下移。肺呼吸音减低，可闻及干、湿性罗音或哮鸣音。或肝肿大、下肢浮肿、颈静脉怒张。<br />&nbsp;&nbsp;4.合并感染者，白细胞总数及中性粒细胞可增高。必要时查血钾、钠、二氧化碳结合力及X线胸部摄片，心电图，心、肺功能测定，血气分析等。<br />&nbsp;&nbsp;证候分类<br />&nbsp;&nbsp;1.风寒束肺：喘急胸闷，咳嗽痰多清稀，伴有恶寒发热，头痛等症。舌苔薄白，脉浮紧。<br />&nbsp;&nbsp;2.风热犯肺：喘促气粗，咳嗽痰黄而稠粘，心胸烦闷，口干而渴，可有发热恶风。舌边红，苔薄黄，脉浮数。<br />&nbsp;&nbsp;3.痰湿蕴肺：喘咳胸闷，痰多易咯，痰粘或咯吐不爽，胸中窒闷，口腻，脘痞腹胀。舌质淡，舌苔白腻，脉弦滑。<br />&nbsp;&nbsp;4.水气凌心：气喘息涌，痰多呈泡沫状，胸满不能平卧，肢体浮肿，心悸怔忡，尿少肢冷，舌苔白滑，脉弦细数。<br />&nbsp;&nbsp;5.肺脾两虚：喘息短促无力，语声低微，自汗心悸，面色 白，神疲乏力，食少便塘，舌淡苔少，脉弱。或口干咽燥，舌红，脉细。<br />&nbsp;&nbsp;6.肺肾两虚：喘促日久，心悸怔忡，动则喘咳，气不接续，胸闷如窒，不能平卧，痰多而粘，或心烦不寐，唇甲紫绀。舌质紫或舌红苔少，脉微疾或结、代。<br />&nbsp;&nbsp;', '1.喘息<br />&nbsp;&nbsp;2.其他症状<br />&nbsp;&nbsp;3.实验室检查', '1.治愈：喘息及其它症状消失，实验室检查明显好转。<br />&nbsp;&nbsp;2.好转：喘息及其它症状好转，实验室检查有改善。<br />&nbsp;&nbsp;3.未愈：主症未改善或恶化者。\n', '为中医标准，1994年早期版本，规定了喘病的诊断标准、疗效标准、辨证分型等。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('77', '17', 'F04_005', '1', '中华医学会临床诊疗指南', '无', '中华医学会', '2009', '中华医学会. 临床诊疗指南呼吸病学分册[M]. 人民卫生, 2009.', '中文', null, '慢性肺源性心脏病', null, null, '1.有慢性呼吸系统疾病史。主要是慢性支气管炎、阻塞性肺气肿、肺结核、支气管扩张和胸廓疾病史等病史。<br />&nbsp;&nbsp;2.有咳嗽、咳痰，进行性气促的临床症状。<br />&nbsp;&nbsp;3.有肺气肿和（或）肺功脉高压的体征。<br />&nbsp;&nbsp;4.辅助检查X胸片、心电图检查有一项符合诊断标准。有条件可作心电向量图，超声心电图以增加诊断可和性。<br />&nbsp;&nbsp;5.急性加重期可有发热、血白细胞和（或）中性粒细胞增高。痰培养或涂片可获得有价值的病原，具有以上1-3条加上X胸片或心电图符合诊断条件，排除其他心脏疾病即可作出诊断。<br />&nbsp;&nbsp;', null, null, ' ', 'X胸片、心电图、心电向量图、超声心电图诊断标准与1980年全国肺心病专业会议修订版一致。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('78', '17', 'F04_006', '0', '中医内科常见病诊疗指南 西医疾病部分', 'Guidelines for Diagnosis and Treatment of Common Internal Diseases in Chinese Medicine Diseases of Modern Medicine', '中华中医药学会', '2008', 'ZYYXH/T 71-2008, 慢性肺源性心脏病[S].', '中文', null, null, '慢性肺源性心脏病', '1.寒饮射肺；<br />&nbsp;&nbsp;2.痰浊壅肺；<br />&nbsp;&nbsp;3.痰热郁肺；<br />&nbsp;&nbsp;4.气滞血瘀；<br />&nbsp;&nbsp;5.痰蒙神窍；<br />&nbsp;&nbsp;6.阳虚水泛；<br />&nbsp;&nbsp;7.元阳欲脱', ' ', '1诊断依据<br />&nbsp;&nbsp;1.1临床表现<br />&nbsp;&nbsp;1.1.1肺心功能代偿期<br />&nbsp;&nbsp;症状：咳嗽，咯痰，气促，活动后可有心悸，呼吸困难，乏力和劳动耐力下降。急性感染可使上述症状加重，少有胸痛或咯血。<br />&nbsp;&nbsp;体征：发绀和肺气肿体征。偶有干、湿啰音，心音遥远，肺动脉第二心音（P2)＞主动脉第二心音（A2)，三尖瓣区可出现收缩期杂音或剑突下心脏搏动增强，颈静脉充盈，肝界下移。<br />&nbsp;&nbsp;1.1.2肺心功能失代偿期<br />&nbsp;&nbsp;1.1.2.1呼吸衰竭<br />&nbsp;&nbsp;症状：呼吸困难，夜间为甚，常有头痛、失眠、食欲下降，但白天嗜睡，甚至出现表情淡漠，神志恍惚，谵妄等。<br />&nbsp;&nbsp;体征：明显发绀，球结膜充血、水肿，严重时可有视网膜血管扩张，视乳头水肿，腱反射减弱或消失，出现病理反射，皮肤潮红、多汗。<br />&nbsp;&nbsp;1.1.2.2右心衰竭<br />&nbsp;&nbsp;症状：气促心悸，食欲不振，腹胀，恶心等。<br />&nbsp;&nbsp;体征：发绀，颈静脉怒张，心率增快，可出现心律失常，剑突下可闻及收缩期杂音，甚至出现舒张期杂音。肝大且有压痛，肝颈静脉回流征阳性，下肢水肿，重者可有腹水。<br />&nbsp;&nbsp;1.2理化检查<br />&nbsp;&nbsp;1.2.1X线检查：右下肺动脉干扩张，横径≥15mm；右下肺动脉横径与气管横径比值≥1.07；肺动脉段明显突出或其高度≥3mm；中央动脉扩张，外周血管纤细，形成“残根”征，右心室增大。<br />&nbsp;&nbsp;1.2.2心电图检查：电轴右偏，额面平均电轴≥+90°，重度顺钟向转位，Rv1+Sv≥1.05mV，肺型P波，也可见右束支传导阻滞及低电压图形。在V1、V2甚至延至V5，可出现酷似陈旧性心肌梗死图形的QS波。<br />&nbsp;&nbsp;1.2.3超声心动图检查：右心室流出道内径（≥30mm)、右心室内径（≥20mm)、右心室前壁的厚度、左右心室内径比值＜2、右肺动脉内径或肺动脉干及右心房增大等。<br />&nbsp;&nbsp;1.2.4血气分析：肺功能代偿期可出现低氧血症或合并高碳酸血症，当PaC02<60mmHg时，伴或不伴PaCO2＞50mmHg时。<br />&nbsp;&nbsp;1.2.5血液检查：红细胞及血红蛋白可升高。全血黏度及血浆黏度可增加，红细胞电泳时间常延长，合并感染时血细胞总数增高，中性粒细胞增加。部分患者血清学检查可有肾功能或肝功能改变，血清钾、钠、氯、钙、镁均可有变化。除钾以外，其他多低于正常。<br />&nbsp;&nbsp;1.3诊断要点<br />&nbsp;&nbsp;1.3.1慢性肺胸疾病或肺血管疾病主要根据病史、体征、心电图、X线，并可参考放射性同位素、超声心动图、心电向量图、肺功能或其他检查判定。<br />&nbsp;&nbsp;1.3.2右心功能不全。<br />&nbsp;&nbsp;1.3.3肺动脉高压、右心室增大。<br />&nbsp;&nbsp;2辨证论治<br />&nbsp;&nbsp;慢性肺源性心脏病为本虚标实之证。多由于年老体弱，肺脾肾不足，或由于久病不愈，致正气亏损。缓解期以虚为主，发作期以邪实为急。虚者，病位在肺，渐及脾、肾、心；实者，多为气滞、痰浊、瘀血。病情发展到晚期，可发生神闭或喘脱。脱证以阳气暴脱为主，常由肺肾气虚或阳虚水泛发展而来，多属虚、寒。闭证以痰热闭窍为主，常从痰热郁肺发展而来，属实、热。<br />&nbsp;&nbsp;2.1寒饮射肺证<br />&nbsp;&nbsp;证候：咳嗽痰多，痰白而稀，短气喘息，舌淡苔白，脉细。<br />&nbsp;&nbsp;2.2痰浊壅肺证<br />&nbsp;&nbsp;证候：咳嗽喘满，痰多黏腻，胸闷气憋，恶心纳呆，舌苔白厚腻，脉滑。<br />&nbsp;&nbsp;2.3痰热郁肺证<br />&nbsp;&nbsp;证候：咳嗽喘满，不能平卧，痰黄或白黏不易咳出，或身热口渴，大便干燥，舌苔黄或腻，脉弦或滑数。<br />&nbsp;&nbsp;2.4气滞血瘀证<br />&nbsp;&nbsp;证候：喘急气促，胸胁闷胀，急躁易怒，唇甲青紫，舌红，苔薄黄，脉弦。<br />&nbsp;&nbsp;2.5痰蒙神窍证<br />&nbsp;&nbsp;证候：嗜睡昏迷，喉中痰鸣，腹胀便秘，唇甲青紫，舌质紫暗，苔腻，脉滑。<br />&nbsp;&nbsp;2.6阳虚水泛证<br />&nbsp;&nbsp;证候：面色灰暗，四肢厥冷，下肢水肿，小便短少，不能平卧，舌质淡胖，苔滑腻，脉沉细滑。<br />&nbsp;&nbsp;2.7元阳欲脱证<br />&nbsp;&nbsp;证候：呼多吸少，气不接续，身寒肢冷，汗出如油，舌淡，脉沉细。<br />&nbsp;&nbsp;', null, ' ', '为中医标准。有详细诊断及中医辨证分型，并附针灸、穴位贴敷、熨法、推拿等其他治法。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('79', '17', 'F04_007', '0', '慢性肺原性心脏病中医证候诊断标准', '无', '中华中医药学会肺系病专业委员会', '2012', '慢性肺原性心脏病中医证候诊断标准(2012版)[J]. 中医杂志,2012; 53(12):1075-1077.', '中文', null, null, '肺源性心脏病', '1.虚证类；<br />&nbsp;&nbsp;1.1心肺气虚；<br />&nbsp;&nbsp;1.2肺肾气虚；<br />&nbsp;&nbsp;1.3肺肾气阴两虚；<br />&nbsp;&nbsp;2.实证类；<br />&nbsp;&nbsp;2.1寒饮停肺；<br />&nbsp;&nbsp;2.2痰热壅肺；<br />&nbsp;&nbsp;2.3痰浊阻肺；<br />&nbsp;&nbsp;2.4阳虚水泛；<br />&nbsp;&nbsp;2.5痰蒙神窍；<br />&nbsp;&nbsp;3.兼证类；<br />&nbsp;&nbsp;3.1血瘀证', ' ', '临床常见证候中虽有虚实类别，但常虚实兼杂如阳虚水泛证｡各证候可单独存在也常兼见，如心肺气虚兼痰浊阻肺､肺肾气阴两虚兼痰热壅肺证等｡血瘀既是慢性肺心病的主要病机环节，也是常见兼证，常兼于其他证候中，如兼于痰浊阻肺证则为痰浊瘀肺证，兼于痰热壅肺证则为痰热瘀肺证，兼于肺肾气虚证则为肺肾气虚血瘀证｡急性加重期以实证为主常兼见虚证，缓解期以虚证为主常多兼见血瘀､痰浊，临床诊断时应予以注意｡<br />&nbsp;&nbsp;2.1虚证类<br />&nbsp;&nbsp;2.1.1心肺气虚证①喘促或气短，动则加重；②心悸或怔仲，动则加重；③易感冒；④神疲乏力或自汗，动则加重；⑤面目虚浮；⑥舌质淡､舌苔白，或脉沉细或细弱｡具备①､②2项，加③､④､⑤､⑥中的2项｡<br />&nbsp;&nbsp;2.1.2肺肾气虚证①胸闷气短，动则加重，甚则喘促；②神疲乏力或自汗，动则加重；③易感冒；④腰膝酸软；⑤头昏或耳鸣；⑥面目浮肿；⑦小便频数，或夜尿增多，或咳时遗尿；⑧舌质淡､舌苔白，或脉沉细或细弱｡具备①､②､③中2项，加④､⑤､⑥､⑦､⑧中的3项｡<br />&nbsp;&nbsp;2.1.3肺肾气阴两虚证①胸闷气短或喘促，动则加重，甚则不能平卧；②神疲乏力或自汗，动则加重；③易感冒；④腰膝酸软；⑤耳鸣，或头昏；⑥干咳或少痰，咯痰不爽；⑦盗汗；⑧手足心热；⑨舌质淡或红，或舌苔薄少或花剥，或脉沉细或细弱或细数｡具备①､②､③中2项，加④､⑤中的1项，加⑥､⑦､⑧､⑨中的2项｡<br />&nbsp;&nbsp;2.2实证类<br />&nbsp;&nbsp;2.2.1寒饮停肺证①咳逆喘满不得卧或气短；②咳痰､色白､清稀或呈泡沫状；③恶寒或并发热，遇寒加重；④周身酸痛；⑤舌苔白或白滑，或脉紧或弦紧｡具备①､②2项，加③､④､⑤中的1项｡<br />&nbsp;&nbsp;2.2.2痰热壅肺证①喘促或胸闷气短､甚者不能平卧，动则加重，或咳嗽；②痰色黄或黏稠，咯痰不爽；③发热或口渴；④大便秘结；⑤舌质红，或舌苔黄或黄腻，或脉数或滑数｡具备①､②2项，加③､④､⑤中的2项｡<br />&nbsp;&nbsp;2.2.3痰浊阻肺证①喘促或胸闷气短，甚者不能平卧，动则加重，或咳嗽；②痰多､色白或清稀或黏稠；③纳呆或食少；④胃脘痞满或腹胀；⑤舌苔白腻，或脉滑或弦滑｡具备①､②2项，加③､④､⑤中的2项｡<br />&nbsp;&nbsp;2.2.4阳虚水泛证①喘促或胸闷气短，甚者不能平卧，动则加重，或咳嗽；②肢体浮肿；③神疲乏力､动则加重；④心悸，动则尤甚；⑤肢冷，或畏寒；⑥舌苔白或白滑，或脉沉滑或沉弦｡具备①､②2项，加③､④､⑤､⑥中的3项｡<br />&nbsp;&nbsp;2.2.5痰蒙神窍证①神志异常(恍惚､嗜睡､谵妄､昏迷)，或伴瘛疭甚则抽搐；②烦躁或伴头痛；③喘促，动则加重；④喉中痰鸣；⑤舌苔白腻或黄腻，或脉滑或脉数｡具备①､②中1项，加③､④､⑤中2项｡<br />&nbsp;&nbsp;2.3兼证类(血瘀证)①面色紫暗；②唇甲青紫；③舌质紫暗或有瘀斑或瘀点；④舌下脉络迂曲､粗乱｡具备①､②､③､④中的1项｡<br />&nbsp;&nbsp;该标准供中医内科､中西医结合内科医生临床使用｡适合于慢性肺心病的证候分类及诊断，对于合并支气管哮喘､支气管扩张､COPD患者的证候诊断可参考使用，对于急性肺心脏病和慢性肺心病合并有气胸､肺栓塞､急性呼吸窘迫综合征者不建议使用｡<br />&nbsp;&nbsp;', null, ' ', '为中医证候诊断标准。详细明确了证候的分类特征及相关诊断标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('8', '10', 'D02_008', '1', '美国国家胆固醇教育计划（NCEP）关于成人高胆固醇血症诊断、评估及治疗的第三次报告（成人治疗组III）', 'Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)', '国家胆固醇教育计划<br />&nbsp;&nbsp;美国国家心脏、肺和血液研究所<br />&nbsp;&nbsp;美国国立卫生研究院<br />&nbsp;&nbsp;（National Cholesterol Education Program<br />&nbsp;&nbsp;National Heart, Lung, and Blood Institute<br />&nbsp;&nbsp;National Institutes of Health）', '2001', 'Third Report of the National Cholesterol Education Program (NCEP)\nExpert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in\nAdults (Adult Treatment Panel III) final report. Circulation. 2002 Dec\n17;106(25):3143-421.$$$$Executive su畻坴畿\0\0\0\0醼畻聱盯\0\0\0痭盠ੴ໰%\0ੴĀ\0\0㺣盭\0\0\0\0帉盭\0Ѐ\0\0\0\0瑖矢\0\0\0ﱔ�ກੴĀ\0렰ກ彿矣奋矣巫矣∴ຂ䡘ຂ彿矣䡌ຂ塚矣䡘ຂꍈ矨\0\0�ກ學矣漸矨圔矣�ກ圞矣\0\0圭矣ﱔ霪W໰% \0໰%戤痝\0#\0\0꒠ੴ䐺盭暼痭꒠ੴ໰% \0꒠ੴÀ\0\0㺣盭꒠ੴ\0ﱔ꒤ੴ\0팃目꒤ੴ௾꒤ੴ큁目꒤ੴ�ກ﫬\0Item\0\0䣜ຂ', '英文', null, 'Metabolic Syndrome', null, null, 'For present purposes, the metabolic syndrome is identified by the presence of three or more of the components listed in Table 1.D02_008_图表1', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('80', '17', 'F04_008', '0', '慢性肺原性心脏病中医诊疗指南（2014版）', '无', '中华中医药学会肺系病专业委员会', '2014', '中华中医药学会肺系病专业委员会. 慢性肺原性心脏病中医诊疗指南(2014版)[J].中医杂志, 2014;55(6):526-531.', '中文', '1代偿期与失代偿期根据肺、心功能状态分为：<br />&nbsp;&nbsp;1.1肺、心功能代偿期；<br />&nbsp;&nbsp;1.2肺、心功能失代偿期。<br />&nbsp;&nbsp;2根据肺、心功能代偿或失代偿的发病缓急和病程情况分为：<br />&nbsp;&nbsp;2.1急性加重期；<br />&nbsp;&nbsp;2.2缓解期。', null, '肺原性心脏病', '1.实证类；<br />&nbsp;&nbsp;1.1寒饮停肺；<br />&nbsp;&nbsp;1.2痰热壅肺；<br />&nbsp;&nbsp;1.3痰湿阻肺；<br />&nbsp;&nbsp;1.4阳虚水泛；<br />&nbsp;&nbsp;1.5痰蒙神窍；<br />&nbsp;&nbsp;2.虚证类；<br />&nbsp;&nbsp;2.1心肺气虚；<br />&nbsp;&nbsp;2.2肺肾气虚；<br />&nbsp;&nbsp;2.3肺肾气阴两虚；<br />&nbsp;&nbsp;3.兼证类；<br />&nbsp;&nbsp;3.1血瘀证', '1诊断依据<br />&nbsp;&nbsp;1.1诊断要点<br />&nbsp;&nbsp;1.1.1病史有慢性呼吸系统疾病病史，主要是慢性支气管炎、阻塞性肺气肿、肺结核、支气管扩张和胸廓疾病等病史。<br />&nbsp;&nbsp;1.1.2症状有咳嗽、咯痰，进行性气促的临床症状。<br />&nbsp;&nbsp;1.1.3体征有肺气肿和(或)肺动脉高压的体征。<br />&nbsp;&nbsp;1.1.4辅助检查X线胸片、心电图检查有1项符合诊断标准。有条件可作心电向量图、超声心动图以增加诊断的可靠性。<br />&nbsp;&nbsp;X线征象：具备以下①～④项中1项可提示，2项或以上者可以诊断，具有第⑤项情况者即可诊断。①右肺下动脉干扩张：横径≥15mm；右肺下动脉横径与气管横径比值≥1.07；经动态观察，较原右肺下动脉干增宽2mm以上。②肺动脉段中度凸出或其高度≥3mm。③中心动脉扩张和外周分支纤细形成鲜明对比。④圆锥部显著凸出(右前斜位45°)或锥高≥7mm。⑤右心室增大(结合不同体位判断)。<br />&nbsp;&nbsp;心电图检查：具有1条主要条件即可诊断，2条次要条件为可疑肺心病的心电图表现。主要条件：①额面平均电轴≥+90°；②V1导连Ｒ/S≥1；③重度顺钟向转位(V5导连Ｒ/S≤1)；④ＲV1+SV5＞1.05mV；⑤aVＲ导连Ｒ/S或Ｒ/Q≥1；⑥V1～3导连呈Qs、qr、Qr(除外心肌梗死)；⑦肺型P波：a：P电压≥0.22mV；或b：电压≥0.2mV呈尖峰型，结合P电轴＞+80°，或c：当低电压时P电压＞1/2Ｒ，呈尖峰型，结合电轴＞+80°。次要条件：①可有肢导连低电压；②右束支传导阻滞(完全性或不完全性)。<br />&nbsp;&nbsp;超声心动图检查：凡有胸肺疾病的患者，具有以下2条者(其中必具1条主要条件)均可诊断，仅适用于心前区探测部位。主要条件：①右心室流出道内径≥30mm；②右心室内径≥20mm；③右心室前壁的厚度≥5.0mm，或前壁搏动幅度增强；④左/右心室内径比值＜2；⑤右肺动脉内径≥18mm，或肺动脉干内径≥20mm；⑥右心室流出道/左心房内径比值＞1.4；⑦肺动脉瓣曲线出现肺动脉高压征象者(a波低平或幅度＜2mm，有收缩中期关闭征等)。参考条件：①室间隔厚度≥12mm，搏幅＜5mm或呈矛盾运动征象；②右心房增大，直径≥25mm(剑突下区)；③三尖瓣前叶曲线DE、EF速度增快，E峰呈尖高型，或有AC间期延长；④二尖瓣前叶曲线幅度低，CE＜18mm，CD段上升缓慢、延长、呈水平位或有EF下降速度减慢，＜90mm/s。<br />&nbsp;&nbsp;心电向量图检查：具有右心室及(或)右心房增大指征。<br />&nbsp;&nbsp;1.1.5急性加重期可有发热、血白细胞和(或)中性粒细胞增高。痰培养或痰涂片可获得有价值的病原。<br />&nbsp;&nbsp;具有以上病史、症状、体征加上X线胸片或心电图符合诊断条件，排除其他心脏疾病即可诊断。', '1实证类<br />&nbsp;&nbsp;1.1寒饮停肺证主症：喘满不得卧，咳嗽，痰多、色白、质清稀或呈泡沫状，气短，恶寒，遇寒发作或加重，舌质淡。次症：周身酸痛，发热，舌体胖大，舌苔白、滑，脉弦、紧。<br />&nbsp;&nbsp;诊断：①咳逆喘满不得卧或气短；②咳痰、色白、清稀或呈泡沫状；③恶寒或并发热，遇寒加重；④周身酸痛；⑤舌苔白或白滑，脉紧或弦紧。具备①、②2项，加③、④、⑤中1项。<br />&nbsp;&nbsp;1.2痰热壅肺证主症：喘促，动则喘甚，咳嗽，痰黏稠，痰黄，胸闷，口渴，尿黄，大便秘结，舌质红，舌苔黄、腻，脉滑、数。次症：发热，烦躁，紫绀，不能平卧，纳呆，咯痰不爽，气短，舌苔干燥。<br />&nbsp;&nbsp;诊断：①喘促或胸闷气短、甚者不能平卧，动则加重，或咳嗽；②痰色黄或黏稠，咯痰不爽；③发热或口渴；④大便干结；⑤舌质红，或舌苔黄或黄腻，或脉数或滑数。具备①、②2项，加③、④、⑤中2项。<br />&nbsp;&nbsp;1.3痰湿阻肺证主症：喘促，动则喘甚，咳嗽，痰黏稠，痰白，胸闷，胃脘痞满，纳呆，食少，舌苔白、腻，脉滑。次症：咯痰不爽，气短，痰多，痰清稀，乏力，腹胀，便溏，舌苔薄，脉弦。<br />&nbsp;&nbsp;诊断：①喘促或胸闷气短，甚者不能平卧，动则加重，或咳嗽；②痰多、色白或清稀或黏稠；③纳呆或食少；④胃脘痞满或腹胀；⑤舌苔白腻，或脉滑或弦滑。具备①、②2项，加③、④、⑤中2项。<br />&nbsp;&nbsp;1.4阳虚水泛证主症：咳嗽，喘促，气短，肢体浮肿，痰白，胸闷，不能平卧，乏力，紫绀，舌苔白。次症：心悸，痰少，肢冷，畏寒，纳呆，神疲，尿少，舌苔滑，脉沉、滑、弦。<br />&nbsp;&nbsp;诊断：①喘促或胸闷气短，甚者不能平卧，动则加重，或咳嗽；②肢体浮肿；③神疲乏力、动则加重；④心悸，动则尤甚；⑤肢冷，或畏寒；⑥舌苔白或白滑，或脉沉滑或沉弦；具备①、②2项，加③、④、⑤、⑥中3项。<br />&nbsp;&nbsp;1.5痰蒙神窍证主症：喉中痰鸣，痰黏稠，喘促，动则喘甚，头痛，烦躁，恍惚，嗜睡，谵妄，昏迷，瘛疭甚则抽搐，舌苔腻，脉滑、数。次症：舌苔白、黄。<br />&nbsp;&nbsp;诊断：①神志异常(恍惚、嗜睡、谵妄、昏迷)，或伴瘛疭甚则抽搐；②烦躁或伴头痛；③喘促，动则加重；④喉中痰鸣；⑤舌苔白腻或黄腻，或脉滑或脉数。具备①、②中1项，加③、④、⑤中2项。<br />&nbsp;&nbsp;2虚证类<br />&nbsp;&nbsp;2.1心肺气虚证主症：喘促，动则喘甚，胸闷，气短，心悸，怔忡，乏力，动则气短、乏力、心悸加重，神疲，自汗，易感冒，舌质淡，舌苔白。次症：咳嗽，脉结、代。<br />&nbsp;&nbsp;诊断：①喘促或气短，动则加重；②心悸或怔忡，动则加重；③易感冒；④神疲乏力或自汗，动则加重；⑤面目虚浮；⑥舌质淡、舌苔白，脉沉细或细弱。具备①、②2项，加③、④、⑤、⑥中2项。<br />&nbsp;&nbsp;2.2肺肾气虚证主症：喘促、胸闷、气短，动则加重，咳嗽，面目浮肿，头昏，神疲，乏力，易感冒，腰膝酸软，小便频数，夜尿增多，舌质淡，舌苔白，脉沉、弱。次症：痰白，耳鸣，咳时遗尿，舌苔腻，脉细。<br />&nbsp;&nbsp;诊断：①胸闷气短，动则加重，甚则喘促；②神疲乏力或自汗，动则加重；③易感冒；④腰膝酸软；⑤头昏或耳鸣；⑥面目浮肿；⑦小便频数，或夜尿增多，或咳时遗尿；⑧舌质淡、舌苔白，或脉沉细或细弱。具备①、②、③中2项，加④、⑤、⑥、⑦、⑧中3项。<br />&nbsp;&nbsp;2.3肺肾气阴两虚证主症：喘促、气短、动则加重，不能平卧，气不得续，胸闷，咳嗽，少痰，咯痰不爽，自汗，盗汗，神疲，乏力，易感冒，手足心热，腰膝酸软，舌质红，舌苔少，脉数、沉、细、弱。次症：面红，耳鸣，头昏，头晕，少气懒言，紫绀，舌质淡，舌苔花剥。<br />&nbsp;&nbsp;诊断：①胸闷气短或喘促，动则加重，甚则不能平卧；②神疲乏力或自汗，动则加重；③易感冒；④腰膝酸软；⑤耳鸣，或头昏；⑥干咳或少痰，咯痰不爽；⑦盗汗；⑧手足心热；⑨舌质淡或红，或舌苔薄少或花剥，或脉沉细或细弱或细数。具备①、②、③中2项加④、⑤中1项加⑥、⑦、⑧、⑨中2项。<br />&nbsp;&nbsp;3兼证类<br />&nbsp;&nbsp;血瘀证：主症：面色紫暗，唇甲青紫，舌下脉络迂曲、粗乱，舌质暗红、瘀斑、瘀点、紫暗，脉涩、结、代。次症：胸闷，胸痛。<br />&nbsp;&nbsp;诊断：①面色紫暗；②唇甲青紫；③舌质紫暗或有瘀斑或瘀点；④舌下脉络迂曲、粗乱。具备①、②、③、④中的1项。<br />&nbsp;&nbsp;', null, ' ', '相比2012版，增加了西医诊断标准', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('806156b61f1749558d416efb9b4819aa', '4', 'a', '0', 'a', 'bbb', 'a', null, 'aa', '中文', '', '', '', '', '', '', '', '', '', '7', '0', 'admin', '2016-05-11 16:17:08', 'admin', '2016-05-13 15:59:59');
INSERT INTO `biz_standard` VALUES ('81', '17', 'F04_009', '0', '中华中医药学会标准-喘病', '无', '中华中医药学会', '2008', 'ZYYXH/T 6-2008, 喘病[S].', '中文', null, null, '喘病', '1.实喘；<br />&nbsp;&nbsp;1.1风寒闭肺证；<br />&nbsp;&nbsp;1.2痰热壅肺证；<br />&nbsp;&nbsp;1.3痰浊阻肺证；<br />&nbsp;&nbsp;1.4肝气犯肺证；<br />&nbsp;&nbsp;1.5水凌心肺证；<br />&nbsp;&nbsp;2.虚喘；<br />&nbsp;&nbsp;2.1肺虚证；<br />&nbsp;&nbsp;2.2肾虚证；<br />&nbsp;&nbsp;2.3肺肾气虚证', '1.诊断要点<br />&nbsp;&nbsp;1.1以喘促不宁，呼吸困难，甚至张口抬肩，鼻翼煽动，不能平卧，或口唇青紫为主要临床表现。<br />&nbsp;&nbsp;1.2多有慢性咳嗽、胸痹等心、肺疾病史。<br />&nbsp;&nbsp;1.3发病多有外感六淫、情志刺激等诱因。<br />&nbsp;&nbsp;2.鉴别诊断<br />&nbsp;&nbsp;2.1哮病：哮与喘都表现为呼吸困难，但哮指声响言，呼吸困难而兼喉中哮鸣；喘指气息言，为呼吸气促困难而无喉中哮鸣，可见于多种急、慢性疾病中。一般来说，哮必兼喘，喘未必兼哮。<br />&nbsp;&nbsp;2.2肺痿：肺痿系肺气受损，津液耗伤，肺叶痿弱不用，以咳嗽、气短、咳吐浊唾涎沫为特征，晚期可表现为喘促、呼吸困难。喘病日久也可致肺叶痿弱不用而成肺痿。<br />&nbsp;&nbsp;', '1.实喘<br />&nbsp;&nbsp;1.1风寒闭肺证：喘息，呼吸气促，胸部胀闷，伴见咳嗽，痰多稀薄色白，头痛，鼻塞，喷嚏，流清涕，无汗，恶寒，或伴发热，口不渴，舌苔薄白而滑，脉浮紧。<br />&nbsp;&nbsp;1.2痰热壅肺证：喘咳气涌，胸闷烦热，痰多黏稠色黄，或痰中带血，面红咽干，渴喜冷饮，尿赤便秘，舌质红，苔黄或黄腻，脉滑数。<br />&nbsp;&nbsp;1.3痰浊阻肺证：喘息胸闷，咳嗽痰多，黏腻色白，咯吐不利，或脘闷，呕恶，纳呆，口黏不渴，舌质淡，苔厚腻色白，脉滑。<br />&nbsp;&nbsp;1.4肝气犯肺证：每遇情志刺激而诱发，突然呼吸短促，胸闷发憋，咽中如窒，但喉中痰声不著，平素多忧思抑郁，或失眠，心悸，或不思饮食，大便不爽，或心烦易怒，面红目赤，舌质淡或红，苔薄白或薄黄，脉象弦或弦而数。<br />&nbsp;&nbsp;1.5水凌心肺证：喘咳气逆，倚息难以平卧，伴咯痰稀白，心悸，面目肢体浮肿，小便量少，怯寒肢冷，或面色晦暗，唇甲青紫，舌淡胖或胖暗或有瘀斑、瘀点，舌下青筋显露，苔白滑，脉沉细或带涩。<br />&nbsp;&nbsp;2.虚喘<br />&nbsp;&nbsp;2.1肺虚证：喘促短气，气怯声低，咳声低弱，咯痰稀薄，自汗畏风，或呛咳少痰质黏，烦热口干，咽喉不利，舌质淡红或舌红苔剥，脉细数。<br />&nbsp;&nbsp;2.2肾虚证：喘促日久，动则喘甚，呼多吸少，气不得续，面青唇紫，汗出肢冷，舌苔淡白，脉微细或沉弱。<br />&nbsp;&nbsp;2.3肺肾气虚证：平素气息短促，动则为甚，腰酸腿软，脑转耳鸣，不耐劳累，下肢欠温，小便清长，舌质淡，脉沉细。<br />&nbsp;&nbsp;', null, ' ', '为中医标准。有详细诊断及中医辨证分型，并附单方验方、针刺、穴位贴敷、调摄与预防等其他治法。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('82', '17', 'F04_010', '0', '中华中医药学会标准-肺胀', '无', '中华中医药学会', '2008', 'ZYYXH/T 7-2008, 肺胀[S].', '中文', null, null, '肺胀', '1.外寒内饮证；<br />&nbsp;&nbsp;2.痰浊阻肺证；<br />&nbsp;&nbsp;3.痰热郁肺证；<br />&nbsp;&nbsp;4.肺肾气虚证；<br />&nbsp;&nbsp;5.阳虚水泛证', '1.诊断要点<br />&nbsp;&nbsp;1.1典型临床表现为胸部膨满，胸中憋闷如塞，咳逆上气，痰多喘息，动则加剧；日久可见心慌动悸，面唇紫绀，肢体浮肿；严重者可出现喘脱，神昏，谵语，出血等。<br />&nbsp;&nbsp;1.2有慢性肺系疾患病史，反复发作，经久难愈；发病年龄多为老年，中青年少见。<br />&nbsp;&nbsp;1.3常因外感诱发，其他如饮食、劳倦、情绪等亦可诱发加重。<br />&nbsp;&nbsp;1.4胸部X线、心电图、超声心动图、肺功能等检查有助于诊断和鉴别诊断。<br />&nbsp;&nbsp;2.鉴别诊断<br />&nbsp;&nbsp;2.1哮病：哮病是一种发作性的痰鸣气喘疾患，常突然发病，经治疗或可自行缓解，以夜间发作多见。肺胀为多种慢性肺部疾病长期反复发作、迁延不愈发展而来，以喘促、咳嗽、咯痰、胸部膨满、憋闷如塞等为临床特征，二者有明显区别。哮病长期反复发作，可发展为肺胀。<br />&nbsp;&nbsp;2.2喘病：喘病以喘促、呼吸困难为临床表现，可见于哮病、肺胀、胸痹等多种急、慢性疾病过程中。肺胀为多种慢性肺部疾病长期反复发作、迁延不愈而成，临床除喘促、呼吸困难外，尚具有咳嗽、咯痰、胸部膨满、憋闷如塞等特征，喘促仅是肺胀的一个症状。<br />&nbsp;&nbsp;', '1.外寒内饮证：咳逆喘满不得卧，气短息促，咯痰稀白量多，呈泡沫状，胸部膨满，面色青暗，周身酸楚，头痛，恶寒，无汗，舌体胖大，舌质暗淡，苔白滑，脉浮紧。<br />&nbsp;&nbsp;2.痰浊阻肺证：胸膺满闷，短气喘息，咳嗽痰多，色白黏腻或呈泡沫，畏风易汗，脘腹痞胀，纳少，泛恶，便溏，倦怠乏力，舌质偏淡或淡胖，苔薄腻或浊腻，脉细滑。<br />&nbsp;&nbsp;3.痰热郁肺证：咳嗽喘急，胸满气粗，咯痰黄或白，黏稠难咯，身热，烦躁，微恶寒，有汗不多，口渴欲饮，尿黄，便干，舌质红或边尖红，舌苔黄或黄腻，脉滑数或浮滑数。<br />&nbsp;&nbsp;4.肺肾气虚证：呼吸浅短难续，甚则张口抬肩，倚息不能平卧，咳嗽，痰白如沫，咯吐不利，胸闷心慌，形寒汗出，或腰膝酸软，小便清长，或尿后余沥，或咳则小便自遗，舌淡或暗紫，苔白润，脉沉细虚数无力，或有结代。<br />&nbsp;&nbsp;5.阳虚水泛证：喘咳不能平卧，咯痰清稀，心悸，胸满气憋，面浮，下肢肿，甚则一身悉肿，腹部胀满有水，尿少，脘痞，纳差，怕冷，面唇青紫，舌胖质暗，苔白滑，脉沉细滑或结代。<br />&nbsp;&nbsp;', null, ' ', '为中医标准。有详细诊断及中医辨证分型，并附单方验方、针刺、灸法、调摄与预防等其他治法。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('83', '17', 'F04_011', '1', '澳大利亚和新西兰慢性阻塞性肺疾病管理指南', 'Chronic Obstructive Pulmonary Disease (COPD) Australian and New Zealand Management Guidelines and the COPD Handbook', '澳大利亚胸肺基金会；澳大利亚、新西兰胸科学会（The Australian Lung Foundation；Thoracic Society of Australia and New Zealand）', '2002', 'http://www.asthmafoundation.org.nz/wp-content/uploads/2012/03/COPDguidelines.pdf', '英文', null, 'cor pulmonale', null, null, 'Identify and Treat Complications<br />&nbsp;&nbsp;Pulmonary hypertension and cor pulmonale<br />&nbsp;&nbsp;Pulmonary hypertension in COPD results mainly from vasoconstriction of pulmonary arterioles in response to local hypoxia usually due to impaired ventilation and vasoconstrictor peptides produced by inflammatory cells. The vasoconstriction minimises blood flow through poorly ventilated lung reducing the mismatch of ventilation and perfusion. While this compensatory mechanism initially helps to maintain the blood gases the price is increased pulmonary vascular resistance, ultimately leading to right ventricular strain and failure (cor pulmonale). The vascoconstriction is reversible initially but vascular remodeling occurs eventually and the condition becomes irreversible. In pulmonary emphysema there is also an anatomical disruption of capillaries in alveolar walls. <br />&nbsp;&nbsp;Right ventricular hypertrophy is seen in about 40% of patients with FEV1 <1.0 L and 70% of those with FEV1 < 0.6 L. The presence of hypercapnia is strongly associated with cor pulmonale.<br />&nbsp;&nbsp;When pulmonary hypertension and cor pulmonale seem out of proportion with the severity of airway narrowing, additional mechanisms should be considered. These include sleep apnoea (central and obstructive) leading to repetitive hypoxia, polycythaemia (either primary or secondary), and recurrent pulmonary thromboembolism, which occurs with increased frequency in COPD.<br />&nbsp;&nbsp;The development of pulmonary hypertension and peripheral oedema is a poor prognostic sign in COPD. If left untreated, the five-year survival rate is about 30%. Investigations<br />&nbsp;&nbsp;(1) Chest radiographs<br />&nbsp;&nbsp;Enlargement of proximal pulmonary arteries. Right ventricular enlargement may be difficult to detect due to hyperinflation.<br />&nbsp;&nbsp;(2) Electrocardiograph<br />&nbsp;&nbsp;Right axis deviation and pulmonale may be difficult to detect because of low voltage traces (due to hyperinflation). Multifocal atrial tachycardia and atrial fibrillation are common.<br />&nbsp;&nbsp;(3) Echocardiography<br />&nbsp;&nbsp;Echocardiography is the best non-invasive assessment of pulmonary hypertension but image quality is reduced by hyperinflation. Estimation of pressure relies on the presence of at least some tricuspid regurgitation. Other findings include midsystolic closure of the pulmonic valve and increased right ventricular wall thickness.<br />&nbsp;&nbsp;', null, null, ' ', '1.在此诊断标准中，肺心病作为并发症；2.之后2003年、2014年的修改版本中，并发症中也取消肺心病的独立内容。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('84', '17', 'F04_012', '1', '初级和二级医疗卫生保健中成人慢性阻塞性肺疾病管理', 'Chronic obstructive pulmonary disease. Management of chronic obstructive pulmonary disease in adults in primary and secondary care', '英国急慢性病临床指南中心（National Clinical Guideline Centre - Acute and Chronic Conditions）', '2010', 'https://www.nice.org.uk/guidance/cg101', '英文', null, 'cor pulmonale', null, null, 'In the context of this guideline, the term \'cor pulmonale\' has been adopted to define a clinical condition that is identified and managed on the basis of clinical features. This clinical syndrome of cor pulmonale includes patients who have right heart failure secondary to lung disease and those in whom the primary pathology is retention of salt and water, leading to the development of peripheral oedema.<br />&nbsp;&nbsp;Diagnosis of pulmonary hypertension and cor pulmonale<br />&nbsp;&nbsp;1.2.7.1 A diagnosis of cor pulmonale should be considered if patients have:<br />&nbsp;&nbsp;peripheral oedema<br />&nbsp;&nbsp;a raised venous pressure<br />&nbsp;&nbsp;a systolic parasternal heave<br />&nbsp;&nbsp;a loud pulmonary second heart sound. [2004]<br />&nbsp;&nbsp;1.2.7.2 It is recommended that the diagnosis of cor pulmonale is made clinically and that this process should involve excluding other causes of peripheral oedema.[2004]<br />&nbsp;&nbsp;', null, null, ' ', '该指南起草于2004年，此版本为2010年修订版本', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('85', '11', 'G03_001', '0', '中华人民共和国中医药行业标准-中医病证诊断疗效标准', 'Criteria of diagnosis and therapeutic effect of diseases and syndromes in traditional Chinese medicine', '国家中医药管理局', '1994', 'ZY/T001.1～001.9-94,中华人民共和国中医药行业标准-中医病证诊断疗效标准[S].', '中文', null, null, '绝经前后诸症', '1.肝肾阴虚<br />&nbsp;&nbsp;2.肾阳亏虚', '1.发病年龄一般在45～55周岁绝经前后。<br />&nbsp;&nbsp;2.见有月经紊乱，潮热面红，烘热汗出，情绪激动，情志异常，皮肤感觉异常等症。', '1.肝肾阴虚：经行先期，量多色红或淋漓不绝。烘热汗出，五心烦热，口干便艰，腰膝酸软，头晕耳鸣。舌红少苔，脉细数。兼肝旺者多见烦躁易怒；心火旺者可见心悸失眠。<br />&nbsp;&nbsp;2.肾阳亏虚：月经后愆或闭阻不行，行则量多，色淡质稀或淋漓不止。神萎肢冷，面色晦暗，头目晕眩，腰酸尿频。舌淡，苔薄，脉沉细无力。兼脾阳虚者可见纳少便溏，面浮肢肿；兼心脾两虚者，可见心悸善忘，少寐多梦。', '诸症', '1.治愈：烘热汗出，情志异常等症状消除。<br />&nbsp;&nbsp;2.好转：诸症减轻。<br />&nbsp;&nbsp;3.未愈：诸症无变化。', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('86', '11', 'G03_002', '1', '临床诊疗指南 妇产科学分册', '无', '中华医学会', '2007', '中华医学会编著.临床诊疗指南 妇产科学分册[M].北京：人民卫生出版社.2007.', '中文', null, '绝经综合征', null, null, '1.临床表现<br />&nbsp;&nbsp;本症常出现在年龄40岁以后的妇女，有手术、药物或放射线破坏卵巢病史者可能提前，也可在绝经后。在月经紊乱或绝经的同时可出现三组症状：<br />&nbsp;&nbsp;1.1最典型的是血管舒缩功能不稳定，潮热、出汗、胸闷、心悸或血压波动。约70%的妇女可发生，但严重者仅10%-20%。<br />&nbsp;&nbsp;1.2神经精神症状：头痛、头晕、耳鸣、抑郁、焦虑、烦躁、易激动、眩晕、失眠、紧张、四肢麻木、关节痛、皮肤感觉异常等。<br />&nbsp;&nbsp;1.3泌尿生殖道萎缩症状：在绝经后才出现。如阴道干、烧灼感、性交痛、性欲改变、尿频、尿急、压力性尿失禁、反复泌尿道感染等。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1年龄在40岁以上，血FSH升高或正常，E2水平可升高、降低或正常。盆腔超声检查可了解子宫、卵巢情况，并帮助排除器质性疾病。<br />&nbsp;&nbsp;2.2根据症状累及的不同系统请相关学科会诊，选择有关检查以排除冠心病、高血压、甲亢、精神病等。', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('87', '11', 'G03_003', '0', '中医妇科常见病诊疗指南', 'Guidelines for Diagnosis and Treatment of Common Diseases of Gynecology in Traditional Chinese Medicine', '中华中医药学会', '2012', 'ZYYXH/T203～246-2012,中医妇科常见病诊疗指南[S].', '中文', null, null, '更年期综合征', '1.肝肾阴虚证<br />&nbsp;&nbsp;2.肾虚肝郁证<br />&nbsp;&nbsp;3.心肾不交证<br />&nbsp;&nbsp;4.肾阴阳两虚证', '1.诊断要点<br />&nbsp;&nbsp;1.1病史<br />&nbsp;&nbsp;40 -60岁的妇女，出现月经紊乱或停闭，或有手术切除双侧卵巢及其他因素损伤双侧卵巢功能病史。<br />&nbsp;&nbsp;1.2症状<br />&nbsp;&nbsp;月经的改变：月经紊乱，如月经先期，量多或少，经期延长，崩漏，或月经后期，闭经。<br />&nbsp;&nbsp;血管舒缩症状：烘热汗出，眩晕，心悸等。<br />&nbsp;&nbsp;精神神经症状：烦躁易怒，情绪抑郁，失眠多梦，健忘多疑等。<br />&nbsp;&nbsp;泌尿生殖系统症状：绝经后期可出现尿频尿急或尿失禁，阴道于涩，灼热，阴痒，性交疼痛，易反复发作膀胱炎。<br />&nbsp;&nbsp;皮肤症状：皮肤干燥，瘙痒，感觉异常，或有蚁行感。<br />&nbsp;&nbsp;骨、关节肌肉症状：绝经后期可出现肌肉、关节疼痛，腰背、足跟酸痛，易骨折等。<br />&nbsp;&nbsp;1.3体征<br />&nbsp;&nbsp;妇科检查：绝经后期可见外阴及阴道萎缩，阴道分泌物减少，阴道皱襞消失，宫颈、子宫可有萎缩。<br />&nbsp;&nbsp;1.4辅助检查<br />&nbsp;&nbsp;1.4.1阴道细胞学涂片<br />&nbsp;&nbsp;阴道脱落细胞以底、中层细胞为主。<br />&nbsp;&nbsp;1.4.2生殖内分泌激素测定<br />&nbsp;&nbsp;大多患者血清E2水平<20pg/ml（或<150pmol/L），E2水平周期性变化消失，FSH、LH升高，FSH>10U/L。<br />&nbsp;&nbsp;2鉴别诊断<br />&nbsp;&nbsp;2.1高血压<br />&nbsp;&nbsp;舒张压及收缩压持续升高（>140/90mmHg），常合并有心、脑、肾等器官病变，更年期综合征患者血压不稳定，呈波动状态。<br />&nbsp;&nbsp;2.2冠心病<br />&nbsp;&nbsp;心电图异常，胸前区疼痛，服用硝酸甘油症状可缓解，而更年期综合征患者胸闷、胸痛时服用硝酸甘油无效。<br />&nbsp;&nbsp;2.3甲状腺功能亢进症<br />&nbsp;&nbsp;甲状腺功能亢进症患者血清TSH减低、FT4增高，而更年期综合征患者甲状腺功能正常。<br />&nbsp;&nbsp;2.4更年期精神病<br />&nbsp;&nbsp;更年期精神病患者以精神神经症状为最主要临床表现，往往较更年期综合征者的精神神经症状严重。', '1.辨证要点<br />&nbsp;&nbsp;更年期综合征以肾虚为本，常影响到心、肝、脾等脏腑，辨证注意有无水湿、痰浊、瘀血之兼夹证。<br />&nbsp;&nbsp;2.证候<br />&nbsp;&nbsp;2.1肝肾阴虚证<br />&nbsp;&nbsp;绝经前后，月经紊乱，月经提前，量或多或少，经色鲜红；烘热汗出，眩晕耳鸣，目涩，五心烦热，口燥咽干，失眠多梦，健忘，腰膝酸痛，阴部干涩，或皮肤干燥、痛痒、感觉异常，溲黄便秘；舌红，少苔，脉细数。<br />&nbsp;&nbsp;2.2肾虚肝郁证<br />&nbsp;&nbsp;绝经前后，月经紊乱，烘热汗出，精神抑郁；胸闷叹息，烦躁易怒，睡眠不安，大便时干时搪；舌红，苔薄白或薄黄，脉沉弦或细弦。<br />&nbsp;&nbsp;2.3心肾不交证<br />&nbsp;&nbsp;绝经前后，月经紊乱，烘热汗出；心悸怔忡，心烦不宁，失眠健忘，多梦易惊，腰膝疲软，精神涣散，思维迟缓；舌红，少苔，脉细或细数。<br />&nbsp;&nbsp;2.4肾阴阳两虚证<br />&nbsp;&nbsp;绝经前后，月经紊乱，经色暗或淡红，时而烘热，时而畏寒；自汗，盗汗，头晕耳鸣，失眠健忘，腰背冷痛，足跟痛，浮肿便搪，小便频数；舌淡，苔白，脉沉细弱。', null, null, null, '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('88', '11', 'G03_004', '1', '美国内分泌学会围绝经期症状治疗临床指南', 'Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline', '美国内分泌学会（Endocrine Society）', '2015', 'Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015 Nov;100(11):3975-4011.', '英文', null, 'Symptoms of the Menopause', null, null, '1.We suggest diagnosing menopause based on the clinical criteria of the menstrual cycle. <br />&nbsp;&nbsp;2.If establishing a diagnosis of menopause is necessary for patient management in women having undergone a hysterectomy without bilateral oophorectomy or presenting with a menstrual history that is inadequate to ascertain menopausal status, we suggest making a presumptive diagnosis of menopause based on the presence of vasomotor symptoms (VMS) and, when indicated, laboratory testing that includes replicate measures of FSH and serum estradiol.<br />&nbsp;&nbsp;Table 1 lists definitions of the clinical spectrum of menopause. In a woman with an intact uterus, menopause is a clinical diagnosis based upon cessation of menses for at least 12 months. Sex steroids, gonadotropins, inhibin B, or anti-Mullerian hormone measurements do not further inform the diagnosis, do not indicate precisely when the final menstrual period will occur, and will not influence management unless a woman is seeking fertility. In women having undergone a hysterectomy but not bilateral oophorectomy, elevated FSH levels and estradiol concentrations < 20 pg/mL on several occasions support but do not confirm the diagnosis. A distinction between the late perimenopause transition, marked by episodes of > 60 days of amenorrhea and increasing severity of VMS, and early postmenopause cannot be made on the sole basis of hormone measurements. With radiotherapy- or chemotherapy-induced menopause, it is important to recognize that ovarian function may resume after 12 months of amenorrhea, depending on the age of the woman and the dose and duration of treatment. For POI, persistent FSH elevation in women < age 40 provides a tentative diagnosis.<br />&nbsp;&nbsp;G03_004_图表1', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('89', '11', 'G03_005', '1', 'EMAS立场声明：更年期健康管理的10点指导意见', 'EMAS position statement: The ten point guide to the integral management of menopausal health', '欧洲女性与男性更年期协会（European Menopause and Andropause Society,EMAS）', '2015', 'EMAS position statement: The ten point guide to the integral management of menopausal health. Maturitas. 2015 May;81(1):88-92.', '英文', null, 'menopausal health', null, null, 'In women over 45 years irregular or absent menstruation especially in the presence of vasomotor symptoms is diagnostic of the menopause and in the vast majority of women no investigations are required. In younger women with suspected premature ovarian failure or early menopause serial follicle-stimulating hormone (FSH) measurements should be undertaken. In menstruating women, measurement of FSH should be performed at the beginning of the follicular phase (days 2–5 of the cycle) to avoid ovulation induced elevations of FSH. Measurement of thyroid stimulating hormone (TSH) and prolactin are also helpful in investigating menstrual irregularity. Pregnancy needs to be excluded. Estimates of the levels of luteinizing hormone, estradiol, progesterone and testosterone are of no value in the diagnosis of ovarian failure, but may provide information about other menstrual cycle disorders. Routine measurement of Anti-Mullerian Hormone (AMH) is not recommended to diagnose menopause in women over the age of 45, but may be helpful in women with suspected premature ovarian failure to asssess ovarian reserve. However, while AMH has a relationship to age at menopause, the marked variability in levels needs further exploration and improved assay validity is required.', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('8fc34696d353499caa5338477a047e7a', '57', '序号1', '1', '中文题名1', '英文题名', '发布机构1', '1988', '来源1', '英文', '<span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">分型分期</span><span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">分型分期1</span>', '西医病名1', '', '<span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">中医辨证</span><span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">中医辨证</span><span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">中医辨证1</span>', '<span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">西医诊断标准</span><span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">西医诊断标准</span><span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">西医诊断标准</span><span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">西医诊断标准1</span>', '<span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">中医诊断标准</span><span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">中医诊断标准</span><span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">中医诊断标准1</span>', '<span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">疗效指标</span><span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">疗效指标1</span>', '<span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">疗效判定标准</span><span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">疗效判定标准</span><span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">疗效判定标准1</span>', '<span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">备注</span><span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">备注</span><span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">备注</span><span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">备注</span><span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">备注</span><span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">备注</span><span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">备注</span><span style=\"color:#333333;font-family:微软雅黑;font-size:13.3333339691162px;font-weight:bold;background-color:#F5F5F5;\">备注1</span>', '1', '0', 'admin', '2016-05-10 18:51:52', 'admin', '2016-05-10 18:52:54');
INSERT INTO `biz_standard` VALUES ('9', '10', 'D02_009', '1', '国际糖尿病联盟关于代谢综合征定义的全球共识', 'IDF Consensus Worldwide Definition of the Metabolic Syndrome', '国际糖尿病联盟（International Diabetes Federation,IDF）', '2005', 'http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf', '英文', null, 'Metabolic Syndrome', null, null, '1. Worldwide definition for use in clinical practice<br />&nbsp;&nbsp;1.1 The new International Diabetes Federation (IDF) definition<br />&nbsp;&nbsp;According to the new IDF definition, for a person to be defined as having the metabolic syndrome they must have:<br />&nbsp;&nbsp;1.1.1 Central obesity (defined as waist circumference≥94cm for Europid men and ≥ 80cm for Europid women, with ethnicity specific values for other groups)<br />&nbsp;&nbsp;Table 1: Ethnic specific values for waist circumference<br />&nbsp;&nbsp;Central obesity is most easily measured by waist circumference using the guidelines in Table 1 which are gender and ethnic-group (not country of residence) specific. The consensus group acknowledges that these are pragmatic cut-points taken from various different data sources and that better data will be needed to link these to risk. D02_009_图表1<br />&nbsp;&nbsp;1.1.2 plus any two of the following four factors:<br />&nbsp;&nbsp;• raised TG level:≥150 mg/dL(1.7 mmol/L), or specific treatment for this lipid abnormality<br />&nbsp;&nbsp;• reduced HDL cholesterol: <40 mg/dL (1.03 mmol/L*) in males and < 50 mg/dL (1.29 mmol/L*) in females, or specific treatment for this lipid abnormality<br />&nbsp;&nbsp;• raised blood pressure: systolic BP≥130 or diastolic BP≥85 mm Hg, or treatment of previously diagnosed hypertension<br />&nbsp;&nbsp;• raised fasting plasma glucose (FPG)≥100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes If above 5.6 mmol/L or 100 mg/dL, OGTT is strongly recommended but is not necessary to define presence of the syndrome.<br />&nbsp;&nbsp;* These values have been updated from those originally presented to ensure consistency with ATP III cutpoints<br />&nbsp;&nbsp;2.‘Platinum standard’ definition—additional metabolic criteria for research<br />&nbsp;&nbsp;The IDF consensus group has highlighted a number of other parameters that appear to be related to the metabolic syndrome (Table 2) which should be included in research studies to help determine the predictive power of these extra criteria for CVD and/or diabetes. The use of these additional factors in research will also allow further modification of the definition if necessary and the validation of the new clinical definition in different ethnic groups. D02_009_图表2', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('90', '11', 'G03_006', '1', '更年期的诊断与管理', 'Menopause: diagnosis and management (NG23)', '英国国家卫生与临床优化研究所（National Institute for Health and Clinical Excellence,NICE）', '2015', 'http://www.nice.org.uk/guidance/ng23', '英文', null, 'perimenopause and menopause', null, null, 'Diagnosis of perimenopause and menopause<br />&nbsp;&nbsp;1.Diagnose the following without laboratory tests in otherwise healthy women aged over 45 years with menopausal symptoms:<br />&nbsp;&nbsp;perimenopause based on vasomotor symptoms and irregular periods<br />&nbsp;&nbsp;menopause in women who have not had a period for at least 12 months and are not using hormonal contraception<br />&nbsp;&nbsp;menopause based on symptoms in women without a uterus.<br />&nbsp;&nbsp;2.Take into account that it can be difficult to diagnose menopause in women who are taking hormonal treatments, for example for the treatment of heavy periods.<br />&nbsp;&nbsp;3.Do not use the following laboratory and imaging tests to diagnose perimenopause or menopause in women aged over 45 years:<br />&nbsp;&nbsp;anti-Müllerian hormone<br />&nbsp;&nbsp;inhibin A<br />&nbsp;&nbsp;inhibin B<br />&nbsp;&nbsp;oestradiol<br />&nbsp;&nbsp;antral follicle count<br />&nbsp;&nbsp;ovarian volume.<br />&nbsp;&nbsp;4.Do not use a serum follicle-stimulating hormone (FSH) test to diagnose menopause in women using combined oestrogen and progestogen contraception or high-dose progestogen.<br />&nbsp;&nbsp;5.Consider using a FSH test to diagnose menopause only:<br />&nbsp;&nbsp;in women aged 40 to 45 years with menopausal symptoms, including a change in their menstrual cycle<br />&nbsp;&nbsp;in women aged under 40 years in whom menopause is suspected.', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('91', '11', 'G03_007', '1', '绝经前后激素疗法', 'Hormone therapy in perimenopause and postmenopause (HT)', '德国科学医学组织协会（Association of the Scientific Medical Societies in Germany,AWMF）', '2015', 'Hormone therapy in perimenopause and postmenopause (HT).\nInterdisciplinary S3 Guideline, Association of the Scientific Medical Societies\nin Germany AWMF 015/062-short version. Arch Gynecol Obstet. 2011\nAug;284(2):343-55. ', null, null, 'Climacteric symptoms', null, null, 'Hot flushes and vaginal dryness are associated with the transition from premenopause to postmenopause; the frequency of reports on these symptoms varies (LoE 2a).<br />&nbsp;&nbsp;Other complaints like disturbed sleep, various physical symptoms, urinary tract disorders, sexual problems, or mood fluctuations are inconsistently reported symptoms(LoE 2a).', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('92', '18', 'J04_001', '0', '中华人民共和国中医药行业标准-中医内科病证诊断疗效标准', 'Criteria of diagnosis and therapeutic effect of diseases and syndromes in traditional Chinese medicine', '国家中医药管理局', '1994', 'ZY/T 001.1-94, 中医内科病证诊断疗效标准[S].', '中文', null, null, '咳嗽', '1.风寒袭肺；<br />&nbsp;&nbsp;2.风热犯肺；<br />&nbsp;&nbsp;3.燥邪伤肺；<br />&nbsp;&nbsp;4.痰热雍肺；<br />&nbsp;&nbsp;5.肝火犯肺；<br />&nbsp;&nbsp;6.痰湿蕴肺；<br />&nbsp;&nbsp;7.肺阴亏虚；<br />&nbsp;&nbsp;8.肺气亏虚', '1.咳逆有声，或伴咽痒咳痰。<br />&nbsp;&nbsp;2.外感咳嗽，起病急，可伴有寒热等表证。<br />&nbsp;&nbsp;3.内伤咳嗽，每因外感反复发作，病程较长，可咳而伴喘。<br />&nbsp;&nbsp;4.急性期查血白细胞总数和中性粒细胞增高。<br />&nbsp;&nbsp;5.两肺听诊可闻及呼吸音增粗，或伴散在干湿性罗音。<br />&nbsp;&nbsp;6.肺部X线摄片检查，正常或肺纹理增粗。<br />&nbsp;&nbsp;', '1.风寒袭肺：咳嗽声重，咯痰稀薄色白，恶寒，或有发热，无汗。舌苔薄白，脉浮紧。<br />&nbsp;&nbsp;2.风热犯肺：咳嗽气粗，咯痰粘白或黄，咽痛或咳声嘶哑，或有发热，微恶风寒，口微渴。舌尖红，苔薄自或黄，脉浮数。<br />&nbsp;&nbsp;3.燥邪伤肺：干咳少痰，咯痰不爽，鼻咽干燥，口干。舌尖红，苔薄黄少津，脉细数。<br />&nbsp;&nbsp;4.痰热雍肺：咳嗽气粗，痰多稠黄，烦热口干。舌质红，苔黄腻，脉滑数。<br />&nbsp;&nbsp;5.肝火犯肺：咳呛气逆阵作，咳时胸胁引痛，甚则咯血。舌红，苔薄黄少津，脉弦数。<br />&nbsp;&nbsp;6.痰湿蕴肺：咳声重浊，痰多色白，晨起为甚，胸闷脘痞，纳少。舌苔户腻，脉滑。<br />&nbsp;&nbsp;7.肺阴亏虚：咳久痰少，咯吐不爽，痰粘或夹血丝，咽干口燥，手足心热。舌红，少苔，脉细数。<br />&nbsp;&nbsp;8.肺气亏虚：病久咳声低微，咳而伴喘，咯痰清稀色白，食少，气短胸闷，神倦乏力，自汗畏寒。舌淡嫩，苔自，脉弱。<br />&nbsp;&nbsp;', '咳嗽；体征；痰量', '1.治愈：咳嗽及临床体征消失；内伤咳嗽在两周以上未发作者为临床治愈。<br />&nbsp;&nbsp;2.好转：咳嗽减轻，痰量减少。<br />&nbsp;&nbsp;3.未愈：症状无明显改变<br />&nbsp;&nbsp;', '为中医标准。为早期的权威中医标准，首次对急性气管一支气管炎的中医\n辨证进行了规范，明确了诊断标准及疗效标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('93', '18', 'J04_002', '0', '中华人民共和国中医药行业标准-中医儿科病证诊断疗效标准', ' Criteria of diagnosis and therapeutic effect of paediatric diseases and syndromes in traditional Chinese medicine', '国家中医药管理局', '1994', 'ZY/T 001.4-94, 中医儿科病证诊断疗效标准[S].', '中文', null, null, '咳嗽', '1.风寒袭肺；<br />&nbsp;&nbsp;2.风热犯肺；<br />&nbsp;&nbsp;3.痰热雍肺；<br />&nbsp;&nbsp;4.痰湿蕴肺；<br />&nbsp;&nbsp;5.肺气亏虚；<br />&nbsp;&nbsp;6.肺阴亏虚', '1.咳嗽为主要症状，多继发于感冒之后，常因气候变化而发作。<br />&nbsp;&nbsp;2.好发于冬春季节。<br />&nbsp;&nbsp;3.肺部听诊：两肺呼吸音粗糙，或有少量的散在的干、湿性罗音。<br />&nbsp;&nbsp;4.X线摄片或透视检查，示肺纹理增粗。<br />&nbsp;&nbsp;', '1.风寒袭肺：咳嗽，痰稀色白，鼻塞流清涕。或伴恶寒，无汗，咽部不红。苔薄白，脉浮紧。<br />&nbsp;&nbsp;2.风热犯肺：咳嗽，痰黄而稠，鼻塞，流浊涕，发热恶风，咽红而肿。舌尖红，苔薄白或微黄，脉浮数。<br />&nbsp;&nbsp;3.痰热壅肺：咳嗽，痰黄白稠粘，咯吐不爽，咳时面赤唇红，或伴发热口渴，咽喉痛。舌质红，苔黄腻，脉滑数。<br />&nbsp;&nbsp;4.痰湿蕴肺：咳嗽，痰多色白如泡沫，咳时喉有痰声，或呼吸气粗，多不发热。苔白腻，脉滑。<br />&nbsp;&nbsp;5.肺气亏虚：咳声无力，痰白清稀，面色淡白，体弱多汗，易于感冒。舌淡，脉无力。<br />&nbsp;&nbsp;6.肺阴亏虚：干咳无痰，或痰少而粘，不易咯出，口渴咽干，咳声嘶哑，手足心热。舌红苔少，脉细数。<br />&nbsp;&nbsp;', '咳嗽；干性罗音；湿性罗音', '1.治愈：咳嗽消失，听诊干、湿性罗音消失。如有发热则体温降至正常。<br />&nbsp;&nbsp;2.好转：咳嗽减轻。呼吸音清晰，痰减少。<br />&nbsp;&nbsp;3.未愈：咳嗽症状及体征未见改善或加重。<br />&nbsp;&nbsp;', '为中医儿科标准。小儿咳嗽的标准，', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('94', '18', 'J04_003', '0', '中医内科常见病诊疗指南西医疾病部分', 'Guidelines for Diagnosis and Treatment of Common Internal Diseases in Chinese Medicine Diseases of Modern Medicine', '中华中医药学会', '2008', 'ZYYXH/T50～135—2008,中医内科常见病诊疗指南西医疾病部分[S].', '中文', null, '急性气管-支气管炎', null, '1.风寒袭肺证；<br />&nbsp;&nbsp;2.风热犯肺证；<br />&nbsp;&nbsp;3.燥邪伤肺证', '1.临床表现<br />&nbsp;&nbsp;1.1症状：常先有急性上呼吸道感染症状如咳嗽、咳痰，先为干咳或咯少量痰，继而为私液脓性痰，痰量增多，咳嗽加剧，偶见痰中带血。如支气管发生痉挛，可出现程度不等的气促。咳嗽和咳痰可延续一周，有时可延长数周。<br />&nbsp;&nbsp;1.2体征：两肺呼吸音粗，有时可闻及散在湿啰音。<br />&nbsp;&nbsp;2.理化检查：<br />&nbsp;&nbsp;2.1血常规：白细胞计数和分类多无明显改变。细菌性感染时白细胞总数和中性粒细胞比例增高。<br />&nbsp;&nbsp;2.2痰涂片或培养：可发现致病菌。<br />&nbsp;&nbsp;2.3胸片：大多数正常或肺纹理增粗。<br />&nbsp;&nbsp;3.诊断要点<br />&nbsp;&nbsp;3.1起病较急，常有急性上呼吸道感染的症状。<br />&nbsp;&nbsp;3.2常有刺激性干咳，咯少量黏液性痰伴胸骨后不适感；伴有细菌感染时咳嗽剧烈，咯痰量较多，为黏液性或黏液脓性痰，偶尔痰中带血。<br />&nbsp;&nbsp;3.3全身症状较轻，体温一般不超过38℃。<br />&nbsp;&nbsp;3.4两肺呼吸音粗，有时可闻及散在湿啰音，在咳嗽、咯痰后消失。<br />&nbsp;&nbsp;3.5胸片检查，可见肺纹理增多或正常。<br />&nbsp;&nbsp;3.6排除肺炎、肺结核、支气管肺癌、支气管内膜结核等疾病<br />&nbsp;&nbsp;', '1.风寒袭肺证：咳嗽声重，气急咽痒，咳痰稀白，鼻塞流涕，恶寒发热，无汗，头痛，肢体酸楚，舌苔薄白，脉浮或浮紧。<br />&nbsp;&nbsp;2.风热犯肺证：咳嗽频剧，咳时汗出，呼吸气粗或咳声嘶哑，喉燥咽痛，咯痰不爽，痰稠且黄，常伴鼻流清涕，口渴引饮，头痛肢楚，身热恶风，舌质红，苔薄黄，脉浮数或浮滑。<br />&nbsp;&nbsp;3.燥邪伤肺证：温燥伤肺证见咳嗽少痰，不易咳出，或痰中带血丝，咽干，咽痛，唇鼻干燥，咳甚则胸痛，初起或有恶寒，发热，舌尖红，舌苔薄黄而干，脉细数或无变化；凉燥伤肺证见咳嗽，痰少或无痰，喉痒，咽干唇燥，头痛，恶寒，发热，无汗，舌苔薄白而干，脉浮紧。<br />&nbsp;&nbsp;', null, ' ', '为中医标准。诊断标准较为全面，辨证分型为风寒、风热、燥邪伤肺等，并附单方验方、针刺拔罐等。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('95', '18', 'J04_004', '0', '中医内科常见病诊疗指南中医病证部分', 'Guidelines for Diagnosis and Treatment of Common Internal Diseases in Chinese Medicine Symptoms in Chinese Medicine', '中华中医药学会', '2008', 'ZYYXH/T4～49-2008, 中医内科常见病诊疗指南中医病证部分[S].', '中文', null, null, '咳嗽', '1.外感咳嗽；<br />&nbsp;&nbsp;1.1风寒袭肺证；<br />&nbsp;&nbsp;1.2风热犯肺证；<br />&nbsp;&nbsp;1.3燥邪伤肺证；<br />&nbsp;&nbsp;1.4风盛挛急证；<br />&nbsp;&nbsp;2.内伤咳嗽；<br />&nbsp;&nbsp;2.1痰湿蕴肺证；<br />&nbsp;&nbsp;2.2痰热郁肺证；<br />&nbsp;&nbsp;2.3肝火犯肺证；<br />&nbsp;&nbsp;2.4肺阴亏虚证<br />&nbsp;&nbsp;', '1.诊断要点<br />&nbsp;&nbsp;1.1咳而有声，或伴咯痰。<br />&nbsp;&nbsp;1.2由外感引发者，多起病急、病程短，常伴恶寒发热等表证；由外感反复发作或其他脏腑功能失调引发者，多病程较长，可伴喘及其他脏腑失调的症状。<br />&nbsp;&nbsp;2.鉴别诊断<br />&nbsp;&nbsp;2.1肺痨：以干咳，或痰中带血，或咳血痰为特征，常伴有低热、盗汗、消瘦等症状。其发病是由于体质虚弱，气血不足，痨虫侵肺所致。<br />&nbsp;&nbsp;2.2肺痈：以咳吐大量腥臭脓血痰为特征，多伴有咳嗽、胸痛、发热等症。病机为热壅血瘀、蕴毒化脓而成痈。根据病变病理演变过程，可分为初期、成痈期、溃脓期、恢复期。<br />&nbsp;&nbsp;', '1.外感咳嗽<br />&nbsp;&nbsp;1.1风寒袭肺证：咳嗽声重，气急咽痒，咳痰稀薄色白，鼻塞，流清涕，头痛，肢体酸痛，恶寒，发热，无汗，舌苔薄白，脉浮或浮紧。<br />&nbsp;&nbsp;1.2风热犯肺证：咳嗽频剧，气粗或咳声音哑，喉燥咽痛，咯痰不爽，痰黏或稠黄，鼻流黄涕，口渴，头痛，恶风，身热，舌质红，舌苔薄黄，脉浮数或浮滑。<br />&nbsp;&nbsp;1.3燥邪伤肺证：干咳少痰或无痰，咽干鼻燥，咳甚胸痛，或痰黏不易咯出，初起可有恶寒，身热头痛，舌尖红，苔薄黄，脉小而数。<br />&nbsp;&nbsp;1.4风盛挛急证：咳嗽，干咳无痰或少痰，咽痒，痒即咳嗽，或呛咳阵作，气急，遇外界寒热变化、异味等因素突发或加重，多见夜卧晨起咳剧，呈反复性发作，舌苔薄白，脉弦。<br />&nbsp;&nbsp;2.内伤咳嗽<br />&nbsp;&nbsp;2.1痰湿蕴肺证：咳嗽痰多，咳声重浊，痰白黏腻或稠厚或稀薄，每于清晨咯痰尤甚，因痰而嗽，痰出则咳缓，胸闷，院腹胀满，纳差，舌苔白腻，脉濡滑。<br />&nbsp;&nbsp;2.2痰热郁肺证：咳嗽气息粗促，或喉中有痰声，痰多，痰质黏厚或稠黄，咯吐不爽，或有热腥味，或吐血痰，胸胁胀满，咳时引痛，面赤，或有身热，口干欲饮，舌质红，苔薄黄腻，脉滑数。<br />&nbsp;&nbsp;2.3肝火犯肺证：上气咳逆阵作，咳时面红目赤，咳引胸痛，可随情绪波动增减，烦热咽干，常感痰滞咽喉，咯之难出，量少质黏，或痰如絮条，口干口苦，胸胁胀痛，舌质红，苔薄黄少津，脉弦数。<br />&nbsp;&nbsp;2.4肺阴亏虚证：干咳，咳声短促，痰少戮白，或痰中见血，或声音逐渐嘶哑，午后潮热，颧红，手足心热，夜寐盗汗，口干咽燥，起病缓慢，日渐消瘦，神疲，舌质红，少苔，脉细数。<br />&nbsp;&nbsp;', null, ' ', '为中医标准。诊断标准较为全面，辨证分型为外感与内伤咳嗽。附针刺、灸法、穴位贴敷等其它治法。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('96', '18', 'J04_005', '0', '急性气管-支气管炎的中医证候诊断标准（2013版）', '无', '中华中医药学会肺系病专业委员会', '2013', '中华中医药学会肺系病专业委员会.中华中医药学会肺系病专业委员会[J].中医杂志, 2014;55(3):259-261.', '中文', null, '急性气管-支气管炎', null, '1实证类<br />&nbsp;&nbsp;1.1风寒袭肺证；<br />&nbsp;&nbsp;1.2风热犯肺证；<br />&nbsp;&nbsp;1.3燥邪犯肺证；<br />&nbsp;&nbsp;1.4痰热壅肺证；<br />&nbsp;&nbsp;1.5痰湿阻肺证；<br />&nbsp;&nbsp;2正虚邪恋类；<br />&nbsp;&nbsp;2.1肺气虚证；<br />&nbsp;&nbsp;2.2气阴两虚证<br />&nbsp;&nbsp;', null, '1实证类<br />&nbsp;&nbsp;1.1风寒袭肺证：主症：咳嗽，痰白，痰清稀，恶寒，舌苔薄白，脉浮或浮紧。次症：鼻塞，流清涕，咽痒，发热，无汗，肢体酸痛。<br />&nbsp;&nbsp;1.2风热犯肺证：主症：咳嗽，痰黄，咽干甚则咽痛，发热，恶风，舌尖红，舌苔黄，脉浮或浮数。次症：痰黏稠，咯痰不爽，鼻塞，流浊涕，鼻窍干热，咽痒，口渴，舌苔薄。<br />&nbsp;&nbsp;1.3燥邪犯肺证：主症：干咳，咳嗽，唇鼻干燥，口干，咽干甚则咽痛，舌苔薄，脉浮。次症：痰黏难以咯出，口渴，发热，恶风，舌尖红，舌苔薄黄或薄白干，脉数。<br />&nbsp;&nbsp;1.4痰热壅肺证：主症：咳嗽，痰黄，痰黏稠，舌质红，舌苔黄腻，脉滑或滑数。次症：痰多，咯痰不爽，口渴，胸闷，发热，大便秘结。<br />&nbsp;&nbsp;1.5痰湿阻肺证：主症：咳嗽，痰多，痰白黏或有泡沫，舌苔白或白腻，脉滑。次症：痰易咯出，口黏腻，胸闷，纳呆，食少，胃脘痞满，舌边齿痕，脉弦或脉濡。<br />&nbsp;&nbsp;2正虚邪恋类<br />&nbsp;&nbsp;2.1肺气虚证 主症：咳嗽，气短，乏力，自汗，动则加重，畏风寒，舌质淡，舌苔白，脉弱或细。次症：神疲，易感冒，舌苔薄，脉沉或缓。<br />&nbsp;&nbsp;2.2气阴两虚证 主症：咳嗽，少痰，干咳，神疲，乏力，动则加重，易感冒，自汗，盗汗，舌质红，舌苔少，脉细。次症：气短，畏风，手足心热，口干，口渴，舌体胖大甚至舌边齿痕或瘦小，舌质淡或红，舌苔薄或花剥，脉沉或数或弱。<br />&nbsp;&nbsp;2证候诊断标准<br />&nbsp;&nbsp;2.1实证类<br />&nbsp;&nbsp;2.1.1风寒袭肺证①咳嗽、痰白、痰清稀，或干咳；②鼻塞、流清涕；③恶寒、无汗或并发热；④肢体酸痛；⑤舌苔白．或脉浮或浮紧。具备①项，加②、③、④、⑤中2项。<br />&nbsp;&nbsp;2.1.2风热犯肺讧①咳嗽、痰黄或白黏，或痰少、咯痰不爽，或干咳；②鼻塞、流浊涕，或鼻窍干热；③恶风或并发热；④咽干甚则咽痛；⑤口干渴；⑥舌尖红，或舌苔薄黄或薄白干，或脉浮数。具备①项，加②、③、④、⑤、⑥中3项。<br />&nbsp;&nbsp;2.1.3燥邪犯肺证①干咳，或痰少或黏、难以略出；②唇鼻干燥；③口干甚则口渴；④咽干甚则咽痛；⑤恶风或并发热；⑥舌尖红，或舌苔薄黄或薄白干，或脉浮或浮数。具备①、②2项，加③、④、⑤、⑥中2项。<br />&nbsp;&nbsp;2.1.4痰热壅肺证①咳嗽；②痰黏、色黄，或咯痰不爽；③发热，或口渴；④大便秘结；⑤舌质红，或舌苔黄或黄腻，或脉数或滑数。具备①、②2项，加③、④、⑤中2项。<br />&nbsp;&nbsp;2.1.5痰湿阻肺证①咳嗽；②痰多、白黏或泡沫；③口黏腻，或纳呆或食少；④胃脘痞满；⑤舌边齿痕，或舌苔白或白腻，或脉滑或脉濡或弦滑。具备①、②2项，加③、④、⑤中2项。<br />&nbsp;&nbsp;2.2正虚邪恋类<br />&nbsp;&nbsp;2.2.1肺气虚证①咳嗽，或咯痰无力；②神疲或乏力或气短，动则加重；③自汗、动则加重；④畏风寒，或易感冒；⑤舌质淡，或脉沉细或沉缓或细弱。具备①项，加②、③、④、⑤中2项。<br />&nbsp;&nbsp;2.2.2气阴两虚证①干咳或咴嗽少痰；②神疲或乏力或气短，动则加重；③畏风寒，或易感冒；④自汗或盗汗；⑤手足心热；⑥口干甚则口渴；⑦舌体胖大甚至边有齿痕或舌体瘦小，或舌质淡或红，或舌苔薄少或花剥，或脉沉细或细弱或细数。具备①项，加②、③、④中2项及⑤、⑥、⑦中2项。<br />&nbsp;&nbsp;', null, null, '为中医证候诊断标准。完善2008年发布的《中医内科常见病诊疗指南•西医\n疾病部分》急性气管-支气管炎辨证标准，更加科学化。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('97', '18', 'J04_006', '1', '中华医学会临床诊疗指南', '无', ' 中华医学会', '2009', '中华医学会.临床诊疗指南呼吸病学分册[M].北京：人民卫生出版社，2009.', '中文', null, '急性气管-支气管炎', null, null, '1.临床表现<br />&nbsp;&nbsp;1.1起病往往先有上呼吸道感染的症状，如鼻塞、流涕、咽痛、声音嘶哑。全身症状有发热、轻度畏寒、头痛、全身酸痛等，全身症状一般3～5天可消退。<br />&nbsp;&nbsp;1.2开始一般为刺激性干咳，随着卡他症状的减轻，咳嗽逐渐明显并成为突出症状，受凉、吸人冷空气、晨起、睡觉体位改变或体力活动后咳嗽加重。咳嗽症状一般持续1～3周，吸烟者可更长。如为百日咳杆菌感染，咳嗽症状常超过3周以上，通常可达4～6周。超过半数可伴有咳痰，开始时常为黏液痰，部分病人随着病程发展可转为脓性痰。<br />&nbsp;&nbsp;1.3相当一部分病人由于气道高反应性发生支气管痉挛时，可表现为气急、喘鸣、胸闷等症状。<br />&nbsp;&nbsp;1.4该病体征不多，主要有呼吸音增粗、干性啰音、湿性啰音等，支气管痉挛时可闻及哮呜音，部分患者亦可无明显体征。<br />&nbsp;&nbsp;1.5病毒感染时，血白细胞计数可降低，当有细菌感染时，血白细胞总数及中性粒细胞比例增高。<br />&nbsp;&nbsp;1.6X线胸片一般无异常或仅有肺纹理增粗。<br />&nbsp;&nbsp;2.诊断要点<br />&nbsp;&nbsp;2.1根据以上临床表现往往可得到明确的临床诊断，进行相关的实验室检查则可进一步作出病原学诊断。须注意与肺炎、肺结核、支气管扩张症、肺脓肿、肺癌等鉴别，以上疾病常以咳嗽、咳痰为主要症状，但胸部X线检查可发现各自特征性的影像学改变。<br />&nbsp;&nbsp;2.2肺功能检查可发现相当一部分患者气道反应性增高，但通常为一过性。由于本病部分患者有气道反应性增高的现象，少数患者可闻及干性啰音，应注意与支气管哮喘相鉴别。<br />&nbsp;&nbsp;2.3流行性感冒的症状与本病相似，但流行性感冒以发热、头痛、全身酸痛等全身症状为主，而本病以咳嗽等呼吸道症状为主要表现。<br />&nbsp;&nbsp;2.4该病很少超过3周，如咳嗽超过3周称为“持续性”或“慢性”咳嗽，应注意是否由于后鼻漏、哮喘、吸人性肺炎、胃食管反流等疾病所致。<br />&nbsp;&nbsp;', null, null, ' ', '为西医标准。缺乏疗效判定标准，倾向于临床诊断与治疗的标准。', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('98', '18', 'J04_007', '0', '咳嗽中医诊疗专家共识意见（2011版）', '无', '中华中医药学会内科分会肺系病专业委员会', '2011', '中华中医药学会内科分会肺系病专业委员会.咳嗽中医诊疗专家共识意见（2011版）[J].中医杂志，2011,52（10）：896-899.', '中文', null, null, '咳嗽', '1.风寒袭肺证；<br />&nbsp;&nbsp;2.风热犯肺证；<br />&nbsp;&nbsp;3.燥邪伤肺证；<br />&nbsp;&nbsp;4.风盛挛急证；<br />&nbsp;&nbsp;5.痰湿蕴肺证；<br />&nbsp;&nbsp;6.痰热郁肺证；<br />&nbsp;&nbsp;7.胃气上逆证；<br />&nbsp;&nbsp;8.肝火犯肺证；<br />&nbsp;&nbsp;9.肺阴亏虚证', null, '1.辨证要点：<br />&nbsp;&nbsp;感咳嗽多为新病，起病急，病程短，常伴肺卫表证。内伤咳嗽多为久病，常反复发作，病程长，可伴见他脏兼证。外感咳嗽以风寒、风热、风燥为主，均属实，而内伤咳嗽中的痰湿、痰热、胃气上逆、肝火犯肺多以邪实为主兼有虚象，阴津亏耗咳嗽则属虚。而其他临床所见风盛挛急、气道失畅之咳嗽，以呛咳阵作、喉痒或胸闷为主，不伴有肺卫表证，亦无明显脏腑虚实表现。<br />&nbsp;&nbsp;2.辨证分型<br />&nbsp;&nbsp;2.1风寒袭肺证：咳嗽声重，气急咽痒，咳痰稀薄色白，鼻塞，流清涕，头痛，肢体酸痛，恶寒发热，无汗，舌苔薄白，脉浮或浮紧。<br />&nbsp;&nbsp;2.2风热犯肺证：咳嗽频剧，气粗或咳声音哑，喉燥咽痛，咯痰不爽，痰黏或稠黄，鼻流黄涕，口渴，头痛，恶风，身热，舌质红，舌苔薄黄，脉浮数或浮滑。<br />&nbsp;&nbsp;2.3燥邪伤肺证：干咳少痰或无痰，咽干鼻燥，咳甚胸痛，或痰黏不易咯出，初起可有恶寒，身热头1.诊断要点：<br />&nbsp;&nbsp;①咳而有声，咯痰或无痰；②由外感引发者，多起病急、病程短，常伴恶寒发热等表证；由外感反复发作或其他脏腑功能失调引发者，多病程较长，可伴喘及其他脏腑失调的症状。<br />&nbsp;&nbsp;2.鉴别诊断<br />&nbsp;&nbsp;2.1肺胀：肺胀是多种慢性肺系疾病反复迁延而致，除咳嗽症状外，并有胸部膨满，喘咳上气，烦躁心慌，甚则肢体浮肿，面色晦暗。病机为肺脾肾功能失调，痰浊、水饮与瘀血互结。病情缠绵，经久难愈。<br />&nbsp;&nbsp;2.2肺痈：以咳吐大量腥臭脓血痰为特征，多伴有咳嗽、胸痛、发热等症。病机为热壅血瘀、蕴毒化脓而成痈。根据病变病理演变过程，可分为初期、成痈期、溃脓期和恢复期。<br />&nbsp;&nbsp;2.3肺痨：以干咳，或痰中带血、或咯血痰为特征,常伴有低热、盗汗、消瘦等症状。其发病是由于体质虚弱、气血不足、痨虫侵肺所致。<br />&nbsp;&nbsp;2.4肺癌：咳嗽持续、顽固不愈，反复咯血痰，或不明原因的胸痛、气急、发热，伴消瘦、乏力等。其病机为脏腑阴阳气血失调、正气虚弱，外邪入侵，痰、湿、气、瘀、毒等搏结日久，积渐而成。<br />&nbsp;&nbsp;3.辨证要点：<br />&nbsp;&nbsp;感咳嗽多为新病，起病急，病程短，常伴肺卫表证。内伤咳嗽多为久病，常反复发作，病程长，可伴见他脏兼证。外感咳嗽以风寒、风热、风燥为主，均属实，而内伤咳嗽中的痰湿、痰热、胃气上逆、肝火犯肺多以邪实为主兼有虚象，阴津亏耗咳嗽则属虚。而其他临床所见风盛挛急、气道失畅之咳嗽，以呛咳阵作、喉痒或胸闷为主，不伴有肺卫表证，亦无明显脏腑虚实表现。<br />&nbsp;&nbsp;4.辨证分型<br />&nbsp;&nbsp;4.1风寒袭肺证：咳嗽声重，气急咽痒，咳痰稀薄色白，鼻塞，流清涕，头痛，肢体酸痛，恶寒发热，无汗，舌苔薄白，脉浮或浮紧。<br />&nbsp;&nbsp;4.2风热犯肺证：咳嗽频剧，气粗或咳声音哑，喉燥咽痛，咯痰不爽，痰黏或稠黄，鼻流黄涕，口渴，头痛，恶风，身热，舌质红，舌苔薄黄，脉浮数或浮滑。<br />&nbsp;&nbsp;4.3燥邪伤肺证：干咳少痰或无痰，咽干鼻燥，咳甚胸痛，或痰黏不易咯出，初起可有恶寒，身热头痛，舌尖红，苔薄黄，脉小而数。<br />&nbsp;&nbsp;4.4风盛挛急证：咳嗽，干咳无痰或少痰，咽痒，痒即咳嗽，或呛咳阵作，气急，遇外界寒热变化、异味等因素突发或加重，多见夜卧晨起咳剧，呈反复性发作，舌苔薄白，脉弦。<br />&nbsp;&nbsp;4.5痰湿蕴肺证：咳嗽痰多，咳声重浊，痰白黏腻或稠厚或稀薄，每于清晨咯痰尤甚，因痰而嗽，痰出则咳缓，胸闷，脘腹胀满，纳差，舌苔白腻，脉濡滑。<br />&nbsp;&nbsp;4.6痰热郁肺证：咳嗽气息粗促，或喉中有痰声，痰多，痰质黏厚或稠黄，咯吐不爽，或有热腥味，或吐血痰，胸胁胀满，咳时引痛，面赤，或有身热，口干欲饮，舌质红，苔薄黄腻，脉滑数。<br />&nbsp;&nbsp;4.7胃气上逆证：阵发性呛咳、气急，咳甚时呕吐酸苦水，平卧或饱食后症状加重，平素上腹部不适，常伴嗳腐吞酸、嘈杂或灼痛，舌红，苔白腻，脉弦弱。<br />&nbsp;&nbsp;4.8肝火犯肺：上气咳逆阵作，咳时面红目赤，咳引胸痛，可随情绪波动增减，烦热咽干，常感痰滞咽喉，咯之难出，量少质黏，或痰如絮条，口干口苦，胸胁胀痛，舌质红，苔薄黄少津，脉弦数。<br />&nbsp;&nbsp;4.9肺阴亏虚证：干咳，咳声短促，痰少黏白，或痰中见血，或声音逐渐嘶哑，午后潮热，颧红，手足心热，夜寐盗汗，口干咽燥，起病缓慢，日渐消瘦，神疲，舌质红，少苔，脉细数。<br />&nbsp;&nbsp;', null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('98c5c256b698474fbebce8bcc3e7fd31', '4', '141841847', '0', '35234562346', '', '2523535235', null, '', '中文', '', '', '', '', '', '', '', '', '', '1', '0', 'admin', '2016-05-13 14:04:37', 'admin', '2016-05-13 14:04:37');
INSERT INTO `biz_standard` VALUES ('99', '18', 'J04_008', '1', '咳嗽的诊断与治疗指南（2009版）', '无', '中华医学会呼吸病学分会哮喘学组', '2009', '咳嗽的诊断与治疗指南(2009版)[J].中华结核和呼吸杂志,2009,32(6):407-413.', '中文', null, '急性气管-支气管炎', null, null, '临床表现：起病初期常有上呼吸道感染症状。随后咳嗽可渐加剧，伴或不伴咳痰，伴细菌感染者常咳黄脓痰。急性气管、支气管炎常呈自限性，全身症状可在数天内消失，但咳嗽、咳痰一般持续2～3周。x线检查无明显异常或仅有肺纹理增加。查体双肺呼吸音粗，有时可闻及湿性或干性啰音。<br />&nbsp;&nbsp;诊断：主要依据临床表现，要注意与流感、肺炎、肺结核、百日咳、急性扁桃体炎等疾病鉴别。 ', null, null, ' ', ' ', '1', '0', 'admin', null, 'admin', null);
INSERT INTO `biz_standard` VALUES ('9b57a007ab8343d49db15caaa455ab2a', '4', 'adfadf', '0', 'adff', '', 'adfd', null, '', '中文', '', '', '', '', '', '', '', '', '', '1', '0', 'admin', '2016-05-13 16:28:19', 'admin', '2016-05-13 16:28:27');
INSERT INTO `biz_standard` VALUES ('9d5dff3294b948259a559b8f6f577f7f', '6', 'fadfd', '0', 'adsf', '', 'afdsfd', null, '', '中文', '', '', '', '', '', '', '', '', '', '7', '0', 'admin', '2016-05-12 13:10:08', 'admin', '2016-05-13 16:05:12');
INSERT INTO `biz_standard` VALUES ('a3f6f81502e74ebb9b8b5403a419f4d2', '56', 'bb', '0', 'bb', '', 'bbbbb', null, '', '中文', 'b2', '', '', 'b1币', 'b4', 'b5', 'b3', 'b6', 'b7', '3', '0', 'admin', '2016-05-09 17:41:04', 'admin', '2016-05-11 11:45:15');
INSERT INTO `biz_standard` VALUES ('abd594b94bf7494681d61494728af7ab', '56', 'aaaaa', '0', 'aa', '', 'aa', null, '', '', '', '', '', '', '', '', '', '', '', '1', '0', 'admin', '2016-05-06 10:53:26', 'admin', '2016-05-06 10:53:26');
INSERT INTO `biz_standard` VALUES ('abfd7bb30dc040e28e8a860cf6ce965e', '57', 'adf', '0', 'adfa', '', 'ad', null, '', '中文', 'adfa', '', '', 'a', 'fadz', '', '', '', '', '2', '0', 'admin', '2016-05-10 19:29:36', 'admin', '2016-05-10 19:29:36');
INSERT INTO `biz_standard` VALUES ('ad22746ef39f4e3c90898a8f20d51001', '57', 'adfad', '0', 'adf', '', 'adf', null, '', '中文', '', '', '', '', '', '', '', '', '', '1', '0', 'admin', '2016-05-10 17:28:12', 'admin', '2016-05-10 17:28:12');
INSERT INTO `biz_standard` VALUES ('b17bd00f17304df5bf37f6ec0badf08a', '57', 'aaaaa', '0', 'aaaaa', '', 'aaaaa', null, '', '中文', '', '', '', '', '', '', '', '', '', '6', '0', 'admin', '2016-05-10 17:29:55', 'admin', '2016-05-10 17:29:55');
INSERT INTO `biz_standard` VALUES ('b1e2d7ffbb4f48698a19d5e269194636', '3', 'dd', '0', 'dd', '', 'dd', null, '', '中文', '', '', '', '', '', '', '', '', '', '1', '0', 'admin', '2016-05-11 16:14:11', 'admin', '2016-05-11 16:14:11');
INSERT INTO `biz_standard` VALUES ('e745d12081ec4f58af7962a2ea6ba303', '57', 'aaa', '0', 'aaa444bbb', '', 'aaa44444', null, '', '中文', '', '', '', '', '', '', '', '', '', '1', '0', 'admin', '2016-05-10 17:28:31', 'admin', '2016-05-10 18:17:58');
INSERT INTO `biz_standard` VALUES ('f44b3b54c20b425b86a8ff55975f1737', '3', 'aa', '0', 'ssssaaa', '', 'aa', null, '', '中文', '', '', '', '', '', '', '', '', '', '1', '0', 'admin', '2016-05-11 16:07:08', 'admin', '2016-05-11 16:14:28');

-- ----------------------------
-- Table structure for biz_suggest
-- ----------------------------
DROP TABLE IF EXISTS `biz_suggest`;
CREATE TABLE `biz_suggest` (
  `id` varchar(32) NOT NULL COMMENT '主键UUID',
  `standard_id` varchar(32) NOT NULL COMMENT '标准ID',
  `type` varchar(2) DEFAULT NULL COMMENT '意见类型:0:提交审核,1:审核,2:发布,3:撤销',
  `content` text COMMENT '意见内容',
  `create_user` varchar(32) DEFAULT NULL COMMENT '发表人',
  `create_time` datetime DEFAULT NULL COMMENT '发表时间',
  `isPass` varchar(2) DEFAULT NULL COMMENT '1:通过,2:未通过',
  PRIMARY KEY (`id`),
  KEY `biz_suggest_ibfk_1` (`standard_id`) USING BTREE,
  CONSTRAINT `biz_suggest_ibfk_1` FOREIGN KEY (`standard_id`) REFERENCES `biz_standard` (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of biz_suggest
-- ----------------------------
INSERT INTO `biz_suggest` VALUES ('060388fa4f0b420ebc5971e51d9ffff9', '528', '1', 'adf', 'admin', '2016-05-09 09:52:49', '1');
INSERT INTO `biz_suggest` VALUES ('064f06f51080451dab07d42d023d39c1', '9d5dff3294b948259a559b8f6f577f7f', '2', 'afadafadafadafadafadafadafadafadafadafadafadafadafadafadafadafadafadafadafadafadafadafadafad', 'admin', '2016-05-12 13:21:41', '1');
INSERT INTO `biz_suggest` VALUES ('06526836348543e1a659cf15d0c9d79f', '806156b61f1749558d416efb9b4819aa', '2', 'adfadf', 'admin', '2016-05-13 09:21:55', '2');
INSERT INTO `biz_suggest` VALUES ('0af76eaca3d2400094565704152aa368', '605', '0', null, 'admin', '2016-05-10 15:33:46', null);
INSERT INTO `biz_suggest` VALUES ('0bddf8f9889a4cca94f5c8db3e398df2', '504c17409e934a358507741011c5a0e6', '0', null, 'admin', '2016-05-13 09:52:56', null);
INSERT INTO `biz_suggest` VALUES ('171c1bf85b6845fe9277f96349bc1b8e', '528', '0', null, 'admin', '2016-05-09 09:52:44', null);
INSERT INTO `biz_suggest` VALUES ('17fdc9fb032e455badd967601cdcfb45', '529', '2', 'adfasdfasdf', 'admin', '2016-05-09 17:08:00', '1');
INSERT INTO `biz_suggest` VALUES ('1d87505f122648bea4228041da75f1df', '532', '0', null, 'edit', '2016-05-10 15:12:49', null);
INSERT INTO `biz_suggest` VALUES ('2281eb95bcb147bab6b79da2f8ae1436', '806156b61f1749558d416efb9b4819aa', '1', 'adfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadfadf', 'admin', '2016-05-12 12:53:02', '1');
INSERT INTO `biz_suggest` VALUES ('28b998720875416a8f431064efc53264', '527', '1', 'adf', 'admin', '2016-05-09 08:58:50', '1');
INSERT INTO `biz_suggest` VALUES ('305b0586943a490d8c88a93be16cfa84', '806156b61f1749558d416efb9b4819aa', '3', 'adfadfadfadf', 'admin', '2016-05-13 09:23:23', null);
INSERT INTO `biz_suggest` VALUES ('3868ca55d39a49d4a6799d7dbc5dc2d4', '605', '1', 'dfad', 'admin', '2016-05-10 15:33:54', '2');
INSERT INTO `biz_suggest` VALUES ('39f60be042314b80abff013719df55c3', '530', '1', 'adfas', 'admin', '2016-05-09 17:08:30', '1');
INSERT INTO `biz_suggest` VALUES ('3ce91133fa88471498d6da967e301063', '194', '0', null, 'admin', '2016-05-11 16:28:21', null);
INSERT INTO `biz_suggest` VALUES ('4061d1b1370a4ea6805eb66dc849bacb', '530', '2', 'dad', 'admin', '2016-05-09 17:08:15', '2');
INSERT INTO `biz_suggest` VALUES ('47dfaf90dc38425182590aae39d28a67', '607', '0', null, 'admin', '2016-05-11 10:42:54', null);
INSERT INTO `biz_suggest` VALUES ('52ff66567c5146a58991f3bbd2eaba77', '530', '2', 'asdfd', 'admin', '2016-05-09 17:08:35', '1');
INSERT INTO `biz_suggest` VALUES ('554419228a18424f884ba169d142a106', '529', '2', 'adfa', 'admin', '2016-05-09 16:59:40', '1');
INSERT INTO `biz_suggest` VALUES ('562d86fc885d43ed9af92c442c106528', '806156b61f1749558d416efb9b4819aa', '2', 'adsfadf', 'admin', '2016-05-13 09:22:32', '2');
INSERT INTO `biz_suggest` VALUES ('59aeb211882e480a92a330fd4307a6c0', '9d5dff3294b948259a559b8f6f577f7f', '3', '', 'admin', '2016-05-12 13:22:54', null);
INSERT INTO `biz_suggest` VALUES ('5bfcfa28c72f46bcbc7cc0aaa19c95ec', '529', '3', 'afd', 'admin', '2016-05-09 17:00:50', null);
INSERT INTO `biz_suggest` VALUES ('6e3c0889feb34ed0ae20b543c5355303', '530', '1', 'adf', 'admin', '2016-05-09 17:07:46', '1');
INSERT INTO `biz_suggest` VALUES ('76b5f53d29d94bc488b998b794dacda0', '806156b61f1749558d416efb9b4819aa', '0', null, 'admin', '2016-05-12 11:11:34', null);
INSERT INTO `biz_suggest` VALUES ('7cf43e23e0014f8f854b00365f1fc983', '34b2eca42c8740ad99341d639238d209', '1', '合格了', 'admin', '2016-05-13 13:19:01', '1');
INSERT INTO `biz_suggest` VALUES ('7d1661c8b3cb42d098e478ee0eca2e77', '806156b61f1749558d416efb9b4819aa', '1', 'adfa', 'admin', '2016-05-13 09:22:21', '1');
INSERT INTO `biz_suggest` VALUES ('81eba0d9a7de418482f4cd2ab27a8e6c', '806156b61f1749558d416efb9b4819aa', '2', '', 'admin', '2016-05-12 13:16:05', '1');
INSERT INTO `biz_suggest` VALUES ('82e84b4af3c34a89b35e713b57245fcb', '194', '2', '', 'admin', '2016-05-11 16:28:29', '1');
INSERT INTO `biz_suggest` VALUES ('8b157f0dd68342e5a273eb396da1d580', '9d5dff3294b948259a559b8f6f577f7f', '0', null, 'admin', '2016-05-12 13:10:11', null);
INSERT INTO `biz_suggest` VALUES ('8d51e0150f304167997e2eeb3b0feb8e', '194', '1', '', 'admin', '2016-05-11 16:28:25', '1');
INSERT INTO `biz_suggest` VALUES ('9108e35f7ca547dc9858b3e7f95f7750', '806156b61f1749558d416efb9b4819aa', '1', 'adf', 'admin', '2016-05-13 09:22:59', '1');
INSERT INTO `biz_suggest` VALUES ('96ebf506c38b472aad5f7f2a016574d1', 'b17bd00f17304df5bf37f6ec0badf08a', '2', '222', 'admin', '2016-05-10 18:41:52', '2');
INSERT INTO `biz_suggest` VALUES ('9736e50c1c854221bfdfc97add6f0e11', '9d5dff3294b948259a559b8f6f577f7f', '1', 'afadafadafadafadafadafadafadafadafadafadafadafadafadafadafadafadafadafadafadafadafadafadafad', 'admin', '2016-05-12 13:21:24', '1');
INSERT INTO `biz_suggest` VALUES ('9dcbad23bd3e4fc3a3b4e13ac0a2f32c', '530', '0', null, 'admin', '2016-05-09 17:07:32', null);
INSERT INTO `biz_suggest` VALUES ('ae9d433d78414f8f8777eb5eb2a88f8c', '194', '2', 'adf', 'admin', '2016-05-11 16:28:40', '1');
INSERT INTO `biz_suggest` VALUES ('b2f80f589afb4da1b881ebe3c3e40dad', '527', '0', null, 'admin', '2016-05-09 08:58:44', null);
INSERT INTO `biz_suggest` VALUES ('b437150cadd94deeb3d72ae15eea7987', '504c17409e934a358507741011c5a0e6', '0', null, 'admin', '2016-05-13 09:46:24', null);
INSERT INTO `biz_suggest` VALUES ('c8b66e3adb6f411b8338c47bc5958f30', '504c17409e934a358507741011c5a0e6', '1', '理由不充分', 'admin', '2016-05-13 13:19:38', '2');
INSERT INTO `biz_suggest` VALUES ('d1661c27d6e34199954690f76cebbddb', '607', '1', 'adf', 'admin', '2016-05-11 10:43:00', '1');
INSERT INTO `biz_suggest` VALUES ('d25b223b067548c199f5f24d1c1516cf', '194', '3', 'adsfa', 'admin', '2016-05-11 16:28:32', null);
INSERT INTO `biz_suggest` VALUES ('d49c8f8115ef42a2997d135bf9bd1855', 'a3f6f81502e74ebb9b8b5403a419f4d2', '1', 'ada', 'audit', '2016-05-10 15:13:10', '1');
INSERT INTO `biz_suggest` VALUES ('d50a25672e5e4d01a0e6167945548cbd', '806156b61f1749558d416efb9b4819aa', '2', 'adfad', 'admin', '2016-05-13 09:23:05', '1');
INSERT INTO `biz_suggest` VALUES ('d7f681fc43034625b293af8f552c3e85', '528', '2', 'fadfd', 'admin', '2016-05-09 09:52:54', '1');
INSERT INTO `biz_suggest` VALUES ('da56451d8d54459296f08ddbf96bd350', '529', '1', 'adfa', 'admin', '2016-05-09 16:58:56', '1');
INSERT INTO `biz_suggest` VALUES ('db681737e1d54b6b89ca52d2977ac1c8', '529', '0', null, 'admin', '2016-05-09 16:57:56', null);
INSERT INTO `biz_suggest` VALUES ('e5143217ea024b118a8a13b7b1fffb03', '34b2eca42c8740ad99341d639238d209', '0', null, 'admin', '2016-05-12 16:56:53', null);
INSERT INTO `biz_suggest` VALUES ('e7c18a0fdc494373a8e559489a57a4c0', 'a3f6f81502e74ebb9b8b5403a419f4d2', '0', null, 'edit', '2016-05-10 15:12:46', null);
INSERT INTO `biz_suggest` VALUES ('e8f7761b26794749941698f8edcb9967', 'b17bd00f17304df5bf37f6ec0badf08a', '1', '111', 'admin', '2016-05-10 18:41:47', '1');
INSERT INTO `biz_suggest` VALUES ('e942e4690ff24d6e8b59c0f172c46169', '527', '2', 'adf', 'admin', '2016-05-09 08:58:54', '1');
INSERT INTO `biz_suggest` VALUES ('e9c6891ea2414565b8555ec08d7c8380', '806156b61f1749558d416efb9b4819aa', '3', '', 'admin', '2016-05-12 13:16:19', null);
INSERT INTO `biz_suggest` VALUES ('f429a4a072904502a186a1aaefa4fa93', '530', '3', 'ads', 'admin', '2016-05-09 17:10:45', null);
INSERT INTO `biz_suggest` VALUES ('f9193acb2f214cb789e5c8fd67932331', '605', '0', null, 'admin', '2016-05-10 15:33:56', null);

-- ----------------------------
-- Table structure for biz_symptom
-- ----------------------------
DROP TABLE IF EXISTS `biz_symptom`;
CREATE TABLE `biz_symptom` (
  `id` varchar(32) NOT NULL COMMENT '主键UUID',
  `name` varchar(100) DEFAULT NULL COMMENT '证侯名称',
  `disease_name` varchar(100) DEFAULT NULL COMMENT '疾病名称',
  `symptom_name` varchar(100) DEFAULT NULL COMMENT '症状名称',
  `literature_name` varchar(255) DEFAULT NULL COMMENT '文献题名',
  `journal_name` varchar(100) DEFAULT NULL COMMENT '期刊名称',
  `year_journal_page` varchar(60) DEFAULT NULL COMMENT '年期页',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of biz_symptom
-- ----------------------------

-- ----------------------------
-- Table structure for temp_biz_standard
-- ----------------------------
DROP TABLE IF EXISTS `temp_biz_standard`;
CREATE TABLE `temp_biz_standard` (
  `id` varchar(32) NOT NULL COMMENT '主键UUID',
  `order_num` varchar(50) DEFAULT NULL COMMENT '序号(T01代表疾病名称，_001代表标准顺序号，如：F04_001)',
  `cn_title` varchar(500) DEFAULT NULL COMMENT '中文题名',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of temp_biz_standard
-- ----------------------------
INSERT INTO `temp_biz_standard` VALUES ('101', 'R01_002', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('102', 'R01_003', '中医外科病证诊断疗效标准（试行）');
INSERT INTO `temp_biz_standard` VALUES ('103', 'R01_004', '乳腺增生病诊断及疗效评定标准');
INSERT INTO `temp_biz_standard` VALUES ('104', 'Q01_001', '中医外科病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('105', 'Q01_002', '中华中医药学会标准-癃闭');
INSERT INTO `temp_biz_standard` VALUES ('106', 'Q01_003', '中华中医药学会标准-淋证');
INSERT INTO `temp_biz_standard` VALUES ('107', 'Q01_004', '中国泌尿外科疾病诊断治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('108', 'Q01_005', '中国泌尿外科疾病诊断治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('109', 'Q01_006', '美国泌尿协会指南:良性前列腺增生的管理');
INSERT INTO `temp_biz_standard` VALUES ('11', 'D02_011', '美国内分泌协会胰岛素抵抗综合征立场声明');
INSERT INTO `temp_biz_standard` VALUES ('110', 'Q01_007', '韩国良性前列腺增生的临床实践指南');
INSERT INTO `temp_biz_standard` VALUES ('111', 'M02_001', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('112', 'M02_002', '慢性支气管炎临床诊断及疗效判断标准');
INSERT INTO `temp_biz_standard` VALUES ('113', 'M02_003', '中华中医药学会标准-慢性阻塞性肺疾病');
INSERT INTO `temp_biz_standard` VALUES ('114', 'M02_004', '慢性阻塞性肺疾病诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('115', 'M02_005', '中华中医药学会标准-喘病');
INSERT INTO `temp_biz_standard` VALUES ('116', 'M02_006', '中华中医药学会标准-肺胀');
INSERT INTO `temp_biz_standard` VALUES ('117', 'M02_007', '慢性阻塞性肺疾病中医诊疗指南（2011版）');
INSERT INTO `temp_biz_standard` VALUES ('118', 'M02_008', '慢性阻塞性肺疾病诊疗规范（2011年版）');
INSERT INTO `temp_biz_standard` VALUES ('119', 'M02_009', '慢性阻塞性肺疾病诊治指南');
INSERT INTO `temp_biz_standard` VALUES ('12', 'D02_012', '欧洲胰岛素抵抗研究组关于世界卫生组织临时报的评论');
INSERT INTO `temp_biz_standard` VALUES ('120', 'M02_010', '慢性阻塞性肺疾病诊治指南（2007年修订版）');
INSERT INTO `temp_biz_standard` VALUES ('121', 'M02_011', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('122', 'M02_012', '慢性阻塞性肺疾病诊治指南（2013年修订版）');
INSERT INTO `temp_biz_standard` VALUES ('123', 'M02_013', '稳定期慢性阻塞性肺疾病的诊断和管理:美国医师学会的临床实践指南');
INSERT INTO `temp_biz_standard` VALUES ('124', 'M02_014', '卫生保健指南:慢性阻塞性肺病(COPD)的诊断和管理');
INSERT INTO `temp_biz_standard` VALUES ('125', 'M02_015', '卫生保健指南:慢性阻塞性肺病(COPD)的诊断和管理');
INSERT INTO `temp_biz_standard` VALUES ('126', 'M02_016', '慢性阻塞性疾病全球倡议-慢性阻塞性肺疾病的诊断、处理和预防');
INSERT INTO `temp_biz_standard` VALUES ('127', 'M02_017', '慢性阻塞性疾病全球倡议-慢性阻塞性肺疾病的诊断、处理和预防');
INSERT INTO `temp_biz_standard` VALUES ('128', 'M02_018', '慢性阻塞性疾病全球倡议-慢性阻塞性肺疾病的诊断、处理和预防');
INSERT INTO `temp_biz_standard` VALUES ('129', 'M02_019', '慢性阻塞性疾病全球倡议-慢性阻塞性肺疾病的诊断、处理和预防');
INSERT INTO `temp_biz_standard` VALUES ('13', 'G02_001', 'ZYYXH/T60-2008高脂血症');
INSERT INTO `temp_biz_standard` VALUES ('130', 'M02_020', '慢性阻塞性疾病全球倡议-慢性阻塞性肺疾病的诊断、处理和预防');
INSERT INTO `temp_biz_standard` VALUES ('131', 'M02_021', '慢阻肺的诊断和治疗指南(慢性阻塞性肺病)');
INSERT INTO `temp_biz_standard` VALUES ('132', 'M02_022', '成人慢性阻塞性肺疾病的初级和二级保健');
INSERT INTO `temp_biz_standard` VALUES ('133', 'M02_023', 'COPDX计划:澳大利亚和新西兰的慢性阻塞性肺疾病管理指南');
INSERT INTO `temp_biz_standard` VALUES ('134', 'M02_024', '稳定期慢性阻塞性肺疾病的诊断和管理:临床实践指南更新来自美国内科医师学会，美国胸科医师学会,美国胸科学会,欧洲呼吸协会');
INSERT INTO `temp_biz_standard` VALUES ('135', 'M02_025', '慢性阻塞性肺疾病（慢阻肺）');
INSERT INTO `temp_biz_standard` VALUES ('136', 'M07_001', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('137', 'M07_002', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('138', 'M07_003', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('139', 'M07_004', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('14', 'G02_002', '中国儿童青少年血脂防治专家共识');
INSERT INTO `temp_biz_standard` VALUES ('140', 'M07_005', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('141', 'M07_006', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('142', 'M07_007', '盆腔炎症性疾病诊治规范（修订版）');
INSERT INTO `temp_biz_standard` VALUES ('143', 'M07_008', '英国国家2011年盆腔炎性疾病的管理方针');
INSERT INTO `temp_biz_standard` VALUES ('144', 'X01_001', '中华中医药学会标准-心悸');
INSERT INTO `temp_biz_standard` VALUES ('145', 'X01_002', '中华中医药学会标准-室性早搏');
INSERT INTO `temp_biz_standard` VALUES ('146', 'X01_003', '中医内科病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('147', 'X01_004', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('148', 'X01_005', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('149', 'X01_006', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('14b59c3f76304480a108e46faf28b9f6', 'aaaa', 'aaaa11122');
INSERT INTO `temp_biz_standard` VALUES ('15', 'G02_003', '儿童青少年血脂异常防治专家共识');
INSERT INTO `temp_biz_standard` VALUES ('150', 'X01_007', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('151', 'X01_008', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('152', 'X01_009', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('153', 'X01_010', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('154', 'X01_011', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('155', 'X01_012', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('156', 'X01_013', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('157', 'X01_014', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('158', 'X01_015', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('159', 'X01_016', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('16', 'G02_004', '2014年中国胆固醇教育计划血脂异常防治专家建议');
INSERT INTO `temp_biz_standard` VALUES ('160', 'X01_017', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('161', 'X01_018', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('162', 'X01_019', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('163', 'X01_020', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('164', 'X01_021', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('165', 'X01_022', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('166', 'X01_023', '室上性快速心律失常治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('167', 'X01_024', '室上性快速心律失常治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('168', 'X01_025', '室上性快速心律失常治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('169', 'X01_026', '室上性快速心律失常治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('17', 'G02_005_E', '国际动脉粥样硬化学会立场报告：全球血脂异常诊治建议');
INSERT INTO `temp_biz_standard` VALUES ('170', 'X01_027', '室上性快速心律失常治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('171', 'X01_028', '小儿过早搏动（期前收缩）的诊断治疗建议');
INSERT INTO `temp_biz_standard` VALUES ('172', 'X01_029', '小儿过早搏动（期前收缩）的诊断治疗建议');
INSERT INTO `temp_biz_standard` VALUES ('173', 'X01_030', '小儿过早搏动（期前收缩）的诊断治疗建议');
INSERT INTO `temp_biz_standard` VALUES ('174', 'X01_031', '心房颤动的命名和分类国际共识');
INSERT INTO `temp_biz_standard` VALUES ('175', 'X01_032', '心房颤动管理临床指南( CG180)');
INSERT INTO `temp_biz_standard` VALUES ('176', 'X01_033', '2015美国心脏协会/美国心脏病学会/美国心律学会指南：成人室上性心动过速患者的管理（执行摘要）');
INSERT INTO `temp_biz_standard` VALUES ('177', 'X01_034', '2015欧洲心脏病学会室性心律失常治疗与心脏性猝死预防指南');
INSERT INTO `temp_biz_standard` VALUES ('178', 'X01_035', '2015欧洲心脏病学会室性心律失常治疗与心脏性猝死预防指南');
INSERT INTO `temp_biz_standard` VALUES ('179', 'X01_036', '2015欧洲心脏病学会室性心律失常治疗与心脏性猝死预防指南');
INSERT INTO `temp_biz_standard` VALUES ('18', 'G02_005_C', '国际动脉粥样硬化学会立场报告：全球血脂异常诊治建议（中文翻译）');
INSERT INTO `temp_biz_standard` VALUES ('180', 'X01_037', '2015欧洲心脏病学会室性心律失常治疗与心脏性猝死预防指南');
INSERT INTO `temp_biz_standard` VALUES ('181', 'X01_038', '2013法国老年学及老年病学学会/法国心血管学会老年房颤患者管理专家共识');
INSERT INTO `temp_biz_standard` VALUES ('182', 'X01_039', '欧洲心律学会/心律协会/亚太心律学会室性心律失常专家共识');
INSERT INTO `temp_biz_standard` VALUES ('183', 'X01_040', '2005新西兰指南组织：房颤和房扑的患者管理');
INSERT INTO `temp_biz_standard` VALUES ('184', 'X01_041', '美国心脏协会/美国心脏病学会/欧洲心脏病学会2006房颤患者管理指南');
INSERT INTO `temp_biz_standard` VALUES ('185', 'X01_042', '2010欧洲心脏病学会房颤管理指南');
INSERT INTO `temp_biz_standard` VALUES ('186', 'X01_043', '2011美国心脏病学会基金会/美国心脏协会/心律协会心房颤动治疗指南(更新2006版指南）');
INSERT INTO `temp_biz_standard` VALUES ('187', 'X01_044', '2013美国心律协会/欧洲心律学会/亚太心律学会遗传性心律失常综合征诊治专家共识');
INSERT INTO `temp_biz_standard` VALUES ('188', 'X01_045', '2013美国心律协会/欧洲心律学会/亚太心律学会遗传性心律失常综合征诊治专家共识');
INSERT INTO `temp_biz_standard` VALUES ('189', 'X01_046', '2013美国心律协会/欧洲心律学会/亚太心律学会遗传性心律失常综合征诊治专家共识');
INSERT INTO `temp_biz_standard` VALUES ('19', 'G02_007', '绝经后女性血脂异常管理的中国专家共识');
INSERT INTO `temp_biz_standard` VALUES ('190', 'X01_047', '2013美国心律协会/欧洲心律学会/亚太心律学会遗传性心律失常综合征诊治专家共识');
INSERT INTO `temp_biz_standard` VALUES ('191', 'X01_048', '2013美国心律协会/欧洲心律学会/亚太心律学会遗传性心律失常综合征诊治专家共识');
INSERT INTO `temp_biz_standard` VALUES ('192', 'X01_049', '2013美国心律协会/欧洲心律学会/亚太心律学会遗传性心律失常综合征诊治专家共识');
INSERT INTO `temp_biz_standard` VALUES ('193', 'X01_050', '2013美国心律协会/欧洲心律学会/亚太心律学会遗传性心律失常综合征诊治专家共识');
INSERT INTO `temp_biz_standard` VALUES ('194', 'T01_001', '中国2型糖尿病防治指南-2013');
INSERT INTO `temp_biz_standard` VALUES ('195', 'T01_002', 'ADA糖尿病医学诊疗标准-2005');
INSERT INTO `temp_biz_standard` VALUES ('196', 'T01_003', 'ADA糖尿病医学诊疗标准-2006');
INSERT INTO `temp_biz_standard` VALUES ('197', 'T01_004', 'ADA糖尿病医学诊疗标准-2007');
INSERT INTO `temp_biz_standard` VALUES ('198', 'T01_005', 'ADA糖尿病医学诊疗标准-2008');
INSERT INTO `temp_biz_standard` VALUES ('199', 'T01_006', 'ADA糖尿病医学诊疗标准-2009');
INSERT INTO `temp_biz_standard` VALUES ('2', 'D02_002', '糖尿病中医防治指南');
INSERT INTO `temp_biz_standard` VALUES ('20', 'G02_008', '中国成人血脂异常防治指南');
INSERT INTO `temp_biz_standard` VALUES ('200', 'T01_007', 'ADA糖尿病医学诊疗标准-2010');
INSERT INTO `temp_biz_standard` VALUES ('201', 'T01_008', 'ADA糖尿病医学诊疗标准-2011');
INSERT INTO `temp_biz_standard` VALUES ('202', 'T01_009', 'ADA糖尿病医学诊疗标准-2012');
INSERT INTO `temp_biz_standard` VALUES ('203', 'T01_010', 'ADA糖尿病医学诊疗标准-2013');
INSERT INTO `temp_biz_standard` VALUES ('204', 'T01_011', 'ADA糖尿病医学诊疗标准-2014');
INSERT INTO `temp_biz_standard` VALUES ('205', 'T01_012', 'ADA糖尿病医学诊疗标准-2015');
INSERT INTO `temp_biz_standard` VALUES ('206', 'T01_013', 'ADA糖尿病医学诊疗标准-2016');
INSERT INTO `temp_biz_standard` VALUES ('207', 'T01_014', '妊娠期糖尿病诊断-WS 331-2011');
INSERT INTO `temp_biz_standard` VALUES ('208', 'T01_015', '糖尿病的筛查和诊断-WS 397-2012');
INSERT INTO `temp_biz_standard` VALUES ('209', 'T01_016', '中华医学会临床诊疗指南-内分泌及代谢性疾病分册-糖尿病-2005');
INSERT INTO `temp_biz_standard` VALUES ('21', 'G02_009', '甘油三酯增高的血脂异常防治中国专家共识');
INSERT INTO `temp_biz_standard` VALUES ('210', 'T01_017', '中国1型糖尿病防治指南-2013');
INSERT INTO `temp_biz_standard` VALUES ('211', 'B01_001', '变应性鼻炎的诊治原则和推荐方案');
INSERT INTO `temp_biz_standard` VALUES ('212', 'B01_002', '变应性鼻炎诊断和治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('213', 'B01_003', '临床指南：变应性鼻炎');
INSERT INTO `temp_biz_standard` VALUES ('214', 'B01_004', '变应性鼻炎诊断标准及疗效评定标准(1997年修订,海口)');
INSERT INTO `temp_biz_standard` VALUES ('215', 'B01_005', '变应性鼻炎诊断和治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('216', 'B01_006', '变应性鼻炎特异性免疫治疗专家共识');
INSERT INTO `temp_biz_standard` VALUES ('217', 'B01_007', '儿童变应性鼻炎诊断和治疗指南(2010年，重庆)');
INSERT INTO `temp_biz_standard` VALUES ('218', 'B01_008', '中医耳鼻咽喉科常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('219', 'B01_009', '中医耳鼻咽喉科常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('22', 'G02_010', 'ESC/EAS血脂异常管理指南');
INSERT INTO `temp_biz_standard` VALUES ('220', 'B01_010', '过敏性鼻炎及其对哮喘的影响（2008）');
INSERT INTO `temp_biz_standard` VALUES ('221', 'B01_011', '过敏性鼻炎及其对哮喘的影响的指南（2010版本）');
INSERT INTO `temp_biz_standard` VALUES ('222', 'B01_012', '变应性鼻炎');
INSERT INTO `temp_biz_standard` VALUES ('223', 'D03_001', '中医内科常见病诊疗指南西医疾病部分');
INSERT INTO `temp_biz_standard` VALUES ('224', 'D03_002', '临床诊疗指南 内分泌及代谢性疾病分册');
INSERT INTO `temp_biz_standard` VALUES ('225', 'D03_003', '中国成人超重和肥胖症预防控制指南');
INSERT INTO `temp_biz_standard` VALUES ('226', 'D03_004', '中国肥胖问题工作组数据汇总分析协作组建议的我国成人超重和肥胖界限');
INSERT INTO `temp_biz_standard` VALUES ('227', 'D03_005', '成人体重判定');
INSERT INTO `temp_biz_standard` VALUES ('228', 'D03_006', '单纯性肥胖病的诊断及疗效评定标准');
INSERT INTO `temp_biz_standard` VALUES ('229', 'D03_007', '2013 美国心脏协会/美国心脏病学会/美国肥胖学会 成人超重与肥胖管理指南');
INSERT INTO `temp_biz_standard` VALUES ('23', 'G02_011', '血脂异常管理:合作方式:联合委员会包括-心血管护理;动脉硬化、血栓形成,血管生物学;基本心血管科学;心血管疾病在年轻的时候;临床心脏病学;流行病学和预防;营养,体育活动,和新陈代谢,和中风,预防心血管护士协会');
INSERT INTO `temp_biz_standard` VALUES ('230', 'D03_008', '美国临床内分泌协会与美国内分泌学会2014 年关于肥胖作为慢性疾病新诊断框架立的场声明');
INSERT INTO `temp_biz_standard` VALUES ('231', 'D03_009', 'EASO 立场声明：成人肥胖的多学科管理');
INSERT INTO `temp_biz_standard` VALUES ('232', 'D03_010', '美国内分泌学会肥胖药物管理临床实践指南');
INSERT INTO `temp_biz_standard` VALUES ('233', 'G08-001', '慢性乙型肝炎防治指南（2015年版）');
INSERT INTO `temp_biz_standard` VALUES ('234', 'G08-002', '丙型肝炎防治指南（2015 年更新版）');
INSERT INTO `temp_biz_standard` VALUES ('235', 'G08-003', '病毒性肝炎防治方案');
INSERT INTO `temp_biz_standard` VALUES ('236', 'G08_004', '慢性丙型肝炎抗病毒治疗专家共识');
INSERT INTO `temp_biz_standard` VALUES ('237', 'G08_005', '戊型病毒性肝炎诊疗规范');
INSERT INTO `temp_biz_standard` VALUES ('238', 'G08_006', '中国肝病诊疗管理规范白皮书( 节选)');
INSERT INTO `temp_biz_standard` VALUES ('239', 'G08_007', '中国丙型病毒性肝炎医院感染防控指南');
INSERT INTO `temp_biz_standard` VALUES ('24', 'G02_012', '加拿大心血管病学立场声明-血脂异常的诊断、治疗及心血管疾病预防建议');
INSERT INTO `temp_biz_standard` VALUES ('240', 'G08_008', '丙型病毒性肝炎筛查及管理');
INSERT INTO `temp_biz_standard` VALUES ('241', 'G08_009', '乙型肝炎病毒母婴传播预防临床指南(第1版)');
INSERT INTO `temp_biz_standard` VALUES ('242', 'G08_010', '慢性乙型肝炎抗病毒治疗专家共识');
INSERT INTO `temp_biz_standard` VALUES ('243', 'G08_011', '丙型病毒性肝炎诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('244', 'G08_012', '甲型病毒性肝炎诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('245', 'G08_013', '乙型病毒性肝炎诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('246', 'G08_014', '丁型病毒性肝炎诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('247', 'G08_015', '戍型病毒性肝炎诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('248', 'G08_016', '病毒性肝炎中医辩证标准(试行)');
INSERT INTO `temp_biz_standard` VALUES ('249', 'G08_017', '病毒性肝炎中医疗效判定标准( 试行)');
INSERT INTO `temp_biz_standard` VALUES ('25', 'G02_013', 'VA/DoD 血脂异常治疗临床实践指南');
INSERT INTO `temp_biz_standard` VALUES ('250', 'G08_018', '慢性乙型肝炎防治指南(2010年版)');
INSERT INTO `temp_biz_standard` VALUES ('251', 'G08_019', '慢性乙型肝炎中医诊疗专家共识(2012年1月)');
INSERT INTO `temp_biz_standard` VALUES ('252', 'G08_020', '亚太地区慢性乙型肝炎治疗共识(2012最新版)');
INSERT INTO `temp_biz_standard` VALUES ('253', 'G08_021', '慢性乙型肝炎指南');
INSERT INTO `temp_biz_standard` VALUES ('254', 'G08_022', '特殊的感染—乙型肝炎病毒感染的处理和治疗');
INSERT INTO `temp_biz_standard` VALUES ('255', 'G08_023', '乙型肝炎病毒感染');
INSERT INTO `temp_biz_standard` VALUES ('256', 'G08_024', '丙型肝炎指南：美国肝病研究学会-美国感染病学会对成人HCV感染的检测、管理和治疗建议');
INSERT INTO `temp_biz_standard` VALUES ('257', 'G08_025', '急性病毒性肝炎检测-美国，2006');
INSERT INTO `temp_biz_standard` VALUES ('258', 'G08_026', '儿童时期慢性乙型肝炎的诊治指南: 欧洲儿科胃肠病学、肝病学和营养协会临床实践指南');
INSERT INTO `temp_biz_standard` VALUES ('259', 'G08_027', '欧洲肝脏研究学会临床实践指南：慢性乙型肝炎病毒感染的管理');
INSERT INTO `temp_biz_standard` VALUES ('26', 'G02_014', '2009CCS 指南推荐：成人血脂异常的诊断_治疗及心血管疾病预防');
INSERT INTO `temp_biz_standard` VALUES ('260', 'G08_028', '欧洲肝脏研究学会丙型肝炎的治疗建议2015');
INSERT INTO `temp_biz_standard` VALUES ('261', 'G08_029', '日本肝脏病学会指南：乙型肝炎病毒感染的管理');
INSERT INTO `temp_biz_standard` VALUES ('262', 'G08_030', '日本肝脏病学会指南：丙型肝炎病毒感染的管理（基因1型和基因2型）');
INSERT INTO `temp_biz_standard` VALUES ('263', 'G08_031', '丙肝病毒感染者的筛查，护理和治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('264', 'G08_032', '慢性乙型肝炎感染患者的预防，护理和治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('265', 'G08_033', '美国慢性乙型病毒感染的治疗规范：2015年更新');
INSERT INTO `temp_biz_standard` VALUES ('266', 'G08_034', '亚太共识声明：慢性乙型肝炎的治疗：2012年更新');
INSERT INTO `temp_biz_standard` VALUES ('267', 'G08_035', '阿德福韦酯和干扰素α-2a治疗慢性乙型肝炎');
INSERT INTO `temp_biz_standard` VALUES ('268', 'G08_036', '英国国家指南：甲型、乙型和丙型肝炎病毒的管理');
INSERT INTO `temp_biz_standard` VALUES ('269', 'G08_037', '注射毒品者艾滋病、病毒性肝炎和其他感染检测指南');
INSERT INTO `temp_biz_standard` VALUES ('27', 'G02_015', '卫生保健指南：成人血脂管理');
INSERT INTO `temp_biz_standard` VALUES ('270', 'G08_038', '国家临床实践指南：丙型肝炎管理');
INSERT INTO `temp_biz_standard` VALUES ('271', 'G08_039', '丙型肝炎管理临床指南');
INSERT INTO `temp_biz_standard` VALUES ('272', 'G08_040', '儿童、青年和成人慢性乙型肝炎诊断和管理指南');
INSERT INTO `temp_biz_standard` VALUES ('273', 'G08_041', '韩国肝脏病研究学会临床实践指南：丙肝的管理');
INSERT INTO `temp_biz_standard` VALUES ('274', 'B02_001', '委员会意见：女性不孕诊断评估');
INSERT INTO `temp_biz_standard` VALUES ('275', 'B02_002', '委员会意见：女性不孕诊断评估');
INSERT INTO `temp_biz_standard` VALUES ('276', 'B02_003', '委员会意见:输卵管手术在辅助生殖技术时代的角色');
INSERT INTO `temp_biz_standard` VALUES ('277', 'B02_004', '委员会意见:子宫内膜异位症与不孕症');
INSERT INTO `temp_biz_standard` VALUES ('278', 'B02_005', '优化自然生育力');
INSERT INTO `temp_biz_standard` VALUES ('279', 'B02_006', '教育公告：孕酮补充在黄体期、怀孕初期及不孕不育治疗中的作用 ');
INSERT INTO `temp_biz_standard` VALUES ('28', 'G02_016', '卫生保健指南：成人血脂管理');
INSERT INTO `temp_biz_standard` VALUES ('280', 'B02_007', '吸烟与不孕症');
INSERT INTO `temp_biz_standard` VALUES ('281', 'B02_008', '委员会意见：年龄与生育率下降的关系');
INSERT INTO `temp_biz_standard` VALUES ('282', 'B02_009', '原因不明性不孕症的治疗及疗效');
INSERT INTO `temp_biz_standard` VALUES ('283', 'B02_010', '女性不孕症与年龄的关系');
INSERT INTO `temp_biz_standard` VALUES ('284', 'B02_011', '原发性不孕症和继发性不孕症的腹腔镜诊断');
INSERT INTO `temp_biz_standard` VALUES ('285', 'B02_012', '手术减肥在不孕症中的角色');
INSERT INTO `temp_biz_standard` VALUES ('286', 'B02_013', '二甲双胍疗法在多囊卵巢综合征不孕患者中的应用');
INSERT INTO `temp_biz_standard` VALUES ('287', 'B02_014', '生育类疾病的评估及治疗');
INSERT INTO `temp_biz_standard` VALUES ('288', 'B02_015', '晚期育龄与生育');
INSERT INTO `temp_biz_standard` VALUES ('289', 'B02_016', '子宫内膜异位症、妊娠高血压综合征及女性不孕症的中西医结合诊疗标准(试行草案)');
INSERT INTO `temp_biz_standard` VALUES ('29', 'T02_001', '原发性痛风诊断和治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('290', 'B02_017', '子宫内膜异位症、妊娠高血压综合征及女性不孕症的中西医结合诊疗标准');
INSERT INTO `temp_biz_standard` VALUES ('291', 'D04-001', '东京指南');
INSERT INTO `temp_biz_standard` VALUES ('292', 'D04-002', '急性胆道系统感染的诊断和治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('293', 'D04-003', '中国慢性胆囊炎、胆囊结石内科诊疗共识意见');
INSERT INTO `temp_biz_standard` VALUES ('294', 'D04-004', '胆囊炎中医诊疗共识意见');
INSERT INTO `temp_biz_standard` VALUES ('296', 'G01_002', '中国高血压防治指南');
INSERT INTO `temp_biz_standard` VALUES ('297', 'G01_003', '美国高血压检测治疗全国联合委员会1980年报告');
INSERT INTO `temp_biz_standard` VALUES ('298', 'G01_004', '高血压防治指南');
INSERT INTO `temp_biz_standard` VALUES ('299', 'G01_006', '中国高血压防治指南2010');
INSERT INTO `temp_biz_standard` VALUES ('3', 'D02_003', '中国2型糖尿病防治指南（2007年版）');
INSERT INTO `temp_biz_standard` VALUES ('30', 'T02_002', '临床诊疗指南-痛风');
INSERT INTO `temp_biz_standard` VALUES ('300', 'G01_007', '《1984美国成人高血压管理指南（JNC3）》');
INSERT INTO `temp_biz_standard` VALUES ('301', 'G01_008', '《1993美国成人高血压管理指南（JNC5）》');
INSERT INTO `temp_biz_standard` VALUES ('302', 'G01_009', '《1997美国成人高血压管理指南（JNC6）》');
INSERT INTO `temp_biz_standard` VALUES ('303', 'G01_010', '美国高血压联合会第七次报告');
INSERT INTO `temp_biz_standard` VALUES ('304', 'G01_011', '2006AACE 高血压的诊断和治疗临床实践指南');
INSERT INTO `temp_biz_standard` VALUES ('305', 'G01_012', '《2014美国成人高血压管理指南（JNC8）》');
INSERT INTO `temp_biz_standard` VALUES ('306', 'G01_013', '《美国社区高血压管理临床实践指南》');
INSERT INTO `temp_biz_standard` VALUES ('307', 'G01_014', '2014高血压诊断与治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('308', 'G01_015', '2008ICSI 高血压诊断和治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('309', 'G01_016', '2003欧州高血压学会，心脏学会高血压防治指南');
INSERT INTO `temp_biz_standard` VALUES ('31', 'T02_003', 'ZYYXH/T 120-2008 痛风和高尿酸血症');
INSERT INTO `temp_biz_standard` VALUES ('310', 'G01_017', '2007欧州高血压学会，心脏学会高血压防治指南');
INSERT INTO `temp_biz_standard` VALUES ('311', 'G01_018', '2013年欧洲高血压学会（ESH）/ESC 动脉高血压指南');
INSERT INTO `temp_biz_standard` VALUES ('312', 'G01_019', '2009ESH 欧洲儿童和青少年高血压指南');
INSERT INTO `temp_biz_standard` VALUES ('313', 'G01_021', '日本高血压指南');
INSERT INTO `temp_biz_standard` VALUES ('314', 'G01_022', '日本高血压指南');
INSERT INTO `temp_biz_standard` VALUES ('315', 'G01_023', '日本高血压指南');
INSERT INTO `temp_biz_standard` VALUES ('316', 'G01_024', '英国高血压防治指南');
INSERT INTO `temp_biz_standard` VALUES ('317', 'G01_025', '英国成人原发性高血压临床管理指南');
INSERT INTO `temp_biz_standard` VALUES ('318', 'G01_026', '高血压诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('319', 'G01_027', '高血压诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('32', 'T02_004', '高尿酸血症和痛风治疗中国专家共识');
INSERT INTO `temp_biz_standard` VALUES ('320', 'G01_028', '高血压诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('321', 'G01_029', '高血压诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('322', 'G01_030', '高血压诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('323', 'G01_031', '2015 CHEP高血压管理建议：血压的测量、诊断、风险评估、预防和治疗');
INSERT INTO `temp_biz_standard` VALUES ('324', 'G01_032', '2014加拿大高血压教育计划');
INSERT INTO `temp_biz_standard` VALUES ('325', 'G01_033', '2013年CHEP 加拿大高血压管理推荐');
INSERT INTO `temp_biz_standard` VALUES ('326', 'G01_034', '2012年CHEP 加拿大高血压教育计划');
INSERT INTO `temp_biz_standard` VALUES ('327', 'G01_035', '2011加拿大高血压教育计划');
INSERT INTO `temp_biz_standard` VALUES ('328', 'G01_036', '2015年中国台湾地区高血压管理指南');
INSERT INTO `temp_biz_standard` VALUES ('329', 'G01_038', '2010 ISHB 黑人高血压指南管理共识');
INSERT INTO `temp_biz_standard` VALUES ('33', 'T02_005', '痛风诊断与管理的多国证据推荐意见：源自文献系统回顾整合及风湿专家\"3e\"方案意见');
INSERT INTO `temp_biz_standard` VALUES ('330', 'G01_039', '2011年南非高血压指南');
INSERT INTO `temp_biz_standard` VALUES ('331', 'G01_040', '2014南非高血压指南');
INSERT INTO `temp_biz_standard` VALUES ('332', 'G01_041', '2013 年法国高血压学会成人高血压治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('333', 'G01_042', '2009拉丁美洲高血压指南');
INSERT INTO `temp_biz_standard` VALUES ('334', 'G01_043', '2013年印度高血压指南');
INSERT INTO `temp_biz_standard` VALUES ('335', 'G01_044', '澳大利亚成人高血压管理指南（修订版）2010NHFA 成人高血压管理指南');
INSERT INTO `temp_biz_standard` VALUES ('336', 'G01_045', '2008 NHFA 成人高血压管理指南');
INSERT INTO `temp_biz_standard` VALUES ('337', 'G01_046', '中医病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('338', 'G01_047', '临床诊疗指南心血管分册');
INSERT INTO `temp_biz_standard` VALUES ('339', 'G01_048', '中医内科常见病诊疗指南中医疾病部分');
INSERT INTO `temp_biz_standard` VALUES ('34', 'T02_006', '2012 ACR 痛风管理指南第1部分:高尿酸血非药物和药物的系统治疗方法');
INSERT INTO `temp_biz_standard` VALUES ('340', 'G01_049', '中医内科常见病诊疗指南西医疾病部分');
INSERT INTO `temp_biz_standard` VALUES ('341', 'G01_050', '常见疾病的诊断与疗效判断标准');
INSERT INTO `temp_biz_standard` VALUES ('342', 'G01_053', '2006年加拿大高血压教育计划: 高血压治疗部份');
INSERT INTO `temp_biz_standard` VALUES ('343', 'G01_054', '中国脑血管病一级预防指南');
INSERT INTO `temp_biz_standard` VALUES ('344', 'G01_055', '2004英国高血压学会高血压治疗指南(BHS-IV):概要');
INSERT INTO `temp_biz_standard` VALUES ('345', 'G01_056', '2013 KSH指南：高血压的管理');
INSERT INTO `temp_biz_standard` VALUES ('346', 'G01_057', '2016年加拿大高血压指南');
INSERT INTO `temp_biz_standard` VALUES ('347', 'Y04_001', '中医病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('348', 'Y04_002', '临床诊疗指南皮肤病与性病分册');
INSERT INTO `temp_biz_standard` VALUES ('349', 'Y04_003', '常见疾病的诊断与疗效判断标准');
INSERT INTO `temp_biz_standard` VALUES ('35', 'T02_007', '2012 ACR 痛风管理指南第2部分:急性痛风性关节炎治疗和抗炎预防');
INSERT INTO `temp_biz_standard` VALUES ('350', 'Y04_004', '牛皮癣：儿童牛皮癣');
INSERT INTO `temp_biz_standard` VALUES ('351', 'Y04_006', '银屑病面积和严重程度指数(PASI)工作表');
INSERT INTO `temp_biz_standard` VALUES ('352', 'Y04_007', '中国银屑病治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('353', 'Y04_008', '寻常型银屑病的系统性治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('354', 'Y04_009', '2005 英国皮肤医师协会(BAD)《 银屑病生物制剂干预指南》');
INSERT INTO `temp_biz_standard` VALUES ('355', 'Y04_010', '寻常型银屑病（白疕）中医药循证实践指南（2013年版）');
INSERT INTO `temp_biz_standard` VALUES ('356', 'Y04_011', '银屑病和银屑病关节炎的管理指南');
INSERT INTO `temp_biz_standard` VALUES ('357', 'Y04_012', '临床指南：牛皮癣');
INSERT INTO `temp_biz_standard` VALUES ('358', 'Y04_013', '依那西普和依法利珠治疗成人银屑病指南');
INSERT INTO `temp_biz_standard` VALUES ('359', 'Y04_014', '牛皮癣患者管理指南');
INSERT INTO `temp_biz_standard` VALUES ('36', 'T02_008', '痛风的管理指南');
INSERT INTO `temp_biz_standard` VALUES ('360', 'Y04_015', '2009BAD/PCDS 银屑病的初始管理的建议');
INSERT INTO `temp_biz_standard` VALUES ('361', 'Y04_016', '中国银屑病治疗指南2013');
INSERT INTO `temp_biz_standard` VALUES ('362', 'Y04_017', '2012 NPF共识指南：斑块状银屑病的管理');
INSERT INTO `temp_biz_standard` VALUES ('363', 'Y04_018', '维吾尔医常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('364', 'Y04_001', '中医病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('365', 'Y04_002', '临床诊疗指南皮肤病与性病分册');
INSERT INTO `temp_biz_standard` VALUES ('366', 'Y04_003', '常见疾病的诊断与疗效判断标准');
INSERT INTO `temp_biz_standard` VALUES ('367', 'Y04_004', '牛皮癣：儿童牛皮癣');
INSERT INTO `temp_biz_standard` VALUES ('368', 'Y04_006', '银屑病面积和严重程度指数(PASI)工作表');
INSERT INTO `temp_biz_standard` VALUES ('369', 'Y04_007', '中国银屑病治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('37', 'M03_001', '慢性肾功能衰竭');
INSERT INTO `temp_biz_standard` VALUES ('370', 'Y04_008', '寻常型银屑病的系统性治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('371', 'Y04_009', '2005 英国皮肤医师协会(BAD)《 银屑病生物制剂干预指南》');
INSERT INTO `temp_biz_standard` VALUES ('372', 'Y04_010', '寻常型银屑病（白疕）中医药循证实践指南（2013年版）');
INSERT INTO `temp_biz_standard` VALUES ('373', 'Y04_011', '银屑病和银屑病关节炎的管理指南');
INSERT INTO `temp_biz_standard` VALUES ('374', 'Y04_012', '临床指南：牛皮癣');
INSERT INTO `temp_biz_standard` VALUES ('375', 'Y04_013', '依那西普和依法利珠治疗成人银屑病指南');
INSERT INTO `temp_biz_standard` VALUES ('376', 'Y04_014', '牛皮癣患者管理指南');
INSERT INTO `temp_biz_standard` VALUES ('377', 'Y04_015', '2009BAD/PCDS 银屑病的初始管理的建议');
INSERT INTO `temp_biz_standard` VALUES ('378', 'Y04_016', '中国银屑病治疗指南2013');
INSERT INTO `temp_biz_standard` VALUES ('379', 'Y04_017', '2012 NPF共识指南：斑块状银屑病的管理');
INSERT INTO `temp_biz_standard` VALUES ('38', 'M03_002', '临床诊疗指南肾脏病学分册');
INSERT INTO `temp_biz_standard` VALUES ('380', 'Y04_018', '维吾尔医常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('381', 'G06_001', '临床诊疗指南·消化系统疾病分册');
INSERT INTO `temp_biz_standard` VALUES ('382', 'G06_002', '亚洲功能性消化不良共识意见');
INSERT INTO `temp_biz_standard` VALUES ('383', 'G06_003', '功能性胃肠病诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('384', 'G06_004', '成人消化不良初级保健管理');
INSERT INTO `temp_biz_standard` VALUES ('385', 'G06_006', '消化不良和胃食管返流性疾病。调查和管理消化不良或胃食管返流疾病或两者兼而有之。');
INSERT INTO `temp_biz_standard` VALUES ('386', 'G06_007', '中国儿童功能性消化不良诊断和治疗共识');
INSERT INTO `temp_biz_standard` VALUES ('387', 'G06_008', '中国消化不良的诊治指南');
INSERT INTO `temp_biz_standard` VALUES ('388', 'G06_009', '功能性消化不良的中西医结合诊疗共识意见');
INSERT INTO `temp_biz_standard` VALUES ('389', 'G06_010', '消化不良中医诊疗共识意见(2009)');
INSERT INTO `temp_biz_standard` VALUES ('39', 'M03_003', '慢性肾衰竭中西医结合诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('390', 'Y01_001', '中医病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('391', 'Y01_002', '神经根型腰椎间盘突出症临床指南');
INSERT INTO `temp_biz_standard` VALUES ('392', 'Y01_003', '临床诊疗指南·骨科分册');
INSERT INTO `temp_biz_standard` VALUES ('393', 'Y01_004', '中医整脊常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('394', 'Y02_001', '中医妇科病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('395', 'Y02_002', '中医妇科病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('396', 'Y02_003', '中医妇科病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('397', 'Y02_004', '中医妇科病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('398', 'Y02_005', '中医妇科病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('399', 'Y02_006', '中医妇科病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('4', 'D02_004', '中国2型糖尿病防治指南（2010年版）');
INSERT INTO `temp_biz_standard` VALUES ('40', 'M03_004', 'KDIGO 2012年临床实践指南的慢性肾脏疾病的评估和管理');
INSERT INTO `temp_biz_standard` VALUES ('400', 'Y02_007', '中医妇科病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('401', 'Y02_008', '中医妇科病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('402', 'Y02_009', '中医妇科病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('403', 'Y02_010', '原发性痛经诊疗共识指南');
INSERT INTO `temp_biz_standard` VALUES ('404', 'Y02_011', '月经过多临床指南');
INSERT INTO `temp_biz_standard` VALUES ('405', 'Y02_012', '月经过多临床指南');
INSERT INTO `temp_biz_standard` VALUES ('406', 'Y02_013', '临床诊疗指南·妇产科学分册');
INSERT INTO `temp_biz_standard` VALUES ('407', 'Y02_014', '临床诊疗指南·妇产科学分册');
INSERT INTO `temp_biz_standard` VALUES ('408', 'Y02_015', '临床诊疗指南·妇产科学分册');
INSERT INTO `temp_biz_standard` VALUES ('409', 'Y02_016', '闭经诊断与治疗指南（试行）');
INSERT INTO `temp_biz_standard` VALUES ('41', 'M03_005', 'ACR肾功能衰竭适当性标准');
INSERT INTO `temp_biz_standard` VALUES ('410', 'Y02_017', '中医妇科常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('411', 'Y02_018', '中医妇科常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('412', 'Y02_019', '中医妇科常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('413', 'Y02_020', '中医妇科常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('414', 'Y02_021', '中医妇科常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('415', 'Y02_022', '中医妇科常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('416', 'Y02_023', '中医妇科常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('417', 'Y02_024', '中医妇科常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('418', 'Y02_025', '中医妇科常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('419', 'Y02_026', '中医妇科常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('42', 'M03_006', 'ACR肾功能衰竭适当性标准');
INSERT INTO `temp_biz_standard` VALUES ('420', 'Y02_027', '异常子宫出血管理指南');
INSERT INTO `temp_biz_standard` VALUES ('421', 'Y02_028', '绝经期前异常子宫出血');
INSERT INTO `temp_biz_standard` VALUES ('422', 'Y02_029', '异常子宫出血诊断与治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('423', 'Y02_030', '生殖期妇女异常子宫出血诊断');
INSERT INTO `temp_biz_standard` VALUES ('424', 'Y02_031', '育龄女性非妊娠急性异常子宫出血的管理');
INSERT INTO `temp_biz_standard` VALUES ('425', 'Y02_032', '与妊娠无关的急性子宫出血');
INSERT INTO `temp_biz_standard` VALUES ('426', 'M04_001', '前列腺炎诊断治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('427', 'M04_002', '慢性前列腺中西医结合诊疗专家共识');
INSERT INTO `temp_biz_standard` VALUES ('428', 'M04_003', '慢性前列腺炎中西医结合诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('429', 'M04_004', '慢性细菌性前列腺炎和慢性前列腺炎/慢性盆腔综合征诊断治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('43', 'M03_007', 'ACR适当性标准');
INSERT INTO `temp_biz_standard` VALUES ('430', 'M04_005', '前列腺炎诊断治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('431', 'C01_001', 'ZY／T001.8-94，中医病证诊断疗效标准·中医皮肤科病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('432', 'C01_002', 'GB17149.3-1997化妆品痤疮诊断标准及处理原则');
INSERT INTO `temp_biz_standard` VALUES ('433', 'C01_003', 'GB16375-1996 职业性痤疮诊断标准及处理原则');
INSERT INTO `temp_biz_standard` VALUES ('434', 'C01_004', 'GBZ 55-2002 职业性座疮诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('435', 'C01_005', '儿科痤疮诊断和治疗循证推荐');
INSERT INTO `temp_biz_standard` VALUES ('436', 'C01_006', '寻常痤疮分级和疗效标准初步制定');
INSERT INTO `temp_biz_standard` VALUES ('437', 'C01_007', 'ZYYXH/T342～361-2012中医皮肤科常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('438', 'C01_008', '临床诊疗指南·皮肤病与性病分册');
INSERT INTO `temp_biz_standard` VALUES ('439', 'Z03_001', 'ZY／T001.7-94，中医病证诊断疗效标准·中医肛肠科病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('44', 'M03_008', 'ACR适当性标准');
INSERT INTO `temp_biz_standard` VALUES ('440', 'Z03_002', 'ZY／T001.7-94，中医病证诊断疗效标准·中医肛肠科病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('441', 'Z03_003', 'ZY／T001.7-94，中医病证诊断疗效标准·中医肛肠科病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('442', 'Z03_004', 'ZYYXH/T322～341-2012，中医肛肠科常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('443', 'Z03_005', '痔诊治暂行标准');
INSERT INTO `temp_biz_standard` VALUES ('444', 'Z03_006', '痔诊治暂行标准2002');
INSERT INTO `temp_biz_standard` VALUES ('445', 'Z03_007', '痔临床诊治指南（2006版）');
INSERT INTO `temp_biz_standard` VALUES ('446', 'Z03_008', '痔诊断和治疗指南（2010修订版）');
INSERT INTO `temp_biz_standard` VALUES ('447', 'Z03_009', '痔疮的诊疗标准（试行）');
INSERT INTO `temp_biz_standard` VALUES ('448', 'Z03_010', '痔、肛瘘、肛裂、直肠脱垂的诊断标准(试行草案)');
INSERT INTO `temp_biz_standard` VALUES ('449', 'Z03_011', '痔的诊疗指南(初稿)');
INSERT INTO `temp_biz_standard` VALUES ('45', 'M03_009', '筛查、监测和治疗慢性肾病1到3阶段:美国医师学会临床实践指南委员临床指南');
INSERT INTO `temp_biz_standard` VALUES ('450', 'Z03_012', '临床诊疗指南·外科学分册');
INSERT INTO `temp_biz_standard` VALUES ('451', 'Z03_013', 'SICCR共识声明：痔疮的评估和管理');
INSERT INTO `temp_biz_standard` VALUES ('452', 'S02_001', 'ZYYXH/T50～135-2008，中医内科常见病诊疗指南西医疾病部分');
INSERT INTO `temp_biz_standard` VALUES ('453', 'S02_002', '儿童常见肾脏疾病诊治循证指南（试行）(三)：激素敏感耐药型肾病综合征诊治循证指南');
INSERT INTO `temp_biz_standard` VALUES ('454', 'S02_003', '儿童常见肾脏疾病诊治循证指南(一)：激素敏感、复发/依赖肾病综合征诊治循证指南(试行)');
INSERT INTO `temp_biz_standard` VALUES ('455', 'S02_004', '肾病综合征');
INSERT INTO `temp_biz_standard` VALUES ('456', 'S02_005', '小儿肾小球疾病的临床分类、诊断及治疗');
INSERT INTO `temp_biz_standard` VALUES ('457', 'S02_006', '激素敏感型肾病综合征治疗的修订指南');
INSERT INTO `temp_biz_standard` VALUES ('458', 'S02_007', '儿童激素耐药型肾病综合征治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('459', 'S02_008', '肾病综合征管理指南');
INSERT INTO `temp_biz_standard` VALUES ('46', 'M06_001', 'ZYYXH/T 107-2008 泌尿系统结石');
INSERT INTO `temp_biz_standard` VALUES ('460', 'S02_009', 'ZYYXH/T247～286-2012，中医儿科科常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('461', 'S02_010', 'KDIGO肾小球肾炎指南-内固醇敏感儿童肾病综合症');
INSERT INTO `temp_biz_standard` VALUES ('462', 'S02_011', 'KDIGO肾小球肾炎指南-激素抵抗型儿童肾病综合症');
INSERT INTO `temp_biz_standard` VALUES ('464', 'M05_001', 'ZYYXH/T64-2008心力衰竭');
INSERT INTO `temp_biz_standard` VALUES ('465', 'M05_002', '中国心力衰竭诊断和治疗指南2014');
INSERT INTO `temp_biz_standard` VALUES ('466', 'M05_003', '慢性心力衰竭中医诊疗专家共识');
INSERT INTO `temp_biz_standard` VALUES ('467', 'M05_004', '慢性心力衰竭诊断治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('468', 'M05_005', '急性心力衰竭诊断和治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('469', 'M05_006', '慢性收缩性心力衰竭治疗建议');
INSERT INTO `temp_biz_standard` VALUES ('47', 'M06_002', '尿石症诊断治疗指南(2007)');
INSERT INTO `temp_biz_standard` VALUES ('470', 'X03_001', '中医病证诊断疗效标准·中医内科病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('471', 'X03_002', '临床诊疗指南·骨科分册');
INSERT INTO `temp_biz_standard` VALUES ('472', 'Y05_001', '临床诊疗指南消化系统疾病分册');
INSERT INTO `temp_biz_standard` VALUES ('473', 'Y05_002', '中医内科常见病诊疗指南西医疾病部分');
INSERT INTO `temp_biz_standard` VALUES ('474', 'Y05_003', '中医内科常见病诊疗指南中医病证部分');
INSERT INTO `temp_biz_standard` VALUES ('475', 'Y05_004', '急性胰腺炎诊治指南（2014）');
INSERT INTO `temp_biz_standard` VALUES ('476', 'Y05_005', '中国急性胰腺炎诊治指南');
INSERT INTO `temp_biz_standard` VALUES ('477', 'Y05_006', '美国AP指南');
INSERT INTO `temp_biz_standard` VALUES ('478', 'Y05_007', '慢性胰腺炎诊治指南 （2014）');
INSERT INTO `temp_biz_standard` VALUES ('479', 'Y05_008', '2006ACG急性胰腺炎诊疗指南 ');
INSERT INTO `temp_biz_standard` VALUES ('48', 'M06_003', '尿石症诊断治疗指南 (2010)');
INSERT INTO `temp_biz_standard` VALUES ('480', 'Y05_009', '重症急性胰腺炎诊治指南');
INSERT INTO `temp_biz_standard` VALUES ('481', 'Y05_010', ' APA循证诊断报告指南：慢性胰腺炎');
INSERT INTO `temp_biz_standard` VALUES ('482', 'Y05_011', '2015 JSHBPS指南：日本急性胰腺炎的管理');
INSERT INTO `temp_biz_standard` VALUES ('483', 'Y05_012', '2013 急性胰腺炎中医诊疗专家共识意见');
INSERT INTO `temp_biz_standard` VALUES ('484', 'Y05_013', '慢性胰腺炎诊治指南（2012，上海）');
INSERT INTO `temp_biz_standard` VALUES ('485', 'Y05_014', '2005BSG英国急性胰腺炎的管理指南');
INSERT INTO `temp_biz_standard` VALUES ('486', 'Y05_015', '慢性胰腺炎诊治指南（2005，南京）');
INSERT INTO `temp_biz_standard` VALUES ('487', 'Y05_016', '2015 JSGE循证临床实践指南：慢性胰腺炎');
INSERT INTO `temp_biz_standard` VALUES ('488', 'Y05_017', '2012版急性胰腺炎分类-亚特兰大国际共识的分类和定义的修订');
INSERT INTO `temp_biz_standard` VALUES ('489', 'Y05_018', '2006JPN 日本急性胰腺炎管理指南：诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('49', 'M06_004', '鹿角形肾结石评估(2011)');
INSERT INTO `temp_biz_standard` VALUES ('490', 'Y05_019', 'AGA研究所急性胰腺炎声明');
INSERT INTO `temp_biz_standard` VALUES ('491', 'Y05_020', 'IAP/APA急性胰腺炎的循证管理指南');
INSERT INTO `temp_biz_standard` VALUES ('492', 'Y05_022', 'Rosemont诊断分层');
INSERT INTO `temp_biz_standard` VALUES ('493', 'Y05_023', '急性胰腺炎的新的诊断标准JPN Guidelines 2010');
INSERT INTO `temp_biz_standard` VALUES ('494', 'Y05_024', '\n急性胰腺炎:日本2015年指南');
INSERT INTO `temp_biz_standard` VALUES ('495', 'X02_001', '中医病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('496', 'X02_002', '临床诊疗指南消化系统疾病分册');
INSERT INTO `temp_biz_standard` VALUES ('497', 'X02_003', '中医内科常见病诊疗指南西医疾病部分');
INSERT INTO `temp_biz_standard` VALUES ('498', 'X02_004', '常见疾病的诊断与疗效判断标准');
INSERT INTO `temp_biz_standard` VALUES ('499', 'X02_005', '2002 AIHA 成人消化性溃疡的诊断与治疗草案');
INSERT INTO `temp_biz_standard` VALUES ('5', 'D02_005', '中国2型糖尿病防治指南（2013年版）');
INSERT INTO `temp_biz_standard` VALUES ('50', 'M06_005', '尿路结石');
INSERT INTO `temp_biz_standard` VALUES ('500', 'X02_006', '2015 JSGE循证临床实践指南：消化性溃疡');
INSERT INTO `temp_biz_standard` VALUES ('501', 'X02_007', '2002 小儿慢性胃炎、消化性溃疡胃镜诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('502', 'X02_008', '2011 消化性溃疡中西医结合诊疗共识意见（2011年天津）');
INSERT INTO `temp_biz_standard` VALUES ('502dcfc4e01c4b2c81b391b772eb6b1a', 'addd', 'adddaddd');
INSERT INTO `temp_biz_standard` VALUES ('503', 'X02_009', '消化性溃疡病诊断与治疗规范建议(2008，黄山)');
INSERT INTO `temp_biz_standard` VALUES ('504', 'X02_010', '消化性溃疡中医诊疗共识意见(2009,深圳)');
INSERT INTO `temp_biz_standard` VALUES ('505', 'X02_011', '十二指肠溃疡诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('506', 'X02_019', '难治性消化性溃疡的诊断和治疗方法');
INSERT INTO `temp_biz_standard` VALUES ('507', 'Y03_002', '2006 CMA抑郁障碍防治指南（中国精神障碍分类与诊断标准）');
INSERT INTO `temp_biz_standard` VALUES ('508', 'Y03_004', '2010 APA 重性抑郁障碍的治疗指南（第三版）');
INSERT INTO `temp_biz_standard` VALUES ('509', 'Y03_005', '2010英属哥伦比亚卫生部儿童和青少年焦虑和抑郁的诊断和治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('51', 'M06_006', '尿石症诊断治疗指南（2014）');
INSERT INTO `temp_biz_standard` VALUES ('510', 'Y03_011', '精神障碍诊断与统计手册-IV ');
INSERT INTO `temp_biz_standard` VALUES ('511', 'Y03_012', '精神障碍诊断与统计手册-IV-TR');
INSERT INTO `temp_biz_standard` VALUES ('512', 'Y03_013', '精神障碍诊断与统计手册-5');
INSERT INTO `temp_biz_standard` VALUES ('513', 'Y03_013', '精神障碍诊断与统计手册-5');
INSERT INTO `temp_biz_standard` VALUES ('514', 'Y03_013', '精神障碍诊断与统计手册-5');
INSERT INTO `temp_biz_standard` VALUES ('515', 'Y03_013', '精神障碍诊断与统计手册-5');
INSERT INTO `temp_biz_standard` VALUES ('516', 'Y03_013', '精神障碍诊断与统计手册-5');
INSERT INTO `temp_biz_standard` VALUES ('517', 'Y03_013', '精神障碍诊断与统计手册-5');
INSERT INTO `temp_biz_standard` VALUES ('518', 'Y03_014', '临床诊疗指南——精神病学分册');
INSERT INTO `temp_biz_standard` VALUES ('519', 'Y03_015', '中医病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('52', 'M06_007', '鹿角形肾结石诊断治疗指南（2014）');
INSERT INTO `temp_biz_standard` VALUES ('520', 'Y03_017', '中医内科常见病诊疗指南 中医病证部分');
INSERT INTO `temp_biz_standard` VALUES ('521', 'Y03_018', '中国精神障碍分类与诊断标准CCMD-3');
INSERT INTO `temp_biz_standard` VALUES ('522', 'Y03_020', '中国精神障碍分类与诊断标准CCMD-4（征询意见稿）');
INSERT INTO `temp_biz_standard` VALUES ('523', 'Y03_022', '疾病和有关健康问题的国际统计分类');
INSERT INTO `temp_biz_standard` VALUES ('524', 'Y03_024', '成人抑郁症临床实践指南');
INSERT INTO `temp_biz_standard` VALUES ('525', 'Y03_025', '中国精神障碍分类与诊断标准CCMD-2R');
INSERT INTO `temp_biz_standard` VALUES ('526', 'Y03_026', '中医神志病临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('527', 'Z02_007', '自发性脑出血诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('528', 'Z02_008', '成人自发性脑出血诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('529', 'Z02_012', '脑出血中医诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('53', 'M06_008', '输尿管结石');
INSERT INTO `temp_biz_standard` VALUES ('530', 'Z02_027', '脑出血诊断标准（自拟 ）');
INSERT INTO `temp_biz_standard` VALUES ('531', 'Z02_028', '脑出血诊断标准（自拟 ）');
INSERT INTO `temp_biz_standard` VALUES ('532', 'Z02_030', '脑蛛网膜下腔出血诊断标准（自拟 ）');
INSERT INTO `temp_biz_standard` VALUES ('533', 'Z02_031', '脑蛛网膜下腔出血诊断标准（自拟 ）');
INSERT INTO `temp_biz_standard` VALUES ('534', 'Z02_032', '欧州中风协会自发性脑出血管理指南');
INSERT INTO `temp_biz_standard` VALUES ('535', 'Z02_037', '颅内动脉瘤和蛛网膜下腔出血欧州中风协会管理指南');
INSERT INTO `temp_biz_standard` VALUES ('536', 'Z02_038', ' AHA/ASA 自发性脑出血管理指南');
INSERT INTO `temp_biz_standard` VALUES ('537', 'Z02_046', '短暂性脑出血的诊断与初步治疗');
INSERT INTO `temp_biz_standard` VALUES ('538', 'Z02_061', '短暂性脑出血病人的评估和管理');
INSERT INTO `temp_biz_standard` VALUES ('539', 'Z02_052', '临床诊疗指南神经病学分册');
INSERT INTO `temp_biz_standard` VALUES ('54', 'M06_009', 'EAU尿路结石诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('540', 'Z02_017', '临床诊疗指南神经病学分册');
INSERT INTO `temp_biz_standard` VALUES ('541', 'Z02_029', '中风病疗效评定标准');
INSERT INTO `temp_biz_standard` VALUES ('542', 'Z02_004', '中医内科常见病诊疗指南西医疾病部分\n');
INSERT INTO `temp_biz_standard` VALUES ('543', 'Z02_003', '各类脑血管疾病诊断要点及疗效评定标准');
INSERT INTO `temp_biz_standard` VALUES ('544', 'P01_001', '中华中医药学会标准-头痛');
INSERT INTO `temp_biz_standard` VALUES ('545', 'P01_002', '中华中医药学会标准-偏头痛');
INSERT INTO `temp_biz_standard` VALUES ('546', 'P01_003', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('547', 'P01_004', '中国偏头痛诊断治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('548', 'P01_005', '偏头痛、紧张型头痛、丛集性头痛、药物过度使用头痛的所有医疗专业人员的诊治指南');
INSERT INTO `temp_biz_standard` VALUES ('549', 'P01_006', '2012NICE 青少年和成年患者头痛诊断和管理指南');
INSERT INTO `temp_biz_standard` VALUES ('55', 'M06_010', 'EAU尿路结石诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('550', 'P01_007', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('551', 'P01_008', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('552', 'P01_009', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('553', 'P01_010', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('554', 'P01_011', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('555', 'P01_012', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('556', 'P01_013', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('557', 'P01_014', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('558', 'P01_015', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('559', 'P01_016', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('56', 'M06_011', 'EAU尿路结石诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('560', 'P01_017', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('561', 'P01_018', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('562', 'P01_019', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('563', 'P01_020', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('564', 'P01_021', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('565', 'P01_022', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('566', 'P01_023', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('567', 'P01_024', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('568', 'P01_025', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('569', 'P01_026', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('57', 'M06_012', 'EAU尿路结石诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('570', 'P01_027', 'IHS 国际头痛分类第三版（beta版）');
INSERT INTO `temp_biz_standard` VALUES ('571', 'P01_028', '2012 Barany学会/IHS共识：前庭性偏头痛诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('572', 'M09_001', '泌尿系感染诊断治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('573', 'M09_002', '泌尿系感染诊断治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('574', 'M09_003', '泌尿系感染诊断治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('575', 'M09_004', '泌尿系感染诊断治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('576', 'M09_005', '泌尿系感染诊断治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('577', 'M09_006', '中国儿童常见肾脏疾病诊治循证指南(试行)(七)：泌尿系感染诊断治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('578', 'M09_007', '尿路感染诊断与治疗中国专家共识（2015版）—复杂性尿路感染');
INSERT INTO `temp_biz_standard` VALUES ('579', 'M09_008', '尿路感染诊断与治疗中国专家共识(2015版)--尿路感染抗菌药物选择策略及特殊类型尿路感染的治疗建议');
INSERT INTO `temp_biz_standard` VALUES ('58', 'M06_013', 'EAU指南：尿路结石的诊断和保守治疗');
INSERT INTO `temp_biz_standard` VALUES ('580', 'M09_009', '尿路感染诊断与治疗中国专家共识(2016版)--尿路感染抗菌药物选择策略及特殊类型尿路感染的治疗建议');
INSERT INTO `temp_biz_standard` VALUES ('581', 'M09_010', '尿路感染诊断与治疗中国专家共识(2017版)--尿路感染抗菌药物选择策略及特殊类型尿路感染的治疗建议');
INSERT INTO `temp_biz_standard` VALUES ('582', 'M09_011', 'EAU泌尿系感染诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('583', 'M08_001', '中医内科常见病诊疗指南西医疾病部分');
INSERT INTO `temp_biz_standard` VALUES ('584', 'M08_002', '溃疡性结肠炎中医诊疗共识意见');
INSERT INTO `temp_biz_standard` VALUES ('585', 'M08_003', '对我国炎症性肠病诊断治疗规范的共识意见');
INSERT INTO `temp_biz_standard` VALUES ('586', 'M08_004', '多伦多共识：非住院性溃疡性结肠炎的医学管理指南');
INSERT INTO `temp_biz_standard` VALUES ('587', 'M08_005', 'T/ZGMZYYXH001-007-2015维吾尔医常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('588', 'M08_006', '儿童炎症性肠病诊断规范共识意见');
INSERT INTO `temp_biz_standard` VALUES ('589', 'M08_007', '炎症性肠病诊断与治疗的共识意见（2012年·广州）');
INSERT INTO `temp_biz_standard` VALUES ('59', 'S01_001', 'ZYYXH/T 97-2008慢性肾小球肾炎');
INSERT INTO `temp_biz_standard` VALUES ('590', 'Z02_018', '短暂性脑缺血发作诊断标准（自拟）');
INSERT INTO `temp_biz_standard` VALUES ('591', 'Z02_019', '短暂性脑缺血发作诊断标准（自拟）');
INSERT INTO `temp_biz_standard` VALUES ('592', 'Z02_013', '短暂性脑缺血发作与轻型卒中抗血小板治疗中国专家共识');
INSERT INTO `temp_biz_standard` VALUES ('593', 'Z02_039', ' AHA/ASA 早期急性缺血性中风患者的管理');
INSERT INTO `temp_biz_standard` VALUES ('594', 'Z02_064', '南非缺血性中风和短暂性缺血性发作管理2010');
INSERT INTO `temp_biz_standard` VALUES ('595', 'Z02_040', '急性缺血性卒中血管内治疗中国指南2015');
INSERT INTO `temp_biz_standard` VALUES ('596', 'Z02_041', '诊断和初始管理的急性中风和短暂性缺血性发作(TIA)');
INSERT INTO `temp_biz_standard` VALUES ('597', 'Z02_042', '缺血性中风的诊断和初始治疗');
INSERT INTO `temp_biz_standard` VALUES ('598', 'Z02_069', '急性缺血性中风患者的早期管理');
INSERT INTO `temp_biz_standard` VALUES ('599', 'Z02_064', '小脑缺血性中风:瑞士建议');
INSERT INTO `temp_biz_standard` VALUES ('6', 'D02_006', '中国成人血脂异常防治指南');
INSERT INTO `temp_biz_standard` VALUES ('60', 'S01_002', '慢性肾小球肾炎诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('600', 'Z02_063', '缺血性中风和短暂性缺血性发作管理指南\n');
INSERT INTO `temp_biz_standard` VALUES ('601', 'Z02_060', '新西兰短暂性脑缺血的评估管理');
INSERT INTO `temp_biz_standard` VALUES ('602', 'Z02_053', '临床诊疗指南神经病学分册');
INSERT INTO `temp_biz_standard` VALUES ('603', 'Z02_002', '中医内科常见病诊疗指南(西医疾病部分)\n');
INSERT INTO `temp_biz_standard` VALUES ('604', 'Z02_003', '各类脑血管疾病诊断要点及疗效评定标准');
INSERT INTO `temp_biz_standard` VALUES ('605', 'Z02_003', '各类脑血管疾病诊断要点及疗效评定标准');
INSERT INTO `temp_biz_standard` VALUES ('606', 'Z02_024', '脑栓塞诊断标准（自拟）');
INSERT INTO `temp_biz_standard` VALUES ('607', 'Z02_025', '脑栓塞诊断标准（自拟）');
INSERT INTO `temp_biz_standard` VALUES ('6073fb408b854b9b9fd4a1eb3a387487', 'bbb', 'bbb');
INSERT INTO `temp_biz_standard` VALUES ('608', 'Z02_021', '脑血栓诊断标准（自拟）');
INSERT INTO `temp_biz_standard` VALUES ('609', 'Z02_022', '脑血栓诊断标准（自拟）');
INSERT INTO `temp_biz_standard` VALUES ('61', 'S01_003', 'IgＡ肾病西医诊断和中医辨证分型的实践指南');
INSERT INTO `temp_biz_standard` VALUES ('62', 'S01_004', 'KDIGO肾小球肾炎指南-内固醇敏感儿童肾病综合症');
INSERT INTO `temp_biz_standard` VALUES ('63', 'S01_005', 'KDIGO肾小球肾炎指南-激素抵抗型儿童肾病综合症');
INSERT INTO `temp_biz_standard` VALUES ('64', 'S01_006', 'KDIGO肾小球肾炎指南-成人特发性局灶节段性肾小球硬化症');
INSERT INTO `temp_biz_standard` VALUES ('65', 'S01_007', 'KDIGO肾小球肾炎指南-特发性膜性肾病');
INSERT INTO `temp_biz_standard` VALUES ('66', 'S01_008', 'KDIGO肾小球肾炎指南');
INSERT INTO `temp_biz_standard` VALUES ('67', 'S01_009', '肾小球肾炎');
INSERT INTO `temp_biz_standard` VALUES ('68', 'S01_010', '急性肾小球肾炎的循证诊治指南');
INSERT INTO `temp_biz_standard` VALUES ('69', 'S01_011', '中国儿童常见肾脏疾病诊治循证指南(试行)(四):原发性IgA肾病诊断治疗指南');
INSERT INTO `temp_biz_standard` VALUES ('7', 'D02_007', '糖尿病及其并发症的定义、诊断与分类');
INSERT INTO `temp_biz_standard` VALUES ('70', 'S01_012', '2014 JSN临床实践指南：IgA肾病');
INSERT INTO `temp_biz_standard` VALUES ('71', 'S01_013', '2009 IgA肾病-牛津分类：原理，临床病理相关性以及分类');
INSERT INTO `temp_biz_standard` VALUES ('72', 'S01_014', '2009 IgA肾病-牛津分类：病理学定义，相互关系以及复现\n');
INSERT INTO `temp_biz_standard` VALUES ('73', 'F04_001', '慢性肺原性心脏病诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('74', 'F04_002', '慢性肺原性心脏病诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('75', 'F04_003', '慢性肺原性心脏病中西医结合辨证分型和治疗原则');
INSERT INTO `temp_biz_standard` VALUES ('76', 'F04_004', '中华人民共和国中医药行业标准-中医病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('77', 'F04_005', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('78', 'F04_006', '中医内科常见病诊疗指南 西医疾病部分');
INSERT INTO `temp_biz_standard` VALUES ('79', 'F04_007', '慢性肺原性心脏病中医证候诊断标准');
INSERT INTO `temp_biz_standard` VALUES ('8', 'D02_008', '美国国家胆固醇教育计划（NCEP）关于成人高胆固醇血症诊断、评估及治疗的第三次报告（成人治疗组III）');
INSERT INTO `temp_biz_standard` VALUES ('80', 'F04_008', '慢性肺原性心脏病中医诊疗指南（2014版）');
INSERT INTO `temp_biz_standard` VALUES ('806156b61f1749558d416efb9b4819aa', 'a', 'a');
INSERT INTO `temp_biz_standard` VALUES ('81', 'F04_009', '中华中医药学会标准-喘病');
INSERT INTO `temp_biz_standard` VALUES ('82', 'F04_010', '中华中医药学会标准-肺胀');
INSERT INTO `temp_biz_standard` VALUES ('83', 'F04_011', '澳大利亚和新西兰慢性阻塞性肺疾病管理指南');
INSERT INTO `temp_biz_standard` VALUES ('84', 'F04_012', '初级和二级医疗卫生保健中成人慢性阻塞性肺疾病管理');
INSERT INTO `temp_biz_standard` VALUES ('85', 'G03_001', '中华人民共和国中医药行业标准-中医病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('86', 'G03_002', '临床诊疗指南 妇产科学分册');
INSERT INTO `temp_biz_standard` VALUES ('87', 'G03_003', '中医妇科常见病诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('88', 'G03_004', '美国内分泌学会围绝经期症状治疗临床指南');
INSERT INTO `temp_biz_standard` VALUES ('89', 'G03_005', 'EMAS立场声明：更年期健康管理的10点指导意见');
INSERT INTO `temp_biz_standard` VALUES ('8fc34696d353499caa5338477a047e7a', '序号1', '中文题名1');
INSERT INTO `temp_biz_standard` VALUES ('9', 'D02_009', '国际糖尿病联盟关于代谢综合征定义的全球共识');
INSERT INTO `temp_biz_standard` VALUES ('90', 'G03_006', '更年期的诊断与管理');
INSERT INTO `temp_biz_standard` VALUES ('91', 'G03_007', '绝经前后激素疗法');
INSERT INTO `temp_biz_standard` VALUES ('92', 'J04_001', '中华人民共和国中医药行业标准-中医内科病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('93', 'J04_002', '中华人民共和国中医药行业标准-中医儿科病证诊断疗效标准');
INSERT INTO `temp_biz_standard` VALUES ('94', 'J04_003', '中医内科常见病诊疗指南西医疾病部分');
INSERT INTO `temp_biz_standard` VALUES ('95', 'J04_004', '中医内科常见病诊疗指南中医病证部分');
INSERT INTO `temp_biz_standard` VALUES ('96', 'J04_005', '急性气管-支气管炎的中医证候诊断标准（2013版）');
INSERT INTO `temp_biz_standard` VALUES ('97', 'J04_006', '中华医学会临床诊疗指南');
INSERT INTO `temp_biz_standard` VALUES ('98', 'J04_007', '咳嗽中医诊疗专家共识意见（2011版）');
INSERT INTO `temp_biz_standard` VALUES ('99', 'J04_008;J04_009', '咳嗽的诊断与治疗指南（2009版)');
INSERT INTO `temp_biz_standard` VALUES ('a3f6f81502e74ebb9b8b5403a419f4d2', 'bb', 'bb');
INSERT INTO `temp_biz_standard` VALUES ('abd594b94bf7494681d61494728af7ab', 'aaaaa', 'aa');
INSERT INTO `temp_biz_standard` VALUES ('abfd7bb30dc040e28e8a860cf6ce965e', 'adf', 'adfa');
INSERT INTO `temp_biz_standard` VALUES ('ad22746ef39f4e3c90898a8f20d51001', 'adfad', 'adf');
INSERT INTO `temp_biz_standard` VALUES ('b17bd00f17304df5bf37f6ec0badf08a', 'aaaaa', 'aaaaa');
INSERT INTO `temp_biz_standard` VALUES ('b1e2d7ffbb4f48698a19d5e269194636', 'dd', 'dd');
INSERT INTO `temp_biz_standard` VALUES ('e745d12081ec4f58af7962a2ea6ba303', 'aaa', 'aaa444bbb');
INSERT INTO `temp_biz_standard` VALUES ('f44b3b54c20b425b86a8ff55975f1737', 'aa', 'ssssaaa');

-- ----------------------------
-- Table structure for tgen_button
-- ----------------------------
DROP TABLE IF EXISTS `tgen_button`;
CREATE TABLE `tgen_button` (
  `id` varchar(32) NOT NULL COMMENT '按钮的名称',
  `name` varchar(255) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of tgen_button
-- ----------------------------

-- ----------------------------
-- Table structure for tgen_check
-- ----------------------------
DROP TABLE IF EXISTS `tgen_check`;
CREATE TABLE `tgen_check` (
  `id` varchar(32) NOT NULL COMMENT '主键ID',
  `name` varchar(255) DEFAULT NULL COMMENT '名称',
  `order_numer` int(11) DEFAULT NULL COMMENT '排序号',
  `check_context` varchar(255) DEFAULT NULL COMMENT '校验的内容(css)',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of tgen_check
-- ----------------------------
INSERT INTO `tgen_check` VALUES ('1', '电话', '1', null);
INSERT INTO `tgen_check` VALUES ('2', 'EMAIL', '2', '');
INSERT INTO `tgen_check` VALUES ('3', '手机', '3', null);
INSERT INTO `tgen_check` VALUES ('4', '数字', '4', null);
INSERT INTO `tgen_check` VALUES ('5', '用户名', '5', null);
INSERT INTO `tgen_check` VALUES ('6', '密码', '6', null);

-- ----------------------------
-- Table structure for tgen_element
-- ----------------------------
DROP TABLE IF EXISTS `tgen_element`;
CREATE TABLE `tgen_element` (
  `id` varchar(32) NOT NULL,
  `element_id` varchar(32) DEFAULT NULL COMMENT '元素ID',
  `element_name` varchar(255) DEFAULT NULL COMMENT '元素名称（英）',
  `element_name_remark` varchar(255) DEFAULT NULL COMMENT '元素名称（中）',
  `element_order_number` int(11) DEFAULT NULL COMMENT '元素排序号',
  `element_size` int(11) DEFAULT NULL COMMENT '元素长度',
  `element_page_id` varchar(32) DEFAULT NULL COMMENT '元素所属的页面',
  `element_width` int(11) DEFAULT NULL COMMENT '元素宽度',
  `element_rules` varchar(500) DEFAULT NULL COMMENT '元素规则',
  `element_input_id` varchar(32) DEFAULT NULL,
  PRIMARY KEY (`id`),
  KEY `FK_pl37i3a2ec65329x9hby8a1ej` (`element_page_id`),
  KEY `FK_q2m9fhx5a2b674k5s5tlkrxfm` (`element_input_id`),
  CONSTRAINT `FK_q2m9fhx5a2b674k5s5tlkrxfm` FOREIGN KEY (`element_input_id`) REFERENCES `tgen_input` (`id`),
  CONSTRAINT `FK_pl37i3a2ec65329x9hby8a1ej` FOREIGN KEY (`element_page_id`) REFERENCES `tgen_page` (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of tgen_element
-- ----------------------------
INSERT INTO `tgen_element` VALUES ('05ec527031084dc99e7b635b0013151e', null, 'orderNum', '', '13', null, 'd68db154b19941469d3f87c0e12f1250', null, null, null);
INSERT INTO `tgen_element` VALUES ('0ca39a00fac64dd08afe60933c48c306', null, 'tcmDiseaseName', '', '5', null, '87d1d193e1d64d0ba944c444328b670e', null, null, null);
INSERT INTO `tgen_element` VALUES ('0fb1a5a4e10f4a739bdb45ba696dc71e', null, 'tstandards', '', '15', null, 'd68db154b19941469d3f87c0e12f1250', null, null, null);
INSERT INTO `tgen_element` VALUES ('13f35881ca024573b71035d0eaac92d3', null, 'name', '', '4', null, '87d1d193e1d64d0ba944c444328b670e', null, null, null);
INSERT INTO `tgen_element` VALUES ('17b8e757b07b4b28b2f37f5edc6f6d91', null, 'enName', '', '7', null, 'c57775fbae6845839b16b9ce39c8ce79', null, null, null);
INSERT INTO `tgen_element` VALUES ('1c544d09bdf24461a879f3ad5fb7833b', null, 'tdiseasePrivileges', '', '14', null, 'c57775fbae6845839b16b9ce39c8ce79', null, null, null);
INSERT INTO `tgen_element` VALUES ('24240951433b47c2a4f703f0e5409b7d', null, 'mmDiseaseName', '', '6', null, 'c57775fbae6845839b16b9ce39c8ce79', null, null, null);
INSERT INTO `tgen_element` VALUES ('2dd3e1ba8a9e4b4abee31ab0bf06dbe2', null, 'remark', '', '8', null, 'c57775fbae6845839b16b9ce39c8ce79', null, null, null);
INSERT INTO `tgen_element` VALUES ('32f40f2f24e94f558b5c14b3534d8117', null, 'id', '', '1', null, 'd68db154b19941469d3f87c0e12f1250', null, null, null);
INSERT INTO `tgen_element` VALUES ('3716e3fa30e2442d8c1cc7e757c8a4b5', null, 'code', '代码', '3', null, 'd68db154b19941469d3f87c0e12f1250', null, null, null);
INSERT INTO `tgen_element` VALUES ('3c332b5eba7948d49774c9bc75704a79', null, 'createUser', '', '9', null, '87d1d193e1d64d0ba944c444328b670e', null, null, null);
INSERT INTO `tgen_element` VALUES ('3ceb968c6f564d359eefbbddfccef9fc', null, 'updateTime', '', '12', null, '87d1d193e1d64d0ba944c444328b670e', null, null, null);
INSERT INTO `tgen_element` VALUES ('489d2f428b2845e7a25cd828ba9175cc', null, 'updateUser', '', '11', null, 'd68db154b19941469d3f87c0e12f1250', null, null, null);
INSERT INTO `tgen_element` VALUES ('4ceab4dd45b148a7ada4e1e5115f928c', null, 'updateUser', '', '11', null, '87d1d193e1d64d0ba944c444328b670e', null, null, null);
INSERT INTO `tgen_element` VALUES ('4d20ad8c52af4aa4a08059b2b06ba19b', null, 'firstLetter', '首字符', '2', null, 'c57775fbae6845839b16b9ce39c8ce79', null, null, null);
INSERT INTO `tgen_element` VALUES ('4d87121d9c074c13bc9a52f6cd501313', null, 'tcmDiseaseName', '', '5', null, 'c57775fbae6845839b16b9ce39c8ce79', null, null, null);
INSERT INTO `tgen_element` VALUES ('4f25d4073d7d43f18df81a604d2ede50', null, 'createTime', '', '10', null, '87d1d193e1d64d0ba944c444328b670e', null, null, null);
INSERT INTO `tgen_element` VALUES ('5185255f9b884e1c9b032c9010b5a86c', null, 'tstandards', '', '15', null, 'c57775fbae6845839b16b9ce39c8ce79', null, null, null);
INSERT INTO `tgen_element` VALUES ('64b2f1abba0c4b5c93d307aed2a9c9e4', null, 'tcmDiseaseName', '', '5', null, 'd68db154b19941469d3f87c0e12f1250', null, null, null);
INSERT INTO `tgen_element` VALUES ('6b40d7d0200146d4a4ab6cda3cb58605', null, 'firstLetter', '首字符', '2', null, 'd68db154b19941469d3f87c0e12f1250', null, null, null);
INSERT INTO `tgen_element` VALUES ('79cfec5f7f98465387dd8fad2bd7079d', null, 'orderNum', '', '13', null, 'c57775fbae6845839b16b9ce39c8ce79', null, null, null);
INSERT INTO `tgen_element` VALUES ('8634e43c28ae43a082bf1f78f9d9640c', null, 'id', '', '1', null, 'c57775fbae6845839b16b9ce39c8ce79', null, null, null);
INSERT INTO `tgen_element` VALUES ('8658e23c7f134b699119cdad2c598c51', null, 'createTime', '', '10', null, 'd68db154b19941469d3f87c0e12f1250', null, null, null);
INSERT INTO `tgen_element` VALUES ('876406148dc844a3bf4ad51ced1d8e72', null, 'id', '', '1', null, '87d1d193e1d64d0ba944c444328b670e', null, null, null);
INSERT INTO `tgen_element` VALUES ('8ac0c36cbfa14bbf9d137acd714e1d96', null, 'remark', '', '8', null, '87d1d193e1d64d0ba944c444328b670e', null, null, null);
INSERT INTO `tgen_element` VALUES ('97020a7eb66d46d592c57f11177ed99f', null, 'tdiseasePrivileges', '', '14', null, '87d1d193e1d64d0ba944c444328b670e', null, null, null);
INSERT INTO `tgen_element` VALUES ('992f850e3b4d4b0b800e8907a0181311', null, 'tstandards', '', '15', null, '87d1d193e1d64d0ba944c444328b670e', null, null, null);
INSERT INTO `tgen_element` VALUES ('a0f4d5176614495db23d13048bca1a93', null, 'name', '33', '4', null, 'd68db154b19941469d3f87c0e12f1250', null, null, null);
INSERT INTO `tgen_element` VALUES ('a800fbf2349645b09f96bcdf6cbea789', null, 'firstLetter', '首字符', '2', null, '87d1d193e1d64d0ba944c444328b670e', null, null, null);
INSERT INTO `tgen_element` VALUES ('a991a694d3214452aff02dfbe88d7624', null, 'createTime', '', '10', null, 'c57775fbae6845839b16b9ce39c8ce79', null, null, null);
INSERT INTO `tgen_element` VALUES ('aa6149612e7441b2ae6433425a272b77', null, 'enName', '', '7', null, 'd68db154b19941469d3f87c0e12f1250', null, null, null);
INSERT INTO `tgen_element` VALUES ('ac3c388237804856bf629f6ae48f0010', null, 'updateUser', '', '11', null, 'c57775fbae6845839b16b9ce39c8ce79', null, null, null);
INSERT INTO `tgen_element` VALUES ('b376e23749ed4c9a818f053fd0f998e9', null, 'createUser', '', '9', null, 'd68db154b19941469d3f87c0e12f1250', null, null, null);
INSERT INTO `tgen_element` VALUES ('bda0ebf36a2d4c1d8abff04d69d9e20e', null, 'enName', '', '7', null, '87d1d193e1d64d0ba944c444328b670e', null, null, null);
INSERT INTO `tgen_element` VALUES ('bf7b1d8adf7545fa9e5e9f0a68376d68', null, 'name', '', '4', null, 'c57775fbae6845839b16b9ce39c8ce79', null, null, null);
INSERT INTO `tgen_element` VALUES ('c5cbd330511d4e49a7780e24b03c8ce3', null, 'updateTime', '', '12', null, 'd68db154b19941469d3f87c0e12f1250', null, null, null);
INSERT INTO `tgen_element` VALUES ('c68cbc9d40af404ba9b7d46d502b1f8e', null, 'createUser', '', '9', null, 'c57775fbae6845839b16b9ce39c8ce79', null, null, null);
INSERT INTO `tgen_element` VALUES ('c859e802a0864467b76b164d37e8b0f1', null, 'code', '代码', '3', null, '87d1d193e1d64d0ba944c444328b670e', null, null, null);
INSERT INTO `tgen_element` VALUES ('d6fdd84fa6384515bcbc4955e7b6c825', null, 'mmDiseaseName', '', '6', null, '87d1d193e1d64d0ba944c444328b670e', null, null, null);
INSERT INTO `tgen_element` VALUES ('d822c58b617044e986ae62a830200a0b', null, 'code', '代码', '3', null, 'c57775fbae6845839b16b9ce39c8ce79', null, null, null);
INSERT INTO `tgen_element` VALUES ('d95e9e698e804219ab1f82a7a90585cf', null, 'orderNum', '', '13', null, '87d1d193e1d64d0ba944c444328b670e', null, null, null);
INSERT INTO `tgen_element` VALUES ('e1f4becc6ff64540ae939e511ddd9ba8', null, 'tdiseasePrivileges', '', '14', null, 'd68db154b19941469d3f87c0e12f1250', null, null, null);
INSERT INTO `tgen_element` VALUES ('f10ee4c27b834b45b02903abd85f9148', null, 'remark', '', '8', null, 'd68db154b19941469d3f87c0e12f1250', null, null, null);
INSERT INTO `tgen_element` VALUES ('f7f650de9f83419d9d42da918697a6ef', null, 'updateTime', '', '12', null, 'c57775fbae6845839b16b9ce39c8ce79', null, null, null);
INSERT INTO `tgen_element` VALUES ('fef09029535b4883af872333cbec77e9', null, 'mmDiseaseName', '', '6', null, 'd68db154b19941469d3f87c0e12f1250', null, null, null);

-- ----------------------------
-- Table structure for tgen_input
-- ----------------------------
DROP TABLE IF EXISTS `tgen_input`;
CREATE TABLE `tgen_input` (
  `id` varchar(32) NOT NULL,
  `name` varchar(255) DEFAULT NULL COMMENT '元素类型',
  `order_num` int(11) DEFAULT NULL COMMENT '排序号',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of tgen_input
-- ----------------------------
INSERT INTO `tgen_input` VALUES ('1', '普通输入框', '1');
INSERT INTO `tgen_input` VALUES ('2', '下拉框', '2');
INSERT INTO `tgen_input` VALUES ('3', '多行文本', '3');
INSERT INTO `tgen_input` VALUES ('4', '大文本(KindEdit)', '4');
INSERT INTO `tgen_input` VALUES ('5', '上传组件(uploadify)', '5');
INSERT INTO `tgen_input` VALUES ('6', '下拉树', '6');

-- ----------------------------
-- Table structure for tgen_page
-- ----------------------------
DROP TABLE IF EXISTS `tgen_page`;
CREATE TABLE `tgen_page` (
  `id` varchar(32) NOT NULL,
  `page_button_typeid` varchar(255) DEFAULT NULL COMMENT '页面按钮类型ID',
  `page_height` int(11) DEFAULT NULL COMMENT '页面高',
  `page_id` varchar(32) DEFAULT NULL COMMENT '页面的父ID',
  `page_model_id` varchar(32) DEFAULT NULL COMMENT 'pageModel的主键',
  `page_location` varchar(1000) DEFAULT NULL,
  `page_order_number` int(11) DEFAULT NULL COMMENT '页面排序号',
  `page_title` varchar(255) DEFAULT NULL COMMENT '页面标题',
  `page_url` varchar(255) DEFAULT NULL COMMENT '页面的访问URL',
  `page_width` int(11) DEFAULT NULL COMMENT '页面宽',
  PRIMARY KEY (`id`),
  KEY `page_id` (`page_id`),
  KEY `page_model_id` (`page_model_id`),
  CONSTRAINT `tgen_page_ibfk_1` FOREIGN KEY (`page_id`) REFERENCES `tgen_page` (`id`),
  CONSTRAINT `tgen_page_ibfk_2` FOREIGN KEY (`page_model_id`) REFERENCES `tgen_page_model` (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of tgen_page
-- ----------------------------
INSERT INTO `tgen_page` VALUES ('84ec1b130c8740628715f52ed0a9fc85', '1', '400', null, 'e36937ab8f58464bba38093fe38846fb', null, '1', '疾病管理', '/admin/disease', '500');
INSERT INTO `tgen_page` VALUES ('87d1d193e1d64d0ba944c444328b670e', '1', '400', '84ec1b130c8740628715f52ed0a9fc85', 'e36937ab8f58464bba38093fe38846fb', null, '3', '详情', '/admin/tdisease/detailPage', '500');
INSERT INTO `tgen_page` VALUES ('c57775fbae6845839b16b9ce39c8ce79', '1', '400', '84ec1b130c8740628715f52ed0a9fc85', 'e36937ab8f58464bba38093fe38846fb', null, '2', '修改', '/admin/tdisease/editPage', '500');
INSERT INTO `tgen_page` VALUES ('d68db154b19941469d3f87c0e12f1250', '1', '400', '84ec1b130c8740628715f52ed0a9fc85', 'e36937ab8f58464bba38093fe38846fb', null, '1', '添加', '/admin/tdisease/addPage', '500');

-- ----------------------------
-- Table structure for tgen_page_buttton
-- ----------------------------
DROP TABLE IF EXISTS `tgen_page_buttton`;
CREATE TABLE `tgen_page_buttton` (
  `button_id` varchar(32) NOT NULL,
  `page_id` varchar(32) NOT NULL,
  PRIMARY KEY (`button_id`,`page_id`),
  KEY `FK_6toovctly4o7e47k7oslxj8mb` (`button_id`),
  KEY `FK_26sugxvevl4jo4rhyo13g4een` (`page_id`),
  CONSTRAINT `FK_6toovctly4o7e47k7oslxj8mb` FOREIGN KEY (`button_id`) REFERENCES `tgen_button` (`id`),
  CONSTRAINT `FK_26sugxvevl4jo4rhyo13g4een` FOREIGN KEY (`page_id`) REFERENCES `tgen_page` (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of tgen_page_buttton
-- ----------------------------

-- ----------------------------
-- Table structure for tgen_page_model
-- ----------------------------
DROP TABLE IF EXISTS `tgen_page_model`;
CREATE TABLE `tgen_page_model` (
  `id` varchar(32) NOT NULL COMMENT '主键',
  `pageModelName` varchar(255) DEFAULT NULL COMMENT 'pageModel中文名称',
  `pageModelFullName` varchar(255) DEFAULT NULL COMMENT 'PageModel类全名',
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of tgen_page_model
-- ----------------------------
INSERT INTO `tgen_page_model` VALUES ('e36937ab8f58464bba38093fe38846fb', '疾病管理', 'cn.com.infcn.core.modelAdd.Tdisease');

-- ----------------------------
-- Table structure for tgen_page_model_colum
-- ----------------------------
DROP TABLE IF EXISTS `tgen_page_model_colum`;
CREATE TABLE `tgen_page_model_colum` (
  `id` varchar(32) NOT NULL,
  `pageModelId` varchar(32) NOT NULL COMMENT 'pageModel长类名',
  `columName` varchar(255) DEFAULT NULL COMMENT 'model属性',
  `columRemark` varchar(255) DEFAULT NULL COMMENT 'model属性对应的注释(页面上显示的)',
  `order_number` int(11) DEFAULT NULL COMMENT '排序号',
  PRIMARY KEY (`id`),
  KEY `pageModelId` (`pageModelId`),
  CONSTRAINT `tgen_page_model_colum_ibfk_1` FOREIGN KEY (`pageModelId`) REFERENCES `tgen_page_model` (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of tgen_page_model_colum
-- ----------------------------
INSERT INTO `tgen_page_model_colum` VALUES ('206fbe4f8a60403aa03f3480e06d529b', 'e36937ab8f58464bba38093fe38846fb', 'createUser', '', '9');
INSERT INTO `tgen_page_model_colum` VALUES ('26f26b52e7924593b038ec16b699f3f8', 'e36937ab8f58464bba38093fe38846fb', 'id', '', '1');
INSERT INTO `tgen_page_model_colum` VALUES ('2876731d89ab4bae91203dd3049b3416', 'e36937ab8f58464bba38093fe38846fb', 'orderNum', '', '13');
INSERT INTO `tgen_page_model_colum` VALUES ('2d0553b3915d4a35abd08d5b7fc0f8fb', 'e36937ab8f58464bba38093fe38846fb', 'tcmDiseaseName', '', '5');
INSERT INTO `tgen_page_model_colum` VALUES ('3ad819d668b6427ead7a25f15e6cd971', 'e36937ab8f58464bba38093fe38846fb', 'mmDiseaseName', '', '6');
INSERT INTO `tgen_page_model_colum` VALUES ('41ee38df8aab465db037d2ed90f30e6a', 'e36937ab8f58464bba38093fe38846fb', 'firstLetter', '首字符', '2');
INSERT INTO `tgen_page_model_colum` VALUES ('45b333036c4c4d70b496a313a04cf94d', 'e36937ab8f58464bba38093fe38846fb', 'updateUser', '', '11');
INSERT INTO `tgen_page_model_colum` VALUES ('5b9e6fea4a0d47788bfd1444517b0cc1', 'e36937ab8f58464bba38093fe38846fb', 'createTime', '', '10');
INSERT INTO `tgen_page_model_colum` VALUES ('5ed4a43eb1314d7a9f1f90b0c0f0a162', 'e36937ab8f58464bba38093fe38846fb', 'tstandards', '', '15');
INSERT INTO `tgen_page_model_colum` VALUES ('8e951950ad1a4e68892a962027c4ae86', 'e36937ab8f58464bba38093fe38846fb', 'enName', '', '7');
INSERT INTO `tgen_page_model_colum` VALUES ('96929048f41c40c7a1b2388b9a528786', 'e36937ab8f58464bba38093fe38846fb', 'updateTime', '', '12');
INSERT INTO `tgen_page_model_colum` VALUES ('a899c14271174ee5a49762b0f5867120', 'e36937ab8f58464bba38093fe38846fb', 'name', '', '4');
INSERT INTO `tgen_page_model_colum` VALUES ('b1f79032c8944c6d9c95026749831e95', 'e36937ab8f58464bba38093fe38846fb', 'code', '代码', '3');
INSERT INTO `tgen_page_model_colum` VALUES ('bffa7015c9db4b7287f5664346817ce9', 'e36937ab8f58464bba38093fe38846fb', 'remark', '', '8');
INSERT INTO `tgen_page_model_colum` VALUES ('c7eb68b8eb5f4a8a87468b0304d7d529', 'e36937ab8f58464bba38093fe38846fb', 'tdiseasePrivileges', '', '14');

-- ----------------------------
-- Table structure for tgen_rule
-- ----------------------------
DROP TABLE IF EXISTS `tgen_rule`;
CREATE TABLE `tgen_rule` (
  `id` varchar(32) NOT NULL,
  `rule_length` int(11) DEFAULT NULL,
  `rule_ismust` varchar(2) DEFAULT NULL COMMENT '是否必填(1是，2否)',
  `finput_type_id` varchar(32) DEFAULT NULL COMMENT '控件类型ID',
  `fcheck_id` varchar(32) DEFAULT NULL COMMENT '检查的ID',
  `rule_context` varchar(255) DEFAULT NULL COMMENT '规则内容',
  `rule_source` varchar(255) DEFAULT NULL COMMENT '数据来源',
  PRIMARY KEY (`id`),
  KEY `fcheck_id` (`fcheck_id`),
  KEY `finput_type_id` (`finput_type_id`),
  CONSTRAINT `tgen_rule_ibfk_3` FOREIGN KEY (`finput_type_id`) REFERENCES `tgen_input` (`id`),
  CONSTRAINT `tgen_rule_ibfk_1` FOREIGN KEY (`id`) REFERENCES `tgen_element` (`id`),
  CONSTRAINT `tgen_rule_ibfk_2` FOREIGN KEY (`fcheck_id`) REFERENCES `tgen_check` (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- ----------------------------
-- Records of tgen_rule
-- ----------------------------
INSERT INTO `tgen_rule` VALUES ('32f40f2f24e94f558b5c14b3534d8117', '33', '1', '5', '6', null, null);

-- ----------------------------
-- Procedure structure for dealAttach
-- ----------------------------
DROP PROCEDURE IF EXISTS `dealAttach`;
DELIMITER ;;
CREATE DEFINER=`root`@`localhost` PROCEDURE `dealAttach`()
BEGIN
      DECLARE Done INT DEFAULT 0;
     
			DECLARE t_id VARCHAR(60);  
			DECLARE t_name VARCHAR(500);  
			DECLARE t_order_num VARCHAR(100);  


      DECLARE rs CURSOR FOR SELECT id,cn_title,order_num from temp_biz_standard;

      DECLARE CONTINUE HANDLER FOR SQLSTATE '02000' SET Done = 1;
     

      OPEN rs;  
     

      FETCH NEXT FROM rs INTO t_id, t_name,t_order_num;     

      REPEAT
            IF NOT Done THEN
								
										BEGIN
															DECLARE ss_str VARCHAR(100);  
															DECLARE ss_next int DEFAULT 1;
															DECLARE ss_strCur VARCHAR(50); 

															set ss_str=  t_order_num ;
																		
															while ss_next <= Get_StrArrayLength(ss_str,';') do
								 
																set ss_strCur= Get_StrArrayStrOfIndex(ss_str,';',ss_next) ;

																	if LENGTH(ss_strCur)>0 THEN
																			INSERT INTO biz_attach_standard(id,standard_id,`name`,url)VALUES(UUID_SHORT(),t_id,ss_strCur,ss_strCur);
																	END if;

																set ss_next=ss_next+1 ;
													

															end WHILE;             
										end;
								

            END IF;
           
		  FETCH NEXT FROM rs INTO t_id, t_name,t_order_num;     
 
      UNTIL Done END REPEAT;
     
      CLOSE rs;
 END
;;
DELIMITER ;

-- ----------------------------
-- Function structure for Get_StrArrayLength
-- ----------------------------
DROP FUNCTION IF EXISTS `Get_StrArrayLength`;
DELIMITER ;;
CREATE DEFINER=`root`@`localhost` FUNCTION `Get_StrArrayLength`(ss_str varchar(255),ss_split varchar(10)) RETURNS int(11)
begin 
declare ss_location int; 
declare ss_start int; 
declare ss_length int; 
set ss_str=ltrim(rtrim(ss_str)); 
set ss_location=LOCATE(ss_split,ss_str); 
set ss_length=1; 
while ss_location<>0 do

set ss_start=ss_location+1; 
set ss_location=LOCATE(ss_split,ss_str,ss_start); 
set ss_length=ss_length+1;
end WHILE;
return ss_length; 
end
;;
DELIMITER ;

-- ----------------------------
-- Function structure for Get_StrArrayStrOfIndex
-- ----------------------------
DROP FUNCTION IF EXISTS `Get_StrArrayStrOfIndex`;
DELIMITER ;;
CREATE DEFINER=`root`@`localhost` FUNCTION `Get_StrArrayStrOfIndex`(
ss_str VARCHAR(1024), 
ss_split VARCHAR(10), 
ss_index INT) RETURNS varchar(1024) CHARSET utf8
BEGIN

DECLARE ss_location INT ;
DECLARE ss_start INT ;
DECLARE ss_next INT ;
DECLARE ss_seed INT ;
SET ss_str=LTRIM(RTRIM(ss_str)) ;
SET ss_start=1 ;
SET ss_next=1 ;
SET ss_seed=LENGTH(ss_split) ;
SET ss_location=LOCATE(ss_split,ss_str) ;
WHILE ss_location<>0 AND ss_index>ss_next DO
 
SET ss_start=ss_location+ss_seed ;
SET ss_location=LOCATE(ss_split,ss_str,ss_start) ;
SET ss_next=ss_next+1 ;
END WHILE;
IF ss_location =0 THEN	set ss_location =LENGTH(ss_str)+1 ;
END IF;
RETURN SUBSTRING(ss_str,ss_start,ss_location-ss_start) ;
    END
;;
DELIMITER ;
